US20160108473A1 - Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof - Google Patents

Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof Download PDF

Info

Publication number
US20160108473A1
US20160108473A1 US14/834,946 US201514834946A US2016108473A1 US 20160108473 A1 US20160108473 A1 US 20160108473A1 US 201514834946 A US201514834946 A US 201514834946A US 2016108473 A1 US2016108473 A1 US 2016108473A1
Authority
US
United States
Prior art keywords
snp
allele
cvd
nucleic acid
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/834,946
Inventor
Dov Shiffman
James J. Devlin
May Luke
David Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celera Corp
Original Assignee
Celera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celera Corp filed Critical Celera Corp
Priority to US14/834,946 priority Critical patent/US20160108473A1/en
Publication of US20160108473A1 publication Critical patent/US20160108473A1/en
Priority to US15/952,792 priority patent/US10563263B2/en
Priority to US16/728,333 priority patent/US11827937B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Definitions

  • the present invention is in the field of drug response and disease risk, particularly genetic polymorphisms that are associated with response to statins, especially for the prevention or treatment of cardiovascular diseases (CVD) such as coronary heart disease (CHD) (which includes coronary events such as myocardial infarction (MI)) and cerebrovascular events (such as stroke).
  • CVD cardiovascular diseases
  • CHD coronary heart disease
  • MI myocardial infarction
  • cerebrovascular events such as stroke
  • the present invention relates to specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with variability in responsiveness to statin treatment (including preventive treatment) in reducing CVD risk between different individuals.
  • SNPs are also useful for assessing an individual's risk for developing CVD.
  • the SNPs disclosed herein can be used, for example, as targets for diagnostic reagents and for the development of therapeutic agents.
  • the SNPs of the present invention are useful for such uses as predicting an individual's response to therapeutic agents such as evaluating the likelihood of an individual differentially responding positively to statins, particularly for the treatment or prevention of CVD (particularly CHD such as MI, as well as stroke), identifying an individual who has an increased or decreased risk of developing CVD (particularly CHD such as MI, as well as stroke), for early detection of the disease, for providing clinically important information for the prevention and/or treatment of CVD, for predicting recurrence of CVD, and for screening and selecting therapeutic agents.
  • Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and their encoded products are provided.
  • the present invention relates to SNPs that are associated with variability between individuals in their response to statins, particularly for the prevention or treatment of cardiovascular disease (CVD), which includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke and transient ischemic attack (TIA).
  • CVD cardiovascular disease
  • CHD coronary heart disease
  • MI myocardial infarction
  • TIA stroke and transient ischemic attack
  • CHD including coronary events such as MI
  • cerebrovascular events such as stroke and transient ischemic attack
  • HMG-CoA reductase inhibitors are used for the treatment and prevention of CVD, particularly CHD (including coronary events such as MI) and cerebrovascular events (such as stroke). Reduction of MI, stroke, and other coronary and cerebrovascular events and total mortality by treatment with HMG-CoA reductase inhibitors has been demonstrated in a number of randomized, double-blinded, placebo-controlled prospective trials (D. D. Waters, Clin Cardiol 24(8 Suppl):III3-7 (2001); B. K. Singh and J. L. Mehta, Curr Opin Cardiol 17(5):503-11 (2002)). These drugs are thought to typically have their primary effect through the inhibition of hepatic cholesterol synthesis, thereby upregulating LDL receptors in the liver. The resultant increase in LDL catabolism results in decreased circulating LDL, a major risk factor for cardiovascular disease.
  • statins include, but are not limited to, atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), simvastatin (Zocor®), fluvastatin (Lescol®), and lovastatin (Mevacor®), as well as combination therapies that include a statin such as simvastatin+ezetimibe (Vytorin®), lovastatin+niacin (Advicor®), atorvastatin+amlodipine besylate (Caduet®), and simvastatin+niacin (Simcor®).
  • Statins can be divided into two types according to their physicochemical and pharmacokinetic properties.
  • Statins such as atorvastatin, simvastatin, lovastatin, and cerivastatin are lipophilic in nature and, as such, diffuse across membranes and thus are highly cell permeable.
  • Hydrophilic statins such as pravastatin are more polar, such that they require specific cell surface transporters for cellular uptake.
  • statins utilizes a transporter, OATP2, whose tissue distribution is confined to the liver and, therefore, they are relatively hepato-specific inhibitors.
  • OATP2 a transporter
  • the former statins not requiring specific transport mechanisms, are available to all cells and they can directly impact a much broader spectrum of cells and tissues. These differences in properties may influence the spectrum of activities that each statin possesses.
  • Pravastatin for instance, has a low myopathic potential in animal models and myocyte cultures compared to lipophilic statins.
  • a polymorphism in the KIF6 gene is associated with response to statin treatment (Iakoubova et al., “Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):449-55; Iakoubova et al., “Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy”, J Am Coll Cardiol. 2008 Jun.
  • statins There is a need for genetic markers that can be used to predict an individual's responsiveness to statins. For example, there is a growing need to better identify people who have a high chance of benefiting from statins, and those who have a low risk of developing side-effects. For example, severe myopathies represent a significant risk for a low percentage of the patient population, and this may be a particular concern for patients who are treated more aggressively with statins. Furthermore, different patients may have the same the risk for adverse events but are more likely to benefit from a drug (such as statins) and this may justify use of the drug in those individuals who are more likely to benefit. Similarly, in individuals who are less likely to benefit from a drug but are at risk for adverse events, use of the drug in these individuals can be de-prioritized or delayed.
  • statins for stroke are also described in O'Regan et al., “Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients”, Am J Med. 2008 January; 121(1):24-33 and Everett et al., “Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)”, Circulation. 2010 Jan. 5; 121(1):143-50.
  • CVD Cardiovascular Disease
  • CHD Coronary Heart Disease
  • Cardiovascular disease includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke and transient ischemic attack (TIA).
  • CHD coronary heart disease
  • MI myocardial infarction
  • TIA stroke and transient ischemic attack
  • Coronary heart disease is defined herein as encompassing MI (fatal or non-fatal) and other coronary events, death from coronary disease, angina pectoris (particularly unstable angina), and coronary stenosis.
  • the presence of CHD may be indicated by the occurrence of medical interventions such as coronary revascularization, which can include percutaneous transluminal coronary angioplasty (PTCA), coronary stent placement, and coronary artery bypass graft (CABG).
  • PTCA percutaneous transluminal coronary angioplasty
  • CABG coronary artery bypass graft
  • Cardiovascular disease is defined herein as encompassing CHD as well as cerebrovascular events such as stroke and transient ischemic attack (TIA).
  • MI Myocardial Infarction
  • MI Myocardial infarction
  • MI is a multifactorial disease that involves atherogenesis, thrombus formation and propagation. Thrombosis can result in complete or partial occlusion of coronary arteries. The luminal narrowing or blockage of coronary arteries reduces oxygen and nutrient supply to the cardiac muscle (cardiac ischemia), leading to myocardial necrosis and/or stunning. MI, unstable angina, and sudden ischemic death are clinical manifestations of cardiac muscle damage. All three endpoints are part of acute coronary syndrome since the underlying mechanisms of acute complications of atherosclerosis are considered to be the same.
  • Atherogenesis the first step of pathogenesis of MI, is an interaction between blood elements, mechanical forces, disturbed blood flow, and vessel wall abnormality that results in plaque accumulation.
  • An unstable (vulnerable) plaque is an underlying cause of arterial thrombotic events and MI.
  • a vulnerable plaque is a plaque, often not stenotic, that has a high likelihood of becoming disrupted or eroded, thus forming a thrombogenic focus.
  • the “vulnerability” of an individual to MI may be due to vulnerable plaque, blood vulnerability (hypercoagulation, hypothrombolysis), and heart vulnerability (sensitivity of the heart to ischemia or propensity for arrhythmia).
  • Recurrent myocardial infarction (RMI) can generally be viewed as a severe form of MI progression caused by multiple vulnerable plaques that are able to undergo pre-rupture or a pre-erosive state, coupled with extreme blood coagulability.
  • the current diagnosis of MI with presentation is based on the levels of troponin I or T that indicate the cardiac muscle progressive necrosis, impaired electrocardiogram (ECG), and detection of abnormal ventricular wall motion or angiographic data (the presence of acute thrombi).
  • ECG impaired electrocardiogram
  • detection of abnormal ventricular wall motion or angiographic data the presence of acute thrombi.
  • a significant portion of MIs are not diagnosed and therefore not treated appropriately (e.g., prevention of recurrent MIs).
  • MI risk assessment and prognosis is currently done using classic risk factors or the recently introduced Framingham Risk Index. Both of these assessments put a significant weight on LDL levels to justify preventive treatment. However, it is well established that half of all MIs occur in individuals without overt hyperlipidemia.
  • CRP C-reactive protein
  • ICAM-1 ICAM-1
  • SAA TNF a
  • homocysteine impaired fasting glucose
  • new lipid markers ox LDL, Lp-a, MAD-LDL, etc.
  • pro-thrombotic factors pro-thrombotic factors
  • Genetic markers such as single nucleotide polymorphisms (SNPs) are preferable to other types of biomarkers. Genetic markers that are prognostic for MI can be genotyped early in life and could predict individual response to various risk factors. The combination of serum protein levels and genetic predisposition revealed by genetic analysis of susceptibility genes can provide an integrated assessment of the interaction between genotypes and environmental factors, resulting in synergistically increased prognostic value of diagnostic tests.
  • SNPs single nucleotide polymorphisms
  • Such genetic markers may enable prognosis of MI in much larger populations compared with the populations that can currently be evaluated by using existing risk factors and biomarkers.
  • the availability of a genetic test may allow, for example, appropriate preventive treatments for acute coronary events to be provided for susceptible individuals (such preventive treatments may include, for example, statin treatments and statin dose escalation, as well as changes to modifiable risk factors), lowering of the thresholds for ECG and angiography testing, and allow adequate monitoring of informative biomarkers.
  • the discovery of genetic markers associated with MI can provide novel targets for therapeutic intervention or preventive treatments of MI, and enable the development of new therapeutic agents for treating or preventing MI and other cardiovascular disorders.
  • Early-onset MI may be defined as MI in men who are less than 55 years of age and women who are less than 65 years of age (K. O. Akosah et al., “Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform?” JACC 41(9):1475-1479 (2003)). Individuals who experience early-onset MI may not be effectively identified by current cholesterol treatment guidelines, such as those suggested by the National Cholesterol Education Program.
  • Stroke is a prevalent and serious cerebrovascular disease. It affects 4.7 million individuals in the United States, with 500,000 first attacks and 200,000 recurrent cases yearly. Approximately one in four men and one in five women aged 45 years will have a stroke if they live to their 85th year. About 25% of those who have a stroke die within a year. Stroke is the third leading cause of mortality in the United States and is responsible for 170,000 deaths a year. Among those who survive a stroke attack, 30 to 50% do not regain functional independence. Stroke therefore is the most common cause of disability and the second leading cause of dementia (Heart Disease and Stroke Statistics—2004 Update, American Heart Association).
  • Ischemic stroke occurs when an artery bringing oxygen and nutrients to the brain either ruptures, causing hemorrhagic stroke, or gets occluded, causing ischemic stroke.
  • Ischemic stroke can be caused by thrombi formation at the site of an atherosclerotic plaque rupture (this type of ischemic stroke is interchangeably referred to as thrombotic or atherothrombotic stroke) or by emboli (clots) that have travelled from another part of the vasculature (this type of ischemic stroke is referred to as embolic stroke), often from the heart (this type of embolic stroke may be referred to as cardioembolic stroke).
  • ischemic In both ischemic and hemorrhagic stroke, a cascade of cellular changes due to ischemia or increased cranial pressure leads to injuries or death of the brain cells.
  • ischemic In the United States, the majority (about 80-90%) of stroke cases are ischemic (Rathore, et al., Stroke 33:2718-2721 ((2002)), including 30% large-vessel thrombotic (also referred to as large-vessel occlusive disease), 20% small-vessel thrombotic (also referred to as small-vessel occlusive disease), and 30% embolic or cardiogenic (caused by a clot originating from elsewhere in the body, e.g., from blood pooling due to atrial fibrillation, or from carotid artery stenosis).
  • embolic or cardiogenic caused by a clot originating from elsewhere in the body, e.g., from blood pooling due to atrial fibrillation, or from carotid
  • Transient ischemic attack is a condition related to stroke.
  • a transient ischemic attack is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination”.
  • NINDS further states that, “TIAs are often warning signs that a person is at risk for a more serious and debilitating stroke. About one-third of those who have a TIA will have an acute stroke some time in the future. Many strokes can be prevented by heeding the warning signs of TIAs and treating underlying risk factors.”
  • Known risk factors for stroke or TIA can be divided into modifiable and non-modifiable risk factors. Older age, male sex, black or Hispanic ethnicity, and family history of stroke are non-modifiable risk factors. Modifiable risk factors include hypertension, smoking, increased insulin levels, asymptomatic carotid disease, cardiac vessel disease, and hyperlipidemia.
  • SNPs in the 4q25 region were reported to be associated with stroke (Gretarsdottir et al., “Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke”, Ann Neurol. 2008; 64:402-409) and with atrial fibrillation (AF) (Gudbjartsson et al., “Variants conferring risk of atrial fibrillation on chromosome 4q25 ”, Nature. 2007; 448:353-357), SNPs in the 16q22 region (Gudbjartsson et al., “A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke”, Nat Genet.
  • risk factors for stroke or TIA are not modifiable, such as age and family history
  • other underlying pathology or risk factors of stroke or TIA such as atherosclerosis, hypertension, smoking, diabetes, aneurysm, and atrial fibrillation
  • atherosclerosis a pathology or risk factors of stroke or TIA
  • hypertension a pathology or risk factors of stroke or TIA
  • SNPs Single Nucleotide Polymorphisms
  • a variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral.
  • a variant form confers an evolutionary advantage to individual members of a species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form.
  • the effects of a variant form may be both beneficial and detrimental, depending on the environment. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal.
  • SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population.
  • the SNP position (interchangeably referred to herein as SNP, SNP site, SNP locus, SNP marker, or marker) is usually preceded by and followed by highly conserved sequences (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations).
  • An individual may be homozygous or heterozygous for an allele at each SNP position.
  • a SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP is an amino acid coding sequence.
  • a SNP may arise from a substitution of one nucleotide for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or vice versa.
  • a SNP may also be a single base insertion or deletion variant referred to as an “indel.” Weber et al., “Human diallelic insertion/deletion polymorphisms,” Am J Hum Genet 71(4):854-62 (October 2002).
  • a synonymous codon change, or silent mutation/SNP is one that does not result in a change of amino acid due to the degeneracy of the genetic code.
  • a substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid is referred to as a missense mutation.
  • a nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein.
  • a read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product. While SNPs can be bi-, tri-, or tetra-allelic, the vast majority of SNPs are bi-allelic, and are thus often referred to as “bi-allelic markers,” or “di-allelic markers.”
  • references to SNPs and SNP genotypes include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases. Stephens et al., Science 293:489-493 (July 2001).
  • SNPs are those SNPs that produce alterations in gene expression or in the expression, structure, and/or function of a gene product, and therefore are most predictive of a possible clinical phenotype.
  • One such class includes SNPs falling within regions of genes encoding a polypeptide product, i.e. cSNPs. These SNPs may result in an alteration of the amino acid sequence of the polypeptide product (i.e., non-synonymous codon changes) and give rise to the expression of a defective or other variant protein. Furthermore, in the case of nonsense mutations, a SNP may lead to premature termination of a polypeptide product. Such variant products can result in a pathological condition, e.g., genetic disease. Examples of genes in which a SNP within a coding sequence causes a genetic disease include sickle cell anemia and cystic fibrosis.
  • causative SNPs do not necessarily have to occur in coding regions; causative SNPs can occur in, for example, any genetic region that can ultimately affect the expression, structure, and/or activity of the protein encoded by a nucleic acid.
  • Such genetic regions include, for example, those involved in transcription, such as SNPs in transcription factor binding domains, SNPs in promoter regions, in areas involved in transcript processing, such as SNPs at intron-exon boundaries that may cause defective splicing, or SNPs in mRNA processing signal sequences such as polyadenylation signal regions.
  • SNP SNP-associated neurotrophic factor
  • An association study of a SNP and a specific disorder involves determining the presence or frequency of the SNP allele in biological samples from individuals with the disorder of interest, such as CVD, and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals) who are preferably of similar age and race.
  • controls i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals
  • the appropriate selection of patients and controls is important to the success of SNP association studies. Therefore, a pool of individuals with well-characterized phenotypes is extremely desirable.
  • a SNP may be screened in diseased tissue samples or any biological sample obtained from a diseased individual, and compared to control samples, and selected for its increased (or decreased) occurrence in a specific pathological condition, such as pathologies related to CVD and in particular, CHD (e.g., MI).
  • CHD e.g., MI
  • the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence(s) (e.g., causative SNP/mutation, gene, regulatory region, etc.) that influences the pathological condition or phenotype.
  • Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies).
  • SNPs can be used to identify patients most suited to therapy with particular pharmaceutical agents (this is often termed “pharmacogenomics”). Similarly, SNPs can be used to exclude patients from certain treatment due to the patient's increased likelihood of developing toxic side effects or their likelihood of not responding to the treatment. Pharmacogenomics can also be used in pharmaceutical research to assist the drug development and selection process. Linder et al., Clinical Chemistry 43:254 (1997); Marshall, Nature Biotechnology 15:1249 (1997); International Patent Application WO 97/40462, Spectra Biomedical; and Schafer et al., Nature Biotechnology 16:3 (1998).
  • Exemplary embodiments of the present invention relate to the identification of SNPs, as well as unique combinations of such SNPs and haplotypes of SNPs, that are associated with variability between individuals in their response to statins, particularly for the prevention or treatment of cardiovascular disease (CVD), which includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke.
  • CVD cardiovascular disease
  • CHD coronary heart disease
  • MI myocardial infarction
  • CHD including coronary events such as MI
  • cerebrovascular events such as stroke.
  • the polymorphisms disclosed herein are directly useful as targets for the design of diagnostic and prognostic reagents and the development of therapeutic and preventive agents for use in the diagnosis, prognosis, treatment, and/or prevention of CVD (particularly CHD, such as MI), as well as for predicting a patient's response to therapeutic agents such as statins, particularly for the treatment or prevention of CVD (particularly CHD, such as MI).
  • exemplary embodiments of the present invention Based on the identification of SNPs associated with variability between individuals in their response to statins, particularly for reducing the risk of CVD such as CHD (e.g., MI) and stroke, exemplary embodiments of the present invention also provide methods of detecting these variants as well as the design and preparation of detection reagents needed to accomplish this task.
  • CVD e.g., MI
  • exemplary embodiments of the present invention also provide methods of detecting these variants as well as the design and preparation of detection reagents needed to accomplish this task.
  • the invention specifically provides, for example, SNPs associated with responsiveness to statin treatment, isolated nucleic acid molecules (including DNA and RNA molecules) containing these SNPs, variant proteins encoded by nucleic acid molecules containing such SNPs, antibodies to the encoded variant proteins, computer-based and data storage systems containing the novel SNP information, methods of detecting these SNPs in a test sample, methods of identifying individuals who have an altered (i.e., increased or decreased) risk of developing CVD (such as CHD (e.g., MI) or stroke), methods for determining the risk of an individual for recurring CVD (e.g., recurrent MI), methods of treating an individual who has an increased risk for CVD and/or increased likelihood of responding to statin treatment, and methods for identifying individuals (e.g., determining a particular individual's likelihood) who have an altered (i.e., increased or decreased) likelihood of responding to drug treatment (especially statin treatment), particularly drug treatment of CVD (e.g., prevention or treatment of CHD such as MI
  • Exemplary embodiments of the present invention further provide methods for selecting or formulating a treatment regimen (e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for developing CVD in the future, or who has previously had CVD, methods for selecting a particular statin-based treatment regimen such as dosage and frequency of administration of statin, or a particular form/type of statin such as a particular pharmaceutical formulation or statin compound, methods for administering (either in addition to or instead of a statin) an alternative, non-statin-based treatment, such as niacin, fibrates, or ezetimibe (e.g., Zetia® or Ezetrol®), to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and methods for determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, etc.
  • a treatment regimen e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for
  • Various embodiments of the present invention also provide methods for selecting individuals to whom a statin or other therapeutic will be administered based on the individual's genotype, and methods for selecting individuals for a clinical trial of a statin or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s), or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them).
  • CHD e.g., MI
  • Tables 1 and 2 provides gene information, references to the identification of transcript sequences (SEQ ID NOS:1-51), encoded amino acid sequences (SEQ ID NOS:52-102), genomic sequences (SEQ ID NOS:177-622), transcript-based context sequences (SEQ ID NOS:103-176) and genomic-based context sequences (SEQ ID NOS:623-3661) that contain the SNPs of the present application, and extensive SNP information that includes observed alleles, allele frequencies, populations/ethnic groups in which alleles have been observed, information about the type of SNP and corresponding functional effect, and, for cSNPs, information about the encoded polypeptide product.
  • transcript sequences SEQ ID NOS:1-51
  • amino acid sequences SEQ ID NOS:52-102
  • genomic sequences SEQ ID NOS:177-622
  • transcript-based SNP context sequences SEQ ID NOS:103-176
  • genomic-based SNP context sequences SEQ ID NOS:623-3661
  • the invention provides methods for identifying an individual who has an altered likelihood of responding to statin treatment or an altered risk for developing CVD, particularly CHD or stroke (including, for example, a first incidence and/or a recurrence of the disease, such as primary or recurrent MI), in which the method comprises detecting a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences of SEQ ID NOS:1-51, SEQ ID NOS:103-176, SEQ ID NOS:177-622, and SEQ ID NOS:623-3661 in said individual's nucleic acids, wherein the SNP is specified in Table 1 and/or Table 2, and the presence of the SNP is indicative of an altered response to statin treatment of an altered risk for CVD in said individual.
  • SNP single nucleotide polymorphism
  • the CVD is CHD, particularly MI.
  • the CVD is stroke.
  • SNPs that occur naturally in the human genome are provided within isolated nucleic acid molecules. These SNPs are associated with response to statin treatment thereby reducing the risk of CVD, such as CHD (e.g., MI) or stroke, such that they can have a variety of uses in the diagnosis, prognosis, treatment, and/or prevention of CVD, and particularly in the treatment or prevention of CVD using statins.
  • a nucleic acid of the invention is an amplified polynucleotide, which is produced by amplification of a SNP-containing nucleic acid template.
  • the invention provides for a variant protein that is encoded by a nucleic acid molecule containing a SNP disclosed herein.
  • reagents for detecting a SNP in the context of its naturally-occurring flanking nucleotide sequences are provided.
  • a reagent may be in the form of, for example, a hybridization probe or an amplification primer that is useful in the specific detection of a SNP of interest.
  • a protein detection reagent is used to detect a variant protein that is encoded by a nucleic acid molecule containing a SNP disclosed herein.
  • a preferred embodiment of a protein detection reagent is an antibody or an antigen-reactive antibody fragment.
  • kits comprising SNP detection reagents, and methods for detecting the SNPs disclosed herein by employing the SNP detection reagents.
  • An exemplary embodiment of the present invention provides a kit comprising a SNP detection reagent for use in determining whether a human's risk for CVD is reduced by treatment with statins based upon the presence or absence of a particular allele of one or more SNPs disclosed herein.
  • the present invention provides methods for evaluating whether an individual is likely (or unlikely) to respond to statin treatment (i.e., benefit from statin treatment)), particularly statin treatment for reducing the risk of CVD, particularly CHD (such as MI) or stroke, by detecting the presence or absence of one or more SNP alleles disclosed herein.
  • statin treatment i.e., benefit from statin treatment
  • CHD such as MI
  • stroke a statin treatment for reducing the risk of CVD
  • CHD such as MI
  • stroke detecting the presence or absence of one or more SNP alleles disclosed herein.
  • the presence of a statin response allele disclosed herein in Tables 4-22 is detected and indicates that an individual has an increased risk for developing CVD, such as CHD (e.g., MI) or stroke.
  • CHD e.g., MI
  • this increased risk for developing CVD can be reduced by administering statin treatment to an individual having the allele.
  • the nucleic acid molecules of the invention can be inserted in an expression vector, such as to produce a variant protein in a host cell.
  • an expression vector such as to produce a variant protein in a host cell.
  • the present invention also provides for a vector comprising a SNP-containing nucleic acid molecule, genetically-engineered host cells containing the vector, and methods for expressing a recombinant variant protein using such host cells.
  • the host cells, SNP-containing nucleic acid molecules, and/or variant proteins can be used as targets in a method for screening and identifying therapeutic agents or pharmaceutical compounds useful in the treatment or prevention of CVD, such as CHD (e.g., MI) or stroke.
  • CHD e.g., MI
  • An aspect of this invention is a method for treating or preventing CVD such as CHD or stroke (including, for example, a first occurrence and/or a recurrence of the disease, such as primary or recurrent MI), in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1 and 2, which method comprises administering to said human subject a therapeutically or prophylactically effective amount of one or more agents counteracting the effects of the disease, such as by inhibiting (or stimulating) the activity of a gene, transcript, and/or encoded protein identified in Tables 1 and 2.
  • Another aspect of this invention is a method for identifying an agent useful in therapeutically or prophylactically treating CVD (particularly CHD or stroke), in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1 and 2, which method comprises contacting the gene, transcript, or encoded protein with a candidate agent under conditions suitable to allow formation of a binding complex between the gene, transcript, or encoded protein and the candidate agent and detecting the formation of the binding complex, wherein the presence of the complex identifies said agent.
  • Another aspect of this invention is a method for treating or preventing CVD such as CHD (e.g., MI) or stroke, in a human subject, in which the method comprises:
  • Another aspect of the invention is a method for identifying a human who is likely to benefit from statin treatment, in which the method comprises detecting an allele of one or more SNPs disclosed herein in said human's nucleic acids, wherein the presence of the allele indicates that said human is likely to benefit from statin treatment.
  • Another aspect of the invention is a method for identifying a human who is likely to benefit from statin treatment, in which the method comprises detecting an allele of one or more SNPs that are in LD with one or more SNPs disclosed herein in said human's nucleic acids, wherein the presence of the allele of the LD SNP indicates that said human is likely to benefit from statin treatment.
  • the context sequences generally provide 100 bp upstream (5′) and 100 bp downstream (3′) of each SNP, with the SNP in the middle of the context sequence, for a total of 200 bp of context sequence surrounding each SNP.
  • File SEQLIST_CD000027ORD.txt is 63,960 KB in size, and was created on Apr. 5, 2011.
  • Table 1 and Table 2 (both submitted electronically via EFS-Web as part of the instant application) disclose the SNP and associated gene/transcript/protein information and sequences for the SNPs disclosed in Tables 4-22, as well as for the LD SNPs disclosed in Table 3.
  • Table 1 is based on transcript and protein sequences, whereas Table 2 is based on genomic sequences.
  • Table 1 For each gene, Table 1 provides a header containing gene, transcript and protein information, followed by a transcript and protein sequence identifier (SEQ ID NO), and then SNP information regarding each SNP found in that gene/transcript including the transcript context sequence.
  • SEQ ID NO transcript and protein sequence identifier
  • a header is provided that contains gene and genomic information, followed by a genomic sequence identifier (SEQ ID NO) and then SNP information regarding each SNP found in that gene, including the genomic context sequence.
  • SNP markers may be included in both Table 1 and Table 2; Table 1 presents the SNPs relative to their transcript sequences and encoded protein sequences, whereas Table 2 presents the SNPs relative to their genomic sequences. In some instances Table 2 may also include, after the last gene sequence, genomic sequences of one or more intergenic regions, as well as SNP context sequences and other SNP information for any SNPs that lie within these intergenic regions. Additionally, in either Table 1 or 2, a “Related Interrogated SNP” may be listed following a SNP which is determined to be in LD with that interrogated SNP according to the given Power value.
  • SNPs can be readily cross-referenced between all Tables based on their Celera hCV (or, in some instances, hDV) identification numbers and/or public rs identification numbers, and to the Sequence Listing based on their corresponding SEQ ID NOs.
  • the gene/transcript/protein information includes:
  • transcript/protein entries may be provided for a single gene entry in Table 1; i.e., for a single Gene Number, multiple entries may be provided in series that differ in their transcript/protein information and sequences.
  • transcript context sequence (Table 1), or a genomic context sequence (Table 2), for each SNP within that gene.
  • Table 2 may include additional genomic sequences of intergenic regions (in such instances, these sequences are identified as “Intergenic region:” followed by a numerical identification number), as well as SNP context sequences and other SNP information for any SNPs that lie within each intergenic region (such SNPs are identified as “INTERGENIC” for SNP type).
  • transcript, protein, and transcript-based SNP context sequences are all provided in the Sequence Listing.
  • the transcript-based SNP context sequences are provided in both Table 1 and also in the Sequence Listing.
  • the genomic and genomic-based SNP context sequences are provided in the Sequence Listing.
  • the genomic-based SNP context sequences are provided in both Table 2 and in the Sequence Listing. SEQ ID NOs are indicated in Table 1 for the transcript-based context sequences (SEQ ID NOS:103-176); SEQ ID NOs are indicated in Table 2 for the genomic-based context sequences (SEQ ID NOS:623-3661).
  • the SNP information includes:
  • semicolons separate population/allele/count information corresponding to each indicated SNP source; i.e., if four SNP sources are indicated, such as “Celera,” “dbSNP,” “HGBASE,” and “HGMD,” then population/allele/count information is provided in four groups which are separated by semicolons and listed in the same order as the listing of SNP sources, with each population/allele/count information group corresponding to the respective SNP source based on order; thus, in this example, the first population/allele/count information group would correspond to the first listed SNP source (Celera) and the third population/allele/count information group separated by semicolons would correspond to the third listed SNP source (HGBASE); if population/allele/count information is not available for any particular SNP source, then a pair of semicolons is still inserted as a place-holder in order to maintain correspondence between the list of SNP sources and the corresponding listing of population/allele/count information.
  • SNP sources such as “Celera,” “
  • Table 3 provides a list of linkage disequilibrium (LD) SNPs that are related to and derived from certain interrogated SNPs.
  • the interrogated SNPs which are those SNPs provided in Tables 4-22, are statistically significantly associated with, for example, response to statin treatment for reducing CVD/CHD risk, as described and shown herein.
  • the LD SNPs provided in Table 3 all have an r 2 value at or above 0.9 (which was set as the Threshold r 2 value), and are provided as examples of SNPs which can also be used as markers for, for example, response to statin treatment for reducing risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke) based on their being in high LD with an interrogated statin response-associated SNP.
  • CVD especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke
  • the columns labeled “Interrogated SNP” presents each interrogated SNP as identified by its unique hCV and rs identification number.
  • the columns labeled “LD SNP” presents the hCV and rs numbers of the LD SNPs that are derived from their corresponding interrogated SNPs.
  • the column labeled “Threshold r 2 ” presents the minimum value of r 2 that an LD SNP must meet in reference to an interrogated SNP in order to be included in Table 3 (the Threshold r 2 value is set at 0.9 for all SNPs in Table 3).
  • the column labeled “r 2 ” presents the actual r 2 value of the LD SNP in reference to the interrogated SNP to which it is related (since the Threshold r 2 value is set at 0.9, all SNPs in Table 3 will have an r 2 value at or above 0.9).
  • the criteria for selecting the LD SNPs provided in Table 3 are further described in Example 4 below.
  • Tables 4-22 provide the results of analyses for SNPs disclosed in Tables 1 and 2 (SNPs can be cross-referenced between all the tables herein based on their hCV and/or rs identification numbers). The results shown in Tables 4-22 provide support for the association of these SNPs with, for example, response to statin treatment for reducing the risk of CVD, particularly CHD (e.g., MI) and stroke.
  • CHD e.g., MI
  • Tables 4-7 provides SNPs that had a synergy index (odds ratio) with P value lower than 10 ⁇ 4 in a meta-analysis of CARE and WOSCOPS combined (Table 4-5) or in a meta-analysis of CARE, WOSCOPS, and PROVE-IT combined (Table 6-7), in any genetic model (dominant, recessive, or additive) in either the CHD or CVD endpoint (the CHD or CVD endpoint is indicated in the last column, labeled “Endpoint”, of Tables 4-7, and the genetic model is indicated in the next to last column, labeled “Model”, of Tables 4-7).
  • Tables 4-7 indicate whether the data comes from case-only analysis (“CaseOnly” in the “Source” column) or from analysis of the entire cohort (“cohort” in the “Source” column). Whenever cohort data was available, it was used in the meta-analysis.
  • Tables 4-5 provide meta-analyses of CARE and WOSCOPS combined (2 nd section of each table) for two endpoints (CHD and CVD) and three genetic models (dominant, recessive, and additive), as well as logistic regression analyses of CARE (3 rd section of each table) and WOSCOPS (4 th section of each table) individually.
  • Tables 6-7 provide meta-analyses of CARE, WOSCOPS, and PROVE-IT combined (2 nd section of each table) for two endpoints (CHD and CVD) and three genetic models (dominant, recessive, and additive), as well as logistic regression analyses of CARE (3 rd section of each table), WOSCOPS (4 th section of each table), and PROVE-IT (5 th section of each table) individually.
  • PROVE-IT there was only one endpoint (the composite primary endpoint of the original PROVE-IT study, which includes some stroke cases), and this endpoint was used in meta-analysis of both CHD and CVD.
  • Tables 5 and 7 provide analyses of certain LD SNPs in CARE and WOSCOPS (Table 5) and in CARE, WOSCOPS, and PROVE-IT (Table 7).
  • case-only data was available for a first SNP while cohort data was available for a SNP in LD with the first SNP (LD SNP), which occurred when a working kPCR assay could not be made for the first SNP.
  • LD SNP first SNP
  • the meta-analysis was performed using the cohort data when available.
  • “allele A1” may be interchangeably referred to as the “non-reference allele” (“non-ref”), and “allele A2” may be interchangeably referred to as the “reference allele” (“ref”).
  • the OR's that are indicated in Tables 4-7 correspond to the indicated “non-reference allele” (“allele A1”).
  • OR ⁇ 1 the “non-reference allele” (“allele A1”) is associated with reduction of CVD/CHD risk by statin treatment
  • OR>1 the other alternative allele at the SNP (the “reference allele” or “allele A2”) is associated with reduction of CVD/CHD risk by statin treatment.
  • the counts are indicated in the following format: allele A1 homozygotes/heterozygotes/allele A2 homozygotes. These counts indicate the number of individuals in the pravastatin (“Prava”), placebo, or atorvastatin (“Atorva”) arms of the CARE, WOSCOPS, or PROVE-IT trials (as indicated) who have the corresponding genotypes.
  • P value indicates the p-value
  • OR indicates the odds ratio (synergy index)
  • OR L95 indicates the lower and upper (respectively) 95% confidence interval for the odds ratio
  • Source indicates whether the data comes from case-only analysis (“CaseOnly”) or from analysis of the entire cohort (“cohort”).
  • Tables 9-18 provide additional SNPs associated with response to statin treatment for reducing CVD/CHD risk.
  • Tables 9-18 differ from Tables 4-8 in that Tables 9-18 include SNPs analyzed by imputation as well as by genotyping, whereas all of the SNPs in Tables 4-8 were analyzed by genotyping. Imputation involves imputing the allele/genotype present at a SNP for each individual in the sample set (CARE, WOSCOPS, and PROVE-IT) rather than directly genotyping the SNP in a sample from the individual.
  • the column labeled “Source” in each of Tables 9-18 indicates whether the data presented for each SNP was derived from imputation or from genotyping.
  • Tables 9-18 provide results of analyses of statin response for the same two endpoints as in Tables 4-8 (CHD in Tables 9-13, and CVD in Tables 14-18) and four genetic models (dominant, recessive, additive, and genotypic 2df).
  • Tables 9-18 provide genotyped and imputed SNPs for which the p-value for a random effect was lower than 10 ⁇ 4 for either the meta-analysis of CARE and WOSCOPS combined or the meta-analysis of CARE, WOSCOPS, and PROVE-IT combined, for either the CHD or CVD endpoint, and for any genetic model (dominant, recessive, additive, or genotypic). Association interaction between statin response and either the CHD or CVD phenotype was performed.
  • Tables 9-13 have CHD as an endpoint, whereas Tables 14-18 have CVD as an endpoint (CVD includes CHD and stroke).
  • Tables 9 and 14 provide results of logistic regression analysis of the CARE sample set by direct genotyping and by imputing genotypes.
  • Tables 10 and 15 provide results of logistic regression analysis of the WOSCOPS sample set by direct genotyping and by imputing genotypes.
  • Tables 11 and 16 provide results of logistic regression analysis of the PROVE-IT sample set by direct genotyping and by imputing genotypes.
  • Tables 12 and 17 provide results of meta-analysis of the CARE and WOSCOPS sample sets combined by direct genotyping and by imputing genotypes.
  • Tables 13 and 18 provide results of meta-analysis of the CARE, WOSCOPS, and PROVE-IT sample sets combined by direct genotyping and by imputing genotypes.
  • SOURCE indicates whether each SNP was genotyped (“Genotyped”) or imputed (“Imputed”).
  • ALLELE indicates the allele for which the given data (such as the OR) correspond to, which is also referred to herein as allele “A1” (and the other alternative allele at each SNP, which is not shown in Tables 9-11 and 14-16, but is shown in Tables 1-2 for each SNP, is referred to as allele “A2”).
  • MODEL indicates whether the model was additive (“ADD”), recessive (“REC”), dominant (“DOM”), or genotypic 2df (“GEN”).
  • NMISS indicates the number of genotypes present in the analysis (the number of non-missing genotypes).
  • “OR” indicates the odds ratio (synergy index (SI)). If the odds ratio is less than one for the indicated allele (i.e., allele A1) then this indicates that this allele is associated with statin response (benefit from statin treatment), i.e., fewer CVD or CHD events (e.g., MI) were observed in individuals with this allele in the pravastatin arm of CARE or WOSCOPS or the atorvastatin arm of PROVE-IT, relative to individuals with this allele in the placebo arm of CARE or WOSCOPS or the pravastatin arm of PROVE-IT.
  • SI odds ratio
  • SE indicates standard error of the natural log of the synergy index (the synergy index is the odds ratio, labeled “OR”).
  • STAT is the test statistic used in evaluating the significance of an association in logistic regression analysis. The statistic is equal to the natural log of the synergy index divided by its standard error and follows a Gaussian distribution under the null hypothesis that the synergy index is equal to one.
  • P indicates the p-value (corresponding to a statistical test of whether the synergy index is equal to one)
  • HW_PVALUE indicates the p-value corresponding to a statistical test of whether the distribution of genotypes among subjects in the study agrees with the distribution expected according to Hardy-Weinberg equilibrium.
  • ALLELE_FREQ indicates the allele frequency of the given allele in the analyzed sample set (CARE in Tables 9 and 14; WOSCOPS in Tables 10 and 15; or PROVE-IT in Tables 11 and 16).
  • PRAVA_ALLELE_FREQ indicates the allele frequency of the given allele in the pravastatin or atorvastatin-treated arms (respectively) of the CARE, WOSCOPS, or PROVE-IT trials.
  • “PRAVA_A1_HZ_COUNT”, “PRAVA_HET_COUNT”, and “PRAVA_A2_HZ_COUNT” indicate the number of homozygotes of the allele that is indicated in the table (allele A1), the number of heterozygotes, and the number of homozygotes of the other alternative allele (allele A2) at the SNP, respectively, in the pravastatin arm of the CARE trial (in Tables 9 and 14) or the WOSCOPS trial (in Tables 10 and 15), or in the atorvastatin arm of the PROVE-IT trial (in Tables 11 and 16, in which the column headings labeled “atorvastatin” (“atorva”) are analogous to the column headings labeled “pravastatin” (“prava”) in Tables 9-10 and 14-15).
  • “PLACEBO_A1_HZ_COUNT”, “PLACEBO_HET_COUNT”, and “PLACEBO_A2_HZ_COUNT” indicate the number of homozygotes of the allele that is indicated in the table (allele A1), the number of heterozygotes, and the number of homozygotes of the other alternative allele (allele A2) at the SNP, respectively, in the placebo arm of the CARE trial (in Tables 9 and 14) or the WOSCOPS trial (in Tables 10 and 15), or in the pravastatin arm of the PROVE-IT trial (in Tables 11 and 16, in which the column headings labeled “pravastatin” (“prava”) are analogous to the column headings labeled “placebo” in Tables 9-10 and 14-15).
  • SOURCE indicates whether each SNP was genotyped or imputed.
  • ALLELE indicates the allele for which the given data (such as the OR) correspond to, which is also referred to herein as allele “A1” (and the other alternative allele at each SNP, which is not shown in Tables 12-13 and 17-18, but is shown in Tables 1-2 for each SNP, is referred to as allele “A2”).
  • MODEL indicates whether the model was additive, recessive, dominant, or genotypic.
  • P indicates the p-value
  • P(R) indicates the p-value random effect. Both of these are p-values corresponding to a statistical test of whether the combined synergy index is equal to one but use different assumptions to derive the p-value. “P” is calculated using a fixed effects model, and “P(R)” is calculated using a random effects model.
  • OR indicates the odds ratio (synergy index) calculated from a fixed effects model
  • OR(R) indicates the odds ratio (synergy index) calculated from a random effects model. If the odds ratio is less than one for the indicated allele (i.e., allele A1) then this indicates that this allele is associated with statin response (benefit from statin treatment), i.e., fewer CVD or CHD events (e.g., MI) were observed in individuals with this allele in a combined meta-analysis of the pravastatin arms of CARE and WOSCOPS (Tables 12 and 17) and the atorvastatin arm of PROVE-IT (Tables 13 and 18), relative to individuals with this allele in the placebo arms of CARE and WOSCOPS (Tables 12 and 17) and the pravastatin arm of PROVE-IT (Tables 13 and 18).
  • Q indicates the Cochran Q test p-value, which is a p-value corresponding to the statistical test of the homogeneity of the synergy index across studies (small p-values indicate a greater degree of heterogeneity between studies).
  • I indicates the I 2 heterogeneity index, which can be interpreted as the proportion of total variation in the estimates of effect that is due to heterogeneity between studies.
  • Table 19 shows that SNP rs11556924 (hCV31283062) in the ZC3HC1 gene is associated with differential reduction of CHD risk by pravastatin therapy in both the CARE and WOSCOPS sample sets.
  • Tables 20-22 provide support for the association of these SNPs with CVD risk and/or statin response, particularly risk for stroke and/or response to statin treatment for reducing the risk of stroke (Tables 20-21) and CHD (Table 22).
  • Tables 20-21 provides SNPs associated with stroke risk and/or stroke statin response (reduction in stroke risk by statin treatment) in the CARE sample set. Consistent with the CARE trial, the stroke endpoint in the analysis for which the results are provided in Tables 20-21 included stroke as well as transient ischemic attack (TIA).
  • TIA transient ischemic attack
  • Table 22 provides a SNP associated with CHD statin response in the CARE sample set.
  • Table 22 shows that SNP rs873134 in the B4GALNT3 gene is associated with response to statin treatment for reducing the risk of CHD, particularly recurrent MI.
  • the endpoint was recurrent MI, and the analysis was adjusted for age, gender, hypertension, diabetes, base LDL and HDL, and whether an individual was a current smoker.
  • RESP is for statin response as measured by comparing risk (risk for stroke, including TIA, in Tables 20-21, and risk for CHD, specifically recurrent MI, in Table 22) in the pravastatin-treated group with risk in the placebo-treated group, “PLACEBO” is the placebo-treated group, and “ALL” is the combination of the placebo-treated group and the pravastatin-treated group. “RESP” is the analysis to assess statin response in the indicated genotype group.
  • MODE indicates whether the model was additive (“ADD”), recessive (“REC”), dominant (“DOM”), or genotypic (“GEN”).
  • STATIN indicates either the pravastatin-treated (“Pravastatin”) or placebo-treated (“Placebo”) groups (i.e., arms of the CARE trial).
  • EVENTS indicates the total number of events (stroke or TIA for Tables 20-21, and recurrent MI for Table 22) in individuals with the indicated genotype.
  • TOTAL indicates the total number of individuals with the indicated genotype.
  • “L95” and “U95” indicates the lower and upper (respectively) 95% confidence interval for the hazard ratio.
  • P indicates the p-value
  • P_INT indicates p-interaction
  • P_DF2 indicates two degrees of freedom p-value
  • HW(ALL)pExact (Table 21 only) indicates p exact for Hardy Weinberg Equilibrium for the ALL group.
  • OR refers to the odds ratio
  • HR refers to the hazard ratio
  • OR L95 refers to the lower and upper (respectively) 95% confidence interval for the odds ratio or hazard ratio.
  • drug response e.g., response to a statin
  • the term “benefit” is defined as achieving a reduced risk for a disease that the drug is intended to treat or prevent (e.g., CVD such as CHD, particularly MI) by administering the drug treatment, compared with the risk for the disease in the absence of receiving the drug treatment (or receiving a placebo in lieu of the drug treatment) for the same genotype.
  • an OR or HR that is greater than one indicates that a given allele is a risk allele (which may also be referred to as a susceptibility allele), whereas an OR or HR that is less than one indicates that a given allele is a non-risk allele (which may also be referred to as a protective allele).
  • the other alternative allele at the SNP position (which can be derived from the information provided in Tables 1-2, for example) may be considered a non-risk allele.
  • the other alternative allele at the SNP position may be considered a risk allele.
  • Exemplary embodiments of the present invention provide SNPs associated with response to statin treatment, particularly for reducing the risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke), and methods for their use.
  • the present invention further provides nucleic acid molecules containing these SNPs, methods and reagents for the detection of the SNPs disclosed herein, uses of these SNPs for the development of detection reagents, and assays or kits that utilize such reagents.
  • statin response-associated SNPs disclosed herein are particularly useful for predicting, screening for, and evaluating response to statin treatment, particularly for prevention or treatment of CVD (particularly CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke) using statins, in humans.
  • the SNPs disclosed herein are also useful for diagnosing, prognosing, screening for, and evaluating predisposition to CVD, particularly CHD (such as MI) as well as cerebrovascular events such as stroke, in humans.
  • CHD such as MI
  • cerebrovascular events such as stroke
  • SNPs and their encoded products are useful targets for the development of therapeutic and preventive agents.
  • exemplary embodiments of the present invention provide individual SNPs associated with response to statin treatments, particularly for reducing the risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke), as well as combinations of SNPs and haplotypes, polymorphic/variant transcript sequences (SEQ ID NOS:1-51) and genomic sequences (SEQ ID NOS:177-622) containing SNPs, encoded amino acid sequences (SEQ ID NOS:52-102), and both transcript-based SNP context sequences (SEQ ID NOS:103-176) and genomic-based SNP context sequences (SEQ ID NOS:623-3661) (transcript sequences, protein sequences, and transcript-based SNP context sequences are provided in Table 1 and the Sequence Listing; genomic sequences and genomic-based SNP context sequences are provided in Table 2 and the Sequence Listing), methods of detecting these polymorphisms in a test sample, methods of determining if an individual is likely to respond to a particular treatment
  • Exemplary embodiments of the present invention further provide methods for selecting or formulating a treatment regimen (e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for developing CVD in the future, or who has previously had CVD, methods for selecting a particular statin-based treatment regimen such as dosage and frequency of administration of statin, or a particular form/type of statin such as a particular pharmaceutical formulation or statin compound, methods for administering (either in addition to or instead of a statin) an alternative, non-statin-based treatment, such as niacin, fibrates, or ezetimibe (e.g., Zetia® or Ezetrol®), to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and methods for determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, etc.
  • a treatment regimen e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for
  • the present invention also provides methods for selecting individuals to whom a statin or other therapeutic will be administered based on the individual's genotype, and methods for selecting individuals for a clinical trial of a statin or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s), or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them).
  • selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s) or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them).
  • Exemplary embodiments of the present invention may include novel SNPs associated with response to statin treatment, as well as SNPs that were previously known in the art, but were not previously known to be associated with response to statin treatment. Accordingly, the present invention may provide novel compositions and methods based on novel SNPs disclosed herein, and may also provide novel methods of using known, but previously unassociated, SNPs in methods relating to, for example, methods relating to evaluating an individual's likelihood of responding to statin treatment (particularly statin treatment, including preventive treatment, of CVD, such as CHD or stroke), evaluating an individual's likelihood of having or developing CVD (particularly CHD or stroke), and predicting the likelihood of an individual experiencing a reccurrence of CVD (e.g., experiencing recurrent MI).
  • dbSNP SNP observed in dbSNP
  • HGBASE SNP observed in HGBASE
  • HGMD SNP observed in the Human Gene Mutation Database
  • Particular alleles of the SNPs disclosed herein can be associated with either an increased likelihood of responding to statin treatment (particularly for reducing the risk of CVD, such as CHD (e.g., MI) or stroke) or increased risk of developing CVD (e.g., CHD or stroke), or a decreased likelihood of responding to statin treatment or a decreased risk of developing CVD.
  • CVD e.g., MI
  • CHD e.g., MI
  • stroke e.g., CHD or stroke
  • CHD e.g., CHD or stroke
  • SNPs or their encoded products
  • other SNPs can be assayed to determine whether an individual possesses a SNP allele that is indicative of a decreased likelihood of responding to statin treatment or a decreased risk of developing CVD.
  • particular alleles of the SNPs disclosed herein can be associated with either an increased or decreased likelihood of having a reccurrence of CVD (e.g., recurrent MI), etc.
  • the term “altered” may be used herein to encompass either of these two possibilities (e.g., either an increased or a decreased likelihood/risk).
  • SNP alleles that are associated with increased response to statin treatment for reducing CVD risk may be referred to as “response” alleles
  • SNP alleles that are associated with a lack of response to statin treatment may be referred to as “non-response” alleles
  • SNP alleles that are associated with an increased risk of having or developing CVD may be referred to as “risk” or “susceptibility” alleles
  • SNP alleles that are associated with a decreased risk of having or developing CVD may be referred to as “non-risk” or “protective” alleles.
  • the presence of a statin response allele disclosed herein in Tables 4-22 is detected and indicates that an individual has an increased risk for developing CVD, such as CHD (e.g., MI) or stroke.
  • CHD e.g., MI
  • this increased risk for developing CVD can be reduced by administering statin treatment to an individual having the allele.
  • nucleic acid molecules may be double-stranded molecules and that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand.
  • reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule.
  • probes and primers may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand.
  • SNP genotyping methods disclosed herein may generally target either strand.
  • references to variant peptides, polypeptides, or proteins of the present invention include peptides, polypeptides, proteins, or fragments thereof, that contain at least one amino acid residue that differs from the corresponding amino acid sequence of the art-known peptide/polypeptide/protein (the art-known protein may be interchangeably referred to as the “wild-type,” “reference,” or “normal” protein).
  • Such variant peptides/polypeptides/proteins can result from a codon change caused by a nonsynonymous nucleotide substitution at a protein-coding SNP position (i.e., a missense mutation) disclosed by the present invention.
  • Variant peptides/polypeptides/proteins of the present invention can also result from a nonsense mutation (i.e., a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon), or due to any SNP disclosed by the present invention that otherwise alters the structure, function, activity, or expression of a protein, such as a SNP in a regulatory region (e.g. a promoter or enhancer) or a SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary.
  • a nonsense mutation i.e., a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon
  • any SNP disclosed by the present invention that otherwise alters the structure, function, activity, or expression of a protein, such as a SNP in a regulatory region (e.g
  • an “allele” may refer to a nucleotide at a SNP position (wherein at least two alternative nucleotides exist in the population at the SNP position, in accordance with the inherent definition of a SNP) or may refer to an amino acid residue that is encoded by the codon which contains the SNP position (where the alternative nucleotides that are present in the population at the SNP position form alternative codons that encode different amino acid residues).
  • An “allele” may also be referred to herein as a “variant”.
  • an amino acid residue that is encoded by a codon containing a particular SNP may simply be referred to as being encoded by the SNP.
  • a phrase such as “as represented by”, “as shown by”, “as symbolized by”, or “as designated by” may be used herein to refer to a SNP within a sequence (e.g., a polynucleotide context sequence surrounding a SNP), such as in the context of “a polymorphism as represented by position 101 of SEQ ID NO:X or its complement”.
  • a sequence surrounding a SNP may be recited when referring to a SNP, however the sequence is not intended as a structural limitation beyond the specific SNP position itself.
  • sequence is recited merely as a way of referring to the SNP (in this example, “SEQ ID NO:X or its complement” is recited in order to refer to the SNP located at position 101 of SEQ ID NO:X, but SEQ ID NO:X or its complement is not intended as a structural limitation beyond the specific SNP position itself).
  • SEQ ID NO:X in this example may contain one or more polymorphic nucleotide positions outside of position 101 and therefore an exact match over the full-length of SEQ ID NO:X is irrelevant since SEQ ID NO:X is only meant to provide context for referring to the SNP at position 101 of SEQ ID NO:X.
  • the length of the context sequence is also irrelevant (100 nucleotides on each side of a SNP position has been arbitrarily used in the present application as the length for context sequences merely for convenience and because 201 nucleotides of total length is expected to provide sufficient uniqueness to unambiguously identify a given nucleotide sequence).
  • a SNP is a variation at a single nucleotide position, it is customary to refer to context sequence (e.g., SEQ ID NO:X in this example) surrounding a particular SNP position in order to uniquely identify and refer to the SNP.
  • a SNP can be referred to by a unique identification number such as a public “rs” identification number or an internal “hCV” identification number, such as provided herein for each SNP (e.g., in Tables 1-2).
  • rs11556924”, “hCV31283062”, and “position 101 of SEQ ID NO:1074” all refer to the same SNP.
  • the term “benefit” (with respect to a preventive or therapeutic drug treatment, such as statin treatment) is defined as achieving a reduced risk for a disease that the drug is intended to treat or prevent (e.g., CVD such as CHD (particularly MI) or stroke) by administrating the drug treatment, compared with the risk for the disease in the absence of receiving the drug treatment (or receiving a placebo in lieu of the drug treatment) for the same genotype.
  • CVD cardiovascular disease
  • CHD particularly MI
  • stroke a reduced risk for the disease in the absence of receiving the drug treatment
  • the term “benefit” may be used herein interchangeably with terms such as “respond positively” or “positively respond”.
  • drug and “therapeutic agent” are used interchangeably, and may include, but are not limited to, small molecule compounds, biologics (e.g., antibodies, proteins, protein fragments, fusion proteins, glycoproteins, etc.), nucleic acid agents (e.g., antisense, RNAi/siRNA, and microRNA molecules, etc.), vaccines, etc., which may be used for therapeutic and/or preventive treatment of a disease (e.g., CVD such as CHD or stroke).
  • biologics e.g., antibodies, proteins, protein fragments, fusion proteins, glycoproteins, etc.
  • nucleic acid agents e.g., antisense, RNAi/siRNA, and microRNA molecules, etc.
  • vaccines etc., which may be used for therapeutic and/or preventive treatment of a disease (e.g., CVD such as CHD or stroke).
  • CVD such as CHD or stroke.
  • statins also known as HMG-CoA reductase inhibitors
  • examples of statins include, but are not limited to, atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), simvastatin (Zocor®), fluvastatin (Lescol®), and lovastatin (Mevacor®), as well as combination therapies that include a statin such as simvastatin+ezetimibe (Vytorin®), lovastatin+niacin (Advicor®), atorvastatin+amlodipine besylate (Caduet®), and simvastatin+niacin (Simcor®).
  • compositions and uses (1) a reagent (such as an allele-specific probe or primer, or any other oligonucleotide or other reagent suitable for detecting a polymorphism disclosed herein, which can include detection of any allele of the polymorphism) for use as a diagnostic or predictive agent for determining statin response, particularly for reducing the risk of CVD such as CHD (e.g., MI) or stroke (and/or for determining risk for developing CVD); (2) a kit, device, array, or assay component that includes or is coupled with the reagent of (1) above for use in determining statin response, particularly for reducing the risk of CVD (and/or for determining risk for developing CVD); (3) the use of the reagent of (1) above for the manufacture of a kit, device, array, or assay component for determining statin response, particularly for reducing the risk of CVD (and/or for determining risk for CVD); and (4) the use of a polymorphism
  • the various methods described herein such as correlating the presence or absence of a polymorphism with the predicted response of an individual to a drug such as a statin, particularly for reducing the risk for CVD such as CHD (e.g., MI) or stroke (and/or correlating the presence or absence of a polymorphism with an altered (e.g., increased or decreased) risk (or no altered risk) for developing CVD), can be carried out by automated methods such as by using a computer (or other apparatus/devices such as biomedical devices, laboratory instrumentation, or other apparatus/devices having a computer processor) programmed to carry out any of the methods described herein.
  • a computer or other apparatus/devices such as biomedical devices, laboratory instrumentation, or other apparatus/devices having a computer processor programmed to carry out any of the methods described herein.
  • computer software (which may be interchangeably referred to herein as a computer program) can perform the step of correlating the presence or absence of a polymorphism in an individual with an altered (e.g., increased or decreased) response (or no altered response) to statin treatment, particularly for reducing the risk for CVD such as CHD (e.g., MI) or stroke.
  • CVD e.g., MI
  • certain embodiments of the invention provide a computer (or other apparatus/device) programmed to carry out any of the methods described herein.
  • results of a test e.g., an individual's predicted responsiveness to statin treatment for reducing CVD risk, or an individual's risk for developing CVD, based on assaying one or more SNPs disclosed herein, and/or an individual's allele(s)/genotype at one or more SNPs disclosed herein, etc.
  • a report A tangible report can optionally be generated as part of a testing process (which may be interchangeably referred to herein as “reporting”, or as “providing” a report, “producing” a report, or “generating” a report).
  • Examples of tangible reports may include, but are not limited to, reports in paper (such as computer-generated printouts of test results) or equivalent formats and reports stored on computer readable medium (such as a CD, USB flash drive or other removable storage device, computer hard drive, or computer network server, etc.). Reports, particularly those stored on computer readable medium, can be part of a database, which may optionally be accessible via the internet (such as a database of patient records or genetic information stored on a computer network server, which may be a “secure database” that has security features that limit access to the report, such as to allow only the patient and the patient's medical practioners to view the report while preventing other unauthorized individuals from viewing the report, for example). In addition to, or as an alternative to, generating a tangible report, reports can also be displayed on a computer screen (or the display of another electronic device or instrument).
  • a report can include, for example, an individual's predicted responsiveness to statin treatment (e.g., whether the individual will benefit from statin treatment by having their risk for CVD, particularly CHD (e.g., MI) or stroke, reduced), or may just include the allele(s)/genotype that an individual carries at one or more SNPs disclosed herein, which may optionally be linked to information regarding the significance of having the allele(s)/genotype at the SNP (for example, a report on computer readable medium such as a network server may include hyperlink(s) to one or more journal publications or websites that describe the medical/biological implications, such as statin response and/or CVD risk, for individuals having a certain allele/genotype at the SNP).
  • the report can include drug responsiveness, disease risk, and/or other medical/biological significance, as well as optionally also including the allele/genotype information, or the report may just include allele/genotype information without including drug responsiveness, disease risk, or other medical/biological significance (such that an individual viewing the report can use the allele/genotype information to determine the associated drug response, disease risk, or other medical/biological significance from a source outside of the report itself, such as from a medical practioner, publication, website, etc., which may optionally be linked to the report such as by a hyperlink).
  • a report can further be “transmitted” or “communicated” (these terms may be used herein interchangeably), such as to the individual who was tested, a medical practitioner (e.g., a doctor, nurse, clinical laboratory practitioner, genetic counselor, etc.), a healthcare organization, a clinical laboratory, and/or any other party or requester intended to view or possess the report.
  • the act of “transmitting” or “communicating” a report can be by any means known in the art, based on the format of the report.
  • “transmitting” or “communicating” a report can include delivering/sending a report (“pushing”) and/or retrieving (“pulling”) a report.
  • reports can be transmitted/communicated by various means, including being physically transferred between parties (such as for reports in paper format) such as by being physically delivered from one party to another, or by being transmitted electronically or in signal form (e.g., via e-mail or over the internet, by facsimile, and/or by any wired or wireless communication methods known in the art) such as by being retrieved from a database stored on a computer network server, etc.
  • parties such as for reports in paper format
  • signals form e.g., via e-mail or over the internet, by facsimile, and/or by any wired or wireless communication methods known in the art
  • the invention provides computers (or other apparatus/devices such as biomedical devices or laboratory instrumentation) programmed to carry out the methods described herein.
  • the invention provides a computer programmed to receive (i.e., as input) the identity (e.g., the allele(s) or genotype at a SNP) of one or more SNPs disclosed herein and provide (i.e., as output) the predicted drug responsiveness or disease risk (e.g., an individual's predicted statin responsiveness or risk for developing CVD) or other result based on the identity of the SNP(s).
  • the identity e.g., the allele(s) or genotype at a SNP
  • the predicted drug responsiveness or disease risk e.g., an individual's predicted statin responsiveness or risk for developing CVD
  • Such output may be, for example, in the form of a report on computer readable medium, printed in paper form, and/or displayed on a computer screen or other display.
  • exemplary methods of doing business can comprise assaying one or more SNPs disclosed herein and providing a report that includes, for example, a customer's predicted response to statin treatment (e.g., for reducing their risk for CVD, particularly CHD (such as MI) or stroke) or their risk for developing CVD (based on which allele(s)/genotype is present at the assayed SNP(s)) and/or that includes the allele(s)/genotype at the assayed SNP(s) which may optionally be linked to information (e.g., journal publications, websites, etc.) pertaining to disease risk or other biological/medical significance such as by means of a hyperlink (the report may be provided, for example, on a computer network server or other computer readable medium that is internet-accessible, and the report may be included in a secure database
  • Customers can request/order (e.g., purchase) the test online via the internet (or by phone, mail order, at an outlet/store, etc.), for example, and a kit can be sent/delivered (or otherwise provided) to the customer (or another party on behalf of the customer, such as the customer's doctor, for example) for collection of a biological sample from the customer (e.g., a buccal swab for collecting buccal cells), and the customer (or a party who collects the customer's biological sample) can submit their biological samples for assaying (e.g., to a laboratory or party associated with the laboratory such as a party that accepts the customer samples on behalf of the laboratory, a party for whom the laboratory is under the control of (e.g., the laboratory carries out the assays by request of the party or under a contract with the party, for example), and/or a party that receives at least a portion of the customer's
  • assaying e.g., to a laboratory or party associated with the laboratory
  • the report (e.g., results of the assay including, for example, the customer's disease risk and/or allele(s)/genotype at the assayed SNP(s)) may be provided to the customer by, for example, the laboratory that assays the SNP(s) or a party associated with the laboratory (e.g., a party that receives at least a portion of the customer's payment for the assay, or a party that requests the laboratory to carry out the assays or that contracts with the laboratory for the assays to be carried out) or a doctor or other medical practitioner who is associated with (e.g., employed by or having a consulting or contracting arrangement with) the laboratory or with a party associated with the laboratory, or the report may be provided to a third party (e.g., a doctor, genetic counselor, hospital, etc.) which optionally provides the report to the customer.
  • a third party e.g., a doctor, genetic counselor, hospital, etc.
  • the customer may be a doctor or other medical practitioner, or a hospital, laboratory, medical insurance organization, or other medical organization that requests/orders (e.g., purchases) tests for the purposes of having other individuals (e.g., their patients or customers) assayed for one or more SNPs disclosed herein and optionally obtaining a report of the assay results.
  • a kit for collecting a biological sample (e.g., a buccal swab for collecting buccal cells, or other sample collection device) is provided to a medical practitioner (e.g., a physician) which the medical practitioner uses to obtain a sample (e.g., buccal cells, saliva, blood, etc.) from a patient, the sample is then sent to a laboratory (e.g., a CLIA-certified laboratory) or other facility that tests the sample for one or more SNPs disclosed herein (e.g., to determine the genotype of one or more SNPs disclosed herein, such as to determine the patient's predicted response to statin treatment for reducing their risk for CVD, particularly CHD (such as MI) or stroke, and/or their risk for developing CVD), and the results of the test (e.g., the patient's genotype at one or more SNPs disclosed herein and/or the patient's predicted statin response or CVD risk based on their SNP genotype) are provided to a laboratory (e.g
  • kits for collecting a biological sample from a customer are provided (e.g., for sale), such as at an outlet (e.g., a drug store, pharmacy, general merchandise store, or any other desirable outlet), online via the internet, by mail order, etc., whereby customers can obtain (e.g., purchase) the kits, collect their own biological samples, and submit (e.g., send/deliver via mail) their samples to a laboratory (e.g., a CLIA-certified laboratory) or other facility which tests the samples for one or more SNPs disclosed herein (e.g., to determine the genotype of one or more SNPs disclosed herein, such as to determine the customer's predicted response to statin treatment for reducing their risk for CVD, particularly CHD (e.g., MI) or stroke, and/or their risk for developing CVD) and provides the results of the test (e.g.
  • results are typically provided in the form of a report, such as described above.
  • this third party may optionally provide another report to the customer based on the results of the test (e.g., the result of the test from the laboratory may provide the customer's genotype at one or more SNPs disclosed herein without statin response or CVD risk information, and the third party may provide a report of the customer's statin response or CVD risk based on this genotype result).
  • Certain further embodiments of the invention provide a system for determining whether an individual will benefit from statin treatment (or other therapy) in reducing CVD risk (particularly risk for CHD (such as MI) or stroke), or for determining an individual's risk for developing CVD.
  • Certain exemplary systems comprise an integrated “loop” in which an individual (or their medical practitioner) requests a determination of such individual's predicted statin response (or CVD risk, etc.), this determination is carried out by testing a sample from the individual, and then the results of this determination are provided back to the requestor.
  • a sample e.g., buccal cells, saliva, blood, etc.
  • the sample may be obtained by the individual or, for example, by a medical practitioner
  • the sample is submitted to a laboratory (or other facility) for testing (e.g., determining the genotype of one or more SNPs disclosed herein)
  • the results of the testing are sent to the patient (which optionally can be done by first sending the results to an intermediary, such as a medical practioner, who then provides or otherwise conveys the results to the individual and/or acts on the results), thereby forming an integrated loop system for determining an individual's predicted statin response (or CVD risk, etc.).
  • the portions of the system in which the results are transmitted can be carried out by way of electronic or signal transmission (e.g., by computer such as via e-mail or the internet, by providing the results on a website or computer network server which may optionally be a secure database, by phone or fax, or by any other wired or wireless transmission methods known in the art).
  • the system can further include a risk reduction component (i.e., a disease management system) as part of the integrated loop (for an example of a disease management system, see U.S. Pat. No. 6,770,029, “Disease management system and method including correlation assessment”).
  • the results of the test can be used to reduce the risk of the disease in the individual who was tested, such as by implementing a preventive therapy regimen (e.g., administration of a statin or other drug for reducing CVD risk), modifying the individual's diet, increasing exercise, reducing stress, and/or implementing any other physiological or behavioral modifications in the individual with the goal of reducing disease risk.
  • a preventive therapy regimen e.g., administration of a statin or other drug for reducing CVD risk
  • modifying the individual's diet increasing exercise, reducing stress, and/or implementing any other physiological or behavioral modifications in the individual with the goal of reducing disease risk.
  • reducing CVD risk this may include any means used in the art for improving aspects of an individual's health relevant to reducing CVD risk.
  • the system is controlled by the individual and/or their medical practioner in that the individual and/or their medical practioner requests the test, receives the test results back, and (optionally) acts on the test results to reduce the individual's disease risk, such as by implementing a disease management system.
  • Tables 1 and 2 provide a variety of information about each SNP of the present invention that is associated with response to statin treatment, particularly for reducing an individual's risk for CVD such as CHD (e.g., MI) or stroke, including the transcript sequences (SEQ ID NOS:1-51), genomic sequences (SEQ ID NOS:177-622), and protein sequences (SEQ ID NOS:52-102) of the encoded gene products (with the SNPs indicated by IUB codes in the nucleic acid sequences).
  • CHD e.g., MI
  • stroke including the transcript sequences (SEQ ID NOS:1-51), genomic sequences (SEQ ID NOS:177-622), and protein sequences (SEQ ID NOS:52-102) of the encoded gene products (with the SNPs indicated by IUB codes in the nucleic acid sequences).
  • Tables 1 and 2 include SNP context sequences, which generally include 100 nucleotide upstream (5′) plus 100 nucleotides downstream (3′) of each SNP position (SEQ ID NOS:103-176 correspond to transcript-based SNP context sequences disclosed in Table 1, and SEQ ID NOS:623-3661 correspond to genomic-based context sequences disclosed in Table 2), the alternative nucleotides (alleles) at each SNP position, and additional information about the variant where relevant, such as SNP type (coding, missense, splice site, UTR, etc.), human populations in which the SNP was observed, observed allele frequencies, information about the encoded protein, etc.
  • SNP context sequences generally include 100 nucleotide upstream (5′) plus 100 nucleotides downstream (3′) of each SNP position (SEQ ID NOS:103-176 correspond to transcript-based SNP context sequences disclosed in Table 1, and SEQ ID NOS:623-3661 correspond to genomic-based context sequences disclosed in Table 2), the alternative nucleo
  • Exemplary embodiments of the invention provide isolated nucleic acid molecules that contain one or more SNPs disclosed herein, particularly SNPs disclosed in Table 1 and/or Table 2.
  • Isolated nucleic acid molecules containing one or more SNPs disclosed herein may be interchangeably referred to throughout the present text as “SNP-containing nucleic acid molecules.”
  • Isolated nucleic acid molecules may optionally encode a full-length variant protein or fragment thereof.
  • the isolated nucleic acid molecules of the present invention also include probes and primers (which are described in greater detail below in the section entitled “SNP Detection Reagents”), which may be used for assaying the disclosed SNPs, and isolated full-length genes, transcripts, cDNA molecules, and fragments thereof, which may be used for such purposes as expressing an encoded protein.
  • probes and primers which are described in greater detail below in the section entitled “SNP Detection Reagents”
  • an “isolated nucleic acid molecule” generally is one that contains a SNP of the present invention or one that hybridizes to such molecule such as a nucleic acid with a complementary sequence, and is separated from most other nucleic acids present in the natural source of the nucleic acid molecule.
  • an “isolated” nucleic acid molecule, such as a cDNA molecule containing a SNP of the present invention can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
  • a nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered “isolated.” Nucleic acid molecules present in non-human transgenic animals, which do not naturally occur in the animal, are also considered “isolated.” For example, recombinant DNA molecules contained in a vector are considered “isolated.” Further examples of “isolated” DNA molecules include recombinant DNA molecules maintained in heterologous host cells, and purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated SNP-containing DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
  • an isolated SNP-containing nucleic acid molecule comprises one or more SNP positions disclosed by the present invention with flanking nucleotide sequences on either side of the SNP positions.
  • a flanking sequence can include nucleotide residues that are naturally associated with the SNP site and/or heterologous nucleotide sequences.
  • the flanking sequence is up to about 500, 300, 100, 60, 50, 30, 25, 20, 15, 10, 8, or 4 nucleotides (or any other length in-between) on either side of a SNP position, or as long as the full-length gene or entire protein-coding sequence (or any portion thereof such as an exon), especially if the SNP-containing nucleic acid molecule is to be used to produce a protein or protein fragment.
  • a SNP flanking sequence can be, for example, up to about 5 KB, 4 KB, 3 KB, 2 KB, 1 KB on either side of the SNP.
  • the isolated nucleic acid molecule comprises exonic sequences (including protein-coding and/or non-coding exonic sequences), but may also include intronic sequences.
  • any protein coding sequence may be either contiguous or separated by introns.
  • nucleic acid is isolated from remote and unimportant flanking sequences and is of appropriate length such that it can be subjected to the specific manipulations or uses described herein such as recombinant protein expression, preparation of probes and primers for assaying the SNP position, and other uses specific to the SNP-containing nucleic acid sequences.
  • An isolated SNP-containing nucleic acid molecule can comprise, for example, a full-length gene or transcript, such as a gene isolated from genomic DNA (e.g., by cloning or PCR amplification), a cDNA molecule, or an mRNA transcript molecule.
  • Polymorphic transcript sequences are referred to in Table 1 and provided in the Sequence Listing (SEQ ID NOS:1-51), and polymorphic genomic sequences are referred to in Table 2 and provided in the Sequence Listing (SEQ ID NOS:177-622).
  • fragments of such full-length genes and transcripts that contain one or more SNPs disclosed herein are also encompassed by the present invention, and such fragments may be used, for example, to express any part of a protein, such as a particular functional domain or an antigenic epitope.
  • the present invention also encompasses fragments of the nucleic acid sequences as disclosed in Tables 1 and 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661) and their complements.
  • the actual sequences referred to in the tables are provided in the Sequence Listing.
  • a fragment typically comprises a contiguous nucleotide sequence at least about 8 or more nucleotides, more preferably at least about 12 or more nucleotides, and even more preferably at least about 16 or more nucleotides.
  • a fragment could comprise at least about 18, 20, 22, 25, 30, 40, 50, 60, 80, 100, 150, 200, 250 or 500 nucleotides in length (or any other number in between).
  • the length of the fragment will be based on its intended use.
  • the fragment can encode epitope-bearing regions of a variant peptide or regions of a variant peptide that differ from the normal/wild-type protein, or can be useful as a polynucleotide probe or primer.
  • Such fragments can be isolated using the nucleotide sequences provided in Table 1 and/or Table 2 for the synthesis of a polynucleotide probe.
  • a labeled probe can then be used, for example, to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region.
  • primers can be used in amplification reactions, such as for purposes of assaying one or more SNPs sites or for cloning specific regions of a gene.
  • An isolated nucleic acid molecule of the present invention further encompasses a SNP-containing polynucleotide that is the product of any one of a variety of nucleic acid amplification methods, which are used to increase the copy numbers of a polynucleotide of interest in a nucleic acid sample.
  • amplification methods are well known in the art, and they include but are not limited to, polymerase chain reaction (PCR) (U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Technology: Principles and Applications for DNA Amplification, ed. H. A. Erlich, Freeman Press, NY, N.Y.
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • TMA transcription-mediated amplification
  • LMA linked linear amplification
  • an “amplified polynucleotide” of the invention is a SNP-containing nucleic acid molecule whose amount has been increased at least two fold by any nucleic acid amplification method performed in vitro as compared to its starting amount in a test sample.
  • an amplified polynucleotide is the result of at least ten fold, fifty fold, one hundred fold, one thousand fold, or even ten thousand fold increase as compared to its starting amount in a test sample.
  • a polynucleotide of interest is often amplified at least fifty thousand fold in amount over the unamplified genomic DNA, but the precise amount of amplification needed for an assay depends on the sensitivity of the subsequent detection method used.
  • an amplified polynucleotide is at least about 16 nucleotides in length. More typically, an amplified polynucleotide is at least about 20 nucleotides in length. In a preferred embodiment of the invention, an amplified polynucleotide is at least about 30 nucleotides in length. In a more preferred embodiment of the invention, an amplified polynucleotide is at least about 32, 40, 45, 50, or 60 nucleotides in length. In yet another preferred embodiment of the invention, an amplified polynucleotide is at least about 100, 200, 300, 400, or 500 nucleotides in length.
  • an amplified product of the invention can be as long as an exon, an intron or the entire gene where the SNP of interest resides, an amplified product is typically up to about 1,000 nucleotides in length (although certain amplification methods may generate amplified products greater than 1000 nucleotides in length). More preferably, an amplified polynucleotide is not greater than about 600-700 nucleotides in length. It is understood that irrespective of the length of an amplified polynucleotide, a SNP of interest may be located anywhere along its sequence.
  • the amplified product is at least about 201 nucleotides in length, comprises one of the transcript-based context sequences or the genomic-based context sequences shown in Tables 1 and 2. Such a product may have additional sequences on its 5′ end or 3′ end or both. In another embodiment, the amplified product is about 101 nucleotides in length, and it contains a SNP disclosed herein.
  • the SNP is located at the middle of the amplified product (e.g., at position 101 in an amplified product that is 201 nucleotides in length, or at position 51 in an amplified product that is 101 nucleotides in length), or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or 20 nucleotides from the middle of the amplified product.
  • the SNP of interest may be located anywhere along the length of the amplified product.
  • the present invention provides isolated nucleic acid molecules that comprise, consist of, or consist essentially of one or more polynucleotide sequences that contain one or more SNPs disclosed herein, complements thereof, and SNP-containing fragments thereof.
  • nucleic acid molecules that consist of any of the nucleotide sequences shown in Table 1 and/or Table 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins referred to in Table 1 (SEQ ID NOS:52-102).
  • the actual sequences referred to in the tables are provided in the Sequence Listing.
  • a nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.
  • the present invention further provides nucleic acid molecules that consist essentially of any of the nucleotide sequences referred to in Table 1 and/or Table 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins referred to in Table 1 (SEQ ID NOS:52-102).
  • the actual sequences referred to in the tables are provided in the Sequence Listing.
  • a nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleotide residues in the final nucleic acid molecule.
  • the present invention further provides nucleic acid molecules that comprise any of the nucleotide sequences shown in Table 1 and/or Table 2 or a SNP-containing fragment thereof (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins provided in Table 1 (SEQ ID NOS:52-102).
  • the actual sequences referred to in the tables are provided in the Sequence Listing.
  • a nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule.
  • the nucleic acid molecule can be only the nucleotide sequence or have additional nucleotide residues, such as residues that are naturally associated with it or heterologous nucleotide sequences.
  • Such a nucleic acid molecule can have one to a few additional nucleotides or can comprise many more additional nucleotides.
  • the isolated nucleic acid molecules can encode mature proteins plus additional amino or carboxyl-terminal amino acids or both, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life, or facilitate manipulation of a protein for assay or production. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.
  • the isolated nucleic acid molecules include, but are not limited to, nucleic acid molecules having a sequence encoding a peptide alone, a sequence encoding a mature peptide and additional coding sequences such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), a sequence encoding a mature peptide with or without additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but untranslated sequences that play a role in, for example, transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding, and/or stability of mRNA.
  • the nucleic acid molecules may be fused to heterologous marker sequences encoding, for example, a peptide that facilitates purification.
  • Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA, which may be obtained, for example, by molecular cloning or produced by chemical synthetic techniques or by a combination thereof. Sambrook and Russell, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Press, N.Y. (2000).
  • isolated nucleic acid molecules particularly SNP detection reagents such as probes and primers, can also be partially or completely in the form of one or more types of nucleic acid analogs, such as peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • the nucleic acid can be double-stranded or single-stranded.
  • Single-stranded nucleic acid can be the coding strand (sense strand) or the complementary non-coding strand (anti-sense strand).
  • DNA, RNA, or PNA segments can be assembled, for example, from fragments of the human genome (in the case of DNA or RNA) or single nucleotides, short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic nucleic acid molecule.
  • Nucleic acid molecules can be readily synthesized using the sequences provided herein as a reference; oligonucleotide and PNA oligomer synthesis techniques are well known in the art.
  • oligonucleotide/PNA synthesis can readily be accomplished using commercially available nucleic acid synthesizers, such as the Applied Biosystems (Foster City, Calif.) 3900 High-Throughput DNA Synthesizer or Expedite 8909 Nucleic Acid Synthesis System, and the sequence information provided herein.
  • the present invention encompasses nucleic acid analogs that contain modified, synthetic, or non-naturally occurring nucleotides or structural elements or other alternative/modified nucleic acid chemistries known in the art.
  • nucleic acid analogs are useful, for example, as detection reagents (e.g., primers/probes) for detecting one or more SNPs identified in Table 1 and/or Table 2.
  • detection reagents e.g., primers/probes
  • kits/systems such as beads, arrays, etc.
  • PNA oligomers that are based on the polymorphic sequences of the present invention are specifically contemplated.
  • PNA oligomers are analogs of DNA in which the phosphate backbone is replaced with a peptide-like backbone.
  • PNA hybridizes to complementary RNA or DNA with higher affinity and specificity than conventional oligonucleotides and oligonucleotide analogs.
  • the properties of PNA enable novel molecular biology and biochemistry applications unachievable with traditional oligonucleotides and peptides.
  • nucleic acid modifications that improve the binding properties and/or stability of a nucleic acid include the use of base analogs such as inosine, intercalators (U.S. Pat. No. 4,835,263) and the minor groove binders (U.S. Pat. No. 5,801,115).
  • references herein to nucleic acid molecules, SNP-containing nucleic acid molecules, SNP detection reagents (e.g., probes and primers), oligonucleotides/polynucleotides include PNA oligomers and other nucleic acid analogs.
  • Other examples of nucleic acid analogs and alternative/modified nucleic acid chemistries known in the art are described in Current Protocols in Nucleic Acid Chemistry , John Wiley & Sons, N.Y. (2002).
  • the present invention further provides nucleic acid molecules that encode fragments of the variant polypeptides disclosed herein as well as nucleic acid molecules that encode obvious variants of such variant polypeptides.
  • Such nucleic acid molecules may be naturally occurring, such as paralogs (different locus) and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis.
  • Non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms.
  • the variants can contain nucleotide substitutions, deletions, inversions and insertions (in addition to the SNPs disclosed in Tables 1 and 2). Variation can occur in either or both the coding and non-coding regions. The variations can produce conservative and/or non-conservative amino acid substitutions.
  • nucleic acid molecules disclosed in Tables 1 and 2 such as naturally occurring allelic variants (as well as orthologs and paralogs) and synthetic variants produced by mutagenesis techniques, can be identified and/or produced using methods well known in the art.
  • Such further variants can comprise a nucleotide sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a nucleic acid sequence disclosed in Table 1 and/or Table 2 (or a fragment thereof) and that includes a novel SNP allele disclosed in Table 1 and/or Table 2.
  • variants can comprise a nucleotide sequence that encodes a polypeptide that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a polypeptide sequence disclosed in Table 1 (or a fragment thereof) and that includes a novel SNP allele disclosed in Table 1 and/or Table 2.
  • a polypeptide sequence disclosed in Table 1 or a fragment thereof
  • an aspect of the present invention that is specifically contemplated are isolated nucleic acid molecules that have a certain degree of sequence variation compared with the sequences shown in Tables 1-2, but that contain a novel SNP allele disclosed herein.
  • nucleic acid molecule contains a novel SNP allele disclosed herein
  • other portions of the nucleic acid molecule that flank the novel SNP allele can vary to some degree from the specific transcript, genomic, and context sequences referred to and shown in Tables 1 and 2, and can encode a polypeptide that varies to some degree from the specific polypeptide sequences referred to in Table 1.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • the percent identity between two amino acid sequences is determined using the Needleman and Wunsch algorithm ( J Mol Biol (48):444-453 (1970)) which has been incorporated into the GAP program in the GCG software package, using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
  • the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. J. Devereux et al., Nucleic Acids Res. 12(1):387 (1984).
  • the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
  • nucleotide and amino acid sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases; for example, to identify other family members or related sequences.
  • search can be performed using the NBLAST and XBLAST programs (version 2.0). Altschul et al., J Mol Biol 215:403-10 (1990).
  • Gapped BLAST can be utilized. Altschul et al., Nucleic Acids Res 25(17):3389-3402 (1997). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. In addition to BLAST, examples of other search and sequence comparison programs used in the art include, but are not limited to, FASTA (Pearson, Methods Mol Biol 25, 365-389 (1994)) and KERR (Dufresne et al., Nat Biotechnol 20(12):1269-71 (December 2002)). For further information regarding bioinformatics techniques, see Current Protocols in Bioinformatics , John Wiley & Sons, Inc., N.Y.
  • the present invention further provides non-coding fragments of the nucleic acid molecules disclosed in Table 1 and/or Table 2.
  • Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, intronic sequences, 5′ untranslated regions (UTRs), 3′ untranslated regions, gene modulating sequences and gene termination sequences. Such fragments are useful, for example, in controlling heterologous gene expression and in developing screens to identify gene-modulating agents.
  • the SNPs disclosed in Table 1 and/or Table 2 can be used for the design of SNP detection reagents.
  • the actual sequences referred to in the tables are provided in the Sequence Listing.
  • a “SNP detection reagent” is a reagent that specifically detects a specific target SNP position disclosed herein, and that is preferably specific for a particular nucleotide (allele) of the target SNP position (i.e., the detection reagent preferably can differentiate between different alternative nucleotides at a target SNP position, thereby allowing the identity of the nucleotide present at the target SNP position to be determined).
  • detection reagent hybridizes to a target SNP-containing nucleic acid molecule by complementary base-pairing in a sequence specific manner, and discriminates the target variant sequence from other nucleic acid sequences such as an art-known form in a test sample.
  • a detection reagent is a probe that hybridizes to a target nucleic acid containing one or more of the SNPs referred to in Table 1 and/or Table 2.
  • a probe can differentiate between nucleic acids having a particular nucleotide (allele) at a target SNP position from other nucleic acids that have a different nucleotide at the same target SNP position.
  • a detection reagent may hybridize to a specific region 5′ and/or 3′ to a SNP position, particularly a region corresponding to the context sequences referred to in Table 1 and/or Table 2 (transcript-based context sequences are referred to in Table 1 as SEQ ID NOS:103-176; genomic-based context sequences are referred to in Table 2 as SEQ ID NOS:623-3661).
  • Another example of a detection reagent is a primer that acts as an initiation point of nucleotide extension along a complementary strand of a target polynucleotide.
  • the SNP sequence information provided herein is also useful for designing primers, e.g. allele-specific primers, to amplify (e.g., using PCR) any SNP of the present invention.
  • a SNP detection reagent is an isolated or synthetic DNA or RNA polynucleotide probe or primer or PNA oligomer, or a combination of DNA, RNA and/or PNA, that hybridizes to a segment of a target nucleic acid molecule containing a SNP identified in Table 1 and/or Table 2.
  • a detection reagent in the form of a polynucleotide may optionally contain modified base analogs, intercalators or minor groove binders.
  • Multiple detection reagents such as probes may be, for example, affixed to a solid support (e.g., arrays or beads) or supplied in solution (e.g. probe/primer sets for enzymatic reactions such as PCR, RT-PCR, TaqMan assays, or primer-extension reactions) to form a SNP detection kit.
  • a probe or primer typically is a substantially purified oligonucleotide or PNA oligomer.
  • Such oligonucleotide typically comprises a region of complementary nucleotide sequence that hybridizes under stringent conditions to at least about 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 (or any other number in-between) or more consecutive nucleotides in a target nucleic acid molecule.
  • the consecutive nucleotides can either include the target SNP position, or be a specific region in close enough proximity 5′ and/or 3′ to the SNP position to carry out the desired assay.
  • primer and probe sequences can readily be determined using the transcript sequences (SEQ ID NOS:1-51), genomic sequences (SEQ ID NOS:177-622), and SNP context sequences (transcript-based context sequences are referred to in Table 1 as SEQ ID NOS:103-176; genomic-based context sequences are referred to in Table 2 as SEQ ID NOS:623-3661) disclosed in the Sequence Listing and in Tables 1 and 2.
  • SEQ ID NOS:623-3661 transcript-based context sequences
  • the actual sequences referred to in the tables are provided in the Sequence Listing. It will be apparent to one of skill in the art that such primers and probes are directly useful as reagents for genotyping the SNPs of the present invention, and can be incorporated into any kit/system format.
  • the gene/transcript and/or context sequence surrounding the SNP of interest is typically examined using a computer algorithm that starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene/SNP context sequence, have a GC content within a range suitable for hybridization, lack predicted secondary structure that may interfere with hybridization, and/or possess other desired characteristics or that lack other undesired characteristics.
  • a primer or probe of the present invention is typically at least about 8 nucleotides in length. In one embodiment of the invention, a primer or a probe is at least about 10 nucleotides in length. In a preferred embodiment, a primer or a probe is at least about 12 nucleotides in length. In a more preferred embodiment, a primer or probe is at least about 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. While the maximal length of a probe can be as long as the target sequence to be detected, depending on the type of assay in which it is employed, it is typically less than about 50, 60, 65, or 70 nucleotides in length. In the case of a primer, it is typically less than about 30 nucleotides in length.
  • a primer or a probe is within the length of about 18 and about 28 nucleotides.
  • the probes can be longer, such as on the order of 30-70, 75, 80, 90, 100, or more nucleotides in length (see the section below entitled “SNP Detection Kits and Systems”).
  • oligonucleotides specific for alternative SNP alleles For analyzing SNPs, it may be appropriate to use oligonucleotides specific for alternative SNP alleles. Such oligonucleotides that detect single nucleotide variations in target sequences may be referred to by such terms as “allele-specific oligonucleotides,” “allele-specific probes,” or “allele-specific primers.”
  • allele-specific probes for analyzing polymorphisms is described in, e.g., Mutation Detection: A Practical Approach , Cotton et al., eds., Oxford University Press (1998); Saiki et al., Nature 324:163-166 (1986); Dattagupta, EP235,726; and Saiki, WO 89/11548.
  • each allele-specific primer or probe depends on variables such as the precise composition of the nucleotide sequences flanking a SNP position in a target nucleic acid molecule, and the length of the primer or probe
  • another factor in the use of primers and probes is the stringency of the condition under which the hybridization between the probe or primer and the target sequence is performed. Higher stringency conditions utilize buffers with lower ionic strength and/or a higher reaction temperature, and tend to require a more perfect match between probe/primer and a target sequence in order to form a stable duplex. If the stringency is too high, however, hybridization may not occur at all.
  • lower stringency conditions utilize buffers with higher ionic strength and/or a lower reaction temperature, and permit the formation of stable duplexes with more mismatched bases between a probe/primer and a target sequence.
  • exemplary conditions for high stringency hybridization conditions using an allele-specific probe are as follows: prehybridization with a solution containing 5 ⁇ standard saline phosphate EDTA (SSPE), 0.5% NaDodSO 4 (SDS) at 55° C., and incubating probe with target nucleic acid molecules in the same solution at the same temperature, followed by washing with a solution containing 2 ⁇ SSPE, and 0.1% SDS at 55° C. or room temperature.
  • SSPE standard saline phosphate EDTA
  • SDS NaDodSO 4
  • Moderate stringency hybridization conditions may be used for allele-specific primer extension reactions with a solution containing, e.g., about 50 mM KCl at about 46° C.
  • the reaction may be carried out at an elevated temperature such as 60° C.
  • a moderately stringent hybridization condition suitable for oligonucleotide ligation assay (OLA) reactions wherein two probes are ligated if they are completely complementary to the target sequence may utilize a solution of about 100 mM KCl at a temperature of 46° C.
  • allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms (e.g., alternative SNP alleles/nucleotides) in the respective DNA segments from the two individuals.
  • Hybridization conditions should be sufficiently stringent that there is a significant detectable difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles or significantly more strongly to one allele.
  • a probe may be designed to hybridize to a target sequence that contains a SNP site such that the SNP site aligns anywhere along the sequence of the probe
  • the probe is preferably designed to hybridize to a segment of the target sequence such that the SNP site aligns with a central position of the probe (e.g., a position within the probe that is at least three nucleotides from either end of the probe).
  • This design of probe generally achieves good discrimination in hybridization between different allelic forms.
  • a probe or primer may be designed to hybridize to a segment of target DNA such that the SNP aligns with either the 5′ most end or the 3′ most end of the probe or primer.
  • the 3′ most nucleotide of the probe aligns with the SNP position in the target sequence.
  • Oligonucleotide probes and primers may be prepared by methods well known in the art. Chemical synthetic methods include, but are not limited to, the phosphotriester method described by Narang et al., Methods in Enzymology 68:90 (1979); the phosphodiester method described by Brown et al., Methods in Enzymology 68:109 (1979); the diethylphosphoamidate method described by Beaucage et al., Tetrahedron Letters 22:1859 (1981); and the solid support method described in U.S. Pat. No. 4,458,066.
  • Allele-specific probes are often used in pairs (or, less commonly, in sets of 3 or 4, such as if a SNP position is known to have 3 or 4 alleles, respectively, or to assay both strands of a nucleic acid molecule for a target SNP allele), and such pairs may be identical except for a one nucleotide mismatch that represents the allelic variants at the SNP position.
  • one member of a pair perfectly matches a reference form of a target sequence that has a more common SNP allele (i.e., the allele that is more frequent in the target population) and the other member of the pair perfectly matches a form of the target sequence that has a less common SNP allele (i.e., the allele that is rarer in the target population).
  • multiple pairs of probes can be immobilized on the same support for simultaneous analysis of multiple different polymorphisms.
  • an allele-specific primer hybridizes to a region on a target nucleic acid molecule that overlaps a SNP position and only primes amplification of an allelic form to which the primer exhibits perfect complementarity.
  • Gibbs Nucleic Acid Res 17:2427-2448 (1989).
  • the primer's 3′-most nucleotide is aligned with and complementary to the SNP position of the target nucleic acid molecule.
  • This primer is used in conjunction with a second primer that hybridizes at a distal site. Amplification proceeds from the two primers, producing a detectable product that indicates which allelic form is present in the test sample.
  • a control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site.
  • the single-base mismatch prevents amplification or substantially reduces amplification efficiency, so that either no detectable product is formed or it is formed in lower amounts or at a slower pace.
  • the method generally works most effectively when the mismatch is at the 3′-most position of the oligonucleotide (i.e., the 3′-most position of the oligonucleotide aligns with the target SNP position) because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).
  • This PCR-based assay can be utilized as part of the TaqMan assay, described below.
  • a primer of the invention contains a sequence substantially complementary to a segment of a target SNP-containing nucleic acid molecule except that the primer has a mismatched nucleotide in one of the three nucleotide positions at the 3′-most end of the primer, such that the mismatched nucleotide does not base pair with a particular allele at the SNP site.
  • the mismatched nucleotide in the primer is the second from the last nucleotide at the 3′-most position of the primer.
  • the mismatched nucleotide in the primer is the last nucleotide at the 3′-most position of the primer.
  • a SNP detection reagent of the invention is labeled with a fluorogenic reporter dye that emits a detectable signal.
  • a fluorogenic reporter dye that emits a detectable signal.
  • the preferred reporter dye is a fluorescent dye
  • any reporter dye that can be attached to a detection reagent such as an oligonucleotide probe or primer is suitable for use in the invention.
  • Such dyes include, but are not limited to, Acridine, AMCA, BODIPY, Cascade Blue, Cy2, Cy3, Cy5, Cy7, Dabcyl, Edans, Eosin, Erythrosin, Fluorescein, 6-Fam, Tet, Joe, Hex, Oregon Green, Rhodamine, Rhodol Green, Tamra, Rox, and Texas Red.
  • the detection reagent may be further labeled with a quencher dye such as Tamra, especially when the reagent is used as a self-quenching probe such as a TaqMan (U.S. Pat. Nos. 5,210,015 and 5,538,848) or Molecular Beacon probe (U.S. Pat. Nos. 5,118,801 and 5,312,728), or other stemless or linear beacon probe (Livak et al., PCR Method Appl 4:357-362 (1995); Tyagi et al., Nature Biotechnology 14:303-308 (1996); Nazarenko et al., Nucl Acids Res 25:2516-2521 (1997); U.S. Pat. Nos. 5,866,336 and 6,117,635.
  • a quencher dye such as Tamra
  • the detection reagents of the invention may also contain other labels, including but not limited to, biotin for streptavidin binding, hapten for antibody binding, and oligonucleotide for binding to another complementary oligonucleotide such as pairs of zipcodes.
  • the present invention also contemplates reagents that do not contain (or that are complementary to) a SNP nucleotide identified herein but that are used to assay one or more SNPs disclosed herein.
  • primers that flank, but do not hybridize directly to a target SNP position provided herein are useful in primer extension reactions in which the primers hybridize to a region adjacent to the target SNP position (i.e., within one or more nucleotides from the target SNP site).
  • a primer is typically not able to extend past a target SNP site if a particular nucleotide (allele) is present at that target SNP site, and the primer extension product can be detected in order to determine which SNP allele is present at the target SNP site.
  • particular ddNTPs are typically used in the primer extension reaction to terminate primer extension once a ddNTP is incorporated into the extension product (a primer extension product which includes a ddNTP at the 3′-most end of the primer extension product, and in which the ddNTP is a nucleotide of a SNP disclosed herein, is a composition that is specifically contemplated by the present invention).
  • reagents that bind to a nucleic acid molecule in a region adjacent to a SNP site and that are used for assaying the SNP site, even though the bound sequences do not necessarily include the SNP site itself, are also contemplated by the present invention.
  • detection reagents can be developed and used to assay any SNP of the present invention individually or in combination, and such detection reagents can be readily incorporated into one of the established kit or system formats which are well known in the art.
  • kits and “systems,” as used herein in the context of SNP detection reagents, are intended to refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.). Accordingly, the present invention further provides SNP detection kits and systems, including but not limited to, packaged probe and primer sets (e.g.
  • kits/systems can optionally include various electronic hardware components; for example, arrays (“DNA chips”) and microfluidic systems (“lab-on-a-chip” systems) provided by various manufacturers typically comprise hardware components.
  • Other kits/systems e.g., probe/primer sets
  • a SNP detection kit typically contains one or more detection reagents and other components (e.g. a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like) necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule.
  • detection reagents e.g. a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like
  • kits may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest.
  • kits are provided which contain the necessary reagents to carry out one or more assays to detect one or more SNPs disclosed herein.
  • SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.
  • kits of the invention can comprise a container containing a SNP detection reagent which detects a SNP disclosed herein, said container can optionally be enclosed in a package (e.g., a box for commercial sale), and said package can further include other containers containing any or all of the following: enzyme (e.g., polymerase or ligase, any of which can be thermostable), dNTPs and/or ddNTPs (which can optionally be detectably labeled, such as with a fluorescent label or mass tag, and such label can optionally differ between any of the dATPs, dCTPs, dGTPs, dTTPs, ddATPs, ddCTPs, ddGTPs, and/or ddTTPs, so that each of these dNTPs and/or ddNTPs can be distinguished from each other by detection of the label, and any of these dNTPs and/or ddNTPs can optionally be stored in the
  • SNP detection kits/systems may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position. Multiple pairs of allele-specific probes may be included in the kit/system to simultaneously assay large numbers of SNPs, at least one of which is a SNP of the present invention.
  • the allele-specific probes are immobilized to a substrate such as an array or bead.
  • the same substrate can comprise allele-specific probes for detecting at least 1; 10; 100; 1000; 10,000; 100,000 (or any other number in-between) or substantially all of the SNPs shown in Table 1 and/or Table 2.
  • arrays are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support.
  • the polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate.
  • the microarray is prepared and used according to the methods described in Chee et al., U.S. Pat. No. 5,837,832 and PCT application WO95/11995; D. J. Lockhart et al., Nat Biotech 14:1675-1680 (1996); and M.
  • Nucleic acid arrays are reviewed in the following references: Zammatteo et al., “New chips for molecular biology and diagnostics,” Biotechnol Annu Rev 8:85-101 (2002); Sosnowski et al., “Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications,” Psychiatr Genet 12(4):181-92 (December 2002); Heller, “DNA microarray technology: devices, systems, and applications,” Annu Rev Biomed Eng 4:129-53 (2002); Epub Mar.
  • probes such as allele-specific probes
  • each probe or pair of probes can hybridize to a different SNP position.
  • polynucleotide probes they can be synthesized at designated areas (or synthesized separately and then affixed to designated areas) on a substrate using a light-directed chemical process.
  • Each DNA chip can contain, for example, thousands to millions of individual synthetic polynucleotide probes arranged in a grid-like pattern and miniaturized (e.g., to the size of a dime).
  • probes are attached to a solid support in an ordered, addressable array.
  • a microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support.
  • Typical polynucleotides are preferably about 6-60 nucleotides in length, more preferably about 15-30 nucleotides in length, and most preferably about 18-25 nucleotides in length.
  • preferred probe lengths can be, for example, about 15-80 nucleotides in length, preferably about 50-70 nucleotides in length, more preferably about 55-65 nucleotides in length, and most preferably about 60 nucleotides in length.
  • the microarray or detection kit can contain polynucleotides that cover the known 5′ or 3′ sequence of a gene/transcript or target SNP site, sequential polynucleotides that cover the full-length sequence of a gene/transcript; or unique polynucleotides selected from particular areas along the length of a target gene/transcript sequence, particularly areas corresponding to one or more SNPs disclosed in Table 1 and/or Table 2.
  • Polynucleotides used in the microarray or detection kit can be specific to a SNP or SNPs of interest (e.g., specific to a particular SNP allele at a target SNP site, or specific to particular SNP alleles at multiple different SNP sites), or specific to a polymorphic gene/transcript or genes/transcripts of interest.
  • Hybridization assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants.
  • stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position).
  • Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection.
  • Such high stringency conditions are described in the preceding section, and are well known to those skilled in the art and can be found in, for example, Current Protocols in Molecular Biology 6.3.1-6.3.6, John Wiley & Sons, N.Y. (1989).
  • the arrays are used in conjunction with chemiluminescent detection technology.
  • the following patents and patent applications which are all hereby incorporated by reference, provide additional information pertaining to chemiluminescent detection.
  • U.S. patent applications that describe chemiluminescent approaches for microarray detection Ser. Nos. 10/620,332 and 10/620,333.
  • U.S. patents that describe methods and compositions of dioxetane for performing chemiluminescent detection U.S. Pat. Nos. 6,124,478; 6,107,024; 5,994,073; 5,981,768; 5,871,938; 5,843,681; 5,800,999 and 5,773,628.
  • U.S. published application that discloses methods and compositions for microarray controls: US2002/0110828.
  • a nucleic acid array can comprise an array of probes of about 15-25 nucleotides in length.
  • a nucleic acid array can comprise any number of probes, in which at least one probe is capable of detecting one or more SNPs disclosed in Table 1 and/or Table 2, and/or at least one probe comprises a fragment of one of the sequences selected from the group consisting of those disclosed in Table 1, Table 2, the Sequence Listing, and sequences complementary thereto, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 12, 15, 16, 18, 20, more preferably 22, 25, 30, 40, 47, 50, 55, 60, 65, 70, 80, 90, 100, or more consecutive nucleotides (or any other number in-between) and containing (or being complementary to) a novel SNP allele disclosed in Table 1 and/or Table 2.
  • the nucleotide complementary to the SNP site is within 5, 4, 3, 2, or 1 nucleotide from the center of the probe, more preferably at the
  • a polynucleotide probe can be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference.
  • a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures.
  • An array such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more polynucleotides, or any other number which lends itself to the efficient use of commercially available instrumentation.
  • the present invention provides methods of identifying the SNPs disclosed herein in a test sample. Such methods typically involve incubating a test sample of nucleic acids with an array comprising one or more probes corresponding to at least one SNP position of the present invention, and assaying for binding of a nucleic acid from the test sample with one or more of the probes. Conditions for incubating a SNP detection reagent (or a kit/system that employs one or more such SNP detection reagents) with a test sample vary. Incubation conditions depend on such factors as the format employed in the assay, the detection methods employed, and the type and nature of the detection reagents used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification and array assay formats can readily be adapted to detect the SNPs disclosed herein.
  • a SNP detection kit/system of the present invention may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule.
  • sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells) such as buccal cells (e.g., as obtained by buccal swabs), biopsies, or tissue specimens.
  • test samples used in the above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed.
  • Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
  • Automated sample preparation systems for extracting nucleic acids from a test sample are commercially available, and examples are Qiagen's BioRobot 9600, Applied Biosystems' PRISMTM 6700 sample preparation system, and Roche Molecular Systems' COBAS AmpliPrep System.
  • kits contemplated by the present invention are a compartmentalized kit.
  • a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel.
  • Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting one or more SNPs of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents.
  • wash reagents such as phosphate buffered saline, Tris-buffers, etc.
  • the kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection.
  • the kit may also include instructions for using the kit.
  • Exemplary compartmentalized kits include microfluidic devices known in the art. See, e.g., Weigl et al., “Lab-on-a-chip for drug development,” Adv Drug Deliv Rev 55(3):349-77 (February 2003). In such microfluidic devices, the containers may be referred to as, for example, microfluidic “compartments,” “chambers,” or “channels.”
  • Microfluidic devices which may also be referred to as “lab-on-a-chip” systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems of the present invention for analyzing SNPs.
  • Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device.
  • Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect one or more SNPs of the present invention.
  • detection reagents may be used to detect one or more SNPs of the present invention.
  • microfluidic systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip.
  • the movements of the samples may be controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts. Varying the voltage can be used as a means to control the liquid flow at intersections between the micro-machined channels and to change the liquid flow rate for pumping across different sections of the microchip. See, for example, U.S. Pat. No. 6,153,073, Dubrow et al., and U.S. Pat. No. 6,156,181, Parce et al.
  • an exemplary microfluidic system may integrate, for example, nucleic acid amplification, primer extension, capillary electrophoresis, and a detection method such as laser induced fluorescence detection.
  • nucleic acid samples are amplified, preferably by PCR.
  • the amplification products are subjected to automated primer extension reactions using ddNTPs (specific fluorescence for each ddNTP) and the appropriate oligonucleotide primers to carry out primer extension reactions which hybridize just upstream of the targeted SNP.
  • the primers are separated from the unincorporated fluorescent ddNTPs by capillary electrophoresis.
  • the separation medium used in capillary electrophoresis can be, for example, polyacrylamide, polyethyleneglycol or dextran.
  • the incorporated ddNTPs in the single nucleotide primer extension products are identified by laser-induced fluorescence detection.
  • Such an exemplary microchip can be used to process, for example, at least 96 to 384 samples, or more, in parallel.
  • the nucleic acid molecules of the present invention have a variety of uses, particularly for predicting whether an individual will benefit from statin treatment by reducing their risk for CVD (particularly CHD, such as MI) in response to the statin treatment, as well as for the diagnosis, prognosis, treatment, and prevention of CVD (particularly CHD, such as MI).
  • the nucleic acid molecules of the invention are useful for determining the likelihood of an individual who currently or previously has or has had CVD (such as an individual who has previously had an MI) or who is at increased risk for developing CVD (such as an individual who has not yet had an MI but is at increased risk for having an MI in the future) of responding to treatment (or prevention) of CVD with statins (such as by reducing their risk of developing primary or recurrent CVD, such as MI, in the future), predicting the likelihood that the individual will experience toxicity or other undesirable side effects from the statin treatment, predicting an individual's risk for developing CVD (particularly the risk for CHD such as MI), etc.
  • CVD such as an individual who has previously had an MI
  • statins such as by reducing their risk of developing primary or recurrent CVD, such as MI, in the future
  • the nucleic acid molecules are useful as hybridization probes, such as for genotyping SNPs in messenger RNA, transcript, cDNA, genomic DNA, amplified DNA or other nucleic acid molecules, and for isolating full-length cDNA and genomic clones encoding the variant peptides disclosed in Table 1 as well as their orthologs.
  • a probe can hybridize to any nucleotide sequence along the entire length of a nucleic acid molecule referred to in Table 1 and/or Table 2.
  • a probe of the present invention hybridizes to a region of a target sequence that encompasses a SNP position indicated in Table 1 and/or Table 2. More preferably, a probe hybridizes to a SNP-containing target sequence in a sequence-specific manner such that it distinguishes the target sequence from other nucleotide sequences which vary from the target sequence only by which nucleotide is present at the SNP site.
  • Such a probe is particularly useful for detecting the presence of a SNP-containing nucleic acid in a test sample, or for determining which nucleotide (allele) is present at a particular SNP site (i.e., genotyping the SNP site).
  • a nucleic acid hybridization probe may be used for determining the presence, level, form, and/or distribution of nucleic acid expression.
  • the nucleic acid whose level is determined can be DNA or RNA.
  • probes specific for the SNPs described herein can be used to assess the presence, expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in gene expression relative to normal levels.
  • In vitro techniques for detection of mRNA include, for example, Northern blot hybridizations and in situ hybridizations.
  • In vitro techniques for detecting DNA include Southern blot hybridizations and in situ hybridizations. Sambrook and Russell, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Press, N.Y. (2000).
  • Probes can be used as part of a diagnostic test kit for identifying cells or tissues in which a variant protein is expressed, such as by measuring the level of a variant protein-encoding nucleic acid (e.g., mRNA) in a sample of cells from a subject or determining if a polynucleotide contains a SNP of interest.
  • a variant protein-encoding nucleic acid e.g., mRNA
  • the nucleic acid molecules of the invention can be used as hybridization probes to detect the SNPs disclosed herein, thereby determining the likelihood that an individual will respond positively to statin treatment for reducing the risk of CVD (particularly CHD such as MI), or whether an individual with the polymorphism(s) is at risk for developing CVD (or has already developed early stage CVD). Detection of a SNP associated with a disease phenotype provides a diagnostic tool for an active disease and/or genetic predisposition to the disease.
  • nucleic acid molecules of the invention are therefore useful for detecting a gene (gene information is disclosed in Table 2, for example) which contains a SNP disclosed herein and/or products of such genes, such as expressed mRNA transcript molecules (transcript information is disclosed in Table 1, for example), and are thus useful for detecting gene expression.
  • the nucleic acid molecules can optionally be implemented in, for example, an array or kit format for use in detecting gene expression.
  • nucleic acid molecules of the invention are also useful as primers to amplify any given region of a nucleic acid molecule, particularly a region containing a SNP identified in Table 1 and/or Table 2.
  • the nucleic acid molecules of the invention are also useful for constructing recombinant vectors (described in greater detail below).
  • Such vectors include expression vectors that express a portion of, or all of, any of the variant peptide sequences referred to in Table 1.
  • Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product.
  • an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced SNPs.
  • nucleic acid molecules of the invention are also useful for expressing antigenic portions of the variant proteins, particularly antigenic portions that contain a variant amino acid sequence (e.g., an amino acid substitution) caused by a SNP disclosed in Table 1 and/or Table 2.
  • a variant amino acid sequence e.g., an amino acid substitution
  • nucleic acid molecules of the invention are also useful for constructing vectors containing a gene regulatory region of the nucleic acid molecules of the present invention.
  • nucleic acid molecules of the invention are also useful for designing ribozymes corresponding to all, or a part, of an mRNA molecule expressed from a SNP-containing nucleic acid molecule described herein.
  • nucleic acid molecules of the invention are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and variant peptides.
  • the nucleic acid molecules of the invention are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and variant peptides.
  • the production of recombinant cells and transgenic animals having nucleic acid molecules which contain the SNPs disclosed in Table 1 and/or Table 2 allows, for example, effective clinical design of treatment compounds and dosage regimens.
  • nucleic acid molecules of the invention are also useful in assays for drug screening to identify compounds that, for example, modulate nucleic acid expression.
  • nucleic acid molecules of the invention are also useful in gene therapy in patients whose cells have aberrant gene expression.
  • recombinant cells which include a patient's cells that have been engineered ex vivo and returned to the patient, can be introduced into an individual where the recombinant cells produce the desired protein to treat the individual.
  • the process of determining which nucleotide(s) is/are present at each of one or more SNP positions may be referred to by such phrases as SNP genotyping, determining the “identity” of a SNP, determining the “content” of a SNP, or determining which nucleotide(s)/allele(s) is/are present at a SNP position.
  • these terms can refer to detecting a single allele (nucleotide) at a SNP position or can encompass detecting both alleles (nucleotides) at a SNP position (such as to determine the homozygous or heterozygous state of a SNP position). Furthermore, these terms may also refer to detecting an amino acid residue encoded by a SNP (such as alternative amino acid residues that are encoded by different codons created by alternative nucleotides at a missense SNP position, for example).
  • the present invention provides methods of SNP genotyping, such as for use in implementing a preventive or treatment regimen for an individual based on that individual having an increased susceptibility for developing CVD (e.g., increased risk for CHD, such as MI) and/or an increased likelihood of benefiting from statin treatment for reducing the risk of CVD, in evaluating an individual's likelihood of responding to statin treatment (particularly for treating or preventing CVD), in selecting a treatment or preventive regimen (e.g., in deciding whether or not to administer statin treatment to an individual having CVD, or who is at increased risk for developing CVD, such as MI, in the future), or in formulating or selecting a particular statin-based treatment or preventive regimen such as dosage and/or frequency of administration of statin treatment or choosing which form/type of statin to be administered, such as a particular pharmaceutical composition or compound, etc.), determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, or selecting individuals for a clinical trial of a statin (e.g., selecting individuals to
  • the SNP genotyping methods of the invention can also be useful for evaluating an individual's risk for developing CVD (particularly CHD, such as MI) and for predicting the likelihood that an individual who has previously had CVD will have a recurrence of CVD again in the future (e.g., recurrent MI).
  • Nucleic acid samples can be genotyped to determine which allele(s) is/are present at any given genetic region (e.g., SNP position) of interest by methods well known in the art.
  • the neighboring sequence can be used to design SNP detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format.
  • SNP genotyping methods are described in Chen et al., “Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput,” Pharmacogenomics J 3(2):77-96 (2003); Kwok et al., “Detection of single nucleotide polymorphisms,” Curr Issues Mol Biol 5(2):43-60 (April 2003); Shi, “Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes,” Am J Pharmacogenomics 2(3):197-205 (2002); and Kwok, “Methods for genotyping single nucleotide polymorphisms,” Annu Rev Genomics Hum Genet 2:235-58 (2001).
  • SNP genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA (U.S. Pat. No.
  • multiplex ligation reaction sorted on genetic arrays restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay.
  • detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • RNA/RNA or RNA/DNA duplexes Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985); Cotton et al., PNAS 85:4397 (1988); and Saleeba et al., Meth.
  • Enzymol 217:286-295 (1992) comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules (Orita et al., PNAS 86:2766 (1989); Cotton et al., Mutat Res 285:125-144 (1993); and Hayashi et al., Genet Anal Tech Appl 9:73-79 (1992)), and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE) (Myers et al., Nature 313:495 (1985)). Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or chemical cleavage methods.
  • DGGE denaturing gradient gel electrophoresis
  • SNP genotyping is performed using the TaqMan assay, which is also known as the 5′ nuclease assay (U.S. Pat. Nos. 5,210,015 and 5,538,848).
  • the TaqMan assay detects the accumulation of a specific amplified product during PCR.
  • the TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye.
  • the reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET). When attached to the probe, the excited reporter dye does not emit a signal.
  • FRET fluorescence resonance energy transfer
  • the proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter.
  • the reporter dye and quencher dye may be at the 5′ most and the 3′ most ends, respectively, or vice versa.
  • the reporter dye may be at the 5′ or 3′ most end while the quencher dye is attached to an internal nucleotide, or vice versa.
  • both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.
  • the 5′ nuclease activity of DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye.
  • the DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.
  • Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein.
  • a number of computer programs such as Primer Express (Applied Biosystems, Foster City, Calif.), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the SNPs of the present invention are useful in, for example, screening individuals for their likelihood of responding to statin treatment (i.e., benefiting from statin treatment), particularly individuals who have or are susceptible to CVD (particularly CHD, such as MI), or in screening for individuals who are susceptible to developing CVD. These probes and primers can be readily incorporated into a kit format.
  • the present invention also includes modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes (U.S. Pat. Nos. 5,118,801 and 5,312,728) and other variant formats (U.S. Pat. Nos. 5,866,336 and 6,117,635).
  • Another preferred method for genotyping the SNPs of the present invention is the use of two oligonucleotide probes in an OLA (see, e.g., U.S. Pat. No. 4,988,617).
  • one probe hybridizes to a segment of a target nucleic acid with its 3′ most end aligned with the SNP site.
  • a second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3′ to the first probe.
  • the two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3′ most nucleotide of the first probe with the SNP site. If there is a mismatch, ligation would not occur.
  • the ligated probes are separated from the target nucleic acid molecule, and detected as indicators of the presence of a SNP.
  • Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. SNPs can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative SNP alleles.
  • MALDI-TOF Microx Assisted Laser Desorption Ionization-Time of Flight mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as SNPs.
  • Numerous approaches to SNP analysis have been developed based on mass spectrometry.
  • Preferred mass spectrometry-based methods of SNP genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
  • the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5′) from a target SNP position.
  • a mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template (e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR), primer, and DNA polymerase.
  • template e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • primer e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • DNA polymerase e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • the primer can be either immediately adjacent (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the SNP position. If the primer is several nucleotides removed from the target SNP position, the only limitation is that the template sequence between the 3′ end of the primer and the SNP position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer. Alternatively, if all four ddNTPs alone, with no dNTPs, are added to the reaction mixture, the primer will always be extended by only one nucleotide, corresponding to the target SNP position.
  • primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5′ side of the target SNP site).
  • Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides.
  • mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.
  • the extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position.
  • the products from the primer extension reaction are combined with light absorbing crystals that form a matrix.
  • the matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase.
  • the ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector.
  • the time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule.
  • the time of flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z. In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position.
  • primer extension assays in conjunction with MALDI-TOF mass spectrometry for SNP genotyping, see, e.g., Wise et al., “A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,” Rapid Commun Mass Spectrom 17(11):1195-202 (2003).
  • SNPs can also be scored by direct DNA sequencing.
  • a variety of automated sequencing procedures can be utilized (e.g. Biotechniques 19:448 (1995)), including sequencing by mass spectrometry. See, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv Chromatogr 36:127-162 (1996); and Griffin et al., Appl Biochem Biotechnol 38:147-159 (1993).
  • the nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures.
  • Commercial instrumentation such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730xl DNA Analyzers (Foster City, Calif.), is commonly used in the art for automated sequencing.
  • SNPs of the present invention include single-strand conformational polymorphism (SSCP), and denaturing gradient gel electrophoresis (DGGE).
  • SSCP single-strand conformational polymorphism
  • DGGE denaturing gradient gel electrophoresis
  • SSCP identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad.
  • Single-stranded PCR products can be generated by heating or otherwise denaturing double stranded PCR products.
  • Single-stranded nucleic acids may refold or form secondary structures that are partially dependent on the base sequence.
  • the different electrophoretic mobilities of single-stranded amplification products are related to base-sequence differences at SNP positions.
  • DGGE differentiates SNP alleles based on the different sequence-dependent stabilities and melting properties inherent in polymorphic DNA and the corresponding differences in electrophoretic migration patterns in a denaturing gradient gel.
  • Sequence-specific ribozymes can also be used to score SNPs based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature. If the SNP affects a restriction enzyme cleavage site, the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis.
  • SNP genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent).
  • the size of the amplification product is detected and compared to the length of a control sample; for example, deletions and insertions can be detected by a change in size of the amplified product
  • SNP genotyping is useful for numerous practical applications, as described below. Examples of such applications include, but are not limited to, SNP-disease association analysis, disease predisposition screening, disease diagnosis, disease prognosis, disease progression monitoring, determining therapeutic strategies based on an individual's genotype (“pharmacogenomics”), developing therapeutic agents based on SNP genotypes associated with a disease or likelihood of responding to a drug, stratifying patient populations for clinical trials of a therapeutic, preventive, or diagnostic agent, and predicting the likelihood that an individual will experience toxic side effects from a therapeutic agent.
  • pharmacogenomics determining therapeutic strategies based on an individual's genotype
  • SNP genotyping for disease diagnosis, disease predisposition screening, disease prognosis, determining drug responsiveness (pharmacogenomics), drug toxicity screening, and other uses described herein, typically relies on initially establishing a genetic association between one or more specific SNPs and the particular phenotypic traits of interest.
  • the first type of observational study identifies a sample of persons in whom the suspected cause of the disease is present and another sample of persons in whom the suspected cause is absent, and then the frequency of development of disease in the two samples is compared. These sampled populations are called cohorts, and the study is a prospective study.
  • the other type of observational study is case-control or a retrospective study.
  • case-control studies samples are collected from individuals with the phenotype of interest (cases) such as certain manifestations of a disease, and from individuals without the phenotype (controls) in a population (target population) that conclusions are to be drawn from. Then the possible causes of the disease are investigated retrospectively. As the time and costs of collecting samples in case-control studies are considerably less than those for prospective studies, case-control studies are the more commonly used study design in genetic association studies, at least during the exploration and discovery stage.
  • Case-only studies are an alternative to case-control studies when gene-environment interaction is the association of interest (Piegorsch et al., “Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies”, Statistics in Medicine 13 (1994) pp 153-162).
  • genotypes are obtained only from cases who are often selected from an existing cohort study. The association between genotypes and the environmental factor is then assessed and a significant association implies that the effect of the environmental factor on the endpoint of interest (the case definition) differs by genotype.
  • Confounding factors are those that are associated with both the real cause(s) of the disease and the disease itself, and they include demographic information such as age, gender, ethnicity as well as environmental factors. When confounding factors are not matched in cases and controls in a study, and are not controlled properly, spurious association results can arise. If potential confounding factors are identified, they should be controlled for by analysis methods explained below.
  • tissue specimens e.g., whole blood
  • genomic DNA genotyped for the SNP(s) of interest.
  • other information such as demographic (e.g., age, gender, ethnicity, etc.), clinical, and environmental information that may influence the outcome of the trait can be collected to further characterize and define the sample set.
  • these factors are known to be associated with diseases and/or SNP allele frequencies.
  • gene-environment and/or gene-gene interactions are likely gene-environment and/or gene-gene interactions as well. Analysis methods to address gene-environment and gene-gene interactions (for example, the effects of the presence of both susceptibility alleles at two different genes can be greater than the effects of the individual alleles at two genes combined) are discussed below.
  • phenotypic and genotypic information After all the relevant phenotypic and genotypic information has been obtained, statistical analyses are carried out to determine if there is any significant correlation between the presence of an allele or a genotype with the phenotypic characteristics of an individual.
  • data inspection and cleaning are first performed before carrying out statistical tests for genetic association.
  • Epidemiological and clinical data of the samples can be summarized by descriptive statistics with tables and graphs.
  • Data validation is preferably performed to check for data completion, inconsistent entries, and outliers. Chi-squared tests and t-tests (Wilcoxon rank-sum tests if distributions are not normal) may then be used to check for significant differences between cases and controls for discrete and continuous variables, respectively.
  • Hardy-Weinberg disequilibrium tests can be performed on cases and controls separately. Significant deviation from Hardy-Weinberg equilibrium (HWE) in both cases and controls for individual markers can be indicative of genotyping errors. If HWE is violated in a majority of markers, it is indicative of population substructure that should be further investigated. Moreover, Hardy-Weinberg disequilibrium in cases only can indicate genetic association of the markers with the disease. B. Weir, Genetic Data Analysis , Sinauer (1990).
  • Score tests are also carried out for genotypic association to contrast the three genotypic frequencies (major homozygotes, heterozygotes and minor homozygotes) in cases and controls, and to look for trends using 3 different modes of inheritance, namely dominant (with contrast coefficients 2, ⁇ 1, ⁇ 1), additive or allelic (with contrast coefficients 1, 0, ⁇ 1) and recessive (with contrast coefficients 1, 1, ⁇ 2). Odds ratios for minor versus major alleles, and odds ratios for heterozygote and homozygote variants versus the wild type genotypes are calculated with the desired confidence limits, usually 95%.
  • stratified analyses may be performed using stratified factors that are likely to be confounding, including demographic information such as age, ethnicity, and gender, or an interacting element or effect modifier, such as a known major gene (e.g., APOE for Alzheimer's disease or HLA genes for autoimmune diseases), or environmental factors such as smoking in lung cancer.
  • stratified association tests may be carried out using Cochran-Mantel-Haenszel tests that take into account the ordinal nature of genotypes with 0, 1, and 2 variant alleles. Exact tests by StatXact may also be performed when computationally possible.
  • Another way to adjust for confounding effects and test for interactions is to perform stepwise multiple logistic regression analysis using statistical packages such as SAS or R.
  • Logistic regression is a model-building technique in which the best fitting and most parsimonious model is built to describe the relation between the dichotomous outcome (for instance, getting a certain disease or not) and a set of independent variables (for instance, genotypes of different associated genes, and the associated demographic and environmental factors).
  • the most common model is one in which the logit transformation of the odds ratios is expressed as a linear combination of the variables (main effects) and their cross-product terms (interactions). Hosmer and Lemeshow, Applied Logistic Regression , Wiley (2000). To test whether a certain variable or interaction is significantly associated with the outcome, coefficients in the model are first estimated and then tested for statistical significance of their departure from zero.
  • haplotype association analysis may also be performed to study a number of markers that are closely linked together.
  • Haplotype association tests can have better power than genotypic or allelic association tests when the tested markers are not the disease-causing mutations themselves but are in linkage disequilibrium with such mutations. The test will even be more powerful if the disease is indeed caused by a combination of alleles on a haplotype (e.g., APOE is a haplotype formed by 2 SNPs that are very close to each other).
  • marker-marker linkage disequilibrium measures both D′ and r 2 , are typically calculated for the markers within a gene to elucidate the haplotype structure.
  • Haplotype association tests can be carried out in a similar fashion as the allelic and genotypic association tests. Each haplotype in a gene is analogous to an allele in a multi-allelic marker. One skilled in the art can either compare the haplotype frequencies in cases and controls or test genetic association with different pairs of haplotypes. It has been proposed that score tests can be done on haplotypes using the program “haplo.score.” Schaid et al, Am J Hum Genet 70:425-434 (2002). In that method, haplotypes are first inferred by EM algorithm and score tests are carried out with a generalized linear model (GLM) framework that allows the adjustment of other factors.
  • GLM generalized linear model
  • an important decision in the performance of genetic association tests is the determination of the significance level at which significant association can be declared when the P value of the tests reaches that level.
  • an unadjusted P value ⁇ 0.2 (a significance level on the lenient side), for example, may be used for generating hypotheses for significant association of a SNP with certain phenotypic characteristics of a disease. It is preferred that a p-value ⁇ 0.05 (a significance level traditionally used in the art) is achieved in order for a SNP to be considered to have an association with a disease. It is more preferred that a p-value ⁇ 0.01 (a significance level on the stringent side) is achieved for an association to be declared.
  • sensitivity analyses may be performed to see how odds ratios and p-values would change upon various estimates on genotyping and disease classification error rates.
  • the next step is to set up a classification/prediction scheme to predict the category (for instance, disease or no-disease) that an individual will be in depending on his genotypes of associated SNPs and other non-genetic risk factors.
  • Logistic regression for discrete trait and linear regression for continuous trait are standard techniques for such tasks. Draper and Smith, Applied Regression Analysis , Wiley (1998).
  • other techniques can also be used for setting up classification. Such techniques include, but are not limited to, MART, CART, neural network, and discriminant analyses that are suitable for use in comparing the performance of different methods.
  • MART Markov model
  • CART CART
  • neural network and discriminant analyses that are suitable for use in comparing the performance of different methods.
  • association/correlation between genotypes and disease-related phenotypes can be exploited in several ways. For example, in the case of a highly statistically significant association between one or more SNPs with predisposition to a disease for which treatment is available, detection of such a genotype pattern in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of the susceptibility alleles associated with serious disease in a couple contemplating having children may also be valuable to the couple in their reproductive decisions. In the case of a weaker but still statistically significant association between a SNP and a human disease, immediate therapeutic intervention or monitoring may not be justified after detecting the susceptibility allele or SNP.
  • the subject can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little or no cost to the individual but would confer potential benefits in reducing the risk of developing conditions for which that individual may have an increased risk by virtue of having the risk allele(s).
  • simple life-style changes e.g., diet, exercise
  • the SNPs of the invention may contribute to responsiveness of an individual to statin treatment, or to the development of CVD (e.g., CHD, such as MI), in different ways. Some polymorphisms occur within a protein coding sequence and contribute to disease phenotype by affecting protein structure. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on, for example, replication, transcription, and/or translation. A single SNP may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by multiple SNPs in different genes.
  • CVD e.g., CHD, such as MI
  • the terms “diagnose,” “diagnosis,” and “diagnostics” include, but are not limited to, any of the following: detection of CVD (e.g., CHD, such as MI) that an individual may presently have, predisposition/susceptibility/predictive screening (i.e., determining whether an individual has an increased or decreased risk of developing CVD in the future), predicting recurrence of CVD (e.g., recurrent MI) in an individual, determining a particular type or subclass of CVD in an individual who currently or previously had CVD, confirming or reinforcing a previously made diagnosis of CVD, evaluating an individual's likelihood of responding positively to a particular treatment or therapeutic agent (i.e., benefiting) such as statin treatment (particularly treatment or prevention of CVD, especially CHD such as MI, using statins), determining or selecting a therapeutic or preventive strategy that an individual is most likely to positively respond to (e.g., selecting a particular therapeutic agent such as a statin
  • Haplotypes are particularly useful in that, for example, fewer SNPs can be genotyped to determine if a particular genomic region harbors a locus that influences a particular phenotype, such as in linkage disequilibrium-based SNP association analysis.
  • Linkage disequilibrium refers to the co-inheritance of alleles (e.g., alternative nucleotides) at two or more different SNP sites at frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given population.
  • the expected frequency of co-occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in “linkage equilibrium.”
  • LD refers to any non-random genetic association between allele(s) at two or more different SNP sites, which is generally due to the physical proximity of the two loci along a chromosome.
  • LD can occur when two or more SNPs sites are in close physical proximity to each other on a given chromosome and therefore alleles at these SNP sites will tend to remain unseparated for multiple generations with the consequence that a particular nucleotide (allele) at one SNP site will show a non-random association with a particular nucleotide (allele) at a different SNP site located nearby. Hence, genotyping one of the SNP sites will give almost the same information as genotyping the other SNP site that is in LD.
  • Various degrees of LD can be encountered between two or more SNPs with the result being that some SNPs are more closely associated (i.e., in stronger LD) than others.
  • the physical distance over which LD extends along a chromosome differs between different regions of the genome, and therefore the degree of physical separation between two or more SNP sites necessary for LD to occur can differ between different regions of the genome.
  • polymorphisms e.g., SNPs and/or haplotypes
  • SNPs and/or haplotypes that are not the actual disease-causing (causative) polymorphisms, but are in LD with such causative polymorphisms
  • the genotype of the polymorphism(s) that is/are in LD with the causative polymorphism is predictive of the genotype of the causative polymorphism and, consequently, predictive of the phenotype (e.g., response to statin treatment or risk for developing CVD) that is influenced by the causative SNP(s). Therefore, polymorphic markers that are in LD with causative polymorphisms are useful as diagnostic markers, and are particularly useful when the actual causative polymorphism(s) is/are unknown.
  • Examples of polymorphisms that can be in LD with one or more causative polymorphisms (and/or in LD with one or more polymorphisms that have a significant statistical association with a condition) and therefore useful for diagnosing the same condition that the causative/associated SNP(s) is used to diagnose include other SNPs in the same gene, protein-coding, or mRNA transcript-coding region as the causative/associated SNP, other SNPs in the same exon or same intron as the causative/associated SNP, other SNPs in the same haplotype block as the causative/associated SNP, other SNPs in the same intergenic region as the causative/associated SNP, SNPs that are outside but near a gene (e.g., within 6 kb on either side, 5′ or 3′, of a gene boundary) that harbors a causative/associated SNP, etc.
  • Such useful LD SNPs can be selected from among the SNPs disclosed in Table 3, for example.
  • an aspect of the present invention relates to SNPs that are in LD with an interrogated SNP and which can also be used as valid markers for determining an individual's likelihood of benefiting from statin treatment, or whether an individual has an increased or decreased risk of having or developing CVD.
  • interrogated SNP refers to SNPs that have been found to be associated with statin response, particularly for reducing CVD risk, using genotyping results and analysis, or other appropriate experimental method as exemplified in the working examples described in this application.
  • LD SNP refers to a SNP that has been characterized as a SNP associated with statin response or an increased or decreased risk of CVD due to their being in LD with the “interrogated SNP” under the methods of calculation described in the application. Below, applicants describe the methods of calculation with which one of ordinary skilled in the art may determine if a particular SNP is in LD with an interrogated SNP.
  • the parameter r 2 is commonly used in the genetics art to characterize the extent of linkage disequilibrium between markers (Hudson, 2001).
  • in LD with refers to a particular SNP that is measured at above the threshold of a parameter such as r 2 with an interrogated SNP.
  • the individual in question could have the alleles A 1 B 1 on one chromosome and A 2 B 2 on the remaining chromosome; alternatively, the individual could have alleles A 1 B 2 on one chromosome and A 2 B 1 on the other.
  • the arrangement of alleles on a chromosome is called a haplotype.
  • the individual could have haplotypes A 1 B 1 /A 2 B 2 or A 1 B 2 /A 2 B 1 (see Hartl and Clark (1989) for a more complete description).
  • the concept of linkage equilibrium relates the frequency of haplotypes to the allele frequencies.
  • values of r 2 close to 0 indicate linkage equilibrium between the two markers examined in the sample set. As values of r 2 increase, the two markers are said to be in linkage disequilibrium.
  • Haplotype frequencies were explicit arguments in equation (18) above. However, knowing the 2-marker haplotype frequencies requires that phase to be determined for doubly heterozygous samples. When phase is unknown in the data examined, various algorithms can be used to infer phase from the genotype data. This issue was discussed earlier where the doubly heterozygous individual with a 2-SNP genotype of A 1 A 2 B 1 B 2 could have one of two different sets of chromosomes: A 1 B 1 /A 2 B 2 or A 1 B 2 /A 2 B 1 .
  • One such algorithm to estimate haplotype frequencies is the expectation-maximization (EM) algorithm first formalized by Dempster et al. (1977). This algorithm is often used in genetics to infer haplotype frequencies from genotype data (e.g.
  • interrogation of SNP markers in LD with a disease-associated SNP marker can also have sufficient power to detect disease association (Long and Langley (1999)).
  • the relationship between the power to directly find disease-associated alleles and the power to indirectly detect disease-association was investigated by Pritchard and Przeworski (2001). In a straight-forward derivation, it can be shown that the power to detect disease association indirectly at a marker locus in linkage disequilibrium with a disease-association locus is approximately the same as the power to detect disease-association directly at the disease-association locus if the sample size is increased by a factor of
  • n 4 ⁇ ⁇ N cs ⁇ N ct N cs + N ct ;
  • N cs and N ct are the numbers of diploid cases and controls, respectively. This is necessary to handle situations where the numbers of cases and controls are not equivalent.
  • ⁇ ⁇ ( x ) 1 2 ⁇ ⁇ ⁇ ⁇ - ⁇ x ⁇ ⁇ - ⁇ 2 2 ⁇ ⁇ ⁇ ⁇ ( 28 )
  • Erf error function notation
  • ⁇ (1.644854) 0.95.
  • the value of r 2 may be derived to yield a pre-specified minimum amount of power to detect disease association though indirect interrogation. Noting that the LD SNP marker could be the one that is carrying the disease-association allele, therefore that this approach constitutes a lower-bound model where all indirect power results are expected to be at least as large as those interrogated.
  • Z u is the inverse of the standard normal cumulative distribution evaluated at u (u ⁇ (0,1)).
  • Z u ⁇ ⁇ 1 (u)
  • setting power equal to a threshold of a minimum power of T
  • T ⁇ [ ⁇ q 1 , cs - q 1 , ct ⁇ q 1 , cs ⁇ ( 1 - q 1 , cs ) + q 1 , ct ⁇ ( 1 - q 1 , ct ) r 2 ⁇ n - Z 1 - ⁇ 2 ] ( 31 )
  • r 2 is calculated between an interrogated SNP and a number of other SNPs with varying levels of LD with the interrogated SNP.
  • the threshold value r T 2 is the minimum value of linkage disequilibrium between the interrogated SNP and the potential LD SNPs such that the LD SNP still retains a power greater or equal to T for detecting disease-association.
  • SNP rs200 is genotyped in a case-control disease-association study and it is found to be associated with a disease phenotype. Further suppose that the minor allele frequency in 1,000 case chromosomes was found to be 16% in contrast with a minor allele frequency of 10% in 1,000 control chromosomes.
  • Genotypes of SNPs can be imputed without actually having to be directly genotyped (referred to as “imputation”), by using known haplotype information.
  • Imputation is a process to provide “missing” data, either missing individual genotypes (alleles) or missing SNPs and concomitant genotypes, which have not been directly genotyped (i.e., assayed). Imputation is particularly useful for identifying disease associations for specific ungenotyped SNPs by inferring the missing genotypes to these acheotyped SNPs.
  • the process uses similar information to LD, since the phasing and imputation process uses information from multiple SNPs at the same time, the phased haplotype, it is able to infer the genotype and achieve high identifiable accuracy.
  • Genotype information (such as from the HapMap project by The International HapMap Consortium, NCBI, NLM, NIH) can be used to infer haplotype phase and impute genotypes for SNPs that are not directly genotyped in a given individual or sample set (such as for a disease association study).
  • imputation uses a reference dataset in which the genotypes of potential SNPs that are to be tested for disease association have been determined in multiple individuals (such as in HapMap); the individuals in the reference dataset are then haplotype phased.
  • This phasing can be done with independent programs such as fastPHASE (Sheet and Stephens, Am J Hum Genet (2006) 76: 629-644) or a combination program such as BEAGLE which does both the phasing and the imputation.
  • the reference phased haplotypes and process can be checked using the children of the HapMap individual parents, among other mechanisms. Once the reference phased haplotypes have been created, the imputation of additional individuals for SNPs genotyped or complete sets of SNPs that have not been directly genotyped can then proceed.
  • the HapMap dataset is particularly useful as the reference dataset, however other datasets can be used.
  • haplotype phase inference and imputation of missing genotypes utilize the BEAGLE genetic analysis program, (Browning, Hum Genet (2008) 124:439-450).
  • SNPs for which genotypes are imputed can be tested for association with a disease or other trait even though these SNPs are not directly genotyped.
  • the SNPs for which genotypes are imputed have genotype data available in the reference dataset, e.g. HapMap individuals, but they are not directly genotyped in a particular individual or sample set (such as in a particular disease association study).
  • imputation can provide genotypes of SNPs that were directly genotyped in a study but for which the genotypes are missing in some or most of the individuals for some reason, such as because they failed to pass quality control. Imputation can also be used to combine genotyping results from multiple studies in which different sets of SNPs were genotyped to construct a complete meta-analysis.
  • a reference dataset e.g., HapMap
  • genotyped and imputed genotyped SNP results from multiple different studies can be combined, and the overlapping SNP genotypes (e.g., genotyped in one study, imputed in another study or imputed in both or genotyped in both) can be analyzed across all of the studies (Browning, Hum Genet (2008) 124:439-450).
  • SNPs of the present invention can be used to develop superior diagnostic tests capable of identifying individuals who express a detectable trait, such as reduced risk for CVD (particularly CHD, such as MI) in response to statin treatment, as the result of a specific genotype, or individuals whose genotype places them at an increased or decreased risk of developing a detectable trait at a subsequent time as compared to individuals who do not have that genotype.
  • diagnostics may be based on a single SNP or a group of SNPs.
  • Combined detection of a plurality of SNPs typically increases the probability of an accurate diagnosis.
  • the presence of a single SNP known to correlate with CVD might indicate a probability of 20% that an individual has or is at risk of developing CVD
  • detection of five SNPs, each of which correlates with CVD might indicate a probability of 80% that an individual has or is at risk of developing CVD.
  • analysis of the SNPs of the present invention can be combined with that of other polymorphisms or other risk factors of CVD, such as disease symptoms, pathological characteristics, family history, diet, environmental factors, or lifestyle factors.
  • the present invention generally does not intend to provide an absolute identification of individuals who benefit from statin treatment or individuals who are at risk (or less at risk) of developing CVD, but rather to indicate a certain increased (or decreased) degree or likelihood of responding to statin therapy or developing CVD based on statistically significant association results.
  • this information is extremely valuable as it can be used to, for example, encourage individuals to comply with their statin regimens as prescribed by their doctors (even though the benefit of maintaining statin therapy may not be overtly apparent, which often leads to lack of compliance with prescribed statin treatment), to initiate preventive treatments or to allow an individual carrying one or more significant SNPs or SNP haplotypes to foresee warning signs such as minor clinical symptoms, or to have regularly scheduled physical exams to monitor for appearance of a condition in order to identify and begin treatment of the condition at an early stage.
  • the knowledge of a potential predisposition even if this predisposition is not absolute, would likely contribute in a very significant manner to treatment efficacy.
  • the diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a SNP or combination of SNPs associated with an increased or decreased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular polymorphism/mutation, including, for example, methods which enable the analysis of individual chromosomes for haplotyping, family studies, single sperm DNA analysis, or somatic hybrids.
  • the trait analyzed using the diagnostics of the invention may be any detectable trait that is commonly observed in pathologies and disorders related to CVD or drug response.
  • Another aspect of the present invention relates to a method of determining whether an individual is at risk (or less at risk) of developing one or more traits or whether an individual expresses one or more traits as a consequence of possessing a particular trait-causing or trait-influencing allele.
  • These methods generally involve obtaining a nucleic acid sample from an individual and assaying the nucleic acid sample to determine which nucleotide(s) is/are present at one or more SNP positions, wherein the assayed nucleotide(s) is/are indicative of an increased or decreased risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular trait-causing or trait-influencing allele.
  • the SNP detection reagents of the present invention are used to determine whether an individual has one or more SNP allele(s) affecting the level (e.g., the concentration of mRNA or protein in a sample, etc.) or pattern (e.g., the kinetics of expression, rate of decomposition, stability profile, Km, Vmax, etc.) of gene expression (collectively, the “gene response” of a cell or bodily fluid).
  • level e.g., the concentration of mRNA or protein in a sample, etc.
  • pattern e.g., the kinetics of expression, rate of decomposition, stability profile, Km, Vmax, etc.
  • Such a determination can be accomplished by screening for mRNA or protein expression (e.g., by using nucleic acid arrays, RT-PCR, TaqMan assays, or mass spectrometry), identifying genes having altered expression in an individual, genotyping SNPs disclosed in Table 1 and/or Table 2 that could affect the expression of the genes having altered expression (e.g., SNPs that are in and/or around the gene(s) having altered expression, SNPs in regulatory/control regions, SNPs in and/or around other genes that are involved in pathways that could affect the expression of the gene(s) having altered expression, or all SNPs could be genotyped), and correlating SNP genotypes with altered gene expression. In this manner, specific SNP alleles at particular SNP sites can be identified that affect gene expression.
  • SNPs that are in and/or around the gene(s) having altered expression, SNPs in regulatory/control regions, SNPs in and/or around other genes that are involved in pathways that could affect the expression of the gene(s) having altered
  • methods of assaying i.e., testing) one or more SNPs provided by the present invention in an individual's nucleic acids, and administering a therapeutic or preventive agent to the individual based on the allele(s) present at the SNP(s) having indicated that the individual can benefit from the therapeutic or preventive agent.
  • a diagnostic agent e.g., an imaging agent
  • methods of assaying one or more SNPs provided by the present invention in an individual's nucleic acids and administering a diagnostic agent (e.g., an imaging agent), or otherwise carrying out further diagnostic procedures on the individual, based on the allele(s) present at the SNP(s) having indicated that the diagnostic agents or diagnostics procedures are justified in the individual.
  • a diagnostic agent e.g., an imaging agent
  • a pharmaceutical pack comprising a therapeutic agent (e.g., a small molecule drug, antibody, peptide, antisense or RNAi nucleic acid molecule, etc.) and a set of instructions for administration of the therapeutic agent to an individual who has been tested for one or more SNPs provided by the present invention.
  • a therapeutic agent e.g., a small molecule drug, antibody, peptide, antisense or RNAi nucleic acid molecule, etc.
  • the present invention provides methods for assessing the pharmacogenomics of a subject harboring particular SNP alleles or haplotypes to a particular therapeutic agent or pharmaceutical compound, or to a class of such compounds.
  • Pharmacogenomics deals with the roles which clinically significant hereditary variations (e.g., SNPs) play in the response to drugs due to altered drug disposition and/or abnormal action in affected persons. See, e.g., Roses, Nature 405, 857-865 (2000); Gould Rothberg, Nature Biotechnology 19, 209-211 (2001); Eichelbaum, Clin Exp Pharmacol Physiol 23(10-11):983-985 (1996); and Linder, Clin Chem 43(2):254-266 (1997).
  • the clinical outcomes of these variations can result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism.
  • the SNP genotype of an individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound.
  • SNPs in drug metabolizing enzymes can affect the activity of these enzymes, which in turn can affect both the intensity and duration of drug action, as well as drug metabolism and clearance.
  • SNPs in drug metabolizing enzymes, drug transporters, proteins for pharmaceutical agents, and other drug targets has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages.
  • SNPs can be expressed in the phenotype of the extensive metabolizer and in the phenotype of the poor metabolizer. Accordingly, SNPs may lead to allelic variants of a protein in which one or more of the protein functions in one population are different from those in another population. SNPs and the encoded variant peptides thus provide targets to ascertain a genetic predisposition that can affect treatment modality.
  • SNPs may give rise to amino terminal extracellular domains and/or other ligand-binding regions of a receptor that are more or less active in ligand binding, thereby affecting subsequent protein activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing particular SNP alleles or haplotypes.
  • transgenic animals can be produced that differ only in specific SNP alleles in a gene that is orthologous to a human disease susceptibility gene.
  • Pharmacogenomic uses of the SNPs of the present invention provide several significant advantages for patient care, particularly in predicting an individual's responsiveness to statin treatment (particularly for reducing the risk of CVD, especially CHD such as MI) and in predicting an individual's predisposition to CVD (e.g., CHD such as MI).
  • Pharmacogenomic characterization of an individual based on an individual's SNP genotype, can identify those individuals unlikely to respond to treatment with a particular medication and thereby allows physicians to avoid prescribing the ineffective medication to those individuals.
  • SNP genotyping of an individual may enable physicians to select the appropriate medication and dosage regimen that will be most effective based on an individual's SNP genotype.
  • pharmacogenomics may identify patients predisposed to toxicity and adverse reactions to particular drugs or drug dosages. Adverse drug reactions lead to more than 100,000 avoidable deaths per year in the United States alone and therefore represent a significant cause of hospitalization and death, as well as a significant economic burden on the healthcare system (Pfost et al., Trends in Biotechnology , August 2000). Thus, pharmacogenomics based on the SNPs disclosed herein has the potential to both save lives and reduce healthcare costs substantially.
  • Pharmacogenomics in general is discussed further in Rose et al., “Pharmacogenetic analysis of clinically relevant genetic polymorphisms,” Methods Mol Med 85:225-37 (2003).
  • Pharmacogenomics as it relates to Alzheimer's disease and other neurodegenerative disorders is discussed in Cacabelos, “Pharmacogenomics for the treatment of dementia,” Ann Med 34(5):357-79 (2002); Maimone et al., “Pharmacogenomics of neurodegenerative diseases,” Eur J Pharmacol 413(1):11-29 (February 2001); and Poirier, “Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease,” Mol Diagn 4(4):335-41 (December 1999).
  • an aspect of the present invention includes selecting individuals for clinical trials based on their SNP genotype, such as selecting individuals for inclusion in a clinical trial and/or assigning individuals to a particular group within a clinical trial (e.g., an “arm” of the trial). For example, individuals with SNP genotypes that indicate that they are likely to positively respond to a drug can be included in the trials, whereas those individuals whose SNP genotypes indicate that they are less likely to or would not respond to the drug, or who are at risk for suffering toxic effects or other adverse reactions, can be excluded from the clinical trials. This not only can improve the safety of clinical trials, but also can enhance the chances that the trial will demonstrate statistically significant efficacy. Further, one can stratify a prospective trial with patients with different SNP variants to determine the impact of differential drug treatment.
  • certain embodiments of the invention provide methods for conducting a clinical trial of a therapeutic agent in which a human is selected for inclusion in the clinical trial and/or assigned to a particular group within a clinical trial based on the presence or absence of one or more SNPs disclosed herein.
  • the therapeutic agent is a statin.
  • SNPs of the invention can be used to select individuals who are unlikely to respond positively to a particular therapeutic agent (or class of therapeutic agents) based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them.
  • the SNPs of the invention can be used to identify patient populations who do not adequately respond to current treatments and are therefore in need of new therapies. This not only benefits the patients themselves, but also benefits organizations such as pharmaceutical companies by enabling the identification of populations that represent markets for new drugs, and enables the efficacy of these new drugs to be tested during clinical trials directly in individuals within these markets.
  • the SNP-containing nucleic acid molecules of the present invention are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of a variant gene, or encoded product, particularly in a treatment regimen or in clinical trials.
  • the gene expression pattern can serve as an indicator for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance, as well as an indicator for toxicities.
  • the gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant.
  • the SNPs of the present invention may have utility in determining why certain previously developed drugs performed poorly in clinical trials and may help identify a subset of the population that would benefit from a drug that had previously performed poorly in clinical trials, thereby “rescuing” previously developed drugs, and enabling the drug to be made available to a particular patient population (e.g., particular CVD patients) that can benefit from it.
  • the SNPs of the present invention also can be used to identify novel therapeutic targets for CVD, particularly CHD, such as MI, or stroke.
  • genes containing the disease-associated variants (“variant genes”) or their products, as well as genes or their products that are directly or indirectly regulated by or interacting with these variant genes or their products can be targeted for the development of therapeutics that, for example, treat the disease or prevent or delay disease onset.
  • the therapeutics may be composed of, for example, small molecules, proteins, protein fragments or peptides, antibodies, nucleic acids, or their derivatives or mimetics which modulate the functions or levels of the target genes or gene products.
  • the invention further provides methods for identifying a compound or agent that can be used to treat CVD, particularly CHD such as MI.
  • the SNPs disclosed herein are useful as targets for the identification and/or development of therapeutic agents.
  • a method for identifying a therapeutic agent or compound typically includes assaying the ability of the agent or compound to modulate the activity and/or expression of a SNP-containing nucleic acid or the encoded product and thus identifying an agent or a compound that can be used to treat a disorder characterized by undesired activity or expression of the SNP-containing nucleic acid or the encoded product.
  • the assays can be performed in cell-based and cell-free systems.
  • Cell-based assays can include cells naturally expressing the nucleic acid molecules of interest or recombinant cells genetically engineered to express certain nucleic acid molecules.
  • Variant gene expression in a CVD patient can include, for example, either expression of a SNP-containing nucleic acid sequence (for instance, a gene that contains a SNP can be transcribed into an mRNA transcript molecule containing the SNP, which can in turn be translated into a variant protein) or altered expression of a normal/wild-type nucleic acid sequence due to one or more SNPs (for instance, a regulatory/control region can contain a SNP that affects the level or pattern of expression of a normal transcript).
  • a SNP-containing nucleic acid sequence for instance, a gene that contains a SNP can be transcribed into an mRNA transcript molecule containing the SNP, which can in turn be translated into a variant protein
  • altered expression of a normal/wild-type nucleic acid sequence due to one or more SNPs for instance, a regulatory/control region can contain a SNP that affects the level or pattern of expression of a normal transcript.
  • Assays for variant gene expression can involve direct assays of nucleic acid levels (e.g., mRNA levels), expressed protein levels, or of collateral compounds involved in a signal pathway. Further, the expression of genes that are up- or down-regulated in response to the signal pathway can also be assayed. In this embodiment, the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.
  • Modulators of variant gene expression can be identified in a method wherein, for example, a cell is contacted with a candidate compound/agent and the expression of mRNA determined. The level of expression of mRNA in the presence of the candidate compound is compared to the level of expression of mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of variant gene expression based on this comparison and be used to treat a disorder such as CVD that is characterized by variant gene expression (e.g., either expression of a SNP-containing nucleic acid or altered expression of a normal/wild-type nucleic acid molecule due to one or more SNPs that affect expression of the nucleic acid molecule) due to one or more SNPs of the present invention.
  • a disorder such as CVD that is characterized by variant gene expression (e.g., either expression of a SNP-containing nucleic acid or altered expression of a normal/wild-type nucleic acid molecule due to one or more SNPs that affect expression of the
  • the candidate compound When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.
  • the invention further provides methods of treatment, with the SNP or associated nucleic acid domain (e.g., catalytic domain, ligand/substrate-binding domain, regulatory/control region, etc.) or gene, or the encoded mRNA transcript, as a target, using a compound identified through drug screening as a gene modulator to modulate variant nucleic acid expression.
  • Modulation can include either up-regulation (i.e., activation or agonization) or down-regulation (i.e., suppression or antagonization) of nucleic acid expression.
  • mRNA transcripts and encoded proteins may be altered in individuals with a particular SNP allele in a regulatory/control element, such as a promoter or transcription factor binding domain, that regulates expression.
  • a regulatory/control element such as a promoter or transcription factor binding domain
  • methods of treatment and compounds can be identified, as discussed herein, that regulate or overcome the variant regulatory/control element, thereby generating normal, or healthy, expression levels of either the wild type or variant protein.
  • statin response-associated proteins, and encoding nucleic acid molecules, disclosed herein can be used as therapeutic targets (or directly used themselves as therapeutic compounds) for treating or preventing CVD, and the present disclosure enables therapeutic compounds (e.g., small molecules, antibodies, therapeutic proteins, RNAi and antisense molecules, etc.) to be developed that target (or are comprised of) any of these therapeutic targets.
  • therapeutic compounds e.g., small molecules, antibodies, therapeutic proteins, RNAi and antisense molecules, etc.
  • a therapeutic compound will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • the actual amount of the therapeutic compound of this invention, i.e., the active ingredient will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
  • Therapeutically effective amounts of therapeutic compounds may range from, for example, approximately 0.01-50 mg per kilogram body weight of the recipient per day; preferably about 0.1-20 mg/kg/day. Thus, as an example, for administration to a 70-kg person, the dosage range would most preferably be about 7 mg to 1.4 g per day.
  • therapeutic compounds will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous) administration.
  • oral systemic
  • parenteral e.g., intramuscular, intravenous, or subcutaneous
  • the preferred manner of administration is oral or parenteral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction.
  • Oral compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills, or capsules are preferred) and the bioavailability of the drug substance.
  • pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size.
  • U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a cross-linked matrix of macromolecules.
  • 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
  • compositions are comprised of, in general, a therapeutic compound in combination with at least one pharmaceutically acceptable excipient.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the therapeutic compound.
  • excipients may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one skilled in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • Compressed gases may be used to disperse a compound of this invention in aerosol form.
  • Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
  • the amount of the therapeutic compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of the therapeutic compound based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compound is present at a level of about 1-80% wt.
  • Therapeutic compounds can be administered alone or in combination with other therapeutic compounds or in combination with one or more other active ingredient(s).
  • an inhibitor or stimulator of a CVD-associated protein can be administered in combination with another agent that inhibits or stimulates the activity of the same or a different CVD-associated protein to thereby counteract the effects of CVD.
  • SNP-containing nucleic acid molecules disclosed herein, and their complementary nucleic acid molecules may be used as antisense constructs to control gene expression in cells, tissues, and organisms.
  • Antisense technology is well established in the art and extensively reviewed in Antisense Drug Technology: Principles, Strategies, and Applications , Crooke, ed., Marcel Dekker, Inc., N.Y. (2001).
  • An antisense nucleic acid molecule is generally designed to be complementary to a region of mRNA expressed by a gene so that the antisense molecule hybridizes to the mRNA and thereby blocks translation of mRNA into protein.
  • Various classes of antisense oligonucleotides are used in the art, two of which are cleavers and blockers.
  • Cleavers by binding to target RNAs, activate intracellular nucleases (e.g., RNaseH or RNase L) that cleave the target RNA.
  • Blockers which also bind to target RNAs, inhibit protein translation through steric hindrance of ribosomes.
  • Exemplary blockers include peptide nucleic acids, morpholinos, locked nucleic acids, and methylphosphonates. See, e.g., Thompson, Drug Discovery Today 7(17): 912-917 (2002).
  • Antisense oligonucleotides are directly useful as therapeutic agents, and are also useful for determining and validating gene function (e.g., in gene knock-out or knock-down experiments).
  • Antisense technology is further reviewed in: Lavery et al., “Antisense and RNAi: powerful tools in drug target discovery and validation,” Curr Opin Drug Discov Devel 6(4):561-9 (July 2003); Stephens et al., “Antisense oligonucleotide therapy in cancer,” Curr Opin Mol Ther 5(2):118-22 (April 2003); Kurreck, “Antisense technologies.
  • the SNPs of the present invention are particularly useful for designing antisense reagents that are specific for particular nucleic acid variants. Based on the SNP information disclosed herein, antisense oligonucleotides can be produced that specifically target mRNA molecules that contain one or more particular SNP nucleotides. In this manner, expression of mRNA molecules that contain one or more undesired polymorphisms (e.g., SNP nucleotides that lead to a defective protein such as an amino acid substitution in a catalytic domain) can be inhibited or completely blocked.
  • SNP nucleotides that lead to a defective protein such as an amino acid substitution in a catalytic domain
  • antisense oligonucleotides can be used to specifically bind a particular polymorphic form (e.g., a SNP allele that encodes a defective protein), thereby inhibiting translation of this form, but which do not bind an alternative polymorphic form (e.g., an alternative SNP nucleotide that encodes a protein having normal function).
  • a particular polymorphic form e.g., a SNP allele that encodes a defective protein
  • an alternative polymorphic form e.g., an alternative SNP nucleotide that encodes a protein having normal function
  • Antisense molecules can be used to inactivate mRNA in order to inhibit gene expression and production of defective proteins. Accordingly, these molecules can be used to treat a disorder, such as CVD, characterized by abnormal or undesired gene expression or expression of certain defective proteins.
  • This technique can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated.
  • Possible mRNA regions include, for example, protein-coding regions and particularly protein-coding regions corresponding to catalytic activities, substrate/ligand binding, or other functional activities of a protein.
  • RNA interference also referred to as gene silencing
  • dsRNA double-stranded RNA
  • siRNA small interfering RNAs
  • an aspect of the present invention specifically contemplates isolated nucleic acid molecules that are about 18-26 nucleotides in length, preferably 19-25 nucleotides in length, and more preferably 20, 21, 22, or 23 nucleotides in length, and the use of these nucleic acid molecules for RNAi.
  • RNAi molecules including siRNAs, act in a sequence-specific manner
  • the SNPs of the present invention can be used to design RNAi reagents that recognize and destroy nucleic acid molecules having specific SNP alleles/nucleotides (such as deleterious alleles that lead to the production of defective proteins), while not affecting nucleic acid molecules having alternative SNP alleles (such as alleles that encode proteins having normal function).
  • RNAi reagents may be directly useful as therapeutic agents (e.g., for turning off defective, disease-causing genes), and are also useful for characterizing and validating gene function (e.g., in gene knock-out or knock-down experiments).
  • RNAi Reassisted et al., “Rational siRNA design for RNA interference,” Nat Biotechnol 22(3):326-30 (March 2004); Epub Feb. 1, 2004; Chi et al., “Genomewide view of gene silencing by small interfering RNAs,” PNAS 100(11):6343-6346 (2003); Vickers et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” J Biol Chem 278:7108-7118 (2003); Agami, “RNAi and related mechanisms and their potential use for therapy,” Curr Opin Chem Biol 6(6):829-34 (December 2002); Lavery et al., “Antisense and RNAi: powerful tools in drug target discovery and validation,” Curr Opin Drug Discov Devel 6(4):561-9 (July 2003); Shi, “Mammalian RNAi for the masses,” Trends Genet 19(1):9-12
  • SNPs have many important uses in drug discovery, screening, and development, and thus the SNPs of the present invention are useful for improving many different aspects of the drug development process.
  • variants e.g., SNPs and any corresponding amino acid polymorphisms
  • a particular therapeutic target e.g., a gene, mRNA transcript, or protein
  • therapeutic candidates e.g., small molecule compounds, antibodies, antisense or RNAi nucleic acid compounds, etc.
  • Rothberg Nat Biotechnol 19(3):209-11 (March 2001).
  • Such therapeutic candidates would be expected to show equal efficacy across a larger segment of the patient population, thereby leading to a larger potential market for the therapeutic candidate.
  • identifying variants of a potential therapeutic target enables the most common form of the target to be used for selection of therapeutic candidates, thereby helping to ensure that the experimental activity that is observed for the selected candidates reflects the real activity expected in the largest proportion of a patient population. Jazwinska, A Trends Guide to Genetic Variation and Genomic Medicine S30-S36 (March 2002).
  • screening therapeutic candidates against all known variants of a target can enable the early identification of potential toxicities and adverse reactions relating to particular variants.
  • variability in drug absorption, distribution, metabolism and excretion (ADME) caused by, for example, SNPs in therapeutic targets or drug metabolizing genes can be identified, and this information can be utilized during the drug development process to minimize variability in drug disposition and develop therapeutic agents that are safer across a wider range of a patient population.
  • the SNPs of the present invention including the variant proteins and encoding polymorphic nucleic acid molecules provided in Tables 1 and 2, are useful in conjunction with a variety of toxicology methods established in the art, such as those set forth in Current Protocols in Toxicology , John Wiley & Sons, Inc., N.Y.
  • therapeutic agents that target any art-known proteins may cross-react with the variant proteins (or polymorphic nucleic acid molecules) disclosed in Table 1, thereby significantly affecting the pharmacokinetic properties of the drug. Consequently, the protein variants and the SNP-containing nucleic acid molecules disclosed in Tables 1 and 2 are useful in developing, screening, and evaluating therapeutic agents that target corresponding art-known protein forms (or nucleic acid molecules). Additionally, as discussed above, knowledge of all polymorphic forms of a particular drug target enables the design of therapeutic agents that are effective against most or all such polymorphic forms of the drug target.
  • a subject suffering from a pathological condition ascribed to a SNP may be treated so as to correct the genetic defect.
  • a pathological condition ascribed to a SNP such as CVD
  • Such a subject can be identified by any method that can detect the polymorphism in a biological sample drawn from the subject.
  • Such a genetic defect may be permanently corrected by administering to such a subject a nucleic acid fragment incorporating a repair sequence that supplies the normal/wild-type nucleotide at the position of the SNP.
  • This site-specific repair sequence can encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA.
  • the site-specific repair sequence is administered in an appropriate vehicle, such as a complex with polyethylenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus, or other pharmaceutical composition that promotes intracellular uptake of the administered nucleic acid.
  • an appropriate vehicle such as a complex with polyethylenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus, or other pharmaceutical composition that promotes intracellular uptake of the administered nucleic acid.
  • a genetic defect leading to an inborn pathology may then be overcome, as the chimeric oligonucleotides induce incorporation of the normal sequence into the subject's genome.
  • the normal gene product Upon incorporation, the normal gene product is expressed, and the replacement is propagated, thereby engendering a permanent repair and therapeutic enhancement of the clinical condition of the subject.
  • a method of treating such a condition can include administering to a subject experiencing the pathology the wild-type/normal cognate of the variant protein. Once administered in an effective dosing regimen, the wild-type cognate provides complementation or remediation of the pathological condition.
  • the present invention provides SNP-containing nucleic acid molecules, many of which encode proteins having variant amino acid sequences as compared to the art-known (i.e., wild-type) proteins.
  • Amino acid sequences encoded by the polymorphic nucleic acid molecules of the present invention are referred to as SEQ ID NOS:52-102 in Table 1 and provided in the Sequence Listing. These variants will generally be referred to herein as variant proteins/peptides/polypeptides, or polymorphic proteins/peptides/polypeptides of the present invention.
  • the terms “protein,” “peptide,” and “polypeptide” are used herein interchangeably.
  • variant protein of the present invention may be encoded by, for example, a nonsynonymous nucleotide substitution at any one of the cSNP positions disclosed herein.
  • variant proteins may also include proteins whose expression, structure, and/or function is altered by a SNP disclosed herein, such as a SNP that creates or destroys a stop codon, a SNP that affects splicing, and a SNP in control/regulatory elements, e.g. promoters, enhancers, or transcription factor binding domains.
  • a protein or peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or chemical precursors or other chemicals.
  • the variant proteins of the present invention can be purified to homogeneity or other lower degrees of purity. The level of purification will be based on the intended use. The key feature is that the preparation allows for the desired function of the variant protein, even if in the presence of considerable amounts of other components.
  • substantially free of cellular material includes preparations of the variant protein having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins.
  • the variant protein when it is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.
  • the language “substantially free of chemical precursors or other chemicals” includes preparations of the variant protein in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the variant protein having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.
  • An isolated variant protein may be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant host cells), or synthesized using known protein synthesis methods.
  • a nucleic acid molecule containing SNP(s) encoding the variant protein can be cloned into an expression vector, the expression vector introduced into a host cell, and the variant protein expressed in the host cell.
  • the variant protein can then be isolated from the cells by any appropriate purification scheme using standard protein purification techniques. Examples of these techniques are described in detail below. Sambrook and Russell, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • the present invention provides isolated variant proteins that comprise, consist of or consist essentially of amino acid sequences that contain one or more variant amino acids encoded by one or more codons that contain a SNP of the present invention.
  • variant proteins that consist of amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2.
  • a protein consists of an amino acid sequence when the amino acid sequence is the entire amino acid sequence of the protein.
  • the present invention further provides variant proteins that consist essentially of amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2.
  • a protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues in the final protein.
  • the present invention further provides variant proteins that comprise amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2.
  • a protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein may contain only the variant amino acid sequence or have additional amino acid residues, such as a contiguous encoded sequence that is naturally associated with it or heterologous amino acid residues. Such a protein can have a few additional amino acid residues or can comprise many more additional amino acids.
  • the variant proteins of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins.
  • Such chimeric and fusion proteins comprise a variant protein operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the variant protein.
  • “Operatively linked” indicates that the coding sequences for the variant protein and the heterologous protein are ligated in-frame.
  • the heterologous protein can be fused to the N-terminus or C-terminus of the variant protein.
  • the fusion protein is encoded by a fusion polynucleotide that is synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence.
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence.
  • many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein).
  • a variant protein-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the variant protein.
  • the fusion protein does not affect the activity of the variant protein.
  • the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example, beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions.
  • Such fusion proteins, particularly poly-His fusions can facilitate their purification following recombinant expression.
  • expression and/or secretion of a protein can be increased by using a heterologous signal sequence.
  • Fusion proteins are further described in, for example, Terpe, “Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems,” Appl Microbiol Biotechnol 60(5):523-33 (January 2003); Epub Nov. 7, 2002; Graddis et al., “Designing proteins that work using recombinant technologies,” Curr Pharm Biotechnol 3(4):285-97 (December 2002); and Nilsson et al., “Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins,” Protein Expr Purif 11(1):1-16 (October 1997).
  • novel compositions of the present invention also relate to further obvious variants of the variant polypeptides of the present invention, such as naturally-occurring mature forms (e.g., allelic variants), non-naturally occurring recombinantly-derived variants, and orthologs and paralogs of such proteins that share sequence homology.
  • variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry.
  • variants of the variant polypeptides disclosed in Table 1 can comprise an amino acid sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with an amino acid sequence disclosed in Table 1 (or a fragment thereof) and that includes a novel amino acid residue (allele) disclosed in Table 1 (which is encoded by a novel SNP allele).
  • an aspect of the present invention that is specifically contemplated are polypeptides that have a certain degree of sequence variation compared with the polypeptide sequences shown in Table 1, but that contain a novel amino acid residue (allele) encoded by a novel SNP allele disclosed herein.
  • other portions of the polypeptide that flank the novel amino acid residue can vary to some degree from the polypeptide sequences shown in Table 1.
  • Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the amino acid sequences disclosed herein can readily be identified as having complete sequence identity to one of the variant proteins of the present invention as well as being encoded by the same genetic locus as the variant proteins provided herein.
  • Orthologs of a variant peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of a variant peptide as well as being encoded by a gene from another organism.
  • Preferred orthologs will be isolated from non-human mammals, preferably primates, for the development of human therapeutic targets and agents.
  • Such orthologs can be encoded by a nucleic acid sequence that hybridizes to a variant peptide-encoding nucleic acid molecule under moderate to stringent conditions depending on the degree of relatedness of the two organisms yielding the homologous proteins.
  • Variant proteins include, but are not limited to, proteins containing deletions, additions and substitutions in the amino acid sequence caused by the SNPs of the present invention.
  • One class of substitutions is conserved amino acid substitutions in which a given amino acid in a polypeptide is substituted for another amino acid of like characteristics.
  • Typical conservative substitutions are replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr.
  • Guidance concerning which amino acid changes are likely to be phenotypically silent are found, for example, in Bowie et al., Science 247:1306-1310 (1990).
  • Variant proteins can be fully functional or can lack function in one or more activities, e.g. ability to bind another molecule, ability to catalyze a substrate, ability to mediate signaling, etc.
  • Fully functional variants typically contain only conservative variations or variations in non-critical residues or in non-critical regions.
  • Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.
  • Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, truncations or extensions, or a substitution, insertion, inversion, or deletion of a critical residue or in a critical region.
  • Amino acids that are essential for function of a protein can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis, particularly using the amino acid sequence and polymorphism information provided in Table 1. Cunningham et al., Science 244:1081-1085 (1989). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as enzyme activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling. Smith et al., J Mol Biol 224:899-904 (1992); de Vos et al., Science 255:306-312 (1992).
  • Polypeptides can contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art.
  • variant proteins of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (e.g., polyethylene glycol), or in which additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence for purification of the mature polypeptide or a pro-protein sequence.
  • a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (e.g., polyethylene glycol), or in which additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence for purification of the mature polypeptide or a pro-protein sequence.
  • Known protein modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
  • the present invention further provides fragments of the variant proteins in which the fragments contain one or more amino acid sequence variations (e.g., substitutions, or truncations or extensions due to creation or destruction of a stop codon) encoded by one or more SNPs disclosed herein.
  • the fragments to which the invention pertains are not to be construed as encompassing fragments that have been disclosed in the prior art before the present invention.
  • a fragment may comprise at least about 4, 8, 10, 12, 14, 16, 18, 20, 25, 30, 50, 100 (or any other number in-between) or more contiguous amino acid residues from a variant protein, wherein at least one amino acid residue is affected by a SNP of the present invention, e.g., a variant amino acid residue encoded by a nonsynonymous nucleotide substitution at a cSNP position provided by the present invention.
  • the variant amino acid encoded by a cSNP may occupy any residue position along the sequence of the fragment.
  • Such fragments can be chosen based on the ability to retain one or more of the biological activities of the variant protein or the ability to perform a function, e.g., act as an immunogen.
  • fragments are biologically active fragments.
  • Such fragments will typically comprise a domain or motif of a variant protein of the present invention, e.g., active site, transmembrane domain, or ligand/substrate binding domain.
  • Other fragments include, but are not limited to, domain or motif-containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known to those of skill in the art (e.g., PROSITE analysis). Current Protocols in Protein Science , John Wiley & Sons, N.Y. (2002).
  • the variant proteins of the present invention can be used in a variety of ways, including but not limited to, in assays to determine the biological activity of a variant protein, such as in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another type of immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the variant protein (or its binding partner) in biological fluids; as a marker for cells or tissues in which it is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); as a target for screening for a therapeutic agent; and as a direct therapeutic agent to be administered into a human subject.
  • any of the variant proteins disclosed herein may be developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art. See, e.g., Molecular Cloning: A Laboratory Manual , Sambrook and Russell, Cold Spring Harbor Laboratory Press, N.Y. (2000), and Methods in Enzymology: Guide to Molecular Cloning Techniques , S. L. Berger and A. R. Kimmel, eds., Academic Press (1987).
  • the methods of the present invention include detection of one or more variant proteins disclosed herein.
  • Variant proteins are disclosed in Table 1 and in the Sequence Listing as SEQ ID NOS:52-102. Detection of such proteins can be accomplished using, for example, antibodies, small molecule compounds, aptamers, ligands/substrates, other proteins or protein fragments, or other protein-binding agents.
  • protein detection agents are specific for a variant protein of the present invention and can therefore discriminate between a variant protein of the present invention and the wild-type protein or another variant form.
  • variant proteins of the present invention can be used as targets for predicting an individual's response to statin treatment (particularly for reducing the risk of CVD, especially CHD such as MI), for determining predisposition to CVD (particularly CHD, such as MI), for diagnosing CVD, or for treating and/or preventing CVD, etc.
  • the invention provides methods for detecting the presence of, or levels of, one or more variant proteins of the present invention in a cell, tissue, or organism. Such methods typically involve contacting a test sample with an agent (e.g., an antibody, small molecule compound, or peptide) capable of interacting with the variant protein such that specific binding of the agent to the variant protein can be detected.
  • an agent e.g., an antibody, small molecule compound, or peptide
  • Such an assay can be provided in a single detection format or a multi-detection format such as an array, for example, an antibody or aptamer array (arrays for protein detection may also be referred to as “protein chips”).
  • the variant protein of interest can be isolated from a test sample and assayed for the presence of a variant amino acid sequence encoded by one or more SNPs disclosed by the present invention.
  • the SNPs may cause changes to the protein and the corresponding protein function/activity, such as through non-synonymous substitutions in protein coding regions that can lead to amino acid substitutions, deletions, insertions, and/or rearrangements; formation or destruction of stop codons; or alteration of control elements such as promoters. SNPs may also cause inappropriate post-translational modifications.
  • One preferred agent for detecting a variant protein in a sample is an antibody capable of selectively binding to a variant form of the protein (antibodies are described in greater detail in the next section).
  • samples include, for example, tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.
  • ELISAs enzyme linked immunosorbent assays
  • RIA radioimmunoassays
  • Western blots immunoprecipitations
  • immunofluorescence protein arrays/chips (e.g., arrays of antibodies or aptamers).
  • protein arrays/chips e.g., arrays of antibodies or aptamers.
  • Additional analytic methods of detecting amino acid variants include, but are not limited to, altered electrophoretic mobility, altered tryptic peptide digest, altered protein activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, and direct amino acid sequencing.
  • variant proteins can be detected in vivo in a subject by introducing into the subject a labeled antibody (or other type of detection reagent) specific for a variant protein.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • variant peptides of the present invention are based on the class or action of the protein.
  • proteins isolated from humans and their mammalian orthologs serve as targets for identifying agents (e.g., small molecule drugs or antibodies) for use in therapeutic applications, particularly for modulating a biological or pathological response in a cell or tissue that expresses the protein.
  • Pharmaceutical agents can be developed that modulate protein activity.
  • therapeutic compounds can be developed that modulate protein function.
  • many SNPs disclosed herein affect the amino acid sequence of the encoded protein (e.g., non-synonymous cSNPs and nonsense mutation-type SNPs). Such alterations in the encoded amino acid sequence may affect protein function, particularly if such amino acid sequence variations occur in functional protein domains, such as catalytic domains, ATP-binding domains, or ligand/substrate binding domains. It is well established in the art that variant proteins having amino acid sequence variations in functional domains can cause or influence pathological conditions. In such instances, compounds (e.g., small molecule drugs or antibodies) can be developed that target the variant protein and modulate (e.g., up- or down-regulate) protein function/activity.
  • the therapeutic methods of the present invention further include methods that target one or more variant proteins of the present invention.
  • Variant proteins can be targeted using, for example, small molecule compounds, antibodies, aptamers, ligands/substrates, other proteins, or other protein-binding agents. Additionally, the skilled artisan will recognize that the novel protein variants (and polymorphic nucleic acid molecules) disclosed in Table 1 may themselves be directly used as therapeutic agents by acting as competitive inhibitors of corresponding art-known proteins (or nucleic acid molecules such as mRNA molecules).
  • the variant proteins of the present invention are particularly useful in drug screening assays, in cell-based or cell-free systems.
  • Cell-based systems can utilize cells that naturally express the protein, a biopsy specimen, or cell cultures.
  • cell-based assays involve recombinant host cells expressing the variant protein.
  • Cell-free assays can be used to detect the ability of a compound to directly bind to a variant protein or to the corresponding SNP-containing nucleic acid fragment that encodes the variant protein.
  • a variant protein of the present invention can be used in high-throughput screening assays to test candidate compounds for the ability to bind and/or modulate the activity of the variant protein.
  • candidate compounds can be further screened against a protein having normal function (e.g., a wild-type/non-variant protein) to further determine the effect of the compound on the protein activity.
  • these compounds can be tested in animal or invertebrate systems to determine in vivo activity/effectiveness.
  • Compounds can be identified that activate (agonists) or inactivate (antagonists) the variant protein, and different compounds can be identified that cause various degrees of activation or inactivation of the variant protein.
  • the variant proteins can be used to screen a compound for the ability to stimulate or inhibit interaction between the variant protein and a target molecule that normally interacts with the protein.
  • the target can be a ligand, a substrate or a binding partner that the protein normally interacts with (for example, epinephrine or norepinephrine).
  • assays typically include the steps of combining the variant protein with a candidate compound under conditions that allow the variant protein, or fragment thereof, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the variant protein and the target, such as any of the associated effects of signal transduction.
  • Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′) 2 , Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e
  • One candidate compound is a soluble fragment of the variant protein that competes for ligand binding.
  • Other candidate compounds include mutant proteins or appropriate fragments containing mutations that affect variant protein function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.
  • the invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) variant protein activity.
  • the assays typically involve an assay of events in the signal transduction pathway that indicate protein activity.
  • the expression of genes that are up or down-regulated in response to the variant protein dependent signal cascade can be assayed.
  • the regulatory region of such genes can be operably linked to a marker that is easily detectable, such as luciferase.
  • phosphorylation of the variant protein, or a variant protein target could also be measured.
  • Any of the biological or biochemical functions mediated by the variant protein can be used as an endpoint assay. These include all of the biochemical or biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art.
  • Binding and/or activating compounds can also be screened by using chimeric variant proteins in which an amino terminal extracellular domain or parts thereof, an entire transmembrane domain or subregions, and/or the carboxyl terminal intracellular domain or parts thereof, can be replaced by heterologous domains or subregions.
  • a substrate-binding region can be used that interacts with a different substrate than that which is normally recognized by a variant protein. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the variant protein is derived.
  • the variant proteins are also useful in competition binding assays in methods designed to discover compounds that interact with the variant protein.
  • a compound can be exposed to a variant protein under conditions that allow the compound to bind or to otherwise interact with the variant protein.
  • a binding partner such as ligand, that normally interacts with the variant protein is also added to the mixture. If the test compound interacts with the variant protein or its binding partner, it decreases the amount of complex formed or activity from the variant protein.
  • This type of assay is particularly useful in screening for compounds that interact with specific regions of the variant protein. Hodgson, Bio/technology, 10(9), 973-80 (September 1992).
  • a fusion protein containing an added domain allows the protein to be bound to a matrix.
  • glutathione-S-transferase/ 125 I fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St.
  • the cells lysates e.g., 35 S-labeled
  • a candidate compound such as a drug candidate
  • the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH).
  • the beads can be washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated.
  • the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of bound material found in the bead fraction quantitated from the gel using standard electrophoretic techniques.
  • Either the variant protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
  • antibodies reactive with the variant protein but which do not interfere with binding of the variant protein to its target molecule can be derivatized to the wells of the plate, and the variant protein trapped in the wells by antibody conjugation. Preparations of the target molecule and a candidate compound are incubated in the variant protein-presenting wells and the amount of complex trapped in the well can be quantitated.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the protein target molecule, or which are reactive with variant protein and compete with the target molecule, and enzyme-linked assays that rely on detecting an enzymatic activity associated with the target molecule.
  • Modulators of variant protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the protein pathway, such as CVD. These methods of treatment typically include the steps of administering the modulators of protein activity in a pharmaceutical composition to a subject in need of such treatment.
  • variant proteins, or fragments thereof, disclosed herein can themselves be directly used to treat a disorder characterized by an absence of, inappropriate, or unwanted expression or activity of the variant protein. Accordingly, methods for treatment include the use of a variant protein disclosed herein or fragments thereof.
  • variant proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay to identify other proteins that bind to or interact with the variant protein and are involved in variant protein activity. See, e.g., U.S. Pat. No. 5,283,317; Zervos et al., Cell 72:223-232 (1993); Madura et al., J Biol Chem 268:12046-12054 (1993); Bartel et al., Biotechniques 14:920-924 (1993); Iwabuchi et al., Oncogene 8:1693-1696 (1993); and Brent, WO 94/10300.
  • variant protein-binding proteins are also likely to be involved in the propagation of signals by the variant proteins or variant protein targets as, for example, elements of a protein-mediated signaling pathway. Alternatively, such variant protein-binding proteins are inhibitors of the variant protein.
  • the two-hybrid system is based on the modular nature of most transcription factors, which typically consist of separable DNA-binding and activation domains.
  • the assay typically utilizes two different DNA constructs.
  • the gene that codes for a variant protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4).
  • a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor.
  • the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein that interacts with the variant protein.
  • a reporter gene e.g., LacZ
  • the present invention also provides antibodies that selectively bind to the variant proteins disclosed herein and fragments thereof. Such antibodies may be used to quantitatively or qualitatively detect the variant proteins of the present invention.
  • an antibody selectively binds a target variant protein when it binds the variant protein and does not significantly bind to non-variant proteins, i.e., the antibody does not significantly bind to normal, wild-type, or art-known proteins that do not contain a variant amino acid sequence due to one or more SNPs of the present invention (variant amino acid sequences may be due to, for example, nonsynonymous cSNPs, nonsense SNPs that create a stop codon, thereby causing a truncation of a polypeptide or SNPs that cause read-through mutations resulting in an extension of a polypeptide).
  • an antibody is defined in terms consistent with that recognized in the art: they are multi-subunit proteins produced by an organism in response to an antigen challenge.
  • the antibodies of the present invention include both monoclonal antibodies and polyclonal antibodies, as well as antigen-reactive proteolytic fragments of such antibodies, such as Fab, F(ab)′ 2 , and Fv fragments.
  • an antibody of the present invention further includes any of a variety of engineered antigen-binding molecules such as a chimeric antibody (U.S. Pat. Nos.
  • an isolated peptide e.g., a variant protein of the present invention
  • a mammalian organism such as a rat, rabbit, hamster or mouse.
  • Either a full-length protein, an antigenic peptide fragment (e.g., a peptide fragment containing a region that varies between a variant protein and a corresponding wild-type protein), or a fusion protein can be used.
  • a protein used as an immunogen may be naturally-occurring, synthetic or recombinantly produced, and may be administered in combination with an adjuvant, including but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substance such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like.
  • an adjuvant including but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substance such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like.
  • Monoclonal antibodies can be produced by hybridoma technology, which immortalizes cells secreting a specific monoclonal antibody. Kohler and Milstein, Nature 256:495 (1975).
  • the immortalized cell lines can be created in vitro by fusing two different cell types, typically lymphocytes, and tumor cells.
  • the hybridoma cells may be cultivated in vitro or in vivo.
  • fully human antibodies can be generated by transgenic animals. He et al., J Immunol 169:595 (2002).
  • Fd phage and Fd phagemid technologies may be used to generate and select recombinant antibodies in vitro.
  • Antibodies are preferably prepared against regions or discrete fragments of a variant protein containing a variant amino acid sequence as compared to the corresponding wild-type protein (e.g., a region of a variant protein that includes an amino acid encoded by a nonsynonymous cSNP, a region affected by truncation caused by a nonsense SNP that creates a stop codon, or a region resulting from the destruction of a stop codon due to read-through mutation caused by a SNP).
  • preferred regions will include those involved in function/activity and/or protein/binding partner interaction.
  • Such fragments can be selected on a physical property, such as fragments corresponding to regions that are located on the surface of the protein, e.g., hydrophilic regions, or can be selected based on sequence uniqueness, or based on the position of the variant amino acid residue(s) encoded by the SNPs provided by the present invention.
  • An antigenic fragment will typically comprise at least about 8-10 contiguous amino acid residues in which at least one of the amino acid residues is an amino acid affected by a SNP disclosed herein.
  • the antigenic peptide can comprise, however, at least 12, 14, 16, 20, 25, 50, 100 (or any other number in-between) or more amino acid residues, provided that at least one amino acid is affected by a SNP disclosed herein.
  • Detection of an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody or an antigen-reactive fragment thereof to a detectable substance.
  • Detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 I, 131 I, 35 S or 3 H.
  • Antibodies particularly the use of antibodies as therapeutic agents, are reviewed in: Morgan, “Antibody therapy for Alzheimer's disease,” Expert Rev Vaccines (1):53-9 (February 2003); Ross et al., “Anticancer antibodies,” Am J Clin Pathol 119(4):472-85 (April 2003); Goldenberg, “Advancing role of radiolabeled antibodies in the therapy of cancer,” Cancer Immunol Immunother 52(5):281-96 (May 2003); Epub Mar.
  • Antibodies can be used to isolate the variant proteins of the present invention from a natural cell source or from recombinant host cells by standard techniques, such as affinity chromatography or immunoprecipitation.
  • antibodies are useful for detecting the presence of a variant protein of the present invention in cells or tissues to determine the pattern of expression of the variant protein among various tissues in an organism and over the course of normal development or disease progression.
  • antibodies can be used to detect variant protein in situ, in vitro, in a bodily fluid, or in a cell lysate or supernatant in order to evaluate the amount and pattern of expression.
  • antibodies can be used to assess abnormal tissue distribution, abnormal expression during development, or expression in an abnormal condition, such as in CVD, or during statin treatment. Additionally, antibody detection of circulating fragments of the full-length variant protein can be used to identify turnover.
  • Antibodies to the variant proteins of the present invention are also useful in pharmacogenomic analysis. Thus, antibodies against variant proteins encoded by alternative SNP alleles can be used to identify individuals that require modified treatment modalities.
  • antibodies can be used to assess expression of the variant protein in disease states such as in active stages of the disease or in an individual with a predisposition to a disease related to the protein's function, such as CVD, or during the course of a treatment regime, such as during statin treatment.
  • Antibodies specific for a variant protein encoded by a SNP-containing nucleic acid molecule of the present invention can be used to assay for the presence of the variant protein, such as to determine an individual's response to statin treatment (particularly for reducing their risk for CVD, particularly CHD, such as MI, or stroke) or to diagnose CVD or predisposition/susceptibility to CVD, as indicated by the presence of the variant protein.
  • Antibodies are also useful as diagnostic tools for evaluating the variant proteins in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays well known in the art.
  • Antibodies are also useful for tissue typing. Thus, where a specific variant protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.
  • Antibodies can also be used to assess aberrant subcellular localization of a variant protein in cells in various tissues.
  • the diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting the expression level or the presence of variant protein or aberrant tissue distribution or developmental expression of a variant protein, antibodies directed against the variant protein or relevant fragments can be used to monitor therapeutic efficacy.
  • the antibodies are also useful for inhibiting variant protein function, for example, by blocking the binding of a variant protein to a binding partner. These uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function.
  • An antibody can be used, for example, to block or competitively inhibit binding, thus modulating (agonizing or antagonizing) the activity of a variant protein.
  • Antibodies can be prepared against specific variant protein fragments containing sites required for function or against an intact variant protein that is associated with a cell or cell membrane.
  • an antibody may be linked with an additional therapeutic payload such as a radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent.
  • Suitable cytotoxic agents include, but are not limited to, bacterial toxin such as diphtheria, and plant toxin such as ricin.
  • the in vivo half-life of an antibody or a fragment thereof may be lengthened by pegylation through conjugation to polyethylene glycol. Leong et al., Cytokine 16:106 (2001).
  • kits for using antibodies such as kits for detecting the presence of a variant protein in a test sample.
  • An exemplary kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample; means for determining the amount, or presence/absence of variant protein in the sample; means for comparing the amount of variant protein in the sample with a standard; and instructions for use.
  • the present invention also provides vectors containing the SNP-containing nucleic acid molecules described herein.
  • the term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport a SNP-containing nucleic acid molecule.
  • the SNP-containing nucleic acid molecule can be covalently linked to the vector nucleic acid.
  • Such vectors include, but are not limited to, a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, or MAC.
  • a vector can be maintained in a host cell as an extrachromosomal element where it replicates and produces additional copies of the SNP-containing nucleic acid molecules.
  • the vector may integrate into the host cell genome and produce additional copies of the SNP-containing nucleic acid molecules when the host cell replicates.
  • the invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the SNP-containing nucleic acid molecules.
  • the vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).
  • Expression vectors typically contain cis-acting regulatory regions that are operably linked in the vector to the SNP-containing nucleic acid molecules such that transcription of the SNP-containing nucleic acid molecules is allowed in a host cell.
  • the SNP-containing nucleic acid molecules can also be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription.
  • the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the SNP-containing nucleic acid molecules from the vector.
  • a trans-acting factor may be supplied by the host cell.
  • a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.
  • the regulatory sequences to which the SNP-containing nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage ⁇ , the lac, TRP, and TAC promoters from E. coli , the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.
  • expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers.
  • regions that modulate transcription include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.
  • expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region, a ribosome-binding site for translation.
  • Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals.
  • a variety of expression vectors can be used to express a SNP-containing nucleic acid molecule.
  • Such vectors include chromosomal, episomal, and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses.
  • viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses.
  • Vectors can also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g., cosmids and phagemids.
  • Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook and Russell, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • the regulatory sequence in a vector may provide constitutive expression in one or more host cells (e.g., tissue specific expression) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor, e.g., a hormone or other ligand.
  • tissue specific expression e.g., tissue specific expression
  • exogenous factor e.g., a hormone or other ligand.
  • a variety of vectors that provide constitutive or inducible expression of a nucleic acid sequence in prokaryotic and eukaryotic host cells are well known to those of ordinary skill in the art.
  • a SNP-containing nucleic acid molecule can be inserted into the vector by methodology well-known in the art. Generally, the SNP-containing nucleic acid molecule that will ultimately be expressed is joined to an expression vector by cleaving the SNP-containing nucleic acid molecule and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.
  • Bacterial host cells include, but are not limited to, Escherichia coli, Streptomyces spp., and Salmonella typhimurium .
  • Eukaryotic host cells include, but are not limited to, yeast, insect cells such as Drosophila spp., animal cells such as COS and CHO cells, and plant cells.
  • the invention provides fusion vectors that allow for the production of the variant peptides.
  • Fusion vectors can, for example, increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting, for example, as a ligand for affinity purification.
  • a proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired variant peptide can ultimately be separated from the fusion moiety.
  • Proteolytic enzymes suitable for such use include, but are not limited to, factor Xa, thrombin, and enterokinase.
  • Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S-transferase
  • suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).
  • Recombinant protein expression can be maximized in a bacterial host by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein (S. Gottesman, Gene Expression Technology: Methods in Enzymology 185:119-128, Academic Press, Calif. (1990)).
  • the sequence of the SNP-containing nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example, E. coli. Wada et al., Nucleic Acids Res 20:2111-2118 (1992).
  • the SNP-containing nucleic acid molecules can also be expressed by expression vectors that are operative in yeast.
  • yeast e.g., S. cerevisiae
  • vectors for expression in yeast include pYepSec1 (Baldari et al., EMBO J 6:229-234 (1987)), pMFa (Kurjan et al., Cell 30:933-943 (1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).
  • the SNP-containing nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al., Mol Cell Biol 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).
  • the SNP-containing nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors.
  • mammalian expression vectors include pCDM8 (B. Seed, Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J 6:187-195 (1987)).
  • the invention also encompasses vectors in which the SNP-containing nucleic acid molecules described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA.
  • an antisense transcript can be produced to the SNP-containing nucleic acid sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).
  • the invention also relates to recombinant host cells containing the vectors described herein.
  • Host cells therefore include, for example, prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.
  • the recombinant host cells can be prepared by introducing the vector constructs described herein into the cells by techniques readily available to persons of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those described in Sambrook and Russell, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • Host cells can contain more than one vector.
  • different SNP-containing nucleotide sequences can be introduced in different vectors into the same cell.
  • the SNP-containing nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the SNP-containing nucleic acid molecules, such as those providing trans-acting factors for expression vectors.
  • the vectors can be introduced independently, co-introduced, or joined to the nucleic acid molecule vector.
  • bacteriophage and viral vectors these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction.
  • Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication can occur in host cells that provide functions that complement the defects.
  • Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs.
  • the marker can be inserted in the same vector that contains the SNP-containing nucleic acid molecules described herein or may be in a separate vector.
  • Markers include, for example, tetracycline or ampicillin-resistance genes for prokaryotic host cells, and dihydrofolate reductase or neomycin resistance genes for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait can be effective.
  • RNA derived from the DNA constructs described herein can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these variant proteins using RNA derived from the DNA constructs described herein.
  • secretion of the variant protein is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as G-protein-coupled receptors (GPCRs)
  • GPCRs G-protein-coupled receptors
  • appropriate secretion signals can be incorporated into the vector.
  • the signal sequence can be endogenous to the peptides or heterologous to these peptides.
  • the protein can be isolated from the host cell by standard disruption procedures, including freeze/thaw, sonication, mechanical disruption, use of lysing agents, and the like.
  • the variant protein can then be recovered and purified by well-known purification methods including, for example, ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.
  • variant proteins described herein can have various glycosylation patterns, or may be non-glycosylated, as when produced in bacteria.
  • the variant proteins may include an initial modified methionine in some cases as a result of a host-mediated process.
  • Recombinant host cells that express the variant proteins described herein have a variety of uses.
  • the cells are useful for producing a variant protein that can be further purified into a preparation of desired amounts of the variant protein or fragments thereof.
  • host cells containing expression vectors are useful for variant protein production.
  • Host cells are also useful for conducting cell-based assays involving the variant protein or variant protein fragments, such as those described above as well as other formats known in the art.
  • a recombinant host cell expressing a variant protein is useful for assaying compounds that stimulate or inhibit variant protein function. Such an ability of a compound to modulate variant protein function may not be apparent from assays of the compound on the native/wild-type protein, or from cell-free assays of the compound.
  • Recombinant host cells are also useful for assaying functional alterations in the variant proteins as compared with a known function.
  • a transgenic animal is preferably a non-human mammal, for example, a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene.
  • a transgene is exogenous DNA containing a SNP of the present invention which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more of its cell types or tissues.
  • Such animals are useful for studying the function of a variant protein in vivo, and identifying and evaluating modulators of variant protein activity.
  • transgenic animals include, but are not limited to, non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.
  • Transgenic non-human mammals such as cows and goats can be used to produce variant proteins which can be secreted in the animal's milk and then recovered.
  • a transgenic animal can be produced by introducing a SNP-containing nucleic acid molecule into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • Any nucleic acid molecules that contain one or more SNPs of the present invention can potentially be introduced as a transgene into the genome of a non-human animal.
  • Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included.
  • a tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the variant protein in particular cells or tissues.
  • transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene.
  • transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes.
  • a transgenic animal also includes a non-human animal in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.
  • transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene.
  • a system is the cre/loxP recombinase system of bacteriophage P1. Lakso et al., PNAS 89:6232-6236 (1992).
  • Another example of a recombinase system is the FLP recombinase system of S. cerevisiae . O'Gorman et al., Science 251:1351-1355 (1991).
  • mice containing transgenes encoding both the Cre recombinase and a selected protein are generally needed.
  • Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected variant protein and the other containing a transgene encoding a recombinase.
  • Clones of the non-human transgenic animals described herein can also be produced according to the methods described, for example, in I. Wilmut et al., Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669.
  • a cell e.g., a somatic cell
  • the quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated.
  • the reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal.
  • the offspring born of this female foster animal will be a clone of the animal from which the cell (e.g., a somatic cell) is isolated.
  • Transgenic animals containing recombinant cells that express the variant proteins described herein are useful for conducting the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could influence ligand or substrate binding, variant protein activation, signal transduction, or other processes or interactions, may not be evident from in vitro cell-free or cell-based assays. Thus, non-human transgenic animals of the present invention may be used to assay in vivo variant protein function as well as the activities of a therapeutic agent or compound that modulates variant protein function/activity or expression. Such animals are also suitable for assessing the effects of null mutations (i.e., mutations that substantially or completely eliminate one or more variant protein functions).
  • transgenic animals For further information regarding transgenic animals, see Houdebine, “Antibody manufacture in transgenic animals and comparisons with other systems,” Curr Opin Biotechnol 13(6):625-9 (December 2002); Petters et al., “Transgenic animals as models for human disease,” Transgenic Res 9(4-5):347-51, discussion 345-6 (2000); Wolf et al., “Use of transgenic animals in understanding molecular mechanisms of toxicity,” J Pharm Pharmacol 50(6):567-74 (June 1998); Echelard, “Recombinant protein production in transgenic animals,” Curr Opin Biotechnol 7(5):536-40 (October 1996); Houdebine, “Transgenic animal bioreactors,” Transgenic Res 9(4-5):305-20 (2000); Pirity et al., “Embryonic stem cells, creating transgenic animals,” Methods Cell Biol 57:279-93 (1998); and Robl et al., “Artificial chromosome vectors and expression of complex proteins in trans
  • Tables 4-7 provide results of analyses of statin response for either CHD or CVD reduction, in three genetic models (dominant, recessive, and additive). Tables 4-7 provide SNPs that had a synergy index (odds ratio) with P value lower than 10 ⁇ 4 in a meta-analysis of CARE and WOSCOPS combined (Table 4-5) or in a meta-analysis of CARE, WOSCOPS, and PROVE-IT combined (Table 6-7), in any genetic model in either the CHD or CVD endpoint. Tables 4-5 provide meta-analyses of CARE and WOSCOPS combined, as well as logistic regression analysis of each sample set individually. Tables 6-7 provide meta-analyses of CARE, WOSCOPS, and PROVE-IT combined, as well as logistic regression analysis of each sample set individually.
  • Tables 5 and 7 provide analyses of certain LD SNPs in CARE and WOSCOPS (Table 5) and in CARE, WOSCOPS, and PROVE-IT (Table 7).
  • case-only data was available for a first SNP while cohort data was available for a SNP in LD with the first SNP (LD SNP), which occurred when a working kPCR assay could not be made for the first SNP.
  • LD SNP first SNP
  • the meta-analysis was performed with the cohort data when available.
  • CARE Choesterol and Recurrent Events
  • WOSCOPS West of Scotland Coronary Prevention Study
  • PROVE IT-TIMI 22 (“Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22”; which is interchangeably referred to herein as “PROVE-IT”) trial evaluated the effectiveness of intensive therapy with high-dose atorvastatin (80 mg/day) versus moderate therapy with standard-dose pravastatin (40 mg/day, which was the dose used in the CARE and WOSCOPS trials) in preventing death or cardiovascular events in patients with a recent acute coronary syndrome.
  • PROVE-IT is described in Iakoubova et al., Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):449-55 and Cannon et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes”, N Engl J Med 2004; 350:1495-504.
  • the endpoint definitions used in these analyses of CARE, WOSCOPS, and PROVE-IT were as follows.
  • the CHD endpoint was defined in the analyses herein of CARE as a composite endpoint of fatal CHD, definite non-fatal MI, or revascularization, and was defined in the analyses herein of WOSCOPS as a composite endpoint of death from CHD, nonfatal MI, or revascularization.
  • the CVD endpoint was defined as a composite endpoint of CHD or stroke.
  • PROVE-IT The analyses herein of PROVE-IT analyzed the primary endpoint of PROVE-IT, which was a composite endpoint of revascularization (if performed at least 30 days after randomization), unstable angina requiring hospitalization, MI, all causes of death, or stroke. Thus, there was only one endpoint for PROVE-IT (the composite primary endpoint of the original PROVE-IT study, which includes some stroke cases), and this endpoint was used in the meta-analysis for both CHD and CVD provided in Tables 6-7. With respect to stroke, in the analyses herein of CARE and PROVE-IT, stroke was defined as stroke or transient ischemic attack (TIA), and in the analyses herein of WOSCOPS, stroke was defined as fatal or non-fatal stroke. Revascularization, which can include percutaneous transluminal coronary angioplasty (PTCA), stent placement, and coronary artery bypass graft (CABG), are medical interventions that indicate the presence of CHD.
  • PTCA percutaneous transluminal coronary angioplasty
  • Cohort and case-only study designs were used to identify SNPs associated with response to statin treatment.
  • the entire cohort (individuals with and without incident CHD or CVD events; identified as “cohort” in the “Source” column of Tables 4-7) or only individuals with an incident CHD or CVD event (identified as “CaseOnly” in the “Source” column of Tables 4-7) were analyzed in sample sets from the CARE, WOSCOPS, and PROVE-IT trials to test whether the reduction of CHD/CVD events by statin therapy (for CARE and WOSCOPS studies), or by high dose atorvastatin therapy (for the PROVE IT study), differed according to genotype (a treatment by SNP interaction) for each SNP evaluated in the study.
  • a logistic regression model having treatment status as the dependent variable and SNP as the independent predictor variable was performed, with terms for age, sex and race included in the model as covariates.
  • the anti-log of the regression coefficient corresponding to the SNP is an estimate of the synergy index (SI) (Davis et al., “Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses—a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study”, Statistics in Medicine 23: (2004), pages 2413-2427).
  • the SI is a ratio of odds ratios: for example in the CARE and WOSCOPS studies, the SI represents the factor by which the odds-ratio of statin treatment, compared with placebo, among major homozygous individuals is multiplied by in order to obtain the odds-ratio of treatment vs. placebo among heterozygous individuals; and multiplied by a second time to obtain the odds-ratio of treatment vs. placebo in minor homozygous individuals.
  • the case-only study design results in a valid estimate of the SI under the assumption that genotype and treatment are independent in the population. In a randomized clinical trial, genotype and treatment are independent by design.
  • the p-value for the regression coefficient corresponding to the SNP results from a test of the null hypothesis that the regression coefficient is equal to zero (SI is equal to one) and thus small p-values indicate the SI is unlikely equal to one and that the effect of treatment likely differs by genotype.
  • the logistic regression models were performed separately for each of CARE, WOSCOPS, and PROVE-IT in order to obtain study-specific results.
  • a meta-analysis was then used to estimate the combined evidence for interaction when considering either the CARE and WOSCOPS studies (Tables 4-5), or all three studies (CARE, WOSCOPS, and PROVE-IT) (Tables 6-7).
  • the meta-analysis used the inverse variance method (Rothman et al., 1998 ; Modern Epidemiology, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, Pa., pages 660-661) to calculate the combined SI using a weighted average of the effects of the individual studies with weights equal to the inverse variance from each study.
  • Additional genotyped and imputed SNPs were identified as being associated with statin response in the CARE, WOSCOPS, and PROVE-IT sample sets, and these additional SNPs are provided in Tables 9-18.
  • the association of certain of these SNPs with statin response was identified by genotyping, whereas the association of certain other SNPs with statin response was identified by imputation. Imputation involves imputing the allele/genotype present at a SNP for each individual in the sample set (CARE, WOSCOPS, and PROVE-IT) rather than directly genotyping the SNP in a sample from the individual.
  • Tables 9-18 include SNPs identified by imputation as well as SNPs identified by genotyping, and the column labeled “Source” in Tables 9-18 indicates whether each SNP was genotyped or imputed (all of the SNPs provided in Tables 4-7 were identified by genotyping).
  • Tables 9-18 provide SNPs for which the p-value for a random effect was lower than 10 ⁇ 4 for either the meta-analysis of CARE and WOSCOPS combined or the meta-analysis of CARE, WOSCOPS, and PROVE-IT combined, for either the CHD or CVD endpoint, and for any genetic model (dominant, recessive, additive, or genotypic). Association interaction between statin response and either the CHD or CVD phenotype was performed. SNPs were either imputed or genotyped.
  • Imputation was carried out using the BEAGLE genetic analysis program to analyze genotyping data from the HapMap project (The International HapMap Consortium, NCBI, NLM, NIH). Imputation and the BEAGLE program (including the modeling algorithm that BEAGLE utilizes) are described in the following references: Browning, “Missing data imputation and haplotype phase inference for genome-wide association studies”, Hum Genet (2008) 124:439-450 (which reviews imputation and BEAGLE); B L Browning and S R Browning (2009) “A unified approach to genotype imputation and haplotype phase inference for large data sets of trios and unrelated individuals”.
  • Am J Hum Genet 84:210-223 (which describes BEAGLE's methods for imputing ungenotyped markers and phasing parent-offspring trios); S R Browning and B L Browning (2007) “Rapid and accurate haplotype phasing and missing data inference for whole genome association studies using localized haplotype clustering”.
  • Am J Hum Genet 81:1084-1097 (which describes BEAGLE's methods for inferring haplotype phase or sporadic missing data in unrelated individuals); B L Browning and S R Browning (2007) “Efficient multilocus association mapping for whole genome association studies using localized haplotype clustering”.
  • Polymorphism rs11556924 in the ZC3HC1 Gene is Associated with Differential CHD Risk Reduction by Statin Therapy in CARE and WOSCOPS
  • a case-only study design was used to test whether the reduction of CHD events by statin therapy (for CARE and WOSCOPS studies) differed according to genotype (a treatment by SNP interaction) for each SNP evaluated in the study.
  • Example 2 SNPs previously reported to be associated with coronary artery disease (Schunkert et al., “Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease”, Nat Genet. 2011 Mar. 6; and Peden et al., “A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease”, Nat Genet. 2011 Mar. 6) were analyzed using the same methodology as described above in Example 1 in order to determine whether any of these SNP are associated with differential CHD risk reduction by statin therapy in a genome wide association study conducted among cases of CARE and WOSCOPS.
  • Example 3 relates to genetic polymorphisms that are associated with stroke risk and/or stroke statin response (reduction of stroke risk by statin treatment) (Tables 20-21) and CHD statin response (Table 22).
  • Table 20 provides SNPs associated with stroke risk and/or stroke statin response in the CARE sample set.
  • SNPs rs10757278 and rs1333049 at chromosomal location 9p21 were associated with a reduction of stroke events by statin treatment in CARE, particularly for heterozygotes (see Table 20).
  • SNPs rs12425791 and rs11833579 at chromosomal location 12p13 near the NINJ2 gene were associated with stroke risk in the placebo arm of CARE (see Table 20).
  • SNPs rs12425791 and rs11833579 were also associated with stroke statin response in that the homozygous and heterozygous carriers of either of these SNPs (i.e., carriers of the ‘A’ allele for either rs12425791 or rs11833579) had a greater reduction in stroke events with statin treatment compared with noncarriers (see Table 20). Consistent with the CARE trial, the stroke endpoint in the analysis for which the results are provided in Tables 20-21 included stroke as well as transient ischemic attack (TIA).
  • TIA transient ischemic attack
  • Fine-mapping at the chromosome 12p13 locus was carried out by selecting 77 tagging SNPs from a 400 kb region of the chromosome 12p13 locus which covered the NINJ2 gene and other genes, genotyping these 77 SNPs, and further imputing the genotypes of approximately 250 additional SNPs in this region, for individuals in the CARE study. Analyzing these fine-mapping SNPs for association with stroke risk in the placebo arm of CARE and for stroke statin response in CARE identified SNP rs873134 in the B4GALNT3 gene in the chromosome 12p13 region near NINJ2 (see Table 21).
  • Table 22 provides results of an analysis of CHD statin response in CARE.
  • Table 22 shows that SNP rs873134 is associated with response to statin treatment for reducing the risk of CHD (as well as for reducing the risk of stroke, as shown in Table 21).
  • Table 22 shows that SNP rs873134 is associated with a reduced occurrence of recurrent MI in individuals in the CARE study who were treated with statins.
  • SNP rs873134 is an example of a SNP that is associated with statin response for reducing risk for both stroke and CHD.
  • the endpoint was recurrent MI, and the analysis was adjusted for age, gender, hypertension, diabetes, base LDL and HDL, and whether an individual was a current smoker.
  • interrogated SNPs were those SNPs provided in Tables 4-22 (the interrogated SNPs are shown in columns 1-2 of Table 3, which indicates the hCV and rs identification numbers of each interrogated SNP), and the LD SNPs which were identified as being in high LD are provided in Table 3 (in the columns labeled “LD SNP”, which indicate the hCV and rs identification numbers of each LD SNP).
  • Table 3 provides LD SNPs from the HapMap database (NCBI, NLM, NIH) that have linkage disequilibrium r 2 values of at least 0.9 (the threshold r 2 value, which may also be designated as r T 2 ) with an interrogated SNP.
  • r 2 values are calculated based on genotypes of HapMap Caucasian subjects. If an interrogated SNP is not in the HapMap database, then there will not be any LD SNPs listed in Table 3 for that interrogated SNP.
  • the interrogated SNP rs688358 (hCV1056543) was calculated to be in LD with rs675163 (hCV1056544) at an r 2 value of 1 (which is above the threshold r 2 value of 0.9), thus establishing the latter SNP as a marker associated with statin response as well.
  • the threshold r 2 value was set at 0.9.
  • the threshold r 2 value can be set at other values such that one of ordinary skill in the art would consider that any two SNPs having an r 2 value greater than or equal to the threshold r 2 value would be in sufficient LD with each other such that either SNP is useful for the same utilities, such as determining an individual's response to statin treatment.
  • the threshold r 2 value used to classify SNPs as being in sufficient LD with an interrogated SNP can be set at, for example, 0.7, 0.75, 0.8, 0.85, 0.95, 0.96, 0.97, 0.98, 0.99, 1, etc. (or any other threshold r 2 value in-between these values). Threshold r 2 values may be utilized with or without considering power or other calculations.
  • Sequences, SNP information, and associated gene/transcript/protein information for each of the LD SNPs listed in Table 3 is provided in Tables 1-2.
  • sequence and allele information can be found by searching Tables 1-2 using the hCV or rs identification number of the LD SNP of interest.
  • cebo hCV1754666 rs1333049 9p21 0.492 GEN CC Prava- 24 405 1.11 0.616 1.99 0.7346 0.1288 CC 21 statin hCV1754666 rs1333049 9p21 0.492 GEN CC Pla- 21 393 ref . . . 0.1288 . cebo hCV1754666 rs1333049 9p21 0.492 DOM GC + Prava- 43 994 0.63 0.429 0.92 0.018 0.1139 GC + 67 GG statin GG hCV1754666 rs1333049 9p21 0.492 DOM GC + Pla- 67 980 ref . . . 0.1139 .
  • hCV11841860 689 1.47 0.826 2.607 0.1905 0.2663 GA 79 1342 1.22 0.803 1.862 0.3478 0.639 hCV11841860 . . . . . . . hCV11841860 289 ref . . . 0.2663 AA 30 623 ref . . . 0.639 hCV11841860 . . . . . . . . hCV11841860 1079 1.32 0.758 2.302 0.3269 . GA + 124 2142 1.21 0.81 1.8 0.3537 . GG hCV11841860 . . . .
  • hCV1754666 689 1.4 0.842 2.319 0.1961 0.2539 GC 79 1348 1.03 0.711 1.478 0.8939 0.727 hCV1754666 . . . . . . . . hCV1754666 393 ref . . . 0.2539 CC 45 798 ref . . . 0.727 hCV1754666 . . . . . . . . hCV1754666 980 1.26 0.773 2.061 0.3517 . GC + 110 1974 0.98 0.689 1.379 0.8869 .
  • hCV12094896 442 1.51 0.971 2.339 0.0674 0.0584 AG 57 927 1.19 0.854 1.66 0.3045 0.421 hCV12094896 . . . . . . . . hCV12094896 867 ref . . . 0.0584 GG 89 1719 ref . . . 0.421 hCV12094896 . . . . . . . . hCV12094896 502 1.59 1.046 2.414 0.0301 . AG + 66 1047 1.22 0.885 1.673 0.2267 .
  • AA hCV12094896 . . . . . . . . . . hCV12094896 60 1.86 0.861 4.034 0.1142 . AA 9 120 1.33 0.679 2.609 0.4055 . hCV12094896 . . . . . . . . hCV1665834 91 2 1 3.985 0.05 0.1371 AA 13 190 1.3 0.721 2.339 0.3837 0.555 hCV1665834 . . . . . . . . . . . . . .
  • hCV1665834 541 1.24 0.795 1.933 0.344 0.1371 AG 66 1107 1.15 0.83 1.605 0.3942 0.555 hCV1665834 . . . . . . . . hCV1665834 739 ref . . . 0.1371 GG 76 1469 ref . . . 0.555 hCV1665834 . . . . . . . . hCV1665834 632 1.35 0.887 2.049 0.1622 . AG + 79 1297 1.18 0.858 1.612 0.3124 . AA hCV1665834 . . . .
  • hCV2652047 rs873134 GEN CT Pravastatin 24 680 0.5 0.308 0.818 0.0057 0.00164 CT 49 697 hCV2652047 rs873134 GEN CT Placebo 49 697 ref . . . 0.00164 . . hCV2652047 rs873134 GEN TT Pravastatin 16 366 0.54 0.291 1.01 0.0538 0.00164 TT 26 336 hCV2652047 rs873134 GEN TT Placebo 26 336 ref . . . 0.00164 . .
  • hCV2652047 rs873134 GEN TC Pravastatin 63 676 1 0.705 1.405 0.9783 0.05825 TC 67 693 hCV2652047 rs873134 GEN TC Placebo 67 693 ref . . . 0.05825 . . hCV2652047 rs873134 GEN CC Pravastatin 23 352 0.48 0.29 0.809 0.0056 0.05825 CC 42 335 hCV2652047 rs873134 GEN CC Placebo 42 335 ref . . . 0.05825 . .
  • hCV2652047 0.75 0.509 1.105 0.1454 0.3415 TC 130 1369 1.02 0.756 1.372 0.9047 0.8281 hCV2652047 . . . . . . . . hCV2652047 ref . . . 0.3415 CC 65 687 ref . . . 0.8281 hCV2652047 . . . . . . . hCV2652047 0.79 0.549 1.128 0.1924 . TC + TT 192 2066 0.99 0.745 1.308 0.9269 . hCV2652047 . . . . . . . . . . .

Abstract

The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation application of U.S. non-provisional application Ser. No. 13/833,905, dated Mar. 15, 2013, which is a continuation application of U.S. non-provisional application Ser. No. 13/085,955, dated Apr. 13, 2011, which claims the benefit of U.S. provisional application Ser. No. 61/325,689 filed Apr. 19, 2010, U.S. provisional application Ser. No. 61/332,509 filed May 7, 2010, and U.S. provisional application Ser. No. 61/405,972 filed Oct. 22, 2010, the contents of each of which are hereby incorporated by reference in their entirety into this application.
  • FIELD OF THE INVENTION
  • The present invention is in the field of drug response and disease risk, particularly genetic polymorphisms that are associated with response to statins, especially for the prevention or treatment of cardiovascular diseases (CVD) such as coronary heart disease (CHD) (which includes coronary events such as myocardial infarction (MI)) and cerebrovascular events (such as stroke). In particular, the present invention relates to specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with variability in responsiveness to statin treatment (including preventive treatment) in reducing CVD risk between different individuals. These SNPs are also useful for assessing an individual's risk for developing CVD. The SNPs disclosed herein can be used, for example, as targets for diagnostic reagents and for the development of therapeutic agents. In particular, the SNPs of the present invention are useful for such uses as predicting an individual's response to therapeutic agents such as evaluating the likelihood of an individual differentially responding positively to statins, particularly for the treatment or prevention of CVD (particularly CHD such as MI, as well as stroke), identifying an individual who has an increased or decreased risk of developing CVD (particularly CHD such as MI, as well as stroke), for early detection of the disease, for providing clinically important information for the prevention and/or treatment of CVD, for predicting recurrence of CVD, and for screening and selecting therapeutic agents. Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and their encoded products are provided.
  • BACKGROUND OF THE INVENTION
  • The present invention relates to SNPs that are associated with variability between individuals in their response to statins, particularly for the prevention or treatment of cardiovascular disease (CVD), which includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke and transient ischemic attack (TIA). These SNPs are also useful for determining an individual's risk for developing CVD, particularly CHD (including coronary events such as MI) as well as cerebrovascular events (such as stroke and TIA).
  • HMG-CoA Reductase Inhibitors (Statins)
  • HMG-CoA reductase inhibitors (statins) are used for the treatment and prevention of CVD, particularly CHD (including coronary events such as MI) and cerebrovascular events (such as stroke). Reduction of MI, stroke, and other coronary and cerebrovascular events and total mortality by treatment with HMG-CoA reductase inhibitors has been demonstrated in a number of randomized, double-blinded, placebo-controlled prospective trials (D. D. Waters, Clin Cardiol 24(8 Suppl):III3-7 (2001); B. K. Singh and J. L. Mehta, Curr Opin Cardiol 17(5):503-11 (2002)). These drugs are thought to typically have their primary effect through the inhibition of hepatic cholesterol synthesis, thereby upregulating LDL receptors in the liver. The resultant increase in LDL catabolism results in decreased circulating LDL, a major risk factor for cardiovascular disease.
  • Examples of statins include, but are not limited to, atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), simvastatin (Zocor®), fluvastatin (Lescol®), and lovastatin (Mevacor®), as well as combination therapies that include a statin such as simvastatin+ezetimibe (Vytorin®), lovastatin+niacin (Advicor®), atorvastatin+amlodipine besylate (Caduet®), and simvastatin+niacin (Simcor®).
  • Statins can be divided into two types according to their physicochemical and pharmacokinetic properties. Statins such as atorvastatin, simvastatin, lovastatin, and cerivastatin are lipophilic in nature and, as such, diffuse across membranes and thus are highly cell permeable. Hydrophilic statins such as pravastatin are more polar, such that they require specific cell surface transporters for cellular uptake. K. Ziegler and W. Stunkel, Biochim Biophys Acta 1139(3):203-9 (1992); M. Yamazaki et al., Am J Physiol 264(1 Pt 1):G36-44 (1993); T. Komai et al., Biochem Pharmacol 43(4):667-70 (1992). The latter statins utilizes a transporter, OATP2, whose tissue distribution is confined to the liver and, therefore, they are relatively hepato-specific inhibitors. B. Hsiang et al., J Biol Chem 274(52):37161-37168 (1999). The former statins, not requiring specific transport mechanisms, are available to all cells and they can directly impact a much broader spectrum of cells and tissues. These differences in properties may influence the spectrum of activities that each statin possesses. Pravastatin, for instance, has a low myopathic potential in animal models and myocyte cultures compared to lipophilic statins. B. A. Masters et al., Toxicol Appl Pharmacol 131(1):163-174 (1995); K. Nakahara et al., Toxicol Appl Pharmacol 152(1):99-106 (1998); J. C. Reijneveld et al., Pediatr Res 39(6):1028-1035 (1996). Statins are reviewed in Vaughan et al., “Update on Statins: 2003”, Circulation 2004; 110; 886-892.
  • Evidence from gene association studies is accumulating to indicate that responses to drugs are, indeed, at least partly under genetic control. As such, pharmacogenetics—the study of variability in drug responses attributed to hereditary factors in different populations—may significantly assist in providing answers toward meeting this challenge. A. D. Roses, Nature 405(6788):857-865 (2000); V. Mooser et al., J Thromb Haemost 1(7):1398-1402 (2003); L. M. Humma and S. G. Terra, Am J Health Syst Pharm 59(13):1241-1252 (2002). Associations have been reported between specific genotypes, as defined by SNPs and other genetic sequence variations, and specific responses to cardiovascular drugs. For example, a polymorphism in the KIF6 gene is associated with response to statin treatment (Iakoubova et al., “Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):449-55; Iakoubova et al., “Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy”, J Am Coll Cardiol. 2008 Jun. 3; 51(22):2195; Iakoubova et al., “KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study”, Eur J Cardiovasc Prev Rehabil. 2010 Apr. 20; and Shiffman et al., “Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial”, Am J Cardiol. 2010 May 1; 105(9):1300-5).
  • There is a need for genetic markers that can be used to predict an individual's responsiveness to statins. For example, there is a growing need to better identify people who have a high chance of benefiting from statins, and those who have a low risk of developing side-effects. For example, severe myopathies represent a significant risk for a low percentage of the patient population, and this may be a particular concern for patients who are treated more aggressively with statins. Furthermore, different patients may have the same the risk for adverse events but are more likely to benefit from a drug (such as statins) and this may justify use of the drug in those individuals who are more likely to benefit. Similarly, in individuals who are less likely to benefit from a drug but are at risk for adverse events, use of the drug in these individuals can be de-prioritized or delayed.
  • An example of a large trial which analyzed the benefits of statin treatment for reducing the risk of CVD in a large population was the JUPITER Study (described in Ridker et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein”, N Engl J Med. 2008 Nov. 20; 359(21):2195-207), which demonstrated that rosuvastatin (Crestor®) significantly reduced the incidence of major cardiovascular events (including MI, stroke, arterial revascularization, hospitalization for unstable angina, and death from cardiovascular causes) in a study of 17,802 individuals.
  • The benefits of using statins for stroke is also described in O'Regan et al., “Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients”, Am J Med. 2008 January; 121(1):24-33 and Everett et al., “Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)”, Circulation. 2010 Jan. 5; 121(1):143-50.
  • Cardiovascular Disease (CVD), Including Coronary Heart Disease (CHD) and Stroke
  • Cardiovascular disease (CVD) includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke and transient ischemic attack (TIA).
  • Coronary heart disease (CHD) is defined herein as encompassing MI (fatal or non-fatal) and other coronary events, death from coronary disease, angina pectoris (particularly unstable angina), and coronary stenosis. The presence of CHD may be indicated by the occurrence of medical interventions such as coronary revascularization, which can include percutaneous transluminal coronary angioplasty (PTCA), coronary stent placement, and coronary artery bypass graft (CABG). Cardiovascular disease (CVD) is defined herein as encompassing CHD as well as cerebrovascular events such as stroke and transient ischemic attack (TIA).
  • Myocardial Infarction (MI)
  • Myocardial infarction (MI) is encompassed within CHD. MI, also referred to as a “heart attack”, is the most common cause of mortality in developed countries. The incidence of MI is still high despite currently available preventive measures and therapeutic intervention. More than 1,500,000 people in the U.S. suffer acute MI each year, many without seeking help due to unrecognized MI, and one third of these people die. The lifetime risk of coronary artery disease events at age 40 is 42.4% for men, nearly one in two, and 24.9% for women, or one in four (D. M. Lloyd-Jones, Lancet 353:89-92 (1999)).
  • MI is a multifactorial disease that involves atherogenesis, thrombus formation and propagation. Thrombosis can result in complete or partial occlusion of coronary arteries. The luminal narrowing or blockage of coronary arteries reduces oxygen and nutrient supply to the cardiac muscle (cardiac ischemia), leading to myocardial necrosis and/or stunning. MI, unstable angina, and sudden ischemic death are clinical manifestations of cardiac muscle damage. All three endpoints are part of acute coronary syndrome since the underlying mechanisms of acute complications of atherosclerosis are considered to be the same.
  • Atherogenesis, the first step of pathogenesis of MI, is an interaction between blood elements, mechanical forces, disturbed blood flow, and vessel wall abnormality that results in plaque accumulation. An unstable (vulnerable) plaque is an underlying cause of arterial thrombotic events and MI. A vulnerable plaque is a plaque, often not stenotic, that has a high likelihood of becoming disrupted or eroded, thus forming a thrombogenic focus. The “vulnerability” of an individual to MI may be due to vulnerable plaque, blood vulnerability (hypercoagulation, hypothrombolysis), and heart vulnerability (sensitivity of the heart to ischemia or propensity for arrhythmia). Recurrent myocardial infarction (RMI) can generally be viewed as a severe form of MI progression caused by multiple vulnerable plaques that are able to undergo pre-rupture or a pre-erosive state, coupled with extreme blood coagulability.
  • The current diagnosis of MI with presentation (rather than to predict if MI is likely to occur in the future) is based on the levels of troponin I or T that indicate the cardiac muscle progressive necrosis, impaired electrocardiogram (ECG), and detection of abnormal ventricular wall motion or angiographic data (the presence of acute thrombi). However, due to the asymptomatic nature of 25% of acute MIs (absence of atypical chest pain, low ECG sensitivity), a significant portion of MIs are not diagnosed and therefore not treated appropriately (e.g., prevention of recurrent MIs).
  • MI risk assessment and prognosis is currently done using classic risk factors or the recently introduced Framingham Risk Index. Both of these assessments put a significant weight on LDL levels to justify preventive treatment. However, it is well established that half of all MIs occur in individuals without overt hyperlipidemia.
  • Other emerging risk factors of MI are inflammatory biomarkers such as C-reactive protein (CRP), ICAM-1, SAA, TNF a, homocysteine, impaired fasting glucose, new lipid markers (ox LDL, Lp-a, MAD-LDL, etc.) and pro-thrombotic factors (fibrinogen, PAI-1). These markers have significant limitations such as low specificity and low positive predictive value, and the need for multiple reference intervals to be used for different groups of people (e.g., males-females, smokers-non smokers, hormone replacement therapy users, different age groups). These limitations diminish the utility of such markers as independent prognostic markers for MI screening.
  • Genetics plays an important role in MI risk. Families with a positive family history of MI account for 14% of the general population, 72% of premature MIs, and 48% of all MIs (R. R. Williams, Am J Cardiology 87:129 (2001)). Associations have been reported between genetic polymorphisms and MI risk. For example, polymorphism in the KIF6, LPA, and other genes and chromosomal regions are associated with MI risk (Shiffman et al., “Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study”, Arterioscler Thromb Vasc Biol. 2008 January; 28(1):173-9; Bare et al., “Five common gene variants identify elevated genetic risk for coronary heart disease”, Genet Med. 2007 October; 9(10):682-9; Iakoubova et al., “Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):435-43; and Shiffman et al., “A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):444-8.
  • Genetic markers such as single nucleotide polymorphisms (SNPs) are preferable to other types of biomarkers. Genetic markers that are prognostic for MI can be genotyped early in life and could predict individual response to various risk factors. The combination of serum protein levels and genetic predisposition revealed by genetic analysis of susceptibility genes can provide an integrated assessment of the interaction between genotypes and environmental factors, resulting in synergistically increased prognostic value of diagnostic tests.
  • Thus, there is an urgent need for novel genetic markers that are predictive of predisposition to CHD such as MI, particularly for individuals who are unrecognized as having a predisposition to MI. Such genetic markers may enable prognosis of MI in much larger populations compared with the populations that can currently be evaluated by using existing risk factors and biomarkers. The availability of a genetic test may allow, for example, appropriate preventive treatments for acute coronary events to be provided for susceptible individuals (such preventive treatments may include, for example, statin treatments and statin dose escalation, as well as changes to modifiable risk factors), lowering of the thresholds for ECG and angiography testing, and allow adequate monitoring of informative biomarkers. Moreover, the discovery of genetic markers associated with MI can provide novel targets for therapeutic intervention or preventive treatments of MI, and enable the development of new therapeutic agents for treating or preventing MI and other cardiovascular disorders.
  • Furthermore, novel genetic markers that are predictive of predisposition to MI can be particularly useful for identifying individuals who are at risk for early-onset MI. “Early-onset MI” may be defined as MI in men who are less than 55 years of age and women who are less than 65 years of age (K. O. Akosah et al., “Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform?” JACC 41(9):1475-1479 (2003)). Individuals who experience early-onset MI may not be effectively identified by current cholesterol treatment guidelines, such as those suggested by the National Cholesterol Education Program. In one study, for example, a significant number of individuals who suffered MI at an earlier age (≦50 years) were shown to have LDL cholesterol below 100 mg/dl (K. O. Akosah et al., “Myocardial infarction in young adults with low-density lipoprotein cholesterol levels less than or equal to 100 mg/dl. Clinical profile and 1-year outcomes.” Chest 120:1953-1958 (2001)). Because risk for MI can be reduced by lifestyle changes and by treatment of modifiable risk factors, better methods to identify individuals at risk for early-onset MI could be useful for making preventive treatment decisions, especially considering that these patients may not be identified for medical management by conventional treatment guidelines. Genetic markers for risk of early-onset MI could potentially be incorporated into individual risk assessment protocols, as they have the advantage of being easily detected at any age.
  • Stroke
  • Stroke is a prevalent and serious cerebrovascular disease. It affects 4.7 million individuals in the United States, with 500,000 first attacks and 200,000 recurrent cases yearly. Approximately one in four men and one in five women aged 45 years will have a stroke if they live to their 85th year. About 25% of those who have a stroke die within a year. Stroke is the third leading cause of mortality in the United States and is responsible for 170,000 deaths a year. Among those who survive a stroke attack, 30 to 50% do not regain functional independence. Stroke therefore is the most common cause of disability and the second leading cause of dementia (Heart Disease and Stroke Statistics—2004 Update, American Heart Association).
  • Stroke occurs when an artery bringing oxygen and nutrients to the brain either ruptures, causing hemorrhagic stroke, or gets occluded, causing ischemic stroke. Ischemic stroke can be caused by thrombi formation at the site of an atherosclerotic plaque rupture (this type of ischemic stroke is interchangeably referred to as thrombotic or atherothrombotic stroke) or by emboli (clots) that have travelled from another part of the vasculature (this type of ischemic stroke is referred to as embolic stroke), often from the heart (this type of embolic stroke may be referred to as cardioembolic stroke). In both ischemic and hemorrhagic stroke, a cascade of cellular changes due to ischemia or increased cranial pressure leads to injuries or death of the brain cells. In the United States, the majority (about 80-90%) of stroke cases are ischemic (Rathore, et al., Stroke 33:2718-2721 ((2002)), including 30% large-vessel thrombotic (also referred to as large-vessel occlusive disease), 20% small-vessel thrombotic (also referred to as small-vessel occlusive disease), and 30% embolic or cardiogenic (caused by a clot originating from elsewhere in the body, e.g., from blood pooling due to atrial fibrillation, or from carotid artery stenosis). The ischemic form of stroke results from obstruction of blood flow in cerebral blood vessels, and it shares common pathological etiology with atherosclerosis and thrombosis.
  • About 10-20% of stroke cases are of the hemorrhagic type (Rathore, et al., Stroke 33:2718-2721 ((2002)), involving bleeding within or around the brain. Bleeding within the brain is known as cerebral hemorrhage, which is often linked to high blood pressure. Bleeding into the meninges surrounding the brain is known as a subarachnoid hemorrhage, which could be caused by a ruptured cerebral aneurysm, an arteriovenous malformation, or a head injury. The hemorrhagic stroke, although less prevalent, poses a greater danger. Whereas about 8% of ischemic stroke cases result in death within 30 days, about 38% of hemorrhagic stroke cases result in death within the same time period (Collins, et al., J. Clin. Epidemiol. 56:81-87 (2003)).
  • Transient ischemic attack (TIA) is a condition related to stroke. According to the National Institute of Neurological Disorders and Stroke (NINDS), “A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination”. NINDS further states that, “TIAs are often warning signs that a person is at risk for a more serious and debilitating stroke. About one-third of those who have a TIA will have an acute stroke some time in the future. Many strokes can be prevented by heeding the warning signs of TIAs and treating underlying risk factors.”
  • Known risk factors for stroke or TIA can be divided into modifiable and non-modifiable risk factors. Older age, male sex, black or Hispanic ethnicity, and family history of stroke are non-modifiable risk factors. Modifiable risk factors include hypertension, smoking, increased insulin levels, asymptomatic carotid disease, cardiac vessel disease, and hyperlipidemia.
  • Multiple reports based on twin studies (Brass et al., Stroke. 1992; 23:221-223 and Bak et al., Stroke. 2002; 33:769-774) and family studies (Welin L, et al. N Engl J Med. 1987; 317:521-526 and Jousilahti et al., Stroke. 1997; 28:1361-136) have shown that genetics contributes to risk of stroke independently of traditional risk factors. A number of genetic markers have been reported to be associated with stroke. For example, SNPs in the 4q25 region were reported to be associated with stroke (Gretarsdottir et al., “Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke”, Ann Neurol. 2008; 64:402-409) and with atrial fibrillation (AF) (Gudbjartsson et al., “Variants conferring risk of atrial fibrillation on chromosome 4q25”, Nature. 2007; 448:353-357), SNPs in the 16q22 region (Gudbjartsson et al., “A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke”, Nat Genet. 2009; 41:876-878) and in the 9p21 region were found to be associated with noncardioembolic or atherothrombotic stroke (Luke et al., “Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: vienna stroke registry”, Cerebrovasc Dis. 2009; 28:499-504 and Gschwendtner et al., “Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke”, Ann Neurol. 2009; 65:531-539), and variants in the 12p13 region were associated with stroke in general and with atherothrombotic stroke in particular (Ikram et al., “Genomewide association studies of stroke”, N Engl J Med. 2009; 360:1718-1728).
  • The acute nature of stroke leaves physicians with little time to prevent or lessen the devastation of brain damage. Strategies to diminish the impact of stroke include prevention and treatment with thrombolytic and, possibly, neuroprotective agents. The success of preventive measures will depend on the identification of risk factors in individual patients and means to modulate their impact.
  • Although some risk factors for stroke or TIA are not modifiable, such as age and family history, other underlying pathology or risk factors of stroke or TIA such as atherosclerosis, hypertension, smoking, diabetes, aneurysm, and atrial fibrillation, are chronic and amenable to effective life-style changes, pharmacological interventions, as well as surgical treatments. Early recognition of patients with informative risk factors, and especially those with a family history, using a non-invasive test of genetic markers associated with stroke can enable physicians to target the highest risk individuals for aggressive risk reduction.
  • Thus, there is a need for the identification of genetic markers that are predictive of an individual's predisposition to stroke or TIA and other vascular diseases. Furthermore, the identification of genetic markers which are useful for identifying individuals who are at an increased risk of having a stroke may lead to, for example, better preventive and therapeutic strategies, economic models, and health care policy decisions.
  • Single Nucleotide Polymorphisms (SNPs)
  • The genomes of all organisms undergo spontaneous mutations in the course of their continuing evolution, generating variant forms of progenitor genetic sequences. Gusella, Ann Rev Biochem 55:831-854 (1986). A variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. In some instances, a variant form confers an evolutionary advantage to individual members of a species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. Additionally, the effects of a variant form may be both beneficial and detrimental, depending on the environment. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. In many cases, both progenitor and variant forms survive and co-exist in a species population. The coexistence of multiple forms of a genetic sequence segregating at appreciable frequencies is defined as a genetic polymorphism, which includes single nucleotide polymorphisms (SNPs).
  • Approximately 90% of all genetic polymorphisms in the human genome are SNPs. SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population. The SNP position (interchangeably referred to herein as SNP, SNP site, SNP locus, SNP marker, or marker) is usually preceded by and followed by highly conserved sequences (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual may be homozygous or heterozygous for an allele at each SNP position. A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP is an amino acid coding sequence.
  • A SNP may arise from a substitution of one nucleotide for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or vice versa. A SNP may also be a single base insertion or deletion variant referred to as an “indel.” Weber et al., “Human diallelic insertion/deletion polymorphisms,” Am J Hum Genet 71(4):854-62 (October 2002).
  • A synonymous codon change, or silent mutation/SNP (terms such as “SNP”, “polymorphism”, “mutation”, “mutant”, “variation”, and “variant” are used herein interchangeably), is one that does not result in a change of amino acid due to the degeneracy of the genetic code. A substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid (i.e., a non-synonymous codon change) is referred to as a missense mutation. A nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein. A read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product. While SNPs can be bi-, tri-, or tetra-allelic, the vast majority of SNPs are bi-allelic, and are thus often referred to as “bi-allelic markers,” or “di-allelic markers.”
  • As used herein, references to SNPs and SNP genotypes include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases. Stephens et al., Science 293:489-493 (July 2001).
  • Causative SNPs are those SNPs that produce alterations in gene expression or in the expression, structure, and/or function of a gene product, and therefore are most predictive of a possible clinical phenotype. One such class includes SNPs falling within regions of genes encoding a polypeptide product, i.e. cSNPs. These SNPs may result in an alteration of the amino acid sequence of the polypeptide product (i.e., non-synonymous codon changes) and give rise to the expression of a defective or other variant protein. Furthermore, in the case of nonsense mutations, a SNP may lead to premature termination of a polypeptide product. Such variant products can result in a pathological condition, e.g., genetic disease. Examples of genes in which a SNP within a coding sequence causes a genetic disease include sickle cell anemia and cystic fibrosis.
  • Causative SNPs do not necessarily have to occur in coding regions; causative SNPs can occur in, for example, any genetic region that can ultimately affect the expression, structure, and/or activity of the protein encoded by a nucleic acid. Such genetic regions include, for example, those involved in transcription, such as SNPs in transcription factor binding domains, SNPs in promoter regions, in areas involved in transcript processing, such as SNPs at intron-exon boundaries that may cause defective splicing, or SNPs in mRNA processing signal sequences such as polyadenylation signal regions. Some SNPs that are not causative SNPs nevertheless are in close association with, and therefore segregate with, a disease-causing sequence. In this situation, the presence of a SNP correlates with the presence of, or predisposition to, or an increased risk in developing the disease. These SNPs, although not causative, are nonetheless also useful for diagnostics, disease predisposition screening, and other uses.
  • An association study of a SNP and a specific disorder involves determining the presence or frequency of the SNP allele in biological samples from individuals with the disorder of interest, such as CVD, and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals) who are preferably of similar age and race. The appropriate selection of patients and controls is important to the success of SNP association studies. Therefore, a pool of individuals with well-characterized phenotypes is extremely desirable.
  • A SNP may be screened in diseased tissue samples or any biological sample obtained from a diseased individual, and compared to control samples, and selected for its increased (or decreased) occurrence in a specific pathological condition, such as pathologies related to CVD and in particular, CHD (e.g., MI). Once a statistically significant association is established between one or more SNP(s) and a pathological condition (or other phenotype) of interest, then the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence(s) (e.g., causative SNP/mutation, gene, regulatory region, etc.) that influences the pathological condition or phenotype. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies).
  • Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. There is a continuing need to improve pharmaceutical agent design and therapy. In that regard, SNPs can be used to identify patients most suited to therapy with particular pharmaceutical agents (this is often termed “pharmacogenomics”). Similarly, SNPs can be used to exclude patients from certain treatment due to the patient's increased likelihood of developing toxic side effects or their likelihood of not responding to the treatment. Pharmacogenomics can also be used in pharmaceutical research to assist the drug development and selection process. Linder et al., Clinical Chemistry 43:254 (1997); Marshall, Nature Biotechnology 15:1249 (1997); International Patent Application WO 97/40462, Spectra Biomedical; and Schafer et al., Nature Biotechnology 16:3 (1998).
  • SUMMARY OF THE INVENTION
  • Exemplary embodiments of the present invention relate to the identification of SNPs, as well as unique combinations of such SNPs and haplotypes of SNPs, that are associated with variability between individuals in their response to statins, particularly for the prevention or treatment of cardiovascular disease (CVD), which includes coronary heart disease (CHD) (which further includes myocardial infarction (MI) and other coronary events) and cerebrovascular events such as stroke. These SNPs are also useful for determining an individual's risk for developing CVD, particularly CHD (including coronary events such as MI) as well as cerebrovascular events such as stroke. The polymorphisms disclosed herein are directly useful as targets for the design of diagnostic and prognostic reagents and the development of therapeutic and preventive agents for use in the diagnosis, prognosis, treatment, and/or prevention of CVD (particularly CHD, such as MI), as well as for predicting a patient's response to therapeutic agents such as statins, particularly for the treatment or prevention of CVD (particularly CHD, such as MI).
  • Based on the identification of SNPs associated with variability between individuals in their response to statins, particularly for reducing the risk of CVD such as CHD (e.g., MI) and stroke, exemplary embodiments of the present invention also provide methods of detecting these variants as well as the design and preparation of detection reagents needed to accomplish this task. The invention specifically provides, for example, SNPs associated with responsiveness to statin treatment, isolated nucleic acid molecules (including DNA and RNA molecules) containing these SNPs, variant proteins encoded by nucleic acid molecules containing such SNPs, antibodies to the encoded variant proteins, computer-based and data storage systems containing the novel SNP information, methods of detecting these SNPs in a test sample, methods of identifying individuals who have an altered (i.e., increased or decreased) risk of developing CVD (such as CHD (e.g., MI) or stroke), methods for determining the risk of an individual for recurring CVD (e.g., recurrent MI), methods of treating an individual who has an increased risk for CVD and/or increased likelihood of responding to statin treatment, and methods for identifying individuals (e.g., determining a particular individual's likelihood) who have an altered (i.e., increased or decreased) likelihood of responding to drug treatment (especially statin treatment), particularly drug treatment of CVD (e.g., prevention or treatment of CHD such as MI), based on the presence or absence of one or more particular nucleotides (alleles) at one or more SNP sites disclosed herein or the detection of one or more encoded variant products (e.g., variant mRNA transcripts or variant proteins), methods of screening for compounds useful in the treatment or prevention of CVD, compounds identified by these methods, methods of treating or preventing CVD, etc.
  • Exemplary embodiments of the present invention further provide methods for selecting or formulating a treatment regimen (e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for developing CVD in the future, or who has previously had CVD, methods for selecting a particular statin-based treatment regimen such as dosage and frequency of administration of statin, or a particular form/type of statin such as a particular pharmaceutical formulation or statin compound, methods for administering (either in addition to or instead of a statin) an alternative, non-statin-based treatment, such as niacin, fibrates, or ezetimibe (e.g., Zetia® or Ezetrol®), to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and methods for determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, etc. Various embodiments of the present invention also provide methods for selecting individuals to whom a statin or other therapeutic will be administered based on the individual's genotype, and methods for selecting individuals for a clinical trial of a statin or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s), or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them). Further embodiments of the present invention provide methods for reducing an individual's risk of developing CVD (such as CHD (e.g., MI) or stroke) using statin treatment, including preventing recurring CVD (e.g., recurrent MI) using statin treatment, when said individual carries one or more SNPs identified herein as being associated with statin response.
  • Tables 1 and 2 provides gene information, references to the identification of transcript sequences (SEQ ID NOS:1-51), encoded amino acid sequences (SEQ ID NOS:52-102), genomic sequences (SEQ ID NOS:177-622), transcript-based context sequences (SEQ ID NOS:103-176) and genomic-based context sequences (SEQ ID NOS:623-3661) that contain the SNPs of the present application, and extensive SNP information that includes observed alleles, allele frequencies, populations/ethnic groups in which alleles have been observed, information about the type of SNP and corresponding functional effect, and, for cSNPs, information about the encoded polypeptide product. The actual transcript sequences (SEQ ID NOS:1-51), amino acid sequences (SEQ ID NOS:52-102), genomic sequences (SEQ ID NOS:177-622), transcript-based SNP context sequences (SEQ ID NOS:103-176), and genomic-based SNP context sequences (SEQ ID NOS:623-3661) are provided in the Sequence Listing.
  • In certain exemplary embodiments, the invention provides methods for identifying an individual who has an altered likelihood of responding to statin treatment or an altered risk for developing CVD, particularly CHD or stroke (including, for example, a first incidence and/or a recurrence of the disease, such as primary or recurrent MI), in which the method comprises detecting a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences of SEQ ID NOS:1-51, SEQ ID NOS:103-176, SEQ ID NOS:177-622, and SEQ ID NOS:623-3661 in said individual's nucleic acids, wherein the SNP is specified in Table 1 and/or Table 2, and the presence of the SNP is indicative of an altered response to statin treatment of an altered risk for CVD in said individual. In certain embodiments, the CVD is CHD, particularly MI. In certain other embodiments, the CVD is stroke. In certain exemplary embodiments of the invention, SNPs that occur naturally in the human genome are provided within isolated nucleic acid molecules. These SNPs are associated with response to statin treatment thereby reducing the risk of CVD, such as CHD (e.g., MI) or stroke, such that they can have a variety of uses in the diagnosis, prognosis, treatment, and/or prevention of CVD, and particularly in the treatment or prevention of CVD using statins. In certain embodiments, a nucleic acid of the invention is an amplified polynucleotide, which is produced by amplification of a SNP-containing nucleic acid template. In another embodiment, the invention provides for a variant protein that is encoded by a nucleic acid molecule containing a SNP disclosed herein.
  • In further embodiments of the invention, reagents for detecting a SNP in the context of its naturally-occurring flanking nucleotide sequences (which can be, e.g., either DNA or mRNA) are provided. In particular, such a reagent may be in the form of, for example, a hybridization probe or an amplification primer that is useful in the specific detection of a SNP of interest. In an alternative embodiment, a protein detection reagent is used to detect a variant protein that is encoded by a nucleic acid molecule containing a SNP disclosed herein. A preferred embodiment of a protein detection reagent is an antibody or an antigen-reactive antibody fragment. Various embodiments of the invention also provide kits comprising SNP detection reagents, and methods for detecting the SNPs disclosed herein by employing the SNP detection reagents. An exemplary embodiment of the present invention provides a kit comprising a SNP detection reagent for use in determining whether a human's risk for CVD is reduced by treatment with statins based upon the presence or absence of a particular allele of one or more SNPs disclosed herein.
  • In various embodiments, the present invention provides methods for evaluating whether an individual is likely (or unlikely) to respond to statin treatment (i.e., benefit from statin treatment)), particularly statin treatment for reducing the risk of CVD, particularly CHD (such as MI) or stroke, by detecting the presence or absence of one or more SNP alleles disclosed herein. The present invention also provides methods of identifying an individual having an increased or decreased risk of developing CVD, such as CHD (e.g., MI) or stroke, by detecting the presence or absence of one or more SNP alleles disclosed herein.
  • In certain embodiments, the presence of a statin response allele disclosed herein in Tables 4-22 (an allele associated with increased response to statin treatment for reducing CVD or CHD risk) is detected and indicates that an individual has an increased risk for developing CVD, such as CHD (e.g., MI) or stroke. In these embodiments, in which the same allele is associated with both increased risk for developing CVD and increased response to statin treatment (i.e., the same allele is both a risk and a response allele), this increased risk for developing CVD can be reduced by administering statin treatment to an individual having the allele.
  • The nucleic acid molecules of the invention can be inserted in an expression vector, such as to produce a variant protein in a host cell. Thus, the present invention also provides for a vector comprising a SNP-containing nucleic acid molecule, genetically-engineered host cells containing the vector, and methods for expressing a recombinant variant protein using such host cells. In another specific embodiment, the host cells, SNP-containing nucleic acid molecules, and/or variant proteins can be used as targets in a method for screening and identifying therapeutic agents or pharmaceutical compounds useful in the treatment or prevention of CVD, such as CHD (e.g., MI) or stroke.
  • An aspect of this invention is a method for treating or preventing CVD such as CHD or stroke (including, for example, a first occurrence and/or a recurrence of the disease, such as primary or recurrent MI), in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1 and 2, which method comprises administering to said human subject a therapeutically or prophylactically effective amount of one or more agents counteracting the effects of the disease, such as by inhibiting (or stimulating) the activity of a gene, transcript, and/or encoded protein identified in Tables 1 and 2.
  • Another aspect of this invention is a method for identifying an agent useful in therapeutically or prophylactically treating CVD (particularly CHD or stroke), in a human subject wherein said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1 and 2, which method comprises contacting the gene, transcript, or encoded protein with a candidate agent under conditions suitable to allow formation of a binding complex between the gene, transcript, or encoded protein and the candidate agent and detecting the formation of the binding complex, wherein the presence of the complex identifies said agent.
  • Another aspect of this invention is a method for treating or preventing CVD such as CHD (e.g., MI) or stroke, in a human subject, in which the method comprises:
  • (i) determining that said human subject harbors a SNP, gene, transcript, and/or encoded protein identified in Tables 1 and 2, and
  • (ii) administering to said subject a therapeutically or prophylactically effective amount of one or more agents counteracting the effects of the disease, such as statins.
  • Another aspect of the invention is a method for identifying a human who is likely to benefit from statin treatment, in which the method comprises detecting an allele of one or more SNPs disclosed herein in said human's nucleic acids, wherein the presence of the allele indicates that said human is likely to benefit from statin treatment.
  • Another aspect of the invention is a method for identifying a human who is likely to benefit from statin treatment, in which the method comprises detecting an allele of one or more SNPs that are in LD with one or more SNPs disclosed herein in said human's nucleic acids, wherein the presence of the allele of the LD SNP indicates that said human is likely to benefit from statin treatment.
  • Many other uses and advantages of the present invention will be apparent to those skilled in the art upon review of the detailed description of the exemplary embodiments herein. Solely for clarity of discussion, the invention is described in the sections below by way of non-limiting examples.
  • Description of the Text (ASCII) Files Submitted Electronically Via EFS-Web
  • The following three text (ASCII) files are submitted electronically via EFS-Web as part of the instant application:
  • 1) File SEQLIST_CD000027ORD.txt provides the Sequence Listing. The Sequence Listing provides the transcript sequences (SEQ ID NOS:1-51) and protein sequences (SEQ ID NOS:52-102) as referred to in Table 1, and genomic sequences (SEQ ID NOS:177-622) as referred to in Table 2, for each gene (or genomic region for intergenic SNPs) that contains one or more statin response-associated SNPs of the present invention. Also provided in the Sequence Listing are context sequences flanking each SNP, including both transcript-based context sequences as referred to in Table 1 (SEQ ID NOS:103-176) and genomic-based context sequences as referred to in Table 2 (SEQ ID NOS:623-3661). The context sequences generally provide 100 bp upstream (5′) and 100 bp downstream (3′) of each SNP, with the SNP in the middle of the context sequence, for a total of 200 bp of context sequence surrounding each SNP. File SEQLIST_CD000027ORD.txt is 63,960 KB in size, and was created on Apr. 5, 2011.
  • LENGTHY TABLES
    The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160108473A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).
  • 2) File TABLE1_CD000027ORD.txt provides Table 1, which is 78 KB in size and was created on Apr. 6, 2011.
  • 3) File TABLE2_CD000027ORD.txt provides Table 2, which is 1,971 KB in size and was created on Apr. 6, 2011.
  • These three text files are hereby incorporated by reference pursuant to 37 CFR 1.77(b)(4).
  • Description of Table 1 and Table 2
  • Table 1 and Table 2 (both submitted electronically via EFS-Web as part of the instant application) disclose the SNP and associated gene/transcript/protein information and sequences for the SNPs disclosed in Tables 4-22, as well as for the LD SNPs disclosed in Table 3. Table 1 is based on transcript and protein sequences, whereas Table 2 is based on genomic sequences.
  • For each gene, Table 1 provides a header containing gene, transcript and protein information, followed by a transcript and protein sequence identifier (SEQ ID NO), and then SNP information regarding each SNP found in that gene/transcript including the transcript context sequence. For each gene in Table 2, a header is provided that contains gene and genomic information, followed by a genomic sequence identifier (SEQ ID NO) and then SNP information regarding each SNP found in that gene, including the genomic context sequence.
  • Note that SNP markers may be included in both Table 1 and Table 2; Table 1 presents the SNPs relative to their transcript sequences and encoded protein sequences, whereas Table 2 presents the SNPs relative to their genomic sequences. In some instances Table 2 may also include, after the last gene sequence, genomic sequences of one or more intergenic regions, as well as SNP context sequences and other SNP information for any SNPs that lie within these intergenic regions. Additionally, in either Table 1 or 2, a “Related Interrogated SNP” may be listed following a SNP which is determined to be in LD with that interrogated SNP according to the given Power value. SNPs can be readily cross-referenced between all Tables based on their Celera hCV (or, in some instances, hDV) identification numbers and/or public rs identification numbers, and to the Sequence Listing based on their corresponding SEQ ID NOs.
  • The gene/transcript/protein information includes:
      • a gene number (1 through n, where n=the total number of genes in the Table),
      • a gene symbol, along with an Entrez gene identification number (Entrez Gene database, National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), National Institutes of Health (NIH))
      • a gene name,
      • an accession number for the transcript (e.g., RefSeq NM number, or a Celera hCT identification number if no RefSeq NM number is available) (Table 1 only),
      • an accession number for the protein (e.g., RefSeq NP number, or a Celera hCP identification number if no RefSeq NP number is available) (Table 1 only),
      • the chromosome number of the chromosome on which the gene is located,
      • an OMIM (“Online Mendelian Inheritance in Man” database, Johns Hopkins University/NCBI) public reference number for the gene, and OMIM information such as alternative gene/protein name(s) and/or symbol(s) in the OMIM entry.
  • Note that, due to the presence of alternative splice forms, multiple transcript/protein entries may be provided for a single gene entry in Table 1; i.e., for a single Gene Number, multiple entries may be provided in series that differ in their transcript/protein information and sequences.
  • Following the gene/transcript/protein information is a transcript context sequence (Table 1), or a genomic context sequence (Table 2), for each SNP within that gene.
  • After the last gene sequence, Table 2 may include additional genomic sequences of intergenic regions (in such instances, these sequences are identified as “Intergenic region:” followed by a numerical identification number), as well as SNP context sequences and other SNP information for any SNPs that lie within each intergenic region (such SNPs are identified as “INTERGENIC” for SNP type).
  • Note that the transcript, protein, and transcript-based SNP context sequences are all provided in the Sequence Listing. The transcript-based SNP context sequences are provided in both Table 1 and also in the Sequence Listing. The genomic and genomic-based SNP context sequences are provided in the Sequence Listing. The genomic-based SNP context sequences are provided in both Table 2 and in the Sequence Listing. SEQ ID NOs are indicated in Table 1 for the transcript-based context sequences (SEQ ID NOS:103-176); SEQ ID NOs are indicated in Table 2 for the genomic-based context sequences (SEQ ID NOS:623-3661).
  • The SNP information includes:
      • Context sequence (taken from the transcript sequence in Table 1, the genomic sequence in Table 2) with the SNP represented by its IUB code, including 100 bp upstream (5′) of the SNP position plus 100 bp downstream (3′) of the SNP position (the transcript-based SNP context sequences in Table 1 are provided in the Sequence Listing as SEQ ID NOS:103-176; the genomic-based SNP context sequences in Table 2 are provided in the Sequence Listing as SEQ ID NOS:623-3661).
      • Celera hCV internal identification number for the SNP (in some instances, an “hDV” number is given instead of an “hCV” number).
      • The corresponding public identification number for the SNP, the rs number.
      • “SNP Chromosome Position” indicates the nucleotide position of the SNP along the entire sequence of the chromosome as provided in NCBI Genome Build 36.
      • SNP position (nucleotide position of the SNP within the given transcript sequence (Table 1) or within the given genomic sequence (Table 2)).
      • “Related Interrogated SNP” is the interrogated SNP with which the listed SNP is in LD at the given value of Power.
      • SNP source (may include any combination of one or more of the following five codes, depending on which internal sequencing projects and/or public databases the SNP has been observed in: “Applera”=SNP observed during the re-sequencing of genes and regulatory regions of 39 individuals, “Celera”=SNP observed during shotgun sequencing and assembly of the Celera human genome sequence, “Celera Diagnostics”=SNP observed during re-sequencing of nucleic acid samples from individuals who have a disease, “dbSNP”=SNP observed in the dbSNP public database, “HGBASE”=SNP observed in the HGBASE public database, “HGMD”=SNP observed in the Human Gene Mutation Database (HGMD) public database, “HapMap”=SNP observed in the International HapMap Project public database, “CSNP”=SNP observed in an internal Applied Biosystems (Foster City, Calif.) database of coding SNPS (cSNPs).
  • Note that multiple “Applera” source entries for a single SNP indicate that the same SNP was covered by multiple overlapping amplification products and the re-sequencing results (e.g., observed allele counts) from each of these amplification products is being provided.
      • Population/allele/allele count information in the format of [population1(first_allele,count|second_allele,count)population2(first_allele,count|second_allele,count) total (first_allele,total count|second_allele,total count)]. The information in this field includes populations/ethnic groups in which particular SNP alleles have been observed (“cau”=Caucasian, “his”=Hispanic, “chn”=Chinese, and “afr”=African-American, “jpn”=Japanese, “ind”=Indian, “mex”=Mexican, “ain”=“American Indian, “cra”=Celera donor, “no_pop”=no population information available), identified SNP alleles, and observed allele counts (within each population group and total allele counts), where available [“−” in the allele field represents a deletion allele of an insertion/deletion (“indel”) polymorphism (in which case the corresponding insertion allele, which may be comprised of one or more nucleotides, is indicated in the allele field on the opposite side of the “|”); “−” in the count field indicates that allele count information is not available]. For certain SNPs from the public dbSNP database, population/ethnic information is indicated as follows (this population information is publicly available in dbSNP): “HISP1”=human individual DNA (anonymized samples) from 23 individuals of self-described HISPANIC heritage; “PAC1”=human individual DNA (anonymized samples) from 24 individuals of self-described PACIFIC RIM heritage; “CAUC1”=human individual DNA (anonymized samples) from 31 individuals of self-described CAUCASIAN heritage; “AFR1”=human individual DNA (anonymized samples) from 24 individuals of self-described AFRICAN/AFRICAN AMERICAN heritage; “P1”=human individual DNA (anonymized samples) from 102 individuals of self-described heritage; “PA130299515”; “SC_12_A”=SANGER 12 DNAs of Asian origin from Corielle cell repositories, 6 of which are male and 6 female; “SC_12_C”=SANGER 12 DNAs of Caucasian origin from Corielle cell repositories from the CEPH/UTAH library, six male and six female; “SC_12_AA”=SANGER 12 DNAs of African-American origin from Corielle cell repositories 6 of which are male and 6 female; “SC_95_C”=SANGER 95 DNAs of Caucasian origin from Corielle cell repositories from the CEPH/UTAH library; and “SC_12_CA”=Caucasians—12 DNAs from Corielle cell repositories that are from the CEPH/UTAH library, six male and six female.
  • Note that for SNPs of “Applera” SNP source, genes/regulatory regions of 39 individuals (20 Caucasians and 19 African Americans) were re-sequenced and, since each SNP position is represented by two chromosomes in each individual (with the exception of SNPs on X and Y chromosomes in males, for which each SNP position is represented by a single chromosome), up to 78 chromosomes were genotyped for each SNP position. Thus, the sum of the African-American (“afr”) allele counts is up to 38, the sum of the Caucasian allele counts (“cau”) is up to 40, and the total sum of all allele counts is up to 78.
  • Note that semicolons separate population/allele/count information corresponding to each indicated SNP source; i.e., if four SNP sources are indicated, such as “Celera,” “dbSNP,” “HGBASE,” and “HGMD,” then population/allele/count information is provided in four groups which are separated by semicolons and listed in the same order as the listing of SNP sources, with each population/allele/count information group corresponding to the respective SNP source based on order; thus, in this example, the first population/allele/count information group would correspond to the first listed SNP source (Celera) and the third population/allele/count information group separated by semicolons would correspond to the third listed SNP source (HGBASE); if population/allele/count information is not available for any particular SNP source, then a pair of semicolons is still inserted as a place-holder in order to maintain correspondence between the list of SNP sources and the corresponding listing of population/allele/count information.
      • SNP type (e.g., location within gene/transcript and/or predicted functional effect) [“MISSENSE MUTATION”=SNP causes a change in the encoded amino acid (i.e., a non-synonymous coding SNP); “SILENT MUTATION”=SNP does not cause a change in the encoded amino acid (i.e., a synonymous coding SNP); “STOP CODON MUTATION”=SNP is located in a stop codon; “NONSENSE MUTATION”=SNP creates or destroys a stop codon; “UTR 5”=SNP is located in a 5′ UTR of a transcript; “UTR 3”=SNP is located in a 3′ UTR of a transcript; “PUTATIVE UTR 5”=SNP is located in a putative 5′ UTR; “PUTATIVE UTR 3”=SNP is located in a putative 3′ UTR; “DONOR SPLICE SITE”=SNP is located in a donor splice site (5′ intron boundary); “ACCEPTOR SPLICE SITE”=SNP is located in an acceptor splice site (3′ intron boundary); “CODING REGION”=SNP is located in a protein-coding region of the transcript; “EXON”=SNP is located in an exon; “INTRON”=SNP is located in an intron; “hmCS”=SNP is located in a human-mouse conserved segment; “TFBS”=SNP is located in a transcription factor binding site; “UNKNOWN”=SNP type is not defined; “INTERGENIC”=SNP is intergenic, i.e., outside of any gene boundary].
      • Protein coding information (Table 1 only), where relevant, in the format of [protein SEQ ID NO, amino acid position, (amino acid-1, codon1) (amino acid-2, codon2)]. The information in this field includes SEQ ID NO of the encoded protein sequence, position of the amino acid residue within the protein identified by the SEQ ID NO that is encoded by the codon containing the SNP, amino acids (represented by one-letter amino acid codes) that are encoded by the alternative SNP alleles (in the case of stop codons, “X” is used for the one-letter amino acid code), and alternative codons containing the alternative SNP nucleotides which encode the amino acid residues (thus, for example, for missense mutation-type SNPs, at least two different amino acids and at least two different codons are generally indicated; for silent mutation-type SNPs, one amino acid and at least two different codons are generally indicated, etc.). In instances where the SNP is located outside of a protein-coding region (e.g., in a UTR region), “None” is indicated following the protein SEQ ID NO.
  • Description of Table 3
  • Table 3 provides a list of linkage disequilibrium (LD) SNPs that are related to and derived from certain interrogated SNPs. The interrogated SNPs, which are those SNPs provided in Tables 4-22, are statistically significantly associated with, for example, response to statin treatment for reducing CVD/CHD risk, as described and shown herein. The LD SNPs provided in Table 3 all have an r2 value at or above 0.9 (which was set as the Threshold r2 value), and are provided as examples of SNPs which can also be used as markers for, for example, response to statin treatment for reducing risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke) based on their being in high LD with an interrogated statin response-associated SNP.
  • In Table 3, the columns labeled “Interrogated SNP” presents each interrogated SNP as identified by its unique hCV and rs identification number. The columns labeled “LD SNP” presents the hCV and rs numbers of the LD SNPs that are derived from their corresponding interrogated SNPs. The column labeled “Threshold r2” presents the minimum value of r2 that an LD SNP must meet in reference to an interrogated SNP in order to be included in Table 3 (the Threshold r2 value is set at 0.9 for all SNPs in Table 3). The column labeled “r2” presents the actual r2 value of the LD SNP in reference to the interrogated SNP to which it is related (since the Threshold r2 value is set at 0.9, all SNPs in Table 3 will have an r2 value at or above 0.9). The criteria for selecting the LD SNPs provided in Table 3 are further described in Example 4 below.
  • Sequences, SNP information, and associated gene/transcript/protein information for each of the LD SNPs listed in Table 3 is provided in Tables 1-2.
  • Description of Tables 4-22
  • Tables 4-22 provide the results of analyses for SNPs disclosed in Tables 1 and 2 (SNPs can be cross-referenced between all the tables herein based on their hCV and/or rs identification numbers). The results shown in Tables 4-22 provide support for the association of these SNPs with, for example, response to statin treatment for reducing the risk of CVD, particularly CHD (e.g., MI) and stroke.
  • Tables 4-8
  • The analyses in Tables 4-8 are further described in Example 1 below.
  • Cohort and case-only study designs were used to identify SNPs associated with response to statin treatment in sample sets from the CARE, WOSCOPS, and PROVE-IT trials (these sample sets, with corresponding references, are described in Example 1 below). Specifically, analyses were carried out using the entire cohorts (individuals with and without incident CHD or CVD events) or cases only (only individuals with an incident CHD or CVD event) from these three sample sets (individually, as well as in combined meta-analyses) to identify SNPs associated with a reduction in the risk of CHD or CVD (CVD includes CHD and stroke) in response to statin treatment, and the results of these analyses are provided in Table 4-7 (Table 8 provides the degree of LD (r2) between pairs of SNPs listed in Tables 5 and 7).
  • Tables 4-7 provides SNPs that had a synergy index (odds ratio) with P value lower than 10−4 in a meta-analysis of CARE and WOSCOPS combined (Table 4-5) or in a meta-analysis of CARE, WOSCOPS, and PROVE-IT combined (Table 6-7), in any genetic model (dominant, recessive, or additive) in either the CHD or CVD endpoint (the CHD or CVD endpoint is indicated in the last column, labeled “Endpoint”, of Tables 4-7, and the genetic model is indicated in the next to last column, labeled “Model”, of Tables 4-7). For each analysis, Tables 4-7 indicate whether the data comes from case-only analysis (“CaseOnly” in the “Source” column) or from analysis of the entire cohort (“cohort” in the “Source” column). Whenever cohort data was available, it was used in the meta-analysis.
  • Tables 4-5 provide meta-analyses of CARE and WOSCOPS combined (2nd section of each table) for two endpoints (CHD and CVD) and three genetic models (dominant, recessive, and additive), as well as logistic regression analyses of CARE (3rd section of each table) and WOSCOPS (4th section of each table) individually.
  • Tables 6-7 provide meta-analyses of CARE, WOSCOPS, and PROVE-IT combined (2nd section of each table) for two endpoints (CHD and CVD) and three genetic models (dominant, recessive, and additive), as well as logistic regression analyses of CARE (3rd section of each table), WOSCOPS (4th section of each table), and PROVE-IT (5th section of each table) individually. For PROVE-IT, there was only one endpoint (the composite primary endpoint of the original PROVE-IT study, which includes some stroke cases), and this endpoint was used in meta-analysis of both CHD and CVD.
  • Tables 5 and 7 provide analyses of certain LD SNPs in CARE and WOSCOPS (Table 5) and in CARE, WOSCOPS, and PROVE-IT (Table 7). For some SNPs, case-only data was available for a first SNP while cohort data was available for a SNP in LD with the first SNP (LD SNP), which occurred when a working kPCR assay could not be made for the first SNP. For these SNPs, the data for case-only analysis and the available data for the cohort is reported. The meta-analysis was performed using the cohort data when available. These SNPs are listed in Tables 5 and 7, with the two SNPs in LD listed one below the other, and the degree of LD between each of these pairs of SNPs is provided in Table 8.
  • Notations in Tables 4-7 are as follows:
  • In Tables 4-7, “allele A1” may be interchangeably referred to as the “non-reference allele” (“non-ref”), and “allele A2” may be interchangeably referred to as the “reference allele” (“ref”). The OR's that are indicated in Tables 4-7 correspond to the indicated “non-reference allele” (“allele A1”). Thus, if OR<1, the “non-reference allele” (“allele A1”) is associated with reduction of CVD/CHD risk by statin treatment, whereas if OR>1, the other alternative allele at the SNP (the “reference allele” or “allele A2”) is associated with reduction of CVD/CHD risk by statin treatment.
  • The counts are indicated in the following format: allele A1 homozygotes/heterozygotes/allele A2 homozygotes. These counts indicate the number of individuals in the pravastatin (“Prava”), placebo, or atorvastatin (“Atorva”) arms of the CARE, WOSCOPS, or PROVE-IT trials (as indicated) who have the corresponding genotypes.
  • In Tables 4-7, “P value” indicates the p-value, “OR” indicates the odds ratio (synergy index), “OR L95” and “OR U95” indicates the lower and upper (respectively) 95% confidence interval for the odds ratio, and “Source” indicates whether the data comes from case-only analysis (“CaseOnly”) or from analysis of the entire cohort (“cohort”).
  • Tables 9-18
  • Tables 9-18 provide additional SNPs associated with response to statin treatment for reducing CVD/CHD risk. Tables 9-18 differ from Tables 4-8 in that Tables 9-18 include SNPs analyzed by imputation as well as by genotyping, whereas all of the SNPs in Tables 4-8 were analyzed by genotyping. Imputation involves imputing the allele/genotype present at a SNP for each individual in the sample set (CARE, WOSCOPS, and PROVE-IT) rather than directly genotyping the SNP in a sample from the individual. The column labeled “Source” in each of Tables 9-18 indicates whether the data presented for each SNP was derived from imputation or from genotyping.
  • Specifically, analyses were carried out using the same three sample sets as in Tables 4-8 (CARE, WOSCOPS, and PROVE-IT) to identify (by both genotyping and imputation) additional SNPs beyond those provided in Tables 4-8 that are also associated with a reduction in the risk of CHD or CVD. Tables 9-18 provide results of analyses of statin response for the same two endpoints as in Tables 4-8 (CHD in Tables 9-13, and CVD in Tables 14-18) and four genetic models (dominant, recessive, additive, and genotypic 2df).
  • Tables 9-18 provide genotyped and imputed SNPs for which the p-value for a random effect was lower than 10−4 for either the meta-analysis of CARE and WOSCOPS combined or the meta-analysis of CARE, WOSCOPS, and PROVE-IT combined, for either the CHD or CVD endpoint, and for any genetic model (dominant, recessive, additive, or genotypic). Association interaction between statin response and either the CHD or CVD phenotype was performed.
  • Tables 9-13 have CHD as an endpoint, whereas Tables 14-18 have CVD as an endpoint (CVD includes CHD and stroke).
  • Tables 9 and 14 provide results of logistic regression analysis of the CARE sample set by direct genotyping and by imputing genotypes.
  • Tables 10 and 15 provide results of logistic regression analysis of the WOSCOPS sample set by direct genotyping and by imputing genotypes.
  • Tables 11 and 16 provide results of logistic regression analysis of the PROVE-IT sample set by direct genotyping and by imputing genotypes.
  • Tables 12 and 17 provide results of meta-analysis of the CARE and WOSCOPS sample sets combined by direct genotyping and by imputing genotypes.
  • Tables 13 and 18 provide results of meta-analysis of the CARE, WOSCOPS, and PROVE-IT sample sets combined by direct genotyping and by imputing genotypes.
  • Notations in Tables 9-11 and 14-16 (for the analysis of CARE, WOSCOPS, and PROVE-IT sample sets individually) are as follows:
  • “SOURCE” indicates whether each SNP was genotyped (“Genotyped”) or imputed (“Imputed”).
  • “ALLELE” indicates the allele for which the given data (such as the OR) correspond to, which is also referred to herein as allele “A1” (and the other alternative allele at each SNP, which is not shown in Tables 9-11 and 14-16, but is shown in Tables 1-2 for each SNP, is referred to as allele “A2”).
  • “MODEL” indicates whether the model was additive (“ADD”), recessive (“REC”), dominant (“DOM”), or genotypic 2df (“GEN”).
  • “NMISS” indicates the number of genotypes present in the analysis (the number of non-missing genotypes).
  • “OR” indicates the odds ratio (synergy index (SI)). If the odds ratio is less than one for the indicated allele (i.e., allele A1) then this indicates that this allele is associated with statin response (benefit from statin treatment), i.e., fewer CVD or CHD events (e.g., MI) were observed in individuals with this allele in the pravastatin arm of CARE or WOSCOPS or the atorvastatin arm of PROVE-IT, relative to individuals with this allele in the placebo arm of CARE or WOSCOPS or the pravastatin arm of PROVE-IT. If the odds ratio is greater than one for the indicated allele, then this indicates that the other alternative allele at the SNP (the allele which is not shown in Tables 9-11 and 14-16, but is indicated in Tables 1-2, i.e., allele A2), is associated with statin response (benefit from statin treatment).
  • “SE” indicates standard error of the natural log of the synergy index (the synergy index is the odds ratio, labeled “OR”).
  • “L95” and “U95” indicates the lower and upper (respectively) 95% confidence interval for the odds ratio.
  • “STAT” is the test statistic used in evaluating the significance of an association in logistic regression analysis. The statistic is equal to the natural log of the synergy index divided by its standard error and follows a Gaussian distribution under the null hypothesis that the synergy index is equal to one.
  • “P” indicates the p-value (corresponding to a statistical test of whether the synergy index is equal to one), and “HW_PVALUE” indicates the p-value corresponding to a statistical test of whether the distribution of genotypes among subjects in the study agrees with the distribution expected according to Hardy-Weinberg equilibrium.
  • “ALLELE_FREQ” indicates the allele frequency of the given allele in the analyzed sample set (CARE in Tables 9 and 14; WOSCOPS in Tables 10 and 15; or PROVE-IT in Tables 11 and 16).
  • “PRAVA_ALLELE_FREQ” or “ATORVA_ALLELE_FREQ” indicates the allele frequency of the given allele in the pravastatin or atorvastatin-treated arms (respectively) of the CARE, WOSCOPS, or PROVE-IT trials.
  • “PRAVA_A1_HZ_COUNT”, “PRAVA_HET_COUNT”, and “PRAVA_A2_HZ_COUNT” (or, in Tables 11 and 16, “ATORVA_A1_HZ_COUNT”, “ATORVA_HET_COUNT”, and “ATORVA_A2_HZ_COUNT”) indicate the number of homozygotes of the allele that is indicated in the table (allele A1), the number of heterozygotes, and the number of homozygotes of the other alternative allele (allele A2) at the SNP, respectively, in the pravastatin arm of the CARE trial (in Tables 9 and 14) or the WOSCOPS trial (in Tables 10 and 15), or in the atorvastatin arm of the PROVE-IT trial (in Tables 11 and 16, in which the column headings labeled “atorvastatin” (“atorva”) are analogous to the column headings labeled “pravastatin” (“prava”) in Tables 9-10 and 14-15).
  • “PLACEBO_A1_HZ_COUNT”, “PLACEBO_HET_COUNT”, and “PLACEBO_A2_HZ_COUNT” (or, in Tables 11 and 16, “PRAVA_A1_HZ_COUNT”, “PRAVA_HET_COUNT”, and “PRAVA_A2_HZ_COUNT”) indicate the number of homozygotes of the allele that is indicated in the table (allele A1), the number of heterozygotes, and the number of homozygotes of the other alternative allele (allele A2) at the SNP, respectively, in the placebo arm of the CARE trial (in Tables 9 and 14) or the WOSCOPS trial (in Tables 10 and 15), or in the pravastatin arm of the PROVE-IT trial (in Tables 11 and 16, in which the column headings labeled “pravastatin” (“prava”) are analogous to the column headings labeled “placebo” in Tables 9-10 and 14-15).
  • Notations in Tables 12-13 and 17-18 (for the meta-analysis of CARE and WOSCOPS combined, and CARE, WOSCOPS, and PROVE-IT combined) are as follows:
  • “SOURCE” indicates whether each SNP was genotyped or imputed.
  • “ALLELE” indicates the allele for which the given data (such as the OR) correspond to, which is also referred to herein as allele “A1” (and the other alternative allele at each SNP, which is not shown in Tables 12-13 and 17-18, but is shown in Tables 1-2 for each SNP, is referred to as allele “A2”).
  • “MODEL” indicates whether the model was additive, recessive, dominant, or genotypic.
  • “P” indicates the p-value, and “P(R)” (or “P.R.”) indicates the p-value random effect. Both of these are p-values corresponding to a statistical test of whether the combined synergy index is equal to one but use different assumptions to derive the p-value. “P” is calculated using a fixed effects model, and “P(R)” is calculated using a random effects model.
  • “OR” indicates the odds ratio (synergy index) calculated from a fixed effects model, and “OR(R)” (or “OR.R.”) indicates the odds ratio (synergy index) calculated from a random effects model. If the odds ratio is less than one for the indicated allele (i.e., allele A1) then this indicates that this allele is associated with statin response (benefit from statin treatment), i.e., fewer CVD or CHD events (e.g., MI) were observed in individuals with this allele in a combined meta-analysis of the pravastatin arms of CARE and WOSCOPS (Tables 12 and 17) and the atorvastatin arm of PROVE-IT (Tables 13 and 18), relative to individuals with this allele in the placebo arms of CARE and WOSCOPS (Tables 12 and 17) and the pravastatin arm of PROVE-IT (Tables 13 and 18). If the odds ratio is greater than one for the indicated allele, then this indicates that the other alternative allele at the SNP (the allele which is not shown in Tables 12-13 and 17-18, but is indicated in Tables 1-2, i.e., allele A2), is associated with statin response (benefit from statin treatment).
  • “Q” indicates the Cochran Q test p-value, which is a p-value corresponding to the statistical test of the homogeneity of the synergy index across studies (small p-values indicate a greater degree of heterogeneity between studies).
  • “I” indicates the I2 heterogeneity index, which can be interpreted as the proportion of total variation in the estimates of effect that is due to heterogeneity between studies.
  • Table 19
  • The analysis in Table 19 is further described in Example 2 below.
  • Notations in Table 19 are similar to Tables 4-7. “P.R.” and “OR.R.” indicate the p-value and odds ratio (synergy index), respectively, calculated from a random effects model (rather than a fixed effects model).
  • Table 19 shows that SNP rs11556924 (hCV31283062) in the ZC3HC1 gene is associated with differential reduction of CHD risk by pravastatin therapy in both the CARE and WOSCOPS sample sets.
  • Tables 20-22
  • The analyses in Tables 20-22 are further described in Example 3 below.
  • The results shown in Tables 20-22 provide support for the association of these SNPs with CVD risk and/or statin response, particularly risk for stroke and/or response to statin treatment for reducing the risk of stroke (Tables 20-21) and CHD (Table 22).
  • Tables 20-21 provides SNPs associated with stroke risk and/or stroke statin response (reduction in stroke risk by statin treatment) in the CARE sample set. Consistent with the CARE trial, the stroke endpoint in the analysis for which the results are provided in Tables 20-21 included stroke as well as transient ischemic attack (TIA).
  • Table 22 provides a SNP associated with CHD statin response in the CARE sample set. Table 22 shows that SNP rs873134 in the B4GALNT3 gene is associated with response to statin treatment for reducing the risk of CHD, particularly recurrent MI. In the analysis for which the results are provided in Table 22, the endpoint was recurrent MI, and the analysis was adjusted for age, gender, hypertension, diabetes, base LDL and HDL, and whether an individual was a current smoker.
  • Notations in Tables 20-22 are as follows:
  • In Tables 20-22, certain columns are labeled “RESP”, “PLACEBO, OR “ALL”. “RESP” is for statin response as measured by comparing risk (risk for stroke, including TIA, in Tables 20-21, and risk for CHD, specifically recurrent MI, in Table 22) in the pravastatin-treated group with risk in the placebo-treated group, “PLACEBO” is the placebo-treated group, and “ALL” is the combination of the placebo-treated group and the pravastatin-treated group. “RESP” is the analysis to assess statin response in the indicated genotype group.
  • “MODE” indicates whether the model was additive (“ADD”), recessive (“REC”), dominant (“DOM”), or genotypic (“GEN”).
  • “mAF CEU” (Table 20 only) indicates the frequency of the minor allele in HapMap for Europeans.
  • “GENO” indicates the genotype.
  • “STATIN” indicates either the pravastatin-treated (“Pravastatin”) or placebo-treated (“Placebo”) groups (i.e., arms of the CARE trial).
  • “EVENTS” indicates the total number of events (stroke or TIA for Tables 20-21, and recurrent MI for Table 22) in individuals with the indicated genotype.
  • “TOTAL” indicates the total number of individuals with the indicated genotype.
  • “HR” indicates the hazard ratio.
  • “L95” and “U95” indicates the lower and upper (respectively) 95% confidence interval for the hazard ratio.
  • “P” indicates the p-value, “P_INT” indicates p-interaction, “P_DF2” indicates two degrees of freedom p-value, and “HW(ALL)pExact” (Table 21 only) indicates p exact for Hardy Weinberg Equilibrium for the ALL group.
  • Throughout Tables 4-22, “OR” refers to the odds ratio, “HR” refers to the hazard ratio, and “OR L95” or “OR U95” refers to the lower and upper (respectively) 95% confidence interval for the odds ratio or hazard ratio. With respect to drug response (e.g., response to a statin), if the OR or HR of those treated with the drug (e.g., a statin) compared with those treated with a placebo within a particular genotype (or with a particular allele) is less than one, this indicates that an individual with this particular genotype or allele would benefit from the drug (an OR or HR equal to one would indicate that the drug has no effect). In contrast, with respect to drug response, if the OR or HR is greater than one for a particular allele, then this indicates that an individual with the other alternative allele would benefit from the drug. As used herein, the term “benefit” (with respect to a preventive or therapeutic drug treatment) is defined as achieving a reduced risk for a disease that the drug is intended to treat or prevent (e.g., CVD such as CHD, particularly MI) by administering the drug treatment, compared with the risk for the disease in the absence of receiving the drug treatment (or receiving a placebo in lieu of the drug treatment) for the same genotype.
  • With respect to disease risk, an OR or HR that is greater than one indicates that a given allele is a risk allele (which may also be referred to as a susceptibility allele), whereas an OR or HR that is less than one indicates that a given allele is a non-risk allele (which may also be referred to as a protective allele). For a given risk allele, the other alternative allele at the SNP position (which can be derived from the information provided in Tables 1-2, for example) may be considered a non-risk allele. For a given non-risk allele, the other alternative allele at the SNP position may be considered a risk allele. Thus, with respect to disease risk, if the OR or HR for a particular allele at a SNP position is greater than one, this indicates that an individual with this particular allele has a higher risk for the disease than an individual who has the other allele at the SNP position. In contrast, if the OR or HR for a particular allele is less than one, this indicates that an individual with this particular allele has a reduced risk for the disease compared with an individual who has the other allele at the SNP position.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Exemplary embodiments of the present invention provide SNPs associated with response to statin treatment, particularly for reducing the risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke), and methods for their use. The present invention further provides nucleic acid molecules containing these SNPs, methods and reagents for the detection of the SNPs disclosed herein, uses of these SNPs for the development of detection reagents, and assays or kits that utilize such reagents. The statin response-associated SNPs disclosed herein are particularly useful for predicting, screening for, and evaluating response to statin treatment, particularly for prevention or treatment of CVD (particularly CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke) using statins, in humans. The SNPs disclosed herein are also useful for diagnosing, prognosing, screening for, and evaluating predisposition to CVD, particularly CHD (such as MI) as well as cerebrovascular events such as stroke, in humans. Furthermore, such SNPs and their encoded products are useful targets for the development of therapeutic and preventive agents.
  • Thus, exemplary embodiments of the present invention provide individual SNPs associated with response to statin treatments, particularly for reducing the risk of CVD (especially CHD, such as MI and other coronary events, as well as cerebrovascular events such as stroke), as well as combinations of SNPs and haplotypes, polymorphic/variant transcript sequences (SEQ ID NOS:1-51) and genomic sequences (SEQ ID NOS:177-622) containing SNPs, encoded amino acid sequences (SEQ ID NOS:52-102), and both transcript-based SNP context sequences (SEQ ID NOS:103-176) and genomic-based SNP context sequences (SEQ ID NOS:623-3661) (transcript sequences, protein sequences, and transcript-based SNP context sequences are provided in Table 1 and the Sequence Listing; genomic sequences and genomic-based SNP context sequences are provided in Table 2 and the Sequence Listing), methods of detecting these polymorphisms in a test sample, methods of determining if an individual is likely to respond to a particular treatment such as statins (particularly for treating or preventing CVD, such as CHD or stroke), methods of determining an individual's risk for developing CVD, methods of screening for compounds useful for treating CVD, compounds identified by these screening methods, methods of using the disclosed SNPs to select a treatment/preventive strategy or therapeutic agent, and methods of treating or preventing CVD.
  • Exemplary embodiments of the present invention further provide methods for selecting or formulating a treatment regimen (e.g., methods for determining whether or not to administer statin treatment to an individual having CVD, or who is at risk for developing CVD in the future, or who has previously had CVD, methods for selecting a particular statin-based treatment regimen such as dosage and frequency of administration of statin, or a particular form/type of statin such as a particular pharmaceutical formulation or statin compound, methods for administering (either in addition to or instead of a statin) an alternative, non-statin-based treatment, such as niacin, fibrates, or ezetimibe (e.g., Zetia® or Ezetrol®), to individuals who are predicted to be unlikely to respond positively to statin treatment, etc.), and methods for determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, etc. The present invention also provides methods for selecting individuals to whom a statin or other therapeutic will be administered based on the individual's genotype, and methods for selecting individuals for a clinical trial of a statin or other therapeutic agent based on the genotypes of the individuals (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s), or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them).
  • Exemplary embodiments of the present invention may include novel SNPs associated with response to statin treatment, as well as SNPs that were previously known in the art, but were not previously known to be associated with response to statin treatment. Accordingly, the present invention may provide novel compositions and methods based on novel SNPs disclosed herein, and may also provide novel methods of using known, but previously unassociated, SNPs in methods relating to, for example, methods relating to evaluating an individual's likelihood of responding to statin treatment (particularly statin treatment, including preventive treatment, of CVD, such as CHD or stroke), evaluating an individual's likelihood of having or developing CVD (particularly CHD or stroke), and predicting the likelihood of an individual experiencing a reccurrence of CVD (e.g., experiencing recurrent MI). In Tables 1 and 2, known SNPs are identified based on the public database in which they have been observed, which is indicated as one or more of the following SNP types: “dbSNP”=SNP observed in dbSNP, “HGBASE”=SNP observed in HGBASE, and “HGMD”=SNP observed in the Human Gene Mutation Database (HGMD).
  • Particular alleles of the SNPs disclosed herein can be associated with either an increased likelihood of responding to statin treatment (particularly for reducing the risk of CVD, such as CHD (e.g., MI) or stroke) or increased risk of developing CVD (e.g., CHD or stroke), or a decreased likelihood of responding to statin treatment or a decreased risk of developing CVD. Thus, whereas certain SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of an increased likelihood of responding to statin treatment or an increased risk of developing CVD, other SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of a decreased likelihood of responding to statin treatment or a decreased risk of developing CVD. Similarly, particular alleles of the SNPs disclosed herein can be associated with either an increased or decreased likelihood of having a reccurrence of CVD (e.g., recurrent MI), etc. The term “altered” may be used herein to encompass either of these two possibilities (e.g., either an increased or a decreased likelihood/risk).
  • SNP alleles that are associated with increased response to statin treatment for reducing CVD risk (benefit from statin treatment) may be referred to as “response” alleles, and SNP alleles that are associated with a lack of response to statin treatment may be referred to as “non-response” alleles. SNP alleles that are associated with an increased risk of having or developing CVD may be referred to as “risk” or “susceptibility” alleles, and SNP alleles that are associated with a decreased risk of having or developing CVD may be referred to as “non-risk” or “protective” alleles.
  • In certain embodiments, the presence of a statin response allele disclosed herein in Tables 4-22 (an allele associated with increased response to statin treatment for reducing CVD or CHD risk) is detected and indicates that an individual has an increased risk for developing CVD, such as CHD (e.g., MI) or stroke. In these embodiments, in which the same allele is associated with both increased risk for developing CVD and increased response to statin treatment (i.e., the same allele is both a risk and a response allele), this increased risk for developing CVD can be reduced by administering statin treatment to an individual having the allele.
  • Those skilled in the art will readily recognize that nucleic acid molecules may be double-stranded molecules and that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand. In defining a SNP position, SNP allele, or nucleotide sequence, reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule. Thus, reference may be made to either strand in order to refer to a particular SNP position, SNP allele, or nucleotide sequence. Probes and primers, may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand. Throughout the specification, in identifying a SNP position, reference is generally made to the protein-encoding strand, only for the purpose of convenience.
  • References to variant peptides, polypeptides, or proteins of the present invention include peptides, polypeptides, proteins, or fragments thereof, that contain at least one amino acid residue that differs from the corresponding amino acid sequence of the art-known peptide/polypeptide/protein (the art-known protein may be interchangeably referred to as the “wild-type,” “reference,” or “normal” protein). Such variant peptides/polypeptides/proteins can result from a codon change caused by a nonsynonymous nucleotide substitution at a protein-coding SNP position (i.e., a missense mutation) disclosed by the present invention. Variant peptides/polypeptides/proteins of the present invention can also result from a nonsense mutation (i.e., a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon), or due to any SNP disclosed by the present invention that otherwise alters the structure, function, activity, or expression of a protein, such as a SNP in a regulatory region (e.g. a promoter or enhancer) or a SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary. As used herein, the terms “polypeptide,” “peptide,” and “protein” are used interchangeably.
  • As used herein, an “allele” may refer to a nucleotide at a SNP position (wherein at least two alternative nucleotides exist in the population at the SNP position, in accordance with the inherent definition of a SNP) or may refer to an amino acid residue that is encoded by the codon which contains the SNP position (where the alternative nucleotides that are present in the population at the SNP position form alternative codons that encode different amino acid residues). An “allele” may also be referred to herein as a “variant”. Also, an amino acid residue that is encoded by a codon containing a particular SNP may simply be referred to as being encoded by the SNP.
  • A phrase such as “as represented by”, “as shown by”, “as symbolized by”, or “as designated by” may be used herein to refer to a SNP within a sequence (e.g., a polynucleotide context sequence surrounding a SNP), such as in the context of “a polymorphism as represented by position 101 of SEQ ID NO:X or its complement”. Typically, the sequence surrounding a SNP may be recited when referring to a SNP, however the sequence is not intended as a structural limitation beyond the specific SNP position itself. Rather, the sequence is recited merely as a way of referring to the SNP (in this example, “SEQ ID NO:X or its complement” is recited in order to refer to the SNP located at position 101 of SEQ ID NO:X, but SEQ ID NO:X or its complement is not intended as a structural limitation beyond the specific SNP position itself). In other words, it is recognized that the context sequence of SEQ ID NO:X in this example may contain one or more polymorphic nucleotide positions outside of position 101 and therefore an exact match over the full-length of SEQ ID NO:X is irrelevant since SEQ ID NO:X is only meant to provide context for referring to the SNP at position 101 of SEQ ID NO:X. Likewise, the length of the context sequence is also irrelevant (100 nucleotides on each side of a SNP position has been arbitrarily used in the present application as the length for context sequences merely for convenience and because 201 nucleotides of total length is expected to provide sufficient uniqueness to unambiguously identify a given nucleotide sequence). Thus, since a SNP is a variation at a single nucleotide position, it is customary to refer to context sequence (e.g., SEQ ID NO:X in this example) surrounding a particular SNP position in order to uniquely identify and refer to the SNP. Alternatively, a SNP can be referred to by a unique identification number such as a public “rs” identification number or an internal “hCV” identification number, such as provided herein for each SNP (e.g., in Tables 1-2). For example, in the instant application, “rs11556924”, “hCV31283062”, and “position 101 of SEQ ID NO:1074” all refer to the same SNP.
  • As used herein, the term “benefit” (with respect to a preventive or therapeutic drug treatment, such as statin treatment) is defined as achieving a reduced risk for a disease that the drug is intended to treat or prevent (e.g., CVD such as CHD (particularly MI) or stroke) by administrating the drug treatment, compared with the risk for the disease in the absence of receiving the drug treatment (or receiving a placebo in lieu of the drug treatment) for the same genotype. The term “benefit” may be used herein interchangeably with terms such as “respond positively” or “positively respond”.
  • As used herein, the terms “drug” and “therapeutic agent” are used interchangeably, and may include, but are not limited to, small molecule compounds, biologics (e.g., antibodies, proteins, protein fragments, fusion proteins, glycoproteins, etc.), nucleic acid agents (e.g., antisense, RNAi/siRNA, and microRNA molecules, etc.), vaccines, etc., which may be used for therapeutic and/or preventive treatment of a disease (e.g., CVD such as CHD or stroke).
  • Examples of statins (also known as HMG-CoA reductase inhibitors) include, but are not limited to, atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), simvastatin (Zocor®), fluvastatin (Lescol®), and lovastatin (Mevacor®), as well as combination therapies that include a statin such as simvastatin+ezetimibe (Vytorin®), lovastatin+niacin (Advicor®), atorvastatin+amlodipine besylate (Caduet®), and simvastatin+niacin (Simcor®).
  • Certain exemplary embodiments of the invention provide the following compositions and uses: (1) a reagent (such as an allele-specific probe or primer, or any other oligonucleotide or other reagent suitable for detecting a polymorphism disclosed herein, which can include detection of any allele of the polymorphism) for use as a diagnostic or predictive agent for determining statin response, particularly for reducing the risk of CVD such as CHD (e.g., MI) or stroke (and/or for determining risk for developing CVD); (2) a kit, device, array, or assay component that includes or is coupled with the reagent of (1) above for use in determining statin response, particularly for reducing the risk of CVD (and/or for determining risk for developing CVD); (3) the use of the reagent of (1) above for the manufacture of a kit, device, array, or assay component for determining statin response, particularly for reducing the risk of CVD (and/or for determining risk for CVD); and (4) the use of a polymorphism disclosed herein for the manufacture of a reagent for use as a diagnostic or predictive agent for determining statin response, particularly for reducing the risk of CVD (and/or for determining risk for developing CVD).
  • The various methods described herein, such as correlating the presence or absence of a polymorphism with the predicted response of an individual to a drug such as a statin, particularly for reducing the risk for CVD such as CHD (e.g., MI) or stroke (and/or correlating the presence or absence of a polymorphism with an altered (e.g., increased or decreased) risk (or no altered risk) for developing CVD), can be carried out by automated methods such as by using a computer (or other apparatus/devices such as biomedical devices, laboratory instrumentation, or other apparatus/devices having a computer processor) programmed to carry out any of the methods described herein. For example, computer software (which may be interchangeably referred to herein as a computer program) can perform the step of correlating the presence or absence of a polymorphism in an individual with an altered (e.g., increased or decreased) response (or no altered response) to statin treatment, particularly for reducing the risk for CVD such as CHD (e.g., MI) or stroke. Accordingly, certain embodiments of the invention provide a computer (or other apparatus/device) programmed to carry out any of the methods described herein.
  • Reports, Programmed Computers, Business Methods, and Systems
  • The results of a test (e.g., an individual's predicted responsiveness to statin treatment for reducing CVD risk, or an individual's risk for developing CVD, based on assaying one or more SNPs disclosed herein, and/or an individual's allele(s)/genotype at one or more SNPs disclosed herein, etc.), and/or any other information pertaining to a test, may be referred to herein as a “report”. A tangible report can optionally be generated as part of a testing process (which may be interchangeably referred to herein as “reporting”, or as “providing” a report, “producing” a report, or “generating” a report).
  • Examples of tangible reports may include, but are not limited to, reports in paper (such as computer-generated printouts of test results) or equivalent formats and reports stored on computer readable medium (such as a CD, USB flash drive or other removable storage device, computer hard drive, or computer network server, etc.). Reports, particularly those stored on computer readable medium, can be part of a database, which may optionally be accessible via the internet (such as a database of patient records or genetic information stored on a computer network server, which may be a “secure database” that has security features that limit access to the report, such as to allow only the patient and the patient's medical practioners to view the report while preventing other unauthorized individuals from viewing the report, for example). In addition to, or as an alternative to, generating a tangible report, reports can also be displayed on a computer screen (or the display of another electronic device or instrument).
  • A report can include, for example, an individual's predicted responsiveness to statin treatment (e.g., whether the individual will benefit from statin treatment by having their risk for CVD, particularly CHD (e.g., MI) or stroke, reduced), or may just include the allele(s)/genotype that an individual carries at one or more SNPs disclosed herein, which may optionally be linked to information regarding the significance of having the allele(s)/genotype at the SNP (for example, a report on computer readable medium such as a network server may include hyperlink(s) to one or more journal publications or websites that describe the medical/biological implications, such as statin response and/or CVD risk, for individuals having a certain allele/genotype at the SNP). Thus, for example, the report can include drug responsiveness, disease risk, and/or other medical/biological significance, as well as optionally also including the allele/genotype information, or the report may just include allele/genotype information without including drug responsiveness, disease risk, or other medical/biological significance (such that an individual viewing the report can use the allele/genotype information to determine the associated drug response, disease risk, or other medical/biological significance from a source outside of the report itself, such as from a medical practioner, publication, website, etc., which may optionally be linked to the report such as by a hyperlink).
  • A report can further be “transmitted” or “communicated” (these terms may be used herein interchangeably), such as to the individual who was tested, a medical practitioner (e.g., a doctor, nurse, clinical laboratory practitioner, genetic counselor, etc.), a healthcare organization, a clinical laboratory, and/or any other party or requester intended to view or possess the report. The act of “transmitting” or “communicating” a report can be by any means known in the art, based on the format of the report. Furthermore, “transmitting” or “communicating” a report can include delivering/sending a report (“pushing”) and/or retrieving (“pulling”) a report. For example, reports can be transmitted/communicated by various means, including being physically transferred between parties (such as for reports in paper format) such as by being physically delivered from one party to another, or by being transmitted electronically or in signal form (e.g., via e-mail or over the internet, by facsimile, and/or by any wired or wireless communication methods known in the art) such as by being retrieved from a database stored on a computer network server, etc.
  • In certain exemplary embodiments, the invention provides computers (or other apparatus/devices such as biomedical devices or laboratory instrumentation) programmed to carry out the methods described herein. For example, in certain embodiments, the invention provides a computer programmed to receive (i.e., as input) the identity (e.g., the allele(s) or genotype at a SNP) of one or more SNPs disclosed herein and provide (i.e., as output) the predicted drug responsiveness or disease risk (e.g., an individual's predicted statin responsiveness or risk for developing CVD) or other result based on the identity of the SNP(s). Such output (e.g., communication of disease risk, disease diagnosis or prognosis, drug responsiveness, etc.) may be, for example, in the form of a report on computer readable medium, printed in paper form, and/or displayed on a computer screen or other display.
  • In various exemplary embodiments, the invention further provides methods of doing business (with respect to methods of doing business, the terms “individual” and “customer” are used herein interchangeably). For example, exemplary methods of doing business can comprise assaying one or more SNPs disclosed herein and providing a report that includes, for example, a customer's predicted response to statin treatment (e.g., for reducing their risk for CVD, particularly CHD (such as MI) or stroke) or their risk for developing CVD (based on which allele(s)/genotype is present at the assayed SNP(s)) and/or that includes the allele(s)/genotype at the assayed SNP(s) which may optionally be linked to information (e.g., journal publications, websites, etc.) pertaining to disease risk or other biological/medical significance such as by means of a hyperlink (the report may be provided, for example, on a computer network server or other computer readable medium that is internet-accessible, and the report may be included in a secure database that allows the customer to access their report while preventing other unauthorized individuals from viewing the report), and optionally transmitting the report. Customers (or another party who is associated with the customer, such as the customer's doctor, for example) can request/order (e.g., purchase) the test online via the internet (or by phone, mail order, at an outlet/store, etc.), for example, and a kit can be sent/delivered (or otherwise provided) to the customer (or another party on behalf of the customer, such as the customer's doctor, for example) for collection of a biological sample from the customer (e.g., a buccal swab for collecting buccal cells), and the customer (or a party who collects the customer's biological sample) can submit their biological samples for assaying (e.g., to a laboratory or party associated with the laboratory such as a party that accepts the customer samples on behalf of the laboratory, a party for whom the laboratory is under the control of (e.g., the laboratory carries out the assays by request of the party or under a contract with the party, for example), and/or a party that receives at least a portion of the customer's payment for the test). The report (e.g., results of the assay including, for example, the customer's disease risk and/or allele(s)/genotype at the assayed SNP(s)) may be provided to the customer by, for example, the laboratory that assays the SNP(s) or a party associated with the laboratory (e.g., a party that receives at least a portion of the customer's payment for the assay, or a party that requests the laboratory to carry out the assays or that contracts with the laboratory for the assays to be carried out) or a doctor or other medical practitioner who is associated with (e.g., employed by or having a consulting or contracting arrangement with) the laboratory or with a party associated with the laboratory, or the report may be provided to a third party (e.g., a doctor, genetic counselor, hospital, etc.) which optionally provides the report to the customer. In further embodiments, the customer may be a doctor or other medical practitioner, or a hospital, laboratory, medical insurance organization, or other medical organization that requests/orders (e.g., purchases) tests for the purposes of having other individuals (e.g., their patients or customers) assayed for one or more SNPs disclosed herein and optionally obtaining a report of the assay results.
  • In certain exemplary methods of doing business, a kit for collecting a biological sample (e.g., a buccal swab for collecting buccal cells, or other sample collection device) is provided to a medical practitioner (e.g., a physician) which the medical practitioner uses to obtain a sample (e.g., buccal cells, saliva, blood, etc.) from a patient, the sample is then sent to a laboratory (e.g., a CLIA-certified laboratory) or other facility that tests the sample for one or more SNPs disclosed herein (e.g., to determine the genotype of one or more SNPs disclosed herein, such as to determine the patient's predicted response to statin treatment for reducing their risk for CVD, particularly CHD (such as MI) or stroke, and/or their risk for developing CVD), and the results of the test (e.g., the patient's genotype at one or more SNPs disclosed herein and/or the patient's predicted statin response or CVD risk based on their SNP genotype) are provided back to the medical practitioner (and/or directly to the patient and/or to another party such as a hospital, medical insurance company, genetic counselor, etc.) who may then provide or otherwise convey the results to the patient. The results are typically provided in the form of a report, such as described above.
  • In certain further exemplary methods of doing business, kits for collecting a biological sample from a customer (e.g., a buccal swab for collecting buccal cells, or other sample collection device) are provided (e.g., for sale), such as at an outlet (e.g., a drug store, pharmacy, general merchandise store, or any other desirable outlet), online via the internet, by mail order, etc., whereby customers can obtain (e.g., purchase) the kits, collect their own biological samples, and submit (e.g., send/deliver via mail) their samples to a laboratory (e.g., a CLIA-certified laboratory) or other facility which tests the samples for one or more SNPs disclosed herein (e.g., to determine the genotype of one or more SNPs disclosed herein, such as to determine the customer's predicted response to statin treatment for reducing their risk for CVD, particularly CHD (e.g., MI) or stroke, and/or their risk for developing CVD) and provides the results of the test (e.g., of the customer's genotype at one or more SNPs disclosed herein and/or the customer's statin response or CVD risk based on their SNP genotype) back to the customer and/or to a third party (e.g., a physician or other medical practitioner, hospital, medical insurance company, genetic counselor, etc.). The results are typically provided in the form of a report, such as described above. If the results of the test are provided to a third party, then this third party may optionally provide another report to the customer based on the results of the test (e.g., the result of the test from the laboratory may provide the customer's genotype at one or more SNPs disclosed herein without statin response or CVD risk information, and the third party may provide a report of the customer's statin response or CVD risk based on this genotype result).
  • Certain further embodiments of the invention provide a system for determining whether an individual will benefit from statin treatment (or other therapy) in reducing CVD risk (particularly risk for CHD (such as MI) or stroke), or for determining an individual's risk for developing CVD. Certain exemplary systems comprise an integrated “loop” in which an individual (or their medical practitioner) requests a determination of such individual's predicted statin response (or CVD risk, etc.), this determination is carried out by testing a sample from the individual, and then the results of this determination are provided back to the requestor. For example, in certain systems, a sample (e.g., buccal cells, saliva, blood, etc.) is obtained from an individual for testing (the sample may be obtained by the individual or, for example, by a medical practitioner), the sample is submitted to a laboratory (or other facility) for testing (e.g., determining the genotype of one or more SNPs disclosed herein), and then the results of the testing are sent to the patient (which optionally can be done by first sending the results to an intermediary, such as a medical practioner, who then provides or otherwise conveys the results to the individual and/or acts on the results), thereby forming an integrated loop system for determining an individual's predicted statin response (or CVD risk, etc.). The portions of the system in which the results are transmitted (e.g., between any of a testing facility, a medical practitioner, and/or the individual) can be carried out by way of electronic or signal transmission (e.g., by computer such as via e-mail or the internet, by providing the results on a website or computer network server which may optionally be a secure database, by phone or fax, or by any other wired or wireless transmission methods known in the art). Optionally, the system can further include a risk reduction component (i.e., a disease management system) as part of the integrated loop (for an example of a disease management system, see U.S. Pat. No. 6,770,029, “Disease management system and method including correlation assessment”). For example, the results of the test can be used to reduce the risk of the disease in the individual who was tested, such as by implementing a preventive therapy regimen (e.g., administration of a statin or other drug for reducing CVD risk), modifying the individual's diet, increasing exercise, reducing stress, and/or implementing any other physiological or behavioral modifications in the individual with the goal of reducing disease risk. For reducing CVD risk, this may include any means used in the art for improving aspects of an individual's health relevant to reducing CVD risk. Thus, in exemplary embodiments, the system is controlled by the individual and/or their medical practioner in that the individual and/or their medical practioner requests the test, receives the test results back, and (optionally) acts on the test results to reduce the individual's disease risk, such as by implementing a disease management system.
  • Isolated Nucleic Acid Molecules and SNP Detection Reagents & Kits
  • Tables 1 and 2 provide a variety of information about each SNP of the present invention that is associated with response to statin treatment, particularly for reducing an individual's risk for CVD such as CHD (e.g., MI) or stroke, including the transcript sequences (SEQ ID NOS:1-51), genomic sequences (SEQ ID NOS:177-622), and protein sequences (SEQ ID NOS:52-102) of the encoded gene products (with the SNPs indicated by IUB codes in the nucleic acid sequences). In addition, Tables 1 and 2 include SNP context sequences, which generally include 100 nucleotide upstream (5′) plus 100 nucleotides downstream (3′) of each SNP position (SEQ ID NOS:103-176 correspond to transcript-based SNP context sequences disclosed in Table 1, and SEQ ID NOS:623-3661 correspond to genomic-based context sequences disclosed in Table 2), the alternative nucleotides (alleles) at each SNP position, and additional information about the variant where relevant, such as SNP type (coding, missense, splice site, UTR, etc.), human populations in which the SNP was observed, observed allele frequencies, information about the encoded protein, etc.
  • Isolated Nucleic Acid Molecules
  • Exemplary embodiments of the invention provide isolated nucleic acid molecules that contain one or more SNPs disclosed herein, particularly SNPs disclosed in Table 1 and/or Table 2. Isolated nucleic acid molecules containing one or more SNPs disclosed herein (such as in at least one of Tables 1 and 2) may be interchangeably referred to throughout the present text as “SNP-containing nucleic acid molecules.” Isolated nucleic acid molecules may optionally encode a full-length variant protein or fragment thereof. The isolated nucleic acid molecules of the present invention also include probes and primers (which are described in greater detail below in the section entitled “SNP Detection Reagents”), which may be used for assaying the disclosed SNPs, and isolated full-length genes, transcripts, cDNA molecules, and fragments thereof, which may be used for such purposes as expressing an encoded protein.
  • As used herein, an “isolated nucleic acid molecule” generally is one that contains a SNP of the present invention or one that hybridizes to such molecule such as a nucleic acid with a complementary sequence, and is separated from most other nucleic acids present in the natural source of the nucleic acid molecule. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule containing a SNP of the present invention, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. A nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered “isolated.” Nucleic acid molecules present in non-human transgenic animals, which do not naturally occur in the animal, are also considered “isolated.” For example, recombinant DNA molecules contained in a vector are considered “isolated.” Further examples of “isolated” DNA molecules include recombinant DNA molecules maintained in heterologous host cells, and purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated SNP-containing DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
  • Generally, an isolated SNP-containing nucleic acid molecule comprises one or more SNP positions disclosed by the present invention with flanking nucleotide sequences on either side of the SNP positions. A flanking sequence can include nucleotide residues that are naturally associated with the SNP site and/or heterologous nucleotide sequences. Preferably, the flanking sequence is up to about 500, 300, 100, 60, 50, 30, 25, 20, 15, 10, 8, or 4 nucleotides (or any other length in-between) on either side of a SNP position, or as long as the full-length gene or entire protein-coding sequence (or any portion thereof such as an exon), especially if the SNP-containing nucleic acid molecule is to be used to produce a protein or protein fragment.
  • For full-length genes and entire protein-coding sequences, a SNP flanking sequence can be, for example, up to about 5 KB, 4 KB, 3 KB, 2 KB, 1 KB on either side of the SNP. Furthermore, in such instances the isolated nucleic acid molecule comprises exonic sequences (including protein-coding and/or non-coding exonic sequences), but may also include intronic sequences. Thus, any protein coding sequence may be either contiguous or separated by introns. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences and is of appropriate length such that it can be subjected to the specific manipulations or uses described herein such as recombinant protein expression, preparation of probes and primers for assaying the SNP position, and other uses specific to the SNP-containing nucleic acid sequences.
  • An isolated SNP-containing nucleic acid molecule can comprise, for example, a full-length gene or transcript, such as a gene isolated from genomic DNA (e.g., by cloning or PCR amplification), a cDNA molecule, or an mRNA transcript molecule. Polymorphic transcript sequences are referred to in Table 1 and provided in the Sequence Listing (SEQ ID NOS:1-51), and polymorphic genomic sequences are referred to in Table 2 and provided in the Sequence Listing (SEQ ID NOS:177-622). Furthermore, fragments of such full-length genes and transcripts that contain one or more SNPs disclosed herein are also encompassed by the present invention, and such fragments may be used, for example, to express any part of a protein, such as a particular functional domain or an antigenic epitope.
  • Thus, the present invention also encompasses fragments of the nucleic acid sequences as disclosed in Tables 1 and 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661) and their complements. The actual sequences referred to in the tables are provided in the Sequence Listing. A fragment typically comprises a contiguous nucleotide sequence at least about 8 or more nucleotides, more preferably at least about 12 or more nucleotides, and even more preferably at least about 16 or more nucleotides. Furthermore, a fragment could comprise at least about 18, 20, 22, 25, 30, 40, 50, 60, 80, 100, 150, 200, 250 or 500 nucleotides in length (or any other number in between). The length of the fragment will be based on its intended use. For example, the fragment can encode epitope-bearing regions of a variant peptide or regions of a variant peptide that differ from the normal/wild-type protein, or can be useful as a polynucleotide probe or primer. Such fragments can be isolated using the nucleotide sequences provided in Table 1 and/or Table 2 for the synthesis of a polynucleotide probe. A labeled probe can then be used, for example, to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in amplification reactions, such as for purposes of assaying one or more SNPs sites or for cloning specific regions of a gene.
  • An isolated nucleic acid molecule of the present invention further encompasses a SNP-containing polynucleotide that is the product of any one of a variety of nucleic acid amplification methods, which are used to increase the copy numbers of a polynucleotide of interest in a nucleic acid sample. Such amplification methods are well known in the art, and they include but are not limited to, polymerase chain reaction (PCR) (U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Technology: Principles and Applications for DNA Amplification, ed. H. A. Erlich, Freeman Press, NY, N.Y. (1992)), ligase chain reaction (LCR) (Wu and Wallace, Genomics 4:560 (1989); Landegren et al., Science 241:1077 (1988)), strand displacement amplification (SDA) (U.S. Pat. Nos. 5,270,184 and 5,422,252), transcription-mediated amplification (TMA) (U.S. Pat. No. 5,399,491), linked linear amplification (LLA) (U.S. Pat. No. 6,027,923) and the like, and isothermal amplification methods such as nucleic acid sequence based amplification (NASBA) and self-sustained sequence replication (Guatelli et al., Proc Natl Acad Sci USA 87:1874 (1990)). Based on such methodologies, a person skilled in the art can readily design primers in any suitable regions 5′ and 3′ to a SNP disclosed herein. Such primers may be used to amplify DNA of any length so long that it contains the SNP of interest in its sequence.
  • As used herein, an “amplified polynucleotide” of the invention is a SNP-containing nucleic acid molecule whose amount has been increased at least two fold by any nucleic acid amplification method performed in vitro as compared to its starting amount in a test sample. In other preferred embodiments, an amplified polynucleotide is the result of at least ten fold, fifty fold, one hundred fold, one thousand fold, or even ten thousand fold increase as compared to its starting amount in a test sample. In a typical PCR amplification, a polynucleotide of interest is often amplified at least fifty thousand fold in amount over the unamplified genomic DNA, but the precise amount of amplification needed for an assay depends on the sensitivity of the subsequent detection method used.
  • Generally, an amplified polynucleotide is at least about 16 nucleotides in length. More typically, an amplified polynucleotide is at least about 20 nucleotides in length. In a preferred embodiment of the invention, an amplified polynucleotide is at least about 30 nucleotides in length. In a more preferred embodiment of the invention, an amplified polynucleotide is at least about 32, 40, 45, 50, or 60 nucleotides in length. In yet another preferred embodiment of the invention, an amplified polynucleotide is at least about 100, 200, 300, 400, or 500 nucleotides in length. While the total length of an amplified polynucleotide of the invention can be as long as an exon, an intron or the entire gene where the SNP of interest resides, an amplified product is typically up to about 1,000 nucleotides in length (although certain amplification methods may generate amplified products greater than 1000 nucleotides in length). More preferably, an amplified polynucleotide is not greater than about 600-700 nucleotides in length. It is understood that irrespective of the length of an amplified polynucleotide, a SNP of interest may be located anywhere along its sequence.
  • In a specific embodiment of the invention, the amplified product is at least about 201 nucleotides in length, comprises one of the transcript-based context sequences or the genomic-based context sequences shown in Tables 1 and 2. Such a product may have additional sequences on its 5′ end or 3′ end or both. In another embodiment, the amplified product is about 101 nucleotides in length, and it contains a SNP disclosed herein. Preferably, the SNP is located at the middle of the amplified product (e.g., at position 101 in an amplified product that is 201 nucleotides in length, or at position 51 in an amplified product that is 101 nucleotides in length), or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or 20 nucleotides from the middle of the amplified product. However, as indicated above, the SNP of interest may be located anywhere along the length of the amplified product.
  • The present invention provides isolated nucleic acid molecules that comprise, consist of, or consist essentially of one or more polynucleotide sequences that contain one or more SNPs disclosed herein, complements thereof, and SNP-containing fragments thereof.
  • Accordingly, the present invention provides nucleic acid molecules that consist of any of the nucleotide sequences shown in Table 1 and/or Table 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins referred to in Table 1 (SEQ ID NOS:52-102). The actual sequences referred to in the tables are provided in the Sequence Listing. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.
  • The present invention further provides nucleic acid molecules that consist essentially of any of the nucleotide sequences referred to in Table 1 and/or Table 2 (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins referred to in Table 1 (SEQ ID NOS:52-102). The actual sequences referred to in the tables are provided in the Sequence Listing. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleotide residues in the final nucleic acid molecule.
  • The present invention further provides nucleic acid molecules that comprise any of the nucleotide sequences shown in Table 1 and/or Table 2 or a SNP-containing fragment thereof (transcript sequences are referred to in Table 1 as SEQ ID NOS:1-51, genomic sequences are referred to in Table 2 as SEQ ID NOS:177-622, transcript-based SNP context sequences are referred to in Table 1 as SEQ ID NOS:103-176, and genomic-based SNP context sequences are referred to in Table 2 as SEQ ID NOS:623-3661), or any nucleic acid molecule that encodes any of the variant proteins provided in Table 1 (SEQ ID NOS:52-102). The actual sequences referred to in the tables are provided in the Sequence Listing. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleotide residues, such as residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have one to a few additional nucleotides or can comprise many more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made and isolated is provided below, and such techniques are well known to those of ordinary skill in the art. Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, N.Y. (2000).
  • The isolated nucleic acid molecules can encode mature proteins plus additional amino or carboxyl-terminal amino acids or both, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life, or facilitate manipulation of a protein for assay or production. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.
  • Thus, the isolated nucleic acid molecules include, but are not limited to, nucleic acid molecules having a sequence encoding a peptide alone, a sequence encoding a mature peptide and additional coding sequences such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), a sequence encoding a mature peptide with or without additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but untranslated sequences that play a role in, for example, transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding, and/or stability of mRNA. In addition, the nucleic acid molecules may be fused to heterologous marker sequences encoding, for example, a peptide that facilitates purification.
  • Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA, which may be obtained, for example, by molecular cloning or produced by chemical synthetic techniques or by a combination thereof. Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, N.Y. (2000). Furthermore, isolated nucleic acid molecules, particularly SNP detection reagents such as probes and primers, can also be partially or completely in the form of one or more types of nucleic acid analogs, such as peptide nucleic acid (PNA). U.S. Pat. Nos. 5,539,082; 5,527,675; 5,623,049; and 5,714,331. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the complementary non-coding strand (anti-sense strand). DNA, RNA, or PNA segments can be assembled, for example, from fragments of the human genome (in the case of DNA or RNA) or single nucleotides, short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic nucleic acid molecule. Nucleic acid molecules can be readily synthesized using the sequences provided herein as a reference; oligonucleotide and PNA oligomer synthesis techniques are well known in the art. See, e.g., Corey, “Peptide nucleic acids: expanding the scope of nucleic acid recognition,” Trends Biotechnol 15(6):224-9 (June 1997), and Hyrup et al., “Peptide nucleic acids (PNA): synthesis, properties and potential applications,” Bioorg Med Chem 4(1):5-23) (January 1996). Furthermore, large-scale automated oligonucleotide/PNA synthesis (including synthesis on an array or bead surface or other solid support) can readily be accomplished using commercially available nucleic acid synthesizers, such as the Applied Biosystems (Foster City, Calif.) 3900 High-Throughput DNA Synthesizer or Expedite 8909 Nucleic Acid Synthesis System, and the sequence information provided herein.
  • The present invention encompasses nucleic acid analogs that contain modified, synthetic, or non-naturally occurring nucleotides or structural elements or other alternative/modified nucleic acid chemistries known in the art. Such nucleic acid analogs are useful, for example, as detection reagents (e.g., primers/probes) for detecting one or more SNPs identified in Table 1 and/or Table 2. Furthermore, kits/systems (such as beads, arrays, etc.) that include these analogs are also encompassed by the present invention. For example, PNA oligomers that are based on the polymorphic sequences of the present invention are specifically contemplated. PNA oligomers are analogs of DNA in which the phosphate backbone is replaced with a peptide-like backbone. Lagriffoul et al., Bioorganic & Medicinal Chemistry Letters 4:1081-1082 (1994); Petersen et al., Bioorganic & Medicinal Chemistry Letters 6:793-796 (1996); Kumar et al., Organic Letters 3(9):1269-1272 (2001); WO 96/04000. PNA hybridizes to complementary RNA or DNA with higher affinity and specificity than conventional oligonucleotides and oligonucleotide analogs. The properties of PNA enable novel molecular biology and biochemistry applications unachievable with traditional oligonucleotides and peptides.
  • Additional examples of nucleic acid modifications that improve the binding properties and/or stability of a nucleic acid include the use of base analogs such as inosine, intercalators (U.S. Pat. No. 4,835,263) and the minor groove binders (U.S. Pat. No. 5,801,115). Thus, references herein to nucleic acid molecules, SNP-containing nucleic acid molecules, SNP detection reagents (e.g., probes and primers), oligonucleotides/polynucleotides include PNA oligomers and other nucleic acid analogs. Other examples of nucleic acid analogs and alternative/modified nucleic acid chemistries known in the art are described in Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, N.Y. (2002).
  • The present invention further provides nucleic acid molecules that encode fragments of the variant polypeptides disclosed herein as well as nucleic acid molecules that encode obvious variants of such variant polypeptides. Such nucleic acid molecules may be naturally occurring, such as paralogs (different locus) and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, the variants can contain nucleotide substitutions, deletions, inversions and insertions (in addition to the SNPs disclosed in Tables 1 and 2). Variation can occur in either or both the coding and non-coding regions. The variations can produce conservative and/or non-conservative amino acid substitutions.
  • Further variants of the nucleic acid molecules disclosed in Tables 1 and 2, such as naturally occurring allelic variants (as well as orthologs and paralogs) and synthetic variants produced by mutagenesis techniques, can be identified and/or produced using methods well known in the art. Such further variants can comprise a nucleotide sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a nucleic acid sequence disclosed in Table 1 and/or Table 2 (or a fragment thereof) and that includes a novel SNP allele disclosed in Table 1 and/or Table 2. Further, variants can comprise a nucleotide sequence that encodes a polypeptide that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a polypeptide sequence disclosed in Table 1 (or a fragment thereof) and that includes a novel SNP allele disclosed in Table 1 and/or Table 2. Thus, an aspect of the present invention that is specifically contemplated are isolated nucleic acid molecules that have a certain degree of sequence variation compared with the sequences shown in Tables 1-2, but that contain a novel SNP allele disclosed herein. In other words, as long as an isolated nucleic acid molecule contains a novel SNP allele disclosed herein, other portions of the nucleic acid molecule that flank the novel SNP allele can vary to some degree from the specific transcript, genomic, and context sequences referred to and shown in Tables 1 and 2, and can encode a polypeptide that varies to some degree from the specific polypeptide sequences referred to in Table 1.
  • To determine the percent identity of two amino acid sequences or two nucleotide sequences of two molecules that share sequence homology, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein, amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Computational Molecular Biology, A. M. Lesk, ed., Oxford University Press, N.Y (1988); Biocomputing: Informatics and Genome Projects, D. W. Smith, ed., Academic Press, N.Y. (1993); Computer Analysis of Sequence Data, Part 1, A. M. Griffin and H. G. Griffin, eds., Humana Press, N.J. (1994); Sequence Analysis in Molecular Biology, G. von Heinje, ed., Academic Press, N.Y. (1987); and Sequence Analysis Primer, M. Gribskov and J. Devereux, eds., M. Stockton Press, N.Y. (1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch algorithm (J Mol Biol (48):444-453 (1970)) which has been incorporated into the GAP program in the GCG software package, using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
  • In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. J. Devereux et al., Nucleic Acids Res. 12(1):387 (1984). In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
  • The nucleotide and amino acid sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases; for example, to identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0). Altschul et al., J Mol Biol 215:403-10 (1990). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized. Altschul et al., Nucleic Acids Res 25(17):3389-3402 (1997). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. In addition to BLAST, examples of other search and sequence comparison programs used in the art include, but are not limited to, FASTA (Pearson, Methods Mol Biol 25, 365-389 (1994)) and KERR (Dufresne et al., Nat Biotechnol 20(12):1269-71 (December 2002)). For further information regarding bioinformatics techniques, see Current Protocols in Bioinformatics, John Wiley & Sons, Inc., N.Y.
  • The present invention further provides non-coding fragments of the nucleic acid molecules disclosed in Table 1 and/or Table 2. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, intronic sequences, 5′ untranslated regions (UTRs), 3′ untranslated regions, gene modulating sequences and gene termination sequences. Such fragments are useful, for example, in controlling heterologous gene expression and in developing screens to identify gene-modulating agents.
  • SNP Detection Reagents
  • In a specific aspect of the present invention, the SNPs disclosed in Table 1 and/or Table 2, and their associated transcript sequences (referred to in Table 1 as SEQ ID NOS:1-51), genomic sequences (referred to in Table 2 as SEQ ID NOS:177-622), and context sequences (transcript-based context sequences are referred to in Table 1 as SEQ ID NOS:103-176; genomic-based context sequences are provided in Table 2 as SEQ ID NOS:623-3661), can be used for the design of SNP detection reagents. The actual sequences referred to in the tables are provided in the Sequence Listing. As used herein, a “SNP detection reagent” is a reagent that specifically detects a specific target SNP position disclosed herein, and that is preferably specific for a particular nucleotide (allele) of the target SNP position (i.e., the detection reagent preferably can differentiate between different alternative nucleotides at a target SNP position, thereby allowing the identity of the nucleotide present at the target SNP position to be determined). Typically, such detection reagent hybridizes to a target SNP-containing nucleic acid molecule by complementary base-pairing in a sequence specific manner, and discriminates the target variant sequence from other nucleic acid sequences such as an art-known form in a test sample. An example of a detection reagent is a probe that hybridizes to a target nucleic acid containing one or more of the SNPs referred to in Table 1 and/or Table 2. In a preferred embodiment, such a probe can differentiate between nucleic acids having a particular nucleotide (allele) at a target SNP position from other nucleic acids that have a different nucleotide at the same target SNP position. In addition, a detection reagent may hybridize to a specific region 5′ and/or 3′ to a SNP position, particularly a region corresponding to the context sequences referred to in Table 1 and/or Table 2 (transcript-based context sequences are referred to in Table 1 as SEQ ID NOS:103-176; genomic-based context sequences are referred to in Table 2 as SEQ ID NOS:623-3661). Another example of a detection reagent is a primer that acts as an initiation point of nucleotide extension along a complementary strand of a target polynucleotide. The SNP sequence information provided herein is also useful for designing primers, e.g. allele-specific primers, to amplify (e.g., using PCR) any SNP of the present invention.
  • In one preferred embodiment of the invention, a SNP detection reagent is an isolated or synthetic DNA or RNA polynucleotide probe or primer or PNA oligomer, or a combination of DNA, RNA and/or PNA, that hybridizes to a segment of a target nucleic acid molecule containing a SNP identified in Table 1 and/or Table 2. A detection reagent in the form of a polynucleotide may optionally contain modified base analogs, intercalators or minor groove binders. Multiple detection reagents such as probes may be, for example, affixed to a solid support (e.g., arrays or beads) or supplied in solution (e.g. probe/primer sets for enzymatic reactions such as PCR, RT-PCR, TaqMan assays, or primer-extension reactions) to form a SNP detection kit.
  • A probe or primer typically is a substantially purified oligonucleotide or PNA oligomer. Such oligonucleotide typically comprises a region of complementary nucleotide sequence that hybridizes under stringent conditions to at least about 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 (or any other number in-between) or more consecutive nucleotides in a target nucleic acid molecule. Depending on the particular assay, the consecutive nucleotides can either include the target SNP position, or be a specific region in close enough proximity 5′ and/or 3′ to the SNP position to carry out the desired assay.
  • Other preferred primer and probe sequences can readily be determined using the transcript sequences (SEQ ID NOS:1-51), genomic sequences (SEQ ID NOS:177-622), and SNP context sequences (transcript-based context sequences are referred to in Table 1 as SEQ ID NOS:103-176; genomic-based context sequences are referred to in Table 2 as SEQ ID NOS:623-3661) disclosed in the Sequence Listing and in Tables 1 and 2. The actual sequences referred to in the tables are provided in the Sequence Listing. It will be apparent to one of skill in the art that such primers and probes are directly useful as reagents for genotyping the SNPs of the present invention, and can be incorporated into any kit/system format.
  • In order to produce a probe or primer specific for a target SNP-containing sequence, the gene/transcript and/or context sequence surrounding the SNP of interest is typically examined using a computer algorithm that starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene/SNP context sequence, have a GC content within a range suitable for hybridization, lack predicted secondary structure that may interfere with hybridization, and/or possess other desired characteristics or that lack other undesired characteristics.
  • A primer or probe of the present invention is typically at least about 8 nucleotides in length. In one embodiment of the invention, a primer or a probe is at least about 10 nucleotides in length. In a preferred embodiment, a primer or a probe is at least about 12 nucleotides in length. In a more preferred embodiment, a primer or probe is at least about 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. While the maximal length of a probe can be as long as the target sequence to be detected, depending on the type of assay in which it is employed, it is typically less than about 50, 60, 65, or 70 nucleotides in length. In the case of a primer, it is typically less than about 30 nucleotides in length. In a specific preferred embodiment of the invention, a primer or a probe is within the length of about 18 and about 28 nucleotides. However, in other embodiments, such as nucleic acid arrays and other embodiments in which probes are affixed to a substrate, the probes can be longer, such as on the order of 30-70, 75, 80, 90, 100, or more nucleotides in length (see the section below entitled “SNP Detection Kits and Systems”).
  • For analyzing SNPs, it may be appropriate to use oligonucleotides specific for alternative SNP alleles. Such oligonucleotides that detect single nucleotide variations in target sequences may be referred to by such terms as “allele-specific oligonucleotides,” “allele-specific probes,” or “allele-specific primers.” The design and use of allele-specific probes for analyzing polymorphisms is described in, e.g., Mutation Detection: A Practical Approach, Cotton et al., eds., Oxford University Press (1998); Saiki et al., Nature 324:163-166 (1986); Dattagupta, EP235,726; and Saiki, WO 89/11548.
  • While the design of each allele-specific primer or probe depends on variables such as the precise composition of the nucleotide sequences flanking a SNP position in a target nucleic acid molecule, and the length of the primer or probe, another factor in the use of primers and probes is the stringency of the condition under which the hybridization between the probe or primer and the target sequence is performed. Higher stringency conditions utilize buffers with lower ionic strength and/or a higher reaction temperature, and tend to require a more perfect match between probe/primer and a target sequence in order to form a stable duplex. If the stringency is too high, however, hybridization may not occur at all. In contrast, lower stringency conditions utilize buffers with higher ionic strength and/or a lower reaction temperature, and permit the formation of stable duplexes with more mismatched bases between a probe/primer and a target sequence. By way of example and not limitation, exemplary conditions for high stringency hybridization conditions using an allele-specific probe are as follows: prehybridization with a solution containing 5× standard saline phosphate EDTA (SSPE), 0.5% NaDodSO4 (SDS) at 55° C., and incubating probe with target nucleic acid molecules in the same solution at the same temperature, followed by washing with a solution containing 2×SSPE, and 0.1% SDS at 55° C. or room temperature.
  • Moderate stringency hybridization conditions may be used for allele-specific primer extension reactions with a solution containing, e.g., about 50 mM KCl at about 46° C. Alternatively, the reaction may be carried out at an elevated temperature such as 60° C. In another embodiment, a moderately stringent hybridization condition suitable for oligonucleotide ligation assay (OLA) reactions wherein two probes are ligated if they are completely complementary to the target sequence may utilize a solution of about 100 mM KCl at a temperature of 46° C.
  • In a hybridization-based assay, allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms (e.g., alternative SNP alleles/nucleotides) in the respective DNA segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant detectable difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles or significantly more strongly to one allele. While a probe may be designed to hybridize to a target sequence that contains a SNP site such that the SNP site aligns anywhere along the sequence of the probe, the probe is preferably designed to hybridize to a segment of the target sequence such that the SNP site aligns with a central position of the probe (e.g., a position within the probe that is at least three nucleotides from either end of the probe). This design of probe generally achieves good discrimination in hybridization between different allelic forms.
  • In another embodiment, a probe or primer may be designed to hybridize to a segment of target DNA such that the SNP aligns with either the 5′ most end or the 3′ most end of the probe or primer. In a specific preferred embodiment that is particularly suitable for use in a oligonucleotide ligation assay (U.S. Pat. No. 4,988,617), the 3′ most nucleotide of the probe aligns with the SNP position in the target sequence.
  • Oligonucleotide probes and primers may be prepared by methods well known in the art. Chemical synthetic methods include, but are not limited to, the phosphotriester method described by Narang et al., Methods in Enzymology 68:90 (1979); the phosphodiester method described by Brown et al., Methods in Enzymology 68:109 (1979); the diethylphosphoamidate method described by Beaucage et al., Tetrahedron Letters 22:1859 (1981); and the solid support method described in U.S. Pat. No. 4,458,066.
  • Allele-specific probes are often used in pairs (or, less commonly, in sets of 3 or 4, such as if a SNP position is known to have 3 or 4 alleles, respectively, or to assay both strands of a nucleic acid molecule for a target SNP allele), and such pairs may be identical except for a one nucleotide mismatch that represents the allelic variants at the SNP position. Commonly, one member of a pair perfectly matches a reference form of a target sequence that has a more common SNP allele (i.e., the allele that is more frequent in the target population) and the other member of the pair perfectly matches a form of the target sequence that has a less common SNP allele (i.e., the allele that is rarer in the target population). In the case of an array, multiple pairs of probes can be immobilized on the same support for simultaneous analysis of multiple different polymorphisms.
  • In one type of PCR-based assay, an allele-specific primer hybridizes to a region on a target nucleic acid molecule that overlaps a SNP position and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. Gibbs, Nucleic Acid Res 17:2427-2448 (1989). Typically, the primer's 3′-most nucleotide is aligned with and complementary to the SNP position of the target nucleic acid molecule. This primer is used in conjunction with a second primer that hybridizes at a distal site. Amplification proceeds from the two primers, producing a detectable product that indicates which allelic form is present in the test sample. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification or substantially reduces amplification efficiency, so that either no detectable product is formed or it is formed in lower amounts or at a slower pace. The method generally works most effectively when the mismatch is at the 3′-most position of the oligonucleotide (i.e., the 3′-most position of the oligonucleotide aligns with the target SNP position) because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456). This PCR-based assay can be utilized as part of the TaqMan assay, described below.
  • In a specific embodiment of the invention, a primer of the invention contains a sequence substantially complementary to a segment of a target SNP-containing nucleic acid molecule except that the primer has a mismatched nucleotide in one of the three nucleotide positions at the 3′-most end of the primer, such that the mismatched nucleotide does not base pair with a particular allele at the SNP site. In a preferred embodiment, the mismatched nucleotide in the primer is the second from the last nucleotide at the 3′-most position of the primer. In a more preferred embodiment, the mismatched nucleotide in the primer is the last nucleotide at the 3′-most position of the primer.
  • In another embodiment of the invention, a SNP detection reagent of the invention is labeled with a fluorogenic reporter dye that emits a detectable signal. While the preferred reporter dye is a fluorescent dye, any reporter dye that can be attached to a detection reagent such as an oligonucleotide probe or primer is suitable for use in the invention. Such dyes include, but are not limited to, Acridine, AMCA, BODIPY, Cascade Blue, Cy2, Cy3, Cy5, Cy7, Dabcyl, Edans, Eosin, Erythrosin, Fluorescein, 6-Fam, Tet, Joe, Hex, Oregon Green, Rhodamine, Rhodol Green, Tamra, Rox, and Texas Red.
  • In yet another embodiment of the invention, the detection reagent may be further labeled with a quencher dye such as Tamra, especially when the reagent is used as a self-quenching probe such as a TaqMan (U.S. Pat. Nos. 5,210,015 and 5,538,848) or Molecular Beacon probe (U.S. Pat. Nos. 5,118,801 and 5,312,728), or other stemless or linear beacon probe (Livak et al., PCR Method Appl 4:357-362 (1995); Tyagi et al., Nature Biotechnology 14:303-308 (1996); Nazarenko et al., Nucl Acids Res 25:2516-2521 (1997); U.S. Pat. Nos. 5,866,336 and 6,117,635.
  • The detection reagents of the invention may also contain other labels, including but not limited to, biotin for streptavidin binding, hapten for antibody binding, and oligonucleotide for binding to another complementary oligonucleotide such as pairs of zipcodes.
  • The present invention also contemplates reagents that do not contain (or that are complementary to) a SNP nucleotide identified herein but that are used to assay one or more SNPs disclosed herein. For example, primers that flank, but do not hybridize directly to a target SNP position provided herein are useful in primer extension reactions in which the primers hybridize to a region adjacent to the target SNP position (i.e., within one or more nucleotides from the target SNP site). During the primer extension reaction, a primer is typically not able to extend past a target SNP site if a particular nucleotide (allele) is present at that target SNP site, and the primer extension product can be detected in order to determine which SNP allele is present at the target SNP site. For example, particular ddNTPs are typically used in the primer extension reaction to terminate primer extension once a ddNTP is incorporated into the extension product (a primer extension product which includes a ddNTP at the 3′-most end of the primer extension product, and in which the ddNTP is a nucleotide of a SNP disclosed herein, is a composition that is specifically contemplated by the present invention). Thus, reagents that bind to a nucleic acid molecule in a region adjacent to a SNP site and that are used for assaying the SNP site, even though the bound sequences do not necessarily include the SNP site itself, are also contemplated by the present invention.
  • SNP Detection Kits and Systems
  • A person skilled in the art will recognize that, based on the SNP and associated sequence information disclosed herein, detection reagents can be developed and used to assay any SNP of the present invention individually or in combination, and such detection reagents can be readily incorporated into one of the established kit or system formats which are well known in the art. The terms “kits” and “systems,” as used herein in the context of SNP detection reagents, are intended to refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.). Accordingly, the present invention further provides SNP detection kits and systems, including but not limited to, packaged probe and primer sets (e.g. TaqMan probe/primer sets), arrays/microarrays of nucleic acid molecules, and beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention. The kits/systems can optionally include various electronic hardware components; for example, arrays (“DNA chips”) and microfluidic systems (“lab-on-a-chip” systems) provided by various manufacturers typically comprise hardware components. Other kits/systems (e.g., probe/primer sets) may not include electronic hardware components, but may be comprised of, for example, one or more SNP detection reagents (along with, optionally, other biochemical reagents) packaged in one or more containers.
  • In some embodiments, a SNP detection kit typically contains one or more detection reagents and other components (e.g. a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like) necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule. A kit may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest. In one embodiment of the present invention, kits are provided which contain the necessary reagents to carry out one or more assays to detect one or more SNPs disclosed herein. In a preferred embodiment of the present invention, SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.
  • Exemplary kits of the invention can comprise a container containing a SNP detection reagent which detects a SNP disclosed herein, said container can optionally be enclosed in a package (e.g., a box for commercial sale), and said package can further include other containers containing any or all of the following: enzyme (e.g., polymerase or ligase, any of which can be thermostable), dNTPs and/or ddNTPs (which can optionally be detectably labeled, such as with a fluorescent label or mass tag, and such label can optionally differ between any of the dATPs, dCTPs, dGTPs, dTTPs, ddATPs, ddCTPs, ddGTPs, and/or ddTTPs, so that each of these dNTPs and/or ddNTPs can be distinguished from each other by detection of the label, and any of these dNTPs and/or ddNTPs can optionally be stored in the same container or each in separate containers), buffer, controls (e.g., positive control nucleic acid, or a negative control), reagent(s) for extracting nucleic acid from a test sample, and instructions for using the kit (such as instructions for correlating the presence or absence of a particular allele or genotype with an increased or decreased risk for disease such as CVD, or an increased or decreased likelihood of responding to a drug such as a statin). The SNP detection reagent can comprise, for example, at least one primer and/or probe, any of which can optionally be allele-specific, and any of which can optionally be detectably labeled (e.g., with a fluorescent label).
  • SNP detection kits/systems may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position. Multiple pairs of allele-specific probes may be included in the kit/system to simultaneously assay large numbers of SNPs, at least one of which is a SNP of the present invention. In some kits/systems, the allele-specific probes are immobilized to a substrate such as an array or bead. For example, the same substrate can comprise allele-specific probes for detecting at least 1; 10; 100; 1000; 10,000; 100,000 (or any other number in-between) or substantially all of the SNPs shown in Table 1 and/or Table 2.
  • The terms “arrays,” “microarrays,” and “DNA chips” are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support. The polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate. In one embodiment, the microarray is prepared and used according to the methods described in Chee et al., U.S. Pat. No. 5,837,832 and PCT application WO95/11995; D. J. Lockhart et al., Nat Biotech 14:1675-1680 (1996); and M. Schena et al., Proc Natl Acad Sci 93:10614-10619 (1996), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.
  • Nucleic acid arrays are reviewed in the following references: Zammatteo et al., “New chips for molecular biology and diagnostics,” Biotechnol Annu Rev 8:85-101 (2002); Sosnowski et al., “Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications,” Psychiatr Genet 12(4):181-92 (December 2002); Heller, “DNA microarray technology: devices, systems, and applications,” Annu Rev Biomed Eng 4:129-53 (2002); Epub Mar. 22, 2002; Kolchinsky et al., “Analysis of SNPs and other genomic variations using gel-based chips,” Hum Mutat 19(4):343-60 (April 2002); and McGall et al., “High-density genechip oligonucleotide probe arrays,” Adv Biochem Eng Biotechnol 77:21-42 (2002).
  • Any number of probes, such as allele-specific probes, may be implemented in an array, and each probe or pair of probes can hybridize to a different SNP position. In the case of polynucleotide probes, they can be synthesized at designated areas (or synthesized separately and then affixed to designated areas) on a substrate using a light-directed chemical process. Each DNA chip can contain, for example, thousands to millions of individual synthetic polynucleotide probes arranged in a grid-like pattern and miniaturized (e.g., to the size of a dime). Preferably, probes are attached to a solid support in an ordered, addressable array.
  • A microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support. Typical polynucleotides are preferably about 6-60 nucleotides in length, more preferably about 15-30 nucleotides in length, and most preferably about 18-25 nucleotides in length. For certain types of microarrays or other detection kits/systems, it may be preferable to use oligonucleotides that are only about 7-20 nucleotides in length. In other types of arrays, such as arrays used in conjunction with chemiluminescent detection technology, preferred probe lengths can be, for example, about 15-80 nucleotides in length, preferably about 50-70 nucleotides in length, more preferably about 55-65 nucleotides in length, and most preferably about 60 nucleotides in length. The microarray or detection kit can contain polynucleotides that cover the known 5′ or 3′ sequence of a gene/transcript or target SNP site, sequential polynucleotides that cover the full-length sequence of a gene/transcript; or unique polynucleotides selected from particular areas along the length of a target gene/transcript sequence, particularly areas corresponding to one or more SNPs disclosed in Table 1 and/or Table 2. Polynucleotides used in the microarray or detection kit can be specific to a SNP or SNPs of interest (e.g., specific to a particular SNP allele at a target SNP site, or specific to particular SNP alleles at multiple different SNP sites), or specific to a polymorphic gene/transcript or genes/transcripts of interest.
  • Hybridization assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants. For SNP genotyping, it is generally preferable that stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position). Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection. Such high stringency conditions are described in the preceding section, and are well known to those skilled in the art and can be found in, for example, Current Protocols in Molecular Biology 6.3.1-6.3.6, John Wiley & Sons, N.Y. (1989).
  • In other embodiments, the arrays are used in conjunction with chemiluminescent detection technology. The following patents and patent applications, which are all hereby incorporated by reference, provide additional information pertaining to chemiluminescent detection. U.S. patent applications that describe chemiluminescent approaches for microarray detection: Ser. Nos. 10/620,332 and 10/620,333. U.S. patents that describe methods and compositions of dioxetane for performing chemiluminescent detection: U.S. Pat. Nos. 6,124,478; 6,107,024; 5,994,073; 5,981,768; 5,871,938; 5,843,681; 5,800,999 and 5,773,628. And the U.S. published application that discloses methods and compositions for microarray controls: US2002/0110828.
  • In one embodiment of the invention, a nucleic acid array can comprise an array of probes of about 15-25 nucleotides in length. In further embodiments, a nucleic acid array can comprise any number of probes, in which at least one probe is capable of detecting one or more SNPs disclosed in Table 1 and/or Table 2, and/or at least one probe comprises a fragment of one of the sequences selected from the group consisting of those disclosed in Table 1, Table 2, the Sequence Listing, and sequences complementary thereto, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 12, 15, 16, 18, 20, more preferably 22, 25, 30, 40, 47, 50, 55, 60, 65, 70, 80, 90, 100, or more consecutive nucleotides (or any other number in-between) and containing (or being complementary to) a novel SNP allele disclosed in Table 1 and/or Table 2. In some embodiments, the nucleotide complementary to the SNP site is within 5, 4, 3, 2, or 1 nucleotide from the center of the probe, more preferably at the center of said probe.
  • A polynucleotide probe can be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more polynucleotides, or any other number which lends itself to the efficient use of commercially available instrumentation.
  • Using such arrays or other kits/systems, the present invention provides methods of identifying the SNPs disclosed herein in a test sample. Such methods typically involve incubating a test sample of nucleic acids with an array comprising one or more probes corresponding to at least one SNP position of the present invention, and assaying for binding of a nucleic acid from the test sample with one or more of the probes. Conditions for incubating a SNP detection reagent (or a kit/system that employs one or more such SNP detection reagents) with a test sample vary. Incubation conditions depend on such factors as the format employed in the assay, the detection methods employed, and the type and nature of the detection reagents used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification and array assay formats can readily be adapted to detect the SNPs disclosed herein.
  • A SNP detection kit/system of the present invention may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule. Such sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells) such as buccal cells (e.g., as obtained by buccal swabs), biopsies, or tissue specimens. The test samples used in the above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed. Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized. Automated sample preparation systems for extracting nucleic acids from a test sample are commercially available, and examples are Qiagen's BioRobot 9600, Applied Biosystems' PRISM™ 6700 sample preparation system, and Roche Molecular Systems' COBAS AmpliPrep System.
  • Another form of kit contemplated by the present invention is a compartmentalized kit. A compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel. Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting one or more SNPs of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents. The kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection. The kit may also include instructions for using the kit. Exemplary compartmentalized kits include microfluidic devices known in the art. See, e.g., Weigl et al., “Lab-on-a-chip for drug development,” Adv Drug Deliv Rev 55(3):349-77 (February 2003). In such microfluidic devices, the containers may be referred to as, for example, microfluidic “compartments,” “chambers,” or “channels.”
  • Microfluidic devices, which may also be referred to as “lab-on-a-chip” systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems of the present invention for analyzing SNPs. Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device. Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect one or more SNPs of the present invention. One example of a microfluidic system is disclosed in U.S. Pat. No. 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips. Exemplary microfluidic systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples may be controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts. Varying the voltage can be used as a means to control the liquid flow at intersections between the micro-machined channels and to change the liquid flow rate for pumping across different sections of the microchip. See, for example, U.S. Pat. No. 6,153,073, Dubrow et al., and U.S. Pat. No. 6,156,181, Parce et al.
  • For genotyping SNPs, an exemplary microfluidic system may integrate, for example, nucleic acid amplification, primer extension, capillary electrophoresis, and a detection method such as laser induced fluorescence detection. In a first step of an exemplary process for using such an exemplary system, nucleic acid samples are amplified, preferably by PCR. Then, the amplification products are subjected to automated primer extension reactions using ddNTPs (specific fluorescence for each ddNTP) and the appropriate oligonucleotide primers to carry out primer extension reactions which hybridize just upstream of the targeted SNP. Once the extension at the 3′ end is completed, the primers are separated from the unincorporated fluorescent ddNTPs by capillary electrophoresis. The separation medium used in capillary electrophoresis can be, for example, polyacrylamide, polyethyleneglycol or dextran. The incorporated ddNTPs in the single nucleotide primer extension products are identified by laser-induced fluorescence detection. Such an exemplary microchip can be used to process, for example, at least 96 to 384 samples, or more, in parallel.
  • Uses of Nucleic Acid Molecules
  • The nucleic acid molecules of the present invention have a variety of uses, particularly for predicting whether an individual will benefit from statin treatment by reducing their risk for CVD (particularly CHD, such as MI) in response to the statin treatment, as well as for the diagnosis, prognosis, treatment, and prevention of CVD (particularly CHD, such as MI). For example, the nucleic acid molecules of the invention are useful for determining the likelihood of an individual who currently or previously has or has had CVD (such as an individual who has previously had an MI) or who is at increased risk for developing CVD (such as an individual who has not yet had an MI but is at increased risk for having an MI in the future) of responding to treatment (or prevention) of CVD with statins (such as by reducing their risk of developing primary or recurrent CVD, such as MI, in the future), predicting the likelihood that the individual will experience toxicity or other undesirable side effects from the statin treatment, predicting an individual's risk for developing CVD (particularly the risk for CHD such as MI), etc. For example, the nucleic acid molecules are useful as hybridization probes, such as for genotyping SNPs in messenger RNA, transcript, cDNA, genomic DNA, amplified DNA or other nucleic acid molecules, and for isolating full-length cDNA and genomic clones encoding the variant peptides disclosed in Table 1 as well as their orthologs.
  • A probe can hybridize to any nucleotide sequence along the entire length of a nucleic acid molecule referred to in Table 1 and/or Table 2. Preferably, a probe of the present invention hybridizes to a region of a target sequence that encompasses a SNP position indicated in Table 1 and/or Table 2. More preferably, a probe hybridizes to a SNP-containing target sequence in a sequence-specific manner such that it distinguishes the target sequence from other nucleotide sequences which vary from the target sequence only by which nucleotide is present at the SNP site. Such a probe is particularly useful for detecting the presence of a SNP-containing nucleic acid in a test sample, or for determining which nucleotide (allele) is present at a particular SNP site (i.e., genotyping the SNP site).
  • A nucleic acid hybridization probe may be used for determining the presence, level, form, and/or distribution of nucleic acid expression. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes specific for the SNPs described herein can be used to assess the presence, expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in gene expression relative to normal levels. In vitro techniques for detection of mRNA include, for example, Northern blot hybridizations and in situ hybridizations. In vitro techniques for detecting DNA include Southern blot hybridizations and in situ hybridizations. Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, N.Y. (2000).
  • Probes can be used as part of a diagnostic test kit for identifying cells or tissues in which a variant protein is expressed, such as by measuring the level of a variant protein-encoding nucleic acid (e.g., mRNA) in a sample of cells from a subject or determining if a polynucleotide contains a SNP of interest.
  • Thus, the nucleic acid molecules of the invention can be used as hybridization probes to detect the SNPs disclosed herein, thereby determining the likelihood that an individual will respond positively to statin treatment for reducing the risk of CVD (particularly CHD such as MI), or whether an individual with the polymorphism(s) is at risk for developing CVD (or has already developed early stage CVD). Detection of a SNP associated with a disease phenotype provides a diagnostic tool for an active disease and/or genetic predisposition to the disease.
  • Furthermore, the nucleic acid molecules of the invention are therefore useful for detecting a gene (gene information is disclosed in Table 2, for example) which contains a SNP disclosed herein and/or products of such genes, such as expressed mRNA transcript molecules (transcript information is disclosed in Table 1, for example), and are thus useful for detecting gene expression. The nucleic acid molecules can optionally be implemented in, for example, an array or kit format for use in detecting gene expression.
  • The nucleic acid molecules of the invention are also useful as primers to amplify any given region of a nucleic acid molecule, particularly a region containing a SNP identified in Table 1 and/or Table 2.
  • The nucleic acid molecules of the invention are also useful for constructing recombinant vectors (described in greater detail below). Such vectors include expression vectors that express a portion of, or all of, any of the variant peptide sequences referred to in Table 1. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced SNPs.
  • The nucleic acid molecules of the invention are also useful for expressing antigenic portions of the variant proteins, particularly antigenic portions that contain a variant amino acid sequence (e.g., an amino acid substitution) caused by a SNP disclosed in Table 1 and/or Table 2.
  • The nucleic acid molecules of the invention are also useful for constructing vectors containing a gene regulatory region of the nucleic acid molecules of the present invention.
  • The nucleic acid molecules of the invention are also useful for designing ribozymes corresponding to all, or a part, of an mRNA molecule expressed from a SNP-containing nucleic acid molecule described herein.
  • The nucleic acid molecules of the invention are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and variant peptides.
  • The nucleic acid molecules of the invention are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and variant peptides. The production of recombinant cells and transgenic animals having nucleic acid molecules which contain the SNPs disclosed in Table 1 and/or Table 2 allows, for example, effective clinical design of treatment compounds and dosage regimens.
  • The nucleic acid molecules of the invention are also useful in assays for drug screening to identify compounds that, for example, modulate nucleic acid expression.
  • The nucleic acid molecules of the invention are also useful in gene therapy in patients whose cells have aberrant gene expression. Thus, recombinant cells, which include a patient's cells that have been engineered ex vivo and returned to the patient, can be introduced into an individual where the recombinant cells produce the desired protein to treat the individual.
  • SNP Genotyping Methods
  • The process of determining which nucleotide(s) is/are present at each of one or more SNP positions (such as a SNP position disclosed in Table 1 and/or Table 2), for either or both alleles, may be referred to by such phrases as SNP genotyping, determining the “identity” of a SNP, determining the “content” of a SNP, or determining which nucleotide(s)/allele(s) is/are present at a SNP position. Thus, these terms can refer to detecting a single allele (nucleotide) at a SNP position or can encompass detecting both alleles (nucleotides) at a SNP position (such as to determine the homozygous or heterozygous state of a SNP position). Furthermore, these terms may also refer to detecting an amino acid residue encoded by a SNP (such as alternative amino acid residues that are encoded by different codons created by alternative nucleotides at a missense SNP position, for example).
  • The present invention provides methods of SNP genotyping, such as for use in implementing a preventive or treatment regimen for an individual based on that individual having an increased susceptibility for developing CVD (e.g., increased risk for CHD, such as MI) and/or an increased likelihood of benefiting from statin treatment for reducing the risk of CVD, in evaluating an individual's likelihood of responding to statin treatment (particularly for treating or preventing CVD), in selecting a treatment or preventive regimen (e.g., in deciding whether or not to administer statin treatment to an individual having CVD, or who is at increased risk for developing CVD, such as MI, in the future), or in formulating or selecting a particular statin-based treatment or preventive regimen such as dosage and/or frequency of administration of statin treatment or choosing which form/type of statin to be administered, such as a particular pharmaceutical composition or compound, etc.), determining the likelihood of experiencing toxicity or other undesirable side effects from statin treatment, or selecting individuals for a clinical trial of a statin (e.g., selecting individuals to participate in the trial who are most likely to respond positively from the statin treatment and/or excluding individuals from the trial who are unlikely to respond positively from the statin treatment based on their SNP genotype(s), or selecting individuals who are unlikely to respond positively to statins based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them), etc. The SNP genotyping methods of the invention can also be useful for evaluating an individual's risk for developing CVD (particularly CHD, such as MI) and for predicting the likelihood that an individual who has previously had CVD will have a recurrence of CVD again in the future (e.g., recurrent MI).
  • Nucleic acid samples can be genotyped to determine which allele(s) is/are present at any given genetic region (e.g., SNP position) of interest by methods well known in the art. The neighboring sequence can be used to design SNP detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format. Exemplary SNP genotyping methods are described in Chen et al., “Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput,” Pharmacogenomics J 3(2):77-96 (2003); Kwok et al., “Detection of single nucleotide polymorphisms,” Curr Issues Mol Biol 5(2):43-60 (April 2003); Shi, “Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes,” Am J Pharmacogenomics 2(3):197-205 (2002); and Kwok, “Methods for genotyping single nucleotide polymorphisms,” Annu Rev Genomics Hum Genet 2:235-58 (2001). Exemplary techniques for high-throughput SNP genotyping are described in Marnellos, “High-throughput SNP analysis for genetic association studies,” Curr Opin Drug Discov Devel 6(3):317-21 (May 2003). Common SNP genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA (U.S. Pat. No. 4,988,167), multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay. Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985); Cotton et al., PNAS 85:4397 (1988); and Saleeba et al., Meth. Enzymol 217:286-295 (1992)), comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules (Orita et al., PNAS 86:2766 (1989); Cotton et al., Mutat Res 285:125-144 (1993); and Hayashi et al., Genet Anal Tech Appl 9:73-79 (1992)), and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE) (Myers et al., Nature 313:495 (1985)). Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or chemical cleavage methods.
  • In a preferred embodiment, SNP genotyping is performed using the TaqMan assay, which is also known as the 5′ nuclease assay (U.S. Pat. Nos. 5,210,015 and 5,538,848). The TaqMan assay detects the accumulation of a specific amplified product during PCR. The TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye. The reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET). When attached to the probe, the excited reporter dye does not emit a signal. The proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter. The reporter dye and quencher dye may be at the 5′ most and the 3′ most ends, respectively, or vice versa. Alternatively, the reporter dye may be at the 5′ or 3′ most end while the quencher dye is attached to an internal nucleotide, or vice versa. In yet another embodiment, both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.
  • During PCR, the 5′ nuclease activity of DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye. The DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.
  • Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein. A number of computer programs, such as Primer Express (Applied Biosystems, Foster City, Calif.), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the SNPs of the present invention are useful in, for example, screening individuals for their likelihood of responding to statin treatment (i.e., benefiting from statin treatment), particularly individuals who have or are susceptible to CVD (particularly CHD, such as MI), or in screening for individuals who are susceptible to developing CVD. These probes and primers can be readily incorporated into a kit format. The present invention also includes modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes (U.S. Pat. Nos. 5,118,801 and 5,312,728) and other variant formats (U.S. Pat. Nos. 5,866,336 and 6,117,635).
  • Another preferred method for genotyping the SNPs of the present invention is the use of two oligonucleotide probes in an OLA (see, e.g., U.S. Pat. No. 4,988,617). In this method, one probe hybridizes to a segment of a target nucleic acid with its 3′ most end aligned with the SNP site. A second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3′ to the first probe. The two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3′ most nucleotide of the first probe with the SNP site. If there is a mismatch, ligation would not occur. After the reaction, the ligated probes are separated from the target nucleic acid molecule, and detected as indicators of the presence of a SNP.
  • The following patents, patent applications, and published international patent applications, which are all hereby incorporated by reference, provide additional information pertaining to techniques for carrying out various types of OLA. The following U.S. patents describe OLA strategies for performing SNP detection: U.S. Pat. Nos. 6,027,889; 6,268,148; 5,494,810; 5,830,711 and 6,054,564. WO 97/31256 and WO 00/56927 describe OLA strategies for performing SNP detection using universal arrays, wherein a zipcode sequence can be introduced into one of the hybridization probes, and the resulting product, or amplified product, hybridized to a universal zip code array. U.S. application US01/17329 (and Ser. No. 09/584,905) describes OLA (or LDR) followed by PCR, wherein zipcodes are incorporated into OLA probes, and amplified PCR products are determined by electrophoretic or universal zipcode array readout. U.S. applications 60/427,818, 60/445,636, and 60/445,494 describe SNPlex methods and software for multiplexed SNP detection using OLA followed by PCR, wherein zipcodes are incorporated into OLA probes, and amplified PCR products are hybridized with a zipchute reagent, and the identity of the SNP determined from electrophoretic readout of the zipchute. In some embodiments, OLA is carried out prior to PCR (or another method of nucleic acid amplification). In other embodiments, PCR (or another method of nucleic acid amplification) is carried out prior to OLA.
  • Another method for SNP genotyping is based on mass spectrometry. Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. SNPs can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative SNP alleles. MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as SNPs. Numerous approaches to SNP analysis have been developed based on mass spectrometry. Preferred mass spectrometry-based methods of SNP genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
  • Typically, the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5′) from a target SNP position. A mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template (e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR), primer, and DNA polymerase. Extension of the primer terminates at the first position in the template where a nucleotide complementary to one of the ddNTPs in the mix occurs. The primer can be either immediately adjacent (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the SNP position. If the primer is several nucleotides removed from the target SNP position, the only limitation is that the template sequence between the 3′ end of the primer and the SNP position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer. Alternatively, if all four ddNTPs alone, with no dNTPs, are added to the reaction mixture, the primer will always be extended by only one nucleotide, corresponding to the target SNP position. In this instance, primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5′ side of the target SNP site). Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides. Furthermore, mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.
  • The extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position. In one method of analysis, the products from the primer extension reaction are combined with light absorbing crystals that form a matrix. The matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase. The ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector. The time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule. The time of flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z. In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position. For further information regarding the use of primer extension assays in conjunction with MALDI-TOF mass spectrometry for SNP genotyping, see, e.g., Wise et al., “A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,” Rapid Commun Mass Spectrom 17(11):1195-202 (2003).
  • The following references provide further information describing mass spectrometry-based methods for SNP genotyping: Bocker, “SNP and mutation discovery using base-specific cleavage and MALDI-TOF mass spectrometry,” Bioinformatics 19 Suppl 1:144-153 (July 2003); Storm et al., “MALDI-TOF mass spectrometry-based SNP genotyping,” Methods Mol Biol 212:241-62 (2003); Jurinke et al., “The use of Mass ARRAY technology for high throughput genotyping,” Adv Biochem Eng Biotechnol 77:57-74 (2002); and Jurinke et al., “Automated genotyping using the DNA MassArray technology,” Methods Mol Biol 187:179-92 (2002).
  • SNPs can also be scored by direct DNA sequencing. A variety of automated sequencing procedures can be utilized (e.g. Biotechniques 19:448 (1995)), including sequencing by mass spectrometry. See, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv Chromatogr 36:127-162 (1996); and Griffin et al., Appl Biochem Biotechnol 38:147-159 (1993). The nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures. Commercial instrumentation, such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730xl DNA Analyzers (Foster City, Calif.), is commonly used in the art for automated sequencing.
  • Other methods that can be used to genotype the SNPs of the present invention include single-strand conformational polymorphism (SSCP), and denaturing gradient gel electrophoresis (DGGE). Myers et al., Nature 313:495 (1985). SSCP identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Single-stranded PCR products can be generated by heating or otherwise denaturing double stranded PCR products. Single-stranded nucleic acids may refold or form secondary structures that are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products are related to base-sequence differences at SNP positions. DGGE differentiates SNP alleles based on the different sequence-dependent stabilities and melting properties inherent in polymorphic DNA and the corresponding differences in electrophoretic migration patterns in a denaturing gradient gel. PCR Technology: Principles and Applications for DNA Amplification Chapter 7, Erlich, ed., W.H. Freeman and Co, N.Y. (1992).
  • Sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can also be used to score SNPs based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature. If the SNP affects a restriction enzyme cleavage site, the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis.
  • SNP genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent). In some assays, the size of the amplification product is detected and compared to the length of a control sample; for example, deletions and insertions can be detected by a change in size of the amplified product compared to a normal genotype.
  • SNP genotyping is useful for numerous practical applications, as described below. Examples of such applications include, but are not limited to, SNP-disease association analysis, disease predisposition screening, disease diagnosis, disease prognosis, disease progression monitoring, determining therapeutic strategies based on an individual's genotype (“pharmacogenomics”), developing therapeutic agents based on SNP genotypes associated with a disease or likelihood of responding to a drug, stratifying patient populations for clinical trials of a therapeutic, preventive, or diagnostic agent, and predicting the likelihood that an individual will experience toxic side effects from a therapeutic agent.
  • Analysis of Genetic Associations Between SNPs and Phenotypic Traits
  • SNP genotyping for disease diagnosis, disease predisposition screening, disease prognosis, determining drug responsiveness (pharmacogenomics), drug toxicity screening, and other uses described herein, typically relies on initially establishing a genetic association between one or more specific SNPs and the particular phenotypic traits of interest.
  • Different study designs may be used for genetic association studies. Modern Epidemiology 609-622, Lippincott, Williams & Wilkins (1998). Observational studies are most frequently carried out in which the response of the patients is not interfered with. The first type of observational study identifies a sample of persons in whom the suspected cause of the disease is present and another sample of persons in whom the suspected cause is absent, and then the frequency of development of disease in the two samples is compared. These sampled populations are called cohorts, and the study is a prospective study. The other type of observational study is case-control or a retrospective study. In typical case-control studies, samples are collected from individuals with the phenotype of interest (cases) such as certain manifestations of a disease, and from individuals without the phenotype (controls) in a population (target population) that conclusions are to be drawn from. Then the possible causes of the disease are investigated retrospectively. As the time and costs of collecting samples in case-control studies are considerably less than those for prospective studies, case-control studies are the more commonly used study design in genetic association studies, at least during the exploration and discovery stage.
  • Case-only studies are an alternative to case-control studies when gene-environment interaction is the association of interest (Piegorsch et al., “Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies”, Statistics in Medicine 13 (1994) pp 153-162). In a typical case-only study of gene-environment interaction, genotypes are obtained only from cases who are often selected from an existing cohort study. The association between genotypes and the environmental factor is then assessed and a significant association implies that the effect of the environmental factor on the endpoint of interest (the case definition) differs by genotype. The primary assumption underlying the test of association in case-only studies is that the environmental effect of interest is independent of genotype (e.g., allocation to statin therapy is independent of genotype) and it has been shown that the case-only design has more power than the case-control design to detect gene-environment interaction when this assumption is true in the population (Yang et al., “Sample Size Requirements in Case-Only Designs to Detect Gene-Environment Interaction”, American Journal of Epidemiology 146:9 (1997) pp 713-720). Selecting cases from a randomized clinical trial may be an ideal setting in which to perform a case-only study since genotypes will be independent of treatment by design.
  • In observational studies, there may be potential confounding factors that should be taken into consideration. Confounding factors are those that are associated with both the real cause(s) of the disease and the disease itself, and they include demographic information such as age, gender, ethnicity as well as environmental factors. When confounding factors are not matched in cases and controls in a study, and are not controlled properly, spurious association results can arise. If potential confounding factors are identified, they should be controlled for by analysis methods explained below.
  • In a genetic association study, the cause of interest to be tested is a certain allele or a SNP or a combination of alleles or a haplotype from several SNPs. Thus, tissue specimens (e.g., whole blood) from the sampled individuals may be collected and genomic DNA genotyped for the SNP(s) of interest. In addition to the phenotypic trait of interest, other information such as demographic (e.g., age, gender, ethnicity, etc.), clinical, and environmental information that may influence the outcome of the trait can be collected to further characterize and define the sample set. In many cases, these factors are known to be associated with diseases and/or SNP allele frequencies. There are likely gene-environment and/or gene-gene interactions as well. Analysis methods to address gene-environment and gene-gene interactions (for example, the effects of the presence of both susceptibility alleles at two different genes can be greater than the effects of the individual alleles at two genes combined) are discussed below.
  • After all the relevant phenotypic and genotypic information has been obtained, statistical analyses are carried out to determine if there is any significant correlation between the presence of an allele or a genotype with the phenotypic characteristics of an individual. Preferably, data inspection and cleaning are first performed before carrying out statistical tests for genetic association. Epidemiological and clinical data of the samples can be summarized by descriptive statistics with tables and graphs. Data validation is preferably performed to check for data completion, inconsistent entries, and outliers. Chi-squared tests and t-tests (Wilcoxon rank-sum tests if distributions are not normal) may then be used to check for significant differences between cases and controls for discrete and continuous variables, respectively. To ensure genotyping quality, Hardy-Weinberg disequilibrium tests can be performed on cases and controls separately. Significant deviation from Hardy-Weinberg equilibrium (HWE) in both cases and controls for individual markers can be indicative of genotyping errors. If HWE is violated in a majority of markers, it is indicative of population substructure that should be further investigated. Moreover, Hardy-Weinberg disequilibrium in cases only can indicate genetic association of the markers with the disease. B. Weir, Genetic Data Analysis, Sinauer (1990).
  • To test whether an allele of a single SNP is associated with the case or control status of a phenotypic trait, one skilled in the art can compare allele frequencies in cases and controls. Standard chi-squared tests and Fisher exact tests can be carried out on a 2×2 table (2 SNP alleles×2 outcomes in the categorical trait of interest). To test whether genotypes of a SNP are associated, chi-squared tests can be carried out on a 3×2 table (3 genotypes×2 outcomes). Score tests are also carried out for genotypic association to contrast the three genotypic frequencies (major homozygotes, heterozygotes and minor homozygotes) in cases and controls, and to look for trends using 3 different modes of inheritance, namely dominant (with contrast coefficients 2, −1, −1), additive or allelic (with contrast coefficients 1, 0, −1) and recessive (with contrast coefficients 1, 1, −2). Odds ratios for minor versus major alleles, and odds ratios for heterozygote and homozygote variants versus the wild type genotypes are calculated with the desired confidence limits, usually 95%.
  • In order to control for confounders and to test for interaction and effect modifiers, stratified analyses may be performed using stratified factors that are likely to be confounding, including demographic information such as age, ethnicity, and gender, or an interacting element or effect modifier, such as a known major gene (e.g., APOE for Alzheimer's disease or HLA genes for autoimmune diseases), or environmental factors such as smoking in lung cancer. Stratified association tests may be carried out using Cochran-Mantel-Haenszel tests that take into account the ordinal nature of genotypes with 0, 1, and 2 variant alleles. Exact tests by StatXact may also be performed when computationally possible. Another way to adjust for confounding effects and test for interactions is to perform stepwise multiple logistic regression analysis using statistical packages such as SAS or R. Logistic regression is a model-building technique in which the best fitting and most parsimonious model is built to describe the relation between the dichotomous outcome (for instance, getting a certain disease or not) and a set of independent variables (for instance, genotypes of different associated genes, and the associated demographic and environmental factors). The most common model is one in which the logit transformation of the odds ratios is expressed as a linear combination of the variables (main effects) and their cross-product terms (interactions). Hosmer and Lemeshow, Applied Logistic Regression, Wiley (2000). To test whether a certain variable or interaction is significantly associated with the outcome, coefficients in the model are first estimated and then tested for statistical significance of their departure from zero.
  • In addition to performing association tests one marker at a time, haplotype association analysis may also be performed to study a number of markers that are closely linked together. Haplotype association tests can have better power than genotypic or allelic association tests when the tested markers are not the disease-causing mutations themselves but are in linkage disequilibrium with such mutations. The test will even be more powerful if the disease is indeed caused by a combination of alleles on a haplotype (e.g., APOE is a haplotype formed by 2 SNPs that are very close to each other). In order to perform haplotype association effectively, marker-marker linkage disequilibrium measures, both D′ and r2, are typically calculated for the markers within a gene to elucidate the haplotype structure. Recent studies in linkage disequilibrium indicate that SNPs within a gene are organized in block pattern, and a high degree of linkage disequilibrium exists within blocks and very little linkage disequilibrium exists between blocks. Daly et al, Nature Genetics 29:232-235 (2001). Haplotype association with the disease status can be performed using such blocks once they have been elucidated.
  • Haplotype association tests can be carried out in a similar fashion as the allelic and genotypic association tests. Each haplotype in a gene is analogous to an allele in a multi-allelic marker. One skilled in the art can either compare the haplotype frequencies in cases and controls or test genetic association with different pairs of haplotypes. It has been proposed that score tests can be done on haplotypes using the program “haplo.score.” Schaid et al, Am J Hum Genet 70:425-434 (2002). In that method, haplotypes are first inferred by EM algorithm and score tests are carried out with a generalized linear model (GLM) framework that allows the adjustment of other factors.
  • An important decision in the performance of genetic association tests is the determination of the significance level at which significant association can be declared when the P value of the tests reaches that level. In an exploratory analysis where positive hits will be followed up in subsequent confirmatory testing, an unadjusted P value <0.2 (a significance level on the lenient side), for example, may be used for generating hypotheses for significant association of a SNP with certain phenotypic characteristics of a disease. It is preferred that a p-value <0.05 (a significance level traditionally used in the art) is achieved in order for a SNP to be considered to have an association with a disease. It is more preferred that a p-value <0.01 (a significance level on the stringent side) is achieved for an association to be declared. When hits are followed up in confirmatory analyses in more samples of the same source or in different samples from different sources, adjustment for multiple testing will be performed as to avoid excess number of hits while maintaining the experiment-wide error rates at 0.05. While there are different methods to adjust for multiple testing to control for different kinds of error rates, a commonly used but rather conservative method is Bonferroni correction to control the experiment-wise or family-wise error rate. Westfall et al., Multiple comparisons and multiple tests, SAS Institute (1999). Permutation tests to control for the false discovery rates, FDR, can be more powerful. Benjamini and Hochberg, Journal of the Royal Statistical Society, Series B 57:1289-1300 (1995); Westfall and Young, Resampling-based Multiple Testing, Wiley (1993). Such methods to control for multiplicity would be preferred when the tests are dependent and controlling for false discovery rates is sufficient as opposed to controlling for the experiment-wise error rates.
  • In replication studies using samples from different populations after statistically significant markers have been identified in the exploratory stage, meta-analyses can then be performed by combining evidence of different studies. Modern Epidemiology 643-673, Lippincott, Williams & Wilkins (1998). If available, association results known in the art for the same SNPs can be included in the meta-analyses.
  • Since both genotyping and disease status classification can involve errors, sensitivity analyses may be performed to see how odds ratios and p-values would change upon various estimates on genotyping and disease classification error rates.
  • It has been well known that subpopulation-based sampling bias between cases and controls can lead to spurious results in case-control association studies when prevalence of the disease is associated with different subpopulation groups. Ewens and Spielman, Am J Hum Genet 62:450-458 (1995). Such bias can also lead to a loss of statistical power in genetic association studies. To detect population stratification, Pritchard and Rosenberg suggested typing markers that are unlinked to the disease and using results of association tests on those markers to determine whether there is any population stratification. Pritchard et al., Am J Hum Gen 65:220-228 (1999). When stratification is detected, the genomic control (GC) method as proposed by Devlin and Roeder can be used to adjust for the inflation of test statistics due to population stratification. Devlin et al., Biometrics 55:997-1004 (1999). The GC method is robust to changes in population structure levels as well as being applicable to DNA pooling designs. Devlin et al., Genet Epidem 21:273-284 (2001).
  • While Pritchard's method recommended using 15-20 unlinked microsatellite markers, it suggested using more than 30 biallelic markers to get enough power to detect population stratification. For the GC method, it has been shown that about 60-70 biallelic markers are sufficient to estimate the inflation factor for the test statistics due to population stratification. Bacanu et al., Am J Hum Genet 66:1933-1944 (2000). Hence, 70 intergenic SNPs can be chosen in unlinked regions as indicated in a genome scan. Kehoe et al., Hum Mol Genet 8:237-245 (1999).
  • Once individual risk factors, genetic or non-genetic, have been found for the predisposition to disease, the next step is to set up a classification/prediction scheme to predict the category (for instance, disease or no-disease) that an individual will be in depending on his genotypes of associated SNPs and other non-genetic risk factors. Logistic regression for discrete trait and linear regression for continuous trait are standard techniques for such tasks. Draper and Smith, Applied Regression Analysis, Wiley (1998). Moreover, other techniques can also be used for setting up classification. Such techniques include, but are not limited to, MART, CART, neural network, and discriminant analyses that are suitable for use in comparing the performance of different methods. The Elements of Statistical Learning, Hastie, Tibshirani & Friedman, Springer (2002).
  • For further information about genetic association studies, see Balding, “A tutorial on statistical methods for population association studies”, Nature Reviews Genetics 7, 781 (2006).
  • Disease Diagnosis and Predisposition Screening
  • Information on association/correlation between genotypes and disease-related phenotypes can be exploited in several ways. For example, in the case of a highly statistically significant association between one or more SNPs with predisposition to a disease for which treatment is available, detection of such a genotype pattern in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of the susceptibility alleles associated with serious disease in a couple contemplating having children may also be valuable to the couple in their reproductive decisions. In the case of a weaker but still statistically significant association between a SNP and a human disease, immediate therapeutic intervention or monitoring may not be justified after detecting the susceptibility allele or SNP. Nevertheless, the subject can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little or no cost to the individual but would confer potential benefits in reducing the risk of developing conditions for which that individual may have an increased risk by virtue of having the risk allele(s).
  • The SNPs of the invention may contribute to responsiveness of an individual to statin treatment, or to the development of CVD (e.g., CHD, such as MI), in different ways. Some polymorphisms occur within a protein coding sequence and contribute to disease phenotype by affecting protein structure. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on, for example, replication, transcription, and/or translation. A single SNP may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by multiple SNPs in different genes.
  • As used herein, the terms “diagnose,” “diagnosis,” and “diagnostics” include, but are not limited to, any of the following: detection of CVD (e.g., CHD, such as MI) that an individual may presently have, predisposition/susceptibility/predictive screening (i.e., determining whether an individual has an increased or decreased risk of developing CVD in the future), predicting recurrence of CVD (e.g., recurrent MI) in an individual, determining a particular type or subclass of CVD in an individual who currently or previously had CVD, confirming or reinforcing a previously made diagnosis of CVD, evaluating an individual's likelihood of responding positively to a particular treatment or therapeutic agent (i.e., benefiting) such as statin treatment (particularly treatment or prevention of CVD, especially CHD such as MI, using statins), determining or selecting a therapeutic or preventive strategy that an individual is most likely to positively respond to (e.g., selecting a particular therapeutic agent such as a statin, or combination of therapeutic agents, or selecting a particular statin from among other statins, or determining a dosing regimen or selecting a dosage formulation, etc.), classifying (or confirming/reinforcing) an individual as a responder/non-responder (or determining a particular subtype of responder/non-responder) with respect to the individual's response to a drug treatment such as statin treatment, and predicting whether a patient is likely to experience toxic effects from a particular treatment or therapeutic compound. Such diagnostic uses can be based on the SNPs individually or a unique combination or SNPs disclosed herein, as well as SNP haplotypes.
  • Haplotypes are particularly useful in that, for example, fewer SNPs can be genotyped to determine if a particular genomic region harbors a locus that influences a particular phenotype, such as in linkage disequilibrium-based SNP association analysis.
  • Linkage disequilibrium (LD) refers to the co-inheritance of alleles (e.g., alternative nucleotides) at two or more different SNP sites at frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given population. The expected frequency of co-occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in “linkage equilibrium.” In contrast, LD refers to any non-random genetic association between allele(s) at two or more different SNP sites, which is generally due to the physical proximity of the two loci along a chromosome. LD can occur when two or more SNPs sites are in close physical proximity to each other on a given chromosome and therefore alleles at these SNP sites will tend to remain unseparated for multiple generations with the consequence that a particular nucleotide (allele) at one SNP site will show a non-random association with a particular nucleotide (allele) at a different SNP site located nearby. Hence, genotyping one of the SNP sites will give almost the same information as genotyping the other SNP site that is in LD.
  • Various degrees of LD can be encountered between two or more SNPs with the result being that some SNPs are more closely associated (i.e., in stronger LD) than others. Furthermore, the physical distance over which LD extends along a chromosome differs between different regions of the genome, and therefore the degree of physical separation between two or more SNP sites necessary for LD to occur can differ between different regions of the genome.
  • For diagnostic purposes and similar uses, if a particular SNP site is found to be useful for, for example, predicting an individual's response to statin treatment or an individual's susceptibility to CVD, then the skilled artisan would recognize that other SNP sites which are in LD with this SNP site would also be useful for the same purposes. Thus, polymorphisms (e.g., SNPs and/or haplotypes) that are not the actual disease-causing (causative) polymorphisms, but are in LD with such causative polymorphisms, are also useful. In such instances, the genotype of the polymorphism(s) that is/are in LD with the causative polymorphism is predictive of the genotype of the causative polymorphism and, consequently, predictive of the phenotype (e.g., response to statin treatment or risk for developing CVD) that is influenced by the causative SNP(s). Therefore, polymorphic markers that are in LD with causative polymorphisms are useful as diagnostic markers, and are particularly useful when the actual causative polymorphism(s) is/are unknown.
  • Examples of polymorphisms that can be in LD with one or more causative polymorphisms (and/or in LD with one or more polymorphisms that have a significant statistical association with a condition) and therefore useful for diagnosing the same condition that the causative/associated SNP(s) is used to diagnose, include other SNPs in the same gene, protein-coding, or mRNA transcript-coding region as the causative/associated SNP, other SNPs in the same exon or same intron as the causative/associated SNP, other SNPs in the same haplotype block as the causative/associated SNP, other SNPs in the same intergenic region as the causative/associated SNP, SNPs that are outside but near a gene (e.g., within 6 kb on either side, 5′ or 3′, of a gene boundary) that harbors a causative/associated SNP, etc. Such useful LD SNPs can be selected from among the SNPs disclosed in Table 3, for example.
  • Linkage disequilibrium in the human genome is reviewed in Wall et al., “Haplotype blocks and linkage disequilibrium in the human genome,” Nat Rev Genet 4(8):587-97 (August 2003); Garner et al., “On selecting markers for association studies: patterns of linkage disequilibrium between two and three diallelic loci,” Genet Epidemiol 24(1):57-67 (January 2003); Ardlie et al., “Patterns of linkage disequilibrium in the human genome,” Nat Rev Genet 3(4):299-309 (April 2002); erratum in Nat Rev Genet 3(7):566 (July 2002); and Remm et al., “High-density genotyping and linkage disequilibrium in the human genome using chromosome 22 as a model,” Curr Opin Chem Biol 6(1):24-30 (February 2002); J. B. S. Haldane, “The combination of linkage values, and the calculation of distances between the loci of linked factors,” J Genet 8:299-309 (1919); G. Mendel, Versuche über Pflanzen-Hybriden. Verhandlungen des naturforschenden Vereines in Brünn (Proceedings of the Natural History Society of Brünn) (1866); Genes IV, B. Lewin, ed., Oxford University Press, N.Y. (1990); D. L. Hartl and A. G. Clark Principles of Population Genetics 2nd ed., Sinauer Associates, Inc., Mass. (1989); J. H. Gillespie Population Genetics: A Concise Guide. 2nd ed., Johns Hopkins University Press (2004); R. C. Lewontin, “The interaction of selection and linkage. I. General considerations; heterotic models,” Genetics 49:49-67 (1964); P. G. Hoel, Introduction to Mathematical Statistics 2nd ed., John Wiley & Sons, Inc., N.Y. (1954); R. R. Hudson, “Two-locus sampling distributions and their application,” Genetics 159:1805-1817 (2001); A. P. Dempster, N. M. Laird, D. B. Rubin, “Maximum likelihood from incomplete data via the EM algorithm,” J R Stat Soc 39:1-38 (1977); L. Excoffier, M. Slatkin, “Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population,” Mol Biol Evol 12(5):921-927 (1995); D. A. Tregouet, S. Escolano, L. Tiret, A. Mallet, J. L. Golmard, “A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm,” Ann Hum Genet 68(Pt 2):165-177 (2004); A. D. Long and C. H. Langley C H, “The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits,” Genome Research 9:720-731 (1999); A. Agresti, Categorical Data Analysis, John Wiley & Sons, Inc., N.Y. (1990); K. Lange, Mathematical and Statistical Methods for Genetic Analysis, Springer-Verlag New York, Inc., N.Y. (1997); The International HapMap Consortium, “The International HapMap Project,” Nature 426:789-796 (2003); The International HapMap Consortium, “A haplotype map of the human genome,” Nature 437:1299-1320 (2005); G. A. Thorisson, A. V. Smith, L. Krishnan, L. D. Stein, “The International HapMap Project Web Site,” Genome Research 15:1591-1593 (2005); G. McVean, C. C. A. Spencer, R. Chaix, “Perspectives on human genetic variation from the HapMap project,” PLoS Genetics 1(4):413-418 (2005); J. N. Hirschhorn, M. J. Daly, “Genome-wide association studies for common diseases and complex traits,” Nat Genet 6:95-108 (2005); S. J. Schrodi, “A probabilistic approach to large-scale association scans: a semi-Bayesian method to detect disease-predisposing alleles,” SAGMB 4(1):31 (2005); W. Y. S. Wang, B. J. Barratt, D. G. Clayton, J. A. Todd, “Genome-wide association studies: theoretical and practical concerns,” Nat Rev Genet 6:109-118 (2005); J. K. Pritchard, M. Przeworski, “Linkage disequilibrium in humans: models and data,” Am J Hum Genet 69:1-14 (2001).
  • As discussed above, an aspect of the present invention relates to SNPs that are in LD with an interrogated SNP and which can also be used as valid markers for determining an individual's likelihood of benefiting from statin treatment, or whether an individual has an increased or decreased risk of having or developing CVD. As used herein, the term “interrogated SNP” refers to SNPs that have been found to be associated with statin response, particularly for reducing CVD risk, using genotyping results and analysis, or other appropriate experimental method as exemplified in the working examples described in this application. As used herein, the term “LD SNP” refers to a SNP that has been characterized as a SNP associated with statin response or an increased or decreased risk of CVD due to their being in LD with the “interrogated SNP” under the methods of calculation described in the application. Below, applicants describe the methods of calculation with which one of ordinary skilled in the art may determine if a particular SNP is in LD with an interrogated SNP. The parameter r2 is commonly used in the genetics art to characterize the extent of linkage disequilibrium between markers (Hudson, 2001). As used herein, the term “in LD with” refers to a particular SNP that is measured at above the threshold of a parameter such as r2 with an interrogated SNP.
  • It is now common place to directly observe genetic variants in a sample of chromosomes obtained from a population. Suppose one has genotype data at two genetic markers located on the same chromosome, for the markers A and B. Further suppose that two alleles segregate at each of these two markers such that alleles A1 and A2 can be found at marker A and alleles B1 and B2 at marker B. Also assume that these two markers are on a human autosome. If one is to examine a specific individual and find that they are heterozygous at both markers, such that their two-marker genotype is A1A2B1B2, then there are two possible configurations: the individual in question could have the alleles A1B1 on one chromosome and A2B2 on the remaining chromosome; alternatively, the individual could have alleles A1B2 on one chromosome and A2B1 on the other. The arrangement of alleles on a chromosome is called a haplotype. In this illustration, the individual could have haplotypes A1B1/A2B2 or A1B2/A2B1 (see Hartl and Clark (1989) for a more complete description). The concept of linkage equilibrium relates the frequency of haplotypes to the allele frequencies.
  • Assume that a sample of individuals is selected from a larger population. Considering the two markers described above, each having two alleles, there are four possible haplotypes: A1B1, A1B2, A2B1 and A2B2. Denote the frequencies of these four haplotypes with the following notation.

  • P 11=freq(A 1 B 1)  (1)

  • P 12=freq(A 1 B 2)  (2)

  • P 21=freq(A 2 B 1)  (3)

  • P 22=freq(A 2 B 2)  (4)
  • The allele frequencies at the two markers are then the sum of different haplotype frequencies, it is straightforward to write down a similar set of equations relating single-marker allele frequencies to two-marker haplotype frequencies:

  • p 1=freq(A 1)=P 11 +P 12  (5)

  • p 2=freq(A 2)=P 21 +P 22  (6)

  • q 1=freq(B 1)=P 11 +P 21  (7)

  • q 2=freq(B 2)=P 12 +P 22  (8)
  • Note that the four haplotype frequencies and the allele frequencies at each marker must sum to a frequency of 1.

  • P 11 +P 12 +P 21 +P 22=1  (9)

  • p 1 +p 2=1  (10)

  • q 1 +q 2=1  (11)
  • If there is no correlation between the alleles at the two markers, one would expect that the frequency of the haplotypes would be approximately the product of the composite alleles. Therefore,

  • P 11 ≈p 1 q 1  (12)

  • P 12 ≈p 1 q 2  (13)

  • P 21 ≈p 2 q 1  (14)

  • P 22 ≈p 2 q 2  (15)
  • These approximating equations (12)-(15) represent the concept of linkage equilibrium where there is independent assortment between the two markers—the alleles at the two markers occur together at random. These are represented as approximations because linkage equilibrium and linkage disequilibrium are concepts typically thought of as properties of a sample of chromosomes; and as such they are susceptible to stochastic fluctuations due to the sampling process. Empirically, many pairs of genetic markers will be in linkage equilibrium, but certainly not all pairs.
  • Having established the concept of linkage equilibrium above, applicants can now describe the concept of linkage disequilibrium (LD), which is the deviation from linkage equilibrium. Since the frequency of the A1B1 haplotype is approximately the product of the allele frequencies for A1 and B1 under the assumption of linkage equilibrium as stated mathematically in (12), a simple measure for the amount of departure from linkage equilibrium is the difference in these two quantities, D,

  • D=P 11 −p 1 q 1  (16)
  • D=0 indicates perfect linkage equilibrium. Substantial departures from D=0 indicates LD in the sample of chromosomes examined. Many properties of D are discussed in Lewontin (1964) including the maximum and minimum values that D can take. Mathematically, using basic algebra, it can be shown that D can also be written solely in terms of haplotypes:

  • D=P 11 P 22 −P 12 P 21  (17)
  • If one transforms D by squaring it and subsequently dividing by the product of the allele frequencies of A1, A2, B1 and B2, the resulting quantity, called r2, is equivalent to the square of the Pearson's correlation coefficient commonly used in statistics (e.g., Hoel, 1954).
  • r 2 = D 2 p 1 p 2 q 1 q 2 ( 18 )
  • As with D, values of r2 close to 0 indicate linkage equilibrium between the two markers examined in the sample set. As values of r2 increase, the two markers are said to be in linkage disequilibrium. The range of values that r2 can take are from 0 to 1. r2=1 when there is a perfect correlation between the alleles at the two markers.
  • In addition, the quantities discussed above are sample-specific. And as such, it is necessary to formulate notation specific to the samples studied. In the approach discussed here, three types of samples are of primary interest: (i) a sample of chromosomes from individuals affected by a disease-related phenotype (cases), (ii) a sample of chromosomes obtained from individuals not affected by the disease-related phenotype (controls), and (iii) a standard sample set used for the construction of haplotypes and calculation pairwise linkage disequilibrium. For the allele frequencies used in the development of the method described below, an additional subscript will be added to denote either the case or control sample sets.

  • p 1,cs=freq(A 1 in cases)  (19)

  • p 2,cs=freq(A 2 in cases)  (20)

  • q 1,cs=freq(B 1 in cases)  (21)

  • q 2,cs=freq(B 2 in cases)  (22)

  • Similarly,

  • p 1,ct=freq(A 1 in controls)  (23)

  • p 2,ct=freq(A 2 in controls)  (24)

  • q 1,ct=freq(B 1 in controls)  (25)

  • q 2,ct=freq(B 2 in controls)  (26)
  • As a well-accepted sample set is necessary for robust linkage disequilibrium calculations, data obtained from the International HapMap project (The International HapMap Consortium 2003, 2005; Thorisson et al, 2005; McVean et al, 2005) can be used for the calculation of pairwise r2 values. Indeed, the samples genotyped for the International HapMap Project were selected to be representative examples from various human sub-populations with sufficient numbers of chromosomes examined to draw meaningful and robust conclusions from the patterns of genetic variation observed. The International HapMap project website (hapmap.org) contains a description of the project, methods utilized and samples examined. It is useful to examine empirical data to get a sense of the patterns present in such data.
  • Haplotype frequencies were explicit arguments in equation (18) above. However, knowing the 2-marker haplotype frequencies requires that phase to be determined for doubly heterozygous samples. When phase is unknown in the data examined, various algorithms can be used to infer phase from the genotype data. This issue was discussed earlier where the doubly heterozygous individual with a 2-SNP genotype of A1A2B1B2 could have one of two different sets of chromosomes: A1B1/A2B2 or A1B2/A2B1. One such algorithm to estimate haplotype frequencies is the expectation-maximization (EM) algorithm first formalized by Dempster et al. (1977). This algorithm is often used in genetics to infer haplotype frequencies from genotype data (e.g. Excoffier and Slatkin (1995); Tregouet et al. (2004)). It should be noted that for the two-SNP case explored here, EM algorithms have very little error provided that the allele frequencies and sample sizes are not too small. The impact on r2 values is typically negligible.
  • As correlated genetic markers share information, interrogation of SNP markers in LD with a disease-associated SNP marker can also have sufficient power to detect disease association (Long and Langley (1999)). The relationship between the power to directly find disease-associated alleles and the power to indirectly detect disease-association was investigated by Pritchard and Przeworski (2001). In a straight-forward derivation, it can be shown that the power to detect disease association indirectly at a marker locus in linkage disequilibrium with a disease-association locus is approximately the same as the power to detect disease-association directly at the disease-association locus if the sample size is increased by a factor of
  • 1 r 2
  • (the reciprocal of equation 18) at the marker in comparison with the disease-association locus.
  • Therefore, if one calculated the power to detect disease-association indirectly with an experiment having N samples, then equivalent power to directly detect disease-association (at the actual disease-susceptibility locus) would necessitate an experiment using approximately r2N samples. This elementary relationship between power, sample size and linkage disequilibrium can be used to derive an r2 threshold value useful in determining whether or not genotyping markers in linkage disequilibrium with a SNP marker directly associated with disease status has enough power to indirectly detect disease-association.
  • To commence a derivation of the power to detect disease-associated markers through an indirect process, define the effective chromosomal sample size as
  • n = 4 N cs N ct N cs + N ct ; ( 27 )
  • where Ncs and Nct are the numbers of diploid cases and controls, respectively. This is necessary to handle situations where the numbers of cases and controls are not equivalent. For equal case and control sample sizes, Ncs=Nct=N, the value of the effective number of chromosomes is simply n=2N—as expected. Let power be calculated for a significance level α (such that traditional P-values below α will be deemed statistically significant). Define the standard Gaussian distribution function as Φ(•). Mathematically,
  • Φ ( x ) = 1 2 π - x - θ 2 2 θ ( 28 )
  • Alternatively, the following error function notation (Erf) may also be used,
  • Φ ( x ) = 1 2 [ 1 + Erf ( x 2 ) ] ( 29 )
  • For example, Φ(1.644854)=0.95. The value of r2 may be derived to yield a pre-specified minimum amount of power to detect disease association though indirect interrogation. Noting that the LD SNP marker could be the one that is carrying the disease-association allele, therefore that this approach constitutes a lower-bound model where all indirect power results are expected to be at least as large as those interrogated.
  • Denote by β the error rate for not detecting truly disease-associated markers. Therefore, 1−β is the classical definition of statistical power. Substituting the Pritchard-Pzreworski result into the sample size, the power to detect disease association at a significance level of α is given by the approximation
  • 1 - β Φ [ q 1 , cs - q 1 , ct q 1 , cs ( 1 - q 1 , cs ) + q 1 , ct ( 1 - q 1 , ct ) r 2 n - Z 1 - α 2 ] ; ( 30 )
  • where Zu is the inverse of the standard normal cumulative distribution evaluated at u (uε(0,1)). Zu−1(u), where Φ(Φ−1(u))=Φ−1(Φ(u))=u. For example, setting α=0.05, and therefore 1−α/2=0.975, one obtains Z0.975=1.95996. Next, setting power equal to a threshold of a minimum power of T,
  • T = Φ [ q 1 , cs - q 1 , ct q 1 , cs ( 1 - q 1 , cs ) + q 1 , ct ( 1 - q 1 , ct ) r 2 n - Z 1 - α 2 ] ( 31 )
  • and solving for r2, the following threshold r2 is obtained:
  • r T 2 = [ q 1 , cs ( 1 - q 1 , cs ) + q 1 , ct ( 1 - q 1 , ct ) ] n ( q 1 , cs - q 1 , ct ) 2 [ Φ - 1 ( T ) + Z 1 - α / 2 ] 2 Or , ( 32 ) r T 2 = ( Z T + Z 1 - α / 2 ) 2 n [ q 1 , cs - ( q 1 , cs ) 2 + q 1 , ct - ( q 1 , ct ) 2 ( q 1 , cs - q 1 , ct ) 2 ] ( 33 )
  • Suppose that r2 is calculated between an interrogated SNP and a number of other SNPs with varying levels of LD with the interrogated SNP. The threshold value rT 2 is the minimum value of linkage disequilibrium between the interrogated SNP and the potential LD SNPs such that the LD SNP still retains a power greater or equal to T for detecting disease-association. For example, suppose that SNP rs200 is genotyped in a case-control disease-association study and it is found to be associated with a disease phenotype. Further suppose that the minor allele frequency in 1,000 case chromosomes was found to be 16% in contrast with a minor allele frequency of 10% in 1,000 control chromosomes. Given those measurements one could have predicted, prior to the experiment, that the power to detect disease association at a significance level of 0.05 was quite high—approximately 98% using a test of allelic association. Applying equation (32) one can calculate a minimum value of r2 to indirectly assess disease association assuming that the minor allele at SNP rs200 is truly disease-predisposing for a threshold level of power. If one sets the threshold level of power to be 80%, then rT 2=0.489 given the same significance level and chromosome numbers as above. Hence, any SNP with a pairwise r2 value with rs200 greater than 0.489 is expected to have greater than 80% power to detect the disease association. Further, this is assuming the conservative model where the LD SNP is disease-associated only through linkage disequilibrium with the interrogated SNP rs200.
  • Imputation
  • Genotypes of SNPs can be imputed without actually having to be directly genotyped (referred to as “imputation”), by using known haplotype information. Imputation is a process to provide “missing” data, either missing individual genotypes (alleles) or missing SNPs and concomitant genotypes, which have not been directly genotyped (i.e., assayed). Imputation is particularly useful for identifying disease associations for specific ungenotyped SNPs by inferring the missing genotypes to these ungenotyped SNPs. Although the process uses similar information to LD, since the phasing and imputation process uses information from multiple SNPs at the same time, the phased haplotype, it is able to infer the genotype and achieve high identifiable accuracy. Genotype information (such as from the HapMap project by The International HapMap Consortium, NCBI, NLM, NIH) can be used to infer haplotype phase and impute genotypes for SNPs that are not directly genotyped in a given individual or sample set (such as for a disease association study). In general, imputation uses a reference dataset in which the genotypes of potential SNPs that are to be tested for disease association have been determined in multiple individuals (such as in HapMap); the individuals in the reference dataset are then haplotype phased. This phasing can be done with independent programs such as fastPHASE (Sheet and Stephens, Am J Hum Genet (2006) 76: 629-644) or a combination program such as BEAGLE which does both the phasing and the imputation. The reference phased haplotypes and process can be checked using the children of the HapMap individual parents, among other mechanisms. Once the reference phased haplotypes have been created, the imputation of additional individuals for SNPs genotyped or complete sets of SNPs that have not been directly genotyped can then proceed. The HapMap dataset is particularly useful as the reference dataset, however other datasets can be used. Since the imputation creates new concommitant phased haplotypes for individuals in the association study and these contain other SNPs within the genomic region, these ungenotyped but imputed SNPs can also be tested for disease associations (or other traits). Certain exemplary methods for haplotype phase inference and imputation of missing genotypes utilize the BEAGLE genetic analysis program, (Browning, Hum Genet (2008) 124:439-450).
  • Thus, SNPs for which genotypes are imputed can be tested for association with a disease or other trait even though these SNPs are not directly genotyped. The SNPs for which genotypes are imputed have genotype data available in the reference dataset, e.g. HapMap individuals, but they are not directly genotyped in a particular individual or sample set (such as in a particular disease association study).
  • In addition to using a reference dataset (e.g., HapMap) to impute genotypes of SNPs that are not directly genotyped in a study, imputation can provide genotypes of SNPs that were directly genotyped in a study but for which the genotypes are missing in some or most of the individuals for some reason, such as because they failed to pass quality control. Imputation can also be used to combine genotyping results from multiple studies in which different sets of SNPs were genotyped to construct a complete meta-analysis. For example, genotyped and imputed genotyped SNP results from multiple different studies can be combined, and the overlapping SNP genotypes (e.g., genotyped in one study, imputed in another study or imputed in both or genotyped in both) can be analyzed across all of the studies (Browning, Hum Genet (2008) 124:439-450).
  • For a review of imputation (as well as the BEAGLE program), see Browning, “Missing data imputation and haplotype phase inference for genome-wide association studies”, Hum Genet (2008) 124:439-450 and Browning et al. “A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals”, Am J Hum Genet. (2009) February; 84(2):210-23, each of which is incorporated herein by reference in its entirety.
  • The contribution or association of particular SNPs with statin response or disease phenotypes, such as CVD, enables the SNPs of the present invention to be used to develop superior diagnostic tests capable of identifying individuals who express a detectable trait, such as reduced risk for CVD (particularly CHD, such as MI) in response to statin treatment, as the result of a specific genotype, or individuals whose genotype places them at an increased or decreased risk of developing a detectable trait at a subsequent time as compared to individuals who do not have that genotype. As described herein, diagnostics may be based on a single SNP or a group of SNPs. Combined detection of a plurality of SNPs (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 48, 50, 64, 96, 100, or any other number in-between, or more, of the SNPs provided in Table 1 and/or Table 2) typically increases the probability of an accurate diagnosis. For example, the presence of a single SNP known to correlate with CVD might indicate a probability of 20% that an individual has or is at risk of developing CVD, whereas detection of five SNPs, each of which correlates with CVD, might indicate a probability of 80% that an individual has or is at risk of developing CVD. To further increase the accuracy of diagnosis or predisposition screening, analysis of the SNPs of the present invention can be combined with that of other polymorphisms or other risk factors of CVD, such as disease symptoms, pathological characteristics, family history, diet, environmental factors, or lifestyle factors.
  • It will be understood by practitioners skilled in the treatment or diagnosis of CVD that the present invention generally does not intend to provide an absolute identification of individuals who benefit from statin treatment or individuals who are at risk (or less at risk) of developing CVD, but rather to indicate a certain increased (or decreased) degree or likelihood of responding to statin therapy or developing CVD based on statistically significant association results. However, this information is extremely valuable as it can be used to, for example, encourage individuals to comply with their statin regimens as prescribed by their doctors (even though the benefit of maintaining statin therapy may not be overtly apparent, which often leads to lack of compliance with prescribed statin treatment), to initiate preventive treatments or to allow an individual carrying one or more significant SNPs or SNP haplotypes to foresee warning signs such as minor clinical symptoms, or to have regularly scheduled physical exams to monitor for appearance of a condition in order to identify and begin treatment of the condition at an early stage. Particularly with diseases that are extremely debilitating or fatal if not treated on time, the knowledge of a potential predisposition, even if this predisposition is not absolute, would likely contribute in a very significant manner to treatment efficacy.
  • The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a SNP or combination of SNPs associated with an increased or decreased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular polymorphism/mutation, including, for example, methods which enable the analysis of individual chromosomes for haplotyping, family studies, single sperm DNA analysis, or somatic hybrids. The trait analyzed using the diagnostics of the invention may be any detectable trait that is commonly observed in pathologies and disorders related to CVD or drug response.
  • Another aspect of the present invention relates to a method of determining whether an individual is at risk (or less at risk) of developing one or more traits or whether an individual expresses one or more traits as a consequence of possessing a particular trait-causing or trait-influencing allele. These methods generally involve obtaining a nucleic acid sample from an individual and assaying the nucleic acid sample to determine which nucleotide(s) is/are present at one or more SNP positions, wherein the assayed nucleotide(s) is/are indicative of an increased or decreased risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular trait-causing or trait-influencing allele.
  • In another embodiment, the SNP detection reagents of the present invention are used to determine whether an individual has one or more SNP allele(s) affecting the level (e.g., the concentration of mRNA or protein in a sample, etc.) or pattern (e.g., the kinetics of expression, rate of decomposition, stability profile, Km, Vmax, etc.) of gene expression (collectively, the “gene response” of a cell or bodily fluid). Such a determination can be accomplished by screening for mRNA or protein expression (e.g., by using nucleic acid arrays, RT-PCR, TaqMan assays, or mass spectrometry), identifying genes having altered expression in an individual, genotyping SNPs disclosed in Table 1 and/or Table 2 that could affect the expression of the genes having altered expression (e.g., SNPs that are in and/or around the gene(s) having altered expression, SNPs in regulatory/control regions, SNPs in and/or around other genes that are involved in pathways that could affect the expression of the gene(s) having altered expression, or all SNPs could be genotyped), and correlating SNP genotypes with altered gene expression. In this manner, specific SNP alleles at particular SNP sites can be identified that affect gene expression.
  • Therapeutics, Pharmacogenomics, and Drug Development
  • Therapeutic Methods and Compositions
  • In certain aspects of the invention, there are provided methods of assaying (i.e., testing) one or more SNPs provided by the present invention in an individual's nucleic acids, and administering a therapeutic or preventive agent to the individual based on the allele(s) present at the SNP(s) having indicated that the individual can benefit from the therapeutic or preventive agent.
  • In further aspects of the invention, there are provided methods of assaying one or more SNPs provided by the present invention in an individual's nucleic acids, and administering a diagnostic agent (e.g., an imaging agent), or otherwise carrying out further diagnostic procedures on the individual, based on the allele(s) present at the SNP(s) having indicated that the diagnostic agents or diagnostics procedures are justified in the individual.
  • In yet other aspects of the invention, there is provided a pharmaceutical pack comprising a therapeutic agent (e.g., a small molecule drug, antibody, peptide, antisense or RNAi nucleic acid molecule, etc.) and a set of instructions for administration of the therapeutic agent to an individual who has been tested for one or more SNPs provided by the present invention.
  • Pharmacogenomics
  • The present invention provides methods for assessing the pharmacogenomics of a subject harboring particular SNP alleles or haplotypes to a particular therapeutic agent or pharmaceutical compound, or to a class of such compounds. Pharmacogenomics deals with the roles which clinically significant hereditary variations (e.g., SNPs) play in the response to drugs due to altered drug disposition and/or abnormal action in affected persons. See, e.g., Roses, Nature 405, 857-865 (2000); Gould Rothberg, Nature Biotechnology 19, 209-211 (2001); Eichelbaum, Clin Exp Pharmacol Physiol 23(10-11):983-985 (1996); and Linder, Clin Chem 43(2):254-266 (1997). The clinical outcomes of these variations can result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the SNP genotype of an individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. For example, SNPs in drug metabolizing enzymes can affect the activity of these enzymes, which in turn can affect both the intensity and duration of drug action, as well as drug metabolism and clearance.
  • The discovery of SNPs in drug metabolizing enzymes, drug transporters, proteins for pharmaceutical agents, and other drug targets has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. SNPs can be expressed in the phenotype of the extensive metabolizer and in the phenotype of the poor metabolizer. Accordingly, SNPs may lead to allelic variants of a protein in which one or more of the protein functions in one population are different from those in another population. SNPs and the encoded variant peptides thus provide targets to ascertain a genetic predisposition that can affect treatment modality. For example, in a ligand-based treatment, SNPs may give rise to amino terminal extracellular domains and/or other ligand-binding regions of a receptor that are more or less active in ligand binding, thereby affecting subsequent protein activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing particular SNP alleles or haplotypes.
  • As an alternative to genotyping, specific variant proteins containing variant amino acid sequences encoded by alternative SNP alleles could be identified. Thus, pharmacogenomic characterization of an individual permits the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic uses based on the individual's SNP genotype, thereby enhancing and optimizing the effectiveness of the therapy. Furthermore, the production of recombinant cells and transgenic animals containing particular SNPs/haplotypes allow effective clinical design and testing of treatment compounds and dosage regimens. For example, transgenic animals can be produced that differ only in specific SNP alleles in a gene that is orthologous to a human disease susceptibility gene.
  • Pharmacogenomic uses of the SNPs of the present invention provide several significant advantages for patient care, particularly in predicting an individual's responsiveness to statin treatment (particularly for reducing the risk of CVD, especially CHD such as MI) and in predicting an individual's predisposition to CVD (e.g., CHD such as MI). Pharmacogenomic characterization of an individual, based on an individual's SNP genotype, can identify those individuals unlikely to respond to treatment with a particular medication and thereby allows physicians to avoid prescribing the ineffective medication to those individuals. On the other hand, SNP genotyping of an individual may enable physicians to select the appropriate medication and dosage regimen that will be most effective based on an individual's SNP genotype. This information increases a physician's confidence in prescribing medications and motivates patients to comply with their drug regimens. Furthermore, pharmacogenomics may identify patients predisposed to toxicity and adverse reactions to particular drugs or drug dosages. Adverse drug reactions lead to more than 100,000 avoidable deaths per year in the United States alone and therefore represent a significant cause of hospitalization and death, as well as a significant economic burden on the healthcare system (Pfost et al., Trends in Biotechnology, August 2000). Thus, pharmacogenomics based on the SNPs disclosed herein has the potential to both save lives and reduce healthcare costs substantially.
  • Pharmacogenomics in general is discussed further in Rose et al., “Pharmacogenetic analysis of clinically relevant genetic polymorphisms,” Methods Mol Med 85:225-37 (2003). Pharmacogenomics as it relates to Alzheimer's disease and other neurodegenerative disorders is discussed in Cacabelos, “Pharmacogenomics for the treatment of dementia,” Ann Med 34(5):357-79 (2002); Maimone et al., “Pharmacogenomics of neurodegenerative diseases,” Eur J Pharmacol 413(1):11-29 (February 2001); and Poirier, “Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease,” Mol Diagn 4(4):335-41 (December 1999). Pharmacogenomics as it relates to cardiovascular disorders is discussed in Siest et al., “Pharmacogenomics of drugs affecting the cardiovascular system,” Clin Chem Lab Med 41(4):590-9 (April 2003); Mukherjee et al., “Pharmacogenomics in cardiovascular diseases,” Prog Cardiovasc Dis 44(6):479-98 (May-June 2002); and Mooser et al., “Cardiovascular pharmacogenetics in the SNP era,” J Thromb Haemost 1(7):1398-402 (July 2003). Pharmacogenomics as it relates to cancer is discussed in McLeod et al., “Cancer pharmacogenomics: SNPs, chips, and the individual patient,” Cancer Invest 21(4):630-40 (2003); and Watters et al., “Cancer pharmacogenomics: current and future applications,” Biochim Biophys Acta 1603(2):99-111 (March 2003).
  • Clinical Trials
  • In certain aspects of the invention, there are provided methods of using the SNPs disclosed herein to identify or stratify patient populations for clinical trials of a therapeutic, preventive, or diagnostic agent.
  • For instance, an aspect of the present invention includes selecting individuals for clinical trials based on their SNP genotype, such as selecting individuals for inclusion in a clinical trial and/or assigning individuals to a particular group within a clinical trial (e.g., an “arm” of the trial). For example, individuals with SNP genotypes that indicate that they are likely to positively respond to a drug can be included in the trials, whereas those individuals whose SNP genotypes indicate that they are less likely to or would not respond to the drug, or who are at risk for suffering toxic effects or other adverse reactions, can be excluded from the clinical trials. This not only can improve the safety of clinical trials, but also can enhance the chances that the trial will demonstrate statistically significant efficacy. Further, one can stratify a prospective trial with patients with different SNP variants to determine the impact of differential drug treatment.
  • Thus, certain embodiments of the invention provide methods for conducting a clinical trial of a therapeutic agent in which a human is selected for inclusion in the clinical trial and/or assigned to a particular group within a clinical trial based on the presence or absence of one or more SNPs disclosed herein. In certain embodiments, the therapeutic agent is a statin.
  • In certain exemplary embodiments, SNPs of the invention can be used to select individuals who are unlikely to respond positively to a particular therapeutic agent (or class of therapeutic agents) based on their SNP genotype(s) to participate in a clinical trial of another type of drug that may benefit them. Thus, in certain embodiments, the SNPs of the invention can be used to identify patient populations who do not adequately respond to current treatments and are therefore in need of new therapies. This not only benefits the patients themselves, but also benefits organizations such as pharmaceutical companies by enabling the identification of populations that represent markets for new drugs, and enables the efficacy of these new drugs to be tested during clinical trials directly in individuals within these markets.
  • The SNP-containing nucleic acid molecules of the present invention are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of a variant gene, or encoded product, particularly in a treatment regimen or in clinical trials. Thus, the gene expression pattern can serve as an indicator for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance, as well as an indicator for toxicities. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant.
  • Furthermore, the SNPs of the present invention may have utility in determining why certain previously developed drugs performed poorly in clinical trials and may help identify a subset of the population that would benefit from a drug that had previously performed poorly in clinical trials, thereby “rescuing” previously developed drugs, and enabling the drug to be made available to a particular patient population (e.g., particular CVD patients) that can benefit from it.
  • Identification, Screening, and Use of Therapeutic Agents
  • The SNPs of the present invention also can be used to identify novel therapeutic targets for CVD, particularly CHD, such as MI, or stroke. For example, genes containing the disease-associated variants (“variant genes”) or their products, as well as genes or their products that are directly or indirectly regulated by or interacting with these variant genes or their products, can be targeted for the development of therapeutics that, for example, treat the disease or prevent or delay disease onset. The therapeutics may be composed of, for example, small molecules, proteins, protein fragments or peptides, antibodies, nucleic acids, or their derivatives or mimetics which modulate the functions or levels of the target genes or gene products.
  • The invention further provides methods for identifying a compound or agent that can be used to treat CVD, particularly CHD such as MI. The SNPs disclosed herein are useful as targets for the identification and/or development of therapeutic agents. A method for identifying a therapeutic agent or compound typically includes assaying the ability of the agent or compound to modulate the activity and/or expression of a SNP-containing nucleic acid or the encoded product and thus identifying an agent or a compound that can be used to treat a disorder characterized by undesired activity or expression of the SNP-containing nucleic acid or the encoded product. The assays can be performed in cell-based and cell-free systems. Cell-based assays can include cells naturally expressing the nucleic acid molecules of interest or recombinant cells genetically engineered to express certain nucleic acid molecules.
  • Variant gene expression in a CVD patient can include, for example, either expression of a SNP-containing nucleic acid sequence (for instance, a gene that contains a SNP can be transcribed into an mRNA transcript molecule containing the SNP, which can in turn be translated into a variant protein) or altered expression of a normal/wild-type nucleic acid sequence due to one or more SNPs (for instance, a regulatory/control region can contain a SNP that affects the level or pattern of expression of a normal transcript).
  • Assays for variant gene expression can involve direct assays of nucleic acid levels (e.g., mRNA levels), expressed protein levels, or of collateral compounds involved in a signal pathway. Further, the expression of genes that are up- or down-regulated in response to the signal pathway can also be assayed. In this embodiment, the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.
  • Modulators of variant gene expression can be identified in a method wherein, for example, a cell is contacted with a candidate compound/agent and the expression of mRNA determined. The level of expression of mRNA in the presence of the candidate compound is compared to the level of expression of mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of variant gene expression based on this comparison and be used to treat a disorder such as CVD that is characterized by variant gene expression (e.g., either expression of a SNP-containing nucleic acid or altered expression of a normal/wild-type nucleic acid molecule due to one or more SNPs that affect expression of the nucleic acid molecule) due to one or more SNPs of the present invention. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.
  • The invention further provides methods of treatment, with the SNP or associated nucleic acid domain (e.g., catalytic domain, ligand/substrate-binding domain, regulatory/control region, etc.) or gene, or the encoded mRNA transcript, as a target, using a compound identified through drug screening as a gene modulator to modulate variant nucleic acid expression. Modulation can include either up-regulation (i.e., activation or agonization) or down-regulation (i.e., suppression or antagonization) of nucleic acid expression.
  • Expression of mRNA transcripts and encoded proteins, either wild type or variant, may be altered in individuals with a particular SNP allele in a regulatory/control element, such as a promoter or transcription factor binding domain, that regulates expression. In this situation, methods of treatment and compounds can be identified, as discussed herein, that regulate or overcome the variant regulatory/control element, thereby generating normal, or healthy, expression levels of either the wild type or variant protein.
  • Pharmaceutical Compositions and Administration Thereof
  • Any of the statin response-associated proteins, and encoding nucleic acid molecules, disclosed herein can be used as therapeutic targets (or directly used themselves as therapeutic compounds) for treating or preventing CVD, and the present disclosure enables therapeutic compounds (e.g., small molecules, antibodies, therapeutic proteins, RNAi and antisense molecules, etc.) to be developed that target (or are comprised of) any of these therapeutic targets.
  • In general, a therapeutic compound will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the therapeutic compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
  • Therapeutically effective amounts of therapeutic compounds may range from, for example, approximately 0.01-50 mg per kilogram body weight of the recipient per day; preferably about 0.1-20 mg/kg/day. Thus, as an example, for administration to a 70-kg person, the dosage range would most preferably be about 7 mg to 1.4 g per day.
  • In general, therapeutic compounds will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous) administration. The preferred manner of administration is oral or parenteral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Oral compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills, or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a cross-linked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
  • Pharmaceutical compositions are comprised of, in general, a therapeutic compound in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the therapeutic compound. Such excipients may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one skilled in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
  • Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
  • Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences 18th ed., E. W. Martin, ed., Mack Publishing Company (1990).
  • The amount of the therapeutic compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of the therapeutic compound based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80% wt.
  • Therapeutic compounds can be administered alone or in combination with other therapeutic compounds or in combination with one or more other active ingredient(s). For example, an inhibitor or stimulator of a CVD-associated protein can be administered in combination with another agent that inhibits or stimulates the activity of the same or a different CVD-associated protein to thereby counteract the effects of CVD.
  • For further information regarding pharmacology, see Current Protocols in Pharmacology, John Wiley & Sons, Inc., N.Y.
  • Nucleic Acid-Based Therapeutic Agents
  • The SNP-containing nucleic acid molecules disclosed herein, and their complementary nucleic acid molecules, may be used as antisense constructs to control gene expression in cells, tissues, and organisms. Antisense technology is well established in the art and extensively reviewed in Antisense Drug Technology: Principles, Strategies, and Applications, Crooke, ed., Marcel Dekker, Inc., N.Y. (2001). An antisense nucleic acid molecule is generally designed to be complementary to a region of mRNA expressed by a gene so that the antisense molecule hybridizes to the mRNA and thereby blocks translation of mRNA into protein. Various classes of antisense oligonucleotides are used in the art, two of which are cleavers and blockers. Cleavers, by binding to target RNAs, activate intracellular nucleases (e.g., RNaseH or RNase L) that cleave the target RNA. Blockers, which also bind to target RNAs, inhibit protein translation through steric hindrance of ribosomes. Exemplary blockers include peptide nucleic acids, morpholinos, locked nucleic acids, and methylphosphonates. See, e.g., Thompson, Drug Discovery Today 7(17): 912-917 (2002). Antisense oligonucleotides are directly useful as therapeutic agents, and are also useful for determining and validating gene function (e.g., in gene knock-out or knock-down experiments).
  • Antisense technology is further reviewed in: Lavery et al., “Antisense and RNAi: powerful tools in drug target discovery and validation,” Curr Opin Drug Discov Devel 6(4):561-9 (July 2003); Stephens et al., “Antisense oligonucleotide therapy in cancer,” Curr Opin Mol Ther 5(2):118-22 (April 2003); Kurreck, “Antisense technologies. Improvement through novel chemical modifications,” Eur J Biochem 270(8):1628-44 (April 2003); Dias et al., “Antisense oligonucleotides: basic concepts and mechanisms,” Mol Cancer Ther 1(5):347-55 (March 2002); Chen, “Clinical development of antisense oligonucleotides as anti-cancer therapeutics,” Methods Mol Med 75:621-36 (2003); Wang et al., “Antisense anticancer oligonucleotide therapeutics,” Curr Cancer Drug Targets 1(3):177-96 (November 2001); and Bennett, “Efficiency of antisense oligonucleotide drug discovery,” Antisense Nucleic Acid Drug Dev 12(3):215-24 (June 2002).
  • The SNPs of the present invention are particularly useful for designing antisense reagents that are specific for particular nucleic acid variants. Based on the SNP information disclosed herein, antisense oligonucleotides can be produced that specifically target mRNA molecules that contain one or more particular SNP nucleotides. In this manner, expression of mRNA molecules that contain one or more undesired polymorphisms (e.g., SNP nucleotides that lead to a defective protein such as an amino acid substitution in a catalytic domain) can be inhibited or completely blocked. Thus, antisense oligonucleotides can be used to specifically bind a particular polymorphic form (e.g., a SNP allele that encodes a defective protein), thereby inhibiting translation of this form, but which do not bind an alternative polymorphic form (e.g., an alternative SNP nucleotide that encodes a protein having normal function).
  • Antisense molecules can be used to inactivate mRNA in order to inhibit gene expression and production of defective proteins. Accordingly, these molecules can be used to treat a disorder, such as CVD, characterized by abnormal or undesired gene expression or expression of certain defective proteins. This technique can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible mRNA regions include, for example, protein-coding regions and particularly protein-coding regions corresponding to catalytic activities, substrate/ligand binding, or other functional activities of a protein.
  • The SNPs of the present invention are also useful for designing RNA interference reagents that specifically target nucleic acid molecules having particular SNP variants. RNA interference (RNAi), also referred to as gene silencing, is based on using double-stranded RNA (dsRNA) molecules to turn genes off. When introduced into a cell, dsRNAs are processed by the cell into short fragments (generally about 21, 22, or 23 nucleotides in length) known as small interfering RNAs (siRNAs) which the cell uses in a sequence-specific manner to recognize and destroy complementary RNAs. Thompson, Drug Discovery Today 7(17): 912-917 (2002). Accordingly, an aspect of the present invention specifically contemplates isolated nucleic acid molecules that are about 18-26 nucleotides in length, preferably 19-25 nucleotides in length, and more preferably 20, 21, 22, or 23 nucleotides in length, and the use of these nucleic acid molecules for RNAi. Because RNAi molecules, including siRNAs, act in a sequence-specific manner, the SNPs of the present invention can be used to design RNAi reagents that recognize and destroy nucleic acid molecules having specific SNP alleles/nucleotides (such as deleterious alleles that lead to the production of defective proteins), while not affecting nucleic acid molecules having alternative SNP alleles (such as alleles that encode proteins having normal function). As with antisense reagents, RNAi reagents may be directly useful as therapeutic agents (e.g., for turning off defective, disease-causing genes), and are also useful for characterizing and validating gene function (e.g., in gene knock-out or knock-down experiments).
  • The following references provide a further review of RNAi: Reynolds et al., “Rational siRNA design for RNA interference,” Nat Biotechnol 22(3):326-30 (March 2004); Epub Feb. 1, 2004; Chi et al., “Genomewide view of gene silencing by small interfering RNAs,” PNAS 100(11):6343-6346 (2003); Vickers et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” J Biol Chem 278:7108-7118 (2003); Agami, “RNAi and related mechanisms and their potential use for therapy,” Curr Opin Chem Biol 6(6):829-34 (December 2002); Lavery et al., “Antisense and RNAi: powerful tools in drug target discovery and validation,” Curr Opin Drug Discov Devel 6(4):561-9 (July 2003); Shi, “Mammalian RNAi for the masses,” Trends Genet 19(1):9-12 (January 2003); Shuey et al., “RNAi: gene-silencing in therapeutic intervention,” Drug Discovery Today 7(20):1040-1046 (October 2002); McManus et al., Nat Rev Genet 3(10):737-47 (October 2002); Xia et al., Nat Biotechnol 20(10):1006-10 (October 2002); Plasterk et al., Curr Opin Genet Dev 10(5):562-7 (October 2000); Bosher et al., Nat Cell Biol 2(2):E31-6 (February 2000); and Hunter, Curr Biol 17; 9(12):R440-2 (June 1999).
  • Other Therapeutic Aspects
  • SNPs have many important uses in drug discovery, screening, and development, and thus the SNPs of the present invention are useful for improving many different aspects of the drug development process.
  • For example, a high probability exists that, for any gene/protein selected as a potential drug target, variants of that gene/protein will exist in a patient population. Thus, determining the impact of gene/protein variants on the selection and delivery of a therapeutic agent should be an integral aspect of the drug discovery and development process. Jazwinska, A Trends Guide to Genetic Variation and Genomic Medicine S30-S36 (March 2002).
  • Knowledge of variants (e.g., SNPs and any corresponding amino acid polymorphisms) of a particular therapeutic target (e.g., a gene, mRNA transcript, or protein) enables parallel screening of the variants in order to identify therapeutic candidates (e.g., small molecule compounds, antibodies, antisense or RNAi nucleic acid compounds, etc.) that demonstrate efficacy across variants. Rothberg, Nat Biotechnol 19(3):209-11 (March 2001). Such therapeutic candidates would be expected to show equal efficacy across a larger segment of the patient population, thereby leading to a larger potential market for the therapeutic candidate.
  • Furthermore, identifying variants of a potential therapeutic target enables the most common form of the target to be used for selection of therapeutic candidates, thereby helping to ensure that the experimental activity that is observed for the selected candidates reflects the real activity expected in the largest proportion of a patient population. Jazwinska, A Trends Guide to Genetic Variation and Genomic Medicine S30-S36 (March 2002).
  • Additionally, screening therapeutic candidates against all known variants of a target can enable the early identification of potential toxicities and adverse reactions relating to particular variants. For example, variability in drug absorption, distribution, metabolism and excretion (ADME) caused by, for example, SNPs in therapeutic targets or drug metabolizing genes, can be identified, and this information can be utilized during the drug development process to minimize variability in drug disposition and develop therapeutic agents that are safer across a wider range of a patient population. The SNPs of the present invention, including the variant proteins and encoding polymorphic nucleic acid molecules provided in Tables 1 and 2, are useful in conjunction with a variety of toxicology methods established in the art, such as those set forth in Current Protocols in Toxicology, John Wiley & Sons, Inc., N.Y.
  • Furthermore, therapeutic agents that target any art-known proteins (or nucleic acid molecules, either RNA or DNA) may cross-react with the variant proteins (or polymorphic nucleic acid molecules) disclosed in Table 1, thereby significantly affecting the pharmacokinetic properties of the drug. Consequently, the protein variants and the SNP-containing nucleic acid molecules disclosed in Tables 1 and 2 are useful in developing, screening, and evaluating therapeutic agents that target corresponding art-known protein forms (or nucleic acid molecules). Additionally, as discussed above, knowledge of all polymorphic forms of a particular drug target enables the design of therapeutic agents that are effective against most or all such polymorphic forms of the drug target.
  • A subject suffering from a pathological condition ascribed to a SNP, such as CVD, may be treated so as to correct the genetic defect. See Kren et al., Proc Natl Acad Sci USA 96:10349-10354 (1999). Such a subject can be identified by any method that can detect the polymorphism in a biological sample drawn from the subject. Such a genetic defect may be permanently corrected by administering to such a subject a nucleic acid fragment incorporating a repair sequence that supplies the normal/wild-type nucleotide at the position of the SNP. This site-specific repair sequence can encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA. The site-specific repair sequence is administered in an appropriate vehicle, such as a complex with polyethylenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus, or other pharmaceutical composition that promotes intracellular uptake of the administered nucleic acid. A genetic defect leading to an inborn pathology may then be overcome, as the chimeric oligonucleotides induce incorporation of the normal sequence into the subject's genome. Upon incorporation, the normal gene product is expressed, and the replacement is propagated, thereby engendering a permanent repair and therapeutic enhancement of the clinical condition of the subject.
  • In cases in which a cSNP results in a variant protein that is ascribed to be the cause of, or a contributing factor to, a pathological condition, a method of treating such a condition can include administering to a subject experiencing the pathology the wild-type/normal cognate of the variant protein. Once administered in an effective dosing regimen, the wild-type cognate provides complementation or remediation of the pathological condition.
  • Variant Proteins, Antibodies, Vectors, Host Cells, & Uses Thereof
  • Variant Proteins Encoded by SNP-Containing Nucleic Acid Molecules
  • The present invention provides SNP-containing nucleic acid molecules, many of which encode proteins having variant amino acid sequences as compared to the art-known (i.e., wild-type) proteins. Amino acid sequences encoded by the polymorphic nucleic acid molecules of the present invention are referred to as SEQ ID NOS:52-102 in Table 1 and provided in the Sequence Listing. These variants will generally be referred to herein as variant proteins/peptides/polypeptides, or polymorphic proteins/peptides/polypeptides of the present invention. The terms “protein,” “peptide,” and “polypeptide” are used herein interchangeably.
  • A variant protein of the present invention may be encoded by, for example, a nonsynonymous nucleotide substitution at any one of the cSNP positions disclosed herein. In addition, variant proteins may also include proteins whose expression, structure, and/or function is altered by a SNP disclosed herein, such as a SNP that creates or destroys a stop codon, a SNP that affects splicing, and a SNP in control/regulatory elements, e.g. promoters, enhancers, or transcription factor binding domains.
  • As used herein, a protein or peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or chemical precursors or other chemicals. The variant proteins of the present invention can be purified to homogeneity or other lower degrees of purity. The level of purification will be based on the intended use. The key feature is that the preparation allows for the desired function of the variant protein, even if in the presence of considerable amounts of other components.
  • As used herein, “substantially free of cellular material” includes preparations of the variant protein having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the variant protein is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.
  • The language “substantially free of chemical precursors or other chemicals” includes preparations of the variant protein in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the variant protein having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.
  • An isolated variant protein may be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant host cells), or synthesized using known protein synthesis methods. For example, a nucleic acid molecule containing SNP(s) encoding the variant protein can be cloned into an expression vector, the expression vector introduced into a host cell, and the variant protein expressed in the host cell. The variant protein can then be isolated from the cells by any appropriate purification scheme using standard protein purification techniques. Examples of these techniques are described in detail below. Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • The present invention provides isolated variant proteins that comprise, consist of or consist essentially of amino acid sequences that contain one or more variant amino acids encoded by one or more codons that contain a SNP of the present invention.
  • Accordingly, the present invention provides variant proteins that consist of amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2. A protein consists of an amino acid sequence when the amino acid sequence is the entire amino acid sequence of the protein.
  • The present invention further provides variant proteins that consist essentially of amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2. A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues in the final protein.
  • The present invention further provides variant proteins that comprise amino acid sequences that contain one or more amino acid polymorphisms (or truncations or extensions due to creation or destruction of a stop codon, respectively) encoded by the SNPs provided in Table 1 and/or Table 2. A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein may contain only the variant amino acid sequence or have additional amino acid residues, such as a contiguous encoded sequence that is naturally associated with it or heterologous amino acid residues. Such a protein can have a few additional amino acid residues or can comprise many more additional amino acids. A brief description of how various types of these proteins can be made and isolated is provided below.
  • The variant proteins of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a variant protein operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the variant protein. “Operatively linked” indicates that the coding sequences for the variant protein and the heterologous protein are ligated in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the variant protein. In another embodiment, the fusion protein is encoded by a fusion polynucleotide that is synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence. See Ausubel et al., Current Protocols in Molecular Biology (1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A variant protein-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the variant protein.
  • In many uses, the fusion protein does not affect the activity of the variant protein. The fusion protein can include, but is not limited to, enzymatic fusion proteins, for example, beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate their purification following recombinant expression. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence. Fusion proteins are further described in, for example, Terpe, “Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems,” Appl Microbiol Biotechnol 60(5):523-33 (January 2003); Epub Nov. 7, 2002; Graddis et al., “Designing proteins that work using recombinant technologies,” Curr Pharm Biotechnol 3(4):285-97 (December 2002); and Nilsson et al., “Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins,” Protein Expr Purif 11(1):1-16 (October 1997).
  • In certain embodiments, novel compositions of the present invention also relate to further obvious variants of the variant polypeptides of the present invention, such as naturally-occurring mature forms (e.g., allelic variants), non-naturally occurring recombinantly-derived variants, and orthologs and paralogs of such proteins that share sequence homology. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry.
  • Further variants of the variant polypeptides disclosed in Table 1 can comprise an amino acid sequence that shares at least 70-80%, 80-85%, 85-90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with an amino acid sequence disclosed in Table 1 (or a fragment thereof) and that includes a novel amino acid residue (allele) disclosed in Table 1 (which is encoded by a novel SNP allele). Thus, an aspect of the present invention that is specifically contemplated are polypeptides that have a certain degree of sequence variation compared with the polypeptide sequences shown in Table 1, but that contain a novel amino acid residue (allele) encoded by a novel SNP allele disclosed herein. In other words, as long as a polypeptide contains a novel amino acid residue disclosed herein, other portions of the polypeptide that flank the novel amino acid residue can vary to some degree from the polypeptide sequences shown in Table 1.
  • Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the amino acid sequences disclosed herein can readily be identified as having complete sequence identity to one of the variant proteins of the present invention as well as being encoded by the same genetic locus as the variant proteins provided herein.
  • Orthologs of a variant peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of a variant peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from non-human mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs can be encoded by a nucleic acid sequence that hybridizes to a variant peptide-encoding nucleic acid molecule under moderate to stringent conditions depending on the degree of relatedness of the two organisms yielding the homologous proteins.
  • Variant proteins include, but are not limited to, proteins containing deletions, additions and substitutions in the amino acid sequence caused by the SNPs of the present invention. One class of substitutions is conserved amino acid substitutions in which a given amino acid in a polypeptide is substituted for another amino acid of like characteristics. Typical conservative substitutions are replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found, for example, in Bowie et al., Science 247:1306-1310 (1990).
  • Variant proteins can be fully functional or can lack function in one or more activities, e.g. ability to bind another molecule, ability to catalyze a substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variations or variations in non-critical residues or in non-critical regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree. Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, truncations or extensions, or a substitution, insertion, inversion, or deletion of a critical residue or in a critical region.
  • Amino acids that are essential for function of a protein can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis, particularly using the amino acid sequence and polymorphism information provided in Table 1. Cunningham et al., Science 244:1081-1085 (1989). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as enzyme activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling. Smith et al., J Mol Biol 224:899-904 (1992); de Vos et al., Science 255:306-312 (1992).
  • Polypeptides can contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Accordingly, the variant proteins of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (e.g., polyethylene glycol), or in which additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence for purification of the mature polypeptide or a pro-protein sequence.
  • Known protein modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
  • Such protein modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Particularly common modifications, for example glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, are described in most basic texts, such as Proteins—Structure and Molecular Properties 2nd Ed., T. E. Creighton, W.H. Freeman and Company, N.Y. (1993); F. Wold, Posttranslational Covalent Modification of Proteins 1-12, B. C. Johnson, ed., Academic Press, N.Y. (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); and Rattan et al., Ann NY Acad Sci 663:48-62 (1992).
  • The present invention further provides fragments of the variant proteins in which the fragments contain one or more amino acid sequence variations (e.g., substitutions, or truncations or extensions due to creation or destruction of a stop codon) encoded by one or more SNPs disclosed herein. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that have been disclosed in the prior art before the present invention.
  • As used herein, a fragment may comprise at least about 4, 8, 10, 12, 14, 16, 18, 20, 25, 30, 50, 100 (or any other number in-between) or more contiguous amino acid residues from a variant protein, wherein at least one amino acid residue is affected by a SNP of the present invention, e.g., a variant amino acid residue encoded by a nonsynonymous nucleotide substitution at a cSNP position provided by the present invention. The variant amino acid encoded by a cSNP may occupy any residue position along the sequence of the fragment. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the variant protein or the ability to perform a function, e.g., act as an immunogen. Particularly important fragments are biologically active fragments. Such fragments will typically comprise a domain or motif of a variant protein of the present invention, e.g., active site, transmembrane domain, or ligand/substrate binding domain. Other fragments include, but are not limited to, domain or motif-containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known to those of skill in the art (e.g., PROSITE analysis). Current Protocols in Protein Science, John Wiley & Sons, N.Y. (2002).
  • Uses of Variant Proteins
  • The variant proteins of the present invention can be used in a variety of ways, including but not limited to, in assays to determine the biological activity of a variant protein, such as in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another type of immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the variant protein (or its binding partner) in biological fluids; as a marker for cells or tissues in which it is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); as a target for screening for a therapeutic agent; and as a direct therapeutic agent to be administered into a human subject. Any of the variant proteins disclosed herein may be developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art. See, e.g., Molecular Cloning: A Laboratory Manual, Sambrook and Russell, Cold Spring Harbor Laboratory Press, N.Y. (2000), and Methods in Enzymology: Guide to Molecular Cloning Techniques, S. L. Berger and A. R. Kimmel, eds., Academic Press (1987).
  • In a specific embodiment of the invention, the methods of the present invention include detection of one or more variant proteins disclosed herein. Variant proteins are disclosed in Table 1 and in the Sequence Listing as SEQ ID NOS:52-102. Detection of such proteins can be accomplished using, for example, antibodies, small molecule compounds, aptamers, ligands/substrates, other proteins or protein fragments, or other protein-binding agents. Preferably, protein detection agents are specific for a variant protein of the present invention and can therefore discriminate between a variant protein of the present invention and the wild-type protein or another variant form. This can generally be accomplished by, for example, selecting or designing detection agents that bind to the region of a protein that differs between the variant and wild-type protein, such as a region of a protein that contains one or more amino acid substitutions that is/are encoded by a non-synonymous cSNP of the present invention, or a region of a protein that follows a nonsense mutation-type SNP that creates a stop codon thereby leading to a shorter polypeptide, or a region of a protein that follows a read-through mutation-type SNP that destroys a stop codon thereby leading to a longer polypeptide in which a portion of the polypeptide is present in one version of the polypeptide but not the other.
  • In another aspect of the invention, variant proteins of the present invention can be used as targets for predicting an individual's response to statin treatment (particularly for reducing the risk of CVD, especially CHD such as MI), for determining predisposition to CVD (particularly CHD, such as MI), for diagnosing CVD, or for treating and/or preventing CVD, etc. Accordingly, the invention provides methods for detecting the presence of, or levels of, one or more variant proteins of the present invention in a cell, tissue, or organism. Such methods typically involve contacting a test sample with an agent (e.g., an antibody, small molecule compound, or peptide) capable of interacting with the variant protein such that specific binding of the agent to the variant protein can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an array, for example, an antibody or aptamer array (arrays for protein detection may also be referred to as “protein chips”). The variant protein of interest can be isolated from a test sample and assayed for the presence of a variant amino acid sequence encoded by one or more SNPs disclosed by the present invention. The SNPs may cause changes to the protein and the corresponding protein function/activity, such as through non-synonymous substitutions in protein coding regions that can lead to amino acid substitutions, deletions, insertions, and/or rearrangements; formation or destruction of stop codons; or alteration of control elements such as promoters. SNPs may also cause inappropriate post-translational modifications.
  • One preferred agent for detecting a variant protein in a sample is an antibody capable of selectively binding to a variant form of the protein (antibodies are described in greater detail in the next section). Such samples include, for example, tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.
  • In vitro methods for detection of the variant proteins associated with statin response that are disclosed herein and fragments thereof include, but are not limited to, enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIA), Western blots, immunoprecipitations, immunofluorescence, and protein arrays/chips (e.g., arrays of antibodies or aptamers). For further information regarding immunoassays and related protein detection methods, see Current Protocols in Immunology, John Wiley & Sons, N. Y., and Hage, “Immunoassays,” Anal Chem 15; 71(12):294R-304R (June 1999).
  • Additional analytic methods of detecting amino acid variants include, but are not limited to, altered electrophoretic mobility, altered tryptic peptide digest, altered protein activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, and direct amino acid sequencing.
  • Alternatively, variant proteins can be detected in vivo in a subject by introducing into the subject a labeled antibody (or other type of detection reagent) specific for a variant protein. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • Other uses of the variant peptides of the present invention are based on the class or action of the protein. For example, proteins isolated from humans and their mammalian orthologs serve as targets for identifying agents (e.g., small molecule drugs or antibodies) for use in therapeutic applications, particularly for modulating a biological or pathological response in a cell or tissue that expresses the protein. Pharmaceutical agents can be developed that modulate protein activity.
  • As an alternative to modulating gene expression, therapeutic compounds can be developed that modulate protein function. For example, many SNPs disclosed herein affect the amino acid sequence of the encoded protein (e.g., non-synonymous cSNPs and nonsense mutation-type SNPs). Such alterations in the encoded amino acid sequence may affect protein function, particularly if such amino acid sequence variations occur in functional protein domains, such as catalytic domains, ATP-binding domains, or ligand/substrate binding domains. It is well established in the art that variant proteins having amino acid sequence variations in functional domains can cause or influence pathological conditions. In such instances, compounds (e.g., small molecule drugs or antibodies) can be developed that target the variant protein and modulate (e.g., up- or down-regulate) protein function/activity.
  • The therapeutic methods of the present invention further include methods that target one or more variant proteins of the present invention. Variant proteins can be targeted using, for example, small molecule compounds, antibodies, aptamers, ligands/substrates, other proteins, or other protein-binding agents. Additionally, the skilled artisan will recognize that the novel protein variants (and polymorphic nucleic acid molecules) disclosed in Table 1 may themselves be directly used as therapeutic agents by acting as competitive inhibitors of corresponding art-known proteins (or nucleic acid molecules such as mRNA molecules).
  • The variant proteins of the present invention are particularly useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can utilize cells that naturally express the protein, a biopsy specimen, or cell cultures. In one embodiment, cell-based assays involve recombinant host cells expressing the variant protein. Cell-free assays can be used to detect the ability of a compound to directly bind to a variant protein or to the corresponding SNP-containing nucleic acid fragment that encodes the variant protein.
  • A variant protein of the present invention, as well as appropriate fragments thereof, can be used in high-throughput screening assays to test candidate compounds for the ability to bind and/or modulate the activity of the variant protein. These candidate compounds can be further screened against a protein having normal function (e.g., a wild-type/non-variant protein) to further determine the effect of the compound on the protein activity. Furthermore, these compounds can be tested in animal or invertebrate systems to determine in vivo activity/effectiveness. Compounds can be identified that activate (agonists) or inactivate (antagonists) the variant protein, and different compounds can be identified that cause various degrees of activation or inactivation of the variant protein.
  • Further, the variant proteins can be used to screen a compound for the ability to stimulate or inhibit interaction between the variant protein and a target molecule that normally interacts with the protein. The target can be a ligand, a substrate or a binding partner that the protein normally interacts with (for example, epinephrine or norepinephrine). Such assays typically include the steps of combining the variant protein with a candidate compound under conditions that allow the variant protein, or fragment thereof, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the variant protein and the target, such as any of the associated effects of signal transduction.
  • Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)2, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).
  • One candidate compound is a soluble fragment of the variant protein that competes for ligand binding. Other candidate compounds include mutant proteins or appropriate fragments containing mutations that affect variant protein function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.
  • The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) variant protein activity. The assays typically involve an assay of events in the signal transduction pathway that indicate protein activity. Thus, the expression of genes that are up or down-regulated in response to the variant protein dependent signal cascade can be assayed. In one embodiment, the regulatory region of such genes can be operably linked to a marker that is easily detectable, such as luciferase. Alternatively, phosphorylation of the variant protein, or a variant protein target, could also be measured. Any of the biological or biochemical functions mediated by the variant protein can be used as an endpoint assay. These include all of the biochemical or biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art.
  • Binding and/or activating compounds can also be screened by using chimeric variant proteins in which an amino terminal extracellular domain or parts thereof, an entire transmembrane domain or subregions, and/or the carboxyl terminal intracellular domain or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is normally recognized by a variant protein. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the variant protein is derived.
  • The variant proteins are also useful in competition binding assays in methods designed to discover compounds that interact with the variant protein. Thus, a compound can be exposed to a variant protein under conditions that allow the compound to bind or to otherwise interact with the variant protein. A binding partner, such as ligand, that normally interacts with the variant protein is also added to the mixture. If the test compound interacts with the variant protein or its binding partner, it decreases the amount of complex formed or activity from the variant protein. This type of assay is particularly useful in screening for compounds that interact with specific regions of the variant protein. Hodgson, Bio/technology, 10(9), 973-80 (September 1992).
  • To perform cell-free drug screening assays, it is sometimes desirable to immobilize either the variant protein or a fragment thereof, or its target molecule, to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Any method for immobilizing proteins on matrices can be used in drug screening assays. In one embodiment, a fusion protein containing an added domain allows the protein to be bound to a matrix. For example, glutathione-S-transferase/125I fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., 35S-labeled) and a candidate compound, such as a drug candidate, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads can be washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of bound material found in the bead fraction quantitated from the gel using standard electrophoretic techniques.
  • Either the variant protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Alternatively, antibodies reactive with the variant protein but which do not interfere with binding of the variant protein to its target molecule can be derivatized to the wells of the plate, and the variant protein trapped in the wells by antibody conjugation. Preparations of the target molecule and a candidate compound are incubated in the variant protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the protein target molecule, or which are reactive with variant protein and compete with the target molecule, and enzyme-linked assays that rely on detecting an enzymatic activity associated with the target molecule.
  • Modulators of variant protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the protein pathway, such as CVD. These methods of treatment typically include the steps of administering the modulators of protein activity in a pharmaceutical composition to a subject in need of such treatment.
  • The variant proteins, or fragments thereof, disclosed herein can themselves be directly used to treat a disorder characterized by an absence of, inappropriate, or unwanted expression or activity of the variant protein. Accordingly, methods for treatment include the use of a variant protein disclosed herein or fragments thereof.
  • In yet another aspect of the invention, variant proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay to identify other proteins that bind to or interact with the variant protein and are involved in variant protein activity. See, e.g., U.S. Pat. No. 5,283,317; Zervos et al., Cell 72:223-232 (1993); Madura et al., J Biol Chem 268:12046-12054 (1993); Bartel et al., Biotechniques 14:920-924 (1993); Iwabuchi et al., Oncogene 8:1693-1696 (1993); and Brent, WO 94/10300. Such variant protein-binding proteins are also likely to be involved in the propagation of signals by the variant proteins or variant protein targets as, for example, elements of a protein-mediated signaling pathway. Alternatively, such variant protein-binding proteins are inhibitors of the variant protein.
  • The two-hybrid system is based on the modular nature of most transcription factors, which typically consist of separable DNA-binding and activation domains. Briefly, the assay typically utilizes two different DNA constructs. In one construct, the gene that codes for a variant protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a variant protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein that interacts with the variant protein.
  • Antibodies Directed to Variant Proteins
  • The present invention also provides antibodies that selectively bind to the variant proteins disclosed herein and fragments thereof. Such antibodies may be used to quantitatively or qualitatively detect the variant proteins of the present invention. As used herein, an antibody selectively binds a target variant protein when it binds the variant protein and does not significantly bind to non-variant proteins, i.e., the antibody does not significantly bind to normal, wild-type, or art-known proteins that do not contain a variant amino acid sequence due to one or more SNPs of the present invention (variant amino acid sequences may be due to, for example, nonsynonymous cSNPs, nonsense SNPs that create a stop codon, thereby causing a truncation of a polypeptide or SNPs that cause read-through mutations resulting in an extension of a polypeptide).
  • As used herein, an antibody is defined in terms consistent with that recognized in the art: they are multi-subunit proteins produced by an organism in response to an antigen challenge. The antibodies of the present invention include both monoclonal antibodies and polyclonal antibodies, as well as antigen-reactive proteolytic fragments of such antibodies, such as Fab, F(ab)′2, and Fv fragments. In addition, an antibody of the present invention further includes any of a variety of engineered antigen-binding molecules such as a chimeric antibody (U.S. Pat. Nos. 4,816,567 and 4,816,397; Morrison et al., Proc Natl Acad Sci USA 81:6851 (1984); Neuberger et al., Nature 312:604 (1984)), a humanized antibody (U.S. Pat. Nos. 5,693,762; 5,585,089 and 5,565,332), a single-chain Fv (U.S. Pat. No. 4,946,778; Ward et al., Nature 334:544 (1989)), a bispecific antibody with two binding specificities (Segal et al., J Immunol Methods 248:1 (2001); Carter, J Immunol Methods 248:7 (2001)), a diabody, a triabody, and a tetrabody (Todorovska et al., J Immunol Methods 248:47 (2001)), as well as a Fab conjugate (dimer or trimer), and a minibody.
  • Many methods are known in the art for generating and/or identifying antibodies to a given target antigen. Harlow, Antibodies, Cold Spring Harbor Press, N.Y. (1989). In general, an isolated peptide (e.g., a variant protein of the present invention) is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit, hamster or mouse. Either a full-length protein, an antigenic peptide fragment (e.g., a peptide fragment containing a region that varies between a variant protein and a corresponding wild-type protein), or a fusion protein can be used. A protein used as an immunogen may be naturally-occurring, synthetic or recombinantly produced, and may be administered in combination with an adjuvant, including but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substance such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like.
  • Monoclonal antibodies can be produced by hybridoma technology, which immortalizes cells secreting a specific monoclonal antibody. Kohler and Milstein, Nature 256:495 (1975). The immortalized cell lines can be created in vitro by fusing two different cell types, typically lymphocytes, and tumor cells. The hybridoma cells may be cultivated in vitro or in vivo. Additionally, fully human antibodies can be generated by transgenic animals. He et al., J Immunol 169:595 (2002). Fd phage and Fd phagemid technologies may be used to generate and select recombinant antibodies in vitro. Hoogenboom and Chames, Immunol Today 21:371 (2000); Liu et al., J Mol Biol 315:1063 (2002). The complementarity-determining regions of an antibody can be identified, and synthetic peptides corresponding to such regions may be used to mediate antigen binding. U.S. Pat. No. 5,637,677.
  • Antibodies are preferably prepared against regions or discrete fragments of a variant protein containing a variant amino acid sequence as compared to the corresponding wild-type protein (e.g., a region of a variant protein that includes an amino acid encoded by a nonsynonymous cSNP, a region affected by truncation caused by a nonsense SNP that creates a stop codon, or a region resulting from the destruction of a stop codon due to read-through mutation caused by a SNP). Furthermore, preferred regions will include those involved in function/activity and/or protein/binding partner interaction. Such fragments can be selected on a physical property, such as fragments corresponding to regions that are located on the surface of the protein, e.g., hydrophilic regions, or can be selected based on sequence uniqueness, or based on the position of the variant amino acid residue(s) encoded by the SNPs provided by the present invention. An antigenic fragment will typically comprise at least about 8-10 contiguous amino acid residues in which at least one of the amino acid residues is an amino acid affected by a SNP disclosed herein. The antigenic peptide can comprise, however, at least 12, 14, 16, 20, 25, 50, 100 (or any other number in-between) or more amino acid residues, provided that at least one amino acid is affected by a SNP disclosed herein.
  • Detection of an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody or an antigen-reactive fragment thereof to a detectable substance. Detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.
  • Antibodies, particularly the use of antibodies as therapeutic agents, are reviewed in: Morgan, “Antibody therapy for Alzheimer's disease,” Expert Rev Vaccines (1):53-9 (February 2003); Ross et al., “Anticancer antibodies,” Am J Clin Pathol 119(4):472-85 (April 2003); Goldenberg, “Advancing role of radiolabeled antibodies in the therapy of cancer,” Cancer Immunol Immunother 52(5):281-96 (May 2003); Epub Mar. 11, 2003; Ross et al., “Antibody-based therapeutics in oncology,” Expert Rev Anticancer Ther 3(1):107-21 (February 2003); Cao et al., “Bispecific antibody conjugates in therapeutics,” Adv Drug Deliv Rev 55(2):171-97 (February 2003); von Mehren et al., “Monoclonal antibody therapy for cancer,” Annu Rev Med 54:343-69 (2003); Epub Dec. 3, 2001; Hudson et al., “Engineered antibodies,” Nat Med 9(1):129-34 (January 2003); Brekke et al., “Therapeutic antibodies for human diseases at the dawn of the twenty-first century,” Nat Rev Drug Discov 2(1):52-62 (January 2003); Erratum in: Nat Rev Drug Discov 2(3):240 (March 2003); Houdebine, “Antibody manufacture in transgenic animals and comparisons with other systems,” Curr Opin Biotechnol 13(6):625-9 (December 2002); Andreakos et al., “Monoclonal antibodies in immune and inflammatory diseases,” Curr Opin Biotechnol 13(6):615-20 (December 2002); Kellermann et al., “Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics,” Curr Opin Biotechnol 13(6):593-7 (December 2002); Pini et al., “Phage display and colony filter screening for high-throughput selection of antibody libraries,” Comb Chem High Throughput Screen 5(7):503-10 (November 2002); Batra et al., “Pharmacokinetics and biodistribution of genetically engineered antibodies,” Curr Opin Biotechnol 13(6):603-8 (December 2002); and Tangri et al., “Rationally engineered proteins or antibodies with absent or reduced immunogenicity,” Curr Med Chem 9(24):2191-9 (December 2002).
  • Uses of Antibodies
  • Antibodies can be used to isolate the variant proteins of the present invention from a natural cell source or from recombinant host cells by standard techniques, such as affinity chromatography or immunoprecipitation. In addition, antibodies are useful for detecting the presence of a variant protein of the present invention in cells or tissues to determine the pattern of expression of the variant protein among various tissues in an organism and over the course of normal development or disease progression. Further, antibodies can be used to detect variant protein in situ, in vitro, in a bodily fluid, or in a cell lysate or supernatant in order to evaluate the amount and pattern of expression. Also, antibodies can be used to assess abnormal tissue distribution, abnormal expression during development, or expression in an abnormal condition, such as in CVD, or during statin treatment. Additionally, antibody detection of circulating fragments of the full-length variant protein can be used to identify turnover.
  • Antibodies to the variant proteins of the present invention are also useful in pharmacogenomic analysis. Thus, antibodies against variant proteins encoded by alternative SNP alleles can be used to identify individuals that require modified treatment modalities.
  • Further, antibodies can be used to assess expression of the variant protein in disease states such as in active stages of the disease or in an individual with a predisposition to a disease related to the protein's function, such as CVD, or during the course of a treatment regime, such as during statin treatment. Antibodies specific for a variant protein encoded by a SNP-containing nucleic acid molecule of the present invention can be used to assay for the presence of the variant protein, such as to determine an individual's response to statin treatment (particularly for reducing their risk for CVD, particularly CHD, such as MI, or stroke) or to diagnose CVD or predisposition/susceptibility to CVD, as indicated by the presence of the variant protein.
  • Antibodies are also useful as diagnostic tools for evaluating the variant proteins in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays well known in the art.
  • Antibodies are also useful for tissue typing. Thus, where a specific variant protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.
  • Antibodies can also be used to assess aberrant subcellular localization of a variant protein in cells in various tissues. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting the expression level or the presence of variant protein or aberrant tissue distribution or developmental expression of a variant protein, antibodies directed against the variant protein or relevant fragments can be used to monitor therapeutic efficacy.
  • The antibodies are also useful for inhibiting variant protein function, for example, by blocking the binding of a variant protein to a binding partner. These uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function. An antibody can be used, for example, to block or competitively inhibit binding, thus modulating (agonizing or antagonizing) the activity of a variant protein. Antibodies can be prepared against specific variant protein fragments containing sites required for function or against an intact variant protein that is associated with a cell or cell membrane. For in vivo administration, an antibody may be linked with an additional therapeutic payload such as a radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent. Suitable cytotoxic agents include, but are not limited to, bacterial toxin such as diphtheria, and plant toxin such as ricin. The in vivo half-life of an antibody or a fragment thereof may be lengthened by pegylation through conjugation to polyethylene glycol. Leong et al., Cytokine 16:106 (2001).
  • The invention also encompasses kits for using antibodies, such as kits for detecting the presence of a variant protein in a test sample. An exemplary kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample; means for determining the amount, or presence/absence of variant protein in the sample; means for comparing the amount of variant protein in the sample with a standard; and instructions for use.
  • Vectors and Host Cells
  • The present invention also provides vectors containing the SNP-containing nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport a SNP-containing nucleic acid molecule. When the vector is a nucleic acid molecule, the SNP-containing nucleic acid molecule can be covalently linked to the vector nucleic acid. Such vectors include, but are not limited to, a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, or MAC.
  • A vector can be maintained in a host cell as an extrachromosomal element where it replicates and produces additional copies of the SNP-containing nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the SNP-containing nucleic acid molecules when the host cell replicates.
  • The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the SNP-containing nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).
  • Expression vectors typically contain cis-acting regulatory regions that are operably linked in the vector to the SNP-containing nucleic acid molecules such that transcription of the SNP-containing nucleic acid molecules is allowed in a host cell. The SNP-containing nucleic acid molecules can also be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the SNP-containing nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.
  • The regulatory sequences to which the SNP-containing nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.
  • In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.
  • In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region, a ribosome-binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. A person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. See, e.g., Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • A variety of expression vectors can be used to express a SNP-containing nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors can also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g., cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • The regulatory sequence in a vector may provide constitutive expression in one or more host cells (e.g., tissue specific expression) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor, e.g., a hormone or other ligand. A variety of vectors that provide constitutive or inducible expression of a nucleic acid sequence in prokaryotic and eukaryotic host cells are well known to those of ordinary skill in the art.
  • A SNP-containing nucleic acid molecule can be inserted into the vector by methodology well-known in the art. Generally, the SNP-containing nucleic acid molecule that will ultimately be expressed is joined to an expression vector by cleaving the SNP-containing nucleic acid molecule and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.
  • The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial host cells include, but are not limited to, Escherichia coli, Streptomyces spp., and Salmonella typhimurium. Eukaryotic host cells include, but are not limited to, yeast, insect cells such as Drosophila spp., animal cells such as COS and CHO cells, and plant cells.
  • As described herein, it may be desirable to express the variant peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the variant peptides. Fusion vectors can, for example, increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting, for example, as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired variant peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes suitable for such use include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).
  • Recombinant protein expression can be maximized in a bacterial host by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein (S. Gottesman, Gene Expression Technology: Methods in Enzymology 185:119-128, Academic Press, Calif. (1990)). Alternatively, the sequence of the SNP-containing nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example, E. coli. Wada et al., Nucleic Acids Res 20:2111-2118 (1992).
  • The SNP-containing nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast (e.g., S. cerevisiae) include pYepSec1 (Baldari et al., EMBO J 6:229-234 (1987)), pMFa (Kurjan et al., Cell 30:933-943 (1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).
  • The SNP-containing nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., Mol Cell Biol 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).
  • In certain embodiments of the invention, the SNP-containing nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (B. Seed, Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J 6:187-195 (1987)).
  • The invention also encompasses vectors in which the SNP-containing nucleic acid molecules described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to the SNP-containing nucleic acid sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).
  • The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include, for example, prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.
  • The recombinant host cells can be prepared by introducing the vector constructs described herein into the cells by techniques readily available to persons of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those described in Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, N.Y. (2000).
  • Host cells can contain more than one vector. Thus, different SNP-containing nucleotide sequences can be introduced in different vectors into the same cell. Similarly, the SNP-containing nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the SNP-containing nucleic acid molecules, such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced, or joined to the nucleic acid molecule vector.
  • In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication can occur in host cells that provide functions that complement the defects.
  • Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be inserted in the same vector that contains the SNP-containing nucleic acid molecules described herein or may be in a separate vector. Markers include, for example, tetracycline or ampicillin-resistance genes for prokaryotic host cells, and dihydrofolate reductase or neomycin resistance genes for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait can be effective.
  • While the mature variant proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these variant proteins using RNA derived from the DNA constructs described herein.
  • Where secretion of the variant protein is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as G-protein-coupled receptors (GPCRs), appropriate secretion signals can be incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.
  • Where the variant protein is not secreted into the medium, the protein can be isolated from the host cell by standard disruption procedures, including freeze/thaw, sonication, mechanical disruption, use of lysing agents, and the like. The variant protein can then be recovered and purified by well-known purification methods including, for example, ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.
  • It is also understood that, depending upon the host cell in which recombinant production of the variant proteins described herein occurs, they can have various glycosylation patterns, or may be non-glycosylated, as when produced in bacteria. In addition, the variant proteins may include an initial modified methionine in some cases as a result of a host-mediated process.
  • For further information regarding vectors and host cells, see Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.
  • Uses of Vectors and Host Cells, and Transgenic Animals
  • Recombinant host cells that express the variant proteins described herein have a variety of uses. For example, the cells are useful for producing a variant protein that can be further purified into a preparation of desired amounts of the variant protein or fragments thereof. Thus, host cells containing expression vectors are useful for variant protein production.
  • Host cells are also useful for conducting cell-based assays involving the variant protein or variant protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a variant protein is useful for assaying compounds that stimulate or inhibit variant protein function. Such an ability of a compound to modulate variant protein function may not be apparent from assays of the compound on the native/wild-type protein, or from cell-free assays of the compound. Recombinant host cells are also useful for assaying functional alterations in the variant proteins as compared with a known function.
  • Genetically-engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a non-human mammal, for example, a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA containing a SNP of the present invention which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more of its cell types or tissues. Such animals are useful for studying the function of a variant protein in vivo, and identifying and evaluating modulators of variant protein activity. Other examples of transgenic animals include, but are not limited to, non-human primates, sheep, dogs, cows, goats, chickens, and amphibians. Transgenic non-human mammals such as cows and goats can be used to produce variant proteins which can be secreted in the animal's milk and then recovered.
  • A transgenic animal can be produced by introducing a SNP-containing nucleic acid molecule into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any nucleic acid molecules that contain one or more SNPs of the present invention can potentially be introduced as a transgene into the genome of a non-human animal.
  • Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the variant protein in particular cells or tissues.
  • Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al.; U.S. Pat. No. 4,873,191 by Wagner et al., and in B. Hogan, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, N.Y. (1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes a non-human animal in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.
  • In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. Lakso et al., PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae. O'Gorman et al., Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are generally needed. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected variant protein and the other containing a transgene encoding a recombinase.
  • Clones of the non-human transgenic animals described herein can also be produced according to the methods described, for example, in I. Wilmut et al., Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell (e.g., a somatic cell) is isolated.
  • Transgenic animals containing recombinant cells that express the variant proteins described herein are useful for conducting the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could influence ligand or substrate binding, variant protein activation, signal transduction, or other processes or interactions, may not be evident from in vitro cell-free or cell-based assays. Thus, non-human transgenic animals of the present invention may be used to assay in vivo variant protein function as well as the activities of a therapeutic agent or compound that modulates variant protein function/activity or expression. Such animals are also suitable for assessing the effects of null mutations (i.e., mutations that substantially or completely eliminate one or more variant protein functions).
  • For further information regarding transgenic animals, see Houdebine, “Antibody manufacture in transgenic animals and comparisons with other systems,” Curr Opin Biotechnol 13(6):625-9 (December 2002); Petters et al., “Transgenic animals as models for human disease,” Transgenic Res 9(4-5):347-51, discussion 345-6 (2000); Wolf et al., “Use of transgenic animals in understanding molecular mechanisms of toxicity,” J Pharm Pharmacol 50(6):567-74 (June 1998); Echelard, “Recombinant protein production in transgenic animals,” Curr Opin Biotechnol 7(5):536-40 (October 1996); Houdebine, “Transgenic animal bioreactors,” Transgenic Res 9(4-5):305-20 (2000); Pirity et al., “Embryonic stem cells, creating transgenic animals,” Methods Cell Biol 57:279-93 (1998); and Robl et al., “Artificial chromosome vectors and expression of complex proteins in transgenic animals,” Theriogenology 59(1):107-13 (January 2003).
  • EXAMPLES
  • The following examples are offered to illustrate, but not limit, the claimed invention.
  • Example 1 SNPs Associated with Statin Response in CARE, WOSCOPS, and PROVE IT-TIMI 22
  • Overview
  • In the study described here in Example 1, cohort and case-only study designs were used to identify SNPs associated with response to statin treatment. The entire cohort (individuals with and without incident CHD or CVD events) or cases only (only individuals with an incident CHD or CVD event) were analyzed in sample sets from the CARE, WOSCOPS, and PROVE IT. Specifically, analyses were carried out using these three sample sets to identify SNPs associated with a reduction in the risk of CHD or CVD (CVD includes CHD and stroke), the results of which are provided in Tables 4-7 and Tables 9-18 (Tables 9-18 provide additional genotyped SNPs as well as imputed SNPs).
  • Tables 4-7 provide results of analyses of statin response for either CHD or CVD reduction, in three genetic models (dominant, recessive, and additive). Tables 4-7 provide SNPs that had a synergy index (odds ratio) with P value lower than 10−4 in a meta-analysis of CARE and WOSCOPS combined (Table 4-5) or in a meta-analysis of CARE, WOSCOPS, and PROVE-IT combined (Table 6-7), in any genetic model in either the CHD or CVD endpoint. Tables 4-5 provide meta-analyses of CARE and WOSCOPS combined, as well as logistic regression analysis of each sample set individually. Tables 6-7 provide meta-analyses of CARE, WOSCOPS, and PROVE-IT combined, as well as logistic regression analysis of each sample set individually.
  • Tables 5 and 7 provide analyses of certain LD SNPs in CARE and WOSCOPS (Table 5) and in CARE, WOSCOPS, and PROVE-IT (Table 7). For some SNPs, case-only data was available for a first SNP while cohort data was available for a SNP in LD with the first SNP (LD SNP), which occurred when a working kPCR assay could not be made for the first SNP. For these SNPs, the data for case-only analysis and the available data for the cohort is reported. The meta-analysis was performed with the cohort data when available. These SNPs are listed in Tables 5 and 7, with the two SNPs in LD listed one below the other, and the degree of LD (r2) between each of these pairs of SNPs is provided in Table 8.
  • CARE, WOSCOPS, and PROVE IT-TIMI 22 Sample Sets
  • The CARE (“Cholesterol and Recurrent Events”) and WOSCOPS (“West of Scotland Coronary Prevention Study”) studies were prospective trials that assessed the effect of pravastatin (40 mg/day) on the prevention of MI and CHD. CARE was a secondary prevention trial and WOSCOPS was a primary prevention trial. The PROVE IT-TIMI 22 (“Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22”; which is interchangeably referred to herein as “PROVE-IT”) trial evaluated the effectiveness of intensive therapy with high-dose atorvastatin (80 mg/day) versus moderate therapy with standard-dose pravastatin (40 mg/day, which was the dose used in the CARE and WOSCOPS trials) in preventing death or cardiovascular events in patients with a recent acute coronary syndrome.
  • These trials and the sample sets from these trials (such as the inclusion criteria for participants) are described in the following references. Those portions of each of the following references that pertain to the CARE, WOSCOPS, and PROVE-IT trials and sample sets are hereby incorporated by reference. CARE is described in Sacks et al., “Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels”, N Engl J Med 1996; 335:1001-9, and WOSCOPS is described in Shepherd et al., “West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia”, N Engl J Med 1995; 333:1301-7. PROVE-IT is described in Iakoubova et al., Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study”, J Am Coll Cardiol. 2008 Jan. 29; 51(4):449-55 and Cannon et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes”, N Engl J Med 2004; 350:1495-504.
  • Endpoints
  • The endpoint definitions used in these analyses of CARE, WOSCOPS, and PROVE-IT (the results of which are provided in Tables 4-7) were as follows. The CHD endpoint was defined in the analyses herein of CARE as a composite endpoint of fatal CHD, definite non-fatal MI, or revascularization, and was defined in the analyses herein of WOSCOPS as a composite endpoint of death from CHD, nonfatal MI, or revascularization. In both the CARE and WOSCOPS analyses herein, the CVD endpoint was defined as a composite endpoint of CHD or stroke. The analyses herein of PROVE-IT analyzed the primary endpoint of PROVE-IT, which was a composite endpoint of revascularization (if performed at least 30 days after randomization), unstable angina requiring hospitalization, MI, all causes of death, or stroke. Thus, there was only one endpoint for PROVE-IT (the composite primary endpoint of the original PROVE-IT study, which includes some stroke cases), and this endpoint was used in the meta-analysis for both CHD and CVD provided in Tables 6-7. With respect to stroke, in the analyses herein of CARE and PROVE-IT, stroke was defined as stroke or transient ischemic attack (TIA), and in the analyses herein of WOSCOPS, stroke was defined as fatal or non-fatal stroke. Revascularization, which can include percutaneous transluminal coronary angioplasty (PTCA), stent placement, and coronary artery bypass graft (CABG), are medical interventions that indicate the presence of CHD.
  • Study Designs
  • Cohort and case-only study designs were used to identify SNPs associated with response to statin treatment. The entire cohort (individuals with and without incident CHD or CVD events; identified as “cohort” in the “Source” column of Tables 4-7) or only individuals with an incident CHD or CVD event (identified as “CaseOnly” in the “Source” column of Tables 4-7) were analyzed in sample sets from the CARE, WOSCOPS, and PROVE-IT trials to test whether the reduction of CHD/CVD events by statin therapy (for CARE and WOSCOPS studies), or by high dose atorvastatin therapy (for the PROVE IT study), differed according to genotype (a treatment by SNP interaction) for each SNP evaluated in the study.
  • For each SNP, a logistic regression model having treatment status as the dependent variable and SNP as the independent predictor variable was performed, with terms for age, sex and race included in the model as covariates. The anti-log of the regression coefficient corresponding to the SNP is an estimate of the synergy index (SI) (Davis et al., “Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses—a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study”, Statistics in Medicine 23: (2004), pages 2413-2427). The SI is a ratio of odds ratios: for example in the CARE and WOSCOPS studies, the SI represents the factor by which the odds-ratio of statin treatment, compared with placebo, among major homozygous individuals is multiplied by in order to obtain the odds-ratio of treatment vs. placebo among heterozygous individuals; and multiplied by a second time to obtain the odds-ratio of treatment vs. placebo in minor homozygous individuals. The case-only study design results in a valid estimate of the SI under the assumption that genotype and treatment are independent in the population. In a randomized clinical trial, genotype and treatment are independent by design. The p-value for the regression coefficient corresponding to the SNP results from a test of the null hypothesis that the regression coefficient is equal to zero (SI is equal to one) and thus small p-values indicate the SI is unlikely equal to one and that the effect of treatment likely differs by genotype.
  • The logistic regression models were performed separately for each of CARE, WOSCOPS, and PROVE-IT in order to obtain study-specific results. A meta-analysis was then used to estimate the combined evidence for interaction when considering either the CARE and WOSCOPS studies (Tables 4-5), or all three studies (CARE, WOSCOPS, and PROVE-IT) (Tables 6-7). The meta-analysis used the inverse variance method (Rothman et al., 1998; Modern Epidemiology, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, Pa., pages 660-661) to calculate the combined SI using a weighted average of the effects of the individual studies with weights equal to the inverse variance from each study.
  • The logistic regression and meta-analyses were performed using PLINK version 1.07 (Purcell et al. (2007), “PLINK: A tool set for whole-genome association and population-based linkage analyses”, Am. J. Hum. Genet. 81, 559-575).
  • Regarding case-only study designs specifically, further information about these study designs is provided in Piegorsch et al., “Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies”, Statistics in Medicine 13 (1994) (pages 153-162); Khoury et al., “Nontraditional Epidemiologic Approaches in the Analysis of Gene-Environment Interaction: Case-Control Studies with No Controls!”, American Journal of Epidemiology 144:3 (1996) (pages 207-213); Pierce et al., “Case-only genome-wide interaction study of disease risk, prognosis and treatment”, Genet Epidemiol. 2010 January; 34(1):7-15; Begg et al., “Statistical analysis of molecular epidemiology studies employing case-series”, Cancer Epidemiology Biomarkers and Prevention 3 (1994) pp 173-175; Yang et al., “Sample Size Requirements in Case-Only Designs to Detect Gene-Environment Interaction”, American Journal of Epidemiology 146:9 (1997) pp 713-720; Albert et al., “Limitations of the Case-only Design for Identifying Gene-Environment Interactions”, American Journal of Epidemiology 154:8 (2001) pp 687-693; and Wang et al., “Population Stratification Bias in the Case-Only Study for Gene-Environment Interactions”, American Journal of Epidemiology 168:2 (2008) pp 197-201, each of which is incorporated herein by reference in its entirety. Further information about genome-wide association studies is provided in Wellcome Trust Case Control Consortium, “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls”, Nature. 2007 Jun. 7; 447(7145):661-78 and Ikram et al., “Genomewide association studies of stroke”, N Engl J Med. 2009 Apr. 23; 360(17):1718-28.
  • Identification of Additional Statin Response-Associated SNPs by Imputation and Genotyping
  • Additional genotyped and imputed SNPs were identified as being associated with statin response in the CARE, WOSCOPS, and PROVE-IT sample sets, and these additional SNPs are provided in Tables 9-18. The association of certain of these SNPs with statin response was identified by genotyping, whereas the association of certain other SNPs with statin response was identified by imputation. Imputation involves imputing the allele/genotype present at a SNP for each individual in the sample set (CARE, WOSCOPS, and PROVE-IT) rather than directly genotyping the SNP in a sample from the individual. Thus, Tables 9-18 include SNPs identified by imputation as well as SNPs identified by genotyping, and the column labeled “Source” in Tables 9-18 indicates whether each SNP was genotyped or imputed (all of the SNPs provided in Tables 4-7 were identified by genotyping).
  • Specifically, Tables 9-18 provide SNPs for which the p-value for a random effect was lower than 10−4 for either the meta-analysis of CARE and WOSCOPS combined or the meta-analysis of CARE, WOSCOPS, and PROVE-IT combined, for either the CHD or CVD endpoint, and for any genetic model (dominant, recessive, additive, or genotypic). Association interaction between statin response and either the CHD or CVD phenotype was performed. SNPs were either imputed or genotyped.
  • Imputation was carried out using the BEAGLE genetic analysis program to analyze genotyping data from the HapMap project (The International HapMap Consortium, NCBI, NLM, NIH). Imputation and the BEAGLE program (including the modeling algorithm that BEAGLE utilizes) are described in the following references: Browning, “Missing data imputation and haplotype phase inference for genome-wide association studies”, Hum Genet (2008) 124:439-450 (which reviews imputation and BEAGLE); B L Browning and S R Browning (2009) “A unified approach to genotype imputation and haplotype phase inference for large data sets of trios and unrelated individuals”. Am J Hum Genet 84:210-223 (which describes BEAGLE's methods for imputing ungenotyped markers and phasing parent-offspring trios); S R Browning and B L Browning (2007) “Rapid and accurate haplotype phasing and missing data inference for whole genome association studies using localized haplotype clustering”. Am J Hum Genet 81:1084-1097 (which describes BEAGLE's methods for inferring haplotype phase or sporadic missing data in unrelated individuals); B L Browning and S R Browning (2007) “Efficient multilocus association mapping for whole genome association studies using localized haplotype clustering”. Genet Epidemiol 31:365-375 (which describes BEAGLE's methods for association testing); S R Browning (2006) “Multilocus association mapping using variable-length Markov chains”. Am J Hum Genet 78:903-13 (which describes BEAGLE's haplotype frequency model); and B L Browning and S R Browning (2008) “Haplotypic analysis of Wellcome Trust Case Control Consortium data”. Human Genetics 123:273-280 (which describes an example in which BEAGLE was used to analyze a large genome-wide association study). Each of these references related to imputation and the BEAGLE program is incorporated herein by reference in its entirety.
  • Example 2 Polymorphism rs11556924 in the ZC3HC1 Gene is Associated with Differential CHD Risk Reduction by Statin Therapy in CARE and WOSCOPS
  • A case-only study design was used to test whether the reduction of CHD events by statin therapy (for CARE and WOSCOPS studies) differed according to genotype (a treatment by SNP interaction) for each SNP evaluated in the study.
  • Herein in Example 2, SNPs previously reported to be associated with coronary artery disease (Schunkert et al., “Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease”, Nat Genet. 2011 Mar. 6; and Peden et al., “A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease”, Nat Genet. 2011 Mar. 6) were analyzed using the same methodology as described above in Example 1 in order to determine whether any of these SNP are associated with differential CHD risk reduction by statin therapy in a genome wide association study conducted among cases of CARE and WOSCOPS.
  • It was determined from this analysis that SNP rs11556924 (hCV31283062) in the ZC3HC1 gene is associated with differential reduction of CHD risk by pravastatin therapy in both CARE and WOSCOPS (see Table 19).
  • Example 3 SNPs Around Chromosomal Locations 9p21 and 12p13 (NINJ2 and B4GALNT3 Gene Region) Associated with Stroke Statin Response and/or Stroke Risk
  • Example 3 relates to genetic polymorphisms that are associated with stroke risk and/or stroke statin response (reduction of stroke risk by statin treatment) (Tables 20-21) and CHD statin response (Table 22).
  • Table 20 provides SNPs associated with stroke risk and/or stroke statin response in the CARE sample set. For example, SNPs rs10757278 and rs1333049 at chromosomal location 9p21 were associated with a reduction of stroke events by statin treatment in CARE, particularly for heterozygotes (see Table 20). Furthermore, SNPs rs12425791 and rs11833579 at chromosomal location 12p13 near the NINJ2 gene were associated with stroke risk in the placebo arm of CARE (see Table 20). SNPs rs12425791 and rs11833579 were also associated with stroke statin response in that the homozygous and heterozygous carriers of either of these SNPs (i.e., carriers of the ‘A’ allele for either rs12425791 or rs11833579) had a greater reduction in stroke events with statin treatment compared with noncarriers (see Table 20). Consistent with the CARE trial, the stroke endpoint in the analysis for which the results are provided in Tables 20-21 included stroke as well as transient ischemic attack (TIA).
  • Fine-mapping at the chromosome 12p13 locus was carried out by selecting 77 tagging SNPs from a 400 kb region of the chromosome 12p13 locus which covered the NINJ2 gene and other genes, genotyping these 77 SNPs, and further imputing the genotypes of approximately 250 additional SNPs in this region, for individuals in the CARE study. Analyzing these fine-mapping SNPs for association with stroke risk in the placebo arm of CARE and for stroke statin response in CARE identified SNP rs873134 in the B4GALNT3 gene in the chromosome 12p13 region near NINJ2 (see Table 21).
  • Table 22 provides results of an analysis of CHD statin response in CARE. Table 22 shows that SNP rs873134 is associated with response to statin treatment for reducing the risk of CHD (as well as for reducing the risk of stroke, as shown in Table 21). Specifically, Table 22 shows that SNP rs873134 is associated with a reduced occurrence of recurrent MI in individuals in the CARE study who were treated with statins. Thus, SNP rs873134 is an example of a SNP that is associated with statin response for reducing risk for both stroke and CHD. In the analysis for which the results are provided in Table 22, the endpoint was recurrent MI, and the analysis was adjusted for age, gender, hypertension, diabetes, base LDL and HDL, and whether an individual was a current smoker.
  • Example 4 LD SNPs Associated with Statin Response and CVD
  • Another investigation was conducted to identify additional SNPs that are in high linkage disequilibrium (LD) with certain “interrogated SNPs” that have been found to be associated with response to statin treatment (particularly for reducing the risk of CVD, especially CHD such as MI). The “interrogated SNPs” were those SNPs provided in Tables 4-22 (the interrogated SNPs are shown in columns 1-2 of Table 3, which indicates the hCV and rs identification numbers of each interrogated SNP), and the LD SNPs which were identified as being in high LD are provided in Table 3 (in the columns labeled “LD SNP”, which indicate the hCV and rs identification numbers of each LD SNP).
  • Specifically, Table 3 provides LD SNPs from the HapMap database (NCBI, NLM, NIH) that have linkage disequilibrium r2 values of at least 0.9 (the threshold r2 value, which may also be designated as rT 2) with an interrogated SNP. Each of these LD SNPs from the HapMap database is within 500 kb of its respective interrogated SNP, and the r2 values are calculated based on genotypes of HapMap Caucasian subjects. If an interrogated SNP is not in the HapMap database, then there will not be any LD SNPs listed in Table 3 for that interrogated SNP.
  • As an example in Table 3, the interrogated SNP rs688358 (hCV1056543) was calculated to be in LD with rs675163 (hCV1056544) at an r2 value of 1 (which is above the threshold r2 value of 0.9), thus establishing the latter SNP as a marker associated with statin response as well.
  • In this example, the threshold r2 value was set at 0.9. However, the threshold r2 value can be set at other values such that one of ordinary skill in the art would consider that any two SNPs having an r2 value greater than or equal to the threshold r2 value would be in sufficient LD with each other such that either SNP is useful for the same utilities, such as determining an individual's response to statin treatment. For example, in various embodiments, the threshold r2 value used to classify SNPs as being in sufficient LD with an interrogated SNP (such that these LD SNPs can be used for the same utilities as the interrogated SNP, for example) can be set at, for example, 0.7, 0.75, 0.8, 0.85, 0.95, 0.96, 0.97, 0.98, 0.99, 1, etc. (or any other threshold r2 value in-between these values). Threshold r2 values may be utilized with or without considering power or other calculations.
  • Sequences, SNP information, and associated gene/transcript/protein information for each of the LD SNPs listed in Table 3 is provided in Tables 1-2. Thus, for any LD SNP listed in Table 3, sequence and allele information (or other information) can be found by searching Tables 1-2 using the hCV or rs identification number of the LD SNP of interest.
  • All publications and patents cited in this specification are herein incorporated by reference in their entirety. Modifications and variations of the described compositions, methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments and certain working examples, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention that are obvious to those skilled in the field of molecular biology, genetics and related fields are intended to be within the scope of the following claims.
  • TABLE 3
    Interrogated SNP Interrogated
    (hCV #) SNP (rs #) LD SNP (hCV #) LD SNP (rs #) Threshold r2 r2
    hCV1056543 rs688358 hCV1056544 rs675163 0.9 1
    hCV1056543 rs688358 hCV32014853 rs11221097 0.9 1
    hCV1056543 rs688358 hCV767324 rs687047 0.9 1
    hCV1056544 rs675163 hCV1056543 rs688358 0.9 1
    hCV1056544 rs675163 hCV32014843 rs11221075 0.9 1
    hCV1056544 rs675163 hCV32014853 rs11221097 0.9 1
    hCV1056544 rs675163 hCV767324 rs687047 0.9 1
    hCV11435810 rs7808536 hCV11435811 rs2057903 0.9 1
    hCV11435810 rs7808536 hCV16010888 rs2402516 0.9 0.9445
    hCV11435810 rs7808536 hCV16151622 rs2896295 0.9 1
    hCV11435810 rs7808536 hCV2580015 rs6973461 0.9 1
    hCV11435810 rs7808536 hCV26499740 rs1344081 0.9 0.9396
    hCV11435810 rs7808536 hCV29630277 rs7799541 0.9 1
    hCV11435810 rs7808536 hCV29720798 rs10228725 0.9 1
    hCV11435810 rs7808536 hCV29738883 rs10237648 0.9 1
    hCV11435810 rs7808536 hCV29865261 rs10226287 0.9 1
    hCV11435810 rs7808536 hCV30243451 rs10270624 0.9 1
    hCV11435810 rs7808536 hCV30441808 rs10487413 0.9 0.9485
    hCV11435810 rs7808536 hCV31281599 rs13438543 0.9 1
    hCV11544885 rs1536506 hCV16243612 rs2478888 0.9 0.963
    hCV11544885 rs1536506 hCV16243614 rs2478885 0.9 0.9587
    hCV11544885 rs1536506 hCV16252195 rs2504709 0.9 1
    hCV11544885 rs1536506 hCV16252196 rs2504710 0.9 1
    hCV11544885 rs1536506 hCV2005097 rs2478886 0.9 0.9622
    hCV11544885 rs1536506 hCV2005121 rs2504708 0.9 1
    hCV11544885 rs1536506 hCV2005126 rs1536507 0.9 1
    hCV11544885 rs1536506 hCV2005128 rs2504705 0.9 1
    hCV11544885 rs1536506 hCV2005129 rs2478872 0.9 1
    hCV11544885 rs1536506 hCV2005135 rs2504702 0.9 0.9615
    hCV11544885 rs1536506 hCV2005136 rs1998950 0.9 0.9273
    hCV11544885 rs1536506 hCV27016744 rs2478874 0.9 0.9625
    hCV11544885 rs1536506 hCV8768604 rs1327283 0.9 0.9447
    hCV11544885 rs1536506 hCV8768614 rs1342619 0.9 0.9637
    hCV11544885 rs1536506 hCV992360 rs748514 0.9 0.9269
    hCV1166098 rs4660234 hCV1166103 rs12407412 0.9 1
    hCV1166098 rs4660234 hCV1166105 rs11576627 0.9 1
    hCV1166098 rs4660234 hCV30202184 rs6685920 0.9 1
    hCV1166103 rs12407412 hCV1166098 rs4660234 0.9 1
    hCV1166103 rs12407412 hCV1166105 rs11576627 0.9 1
    hCV1166103 rs12407412 hCV30202184 rs6685920 0.9 1
    hCV1166105 rs11576627 hCV1166098 rs4660234 0.9 1
    hCV1166105 rs11576627 hCV1166103 rs12407412 0.9 1
    hCV1166105 rs11576627 hCV30202184 rs6685920 0.9 1
    hCV11675665 rs2574 hCV11226242 rs2280210 0.9 1
    hCV11675665 rs2574 hCV11675666 rs2575 0.9 0.9636
    hCV11675665 rs2574 hCV245252 rs9835936 0.9 0.9636
    hCV11675665 rs2574 hCV474806 rs11927308 0.9 1
    hCV11686367 rs7955901 hCV11686374 rs7957932 0.9 0.9161
    hCV11686367 rs7955901 hCV171102 rs7313973 0.9 0.9568
    hCV11686367 rs7955901 hCV240133 rs4760895 0.9 0.9644
    hCV11686367 rs7955901 hCV240134 rs7138300 0.9 0.9432
    hCV11686367 rs7955901 hCV2745807 rs2063591 0.9 0.9303
    hCV11686367 rs7955901 hCV2745815 rs1512991 0.9 1
    hCV11686367 rs7955901 hCV2745822 rs1913201 0.9 0.9432
    hCV11686367 rs7955901 hCV2745828 rs10879240 0.9 0.9274
    hCV11686367 rs7955901 hCV27952502 rs4760894 0.9 0.9644
    hCV11686367 rs7955901 hCV27952503 rs4760785 0.9 0.9644
    hCV11686367 rs7955901 hCV29120310 rs7298255 0.9 0.9442
    hCV11686367 rs7955901 hCV31190748 rs7959965 0.9 0.9442
    hCV11686367 rs7955901 hCV31190777 rs10784891 0.9 1
    hCV11686367 rs7955901 hDV72015086 rs7956274 0.9 1
    hCV11819777 rs13172910 hCV26478734 rs11956952 0.9 1
    hCV11819777 rs13172910 hCV31237558 rs6898857 0.9 1
    hCV11819780 rs12153185 hCV11819782 rs12719415 0.9 1
    hCV11819780 rs12153185 hCV2575318 rs7711358 0.9 0.9232
    hCV11819780 rs12153185 hCV2575336 rs2418541 0.9 0.9232
    hCV11819780 rs12153185 hCV2575340 rs11242020 0.9 0.9232
    hCV11819780 rs12153185 hCV26478744 rs2016194 0.9 1
    hCV11819780 rs12153185 hCV26478745 rs2108426 0.9 1
    hCV11819780 rs12153185 hCV26478747 rs2190598 0.9 1
    hCV11819780 rs12153185 hCV26478763 rs2418542 0.9 0.9232
    hCV11819780 rs12153185 hCV27996154 rs4836502 0.9 1
    hCV11819780 rs12153185 hCV2961244 rs2418548 0.9 1
    hCV11819780 rs12153185 hCV2961250 rs4836507 0.9 1
    hCV11819780 rs12153185 hCV2961252 rs10067895 0.9 1
    hCV11819780 rs12153185 hCV2961253 rs2190600 0.9 1
    hCV11819780 rs12153185 hCV2961259 rs11242023 0.9 0.9571
    hCV11819780 rs12153185 hCV2961260 rs11242022 0.9 0.9785
    hCV11819780 rs12153185 hCV2961261 rs11242021 0.9 1
    hCV11819780 rs12153185 hCV2961267 rs1476714 0.9 1
    hCV11819780 rs12153185 hCV2961268 rs2108425 0.9 1
    hCV11819780 rs12153185 hCV2961269 rs2158958 0.9 1
    hCV11819780 rs12153185 hCV2961270 rs9327555 0.9 1
    hCV11819780 rs12153185 hCV2961278 rs7446891 0.9 1
    hCV11819780 rs12153185 hCV2961280 rs10520072 0.9 1
    hCV11819780 rs12153185 hCV2961282 rs917295 0.9 1
    hCV11819780 rs12153185 hCV2961284 rs10054055 0.9 0.9573
    hCV11819780 rs12153185 hCV2961296 rs10051148 0.9 0.9608
    hCV11819780 rs12153185 hCV2961297 rs2158961 0.9 0.9616
    hCV11819780 rs12153185 hCV2961306 rs264129 0.9 0.9358
    hCV11819780 rs12153185 hCV30621656 rs10478919 0.9 0.9232
    hCV11819780 rs12153185 hCV31237567 rs11749272 0.9 0.9232
    hCV11819780 rs12153185 hCV346713 rs1990023 0.9 0.9358
    hCV11819780 rs12153185 hCV546489 rs264122 0.9 0.9573
    hCV11819780 rs12153185 hCV8932829 rs1116596 0.9 0.9232
    hCV11819782 rs12719415 hCV11819780 rs12153185 0.9 1
    hCV11819782 rs12719415 hCV2575318 rs7711358 0.9 0.927
    hCV11819782 rs12719415 hCV2575336 rs2418541 0.9 0.927
    hCV11819782 rs12719415 hCV2575340 rs11242020 0.9 0.927
    hCV11819782 rs12719415 hCV26478744 rs2016194 0.9 0.9198
    hCV11819782 rs12719415 hCV26478745 rs2108426 0.9 0.9135
    hCV11819782 rs12719415 hCV26478747 rs2190598 0.9 1
    hCV11819782 rs12719415 hCV26478763 rs2418542 0.9 0.927
    hCV11819782 rs12719415 hCV27996154 rs4836502 0.9 1
    hCV11819782 rs12719415 hCV2961244 rs2418548 0.9 1
    hCV11819782 rs12719415 hCV2961250 rs4836507 0.9 1
    hCV11819782 rs12719415 hCV2961252 rs10067895 0.9 1
    hCV11819782 rs12719415 hCV2961253 rs2190600 0.9 1
    hCV11819782 rs12719415 hCV2961259 rs11242023 0.9 0.9621
    hCV11819782 rs12719415 hCV2961260 rs11242022 0.9 1
    hCV11819782 rs12719415 hCV2961261 rs11242021 0.9 1
    hCV11819782 rs12719415 hCV2961267 rs1476714 0.9 1
    hCV11819782 rs12719415 hCV2961268 rs2108425 0.9 1
    hCV11819782 rs12719415 hCV2961269 rs2158958 0.9 1
    hCV11819782 rs12719415 hCV2961270 rs9327555 0.9 1
    hCV11819782 rs12719415 hCV2961278 rs7446891 0.9 1
    hCV11819782 rs12719415 hCV2961280 rs10520072 0.9 1
    hCV11819782 rs12719415 hCV2961282 rs917295 0.9 1
    hCV11819782 rs12719415 hCV2961284 rs10054055 0.9 0.9616
    hCV11819782 rs12719415 hCV2961296 rs10051148 0.9 0.9623
    hCV11819782 rs12719415 hCV2961297 rs2158961 0.9 0.9634
    hCV11819782 rs12719415 hCV2961306 rs264129 0.9 0.9232
    hCV11819782 rs12719415 hCV30621656 rs10478919 0.9 0.927
    hCV11819782 rs12719415 hCV31237567 rs11749272 0.9 0.927
    hCV11819782 rs12719415 hCV346713 rs1990023 0.9 0.9232
    hCV11819782 rs12719415 hCV546489 rs264122 0.9 0.9616
    hCV11819782 rs12719415 hCV8932829 rs1116596 0.9 0.927
    hCV1311177 rs1868616 hCV26853900 rs17718789 0.9 0.9408
    hCV1319507 rs16938626 hCV1319514 rs2383903 0.9 1
    hCV1319507 rs16938626 hCV1319518 rs13265054 0.9 0.9055
    hCV1319514 rs2383903 hCV1319507 rs16938626 0.9 1
    hCV1319516 rs12678600 hCV1319518 rs13265054 0.9 1
    hCV1319516 rs12678600 hCV31080080 rs12679254 0.9 1
    hCV1319518 rs13265054 hCV1319507 rs16938626 0.9 0.9055
    hCV1319518 rs13265054 hCV1319516 rs12678600 0.9 1
    hCV1319518 rs13265054 hCV31080080 rs12679254 0.9 1
    hCV1329037 rs9295154 hCV29673016 rs9458285 0.9 1
    hCV1329037 rs9295154 hCV30231903 rs9458302 0.9 1
    hCV1329037 rs9295154 hCV31883369 rs9458310 0.9 0.9236
    hCV1558085 rs11656608 hCV11625525 rs7222186 0.9 1
    hCV1558085 rs11656608 hCV11625528 rs9911847 0.9 0.9144
    hCV1558085 rs11656608 hCV11625529 rs9911867 0.9 0.9079
    hCV1558085 rs11656608 hCV1558080 rs9914580 0.9 1
    hCV1558085 rs11656608 hCV1558083 rs9916432 0.9 0.9144
    hCV1558085 rs11656608 hCV1558084 rs880718 0.9 0.9137
    hCV1558085 rs11656608 hCV29293441 rs8066502 0.9 1
    hCV1558085 rs11656608 hCV29979212 rs8068714 0.9 1
    hCV1558085 rs11656608 hCV29997278 rs9906737 0.9 1
    hCV1558085 rs11656608 hCV7459667 rs937890 0.9 0.9144
    hCV16126066 rs2110564 hCV2676440 rs6722640 0.9 1
    hCV16126066 rs2110564 hCV27872026 rs4851531 0.9 0.9638
    hCV16126066 rs2110564 hCV349805 rs4851529 0.9 0.9329
    hCV16126066 rs2110564 hCV8905894 rs974950 0.9 1
    hCV1631038 rs9487284 hCV11632712 rs9481031 0.9 0.9098
    hCV1631038 rs9487284 hCV11638660 rs6917496 0.9 0.9098
    hCV1631038 rs9487284 hCV11638661 rs6937788 0.9 0.9098
    hCV1631038 rs9487284 hCV1631013 rs17614034 0.9 0.9098
    hCV1631038 rs9487284 hCV1631015 rs9481026 0.9 0.9098
    hCV1631038 rs9487284 hCV1631022 rs9481029 0.9 0.9098
    hCV1631038 rs9487284 hCV1631034 rs7776217 0.9 0.9098
    hCV1631038 rs9487284 hCV1631035 rs7758270 0.9 0.9098
    hCV1631038 rs9487284 hCV1631067 rs9481038 0.9 0.9098
    hCV1631038 rs9487284 hCV8703496 rs1564077 0.9 0.9098
    hCV1787026 rs475420 hCV1787039 rs538521 0.9 1
    hCV1787026 rs475420 hCV1787042 rs657929 0.9 0.9081
    hCV1973764 rs1866386 hCV1973774 rs1483301 0.9 0.9505
    hCV1973764 rs1866386 hCV1973785 rs2930049 0.9 0.9732
    hCV2053088 rs1155875 hCV2053097 rs4259369 0.9 0.961
    hCV2053088 rs1155875 hCV2053101 rs7795792 0.9 0.9608
    hCV2053088 rs1155875 hCV2053104 rs2163339 0.9 0.961
    hCV2053088 rs1155875 hCV2053105 rs2195672 0.9 0.9604
    hCV2053088 rs1155875 hCV30565702 rs10237019 0.9 0.963
    hCV2053097 rs4259369 hCV2053088 rs1155875 0.9 0.961
    hCV2053097 rs4259369 hCV2053101 rs7795792 0.9 1
    hCV2053097 rs4259369 hCV2053104 rs2163339 0.9 1
    hCV2053097 rs4259369 hCV2053105 rs2195672 0.9 1
    hCV2053097 rs4259369 hCV30565702 rs10237019 0.9 1
    hCV2053101 rs7795792 hCV2053088 rs1155875 0.9 0.9608
    hCV2053101 rs7795792 hCV2053097 rs4259369 0.9 1
    hCV2053101 rs7795792 hCV2053104 rs2163339 0.9 1
    hCV2053101 rs7795792 hCV2053105 rs2195672 0.9 1
    hCV2053101 rs7795792 hCV30565702 rs10237019 0.9 1
    hCV2209126 rs208026 hCV11706604 rs208035 0.9 0.9176
    hCV2209126 rs208026 hCV11706608 rs373886 0.9 0.9466
    hCV2209126 rs208026 hCV16233239 rs2237852 0.9 0.9176
    hCV2209126 rs208026 hCV16233240 rs2237853 0.9 0.9176
    hCV2209126 rs208026 hCV2442004 rs208030 0.9 0.9176
    hCV2209194 rs399485 hCV2209191 rs447024 0.9 0.9164
    hCV2209194 rs399485 hCV2209197 rs7508 0.9 0.9573
    hCV2209197 rs7508 hCV2209194 rs399485 0.9 0.9573
    hCV240133 rs4760895 hCV11686367 rs7955901 0.9 0.9644
    hCV240133 rs4760895 hCV171102 rs7313973 0.9 0.9603
    hCV240133 rs4760895 hCV240134 rs7138300 0.9 1
    hCV240133 rs4760895 hCV2745815 rs1512991 0.9 0.9668
    hCV240133 rs4760895 hCV2745822 rs1913201 0.9 1
    hCV240133 rs4760895 hCV2745828 rs10879240 0.9 0.9664
    hCV240133 rs4760895 hCV27952502 rs4760894 0.9 1
    hCV240133 rs4760895 hCV27952503 rs4760785 0.9 1
    hCV240133 rs4760895 hCV29120310 rs7298255 0.9 0.9644
    hCV240133 rs4760895 hCV31190748 rs7959965 0.9 0.9644
    hCV240133 rs4760895 hCV31190777 rs10784891 0.9 0.962
    hCV240133 rs4760895 hDV72015086 rs7956274 0.9 0.9649
    hCV240134 rs7138300 hCV11686367 rs7955901 0.9 0.9432
    hCV240134 rs7138300 hCV171102 rs7313973 0.9 0.9568
    hCV240134 rs7138300 hCV240133 rs4760895 0.9 1
    hCV240134 rs7138300 hCV2745815 rs1512991 0.9 0.9644
    hCV240134 rs7138300 hCV2745822 rs1913201 0.9 1
    hCV240134 rs7138300 hCV2745828 rs10879240 0.9 0.9639
    hCV240134 rs7138300 hCV27952502 rs4760894 0.9 1
    hCV240134 rs7138300 hCV27952503 rs4760785 0.9 1
    hCV240134 rs7138300 hCV31190777 rs10784891 0.9 0.9588
    hCV240134 rs7138300 hDV72015086 rs7956274 0.9 0.9622
    hCV2442103 rs373983 hCV2209192 rs383499 0.9 0.9297
    hCV2529198 rs742827 hCV2529202 rs6040667 0.9 0.9624
    hCV2529198 rs742827 hCV2529211 rs17189710 0.9 0.9596
    hCV2529198 rs742827 hCV2529224 rs2327412 0.9 0.9596
    hCV2529198 rs742827 hCV2529230 rs4444612 0.9 0.9596
    hCV2529198 rs742827 hCV2529231 rs4315598 0.9 0.9596
    hCV2529198 rs742827 hCV2529239 rs6040638 0.9 0.9596
    hCV2529198 rs742827 hCV2529241 rs6134243 0.9 0.9624
    hCV2529198 rs742827 hCV2529246 rs6040619 0.9 0.9596
    hCV2529198 rs742827 hCV27367681 rs2876227 0.9 1
    hCV2529198 rs742827 hCV27367708 rs1009748 0.9 0.9596
    hCV2529198 rs742827 hCV29840965 rs6040644 0.9 0.9596
    hCV2529198 rs742827 hCV30057061 rs6033138 0.9 0.9624
    hCV2529198 rs742827 hCV30093270 rs6040625 0.9 0.9624
    hCV2529198 rs742827 hCV30129243 rs6040636 0.9 0.9624
    hCV2529198 rs742827 hCV30218977 rs6040633 0.9 0.9624
    hCV2529198 rs742827 hCV30417550 rs6040634 0.9 0.9624
    hCV2529198 rs742827 hCV30453433 rs6131208 0.9 0.9167
    hCV2529198 rs742827 hCV32274419 rs13038146 0.9 0.9624
    hCV2529198 rs742827 hCV330228 rs6040668 0.9 0.9624
    hCV2529202 rs6040667 hCV2529198 rs742827 0.9 0.9624
    hCV2529202 rs6040667 hCV2529211 rs17189710 0.9 1
    hCV2529202 rs6040667 hCV2529224 rs2327412 0.9 1
    hCV2529202 rs6040667 hCV2529230 rs4444612 0.9 1
    hCV2529202 rs6040667 hCV2529231 rs4315598 0.9 1
    hCV2529202 rs6040667 hCV2529239 rs6040638 0.9 1
    hCV2529202 rs6040667 hCV2529241 rs6134243 0.9 1
    hCV2529202 rs6040667 hCV2529246 rs6040619 0.9 1
    hCV2529202 rs6040667 hCV27367681 rs2876227 0.9 0.9649
    hCV2529202 rs6040667 hCV27367708 rs1009748 0.9 1
    hCV2529202 rs6040667 hCV29840965 rs6040644 0.9 1
    hCV2529202 rs6040667 hCV30057061 rs6033138 0.9 1
    hCV2529202 rs6040667 hCV30093270 rs6040625 0.9 1
    hCV2529202 rs6040667 hCV30129243 rs6040636 0.9 1
    hCV2529202 rs6040667 hCV30218977 rs6040633 0.9 1
    hCV2529202 rs6040667 hCV30417550 rs6040634 0.9 1
    hCV2529202 rs6040667 hCV30453433 rs6131208 0.9 0.9585
    hCV2529202 rs6040667 hCV30615489 rs6040630 0.9 0.9294
    hCV2529202 rs6040667 hCV32274419 rs13038146 0.9 1
    hCV2529202 rs6040667 hCV330228 rs6040668 0.9 1
    hCV2529211 rs17189710 hCV2529198 rs742827 0.9 0.9596
    hCV2529211 rs17189710 hCV2529202 rs6040667 0.9 1
    hCV2529211 rs17189710 hCV2529224 rs2327412 0.9 1
    hCV2529211 rs17189710 hCV2529230 rs4444612 0.9 1
    hCV2529211 rs17189710 hCV2529231 rs4315598 0.9 1
    hCV2529211 rs17189710 hCV2529239 rs6040638 0.9 1
    hCV2529211 rs17189710 hCV2529241 rs6134243 0.9 1
    hCV2529211 rs17189710 hCV2529246 rs6040619 0.9 1
    hCV2529211 rs17189710 hCV27367681 rs2876227 0.9 0.9616
    hCV2529211 rs17189710 hCV27367708 rs1009748 0.9 1
    hCV2529211 rs17189710 hCV29840965 rs6040644 0.9 1
    hCV2529211 rs17189710 hCV30057061 rs6033138 0.9 1
    hCV2529211 rs17189710 hCV30093270 rs6040625 0.9 1
    hCV2529211 rs17189710 hCV30129243 rs6040636 0.9 1
    hCV2529211 rs17189710 hCV30218977 rs6040633 0.9 1
    hCV2529211 rs17189710 hCV30417550 rs6040634 0.9 1
    hCV2529211 rs17189710 hCV30453433 rs6131208 0.9 0.9565
    hCV2529211 rs17189710 hCV30615489 rs6040630 0.9 0.9225
    hCV2529211 rs17189710 hCV32274419 rs13038146 0.9 1
    hCV2529211 rs17189710 hCV330228 rs6040668 0.9 1
    hCV2529224 rs2327412 hCV2529198 rs742827 0.9 0.9596
    hCV2529224 rs2327412 hCV2529202 rs6040667 0.9 1
    hCV2529224 rs2327412 hCV2529211 rs17189710 0.9 1
    hCV2529224 rs2327412 hCV2529230 rs4444612 0.9 1
    hCV2529224 rs2327412 hCV2529231 rs4315598 0.9 1
    hCV2529224 rs2327412 hCV2529239 rs6040638 0.9 1
    hCV2529224 rs2327412 hCV2529241 rs6134243 0.9 1
    hCV2529224 rs2327412 hCV2529246 rs6040619 0.9 1
    hCV2529224 rs2327412 hCV27367681 rs2876227 0.9 0.9616
    hCV2529224 rs2327412 hCV27367708 rs1009748 0.9 1
    hCV2529224 rs2327412 hCV29840965 rs6040644 0.9 1
    hCV2529224 rs2327412 hCV30057061 rs6033138 0.9 1
    hCV2529224 rs2327412 hCV30093270 rs6040625 0.9 1
    hCV2529224 rs2327412 hCV30129243 rs6040636 0.9 1
    hCV2529224 rs2327412 hCV30218977 rs6040633 0.9 1
    hCV2529224 rs2327412 hCV30417550 rs6040634 0.9 1
    hCV2529224 rs2327412 hCV30453433 rs6131208 0.9 0.9565
    hCV2529224 rs2327412 hCV30615489 rs6040630 0.9 0.9225
    hCV2529224 rs2327412 hCV32274419 rs13038146 0.9 1
    hCV2529224 rs2327412 hCV330228 rs6040668 0.9 1
    hCV2529230 rs4444612 hCV2529198 rs742827 0.9 0.9596
    hCV2529230 rs4444612 hCV2529202 rs6040667 0.9 1
    hCV2529230 rs4444612 hCV2529211 rs17189710 0.9 1
    hCV2529230 rs4444612 hCV2529224 rs2327412 0.9 1
    hCV2529230 rs4444612 hCV2529231 rs4315598 0.9 1
    hCV2529230 rs4444612 hCV2529239 rs6040638 0.9 1
    hCV2529230 rs4444612 hCV2529241 rs6134243 0.9 1
    hCV2529230 rs4444612 hCV2529246 rs6040619 0.9 1
    hCV2529230 rs4444612 hCV27367681 rs2876227 0.9 0.9616
    hCV2529230 rs4444612 hCV27367708 rs1009748 0.9 1
    hCV2529230 rs4444612 hCV29840965 rs6040644 0.9 1
    hCV2529230 rs4444612 hCV30057061 rs6033138 0.9 1
    hCV2529230 rs4444612 hCV30093270 rs6040625 0.9 1
    hCV2529230 rs4444612 hCV30129243 rs6040636 0.9 1
    hCV2529230 rs4444612 hCV30218977 rs6040633 0.9 1
    hCV2529230 rs4444612 hCV30417550 rs6040634 0.9 1
    hCV2529230 rs4444612 hCV30453433 rs6131208 0.9 0.9565
    hCV2529230 rs4444612 hCV30615489 rs6040630 0.9 0.9225
    hCV2529230 rs4444612 hCV32274419 rs13038146 0.9 1
    hCV2529230 rs4444612 hCV330228 rs6040668 0.9 1
    hCV2529231 rs4315598 hCV2529198 rs742827 0.9 0.9596
    hCV2529231 rs4315598 hCV2529202 rs6040667 0.9 1
    hCV2529231 rs4315598 hCV2529211 rs17189710 0.9 1
    hCV2529231 rs4315598 hCV2529224 rs2327412 0.9 1
    hCV2529231 rs4315598 hCV2529230 rs4444612 0.9 1
    hCV2529231 rs4315598 hCV2529239 rs6040638 0.9 1
    hCV2529231 rs4315598 hCV2529241 rs6134243 0.9 1
    hCV2529231 rs4315598 hCV2529246 rs6040619 0.9 1
    hCV2529231 rs4315598 hCV27367681 rs2876227 0.9 0.9616
    hCV2529231 rs4315598 hCV27367708 rs1009748 0.9 1
    hCV2529231 rs4315598 hCV29840965 rs6040644 0.9 1
    hCV2529231 rs4315598 hCV30057061 rs6033138 0.9 1
    hCV2529231 rs4315598 hCV30093270 rs6040625 0.9 1
    hCV2529231 rs4315598 hCV30129243 rs6040636 0.9 1
    hCV2529231 rs4315598 hCV30218977 rs6040633 0.9 1
    hCV2529231 rs4315598 hCV30417550 rs6040634 0.9 1
    hCV2529231 rs4315598 hCV30453433 rs6131208 0.9 0.9565
    hCV2529231 rs4315598 hCV30615489 rs6040630 0.9 0.9225
    hCV2529231 rs4315598 hCV32274419 rs13038146 0.9 1
    hCV2529231 rs4315598 hCV330228 rs6040668 0.9 1
    hCV2529239 rs6040638 hCV2529198 rs742827 0.9 0.9596
    hCV2529239 rs6040638 hCV2529202 rs6040667 0.9 1
    hCV2529239 rs6040638 hCV2529211 rs17189710 0.9 1
    hCV2529239 rs6040638 hCV2529224 rs2327412 0.9 1
    hCV2529239 rs6040638 hCV2529230 rs4444612 0.9 1
    hCV2529239 rs6040638 hCV2529231 rs4315598 0.9 1
    hCV2529239 rs6040638 hCV2529241 rs6134243 0.9 1
    hCV2529239 rs6040638 hCV2529246 rs6040619 0.9 1
    hCV2529239 rs6040638 hCV27367681 rs2876227 0.9 0.9616
    hCV2529239 rs6040638 hCV27367708 rs1009748 0.9 1
    hCV2529239 rs6040638 hCV29840965 rs6040644 0.9 1
    hCV2529239 rs6040638 hCV30057061 rs6033138 0.9 1
    hCV2529239 rs6040638 hCV30093270 rs6040625 0.9 1
    hCV2529239 rs6040638 hCV30129243 rs6040636 0.9 1
    hCV2529239 rs6040638 hCV30218977 rs6040633 0.9 1
    hCV2529239 rs6040638 hCV30417550 rs6040634 0.9 1
    hCV2529239 rs6040638 hCV30453433 rs6131208 0.9 0.9565
    hCV2529239 rs6040638 hCV30615489 rs6040630 0.9 0.9225
    hCV2529239 rs6040638 hCV32274419 rs13038146 0.9 1
    hCV2529239 rs6040638 hCV330228 rs6040668 0.9 1
    hCV2529241 rs6134243 hCV2529198 rs742827 0.9 0.9624
    hCV2529241 rs6134243 hCV2529202 rs6040667 0.9 1
    hCV2529241 rs6134243 hCV2529211 rs17189710 0.9 1
    hCV2529241 rs6134243 hCV2529224 rs2327412 0.9 1
    hCV2529241 rs6134243 hCV2529230 rs4444612 0.9 1
    hCV2529241 rs6134243 hCV2529231 rs4315598 0.9 1
    hCV2529241 rs6134243 hCV2529239 rs6040638 0.9 1
    hCV2529241 rs6134243 hCV2529246 rs6040619 0.9 1
    hCV2529241 rs6134243 hCV27367681 rs2876227 0.9 0.9649
    hCV2529241 rs6134243 hCV27367708 rs1009748 0.9 1
    hCV2529241 rs6134243 hCV29840965 rs6040644 0.9 1
    hCV2529241 rs6134243 hCV30057061 rs6033138 0.9 1
    hCV2529241 rs6134243 hCV30093270 rs6040625 0.9 1
    hCV2529241 rs6134243 hCV30129243 rs6040636 0.9 1
    hCV2529241 rs6134243 hCV30218977 rs6040633 0.9 1
    hCV2529241 rs6134243 hCV30417550 rs6040634 0.9 1
    hCV2529241 rs6134243 hCV30453433 rs6131208 0.9 0.9585
    hCV2529241 rs6134243 hCV30615489 rs6040630 0.9 0.9294
    hCV2529241 rs6134243 hCV32274419 rs13038146 0.9 1
    hCV2529241 rs6134243 hCV330228 rs6040668 0.9 1
    hCV2529246 rs6040619 hCV2529198 rs742827 0.9 0.9596
    hCV2529246 rs6040619 hCV2529202 rs6040667 0.9 1
    hCV2529246 rs6040619 hCV2529211 rs17189710 0.9 1
    hCV2529246 rs6040619 hCV2529224 rs2327412 0.9 1
    hCV2529246 rs6040619 hCV2529230 rs4444612 0.9 1
    hCV2529246 rs6040619 hCV2529231 rs4315598 0.9 1
    hCV2529246 rs6040619 hCV2529239 rs6040638 0.9 1
    hCV2529246 rs6040619 hCV2529241 rs6134243 0.9 1
    hCV2529246 rs6040619 hCV27367681 rs2876227 0.9 0.9616
    hCV2529246 rs6040619 hCV27367708 rs1009748 0.9 1
    hCV2529246 rs6040619 hCV29840965 rs6040644 0.9 1
    hCV2529246 rs6040619 hCV30057061 rs6033138 0.9 1
    hCV2529246 rs6040619 hCV30093270 rs6040625 0.9 1
    hCV2529246 rs6040619 hCV30129243 rs6040636 0.9 1
    hCV2529246 rs6040619 hCV30218977 rs6040633 0.9 1
    hCV2529246 rs6040619 hCV30417550 rs6040634 0.9 1
    hCV2529246 rs6040619 hCV30453433 rs6131208 0.9 0.9565
    hCV2529246 rs6040619 hCV30615489 rs6040630 0.9 0.9225
    hCV2529246 rs6040619 hCV32274419 rs13038146 0.9 1
    hCV2529246 rs6040619 hCV330228 rs6040668 0.9 1
    hCV25609987 rs10817479 hCV32121729 rs12235345 0.9 1
    hCV2575318 rs7711358 hCV11819780 rs12153185 0.9 0.9232
    hCV2575318 rs7711358 hCV11819782 rs12719415 0.9 0.927
    hCV2575318 rs7711358 hCV2575336 rs2418541 0.9 1
    hCV2575318 rs7711358 hCV2575340 rs11242020 0.9 1
    hCV2575318 rs7711358 hCV26478747 rs2190598 0.9 0.9239
    hCV2575318 rs7711358 hCV26478763 rs2418542 0.9 1
    hCV2575318 rs7711358 hCV27996154 rs4836502 0.9 0.927
    hCV2575318 rs7711358 hCV2961244 rs2418548 0.9 0.9232
    hCV2575318 rs7711358 hCV2961250 rs4836507 0.9 0.927
    hCV2575318 rs7711358 hCV2961252 rs10067895 0.9 0.927
    hCV2575318 rs7711358 hCV2961253 rs2190600 0.9 0.927
    hCV2575318 rs7711358 hCV2961260 rs11242022 0.9 0.9232
    hCV2575318 rs7711358 hCV2961261 rs11242021 0.9 0.9255
    hCV2575318 rs7711358 hCV2961267 rs1476714 0.9 0.9607
    hCV2575318 rs7711358 hCV2961268 rs2108425 0.9 0.927
    hCV2575318 rs7711358 hCV2961269 rs2158958 0.9 0.927
    hCV2575318 rs7711358 hCV2961270 rs9327555 0.9 0.927
    hCV2575318 rs7711358 hCV2961278 rs7446891 0.9 0.927
    hCV2575318 rs7711358 hCV2961280 rs10520072 0.9 0.927
    hCV2575318 rs7711358 hCV2961282 rs917295 0.9 0.927
    hCV2575318 rs7711358 hCV2961284 rs10054055 0.9 0.9616
    hCV2575318 rs7711358 hCV2961296 rs10051148 0.9 0.9623
    hCV2575318 rs7711358 hCV2961297 rs2158961 0.9 0.9634
    hCV2575318 rs7711358 hCV2961306 rs264129 0.9 0.9232
    hCV2575318 rs7711358 hCV30621656 rs10478919 0.9 1
    hCV2575318 rs7711358 hCV31237567 rs11749272 0.9 1
    hCV2575318 rs7711358 hCV346713 rs1990023 0.9 1
    hCV2575318 rs7711358 hCV546489 rs264122 0.9 0.9616
    hCV2575318 rs7711358 hCV8932829 rs1116596 0.9 1
    hCV2575336 rs2418541 hCV11819780 rs12153185 0.9 0.9232
    hCV2575336 rs2418541 hCV11819782 rs12719415 0.9 0.927
    hCV2575336 rs2418541 hCV2575318 rs7711358 0.9 1
    hCV2575336 rs2418541 hCV2575340 rs11242020 0.9 1
    hCV2575336 rs2418541 hCV26478747 rs2190598 0.9 0.9239
    hCV2575336 rs2418541 hCV26478763 rs2418542 0.9 1
    hCV2575336 rs2418541 hCV27996154 rs4836502 0.9 0.927
    hCV2575336 rs2418541 hCV2961244 rs2418548 0.9 0.9232
    hCV2575336 rs2418541 hCV2961250 rs4836507 0.9 0.927
    hCV2575336 rs2418541 hCV2961252 rs10067895 0.9 0.927
    hCV2575336 rs2418541 hCV2961253 rs2190600 0.9 0.927
    hCV2575336 rs2418541 hCV2961260 rs11242022 0.9 0.9232
    hCV2575336 rs2418541 hCV2961261 rs11242021 0.9 0.9255
    hCV2575336 rs2418541 hCV2961267 rs1476714 0.9 0.9607
    hCV2575336 rs2418541 hCV2961268 rs2108425 0.9 0.927
    hCV2575336 rs2418541 hCV2961269 rs2158958 0.9 0.927
    hCV2575336 rs2418541 hCV2961270 rs9327555 0.9 0.927
    hCV2575336 rs2418541 hCV2961278 rs7446891 0.9 0.927
    hCV2575336 rs2418541 hCV2961280 rs10520072 0.9 0.927
    hCV2575336 rs2418541 hCV2961282 rs917295 0.9 0.927
    hCV2575336 rs2418541 hCV2961284 rs10054055 0.9 0.9616
    hCV2575336 rs2418541 hCV2961296 rs10051148 0.9 0.9623
    hCV2575336 rs2418541 hCV2961297 rs2158961 0.9 0.9634
    hCV2575336 rs2418541 hCV2961306 rs264129 0.9 0.9232
    hCV2575336 rs2418541 hCV30621656 rs10478919 0.9 1
    hCV2575336 rs2418541 hCV31237567 rs11749272 0.9 1
    hCV2575336 rs2418541 hCV346713 rs1990023 0.9 1
    hCV2575336 rs2418541 hCV546489 rs264122 0.9 0.9616
    hCV2575336 rs2418541 hCV8932829 rs1116596 0.9 1
    hCV2575340 rs11242020 hCV11819780 rs12153185 0.9 0.9232
    hCV2575340 rs11242020 hCV11819782 rs12719415 0.9 0.927
    hCV2575340 rs11242020 hCV2575318 rs7711358 0.9 1
    hCV2575340 rs11242020 hCV2575336 rs2418541 0.9 1
    hCV2575340 rs11242020 hCV26478747 rs2190598 0.9 0.9239
    hCV2575340 rs11242020 hCV26478763 rs2418542 0.9 1
    hCV2575340 rs11242020 hCV27996154 rs4836502 0.9 0.927
    hCV2575340 rs11242020 hCV2961244 rs2418548 0.9 0.9232
    hCV2575340 rs11242020 hCV2961250 rs4836507 0.9 0.927
    hCV2575340 rs11242020 hCV2961252 rs10067895 0.9 0.927
    hCV2575340 rs11242020 hCV2961253 rs2190600 0.9 0.927
    hCV2575340 rs11242020 hCV2961260 rs11242022 0.9 0.9232
    hCV2575340 rs11242020 hCV2961261 rs11242021 0.9 0.9255
    hCV2575340 rs11242020 hCV2961267 rs1476714 0.9 0.9607
    hCV2575340 rs11242020 hCV2961268 rs2108425 0.9 0.927
    hCV2575340 rs11242020 hCV2961269 rs2158958 0.9 0.927
    hCV2575340 rs11242020 hCV2961270 rs9327555 0.9 0.927
    hCV2575340 rs11242020 hCV2961278 rs7446891 0.9 0.927
    hCV2575340 rs11242020 hCV2961280 rs10520072 0.9 0.927
    hCV2575340 rs11242020 hCV2961282 rs917295 0.9 0.927
    hCV2575340 rs11242020 hCV2961284 rs10054055 0.9 0.9616
    hCV2575340 rs11242020 hCV2961296 rs10051148 0.9 0.9623
    hCV2575340 rs11242020 hCV2961297 rs2158961 0.9 0.9634
    hCV2575340 rs11242020 hCV2961306 rs264129 0.9 0.9232
    hCV2575340 rs11242020 hCV30621656 rs10478919 0.9 1
    hCV2575340 rs11242020 hCV31237567 rs11749272 0.9 1
    hCV2575340 rs11242020 hCV346713 rs1990023 0.9 1
    hCV2575340 rs11242020 hCV546489 rs264122 0.9 0.9616
    hCV2575340 rs11242020 hCV8932829 rs1116596 0.9 1
    hCV26478734 rs11956952 hCV11819777 rs13172910 0.9 1
    hCV26478734 rs11956952 hCV31237558 rs6898857 0.9 1
    hCV26478744 rs2016194 hCV11819780 rs12153185 0.9 1
    hCV26478744 rs2016194 hCV11819782 rs12719415 0.9 0.9198
    hCV26478744 rs2016194 hCV26478745 rs2108426 0.9 1
    hCV26478744 rs2016194 hCV26478747 rs2190598 0.9 0.916
    hCV26478744 rs2016194 hCV27996154 rs4836502 0.9 0.9198
    hCV26478744 rs2016194 hCV2961244 rs2418548 0.9 1
    hCV26478744 rs2016194 hCV2961250 rs4836507 0.9 0.9198
    hCV26478744 rs2016194 hCV2961252 rs10067895 0.9 0.9198
    hCV26478744 rs2016194 hCV2961253 rs2190600 0.9 0.9198
    hCV26478744 rs2016194 hCV2961259 rs11242023 0.9 0.9587
    hCV26478744 rs2016194 hCV2961260 rs11242022 0.9 1
    hCV26478744 rs2016194 hCV2961261 rs11242021 0.9 0.9198
    hCV26478744 rs2016194 hCV2961267 rs1476714 0.9 0.9152
    hCV26478744 rs2016194 hCV2961268 rs2108425 0.9 0.9198
    hCV26478744 rs2016194 hCV2961269 rs2158958 0.9 0.9198
    hCV26478744 rs2016194 hCV2961270 rs9327555 0.9 0.9198
    hCV26478744 rs2016194 hCV2961278 rs7446891 0.9 0.9198
    hCV26478744 rs2016194 hCV2961280 rs10520072 0.9 0.9198
    hCV26478744 rs2016194 hCV2961282 rs917295 0.9 0.9197
    hCV26478744 rs2016194 hCV2961284 rs10054055 0.9 0.9581
    hCV26478744 rs2016194 hCV2961296 rs10051148 0.9 0.9589
    hCV26478744 rs2016194 hCV2961306 rs264129 0.9 0.9162
    hCV26478744 rs2016194 hCV346713 rs1990023 0.9 0.9162
    hCV26478744 rs2016194 hCV546489 rs264122 0.9 0.9581
    hCV26478745 rs2108426 hCV11819780 rs12153185 0.9 1
    hCV26478745 rs2108426 hCV11819782 rs12719415 0.9 0.9135
    hCV26478745 rs2108426 hCV26478744 rs2016194 0.9 1
    hCV26478745 rs2108426 hCV26478747 rs2190598 0.9 0.9092
    hCV26478745 rs2108426 hCV27996154 rs4836502 0.9 0.9135
    hCV26478745 rs2108426 hCV2961244 rs2418548 0.9 1
    hCV26478745 rs2108426 hCV2961250 rs4836507 0.9 0.9135
    hCV26478745 rs2108426 hCV2961252 rs10067895 0.9 0.9135
    hCV26478745 rs2108426 hCV2961253 rs2190600 0.9 0.9135
    hCV26478745 rs2108426 hCV2961259 rs11242023 0.9 0.9557
    hCV26478745 rs2108426 hCV2961260 rs11242022 0.9 1
    hCV26478745 rs2108426 hCV2961261 rs11242021 0.9 0.9135
    hCV26478745 rs2108426 hCV2961267 rs1476714 0.9 0.9081
    hCV26478745 rs2108426 hCV2961268 rs2108425 0.9 0.9135
    hCV26478745 rs2108426 hCV2961269 rs2158958 0.9 0.9135
    hCV26478745 rs2108426 hCV2961270 rs9327555 0.9 0.9135
    hCV26478745 rs2108426 hCV2961278 rs7446891 0.9 0.9135
    hCV26478745 rs2108426 hCV2961280 rs10520072 0.9 0.9135
    hCV26478745 rs2108426 hCV2961282 rs917295 0.9 0.9134
    hCV26478745 rs2108426 hCV2961284 rs10054055 0.9 1
    hCV26478745 rs2108426 hCV2961296 rs10051148 0.9 1
    hCV26478745 rs2108426 hCV2961297 rs2158961 0.9 0.9135
    hCV26478745 rs2108426 hCV2961306 rs264129 0.9 0.9557
    hCV26478745 rs2108426 hCV346713 rs1990023 0.9 0.9557
    hCV26478745 rs2108426 hCV546489 rs264122 0.9 1
    hCV26478747 rs2190598 hCV11819780 rs12153185 0.9 1
    hCV26478747 rs2190598 hCV11819782 rs12719415 0.9 1
    hCV26478747 rs2190598 hCV2575318 rs7711358 0.9 0.9239
    hCV26478747 rs2190598 hCV2575336 rs2418541 0.9 0.9239
    hCV26478747 rs2190598 hCV2575340 rs11242020 0.9 0.9239
    hCV26478747 rs2190598 hCV26478744 rs2016194 0.9 0.916
    hCV26478747 rs2190598 hCV26478745 rs2108426 0.9 0.9092
    hCV26478747 rs2190598 hCV26478763 rs2418542 0.9 0.9239
    hCV26478747 rs2190598 hCV27996154 rs4836502 0.9 1
    hCV26478747 rs2190598 hCV2961244 rs2418548 0.9 1
    hCV26478747 rs2190598 hCV2961250 rs4836507 0.9 1
    hCV26478747 rs2190598 hCV2961252 rs10067895 0.9 1
    hCV26478747 rs2190598 hCV2961253 rs2190600 0.9 1
    hCV26478747 rs2190598 hCV2961259 rs11242023 0.9 0.9604
    hCV26478747 rs2190598 hCV2961260 rs11242022 0.9 1
    hCV26478747 rs2190598 hCV2961261 rs11242021 0.9 1
    hCV26478747 rs2190598 hCV2961267 rs1476714 0.9 1
    hCV26478747 rs2190598 hCV2961268 rs2108425 0.9 1
    hCV26478747 rs2190598 hCV2961269 rs2158958 0.9 1
    hCV26478747 rs2190598 hCV2961270 rs9327555 0.9 1
    hCV26478747 rs2190598 hCV2961278 rs7446891 0.9 1
    hCV26478747 rs2190598 hCV2961280 rs10520072 0.9 1
    hCV26478747 rs2190598 hCV2961282 rs917295 0.9 1
    hCV26478747 rs2190598 hCV2961284 rs10054055 0.9 0.96
    hCV26478747 rs2190598 hCV2961296 rs10051148 0.9 0.9615
    hCV26478747 rs2190598 hCV2961297 rs2158961 0.9 0.9619
    hCV26478747 rs2190598 hCV2961306 rs264129 0.9 0.9198
    hCV26478747 rs2190598 hCV30621656 rs10478919 0.9 0.9239
    hCV26478747 rs2190598 hCV31237567 rs11749272 0.9 0.9239
    hCV26478747 rs2190598 hCV346713 rs1990023 0.9 0.9199
    hCV26478747 rs2190598 hCV546489 rs264122 0.9 0.96
    hCV26478747 rs2190598 hCV8932829 rs1116596 0.9 0.9239
    hCV26478748 rs2190597 hCV2575337 rs2214640 0.9 0.9282
    hCV26478748 rs2190597 hCV2575344 rs10064779 0.9 0.9339
    hCV26478748 rs2190597 hCV29134277 rs6595948 0.9 0.9669
    hCV26478748 rs2190597 hCV2961229 rs12654296 0.9 0.9664
    hCV26478748 rs2190597 hCV2961235 rs6869219 0.9 1
    hCV26478748 rs2190597 hCV2961239 rs6868888 0.9 1
    hCV26478748 rs2190597 hCV2961241 rs2108427 0.9 0.9037
    hCV26478748 rs2190597 hCV2961251 rs1157409 0.9 1
    hCV26478748 rs2190597 hCV31237552 rs6889557 0.9 0.9652
    hCV26478748 rs2190597 hCV546493 rs264126 0.9 0.9328
    hCV26478748 rs2190597 hCV8932783 rs1473132 0.9 1
    hCV26478763 rs2418542 hCV11819780 rs12153185 0.9 0.9232
    hCV26478763 rs2418542 hCV11819782 rs12719415 0.9 0.927
    hCV26478763 rs2418542 hCV2575318 rs7711358 0.9 1
    hCV26478763 rs2418542 hCV2575336 rs2418541 0.9 1
    hCV26478763 rs2418542 hCV2575340 rs11242020 0.9 1
    hCV26478763 rs2418542 hCV26478747 rs2190598 0.9 0.9239
    hCV26478763 rs2418542 hCV27996154 rs4836502 0.9 0.927
    hCV26478763 rs2418542 hCV2961244 rs2418548 0.9 0.9232
    hCV26478763 rs2418542 hCV2961250 rs4836507 0.9 0.927
    hCV26478763 rs2418542 hCV2961252 rs10067895 0.9 0.927
    hCV26478763 rs2418542 hCV2961253 rs2190600 0.9 0.927
    hCV26478763 rs2418542 hCV2961260 rs11242022 0.9 0.9232
    hCV26478763 rs2418542 hCV2961261 rs11242021 0.9 0.9255
    hCV26478763 rs2418542 hCV2961267 rs1476714 0.9 0.9607
    hCV26478763 rs2418542 hCV2961268 rs2108425 0.9 0.927
    hCV26478763 rs2418542 hCV2961269 rs2158958 0.9 0.927
    hCV26478763 rs2418542 hCV2961270 rs9327555 0.9 0.927
    hCV26478763 rs2418542 hCV2961278 rs7446891 0.9 0.927
    hCV26478763 rs2418542 hCV2961280 rs10520072 0.9 0.927
    hCV26478763 rs2418542 hCV2961282 rs917295 0.9 0.927
    hCV26478763 rs2418542 hCV2961284 rs10054055 0.9 0.9616
    hCV26478763 rs2418542 hCV2961296 rs10051148 0.9 0.9623
    hCV26478763 rs2418542 hCV2961297 rs2158961 0.9 0.9634
    hCV26478763 rs2418542 hCV2961306 rs264129 0.9 0.9232
    hCV26478763 rs2418542 hCV30621656 rs10478919 0.9 1
    hCV26478763 rs2418542 hCV31237567 rs11749272 0.9 1
    hCV26478763 rs2418542 hCV346713 rs1990023 0.9 1
    hCV26478763 rs2418542 hCV546489 rs264122 0.9 0.9616
    hCV26478763 rs2418542 hCV8932829 rs1116596 0.9 1
    hCV26499740 rs1344081 hCV11435810 rs7808536 0.9 0.9396
    hCV26499740 rs1344081 hCV11435811 rs2057903 0.9 0.9396
    hCV26499740 rs1344081 hCV16010888 rs2402516 0.9 1
    hCV26499740 rs1344081 hCV16151622 rs2896295 0.9 0.9396
    hCV26499740 rs1344081 hCV2580015 rs6973461 0.9 0.9388
    hCV26499740 rs1344081 hCV29630277 rs7799541 0.9 0.9703
    hCV26499740 rs1344081 hCV29720798 rs10228725 0.9 0.9396
    hCV26499740 rs1344081 hCV29738883 rs10237648 0.9 0.9401
    hCV26499740 rs1344081 hCV29865261 rs10226287 0.9 0.9396
    hCV26499740 rs1344081 hCV30243451 rs10270624 0.9 0.9401
    hCV26499740 rs1344081 hCV30441808 rs10487413 0.9 1
    hCV26499740 rs1344081 hCV31281599 rs13438543 0.9 1
    hCV2676440 rs6722640 hCV16126066 rs2110564 0.9 1
    hCV2676440 rs6722640 hCV27872026 rs4851531 0.9 0.9638
    hCV2676440 rs6722640 hCV349805 rs4851529 0.9 0.9329
    hCV2676440 rs6722640 hCV8905894 rs974950 0.9 1
    hCV26771384 rs10865197 hCV26135665 rs4390811 0.9 0.96
    hCV26771384 rs10865197 hCV26771389 rs10183431 0.9 1
    hCV26771384 rs10865197 hCV27875215 rs4346434 0.9 0.922
    hCV26771384 rs10865197 hCV27933339 rs4586678 0.9 1
    hCV26771384 rs10865197 hCV29229284 rs6741066 0.9 0.9591
    hCV26771384 rs10865197 hCV30817981 rs6723119 0.9 0.96
    hCV26771384 rs10865197 hCV375079 rs9309112 0.9 0.92
    hCV26771384 rs10865197 hCV375083 rs10206724 0.9 1
    hCV26771384 rs10865197 hCV375090 rs4450660 0.9 1
    hCV26771384 rs10865197 hCV514334 rs6544721 0.9 0.961
    hCV26771389 rs10183431 hCV26135665 rs4390811 0.9 0.96
    hCV26771389 rs10183431 hCV26771384 rs10865197 0.9 1
    hCV26771389 rs10183431 hCV27875215 rs4346434 0.9 0.922
    hCV26771389 rs10183431 hCV27933339 rs4586678 0.9 1
    hCV26771389 rs10183431 hCV29229284 rs6741066 0.9 0.9591
    hCV26771389 rs10183431 hCV30817981 rs6723119 0.9 0.96
    hCV26771389 rs10183431 hCV375079 rs9309112 0.9 0.92
    hCV26771389 rs10183431 hCV375083 rs10206724 0.9 1
    hCV26771389 rs10183431 hCV375090 rs4450660 0.9 1
    hCV26771389 rs10183431 hCV514334 rs6544721 0.9 0.961
    hCV26830134 rs2993156 hCV26830128 rs10814709 0.9 1
    hCV26830134 rs2993156 hDV68926946 rs10814708 0.9 0.9583
    hCV26881087 rs4472926 hCV29268001 rs7939893 0.9 0.9787
    hCV2690291 rs2270588 hCV2690292 rs2270589 0.9 0.9243
    hCV2690291 rs2270588 hCV8873448 rs3844207 0.9 1
    hCV2690292 rs2270589 hCV2690291 rs2270588 0.9 0.9243
    hCV2690292 rs2270589 hCV8873448 rs3844207 0.9 0.9298
    hCV2690365 rs11178583 hCV11686277 rs3763978 0.9 0.9654
    hCV2690365 rs11178583 hCV11686292 rs1051334 0.9 0.9627
    hCV2690365 rs11178583 hCV15957961 rs2270586 0.9 0.9627
    hCV2690365 rs11178583 hCV26441048 rs3851610 0.9 0.9654
    hCV2690365 rs11178583 hCV26441140 rs9325191 0.9 1
    hCV2690365 rs11178583 hCV2690286 rs2270584 0.9 0.9622
    hCV2690365 rs11178583 hCV2690333 rs11178602 0.9 1
    hCV2690365 rs11178583 hCV2690348 rs11178594 0.9 1
    hCV2690365 rs11178583 hCV2690350 rs2132242 0.9 1
    hCV2690365 rs11178583 hCV2690354 rs11178589 0.9 1
    hCV2690365 rs11178583 hCV2690362 rs10879249 0.9 1
    hCV2690365 rs11178583 hCV2690375 rs1567740 0.9 1
    hCV2690365 rs11178583 hCV2690377 rs10879245 0.9 1
    hCV2690365 rs11178583 hCV2690378 rs11178579 0.9 1
    hCV2690365 rs11178583 hCV2690379 rs10879242 0.9 1
    hCV2690365 rs11178583 hCV2690380 rs10506623 0.9 1
    hCV2690365 rs11178583 hCV2690388 rs2132241 0.9 1
    hCV2690365 rs11178583 hCV29593612 rs10506626 0.9 0.9627
    hCV2690365 rs11178583 hCV31190567 rs7311994 0.9 1
    hCV2690365 rs11178583 hCV31190598 rs12818936 0.9 1
    hCV2690365 rs11178583 hCV31190625 rs11178648 0.9 0.9627
    hCV2690365 rs11178583 hCV31190877 rs12831292 0.9 0.9654
    hCV2690365 rs11178583 hCV8375364 rs966583 0.9 1
    hCV2690365 rs11178583 hCV8871988 rs1495375 0.9 1
    hCV2690365 rs11178583 hCV8871989 rs1512989 0.9 1
    hCV2690365 rs11178583 hCV8871990 rs1512988 0.9 1
    hCV2690365 rs11178583 hCV8873466 rs1051344 0.9 1
    hCV2690365 rs11178583 hCV8873472 rs1355373 0.9 1
    hCV2690377 rs10879245 hCV11412791 rs1874313 0.9 1
    hCV2690377 rs10879245 hCV11686277 rs3763978 0.9 0.9573
    hCV2690377 rs10879245 hCV11686292 rs1051334 0.9 0.9557
    hCV2690377 rs10879245 hCV15957961 rs2270586 0.9 0.9557
    hCV2690377 rs10879245 hCV26441048 rs3851610 0.9 0.9573
    hCV2690377 rs10879245 hCV26441140 rs9325191 0.9 1
    hCV2690377 rs10879245 hCV2690286 rs2270584 0.9 0.9552
    hCV2690377 rs10879245 hCV2690333 rs11178602 0.9 1
    hCV2690377 rs10879245 hCV2690348 rs11178594 0.9 1
    hCV2690377 rs10879245 hCV2690350 rs2132242 0.9 1
    hCV2690377 rs10879245 hCV2690354 rs11178589 0.9 1
    hCV2690377 rs10879245 hCV2690362 rs10879249 0.9 1
    hCV2690377 rs10879245 hCV2690365 rs11178583 0.9 1
    hCV2690377 rs10879245 hCV2690375 rs1567740 0.9 1
    hCV2690377 rs10879245 hCV2690378 rs11178579 0.9 1
    hCV2690377 rs10879245 hCV2690379 rs10879242 0.9 1
    hCV2690377 rs10879245 hCV2690380 rs10506623 0.9 1
    hCV2690377 rs10879245 hCV2690388 rs2132241 0.9 1
    hCV2690377 rs10879245 hCV29593612 rs10506626 0.9 0.9557
    hCV2690377 rs10879245 hCV31190567 rs7311994 0.9 1
    hCV2690377 rs10879245 hCV31190598 rs12818936 0.9 1
    hCV2690377 rs10879245 hCV31190625 rs11178648 0.9 0.9557
    hCV2690377 rs10879245 hCV31190877 rs12831292 0.9 1
    hCV2690377 rs10879245 hCV8375364 rs966583 0.9 1
    hCV2690377 rs10879245 hCV8871988 rs1495375 0.9 1
    hCV2690377 rs10879245 hCV8871989 rs1512989 0.9 1
    hCV2690377 rs10879245 hCV8871990 rs1512988 0.9 1
    hCV2690377 rs10879245 hCV8873466 rs1051344 0.9 1
    hCV2690377 rs10879245 hCV8873472 rs1355373 0.9 1
    hCV2690378 rs11178579 hCV11412791 rs1874313 0.9 1
    hCV2690378 rs11178579 hCV11686277 rs3763978 0.9 1
    hCV2690378 rs11178579 hCV11686292 rs1051334 0.9 1
    hCV2690378 rs11178579 hCV15957961 rs2270586 0.9 1
    hCV2690378 rs11178579 hCV26441048 rs3851610 0.9 1
    hCV2690378 rs11178579 hCV26441140 rs9325191 0.9 1
    hCV2690378 rs11178579 hCV2690286 rs2270584 0.9 1
    hCV2690378 rs11178579 hCV2690333 rs11178602 0.9 1
    hCV2690378 rs11178579 hCV2690348 rs11178594 0.9 1
    hCV2690378 rs11178579 hCV2690350 rs2132242 0.9 1
    hCV2690378 rs11178579 hCV2690354 rs11178589 0.9 1
    hCV2690378 rs11178579 hCV2690362 rs10879249 0.9 1
    hCV2690378 rs11178579 hCV2690365 rs11178583 0.9 1
    hCV2690378 rs11178579 hCV2690375 rs1567740 0.9 1
    hCV2690378 rs11178579 hCV2690377 rs10879245 0.9 1
    hCV2690378 rs11178579 hCV2690379 rs10879242 0.9 1
    hCV2690378 rs11178579 hCV2690380 rs10506623 0.9 1
    hCV2690378 rs11178579 hCV2690388 rs2132241 0.9 1
    hCV2690378 rs11178579 hCV27530498 rs3942254 0.9 0.9577
    hCV2690378 rs11178579 hCV29593612 rs10506626 0.9 1
    hCV2690378 rs11178579 hCV31190567 rs7311994 0.9 1
    hCV2690378 rs11178579 hCV31190598 rs12818936 0.9 1
    hCV2690378 rs11178579 hCV31190625 rs11178648 0.9 1
    hCV2690378 rs11178579 hCV31190877 rs12831292 0.9 0.9609
    hCV2690378 rs11178579 hCV8375364 rs966583 0.9 1
    hCV2690378 rs11178579 hCV8871988 rs1495375 0.9 1
    hCV2690378 rs11178579 hCV8871989 rs1512989 0.9 1
    hCV2690378 rs11178579 hCV8871990 rs1512988 0.9 1
    hCV2690378 rs11178579 hCV8873466 rs1051344 0.9 1
    hCV2690378 rs11178579 hCV8873472 rs1355373 0.9 1
    hCV2690379 rs10879242 hCV11686277 rs3763978 0.9 0.9645
    hCV2690379 rs10879242 hCV11686292 rs1051334 0.9 0.9627
    hCV2690379 rs10879242 hCV15957961 rs2270586 0.9 0.9627
    hCV2690379 rs10879242 hCV26441048 rs3851610 0.9 0.9645
    hCV2690379 rs10879242 hCV26441140 rs9325191 0.9 1
    hCV2690379 rs10879242 hCV2690286 rs2270584 0.9 0.9622
    hCV2690379 rs10879242 hCV2690333 rs11178602 0.9 1
    hCV2690379 rs10879242 hCV2690348 rs11178594 0.9 1
    hCV2690379 rs10879242 hCV2690350 rs2132242 0.9 1
    hCV2690379 rs10879242 hCV2690354 rs11178589 0.9 1
    hCV2690379 rs10879242 hCV2690362 rs10879249 0.9 1
    hCV2690379 rs10879242 hCV2690365 rs11178583 0.9 1
    hCV2690379 rs10879242 hCV2690375 rs1567740 0.9 1
    hCV2690379 rs10879242 hCV2690377 rs10879245 0.9 1
    hCV2690379 rs10879242 hCV2690378 rs11178579 0.9 1
    hCV2690379 rs10879242 hCV2690380 rs10506623 0.9 1
    hCV2690379 rs10879242 hCV2690388 rs2132241 0.9 1
    hCV2690379 rs10879242 hCV29593612 rs10506626 0.9 0.9627
    hCV2690379 rs10879242 hCV31190567 rs7311994 0.9 1
    hCV2690379 rs10879242 hCV31190598 rs12818936 0.9 1
    hCV2690379 rs10879242 hCV31190625 rs11178648 0.9 0.9627
    hCV2690379 rs10879242 hCV31190877 rs12831292 0.9 0.9645
    hCV2690379 rs10879242 hCV8375364 rs966583 0.9 1
    hCV2690379 rs10879242 hCV8871988 rs1495375 0.9 1
    hCV2690379 rs10879242 hCV8871989 rs1512989 0.9 1
    hCV2690379 rs10879242 hCV8871990 rs1512988 0.9 1
    hCV2690379 rs10879242 hCV8873466 rs1051344 0.9 1
    hCV2690379 rs10879242 hCV8873472 rs1355373 0.9 1
    hCV27084860 rs10758326 hCV29338383 rs7847621 0.9 0.9273
    hCV27084860 rs10758326 hCV31931605 rs7022281 0.9 0.9004
    hCV27084860 rs10758326 hCV31931609 rs10738948 0.9 0.9637
    hCV27344887 rs4038018 hCV27344902 rs4463950 0.9 1
    hCV27344887 rs4038018 hCV28025299 rs4771960 0.9 0.9616
    hCV27344887 rs4038018 hCV32256712 rs9556694 0.9 0.9599
    hCV27367681 rs2876227 hCV2529198 rs742827 0.9 1
    hCV27367681 rs2876227 hCV2529202 rs6040667 0.9 0.9649
    hCV27367681 rs2876227 hCV2529211 rs17189710 0.9 0.9616
    hCV27367681 rs2876227 hCV2529224 rs2327412 0.9 0.9616
    hCV27367681 rs2876227 hCV2529230 rs4444612 0.9 0.9616
    hCV27367681 rs2876227 hCV2529231 rs4315598 0.9 0.9616
    hCV27367681 rs2876227 hCV2529239 rs6040638 0.9 0.9616
    hCV27367681 rs2876227 hCV2529241 rs6134243 0.9 0.9649
    hCV27367681 rs2876227 hCV2529246 rs6040619 0.9 0.9616
    hCV27367681 rs2876227 hCV27367708 rs1009748 0.9 0.9616
    hCV27367681 rs2876227 hCV29840965 rs6040644 0.9 0.9616
    hCV27367681 rs2876227 hCV30057061 rs6033138 0.9 0.9649
    hCV27367681 rs2876227 hCV30093270 rs6040625 0.9 0.9649
    hCV27367681 rs2876227 hCV30129243 rs6040636 0.9 0.9649
    hCV27367681 rs2876227 hCV30218977 rs6040633 0.9 0.9649
    hCV27367681 rs2876227 hCV30417550 rs6040634 0.9 0.9649
    hCV27367681 rs2876227 hCV30453433 rs6131208 0.9 0.9193
    hCV27367681 rs2876227 hCV32274419 rs13038146 0.9 0.9649
    hCV27367681 rs2876227 hCV330228 rs6040668 0.9 0.9649
    hCV27367708 rs1009748 hCV2529198 rs742827 0.9 0.9596
    hCV27367708 rs1009748 hCV2529202 rs6040667 0.9 1
    hCV27367708 rs1009748 hCV2529211 rs17189710 0.9 1
    hCV27367708 rs1009748 hCV2529224 rs2327412 0.9 1
    hCV27367708 rs1009748 hCV2529230 rs4444612 0.9 1
    hCV27367708 rs1009748 hCV2529231 rs4315598 0.9 1
    hCV27367708 rs1009748 hCV2529239 rs6040638 0.9 1
    hCV27367708 rs1009748 hCV2529241 rs6134243 0.9 1
    hCV27367708 rs1009748 hCV2529246 rs6040619 0.9 1
    hCV27367708 rs1009748 hCV27367681 rs2876227 0.9 0.9616
    hCV27367708 rs1009748 hCV29840965 rs6040644 0.9 1
    hCV27367708 rs1009748 hCV30057061 rs6033138 0.9 1
    hCV27367708 rs1009748 hCV30093270 rs6040625 0.9 1
    hCV27367708 rs1009748 hCV30129243 rs6040636 0.9 1
    hCV27367708 rs1009748 hCV30218977 rs6040633 0.9 1
    hCV27367708 rs1009748 hCV30417550 rs6040634 0.9 1
    hCV27367708 rs1009748 hCV30453433 rs6131208 0.9 0.9565
    hCV27367708 rs1009748 hCV30615489 rs6040630 0.9 0.9225
    hCV27367708 rs1009748 hCV32274419 rs13038146 0.9 1
    hCV27367708 rs1009748 hCV330228 rs6040668 0.9 1
    hCV2745822 rs1913201 hCV11686367 rs7955901 0.9 0.9432
    hCV2745822 rs1913201 hCV171102 rs7313973 0.9 0.9568
    hCV2745822 rs1913201 hCV240133 rs4760895 0.9 1
    hCV2745822 rs1913201 hCV240134 rs7138300 0.9 1
    hCV2745822 rs1913201 hCV2745815 rs1512991 0.9 0.9644
    hCV2745822 rs1913201 hCV2745828 rs10879240 0.9 0.9639
    hCV2745822 rs1913201 hCV27952502 rs4760894 0.9 1
    hCV2745822 rs1913201 hCV27952503 rs4760785 0.9 1
    hCV2745822 rs1913201 hCV31190777 rs10784891 0.9 0.9588
    hCV2745822 rs1913201 hDV72015086 rs7956274 0.9 0.9622
    hCV2745828 rs10879240 hCV11686367 rs7955901 0.9 0.9274
    hCV2745828 rs10879240 hCV171102 rs7313973 0.9 0.9208
    hCV2745828 rs10879240 hCV240133 rs4760895 0.9 0.9664
    hCV2745828 rs10879240 hCV240134 rs7138300 0.9 0.9639
    hCV2745828 rs10879240 hCV2745815 rs1512991 0.9 0.9324
    hCV2745828 rs10879240 hCV2745822 rs1913201 0.9 0.9639
    hCV2745828 rs10879240 hCV27952502 rs4760894 0.9 0.9664
    hCV2745828 rs10879240 hCV27952503 rs4760785 0.9 0.9664
    hCV2745828 rs10879240 hCV29120310 rs7298255 0.9 0.9274
    hCV2745828 rs10879240 hCV31190748 rs7959965 0.9 0.9274
    hCV2745828 rs10879240 hCV31190777 rs10784891 0.9 0.9235
    hCV2745828 rs10879240 hDV72015086 rs7956274 0.9 0.9285
    hCV27872026 rs4851531 hCV16126066 rs2110564 0.9 0.9638
    hCV27872026 rs4851531 hCV2676440 rs6722640 0.9 0.9638
    hCV27872026 rs4851531 hCV349805 rs4851529 0.9 0.9646
    hCV27872026 rs4851531 hCV8905894 rs974950 0.9 0.9812
    hCV27894109 rs4879931 hCV29338373 rs7035913 0.9 1
    hCV27894109 rs4879931 hDV70921009 rs17204908 0.9 1
    hCV27933339 rs4586678 hCV26135665 rs4390811 0.9 0.96
    hCV27933339 rs4586678 hCV26771384 rs10865197 0.9 1
    hCV27933339 rs4586678 hCV26771389 rs10183431 0.9 1
    hCV27933339 rs4586678 hCV27875215 rs4346434 0.9 0.922
    hCV27933339 rs4586678 hCV29229284 rs6741066 0.9 0.9591
    hCV27933339 rs4586678 hCV30817981 rs6723119 0.9 0.96
    hCV27933339 rs4586678 hCV375079 rs9309112 0.9 0.92
    hCV27933339 rs4586678 hCV375083 rs10206724 0.9 1
    hCV27933339 rs4586678 hCV375090 rs4450660 0.9 1
    hCV27933339 rs4586678 hCV514334 rs6544721 0.9 0.961
    hCV27952502 rs4760894 hCV11686367 rs7955901 0.9 0.9644
    hCV27952502 rs4760894 hCV171102 rs7313973 0.9 0.9603
    hCV27952502 rs4760894 hCV240133 rs4760895 0.9 1
    hCV27952502 rs4760894 hCV240134 rs7138300 0.9 1
    hCV27952502 rs4760894 hCV2745815 rs1512991 0.9 0.9668
    hCV27952502 rs4760894 hCV2745822 rs1913201 0.9 1
    hCV27952502 rs4760894 hCV2745828 rs10879240 0.9 0.9664
    hCV27952502 rs4760894 hCV27952503 rs4760785 0.9 1
    hCV27952502 rs4760894 hCV29120310 rs7298255 0.9 0.9644
    hCV27952502 rs4760894 hCV31190748 rs7959965 0.9 0.9644
    hCV27952502 rs4760894 hCV31190777 rs10784891 0.9 0.962
    hCV27952502 rs4760894 hDV72015086 rs7956274 0.9 0.9649
    hCV27952503 rs4760785 hCV11686367 rs7955901 0.9 0.9644
    hCV27952503 rs4760785 hCV171102 rs7313973 0.9 0.9603
    hCV27952503 rs4760785 hCV240133 rs4760895 0.9 1
    hCV27952503 rs4760785 hCV240134 rs7138300 0.9 1
    hCV27952503 rs4760785 hCV2745815 rs1512991 0.9 0.9668
    hCV27952503 rs4760785 hCV2745822 rs1913201 0.9 1
    hCV27952503 rs4760785 hCV2745828 rs10879240 0.9 0.9664
    hCV27952503 rs4760785 hCV27952502 rs4760894 0.9 1
    hCV27952503 rs4760785 hCV29120310 rs7298255 0.9 0.9644
    hCV27952503 rs4760785 hCV31190748 rs7959965 0.9 0.9644
    hCV27952503 rs4760785 hCV31190777 rs10784891 0.9 0.962
    hCV27952503 rs4760785 hDV72015086 rs7956274 0.9 0.9649
    hCV27974149 rs4964416 hCV29121666 rs6539231 0.9 0.9266
    hCV27996154 rs4836502 hCV11819780 rs12153185 0.9 1
    hCV27996154 rs4836502 hCV11819782 rs12719415 0.9 1
    hCV27996154 rs4836502 hCV2575318 rs7711358 0.9 0.927
    hCV27996154 rs4836502 hCV2575336 rs2418541 0.9 0.927
    hCV27996154 rs4836502 hCV2575340 rs11242020 0.9 0.927
    hCV27996154 rs4836502 hCV26478744 rs2016194 0.9 0.9198
    hCV27996154 rs4836502 hCV26478745 rs2108426 0.9 0.9135
    hCV27996154 rs4836502 hCV26478747 rs2190598 0.9 1
    hCV27996154 rs4836502 hCV26478763 rs2418542 0.9 0.927
    hCV27996154 rs4836502 hCV2961244 rs2418548 0.9 1
    hCV27996154 rs4836502 hCV2961250 rs4836507 0.9 1
    hCV27996154 rs4836502 hCV2961252 rs10067895 0.9 1
    hCV27996154 rs4836502 hCV2961253 rs2190600 0.9 1
    hCV27996154 rs4836502 hCV2961259 rs11242023 0.9 0.9621
    hCV27996154 rs4836502 hCV2961260 rs11242022 0.9 1
    hCV27996154 rs4836502 hCV2961261 rs11242021 0.9 1
    hCV27996154 rs4836502 hCV2961267 rs1476714 0.9 1
    hCV27996154 rs4836502 hCV2961268 rs2108425 0.9 1
    hCV27996154 rs4836502 hCV2961269 rs2158958 0.9 1
    hCV27996154 rs4836502 hCV2961270 rs9327555 0.9 1
    hCV27996154 rs4836502 hCV2961278 rs7446891 0.9 1
    hCV27996154 rs4836502 hCV2961280 rs10520072 0.9 1
    hCV27996154 rs4836502 hCV2961282 rs917295 0.9 1
    hCV27996154 rs4836502 hCV2961284 rs10054055 0.9 0.9616
    hCV27996154 rs4836502 hCV2961296 rs10051148 0.9 0.9623
    hCV27996154 rs4836502 hCV2961297 rs2158961 0.9 0.9634
    hCV27996154 rs4836502 hCV2961306 rs264129 0.9 0.9232
    hCV27996154 rs4836502 hCV30621656 rs10478919 0.9 0.927
    hCV27996154 rs4836502 hCV31237567 rs11749272 0.9 0.927
    hCV27996154 rs4836502 hCV346713 rs1990023 0.9 0.9232
    hCV27996154 rs4836502 hCV546489 rs264122 0.9 0.9616
    hCV27996154 rs4836502 hCV8932829 rs1116596 0.9 0.927
    hCV2881200 rs2052428 hCV2881217 rs10735411 0.9 0.9234
    hCV2881200 rs2052428 hCV31198182 rs10778446 0.9 0.9234
    hCV29012564 rs7338174 hCV29012561 rs7333988 0.9 0.9184
    hCV29120310 rs7298255 hCV11686367 rs7955901 0.9 0.9442
    hCV29120310 rs7298255 hCV11686374 rs7957932 0.9 0.9161
    hCV29120310 rs7298255 hCV171102 rs7313973 0.9 0.9568
    hCV29120310 rs7298255 hCV240133 rs4760895 0.9 0.9644
    hCV29120310 rs7298255 hCV2745805 rs7132840 0.9 0.9268
    hCV29120310 rs7298255 hCV2745807 rs2063591 0.9 0.9303
    hCV29120310 rs7298255 hCV2745815 rs1512991 0.9 1
    hCV29120310 rs7298255 hCV2745828 rs10879240 0.9 0.9274
    hCV29120310 rs7298255 hCV27952502 rs4760894 0.9 0.9644
    hCV29120310 rs7298255 hCV27952503 rs4760785 0.9 0.9644
    hCV29120310 rs7298255 hCV31190748 rs7959965 0.9 1
    hCV29120310 rs7298255 hCV31190777 rs10784891 0.9 1
    hCV29120310 rs7298255 hDV72015086 rs7956274 0.9 1
    hCV29121666 rs6539231 hCV27974149 rs4964416 0.9 0.9266
    hCV29121666 rs6539231 hCV2881196 rs878612 0.9 0.9637
    hCV29121666 rs6539231 hCV29121664 rs7970318 0.9 0.9078
    hCV29121666 rs6539231 hCV29121665 rs6539230 0.9 0.9078
    hCV29268001 rs7939893 hCV26881087 rs4472926 0.9 0.9787
    hCV2961244 rs2418548 hCV11819780 rs12153185 0.9 1
    hCV2961244 rs2418548 hCV11819782 rs12719415 0.9 1
    hCV2961244 rs2418548 hCV2575318 rs7711358 0.9 0.9232
    hCV2961244 rs2418548 hCV2575336 rs2418541 0.9 0.9232
    hCV2961244 rs2418548 hCV2575340 rs11242020 0.9 0.9232
    hCV2961244 rs2418548 hCV26478744 rs2016194 0.9 1
    hCV2961244 rs2418548 hCV26478745 rs2108426 0.9 1
    hCV2961244 rs2418548 hCV26478747 rs2190598 0.9 1
    hCV2961244 rs2418548 hCV26478763 rs2418542 0.9 0.9232
    hCV2961244 rs2418548 hCV27996154 rs4836502 0.9 1
    hCV2961244 rs2418548 hCV2961250 rs4836507 0.9 1
    hCV2961244 rs2418548 hCV2961252 rs10067895 0.9 1
    hCV2961244 rs2418548 hCV2961253 rs2190600 0.9 1
    hCV2961244 rs2418548 hCV2961259 rs11242023 0.9 0.9571
    hCV2961244 rs2418548 hCV2961260 rs11242022 0.9 0.9785
    hCV2961244 rs2418548 hCV2961261 rs11242021 0.9 1
    hCV2961244 rs2418548 hCV2961267 rs1476714 0.9 1
    hCV2961244 rs2418548 hCV2961268 rs2108425 0.9 1
    hCV2961244 rs2418548 hCV2961269 rs2158958 0.9 1
    hCV2961244 rs2418548 hCV2961270 rs9327555 0.9 1
    hCV2961244 rs2418548 hCV2961278 rs7446891 0.9 1
    hCV2961244 rs2418548 hCV2961280 rs10520072 0.9 1
    hCV2961244 rs2418548 hCV2961282 rs917295 0.9 1
    hCV2961244 rs2418548 hCV2961284 rs10054055 0.9 0.9573
    hCV2961244 rs2418548 hCV2961296 rs10051148 0.9 0.9608
    hCV2961244 rs2418548 hCV2961297 rs2158961 0.9 0.9616
    hCV2961244 rs2418548 hCV2961306 rs264129 0.9 0.9358
    hCV2961244 rs2418548 hCV30621656 rs10478919 0.9 0.9232
    hCV2961244 rs2418548 hCV31237567 rs11749272 0.9 0.9232
    hCV2961244 rs2418548 hCV346713 rs1990023 0.9 0.9358
    hCV2961244 rs2418548 hCV546489 rs264122 0.9 0.9573
    hCV2961244 rs2418548 hCV8932829 rs1116596 0.9 0.9232
    hCV2961250 rs4836507 hCV11819780 rs12153185 0.9 1
    hCV2961250 rs4836507 hCV11819782 rs12719415 0.9 1
    hCV2961250 rs4836507 hCV2575318 rs7711358 0.9 0.927
    hCV2961250 rs4836507 hCV2575336 rs2418541 0.9 0.927
    hCV2961250 rs4836507 hCV2575340 rs11242020 0.9 0.927
    hCV2961250 rs4836507 hCV26478744 rs2016194 0.9 0.9198
    hCV2961250 rs4836507 hCV26478745 rs2108426 0.9 0.9135
    hCV2961250 rs4836507 hCV26478747 rs2190598 0.9 1
    hCV2961250 rs4836507 hCV26478763 rs2418542 0.9 0.927
    hCV2961250 rs4836507 hCV27996154 rs4836502 0.9 1
    hCV2961250 rs4836507 hCV2961244 rs2418548 0.9 1
    hCV2961250 rs4836507 hCV2961252 rs10067895 0.9 1
    hCV2961250 rs4836507 hCV2961253 rs2190600 0.9 1
    hCV2961250 rs4836507 hCV2961259 rs11242023 0.9 0.9621
    hCV2961250 rs4836507 hCV2961260 rs11242022 0.9 1
    hCV2961250 rs4836507 hCV2961261 rs11242021 0.9 1
    hCV2961250 rs4836507 hCV2961267 rs1476714 0.9 1
    hCV2961250 rs4836507 hCV2961268 rs2108425 0.9 1
    hCV2961250 rs4836507 hCV2961269 rs2158958 0.9 1
    hCV2961250 rs4836507 hCV2961270 rs9327555 0.9 1
    hCV2961250 rs4836507 hCV2961278 rs7446891 0.9 1
    hCV2961250 rs4836507 hCV2961280 rs10520072 0.9 1
    hCV2961250 rs4836507 hCV2961282 rs917295 0.9 1
    hCV2961250 rs4836507 hCV2961284 rs10054055 0.9 0.9616
    hCV2961250 rs4836507 hCV2961296 rs10051148 0.9 0.9623
    hCV2961250 rs4836507 hCV2961297 rs2158961 0.9 0.9634
    hCV2961250 rs4836507 hCV2961306 rs264129 0.9 0.9232
    hCV2961250 rs4836507 hCV30621656 rs10478919 0.9 0.927
    hCV2961250 rs4836507 hCV31237567 rs11749272 0.9 0.927
    hCV2961250 rs4836507 hCV346713 rs1990023 0.9 0.9232
    hCV2961250 rs4836507 hCV546489 rs264122 0.9 0.9616
    hCV2961250 rs4836507 hCV8932829 rs1116596 0.9 0.927
    hCV2961252 rs10067895 hCV11819780 rs12153185 0.9 1
    hCV2961252 rs10067895 hCV11819782 rs12719415 0.9 1
    hCV2961252 rs10067895 hCV2575318 rs7711358 0.9 0.927
    hCV2961252 rs10067895 hCV2575336 rs2418541 0.9 0.927
    hCV2961252 rs10067895 hCV2575340 rs11242020 0.9 0.927
    hCV2961252 rs10067895 hCV26478744 rs2016194 0.9 0.9198
    hCV2961252 rs10067895 hCV26478745 rs2108426 0.9 0.9135
    hCV2961252 rs10067895 hCV26478747 rs2190598 0.9 1
    hCV2961252 rs10067895 hCV26478763 rs2418542 0.9 0.927
    hCV2961252 rs10067895 hCV27996154 rs4836502 0.9 1
    hCV2961252 rs10067895 hCV2961244 rs2418548 0.9 1
    hCV2961252 rs10067895 hCV2961250 rs4836507 0.9 1
    hCV2961252 rs10067895 hCV2961253 rs2190600 0.9 1
    hCV2961252 rs10067895 hCV2961259 rs11242023 0.9 0.9621
    hCV2961252 rs10067895 hCV2961260 rs11242022 0.9 1
    hCV2961252 rs10067895 hCV2961261 rs11242021 0.9 1
    hCV2961252 rs10067895 hCV2961267 rs1476714 0.9 1
    hCV2961252 rs10067895 hCV2961268 rs2108425 0.9 1
    hCV2961252 rs10067895 hCV2961269 rs2158958 0.9 1
    hCV2961252 rs10067895 hCV2961270 rs9327555 0.9 1
    hCV2961252 rs10067895 hCV2961278 rs7446891 0.9 1
    hCV2961252 rs10067895 hCV2961280 rs10520072 0.9 1
    hCV2961252 rs10067895 hCV2961282 rs917295 0.9 1
    hCV2961252 rs10067895 hCV2961284 rs10054055 0.9 0.9616
    hCV2961252 rs10067895 hCV2961296 rs10051148 0.9 0.9623
    hCV2961252 rs10067895 hCV2961297 rs2158961 0.9 0.9634
    hCV2961252 rs10067895 hCV2961306 rs264129 0.9 0.9232
    hCV2961252 rs10067895 hCV30621656 rs10478919 0.9 0.927
    hCV2961252 rs10067895 hCV31237567 rs11749272 0.9 0.927
    hCV2961252 rs10067895 hCV346713 rs1990023 0.9 0.9232
    hCV2961252 rs10067895 hCV546489 rs264122 0.9 0.9616
    hCV2961252 rs10067895 hCV8932829 rs1116596 0.9 0.927
    hCV2961253 rs2190600 hCV11819780 rs12153185 0.9 1
    hCV2961253 rs2190600 hCV11819782 rs12719415 0.9 1
    hCV2961253 rs2190600 hCV2575318 rs7711358 0.9 0.927
    hCV2961253 rs2190600 hCV2575336 rs2418541 0.9 0.927
    hCV2961253 rs2190600 hCV2575340 rs11242020 0.9 0.927
    hCV2961253 rs2190600 hCV26478744 rs2016194 0.9 0.9198
    hCV2961253 rs2190600 hCV26478745 rs2108426 0.9 0.9135
    hCV2961253 rs2190600 hCV26478747 rs2190598 0.9 1
    hCV2961253 rs2190600 hCV26478763 rs2418542 0.9 0.927
    hCV2961253 rs2190600 hCV27996154 rs4836502 0.9 1
    hCV2961253 rs2190600 hCV2961244 rs2418548 0.9 1
    hCV2961253 rs2190600 hCV2961250 rs4836507 0.9 1
    hCV2961253 rs2190600 hCV2961252 rs10067895 0.9 1
    hCV2961253 rs2190600 hCV2961259 rs11242023 0.9 0.9621
    hCV2961253 rs2190600 hCV2961260 rs11242022 0.9 1
    hCV2961253 rs2190600 hCV2961261 rs11242021 0.9 1
    hCV2961253 rs2190600 hCV2961267 rs1476714 0.9 1
    hCV2961253 rs2190600 hCV2961268 rs2108425 0.9 1
    hCV2961253 rs2190600 hCV2961269 rs2158958 0.9 1
    hCV2961253 rs2190600 hCV2961270 rs9327555 0.9 1
    hCV2961253 rs2190600 hCV2961278 rs7446891 0.9 1
    hCV2961253 rs2190600 hCV2961280 rs10520072 0.9 1
    hCV2961253 rs2190600 hCV2961282 rs917295 0.9 1
    hCV2961253 rs2190600 hCV2961284 rs10054055 0.9 0.9616
    hCV2961253 rs2190600 hCV2961296 rs10051148 0.9 0.9623
    hCV2961253 rs2190600 hCV2961297 rs2158961 0.9 0.9634
    hCV2961253 rs2190600 hCV2961306 rs264129 0.9 0.9232
    hCV2961253 rs2190600 hCV30621656 rs10478919 0.9 0.927
    hCV2961253 rs2190600 hCV31237567 rs11749272 0.9 0.927
    hCV2961253 rs2190600 hCV346713 rs1990023 0.9 0.9232
    hCV2961253 rs2190600 hCV546489 rs264122 0.9 0.9616
    hCV2961253 rs2190600 hCV8932829 rs1116596 0.9 0.927
    hCV2961259 rs11242023 hCV11819780 rs12153185 0.9 0.9571
    hCV2961259 rs11242023 hCV11819782 rs12719415 0.9 0.9621
    hCV2961259 rs11242023 hCV26478744 rs2016194 0.9 0.9587
    hCV2961259 rs11242023 hCV26478745 rs2108426 0.9 0.9557
    hCV2961259 rs11242023 hCV26478747 rs2190598 0.9 0.9604
    hCV2961259 rs11242023 hCV27996154 rs4836502 0.9 0.9621
    hCV2961259 rs11242023 hCV2961244 rs2418548 0.9 0.9571
    hCV2961259 rs11242023 hCV2961250 rs4836507 0.9 0.9621
    hCV2961259 rs11242023 hCV2961252 rs10067895 0.9 0.9621
    hCV2961259 rs11242023 hCV2961253 rs2190600 0.9 0.9621
    hCV2961259 rs11242023 hCV2961260 rs11242022 0.9 0.9785
    hCV2961259 rs11242023 hCV2961261 rs11242021 0.9 0.9613
    hCV2961259 rs11242023 hCV2961267 rs1476714 0.9 0.9592
    hCV2961259 rs11242023 hCV2961268 rs2108425 0.9 0.9621
    hCV2961259 rs11242023 hCV2961269 rs2158958 0.9 0.9621
    hCV2961259 rs11242023 hCV2961270 rs9327555 0.9 0.9621
    hCV2961259 rs11242023 hCV2961278 rs7446891 0.9 0.9621
    hCV2961259 rs11242023 hCV2961280 rs10520072 0.9 0.9621
    hCV2961259 rs11242023 hCV2961282 rs917295 0.9 0.9621
    hCV2961259 rs11242023 hCV2961284 rs10054055 0.9 0.9573
    hCV2961259 rs11242023 hCV2961296 rs10051148 0.9 0.9236
    hCV2961259 rs11242023 hCV2961297 rs2158961 0.9 0.9252
    hCV2961259 rs11242023 hCV2961306 rs264129 0.9 0.9358
    hCV2961259 rs11242023 hCV346713 rs1990023 0.9 0.9358
    hCV2961259 rs11242023 hCV546489 rs264122 0.9 0.9573
    hCV2961260 rs11242022 hCV11819780 rs12153185 0.9 0.9785
    hCV2961260 rs11242022 hCV11819782 rs12719415 0.9 1
    hCV2961260 rs11242022 hCV2575318 rs7711358 0.9 0.9232
    hCV2961260 rs11242022 hCV2575336 rs2418541 0.9 0.9232
    hCV2961260 rs11242022 hCV2575340 rs11242020 0.9 0.9232
    hCV2961260 rs11242022 hCV26478744 rs2016194 0.9 1
    hCV2961260 rs11242022 hCV26478745 rs2108426 0.9 1
    hCV2961260 rs11242022 hCV26478747 rs2190598 0.9 1
    hCV2961260 rs11242022 hCV26478763 rs2418542 0.9 0.9232
    hCV2961260 rs11242022 hCV27996154 rs4836502 0.9 1
    hCV2961260 rs11242022 hCV2961244 rs2418548 0.9 0.9785
    hCV2961260 rs11242022 hCV2961250 rs4836507 0.9 1
    hCV2961260 rs11242022 hCV2961252 rs10067895 0.9 1
    hCV2961260 rs11242022 hCV2961253 rs2190600 0.9 1
    hCV2961260 rs11242022 hCV2961259 rs11242023 0.9 0.9785
    hCV2961260 rs11242022 hCV2961261 rs11242021 0.9 1
    hCV2961260 rs11242022 hCV2961267 rs1476714 0.9 1
    hCV2961260 rs11242022 hCV2961268 rs2108425 0.9 1
    hCV2961260 rs11242022 hCV2961269 rs2158958 0.9 1
    hCV2961260 rs11242022 hCV2961270 rs9327555 0.9 1
    hCV2961260 rs11242022 hCV2961278 rs7446891 0.9 1
    hCV2961260 rs11242022 hCV2961280 rs10520072 0.9 1
    hCV2961260 rs11242022 hCV2961282 rs917295 0.9 1
    hCV2961260 rs11242022 hCV2961284 rs10054055 0.9 0.9783
    hCV2961260 rs11242022 hCV2961296 rs10051148 0.9 0.9608
    hCV2961260 rs11242022 hCV2961297 rs2158961 0.9 0.9616
    hCV2961260 rs11242022 hCV2961306 rs264129 0.9 0.9567
    hCV2961260 rs11242022 hCV30621656 rs10478919 0.9 0.9232
    hCV2961260 rs11242022 hCV31237567 rs11749272 0.9 0.9232
    hCV2961260 rs11242022 hCV346713 rs1990023 0.9 0.9567
    hCV2961260 rs11242022 hCV546489 rs264122 0.9 0.9783
    hCV2961260 rs11242022 hCV8932829 rs1116596 0.9 0.9232
    hCV2961261 rs11242021 hCV11819780 rs12153185 0.9 1
    hCV2961261 rs11242021 hCV11819782 rs12719415 0.9 1
    hCV2961261 rs11242021 hCV2575318 rs7711358 0.9 0.9255
    hCV2961261 rs11242021 hCV2575336 rs2418541 0.9 0.9255
    hCV2961261 rs11242021 hCV2575340 rs11242020 0.9 0.9255
    hCV2961261 rs11242021 hCV26478744 rs2016194 0.9 0.9198
    hCV2961261 rs11242021 hCV26478745 rs2108426 0.9 0.9135
    hCV2961261 rs11242021 hCV26478747 rs2190598 0.9 1
    hCV2961261 rs11242021 hCV26478763 rs2418542 0.9 0.9255
    hCV2961261 rs11242021 hCV27996154 rs4836502 0.9 1
    hCV2961261 rs11242021 hCV2961244 rs2418548 0.9 1
    hCV2961261 rs11242021 hCV2961250 rs4836507 0.9 1
    hCV2961261 rs11242021 hCV2961252 rs10067895 0.9 1
    hCV2961261 rs11242021 hCV2961253 rs2190600 0.9 1
    hCV2961261 rs11242021 hCV2961259 rs11242023 0.9 0.9613
    hCV2961261 rs11242021 hCV2961260 rs11242022 0.9 1
    hCV2961261 rs11242021 hCV2961267 rs1476714 0.9 1
    hCV2961261 rs11242021 hCV2961268 rs2108425 0.9 1
    hCV2961261 rs11242021 hCV2961269 rs2158958 0.9 1
    hCV2961261 rs11242021 hCV2961270 rs9327555 0.9 1
    hCV2961261 rs11242021 hCV2961278 rs7446891 0.9 1
    hCV2961261 rs11242021 hCV2961280 rs10520072 0.9 1
    hCV2961261 rs11242021 hCV2961282 rs917295 0.9 1
    hCV2961261 rs11242021 hCV2961284 rs10054055 0.9 0.9608
    hCV2961261 rs11242021 hCV2961296 rs10051148 0.9 0.9615
    hCV2961261 rs11242021 hCV2961297 rs2158961 0.9 0.9627
    hCV2961261 rs11242021 hCV2961306 rs264129 0.9 0.9216
    hCV2961261 rs11242021 hCV30621656 rs10478919 0.9 0.9255
    hCV2961261 rs11242021 hCV31237567 rs11749272 0.9 0.9255
    hCV2961261 rs11242021 hCV346713 rs1990023 0.9 0.9216
    hCV2961261 rs11242021 hCV546489 rs264122 0.9 0.9608
    hCV2961261 rs11242021 hCV8932829 rs1116596 0.9 0.9255
    hCV2961267 rs1476714 hCV11819780 rs12153185 0.9 1
    hCV2961267 rs1476714 hCV11819782 rs12719415 0.9 1
    hCV2961267 rs1476714 hCV2575318 rs7711358 0.9 0.9607
    hCV2961267 rs1476714 hCV2575336 rs2418541 0.9 0.9607
    hCV2961267 rs1476714 hCV2575340 rs11242020 0.9 0.9607
    hCV2961267 rs1476714 hCV26478744 rs2016194 0.9 0.9152
    hCV2961267 rs1476714 hCV26478745 rs2108426 0.9 0.9081
    hCV2961267 rs1476714 hCV26478747 rs2190598 0.9 1
    hCV2961267 rs1476714 hCV26478763 rs2418542 0.9 0.9607
    hCV2961267 rs1476714 hCV27996154 rs4836502 0.9 1
    hCV2961267 rs1476714 hCV2961244 rs2418548 0.9 1
    hCV2961267 rs1476714 hCV2961250 rs4836507 0.9 1
    hCV2961267 rs1476714 hCV2961252 rs10067895 0.9 1
    hCV2961267 rs1476714 hCV2961253 rs2190600 0.9 1
    hCV2961267 rs1476714 hCV2961259 rs11242023 0.9 0.9592
    hCV2961267 rs1476714 hCV2961260 rs11242022 0.9 1
    hCV2961267 rs1476714 hCV2961261 rs11242021 0.9 1
    hCV2961267 rs1476714 hCV2961268 rs2108425 0.9 1
    hCV2961267 rs1476714 hCV2961269 rs2158958 0.9 1
    hCV2961267 rs1476714 hCV2961270 rs9327555 0.9 1
    hCV2961267 rs1476714 hCV2961278 rs7446891 0.9 1
    hCV2961267 rs1476714 hCV2961280 rs10520072 0.9 1
    hCV2961267 rs1476714 hCV2961282 rs917295 0.9 1
    hCV2961267 rs1476714 hCV2961284 rs10054055 0.9 0.9587
    hCV2961267 rs1476714 hCV2961296 rs10051148 0.9 0.9595
    hCV2961267 rs1476714 hCV2961297 rs2158961 0.9 0.9607
    hCV2961267 rs1476714 hCV2961306 rs264129 0.9 0.9172
    hCV2961267 rs1476714 hCV30621656 rs10478919 0.9 0.9607
    hCV2961267 rs1476714 hCV31237567 rs11749272 0.9 0.9607
    hCV2961267 rs1476714 hCV346713 rs1990023 0.9 0.9587
    hCV2961267 rs1476714 hCV546489 rs264122 0.9 0.9587
    hCV2961267 rs1476714 hCV8932829 rs1116596 0.9 0.9607
    hCV2961268 rs2108425 hCV11819780 rs12153185 0.9 1
    hCV2961268 rs2108425 hCV11819782 rs12719415 0.9 1
    hCV2961268 rs2108425 hCV2575318 rs7711358 0.9 0.927
    hCV2961268 rs2108425 hCV2575336 rs2418541 0.9 0.927
    hCV2961268 rs2108425 hCV2575340 rs11242020 0.9 0.927
    hCV2961268 rs2108425 hCV26478744 rs2016194 0.9 0.9198
    hCV2961268 rs2108425 hCV26478745 rs2108426 0.9 0.9135
    hCV2961268 rs2108425 hCV26478747 rs2190598 0.9 1
    hCV2961268 rs2108425 hCV26478763 rs2418542 0.9 0.927
    hCV2961268 rs2108425 hCV27996154 rs4836502 0.9 1
    hCV2961268 rs2108425 hCV2961244 rs2418548 0.9 1
    hCV2961268 rs2108425 hCV2961250 rs4836507 0.9 1
    hCV2961268 rs2108425 hCV2961252 rs10067895 0.9 1
    hCV2961268 rs2108425 hCV2961253 rs2190600 0.9 1
    hCV2961268 rs2108425 hCV2961259 rs11242023 0.9 0.9621
    hCV2961268 rs2108425 hCV2961260 rs11242022 0.9 1
    hCV2961268 rs2108425 hCV2961261 rs11242021 0.9 1
    hCV2961268 rs2108425 hCV2961267 rs1476714 0.9 1
    hCV2961268 rs2108425 hCV2961269 rs2158958 0.9 1
    hCV2961268 rs2108425 hCV2961270 rs9327555 0.9 1
    hCV2961268 rs2108425 hCV2961278 rs7446891 0.9 1
    hCV2961268 rs2108425 hCV2961280 rs10520072 0.9 1
    hCV2961268 rs2108425 hCV2961282 rs917295 0.9 1
    hCV2961268 rs2108425 hCV2961284 rs10054055 0.9 0.9616
    hCV2961268 rs2108425 hCV2961296 rs10051148 0.9 0.9623
    hCV2961268 rs2108425 hCV2961297 rs2158961 0.9 0.9634
    hCV2961268 rs2108425 hCV2961306 rs264129 0.9 0.9232
    hCV2961268 rs2108425 hCV30621656 rs10478919 0.9 0.927
    hCV2961268 rs2108425 hCV31237567 rs11749272 0.9 0.927
    hCV2961268 rs2108425 hCV346713 rs1990023 0.9 0.9232
    hCV2961268 rs2108425 hCV546489 rs264122 0.9 0.9616
    hCV2961268 rs2108425 hCV8932829 rs1116596 0.9 0.927
    hCV2961269 rs2158958 hCV11819780 rs12153185 0.9 1
    hCV2961269 rs2158958 hCV11819782 rs12719415 0.9 1
    hCV2961269 rs2158958 hCV2575318 rs7711358 0.9 0.927
    hCV2961269 rs2158958 hCV2575336 rs2418541 0.9 0.927
    hCV2961269 rs2158958 hCV2575340 rs11242020 0.9 0.927
    hCV2961269 rs2158958 hCV26478744 rs2016194 0.9 0.9198
    hCV2961269 rs2158958 hCV26478745 rs2108426 0.9 0.9135
    hCV2961269 rs2158958 hCV26478747 rs2190598 0.9 1
    hCV2961269 rs2158958 hCV26478763 rs2418542 0.9 0.927
    hCV2961269 rs2158958 hCV27996154 rs4836502 0.9 1
    hCV2961269 rs2158958 hCV2961244 rs2418548 0.9 1
    hCV2961269 rs2158958 hCV2961250 rs4836507 0.9 1
    hCV2961269 rs2158958 hCV2961252 rs10067895 0.9 1
    hCV2961269 rs2158958 hCV2961253 rs2190600 0.9 1
    hCV2961269 rs2158958 hCV2961259 rs11242023 0.9 0.9621
    hCV2961269 rs2158958 hCV2961260 rs11242022 0.9 1
    hCV2961269 rs2158958 hCV2961261 rs11242021 0.9 1
    hCV2961269 rs2158958 hCV2961267 rs1476714 0.9 1
    hCV2961269 rs2158958 hCV2961268 rs2108425 0.9 1
    hCV2961269 rs2158958 hCV2961270 rs9327555 0.9 1
    hCV2961269 rs2158958 hCV2961278 rs7446891 0.9 1
    hCV2961269 rs2158958 hCV2961280 rs10520072 0.9 1
    hCV2961269 rs2158958 hCV2961282 rs917295 0.9 1
    hCV2961269 rs2158958 hCV2961284 rs10054055 0.9 0.9616
    hCV2961269 rs2158958 hCV2961296 rs10051148 0.9 0.9623
    hCV2961269 rs2158958 hCV2961297 rs2158961 0.9 0.9634
    hCV2961269 rs2158958 hCV2961306 rs264129 0.9 0.9232
    hCV2961269 rs2158958 hCV30621656 rs10478919 0.9 0.927
    hCV2961269 rs2158958 hCV31237567 rs11749272 0.9 0.927
    hCV2961269 rs2158958 hCV346713 rs1990023 0.9 0.9232
    hCV2961269 rs2158958 hCV546489 rs264122 0.9 0.9616
    hCV2961269 rs2158958 hCV8932829 rs1116596 0.9 0.927
    hCV2961270 rs9327555 hCV11819780 rs12153185 0.9 1
    hCV2961270 rs9327555 hCV11819782 rs12719415 0.9 1
    hCV2961270 rs9327555 hCV2575318 rs7711358 0.9 0.927
    hCV2961270 rs9327555 hCV2575336 rs2418541 0.9 0.927
    hCV2961270 rs9327555 hCV2575340 rs11242020 0.9 0.927
    hCV2961270 rs9327555 hCV26478744 rs2016194 0.9 0.9198
    hCV2961270 rs9327555 hCV26478745 rs2108426 0.9 0.9135
    hCV2961270 rs9327555 hCV26478747 rs2190598 0.9 1
    hCV2961270 rs9327555 hCV26478763 rs2418542 0.9 0.927
    hCV2961270 rs9327555 hCV27996154 rs4836502 0.9 1
    hCV2961270 rs9327555 hCV2961244 rs2418548 0.9 1
    hCV2961270 rs9327555 hCV2961250 rs4836507 0.9 1
    hCV2961270 rs9327555 hCV2961252 rs10067895 0.9 1
    hCV2961270 rs9327555 hCV2961253 rs2190600 0.9 1
    hCV2961270 rs9327555 hCV2961259 rs11242023 0.9 0.9621
    hCV2961270 rs9327555 hCV2961260 rs11242022 0.9 1
    hCV2961270 rs9327555 hCV2961261 rs11242021 0.9 1
    hCV2961270 rs9327555 hCV2961267 rs1476714 0.9 1
    hCV2961270 rs9327555 hCV2961268 rs2108425 0.9 1
    hCV2961270 rs9327555 hCV2961269 rs2158958 0.9 1
    hCV2961270 rs9327555 hCV2961278 rs7446891 0.9 1
    hCV2961270 rs9327555 hCV2961280 rs10520072 0.9 1
    hCV2961270 rs9327555 hCV2961282 rs917295 0.9 1
    hCV2961270 rs9327555 hCV2961284 rs10054055 0.9 0.9616
    hCV2961270 rs9327555 hCV2961296 rs10051148 0.9 0.9623
    hCV2961270 rs9327555 hCV2961297 rs2158961 0.9 0.9634
    hCV2961270 rs9327555 hCV2961306 rs264129 0.9 0.9232
    hCV2961270 rs9327555 hCV30621656 rs10478919 0.9 0.927
    hCV2961270 rs9327555 hCV31237567 rs11749272 0.9 0.927
    hCV2961270 rs9327555 hCV346713 rs1990023 0.9 0.9232
    hCV2961270 rs9327555 hCV546489 rs264122 0.9 0.9616
    hCV2961270 rs9327555 hCV8932829 rs1116596 0.9 0.927
    hCV2961278 rs7446891 hCV11819780 rs12153185 0.9 1
    hCV2961278 rs7446891 hCV11819782 rs12719415 0.9 1
    hCV2961278 rs7446891 hCV2575318 rs7711358 0.9 0.927
    hCV2961278 rs7446891 hCV2575336 rs2418541 0.9 0.927
    hCV2961278 rs7446891 hCV2575340 rs11242020 0.9 0.927
    hCV2961278 rs7446891 hCV26478744 rs2016194 0.9 0.9198
    hCV2961278 rs7446891 hCV26478745 rs2108426 0.9 0.9135
    hCV2961278 rs7446891 hCV26478747 rs2190598 0.9 1
    hCV2961278 rs7446891 hCV26478763 rs2418542 0.9 0.927
    hCV2961278 rs7446891 hCV27996154 rs4836502 0.9 1
    hCV2961278 rs7446891 hCV2961244 rs2418548 0.9 1
    hCV2961278 rs7446891 hCV2961250 rs4836507 0.9 1
    hCV2961278 rs7446891 hCV2961252 rs10067895 0.9 1
    hCV2961278 rs7446891 hCV2961253 rs2190600 0.9 1
    hCV2961278 rs7446891 hCV2961259 rs11242023 0.9 0.9621
    hCV2961278 rs7446891 hCV2961260 rs11242022 0.9 1
    hCV2961278 rs7446891 hCV2961261 rs11242021 0.9 1
    hCV2961278 rs7446891 hCV2961267 rs1476714 0.9 1
    hCV2961278 rs7446891 hCV2961268 rs2108425 0.9 1
    hCV2961278 rs7446891 hCV2961269 rs2158958 0.9 1
    hCV2961278 rs7446891 hCV2961270 rs9327555 0.9 1
    hCV2961278 rs7446891 hCV2961280 rs10520072 0.9 1
    hCV2961278 rs7446891 hCV2961282 rs917295 0.9 1
    hCV2961278 rs7446891 hCV2961284 rs10054055 0.9 0.9616
    hCV2961278 rs7446891 hCV2961296 rs10051148 0.9 0.9623
    hCV2961278 rs7446891 hCV2961297 rs2158961 0.9 0.9634
    hCV2961278 rs7446891 hCV2961306 rs264129 0.9 0.9232
    hCV2961278 rs7446891 hCV30621656 rs10478919 0.9 0.927
    hCV2961278 rs7446891 hCV31237567 rs11749272 0.9 0.927
    hCV2961278 rs7446891 hCV346713 rs1990023 0.9 0.9232
    hCV2961278 rs7446891 hCV546489 rs264122 0.9 0.9616
    hCV2961278 rs7446891 hCV8932829 rs1116596 0.9 0.927
    hCV2961280 rs10520072 hCV11819780 rs12153185 0.9 1
    hCV2961280 rs10520072 hCV11819782 rs12719415 0.9 1
    hCV2961280 rs10520072 hCV2575318 rs7711358 0.9 0.927
    hCV2961280 rs10520072 hCV2575336 rs2418541 0.9 0.927
    hCV2961280 rs10520072 hCV2575340 rs11242020 0.9 0.927
    hCV2961280 rs10520072 hCV26478744 rs2016194 0.9 0.9198
    hCV2961280 rs10520072 hCV26478745 rs2108426 0.9 0.9135
    hCV2961280 rs10520072 hCV26478747 rs2190598 0.9 1
    hCV2961280 rs10520072 hCV26478763 rs2418542 0.9 0.927
    hCV2961280 rs10520072 hCV27996154 rs4836502 0.9 1
    hCV2961280 rs10520072 hCV2961244 rs2418548 0.9 1
    hCV2961280 rs10520072 hCV2961250 rs4836507 0.9 1
    hCV2961280 rs10520072 hCV2961252 rs10067895 0.9 1
    hCV2961280 rs10520072 hCV2961253 rs2190600 0.9 1
    hCV2961280 rs10520072 hCV2961259 rs11242023 0.9 0.9621
    hCV2961280 rs10520072 hCV2961260 rs11242022 0.9 1
    hCV2961280 rs10520072 hCV2961261 rs11242021 0.9 1
    hCV2961280 rs10520072 hCV2961267 rs1476714 0.9 1
    hCV2961280 rs10520072 hCV2961268 rs2108425 0.9 1
    hCV2961280 rs10520072 hCV2961269 rs2158958 0.9 1
    hCV2961280 rs10520072 hCV2961270 rs9327555 0.9 1
    hCV2961280 rs10520072 hCV2961278 rs7446891 0.9 1
    hCV2961280 rs10520072 hCV2961282 rs917295 0.9 1
    hCV2961280 rs10520072 hCV2961284 rs10054055 0.9 0.9616
    hCV2961280 rs10520072 hCV2961296 rs10051148 0.9 0.9623
    hCV2961280 rs10520072 hCV2961297 rs2158961 0.9 0.9634
    hCV2961280 rs10520072 hCV2961306 rs264129 0.9 0.9232
    hCV2961280 rs10520072 hCV30621656 rs10478919 0.9 0.927
    hCV2961280 rs10520072 hCV31237567 rs11749272 0.9 0.927
    hCV2961280 rs10520072 hCV346713 rs1990023 0.9 0.9232
    hCV2961280 rs10520072 hCV546489 rs264122 0.9 0.9616
    hCV2961280 rs10520072 hCV8932829 rs1116596 0.9 0.927
    hCV2961282 rs917295 hCV11819780 rs12153185 0.9 1
    hCV2961282 rs917295 hCV11819782 rs12719415 0.9 1
    hCV2961282 rs917295 hCV2575318 rs7711358 0.9 0.927
    hCV2961282 rs917295 hCV2575336 rs2418541 0.9 0.927
    hCV2961282 rs917295 hCV2575340 rs11242020 0.9 0.927
    hCV2961282 rs917295 hCV26478744 rs2016194 0.9 0.9197
    hCV2961282 rs917295 hCV26478745 rs2108426 0.9 0.9134
    hCV2961282 rs917295 hCV26478747 rs2190598 0.9 1
    hCV2961282 rs917295 hCV26478763 rs2418542 0.9 0.927
    hCV2961282 rs917295 hCV27996154 rs4836502 0.9 1
    hCV2961282 rs917295 hCV2961244 rs2418548 0.9 1
    hCV2961282 rs917295 hCV2961250 rs4836507 0.9 1
    hCV2961282 rs917295 hCV2961252 rs10067895 0.9 1
    hCV2961282 rs917295 hCV2961253 rs2190600 0.9 1
    hCV2961282 rs917295 hCV2961259 rs11242023 0.9 0.9621
    hCV2961282 rs917295 hCV2961260 rs11242022 0.9 1
    hCV2961282 rs917295 hCV2961261 rs11242021 0.9 1
    hCV2961282 rs917295 hCV2961267 rs1476714 0.9 1
    hCV2961282 rs917295 hCV2961268 rs2108425 0.9 1
    hCV2961282 rs917295 hCV2961269 rs2158958 0.9 1
    hCV2961282 rs917295 hCV2961270 rs9327555 0.9 1
    hCV2961282 rs917295 hCV2961278 rs7446891 0.9 1
    hCV2961282 rs917295 hCV2961280 rs10520072 0.9 1
    hCV2961282 rs917295 hCV2961284 rs10054055 0.9 0.9616
    hCV2961282 rs917295 hCV2961296 rs10051148 0.9 0.9623
    hCV2961282 rs917295 hCV2961297 rs2158961 0.9 0.9634
    hCV2961282 rs917295 hCV2961306 rs264129 0.9 0.9232
    hCV2961282 rs917295 hCV30621656 rs10478919 0.9 0.927
    hCV2961282 rs917295 hCV31237567 rs11749272 0.9 0.927
    hCV2961282 rs917295 hCV346713 rs1990023 0.9 0.9232
    hCV2961282 rs917295 hCV546489 rs264122 0.9 0.9616
    hCV2961282 rs917295 hCV8932829 rs1116596 0.9 0.927
    hCV2961284 rs10054055 hCV11819780 rs12153185 0.9 0.9573
    hCV2961284 rs10054055 hCV11819782 rs12719415 0.9 0.9616
    hCV2961284 rs10054055 hCV2575318 rs7711358 0.9 0.9616
    hCV2961284 rs10054055 hCV2575336 rs2418541 0.9 0.9616
    hCV2961284 rs10054055 hCV2575340 rs11242020 0.9 0.9616
    hCV2961284 rs10054055 hCV26478744 rs2016194 0.9 0.9581
    hCV2961284 rs10054055 hCV26478745 rs2108426 0.9 1
    hCV2961284 rs10054055 hCV26478747 rs2190598 0.9 0.96
    hCV2961284 rs10054055 hCV26478763 rs2418542 0.9 0.9616
    hCV2961284 rs10054055 hCV27996154 rs4836502 0.9 0.9616
    hCV2961284 rs10054055 hCV2961244 rs2418548 0.9 0.9573
    hCV2961284 rs10054055 hCV2961250 rs4836507 0.9 0.9616
    hCV2961284 rs10054055 hCV2961252 rs10067895 0.9 0.9616
    hCV2961284 rs10054055 hCV2961253 rs2190600 0.9 0.9616
    hCV2961284 rs10054055 hCV2961259 rs11242023 0.9 0.9573
    hCV2961284 rs10054055 hCV2961260 rs11242022 0.9 0.9783
    hCV2961284 rs10054055 hCV2961261 rs11242021 0.9 0.9608
    hCV2961284 rs10054055 hCV2961267 rs1476714 0.9 0.9587
    hCV2961284 rs10054055 hCV2961268 rs2108425 0.9 0.9616
    hCV2961284 rs10054055 hCV2961269 rs2158958 0.9 0.9616
    hCV2961284 rs10054055 hCV2961270 rs9327555 0.9 0.9616
    hCV2961284 rs10054055 hCV2961278 rs7446891 0.9 0.9616
    hCV2961284 rs10054055 hCV2961280 rs10520072 0.9 0.9616
    hCV2961284 rs10054055 hCV2961282 rs917295 0.9 0.9616
    hCV2961284 rs10054055 hCV2961296 rs10051148 0.9 1
    hCV2961284 rs10054055 hCV2961297 rs2158961 0.9 1
    hCV2961284 rs10054055 hCV2961306 rs264129 0.9 0.9783
    hCV2961284 rs10054055 hCV29666186 rs6871041 0.9 0.9189
    hCV2961284 rs10054055 hCV30621656 rs10478919 0.9 0.9616
    hCV2961284 rs10054055 hCV31237567 rs11749272 0.9 0.9616
    hCV2961284 rs10054055 hCV346713 rs1990023 0.9 0.9783
    hCV2961284 rs10054055 hCV546489 rs264122 0.9 1
    hCV2961284 rs10054055 hCV8932829 rs1116596 0.9 0.9616
    hCV2961296 rs10051148 hCV11819780 rs12153185 0.9 0.9608
    hCV2961296 rs10051148 hCV11819782 rs12719415 0.9 0.9623
    hCV2961296 rs10051148 hCV2575318 rs7711358 0.9 0.9623
    hCV2961296 rs10051148 hCV2575336 rs2418541 0.9 0.9623
    hCV2961296 rs10051148 hCV2575340 rs11242020 0.9 0.9623
    hCV2961296 rs10051148 hCV26478744 rs2016194 0.9 0.9589
    hCV2961296 rs10051148 hCV26478745 rs2108426 0.9 1
    hCV2961296 rs10051148 hCV26478747 rs2190598 0.9 0.9615
    hCV2961296 rs10051148 hCV26478763 rs2418542 0.9 0.9623
    hCV2961296 rs10051148 hCV27996154 rs4836502 0.9 0.9623
    hCV2961296 rs10051148 hCV2961244 rs2418548 0.9 0.9608
    hCV2961296 rs10051148 hCV2961250 rs4836507 0.9 0.9623
    hCV2961296 rs10051148 hCV2961252 rs10067895 0.9 0.9623
    hCV2961296 rs10051148 hCV2961253 rs2190600 0.9 0.9623
    hCV2961296 rs10051148 hCV2961259 rs11242023 0.9 0.9236
    hCV2961296 rs10051148 hCV2961260 rs11242022 0.9 0.9608
    hCV2961296 rs10051148 hCV2961261 rs11242021 0.9 0.9615
    hCV2961296 rs10051148 hCV2961267 rs1476714 0.9 0.9595
    hCV2961296 rs10051148 hCV2961268 rs2108425 0.9 0.9623
    hCV2961296 rs10051148 hCV2961269 rs2158958 0.9 0.9623
    hCV2961296 rs10051148 hCV2961270 rs9327555 0.9 0.9623
    hCV2961296 rs10051148 hCV2961278 rs7446891 0.9 0.9623
    hCV2961296 rs10051148 hCV2961280 rs10520072 0.9 0.9623
    hCV2961296 rs10051148 hCV2961282 rs917295 0.9 0.9623
    hCV2961296 rs10051148 hCV2961284 rs10054055 0.9 1
    hCV2961296 rs10051148 hCV2961297 rs2158961 0.9 1
    hCV2961296 rs10051148 hCV2961306 rs264129 0.9 0.9608
    hCV2961296 rs10051148 hCV29666186 rs6871041 0.9 0.9202
    hCV2961296 rs10051148 hCV30621656 rs10478919 0.9 0.9623
    hCV2961296 rs10051148 hCV31237567 rs11749272 0.9 0.9623
    hCV2961296 rs10051148 hCV346713 rs1990023 0.9 0.9608
    hCV2961296 rs10051148 hCV546489 rs264122 0.9 1
    hCV2961296 rs10051148 hCV8932829 rs1116596 0.9 0.9623
    hCV2961297 rs2158961 hCV11819780 rs12153185 0.9 0.9616
    hCV2961297 rs2158961 hCV11819782 rs12719415 0.9 0.9634
    hCV2961297 rs2158961 hCV2575318 rs7711358 0.9 0.9634
    hCV2961297 rs2158961 hCV2575336 rs2418541 0.9 0.9634
    hCV2961297 rs2158961 hCV2575340 rs11242020 0.9 0.9634
    hCV2961297 rs2158961 hCV26478745 rs2108426 0.9 0.9135
    hCV2961297 rs2158961 hCV26478747 rs2190598 0.9 0.9619
    hCV2961297 rs2158961 hCV26478763 rs2418542 0.9 0.9634
    hCV2961297 rs2158961 hCV27996154 rs4836502 0.9 0.9634
    hCV2961297 rs2158961 hCV2961244 rs2418548 0.9 0.9616
    hCV2961297 rs2158961 hCV2961250 rs4836507 0.9 0.9634
    hCV2961297 rs2158961 hCV2961252 rs10067895 0.9 0.9634
    hCV2961297 rs2158961 hCV2961253 rs2190600 0.9 0.9634
    hCV2961297 rs2158961 hCV2961259 rs11242023 0.9 0.9252
    hCV2961297 rs2158961 hCV2961260 rs11242022 0.9 0.9616
    hCV2961297 rs2158961 hCV2961261 rs11242021 0.9 0.9627
    hCV2961297 rs2158961 hCV2961267 rs1476714 0.9 0.9607
    hCV2961297 rs2158961 hCV2961268 rs2108425 0.9 0.9634
    hCV2961297 rs2158961 hCV2961269 rs2158958 0.9 0.9634
    hCV2961297 rs2158961 hCV2961270 rs9327555 0.9 0.9634
    hCV2961297 rs2158961 hCV2961278 rs7446891 0.9 0.9634
    hCV2961297 rs2158961 hCV2961280 rs10520072 0.9 0.9634
    hCV2961297 rs2158961 hCV2961282 rs917295 0.9 0.9634
    hCV2961297 rs2158961 hCV2961284 rs10054055 0.9 1
    hCV2961297 rs2158961 hCV2961296 rs10051148 0.9 1
    hCV2961297 rs2158961 hCV2961306 rs264129 0.9 0.9616
    hCV2961297 rs2158961 hCV29666186 rs6871041 0.9 0.9226
    hCV2961297 rs2158961 hCV30621656 rs10478919 0.9 0.9634
    hCV2961297 rs2158961 hCV31237567 rs11749272 0.9 0.9634
    hCV2961297 rs2158961 hCV346713 rs1990023 0.9 0.9616
    hCV2961297 rs2158961 hCV546489 rs264122 0.9 1
    hCV2961297 rs2158961 hCV8932829 rs1116596 0.9 0.9634
    hCV2961306 rs264129 hCV11819780 rs12153185 0.9 0.9358
    hCV2961306 rs264129 hCV11819782 rs12719415 0.9 0.9232
    hCV2961306 rs264129 hCV2575318 rs7711358 0.9 0.9232
    hCV2961306 rs264129 hCV2575336 rs2418541 0.9 0.9232
    hCV2961306 rs264129 hCV2575340 rs11242020 0.9 0.9232
    hCV2961306 rs264129 hCV26478744 rs2016194 0.9 0.9162
    hCV2961306 rs264129 hCV26478745 rs2108426 0.9 0.9557
    hCV2961306 rs264129 hCV26478747 rs2190598 0.9 0.9198
    hCV2961306 rs264129 hCV26478763 rs2418542 0.9 0.9232
    hCV2961306 rs264129 hCV27996154 rs4836502 0.9 0.9232
    hCV2961306 rs264129 hCV2961244 rs2418548 0.9 0.9358
    hCV2961306 rs264129 hCV2961250 rs4836507 0.9 0.9232
    hCV2961306 rs264129 hCV2961252 rs10067895 0.9 0.9232
    hCV2961306 rs264129 hCV2961253 rs2190600 0.9 0.9232
    hCV2961306 rs264129 hCV2961259 rs11242023 0.9 0.9358
    hCV2961306 rs264129 hCV2961260 rs11242022 0.9 0.9567
    hCV2961306 rs264129 hCV2961261 rs11242021 0.9 0.9216
    hCV2961306 rs264129 hCV2961267 rs1476714 0.9 0.9172
    hCV2961306 rs264129 hCV2961268 rs2108425 0.9 0.9232
    hCV2961306 rs264129 hCV2961269 rs2158958 0.9 0.9232
    hCV2961306 rs264129 hCV2961270 rs9327555 0.9 0.9232
    hCV2961306 rs264129 hCV2961278 rs7446891 0.9 0.9232
    hCV2961306 rs264129 hCV2961280 rs10520072 0.9 0.9232
    hCV2961306 rs264129 hCV2961282 rs917295 0.9 0.9232
    hCV2961306 rs264129 hCV2961284 rs10054055 0.9 0.9783
    hCV2961306 rs264129 hCV2961296 rs10051148 0.9 0.9608
    hCV2961306 rs264129 hCV2961297 rs2158961 0.9 0.9616
    hCV2961306 rs264129 hCV30621656 rs10478919 0.9 0.9232
    hCV2961306 rs264129 hCV31237567 rs11749272 0.9 0.9232
    hCV2961306 rs264129 hCV346713 rs1990023 0.9 0.9567
    hCV2961306 rs264129 hCV546489 rs264122 0.9 0.9783
    hCV2961306 rs264129 hCV8932829 rs1116596 0.9 0.9232
    hCV29666186 rs6871041 hCV2961284 rs10054055 0.9 0.9189
    hCV29666186 rs6871041 hCV2961296 rs10051148 0.9 0.9202
    hCV29666186 rs6871041 hCV2961297 rs2158961 0.9 0.9226
    hCV29666186 rs6871041 hCV546489 rs264122 0.9 0.9189
    hCV29840965 rs6040644 hCV2529198 rs742827 0.9 0.9596
    hCV29840965 rs6040644 hCV2529202 rs6040667 0.9 1
    hCV29840965 rs6040644 hCV2529211 rs17189710 0.9 1
    hCV29840965 rs6040644 hCV2529224 rs2327412 0.9 1
    hCV29840965 rs6040644 hCV2529230 rs4444612 0.9 1
    hCV29840965 rs6040644 hCV2529231 rs4315598 0.9 1
    hCV29840965 rs6040644 hCV2529239 rs6040638 0.9 1
    hCV29840965 rs6040644 hCV2529241 rs6134243 0.9 1
    hCV29840965 rs6040644 hCV2529246 rs6040619 0.9 1
    hCV29840965 rs6040644 hCV27367681 rs2876227 0.9 0.9616
    hCV29840965 rs6040644 hCV27367708 rs1009748 0.9 1
    hCV29840965 rs6040644 hCV30057061 rs6033138 0.9 1
    hCV29840965 rs6040644 hCV30093270 rs6040625 0.9 1
    hCV29840965 rs6040644 hCV30129243 rs6040636 0.9 1
    hCV29840965 rs6040644 hCV30218977 rs6040633 0.9 1
    hCV29840965 rs6040644 hCV30417550 rs6040634 0.9 1
    hCV29840965 rs6040644 hCV30453433 rs6131208 0.9 0.9565
    hCV29840965 rs6040644 hCV30615489 rs6040630 0.9 0.9225
    hCV29840965 rs6040644 hCV32274419 rs13038146 0.9 1
    hCV29840965 rs6040644 hCV330228 rs6040668 0.9 1
    hCV29997278 rs9906737 hCV11625525 rs7222186 0.9 1
    hCV29997278 rs9906737 hCV1558080 rs9914580 0.9 1
    hCV29997278 rs9906737 hCV1558085 rs11656608 0.9 1
    hCV29997278 rs9906737 hCV29293441 rs8066502 0.9 1
    hCV29997278 rs9906737 hCV29979212 rs8068714 0.9 1
    hCV30057061 rs6033138 hCV2529198 rs742827 0.9 0.9624
    hCV30057061 rs6033138 hCV2529202 rs6040667 0.9 1
    hCV30057061 rs6033138 hCV2529211 rs17189710 0.9 1
    hCV30057061 rs6033138 hCV2529224 rs2327412 0.9 1
    hCV30057061 rs6033138 hCV2529230 rs4444612 0.9 1
    hCV30057061 rs6033138 hCV2529231 rs4315598 0.9 1
    hCV30057061 rs6033138 hCV2529239 rs6040638 0.9 1
    hCV30057061 rs6033138 hCV2529241 rs6134243 0.9 1
    hCV30057061 rs6033138 hCV2529246 rs6040619 0.9 1
    hCV30057061 rs6033138 hCV27367681 rs2876227 0.9 0.9649
    hCV30057061 rs6033138 hCV27367708 rs1009748 0.9 1
    hCV30057061 rs6033138 hCV29840965 rs6040644 0.9 1
    hCV30057061 rs6033138 hCV30093270 rs6040625 0.9 1
    hCV30057061 rs6033138 hCV30129243 rs6040636 0.9 1
    hCV30057061 rs6033138 hCV30218977 rs6040633 0.9 1
    hCV30057061 rs6033138 hCV30417550 rs6040634 0.9 1
    hCV30057061 rs6033138 hCV30453433 rs6131208 0.9 0.9585
    hCV30057061 rs6033138 hCV30615489 rs6040630 0.9 0.9294
    hCV30057061 rs6033138 hCV32274419 rs13038146 0.9 1
    hCV30057061 rs6033138 hCV330228 rs6040668 0.9 1
    hCV30093270 rs6040625 hCV2529198 rs742827 0.9 0.9624
    hCV30093270 rs6040625 hCV2529202 rs6040667 0.9 1
    hCV30093270 rs6040625 hCV2529211 rs17189710 0.9 1
    hCV30093270 rs6040625 hCV2529224 rs2327412 0.9 1
    hCV30093270 rs6040625 hCV2529230 rs4444612 0.9 1
    hCV30093270 rs6040625 hCV2529231 rs4315598 0.9 1
    hCV30093270 rs6040625 hCV2529239 rs6040638 0.9 1
    hCV30093270 rs6040625 hCV2529241 rs6134243 0.9 1
    hCV30093270 rs6040625 hCV2529246 rs6040619 0.9 1
    hCV30093270 rs6040625 hCV27367681 rs2876227 0.9 0.9649
    hCV30093270 rs6040625 hCV27367708 rs1009748 0.9 1
    hCV30093270 rs6040625 hCV29840965 rs6040644 0.9 1
    hCV30093270 rs6040625 hCV30057061 rs6033138 0.9 1
    hCV30093270 rs6040625 hCV30129243 rs6040636 0.9 1
    hCV30093270 rs6040625 hCV30218977 rs6040633 0.9 1
    hCV30093270 rs6040625 hCV30417550 rs6040634 0.9 1
    hCV30093270 rs6040625 hCV30453433 rs6131208 0.9 0.9585
    hCV30093270 rs6040625 hCV30615489 rs6040630 0.9 0.9294
    hCV30093270 rs6040625 hCV32274419 rs13038146 0.9 1
    hCV30093270 rs6040625 hCV330228 rs6040668 0.9 1
    hCV30129243 rs6040636 hCV2529198 rs742827 0.9 0.9624
    hCV30129243 rs6040636 hCV2529202 rs6040667 0.9 1
    hCV30129243 rs6040636 hCV2529211 rs17189710 0.9 1
    hCV30129243 rs6040636 hCV2529224 rs2327412 0.9 1
    hCV30129243 rs6040636 hCV2529230 rs4444612 0.9 1
    hCV30129243 rs6040636 hCV2529231 rs4315598 0.9 1
    hCV30129243 rs6040636 hCV2529239 rs6040638 0.9 1
    hCV30129243 rs6040636 hCV2529241 rs6134243 0.9 1
    hCV30129243 rs6040636 hCV2529246 rs6040619 0.9 1
    hCV30129243 rs6040636 hCV27367681 rs2876227 0.9 0.9649
    hCV30129243 rs6040636 hCV27367708 rs1009748 0.9 1
    hCV30129243 rs6040636 hCV29840965 rs6040644 0.9 1
    hCV30129243 rs6040636 hCV30057061 rs6033138 0.9 1
    hCV30129243 rs6040636 hCV30093270 rs6040625 0.9 1
    hCV30129243 rs6040636 hCV30218977 rs6040633 0.9 1
    hCV30129243 rs6040636 hCV30417550 rs6040634 0.9 1
    hCV30129243 rs6040636 hCV30453433 rs6131208 0.9 0.9585
    hCV30129243 rs6040636 hCV30615489 rs6040630 0.9 0.9294
    hCV30129243 rs6040636 hCV32274419 rs13038146 0.9 1
    hCV30129243 rs6040636 hCV330228 rs6040668 0.9 1
    hCV30202184 rs6685920 hCV1166098 rs4660234 0.9 1
    hCV30202184 rs6685920 hCV1166103 rs12407412 0.9 1
    hCV30202184 rs6685920 hCV1166105 rs11576627 0.9 1
    hCV30218977 rs6040633 hCV2529198 rs742827 0.9 0.9624
    hCV30218977 rs6040633 hCV2529202 rs6040667 0.9 1
    hCV30218977 rs6040633 hCV2529211 rs17189710 0.9 1
    hCV30218977 rs6040633 hCV2529224 rs2327412 0.9 1
    hCV30218977 rs6040633 hCV2529230 rs4444612 0.9 1
    hCV30218977 rs6040633 hCV2529231 rs4315598 0.9 1
    hCV30218977 rs6040633 hCV2529239 rs6040638 0.9 1
    hCV30218977 rs6040633 hCV2529241 rs6134243 0.9 1
    hCV30218977 rs6040633 hCV2529246 rs6040619 0.9 1
    hCV30218977 rs6040633 hCV27367681 rs2876227 0.9 0.9649
    hCV30218977 rs6040633 hCV27367708 rs1009748 0.9 1
    hCV30218977 rs6040633 hCV29840965 rs6040644 0.9 1
    hCV30218977 rs6040633 hCV30057061 rs6033138 0.9 1
    hCV30218977 rs6040633 hCV30093270 rs6040625 0.9 1
    hCV30218977 rs6040633 hCV30129243 rs6040636 0.9 1
    hCV30218977 rs6040633 hCV30417550 rs6040634 0.9 1
    hCV30218977 rs6040633 hCV30453433 rs6131208 0.9 0.9585
    hCV30218977 rs6040633 hCV30615489 rs6040630 0.9 0.9294
    hCV30218977 rs6040633 hCV32274419 rs13038146 0.9 1
    hCV30218977 rs6040633 hCV330228 rs6040668 0.9 1
    hCV3023182 rs2648694 hCV1408878 rs17194378 0.9 1
    hCV3023182 rs2648694 hCV16274605 rs2653496 0.9 0.9203
    hCV3023182 rs2648694 hCV1871425 rs7610808 0.9 0.9234
    hCV3023182 rs2648694 hCV1871428 rs10049421 0.9 0.9616
    hCV3023182 rs2648694 hCV1871433 rs9310741 0.9 0.9382
    hCV3023182 rs2648694 hCV26850538 rs2648687 0.9 0.9392
    hCV3023182 rs2648694 hCV26850540 rs2616575 0.9 0.9392
    hCV3023182 rs2648694 hCV29941790 rs9852630 0.9 0.9203
    hCV3023182 rs2648694 hCV3095156 rs2616569 0.9 0.9011
    hCV3023182 rs2648694 hCV3095166 rs2616571 0.9 0.9613
    hCV30243451 rs10270624 hCV11435810 rs7808536 0.9 1
    hCV30243451 rs10270624 hCV11435811 rs2057903 0.9 1
    hCV30243451 rs10270624 hCV16010888 rs2402516 0.9 0.9338
    hCV30243451 rs10270624 hCV16151622 rs2896295 0.9 1
    hCV30243451 rs10270624 hCV2580015 rs6973461 0.9 1
    hCV30243451 rs10270624 hCV26499740 rs1344081 0.9 0.9401
    hCV30243451 rs10270624 hCV29630277 rs7799541 0.9 0.9714
    hCV30243451 rs10270624 hCV29720798 rs10228725 0.9 1
    hCV30243451 rs10270624 hCV29738883 rs10237648 0.9 1
    hCV30243451 rs10270624 hCV29865261 rs10226287 0.9 1
    hCV30243451 rs10270624 hCV30441808 rs10487413 0.9 0.9396
    hCV30243451 rs10270624 hCV31281599 rs13438543 0.9 1
    hCV30332546 rs9346951 hCV30080541 rs9346948 0.9 1
    hCV30332546 rs9346951 hCV3125579 rs10945874 0.9 0.9549
    hCV30417550 rs6040634 hCV2529198 rs742827 0.9 0.9624
    hCV30417550 rs6040634 hCV2529202 rs6040667 0.9 1
    hCV30417550 rs6040634 hCV2529211 rs17189710 0.9 1
    hCV30417550 rs6040634 hCV2529224 rs2327412 0.9 1
    hCV30417550 rs6040634 hCV2529230 rs4444612 0.9 1
    hCV30417550 rs6040634 hCV2529231 rs4315598 0.9 1
    hCV30417550 rs6040634 hCV2529239 rs6040638 0.9 1
    hCV30417550 rs6040634 hCV2529241 rs6134243 0.9 1
    hCV30417550 rs6040634 hCV2529246 rs6040619 0.9 1
    hCV30417550 rs6040634 hCV27367681 rs2876227 0.9 0.9649
    hCV30417550 rs6040634 hCV27367708 rs1009748 0.9 1
    hCV30417550 rs6040634 hCV29840965 rs6040644 0.9 1
    hCV30417550 rs6040634 hCV30057061 rs6033138 0.9 1
    hCV30417550 rs6040634 hCV30093270 rs6040625 0.9 1
    hCV30417550 rs6040634 hCV30129243 rs6040636 0.9 1
    hCV30417550 rs6040634 hCV30218977 rs6040633 0.9 1
    hCV30417550 rs6040634 hCV30453433 rs6131208 0.9 0.9585
    hCV30417550 rs6040634 hCV30615489 rs6040630 0.9 0.9294
    hCV30417550 rs6040634 hCV32274419 rs13038146 0.9 1
    hCV30417550 rs6040634 hCV330228 rs6040668 0.9 1
    hCV30453433 rs6131208 hCV2529198 rs742827 0.9 0.9167
    hCV30453433 rs6131208 hCV2529202 rs6040667 0.9 0.9585
    hCV30453433 rs6131208 hCV2529210 rs6131206 0.9 0.9129
    hCV30453433 rs6131208 hCV2529211 rs17189710 0.9 0.9565
    hCV30453433 rs6131208 hCV2529224 rs2327412 0.9 0.9565
    hCV30453433 rs6131208 hCV2529230 rs4444612 0.9 0.9565
    hCV30453433 rs6131208 hCV2529231 rs4315598 0.9 0.9565
    hCV30453433 rs6131208 hCV2529239 rs6040638 0.9 0.9565
    hCV30453433 rs6131208 hCV2529241 rs6134243 0.9 0.9585
    hCV30453433 rs6131208 hCV2529246 rs6040619 0.9 0.9565
    hCV30453433 rs6131208 hCV27367681 rs2876227 0.9 0.9193
    hCV30453433 rs6131208 hCV27367708 rs1009748 0.9 0.9565
    hCV30453433 rs6131208 hCV29840965 rs6040644 0.9 0.9565
    hCV30453433 rs6131208 hCV30057061 rs6033138 0.9 0.9585
    hCV30453433 rs6131208 hCV30093270 rs6040625 0.9 0.9585
    hCV30453433 rs6131208 hCV30129243 rs6040636 0.9 0.9585
    hCV30453433 rs6131208 hCV30218977 rs6040633 0.9 0.9585
    hCV30453433 rs6131208 hCV30417550 rs6040634 0.9 0.9585
    hCV30453433 rs6131208 hCV32274419 rs13038146 0.9 0.9585
    hCV30453433 rs6131208 hCV330228 rs6040668 0.9 0.9585
    hCV30615489 rs6040630 hCV2529202 rs6040667 0.9 0.9294
    hCV30615489 rs6040630 hCV2529211 rs17189710 0.9 0.9225
    hCV30615489 rs6040630 hCV2529224 rs2327412 0.9 0.9225
    hCV30615489 rs6040630 hCV2529230 rs4444612 0.9 0.9225
    hCV30615489 rs6040630 hCV2529231 rs4315598 0.9 0.9225
    hCV30615489 rs6040630 hCV2529239 rs6040638 0.9 0.9225
    hCV30615489 rs6040630 hCV2529241 rs6134243 0.9 0.9294
    hCV30615489 rs6040630 hCV2529246 rs6040619 0.9 0.9225
    hCV30615489 rs6040630 hCV27367708 rs1009748 0.9 0.9225
    hCV30615489 rs6040630 hCV29840965 rs6040644 0.9 0.9225
    hCV30615489 rs6040630 hCV30057061 rs6033138 0.9 0.9294
    hCV30615489 rs6040630 hCV30093270 rs6040625 0.9 0.9294
    hCV30615489 rs6040630 hCV30129243 rs6040636 0.9 0.9294
    hCV30615489 rs6040630 hCV30218977 rs6040633 0.9 0.9294
    hCV30615489 rs6040630 hCV30417550 rs6040634 0.9 0.9294
    hCV30615489 rs6040630 hCV32274419 rs13038146 0.9 0.9294
    hCV30615489 rs6040630 hCV330228 rs6040668 0.9 0.9294
    hCV30621656 rs10478919 hCV11819780 rs12153185 0.9 0.9232
    hCV30621656 rs10478919 hCV11819782 rs12719415 0.9 0.927
    hCV30621656 rs10478919 hCV2575318 rs7711358 0.9 1
    hCV30621656 rs10478919 hCV2575336 rs2418541 0.9 1
    hCV30621656 rs10478919 hCV2575340 rs11242020 0.9 1
    hCV30621656 rs10478919 hCV26478747 rs2190598 0.9 0.9239
    hCV30621656 rs10478919 hCV26478763 rs2418542 0.9 1
    hCV30621656 rs10478919 hCV27996154 rs4836502 0.9 0.927
    hCV30621656 rs10478919 hCV2961244 rs2418548 0.9 0.9232
    hCV30621656 rs10478919 hCV2961250 rs4836507 0.9 0.927
    hCV30621656 rs10478919 hCV2961252 rs10067895 0.9 0.927
    hCV30621656 rs10478919 hCV2961253 rs2190600 0.9 0.927
    hCV30621656 rs10478919 hCV2961260 rs11242022 0.9 0.9232
    hCV30621656 rs10478919 hCV2961261 rs11242021 0.9 0.9255
    hCV30621656 rs10478919 hCV2961267 rs1476714 0.9 0.9607
    hCV30621656 rs10478919 hCV2961268 rs2108425 0.9 0.927
    hCV30621656 rs10478919 hCV2961269 rs2158958 0.9 0.927
    hCV30621656 rs10478919 hCV2961270 rs9327555 0.9 0.927
    hCV30621656 rs10478919 hCV2961278 rs7446891 0.9 0.927
    hCV30621656 rs10478919 hCV2961280 rs10520072 0.9 0.927
    hCV30621656 rs10478919 hCV2961282 rs917295 0.9 0.927
    hCV30621656 rs10478919 hCV2961284 rs10054055 0.9 0.9616
    hCV30621656 rs10478919 hCV2961296 rs10051148 0.9 0.9623
    hCV30621656 rs10478919 hCV2961297 rs2158961 0.9 0.9634
    hCV30621656 rs10478919 hCV2961306 rs264129 0.9 0.9232
    hCV30621656 rs10478919 hCV31237567 rs11749272 0.9 1
    hCV30621656 rs10478919 hCV346713 rs1990023 0.9 1
    hCV30621656 rs10478919 hCV546489 rs264122 0.9 0.9616
    hCV30621656 rs10478919 hCV8932829 rs1116596 0.9 1
    hCV30935888 rs13089860 hCV11226226 rs4234592 0.9 1
    hCV30935888 rs13089860 hCV1712351 rs2280209 0.9 0.9621
    hCV30935888 rs13089860 hCV29037733 rs6444109 0.9 1
    hCV30935888 rs13089860 hCV29037738 rs7627157 0.9 1
    hCV30935888 rs13089860 hCV29735597 rs9826842 0.9 0.9051
    hCV30935888 rs13089860 hCV29771757 rs4234591 0.9 1
    hCV31080080 rs12679254 hCV1319516 rs12678600 0.9 1
    hCV31080080 rs12679254 hCV1319518 rs13265054 0.9 1
    hCV31190748 rs7959965 hCV11686367 rs7955901 0.9 0.9442
    hCV31190748 rs7959965 hCV11686374 rs7957932 0.9 0.9161
    hCV31190748 rs7959965 hCV171102 rs7313973 0.9 0.9568
    hCV31190748 rs7959965 hCV240133 rs4760895 0.9 0.9644
    hCV31190748 rs7959965 hCV2745805 rs7132840 0.9 0.9268
    hCV31190748 rs7959965 hCV2745807 rs2063591 0.9 0.9303
    hCV31190748 rs7959965 hCV2745815 rs1512991 0.9 1
    hCV31190748 rs7959965 hCV2745828 rs10879240 0.9 0.9274
    hCV31190748 rs7959965 hCV27952502 rs4760894 0.9 0.9644
    hCV31190748 rs7959965 hCV27952503 rs4760785 0.9 0.9644
    hCV31190748 rs7959965 hCV29120310 rs7298255 0.9 1
    hCV31190748 rs7959965 hCV31190777 rs10784891 0.9 1
    hCV31190748 rs7959965 hDV72015086 rs7956274 0.9 1
    hCV31190777 rs10784891 hCV11686367 rs7955901 0.9 1
    hCV31190777 rs10784891 hCV11686374 rs7957932 0.9 0.9572
    hCV31190777 rs10784891 hCV171102 rs7313973 0.9 0.9553
    hCV31190777 rs10784891 hCV240133 rs4760895 0.9 0.962
    hCV31190777 rs10784891 hCV240134 rs7138300 0.9 0.9588
    hCV31190777 rs10784891 hCV2745797 rs1877527 0.9 0.9555
    hCV31190777 rs10784891 hCV2745800 rs11178531 0.9 1
    hCV31190777 rs10784891 hCV2745805 rs7132840 0.9 1
    hCV31190777 rs10784891 hCV2745807 rs2063591 0.9 0.962
    hCV31190777 rs10784891 hCV2745815 rs1512991 0.9 1
    hCV31190777 rs10784891 hCV2745822 rs1913201 0.9 0.9588
    hCV31190777 rs10784891 hCV2745828 rs10879240 0.9 0.9235
    hCV31190777 rs10784891 hCV27952502 rs4760894 0.9 0.962
    hCV31190777 rs10784891 hCV27952503 rs4760785 0.9 0.962
    hCV31190777 rs10784891 hCV29120310 rs7298255 0.9 1
    hCV31190777 rs10784891 hCV31190748 rs7959965 0.9 1
    hCV31190777 rs10784891 hDV72015086 rs7956274 0.9 1
    hCV31237567 rs11749272 hCV11819780 rs12153185 0.9 0.9232
    hCV31237567 rs11749272 hCV11819782 rs12719415 0.9 0.927
    hCV31237567 rs11749272 hCV2575318 rs7711358 0.9 1
    hCV31237567 rs11749272 hCV2575336 rs2418541 0.9 1
    hCV31237567 rs11749272 hCV2575340 rs11242020 0.9 1
    hCV31237567 rs11749272 hCV26478747 rs2190598 0.9 0.9239
    hCV31237567 rs11749272 hCV26478763 rs2418542 0.9 1
    hCV31237567 rs11749272 hCV27996154 rs4836502 0.9 0.927
    hCV31237567 rs11749272 hCV2961244 rs2418548 0.9 0.9232
    hCV31237567 rs11749272 hCV2961250 rs4836507 0.9 0.927
    hCV31237567 rs11749272 hCV2961252 rs10067895 0.9 0.927
    hCV31237567 rs11749272 hCV2961253 rs2190600 0.9 0.927
    hCV31237567 rs11749272 hCV2961260 rs11242022 0.9 0.9232
    hCV31237567 rs11749272 hCV2961261 rs11242021 0.9 0.9255
    hCV31237567 rs11749272 hCV2961267 rs1476714 0.9 0.9607
    hCV31237567 rs11749272 hCV2961268 rs2108425 0.9 0.927
    hCV31237567 rs11749272 hCV2961269 rs2158958 0.9 0.927
    hCV31237567 rs11749272 hCV2961270 rs9327555 0.9 0.927
    hCV31237567 rs11749272 hCV2961278 rs7446891 0.9 0.927
    hCV31237567 rs11749272 hCV2961280 rs10520072 0.9 0.927
    hCV31237567 rs11749272 hCV2961282 rs917295 0.9 0.927
    hCV31237567 rs11749272 hCV2961284 rs10054055 0.9 0.9616
    hCV31237567 rs11749272 hCV2961296 rs10051148 0.9 0.9623
    hCV31237567 rs11749272 hCV2961297 rs2158961 0.9 0.9634
    hCV31237567 rs11749272 hCV2961306 rs264129 0.9 0.9232
    hCV31237567 rs11749272 hCV30621656 rs10478919 0.9 1
    hCV31237567 rs11749272 hCV346713 rs1990023 0.9 1
    hCV31237567 rs11749272 hCV546489 rs264122 0.9 0.9616
    hCV31237567 rs11749272 hCV8932829 rs1116596 0.9 1
    hCV3125579 rs10945874 hCV30080541 rs9346948 0.9 1
    hCV3125579 rs10945874 hCV30332546 rs9346951 0.9 0.9549
    hCV31587413 rs6746182 hCV31587414 rs6746170 0.9 1
    hCV31587413 rs6746182 hCV31587415 rs6544728 0.9 1
    hCV31587413 rs6746182 hCV31587430 rs11124962 0.9 0.9489
    hCV31587414 rs6746170 hCV31587413 rs6746182 0.9 1
    hCV31587414 rs6746170 hCV31587415 rs6544728 0.9 1
    hCV31587414 rs6746170 hCV31587430 rs11124962 0.9 0.9489
    hCV31587415 rs6544728 hCV25642662 rs10190161 0.9 0.9224
    hCV31587415 rs6544728 hCV31587413 rs6746182 0.9 1
    hCV31587415 rs6544728 hCV31587414 rs6746170 0.9 1
    hCV31587415 rs6544728 hCV31587430 rs11124962 0.9 0.9602
    hCV31587430 rs11124962 hCV31587413 rs6746182 0.9 0.9489
    hCV31587430 rs11124962 hCV31587414 rs6746170 0.9 0.9489
    hCV31587430 rs11124962 hCV31587415 rs6544728 0.9 0.9602
    hCV3172867 rs316720 hCV989588 rs669684 0.9 0.9626
    hCV3172867 rs316720 hCV989658 rs647645 0.9 0.9631
    hCV31931605 rs7022281 hCV27084860 rs10758326 0.9 0.9004
    hCV31931605 rs7022281 hCV31931609 rs10738948 0.9 0.9289
    hCV31931609 rs10738948 hCV27084860 rs10758326 0.9 0.9637
    hCV31931609 rs10738948 hCV31931605 rs7022281 0.9 0.9289
    hCV32014843 rs11221075 hCV1056544 rs675163 0.9 1
    hCV32014843 rs11221075 hCV32014853 rs11221097 0.9 1
    hCV32014843 rs11221075 hCV767324 rs687047 0.9 1
    hCV32274419 rs13038146 hCV2529198 rs742827 0.9 0.9624
    hCV32274419 rs13038146 hCV2529202 rs6040667 0.9 1
    hCV32274419 rs13038146 hCV2529211 rs17189710 0.9 1
    hCV32274419 rs13038146 hCV2529224 rs2327412 0.9 1
    hCV32274419 rs13038146 hCV2529230 rs4444612 0.9 1
    hCV32274419 rs13038146 hCV2529231 rs4315598 0.9 1
    hCV32274419 rs13038146 hCV2529239 rs6040638 0.9 1
    hCV32274419 rs13038146 hCV2529241 rs6134243 0.9 1
    hCV32274419 rs13038146 hCV2529246 rs6040619 0.9 1
    hCV32274419 rs13038146 hCV27367681 rs2876227 0.9 0.9649
    hCV32274419 rs13038146 hCV27367708 rs1009748 0.9 1
    hCV32274419 rs13038146 hCV29840965 rs6040644 0.9 1
    hCV32274419 rs13038146 hCV30057061 rs6033138 0.9 1
    hCV32274419 rs13038146 hCV30093270 rs6040625 0.9 1
    hCV32274419 rs13038146 hCV30129243 rs6040636 0.9 1
    hCV32274419 rs13038146 hCV30218977 rs6040633 0.9 1
    hCV32274419 rs13038146 hCV30417550 rs6040634 0.9 1
    hCV32274419 rs13038146 hCV30453433 rs6131208 0.9 0.9585
    hCV32274419 rs13038146 hCV30615489 rs6040630 0.9 0.9294
    hCV32274419 rs13038146 hCV330228 rs6040668 0.9 1
    hCV330228 rs6040668 hCV2529198 rs742827 0.9 0.9624
    hCV330228 rs6040668 hCV2529202 rs6040667 0.9 1
    hCV330228 rs6040668 hCV2529211 rs17189710 0.9 1
    hCV330228 rs6040668 hCV2529224 rs2327412 0.9 1
    hCV330228 rs6040668 hCV2529230 rs4444612 0.9 1
    hCV330228 rs6040668 hCV2529231 rs4315598 0.9 1
    hCV330228 rs6040668 hCV2529239 rs6040638 0.9 1
    hCV330228 rs6040668 hCV2529241 rs6134243 0.9 1
    hCV330228 rs6040668 hCV2529246 rs6040619 0.9 1
    hCV330228 rs6040668 hCV27367681 rs2876227 0.9 0.9649
    hCV330228 rs6040668 hCV27367708 rs1009748 0.9 1
    hCV330228 rs6040668 hCV29840965 rs6040644 0.9 1
    hCV330228 rs6040668 hCV30057061 rs6033138 0.9 1
    hCV330228 rs6040668 hCV30093270 rs6040625 0.9 1
    hCV330228 rs6040668 hCV30129243 rs6040636 0.9 1
    hCV330228 rs6040668 hCV30218977 rs6040633 0.9 1
    hCV330228 rs6040668 hCV30417550 rs6040634 0.9 1
    hCV330228 rs6040668 hCV30453433 rs6131208 0.9 0.9585
    hCV330228 rs6040668 hCV30615489 rs6040630 0.9 0.9294
    hCV330228 rs6040668 hCV32274419 rs13038146 0.9 1
    hCV346713 rs1990023 hCV11819780 rs12153185 0.9 0.9358
    hCV346713 rs1990023 hCV11819782 rs12719415 0.9 0.9232
    hCV346713 rs1990023 hCV2575318 rs7711358 0.9 1
    hCV346713 rs1990023 hCV2575336 rs2418541 0.9 1
    hCV346713 rs1990023 hCV2575340 rs11242020 0.9 1
    hCV346713 rs1990023 hCV26478744 rs2016194 0.9 0.9162
    hCV346713 rs1990023 hCV26478745 rs2108426 0.9 0.9557
    hCV346713 rs1990023 hCV26478747 rs2190598 0.9 0.9199
    hCV346713 rs1990023 hCV26478763 rs2418542 0.9 1
    hCV346713 rs1990023 hCV27996154 rs4836502 0.9 0.9232
    hCV346713 rs1990023 hCV2961244 rs2418548 0.9 0.9358
    hCV346713 rs1990023 hCV2961250 rs4836507 0.9 0.9232
    hCV346713 rs1990023 hCV2961252 rs10067895 0.9 0.9232
    hCV346713 rs1990023 hCV2961253 rs2190600 0.9 0.9232
    hCV346713 rs1990023 hCV2961259 rs11242023 0.9 0.9358
    hCV346713 rs1990023 hCV2961260 rs11242022 0.9 0.9567
    hCV346713 rs1990023 hCV2961261 rs11242021 0.9 0.9216
    hCV346713 rs1990023 hCV2961267 rs1476714 0.9 0.9587
    hCV346713 rs1990023 hCV2961268 rs2108425 0.9 0.9232
    hCV346713 rs1990023 hCV2961269 rs2158958 0.9 0.9232
    hCV346713 rs1990023 hCV2961270 rs9327555 0.9 0.9232
    hCV346713 rs1990023 hCV2961278 rs7446891 0.9 0.9232
    hCV346713 rs1990023 hCV2961280 rs10520072 0.9 0.9232
    hCV346713 rs1990023 hCV2961282 rs917295 0.9 0.9232
    hCV346713 rs1990023 hCV2961284 rs10054055 0.9 0.9783
    hCV346713 rs1990023 hCV2961296 rs10051148 0.9 0.9608
    hCV346713 rs1990023 hCV2961297 rs2158961 0.9 0.9616
    hCV346713 rs1990023 hCV2961306 rs264129 0.9 0.9567
    hCV346713 rs1990023 hCV30621656 rs10478919 0.9 1
    hCV346713 rs1990023 hCV31237567 rs11749272 0.9 1
    hCV346713 rs1990023 hCV546489 rs264122 0.9 0.9783
    hCV346713 rs1990023 hCV8932829 rs1116596 0.9 1
    hCV349805 rs4851529 hCV16126066 rs2110564 0.9 0.9329
    hCV349805 rs4851529 hCV2676440 rs6722640 0.9 0.9329
    hCV349805 rs4851529 hCV27872026 rs4851531 0.9 0.9646
    hCV349805 rs4851529 hCV8905894 rs974950 0.9 0.9303
    hCV364260 rs2505039 hCV29557190 rs9487275 0.9 0.9632
    hCV364260 rs2505039 hCV35209 rs4329143 0.9 0.9615
    hCV364260 rs2505039 hCV364258 rs2505038 0.9 0.9806
    hCV364260 rs2505039 hCV364261 rs7749240 0.9 0.9639
    hCV375090 rs4450660 hCV26135665 rs4390811 0.9 0.96
    hCV375090 rs4450660 hCV26771384 rs10865197 0.9 1
    hCV375090 rs4450660 hCV26771389 rs10183431 0.9 1
    hCV375090 rs4450660 hCV27875215 rs4346434 0.9 0.922
    hCV375090 rs4450660 hCV27933339 rs4586678 0.9 1
    hCV375090 rs4450660 hCV29229284 rs6741066 0.9 0.9591
    hCV375090 rs4450660 hCV30817981 rs6723119 0.9 0.96
    hCV375090 rs4450660 hCV375079 rs9309112 0.9 0.92
    hCV375090 rs4450660 hCV375083 rs10206724 0.9 1
    hCV375090 rs4450660 hCV514334 rs6544721 0.9 0.961
    hCV443083 rs6742894 hCV48381 rs6743092 0.9 1
    hCV443083 rs6742894 hCV48382 rs12465349 0.9 1
    hCV48381 rs6743092 hCV443083 rs6742894 0.9 1
    hCV48381 rs6743092 hCV48382 rs12465349 0.9 1
    hCV514334 rs6544721 hCV25642662 rs10190161 0.9 0.9211
    hCV514334 rs6544721 hCV26135665 rs4390811 0.9 0.9201
    hCV514334 rs6544721 hCV26771384 rs10865197 0.9 0.961
    hCV514334 rs6544721 hCV26771389 rs10183431 0.9 0.961
    hCV514334 rs6544721 hCV27933339 rs4586678 0.9 0.961
    hCV514334 rs6544721 hCV29229284 rs6741066 0.9 0.9183
    hCV514334 rs6544721 hCV30817981 rs6723119 0.9 1
    hCV514334 rs6544721 hCV375083 rs10206724 0.9 0.96
    hCV514334 rs6544721 hCV375090 rs4450660 0.9 0.961
    hCV546489 rs264122 hCV11819780 rs12153185 0.9 0.9573
    hCV546489 rs264122 hCV11819782 rs12719415 0.9 0.9616
    hCV546489 rs264122 hCV2575318 rs7711358 0.9 0.9616
    hCV546489 rs264122 hCV2575336 rs2418541 0.9 0.9616
    hCV546489 rs264122 hCV2575340 rs11242020 0.9 0.9616
    hCV546489 rs264122 hCV26478744 rs2016194 0.9 0.9581
    hCV546489 rs264122 hCV26478745 rs2108426 0.9 1
    hCV546489 rs264122 hCV26478747 rs2190598 0.9 0.96
    hCV546489 rs264122 hCV26478763 rs2418542 0.9 0.9616
    hCV546489 rs264122 hCV27996154 rs4836502 0.9 0.9616
    hCV546489 rs264122 hCV2961244 rs2418548 0.9 0.9573
    hCV546489 rs264122 hCV2961250 rs4836507 0.9 0.9616
    hCV546489 rs264122 hCV2961252 rs10067895 0.9 0.9616
    hCV546489 rs264122 hCV2961253 rs2190600 0.9 0.9616
    hCV546489 rs264122 hCV2961259 rs11242023 0.9 0.9573
    hCV546489 rs264122 hCV2961260 rs11242022 0.9 0.9783
    hCV546489 rs264122 hCV2961261 rs11242021 0.9 0.9608
    hCV546489 rs264122 hCV2961267 rs1476714 0.9 0.9587
    hCV546489 rs264122 hCV2961268 rs2108425 0.9 0.9616
    hCV546489 rs264122 hCV2961269 rs2158958 0.9 0.9616
    hCV546489 rs264122 hCV2961270 rs9327555 0.9 0.9616
    hCV546489 rs264122 hCV2961278 rs7446891 0.9 0.9616
    hCV546489 rs264122 hCV2961280 rs10520072 0.9 0.9616
    hCV546489 rs264122 hCV2961282 rs917295 0.9 0.9616
    hCV546489 rs264122 hCV2961284 rs10054055 0.9 1
    hCV546489 rs264122 hCV2961296 rs10051148 0.9 1
    hCV546489 rs264122 hCV2961297 rs2158961 0.9 1
    hCV546489 rs264122 hCV2961306 rs264129 0.9 0.9783
    hCV546489 rs264122 hCV29666186 rs6871041 0.9 0.9189
    hCV546489 rs264122 hCV30621656 rs10478919 0.9 0.9616
    hCV546489 rs264122 hCV31237567 rs11749272 0.9 0.9616
    hCV546489 rs264122 hCV346713 rs1990023 0.9 0.9783
    hCV546489 rs264122 hCV8932829 rs1116596 0.9 0.9616
    hCV546493 rs264126 hCV2575337 rs2214640 0.9 1
    hCV546493 rs264126 hCV2575344 rs10064779 0.9 0.9328
    hCV546493 rs264126 hCV26478748 rs2190597 0.9 0.9328
    hCV546493 rs264126 hCV29134277 rs6595948 0.9 0.9001
    hCV546493 rs264126 hCV2961235 rs6869219 0.9 0.9255
    hCV546493 rs264126 hCV2961239 rs6868888 0.9 0.9282
    hCV546493 rs264126 hCV2961251 rs1157409 0.9 0.9328
    hCV546493 rs264126 hCV8932783 rs1473132 0.9 0.9328
    hCV767324 rs687047 hCV1056543 rs688358 0.9 1
    hCV767324 rs687047 hCV1056544 rs675163 0.9 1
    hCV767324 rs687047 hCV32014843 rs11221075 0.9 1
    hCV767324 rs687047 hCV32014853 rs11221097 0.9 1
    hCV8351640 rs842796 hCV9110432 rs12025826 0.9 0.9273
    hCV8375036 rs9960 hCV1166092 rs12406279 0.9 1
    hCV8375036 rs9960 hCV1166096 rs12406643 0.9 1
    hCV8375036 rs9960 hDV70946874 rs17386162 0.9 1
    hCV8375364 rs966583 hCV26441140 rs9325191 0.9 1
    hCV8375364 rs966583 hCV2690333 rs11178602 0.9 1
    hCV8375364 rs966583 hCV2690348 rs11178594 0.9 1
    hCV8375364 rs966583 hCV2690350 rs2132242 0.9 1
    hCV8375364 rs966583 hCV2690354 rs11178589 0.9 1
    hCV8375364 rs966583 hCV2690362 rs10879249 0.9 1
    hCV8375364 rs966583 hCV2690365 rs11178583 0.9 1
    hCV8375364 rs966583 hCV2690375 rs1567740 0.9 1
    hCV8375364 rs966583 hCV2690377 rs10879245 0.9 1
    hCV8375364 rs966583 hCV2690378 rs11178579 0.9 1
    hCV8375364 rs966583 hCV2690379 rs10879242 0.9 1
    hCV8375364 rs966583 hCV2690380 rs10506623 0.9 1
    hCV8375364 rs966583 hCV2690388 rs2132241 0.9 1
    hCV8375364 rs966583 hCV31190567 rs7311994 0.9 1
    hCV8375364 rs966583 hCV31190598 rs12818936 0.9 1
    hCV8375364 rs966583 hCV8871988 rs1495375 0.9 1
    hCV8375364 rs966583 hCV8871989 rs1512989 0.9 1
    hCV8375364 rs966583 hCV8871990 rs1512988 0.9 1
    hCV8375364 rs966583 hCV8873466 rs1051344 0.9 1
    hCV8375364 rs966583 hCV8873472 rs1355373 0.9 1
    hCV8719512 rs4773 hCV8719513 rs1266483 0.9 0.9781
    hCV8719512 rs4773 hCV8719628 rs1266489 0.9 1
    hCV8719628 rs1266489 hCV12100073 rs871078 0.9 0.9543
    hCV8719628 rs1266489 hCV27008723 rs2677744 0.9 0.955
    hCV8719628 rs1266489 hCV2979204 rs734252 0.9 1
    hCV8719628 rs1266489 hCV8718176 rs1550636 0.9 0.955
    hCV8719628 rs1266489 hCV8719512 rs4773 0.9 1
    hCV8719628 rs1266489 hCV8719513 rs1266483 0.9 1
    hCV8793528 rs9857 hCV1973774 rs1483301 0.9 1
    hCV8873448 rs3844207 hCV2690291 rs2270588 0.9 1
    hCV8873448 rs3844207 hCV2690292 rs2270589 0.9 0.9298
    hCV8905894 rs974950 hCV16126066 rs2110564 0.9 1
    hCV8905894 rs974950 hCV2676440 rs6722640 0.9 1
    hCV8905894 rs974950 hCV27872026 rs4851531 0.9 0.9812
    hCV8905894 rs974950 hCV349805 rs4851529 0.9 0.9303
    hCV8932829 rs1116596 hCV11819780 rs12153185 0.9 0.9232
    hCV8932829 rs1116596 hCV11819782 rs12719415 0.9 0.927
    hCV8932829 rs1116596 hCV2575318 rs7711358 0.9 1
    hCV8932829 rs1116596 hCV2575336 rs2418541 0.9 1
    hCV8932829 rs1116596 hCV2575340 rs11242020 0.9 1
    hCV8932829 rs1116596 hCV26478747 rs2190598 0.9 0.9239
    hCV8932829 rs1116596 hCV26478763 rs2418542 0.9 1
    hCV8932829 rs1116596 hCV27996154 rs4836502 0.9 0.927
    hCV8932829 rs1116596 hCV2961244 rs2418548 0.9 0.9232
    hCV8932829 rs1116596 hCV2961250 rs4836507 0.9 0.927
    hCV8932829 rs1116596 hCV2961252 rs10067895 0.9 0.927
    hCV8932829 rs1116596 hCV2961253 rs2190600 0.9 0.927
    hCV8932829 rs1116596 hCV2961260 rs11242022 0.9 0.9232
    hCV8932829 rs1116596 hCV2961261 rs11242021 0.9 0.9255
    hCV8932829 rs1116596 hCV2961267 rs1476714 0.9 0.9607
    hCV8932829 rs1116596 hCV2961268 rs2108425 0.9 0.927
    hCV8932829 rs1116596 hCV2961269 rs2158958 0.9 0.927
    hCV8932829 rs1116596 hCV2961270 rs9327555 0.9 0.927
    hCV8932829 rs1116596 hCV2961278 rs7446891 0.9 0.927
    hCV8932829 rs1116596 hCV2961280 rs10520072 0.9 0.927
    hCV8932829 rs1116596 hCV2961282 rs917295 0.9 0.927
    hCV8932829 rs1116596 hCV2961284 rs10054055 0.9 0.9616
    hCV8932829 rs1116596 hCV2961296 rs10051148 0.9 0.9623
    hCV8932829 rs1116596 hCV2961297 rs2158961 0.9 0.9634
    hCV8932829 rs1116596 hCV2961306 rs264129 0.9 0.9232
    hCV8932829 rs1116596 hCV30621656 rs10478919 0.9 1
    hCV8932829 rs1116596 hCV31237567 rs11749272 0.9 1
    hCV8932829 rs1116596 hCV346713 rs1990023 0.9 1
    hCV8932829 rs1116596 hCV546489 rs264122 0.9 0.9616
    hCV9110432 rs12025826 hCV8351640 rs842796 0.9 0.9273
    hCV940416 rs498657 hCV3125582 rs2243708 0.9 1
    hDV70820190 rs17035071 hDV70820183 rs17035064 0.9 1
    hDV70820190 rs17035071 hDV70820188 rs17035069 0.9 1
    hDV70936275 rs17310169 hDV70936277 rs17310176 0.9 1
    hDV70936277 rs17310176 hDV70936275 rs17310169 0.9 1
    hDV70985165 rs17662322 hDV70995198 rs17718867 0.9 1
    hDV70995198 rs17718867 hDV70985165 rs17662322 0.9 1
    hDV72015086 rs7956274 hCV11686367 rs7955901 0.9 1
    hDV72015086 rs7956274 hCV171102 rs7313973 0.9 0.9584
    hDV72015086 rs7956274 hCV240133 rs4760895 0.9 0.9649
    hDV72015086 rs7956274 hCV240134 rs7138300 0.9 0.9622
    hDV72015086 rs7956274 hCV2745800 rs11178531 0.9 0.9261
    hDV72015086 rs7956274 hCV2745805 rs7132840 0.9 0.9261
    hDV72015086 rs7956274 hCV2745815 rs1512991 0.9 1
    hDV72015086 rs7956274 hCV2745822 rs1913201 0.9 0.9622
    hDV72015086 rs7956274 hCV2745828 rs10879240 0.9 0.9285
    hDV72015086 rs7956274 hCV27952502 rs4760894 0.9 0.9649
    hDV72015086 rs7956274 hCV27952503 rs4760785 0.9 0.9649
    hDV72015086 rs7956274 hCV29120310 rs7298255 0.9 1
    hDV72015086 rs7956274 hCV31190748 rs7959965 0.9 1
    hDV72015086 rs7956274 hCV31190777 rs10784891 0.9 1
    hDV76981734 rs4251569 hCV27943699 rs4238087 0.9 1
  • TABLE 4
    al-
    lele al-
    A1 lele Meta-analysis CARE WOSCOPS
    (non- A2 OR OR P Prava Placebo OR OR Prava Placebo OR OR Mod- End-
    Marker ref) (ref) OR L95 U95 value Count Count OR L95 U95 P value Source Count Count OR L95 U95 P value Source el point
    rs2157673 G A 1.50 1.26 1.78 5.54E− 50/156/151 28/189/ 1.47 1.18 1.82 5.43E−04 Case- 24/85/75 19/93/135 1.56 1.16 2.09 2.99E−03 Caseonly add CVD
    06 227 only
    rs12155847 G A 1.66 1.32 2.09 1.80E− 47/174/136 45/173/226 1.69 1.27 2.24 3.58E−04 Case- 18/90/76 19/99/129 1.61 1.09 2.37 1.71E−02 Caseonly dom CVD
    05 only
    rs9292827 A G 0.34 0.20 0.56 3.46E− 1/14/342 1/47/395 0.37 0.20 0.67 1.08E−03 Case- 2/3/179 1/22/224 0.27 0.10 0.73 9.50E−03 Caseonly dom CVD
    05 only
    rs2695026 A G 0.67 0.55 0.81 3.85E− 18/116/221 43/164/236 0.70 0.55 0.88 2.23E−03 Case- 5/52/124 16/92/137 0.61 0.43 0.86 4.67E−03 Caseonly add CVD
    05 only
    rs205279 A G 1.81 1.36 2.41 4.59E− 5/78/274 2/61/381 1.94 1.36 2.76 2.54E−04 Case- 0/43/141 0/39/208 1.60 0.99 2.60 5.76E−02 Caseonly add CVD
    05 only
    rs17706237 G A 1.69 1.31 2.19 5.77E− 13/111/176 13/94/275 1.80 1.31 2.49 3.42E−04 Case- 7/61/91 9/65/150 1.52 1.00 2.31 5.28E−02 CaseOnly dom CHD
    05 Only
    rs10120126 G A 0.51 0.37 0.71 5.98E− 4/43/253 11/87/284 0.53 0.36 0.78 1.55E−03 Case- 3/16/139 5/44/175 0.48 0.27 0.86 1.30E−02 CaseOnly dom CHD
    05 Only
    rs1948 A G 1.66 1.29 2.13 6.47E− 40/134/126 38/146/198 1.52 1.12 2.07 7.49E−03 Case- 19/88/52 27/88/109 1.96 1.29 3.00 1.83E−03 CaseOnly dom CHD
    05 Only
    rs10088505 A G 1.61 1.27 2.03 6.58E− 38/180/139 51/177/215 1.52 1.14 2.03 4.28E−03 Case- 24/87/70 23/93/127 1.78 1.20 2.63 4.27E−03 Caseonly dom CVD
    05 only
    rs354342 A G 0.67 0.55 0.82 6.82E− 17/115/225 37/171/236 0.70 0.55 0.89 3.07E−03 Case- 5/51/128 15/90/142 0.62 0.44 0.87 6.35E−03 Caseonly add CVD
    05 only
    rs1035618 A C 1.42 1.19 1.68 6.96E− 45/169/140 39/181/219 1.38 1.12 1.71 2.98E−03 Case- 31/86/66 23/111/ 1.48 1.11 1.98 7.61E−03 Caseonly add CVD
    05 only 111
    rs238272 A G 1.45 1.21 1.74 7.57E− 35/139/126 28/149/205 1.44 1.14 1.82 2.44E−03 Case- 32/64/63 22/94/108 1.46 1.09 1.96 1.07E−02 CaseOnly add CHD
    05 Only
    rs10849442 A G 0.57 0.43 0.75 8.56E− 57/207/93 112/220/ 0.56 0.39 0.80 1.36E−03 Case- 37/100/ 73/100/74 0.59 0.37 0.93 2.26E−02 Caseonly rec CVD
    05 112 only 46
    rs2376764 A G 0.56 0.41 0.74 8.56E− 55/185/117 103/220/ 0.61 0.42 0.88 8.65E−03 Case- 30/99/55 71/117/58 0.48 0.29 0.77 2.46E−03 Caseonly rec CVD
    05 121 only
    rs2273816 A G 1.61 1.27 2.05 8.70E− 9/87/204 5/81/296 1.56 1.15 2.12 4.66E−03 Case- 10/46/103 5/49/170 1.69 1.16 2.47 6.17E−03 CaseOnly add CHD
    05 Only
    rs2941528 A G 0.67 0.54 0.82 1.79E− 13/111/176 29/162/191 0.72 0.56 0.93 1.31E−02 Case- 12/50/96 21/112/91 0.58 0.41 0.81 1.38E−03 CaseOnly add CHD
    04 Only
    rs1615197 G A 1.80 1.25 2.60 1.71E− 56/146/98 61/158/163 1.54 1.12 2.11 7.76E−03 Case- 38/81/40 28/98/98 2.25 1.44 3.52 3.75E−04 CaseOnly dom CHD
    03 Only
    rs1349282 A G 0.55 0.44 0.69 3.97E− 254/731/ 290/709/ 0.55 0.41 0.74 1.05E−04 cohort 459/1274/ 469/1271/ 0.55 0.38 0.79 1.10E−03 cohort dom CVD
    07 509 472 924 918
    rs4986146 A G 0.63 0.53 0.76 4.36E− 109/579/807 89/562/818 0.62 0.49 0.77 2.63E−05 cohort 175/1031/ 181/1039/ 0.66 0.50 0.88 4.63E−03 cohort add CVD
    07 1436 1427
    rs3213616 A G 0.62 0.51 0.76 2.68E− 74/479/933 75/465/920 0.62 0.49 0.80 1.60E−04 cohort 77/807/ 79/852/ 0.62 0.45 0.87 5.26E−03 cohort add CVD
    06 1767 1727
    rs2008165 G A 0.59 0.47 0.73 2.77E− 650/115/728 676/99/695 0.57 0.43 0.76 1.06E−04 cohort 1301/6/ 1261/4/ 0.62 0.43 0.89 9.37E−03 cohort add CHD
    06 1343 1393
    rs10500736 G A 0.57 0.45 0.72 2.82E− 254/1214/ 130/603/ 0.61 0.45 0.83 1.62E−03 cohort 230/1135/ 256/1109/ 0.52 0.36 0.75 4.18E−04 cohort dom CHD
    06 1417 700 1290 1296
    rs7705993 G A 1.48 1.24 1.76 9.34E− 370/724/ 333/755/ 1.50 1.21 1.85 1.98E−04 cohort 44/77/38 38/117/69 1.44 1.07 1.94 1.57E−02 CaseOnly add CHD
    06 401 382
    rs12556591 G A 0.59 0.47 0.75 1.04E− 625/114/ 665/95/ 0.57 0.43 0.75 7.93E−05 cohort 66/0/93 115/0/109 0.66 0.44 1.00 4.88E−02 CaseOnly add CHD
    05 755 710
    rs2534752 G A 1.65 1.32 2.07 1.17E− 63/485/947 51/467/951 1.60 1.19 2.15 1.67E−03 cohort 112/890/ 129/915/ 1.74 1.22 2.47 2.10E−03 cohort dom CVD
    05 1649 1613
    rs4830819 G A 0.60 0.48 0.75 1.36E− 641/113/ 673/97/699 0.57 0.43 0.76 8.61E−05 cohort 66/0/93 115/0/109 0.66 0.44 1.00 4.88E−02 CaseOnly add CHD
    05 740
    rs10189905 C A 0.52 0.39 0.70 1.52E− 12/256/ 13/281/ 0.50 0.34 0.73 3.92E−04 cohort 15/496/ 30/434/ 0.56 0.36 0.88 1.21E−02 cohort add CHD
    05 1227 1177 2143 2195
    rs316720 G A 0.71 0.61 0.83 2.28E− 223/758/ 265/690/ 0.67 0.55 0.82 1.19E−04 cohort 531/1320/ 540/1301/ 0.78 0.61 1.00 4.57E−02 cohort add CVD
    05 514 516 796 814
    rs3998860 A G 0.61 0.49 0.77 2.29E− 129/851/ 75/416/941 0.58 0.44 0.76 7.97E−05 cohort 3/44/112 6/80/138 0.70 0.47 1.05 8.17E−02 CaseOnly add CHD
    05 1903
    rs3732788 G A 0.51 0.38 0.70 2.57E− 16/212/ 14/275/ 0.56 0.38 0.81 2.46E−03 cohort 0/21/138 3/53/168 0.44 0.26 0.75 2.64E−03 CaseOnly add CHD
    05 1267 1180
    rs669684 G A 0.72 0.62 0.84 2.85E− 260/758/ 309/690/ 0.69 0.56 0.84 2.75E−04 cohort 633/1333/ 626/1318/ 0.77 0.60 0.97 3.00E−02 cohort add CVD
    05 476 472 689 715
    rs2418412 G A 1.94 1.42 2.65 3.05E− 270/722/ 272/703/ 2.20 1.48 3.25 8.63E−05 cohort 450/1353/ 454/1264/ 1.58 0.96 2.62 7.27E−02 cohort rec CHD
    05 502 494 847 942
    rs13279522 G A 0.62 0.50 0.78 3.67E− 51/391/ 51/438/981 0.62 0.47 0.83 1.13E−03 cohort 73/693/ 57/696/ 0.63 0.44 0.90 1.12E−02 cohort add CHD
    05 1053 1889 1911
    rs7193741 A C 2.04 1.45 2.86 3.91E− 233/716/ 212/700/ 2.16 1.39 3.36 6.33E−04 cohort 368/1263/ 372/1225/ 1.87 1.10 3.18 2.01E−02 cohort rec CHD
    05 546 559 1022 1064
    rs151806 G A 0.63 0.50 0.78 4.01E− 78/545/871 75/578/ 0.60 0.45 0.80 4.38E−04 cohort 142/909/ 124/918/ 0.67 0.47 0.96 2.92E−02 cohort dom CVD
    05 816 1597 1611
    rs9446187 A G 1.96 1.42 2.72 4.36E− 19/268/ 16/238/ 1.92 1.28 2.87 1.53E−03 cohort 11/338/ 8/305/ 2.05 1.19 3.53 9.61E−03 cohort dom CHD
    05 1208 1217 2307 2347
    rs2793086 C A 0.65 0.53 0.80 4.71E− 53/498/944 55/441/975 0.61 0.47 0.80 2.19E−04 cohort 3/56/125 11/85/151 0.72 0.50 1.02 6.63E−02 Caseonly add CVD
    05
    rs17076974 A G 1.40 1.19 1.65 5.58E− 361/727/ 323/756/ 1.46 1.18 1.81 4.91E−04 cohort 594/1320/ 578/1344/ 1.32 1.02 1.71 3.48E−02 cohort add CHD
    05 405 392 729 726
    rs4924215 A G 1.65 1.29 2.11 5.58E− 215/1214/ 106/594/ 1.77 1.30 2.39 2.41E−04 cohort 12/67/80 19/71/134 1.46 0.97 2.21 6.97E−02 CaseOnly dom CHD
    05 1535 769
    rs1884897 A G 2.07 1.45 2.95 5.65E− 214/702/ 192/687/ 2.24 1.45 3.46 2.93E−04 cohort 26/73/60 22/116/86 1.78 0.97 3.29 6.31E−02 CaseOnly rec CHD
    05 578 591
    rs610118 G A 0.49 0.34 0.69 5.81E− 24/201/ 15/201/ 0.43 0.28 0.66 1.35E−04 cohort 1/18/165 1/37/209 0.62 0.34 1.12 1.10E−01 Caseonly dom CVD
    05 1269 1253
    rs7179134 A G 3.52 1.90 6.52 6.11E− 67/464/ 64/466/941 3.54 1.54 8.15 2.91E−03 cohort 102/858/ 109/872/ 3.50 1.40 8.72 7.28E−03 cohort rec CVD
    05 964 1693 1674
    rs4993917 A C 0.60 0.47 0.77 6.48E− 322/746/ 320/722/ 0.57 0.42 0.77 3.33E−04 cohort 37/89/58 52/136/59 0.67 0.43 1.03 6.44E−02 Caseonly dom CVD
    05 427 429
    rs7671659 A G 1.60 1.27 2.02 6.68E− 59/427/ 58/430/983 1.72 1.28 2.32 3.19E−04 cohort 81/726/ 59/733/ 1.43 0.99 2.07 5.96E−02 cohort dom CVD
    05 1009 1845 1863
    rs10889215 A G 1.63 1.28 2.06 6.72E− 35/297/ 30/280/ 1.50 1.13 1.99 5.01E−03 cohort 30/407/ 21/395/ 1.95 1.27 3.00 2.22E−03 cohort add CVD
    05 1162 1158 2217 2247
    rs9487284 A G 0.64 0.52 0.80 6.85E− 212/634/ 163/669/ 0.61 0.46 0.80 4.52E−04 cohort 293/1216/ 335/1259/ 0.70 0.50 0.99 4.62E−02 cohort dom CVD
    05 648 637 1142 1063
    rs7742508 A G 2.08 1.45 2.99 6.86E− 13/205/ 6/192/1272 2.19 1.37 3.49 9.74E−04 cohort 0/296/ 0/257/ 1.93 1.09 3.43 2.42E−02 cohort dom CVD
    05 1277 2357 2401
    rs2492367 A G 0.61 0.47 0.78 7.23E− 16/325/ 17/307/ 0.56 0.40 0.77 4.19E−04 cohort 44/578/ 42/585/ 0.68 0.46 1.00 4.80E−02 cohort add CVD
    05 1153 1146 2033 2033
    rs10429616 G A 1.85 1.36 2.50 7.30E− 276/736/ 282/699/ 2.07 1.41 3.04 2.21E−04 cohort 481/1361/ 479/1282/ 1.54 0.94 2.51 8.52E−02 cohort rec CHD
    05 481 488 815 901
    rs2069542 A G 1.62 1.28 2.05 7.35E− 103/802/ 44/398/ 1.67 1.26 2.22 3.45E−04 cohort 1/49/109 1/51/172 1.49 0.96 2.32 7.85E−02 CaseOnly add CHD
    05 2061 1029
    rs10155047 A G 0.55 0.41 0.74 7.66E− 18/215/ 15/273/ 0.59 0.40 0.85 5.11E−03 cohort 18/437/ 30/467/ 0.50 0.31 0.80 4.45E−03 cohort add CHD
    05 1262 1183 2201 2163
    rs4626316 A G 0.35 0.21 0.59 8.00E− 10/94/ 13/98/ 0.34 0.18 0.64 7.09E−04 cohort 3/118/ 3/111/ 0.38 0.15 0.97 4.23E−02 cohort dom CVD
    05 1388 1358 2537 2547
    rs17138705 A G 0.59 0.45 0.77 8.17E− 25/336/ 36/343/ 0.54 0.39 0.74 1.78E−04 cohort 0/32/127 6/51/167 0.70 0.44 1.11 1.28E−01 CaseOnly add CHD
    05 1134 1092
    rs10494924 C A 0.64 0.51 0.80 9.70E− 143/606/ 141/639/ 0.61 0.46 0.81 6.69E−04 cohort 19/65/ 22/115/ 0.68 0.46 1.00 5.11E−02 Caseonly dom CVD
    05 744 690 100 110
    rs33910446 A G 2.24 1.49 3.36 1.02E− 128/573/ 107/558/ 2.24 1.34 3.75 1.99E−03 cohort 24/74/85 16/113/ 2.23 1.14 4.34 1.87E−02 Caseonly rec CVD
    04 791 804 118
    rs1051344 G C 0.64 0.51 0.80 1.07E− 262/694/ 253/734/ 0.64 0.48 0.86 2.62E−03 cohort 431/1243/ 416/1234/ 0.64 0.45 0.92 1.47E−02 cohort dom CVD
    04 537 484 981 1008
    rs10444402 G A 0.69 0.57 0.83 1.16E− 74/522/ 102/500/ 0.71 0.57 0.89 3.33E−03 cohort 7/62/115 18/103/ 0.65 0.47 0.91 1.12E−02 Caseonly add CVD
    04 899 868 126
    rs7612715 A G 0.50 0.35 0.71 1.21E− 18/161/ 8/160/1303 0.47 0.30 0.73 9.43E−04 cohort 6/242/ 12/257/ 0.55 0.31 0.99 4.49E−02 cohort add CVD
    04 1316 2408 2393
    rs4243071 G A 0.43 0.28 0.66 1.22E− 274/1165/ 143/535/ 0.44 0.26 0.76 2.80E−03 cohort 11/76/97 32/91/124 0.41 0.20 0.85 1.56E−02 Caseonly rec CVD
    04 1527 793
    rs624460 A G 0.73 0.63 0.86 1.24E− 208/651/ 216/667/ 0.73 0.60 0.90 2.54E−03 cohort 350/1250/ 389/1245/ 0.74 0.57 0.95 1.78E−02 cohort add CVD
    04 635 588 1054 1022
    rs4866354 G A 0.35 0.20 0.59 1.25E− 0/102/1392 0/107/1363 0.36 0.19 0.67 1.19E−03 cohort 0/4/180 0/16/231 0.31 0.10 0.94 3.92E−02 Caseonly dom CVD
    04
    rs945020 A G 0.65 0.52 0.81 1.33E− 390/1333/ 203/669/ 0.61 0.45 0.81 6.95E−04 cohort 385/1221/ 395/1260/ 0.72 0.51 1.01 5.77E−02 cohort dom CVD
    04 1162 561 1049 1003
    rs9859901 A C 0.52 0.38 0.73 1.37E− 17/214/1264 16/270/1185 0.59 0.41 0.86 5.91E−03 cohort 0/20/139 3/53/168 0.41 0.24 0.72 1.59E−03 CaseOnly add CHD
    04
    rs7629632 G A 1.62 1.26 2.07 1.38E− 171/687/637 169/638/664 1.56 1.15 2.12 4.23E−03 cohort 15/83/60 22/87/115 1.72 1.13 2.60 1.10E−02 CaseOnly dom CHD
    04
    rs17740227 G A 1.70 1.29 2.23 1.45E− 21/306/1166 21/295/1155 1.80 1.28 2.53 6.94E−04 cohort 0/48/136 2/45/200 1.53 0.96 2.42 7.13E−02 Caseonly dom CVD
    04
    rs2263920 G A 0.46 0.31 0.69 1.45E− 197/704/593 207/668/596 0.49 0.30 0.79 3.40E−03 cohort 11/71/77 36/100/88 0.41 0.20 0.84 1.42E−02 CaseOnly rec CHD
    04
    rs1538185 A G 1.60 1.26 2.05 1.51E− 69/499/927 52/432/987 1.75 1.28 2.41 5.47E−04 cohort 101/868/ 109/864/ 1.41 0.96 2.07 7.60E−02 cohort dom CHD
    04 1686 1680
    rs2843171 A G 0.64 0.51 0.81 1.54E− 103/585/806 124/584/761 0.67 0.50 0.88 4.44E−03 cohort 15/58/111 20/109/ 0.61 0.41 0.89 1.16E−02 Caseonly dom CVD
    04 118
    rs4726711 G A 0.71 0.59 0.85 1.61E− 217/674/604 197/712/562 0.75 0.60 0.94 1.19E−02 cohort 15/62/82 33/109/82 0.62 0.45 0.85 2.88E−03 CaseOnly add CHD
    04
    rs2263901 G A 1.48 1.21 1.81 1.63E− 84/533/876 61/508/899 1.43 1.11 1.84 5.41E−03 cohort 11/62/86 10/62/152 1.57 1.12 2.21 9.90E−03 CaseOnly add CHD
    04
    rs5021480 A C 1.78 1.32 2.40 1.67E− 544/1410/ 254/697/481 1.72 1.18 2.52 4.85E−03 cohort 45/77/62 37/106/ 1.87 1.15 3.04 1.21E−02 Caseonly rec CVD
    04 929 104
    rs1877986 A G 0.62 0.48 0.80 1.73E− 569/1391/ 283/699/451 0.57 0.41 0.78 5.70E−04 cohort 494/1321/ 518/1314/ 0.71 0.48 1.05 8.37E−02 cohort dom CHD
    04 924 831 820
    rs11610993 G A 0.43 0.28 0.67 1.76E− 6/131/1358 3/140/1328 0.41 0.25 0.69 7.19E−04 cohort 0/8/176 0/20/227 0.49 0.21 1.14 9.82E−02 Caseonly dom CVD
    04
    rs1864924 G A 1.40 1.17 1.67 1.78E− 210/620/664 192/652/627 1.42 1.15 1.77 1.40E−03 cohort 28/68/63 19/106/99 1.36 1.00 1.84 4.79E−02 CaseOnly add CHD
    04
    rs17347854 G A 0.61 0.48 0.79 1.79E− 40/356/1099 38/404/1028 0.61 0.44 0.84 2.13E−03 cohort 3/41/140 13/70/164 0.62 0.41 0.96 3.17E−02 Caseonly dom CVD
    04
    rs13137776 G A 0.70 0.58 0.84 1.83E− 148/636/711 158/661/652 0.74 0.59 0.94 1.18E−02 cohort 11/47/101 27/86/111 0.62 0.45 0.86 3.72E−03 CaseOnly add CHD
    04
    rs3759607 G A 1.96 1.38 2.78 1.90E− 4/209/1281 4/165/1302 2.10 1.35 3.28 1.06E−03 cohort 0/29/130 2/24/198 1.73 0.97 3.09 6.18E−02 CaseOnly dom CHD
    04
    rs9896077 G A 0.66 0.53 0.82 2.07E− 209/677/608 196/699/576 0.63 0.47 0.83 1.35E−03 cohort 353/1151/ 406/1253/ 0.71 0.50 1.00 5.20E−02 cohort dom CVD
    04 1146 996
    rs10935907 G A 1.59 1.24 2.03 2.12E− 112/544/838 80/535/856 1.65 1.21 2.23 1.37E−03 cohort 5/74/80 17/72/135 1.49 0.99 2.25 5.72E−02 CaseOnly dom CHD
    04
    rs7625204 A G 1.45 1.19 1.77 2.24E− 119/980/ 52/488/931 1.51 1.16 1.96 2.11E−03 cohort 131/897/ 118/925/ 1.38 1.02 1.87 3.67E−02 cohort add CHD
    04 1866 1628 1616
    rs13431868 A G 1.59 1.24 2.03 2.24E− 82/554/857 71/538/860 1.70 1.25 2.31 7.44E−04 cohort 8/68/83 10/77/137 1.42 0.94 2.14 9.94E−02 CaseOnly dom CHD
    04
    rs2231496 G A 0.72 0.60 0.86 2.27E− 133/622/740 140/618/713 0.74 0.60 0.92 6.39E−03 cohort 8/73/103 26/107/ 0.67 0.49 0.91 1.13E−02 Caseonly add CVD
    04 114
    rs1705244 G A 0.60 0.46 0.79 2.28E− 650/1518/ 307/782/382 0.65 0.46 0.91 1.20E−02 cohort 37/65/57 52/123/49 0.52 0.33 0.82 5.01E−03 CaseOnly dom CHD
    04 798
    rs2274473 G A 0.55 0.40 0.75 2.28E− 27/264/1202 26/297/1147 0.58 0.39 0.85 5.84E−03 cohort 2/17/140 3/46/175 0.48 0.27 0.85 1.21E−02 CaseOnly dom CHD
    04
    rs5750116 G A 1.55 1.23 1.97 2.28E− 139/685/671 129/641/701 1.63 1.20 2.22 1.69E−03 cohort 296/1113/ 232/1174/ 1.45 1.01 2.09 4.63E−02 cohort dom CHD
    04 1245 1254
    rs912366 G A 1.66 1.27 2.18 2.29E− 31/393/1071 21/357/1093 1.60 1.14 2.24 6.82E−03 cohort 6/50/103 7/45/172 1.79 1.14 2.81 1.13E−02 CaseOnly dom CHD
    04
    rs1544214 A G 1.38 1.16 1.64 2.36E− 461/1344/ 212/678/543 1.40 1.13 1.74 2.38E−03 cohort 42/66/51 37/102/85 1.35 1.02 1.78 3.72E−02 CaseOnly add CHD
    04 1080
    rs1861326 A G 0.64 0.51 0.82 2.44E− 226/692/577 238/710/521 0.63 0.47 0.85 1.90E−03 cohort 28/84/72 32/141/74 0.67 0.45 1.00 4.96E−02 Caseonly dom CVD
    04
    rs2265346 C A 0.54 0.39 0.75 2.59E− 20/249/1226 20/287/1164 0.60 0.40 0.90 1.27E−02 cohort 2/15/141 3/46/173 0.42 0.23 0.76 4.46E−03 CaseOnly dom CHD
    04
    rs7521242 A G 0.72 0.61 0.86 2.77E− 630/1424/ 326/707/398 0.71 0.57 0.88 2.19E−03 cohort 31/80/48 59/114/51 0.74 0.55 1.00 4.85E−02 CaseOnly add CHD
    04 829
    rs10305439 A C 0.62 0.48 0.80 2.78E− 245/729/521 269/745/457 0.62 0.45 0.85 2.76E−03 cohort 30/71/58 37/125/60 0.63 0.40 0.98 3.91E−02 CaseOnly dom CHD
    04
    rs1167245 A G 0.62 0.47 0.80 2.79E− 350/728/417 369/693/408 0.68 0.50 0.92 1.29E−02 cohort 45/78/61 63/134/50 0.51 0.33 0.79 2.73E−03 Caseonly dom CVD
    04
    rs2495295 G A 0.66 0.52 0.82 2.89E− 136/608/751 143/629/697 0.65 0.49 0.87 3.00E−03 cohort 19/63/102 22/114/ 0.66 0.45 0.98 3.73E−02 Caseonly dom CVD
    04 111
    rs312929 G A 0.75 0.64 0.87 2.96E− 202/704/589 224/698/549 0.72 0.59 0.88 1.71E−03 cohort 350/1243/ 406/1240/ 0.79 0.61 1.01 6.04E−02 cohort add CVD
    04 1054 1014
    rs969356 G A 0.63 0.49 0.81 3.10E− 207/675/612 192/716/561 0.69 0.51 0.94 2.00E−02 cohort 15/62/82 31/110/83 0.54 0.36 0.82 3.60E−03 CaseOnly dom CHD
    04
    rs5017584 A G 1.74 1.29 2.36 3.25E− 279/720/496 245/694/531 1.61 1.10 2.37 1.46E−02 cohort 45/76/63 35/108/ 1.98 1.21 3.24 6.65E−03 Caseonly rec CVD
    04 104
    rs6491586 G A 1.65 1.26 2.18 3.26E− 28/377/1090 21/336/1114 1.59 1.13 2.24 8.26E−03 cohort 6/48/105 6/44/174 1.78 1.13 2.80 1.37E−02 CaseOnly dom CHD
    04
    rs842796 A G 1.59 1.23 2.05 3.30E− 248/697/550 219/684/568 1.72 1.26 2.37 7.49E−04 cohort 22/80/57 39/88/97 1.38 0.91 2.10 1.35E−01 CaseOnly dom CHD
    04
    rs4869033 G A 0.36 0.21 0.63 3.53E− 244/1142/ 135/569/767 0.31 0.16 0.63 1.20E−03 cohort 7/81/96 18/106/ 0.47 0.19 1.15 9.76E−02 Caseonly rec CVD
    04 1580 123
    rs10973013 A G 0.55 0.40 0.77 3.59E− 21/256/1218 21/297/1153 0.59 0.40 0.88 9.32E−03 cohort 2/17/140 3/46/174 0.48 0.27 0.85 1.16E−02 CaseOnly dom CHD
    04
    rs886469 G A 0.64 0.50 0.82 3.96E− 199/671/625 184/708/579 0.70 0.51 0.95 2.12E−02 cohort 15/62/82 29/111/84 0.55 0.36 0.83 4.53E−03 CaseOnly dom CHD
    04
    rs11076320 C A 0.65 0.52 0.83 4.01E− 233/691/568 249/708/512 0.64 0.48 0.86 2.64E−03 cohort 28/85/71 31/141/73 0.68 0.45 1.02 6.00E−02 Caseonly dom CVD
    04
    rs2145540 A G 0.56 0.40 0.77 4.02E− 18/247/1230 14/282/1175 0.51 0.35 0.75 5.69E−04 cohort 1/18/165 2/32/213 0.70 0.38 1.27 2.37E−01 Caseonly dom CVD
    04
    rs6505669 G A 1.58 1.22 2.03 4.18E− 59/496/940 52/463/956 1.70 1.24 2.34 9.67E−04 cohort 10/59/90 9/71/144 1.37 0.90 2.09 1.36E−01 CaseOnly dom CHD
    04
    rs9375683 G A 1.49 1.19 1.87 4.39E− 86/527/882 67/465/939 1.63 1.22 2.18 8.91E−04 cohort 128/942/ 132/928/ 1.31 0.92 1.86 1.36E−01 cohort dom CVD
    04 1584 1601
    rs10814422 G A 0.57 0.42 0.78 4.75E− 28/284/1182 30/309/1130 0.64 0.44 0.92 1.72E−02 cohort 2/18/139 3/50/170 0.46 0.26 0.80 6.31E−03 CaseOnly dom CHD
    04
    rs72746987 A G 0.40 0.24 0.67 4.89E− 3/96/1396 4/139/1328 0.43 0.24 0.80 7.44E−03 cohort 2/4/178 1/21/225 0.34 0.14 0.86 2.29E−02 Caseonly dom CVD
    04
    rs13318232 G A 0.52 0.36 0.75 5.01E− 17/212/1266 18/264/1189 0.60 0.40 0.90 1.34E−02 cohort 0/20/139 3/54/167 0.40 0.23 0.71 1.55E−03 CaseOnly dom CHD
    04
    rs2268650 A G 0.66 0.53 0.84 5.28E− 190/697/608 215/695/560 0.64 0.48 0.85 2.27E−03 cohort 29/83/72 31/138/78 0.71 0.47 1.06 9.15E−02 Caseonly dom CVD
    04
    rs4682522 C A 0.55 0.39 0.77 5.52E− 29/417/2519 18/224/1229 0.59 0.39 0.90 1.55E−02 cohort 0/21/138 1/51/172 0.49 0.28 0.85 1.17E−02 CaseOnly dom CHD
    04
    rs3798544 A G 1.57 1.21 2.03 5.87E− 32/400/1062 42/342/1087 1.47 1.08 2.02 1.55E−02 cohort 1/55/128 2/46/199 1.78 1.14 2.79 1.12E−02 Caseonly dom CVD
    04
    rs6080603 A C 0.62 0.47 0.81 5.91E− 93/835/2038 46/443/982 0.59 0.42 0.83 2.06E−03 cohort 4/32/123 7/61/156 0.68 0.43 1.09 1.11E−01 CaseOnly dom CHD
    04
    rs10517923 A G 1.61 1.23 2.12 5.93E− 352/720/422 311/730/429 1.62 1.16 2.26 4.84E−03 cohort 47/86/49 44/131/71 1.60 1.00 2.55 4.93E−02 Caseonly rec CVD
    04
    rs2104506 A C 0.71 0.59 0.87 5.99E− 114/593/788 106/608/757 0.75 0.59 0.96 2.07E−02 cohort 15/47/97 23/104/97 0.65 0.47 0.90 8.45E−03 CaseOnly add CHD
    04
    rs2023650 A G 0.71 0.59 0.87 6.11E− 81/533/878 98/523/846 0.76 0.60 0.96 2.20E−02 cohort 5/53/126 16/91/139 0.62 0.44 0.87 5.84E−03 Caseonly add CVD
    04
    rs8051893 A G 0.67 0.53 0.84 6.22E− 424/1374/ 216/699/555 0.69 0.52 0.92 1.05E−02 cohort 20/81/83 34/128/85 0.63 0.43 0.93 2.13E−02 Caseonly dom CVD
    04 1167
    rs8109631 A G 1.53 1.20 1.96 6.35E− 119/625/749 109/573/789 1.53 1.13 2.07 6.36E−03 cohort 17/73/69 19/85/120 1.54 1.02 2.32 4.00E−02 CaseOnly dom CHD
    04
    rs331555 A C 0.74 0.62 0.88 6.42E− 245/1285/ 141/632/695 0.72 0.58 0.89 2.91E−03 cohort 12/83/89 31/108/ 0.77 0.57 1.04 8.69E−02 Caseonly add CVD
    04 1432 108
    rs1343563 C A 0.60 0.45 0.81 6.82E− 22/273/1199 23/301/1145 0.61 0.43 0.88 6.99E−03 cohort 1/20/138 3/46/175 0.58 0.34 0.97 3.81E−02 CaseOnly add CHD
    04
    rs11082492 A C 1.55 1.20 2.00 6.99E− 31/369/1095 27/347/1095 1.46 1.07 1.99 1.65E−02 cohort 4/42/113 1/42/181 1.76 1.13 2.74 1.28E−02 CaseOnly add CHD
    04
    rs17546598 A G 1.71 1.25 2.33 7.18E− 22/465/2471 10/210/1247 1.57 1.08 2.28 1.91E−02 cohort 1/34/149 0/25/222 2.07 1.19 3.61 1.02E−02 Caseonly dom CVD
    04
    rs1382787 G A 1.35 1.13 1.61 7.52E− 558/1447/ 288/679/504 1.37 1.10 1.69 4.46E−03 cohort 36/85/38 40/113/71 1.32 0.98 1.78 6.95E−02 CaseOnly add CHD
    04 961
    rs6075209 A G 0.64 0.50 0.83 7.71E− 499/1425/ 275/687/509 0.63 0.46 0.86 3.35E−03 cohort 26/75/58 40/123/61 0.68 0.44 1.07 9.33E−02 CaseOnly dom CHD
    04 1042
    rs11925875 A G 0.66 0.52 0.84 7.79E− 271/707/516 304/700/467 0.72 0.53 0.97 3.13E−02 cohort 26/83/75 48/129/70 0.57 0.38 0.85 6.05E−03 Caseonly dom CVD
    04
    rs13314266 G A 0.51 0.35 0.76 8.20E− 9/185/1301 11/228/1231 0.60 0.40 0.91 1.49E−02 cohort 0/18/141 3/49/172 0.40 0.23 0.71 1.61E−03 CaseOnly add CHD
    04
    rs3000490 G A 1.38 1.14 1.66 8.36E− 248/1186/ 118/575/778 1.45 1.15 1.83 1.71E−03 cohort 15/72/72 16/91/117 1.25 0.91 1.72 1.72E−01 CaseOnly add CHD
    04 1532
    rs4289236 A G 1.41 1.15 1.72 8.44E− 68/450/975 74/406/990 1.37 1.08 1.75 1.04E−02 cohort 8/61/115 4/67/176 1.49 1.04 2.13 3.03E−02 Caseonly add CVD
    04
    rs2060411 A G 1.39 1.15 1.69 8.75E− 228/1159/ 97/568/806 1.37 1.07 1.74 1.10E−02 cohort 17/71/71 12/95/117 1.44 1.03 2.00 3.07E−02 CaseOnly add CHD
    04 1579
    rs4643388 G A 1.34 1.12 1.59 9.82E− 166/639/690 123/628/720 1.32 1.07 1.62 1.06E−02 cohort 20/80/84 16/98/133 1.38 1.02 1.86 3.61E−02 Caseonly add CVD
    04
    rs9436636 A G 1.35 1.13 1.61 1.02E− 446/1361/ 200/680/554 1.34 1.08 1.67 8.75E−03 cohort 27/81/51 28/102/93 1.36 1.00 1.83 4.76E−02 CaseOnly add CHD
    03 1079
    rs7327364 A G 0.68 0.53 0.85 1.05E− 249/686/560 218/746/507 0.69 0.52 0.93 1.30E−02 cohort 29/81/74 37/136/74 0.64 0.43 0.96 3.08E−02 Caseonly dom CVD
    03
    rs2626130 G A 1.32 1.11 1.55 1.17E− 471/1436/ 220/698/515 1.29 1.05 1.58 1.61E−02 cohort 37/89/58 30/122/95 1.37 1.04 1.82 2.74E−02 Caseonly add CVD
    03 978
    rs4611134 A G 1.55 1.19 2.01 1.20E− 388/723/377 322/721/419 1.54 1.11 2.14 1.05E−02 cohort 55/79/50 55/119/73 1.56 1.01 2.43 4.71E−02 Caseonly rec CVD
    03
    rs17716275 A G 2.03 1.32 3.13 1.32E− 7/286/2593 3/128/1303 1.91 1.11 3.29 2.01E−02 cohort 1/20/138 0/14/210 2.26 1.11 4.62 2.45E−02 CaseOnly dom CHD
    03
    rs7094941 G A 0.74 0.62 0.89 1.36E− 160/670/665 188/640/643 0.78 0.63 0.98 3.41E−02 cohort 14/64/81 27/116/81 0.66 0.48 0.91 1.06E−02 CaseOnly add CHD
    03
    rs1076733 A G 0.67 0.53 0.86 1.37E− 258/765/471 294/740/433 0.70 0.52 0.95 2.12E−02 cohort 34/81/69 40/139/68 0.62 0.41 0.94 2.34E−02 Caseonly dom CVD
    03
    rs2290193 C A 0.47 0.30 0.75 1.38E− 253/1183/ 142/574/755 0.53 0.31 0.92 2.33E−02 cohort 7/80/97 26/100/ 0.35 0.15 0.83 1.66E−02 Caseonly rec CVD
    03 1529 121
    rs10103297 A G 2.03 1.31 3.13 1.46E− 9/146/1339 7/114/1348 1.84 1.12 3.04 1.64E−02 cohort 1/14/144 2/6/216 2.74 1.13 6.65 2.60E−02 CaseOnly dom CHD
    03
    rs12657484 G A 1.49 1.16 1.90 1.49E− 133/632/727 107/581/782 1.36 1.01 1.85 4.48E−02 cohort 18/85/56 19/95/110 1.76 1.16 2.68 8.14E−03 CaseOnly dom CHD
    03
    rs7910196 G A 1.47 1.16 1.87 1.59E− 42/391/1062 26/338/1106 1.36 1.01 1.82 4.11E−02 cohort 4/54/101 2/54/168 1.72 1.14 2.59 1.01E−02 CaseOnly add CHD
    03
    rs7767024 A G 1.42 1.14 1.77 1.78E− 37/388/1070 45/361/1065 1.32 1.01 1.72 4.01E−02 cohort 2/61/121 4/50/193 1.69 1.13 2.51 1.05E−02 CaseOnly add CHD
    03
    rs1474396 A C 1.46 1.15 1.86 1.87E− 277/717/501 272/684/515 1.35 1.00 1.81 4.91E−02 cohort 32/100/52 31/118/98 1.37 1.14 2.62 9.39E−03 Caseonly dom CVD
    03
    rs1182878 A G 0.78 0.66 0.91 1.97E− 314/718/462 319/711/440 0.79 0.65 0.96 1.81E−02 cohort 41/80/63 57/137/53 0.75 0.57 0.99 4.36E−02 Caseonly add CVD
    03
    rs2483641 A G 0.59 0.43 0.83 2.06E− 14/230/1250 16/279/1174 0.65 0.43 0.97 3.34E−02 cohort 2/17/140 3/44/177 0.50 0.28 0.89 1.93E−02 CaseOnly dom CHD
    03
    rs453625 A G 0.62 0.46 0.85 2.44E− 18/236/1240 19/288/1164 0.66 0.46 0.95 2.70E−02 cohort 1/17/141 2/43/179 0.54 0.31 0.95 3.10E−02 CaseOnly add CHD
    03
    rs7497613 A G 0.55 0.37 0.81 2.66E− 649/1470/ 331/720/382 0.65 0.46 0.91 1.17E−02 cohort 29/102/53 74/125/48 0.43 0.26 0.70 6.18E−04 Caseonly rec CVD
    03 765
    rs2129571 A G 0.53 0.34 0.80 2.81E− 17/215/1263 14/269/1186 0.62 0.43 0.90 1.22E−02 cohort 0/19/140 3/52/169 0.40 0.23 0.70 1.30E−03 CaseOnly add CHD
    03
    rs16861467 G A 0.49 0.31 0.78 2.93E− 15/205/1275 12/258/1201 0.60 0.41 0.87 7.69E−03 cohort 0/18/141 3/53/168 0.37 0.21 0.65 5.20E−04 CaseOnly add CHD
    03
    rs10088524 G A 1.57 1.17 2.11 3.00E− 14/255/1226 10/212/1249 1.46 1.00 2.11 4.73E−02 cohort 1/41/142 3/32/212 1.80 1.09 2.96 2.13E−02 Caseonly dom CVD
    03
    rs10875941 G A 0.63 0.45 0.89 9.49E− 118/582/795 141/581/748 0.73 0.54 0.99 4.41E−02 cohort 2/55/101 20/97/107 0.51 0.34 0.78 1.71E−03 CaseOnly dom CHD
    03
    rs7616936 C A 1.77 1.15 2.72 9.52E− 26/335/1133 24/279/1166 1.47 1.01 2.14 4.46E−02 cohort 0/42/117 2/28/194 2.30 1.36 3.88 1.83E−03 CaseOnly dom CHD
    03
    rs6911817 A G 2.85 1.25 6.50 1.28E− 2/80/1413 2/58/1411 2.15 1.08 4.25 2.83E−02 cohort 0/12/172 0/3/244 5.32 1.47 19.19 1.08E−02 Caseonly add CVD
    02
    rs9658127 A G 2.79 1.15 6.77 2.36E− 2/83/1409 2/60/1409 2.03 1.05 3.93 3.58E−02 cohort 0/12/172 0/3/244 5.32 1.47 19.19 1.08E−02 Caseonly add CVD
    02
  • TABLE 5
    Meta-analysis
    allele P
    A1 allele value CARE WOSCOPS
    (non- A2 OR OR (ran- Prava Placebo OR OR Prava Placebo OR OR Mod- End-
    Marker ref) (ref) OR L95 U95 dom) Count Count OR L95 U95 P value Source Count Count OR L95 U95 P value Source el point
    rs11124322 A G 0.64 0.50 0.82 3.92E− 292/733/469 322/733/416 0.70 0.51 0.95 2.18E−02 cohort dom CVD
    04
    rs10193722 C A 71/167/119 100/238/106 0.62 0.46 0.85 3.11E−03 Caseonly 32/81/71 50/133/ 0.55 0.36 0.83 4.27E−03 Case- dom CVD
    64 only
    rs1051344 C G 0.64 0.51 0.80 1.07E−04 262/694/537 253/734/484 0.64 0.48 0.86 2.62E−03 cohort 431/1243/ 416/1234/ 0.64 0.45 0.92 1.47E−02 cohort dom CVD
    981 1008
    rs1051334 C A 52/149/156 73/230/140 0.58 0.44 0.78 3.23E−04 Caseonly 19/85/80 41/132/ 0.58 0.39 0.86 7.16E−03 Case- dom CVD
    rs2030057 T C 0.60 0.47 0.75 1.18E−05 47/425/964 61/410/959 0.56 0.42 0.75 7.88E−05 cohort 74 only add CHD
    rs10740308 A C 7/79/214 28/125/229 0.61 0.47 0.81 5.28E−04 Caseonly 3/41/115 6/79/ 0.66 0.44 0.99 4.49E−02 Case- add CHD
    rs10831416 G A 1.73 1.24 2.42 1.26E−03 253/707/534 233/665/573 1.61 1.08 2.42 2.09E−02 cohort 139 only rec CHD
    rs10831415 G A 62/144/94 50/179/153 1.77 1.17 2.67 7.05E−03 Caseonly 30/89/40 23/118/ 2.02 1.12 3.63 1.97E−02 Case- rec CHD
    rs4657668 G A 1.34 1.14 1.58 4.33E−04 255/675/522 213/689/532 1.32 1.08 1.61 7.53E−03 cohort 83 only add CVD
    rs1229430 G A 77/170/110 59/212/173 1.39 1.13 1.70 1.57E−03 Caseonly 33/87/64 31/105/ 1.38 1.05 1.82 2.11E−02 Case- add CVD
    rs6497117 C T 0.52 0.38 0.70 2.59E−05 308/744/395 328/721/382 0.58 0.40 0.85 5.29E−03 cohort 111 only rec CHD
    rs12914132 A G 52/159/89 97/179/106 0.60 0.41 0.87 7.98E−03 Caseonly 26/89/44 68/114/ 0.42 0.25 0.70 9.73E−04 Case- rec CHD
    rs1529806 G A 1.42 1.17 1.73 3.89E−04 130/570/752 94/561/779 1.43 1.12 1.82 4.17E−03 cohort 40 only add CHD
    rs 1594887 G A 30/126/143 19/134/229 1.56 1.22 2.00 3.71E−04 Caseonly 17/72/70 13/95/ 1.42 1.02 1.97 3.63E−02 Case- add CHD
    rs3732788 C T 0.48 0.32 0.71 2.39E−04 16/212/1267 14/275/1180 0.56 0.38 0.81 2.46E−03 cohort 116 only add CHD
    rs16861476 C A 1/35/263 5/83/294 0.47 0.31 0.71 2.92E−04 Caseonly 0/18/141 3/53/168 0.37 0.21 0.65 5.20E−04 Case- add CHD
    rs1773549 C T 1.45 1.18 1.78 3.68E−04 95/544/812 81/527/826 1.49 1.17 1.91 1.44E−03 cohort only add CHD
    rs 1737478 A G 29/125/146 20/130/232 1.54 1.20 1.96 6.39E−04 Caseonly 6/62/91 8/66/150 1.36 0.94 1.95 9.86E−02 Case- add CHD
    rs1560901 A G 1.41 1.16 1.71 5.74E−04 125/573/753 94/551/789 1.41 1.10 1.80 5.75E−03 cohort only add CHD
    rs2196180 A G 28/126/146 19/132/231 1.53 1.20 1.96 7.53E−04 Caseonly 17/71/71 13/94/ 1.41 1.02 1.95 3.97E−02 Case- add CHD
    rs231355 G C 1.38 1.16 1.64 2.11E−04 357/708/387 325/704/403 1.30 1.05 1.61 1.65E−02 cohort 117 only add CHD
    rs231358 G A 82/159/59 78/196/108 1.39 1.11 1.74 4.61E−03 Caseonly 58/70/31 53/103/ 1.54 1.16 2.04 2.94E−03 Case- add CHD
    rs10875941 C T 0.64 0.47 0.88 5.81E−03 118/582/795 141/581/748 0.73 0.54 0.99 4.41E−02 cohort 68 only dom CHD
    rs2335451 A C 21/111/168 44/157/181 0.70 0.51 0.95 2.33E−02 Caseonly 3/55/101 20/96/ 0.53 0.35 0.80 2.80E−03 Case- dom CHD
    rs9834251 G T 1.75 1.29 2.38 3.12E−04 291/722/482 247/700/524 1.64 1.11 2.41 1.22E−02 cohort 108 only rec CVD
    rs2358931 G A 66/175/114 47/235/159 1.94 1.29 2.92 1.45E−03 Caseonly 44/73/63 35/109/ 1.96 1.19 3.21 8.02E−03 Case- rec CVD
    rs4765531 A C 0.67 0.54 0.81 6.11E−05 91/566/795 113/564/757 0.70 0.55 0.90 5.60E−03 cohort 100 only add CHD
    rs2593270 A G 13/111/176 33/162/187 0.69 0.53 0.88 3.56E−03 Caseonly 7/52/100 28/84/ 0.61 0.44 0.84 2.90E−03 Case- add CHD
    rs4765531 A C 0.66 0.54 0.81 4.85E−05 91/566/795 113/564/757 0.70 0.55 0.90 5.60E−03 cohort 112 only add CHD
    rs2656824 A G 12/111/177 31/157/194 0.71 0.55 0.92 8.72E−03 Caseonly 7/51/101 28/84/ 0.60 0.43 0.83 2.14E−03 Case- add CHD
    rs302290 C T 1.56 1.24 1.97 1.65E−04 102/571/775 113/529/790 1.46 1.10 1.94 9.55E−03 cohort 112 only dom CVD
    rs302296 G A 28/144/183 31/140/273 1.54 1.15 2.05 3.34E−03 Caseonly 7/76/101 12/68/ 1.79 1.20 2.66 4.39E−03 Case- dom CVD
    rs3806005 A C 2.25 1.58 3.21 8.04E−06 10/239/1203 9/207/1218 2.03 1.32 3.11 1.26E−03 cohort 167 only dom CHD
    rs3793048 A C 3/68/228 6/47/328 2.21 1.44 3.41 3.17E−04 Caseonly 1/29/129 2/15/207 2.83 1.50 5.36 1.36E−03 Case- dom CHD
    rs1560901 A G 1.40 1.16 1.71 6.32E−04 125/573/753 94/551/789 1.41 1.10 1.80 5.75E−03 cohort only add CHD
    rs3861810 G A 28/127/145 19/132/231 1.54 1.20 1.97 5.90E−04 Caseonly 17/72/70 14/94/ 1.40 1.01 1.93 4.41E−02 Case- add CHD
    rs7179134 A G 3.72 2.01 6.89 2.88E−05 102/858/ 109/872/ 3.50 1.40 8.72 7.28E−03 cohort 116 only rec CVD
    1693 1674
    rs4128766 A G 65/454/933 68/457/909 3.92 1.70 9.02 1.31E−03 cohort 15/62/ 7/86/154 3.18 1.27 8.01 1.40E−02 Case- rec CVD
    rs2148575 A G 0.35 0.20 0.59 1.24E−04 7/96/1392 12/97/1362 0.36 0.19 0.67 1.17E−03 cohort 107 only dom CVD
    rs4242084 A C 0/12/345 4/38/402 0.26 0.12 0.55 4.34E−04 Caseonly 0/4/180 0/16/231 0.31 0.10 0.94 3.92E−02 Case- dom CVD
    rs5756670 G A 1.75 1.33 2.29 5.75E−05 320/688/443 294/689/451 1.82 1.29 2.56 6.67E−04 cohort only dom CHD
    rs4328731 A C 66/165/69 72/177/133 1.77 1.26 2.51 1.15E−03 Caseonly 27/88/44 43/97/84 1.64 1.05 2.56 2.96E−02 Case- dom CHD
    rs7094941 G A 0.74 0.61 0.89 1.16E−03 160/670/665 188/640/643 0.78 0.63 0.98 3.41E−02 cohort only add CHD
    rs4980176 C A 26/131/143 54/177/151 0.75 0.59 0.95 1.67E−02 Caseonly 13/64/81 26/117/81 0.64 0.47 0.89 8.15E−03 Case- add CHD
    rs1851830 A G 1.73 1.24 2.42 1.29E−03 218/673/560 175/648/611 1.70 1.12 2.60 1.36E−02 cohort only rec CVD
    rs6550706 A G 60/168/129 42/210/192 1.91 1.25 2.93 2.76E−03 Caseonly 34/79/71 28/94/124 1.78 1.03 3.06 3.84E−02 Case- rec CVD
    rs10275879 T A 0.50 0.36 0.71 8.02E−05 349/746/400 363/746/362 0.44 0.30 0.65 3.29E−05 cohort only rec CHD
    rs6950121 A C 44/168/88 105/188/89 0.44 0.29 0.66 6.20E−05 Caseonly 27/83/49 55/99/70 0.63 0.38 1.05 7.68E−02 Case- rec CHD
    rs7765440 T C 2.00 1.49 2.68 4.37E−06 11/210/1229 16/215/1203 1.82 1.26 2.62 1.28E−03 cohort only add CHD
    rs7751843 A G 5/59/236 3/52/327 1.69 1.16 2.46 6.03E−03 Caseonly 2/41/115 1/28/194 2.38 1.44 3.93 7.17E−04 Case- add CHD
    rs2030057 T C 0.60 0.47 0.75 1.18E−05 47/425/964 61/410/959 0.56 0.42 0.75 7.88E−05 cohort only add CHD
    rs7901888 A C 6/80/214 27/124/231 0.62 0.47 0.82 6.91E−04 Caseonly 3/41/115 6/79/139 0.66 0.44 0.99 4.49E−02 Case- add CHD
    rs3998860 A G 0.61 0.49 0.77 2.29E−05 129/851/1903 75/416/941 0.58 0.44 0.76 7.97E−05 cohort only add CHD
    rs7913568 G A 6/79/215 31/121/228 0.57 0.43 0.76 9.24E−05 Caseonly 3/44/112 6/80/138 0.70 0.47 1.05 8.17E−02 Case- add CHD
    rs6931627 G A 0.74 0.63 0.87 3.01 E−04 237/758/500 279/720/472 0.75 0.61 0.92 5.65E−03 cohort only add CVD
    rs9467561 A C 54/164/139 95/221/128 0.71 0.58 0.87 9.73E−04 Caseonly 23/94/67 55/119/73 0.72 0.54 0.95 1.92E−02 Case- add CVD
    rs912366 G A 1.61 1.23 2.11 6.04E−04 31/393/1071 21/357/1093 1.60 1.14 2.24 6.82E−03 cohort only dom CHD
    rs9554735 A G 5/95/200 7/78/297 1.77 1.26 2.49 1.09E−03 Caseonly 6/46/107 6/45/173 1.64 1.04 2.58 3.48E−02 Case- dom CHD
    only
  • TABLE 6
    al- Meta-analysis
    lele al- P
    A1 dele value CARE WOSCOPS
    (non- A2 OR OR (ran- Prava Placebo OR OR P Prava Placebo
    Marker ref) (ref) OR L95 U95 dom) Count Count OR L95 U95 value Source Count Count
    rs1312- A G 1.65 1.30 2.08 3.28E− 7/89/204 8/76/298 1.69 1.19 2.39 3.07E− case- 4/48/107 2/44/178
    9010 05 03 only
    rs4242- A C 1.93 1.41 2.64 3.42E− 51/156/ 33/215/ 2.12 1.33 3.38 1.64E− case- 21/76/87 20/109/
    281 05 149 196 03 only 118
    rs6474- A G 1.54 1.25 1.90 5.17E− 17/120/ 27/108/ 1.55 1.14 2.12 5.78E− case- 14/62/83 8/66/150
    228 05 163 247 03 only
    rs4240- A G 0.61 0.48 0.77 5.59E− 66/181/ 115/215/ 0.63 0.45 0.89 8.21E− case- 32/99/53 65/118/
    808 05 110 114 03 only 64
    rs1312- A G 0.65 0.52 0.80 6.32E− 6/89/262 13/146/ 0.64 0.47 0.87 4.55E− case- 5/53/126 9/82/156
    6170 05 285 03 only
    rs7916- G A 2.09 1.45 2.99 6.46E− 43/136/ 25/184/ 2.33 1.39 3.92 1.37E− case- 18/75/90 15/98/
    629 05 176 235 03 only 130
    rs1172- A C 0.64 0.51 0.80 6.95E− 11/85/ 21/140/ 0.65 0.48 0.89 7.62E− case- 2/34/148 7/65/175
    1179 05 261 283 03 only
    rs2993- A G 0.66 0.54 0.81 7.06E− 9/96/252 29/157/ 0.57 0.42 0.77 2.36E− case- 8/58/118 14/92/
    156 05 257 04 only 141
    rs1077- A G 0.65 0.53 0.81 8.25E− 48/125/ 56/196/ 0.72 0.53 0.99 4.35E− case- 25/64/70 37/119/
    4580 05 127 130 02 only 68
    rs1688- G A 1.56 1.25 1.94 8.49E− 17/95/ 15/85/282 1.71 1.23 2.38 1.34E− case- 7/49/103 6/52/166
    5715 05 188 03 only
    rs4870- A G 1.86 1.36 2.53 8.51E− 51/156/ 35/213/ 2.01 1.27 3.19 2.98E− case- 21/75/87 20/109/
    109 05 148 194 03 only 118
    rs1768- A C 0.69 0.58 0.83 9.66E− 7/96/254 18/155/ 0.65 0.50 0.85 1.46E− case- 5/50/129 10/86/
    8430 05 271 03 only 151
    rs7332- A G 2.06 1.43 2.96 9.98E− 35/147/ 26/195/ 1.83 1.07 3.13 2.75E− case- 22/69/93 15/103/
    076 05 174 223 02 only 129
    rs694- G A 0.55 0.41 0.75 1.26E− 38/157/ 72/175/ 0.61 0.40 0.95 2.89E− case- 20/76/63 43/103/
    780 04 105 135 02 only 78
    rs483- A G 0.68 0.56 0.83 1.30E− 27/138/ 51/193/ 0.72 0.54 0.95 1.94E− case- 17/78/89 25/128/
    6745 04 192 200 02 only 94
    rs701- A G 1.50 1.22 1.86 1.44E− 18/122/ 19/130/ 1.34 0.98 1.82 6.27E− case- 13/75/71 13/75/
    8577 04 160 233 02 only 136
    rs1158- A G 0.62 0.48 0.79 1.46E− 5/64/ 11/107/ 0.67 0.47 0.94 2.23E− case- 5/22/157 1/50/196
    5647 04 288 326 02 only
    rs442- A G 0.66 0.54 0.82 1.51E− 17/87/ 20/140/ 0.73 0.53 1.00 5.30E− case- 11/49/99 16/91/
    0312 04 196 222 02 only 117
    rs744- G A 1.52 1.21 1.91 2.61E− 13/79/ 13/79/290 1.42 1.01 1.99 4.61E− case- 7/53/99 3/57/164
    9527 04 208 02 only
    rs783- A G 1.52 1.21 1.91 2.75E− 47/177/ 62/196/ 1.45 1.04 2.04 3.10E− case- 29/86/44 46/91/87
    9562 04 76 124 02 only
    rs265- A G 0.29 0.15 0.57 3.05E− 6/120/ 20/114/ 0.38 0.15 0.97 4.34E− case- 2/46/111 14/71/
    5222 04 174 248 02 only 139
    rs261- G A 1.57 1.23 2.00 3.23E− 10/73/ 9/75/298 1.43 1.00 2.05 4.98E− case- 3/35/121 1/40/
    6548 04 217 02 only 183
    rs1049- G A 0.71 0.59 0.86 3.37E− 10/90/ 20/134/ 0.75 0.57 0.99 3.91E− case- 4/46/109 8/88/128
    7883 04 200 228 02 only
    rs699- A G 3.99 1.83 8.72 5.20E− 13/89/ 6/126/250 2.76 1.02 7.46 4.55E− case- 7/44/108 1/64/159
    8016 04 198 02 only
    rs1114- A G 1.88 1.32 2.70 5.49E− 37/133/ 27/182/ 1.74 1.03 2.95 3.92E− case- 17/76/91 10/124/
    8285 04 187 235 02 only 113
    rs730- G A 2.22 1.62 3.04 5.97E− 201/674/ 171/681/ 2.50 1.57 4.00 1.26E− cohort 27/74/58 23/115/
    5949 07 620 619 04 86
    rs26- A G 0.62 0.51 0.76 2.80E− 183/654/ 200/642/ 0.54 0.40 0.73 7.41E− cohort 273/ 279/
    4122 06 658 629 05 1142/ 1125/
    1235 1251
    rs100- A G 1.37 1.19 1.57 6.63E− 214/663/ 176/665/ 1.35 1.10 1.65 3.95E− cohort 400/ 384/
    9748 06 617 629 03 1202/ 1214/
    1054 1064
    rs133- A G 1.60 1.30 1.96 6.96E− 306/1284/ 152/631/ 1.87 1.38 2.54 5.89E− cohort 19/67/73 19/87/
    6400 06 1371 686 05 118
    rs210- A G 0.63 0.51 0.77 7.94E− 181/652/ 201/643/ 0.55 0.40 0.74 1.10E− cohort 17/56/83 24/106/
    8425 06 661 624 04 92
    rs232- G A 1.37 1.19 1.57 1.10E− 215/665/ 183/664/ 1.34 1.10 1.64 4.19E− cohort 30/86/68 31/96/
    7412 05 615 623 03 120
    rs1700- A G 1.56 1.28 1.91 1.16E− 89/477/ 61/487/ 1.63 1.22 2.17 1.00E− cohort 8/70/105 6/71/
    2013 05 929 923 03 170
    rs101- G A 1.72 1.35 2.20 1.49E− 18/281/ 22/266/ 1.63 1.14 2.33 7.11E− cohort 1/36/147 3/29/215
    5199 05 1196 1183 03
    rs707- C A 1.54 1.27 1.87 1.49E− 282/1256/ 136/621/ 1.68 1.26 2.23 3.59E− cohort 19/81/84 23/90/
    8016 05 1343 675 04 134
    rs658- A G 1.53 1.26 1.86 1.66E− 281/1256/ 136/618/ 1.68 1.26 2.23 3.56E− cohort 19/81/84 23/90/
    5412 05 1347 678 04 134
    rs19- G A 1.67 1.32 2.11 1.91E− 340/768/ 326/759/ 1.58 1.09 2.30 1.68E− cohort 613/ 588/
    8476 05 384 385 02 1353/ 1343/
    665 710
    rs2648- A G 1.98 1.44 2.72 2.42E− 172/636/ 156/625/ 2.00 1.25 3.19 3.71E− cohort 28/75/81 18/125/
    694 05 683 686 03 104
    rs1094- A G 1.58 1.28 1.96 2.89E− 19/277/ 23/270/ 1.72 1.25 2.36 8.43E− cohort 2/42/140 3/45/198
    5874 05 1197 1178 04
    rs1190- A C 0.67 0.56 0.81 3.38E− 176/666/ 170/666/ 0.61 0.46 0.81 5.65E− cohort 285/ 285/
    706 05 653 635 04 1100/ 1176/
    1252 1190
    rs3763- G C 0.75 0.66 0.86 3.75E− 259/676/ 243/723/ 0.76 0.62 0.92 6.03E− cohort 417/ 411/
    978 05 559 503 03 1255/ 1224/
    984 1024
    rs1113- G A 0.64 0.51 0.79 3.78E− 57/646/ 29/302/ 0.67 0.48 0.92 1.34E− cohort 34/563/ 46/555/
    8314 05 2183 1103 02 2059 2057
    rs1310- C A 0.65 0.53 0.80 4.01E− 104/895/ 52/452/ 0.67 0.49 0.90 8.24E− cohort 8/52/124 12/85/
    7334 05 1967 967 03 150
    rs668- A G 1.60 1.28 2.01 4.01E− 18/382/ 17/347/ 1.83 1.32 2.54 2.93E− cohort 7/45/132 5/49/193
    5920 05 1092 1104 04
    rs261- A C 1.42 1.20 1.68 4.06E− 97/494/ 95/475/ 1.39 1.09 1.78 8.81E− cohort 9/52/98 6/68/150
    6552 05 904 901 03
    rs211- A C 0.66 0.54 0.81 5.17E− 260/679/ 227/753/ 0.76 0.57 1.01 6.27E− cohort 28/74/82 31/139/
    0564 05 556 490 02 77
    rs100- G A 0.66 0.54 0.81 5.34E− 66/494/ 58/525/ 0.76 0.57 1.01 5.90E− cohort 10/52/ 12/97/
    12485 05 931 885 02 122 138
    rs179- G A 1.75 1.33 2.29 5.98E− 241/690/ 183/758/ 1.69 1.10 2.61 1.71E− cohort 473/ 491/
    8093 05 564 530 02 1222/ 1279/
    957 890
    rs478- A G 0.60 0.46 0.77 6.30E− 323/714/ 325/743/ 0.64 0.44 0.92 1.72E− cohort 29/89/41 69/99/
    7415 05 414 364 02 56
    rs1173- G A 0.61 0.48 0.78 7.05E− 645/1484/ 324/732/ 0.54 0.38 0.78 8.84E− cohort 37/100/ 59/111/
    4256 05 756 378 04 47 77
    rs126- A G 0.67 0.55 0.81 7.06E− 257/656/ 256/677/ 0.63 0.47 0.84 1.89E− cohort 20/73/91 32/113/
    6489 05 582 538 03 102
    rs238- A C 1.46 1.21 1.76 7.50E− 62/704/ 27/322/ 1.65 1.23 2.22 8.40E− cohort 55/719/ 68/672/
    250 05 2117 1083 04 1881 1921
    rs258- A G 0.72 0.61 0.85 7.53E− 57/508/ 79/507/ 0.69 0.54 0.87 1.62E− cohort 7/63/114 17/102/
    8350 05 928 883 03 128
    rs498- G A 1.47 1.21 1.77 9.18E− 43/443/ 46/403/ 1.59 1.20 2.11 1.33E− cohort 4/55/100 7/63/154
    657 05 1007 1020 03
    rs642- C A 0.68 0.56 0.83 9.43E− 477/1399/ 237/700/ 0.70 0.53 0.93 1.46E− cohort 391/ 439/
    7807 05 1084 529 02 1269/ 1236/
    993 983
    rs61- G A 0.56 0.41 0.75 1.01E− 238/719/ 247/673/ 0.62 0.41 0.94 2.29E− cohort 20/76/63 43/102/
    9825 04 536 551 02 78
    rs94- G A 1.85 1.36 2.52 1.02E− 193/661/ 158/705/ 1.86 1.18 2.95 7.99E− cohort 21/76/86 19/108/
    78241 04 640 605 03 118
    rs172- A G 1.47 1.21 1.79 1.02E− 216/667/ 169/670/ 1.57 1.18 2.08 1.90E− cohort 21/86/76 22/98/
    7746 04 612 632 03 127
    rs250- A G 0.76 0.66 0.87 1.04E− 370/670/ 300/766/ 0.69 0.56 0.86 7.20E− cohort 486/ 527/
    5039 04 455 405 04 1334/ 1350/
    834 786
    rs447- G A 0.66 0.54 0.82 1.05E− 154/685/ 177/679/ 0.74 0.54 1.00 4.86E− cohort 20/66/73 23/115/
    2926 04 656 615 02 86
    rs653- A G 0.65 0.52 0.81 1.07E− 326/757/ 356/736/ 0.62 0.46 0.86 3.59E− cohort 40/88/56 52/140/
    9231 04 412 379 03 55
    rs795- A G 0.76 0.66 0.87 1.09E− 328/718/ 319/766/ 0.77 0.64 0.94 1.14E− cohort 30/82/72 44/137/
    9965 04 448 386 02 66
    rs974- A G 0.67 0.55 0.82 1.13E− 259/677/ 228/750/ 0.77 0.57 1.03 7.47E− cohort 28/74/82 31/139/
    950 04 558 492 02 77
    rs152- A G 0.72 0.60 0.85 1.14E− 81/566/ 122/580/ 0.63 0.49 0.82 4.61E− cohort 9/60/90 23/86/
    4962 04 848 767 04 115
    rs1782- A C 0.30 0.16 0.55 1.15E− 148/947/ 78/476/ 0.24 0.09 0.64 4.37E− cohort 3/60/96 13/70/
    1383 04 1791 880 03 141
    rs1051- A G 0.67 0.55 0.82 1.19E− 59/493/ 57/525/ 0.76 0.57 1.02 6.53E− cohort 11/52/121 13/96/
    8335 04 942 889 02 138
    rs122- A C 1.66 1.28 2.15 1.21E− 690/1425/ 339/726/ 1.65 1.16 2.36 5.58E− cohort 38/76/45 43/100/
    65891 04 771 369 03 79
    rs480- A G 2.00 1.40 2.85 1.22E− 4/144/ 7/126/ 2.20 1.33 3.64 2.01E− cohort 3/19/162 1/14/232
    7536 04 1346 1338 03
    rs991- A G 0.64 0.51 0.80 1.22E− 34/363/ 29/380/ 0.72 0.51 1.01 5.56E− cohort 5/36/117 6/72/146
    4580 04 1098 1062 02
    rs646- A G 0.56 0.41 0.75 1.24E− 236/723/ 239/683/ 0.62 0.41 0.95 2.76E− cohort 20/75/63 43/101/78
    749 04 536 548 02
    rs100- A C 1.51 1.22 1.86 1.25E− 72/516/ 67/505/ 1.57 1.15 2.13 4.17E− cohort 9/58/92 8/64/152
    3322 04 907 899 03
    rs466- A G 1.56 1.24 1.96 1.26E− 18/382/ 17/347/ 1.86 1.31 2.65 5.46E− cohort 53/567/ 57/576/
    0234 04 1095 1105 04 2036 2031
    rs403- G A 0.65 0.52 0.81 1.27E− 304/693/ 271/747/ 0.65 0.47 0.90 8.85E− cohort 27/65/67 55/105/
    8018 04 498 453 03 64
    rs771- G A 0.68 0.56 0.83 1.32E− 137/588/ 134/612/ 0.69 0.52 0.91 8.96E− cohort 7/67/110 18/106/
    0039 04 769 725 03 123
    rs131- A G 1.48 1.21 1.81 1.33E− 111/911/ 43/443/ 1.38 1.04 1.85 2.74E− cohort 12/70/ 9/67/171
    50189 04 1941 983 02 102
    rs126- A G 0.68 0.55 0.83 1.34E− 65/504/ 60/526/ 0.75 0.57 1.01 5.51E− cohort 10/52/ 13/96/
    46525 04 926 885 02 122 138
    rs211- A G 0.41 0.26 0.65 1.36E− 180/1056/ 97/534/ 0.43 0.23 0.83 1.18E− cohort 6/73/105 15/84/
    3334 04 1730 840 02 148
    rs25- A G 2.19 1.46 3.27 1.37E− 0/84/1359 3/83/ 2.09 1.15 3.80 1.59E− cohort 0/13/170 0/6/241
    1817 04 1341 02
    rs2574 C G 1.53 1.23 1.91 1.39E− 377/740/ 338/715/ 1.48 1.07 2.04 1.77E− cohort 57/87/39 56/128/
    04 378 418 02 63
    rs1267- A G 0.68 0.56 0.83 1.40E− 146/640/ 167/647/ 0.65 0.49 0.87 2.98E− cohort 14/76/94 30/117/
    9254 04 709 657 03 100
    rs1234- A G 2.10 1.43 3.09 1.47E− 138/583/ 98/607/ 2.35 1.30 4.27 4.90E− cohort 180/ 154/
    1095 04 774 766 03 1006/ 1001/
    1468 1503
    rs170- C A 1.31 1.14 1.51 1.47E− 239/709/ 219/690/ 1.26 1.03 1.54 2.34E− cohort 44/90/50 34/125/
    48681 04 546 562 02 88
    rs194- A G 0.56 0.42 0.76 1.48E− 228/724/ 237/679/ 0.62 0.40 0.95 2.82E− cohort 20/75/64 43/102/
    2876 04 543 554 02 79
    rs265- A G 1.40 1.18 1.66 1.52E− 82/530/ 59/504/ 1.43 1.11 1.85 5.19E− cohort 11/62/86 10/62/
    7940 04 882 908 03 152
    rs494- G A 0.57 0.42 0.76 1.54E− 237/727/ 241/690/ 0.63 0.42 0.96 3.08E− cohort 19/77/62 43/104/
    111 04 531 540 02 77
    rs206- G A 0.64 0.51 0.81 1.59E− 320/753/ 364/713/ 0.58 0.41 0.81 1.54E− cohort 45/94/45 79/109/
    0022 04 422 393 03 59
    rs733- A G 2.16 1.45 3.22 1.59E− 3/121/ 0/101/ 2.01 1.13 3.57 1.75E− cohort 1/10/148 1/7/216
    8174 04 1371 1370 02
    rs120- G A 0.76 0.66 0.88 1.61E− 220/701/ 246/692/ 0.74 0.60 0.90 2.93E− cohort 24/90/70 41/120/
    48902 04 574 532 03 86
    rs674- A G 1.49 1.21 1.83 1.63E− 99/581/ 92/528/ 1.52 1.12 2.06 7.63E− cohort 6/66/87 9/62/153
    6182 04 814 851 03
    rs727- A C 0.46 0.31 0.69 1.68E− 3/109/ 5/133/ 0.37 0.19 0.69 1.84E− cohort 0/10/174 1/18/228
    6749 04 1378 1328 03
    rs19- G A 1.56 1.24 1.97 1.68E− 339/773/ 327/761/ 1.59 1.09 2.30 1.48E− cohort 620/ 591/
    8460 04 382 382 02 1368/ 1353/
    663 713
    rs778- A G 1.53 1.23 1.92 1.75E− 362/729/ 343/725/ 1.41 1.02 1.96 3.74E− cohort 59/85/40 56/130/
    5499 04 404 403 02 61
    rs99- C A 0.57 0.42 0.76 1.76E− 227/724/ 237/677/ 0.63 0.41 0.96 3.27E− cohort 20/75/64 43/102/
    6022 04 543 555 02 79
    rs722- A G 0.64 0.51 0.81 1.79E− 34/352/ 25/379/ 0.73 0.52 1.04 7.77E− cohort 6/36/117 6/72/146
    2186 04 1109 1067 02
    rs19- G A 1.57 1.24 1.99 1.80E− 349/771/ 336/765/ 1.44 1.00 2.07 4.86E− cohort 50/69/40 42/122/60
    8464 04 374 369 02
    rs169- C A 0.68 0.55 0.83 1.80E− 197/673/ 205/670/ 0.75 0.55 1.02 7.03E− cohort 13/64/82 33/105/86
    34059 04 625 595 02
    rs156- G A 0.56 0.42 0.76 1.84E− 14/347/ 8/175/ 0.59 0.39 0.88 1.10E− cohort 0/14/145 0/42/182
    6221 04 2605 1288 02
    rs812- A G 0.46 0.31 0.69 1.85E− 3/108/ 5/133/ 0.37 0.19 0.69 1.89E− cohort 0/10/174 1/18/228
    9810 04 1384 1333 03
    rs134- G A 1.45 1.19 1.77 1.89E− 60/459/ 74/439/ 1.45 1.09 1.93 1.14E− cohort 106/820/ 101/844/
    4081 04 976 958 02 1729 1709
    rs79- A G 1.54 1.23 1.94 1.96E− 26/352/ 21/324/ 1.47 1.07 2.03 1.91E− cohort 8/43/133 3/41/203
    18692 04 1117 1126 02
    rs46- A G 1.55 1.23 1.95 2.04E− 341/721/ 302/709/ 1.42 1.02 1.99 3.98E− cohort 55/87/42 54/122/71
    86740 04 433 460 02
    rs128- A G 0.77 0.67 0.88 2.05E− 262/693/ 249/739/ 0.76 0.62 0.93 7.13E− cohort 20/89/75 41/133/73
    17873 04 538 481 03
    rs7508 G A 1.48 1.20 1.82 2.08E− 125/612/ 120/550/ 1.42 1.05 1.93 2.27E− cohort 15/77/67 20/92/112
    04 758 801 02
    rs27- A G 0.57 0.43 0.77 2.13E− 189/670/ 216/652/ 0.51 0.33 0.78 2.30E− cohort 19/94/71 40/115/92
    1046 04 636 603 03
    rs201- A G 0.64 0.51 0.81 2.15E− 21/274/ 18/268/ 0.67 0.47 0.95 2.57E− cohort 2/23/133 8/47/169
    1318 04 1155 1147 02
    rs113- A G 1.48 1.20 1.83 2.29E− 59/663/ 29/317/ 1.64 1.23 2.18 8.11E− cohort 2/35/147 2/43/202
    6046 04 2244 1125 04
    rs145- G A 0.69 0.57 0.84 2.29E− 43/415/ 43/464/ 0.63 0.47 0.84 1.89E− cohort 4/43/112 8/81/135
    0092 04 1037 962 03
    rs707- G A 1.45 1.19 1.78 2.37E− 37/350/ 32/325/ 1.42 1.07 1.88 1.43E− cohort 8/39/135 3/38/206
    0244 04 1107 1114 02
    rs892- G A 0.60 0.46 0.79 2.39E− 273/736/ 279/695/ 0.64 0.43 0.96 2.95E− cohort 20/80/59 51/100/73
    162 04 485 496 02
    rs656- A G 0.65 0.52 0.82 2.41E− 42/350/ 35/383/ 0.76 0.56 1.04 8.26E− cohort 2/24/133 4/54/166
    3805 04 1102 1052 02
    rs99- G A 0.65 0.52 0.82 2.42E− 35/355/ 30/376/ 0.71 0.50 1.01 5.44E− cohort 6/37/116 6/72/146
    06737 04 1104 1064 02
    rs47- G A 1.63 1.25 2.12 2.49E− 20/235/ 8/198/ 1.79 1.24 2.59 1.75E− cohort 0/29/155 0/29/217
    5420 04 1237 1263 03
    rs176- G A 0.51 0.36 0.73 2.61E− 156/606/ 168/601/ 0.58 0.36 0.94 2.65E− cohort 13/78/93 31/116/
    44708 04 732 702 02 100
    rs705- A G 1.53 1.22 1.91 2.61E− 33/353/ 30/321/ 1.43 1.03 1.97 3.11E− cohort 8/43/132 3/38/206
    7780 04 1109 1119 02
    rs4773 A G 0.69 0.56 0.84 2.68E− 249/694/ 250/712/ 0.65 0.48 0.87 3.94E− cohort 20/73/91 32/111/
    04 552 509 03 104
    rs674- G A 1.53 1.22 1.92 2.69E− 395/755/ 335/732/ 1.33 0.96 1.85 8.45E− cohort 49/91/44 47/123/77
    2894 04 343 404 02
    rs104- G A 0.74 0.62 0.87 2.70E− 225/1125/ 118/555/ 0.67 0.52 0.86 1.39E− cohort 157/975/ 170/995/
    5916 04 1533 760 03 1521 1496
    rs643- A G 0.67 0.53 0.83 2.76E− 298/688/ 264/756/ 0.70 0.51 0.97 3.05E− cohort 34/70/55 42/134/48
    5378 04 509 451 02
    rs134- A G 1.44 0.18 1.75 2.78E− 121/612/ 118/565/ 1.33 1.01 1.76 4.53E− cohort 22/84/78 18/87/142
    11119 04 762 788 02
    rs153- A C 0.68 0.56 0.84 2.79E− 330/1271/ 180/641/ 0.65 0.48 0.88 5.54E− cohort 13/54/92 21/89/114
    1842 04 1365 650 03
    rs9857 G A 0.74 0.63 0.87 2.85E− 96/554/ 120/608/ 0.68 0.54 0.86 1.14E− cohort 6/64/114 18/82/147
    04 844 741 03
    rs9960 A G 1.47 1.19 1.80 2.88E− 54/483/ 41/442/ 1.55 1.15 2.08 3.88E− cohort 10/57/117 7/63/177
    04 958 987 03
    rs131- G A 0.67 0.54 0.83 2.88E− 81/850/ 39/434/ 0.70 0.52 0.95 2.39E− cohort 5/53/126 8/83/156
    03899 04 1955 961 02
    rs684- G A 0.66 0.53 0.83 2.88E− 316/740/ 329/731/ 0.75 0.55 1.02 6.96E− cohort 38/90/56 65/133/49
    8512 04 394 373 02
    rs101- A C 1.36 1.15 1.61 2.95E− 64/473/ 54/454/ 1.31 1.02 1.67 3.21E− cohort 11/74/99 8/76/163
    81805 04 957 963 02
    rs11- C A 1.42 1.17 1.71 3.02E− 47/455/ 50/410/ 1.34 1.01 1.77 4.41E− cohort 7/52/100 5/54/165
    29570 04 950 974 02
    rs99- A C 1.77 1.30 2.41 3.07E− 349/1376/ 156/710/ 1.79 1.13 2.84 1.30E− cohort 21/75/87 20/108/
    86576 04 1241 605 02 117
    rs13- A G 0.44 0.28 0.69 3.07E− 133/614/ 145/609/ 0.59 0.34 1.03 6.31E− cohort 6/62/91 28/84/
    52236 04 746 716 02 112
    rs77- A G 0.65 0.52 0.82 3.13E− 20/302/ 20/324/ 0.69 0.50 0.97 3.13E− cohort 0/23/136 6/43/174
    70578 04 1128 1087 02
    rs27- G A 1.58 1.23 2.03 3.14E− 326/750/ 314/702/ 1.57 1.07 2.30 2.05E− cohort 517/ 452/
    48901 04 419 454 02 1250/ 1342/
    885 868
    rs115- G A 0.77 0.67 0.89 3.21E− 286/710/ 298/652/ 0.81 0.66 1.01 5.63E− cohort 21/85/52 61/104/59
    5875 04 499 521 02
    rs67- C A 0.67 0.54 0.83 3.25E− 15/305/ 25/315/ 0.70 0.51 0.95 2.23E− cohort 2/31/151 4/54/189
    5163 04 1175 1131 02
    rs106- G A 0.66 0.53 0.83 3.29E− 335/738/ 342/724/ 0.67 0.48 0.95 2.34E− cohort 615/ 672/
    8705 04 421 405 02 1268/ 1320/
    767 661
    rs150- G A 1.50 1.20 1.88 3.45E− 26/322/ 21/320/ 1.36 0.99 1.87 6.03E− cohort 2/44/113 1/48/175
    5469 04 1147 1130 02
    rs62- A G 0.70 0.57 0.85 3.56E− 107/559/ 115/547/ 0.77 0.58 1.03 7.39E− cohort 16/63/ 25/111/
    3400 04 786 772 02 105 111
    rs60- G A 1.47 1.19 1.82 3.60E− 128/565/ 110/562/ 1.72 1.30 2.28 1.37E− cohort 18/72/94 23/87/137
    40760 04 801 799 04
    rs173- A G 0.68 0.55 0.84 3.68E− 47/422/ 63/453/ 0.65 0.48 0.89 6.66E− cohort 2/54/128 4/81/162
    10169 04 1025 955 03
    rs762- A C 4.25 1.92 9.43 3.74E− 44/369/ 37/324/ 4.02 1.31 12.33 1.50E− cohort 6/46/132 2/58/187
    3808 04 1081 1109 02
    rs77- A G 0.48 0.32 0.72 3.78E− 3/110/ 5/129/ 0.38 0.21 0.71 2.41E− cohort 0/10/174 1/18/228
    638540 04 1382 1337 03
    rs58- A G 0.59 0.44 0.79 3.85E− 239/715/ 240/683/ 0.62 0.41 0.94 2.53E− cohort 19/76/64 43/103/78
    1401 04 539 548 02
    rs42- A G 0.69 0.56 0.84 3.90E− 34/355/ 29/377/ 0.78 0.59 1.04 8.76E− cohort 1/35/148 3/76/168
    51580 04 1106 1065 02
    rs6- G A 0.59 0.44 0.79 3.91E− 238/721/ 242/677/ 0.62 0.40 0.94 2.40E− cohort 19/77/63 43/103/78
    03940 04 534 552 02
    rs13- G A 1.50 1.20 1.88 4.01E− 43/468/ 42/389/ 1.29 0.93 1.79 1.23E− cohort 5/42/112 3/41/180
    117043 04 984 1039 01
    rs380- A G 0.48 0.32 0.72 4.10E− 3/114/ 2/136/ 0.39 0.20 0.76 5.25E− cohort 0/9/150 1/23/200
    0202 04 1375 1329 03
    rs107- A G 0.76 0.65 0.88 4.18E− 202/706/ 231/708/ 0.82 0.65 1.02 7.21E− cohort 19/77/63 36/118/70
    38948 04 587 530 02
    rs62- A G 0.59 0.45 0.79 4.21E− 238/724/ 243/682/ 0.62 0.41 0.94 2.32E− cohort 19/76/64 43/104/77
    3584 04 532 546 02
    rs955- A G 1.49 1.20 1.87 4.24E− 27/383/ 24/334/ 1.70 1.21 2.39 2.28E− cohort 44/636/ 46/585/
    7509 04 1084 1112 03 1977 2031
    rs116 - G A 1.35 1.14 1.60 4.29E− 168/985/ 79/486/ 1.31 1.02 1.69 3.36E− cohort 122/885/ 111/846/
    68038 04 1731 868 02 1648 1702
    rs108- A C 1.29 1.12 1.49 4.62E− 697/1481/ 328/745/ 1.40 1.12 1.74 3.12E− cohort 625/ 604/
    02865 04 705 360 03 1329/ 1353/
    702 706
    rs1703- A G 1.44 1.17 1.77 5.05E− 49/471/ 57/435/ 1.52 1.11 2.09 8.90E− cohort 114/855/ 112/836/
    5071 04 975 979 03 1681 1709
    rs14- A G 1.39 1.16 1.68 5.20E− 118/612/ 113/587/ 1.29 1.02 1.64 3.56E− cohort 20/72/67 15/75/134
    39269 04 765 770 02
    rs20- A G 1.41 1.16 1.72 5.61E− 93/537/ 96/473/ 1.30 0.98 1.72 7.23E− cohort 12/79/93 9/89/149
    8025 04 861 897 02
    rs126- G A 0.67 0.53 0.84 5.65E− 21/337/ 26/366/ 0.70 0.50 0.98 3.67E− cohort 7/36/141 8/70/169
    08167 04 1137 1078 02
    rs13- G A 0.70 0.57 0.85 5.74E− 173/606/ 182/638/ 0.81 0.60 1.09 1.64E− cohort 20/54/85 25/105/94
    3871 04 716 651 01
    rs706- A C 1.65 1.24 2.19 5.82E− 11/240/ 9/204/ 1.69 1.10 2.59 1.62E− cohort 3/32/124 1/26/197
    8975 04 1244 1258 02
    rs186- A G 0.74 0.62 0.88 5.84E− 70/500/ 93/548/ 0.69 0.53 0.88 3.18E− cohort 4/57/123 12/80/155
    6386 04 925 829 03
    rs158- A G 1.57 1.21 2.03 6.11E− 552/1477/ 251/764/ 1.52 1.04 2.22 3.16E− cohort 45/72/41 41/116/66
    0713 04 937 456 02
    rs936- G A 0.70 0.57 0.86 6.61E− 93/549/ 109/559/ 0.73 0.54 0.99 4.56E− cohort 11/58/90 25/92/107
    671 04 852 801 02
    rs373- A G 1.51 1.19 1.91 6.62E− 118/604/ 117/568/ 1.32 0.98 1.79 6.98E− cohort 20/71/68 16/74/134
    2136 04 772 786 02
    rs177- A G 0.72 0.59 0.87 6.84E− 50/407/ 46/464/ 0.67 0.51 0.89 6.28E− cohort 5/45/109 8/82/134
    18867 04 1038 961 03
    rs57- G A 1.53 1.20 1.95 7.02E− 23/261/ 18/240/ 1.40 0.99 1.98 5.39E− cohort 6/38/140 2/33/212
    64592 04 1211 1212 02
    rs28- G A 1.41 1.16 1.72 7.07E− 118/563/ 92/541/ 1.31 0.98 1.74 6.81E− cohort 14/84/86 14/92/141
    80563 04 770 801 02
    rs156- G A 0.78 0.68 0.90 7.07E− 279/650/ 205/735/ 0.73 0.58 0.90 3.95E− cohort 402/ 447/
    4078 04 563 530 03 1248/ 1288/
    992 915
    rs108- A G 1.66 1.24 2.23 7.22E− 0/203/ 0/157/ 1.83 1.19 2.81 5.83E− cohort 0/32/152 2/31/214
    17479 04 1280 1305 03
    rs47- A G 1.26 1.10 1.45 7.28E− 341/724/ 324/705/ 1.20 0.99 1.46 6.17E− cohort 47/101/ 57/112/
    8859 04 430 442 02 36 78
    rs101- G A 1.64 1.23 2.19 7.44E− 190/675/ 167/704/ 1.40 0.92 2.14 1.15E− cohort 27/77/80 25/124/98
    06852 04 630 599 01
    rs1265- A G 1.43 1.16 1.75 7.50E− 105/584/ 85/532/ 1.48 1.09 2.00 1.21E− cohort 17/72/70 12/89/123
    9030 04 806 854 02
    rs15- A G 1.49 1.18 1.89 7.74E− 369/716/ 271/747/ 1.57 1.11 2.23 1.06E− cohort 47/79/58 48/127/72
    36506 04 408 453 02
    rs218- G A 0.70 0.57 0.86 7.76E− 467/1361/ 218/711/ 0.66 0.48 0.90 7.98E− cohort 18/61/80 32/97/95
    4393 04 1166 540 03
    rs110- G A 1.47 1.17 1.84 7.81E− 42/404/ 33/375/ 1.26 0.90 1.75 1.75E− cohort 4/52/103 2/48/174
    77308 04 1005 1026 01
    rs79- C G 0.71 0.58 0.87 8.35E− 225/681/ 260/682/ 0.69 0.51 0.92 1.04E− cohort 28/71/84 41/104/
    15250 04 589 529 02 101
    rs46- G A 1.27 1.10 1.46 8.63E− 319/719/ 266/733/ 1.23 1.01 1.50 3.84E− cohort 37/104/ 36/126/
    89078 04 454 469 02 43 85
    rs286- A G 0.75 0.64 0.89 9.44E− 68/511/ 79/508/ 0.81 0.64 1.03 8.13E− cohort 4/64/116 15/97/135
    9680 04 872 847 02
    rs122- A G 2.18 1.37 3.45 9.89E− 0/150/ 0/62/1368 2.20 1.07 4.55 3.26E− cohort 0/13/171 1/7/239
    86877 04 2726 02
    rs104- A G 0.24 0.08 0.70 9.13E− 0/58/1394 1/68/1365 0.43 0.20 0.92 2.98E− cohort 0/1/183 0/13/234
    60737 03 02
    WOSCOPS PROVEIT
    OR OR P Atorv Prav OR OR Mod- End-
    Marker OR L95 U95 value Source Count Count OR L95 U95 P value Source el point
    rs1312- 1.90 1.19 3.03 6.81E− case- 6/47/ 5/51/196 1.39 0.89 2.16 1.44E− case- dom CHD
    9010 03 only 138 01 only
    rs4242- 1.46 0.76 2.79 2.51E− case- 37/78/ 27/127/ 2.08 1.20 3.60 8.70E− case- rec CVD
    281 01 only 76 98 03 only
    rs6474- 1.83 1.21 2.79 4.63E− case- 9/87/95 19/90/ 1.32 0.90 1.93 1.52E− case- dom CHD
    228 03 only 143 01 only
    rs4240- 0.61 0.38 0.98 4.06E− case- 28/97/66 59/123/ 0.56 0.34 0.92 2.26E− case- rec CVD
    808 02 only 70 02 only
    rs1312- 0.78 0.52 1.17 2.36E− case- 6/37/148 7/81/164 0.53 0.34 0.82 4.23E− case- dom CVD
    6170 01 only 03 only
    rs7916- 1.66 0.81 3.41 1.64E− case- 21/82/86 15/101/ 2.11 1.05 4.26 3.73E− case- rec CVD
    629 01 only 136 02 only
    rs1172- 0.60 0.38 0.95 2.87E− case- 14/41/ 12/80/ 0.64 0.41 0.99 4.53E− case- dom CVD
    1179 02 only 136 160 02 only
    rs2993- 0.76 0.51 1.13 1.73E− case- 11/57/ 23/84/ 0.75 0.50 1.10 1.42E− case- dom CVD
    156 01 only 123 145 01 only
    rs1077- 0.56 0.37 0.86 7.45E− case- 26/85/80 40/132/ 0.63 0.43 0.94 2.27E− case- dom CHD
    4580 03 only 80 02 only
    rs1688- 1.58 1.01 2.46 4.38E− case- 10/60/ 9/67/176 1.34 0.89 2.00 1.59E− case- dom CHD
    5715 02 only 121 01 only
    rs4870- 1.47 0.77 2.80 2.45E− case- 37/78/76 28/124/ 1.97 1.14 3.40 1.48E− case- rec CVD
    109 01 only 98 02 only
    rs1768- 0.71 0.50 1.01 5.62E− case- 4/51/136 10/77/ 0.77 0.54 1.11 1.57E− case- add CVD
    8430 02 only 165 01 only
    rs7332- 2.18 1.09 4.34 2.70E− case- 23/69/99 14/100/ 2.40 1.18 4.88 1.62E− case- rec CVD
    076 02 only 138 02 only
    rs694- 0.62 0.35 1.10 1.02E− case- 19/106/ 50/108/ 0.40 0.21 0.73 3.11E− case- rec CHD
    780 01 only 66 94 03 only
    rs483- 0.65 0.44 0.97 3.26E− case- 13/76/ 25/119/ 0.65 0.44 0.96 2.82E− case- dom CVD
    6745 02 only 102 108 02 only
    rs701- 1.94 1.28 2.94 1.68E− case- 15/79/97 18/83/ 1.44 0.98 2.12 6.13E− case- dom CHD
    8577 03 only 151 02 only
    rs1158- 0.67 0.40 1.12 1.25E− case- 10/26/ 14/61/ 0.49 0.30 0.80 4.76E− case- dom CVD
    5647 01 only 155 177 03 only
    rs442- 0.64 0.42 0.97 3.58E− case- 8/56/127 10/106/ 0.59 0.40 0.87 8.31E− case- dom CHD
    0312 02 only 136 03 only
    rs744- 1.71 1.10 2.65 1.72E− case- 8/61/122 8/60/184 1.53 1.01 2.30 4.28E− case- dom CHD
    9527 02 only 02 only
    rs783- 1.63 1.05 2.53 3.07E− case- 47/95/49 39/125/ 1.54 1.01 2.34 4.35E− case- dom CHD
    9562 02 only 88 02 only
    rs265- 0.20 0.05 0.91 3.78E− case- 3/80/108 17/71/ 0.23 0.07 0.80 2.09E− case- rec CHD
    5222 02 only 164 02 only
    rs261- 1.37 0.83 2.26 2.18E− case- 8/57/126 2/52/198 2.02 1.28 3.16 2.29E− case- dom CHD
    6548 01 only 03 only
    rs1049- 0.67 0.46 0.98 4.15E− case- 3/57/131 13/88/ 0.68 0.48 0.96 2.91E− case- add CHD
    7883 02 only 151 02 only
    rs699- 9.63 1.17 79.34 3.53E− case- 9/61/121 2/73/177 6.19 1.27 30.09 2.39E− case- rec CHD
    8016 02 only 02 only
    rs1114- 2.30 1.02 5.16 4.42E− case- 27/72/92 22/101/ 1.87 1.01 3.48 4.67E− case- rec CVD
    8285 02 only 129 02 only
    rs730- 1.74 0.95 3.17 7.16E− case- 130/459/ 133/443/ 2.34 1.29 4.22 4.97E− cohort rec CHD
    5949 02 only 419 434 03
    rs26- 0.66 0.46 0.95 2.58E− cohort 144/421/ 136/459/ 0.72 0.50 1.05 8.92E− cohort dom CHD
    4122 02 454 419 02
    rs100- 1.35 1.05 1.72 1.81E− cohort 121/455/ 118/435/ 1.43 1.09 1.88 1.06E− cohort add CVD
    9748 02 444 460 02
    rs133- 1.35 0.90 2.04 1.53E− case- 151/404/ 116/431/ 1.46 1.00 2.12 4.82E− cohort dom CHD
    6400 01 only 459 465 02
    rs210- 0.62 0.41 0.94 2.45E− case- 148/415/ 138/469/ 0.77 0.53 1.12 1.69E− cohort dom CHD
    8425 02 only 447 405 01
    rs232- 1.41 1.07 1.86 1.56E− case- 122/453/ 119/431/ 1.38 1.05 1.81 2.08E− cohort add CVD
    7412 02 only 443 463 02
    rs1700- 1.66 1.11 2.48 1.28E− case- 54/346/ 57/351/ 1.38 0.94 2.02 9.55E− cohort dom CVD
    2013 02 only 616 604 02
    rs101- 1.66 0.98 2.78 5.77E− case- 19/226/ 11/200/ 1.93 1.23 3.03 4.06E− cohort dom CVD
    5199 02 only 775 803 03
    rs707- 1.44 0.98 2.12 6.19E− case- 140/415/ 112/439/ 1.41 0.97 2.04 7.29E− cohort dom CVD
    8016 02 only 466 466 02
    rs658- 1.44 0.98 2.12 6.19E− case- 144/404/ 116/433/ 1.39 0.96 2.02 8.12E− cohort dom CVD
    5412 02 only 469 465 02
    rs19- 1.61 1.06 2.46 2.63E− cohort 65/85/41 55/132/ 1.85 1.21 2.84 4.85E− case- rec CHD
    8476 02 65 03 only
    rs2648- 2.29 1.22 4.29 9.83E− case- 108/459/ 113/452/ 1.72 0.95 3.11 7.49E− cohort rec CVD
    694 03 only 453 451 02
    rs1094- 1.24 0.81 1.91 3.19E− case- 22/196/ 20/201/ 1.72 1.15 2.58 8.16E− cohort add CVD
    5874 01 only 799 795 03
    rs1190- 0.70 0.50 0.99 4.37E− cohort 103/476/ 129/443/ 0.76 0.52 1.10 1.42E− cohort dom CVD
    706 02 441 445 01
    rs376- 0.68 0.53 0.87 2.46E− cohort 154/448/ 171/478/ 0.84 0.65 1.10 2.06E− cohort add CVD
    3978 03 418 365 01
    rs111- 0.59 0.39 0.89 1.22E− cohort 22/228/ 19/256/ 0.64 0.43 0.95 2.83E− cohort add CHD
    38314 02 765 740 02
    rs131- 0.74 0.50 1.11 1.49E− case- 46/286/ 37/293/ 0.53 0.35 0.80 2.36E− cohort dom CVD
    07334 01 only 687 683 03
    rs668- 1.40 0.90 2.18 1.35E− case- 28/243/ 19/227/ 1.45 0.93 2.25 9.96E− cohort dom CVD
    5920 01 only 750 771 02
    rs26- 1.32 0.92 1.89 1.37E− case- 86/353/ 73/362/ 1.55 1.15 2.08 3.98E− cohort add CHD
    16552 01 only 581 581 03
    rs21- 0.56 0.37 0.83 3.82E− case- 182/476/ 204/470/ 0.60 0.40 0.89 1.17E− cohort dom CVD
    10564 03 only 360 341 02
    rs100- 0.64 0.43 0.95 2.56E− case- 61/341/ 47/357/ 0.54 0.36 0.79 1.78E− cohort dom CVD
    12485 02 only 619 613 03
    rs1798- 1.63 1.03 2.59 3.71E− cohort 187/469/ 160/456/ 2.00 1.17 3.42 1.13E− cohort rec CHD
    093 02 364 396 02
    rs478- 0.52 0.31 0.85 8.69E− case- 33/101/ 64/118/ 0.62 0.38 0.99 4.76E− case- rec CHD
    7415 03 only 57 70 02 only
    rs117- 0.81 0.51 1.30 3.88E− case- 219/511/ 226/491/ 0.57 0.36 0.89 1.46E− cohort rec CVD
    34256 01 only 278 287 02
    rs126- 0.74 0.50 1.09 1.26E− case- 169/473/ 180/468/ 0.67 0.45 0.98 4.00E− cohort dom CVD
    6489 01 only 368 364 02
    rs23- 1.43 1.03 1.97 3.13E− cohort 22/239/ 22/241/ 1.24 0.86 1.80 2.50E− cohort add CVD
    8250 02 759 752 01
    rs25- 0.68 0.49 0.95 2.31E− case- 52/340/ 41/363/ 0.82 0.59 1.13 2.30E− cohort add CVD
    88350 02 only 616 606 01
    rs498- 1.18 0.81 1.72 4.00E− case- 8/66/117 4/69/179 1.57 1.10 2.24 1.40E− case- add CHD
    657 01 only 02 only
    rs642- 0.67 0.47 0.96 2.85E− cohort 157/456/ 179/464/ 0.66 0.45 0.97 3.26E− cohort dom CVD
    7807 02 393 369 02
    rs61- 0.61 0.34 1.09 9.80E− case- 19/107/ 50/109/ 0.40 0.21 0.73 3.11E− case- rec CHD
    9825 02 only 65 93 03 only
    rs94- 1.54 0.80 2.96 1.97E− case- 37/78/76 27/127/ 2.08 1.20 3.60 8.70E− case- rec CVD
    78241 01 only 98 03 only
    rs172- 1.50 1.02 2.20 4.18E− case- 154/450/ 120/441/ 1.30 0.89 1.90 1.68E− cohort dom CVD
    7746 02 only 409 449 01
    rs250- 0.78 0.60 1.02 6.83E− cohort 252/494/ 254/499/ 0.84 0.65 1.09 1.97E− cohort add CHD
    5039 02 269 258 01
    rs447- 0.71 0.47 1.08 1.10E− case- 22/63/ 29/123/ 0.53 0.36 0.78 1.17E− case- dom CHD
    2926 01 only 106 100 03 only
    rs653- 0.66 0.43 1.02 5.92E− case- 51/80/60 60/131/ 0.68 0.45 1.05 7.89E− case- dom CVD
    9231 02 only 61 02 only
    rs795- 0.75 0.57 1.00 4.97E− case- 34/92/65 67/115/ 0.74 0.57 0.97 2.87E− case- add CVD
    9965 02 only 70 02 only
    rs974- 0.56 0.37 0.83 3.82E− case- 179/455/ 201/455/ 0.64 0.43 0.94 2.37E− cohort dom CVD
    950 03 only 376 352 02
    rs152- 0.78 0.56 1.08 1.28E− case- 11/64/ 15/105/ 0.80 0.58 1.10 1.70E− case- add CHD
    4962 01 only 116 132 01 only
    rs1782- 0.33 0.09 1.18 8.85E− case- 5/70/116 18/89/ 0.35 0.13 0.96 4.18E− case- rec CHD
    1383 02 only 145 02 only
    rs1051- 0.65 0.44 0.97 3.35E− case- 9/47/135 9/99/143 0.55 0.37 0.82 3.26E− case- dom CVD
    8335 02 only 03 only
    rs122- 1.27 0.77 2.09 3.43E− case- 53/82/56 39/127/ 2.13 1.33 3.41 1.78E− case- rec CHD
    65891 01 only 85 03 only
    rs480- 2.13 1.07 4.24 3.22E− case- 1/16/174 1/14/237 1.53 0.74 3.16 2.50E− case- dom CVD
    7536 02 only 01 only
    rs991- 0.67 0.42 1.05 7.85E− case- 3/41/147 10/82/ 0.51 0.33 0.78 2.05E− case- dom CHD
    4580 02 only 160 03 only
    rs646- 0.62 0.35 1.10 9.97E− case- 19/106/ 50/108/ 0.40 0.21 0.73 3.11E− case- rec CHD
    749 02 only 66 94 03 only
    rs100- 1.52 0.99 2.32 5.29E− case- 11/70/ 5/82/ 1.41 0.95 2.08 8.60E− case- dom CHD
    3322 02 only 110 165 02 only
    rs466- 1.32 0.88 1.97 1.80E− cohort 28/238/ 20/222/ 1.45 0.93 2.25 9.97E− cohort dom CHD
    0234 01 750 774 02
    rs403- 0.55 0.36 0.85 6.49E− case- 44/88/59 68/119/ 0.76 0.50 1.17 2.11E− case- dom CHD
    8018 03 only 65 01 only
    rs771- 0.65 0.44 0.96 3.15E− case- 11/63/ 17/102/ 0.70 0.48 1.03 7.21E− case- dom CVD
    0039 02 only 117 133 02 only
    rs131- 1.83 1.23 2.72 3.06E− case- 7/70/114 18/65/ 1.36 0.92 2.02 1.22E− case- dom CVD
    50189 03 only 169 01 only
    rs126- 0.64 0.43 0.95 2.56E− case- 65/338/ 46/360/ 0.59 0.40 0.87 7.91E− cohort dom CVD
    46525 02 only 616 605 03
    rs211- 0.53 0.20 1.41 2.06E− case- 7/73/111 27/92/ 0.29 0.12 0.70 6.07E− case- rec CVD
    3334 01 only 133 03 only
    rs25- 2.98 1.11 8.03 3.08E− case- 1/22/168 0/17/235 2.02 1.06 3.86 3.35E− case- add CVD
    1817 02 only 02 only
    rs2574 1.54 1.00 2.38 5.03E− case- 258/474/ 237/537/ 1.62 1.07 2.44 2.30E− cohort rec CVD
    02 only 287 242 02
    rs1267- 0.65 0.44 0.95 2.77E− case- 19/77/95 26/115/ 0.79 0.53 1.16 2.21E− case- dom CVD
    9254 02 only 111 01 only
    rs1234- 2.38 1.14 4.96 2.05E− cohort 79/404/ 64/384/ 1.63 0.82 3.24 1.68E− cohort rec CHD
    1095 02 536 565 01
    rs170- 1.49 1.13 1.98 5.10E− case- 30/91/70 30/114/ 1.25 0.95 1.66 1.15E− case- add CVD
    48681 03 only 108 01 only
    rs194- 0.62 0.35 1.10 1.02E− case- 18/108/ 48/108/ 0.41 0.23 0.76 4.18E− case- rec CHD
    2876 01 only 65 96 03 only
    rs265- 1.57 1.12 2.21 9.90E− case- 7/75/109 12/80/ 1.20 0.86 1.67 2.77E− case- add CHD
    7940 03 only 160 01 only
    rs494- 0.59 0.33 1.06 7.90E− case- 19/107/ 49/109/ 0.44 0.25 0.79 5.96E− case- rec CHD
    111 02 only 65 94 03 only
    rs206- 0.69 0.45 1.07 9.41E− case- 42/81/68 72/101/ 0.72 0.46 1.12 1.40E− case- rec CVD
    0022 02 only 79 01 only
    rs733- 2.01 0.79 5.14 1.44E− case- 1/24/166 1/14/237 2.50 1.25 4.99 9.45E− case- dom CHD
    8174 01 only 03 only
    rs120- 0.87 0.66 1.16 3.46E− case- 20/77/94 53/90/ 0.72 0.55 0.94 1.73E− case- add CVD
    48902 01 only 109 02 only
    rs674- 1.79 1.17 2.73 6.97E− case- 73/376/ 65/375/ 1.25 0.86 1.81 2.38E− cohort dom CHD
    6182 03 only 568 576 01
    rs727- 0.68 0.31 1.52 3.50E− case- 4/84/931 4/108/ 0.45 0.22 0.90 2.45E− cohort dom CVD
    6749 01 only 904 02
    rs19- 1.54 1.01 2.34 4.59E− cohort 273/496/ 243/509/ 1.55 1.02 2.36 3.93E− cohort rec CHD
    8460 02 244 253 02
    rs778- 1.62 1.05 2.49 2.89E− case- 258/486/ 214/516/ 1.68 1.09 2.61 1.97E− cohort rec CVD
    5499 02 only 267 281 02
    rs99- 0.62 0.35 1.10 1.02E− case- 18/108/ 48/108/ 0.41 0.23 0.76 4.18E− case- rec CHD
    6022 01 only 65 96 03 only
    rs722- 0.68 0.44 1.07 9.51E− case- 2/40/148 9/82/161 0.50 0.32 0.77 1.48E− case- dom CHD
    2186 02 only 03 only
    rs198- 2.04 1.27 3.29 3.35E− case- 291/482/ 263/493/ 1.44 0.96 2.17 7.90E− cohort rec CHD
    464 03 only 231 248 02
    rs169- 0.57 0.38 0.87 8.36E− case- 119/460/ 121/463/ 0.65 0.45 0.95 2.65E− cohort dom CHD
    34059 03 only 439 430 02
    rs15- 0.41 0.21 0.78 6.53E− case- 4/99/917 3/125/ 0.68 0.37 1.26 2.22E− cohort add CHD
    66221 03 only 887 01
    rs812- 0.68 0.31 1.52 3.50E− case- 3/84/933 5/107/ 0.45 0.22 0.91 2.69E− cohort dom CVD
    9810 01 only 902 02
    rs134- 1.58 1.10 2.26 1.25E− cohort 8/61/122 8/68/176 1.31 0.88 1.96 1.86E− case- dom CVD
    4081 02 01 only
    rs791- 1.76 1.11 2.79 1.59E− case- 0/52/139 3/48/201 1.48 0.95 2.32 8.37E− case- dom CVD
    8692 02 only 02 only
    rs468- 1.53 0.98 2.37 5.90E− case- 53/85/53 45/141/ 1.86 1.17 2.97 8.84E− case- rec CVD
    6740 02 only 66 03 only
    rs128- 0.69 0.52 0.93 1.38E− case- 165/458/ 179/482/ 0.85 0.65 1.10 2.15E− cohort add CVD
    17873 02 only 398 355 01
    rs7508 1.39 0.92 2.10 1.17E− case- 10/91/90 15/87/ 1.65 1.13 2.43 1.03E− case- dom CHD
    01 only 150 02 only
    rs27- 0.58 0.32 1.05 6.99E− case- 29/89/73 50/103/ 0.68 0.40 1.18 1.74E− case- rec CVD
    1046 02 only 99 01 only
    rs201- 0.60 0.38 0.95 2.83E− case- 1/34/156 3/64/185 0.63 0.40 0.99 4.35E− case- add CHD
    1318 02 only 02 only
    rs113- 1.16 0.74 1.83 5.13E− case- 5/47/139 2/50/200 1.48 0.98 2.22 6.15E− case- add CVD
    6046 01 only 02 only
    rs145- 0.68 0.46 1.01 5.29E− case- 6/51/134 10/79/ 0.81 0.57 1.15 2.41E− case- add CHD
    0092 02 only 163 01 only
    rs707- 1.72 1.15 2.59 8.56E− case- 3/56/132 5/56/191 1.30 0.87 1.94 2.06E− case- add CVD
    0244 03 only 01 only
    rs89- 0.47 0.27 0.84 9.96E− case- 29/99/63 54/127/ 0.64 0.39 1.06 8.48E− case- rec CHD
    2162 03 only 71 02 only
    rs656- 0.59 0.37 0.94 2.75E− case- 3/29/159 8/66/178 0.53 0.35 0.80 2.73E− case- add CHD
    3805 02 only 03 only
    rs990- 0.70 0.45 1.10 1.23E− case- 2/43/146 9/83/160 0.53 0.35 0.81 3.19E− case- dom CHD
    6737 01 only 03 only
    rs475- 1.37 0.78 2.38 2.73E− case- 2/38/151 1/36/215 1.57 0.95 2.59 7.80E− case- dom CVD
    420 01 only 02 only
    rs176- 0.52 0.26 1.03 5.89E− case- 7/101/83 25/122/ 0.34 0.14 0.81 1.45E− case- rec CVD
    44708 02 only 105 02 only
    rs705- 1.93 1.21 3.07 5.99E− case- 3/53/135 7/50/195 1.41 0.91 2.18 1.24E− case- dom CVD
    7780 03 only 01 only
    rs4773 0.77 0.52 1.13 1.79E− case- 28/86/77 52/120/ 0.68 0.45 1.01 5.68E− case- dom CVD
    01 only 80 02 only
    rs67- 1.56 0.98 2.46 5.86E− case- 60/81/50 50/138/ 1.94 1.24 3.03 3.53E− case- rec CVD
    42894 02 only 64 03 only
    rs104- 0.80 0.58 1.10 1.78E− cohort 15/61/ 20/103/ 0.79 0.58 1.07 1.29E− case- add CHD
    5916 01 115 129 01 only
    rs643- 0.52 0.33 0.82 4.94E− case- 33/84/74 46/125/ 0.74 0.50 1.10 1.40E− case- dom CHD
    5378 03 only 81 01 only
    rs134- 1.83 1.24 2.69 2.34E− case- 23/82/86 24/98/ 1.32 0.89 1.94 1.69E− case- dom CVD
    11119 03 only 130 01 only
    rs153- 0.76 0.50 1.15 1.90E− case- 17/74/ 21/123/ 0.67 0.46 0.98 4.15E− case- dom CHD
    1842 01 only 100 108 02 only
    rs9857 0.83 0.60 1.15 2.67E− case- 12/63/ 15/108/ 0.78 0.57 1.07 1.18E− case- add CVD
    01 only 116 129 01 only
    rs9960 1.41 0.94 2.13 9.91E− case- 11/57/ 8/64/180 1.37 0.92 2.06 1.25E− case- dom CVD
    02 only 123 01 only
    rs131- 0.78 0.52 1.17 2.32E− case- 6/37/148 7/82/163 0.53 0.34 0.81 3.72E− case- dom CVD
    03899 01 only 03 only
    rs684- 0.55 0.35 0.86 8.50E− case- 48/84/59 65/131/ 0.64 0.41 0.98 4.02E− case- dom CVD
    8512 03 only 56 02 only
    rs1018- 1.58 1.13 2.21 7.18E− case- 16/60/ 10/79/ 1.28 0.93 1.75 1.27E− case- add CVD
    1805 03 only 115 163 01 only
    rs112- 1.58 1.08 2.31 1.83E− case- 10/65/ 6/73/173 1.41 1.00 1.98 4.80E− case- add CHD
    9570 02 only 116 02 only
    rs998- 1.46 0.76 2.78 2.54E− case- 36/79/76 27/126/ 2.00 1.15 3.47 1.36E− case- rec CVD
    6576 01 only 98 02 only
    rs135- 0.27 0.11 0.66 4.24E− case- 10/84/97 30/93/ 0.39 0.18 0.84 1.60E− case- rec CHD
    2236 03 only 129 02 only
    rs777- 0.57 0.34 0.94 2.88E− case- 3/35/153 6/66/180 0.65 0.43 0.99 4.58E− case- add CHD
    0578 02 only 02 only
    rs274- 1.81 1.11 2.95 1.80E− cohort 226/504/ 196/502/ 1.43 0.92 2.23 1.14E− cohort rec CHD
    8901 02 290 318 01
    rs115- 0.66 0.49 0.89 6.12E− case- 32/84/75 58/111/ 0.79 0.61 1.03 7.69E− case- add CHD
    5875 03 only 83 02 only
    rs67- 0.71 0.46 1.11 1.32E− case- 1/33/157 5/64/183 0.58 0.38 0.90 1.44E− case- add CVD
    5163 01 only 02 only
    rs106- 0.74 0.49 1.11 1.45E− cohort 44/84/ 55/141/ 0.58 0.38 0.89 1.23E− case- dom CHD
    8705 01 63 56 02 only
    rs150- 1.47 0.94 2.30 9.11E− case- 5/44/142 2/36/213 1.85 1.20 2.85 5.58E− case- add CHD
    5469 02 only 03 only
    rs62- 0.62 0.42 0.92 1.60E− case- 20/55/ 25/100/ 0.65 0.44 0.96 3.00E− case- dom CVD
    3400 02 only 116 127 02 only
    rs60- 1.23 0.83 1.81 2.98E− case- 21/70/99 18/84/ 1.34 0.91 1.97 1.35E− case- dom CVD
    40760 01 only 150 01 only
    rs173- 0.81 0.54 1.23 3.22E− case- 4/43/143 9/79/164 0.61 0.40 0.92 2.01E− case- dom CVD
    10169 01 only 02 only
    rs762- 4.22 0.83 21.33 8.20E− case- 7/37/147 2/55/195 4.79 0.98 23.38 5.28E− case- rec CVD
    3808 02 only 02 only
    rs77- 0.68 0.31 1.52 3.50E− case- 6/76/935 4/106/ 0.49 0.24 1.00 5.04E− cohort dom CVD
    638540 01 only 906 02
    rs58- 0.59 0.33 1.05 7.35E− case- 137/494/ 185/471/ 0.54 0.31 0.95 3.34E− cohort rec CHD
    1401 02 only 385 359 02
    rs42- 0.55 0.35 0.85 6.68E− case- 4/28/159 4/63/185 0.64 0.42 0.98 4.06E− case- add CVD
    51580 03 only 02 only
    rs6- 0.59 0.33 1.05 7.35E− case- 136/503/ 182/481/ 0.55 0.31 0.96 3.64E− cohort rec CHD
    03940 02 only 380 354 02
    rs13- 1.73 1.07 2.78 2.45E− case- 6/61/124 5/55/192 1.74 1.15 2.64 9.53E− case- dom CHD
    117043 02 only 03 only
    rs380- 0.49 0.22 1.07 7.33E− case- 2/67/937 1/77/922 0.59 0.29 1.20 1.43E− cohort add CHD
    0202 02 only 01
    rs107- 0.74 0.55 1.02 6.20E− case- 14/99/78 43/120/ 0.68 0.51 0.91 9.76E− case- add CHD
    38948 02 only 88 03 only
    rs62- 0.59 0.33 1.05 7.35E− case- 141/482/ 186/460/ 0.56 0.33 0.98 4.18E− cohort rec CHD
    3584 02 only 390 360 02
    rs955- 1.42 0.95 2.11 8.72E− cohort 8/47/136 5/55/192 1.29 0.83 2.00 2.62E− case- dom CHD
    7509 02 01 only
    rs116 - 1.25 0.91 1.71 1.62E− cohort 16/82/93 15/83/ 1.54 1.11 2.12 8.96E− case- add CHD
    68038 01 154 03 only
    rs108- 1.16 0.90 1.50 2.52E− cohort 57/88/46 49/137/ 1.29 0.98 1.69 6.73E− case- add CHD
    02865 01 66 02 only
    rs1703- 1.22 0.84 1.77 3.03E− cohort 10/73/ 8/73/171 1.60 1.07 2.37 2.06E− case- dom CHD
    5071 01 108 02 only
    rs14- 1.74 1.27 2.39 6.20E− case- 21/83/87 22/97/ 1.27 0.94 1.72 1.25E− case- add CHD
    39269 04 only 133 01 only
    rs20- 1.52 1.03 2.23 3.55E− case- 8/80/102 11/78/ 1.55 1.05 2.29 2.60E− case- dom CVD
    8025 02 only 162 02 only
    rs126- 0.66 0.42 1.02 5.92E− case- 23/209/ 21/253/ 0.63 0.40 0.98 4.24E− cohort dom CVD
    08167 02 only 785 740 02
    rs13- 0.64 0.42 0.96 3.04E− case- 19/73/99 27/124/ 0.59 0.40 0.87 8.11E− case- dom CHD
    3871 02 only 101 03 only
    rs706- 2.02 1.16 3.51 1.24E− case- 0/33/158 1/34/216 1.32 0.78 2.22 3.05E− case- dom CHD
    8975 02 only 01 only
    rs186- 0.81 0.57 1.14 2.23E− case- 6/61/124 12/93/ 0.77 0.55 1.08 1.32E− case- add CVD
    6386 01 only 147 01 only
    rs158- 1.68 1.03 2.75 3.75E− case- 39/103/ 37/138/ 1.55 0.94 2.56 8.88E− case- rec CHD
    0713 02 only 49 77 02 only
    rs936- 0.70 0.46 1.06 8.80E− case- 14/60/ 21/102/ 0.64 0.44 0.95 2.62E− case- dom CHD
    671 02 only 117 129 02 only
    rs373- 1.99 1.32 3.01 1.13E− case- 22/84/85 25/94/ 1.42 0.96 2.09 8.12E− case- dom CHD
    2136 03 only 133 02 only
    rs177- 0.74 0.51 1.08 1.18E− case- 5/51/135 10/79/ 0.77 0.54 1.10 1.57E− case- add CHD
    18867 01 only 163 01 only
    rs57- 1.87 1.14 3.07 1.29E− case- 3/44/144 6/41/205 1.48 0.91 2.42 1.15E− case- dom CVD
    64592 02 only 01 only
    rs28- 1.51 1.03 2.22 3.69E− case- 15/85/90 23/86/ 1.51 1.02 2.24 3.78E− case- dom CVD
    80563 02 only 143 02 only
    rs156- 0.79 0.61 1.03 8.02E− case- 29/98/64 53/115/ 0.86 0.66 1.14 2.98E− case- add CHD
    4078 02 only 84 01 only
    rs108- 1.37 0.81 2.33 2.42E− case- 2/23/166 0/20/232 1.77 0.95 3.31 7.42E− case- dom CVD
    17479 01 only 02 only
    rs47- 1.33 1.02 1.75 3.89E− case- 49/92/50 59/99/94 1.32 1.01 1.73 4.14E− case- add CVD
    8859 02 only 02 only
    rs101- 1.56 0.87 2.79 1.38E− case- 40/78/73 28/118/ 2.19 1.29 3.71 3.79E− case- rec CVD
    06852 01 only 106 03 only
    rs1265- 1.53 1.01 2.30 4.31E− case- 10/82/99 16/92/ 1.27 0.86 1.86 2.24E− case- dom CHD
    9030 02 only 144 01 only
    rs15- 1.43 0.90 2.26 1.29E− case- 56/80/55 56/132/ 1.44 0.93 2.23 1.05E− case- rec CVD
    36506 01 only 64 01 only
    rs218- 0.72 0.48 1.08 1.13E− case- 30/78/83 44/116/ 0.75 0.51 1.11 1.51E− case- dom CHD
    4393 01 only 92 01 only
    rs110- 1.86 1.18 2.93 7.39E− case- 1/63/127 4/58/190 1.55 1.02 2.36 3.98E− case- dom CHD
    77308 03 only 02 only
    rs79- 0.81 0.55 1.19 2.83E− case- 33/78/80 41/128/ 0.66 0.44 0.99 4.43E− case- dom CVD
    15250 01 only 83 02 only
    rs46- 1.45 1.08 1.93 1.28E− case- 39/98/54 44/123/ 1.20 0.91 1.57 2.00E− case- add CVD
    89078 02 only 85 01 only
    rs286- 0.70 0.50 0.98 3.59E− case- 7/72/112 21/103/ 0.72 0.52 0.99 4.22E− case- add CVD
    9680 02 only 128 02 only
    rs122- 2.30 0.93 5.69 7.06E− case- 1/18/172 1/13/236 2.05 0.92 4.57 8.07E− case- dom CVD
    86877 02 only 02 only
    rs104- 0.10 0.01 0.75 2.54E− case- 0/1/190 1/11/240 0.10 0.01 0.85 3.53E− case- add CVD
    60737 02 only 02 only
  • TABLE 7
    Meta-analysis
    allele P
    A1 allele value CARE WOSCOPS
    (non- A2 OR OR (ran- Prava Placebo OR OR Prava Placebo
    Marker ref) (ref) OR L95 U95 dom) Count Count OR L95 U95 P value Source Count Count
    rs1336- A G 1.56 1.28 1.89 7.06E− 306/1284/ 152/631/ 1.68 1.27 2.22 2.79E− cohort
    400 06 1371 686 04
    rs1078- G A 32/172/ 40/162/ 1.63 1.22 2.17 8.59E− Case- 19/81/82 22/91/132
    7944 152 240 04 only
    rs13103- G A 0.67 0.54 0.83 2.51E− 81/850/ 39/434/ 0.70 0.52 0.95 2.39E− cohort
    899 04 1955 961 02
    rs1312- G A 6/91/260 13/147/ 0.66 0.49 0.89 7.50E− Case- 5/53/126 8/83/156
    1569 284 03 only
    rs6563- A G 0.64 0.50 0.82 4.51E− 42/350/ 35/383/ 0.76 0.56 1.04 8.26E− cohort
    805 04 1102 1052 02
    rs1324- A G 5/68/227 9/105/ 0.78 0.57 1.06 1.15E− Case- 2/26/129 4/57/163
    012 268 01 only
    rs1704- G T 1.30 1.13 1.50 2.15E− 239/709/ 219/690/ 1.26 1.03 1.54 2.34E− cohort
    8681 04 546 562 02
    rs1559- G A 55/182/ 51/200/ 1.34 1.09 1.65 6.39E− Case- 48/85/51 33/127/87
    557 120 193 03 only
    rs7132- T G 0.74 0.65 0.86 3.61E− 341/693/ 312/761/ 0.75 0.61 0.91 4.20E− cohort
    840 05 418 361 03
    rs1877- G A 59/177/ 92/238/ 0.75 0.61 0.93 7.37E− Case- 32/83/69 46/137/64
    527 121 114 03 only
    rs1263- C A 0.61 0.45 0.81 7.53E− 235/712/ 275/738/ 0.54 0.34 0.86 8.70E− cohort
    5482 04 548 458 03
    rs1917- A C 22/152/ 70/194/ 0.34 0.21 0.57 4.02E− Case- 27/74/58 50/99/75
    527 126 118 05 only
    rs198- G A 1.69 1.34 2.13 1.17E− 340/768/ 326/759/ 1.58 1.09 2.30 1.68E− cohort 613/1353/ 588/1343/
    476 05 384 385 02 665 710
    rs198- G A 74/153/ 67/214/ 1.57 1.08 2.28 1.90E− Case- 50/69/40 41/122/61
    462 73 101 02 only
    rs1117- T G 0.77 0.67 0.89 2.86E− 259/693/ 245/735/ 0.76 0.63 0.93 8.77E− cohort
    8579 04 542 490 03
    rs213- A G 51/153/ 74/228/ 0.74 0.60 0.90 3.60E− Case- 20/89/75 41/132/74
    2241 153 142 03 only
    rs384- G C 0.75 0.65 0.86 4.20E− 321/694/ 295/766/ 0.73 0.60 0.89 2.08E− cohort
    4207 05 479 409 03
    rs2270- G A 59/165/ 93/235/ 0.72 0.59 0.88 1.46E− Case- 28/87/69 45/136/66
    588 133 116 03 only
    rs304- A G 2.70 1.54 4.73 5.08E− 61/409/ 48/448/ 1.95 0.89 4.29 9.56E− cohort
    597 04 980 938 02
    rs304- A G 18/101/ 10/144/ 2.28 1.03 5.03 4.10E− Case- 10/55/119 4/75/168
    601 238 290 02 only
    rs1255- C A 1.32 1.12 1.56 7.32E− 314/693/ 292/668/ 1.22 0.98 1.50 7.15E− cohort
    3453 04 445 473 02
    rs4715- A C 70/142/ 72/174/ 1.26 1.02 1.56 3.39E− Case- 32/82/45 27/103/94
    79 88 136 02 only
    rs2768- C T 1.33 1.14 1.54 1.76E− 261/675/ 241/665/ 1.22 0.98 1.51 7.06E− cohort
    652 04 514 527 02
    rs7873- A G 70/143/ 73/175/ 1.25 1.01 1.55 4.05E− Case- 32/82/45 28/103/93
    371 87 134 02 only
    rs1117- T G 0.77 0.67 0.88 2.30E− 259/693/ 245/735/ 0.76 0.63 0.93 8.77E− cohort
    8579 04 542 490 03
    rs9325- A C 51/154/ 74/228/ 0.74 0.60 0.91 4.36E− Case- 20/89/75 41/134/72
    191 152 142 03 only
    rs1094- T C 1.59 1.28 1.97 2.76E− 19/277/ 23/270/ 1.72 1.25 2.36 8.43E− cohort
    5874 05 1197 1178 04
    rs934- A G 7/76/274 4/67/373 1.56 1.12 2.15 7.68E− Case- 2/42/140 3/45/199
    6951 03 only
    rs1310- G T 0.69 0.58 0.83 5.80E− 104/895/ 52/452/ 0.69 0.53 0.89 4.84E− cohort
    7334 05 1967 967 03
    rs988- G A 6/88/263 13/146/ 0.66 0.50 0.87 3.02E− Case- 5/53/126 9/82/156
    146 285 03 only
    WOSCOPS PROVEIT
    OR OR P Atorv Prav OR OR P Mod- End-
    Marker OR L95 U95 value Source Count Count OR L95 U95 value Source el point
    rs1336- 151/404/ 116/431/ 1.46 1.00 2.12 4.82E− cohort dom CVD
    400 459 465 02
    rs1078- 1.45 0.99 2.14 5.84E− Case- 29/84/77 29/101/ 1.37 0.93 2.01 1.15E− Case- dom CVD
    7944 02 only 122 01 only
    rs13103- dom CVD
    899
    rs1312- 0.78 0.52 1.17 2.32E− Case- 6/38/147 7/84/161 0.52 0.34 0.80 3.10E− Case- dom CVD
    1569 01 only 03 only
    rs6563- add CHD
    805
    rs1324- 0.60 0.38 0.96 3.12E− Case- 3/30/158 10/68/ 0.51 0.34 0.76 1.08E− Case- add CHD
    012 02 only 174 03 only
    rs1704- add CVD
    8681
    rs1559- 1.53 1.16 2.02 2.89E− Case- 32/83/76 30/114/ 1.19 0.90 1.56 2.26E− Case- add CVD
    557 03 only 108 01 only
    rs7132- add CVD
    840
    rs1877- 0.77 0.58 1.02 6.90E− Case- 31/93/67 64/117/ 0.72 0.55 0.94 1.70E− Case- add CVD
    527 02 only 71 02 only
    rs1263- rec CHD
    5482
    rs1917- 0.73 0.44 1.24 2.46E− Case- 22/98/70 48/117/ 0.57 0.33 1.00 4.86E− Case- rec CHD
    527 01 only 87 02 only
    rs198- 1.61 1.06 2.46 2.63E− cohort rec CHD
    476 02
    rs198- 2.12 1.31 3.42 2.23E− Case- 67/83/41 55/132/ 1.92 1.26 2.94 2.58E− Case- rec CHD
    462 03 only 65 03 only
    rs1117- 162/444/ 177/462/ 0.85 0.65 1.10 2.20E− cohort add CVD
    8579 403 365 01
    rs213- 0.70 0.52 0.94 1.66E− Case- 26/87/78 45/121/ 0.79 0.60 1.04 9.47E− Case- add CVD
    2241 02 only 86 02 only
    rs384- 190/491/ 235/471/ 0.78 0.60 1.01 5.47E− cohort add CVD
    4207 336 306 02
    rs2270- 0.75 0.57 1.00 5.34E− Case- 30/93/68 62/122/ 0.70 0.53 0.92 1.07E− Case- add CVD
    588 02 only 68 02 only
    rs304- rec CVD
    597
    rs304- 3.93 1.20 12.87 2.38E− Case- 13/52/ 6/70/176 3.63 1.24 10.64 1.88E− Case- rec CVD
    601 02 only 126 02 only
    rs1255- add CHD
    3453
    rs4715- 1.62 1.20 2.19 1.84E− Case- 48/80/63 35/132/ 1.27 0.97 1.66 8.39E− Case- add CHD
    79 03 only 85 02 only
    rs2768- add CHD
    652
    rs7873- 1.59 1.17 2.15 2.68E− Case- 47/82/62 35/129/ 1.31 1.00 1.71 5.23E− Case- add CHD
    371 03 only 88 02 only
    rs1117- 162/444/ 177/462/ 0.85 0.65 1.10 2.20E− cohort add CVD
    8579 403 365 01
    rs9325- 0.69 0.51 0.92 1.19E− Case- 26/86/79 45/121/ 0.78 0.59 1.03 7.96E− Case- add CVD
    191 02 only 86 02 only
    rs1094- 22/196/ 20/201/ 1.72 1.15 2.58 8.16E− cohort add CVD
    5874 799 795 03
    rs934- 1.25 0.81 1.92 3.09E− Case- 5/45/141 0/43/ 1.88 1.22 2.91 4.63E− Case- add CVD
    6951 01 only 209 03 only
    rs1310- 46/286/ 37/293/ 0.60 0.43 0.86 4.97E− cohort add CVD
    7334 687 683 03
    rs988- 0.80 0.56 1.14 2.15E− Case- 6/37/148 7/80/ 0.64 0.44 0.93 2.04E− Case- add CVD
    146 01 only 165 02 only
  • TABLE 8
    Original SNP Genotyped SNP
    (rs #) (rs #) LD (r{circumflex over ( )}2)
    rs10193722 rs11124322 1
    rs1051334 rs1051344 0.9637
    rs10740308 rs2030057 0.9457
    rs10831415 rs10831416 1
    rs1229430 rs4657668 0.9445
    rs12914132 rs6497117 0.9642
    rs1594887 rs1529806 1
    rs16861476 rs3732788 1
    rs1737478 rs1773549 1
    rs2196180 rs1560901 1
    rs231358 rs231355 0.9636
    rs2335451 rs10875941 1
    rs2358931 rs9834251 0.8864
    rs2593270 rs4765531 1
    rs2656824 rs4765531 1
    rs302296 rs302290 1
    rs3793048 rs3806005 1
    rs3861810 rs1560901 1
    rs4128766 rs7179134 0.951
    rs4242084 rs2148575 1
    rs4328731 rs5756670 1
    rs4980176 rs7094941 1
    rs6550706 rs1851830 1
    rs6950121 rs10275879 1
    rs7751843 rs7765440 1
    rs7901888 rs2030057 1
    rs7913568 rs3998860 0.9736
    rs9467561 rs6931627 1
    rs9554735 rs912366 0.9646
    rs10787944 rs1336400 1
    rs13121569 rs13103899 1
    rs1324012 rs6563805 1
    rs1559557 rs17048681 0.8814
    rs1877527 rs7132840 0.9591
    rs1917527 rs12635482 0.9293
    rs198462 rs198476 0.9823
    rs2132241 rs11178579 1
    rs2270588 rs3844207 1
    rs304601 rs304597 0.9732
    rs471579 rs12553453 0.931
    rs7873371 rs2768652 0.8956
    rs9325191 rs11178579 1
    rs9346951 rs10945874 0.9567
    rs988146 rs13107334 0.9491
  • TABLE 9
    PLA- PRA- PRA- PRA- PLA- PLA- PLA-
    AL- HW_ ALL- PRAVA_ CEBO_ VA_ VA_ VA_ CEBO_ CEBO_ CEBO_
    LELE MOD- N- PVAL ELE_F ALLELE_ ALLELE_ A1_HZ_ HET_ A2_HZ_ A1_HZ_ HET_ A2_HZ_
    SNP rs # SOURCE (A1) EL MISS OR SE L95 U95 STAT P UE REQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs198460 Genotyped G REC 682 1.552 0.1926 1.064 2.264 2.284 0.02238 0.02592 0.47507 0.50167 0.4542 73 155 72 66 215 101
    rs603940 Genotyped G REC 682 0.614 0.2233 0.3962 0.9509 −2.185 0.02885 0.812 0.40469 0.38833 0.4175 38 157 105 72 175 135
    rs10021016 Genotyped G GEN 682 7.495 0.02358 0.8438 0.26393 0.29667 0.2382 29 120 151 17 148 217
    rs1003148 Imputed C ADD 674 0.691 0.1112 0.5556 0.8592 −3.325 0.000885 0.04475 0.40059 0.34783 0.4427 38 132 129 83 166 126
    rs1003148 Imputed C GEN 674 11.71 0.002865 0.04475 0.40059 0.34783 0.4427 38 132 129 83 166 126
    rs1003148 Imputed C REC 674 0.511 0.2158 0.3345 0.7794 −3.115 0.001839 0.04475 0.40059 0.34783 0.4427 38 132 129 83 166 126
    rs10046799 Imputed C ADD 671 0.784 0.1099 0.6321 0.9726 −2.212 0.02694 0.1595 0.55365 0.52055 0.5792 82 140 70 133 173 73
    rs10046799 Imputed C GEN 671 4.972 0.08326 0.1595 0.55365 0.52055 0.5792 82 140 70 133 173 73
    rs10051148 Imputed C DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 0.9326 0.34728 0.30833 0.378 36 113 151 45 198 138
    rs10054055 Imputed T DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 0.9326 0.34728 0.30833 0.378 36 113 151 45 198 138
    rs10067895 Imputed A DOM 672 0.561 0.1605 0.4097 0.7686 −3.6 0.000319 0.9321 0.34598 0.3064 0.3773 36 110 151 45 193 137
    rs1008705 Imputed C DOM 505 1.49 0.1837 1.04 2.136 2.172 0.02985 0.9137 0.28812 0.3211 0.2631 21 98 99 20 111 156
    rs10105871 Imputed C DOM 592 1.731 0.1743 1.23 2.436 3.149 0.001636 0.2592 0.38429 0.42278 0.3544 42 135 82 52 132 149
    rs10116807 Imputed A GEN 652 8.336 0.01548 1 0.22469 0.25087 0.2041 23 98 166 10 129 226
    rs10116807 Imputed A REC 652 3.065 0.389 1.43 6.569 2.88 0.003983 1 0.22469 0.25087 0.2041 23 98 166 10 129 226
    rs10121941 Imputed C DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs10128638 Genotyped G DOM 682 0.575 0.1787 0.4054 0.8167 −3.094 0.001978 0.9389 0.49047 0.45167 0.5209 66 139 95 97 204 81
    rs1012924 Imputed G ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs1012924 Imputed G DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs1016030 Genotyped G ADD 680 1.4 0.1137 1.12 1.749 2.956 0.00312 0.6897 0.40074 0.44482 0.3661 61 144 94 51 177 153
    rs1016030 Genotyped G GEN 680 8.902 0.01167 0.6897 0.40074 0.44482 0.3661 61 144 94 51 177 153
    rs1017558 Imputed A REC 668 1.905 0.2304 1.213 2.992 2.798 0.005138 0.4004 0.35853 0.36735 0.3516 52 112 130 39 185 150
    rs10183431 Imputed T DOM 677 1.604 0.1584 1.176 2.188 2.983 0.002854 0.06064 0.24372 0.27534 0.2192 14 135 147 17 133 231
    rs10195401 Imputed C DOM 671 1.633 0.1636 1.185 2.251 2.998 0.002721 0.9348 0.38227 0.41723 0.3547 45 157 94 52 162 161
    rs10239416 Imputed A DOM 658 0.618 0.1624 0.4496 0.8497 −2.963 0.003046 0.8667 0.36702 0.32653 0.3997 34 124 136 53 185 126
    rs1032188 Imputed G GEN 682 6.08 0.04784 1 0.30352 0.27167 0.3285 20 123 157 43 165 174
    rs1032188 Imputed G REC 682 0.55 0.2837 0.3157 0.9599 −2.104 0.03536 1 0.30352 0.27167 0.3285 20 123 157 43 165 174
    rs10468988 Imputed G ADD 679 1.579 0.1261 1.233 2.022 3.624 0.00029 0.6914 0.26068 0.30936 0.2224 30 125 144 18 133 229
    rs10478919 Imputed G DOM 681 0.551 0.1595 0.4029 0.753 −3.738 0.000186 1 0.34802 0.30667 0.3806 36 112 152 46 198 137
    rs10506623 Imputed C DOM 682 0.591 0.1642 0.4287 0.8159 −3.199 0.001378 0.8737 0.40176 0.36667 0.4293 46 128 126 65 198 119
    rs10506626 Imputed A DOM 682 0.565 0.1629 0.4107 0.7779 −3.501 0.000463 0.9364 0.40029 0.36667 0.4267 49 122 129 61 204 117
    rs10509477 Imputed T DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs10511071 Imputed C DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs10511072 Imputed G DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs10511199 Imputed C ADD 679 1.5 0.1343 1.153 1.952 3.019 0.00254 1 0.21944 0.25671 0.1903 21 111 166 11 123 247
    rs10513283 Imputed G GEN 680 13.78 0.001017 0.06901 0.19706 0.2408 0.1627 26 92 181 8 108 265
    rs10520072 Imputed T DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 0.9326 0.34728 0.30833 0.378 36 113 151 45 198 138
    rs1065639 Imputed C DOM 645 1.663 0.1678 1.197 2.311 3.031 0.002438 0.3536 0.37132 0.40071 0.3485 35 156 91 48 157 158
    rs10733846 Imputed G ADD 676 0.554 0.146 0.4165 0.7381 −4.04 5.35E−05 0.02372 0.19009 0.1388 0.2308 5 73 221 29 116 232
    rs10733846 Imputed G DOM 676 0.557 0.1721 0.3978 0.7808 −3.398 0.000679 0.02372 0.19009 0.1388 0.2308 5 73 221 29 116 232
    rs10737390 Imputed T DOM 678 0.561 0.161 0.4094 0.7694 −3.588 0.000333 0.4645 0.38274 0.33833 0.418 42 119 139 62 192 124
    rs10749293 Imputed G DOM 682 1.794 0.1572 1.319 2.442 3.72 0.000199 1 0.29252 0.33167 0.2618 25 149 126 33 134 215
    rs10752159 Imputed G DOM 676 1.431 0.1604 1.045 1.96 2.234 0.02545 1 0.21598 0.24329 0.1944 16 113 169 15 117 246
    rs10753760 Imputed T ADD 650 1.411 0.1167 1.122 1.773 2.949 0.003192 0.6867 0.41692 0.46466 0.3801 61 141 81 49 181 137
    rs10753760 Imputed T GEN 650 9.074 0.01071 0.6867 0.41692 0.46466 0.3801 61 141 81 49 181 137
    rs10757887 Imputed C DOM 677 0.616 0.1602 0.4502 0.8435 −3.023 0.002503 0.8353 0.24446 0.21477 0.2678 18 92 188 21 161 197
    rs10758326 Imputed A ADD 679 0.73 0.1149 0.5831 0.9149 −2.734 0.006266 0.7443 0.37923 0.33893 0.4108 32 138 128 68 177 136
    rs10758326 Imputed A GEN 679 8.015 0.01818 0.7443 0.37923 0.33893 0.4108 32 138 128 68 177 136
    rs10758326 Imputed A REC 679 0.554 0.2314 0.3523 0.8726 −2.549 0.01081 0.7443 0.37923 0.33893 0.4108 32 138 128 68 177 136
    rs10762236 Genotyped G ADD 682 0.583 0.1422 0.4409 0.77 −3.797 0.000146 0.0221 0.19941 0.15 0.2382 7 76 217 30 122 230
    rs10765769 Imputed C ADD 676 1.445 0.1127 1.159 1.802 3.266 0.001089 0.6368 0.42456 0.47475 0.3852 66 150 81 59 174 146
    rs10765769 Imputed C GEN 676 10.87 0.004364 0.6368 0.42456 0.47475 0.3852 66 150 81 59 174 146
    rs10784891 Imputed C ADD 656 0.692 0.117 0.5504 0.8705 −3.146 0.001655 0.5819 0.45503 0.40972 0.4905 49 138 101 83 195 90
    rs10784891 Imputed C DOM 656 0.57 0.1761 0.4039 0.8053 −3.19 0.001424 0.5819 0.45503 0.40972 0.4905 49 138 101 83 195 90
    rs10787923 Imputed G DOM 672 1.834 0.1588 1.343 2.504 3.819 0.000134 1 0.29464 0.33502 0.2627 25 149 123 33 131 211
    rs10787949 Imputed A DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs10787951 Imputed G DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs10787983 Imputed C DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs10788380 Imputed C ADD 675 1.411 0.1153 1.125 1.769 2.984 0.002844 0.2184 0.49333 0.53716 0.4591 78 162 56 78 192 109
    rs10788380 Imputed C DOM 675 1.762 0.1889 1.217 2.552 2.999 0.002704 0.2184 0.49333 0.53716 0.4591 78 162 56 78 192 109
    rs10788380 Imputed C GEN 675 9.862 0.007218 0.2184 0.49333 0.53716 0.4591 78 162 56 78 192 109
    rs10814418 Imputed G DOM 680 0.533 0.2074 0.3547 0.7998 −3.037 0.002389 0.6755 0.10221 0.07383 0.1243 2 40 256 6 83 293
    rs10831417 Imputed A ADD 674 1.436 0.1147 1.147 1.798 3.154 0.001613 0.8092 0.39688 0.44463 0.359 61 143 94 47 176 153
    rs10831417 Imputed A GEN 674 10.39 0.005538 8.09E−01 0.39688 0.44463 0.359 61 143 94 47 176 153
    rs10831422 Imputed C ADD 676 1.421 0.1143 1.135 1.777 3.071 0.002131 0.8726 0.39941 0.44631 0.3624 61 144 93 48 178 152
    rs10831422 Imputed C GEN 676 9.86 0.007226 0.8726 0.39941 0.44631 0.3624 61 144 93 48 178 152
    rs10862931 Imputed C GEN 676 12.36 0.002073 0.2988 0.33284 0.28885 0.3671 21 129 146 60 159 161
    rs10865197 Imputed C DOM 679 1.604 0.1581 1.177 2.186 2.988 0.002806 0.04888 0.24448 0.27609 0.2199 14 136 147 17 134 231
    rs10871302 Imputed A DOM 677 1.561 0.1787 1.099 2.215 2.49 0.01276 0.5241 0.13959 0.16498 0.1197 8 82 207 7 77 296
    rs10877463 Imputed C DOM 681 0.735 0.1583 0.5392 1.003 −1.941 0.05228 0.1829 0.35756 0.34281 0.3691 45 115 139 50 182 150
    rs10877468 Imputed C DOM 681 0.745 0.1584 0.5465 1.017 −1.855 0.06358 0.2438 0.35756 0.34448 0.3678 45 116 138 49 183 150
    rs10879240 Imputed C ADD 561 0.604 0.1586 0.4424 0.824 −3.18 0.001472 1.43E−14 0.34581 0.30632 0.3782 6 143 104 21 191 96
    rs10879242 Imputed A DOM 600 0.502 0.1832 0.3504 0.7186 −3.764 0.000167 1 0.45083 0.41098 0.4821 52 113 99 70 184 82
    rs10879245 Imputed G DOM 600 0.502 0.1832 0.3504 0.7186 −3.764 0.000167 1 0.45083 0.41098 0.4821 52 113 99 70 184 82
    rs10879249 Imputed T DOM 676 0.583 0.1653 0.4214 0.8058 −3.266 0.001091 0.9363 0.40385 0.36745 0.4325 46 127 125 65 197 116
    rs10886452 Imputed A DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs10886463 Imputed C DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs10886465 Imputed A DOM 682 1.778 0.1589 1.302 2.427 3.622 0.000293 0.9278 0.30279 0.34 0.2736 27 150 123 36 137 209
    rs10886526 Imputed C DOM 681 1.762 0.1577 1.293 2.4 3.591 0.000329 1 0.29589 0.33278 0.267 25 149 125 34 136 212
    rs10902437 Imputed G ADD 658 1.415 0.1115 1.137 1.761 3.113 0.001853 0.03266 0.38754 0.43857 0.3466 61 135 97 51 151 163
    rs10941126 Imputed G ADD 682 0.187 0.4378 0.0793 0.441 −3.83 0.000128 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs10941126 Imputed G DOM 682 0.19 0.451 0.0786 0.4606 −3.679 0.000234 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs10947871 Imputed A DOM 682 1.569 0.1754 1.112 2.213 2.567 0.01026 0.1579 0.14223 0.16667 0.123 5 90 205 4 86 292
    rs10972978 Imputed G DOM 658 0.518 0.2117 0.3418 0.7839 −3.11 0.001873 0.6698 0.10258 0.07292 0.1257 2 38 248 6 81 283
    rs10973012 Imputed A DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs10974028 Genotyped G ADD 682 0.605 0.1547 0.4467 0.8194 −3.247 0.001165 0.3256 0.16349 0.125 0.1937 9 57 234 13 122 247
    rs10974028 Genotyped G DOM 682 0.516 0.1777 0.3642 0.7308 −3.725 0.000196 0.3256 0.16349 0.125 0.1937 9 57 234 13 122 247
    rs11021302 Imputed A ADD 681 1.413 0.1142 1.13 1.768 3.029 0.002455 0.873 0.39794 0.44333 0.3622 61 144 95 48 180 153
    rs11021302 Imputed A GEN 681 9.725 0.007733 0.873 0.39794 0.44333 0.3622 61 144 95 48 180 153
    rs11099644 Imputed G REC 668 1.905 0.2304 1.213 2.992 2.798 0.005138 0.4004 0.35853 0.36735 0.3516 52 112 130 39 185 150
    rs11138315 Imputed G ADD 646 0.682 0.1861 0.4732 0.9815 −2.06 0.03937 0.2275 0.11068 0.09123 0.126 3 46 236 8 75 278
    rs11149802 Imputed T DOM 677 1.561 0.1787 1.099 2.215 2.49 0.01276 0.5241 0.13959 0.16498 0.1197 8 82 207 7 77 296
    rs1116596 Imputed T DOM 681 0.551 0.1595 0.4029 0.753 −3.738 0.000186 1 0.34802 0.30667 0.3806 36 112 152 46 198 137
    rs11178531 Imputed A ADD 678 0.722 0.1139 0.5774 0.9022 −2.863 0.004194 0.7006 0.47788 0.43624 0.5105 60 140 98 92 204 84
    rs11178531 Imputed A DOM 678 0.557 0.1766 0.3942 0.7879 −3.31 0.000934 0.7006 0.47788 0.43624 0.5105 60 140 98 92 204 84
    rs11178575 Imputed C GEN 679 9.118 0.01047 0.5966 0.31885 0.35067 0.294 44 121 133 28 168 185
    rs11178575 Imputed C REC 679 2.174 0.2571 1.313 3.598 3.019 0.002532 0.5966 0.31885 0.35067 0.294 44 121 133 28 168 185
    rs11178577 Imputed T GEN 680 9.117 0.01048 0.6589 0.31912 0.35067 0.2945 44 121 133 28 169 185
    rs11178577 Imputed T REC 680 2.173 0.2571 1.313 3.597 3.019 0.002537 0.6589 0.31912 0.35067 0.2945 44 121 133 28 169 185
    rs11178583 Imputed A DOM 665 0.567 0.1672 0.4082 0.7862 −3.399 0.000677 1 0.40827 0.37113 0.4372 46 124 121 65 197 112
    rs11178589 Imputed T DOM 678 0.593 0.1662 0.4283 0.8217 −3.142 0.001679 1 0.41593 0.3796 0.4446 48 131 120 69 199 111
    rs11178594 Imputed C DOM 680 0.579 0.1651 0.4187 0.7999 −3.312 0.000926 0.9365 0.40294 0.36745 0.4306 46 127 125 65 199 118
    rs11178602 Imputed T DOM 680 0.57 0.165 0.4126 0.788 −3.404 0.000665 0.8735 0.40221 0.36577 0.4306 46 126 126 65 199 118
    rs11178648 Imputed T DOM 680 0.564 0.1631 0.4095 0.7761 −3.514 0.000442 0.8107 0.40074 0.36622 0.4278 49 121 129 62 202 117
    rs11198877 Imputed T DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs11198942 Imputed T DOM 680 1.797 0.1579 1.319 2.449 3.712 0.000206 1 0.29706 0.33612 0.2664 26 149 124 34 135 212
    rs11221075 Imputed A ADD 674 0.628 0.1738 0.4466 0.8827 −2.678 0.007404 0.4847 0.12685 0.09966 0.1481 1 57 238 12 88 278
    rs11242020 Imputed T DOM 682 0.548 0.1595 0.4011 0.7494 −3.769 0.000164 0.9329 0.34824 0.30667 0.3809 36 112 152 46 199 137
    rs11242021 Imputed T DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs11242022 Imputed T DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs11242023 Imputed T DOM 682 0.564 0.1596 0.4123 0.7707 −3.592 0.000328 1 0.34531 0.30667 0.3757 36 112 152 45 197 140
    rs1149350 Imputed A DOM 680 1.537 0.1609 1.121 2.106 2.672 0.007551 0.1324 0.21029 0.23913 0.1877 11 121 167 12 119 250
    rs1150143 Imputed G DOM 658 1.631 0.1628 1.186 2.245 3.007 0.002639 0.1849 0.32827 0.35366 0.3086 23 157 107 40 149 182
    rs11576627 Imputed T ADD 682 1.785 0.1742 1.268 2.511 3.325 0.000885 0.05306 0.12463 0.15833 0.0982 3 89 208 2 71 309
    rs11576627 Imputed T DOM 682 1.844 0.1815 1.292 2.632 3.373 0.000744 0.05306 0.12463 0.15833 0.0982 3 89 208 2 71 309
    rs11602189 Imputed A DOM 677 0.604 0.1575 0.4435 0.8223 −3.203 0.001362 0.5429 0.32939 0.2862 0.3632 29 112 156 48 180 152
    rs11605163 Imputed A DOM 679 2.068 0.229 1.32 3.239 3.173 0.001509 0.7687 0.07143 0.09532 0.0526 2 53 244 2 36 342
    rs11615214 Imputed G ADD 660 0.645 0.1143 0.5156 0.807 −3.837 0.000125 0.02544 0.37652 0.31507 0.4253 31 122 139 76 161 131
    rs11615214 Imputed G GEN 660 15.05 0.000541 0.02544 0.37652 0.31507 0.4253 31 122 139 76 161 131
    rs11642394 Imputed C DOM 677 1.561 0.1787 1.099 2.215 2.49 0.01276 0.5241 0.13959 0.16498 0.1197 8 82 207 7 77 296
    rs11644943 Imputed A ADD 655 1.327 0.1361 1.017 1.733 2.081 0.03739 0.6522 0.22214 0.24829 0.2011 21 103 168 9 128 226
    rs11656608 Imputed T DOM 681 0.649 0.1794 0.4567 0.9228 −2.408 0.01605 1 0.14317 0.12375 0.1584 8 58 233 6 109 267
    rs11661309 Imputed A ADD 676 0.626 0.1446 0.4718 0.8317 −3.234 0.00122 0.6206 0.19231 0.15152 0.2243 7 76 214 20 130 229
    rs11661309 Imputed A DOM 676 0.601 0.1674 0.4325 0.8338 −3.046 0.002323 0.6206 0.19231 0.15152 0.2243 7 76 214 20 130 229
    rs11666131 Imputed A ADD 675 1.512 0.136 1.158 1.974 3.04 0.002366 0.4389 0.22444 0.26102 0.1961 20 114 161 10 129 241
    rs11743355 Imputed C ADD 650 0.164 0.4716 0.0652 0.4139 −3.83 0.000128 0.05102 0.03692 0.01394 0.0551 0 8 279 3 34 326
    rs11743355 Imputed C DOM 650 0.166 0.4861 0.064 0.4303 −3.695 0.00022 0.05102 0.03692 0.01394 0.0551 0 8 279 3 34 326
    rs11746806 Imputed T ADD 682 0.217 0.4129 0.0965 0.4867 −3.704 0.000213 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs11746806 Imputed T DOM 682 0.223 0.4255 0.0967 0.5123 −3.532 0.000412 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs11746959 Imputed T ADD 682 0.187 0.4378 0.0793 0.441 −3.83 0.000128 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs11746959 Imputed T DOM 682 0.19 0.451 0.0786 0.4606 −3.679 0.000234 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs11749272 Imputed T DOM 679 0.552 0.16 0.4036 0.7559 −3.709 0.000208 1 0.34831 0.30705 0.3806 36 111 151 46 198 137
    rs11901899 Imputed A DOM 668 1.459 0.1585 1.069 1.99 2.382 0.0172 1 0.26422 0.29223 0.2419 22 129 145 24 132 216
    rs11926319 Imputed G ADD 675 0.479 0.2053 0.3205 0.7167 −3.583 0.00034 0.8261 0.09778 0.06397 0.1243 1 36 260 6 82 290
    rs11926319 Imputed G DOM 675 0.466 0.2155 0.3052 0.7104 −3.546 0.000391 0.8261 0.09778 0.06397 0.1243 1 36 260 6 82 290
    rs11956952 Imputed C DOM 671 0.633 0.1593 0.4632 0.8648 −2.872 0.00408 0.7761 0.28465 0.24662 0.3147 21 104 171 35 166 174
    rs12025826 Imputed G DOM 664 1.73 0.166 1.249 2.395 3.3 0.000968 0.05275 0.40286 0.45313 0.3644 61 139 88 59 156 161
    rs1204522 Imputed C GEN 676 11.67 0.002917 0.87 0.37796 0.33054 0.4153 27 143 128 68 178 132
    rs1204524 Imputed A GEN 678 11.89 0.002625 0.8065 0.37832 0.33054 0.4158 27 143 128 68 180 132
    rs12153185 Imputed T DOM 672 0.561 0.1605 0.4097 0.7686 −3.6 0.000319 0.9321 0.34598 0.3064 0.3773 36 110 151 45 193 137
    rs12182651 Imputed T ADD 678 2.104 0.213 1.386 3.194 3.492 0.000479 0.6166 0.08481 0.11371 0.062 3 62 234 3 41 335
    rs12182651 Imputed T DOM 678 2.304 0.2264 1.478 3.592 3.687 0.000227 0.6166 0.08481 0.11371 0.062 3 62 234 3 41 335
    rs12193568 Imputed G DOM 565 1.551 0.1819 1.086 2.215 2.413 0.01581 0.3148 0.17788 0.20751 0.1538 8 89 156 6 84 222
    rs12264914 Imputed C DOM 361 0.591 0.2158 0.3873 0.9024 −2.436 0.01486 0.08135 0.34349 0.29063 0.3856 17 59 84 33 89 79
    rs12307767 Imputed C DOM 661 0.729 0.1608 0.532 0.9993 −1.964 0.04953 0.2737 0.36157 0.34589 0.374 44 114 134 49 178 142
    rs1232298 Imputed G REC 658 1.65 0.2751 0.9623 2.829 1.82 0.06874 0.2441 0.31839 0.32118 0.3162 33 119 136 27 180 163
    rs12407412 Imputed C ADD 682 1.785 0.1742 1.268 2.511 3.325 0.000885 0.05306 0.12463 0.15833 0.0982 3 89 208 2 71 309
    rs12407412 Imputed C DOM 682 1.844 0.1815 1.292 2.632 3.373 0.000744 0.05306 0.12463 0.15833 0.0982 3 89 208 2 71 309
    rs12420184 Imputed G DOM 681 0.542 0.1789 0.3816 0.7695 −3.424 0.000617 0.4694 0.15639 0.125 0.1811 9 57 234 10 118 253
    rs12422750 Imputed A DOM 679 0.756 0.1585 0.5538 1.031 −1.769 0.07688 0.1821 0.35935 0.34564 0.3701 45 116 137 51 180 150
    rs12446951 Imputed A ADD 520 2.018 0.2623 1.207 3.375 2.678 0.007409 0.4988 0.06923 0.09389 0.0498 1 41 187 0 29 262
    rs12446951 Imputed A DOM 520 2.001 0.2641 1.192 3.358 2.626 0.008639 0.4988 0.06923 0.09389 0.0498 1 41 187 0 29 262
    rs12457400 Imputed G DOM 680 0.553 0.201 0.3727 0.8196 −2.95 0.003178 0.6917 0.10882 0.08361 0.1286 4 42 253 5 88 288
    rs1247340 Imputed C DOM 680 1.537 0.1609 1.121 2.106 2.672 0.007551 0.1324 0.21029 0.23913 0.1877 11 121 167 12 119 250
    rs1247341 Imputed C DOM 680 1.537 0.1609 1.121 2.106 2.672 0.007551 0.1324 0.21029 0.23913 0.1877 11 121 167 12 119 250
    rs12521291 Imputed G ADD 673 0.684 0.1186 0.5424 0.8634 −3.198 0.001382 0.4434 0.34398 0.30034 0.3787 28 123 147 56 172 147
    rs12526849 Imputed T ADD 656 1.462 0.113 1.172 1.825 3.364 0.000769 0.2246 0.40473 0.45819 0.3631 63 137 87 52 164 153
    rs12526849 Imputed T GEN 656 11.33 0.003474 0.2246 0.40473 0.45819 0.3631 63 137 87 52 164 153
    rs12543110 Imputed G DOM 681 1.542 0.1596 1.127 2.108 2.712 0.006696 0.106 0.23128 0.25585 0.212 17 119 163 27 108 247
    rs12678600 Imputed A DOM 675 0.617 0.1585 0.4524 0.8419 −3.046 0.002319 0.7936 0.32889 0.28859 0.3607 27 118 153 44 184 149
    rs12719415 Imputed T DOM 673 0.546 0.1604 0.3989 0.748 −3.771 0.000163 0.548 0.34027 0.29522 0.375 31 111 151 43 199 138
    rs12831292 Imputed G DOM 678 0.574 0.1652 0.4153 0.7936 −3.359 0.000782 0.9364 0.40339 0.367 0.4318 46 126 125 65 199 117
    rs12923993 Imputed C DOM 677 1.561 0.1787 1.099 2.215 2.49 0.01276 0.5241 0.13959 0.16498 0.1197 8 82 207 7 77 296
    rs12936964 Imputed T DOM 673 1.718 0.1622 1.25 2.362 3.338 0.000844 0.6161 0.35958 0.40372 0.3249 45 149 102 45 155 177
    rs12960663 Imputed G ADD 672 0.639 0.1447 0.4809 0.8478 −3.101 0.001927 0.5336 0.19122 0.15203 0.2221 7 76 213 20 127 229
    rs13038146 Imputed C ADD 681 1.338 0.1141 1.07 1.674 2.554 0.01063 0.2789 0.3583 0.39667 0.3281 54 130 116 40 170 171
    rs13038146 Imputed C GEN 681 7.872 0.01953 0.2789 0.3583 0.39667 0.3281 54 130 116 40 170 171
    rs13134222 Imputed A GEN 597 9.274 0.009687 0.917 0.26884 0.23408 0.297 10 105 152 32 132 166
    rs13172910 Imputed A DOM 675 0.633 0.159 0.4637 0.8646 −2.875 0.004042 0.7779 0.28667 0.25 0.3156 22 105 171 35 168 174
    rs13194907 Imputed A ADD 682 2.264 0.2373 1.422 3.606 3.444 0.000573 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs13194907 Imputed A DOM 682 2.432 0.2521 1.484 3.986 3.525 0.000423 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs13195745 Imputed A ADD 682 2.264 0.2373 1.422 3.606 3.444 0.000573 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs13195745 Imputed A DOM 682 2.432 0.2521 1.484 3.986 3.525 0.000423 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs1321432 Imputed A REC 681 2.324 0.2254 1.494 3.615 3.741 0.000183 0.5731 0.3884 0.44314 0.3455 60 145 94 39 186 157
    rs1321457 Imputed G REC 665 2.293 0.2272 1.469 3.58 3.653 0.000259 0.7441 0.38872 0.44178 0.3472 59 140 93 39 181 153
    rs13265054 Imputed T DOM 671 0.623 0.1591 0.4561 0.8511 −2.973 0.002945 0.7921 0.32489 0.28716 0.3547 27 116 153 42 182 151
    rs13282131 Imputed C GEN 675 7.767 0.02058 0.8765 0.44889 0.48639 0.4199 72 142 80 65 190 126
    rs13353526 Imputed C DOM 674 1.752 0.2045 1.174 2.617 2.743 0.006085 0.3687 0.09496 0.11486 0.0794 2 64 230 6 48 324
    rs1336382 Imputed T DOM 682 1.772 0.1576 1.301 2.413 3.63 2.84E−04 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs1336383 Imputed T DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs1336407 Imputed T DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs1336409 Imputed T DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs1336596 Imputed A DOM 682 0.565 0.1607 0.412 0.7735 −3.558 0.000374 0.9327 0.34751 0.31333 0.3743 37 114 149 46 194 142
    rs1343560 Imputed T ADD 678 0.521 0.1923 0.3575 0.7596 −3.39 0.000699 0.3076 0.10546 0.07239 0.1312 3 37 257 7 86 288
    rs1343560 Imputed T DOM 678 0.478 0.2098 0.3168 0.7211 −3.518 0.000435 0.3076 0.10546 0.07239 0.1312 3 37 257 7 86 288
    rs1361987 Imputed T GEN 682 12.45 0.001975 0.9355 0.3849 0.335 0.4241 28 145 127 72 180 130
    rs1386153 Imputed T ADD 677 0.694 0.1194 0.5493 0.8772 −3.057 0.002235 0.7936 0.32718 0.28261 0.3624 27 115 157 47 180 151
    rs1386153 Imputed T DOM 677 0.603 0.1574 0.4431 0.8213 −3.21 0.001326 0.7936 0.32718 0.28261 0.3624 27 115 157 47 180 151
    rs1394015 Imputed C DOM 669 1.658 0.1636 1.203 2.285 3.091 0.001993 0.4527 0.36472 0.39384 0.3422 35 160 97 49 160 168
    rs1407038 Imputed A REC 678 2.31 0.2263 1.483 3.599 3.7 0.000215 0.8076 0.38422 0.4375 0.3429 59 141 96 39 184 159
    rs1407039 Imputed A REC 680 2.185 0.221 1.417 3.37 3.538 4.04E−04 0.748 0.39412 0.44631 0.3534 61 144 93 42 186 154
    rs1412802 Imputed T GEN 681 6.558 0.03767 0.785 0.30176 0.27 0.3268 17 128 155 43 163 175
    rs1414865 Imputed T DOM 682 1.79 0.1585 1.312 2.442 3.671 0.000241 1 0.30132 0.34 0.2709 27 150 123 35 137 210
    rs1414873 Imputed A DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs1414876 Imputed C DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs1418671 Imputed C REC 655 2.259 0.2305 1.437 3.549 3.534 0.000409 0.2728 0.36336 0.41493 0.3229 57 125 106 36 165 166
    rs1419490 Genotyped T GEN 682 12.66 0.001783 0.9357 0.38416 0.33333 0.4241 28 144 128 72 180 130
    rs1434507 Imputed A ADD 681 1.547 0.1268 1.206 1.983 3.439 0.000584 0.8411 0.25698 0.30333 0.2205 28 126 146 18 132 231
    rs1434508 Imputed T ADD 681 1.536 0.1268 1.198 1.97 3.388 0.000705 0.9202 0.25771 0.30333 0.2218 28 126 146 18 133 230
    rs1435205 Imputed A ADD 679 1.5 0.1343 1.153 1.952 3.019 0.00254 1 0.21944 0.25671 0.1903 21 111 166 11 123 247
    rs1443928 Imputed C REC 672 0.59 0.1812 0.4133 0.8409 −2.917 0.003539 0.5875 0.53571 0.50169 0.5625 66 165 65 123 177 76
    rs1452235 Imputed G GEN 682 12.53 0.001899 0.2617 0.33065 0.28667 0.3652 21 130 149 60 159 163
    rs1452236 Imputed G GEN 681 12.63 0.001811 0.2989 0.33113 0.28667 0.3661 21 130 149 60 159 162
    rs1452237 Imputed G GEN 682 12.53 0.001899 0.2617 0.33065 0.28667 0.3652 21 130 149 60 159 163
    rs1452243 Genotyped T GEN 682 12.53 0.001899 0.2617 0.33065 0.28667 0.3652 21 130 149 60 159 163
    rs1463768 Genotyped G REC 682 1.527 0.2037 1.025 2.277 2.08 0.03755 0.3847 0.40982 0.435 0.3901 63 135 102 57 184 141
    rs1463769 Imputed G REC 682 1.561 0.2044 1.045 2.33 2.177 0.02947 0.428 0.40836 0.435 0.3874 63 135 102 56 184 142
    rs1472435 Imputed A ADD 675 0.581 0.2266 0.3727 0.9061 −2.395 0.01663 0.3725 0.07111 0.05201 0.0862 0 31 267 5 55 317
    rs1472435 Imputed A DOM 675 0.6 0.2382 0.376 0.9566 −2.146 0.03185 0.3725 0.07111 0.05201 0.0862 0 31 267 5 55 317
    rs1476714 Imputed A DOM 681 0.558 0.1599 0.4076 0.7628 −3.654 0.000258 1 0.34802 0.30769 0.3796 36 112 151 46 198 138
    rs1495159 Imputed G ADD 671 0.664 0.125 0.5195 0.8479 −3.281 0.001036 0.8591 0.31967 0.27721 0.3528 19 125 150 48 170 159
    rs1495159 Imputed G GEN 671 11.32 0.003475 0.8591 0.31967 0.27721 0.3528 19 125 150 48 170 159
    rs1495375 Imputed A DOM 674 0.571 0.1673 0.4111 0.7921 −3.353 0.0008 1 0.42507 0.3902 0.4524 52 127 117 70 202 106
    rs1495376 Imputed T DOM 649 0.594 0.1848 0.4134 0.8529 −2.821 0.004787 0.8753 0.4923 0.46986 0.5095 70 125 87 86 202 79
    rs1495377 Imputed G DOM 652 0.615 0.1836 0.4294 0.8819 −2.644 0.008185 0.9375 0.49233 0.47183 0.5082 71 126 87 86 202 80
    rs1495381 Imputed T GEN 682 10.43 0.005444 0.3777 0.39443 0.43 0.3665 59 140 101 41 198 143
    rs1495381 Imputed T REC 682 2.043 0.2213 1.324 3.152 3.229 0.001243 0.3777 0.39443 0.43 0.3665 59 140 101 41 198 143
    rs1498992 Imputed G DOM 681 0.583 0.1567 0.4286 0.7922 −3.446 0.000568 0.4296 0.32159 0.27592 0.3573 28 109 162 47 179 156
    rs1499001 Imputed T DOM 661 0.587 0.1603 0.4291 0.8042 −3.32 0.000901 0.5609 0.27761 0.22837 0.3159 16 100 173 38 159 175
    rs1512988 Imputed A DOM 681 0.588 0.1643 0.4264 0.8118 −3.229 0.001243 0.9365 0.40088 0.36455 0.4293 45 128 126 65 198 119
    rs1512989 Imputed T DOM 681 0.588 0.1643 0.4264 0.8118 −3.229 0.001243 0.9365 0.40088 0.36455 0.4293 45 128 126 65 198 119
    rs1512991 Imputed T ADD 677 0.734 0.1143 0.5865 0.9181 −2.707 0.006791 0.6434 0.46824 0.42929 0.4987 57 141 99 88 203 89
    rs1512991 Imputed T DOM 677 0.588 0.1751 0.4173 0.8289 −3.032 0.002431 0.6434 0.46824 0.42929 0.4987 57 141 99 88 203 89
    rs1516855 Imputed G REC 657 1.965 0.2424 1.222 3.16 2.786 0.005328 0.1374 0.38052 0.41176 0.356 49 140 100 37 188 143
    rs1527450 Imputed T ADD 670 1.426 0.1148 1.139 1.787 3.093 0.001982 0.7474 0.39776 0.44463 0.3602 61 143 94 47 174 151
    rs1527450 Imputed T GEN 670 9.977 0.006814 0.7474 0.39776 0.44463 0.3602 61 143 94 47 174 151
    rs1567740 Imputed T DOM 679 0.584 0.165 0.4224 0.8064 −3.264 0.001098 0.8732 0.40206 0.367 0.4293 46 126 125 65 198 119
    rs1572573 Imputed A ADD 657 1.745 0.1419 1.321 2.305 3.923 8.73E−05 0.1585 0.18798 0.23693 0.15 16 104 167 13 85 272
    rs1572573 Imputed A DOM 657 2.014 0.1694 1.445 2.807 4.132 3.60E−05 0.1585 0.18798 0.23693 0.15 16 104 167 13 85 272
    rs1584003 Imputed C DOM 673 1.97 0.1803 1.384 2.806 3.761 0.000169 0.2788 0.47028 0.5119 0.438 70 161 63 86 160 133
    rs1584005 Imputed C DOM 665 1.936 0.181 1.358 2.761 3.652 0.000261 0.2759 0.46842 0.50692 0.4388 67 159 63 86 158 132
    rs1585771 Imputed G ADD 674 1.481 0.1242 1.161 1.889 3.162 0.001567 0.3712 0.26261 0.30678 0.2282 31 119 145 20 133 226
    rs1592015 Imputed G DOM 681 0.523 0.1726 0.373 0.7337 −3.754 0.000174 0.43 0.17621 0.13712 0.2068 10 62 227 14 130 238
    rs1594885 Imputed A ADD 681 1.561 0.1254 1.221 1.995 3.551 0.000384 0.6918 0.26211 0.31 0.2244 30 126 144 19 133 229
    rs1603232 Imputed A DOM 655 0.631 0.1827 0.4408 0.902 −2.525 0.01159 1 0.48779 0.47038 0.5014 72 126 89 84 201 83
    rs1614565 Imputed C DOM 671 0.574 0.1797 0.4034 0.816 −3.091 0.001993 0.9385 0.48957 0.46949 0.5053 75 127 93 85 210 81
    rs1648200 Imputed G ADD 623 1.473 0.135 1.13 1.919 2.868 0.004134 0.833 0.25522 0.29478 0.2254 19 120 129 20 120 215
    rs16877387 Imputed C GEN 677 11.65 0.002959 0.3017 0.33678 0.38047 0.3026 51 124 122 32 166 182
    rs16877387 Imputed C REC 677 2.249 0.2423 1.399 3.616 3.345 0.000823 0.3017 0.33678 0.38047 0.3026 51 124 122 32 166 182
    rs16938626 Imputed G DOM 663 0.631 0.1588 0.4625 0.8618 −2.897 0.00377 0.9255 0.29261 0.25676 0.3215 23 106 167 33 170 164
    rs1694334 Imputed G ADD 599 0.664 0.1373 0.5072 0.8688 −2.984 0.002847 0.01892 0.24207 0.1954 0.2781 10 82 169 36 116 186
    rs16998821 Imputed C DOM 681 0.523 0.1726 0.373 0.7337 −3.754 0.000174 0.43 0.17621 0.13712 0.2068 10 62 227 14 130 238
    rs1700400 Imputed T ADD 672 0.695 0.131 0.5378 0.8989 −2.774 0.005544 0.5481 0.25967 0.22297 0.2886 11 110 175 31 155 190
    rs17007620 Imputed G ADD 599 1.567 0.1431 1.184 2.074 3.138 0.001699 0.8194 0.23372 0.27308 0.2035 16 110 134 15 108 216
    rs17007620 Imputed G DOM 599 1.743 0.171 1.247 2.437 3.251 0.001149 0.8194 0.23372 0.27308 0.2035 16 110 134 15 108 216
    rs17023290 Imputed C DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs17047957 Imputed C DOM 681 1.493 0.168 1.074 2.074 2.384 0.01712 0.4202 0.17181 0.19231 0.1558 7 101 191 16 87 279
    rs1705237 Imputed A DOM 666 0.566 0.1803 0.3973 0.8057 −3.158 0.001589 0.8767 0.48649 0.4622 0.5053 71 127 93 85 209 81
    rs1705261 Imputed A GEN 682 10.46 0.005353 0.4226 0.39296 0.43 0.3639 59 140 101 41 196 145
    rs1705261 Imputed A REC 682 2.043 0.2213 1.324 3.152 3.229 0.001243 0.4226 0.39296 0.43 0.3639 59 140 101 41 196 145
    rs17076972 Imputed C ADD 682 1.427 0.1121 1.146 1.778 3.172 0.001511 1 0.47507 0.52667 0.4346 86 144 70 68 196 118
    rs17076972 Imputed C GEN 682 11.26 0.003593 1 0.47507 0.52667 0.4346 86 144 70 68 196 118
    rs17076972 Imputed C REC 682 1.816 0.1863 1.26 2.616 3.202 0.001365 1 0.47507 0.52667 0.4346 86 144 70 68 196 118
    rs17189710 Imputed T ADD 681 1.338 0.1141 1.07 1.674 2.554 0.01063 0.2789 0.3583 0.39667 0.3281 54 130 116 40 170 171
    rs17189710 Imputed T GEN 681 7.872 0.01953 0.2789 0.3583 0.39667 0.3281 54 130 116 40 170 171
    rs17196143 Imputed A ADD 682 1.57 0.1416 1.189 2.072 3.183 0.001458 0.6286 0.19721 0.23667 0.1662 12 118 170 12 103 267
    rs17353809 Imputed G ADD 674 1.511 0.1348 1.16 1.968 3.062 0.002199 0.9094 0.21588 0.25424 0.186 22 106 167 10 121 248
    rs17368986 Imputed A GEN 682 13.99 0.000919 0.07037 0.19721 0.24167 0.1623 26 93 181 8 108 266
    rs17369097 Imputed A GEN 681 13.12 0.001413 0.1414 0.19457 0.23833 0.1601 24 95 181 8 106 267
    rs17434511 Imputed C GEN 679 13.93 0.000944 0.06935 0.19735 0.24161 0.1627 26 92 180 8 108 265
    rs17434589 Imputed C GEN 673 14.2 0.000826 0.06943 0.19837 0.24407 0.1627 26 92 177 8 107 263
    rs17434603 Imputed G GEN 680 13.78 0.001017 0.06901 0.19706 0.2408 0.1627 26 92 181 8 108 265
    rs17434840 Imputed C GEN 681 13.12 0.001413 0.1414 0.19457 0.23833 0.1601 24 95 181 8 106 267
    rs17446418 Imputed G DOM 678 0.537 0.1603 0.3921 0.7351 −3.88 0.000105 0.8045 0.36873 0.31711 0.4092 35 119 144 59 193 128
    rs17530747 Imputed T DOM 669 0.525 0.1614 0.383 0.7209 −3.988 6.66E−05 0.8027 0.36398 0.30887 0.4069 32 117 144 58 190 128
    rs17604285 Imputed C ADD 681 0.533 0.1972 0.3619 0.7838 −3.195 0.001397 0.2868 0.09912 0.06833 0.1234 2 37 261 7 80 294
    rs17604285 Imputed C DOM 681 0.504 0.212 0.3327 0.7638 −3.231 0.001233 0.2868 0.09912 0.06833 0.1234 2 37 261 7 80 294
    rs17662322 Imputed T DOM 681 0.555 0.17 0.3978 0.7746 −3.463 0.000535 1 0.18135 0.13712 0.216 4 74 221 18 129 235
    rs17769826 Imputed T ADD 677 1.504 0.1347 1.155 1.958 3.029 0.002453 0.9092 0.21492 0.25253 0.1855 22 106 169 10 121 249
    rs17821641 Imputed T ADD 679 1.5 0.1343 1.153 1.952 3.019 0.00254 1 0.21944 0.25671 0.1903 21 111 166 11 123 247
    rs1782328 Imputed A ADD 647 0.613 0.1454 0.4609 0.8148 −3.369 0.000754 0.1051 0.19706 0.15194 0.2321 6 74 203 26 117 221
    rs1796337 Imputed T DOM 669 0.597 0.1833 0.4168 0.8548 −2.816 0.004863 0.5361 0.51121 0.48142 0.5349 77 131 88 102 195 76
    rs1798083 Imputed C DOM 674 0.601 0.179 0.4232 0.8536 −2.845 0.004447 0.8775 0.48813 0.46959 0.5026 74 130 92 85 210 83
    rs1798085 Imputed T DOM 668 0.578 0.1804 0.4058 0.823 −3.04 0.002368 0.9383 0.48952 0.46928 0.5053 74 127 92 85 209 81
    rs1798086 Imputed T DOM 668 0.553 0.1797 0.3886 0.786 −3.3 0.000968 1 0.48653 0.46246 0.5053 73 125 95 85 209 81
    rs1798089 Imputed C GEN 675 11.13 0.00383 0.42 0.39333 0.43098 0.3638 59 138 100 40 195 143
    rs1798089 Imputed C REC 675 2.101 0.2227 1.358 3.252 3.334 0.000855 0.42 0.39333 0.43098 0.3638 59 138 100 40 195 143
    rs1798090 Imputed C GEN 674 10.63 0.004921 0.3765 0.39614 0.43412 0.3664 59 139 98 41 195 142
    rs1798090 Imputed C REC 674 2.054 0.2214 1.331 3.17 3.251 0.001151 0.3765 0.39614 0.43412 0.3664 59 139 98 41 195 142
    rs1832222 Imputed G DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs1838104 Imputed A ADD 668 0.727 0.1159 0.5791 0.9121 −2.754 0.005895 0.3083 0.55539 0.51199 0.5891 71 157 64 128 187 61
    rs1838104 Imputed A GEN 668 7.983 0.01848 0.3083 0.55539 0.51199 0.5891 71 157 64 128 187 61
    rs1868616 Imputed G ADD 671 0.572 0.1501 0.426 0.7672 −3.725 0.000195 0.7063 0.19001 0.14576 0.2247 4 78 213 18 133 225
    rs1874313 Imputed A DOM 674 0.578 0.1655 0.4178 0.7993 −3.314 0.000921 0.9364 0.40504 0.36824 0.4339 46 126 124 65 198 115
    rs1884902 Imputed C REC 678 2.217 0.2224 1.434 3.428 3.579 0.000344 0.6303 0.39381 0.44649 0.3522 61 145 93 41 185 153
    rs1913201 Imputed G ADD 650 0.692 0.1185 0.5487 0.873 −3.106 0.001894 0.3832 0.44692 0.40175 0.4822 45 139 101 79 194 92
    rs1913201 Imputed G DOM 650 0.589 0.1754 0.4175 0.8303 −3.02 0.002528 0.3832 0.44692 0.40175 0.4822 45 139 101 79 194 92
    rs1913201 Imputed G GEN 650 10.22 0.006038 0.3832 0.44692 0.40175 0.4822 45 139 101 79 194 92
    rs1944279 Imputed A ADD 679 1.579 0.1261 1.233 2.022 3.624 0.00029 0.6914 0.26068 0.30936 0.2224 30 125 144 18 133 229
    rs198461 Imputed C DOM 676 0.625 0.1925 0.4287 0.9117 −2.44 0.01467 0.04501 0.52367 0.49495 0.5462 71 152 74 101 212 66
    rs1987179 Imputed T DOM 680 0.701 0.1613 0.5109 0.9616 −2.203 0.0276 0.06175 0.20735 0.18562 0.2244 10 91 198 11 149 221
    rs1990023 Imputed T DOM 682 0.548 0.1595 0.4011 0.7494 −3.769 0.000164 0.9329 0.34824 0.30667 0.3809 36 112 152 46 199 137
    rs2016194 Imputed G DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs2024789 Imputed C ADD 666 0.675 0.1123 0.542 0.8417 −3.495 0.000475 0.3902 0.4542 0.39828 0.4973 49 133 108 94 186 96
    rs2024789 Imputed C GEN 666 12.34 0.002095 0.3902 0.4542 0.39828 0.4973 49 133 108 94 186 96
    rs2024902 Imputed A ADD 678 2.07 0.2296 1.32 3.246 3.168 0.001535 0.2503 0.07375 0.09732 0.0553 3 52 243 3 36 341
    rs2024902 Imputed A DOM 678 2.266 0.2451 1.401 3.663 3.336 0.000849 0.2503 0.07375 0.09732 0.0553 3 52 243 3 36 341
    rs2025107 Imputed A ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs2025107 Imputed A DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs2025108 Imputed T ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs2025108 Imputed T DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs2062448 Imputed T ADD 674 0.545 0.1992 0.3687 0.805 −3.049 0.002299 0.2633 0.09644 0.06711 0.1197 2 36 260 7 76 293
    rs2062448 Imputed T DOM 674 0.517 0.215 0.339 0.7873 −3.072 0.002123 0.2633 0.09644 0.06711 0.1197 2 36 260 7 76 293
    rs2063591 Imputed C ADD 677 0.73 0.1136 0.5839 0.9113 −2.777 0.005479 0.8173 0.47858 0.43792 0.5106 61 139 98 92 203 84
    rs2063591 Imputed C DOM 677 0.56 0.1767 0.3958 0.7911 −3.287 0.001014 0.8173 0.47858 0.43792 0.5106 61 139 98 92 203 84
    rs2065604 Imputed C DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs2066238 Imputed T DOM 682 0.521 0.1725 0.3715 0.7305 −3.78 0.000157 0.4294 0.17595 0.13667 0.2068 10 62 228 14 130 238
    rs2068051 Imputed G ADD 424 0.612 0.1413 0.464 0.8076 −3.472 0.000517 0.1925 0.58726 0.52332 0.6407 55 92 46 98 100 33
    rs2068051 Imputed G GEN 424 12.06 0.002411 0.1925 0.58726 0.52332 0.6407 55 92 46 98 100 33
    rs2077702 Genotyped G GEN 682 9.004 0.01108 0.5971 0.31818 0.35 0.2932 44 122 134 28 168 186
    rs208757 Imputed G ADD 652 1.552 0.1511 1.154 2.087 2.91 0.003619 0.4981 0.17485 0.20833 0.1484 9 102 177 8 92 264
    rs208757 Imputed G DOM 652 1.649 0.1701 1.182 2.302 2.942 0.003266 0.4981 0.17485 0.20833 0.1484 9 102 177 8 92 264
    rs2095586 Imputed A DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs2108426 Imputed C DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs2110664 Imputed A DOM 643 1.503 0.1611 1.096 2.061 2.53 0.01141 0.8422 0.27138 0.30674 0.2438 24 125 133 22 132 207
    rs2132242 Imputed A DOM 680 0.585 0.1661 0.4222 0.8097 −3.231 0.001233 1 0.41544 0.37919 0.4437 48 130 120 69 201 112
    rs2151644 Imputed T DOM 679 0.527 0.2075 0.3509 0.7914 −3.088 0.002018 0.6758 0.10236 0.07358 0.125 2 40 257 6 83 291
    rs2157752 Genotyped A GEN 682 12.46 0.001973 0.676 0.35557 0.30667 0.394 24 136 140 65 171 146
    rs2158958 Imputed A DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs2158961 Imputed G DOM 680 0.564 0.1598 0.412 0.7707 −3.59 0.00033 0.9326 0.34706 0.30833 0.3776 36 113 151 45 197 138
    rs2164099 Imputed G ADD 681 1.561 0.1254 1.221 1.995 3.551 0.000384 0.6918 0.26211 0.31 0.2244 30 126 144 19 133 229
    rs2173254 Imputed G GEN 675 12.63 0.001808 0.08658 0.34074 0.29561 0.376 17 141 138 51 183 145
    rs2173254 Imputed G REC 675 0.382 0.2927 0.2154 0.6786 −3.285 0.001021 0.08658 0.34074 0.29561 0.376 17 141 138 51 183 145
    rs2188079 Imputed C ADD 682 1.482 0.1139 1.186 1.853 3.457 0.000547 0.8148 0.42962 0.48333 0.3874 71 148 81 53 190 139
    rs2188079 Imputed C GEN 682 12.81 0.001651 0.8148 0.42962 0.48333 0.3874 71 148 81 53 190 139
    rs2190304 Imputed G REC 682 0.439 0.2056 0.2933 0.6567 −4.005 6.20E−05 0.2503 0.47947 0.42667 0.5209 44 168 88 105 188 89
    rs2190597 Imputed T DOM 681 0.559 0.174 0.3978 0.7868 −3.338 0.000844 0.9387 0.46916 0.43167 0.4987 63 133 104 86 208 87
    rs2190598 Imputed T DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs2190600 Imputed A DOM 672 0.561 0.1605 0.4097 0.7686 −3.6 0.000319 0.9321 0.34598 0.3064 0.3773 36 110 151 45 193 137
    rs2218084 Imputed T GEN 664 8.488 0.01435 0.02385 0.16416 0.18983 0.1436 19 74 202 7 92 270
    rs2218084 Imputed T REC 664 3.657 0.4516 1.509 8.862 2.871 0.004092 0.02385 0.16416 0.18983 0.1436 19 74 202 7 92 270
    rs2236290 Genotyped C GEN 680 6.499 0.0388 0.5618 0.36103 0.32667 0.3882 30 136 134 62 171 147
    rs2243860 Imputed A GEN 548 9.796 0.00746 0.1582 0.40785 0.45021 0.3746 50 117 74 33 164 110
    rs2243860 Imputed A REC 548 2.168 0.2486 1.332 3.529 3.113 0.00185 0.1582 0.40785 0.45021 0.3746 50 117 74 33 164 110
    rs2246564 Imputed T DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs2248236 Imputed C DOM 681 0.718 0.1608 0.524 0.9842 −2.059 0.03947 0.04865 0.20852 0.18833 0.2244 10 93 197 11 149 221
    rs2250340 Imputed T DOM 600 0.514 0.2136 0.3382 0.7813 −3.115 0.001837 0.8378 0.1125 0.08113 0.1373 2 39 224 6 80 249
    rs2257192 Imputed G DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs2270584 Imputed A DOM 679 0.567 0.1632 0.4117 0.7806 −3.477 0.000507 0.7495 0.40059 0.36622 0.4276 49 121 129 62 201 117
    rs2270586 Imputed A DOM 680 0.564 0.1631 0.4095 0.7761 −3.514 0.000442 0.8731 0.4 0.36622 0.4265 49 121 129 61 203 117
    rs2270589 Imputed A ADD 682 0.711 0.1121 0.5703 0.8851 −3.048 0.002301 0.877 0.44648 0.40167 0.4817 54 133 113 83 202 97
    rs2270589 Imputed A DOM 682 0.552 0.1689 0.3961 0.7679 −3.523 0.000426 0.877 0.44648 0.40167 0.4817 54 133 113 83 202 97
    rs2270589 Imputed A GEN 682 12.43 0.001996 0.877 0.44648 0.40167 0.4817 54 133 113 83 202 97
    rs2296889 Imputed C DOM 672 1.638 0.1743 1.164 2.305 2.832 0.004632 0.7651 0.15253 0.17508 0.1347 3 98 196 11 79 285
    rs2301346 Imputed C ADD 550 1.573 0.133 1.212 2.042 3.407 0.000656 0.2216 0.29818 0.35124 0.2565 32 106 104 23 112 173
    rs2301346 Imputed C DOM 550 1.763 0.1765 1.248 2.492 3.214 0.001311 0.2216 0.29818 0.35124 0.2565 32 106 104 23 112 173
    rs2327929 Imputed G REC 682 2.122 0.1996 1.435 3.137 3.769 0.000164 0.09898 0.42155 0.47333 0.3809 77 130 93 55 181 146
    rs2357486 Imputed C REC 673 2.717 0.2622 1.625 4.542 3.812 0.000138 0.7297 0.33432 0.37752 0.3 48 129 121 25 175 175
    rs2373793 Imputed G DOM 646 1.534 0.1778 1.083 2.173 2.407 0.0161 0.1726 0.15402 0.18151 0.1314 11 84 197 9 75 270
    rs2377622 Imputed T GEN 552 7.759 0.02066 0.9252 0.34692 0.3125 0.3719 18 109 105 49 140 131
    rs2377622 Imputed T REC 552 0.437 0.2982 0.2436 0.784 −2.776 0.005501 0.9252 0.34692 0.3125 0.3719 18 109 105 49 140 131
    rs2383903 Imputed G DOM 681 0.614 0.1576 0.4507 0.836 −3.096 0.001959 0.9247 0.28267 0.245 0.3123 22 103 175 33 172 176
    rs2389866 Imputed C DOM 681 0.697 0.1612 0.508 0.9558 −2.24 0.02509 0.06186 0.20705 0.185 0.2244 10 91 199 11 149 221
    rs2389869 Imputed C DOM 681 0.697 0.1612 0.508 0.9558 −2.24 0.02509 0.06186 0.20705 0.185 0.2244 10 91 199 11 149 221
    rs2418541 Imputed A DOM 681 0.551 0.1595 0.4029 0.753 −3.738 0.000186 1 0.34802 0.30667 0.3806 36 112 152 46 198 137
    rs2418542 Imputed A DOM 681 0.551 0.1595 0.4029 0.753 −3.738 0.000186 1 0.34802 0.30667 0.3806 36 112 152 46 198 137
    rs2418548 Imputed C DOM 630 0.572 0.1639 0.4145 0.788 −3.414 0.00064 0.9279 0.32698 0.29474 0.3536 33 102 150 35 174 136
    rs2476976 Imputed C DOM 681 1.728 0.1579 1.268 2.355 3.465 0.00053 0.855 0.29736 0.33278 0.2696 25 149 125 34 138 210
    rs2483639 Imputed A DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs2483640 Imputed A DOM 682 0.529 0.2074 0.352 0.7937 −3.074 0.00211 0.6748 0.10191 0.07333 0.1243 2 40 258 6 83 293
    rs2544780 Imputed T REC 670 1.881 0.2505 1.151 3.073 2.521 0.0117 0.248 0.3194 0.35959 0.2884 43 124 125 32 154 192
    rs2586458 Imputed T DOM 322 0.507 0.2771 0.2947 0.8733 −2.449 0.01433 0.4953 0.14286 0.10465 0.1684 3 21 105 5 55 133
    rs2593272 Imputed G ADD 682 0.712 0.1296 0.5521 0.9177 −2.623 0.00872 0.6186 0.25953 0.225 0.2866 12 111 177 31 157 194
    rs2593273 Imputed T ADD 678 0.699 0.1321 0.5396 0.9057 −2.71 0.006738 0.3627 0.25516 0.2198 0.2829 10 111 177 29 157 194
    rs2622499 Imputed G DOM 682 0.726 0.1604 0.5299 0.9939 −1.998 0.04572 0.08586 0.21261 0.19333 0.2277 11 94 195 12 150 220
    rs264126 Imputed C DOM 679 0.553 0.1744 0.3932 0.779 −3.392 0.000693 0.9386 0.46981 0.43167 0.5 63 133 104 86 207 86
    rs264129 Imputed T DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 1 0.34802 0.30833 0.3793 36 113 151 46 197 138
    rs2656822 Imputed T ADD 682 0.712 0.1296 0.5521 0.9177 −2.623 0.00872 0.6186 0.25953 0.225 0.2866 12 111 177 31 157 194
    rs2656823 Imputed G ADD 682 0.712 0.1296 0.5521 0.9177 −2.623 0.00872 0.6186 0.25953 0.225 0.2866 12 111 177 31 157 194
    rs2656825 Imputed T ADD 665 0.702 0.1338 0.5398 0.9119 −2.649 0.00807 0.4115 0.25263 0.21747 0.2802 9 109 174 29 151 193
    rs2764766 Imputed C REC 678 1.803 0.2463 1.112 2.922 2.393 0.01673 0.2549 0.32448 0.36364 0.294 44 128 125 34 156 191
    rs2793101 Imputed T ADD 680 0.506 0.1889 0.3491 0.732 −3.612 0.000304 1 0.1125 0.07833 0.1395 1 45 254 7 92 281
    rs2793101 Imputed T DOM 680 0.501 0.2 0.3385 0.7413 −3.457 0.000547 1 0.1125 0.07833 0.1395 1 45 254 7 92 281
    rs2795871 Imputed A ADD 676 0.578 0.2256 0.3717 0.9 −2.427 0.01522 0.3783 0.07175 0.05201 0.0873 0 31 267 5 56 317
    rs2795886 Imputed A ADD 681 0.507 0.2747 0.2962 0.8693 −2.47 0.01352 0.0724 0.04919 0.03167 0.063 0 19 281 4 40 337
    rs2795886 Imputed A DOM 681 0.517 0.2884 0.2939 0.9104 −2.285 0.02229 0.0724 0.04919 0.03167 0.063 0 19 281 4 40 337
    rs2859994 Imputed C GEN 645 9.449 0.008877 0.112 0.37984 0.41986 0.3478 49 143 95 34 181 143
    rs2870464 Imputed G DOM 682 1.534 0.1771 1.084 2.171 2.417 0.01564 0.5379 0.14443 0.17 0.1243 9 84 207 7 81 294
    rs2875528 Imputed T DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs2876227 Imputed C ADD 640 1.393 0.1179 1.106 1.755 2.811 0.00494 0.226 0.35156 0.39785 0.3158 50 122 107 36 156 169
    rs2876227 Imputed C GEN 640 8.788 0.01235 0.226 0.35156 0.39785 0.3158 50 122 107 36 156 169
    rs2882097 Imputed A DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs2921983 Imputed C ADD 640 0.679 0.1387 0.5173 0.8909 −2.793 0.00522 0.5889 0.23984 0.20285 0.2688 9 96 176 25 143 191
    rs2987537 Imputed C DOM 682 0.501 0.1957 0.3413 0.735 −3.533 0.000411 0.2158 0.1239 0.09 0.1505 5 44 251 9 97 276
    rs2996416 Imputed C ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs2996416 Imputed C DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015527 Imputed C ADD 677 0.519 0.1922 0.3558 0.7559 −3.416 0.000635 0.303 0.10487 0.07191 0.131 3 37 259 7 85 286
    rs3015527 Imputed C DOM 677 0.476 0.2098 0.3154 0.7179 −3.54 0.000401 0.303 0.10487 0.07191 0.131 3 37 259 7 85 286
    rs3015530 Imputed C ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015530 Imputed C DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015531 Imputed T ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015531 Imputed T DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015535 Imputed C ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3015535 Imputed C DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs3019407 Imputed A GEN 675 12.63 0.001808 0.08658 0.34074 0.29561 0.376 17 141 138 51 183 145
    rs3019407 Imputed A REC 675 0.382 0.2927 0.2154 0.6786 −3.285 0.001021 0.08658 0.34074 0.29561 0.376 17 141 138 51 183 145
    rs36071725 Genotyped C GEN 682 15.36 0.000463 0.6072 0.33724 0.38333 0.301 49 132 119 25 180 177
    rs373983 Imputed G DOM 661 1.911 0.1684 1.373 2.658 3.844 0.000121 0.4632 0.39334 0.44692 0.3509 55 151 86 52 155 162
    rs3756154 Imputed C DOM 681 0.697 0.1612 0.508 0.9558 −2.24 0.02509 0.06186 0.20705 0.185 0.2244 10 91 199 11 149 221
    rs3793044 Imputed C ADD 682 2.264 0.2373 1.422 3.606 3.444 0.000573 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs3793044 Imputed C DOM 682 2.432 0.2521 1.484 3.986 3.525 0.000423 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs3793053 Imputed C ADD 672 2.017 0.2117 1.332 3.055 3.316 0.000914 0.6256 0.08705 0.11409 0.0655 3 62 233 3 43 328
    rs3793053 Imputed C DOM 672 2.188 0.2249 1.408 3.4 3.48 0.000501 0.6256 0.08705 0.11409 0.0655 3 62 233 3 43 328
    rs3796246 Imputed G ADD 682 0.511 0.2045 0.3419 0.7623 −3.287 0.001012 1 0.09531 0.065 0.1191 1 37 262 5 81 296
    rs3796246 Imputed G DOM 682 0.497 0.2139 0.3265 0.7551 −3.273 0.001063 1 0.09531 0.065 0.1191 1 37 262 5 81 296
    rs3805996 Imputed G ADD 662 2.146 0.2358 1.352 3.407 3.239 0.001199 0.1442 0.07251 0.0976 0.0527 3 51 238 3 33 334
    rs3805996 Imputed G DOM 662 2.368 0.2509 1.448 3.871 3.436 0.00059 0.1442 0.07251 0.0976 0.0527 3 51 238 3 33 334
    rs3806003 Imputed A ADD 682 2.264 0.2373 1.422 3.606 3.444 0.000573 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs3806003 Imputed A DOM 682 2.432 0.2521 1.484 3.986 3.525 0.000423 0.205 0.06598 0.09167 0.0458 3 49 248 2 31 349
    rs3806004 Imputed T ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806004 Imputed T DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806010 Imputed T ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806010 Imputed T DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806014 Imputed T ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806014 Imputed T DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806015 Imputed A ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806015 Imputed A DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806018 Imputed A ADD 682 2.008 0.2082 1.336 3.02 3.35 0.000808 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806018 Imputed A DOM 682 2.219 0.2217 1.437 3.427 3.596 0.000324 0.4997 0.09238 0.12 0.0707 3 66 231 4 46 332
    rs3806019 Imputed A ADD 678 2.145 0.2126 1.414 3.253 3.588 0.000333 0.6198 0.08555 0.11538 0.062 3 63 233 3 41 335
    rs3806019 Imputed A DOM 678 2.353 0.2258 1.511 3.663 3.788 0.000152 0.6198 0.08555 0.11538 0.062 3 63 233 3 41 335
    rs3806024 Imputed T ADD 672 2.017 0.2117 1.332 3.055 3.316 0.000914 0.6256 0.08705 0.11409 0.0655 3 62 233 3 43 328
    rs3806024 Imputed T DOM 672 2.188 0.2249 1.408 3.4 3.48 0.000501 0.6256 0.08705 0.11409 0.0655 3 62 233 3 43 328
    rs3847825 Imputed G ADD 680 0.691 0.112 0.5544 0.8601 −3.305 0.00095 0.03311 0.37353 0.32107 0.4147 33 126 140 75 166 140
    rs3847825 Imputed G GEN 680 11.36 0.003414 0.03311 0.37353 0.32107 0.4147 33 126 140 75 166 140
    rs3852001 Genotyped C GEN 682 13.99 0.000919 0.07037 0.19721 0.24167 0.1623 26 93 181 8 108 266
    rs3852001 Genotyped C REC 682 4.254 0.4136 1.891 9.569 3.5 0.000465 0.07037 0.19721 0.24167 0.1623 26 93 181 8 108 266
    rs3852002 Imputed G GEN 681 13.41 0.001226 0.08816 0.1953 0.23913 0.161 25 93 181 8 107 267
    rs3852002 Imputed G REC 681 4.089 0.4152 1.812 9.226 3.392 0.000694 0.08816 0.1953 0.23913 0.161 25 93 181 8 107 267
    rs3852003 Imputed A GEN 681 13.41 0.001226 0.08816 0.1953 0.23913 0.161 25 93 181 8 107 267
    rs3852003 Imputed A REC 681 4.089 0.4152 1.812 9.226 3.392 0.000694 0.08816 0.1953 0.23913 0.161 25 93 181 8 107 267
    rs3942254 Imputed T DOM 678 0.6 0.1651 0.4341 0.8292 −3.094 0.001974 1 0.40413 0.37037 0.4304 46 128 123 65 198 118
    rs3945085 Imputed A DOM 682 1.794 0.1572 1.319 2.442 3.72 0.000199 1 0.29252 0.33167 0.2618 25 149 126 33 134 215
    rs399485 Imputed A DOM 678 1.537 0.1571 1.129 2.091 2.735 0.006241 0.697 0.26917 0.30705 0.2395 27 129 142 24 134 222
    rs4029119 Imputed G ADD 682 0.217 0.4129 0.0965 0.4867 −3.704 0.000213 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs4029119 Imputed G DOM 682 0.223 0.4255 0.0967 0.5123 −3.532 0.000412 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs412791 Imputed C GEN 675 12.74 0.001714 0.8702 0.38 0.33054 0.4191 27 143 128 69 178 130
    rs4146972 Genotyped T DOM 682 1.42 0.1657 1.026 1.965 2.117 0.0343 0.6059 0.18035 0.19833 0.1662 8 103 189 16 95 271
    rs4259369 Imputed C REC 679 0.645 0.1981 0.4374 0.9509 −2.214 0.02681 0.01503 0.42636 0.40468 0.4434 50 142 107 89 159 132
    rs4273613 Imputed T ADD 682 0.217 0.4129 0.0965 0.4867 −3.704 0.000213 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs4273613 Imputed T DOM 682 0.223 0.4255 0.0967 0.5123 −3.532 0.000412 0.06816 0.03812 0.01667 0.055 0 10 290 3 36 343
    rs4294022 Imputed C DOM 659 0.632 0.1627 0.4591 0.8687 −2.825 0.004728 1 0.23293 0.19792 0.2601 13 88 187 23 147 201
    rs4310554 Genotyped C DOM 682 1.747 0.1888 1.207 2.53 2.956 0.00312 0.2203 0.49707 0.54167 0.462 81 163 56 79 195 108
    rs4315598 Imputed T ADD 682 1.338 0.1141 1.07 1.674 2.555 0.01063 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs4315598 Imputed T GEN 682 7.867 0.01957 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs4370878 Imputed G DOM 682 1.755 0.157 1.29 2.388 3.583 0.00034 0.9265 0.29399 0.33167 0.2644 25 149 126 33 136 213
    rs4436200 Imputed C ADD 682 0.718 0.169 0.5154 0.9996 −1.963 0.0497 0.2391 0.1305 0.11 0.1466 5 56 239 10 92 280
    rs4444612 Imputed G ADD 682 1.338 0.1141 1.07 1.674 2.555 0.01063 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs4444612 Imputed G GEN 682 7.867 0.01957 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs4450660 Imputed C DOM 675 1.654 0.1588 1.212 2.258 3.168 0.001533 0.07497 0.24296 0.27778 0.2156 15 135 147 16 131 231
    rs4463950 Imputed C DOM 671 0.617 0.1688 0.4431 0.8588 −2.862 0.004214 0.9374 0.43294 0.40541 0.4547 56 128 112 69 203 103
    rs4509702 Imputed C DOM 682 1.755 0.157 1.29 2.388 3.583 0.00034 0.9265 0.29399 0.33167 0.2644 25 149 126 33 136 213
    rs4533379 Imputed G ADD 681 1.561 0.1254 1.221 1.995 3.551 0.000384 0.6918 0.26211 0.31 0.2244 30 126 144 19 133 229
    rs4569984 Imputed A DOM 671 0.645 0.1612 0.4706 0.8853 −2.715 0.006623 0.8278 0.231 0.19661 0.258 13 90 192 24 146 206
    rs4570530 Imputed C DOM 681 1.766 0.1571 1.298 2.403 3.62 0.000295 0.9266 0.29369 0.33167 0.2638 25 149 126 33 135 213
    rs4571583 Imputed T DOM 666 0.645 0.162 0.4697 0.8862 −2.706 0.006814 0.9134 0.23123 0.19759 0.2573 13 89 189 23 147 205
    rs4586678 Imputed A DOM 678 1.637 0.1582 1.2 2.232 3.114 0.001843 0.07807 0.24484 0.27852 0.2184 15 136 147 17 132 231
    rs4615971 Imputed C DOM 676 1.8 0.1582 1.32 2.455 3.716 0.000202 0.9269 0.29734 0.33784 0.2658 26 148 122 33 136 211
    rs4629229 Imputed G DOM 682 0.521 0.1725 0.3715 0.7305 −3.78 0.000157 0.4294 0.17595 0.13667 0.2068 10 62 228 14 130 238
    rs4632512 Imputed T GEN 681 13.12 0.001413 0.1414 0.19457 0.23833 0.1601 24 95 181 8 106 267
    rs4641552 Imputed A ADD 678 0.514 0.2311 0.3271 0.8092 −2.876 0.004025 0.7689 0.07153 0.04849 0.0897 0 29 270 4 60 315
    rs4682527 Imputed C DOM 656 1.64 0.1669 1.183 2.275 2.966 0.003017 0.3618 0.37805 0.40941 0.3537 39 157 91 49 163 157
    rs4688632 Imputed G REC 675 0.538 0.1943 0.3678 0.7876 −3.189 0.001429 0.3557 0.48889 0.45424 0.5158 50 168 77 105 182 93
    rs4702720 Imputed A ADD 530 0.596 0.1535 0.4412 0.8051 −3.372 0.000745 0.08183 0.22547 0.17842 0.2647 11 64 166 23 107 159
    rs4702720 Imputed A DOM 530 0.541 0.1863 0.3758 0.7798 −3.295 0.000984 0.08183 0.22547 0.17842 0.2647 11 64 166 23 107 159
    rs4714484 Imputed A ADD 681 0.631 0.1545 0.4661 0.8539 −2.982 0.002861 0.8896 0.1652 0.13 0.1929 5 68 227 14 119 248
    rs4714484 Imputed A DOM 681 0.606 0.1733 0.4315 0.8511 −2.89 0.003849 0.8896 0.1652 0.13 0.1929 5 68 227 14 119 248
    rs4725142 Genotyped G REC 682 0.444 0.2656 0.2639 0.7476 −3.055 0.002251 0.2804 0.3585 0.33667 0.3757 23 156 121 58 171 153
    rs4725144 Imputed G REC 677 0.427 0.2722 0.2502 0.7275 −3.129 0.001756 0.2734 0.35229 0.32886 0.3707 21 154 123 56 169 154
    rs4760785 Imputed A ADD 657 0.709 0.1165 0.5639 0.8903 −2.957 0.003102 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4760785 Imputed A DOM 657 0.595 0.1749 0.4222 0.8382 −2.969 0.002989 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4760894 Imputed T ADD 657 0.709 0.1165 0.5639 0.8903 −2.957 0.003102 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4760894 Imputed T DOM 657 0.595 0.1749 0.4222 0.8382 −2.969 0.002989 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4760895 Imputed A ADD 657 0.709 0.1165 0.5639 0.8903 −2.957 0.003102 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4760895 Imputed A DOM 657 0.595 0.1749 0.4222 0.8382 −2.969 0.002989 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs4767184 Imputed C ADD 678 0.704 0.1112 0.5659 0.8752 −3.159 0.001584 0.02822 0.38127 0.3311 0.4208 37 124 138 75 169 135
    rs4767184 Imputed C GEN 678 9.99 0.006772 0.02822 0.38127 0.3311 0.4208 37 124 138 75 169 135
    rs4773487 Imputed T ADD 682 0.555 0.1837 0.3871 0.7953 −3.207 0.001342 0.2503 0.11364 0.08167 0.1387 3 43 254 9 88 285
    rs4780547 Imputed G GEN 682 8.214 0.01646 0.1488 0.22141 0.19167 0.2448 9 97 194 31 125 226
    rs4780547 Imputed G REC 682 0.327 0.3979 0.1501 0.7141 −2.806 0.005013 0.1488 0.22141 0.19167 0.2448 9 97 194 31 125 226
    rs483159 Imputed T DOM 611 1.742 0.1718 1.244 2.44 3.23 0.001236 0.899 0.19722 0.23432 0.1676 11 105 155 12 90 238
    rs4836502 Imputed T DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.9329 0.34824 0.30833 0.3796 36 113 151 46 198 138
    rs4836507 Imputed C DOM 672 0.561 0.1605 0.4097 0.7686 −3.6 0.000319 0.9321 0.34598 0.3064 0.3773 36 110 151 45 193 137
    rs4851531 Imputed T DOM 677 0.722 0.1629 0.5246 0.9935 −2 0.0455 1 0.4062 0.37584 0.4301 44 136 118 68 190 121
    rs4879931 Imputed G ADD 678 0.672 0.1211 0.5303 0.8526 −3.277 0.00105 0.2044 0.30457 0.25758 0.3412 22 109 166 48 164 169
    rs489441 Imputed G ADD 631 1.549 0.1342 1.191 2.015 3.261 0.00111 0.4702 0.2607 0.30545 0.2261 20 128 127 19 123 214
    rs489441 Imputed G DOM 631 1.778 0.164 1.289 2.452 3.509 0.00045 0.4702 0.2607 0.30545 0.2261 20 128 127 19 123 214
    rs4976276 Imputed T ADD 681 1.45 0.125 1.135 1.853 2.973 0.002945 0.07074 0.3047 0.345 0.273 32 143 125 21 166 194
    rs4977681 Imputed C REC 682 2.487 0.278 1.442 4.288 3.278 0.001047 0.7153 0.29912 0.33 0.2749 41 116 143 22 166 194
    rs4986197 Imputed G ADD 679 1.564 0.1255 1.223 2 3.563 0.000366 0.6211 0.26215 0.3104 0.2244 30 125 143 19 133 229
    rs4986220 Imputed T ADD 681 1.538 0.1266 1.2 1.971 3.4 0.000673 0.8411 0.25698 0.30268 0.2212 28 125 146 18 133 231
    rs525462 Imputed A GEN 682 4.513 0.1047 0.1205 0.56012 0.53 0.5838 88 142 70 136 174 72
    rs552006 Imputed G GEN 678 9.189 0.01011 0.00901 0.2913 0.32886 0.2618 44 108 146 28 143 209
    rs5756669 Imputed C DOM 679 1.798 0.1769 1.271 2.543 3.316 0.000914 1 0.45582 0.49664 0.4239 66 164 68 75 173 133
    rs581905 Imputed T DOM 681 1.742 0.218 1.137 2.671 2.548 0.01085 1 0.08003 0.10167 0.063 3 55 242 1 46 334
    rs6033138 Imputed C ADD 682 1.338 0.1141 1.07 1.674 2.555 0.01063 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6033138 Imputed C GEN 682 7.867 0.01957 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6040619 Imputed C ADD 677 1.341 0.1132 1.074 1.675 2.594 0.009478 0.2114 0.36115 0.40101 0.3298 55 129 114 41 168 170
    rs6040619 Imputed C GEN 677 7.963 0.01866 0.2114 0.36115 0.40101 0.3298 55 129 114 41 168 170
    rs6040625 Imputed T ADD 680 1.351 0.1131 1.082 1.686 2.66 0.007824 0.2138 0.36103 0.40167 0.3289 55 131 114 41 168 171
    rs6040625 Imputed T GEN 680 8.078 0.01761 0.2138 0.36103 0.40167 0.3289 55 131 114 41 168 171
    rs6040630 Imputed A ADD 679 1.356 0.1137 1.085 1.694 2.676 0.007453 0.317 0.35935 0.4 0.3272 54 132 114 40 168 171
    rs6040630 Imputed A GEN 679 8.108 0.01735 0.317 0.35935 0.4 0.3272 54 132 114 40 168 171
    rs6040633 Imputed A ADD 679 1.356 0.1137 1.085 1.694 2.676 0.007453 0.317 0.35935 0.4 0.3272 54 132 114 40 168 171
    rs6040633 Imputed A GEN 679 8.108 0.01735 0.317 0.35935 0.4 0.3272 54 132 114 40 168 171
    rs6040634 Imputed T ADD 682 1.306 0.1123 1.048 1.628 2.378 0.01743 0.2463 0.3629 0.4 0.3338 54 132 114 43 169 170
    rs6040634 Imputed T GEN 682 6.36 0.0416 0.2463 0.3629 0.4 0.3338 54 132 114 43 169 170
    rs6040636 Imputed T ADD 681 1.312 0.1124 1.052 1.635 2.413 0.01583 0.2147 0.3627 0.4 0.3333 54 132 114 43 168 170
    rs6040636 Imputed T GEN 681 6.462 0.03952 0.2147 0.3627 0.4 0.3333 54 132 114 43 168 170
    rs6040638 Imputed C ADD 682 1.338 0.1141 1.07 1.674 2.555 0.01063 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6040638 Imputed C GEN 682 7.867 0.01957 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6040644 Imputed A ADD 680 1.338 0.1141 1.07 1.674 2.554 0.01065 0.2795 0.35882 0.39799 0.3281 54 130 115 40 170 171
    rs6040644 Imputed A GEN 680 7.863 0.01962 0.2795 0.35882 0.39799 0.3281 54 130 115 40 170 171
    rs6040667 Imputed T ADD 669 1.394 0.1165 1.11 1.752 2.853 0.004333 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6040667 Imputed T GEN 669 8.924 0.01154 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6040668 Imputed C ADD 669 1.394 0.1165 1.11 1.752 2.853 0.004333 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6040668 Imputed C GEN 669 8.924 0.01154 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6053005 Imputed C DOM 479 0.644 0.2558 0.3901 1.063 −1.72 0.08545 0.7029 0.60334 0.59709 0.6081 78 90 38 94 144 35
    rs6054405 Imputed A REC 679 2.249 0.2226 1.454 3.478 3.641 0.000271 0.6876 0.39323 0.44631 0.3517 61 144 93 41 186 154
    rs6054427 Genotyped G GEN 682 12.27 0.002167 0.4728 0.39736 0.44667 0.3586 59 150 91 44 186 152
    rs6075186 Imputed G DOM 682 0.521 0.1725 0.3715 0.7305 −3.78 0.000157 0.4294 0.17595 0.13667 0.2068 10 62 228 14 130 238
    rs608278 Imputed A ADD 594 0.702 0.1219 0.5527 0.8913 −2.904 0.003681 0.8663 0.41835 0.37354 0.4525 39 114 104 66 173 98
    rs6111540 Imputed A ADD 630 0.643 0.1186 0.5094 0.8109 −3.727 0.000194 0.8731 0.47619 0.41455 0.5239 45 138 92 99 174 82
    rs6131206 Imputed C ADD 668 1.277 0.1203 1.009 1.617 2.033 0.04201 0.3108 0.29865 0.3299 0.2745 36 120 135 29 149 199
    rs6131208 Imputed T ADD 669 1.394 0.1165 1.11 1.752 2.853 0.004333 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6131208 Imputed T GEN 669 8.924 0.01154 0.3047 0.34529 0.38908 0.3112 50 128 115 36 162 178
    rs6131919 Imputed G DOM 682 0.521 0.1725 0.3715 0.7305 −3.78 0.000157 0.4294 0.17595 0.13667 0.2068 10 62 228 14 130 238
    rs6134243 Imputed C ADD 682 1.338 0.1141 1.07 1.674 2.555 0.01063 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6134243 Imputed C GEN 682 7.867 0.01957 0.2786 0.35777 0.39667 0.3272 54 130 116 40 170 172
    rs6136020 Imputed A DOM 681 0.511 0.1731 0.3638 0.7171 −3.881 0.000104 0.4267 0.17548 0.13545 0.2068 10 61 228 14 130 238
    rs613799 Imputed C DOM 582 1.79 0.1709 1.28 2.502 3.405 0.000663 1 0.28866 0.32738 0.2591 20 125 107 28 115 187
    rs644041 Imputed G ADD 621 1.565 0.135 1.201 2.039 3.319 0.000902 0.4688 0.26329 0.30882 0.2278 21 126 125 18 123 208
    rs644041 Imputed G DOM 621 1.762 0.165 1.275 2.435 3.433 0.000597 0.4688 0.26329 0.30882 0.2278 21 126 125 18 123 208
    rs6464377 Imputed C DOM 681 2.223 0.2258 1.428 3.46 3.538 0.000404 0.5678 0.07269 0.09833 0.0525 0 59 241 2 36 343
    rs6474230 Imputed T DOM 681 1.542 0.1596 1.127 2.108 2.712 0.006696 0.106 0.23128 0.25585 0.212 17 119 163 27 108 247
    rs6476565 Imputed A DOM 677 0.524 0.2092 0.3479 0.7901 −3.086 0.00203 0.6704 0.10118 0.07239 0.1237 2 39 256 6 82 292
    rs6511286 Imputed T ADD 675 1.359 0.1178 1.079 1.712 2.603 0.009243 0.5353 0.31852 0.3557 0.2891 37 138 123 35 148 194
    rs6541829 Genotyped C REC 682 1.978 0.3119 1.073 3.646 2.187 0.02875 0.9213 0.2632 0.28833 0.2435 28 117 155 20 146 216
    rs6544721 Imputed G DOM 675 1.623 0.1588 1.189 2.216 3.049 0.002295 0.05817 0.24148 0.27458 0.2158 14 134 147 16 132 232
    rs6544728 Imputed T DOM 680 1.638 0.158 1.202 2.233 3.124 0.001785 0.03564 0.23971 0.27592 0.2113 15 135 149 14 133 234
    rs6565910 Imputed G DOM 675 0.576 0.1625 0.4188 0.7919 −3.395 0.000685 0.1512 0.24963 0.21044 0.2804 19 87 191 30 152 196
    rs6581985 Imputed G GEN 661 8.243 0.01622 0.7098 0.29728 0.32646 0.2743 35 120 136 21 161 188
    rs6581985 Imputed G REC 661 2.29 0.2899 1.298 4.042 2.859 0.004255 0.7098 0.29728 0.32646 0.2743 35 120 136 21 161 188
    rs6685186 Imputed T ADD 680 1.508 0.1138 1.206 1.884 3.606 0.000312 0.9363 0.39926 0.45485 0.3556 63 146 90 46 179 156
    rs6685186 Imputed T GEN 680 13.11 0.001423 0.9363 0.39926 0.45485 0.3556 63 146 90 46 179 156
    rs670593 Imputed A REC 678 0.594 0.2258 0.3815 0.9244 −2.308 0.02099 0.8731 0.40192 0.38629 0.4142 37 157 105 71 172 136
    rs6722640 Imputed T DOM 682 0.696 0.1624 0.5059 0.9562 −2.236 0.02536 0.7521 0.40909 0.37833 0.4332 47 133 120 69 193 120
    rs6746170 Imputed A DOM 679 1.647 0.1581 1.208 2.245 3.155 0.001604 0.03549 0.24006 0.27685 0.2113 15 135 148 14 133 234
    rs6757316 Imputed A GEN 675 12.53 0.001901 0.4778 0.42222 0.46633 0.3876 73 131 93 52 189 137
    rs6805139 Imputed G DOM 681 1.829 0.1922 1.255 2.666 3.141 0.001685 0.4904 0.51101 0.54333 0.4856 78 170 52 95 180 106
    rs6808571 Imputed G ADD 675 1.794 0.1564 1.32 2.438 3.736 0.000187 0.5429 0.14889 0.19231 0.1144 13 89 197 4 78 294
    rs6816479 Imputed A REC 681 1.903 0.2298 1.213 2.985 2.8 0.005116 0.4521 0.35609 0.36789 0.3469 52 116 131 39 187 156
    rs6865976 Imputed C DOM 636 0.514 0.1832 0.3586 0.7355 −3.636 0.000277 0.5254 0.47799 0.42419 0.5195 53 129 95 88 197 74
    rs687047 Imputed C ADD 682 0.621 0.1734 0.4423 0.8729 −2.744 0.00607 0.485 0.1261 0.09833 0.1479 1 57 242 12 89 281
    rs6871041 Imputed G DOM 625 0.549 0.1652 0.3974 0.7594 −3.626 0.000288 0.7819 0.3176 0.27957 0.3483 28 100 151 33 175 138
    rs688358 Imputed A ADD 672 0.627 0.1736 0.4457 0.8804 −2.693 0.007071 0.4853 0.12723 0.09966 0.1489 1 57 238 12 88 276
    rs6908481 Imputed C REC 664 2.09 0.2119 1.38 3.166 3.479 0.000503 0.1953 0.39759 0.44138 0.3636 66 124 100 47 178 149
    rs6917224 Imputed A ADD 682 1.452 0.1114 1.167 1.806 3.346 0.000821 0.3803 0.40029 0.45167 0.3599 64 143 93 51 173 158
    rs6917224 Imputed A GEN 682 11.22 0.003661 0.3803 0.40029 0.45167 0.3599 64 143 93 51 173 158
    rs6920677 Imputed G DOM 669 0.657 0.1616 0.4785 0.9016 −2.601 0.009294 0.5131 0.38266 0.3468 0.4113 41 124 132 61 184 127
    rs6994498 Imputed G DOM 679 1.535 0.1598 1.122 2.1 2.682 0.007325 0.1286 0.22975 0.25336 0.2113 16 119 163 27 107 247
    rs6998772 Imputed T DOM 682 2.585 0.2693 1.525 4.383 3.526 0.000422 0.1493 0.05572 0.07833 0.038 2 43 255 2 25 355
    rs7022281 Imputed C ADD 678 0.736 0.1153 0.5872 0.9228 −2.656 0.007896 0.8713 0.38569 0.34783 0.4156 33 142 124 69 177 133
    rs7022281 Imputed C GEN 678 7.862 0.01963 0.8713 0.38569 0.34783 0.4156 33 142 124 69 177 133
    rs7022281 Imputed C REC 678 0.551 0.2295 0.3514 0.864 −2.597 0.009407 0.8713 0.38569 0.34783 0.4156 33 142 124 69 177 133
    rs7043983 Imputed T DOM 678 0.526 0.2092 0.3491 0.7928 −3.07 0.00214 0.6702 0.10103 0.07239 0.1234 2 39 256 6 82 293
    rs7077799 Imputed A DOM 682 1.772 0.1576 1.301 2.413 3.63 0.000284 1 0.29692 0.335 0.267 26 149 125 34 136 212
    rs7088947 Imputed A ADD 681 0.579 0.2256 0.372 0.9006 −2.424 0.01536 0.3761 0.07122 0.05167 0.0866 0 31 269 5 56 320
    rs7089661 Imputed C DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs7102072 Imputed A DOM 681 0.569 0.1579 0.4177 0.7758 −3.568 0.00036 0.397 0.28488 0.24167 0.3189 24 97 179 36 171 174
    rs710832 Genotyped A REC 682 0.39 0.3429 0.1992 0.7638 −2.746 0.006038 0.2666 0.25293 0.24 0.2631 12 120 168 37 127 218
    rs712531 Imputed A DOM 671 1.679 0.1639 1.217 2.315 3.16 0.001579 0.2799 0.36587 0.39691 0.3421 35 161 95 48 164 168
    rs7129817 Imputed T ADD 674 0.693 0.1168 0.5509 0.8706 −3.147 0.001649 0.4978 0.34866 0.30201 0.3856 30 120 148 56 178 142
    rs7134262 Imputed T GEN 678 19.92 4.72E−05 0.9333 0.35619 0.3796 0.3377 55 117 127 30 196 153
    rs7134262 Imputed T REC 678 2.671 0.2439 1.656 4.308 4.027 5.66E−05 0.9333 0.35619 0.3796 0.3377 55 117 127 30 196 153
    rs7138300 Imputed C ADD 657 0.709 0.1165 0.5639 0.8903 −2.957 0.003102 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs7138300 Imputed C DOM 657 0.595 0.1749 0.4222 0.8382 −2.969 0.002989 0.5823 0.45282 0.41003 0.4864 49 139 101 82 194 92
    rs722927 Imputed G ADD 660 0.494 0.2288 0.3152 0.773 −3.085 0.002035 0.2612 0.07652 0.04915 0.0986 1 27 267 5 62 298
    rs722927 Imputed G DOM 660 0.474 0.2419 0.2951 0.7616 −3.086 0.002029 0.2612 0.07652 0.04915 0.0986 1 27 267 5 62 298
    rs726424 Genotyped G ADD 682 0.709 0.111 0.57 0.8809 −3.102 0.001922 0.02768 0.37757 0.32833 0.4162 35 127 138 76 166 140
    rs726424 Genotyped G GEN 682 10.03 0.006653 0.02768 0.37757 0.32833 0.4162 35 127 138 76 166 140
    rs7295817 Imputed C ADD 677 0.667 0.1118 0.5356 0.8302 −3.624 0.00029 0.0658 0.40177 0.34343 0.4474 36 132 129 85 170 125
    rs7295817 Imputed C GEN 677 13.77 0.001022 0.0658 0.40177 0.34343 0.4474 36 132 129 85 170 125
    rs7295817 Imputed C REC 677 0.482 0.218 0.3144 0.739 −3.347 0.000816 0.0658 0.40177 0.34343 0.4474 36 132 129 85 170 125
    rs7297372 Imputed A ADD 682 0.69 0.1134 0.5524 0.8617 −3.272 0.001068 0.8151 0.56891 0.52 0.6073 80 152 68 139 186 57
    rs7297372 Imputed A GEN 682 10.73 0.00468 0.8151 0.56891 0.52 0.6073 80 152 68 139 186 57
    rs7298255 Imputed A ADD 682 0.725 0.1134 0.5804 0.9053 −2.837 0.004558 0.701 0.46701 0.42667 0.4987 57 142 101 89 203 90
    rs7298255 Imputed A DOM 682 0.584 0.1737 0.4156 0.8211 −3.095 0.001971 0.701 0.46701 0.42667 0.4987 57 142 101 89 203 90
    rs7305832 Imputed C GEN 678 19.92 4.72E−05 0.9333 0.35619 0.3796 0.3377 55 117 127 30 196 153
    rs7305832 Imputed C REC 678 2.671 0.2439 1.656 4.308 4.027 5.66E−05 0.9333 0.35619 0.3796 0.3377 55 117 127 30 196 153
    rs737542 Imputed A REC 678 1.983 0.312 1.076 3.655 2.194 0.02823 0.8432 0.26327 0.28859 0.2434 28 116 154 20 145 215
    rs742827 Imputed A ADD 637 1.408 0.1178 1.118 1.774 2.905 0.003678 0.2603 0.35479 0.40108 0.3189 50 123 105 37 155 167
    rs742827 Imputed A GEN 637 8.971 0.01127 0.2603 0.35479 0.40108 0.3189 50 123 105 37 155 167
    rs7446891 Imputed G DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 0.9326 0.34728 0.30833 0.378 36 113 151 45 198 138
    rs7448641 Imputed C ADD 682 0.187 0.4378 0.0793 0.441 −3.83 0.000128 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7448641 Imputed C DOM 682 0.19 0.451 0.0786 0.4606 −3.679 0.000234 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7460605 Imputed G DOM 638 1.639 0.1689 1.177 2.283 2.927 0.003421 0.1625 0.40282 0.43816 0.3746 52 144 87 60 146 149
    rs7468898 Imputed T ADD 674 1.412 0.1152 1.127 1.77 2.995 0.002747 0.3143 0.45846 0.50334 0.4227 74 153 72 61 195 119
    rs7468898 Imputed T GEN 674 9.55 0.008438 0.3143 0.45846 0.50334 0.4227 74 153 72 61 195 119
    rs7501186 Imputed A DOM 677 1.561 0.1787 1.099 2.215 2.49 0.01276 0.5241 0.13959 0.16498 0.1197 8 82 207 7 77 296
    rs755117 Imputed A DOM 651 1.658 0.1686 1.192 2.308 2.999 0.002709 0.3232 0.19662 0.22664 0.1727 13 105 171 16 93 253
    rs7557560 Imputed T GEN 679 8.554 0.01389 0.9031 0.19514 0.21906 0.1763 18 95 186 7 120 253
    rs7557560 Imputed T REC 679 3.783 0.4649 1.521 9.41 2.862 0.004208 0.9031 0.19514 0.21906 0.1763 18 95 186 7 120 253
    rs7562462 Imputed T DOM 673 1.896 0.1733 1.35 2.662 3.691 0.000223 0.2091 0.43388 0.48294 0.3961 65 153 75 70 161 149
    rs757173 Genotyped G DOM 682 0.544 0.1595 0.398 0.7436 −3.817 0.000135 1 0.36217 0.31 0.4031 32 122 146 57 194 131
    rs7607447 Imputed T REC 676 1.87 0.2836 1.073 3.26 2.208 0.02726 0.7777 0.28624 0.29798 0.277 33 111 153 24 162 193
    rs7639053 Imputed A ADD 682 1.506 0.1344 1.157 1.96 3.046 0.002322 0.9093 0.21408 0.25167 0.1846 22 107 171 10 121 251
    rs7648163 Imputed C REC 654 1.993 0.25 1.221 3.252 2.758 0.005822 0.3754 0.32875 0.34896 0.3128 45 111 132 31 167 168
    rs7651273 Imputed A GEN 680 14.12 0.00086 0.08957 0.19779 0.24247 0.1627 26 93 180 8 108 265
    rs7653190 Imputed C ADD 677 1.504 0.1347 1.155 1.958 3.029 0.002453 0.9092 0.21492 0.25253 0.1855 22 106 169 10 121 249
    rs7653685 Genotyped C DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs7684899 Imputed C DOM 682 0.713 0.1608 0.5205 0.9774 −2.102 0.03551 0.04848 0.20894 0.18833 0.2251 10 93 197 11 150 221
    rs7701604 Imputed G ADD 682 0.187 0.4378 0.0793 0.441 −3.83 0.000128 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7701604 Imputed G DOM 682 0.19 0.451 0.0786 0.4606 −3.679 0.000234 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7703676 Imputed C ADD 682 0.187 0.4378 0.0793 0.441 −3.83 0.000128 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7703676 Imputed C DOM 682 0.19 0.451 0.0786 0.4606 −3.679 0.000234 0.06181 0.03739 0.015 0.055 0 9 291 3 36 343
    rs7711358 Imputed A DOM 677 0.564 0.1602 0.4123 0.7725 −3.571 0.000355 1 0.34934 0.30976 0.3803 36 112 149 46 197 137
    rs7713251 Imputed C REC 661 2.098 0.2572 1.267 3.474 2.882 0.003956 0.6634 0.33661 0.37075 0.3093 44 130 120 28 171 168
    rs7737608 Imputed G DOM 676 1.904 0.164 1.38 2.625 3.926 8.65E−05 0.5601 0.36169 0.41186 0.3228 44 155 96 48 150 183
    rs7755903 Imputed A GEN 681 7.188 0.02748 0.9377 0.42805 0.38833 0.4593 44 145 111 80 190 111
    rs7762993 Imputed A ADD 677 1.726 0.1392 1.314 2.268 3.921 8.82E−05 0.219 0.19276 0.24074 0.1553 16 111 170 14 90 276
    rs7762993 Imputed A DOM 677 2.011 0.1659 1.453 2.784 4.21 2.55E−05 0.219 0.19276 0.24074 0.1553 16 111 170 14 90 276
    rs7767265 Imputed G DOM 663 2.106 0.1643 1.526 2.905 4.533 5.81E−06 0.07386 0.22323 0.27875 0.1809 22 116 149 19 98 259
    rs7769415 Imputed C GEN 670 4.537 0.1035 0.9297 0.32239 0.34694 0.3032 39 126 129 31 166 179
    rs7771264 Imputed T DOM 654 0.635 0.1631 0.4613 0.8744 −2.783 0.005385 1 0.23471 0.2 0.2615 13 88 184 23 147 199
    rs7795792 Imputed T REC 679 0.645 0.1981 0.4374 0.9509 −2.214 0.02681 0.01503 0.42636 0.40468 0.4434 50 142 107 89 159 132
    rs7806481 Imputed G REC 682 0.439 0.2056 0.2933 0.6567 −4.005 6.20E−05 0.2503 0.47947 0.42667 0.5209 44 168 88 105 188 89
    rs7808536 Imputed G DOM 678 1.455 0.1608 1.062 1.995 2.334 0.01962 0.7257 0.20649 0.2291 0.1887 11 115 173 16 111 252
    rs7814819 Imputed G ADD 395 2.408 0.2698 1.419 4.086 3.256 0.001129 1 0.08734 0.12431 0.0561 2 41 138 1 22 191
    rs7814819 Imputed G DOM 395 2.577 0.2831 1.48 4.488 3.345 0.000824 1 0.08734 0.12431 0.0561 2 41 138 1 22 191
    rs7815952 Imputed T DOM 682 2.585 0.2693 1.525 4.383 3.526 0.000422 0.1493 0.05572 0.07833 0.038 2 43 255 2 25 355
    rs7834090 Imputed T DOM 682 2.585 0.2693 1.525 4.383 3.526 0.000422 0.1493 0.05572 0.07833 0.038 2 43 255 2 25 355
    rs7859250 Imputed C DOM 679 0.52 0.2089 0.345 0.7824 −3.134 0.001722 0.6726 0.10162 0.07239 0.1243 2 39 256 6 83 293
    rs7863577 Genotyped A ADD 682 0.48 0.201 0.3239 0.7122 −3.648 0.000264 0.6823 0.10337 0.07 0.1296 1 40 259 7 85 290
    rs7863577 Genotyped A DOM 682 0.479 0.2131 0.3153 0.7268 −3.458 0.000545 0.6823 0.10337 0.07 0.1296 1 40 259 7 85 290
    rs7902140 Imputed C ADD 673 0.63 0.1425 0.4765 0.8328 −3.244 0.001178 0.1401 0.19539 0.1532 0.2287 6 79 212 26 120 230
    rs7921834 Imputed C DOM 682 1.786 0.1574 1.312 2.431 3.685 0.000229 1 0.29545 0.335 0.2644 26 149 125 33 136 213
    rs7939893 Imputed C ADD 682 0.707 0.1129 0.5669 0.8826 −3.066 0.002167 0.005005 0.34311 0.29833 0.3783 33 113 154 64 161 157
    rs7939893 Imputed C DOM 682 0.641 0.1573 0.4706 0.8718 −2.832 0.004625 0.005005 0.34311 0.29833 0.3783 33 113 154 64 161 157
    rs7955901 Imputed C ADD 675 0.723 0.1135 0.579 0.9035 −2.855 0.00431 0.8771 0.46741 0.42617 0.5 57 140 101 89 199 89
    rs7955901 Imputed C DOM 675 0.582 0.1743 0.4133 0.8183 −3.11 0.001869 0.8771 0.46741 0.42617 0.5 57 140 101 89 199 89
    rs7956274 Imputed T ADD 677 0.74 0.1141 0.5915 0.9251 −2.642 0.00823 0.6995 0.4675 0.42929 0.4974 57 141 99 88 202 90
    rs7956274 Imputed T DOM 677 0.598 0.1747 0.4246 0.8421 −2.944 0.003242 0.6995 0.4675 0.42929 0.4974 57 141 99 88 202 90
    rs7957932 Imputed G ADD 671 0.738 0.1147 0.5895 0.9243 −2.646 0.008151 0.6433 0.47615 0.4375 0.5067 60 139 97 89 202 84
    rs7957932 Imputed G DOM 671 0.57 0.1775 0.4021 0.8065 −3.171 0.001518 0.6433 0.47615 0.4375 0.5067 60 139 97 89 202 84
    rs7984294 Imputed A DOM 678 1.497 0.19 1.032 2.173 2.125 0.03361 0.8479 0.11283 0.13255 0.0974 5 69 224 4 66 310
    rs7994286 Imputed A ADD 674 0.538 0.1883 0.3721 0.7784 −3.29 0.001 0.2388 0.10979 0.07653 0.1355 3 39 252 8 87 285
    rs7994286 Imputed A DOM 674 0.5 0.2066 0.3333 0.7491 −3.358 0.000784 0.2388 0.10979 0.07653 0.1355 3 39 252 8 87 285
    rs8038229 Genotyped A ADD 682 0.809 0.1191 0.6403 1.021 −1.783 0.07457 0.2326 0.29545 0.26833 0.3168 26 109 165 40 162 180
    rs8038229 Genotyped A DOM 682 0.742 0.1556 0.547 1.007 −1.918 0.05517 0.2326 0.29545 0.26833 0.3168 26 109 165 40 162 180
    rs8043336 Imputed C GEN 647 8.706 0.01287 0.9305 0.34312 0.30851 0.3699 21 132 129 56 158 151
    rs8043336 Imputed C REC 647 0.449 0.2712 0.264 0.7645 −2.95 0.003176 0.9305 0.34312 0.30851 0.3699 21 132 129 56 158 151
    rs8054431 Imputed T DOM 652 1.625 0.1667 1.172 2.253 2.915 0.003561 0.5067 0.38037 0.41434 0.3538 41 155 90 49 161 156
    rs8066502 Imputed T DOM 681 0.683 0.1787 0.4814 0.9701 −2.13 0.03319 1 0.14317 0.12667 0.1562 8 60 232 6 107 268
    rs8068714 Imputed T DOM 682 0.671 0.1793 0.4725 0.954 −2.223 0.02623 0.8763 0.14223 0.125 0.1558 8 59 233 6 107 269
    rs892575 Imputed T ADD 681 1.549 0.1262 1.21 1.984 3.471 0.000519 0.7644 0.25844 0.305 0.2218 28 127 145 19 131 231
    rs892583 Imputed G ADD 679 1.541 0.1267 1.202 1.976 3.414 0.00064 0.9202 0.25847 0.30435 0.2224 28 126 145 18 133 229
    rs915494 Imputed A ADD 647 1.548 0.1295 1.201 1.995 3.374 0.00074 0.6962 0.27975 0.32517 0.2438 23 140 123 25 126 210
    rs915494 Imputed A DOM 647 1.881 0.1622 1.369 2.585 3.896 9.77E−05 0.6962 0.27975 0.32517 0.2438 23 140 123 25 126 210
    rs917295 Imputed G DOM 681 0.561 0.1597 0.4104 0.7675 −3.617 0.000298 0.9326 0.34728 0.30833 0.378 36 113 151 45 198 138
    rs922594 Imputed T DOM 681 0.735 0.1583 0.5392 1.003 −1.941 0.05228 0.1829 0.35756 0.34281 0.3691 45 115 139 50 182 150
    rs9301653 Imputed T ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs9301653 Imputed T DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs9309988 Imputed G DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs9309989 Genotyped C DOM 682 1.731 0.2018 1.165 2.57 2.718 0.006576 0.1323 0.09824 0.11667 0.0838 2 66 232 8 48 326
    rs9310221 Imputed A DOM 631 2.083 0.1765 1.474 2.943 4.157 3.23E−05 0.6253 0.42155 0.46277 0.3883 50 161 71 65 141 143
    rs9327555 Imputed T DOM 682 0.56 0.1597 0.4098 0.7664 −3.626 0.000288 0.866 0.34751 0.30833 0.3783 36 113 151 45 199 138
    rs937890 Imputed G DOM 638 0.654 0.1848 0.455 0.939 −2.3 0.02143 0.8728 0.14498 0.12633 0.1597 8 55 218 6 102 249
    rs9454967 Imputed G ADD 678 2.104 0.213 1.386 3.194 3.492 0.000479 0.6166 0.08481 0.11371 0.062 3 62 234 3 41 335
    rs9454967 Imputed G DOM 678 2.304 0.2264 1.478 3.592 3.687 0.000227 0.6166 0.08481 0.11371 0.062 3 62 234 3 41 335
    rs9471295 Imputed T DOM 682 1.569 0.1754 1.112 2.213 2.567 0.01026 0.1579 0.14223 0.16667 0.123 5 90 205 4 86 292
    rs9477007 Imputed A ADD 651 1.476 0.1133 1.182 1.842 3.433 0.000596 0.225 0.41014 0.46503 0.3671 65 136 85 52 164 149
    rs9477007 Imputed A GEN 651 11.79 0.002754 0.225 0.41014 0.46503 0.3671 65 136 85 52 164 149
    rs9487279 Imputed T DOM 653 0.61 0.165 0.4417 0.8435 −2.991 0.002778 0.5145 0.3974 0.35986 0.4272 45 118 126 62 187 115
    rs949016 Imputed C ADD 682 1.55 0.1262 1.21 1.985 3.473 0.000515 0.7642 0.25806 0.305 0.2212 29 125 146 18 133 231
    rs9555973 Imputed G ADD 681 0.538 0.1869 0.3726 0.7754 −3.321 0.000898 0.3277 0.11087 0.07833 0.1365 3 41 256 8 88 285
    rs9555973 Imputed G DOM 681 0.501 0.2048 0.3354 0.7487 −3.373 0.000743 0.3277 0.11087 0.07833 0.1365 3 41 256 8 88 285
    rs9557510 Imputed G ADD 680 1.629 0.1608 1.188 2.232 3.033 0.002418 0.7519 0.14044 0.17224 0.1155 6 91 202 6 76 299
    rs9557510 Imputed G DOM 680 1.768 0.1765 1.251 2.498 3.227 0.001253 0.7519 0.14044 0.17224 0.1155 6 91 202 6 76 299
    rs9560584 Imputed T DOM 660 0.489 0.211 0.3233 0.7393 −3.392 0.000695 0.3013 0.10606 0.07388 0.1314 3 37 251 7 83 279
    rs9588770 Imputed T DOM 680 0.529 0.2039 0.3549 0.7895 −3.119 0.001815 0.3247 0.11029 0.08 0.1342 3 42 255 8 86 286
    rs9588848 Imputed C ADD 682 0.518 0.1922 0.3551 0.7544 −3.426 0.000612 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs9588848 Imputed C DOM 682 0.474 0.2097 0.3145 0.7155 −3.556 0.000376 0.3055 0.10484 0.07167 0.1309 3 37 260 7 86 289
    rs966583 Imputed A ADD 679 0.729 0.1149 0.5819 0.913 −2.752 0.005926 0.9364 0.40133 0.36409 0.4304 45 127 126 65 198 118
    rs966583 Imputed A DOM 679 0.578 0.1648 0.4182 0.7977 −3.332 0.000863 0.9364 0.40133 0.36409 0.4304 45 127 126 65 198 118
    rs974130 Genotyped A REC 682 1.891 0.2296 1.206 2.965 2.775 0.005522 0.4535 0.3563 0.36833 0.3469 52 117 131 39 187 156
    rs977160 Imputed T ADD 681 1.657 0.1289 1.287 2.133 3.916 8.99E−05 0.919 0.25037 0.30333 0.2087 26 130 144 17 125 239
    rs9812206 Imputed G ADD 682 0.481 0.2047 0.3217 0.7177 −3.581 0.000343 0.8253 0.09677 0.06333 0.123 1 36 263 6 82 294
    rs9812206 Imputed G DOM 682 0.466 0.215 0.306 0.7107 −3.548 0.000388 0.8253 0.09677 0.06333 0.123 1 36 263 6 82 294
    rs9813552 Imputed G ADD 673 0.487 0.2063 0.325 0.7298 −3.487 0.000489 1 0.09658 0.06376 0.1227 1 36 261 5 82 288
    rs9813552 Imputed G DOM 673 0.472 0.2155 0.3093 0.7198 −3.486 0.000491 1 0.09658 0.06376 0.1227 1 36 261 5 82 288
    rs9815037 Imputed T ADD 682 0.482 0.206 0.3221 0.7224 −3.539 0.000402 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9815037 Imputed T DOM 682 0.467 0.215 0.3063 0.7115 −3.543 0.000395 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9825349 Imputed A ADD 682 0.482 0.206 0.3221 0.7224 −3.539 0.000402 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9825349 Imputed A DOM 682 0.467 0.215 0.3063 0.7115 −3.543 0.000395 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9834217 Imputed T ADD 681 0.483 0.206 0.3226 0.7234 −3.532 0.000413 1 0.09618 0.06355 0.1217 1 36 262 5 83 294
    rs9834217 Imputed T DOM 681 0.468 0.215 0.3069 0.7127 −3.535 0.000407 1 0.09618 0.06355 0.1217 1 36 262 5 83 294
    rs9840460 Imputed T ADD 682 0.482 0.206 0.3221 0.7224 −3.539 0.000402 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9840460 Imputed T DOM 682 0.467 0.215 0.3063 0.7115 −3.543 0.000395 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9840756 Imputed A ADD 682 0.482 0.206 0.3221 0.7224 −3.539 0.000402 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9840756 Imputed A DOM 682 0.467 0.215 0.3063 0.7115 −3.543 0.000395 1 0.09604 0.06333 0.1217 1 36 263 5 83 294
    rs9844801 Imputed C DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs985375 Imputed A GEN 655 11.2 0.003703 0.4705 0.2542 0.2972 0.2209 30 110 146 16 131 222
    rs9869187 Imputed C ADD 681 0.488 0.2129 0.3218 0.7413 −3.366 0.000764 0.8111 0.08884 0.05853 0.1126 0 35 264 6 74 302
    rs9869187 Imputed C DOM 681 0.497 0.2215 0.3219 0.7671 −3.157 0.001595 0.8111 0.08884 0.05853 0.1126 0 35 264 6 74 302
    rs9872327 Imputed T DOM 682 1.705 0.2034 1.144 2.541 2.623 0.008711 0.3705 0.09457 0.11333 0.0798 2 64 234 6 49 327
    rs9881685 Imputed A ADD 682 0.481 0.2047 0.3217 0.7177 −3.581 0.000343 0.8253 0.09677 0.06333 0.123 1 36 263 6 82 294
    rs9881685 Imputed A DOM 682 0.466 0.215 0.306 0.7107 −3.548 0.000388 0.8253 0.09677 0.06333 0.123 1 36 263 6 82 294
    rs9909499 Imputed C DOM 668 1.42 0.1577 1.042 1.934 2.223 0.02622 0.8536 0.2979 0.3266 0.2749 29 136 132 29 146 196
    rs9911847 Imputed G DOM 680 0.668 0.1793 0.4702 0.9495 −2.249 0.02452 0.7545 0.14338 0.12667 0.1566 9 58 233 6 107 267
    rs9946886 Imputed G REC 232 0.3 0.3567 0.1492 0.6039 −3.374 0.000742 0.08656 0.44828 0.39908 0.4919 13 61 35 40 41 42
    rs9958823 Imputed A ADD 679 1.579 0.1261 1.233 2.022 3.624 0.00029 0.6914 0.26068 0.30936 0.2224 30 125 144 18 133 229
    rs9965248 Imputed T ADD 671 1.556 0.127 1.213 1.996 3.481 0.0005 0.7646 0.2608 0.30847 0.2234 27 128 140 20 128 228
  • TABLE 10
    PRA- PLA- PRA- PRA- PLA- PLA-
    VA_ CEBO_ VA_ PRA- VA_ CEBO_ PLA- CEBO_
    ALL- HW_ ALL- ALL- ALL- A1_ VA_ A2_ A1_ CEBO_ A2_
    ELE MOD- N- PVA ELE_ ELE_ ELE_ HZ_ HET_ HZ HZ_ HET_ HZ_
    SNP rs # SOURCE (A1) EL MISS OR SE L95 U95 STAT P LUE FREQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs198460 Genotyped G REC 383 2.115 0.2449 1.309 3.418 3.058 0.00223 1 0.48695 0.53145 0.45536 50 69 40 41 122 61
    rs603940 Genotyped G REC 383 0.5858 0.2988 0.3261 1.052 −1.79 0.07347 0.7489 0.39687 0.36164 0.42188 19 77 63 43 103 78
    rs10021016 Genotyped G GEN 383 3.838 0.1467 0.8921 0.25196 0.28931 0.22545 14 64 81 11 79 134
    rs1003148 Imputed C ADD 383 0.7355 0.153 0.545 0.9926 −2.009 0.04457 0.9158 0.4047 0.36164 0.43527 22 71 66 40 115 69
    rs1003148 Imputed C GEN 383 4.552 0.1027 0.9158 0.4047 0.36164 0.43527 22 71 66 40 115 69
    rs1003148 Imputed C REC 383 0.7366 0.2895 0.4176 1.299 −1.056 0.2911 0.9158 0.4047 0.36164 0.43527 22 71 66 40 115 69
    rs10046799 Imputed C ADD 381 0.617 0.1556 0.4548 0.837 −3.103 0.00192 0.7499 0.60105 0.53797 0.64574 44 82 32 92 104 27
    rs10046799 Imputed C GEN 381 9.722 0.00774 0.7499 0.60105 0.53797 0.64574 44 82 32 92 104 27
    rs10051148 Imputed C DOM 383 0.609 0.2097 0.4037 0.9185 −2.365 0.01802 0.6338 0.3107 0.27358 0.33705 16 55 88 23 105 96
    rs10054055 Imputed T DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.5542 0.31593 0.27987 0.34152 17 55 87 24 105 95
    rs10067895 Imputed A DOM 379 0.6022 0.2112 0.398 0.911 −2.401 0.01634 0.724 0.3219 0.28526 0.34753 17 55 84 24 107 92
    rs1008705 Imputed C DOM 276 1.451 0.2489 0.8906 2.363 1.495 0.135 0.3442 0.33514 0.36752 0.31132 13 60 44 14 71 74
    rs10105871 Imputed C DOM 355 1.427 0.2237 0.9203 2.212 1.589 0.1121 0.3678 0.37887 0.40203 0.36232 23 73 52 32 86 89
    rs10116807 Imputed A GEN 376 4.005 0.135 1 0.20346 0.23077 0.18409 10 52 94 5 71 144
    rs10116807 Imputed A REC 376 2.952 0.5596 0.9858 8.84 1.934 0.05307 1 0.20346 0.23077 0.18409 10 52 94 5 71 144
    rs10121941 Imputed C DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs10128638 Genotyped G DOM 383 0.6529 0.2374 0.41 1.04 −1.796 0.07252 0.4134 0.50783 0.4717 0.53348 39 72 48 64 111 49
    rs1012924 Imputed G ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs1012924 Imputed G DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs1016030 Genotyped G ADD 382 1.554 0.1629 1.129 2.139 2.707 0.0068 0.02038 0.40969 0.46519 0.37054 29 89 40 24 118 82
    rs1016030 Genotyped G GEN 382 7.336 0.02553 0.02038 0.40969 0.46519 0.37054 29 89 40 24 118 82
    rs1017558 Imputed A REC 382 2.201 0.2868 1.254 3.861 2.75 0.00596 0.8317 0.40052 0.45912 0.35874 35 76 48 25 110 88
    rs10183431 Imputed T DOM 383 1.719 0.2141 1.13 2.615 2.53 0.01141 0.6453 0.21149 0.24843 0.18527 6 67 86 9 65 150
    rs10195401 Imputed C DOM 377 1.766 0.2208 1.146 2.722 2.575 0.01001 0.00985 0.35544 0.39172 0.32955 14 95 48 22 101 97
    rs10239416 Imputed A DOM 381 0.5548 0.2123 0.3659 0.8412 −2.775 0.00553 0.497 0.34646 0.29245 0.38514 16 61 82 33 105 84
    rs1032188 Imputed G GEN 381 8.656 0.01319 0.3118 0.28084 0.2327 0.31532 6 62 91 28 84 110
    rs1032188 Imputed G REC 381 0.2613 0.4645 0.1051 0.6494 −2.89 0.00386 0.3118 0.28084 0.2327 0.31532 6 62 91 28 84 110
    rs10468988 Imputed G ADD 380 1.448 0.1681 1.042 2.013 2.202 0.02767 0.3889 0.29342 0.33228 0.26577 17 71 70 12 94 116
    rs10478919 Imputed G DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs10506623 Imputed C DOM 383 0.6268 0.2197 0.4075 0.9641 −2.126 0.03347 0.133 0.39034 0.34591 0.42188 18 74 67 33 123 68
    rs10506626 Imputed A DOM 371 0.5858 0.2268 0.3756 0.9138 −2.358 0.0184 0.0525 0.40296 0.35526 0.43607 18 72 62 33 125 61
    rs10509477 Imputed T DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs10511071 Imputed C DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs10511072 Imputed G DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs10511199 Imputed C ADD 379 1.571 0.1825 1.099 2.247 2.475 0.01331 0.3801 0.22559 0.2707 0.19369 10 65 82 6 74 142
    rs10513283 Imputed G GEN 383 3.158 0.2061 0.4152 0.19452 0.21384 0.1808 11 46 102 6 69 149
    rs10520072 Imputed T DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs1065639 Imputed C DOM 364 1.785 0.2238 1.151 2.767 2.588 0.00965 0.08775 0.35852 0.40523 0.32464 19 86 48 20 97 94
    rs10733846 Imputed G ADD 381 0.6607 0.2049 0.4422 0.9872 −2.023 0.04308 0.3007 0.18241 0.14968 0.20536 3 41 113 6 80 138
    rs10733846 Imputed G DOM 381 0.6237 0.2255 0.4009 0.9704 −2.093 0.03632 0.3007 0.18241 0.14968 0.20536 3 41 113 6 80 138
    rs10737390 Imputed T DOM 367 0.6571 0.2203 0.4267 1.012 −1.906 0.05666 0.7431 0.39373 0.36218 0.41706 22 69 65 33 110 68
    rs10749293 Imputed G DOM 382 1.379 0.2098 0.914 2.08 1.531 0.1257 0.5373 0.29188 0.31761 0.27354 16 69 74 19 84 120
    rs10752159 Imputed G DOM 382 1.921 0.2194 1.25 2.953 2.976 0.00292 0.8691 0.19241 0.2327 0.16368 5 64 90 8 57 158
    rs10753760 Imputed T ADD 374 1.478 0.1517 1.098 1.99 2.576 0.00999 0.3803 0.37968 0.43506 0.34091 31 72 51 27 96 97
    rs10753760 Imputed T GEN 374 6.677 0.0355 0.3803 0.37968 0.43506 0.34091 31 72 51 27 96 97
    rs10757887 Imputed C DOM 383 0.5825 0.2158 0.3816 0.8891 −2.505 0.01226 0.1637 0.24021 0.19497 0.27232 9 44 106 18 86 120
    rs10758326 Imputed A ADD 382 0.7394 0.1581 0.5424 1.008 −1.91 0.0561 0.2409 0.39921 0.36164 0.42601 19 77 63 36 118 69
    rs10758326 Imputed A GEN 382 3.771 0.1518 0.2409 0.39921 0.36164 0.42601 19 77 63 36 118 69
    rs10758326 Imputed A REC 382 0.6985 0.3059 0.3835 1.272 −1.173 0.2408 0.2409 0.39921 0.36164 0.42601 19 77 63 36 118 69
    rs10762236 Genotyped G ADD 383 0.6676 0.2037 0.4479 0.9952 −1.984 0.04728 0.233 0.18277 0.15094 0.20536 3 42 114 6 80 138
    rs10765769 Imputed C ADD 378 1.537 0.1636 1.115 2.118 2.627 0.00862 0.01547 0.42725 0.48089 0.38914 31 89 37 26 120 75
    rs10765769 Imputed C GEN 378 6.932 0.03125 1.55E−02 0.42725 0.48089 0.38914 31 89 37 26 120 75
    rs10784891 Imputed C ADD 372 0.7477 0.1606 0.5458 1.024 −1.811 0.07022 0.2351 0.40188 0.36129 0.43088 22 68 65 32 123 62
    rs10784891 Imputed C DOM 372 0.5753 0.2241 0.3708 0.8925 −2.467 0.01361 0.2351 0.40188 0.36129 0.43088 22 68 65 32 123 62
    rs10787923 Imputed G DOM 383 1.391 0.2096 0.9222 2.098 1.574 0.1155 0.5365 0.29112 0.31761 0.27232 16 69 74 19 84 121
    rs10787949 Imputed A DOM 382 1.33 0.2097 0.8818 2.006 1.36 0.1737 0.5395 0.29581 0.32075 0.27803 17 68 74 19 86 118
    rs10787951 Imputed G DOM 382 1.33 0.2097 0.8818 2.006 1.36 0.1737 0.5395 0.29581 0.32075 0.27803 17 68 74 19 86 118
    rs10787983 Imputed C DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs10788380 Imputed C ADD 377 1.299 0.1485 0.9713 1.738 1.764 0.07781 0.6046 0.53581 0.57643 0.50682 51 79 27 60 103 57
    rs10788380 Imputed C DOM 377 1.624 0.2633 0.9695 2.721 1.842 0.06541 0.6046 0.53581 0.57643 0.50682 51 79 27 60 103 57
    rs10788380 Imputed C GEN 377 3.622 0.1635 0.6046 0.53581 0.57643 0.50682 51 79 27 60 103 57
    rs10814418 Imputed G DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs10831417 Imputed A ADD 383 1.615 0.1632 1.173 2.224 2.937 0.00332 0.02621 0.40862 0.46855 0.36607 30 89 40 23 118 83
    rs10831417 Imputed A GEN 383 8.69 0.01297 0.02621 0.40862 0.46855 0.36607 30 89 40 23 118 83
    rs10831422 Imputed C ADD 378 1.53 0.1629 1.112 2.106 2.611 0.00902 0.03304 0.40212 0.4557 0.36364 29 86 43 22 116 82
    rs10831422 Imputed C GEN 378 7.075 0.02908 0.03304 0.40212 0.4557 0.36364 29 86 43 22 116 82
    rs10862931 Imputed C GEN 377 3.939 0.1395 0.4279 0.34748 0.30645 0.37613 15 65 75 34 99 89
    rs10865197 Imputed C DOM 383 1.719 0.2141 1.13 2.615 2.53 0.01141 0.6453 0.21149 0.24843 0.18527 6 67 86 9 65 150
    rs10871302 Imputed A DOM 382 1.272 0.2475 0.7828 2.066 0.9709 0.3316 0.8085 0.12042 0.13836 0.10762 4 36 119 2 44 177
    rs10877463 Imputed C DOM 381 0.5962 0.213 0.3927 0.9052 −2.428 0.0152 0.424 0.3399 0.30063 0.36771 15 65 78 25 114 84
    rs10877468 Imputed C DOM 375 0.5825 0.2147 0.3824 0.8872 −2.518 0.01181 0.4237 0.34133 0.3 0.37045 15 63 77 25 113 82
    rs10879240 Imputed C ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs10879242 Imputed A DOM 383 0.643 0.2198 0.418 0.9893 −2.009 0.04455 0.1989 0.39426 0.3522 0.42411 19 74 66 34 122 68
    rs10879245 Imputed G DOM 383 0.643 0.2198 0.418 0.9893 −2.009 0.04455 0.1989 0.39426 0.3522 0.42411 19 74 66 34 122 68
    rs10879249 Imputed T DOM 383 0.6376 0.2187 0.4154 0.9789 −2.057 0.03964 0.1621 0.38903 0.34591 0.41964 18 74 67 33 122 69
    rs10886452 Imputed A DOM 382 1.33 0.2097 0.8818 2.006 1.36 0.1737 0.5395 0.29581 0.32075 0.27803 17 68 74 19 86 118
    rs10886463 Imputed C DOM 381 1.346 0.21 0.8919 2.032 1.415 0.157 0.3912 0.29659 0.32075 0.27928 17 68 74 20 84 118
    rs10886465 Imputed A DOM 383 1.341 0.2095 0.8897 2.022 1.402 0.161 0.3936 0.29634 0.32075 0.27902 17 68 74 20 85 119
    rs10886526 Imputed C DOM 381 1.361 0.21 0.9017 2.054 1.467 0.1423 0.3889 0.29265 0.31646 0.27578 16 68 74 20 83 120
    rs10902437 Imputed G ADD 355 1.176 0.1625 0.8556 1.618 1 0.3172 0.1268 0.41972 0.44257 0.40338 20 91 37 35 97 75
    rs10941126 Imputed G ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs10941126 Imputed G DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs10947871 Imputed A DOM 383 1.488 0.2326 0.9435 2.348 1.71 0.08731 0.5442 0.14883 0.16667 0.13616 2 49 108 8 45 171
    rs10972978 Imputed G DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs10973012 Imputed A DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs10974028 Genotyped G ADD 383 0.6345 0.2091 0.4211 0.956 −2.175 0.02963 0.5604 0.15666 0.12264 0.1808 4 31 124 7 67 150
    rs10974028 Genotyped G DOM 383 0.5711 0.2392 0.3573 0.9127 −2.342 0.01918 0.5604 0.15666 0.12264 0.1808 4 31 124 7 67 150
    rs11021302 Imputed A ADD 378 1.53 0.1629 1.112 2.106 2.611 0.00902 0.03304 0.40212 0.4557 0.36364 29 86 43 22 116 82
    rs11021302 Imputed A GEN 378 7.075 0.02908 0.03304 0.40212 0.4557 0.36364 29 86 43 22 116 82
    rs11099644 Imputed G REC 382 2.201 0.2868 1.254 3.861 2.75 0.00596 0.8317 0.40052 0.45912 0.35874 35 76 48 25 110 88
    rs11138315 Imputed G ADD 364 0.5496 0.2588 0.3309 0.9128 −2.313 0.02075 0.4098 0.10852 0.07566 0.13208 0 23 129 6 44 162
    rs11149802 Imputed T DOM 382 1.272 0.2475 0.7828 2.066 0.9709 0.3316 0.8085 0.12042 0.13836 0.10762 4 36 119 2 44 177
    rs1116596 Imputed T DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs11178531 Imputed A ADD 381 0.778 0.1538 0.5755 1.052 −1.632 0.1027 0.5321 0.42913 0.39172 0.45536 27 69 61 40 124 60
    rs11178531 Imputed A DOM 381 0.5967 0.2247 0.3841 0.9269 −2.298 0.02156 0.5321 0.42913 0.39172 0.45536 27 69 61 40 124 60
    rs11178575 Imputed C GEN 382 2.149 0.3415 0.6639 0.37696 0.39937 0.36099 27 73 59 25 111 87
    rs11178575 Imputed C REC 382 1.549 0.3014 0.8578 2.796 1.451 0.1468 0.6639 0.37696 0.39937 0.36099 27 73 59 25 111 87
    rs11178577 Imputed T GEN 383 2.22 0.3296 0.6635 0.37728 0.39937 0.36161 27 73 59 25 112 87
    rs11178577 Imputed T REC 383 1.557 0.3014 0.8625 2.811 1.469 0.1418 0.6635 0.37728 0.39937 0.36161 27 73 59 25 112 87
    rs11178583 Imputed A DOM 383 0.6376 0.2187 0.4154 0.9789 −2.057 0.03964 0.1621 0.38903 0.34591 0.41964 18 74 67 33 122 69
    rs11178589 Imputed T DOM 382 0.6428 0.2192 0.4183 0.9878 −2.016 0.0438 0.1627 0.38874 0.34591 0.41928 18 74 67 33 121 69
    rs11178594 Imputed C DOM 383 0.6253 0.2193 0.4068 0.9611 −2.141 0.0323 0.133 0.39034 0.34591 0.42188 18 74 67 33 123 68
    rs11178602 Imputed T DOM 383 0.6388 0.2189 0.4159 0.9811 −2.047 0.04066 0.1621 0.38903 0.34591 0.41964 18 74 67 33 122 69
    rs11178648 Imputed T DOM 382 0.5988 0.2187 0.3901 0.9193 −2.345 0.01904 0.2351 0.38613 0.33861 0.41964 18 71 69 33 122 69
    rs11198877 Imputed T DOM 382 1.33 0.2097 0.8818 2.006 1.36 0.1737 0.5395 0.29581 0.32075 0.27803 17 68 74 19 86 118
    rs11198942 Imputed T DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs11221075 Imputed A ADD 378 0.7098 0.2323 0.4502 1.119 −1.475 0.1401 1 0.12434 0.1051 0.13801 2 29 126 4 53 164
    rs11242020 Imputed T DOM 382 0.6024 0.2102 0.399 0.9096 −2.411 0.01591 0.4079 0.31675 0.28165 0.34152 18 53 87 24 105 95
    rs11242021 Imputed T DOM 381 0.602 0.2105 0.3986 0.9094 −2.411 0.01591 0.7248 0.32152 0.28481 0.34753 17 56 85 24 107 92
    rs11242022 Imputed T DOM 380 0.617 0.2103 0.4086 0.9318 −2.296 0.02168 1 0.31316 0.27987 0.3371 16 57 86 21 107 93
    rs11242023 Imputed T DOM 379 0.6116 0.2108 0.4046 0.9244 −2.333 0.01964 0.7243 0.31926 0.28481 0.34389 17 56 85 23 106 92
    rs1149350 Imputed A DOM 382 1.97 0.2254 1.266 3.065 3.007 0.00264 0.05226 0.17801 0.22327 0.14574 8 55 96 10 45 168
    rs1150143 Imputed G DOM 379 1.782 0.2127 1.175 2.704 2.717 0.00659 0.128 0.32586 0.38217 0.28604 24 72 61 23 81 118
    rs11576627 Imputed T ADD 383 1.437 0.2014 0.9684 2.132 1.8 0.0718 0.2168 0.14491 0.17296 0.125 6 43 110 5 46 173
    rs11576627 Imputed T DOM 383 1.496 0.2351 0.9433 2.371 1.712 0.08693 0.2168 0.14491 0.17296 0.125 6 43 110 5 46 173
    rs11602189 Imputed A DOM 374 0.5948 0.2142 0.3909 0.905 −2.426 0.01527 1 0.31818 0.27124 0.35068 12 59 82 26 103 92
    rs11605163 Imputed A DOM 376 2.186 0.3185 1.171 4.08 2.455 0.01408 0.3822 0.0625 0.08654 0.04545 0 27 129 0 20 200
    rs11615214 Imputed G ADD 382 0.7639 0.1532 0.5657 1.032 −1.758 0.07882 1 0.38874 0.35127 0.41518 21 69 68 37 112 75
    rs11615214 Imputed G GEN 382 3.652 0.161 1 0.38874 0.35127 0.41518 21 69 68 37 112 75
    rs11642394 Imputed C DOM 383 1.277 0.2476 0.7859 2.074 0.9866 0.3238 0.8082 0.1201 0.13836 0.10714 4 36 119 2 44 178
    rs11644943 Imputed A ADD 380 1.606 0.1767 1.136 2.27 2.68 0.00736 0.7774 0.23816 0.28616 0.20362 9 73 77 11 68 142
    rs11656608 Imputed T DOM 383 0.7037 0.2279 0.4502 1.1 −1.542 0.1231 0.8589 0.17363 0.15409 0.1875 6 37 116 6 72 146
    rs11661309 Imputed A ADD 383 0.5977 0.199 0.4046 0.8827 −2.587 0.00969 0.1541 0.17493 0.13208 0.20536 4 34 121 12 68 144
    rs11661309 Imputed A DOM 383 0.5564 0.2336 0.352 0.8796 −2.509 0.0121 0.1541 0.17493 0.13208 0.20536 4 34 121 12 68 144
    rs11666131 Imputed A ADD 382 1.578 0.1755 1.119 2.226 2.6 0.00931 0.2905 0.21466 0.26266 0.1808 11 61 86 10 61 153
    rs11743355 Imputed C ADD 379 0.2291 0.7784 0.04984 1.054 −1.893 0.05836 1 0.01715 0.00629 0.025 0 2 157 0 11 209
    rs11743355 Imputed C DOM 379 0.2291 0.7784 0.04984 1.054 −1.893 0.05836 1 0.01715 0.00629 0.025 0 2 157 0 11 209
    rs11746806 Imputed T ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs11746806 Imputed T DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs11746959 Imputed T ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs11746959 Imputed T DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs11749272 Imputed T DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs11901899 Imputed A DOM 378 1.83 0.2121 1.208 2.774 2.851 0.00436 0.1985 0.27646 0.33333 0.23649 18 68 70 16 73 133
    rs11926319 Imputed G ADD 380 0.3536 0.2967 0.1977 0.6325 −3.504 0.00046 1 0.09868 0.05414 0.13004 0 17 140 3 52 168
    rs11926319 Imputed G DOM 380 0.3514 0.3031 0.194 0.6364 −3.451 0.00056 1 0.09868 0.05414 0.13004 0 17 140 3 52 168
    rs11956952 Imputed C DOM 378 0.7003 0.2121 0.4621 1.061 −1.679 0.09313 0.2413 0.26984 0.25478 0.28054 17 46 94 15 94 112
    rs12025826 Imputed G DOM 377 1.354 0.2159 0.8867 2.067 1.403 0.1607 0.1274 0.38462 0.39809 0.375 24 77 56 39 87 94
    rs1204522 Imputed C GEN 378 3.915 0.1412 0.58 0.36243 0.32595 0.38864 14 75 69 33 105 82
    rs1204524 Imputed A GEN 378 3.758 0.1527 0.5784 0.36376 0.32803 0.38914 14 75 68 33 106 82
    rs12153185 Imputed T DOM 379 0.6022 0.2112 0.398 0.911 −2.401 0.01634 0.724 0.3219 0.28526 0.34753 17 55 84 24 107 92
    rs12182651 Imputed T ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs12182651 Imputed T DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs12193568 Imputed G DOM 237 2.406 0.3051 1.323 4.375 2.878 0.00401 0.2704 0.13713 0.18557 0.10357 1 34 62 1 27 112
    rs12264914 Imputed C DOM 204 0.7523 0.29 0.4261 1.328 −0.9814 0.3264 0.7359 0.29167 0.2625 0.31048 5 32 43 11 55 58
    rs12307767 Imputed C DOM 352 0.5633 0.2206 0.3656 0.868 −2.602 0.00928 0.4648 0.32102 0.27931 0.35024 13 55 77 20 105 82
    rs1232298 Imputed G REC 372 2.839 0.3328 1.479 5.45 3.135 0.00172 0.2379 0.32661 0.37742 0.29032 29 59 67 16 94 107
    rs12407412 Imputed C ADD 383 1.437 0.2014 0.9684 2.132 1.8 0.0718 0.2168 0.14491 0.17296 0.125 6 43 110 5 46 173
    rs12407412 Imputed C DOM 383 1.496 0.2351 0.9433 2.371 1.712 0.08693 0.2168 0.14491 0.17296 0.125 6 43 110 5 46 173
    rs12420184 Imputed G DOM 382 0.6069 0.2381 0.3805 0.9678 −2.097 0.03596 0.1285 0.16099 0.1195 0.19058 2 34 123 12 61 150
    rs12422750 Imputed A DOM 383 0.5915 0.2116 0.3907 0.8956 −2.481 0.0131 0.2019 0.32637 0.28616 0.35491 13 65 81 22 115 87
    rs12446951 Imputed A ADD 266 3.123 0.3652 1.526 6.388 3.118 0.00182 0.1047 0.06767 0.11429 0.03727 3 18 84 0 12 149
    rs12446951 Imputed A DOM 266 3.166 0.3883 1.479 6.776 2.968 0.003 0.1047 0.06767 0.11429 0.03727 3 18 84 0 12 149
    rs12457400 Imputed G DOM 383 0.6578 0.2682 0.3889 1.113 −1.562 0.1183 0.7834 0.10444 0.08491 0.1183 1 25 133 2 49 173
    rs1247340 Imputed C DOM 383 1.98 0.2254 1.273 3.079 3.03 0.00244 0.07793 0.17624 0.22327 0.14286 8 55 96 9 46 169
    rs1247341 Imputed C DOM 382 2.017 0.2261 1.295 3.142 3.103 0.00192 0.07501 0.17539 0.22327 0.14126 8 55 96 9 45 169
    rs12521291 Imputed G ADD 380 0.6882 0.1569 0.506 0.9361 −2.381 0.01727 0.6567 0.35921 0.3121 0.39238 19 60 78 32 111 80
    rs12526849 Imputed T ADD 380 1.357 0.1432 1.025 1.797 2.132 0.03298 0.04681 0.42763 0.47484 0.39367 42 67 50 37 100 84
    rs12526849 Imputed T GEN 380 5.531 0.06295 0.04681 0.42763 0.47484 0.39367 42 67 50 37 100 84
    rs12543110 Imputed G DOM 383 1.832 0.2138 1.205 2.786 2.832 0.00463 0.4624 0.22454 0.28302 0.18304 14 62 83 8 66 150
    rs12678600 Imputed A DOM 381 0.5988 0.211 0.396 0.9055 −2.43 0.01509 0.9081 0.33202 0.28616 0.36486 14 63 82 27 108 87
    rs12719415 Imputed T DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs12831292 Imputed G DOM 382 0.643 0.219 0.4186 0.9878 −2.016 0.04381 0.1627 0.38874 0.34591 0.41928 18 74 67 33 121 69
    rs12923993 Imputed C DOM 383 1.277 0.2476 0.7859 2.074 0.9866 0.3238 0.8082 0.1201 0.13836 0.10714 4 36 119 2 44 178
    rs12936964 Imputed T DOM 380 1.581 0.2211 1.025 2.439 2.073 0.03817 0.3863 0.38553 0.40823 0.36937 19 91 48 33 98 91
    rs12960663 Imputed G ADD 383 0.5977 0.199 0.4046 0.8827 −2.587 0.00969 0.1541 0.17493 0.13208 0.20536 4 34 121 12 68 144
    rs13038146 Imputed C ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs13038146 Imputed C GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs13134222 Imputed A GEN 382 6.996 0.03026 0.1929 0.23037 0.18553 0.26233 5 49 105 20 77 126
    rs13172910 Imputed A DOM 379 0.6946 0.212 0.4585 1.052 −1.719 0.08561 0.2969 0.27045 0.25478 0.28153 17 46 94 15 95 112
    rs13194907 Imputed A ADD 383 2.378 0.3248 1.258 4.495 2.668 0.00763 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs13194907 Imputed A DOM 383 2.64 0.3358 1.367 5.099 2.891 0.00384 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs13195745 Imputed A ADD 383 2.378 0.3248 1.258 4.495 2.668 0.00763 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs13195745 Imputed A DOM 383 2.64 0.3358 1.367 5.099 2.891 0.00384 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs1321432 Imputed A REC 383 1.784 0.3115 0.9689 3.286 1.859 0.0631 0.3248 0.37206 0.39308 0.35714 26 73 60 22 116 86
    rs1321457 Imputed G REC 383 1.704 0.3084 0.9308 3.118 1.728 0.08407 0.6599 0.36684 0.38679 0.35268 26 71 62 23 112 89
    rs13265054 Imputed T DOM 381 0.5995 0.211 0.3965 0.9065 −2.425 0.01529 0.9081 0.33202 0.28616 0.36486 14 63 82 27 108 87
    rs13282131 Imputed C GEN 383 4.029 0.1334 0.3575 0.4752 0.51887 0.4442 44 77 38 47 105 72
    rs13353526 Imputed C DOM 383 2.299 0.2671 1.362 3.881 3.116 0.00183 0.2304 0.0953 0.13208 0.0692 0 42 117 1 29 194
    rs1336382 Imputed T DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs1336383 Imputed T DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs1336407 Imputed T DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs1336409 Imputed T DOM 382 1.355 0.2098 0.8985 2.045 1.45 0.1471 0.4624 0.2945 0.31761 0.27803 16 69 74 20 84 119
    rs1336596 Imputed A DOM 380 0.6528 0.2133 0.4297 0.9916 −2 0.04554 0.2643 0.35658 0.32595 0.37838 18 67 73 25 118 79
    rs1343560 Imputed T ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs1343560 Imputed T DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs1361987 Imputed T GEN 383 3.272 0.1948 0.4362 0.3577 0.3239 0.3817 14 75 70 31 109 84
    rs1386153 Imputed T ADD 379 0.6655 0.164 0.4826 0.9177 −2.484 0.01299 0.8128 0.31662 0.26752 0.35135 12 60 85 27 102 93
    rs1386153 Imputed T DOM 379 0.5913 0.212 0.3902 0.8959 −2.478 0.01321 0.8128 0.31662 0.26752 0.35135 12 60 85 27 102 93
    rs1394015 Imputed C DOM 356 1.898 0.243 1.179 3.056 2.637 0.00837 0.08154 0.41854 0.47569 0.37972 27 83 34 27 107 78
    rs1407038 Imputed A REC 382 1.717 0.3085 0.9381 3.144 1.753 0.07963 0.6601 0.36649 0.38608 0.35268 26 70 62 23 112 89
    rs1407039 Imputed A REC 379 1.715 0.3088 0.9365 3.142 1.748 0.08054 0.5818 0.37071 0.38854 0.35811 26 70 61 23 113 86
    rs1412802 Imputed T GEN 381 5.343 0.06914 0.3707 0.27428 0.2327 0.30405 8 58 93 24 87 111
    rs1414865 Imputed T DOM 382 1.33 0.2097 0.8818 2.006 1.36 0.1737 0.5395 0.29581 0.32075 0.27803 17 68 74 19 86 118
    rs1414873 Imputed A DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs1414876 Imputed C DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs1418671 Imputed C REC 377 2.067 0.2706 1.216 3.513 2.684 0.00728 0.8338 0.43236 0.4557 0.41553 39 66 53 30 122 67
    rs1419490 Genotyped T GEN 383 3.125 0.2096 0.4381 0.3564 0.3239 0.37946 14 75 70 31 108 85
    rs1434507 Imputed A ADD 381 1.405 0.1664 1.014 1.947 2.044 0.04098 0.5376 0.29396 0.33019 0.26802 17 71 71 13 93 116
    rs1434508 Imputed T ADD 382 1.399 0.1663 1.01 1.938 2.018 0.04355 0.5378 0.2945 0.33019 0.26906 17 71 71 13 94 116
    rs1435205 Imputed A ADD 379 1.571 0.1825 1.099 2.247 2.475 0.01331 0.3801 0.22559 0.2707 0.19369 10 65 82 6 74 142
    rs1443928 Imputed C REC 380 0.5055 0.2469 0.3116 0.8201 −2.763 0.00572 0.5394 0.51579 0.43671 0.57207 31 76 51 73 108 41
    rs1452235 Imputed G GEN 383 4.025 0.1337 0.3156 0.35248 0.31132 0.3817 16 67 76 36 99 89
    rs1452236 Imputed G GEN 383 4.025 0.1337 0.3156 0.35248 0.31132 0.3817 16 67 76 36 99 89
    rs1452237 Imputed G GEN 383 4.025 0.1337 0.3156 0.35248 0.31132 0.3817 16 67 76 36 99 89
    rs1452243 Genotyped T GEN 383 4.025 0.1337 0.3156 0.35248 0.31132 0.3817 16 67 76 36 99 89
    rs1463768 Genotyped G REC 383 2.557 0.2969 1.429 4.574 3.162 0.00157 0.6662 0.38251 0.41195 0.36161 36 59 64 22 118 84
    rs1463769 Imputed G REC 383 2.557 0.2969 1.429 4.574 3.162 0.00157 0.6662 0.38251 0.41195 0.36161 36 59 64 22 118 84
    rs1472435 Imputed A ADD 374 0.3624 0.3387 0.1866 0.704 −2.996 0.00274 0.2433 0.07353 0.0414 0.09677 0 13 144 0 42 175
    rs1472435 Imputed A DOM 374 0.3624 0.3387 0.1866 0.704 −2.996 0.00274 0.2433 0.07353 0.0414 0.09677 0 13 144 0 42 175
    rs1476714 Imputed A DOM 381 0.5994 0.2104 0.3969 0.9054 −2.432 0.01501 0.6369 0.3189 0.28165 0.34529 17 55 86 24 106 93
    rs1495159 Imputed G ADD 377 0.6292 0.1647 0.4556 0.8688 −2.814 0.0049 0.01409 0.27454 0.21935 0.31306 11 46 98 27 85 110
    rs1495159 Imputed G GEN 377 8.035 0.018 0.01409 0.27454 0.21935 0.31306 11 46 98 27 85 110
    rs1495375 Imputed A DOM 383 0.643 0.2198 0.418 0.9893 −2.009 0.04455 0.1989 0.39426 0.3522 0.42411 19 74 66 34 122 68
    rs1495376 Imputed T DOM 371 0.4469 0.2418 0.2782 0.7178 −3.331 0.00086 0.7551 0.47844 0.43182 0.51152 35 63 56 48 126 43
    rs1495377 Imputed G DOM 370 0.4491 0.2417 0.2797 0.7213 −3.312 0.00093 0.7556 0.47838 0.43182 0.51157 35 63 56 48 125 43
    rs1495381 Imputed T GEN 383 5.394 0.06741 0.7553 0.43473 0.46541 0.41295 40 68 51 34 117 73
    rs1495381 Imputed T REC 383 1.786 0.2638 1.065 2.996 2.199 0.02786 0.7553 0.43473 0.46541 0.41295 40 68 51 34 117 73
    rs1498992 Imputed G DOM 383 0.6967 0.2093 0.4622 1.05 −1.727 0.08421 0.5379 0.29373 0.27358 0.30804 14 59 86 16 106 102
    rs1499001 Imputed T DOM 378 0.6855 0.2116 0.4528 1.038 −1.784 0.07436 0.352 0.2619 0.24214 0.27626 11 55 93 11 99 109
    rs1512988 Imputed A DOM 380 0.6145 0.2204 0.3989 0.9466 −2.209 0.02719 0.161 0.39079 0.34494 0.42342 18 73 67 33 122 67
    rs1512989 Imputed T DOM 380 0.6145 0.2204 0.3989 0.9466 −2.209 0.02719 0.161 0.39079 0.34494 0.42342 18 73 67 33 122 67
    rs1512991 Imputed T ADD 382 0.7489 0.1551 0.5526 1.015 −1.864 0.06235 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs1512991 Imputed T DOM 382 0.571 0.2227 0.3691 0.8835 −2.516 0.01186 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs1516855 Imputed G REC 382 2.635 0.3326 1.373 5.056 2.913 0.00358 0.3164 0.35864 0.38679 0.33857 27 69 63 17 117 89
    rs1527450 Imputed T ADD 383 1.615 0.1632 1.173 2.224 2.937 0.00332 0.02621 0.40862 0.46855 0.36607 30 89 40 23 118 83
    rs1527450 Imputed T GEN 383 8.69 0.01297 0.02621 0.40862 0.46855 0.36607 30 89 40 23 118 83
    rs1567740 Imputed T DOM 381 0.6186 0.2199 0.402 0.9518 −2.185 0.02891 0.1327 0.39108 0.34591 0.42342 18 74 67 33 122 67
    rs1572573 Imputed A ADD 362 1.424 0.201 0.9603 2.112 1.759 0.07865 0.2969 0.18646 0.21622 0.16589 3 58 87 6 59 149
    rs1572573 Imputed A DOM 362 1.608 0.2249 1.035 2.498 2.112 0.03472 0.2969 0.18646 0.21622 0.16589 3 58 87 6 59 149
    rs1584003 Imputed C DOM 380 1.619 0.2537 0.9846 2.661 1.899 0.05761 0.3047 0.49605 0.52548 0.47534 38 89 30 50 112 61
    rs1584005 Imputed C DOM 380 1.619 0.2537 0.9846 2.661 1.899 0.05761 0.3047 0.49605 0.52548 0.47534 38 89 30 50 112 61
    rs1585771 Imputed G ADD 382 1.485 0.1701 1.064 2.073 2.325 0.02005 0.44 0.27225 0.31646 0.24107 15 70 73 10 88 126
    rs1592015 Imputed G DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs1594885 Imputed A ADD 380 1.429 0.1671 1.03 1.983 2.138 0.03253 0.461 0.29737 0.33544 0.27027 17 72 69 13 94 115
    rs1603232 Imputed A DOM 370 0.4692 0.2395 0.2935 0.7503 −3.159 0.00158 0.8353 0.47432 0.43137 0.50461 35 62 56 47 125 45
    rs1614565 Imputed C DOM 372 0.4727 0.2424 0.2939 0.7602 −3.091 0.00199 0.6778 0.48253 0.44156 0.51147 36 64 54 48 127 43
    rs1648200 Imputed G ADD 363 1.513 0.1861 1.05 2.179 2.224 0.02618 0.02626 0.25207 0.29333 0.223 9 70 71 6 83 124
    rs16877387 Imputed C GEN 382 6.901 0.03174 0.8277 0.37304 0.40506 0.35045 30 68 60 22 113 89
    rs16877387 Imputed C REC 382 2.182 0.3041 1.202 3.961 2.566 0.01029 0.8277 0.37304 0.40506 0.35045 30 68 60 22 113 89
    rs16938626 Imputed G DOM 382 0.5784 0.2111 0.3825 0.8747 −2.594 0.00948 0.5218 0.27618 0.23101 0.30804 9 55 94 17 104 103
    rs1694334 Imputed G ADD 351 0.6042 0.1961 0.4114 0.8874 −2.569 0.01019 0.7491 0.21225 0.16443 0.24752 6 37 106 11 78 113
    rs16998821 Imputed C DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs1700400 Imputed T ADD 362 0.5776 0.1758 0.4093 0.8151 −3.123 0.00179 0.05211 0.25552 0.19156 0.30288 6 47 101 25 76 107
    rs17007620 Imputed G ADD 363 1.653 0.1777 1.167 2.341 2.828 0.00468 1 0.24656 0.3 0.20892 13 64 73 9 71 133
    rs17007620 Imputed G DOM 363 1.767 0.2175 1.154 2.707 2.619 0.00883 1 0.24656 0.3 0.20892 13 64 73 9 71 133
    rs17023290 Imputed C DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs17047957 Imputed C DOM 383 1.726 0.2428 1.073 2.778 2.249 0.02453 0.4928 0.12924 0.16352 0.10491 5 42 112 3 41 180
    rs1705237 Imputed A DOM 369 0.4663 0.2431 0.2895 0.7508 −3.139 0.0017 0.7547 0.48238 0.44079 0.51152 36 62 54 48 126 43
    rs1705261 Imputed A GEN 383 5.394 0.06741 0.7553 0.43473 0.46541 0.41295 40 68 51 34 117 73
    rs1705261 Imputed A REC 383 1.786 0.2638 1.065 2.996 2.199 0.02786 0.7553 0.43473 0.46541 0.41295 40 68 51 34 117 73
    rs17076972 Imputed C ADD 383 1.44 0.1509 1.071 1.935 2.416 0.01568 0.7591 0.46736 0.51887 0.4308 44 77 38 38 117 69
    rs17076972 Imputed C GEN 383 6.553 0.03777 0.7591 0.46736 0.51887 0.4308 44 77 38 38 117 69
    rs17076972 Imputed C REC 383 1.85 0.2521 1.128 3.032 2.439 0.01473 0.7591 0.46736 0.51887 0.4308 44 77 38 38 117 69
    rs17189710 Imputed T ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs17189710 Imputed T GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs17196143 Imputed A ADD 383 1.543 0.1879 1.068 2.231 2.308 0.02098 0.869 0.1893 0.22956 0.16071 10 53 96 4 64 156
    rs17353809 Imputed G ADD 382 1.616 0.1806 1.134 2.302 2.658 0.00786 0.3892 0.23037 0.27848 0.19643 11 66 81 6 76 142
    rs17368986 Imputed A GEN 381 3.069 0.2155 0.4122 0.19423 0.21384 0.18018 11 46 102 6 68 148
    rs17369097 Imputed A GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs17434511 Imputed C GEN 383 3.158 0.2061 0.4152 0.19452 0.21384 0.1808 11 46 102 6 69 149
    rs17434589 Imputed C GEN 376 3.386 0.184 0.4114 0.19548 0.2129 0.18326 11 44 100 6 69 146
    rs17434603 Imputed G GEN 383 3.158 0.2061 0.4152 0.19452 0.21384 0.1808 11 46 102 6 69 149
    rs17434840 Imputed C GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs17446418 Imputed G DOM 382 0.6878 0.2135 0.4526 1.045 −1.753 0.07956 0.7451 0.38089 0.34906 0.40359 22 67 70 35 110 78
    rs17530747 Imputed T DOM 382 0.6878 0.2135 0.4526 1.045 −1.753 0.07956 0.7451 0.38089 0.34906 0.40359 22 67 70 35 110 78
    rs17604285 Imputed C ADD 383 0.4148 0.2819 0.2387 0.7208 −3.122 0.0018 0.4026 0.10183 0.06289 0.12946 0 20 139 2 54 168
    rs17604285 Imputed C DOM 383 0.4153 0.2867 0.2368 0.7285 −3.065 0.00218 0.4026 0.10183 0.06289 0.12946 0 20 139 2 54 168
    rs17662322 Imputed T DOM 383 0.6835 0.2193 0.4447 1.05 −1.735 0.08267 0.526 0.19974 0.17296 0.21875 5 45 109 8 82 134
    rs17769826 Imputed T ADD 382 1.616 0.1806 1.134 2.302 2.658 0.00786 0.3892 0.23037 0.27848 0.19643 11 66 81 6 76 142
    rs17821641 Imputed T ADD 379 1.571 0.1825 1.099 2.247 2.475 0.01331 0.3801 0.22559 0.2707 0.19369 10 65 82 6 74 142
    rs1782328 Imputed A ADD 356 0.5789 0.2144 0.3803 0.8814 −2.549 0.0108 0.4722 0.17978 0.13667 0.21117 3 35 112 6 75 125
    rs1796337 Imputed T DOM 379 0.5422 0.239 0.3394 0.8661 −2.561 0.01043 0.8372 0.49208 0.44937 0.52262 37 68 53 56 119 46
    rs1798083 Imputed C DOM 370 0.4733 0.2427 0.2942 0.7617 −3.081 0.00206 0.6044 0.48108 0.43791 0.51152 35 64 54 48 126 43
    rs1798085 Imputed T DOM 372 0.4727 0.2424 0.2939 0.7602 −3.091 0.00199 0.6778 0.48253 0.44156 0.51147 36 64 54 48 127 43
    rs1798086 Imputed T DOM 370 0.4689 0.2427 0.2914 0.7545 −3.12 0.00181 0.7547 0.48243 0.44118 0.51152 36 63 54 48 126 43
    rs1798089 Imputed C GEN 371 5.637 0.0597 0.2536 0.469 0.51316 0.43836 46 64 42 41 110 68
    rs1798089 Imputed C REC 371 1.806 0.2499 1.106 2.947 2.365 0.01804 0.2536 0.469 0.51316 0.43836 46 64 42 41 110 68
    rs1798090 Imputed C GEN 371 5.595 0.06097 0.2992 0.47035 0.51645 0.43836 46 65 41 41 110 68
    rs1798090 Imputed C REC 371 1.806 0.2499 1.106 2.947 2.365 0.01804 0.2992 0.47035 0.51645 0.43836 46 65 41 41 110 68
    rs1832222 Imputed G DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs1838104 Imputed A ADD 370 0.6393 0.1498 0.4766 0.8574 −2.987 0.00282 0.3479 0.52568 0.46104 0.57176 38 66 50 69 109 38
    rs1838104 Imputed A GEN 370 11.02 0.00404 0.3479 0.52568 0.46104 0.57176 38 66 50 69 109 38
    rs1868616 Imputed G ADD 372 0.7123 0.1959 0.4852 1.046 −1.732 0.08332 0.3379 0.2043 0.17419 0.22581 4 46 105 8 82 127
    rs1874313 Imputed A DOM 382 0.6182 0.22 0.4017 0.9516 −2.185 0.02885 0.1324 0.39136 0.34591 0.42377 18 74 67 33 123 67
    rs1884902 Imputed C REC 379 1.796 0.3119 0.9747 3.31 1.878 0.0604 0.4419 0.36939 0.38854 0.35586 26 70 61 22 114 86
    rs1913201 Imputed G ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs1913201 Imputed G DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs1913201 Imputed G GEN 383 6.592 0.03704 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs1944279 Imputed A ADD 377 1.444 0.1687 1.038 2.01 2.179 0.02933 0.3868 0.29576 0.33439 0.26818 17 71 69 12 94 114
    rs198461 Imputed C DOM 382 0.4755 0.245 0.2942 0.7685 −3.035 0.00241 0.9187 0.51309 0.46855 0.54484 40 69 50 61 121 41
    rs1987179 Imputed T DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs1990023 Imputed T DOM 382 0.6024 0.2102 0.399 0.9096 −2.411 0.01591 0.4079 0.31675 0.28165 0.34152 18 53 87 24 105 95
    rs2016194 Imputed G DOM 381 0.602 0.2105 0.3986 0.9094 −2.411 0.01591 0.7248 0.32152 0.28481 0.34753 17 56 85 24 107 92
    rs2024789 Imputed C ADD 381 0.7464 0.1501 0.5562 1.002 −1.949 0.05131 0.9185 0.49081 0.44937 0.52018 31 80 47 60 112 51
    rs2024789 Imputed C GEN 381 3.798 0.1497 0.9185 0.49081 0.44937 0.52018 31 80 47 60 112 51
    rs2024902 Imputed A ADD 382 2.395 0.3248 1.267 4.526 2.688 0.00718 1 0.05759 0.08544 0.03795 0 27 131 1 15 208
    rs2024902 Imputed A DOM 382 2.659 0.3358 1.377 5.135 2.912 0.00359 1 0.05759 0.08544 0.03795 0 27 131 1 15 208
    rs2025107 Imputed A ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs2025107 Imputed A DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs2025108 Imputed T ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs2025108 Imputed T DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs2062448 Imputed T ADD 383 0.4148 0.2819 0.2387 0.7208 −3.122 0.0018 0.4026 0.10183 0.06289 0.12946 0 20 139 2 54 168
    rs2062448 Imputed T DOM 383 0.4153 0.2867 0.2368 0.7285 −3.065 0.00218 0.4026 0.10183 0.06289 0.12946 0 20 139 2 54 168
    rs2063591 Imputed C ADD 382 0.7711 0.1536 0.5706 1.042 −1.692 0.09058 0.6013 0.42801 0.38924 0.45536 27 69 62 40 124 60
    rs2063591 Imputed C DOM 382 0.5884 0.2242 0.3791 0.9131 −2.366 0.018 0.6013 0.42801 0.38924 0.45536 27 69 62 40 124 60
    rs2065604 Imputed C DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2066238 Imputed T DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs2068051 Imputed G ADD 264 0.6426 0.1952 0.4383 0.9422 −2.265 0.02351 0.06451 0.5 0.45045 0.53595 20 60 31 38 88 27
    rs2068051 Imputed G GEN 264 5.343 0.06914 0.06451 0.5 0.45045 0.53595 20 60 31 38 88 27
    rs2077702 Genotyped G GEN 383 2.22 0.3296 0.6635 0.37728 0.39937 0.36161 27 73 59 25 112 87
    rs208757 Imputed G ADD 345 1.353 0.2024 0.9102 2.012 1.495 0.1348 0.8529 0.17536 0.20139 0.15672 5 48 91 6 51 144
    rs208757 Imputed G DOM 345 1.453 0.2347 0.917 2.301 1.591 0.1116 0.8529 0.17536 0.20139 0.15672 5 48 91 6 51 144
    rs2095586 Imputed A DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs2108426 Imputed C DOM 381 0.5994 0.2104 0.3969 0.9054 −2.432 0.01501 0.6369 0.3189 0.28165 0.34529 17 55 86 24 106 93
    rs2110664 Imputed A DOM 349 1.697 0.2201 1.102 2.613 2.403 0.01627 0.1922 0.28797 0.34028 0.25122 18 62 64 16 71 118
    rs2132242 Imputed A DOM 382 0.6291 0.2196 0.4091 0.9676 −2.11 0.03486 0.1617 0.39005 0.34591 0.42152 18 74 67 33 122 68
    rs2151644 Imputed T DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2157752 Genotyped A GEN 383 3.356 0.1868 0.3575 0.3329 0.30189 0.35491 11 74 74 27 105 92
    rs2158958 Imputed A DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs2158961 Imputed G DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.5542 0.31593 0.27987 0.34152 17 55 87 24 105 95
    rs2164099 Imputed G ADD 382 1.424 0.1667 1.027 1.974 2.121 0.03389 0.4616 0.29581 0.33333 0.26906 17 72 70 13 94 116
    rs2173254 Imputed G GEN 381 4.978 0.08298 0.06174 0.32546 0.30063 0.34305 7 81 70 25 103 95
    rs2173254 Imputed G REC 381 0.3756 0.4421 0.1579 0.8933 −2.215 0.02675 0.06174 0.32546 0.30063 0.34305 7 81 70 25 103 95
    rs2188079 Imputed C ADD 383 1.5 0.1541 1.109 2.029 2.63 0.00854 0.6716 0.40339 0.45912 0.36384 32 82 45 28 107 89
    rs2188079 Imputed C GEN 383 6.918 0.03146 0.6716 0.40339 0.45912 0.36384 32 82 45 28 107 89
    rs2190304 Imputed G REC 383 0.628 0.2629 0.3751 1.051 −1.77 0.0768 0.47 0.4517 0.43082 0.46652 27 83 49 55 99 70
    rs2190597 Imputed T DOM 381 0.7825 0.223 0.5054 1.211 −1.1 0.2713 0.8344 0.43045 0.4172 0.43973 29 73 55 40 117 67
    rs2190598 Imputed T DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs2190600 Imputed A DOM 379 0.6022 0.2112 0.398 0.911 −2.401 0.01634 0.724 0.3219 0.28526 0.34753 17 55 84 24 107 92
    rs2218084 Imputed T GEN 383 6.969 0.03066 0.3636 0.16971 0.21069 0.14063 6 55 98 2 59 163
    rs2218084 Imputed T REC 383 4.673 0.8259 0.9259 23.58 1.867 0.06194 0.3636 0.16971 0.21069 0.14063 6 55 98 2 59 163
    rs2236290 Genotyped C GEN 381 3.686 0.1583 1 0.37664 0.33861 0.40359 17 73 68 37 106 80
    rs2243860 Imputed A GEN 306 4.567 0.1019 1 0.35131 0.39431 0.3224 21 55 47 17 84 82
    rs2243860 Imputed A REC 306 2.063 0.3516 1.035 4.108 2.059 0.03949 1 0.35131 0.39431 0.3224 21 55 47 17 84 82
    rs2246564 Imputed T DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2248236 Imputed C DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs2250340 Imputed T DOM 333 0.4723 0.3046 0.26 0.858 −2.463 0.01378 0.3862 0.10511 0.07299 0.12755 2 16 119 3 44 149
    rs2257192 Imputed G DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2270584 Imputed A DOM 382 0.5988 0.2187 0.3901 0.9193 −2.345 0.01904 0.2351 0.38613 0.33861 0.41964 18 71 69 33 122 69
    rs2270586 Imputed A DOM 371 0.5858 0.2268 0.3756 0.9138 −2.358 0.0184 0.0525 0.40296 0.35526 0.43607 18 72 62 33 125 61
    rs2270589 Imputed A ADD 308 0.6907 0.1757 0.4895 0.9746 −2.106 0.03518 0.1384 0.4724 0.42188 0.50833 25 58 45 37 109 34
    rs2270589 Imputed A DOM 308 0.4396 0.2688 0.2596 0.7445 −3.058 0.00223 0.1384 0.4724 0.42188 0.50833 25 58 45 37 109 34
    rs2270589 Imputed A GEN 308 9.89 0.00712 0.1384 0.4724 0.42188 0.50833 25 58 45 37 109 34
    rs2296889 Imputed C DOM 381 1.88 0.2321 1.193 2.963 2.721 0.00651 0.6901 0.15223 0.19811 0.11937 7 49 103 3 47 172
    rs2301346 Imputed C ADD 343 1.627 0.1791 1.145 2.311 2.717 0.00658 0.2971 0.293 0.34932 0.25127 12 78 56 13 73 111
    rs2301346 Imputed C DOM 343 2.008 0.2246 1.293 3.119 3.103 0.00191 0.2971 0.293 0.34932 0.25127 12 78 56 13 73 111
    rs2327929 Imputed G REC 383 1.756 0.2541 1.068 2.89 2.217 0.02662 0.8372 0.45431 0.47799 0.4375 42 68 49 38 120 66
    rs2357486 Imputed C REC 379 1.682 0.4091 0.7542 3.75 1.27 0.2039 0.00149 0.32322 0.33228 0.31674 14 77 67 12 116 93
    rs2373793 Imputed G DOM 374 1.775 0.2221 1.149 2.743 2.583 0.00978 0.6199 0.19251 0.22549 0.16968 4 61 88 8 59 154
    rs2377622 Imputed T GEN 283 3.778 0.1513 0.6851 0.32686 0.28205 0.35843 9 48 60 23 73 70
    rs2377622 Imputed T REC 283 0.5046 0.4168 0.2229 1.142 −1.641 0.1008 0.6851 0.32686 0.28205 0.35843 9 48 60 23 73 70
    rs2383903 Imputed G DOM 381 0.5866 0.211 0.3879 0.8871 −2.528 0.01148 0.444 0.27822 0.23418 0.30942 9 56 93 17 104 102
    rs2389866 Imputed C DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs2389869 Imputed C DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs2418541 Imputed A DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs2418542 Imputed A DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs2418548 Imputed C DOM 378 0.6382 0.211 0.4221 0.965 −2.129 0.03326 0.4132 0.32672 0.29618 0.34842 19 55 83 25 104 92
    rs2476976 Imputed C DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs2483639 Imputed A DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2483640 Imputed A DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs2544780 Imputed T REC 381 1.683 0.3502 0.8473 3.344 1.487 0.137 0.7246 0.3189 0.32166 0.31696 20 61 76 17 108 99
    rs2586458 Imputed T DOM 323 0.4393 0.2682 0.2597 0.7431 −3.067 0.00216 0.65 0.14396 0.09929 0.17857 2 24 115 3 59 120
    rs2593272 Imputed G ADD 383 0.5962 0.1685 0.4285 0.8294 −3.07 0.00214 0.05071 0.26762 0.2044 0.3125 7 51 101 28 84 112
    rs2593273 Imputed T ADD 383 0.5962 0.1685 0.4285 0.8294 −3.07 0.00214 0.05071 0.26762 0.2044 0.3125 7 51 101 28 84 112
    rs2622499 Imputed G DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs264126 Imputed C DOM 381 0.7975 0.2216 0.5165 1.231 −1.022 0.307 1 0.42782 0.4172 0.43527 30 71 56 40 115 69
    rs264129 Imputed T DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.5542 0.31593 0.27987 0.34152 17 55 87 24 105 95
    rs2656822 Imputed T ADD 383 0.5962 0.1685 0.4285 0.8294 −3.07 0.00214 0.05071 0.26762 0.2044 0.3125 7 51 101 28 84 112
    rs2656823 Imputed G ADD 383 0.5962 0.1685 0.4285 0.8294 −3.07 0.00214 0.05071 0.26762 0.2044 0.3125 7 51 101 28 84 112
    rs2656825 Imputed T ADD 362 0.558 0.1868 0.387 0.8047 −3.123 0.00179 0.4731 0.23895 0.17763 0.28333 3 48 101 20 79 111
    rs2764766 Imputed C REC 383 1.776 0.3462 0.901 3.5 1.659 0.09717 0.8147 0.32115 0.32704 0.31696 21 62 76 17 108 99
    rs2793101 Imputed T ADD 383 0.6263 0.2568 0.3786 1.036 −1.822 0.06842 0.2863 0.10705 0.08491 0.12277 1 25 133 1 53 170
    rs2793101 Imputed T DOM 383 0.5997 0.2668 0.3555 1.012 −1.916 0.05534 0.2863 0.10705 0.08491 0.12277 1 25 133 1 53 170
    rs2795871 Imputed A ADD 382 0.3627 0.3488 0.1831 0.7186 −2.908 0.00364 0.2402 0.06806 0.03774 0.08969 0 12 147 0 40 183
    rs2795886 Imputed A ADD 383 0.3343 0.376 0.16 0.6986 −2.914 0.00357 0.3826 0.06005 0.03145 0.08036 0 10 149 0 36 188
    rs2795886 Imputed A DOM 383 0.3343 0.376 0.16 0.6986 −2.914 0.00357 0.3826 0.06005 0.03145 0.08036 0 10 149 0 36 188
    rs2859994 Imputed C GEN 378 6.173 0.04567 0.2908 0.41931 0.47115 0.38288 33 81 42 28 114 80
    rs2870464 Imputed G DOM 383 1.373 0.2699 0.8092 2.331 1.176 0.2398 0.7607 0.09399 0.11006 0.08259 2 31 126 2 33 189
    rs2875528 Imputed T DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs2876227 Imputed C ADD 380 1.396 0.1502 1.04 1.874 2.221 0.02634 0.1846 0.36579 0.41026 0.33482 27 74 55 30 90 104
    rs2876227 Imputed C GEN 380 5.549 0.06238 0.1846 0.36579 0.41026 0.33482 27 74 55 30 90 104
    rs2882097 Imputed A DOM 383 1.367 0.2096 0.9065 2.062 1.491 0.1358 0.4613 0.29373 0.31761 0.27679 16 69 74 20 84 120
    rs2921983 Imputed C ADD 375 0.5761 0.1731 0.4103 0.8087 −3.187 0.00144 0.04386 0.26 0.19355 0.30682 6 48 101 27 81 112
    rs2987537 Imputed C DOM 383 0.5886 0.2614 0.3526 0.9826 −2.027 0.04264 0.8057 0.1188 0.09119 0.13839 2 25 132 4 54 166
    rs2996416 Imputed C ADD 382 0.5791 0.2661 0.3437 0.9755 −2.053 0.04007 0.7684 0.09686 0.06962 0.11607 1 20 137 3 46 175
    rs2996416 Imputed C DOM 382 0.5573 0.2856 0.3184 0.9754 −2.047 0.04066 0.7684 0.09686 0.06962 0.11607 1 20 137 3 46 175
    rs3015527 Imputed C ADD 377 0.5922 0.2667 0.3511 0.9989 −1.964 0.04953 0.7661 0.09682 0.07051 0.11538 1 20 135 3 45 173
    rs3015527 Imputed C DOM 377 0.572 0.2869 0.326 1.004 −1.947 0.05151 0.7661 0.09682 0.07051 0.11538 1 20 135 3 45 173
    rs3015530 Imputed C ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3015530 Imputed C DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3015531 Imputed T ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3015531 Imputed T DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3015535 Imputed C ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3015535 Imputed C DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs3019407 Imputed A GEN 381 5.56 0.06205 0.1023 0.32546 0.30063 0.34305 7 81 70 26 101 96
    rs3019407 Imputed A REC 381 0.3598 0.4403 0.1518 0.8529 −2.321 0.02026 0.1023 0.32546 0.30063 0.34305 7 81 70 26 101 96
    rs36071725 Genotyped C GEN 383 4.835 0.08914 0.9112 0.35248 0.39623 0.32143 24 78 57 24 96 104
    rs373983 Imputed G DOM 380 1.266 0.2223 0.8189 1.957 1.061 0.2888 0.7504 0.41053 0.42038 0.40359 24 84 49 38 104 81
    rs3756154 Imputed C DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs3793044 Imputed C ADD 383 2.378 0.3248 1.258 4.495 2.668 0.00763 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs3793044 Imputed C DOM 383 2.64 0.3358 1.367 5.099 2.891 0.00384 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs3793053 Imputed C ADD 380 2.28 0.3065 1.25 4.157 2.689 0.00717 0.1626 0.06184 0.09177 0.04054 1 27 130 2 14 206
    rs3793053 Imputed C DOM 380 2.764 0.3341 1.436 5.32 3.042 0.00235 0.1626 0.06184 0.09177 0.04054 1 27 130 2 14 206
    rs3796246 Imputed G ADD 383 0.3513 0.2964 0.1965 0.6279 −3.53 0.00042 1 0.09791 0.05346 0.12946 0 17 142 3 52 169
    rs3796246 Imputed G DOM 383 0.3489 0.3028 0.1928 0.6316 −3.478 0.00051 1 0.09791 0.05346 0.12946 0 17 142 3 52 169
    rs3805996 Imputed G ADD 382 2.395 0.3248 1.267 4.526 2.688 0.00718 1 0.05759 0.08544 0.03795 0 27 131 1 15 208
    rs3805996 Imputed G DOM 382 2.659 0.3358 1.377 5.135 2.912 0.00359 1 0.05759 0.08544 0.03795 0 27 131 1 15 208
    rs3806003 Imputed A ADD 383 2.378 0.3248 1.258 4.495 2.668 0.00763 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs3806003 Imputed A DOM 383 2.64 0.3358 1.367 5.099 2.891 0.00384 1 0.05744 0.08491 0.03795 0 27 132 1 15 208
    rs3806004 Imputed T ADD 382 2.473 0.3048 1.361 4.493 2.97 0.00298 0.193 0.06414 0.0981 0.04018 1 29 128 2 14 208
    rs3806004 Imputed T DOM 382 3.015 0.3305 1.578 5.763 3.339 0.00084 0.193 0.06414 0.0981 0.04018 1 29 128 2 14 208
    rs3806010 Imputed T ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806010 Imputed T DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806014 Imputed T ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806014 Imputed T DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806015 Imputed A ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806015 Imputed A DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806018 Imputed A ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806018 Imputed A DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806019 Imputed A ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806019 Imputed A DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs3806024 Imputed T ADD 382 2.274 0.3063 1.248 4.146 2.682 0.00732 0.1608 0.06152 0.09119 0.04036 1 27 131 2 14 207
    rs3806024 Imputed T DOM 382 2.756 0.334 1.432 5.303 3.035 0.0024 0.1608 0.06152 0.09119 0.04036 1 27 131 2 14 207
    rs3847825 Imputed G ADD 382 0.7535 0.1544 0.5568 1.02 −1.833 0.06673 0.9143 0.39005 0.35127 0.41741 21 69 68 36 115 73
    rs3847825 Imputed G GEN 382 4.284 0.1174 0.9143 0.39005 0.35127 0.41741 21 69 68 36 115 73
    rs3852001 Genotyped C GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3852001 Genotyped C REC 383 2.797 0.5134 1.023 7.653 2.004 0.04512 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3852002 Imputed G GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3852002 Imputed G REC 383 2.797 0.5134 1.023 7.653 2.004 0.04512 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3852003 Imputed A GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3852003 Imputed A REC 383 2.797 0.5134 1.023 7.653 2.004 0.04512 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs3942254 Imputed T DOM 351 0.5955 0.227 0.3817 0.9293 −2.283 0.02242 0.737 0.38746 0.33916 0.42067 18 61 64 33 109 66
    rs3945085 Imputed A DOM 383 1.391 0.2096 0.9222 2.098 1.574 0.1155 0.5365 0.29112 0.31761 0.27232 16 69 74 19 84 121
    rs399485 Imputed A DOM 382 1.379 0.2101 0.9136 2.082 1.53 0.126 0.6346 0.31283 0.33648 0.29596 15 77 67 20 92 111
    rs4029119 Imputed G ADD 382 0.1157 1.052 0.01473 0.9094 −2.05 0.04034 1 0.01571 0.00316 0.02455 0 1 157 0 11 213
    rs4029119 Imputed G DOM 382 0.1157 1.052 0.01473 0.9094 −2.05 0.04034 1 0.01571 0.00316 0.02455 0 1 157 0 11 213
    rs412791 Imputed C GEN 367 2.832 0.2427 0.5643 0.34605 0.31731 0.3673 13 73 70 28 99 84
    rs4146972 Genotyped T DOM 383 1.672 0.2418 1.041 2.685 2.125 0.03357 0.4985 0.13055 0.16352 0.10714 5 42 112 3 42 179
    rs4259369 Imputed C REC 383 0.4161 0.2795 0.2406 0.7196 −3.137 0.00171 0.6078 0.46867 0.39937 0.51786 21 85 53 60 112 52
    rs4273613 Imputed T ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs4273613 Imputed T DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs4294022 Imputed C DOM 383 0.5507 0.2147 0.3616 0.8388 −2.779 0.00546 0.3404 0.25065 0.21384 0.27679 9 50 100 11 102 111
    rs4310554 Genotyped C DOM 383 1.609 0.2628 0.9616 2.694 1.811 0.07014 0.681 0.53786 0.57547 0.51116 51 81 27 62 105 57
    rs4315598 Imputed T ADD 382 1.42 0.1496 1.06 1.904 2.347 0.01894 0.1477 0.35864 0.40566 0.32511 27 75 57 29 87 107
    rs4315598 Imputed T GEN 382 6.306 0.04271 0.1477 0.35864 0.40566 0.32511 27 75 57 29 87 107
    rs4370878 Imputed G DOM 383 1.391 0.2096 0.9222 2.098 1.574 0.1155 0.5365 0.29112 0.31761 0.27232 16 69 74 19 84 121
    rs4436200 Imputed C ADD 383 0.5856 0.2343 0.37 0.9269 −2.284 0.02238 0.6515 0.12794 0.09434 0.15179 0 30 129 7 54 163
    rs4444612 Imputed G ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs4444612 Imputed G GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs4450660 Imputed C DOM 383 1.719 0.2141 1.13 2.615 2.53 0.01141 0.6453 0.21149 0.24843 0.18527 6 67 86 9 65 150
    rs4463950 Imputed C DOM 379 0.5555 0.2195 0.3613 0.8542 −2.678 0.00741 0.05998 0.43272 0.37342 0.47511 27 64 67 53 104 64
    rs4509702 Imputed C DOM 383 1.391 0.2096 0.9222 2.098 1.574 0.1155 0.5365 0.29112 0.31761 0.27232 16 69 74 19 84 121
    rs4533379 Imputed G ADD 380 1.429 0.1671 1.03 1.983 2.138 0.03253 0.461 0.29737 0.33544 0.27027 17 72 69 13 94 115
    rs4569984 Imputed A DOM 374 0.5254 0.2168 0.3436 0.8036 −2.969 0.00299 0.2184 0.25401 0.21474 0.28211 9 49 98 10 103 105
    rs4570530 Imputed C DOM 383 1.391 0.2096 0.9222 2.098 1.574 0.1155 0.5365 0.29112 0.31761 0.27232 16 69 74 19 84 121
    rs4571583 Imputed T DOM 383 0.5381 0.2149 0.3531 0.8199 −2.884 0.00392 0.2723 0.24804 0.21069 0.27455 9 49 101 10 103 111
    rs4586678 Imputed A DOM 383 1.719 0.2141 1.13 2.615 2.53 0.01141 0.6453 0.21149 0.24843 0.18527 6 67 86 9 65 150
    rs4615971 Imputed C DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs4629229 Imputed G DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs4632512 Imputed T GEN 383 4.104 0.1285 0.3319 0.19713 0.21698 0.18304 12 45 102 6 70 148
    rs4641552 Imputed A ADD 377 0.5381 0.2751 0.3138 0.9226 −2.253 0.02427 1 0.09682 0.06731 0.11765 1 19 136 2 48 171
    rs4682527 Imputed C DOM 364 1.785 0.2238 1.151 2.767 2.588 0.00965 0.08775 0.35852 0.40523 0.32464 19 86 48 20 97 94
    rs4688632 Imputed G REC 373 0.656 0.2381 0.4113 1.046 −1.77 0.07666 0.12 0.52145 0.49026 0.54338 37 77 40 72 94 53
    rs4702720 Imputed A ADD 320 0.6922 0.2059 0.4623 1.036 −1.787 0.07392 0.7262 0.2 0.16541 0.2246 3 38 92 11 62 114
    rs4702720 Imputed A DOM 320 0.7001 0.2406 0.4369 1.122 −1.481 0.1385 0.7262 0.2 0.16541 0.2246 3 38 92 11 62 114
    rs4714484 Imputed A ADD 383 0.5988 0.1942 0.4093 0.8761 −2.641 0.00827 0.1255 0.18538 0.13836 0.21875 6 32 121 12 74 138
    rs4714484 Imputed A DOM 383 0.5097 0.2319 0.3235 0.803 −2.906 0.00366 0.1255 0.18538 0.13836 0.21875 6 32 121 12 74 138
    rs4725142 Genotyped G REC 383 0.3868 0.3771 0.1847 0.81 −2.519 0.01178 0.9099 0.34204 0.3239 0.35491 10 83 66 34 91 99
    rs4725144 Imputed G REC 383 0.3868 0.3771 0.1847 0.81 −2.519 0.01178 0.9099 0.34204 0.3239 0.35491 10 83 66 34 91 99
    rs4760785 Imputed A ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4760785 Imputed A DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4760894 Imputed T ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4760894 Imputed T DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4760895 Imputed A ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4760895 Imputed A DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs4767184 Imputed C ADD 375 0.7432 0.1558 0.5476 1.009 −1.905 0.05677 1 0.392 0.35065 0.42081 21 66 67 36 114 71
    rs4767184 Imputed C GEN 375 4.92 0.08545 1 0.392 0.35065 0.42081 21 66 67 36 114 71
    rs4773487 Imputed T ADD 380 0.5534 0.2659 0.3287 0.932 −2.225 0.02609 0.7794 0.1 0.07006 0.12108 1 20 136 3 48 172
    rs4780547 Imputed G GEN 382 1.722 0.4228 1 0.22644 0.21519 0.23438 5 58 95 14 77 133
    rs4780547 Imputed G REC 382 0.5086 0.5339 0.1786 1.448 −1.266 0.2054 1 0.22644 0.21519 0.23438 5 58 95 14 77 133
    rs483159 Imputed T DOM 369 1.242 0.2188 0.8087 1.906 0.9893 0.3225 0.7497 0.20461 0.21711 0.19585 5 56 91 9 67 141
    rs4836502 Imputed T DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs4836507 Imputed C DOM 376 0.6042 0.212 0.3988 0.9154 −2.377 0.01745 0.5558 0.32048 0.28387 0.34615 17 54 84 24 105 92
    rs4851531 Imputed T DOM 380 0.5595 0.2166 0.366 0.8553 −2.682 0.00733 0.665 0.38553 0.35127 0.40991 24 63 71 30 122 70
    rs4879931 Imputed G ADD 382 0.7554 0.1662 0.5453 1.046 −1.688 0.09145 0.2407 0.32199 0.28931 0.34529 12 68 79 22 110 91
    rs489441 Imputed G ADD 357 1.491 0.172 1.064 2.089 2.322 0.02024 0.4487 0.29552 0.34354 0.2619 16 69 62 12 86 112
    rs489441 Imputed G DOM 357 1.551 0.2175 1.013 2.376 2.018 0.04362 0.4487 0.29552 0.34354 0.2619 16 69 62 12 86 112
    rs4976276 Imputed T ADD 382 1.499 0.1578 1.1 2.042 2.566 0.01029 0.6569 0.35995 0.41456 0.32143 24 83 51 23 98 103
    rs4977681 Imputed C REC 380 2.078 0.3396 1.068 4.042 2.153 0.03132 0.1768 0.34868 0.37898 0.32735 23 73 61 17 112 94
    rs4986197 Imputed G ADD 379 1.42 0.1672 1.023 1.97 2.097 0.03598 0.4609 0.29683 0.33439 0.27027 17 71 69 13 94 115
    rs4986220 Imputed T ADD 383 1.437 0.1677 1.034 1.996 2.162 0.03065 0.3893 0.29243 0.33019 0.26563 17 71 71 12 95 117
    rs525462 Imputed A GEN 382 9.552 0.00843 0.9148 0.6034 0.54088 0.64798 45 82 32 93 103 27
    rs552006 Imputed G GEN 380 6.857 0.03243 0.3034 0.27237 0.31447 0.24208 16 68 75 8 91 122
    rs5756669 Imputed C DOM 383 1.639 0.2271 1.05 2.558 2.175 0.02962 0.8346 0.42428 0.44654 0.40848 27 88 44 43 97 84
    rs581905 Imputed T DOM 383 1.341 0.2854 0.7666 2.347 1.029 0.3036 0.7263 0.08094 0.09119 0.07366 1 27 131 2 29 193
    rs6033138 Imputed C ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6033138 Imputed C GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040619 Imputed C ADD 374 1.432 0.1515 1.064 1.927 2.368 0.01789 0.1811 0.3623 0.41026 0.32798 27 74 55 28 87 103
    rs6040619 Imputed C GEN 374 6.205 0.04493 0.1811 0.3623 0.41026 0.32798 27 74 55 28 87 103
    rs6040625 Imputed T ADD 380 1.45 0.1506 1.079 1.947 2.466 0.01364 0.1459 0.35658 0.40705 0.32143 27 73 56 28 88 108
    rs6040625 Imputed T GEN 380 6.611 0.03669 0.1459 0.35658 0.40705 0.32143 27 73 56 28 88 108
    rs6040630 Imputed A ADD 383 1.444 0.1501 1.076 1.938 2.448 0.01435 0.1808 0.3564 0.40566 0.32143 27 75 57 28 88 108
    rs6040630 Imputed A GEN 383 6.635 0.03624 0.1808 0.3564 0.40566 0.32143 27 75 57 28 88 108
    rs6040633 Imputed A ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040633 Imputed A GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040634 Imputed T ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040634 Imputed T GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040636 Imputed T ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040636 Imputed T GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040638 Imputed C ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040638 Imputed C GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040644 Imputed A ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040644 Imputed A GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6040667 Imputed T ADD 381 1.419 0.1495 1.058 1.902 2.339 0.01935 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6040667 Imputed T GEN 381 6.102 0.04731 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6040668 Imputed C ADD 381 1.419 0.1495 1.058 1.902 2.339 0.01935 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6040668 Imputed C GEN 381 6.102 0.04731 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6053005 Imputed C DOM 283 0.3707 0.3223 0.1971 0.6972 −3.079 0.00207 0.3237 0.59717 0.52542 0.64848 37 50 31 68 78 19
    rs6054405 Imputed A REC 379 1.796 0.3119 0.9747 3.31 1.878 0.0604 0.4419 0.36939 0.38854 0.35586 26 70 61 22 114 86
    rs6054427 Genotyped G GEN 383 3.524 0.1717 0.1355 0.39687 0.43082 0.37277 28 81 50 25 117 82
    rs6075186 Imputed G DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs608278 Imputed A ADD 345 0.6427 0.1607 0.4691 0.8807 −2.751 0.00594 0.9142 0.48116 0.42414 0.5225 24 75 46 55 99 46
    rs6111540 Imputed A ADD 347 0.7778 0.1612 0.5671 1.067 −1.558 0.1191 0.5914 0.48271 0.44178 0.51244 30 69 47 48 110 43
    rs6131206 Imputed C ADD 380 1.462 0.1555 1.078 1.983 2.445 0.01449 0.1924 0.31447 0.36306 0.28027 22 70 65 21 83 119
    rs6131208 Imputed T ADD 381 1.419 0.1495 1.058 1.902 2.339 0.01935 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6131208 Imputed T GEN 381 6.102 0.04731 0.09512 0.35696 0.40446 0.32366 27 73 57 29 87 108
    rs6131919 Imputed G DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs6134243 Imputed C ADD 383 1.429 0.1494 1.066 1.915 2.388 0.01695 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6134243 Imputed C GEN 383 6.537 0.03806 0.1203 0.3577 0.40566 0.32366 27 75 57 29 87 108
    rs6136020 Imputed A DOM 383 0.6821 0.2397 0.4264 1.091 −1.596 0.1105 0.3197 0.15013 0.12579 0.16741 4 32 123 7 61 156
    rs613799 Imputed C DOM 373 1.426 0.2134 0.9386 2.167 1.663 0.0963 0.4587 0.29759 0.32566 0.27828 16 67 69 20 83 118
    rs644041 Imputed G ADD 349 1.523 0.1742 1.082 2.142 2.415 0.01575 0.5224 0.29799 0.35 0.26316 16 66 58 12 86 111
    rs644041 Imputed G DOM 349 1.58 0.2213 1.024 2.438 2.067 0.03874 0.5224 0.29799 0.35 0.26316 16 66 58 12 86 111
    rs6464377 Imputed C DOM 383 1.743 0.2989 0.9701 3.131 1.859 0.06309 1 0.0718 0.08805 0.06027 0 28 131 2 23 199
    rs6474230 Imputed T DOM 383 1.832 0.2138 1.205 2.786 2.832 0.00463 0.4624 0.22454 0.28302 0.18304 14 62 83 8 66 150
    rs6476565 Imputed A DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs6511286 Imputed T ADD 382 1.657 0.1628 1.204 2.28 3.103 0.00192 0.9052 0.31021 0.37107 0.26682 22 74 63 14 91 118
    rs6541829 Genotyped C REC 383 3.048 0.4236 1.329 6.991 2.631 0.00851 0.7014 0.27415 0.29874 0.2567 18 59 82 9 97 118
    rs6544721 Imputed G DOM 383 1.782 0.2114 1.178 2.697 2.733 0.00628 0.7817 0.24413 0.29245 0.20982 12 69 78 12 70 142
    rs6544728 Imputed T DOM 377 1.8 0.2171 1.177 2.755 2.709 0.00675 0.7509 0.20424 0.24522 0.175 6 65 86 8 61 151
    rs6565910 Imputed G DOM 383 0.6325 0.2139 0.4159 0.9619 −2.141 0.03224 0.3965 0.23629 0.19811 0.26339 5 53 101 13 92 119
    rs6581985 Imputed G GEN 383 5.059 0.07972 0.6393 0.32115 0.34277 0.3058 22 65 72 15 107 102
    rs6581985 Imputed G REC 383 2.122 0.3548 1.058 4.253 2.12 0.03402 0.6393 0.32115 0.34277 0.3058 22 65 72 15 107 102
    rs6685186 Imputed T ADD 383 1.364 0.1533 1.01 1.842 2.026 0.04275 0.9138 0.38251 0.42453 0.35268 27 81 51 28 102 94
    rs6685186 Imputed T GEN 383 4.244 0.1198 0.9138 0.38251 0.42453 0.35268 27 81 51 28 102 94
    rs670593 Imputed A REC 383 0.6178 0.2944 0.347 1.1 −1.636 0.1018 0.6696 0.39817 0.36478 0.42188 20 76 63 43 103 78
    rs6722640 Imputed T DOM 382 0.5778 0.2162 0.3783 0.8827 −2.537 0.01117 0.5916 0.38874 0.35849 0.41031 25 64 70 30 123 70
    rs6746170 Imputed A DOM 380 1.811 0.2168 1.184 2.77 2.739 0.00616 0.7506 0.20263 0.24367 0.17342 6 65 87 8 61 153
    rs6757316 Imputed A GEN 380 5.94 0.05131 0.535 0.44737 0.49367 0.41441 37 82 39 42 100 80
    rs6805139 Imputed G DOM 376 1.64 0.2386 1.028 2.618 2.074 0.03807 0.1787 0.47606 0.51613 0.44796 41 78 36 51 96 74
    rs6808571 Imputed G ADD 378 1.439 0.2034 0.9658 2.143 1.789 0.07364 1 0.15741 0.18671 0.13636 6 47 105 3 54 163
    rs6816479 Imputed A REC 383 2.214 0.2867 1.262 3.883 2.772 0.00557 0.8315 0.40078 0.45912 0.35938 35 76 48 25 111 88
    rs6865976 Imputed C DOM 305 0.5474 0.2612 0.3281 0.9134 −2.307 0.02106 0.646 0.47377 0.42692 0.50857 25 61 44 41 96 38
    rs687047 Imputed C ADD 383 0.7104 0.232 0.4509 1.119 −1.474 0.1405 0.8148 0.12272 0.10377 0.13616 2 29 128 4 53 167
    rs6871041 Imputed G DOM 367 0.6093 0.2145 0.4002 0.9278 −2.31 0.02092 0.7102 0.29837 0.26144 0.32477 14 52 87 20 99 95
    rs688358 Imputed A ADD 382 0.6857 0.2311 0.4359 1.079 −1.632 0.1026 0.4845 0.12304 0.10127 0.13839 2 28 128 5 52 167
    rs6908481 Imputed C REC 375 1.848 0.262 1.106 3.088 2.344 0.01908 0.7545 0.45333 0.46452 0.44545 40 64 51 35 126 59
    rs6917224 Imputed A ADD 382 1.351 0.1419 1.023 1.784 2.118 0.0342 0.02099 0.42408 0.47152 0.39063 43 63 52 37 101 86
    rs6917224 Imputed A GEN 382 6.409 0.04058 0.02099 0.42408 0.47152 0.39063 43 63 52 37 101 86
    rs6920677 Imputed G DOM 380 0.5128 0.2196 0.3335 0.7886 −3.041 0.00235 0.5212 0.39868 0.31847 0.45516 12 76 69 45 113 65
    rs6994498 Imputed G DOM 383 1.832 0.2138 1.205 2.786 2.832 0.00463 0.4624 0.22454 0.28302 0.18304 14 62 83 8 66 150
    rs6998772 Imputed T DOM 383 2.739 0.4524 1.128 6.647 2.227 0.02596 0.00643 0.03394 0.05031 0.02232 1 14 144 2 6 216
    rs7022281 Imputed C ADD 382 0.7264 0.1589 0.532 0.9919 −2.011 0.04432 0.1999 0.39791 0.35849 0.42601 18 78 63 36 118 69
    rs7022281 Imputed C GEN 382 4.073 0.1305 0.1999 0.39791 0.35849 0.42601 18 78 63 36 118 69
    rs7022281 Imputed C REC 382 0.6555 0.3107 0.3565 1.205 −1.359 0.174 0.1999 0.39791 0.35849 0.42601 18 78 63 36 118 69
    rs7043983 Imputed T DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs7077799 Imputed A DOM 382 1.355 0.2098 0.8985 2.045 1.45 0.1471 0.4624 0.2945 0.31761 0.27803 16 69 74 20 84 119
    rs7088947 Imputed A ADD 383 0.3545 0.3478 0.1793 0.7009 −2.982 0.00287 0.2394 0.06919 0.03774 0.09152 0 12 147 0 41 183
    rs7089661 Imputed C DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs7102072 Imputed A DOM 381 0.6088 0.2112 0.4024 0.9209 −2.35 0.01876 0.902 0.29265 0.25316 0.32063 12 56 90 21 101 101
    rs710832 Genotyped A REC 383 0.2657 0.5623 0.08825 0.7997 −2.357 0.0184 0.5936 0.25849 0.24214 0.27009 4 69 86 19 83 122
    rs712531 Imputed A DOM 371 1.787 0.2215 1.158 2.759 2.622 0.00874 0.0548 0.35445 0.40323 0.31944 19 87 49 19 100 97
    rs7129817 Imputed T ADD 383 0.6903 0.1578 0.5066 0.9405 −2.348 0.01886 0.6497 0.34204 0.2956 0.375 15 64 80 32 104 88
    rs7134262 Imputed T GEN 383 3.342 0.1881 0.3841 0.37728 0.40252 0.35938 27 74 58 23 115 86
    rs7134262 Imputed T REC 383 1.737 0.3064 0.9527 3.167 1.802 0.07156 0.3841 0.37728 0.40252 0.35938 27 74 58 23 115 86
    rs7138300 Imputed C ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs7138300 Imputed C DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs722927 Imputed G ADD 383 0.4322 0.319 0.2313 0.8077 −2.63 0.00855 0.7112 0.07572 0.04717 0.09598 0 15 144 1 41 182
    rs722927 Imputed G DOM 383 0.433 0.3231 0.2299 0.8157 −2.59 0.00958 0.7112 0.07572 0.04717 0.09598 0 15 144 1 41 182
    rs726424 Genotyped G ADD 383 0.7473 0.1542 0.5524 1.011 −1.889 0.05889 0.9144 0.38903 0.34906 0.41741 21 69 69 36 115 73
    rs726424 Genotyped G GEN 383 4.55 0.1028 0.9144 0.38903 0.34906 0.41741 21 69 69 36 115 73
    rs7295817 Imputed C ADD 381 0.7394 0.1533 0.5475 0.9985 −1.97 0.04885 0.9158 0.40551 0.36306 0.43527 22 70 65 40 115 69
    rs7295817 Imputed C GEN 381 4.446 0.1083 0.9158 0.40551 0.36306 0.43527 22 70 65 40 115 69
    rs7295817 Imputed C REC 381 0.747 0.2896 0.4235 1.318 −1.007 0.3139 0.9158 0.40551 0.36306 0.43527 22 70 65 40 115 69
    rs7297372 Imputed A ADD 338 0.7506 0.1757 0.532 1.059 −1.633 0.1025 0.00146 0.53846 0.50368 0.56188 29 79 28 54 119 29
    rs7297372 Imputed A GEN 338 2.895 0.2351 0.00146 0.53846 0.50368 0.56188 29 79 28 54 119 29
    rs7298255 Imputed A ADD 382 0.7489 0.1551 0.5526 1.015 −1.864 0.06235 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs7298255 Imputed A DOM 382 0.571 0.2227 0.3691 0.8835 −2.516 0.01186 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs7305832 Imputed C GEN 383 3.342 0.1881 0.3841 0.37728 0.40252 0.35938 27 74 58 23 115 86
    rs7305832 Imputed C REC 383 1.737 0.3064 0.9527 3.167 1.802 0.07156 0.3841 0.37728 0.40252 0.35938 27 74 58 23 115 86
    rs737542 Imputed A REC 381 3.431 0.4396 1.45 8.122 2.804 0.00504 0.6064 0.27297 0.30063 0.25336 18 59 81 8 97 118
    rs742827 Imputed A ADD 361 1.416 0.1525 1.05 1.91 2.282 0.02249 0.1122 0.36704 0.41391 0.33333 27 71 53 29 82 99
    rs742827 Imputed A GEN 361 5.995 0.0499 0.1122 0.36704 0.41391 0.33333 27 71 53 29 82 99
    rs7446891 Imputed G DOM 373 0.5964 0.2125 0.3932 0.9046 −2.432 0.01503 0.6302 0.31099 0.27419 0.33716 16 53 86 22 103 93
    rs7448641 Imputed C ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7448641 Imputed C DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7460605 Imputed G DOM 361 1.533 0.2243 0.988 2.38 1.906 0.05662 0.2254 0.39474 0.42105 0.3756 26 76 50 36 85 88
    rs7468898 Imputed T ADD 379 1.539 0.1544 1.137 2.083 2.791 0.00526 0.7518 0.42084 0.48089 0.37838 34 83 40 31 106 85
    rs7468898 Imputed T GEN 379 7.907 0.01919 0.7518 0.42084 0.48089 0.37838 34 83 40 31 106 85
    rs7501186 Imputed A DOM 383 1.277 0.2476 0.7859 2.074 0.9866 0.3238 0.8082 0.1201 0.13836 0.10714 4 36 119 2 44 178
    rs755117 Imputed A DOM 375 1.758 0.223 1.135 2.722 2.53 0.01142 0.8628 0.18267 0.22436 0.15297 7 56 93 6 55 158
    rs7557560 Imputed T GEN 383 10.8 0.00451 0.08079 0.20104 0.24528 0.16964 17 44 98 4 68 152
    rs7557560 Imputed T REC 383 6.446 0.567 2.122 19.58 3.286 0.00102 0.08079 0.20104 0.24528 0.16964 17 44 98 4 68 152
    rs7562462 Imputed T DOM 380 1.588 0.2435 0.9851 2.559 1.898 0.05765 0.2578 0.46974 0.50316 0.44595 35 89 34 43 112 67
    rs757173 Genotyped G DOM 383 0.683 0.2133 0.4496 1.038 −1.787 0.0739 0.8284 0.3812 0.34906 0.40402 22 67 70 35 111 78
    rs7607447 Imputed T REC 332 1.964 0.3733 0.9451 4.083 1.809 0.0705 0.8998 0.31928 0.34173 0.30311 19 57 63 14 89 90
    rs7639053 Imputed A ADD 383 1.6 0.1803 1.124 2.278 2.608 0.00912 0.3899 0.22977 0.27673 0.19643 11 66 82 6 76 142
    rs7648163 Imputed C REC 358 2.989 0.3458 1.518 5.886 3.166 0.00154 0.816 0.34916 0.39333 0.31731 27 64 59 15 102 91
    rs7651273 Imputed A GEN 383 3.158 0.2061 0.4152 0.19452 0.21384 0.1808 11 46 102 6 69 149
    rs7653190 Imputed C ADD 382 1.616 0.1806 1.134 2.302 2.658 0.00786 0.3892 0.23037 0.27848 0.19643 11 66 81 6 76 142
    rs7653685 Genotyped C DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.758 0.09269 0.12893 0.06696 0 41 118 2 26 196
    rs7684899 Imputed C DOM 383 0.6667 0.216 0.4366 1.018 −1.877 0.06051 0.7691 0.22324 0.20126 0.23884 10 44 105 10 87 127
    rs7701604 Imputed G ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7701604 Imputed G DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7703676 Imputed C ADD 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7703676 Imputed C DOM 383 0.235 0.778 0.05116 1.08 −1.861 0.0627 1 0.01697 0.00629 0.02455 0 2 157 0 11 213
    rs7711358 Imputed A DOM 383 0.6113 0.2097 0.4053 0.9221 −2.347 0.01893 0.4104 0.31723 0.28302 0.34152 18 54 87 24 105 95
    rs7713251 Imputed C REC 367 2.559 0.3384 1.319 4.968 2.777 0.00548 0.7295 0.34605 0.38816 0.31628 26 66 60 16 104 95
    rs7737608 Imputed G DOM 382 1.5 0.2234 0.9683 2.324 1.816 0.06938 0.6005 0.41754 0.4462 0.39732 29 83 46 40 98 86
    rs7755903 Imputed A GEN 382 9.733 0.0077 1 0.42539 0.36478 0.46861 17 82 60 52 105 66
    rs7762993 Imputed A ADD 378 1.373 0.1976 0.9323 2.023 1.605 0.1084 0.2987 0.18122 0.20701 0.1629 3 59 95 6 60 155
    rs7762993 Imputed A DOM 378 1.537 0.2206 0.9974 2.368 1.948 0.0514 0.2987 0.18122 0.20701 0.1629 3 59 95 6 60 155
    rs7767265 Imputed G DOM 382 1.53 0.2141 1.005 2.327 1.985 0.04716 0.453 0.21859 0.24843 0.19731 9 61 89 12 64 147
    rs7769415 Imputed C GEN 376 3.721 0.1556 0.9073 0.32846 0.34295 0.31818 22 63 71 19 102 99
    rs7771264 Imputed T DOM 383 0.5507 0.2147 0.3616 0.8388 −2.779 0.00546 0.3404 0.25065 0.21384 0.27679 9 50 100 11 102 111
    rs7795792 Imputed T REC 383 0.4161 0.2795 0.2406 0.7196 −3.137 0.00171 0.6078 0.46867 0.39937 0.51786 21 85 53 60 112 52
    rs7806481 Imputed G REC 383 0.628 0.2629 0.3751 1.051 −1.77 0.0768 0.47 0.4517 0.43082 0.46652 27 83 49 55 99 70
    rs7808536 Imputed G DOM 383 1.952 0.2193 1.27 3 3.05 0.00229 1 0.19191 0.23899 0.15848 7 62 90 7 57 160
    rs7814819 Imputed G ADD 225 1.743 0.3691 0.8454 3.593 1.505 0.1324 1 0.07333 0.09551 0.05882 0 17 72 1 14 121
    rs7814819 Imputed G DOM 225 1.939 0.386 0.9098 4.131 1.715 0.08632 1 0.07333 0.09551 0.05882 0 17 72 1 14 121
    rs7815952 Imputed T DOM 383 2.739 0.4524 1.128 6.647 2.227 0.02596 0.00643 0.03394 0.05031 0.02232 1 14 144 2 6 216
    rs7834090 Imputed T DOM 383 2.739 0.4524 1.128 6.647 2.227 0.02596 0.00643 0.03394 0.05031 0.02232 1 14 144 2 6 216
    rs7859250 Imputed C DOM 383 0.4711 0.3006 0.2614 0.8493 −2.503 0.0123 0.2271 0.09138 0.06289 0.11161 2 16 141 3 44 177
    rs7863577 Genotyped A ADD 383 0.5916 0.2865 0.3374 1.037 −1.832 0.06689 0.7318 0.08225 0.05975 0.09821 1 17 141 2 40 182
    rs7863577 Genotyped A DOM 383 0.5571 0.3041 0.307 1.011 −1.924 0.0544 0.7318 0.08225 0.05975 0.09821 1 17 141 2 40 182
    rs7902140 Imputed C ADD 378 0.622 0.2115 0.4109 0.9414 −2.245 0.02475 0.5866 0.16931 0.13226 0.19507 3 35 117 6 75 142
    rs7921834 Imputed C DOM 382 1.351 0.2099 0.8952 2.038 1.432 0.152 0.4588 0.29319 0.31646 0.27679 16 68 74 20 84 120
    rs7939893 Imputed C ADD 382 0.8314 0.1592 0.6085 1.136 −1.16 0.2462 0.4351 0.3534 0.33333 0.36771 20 66 73 24 116 83
    rs7939893 Imputed C DOM 382 0.6782 0.2127 0.447 1.029 −1.826 0.0679 0.4351 0.3534 0.33333 0.36771 20 66 73 24 116 83
    rs7955901 Imputed C ADD 383 0.7632 0.1542 0.5641 1.032 −1.753 0.07966 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs7955901 Imputed C DOM 383 0.5772 0.2224 0.3733 0.8926 −2.471 0.01349 0.6 0.41775 0.37736 0.44643 26 68 65 38 124 62
    rs7956274 Imputed T ADD 382 0.7489 0.1551 0.5526 1.015 −1.864 0.06235 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs7956274 Imputed T DOM 382 0.571 0.2227 0.3691 0.8835 −2.516 0.01186 0.5292 0.41623 0.37342 0.44643 25 68 65 38 124 62
    rs7957932 Imputed G ADD 380 0.7622 0.1541 0.5635 1.031 −1.762 0.07806 0.6008 0.42895 0.38854 0.4574 27 68 62 40 124 59
    rs7957932 Imputed G DOM 380 0.5724 0.2251 0.3682 0.8898 −2.479 0.01319 0.6008 0.42895 0.38854 0.4574 27 68 62 40 124 59
    rs7984294 Imputed A DOM 341 1.992 0.4122 0.888 4.468 1.672 0.09458 1 0.03959 0.05594 0.02778 0 16 127 0 11 187
    rs7994286 Imputed A ADD 377 0.5714 0.2665 0.3389 0.9633 −2.1 0.03571 0.7705 0.09814 0.07006 0.11818 1 20 136 3 46 171
    rs7994286 Imputed A DOM 377 0.5491 0.2859 0.3135 0.9616 −2.097 0.03601 0.7705 0.09814 0.07006 0.11818 1 20 136 3 46 171
    rs8038229 Genotyped A ADD 383 0.6055 0.165 0.4381 0.8367 −3.04 0.00237 0.3986 0.30418 0.24528 0.34598 11 56 92 28 99 97
    rs8038229 Genotyped A DOM 383 0.534 0.2122 0.3523 0.8093 −2.957 0.0031 0.3986 0.30418 0.24528 0.34598 11 56 92 28 99 97
    rs8043336 Imputed C GEN 370 8.202 0.01656 0.3028 0.34865 0.2987 0.38426 9 74 71 31 104 81
    rs8043336 Imputed C REC 370 0.3477 0.3977 0.1595 0.758 −2.657 0.00789 0.3028 0.34865 0.2987 0.38426 9 74 71 31 104 81
    rs8054431 Imputed T DOM 372 2.022 0.2234 1.305 3.133 3.153 0.00162 0.3127 0.3629 0.42308 0.31944 22 88 46 22 94 100
    rs8066502 Imputed T DOM 383 0.6823 0.229 0.4356 1.069 −1.669 0.09506 0.8575 0.17232 0.15094 0.1875 6 36 117 6 72 146
    rs8068714 Imputed T DOM 383 0.7037 0.2279 0.4502 1.1 −1.542 0.1231 0.8589 0.17363 0.15409 0.1875 6 37 116 6 72 146
    rs892575 Imputed T ADD 383 1.417 0.1666 1.022 1.964 2.092 0.03642 0.4618 0.29634 0.33333 0.27009 17 72 70 13 95 116
    rs892583 Imputed G ADD 383 1.437 0.1677 1.034 1.996 2.162 0.03065 0.3893 0.29243 0.33019 0.26563 17 71 71 12 95 117
    rs915494 Imputed A ADD 374 1.204 0.1605 0.8791 1.649 1.157 0.2474 0.3776 0.28877 0.31046 0.27376 16 63 74 19 83 119
    rs915494 Imputed A DOM 374 1.279 0.2121 0.8439 1.938 1.16 0.2462 0.3776 0.28877 0.31046 0.27376 16 63 74 19 83 119
    rs917295 Imputed G DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs922594 Imputed T DOM 375 0.5825 0.2147 0.3824 0.8872 −2.518 0.01181 0.4237 0.34133 0.3 0.37045 15 63 77 25 113 82
    rs9301653 Imputed T ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs9301653 Imputed T DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs9309988 Imputed G DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.758 0.09269 0.12893 0.06696 0 41 118 2 26 196
    rs9309989 Genotyped C DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.758 0.09269 0.12893 0.06696 0 41 118 2 26 196
    rs9310221 Imputed A DOM 352 1.531 0.2314 0.9727 2.41 1.84 0.06574 0.7387 0.39915 0.40972 0.39183 17 84 43 37 89 82
    rs9327555 Imputed T DOM 383 0.6021 0.2099 0.3991 0.9085 −2.417 0.01564 0.7244 0.31984 0.28302 0.34598 17 56 86 24 107 93
    rs937890 Imputed G DOM 383 0.7037 0.2279 0.4502 1.1 −1.542 0.1231 0.8589 0.17363 0.15409 0.1875 6 37 116 6 72 146
    rs9454967 Imputed G ADD 382 2.387 0.3056 1.311 4.345 2.847 0.00442 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs9454967 Imputed G DOM 382 2.904 0.3322 1.514 5.569 3.209 0.00133 0.1765 0.06283 0.09494 0.04018 1 28 129 2 14 208
    rs9471295 Imputed T DOM 383 1.488 0.2326 0.9435 2.348 1.71 0.08731 0.5442 0.14883 0.16667 0.13616 2 49 108 8 45 171
    rs9477007 Imputed A ADD 380 1.357 0.1432 1.025 1.797 2.132 0.03298 0.04681 0.42763 0.47484 0.39367 42 67 50 37 100 84
    rs9477007 Imputed A GEN 380 5.531 0.06295 0.04681 0.42763 0.47484 0.39367 42 67 50 37 100 84
    rs9487279 Imputed T DOM 366 0.5667 0.2254 0.3643 0.8814 −2.52 0.01173 0.1024 0.40164 0.33882 0.44626 13 77 62 38 115 61
    rs949016 Imputed C ADD 383 1.437 0.1677 1.034 1.996 2.162 0.03065 0.3893 0.29243 0.33019 0.26563 17 71 71 12 95 117
    rs9555973 Imputed G ADD 379 0.5702 0.2704 0.3356 0.9686 −2.078 0.03773 0.7618 0.09499 0.06731 0.11435 1 19 136 3 45 175
    rs9555973 Imputed G DOM 379 0.5463 0.2905 0.3091 0.9655 −2.081 0.03744 0.7618 0.09499 0.06731 0.11435 1 19 136 3 45 175
    rs9557510 Imputed G ADD 383 1.582 0.1986 1.072 2.334 2.308 0.02098 0.2295 0.15144 0.18868 0.125 6 48 105 6 44 174
    rs9557510 Imputed G DOM 383 1.775 0.2327 1.125 2.801 2.466 0.01365 0.2295 0.15144 0.18868 0.125 6 48 105 6 44 174
    rs9560584 Imputed T DOM 382 0.5572 0.2856 0.3184 0.9752 −2.048 0.04058 0.7684 0.09686 0.06962 0.11607 1 20 137 3 46 175
    rs9588770 Imputed T DOM 381 0.497 0.2943 0.2792 0.8849 −2.376 0.01752 0.7612 0.09449 0.06329 0.11659 1 18 139 3 46 174
    rs9588848 Imputed C ADD 383 0.5758 0.2661 0.3418 0.97 −2.074 0.03805 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs9588848 Imputed C DOM 383 0.554 0.2856 0.3166 0.9696 −2.068 0.03864 0.7681 0.09661 0.06918 0.11607 1 20 138 3 46 175
    rs966583 Imputed A ADD 382 0.7239 0.1599 0.5291 0.9903 −2.021 0.04332 0.1993 0.39398 0.34906 0.42601 19 73 67 34 122 67
    rs966583 Imputed A DOM 382 0.6175 0.2202 0.4011 0.9507 −2.189 0.02856 0.1993 0.39398 0.34906 0.42601 19 73 67 34 122 67
    rs974130 Genotyped A REC 383 2.214 0.2867 1.262 3.883 2.772 0.00557 0.8315 0.40078 0.45912 0.35938 35 76 48 25 111 88
    rs977160 Imputed T ADD 382 1.378 0.1666 0.9945 1.911 1.927 0.05403 0.7069 0.28403 0.31761 0.26009 17 67 75 12 92 119
    rs9812206 Imputed G ADD 383 0.3883 0.2849 0.2221 0.6787 −3.321 0.0009 0.7825 0.10183 0.05975 0.1317 0 19 140 3 53 168
    rs9812206 Imputed G DOM 383 0.3876 0.2917 0.2188 0.6867 −3.248 0.00116 0.7825 0.10183 0.05975 0.1317 0 19 140 3 53 168
    rs9813552 Imputed G ADD 379 0.3826 0.2913 0.2162 0.6772 −3.298 0.00097 1 0.09894 0.05732 0.12838 0 18 139 3 51 168
    rs9813552 Imputed G DOM 379 0.3816 0.2983 0.2127 0.6847 −3.23 0.00124 1 0.09894 0.05732 0.12838 0 18 139 3 51 168
    rs9815037 Imputed T ADD 382 0.3819 0.2906 0.2161 0.675 −3.313 0.00092 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9815037 Imputed T DOM 382 0.3809 0.2976 0.2125 0.6825 −3.243 0.00118 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9825349 Imputed A ADD 382 0.3819 0.2906 0.2161 0.675 −3.313 0.00092 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9825349 Imputed A DOM 382 0.3809 0.2976 0.2125 0.6825 −3.243 0.00118 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9834217 Imputed T ADD 382 0.3819 0.2906 0.2161 0.675 −3.313 0.00092 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9834217 Imputed T DOM 382 0.3809 0.2976 0.2125 0.6825 −3.243 0.00118 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9840460 Imputed T ADD 382 0.3819 0.2906 0.2161 0.675 −3.313 0.00092 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9840460 Imputed T DOM 382 0.3809 0.2976 0.2125 0.6825 −3.243 0.00118 1 0.09817 0.0566 0.1278 0 18 141 3 51 169
    rs9840756 Imputed A ADD 380 0.3808 0.291 0.2153 0.6737 −3.317 0.00091 1 0.09868 0.05696 0.12838 0 18 140 3 51 168
    rs9840756 Imputed A DOM 380 0.3798 0.298 0.2118 0.681 −3.249 0.00116 1 0.09868 0.05696 0.12838 0 18 140 3 51 168
    rs9844801 Imputed C DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs985375 Imputed A GEN 374 5.977 0.05036 0.5979 0.26471 0.30844 0.23409 15 65 74 9 85 126
    rs9869187 Imputed C ADD 383 0.4258 0.2859 0.2431 0.7458 −2.986 0.00283 1 0.09661 0.05975 0.12277 0 19 140 3 49 172
    rs9869187 Imputed C DOM 383 0.4271 0.294 0.24 0.7599 −2.894 0.0038 1 0.09661 0.05975 0.12277 0 19 140 3 49 172
    rs9872327 Imputed T DOM 383 2.42 0.2725 1.419 4.128 3.244 0.00118 0.3464 0.09138 0.12893 0.06473 0 41 118 1 27 196
    rs9881685 Imputed A ADD 379 0.377 0.2935 0.2121 0.6701 −3.324 0.00089 0.5599 0.09894 0.05769 0.1278 0 18 138 2 53 168
    rs9881685 Imputed A DOM 379 0.3761 0.298 0.2098 0.6745 −3.282 0.00103 0.5599 0.09894 0.05769 0.1278 0 18 138 2 53 168
    rs9909499 Imputed C DOM 362 1.559 0.2159 1.021 2.381 2.058 0.03962 0.08453 0.2721 0.29801 0.25355 7 76 68 13 81 117
    rs9911847 Imputed G DOM 382 0.6877 0.2291 0.4389 1.078 −1.634 0.1023 0.8576 0.17277 0.1519 0.1875 6 36 116 6 72 146
    rs9946886 Imputed G REC 156 0.3262 0.5121 0.1196 0.8902 −2.187 0.02873 0.3882 0.36218 0.29452 0.42169 6 31 36 17 36 30
    rs9958823 Imputed A ADD 377 1.444 0.1687 1.038 2.01 2.179 0.02933 0.3868 0.29576 0.33439 0.26818 17 71 69 12 94 114
    rs9965248 Imputed T ADD 379 1.399 0.167 1.009 1.941 2.011 0.04433 0.537 0.29551 0.33121 0.27027 17 70 70 13 94 115
  • TABLE 11
    ATOR- PRA- ATOR- ATOR- PRA- PRA-
    VA_ VA_ VA_ ATOR- VA_ VA_ PRA- VA_
    ALL- HW_ ALL- ALL- ALL- A1_ VA_ A2_ A1_ VA_ A2_
    ELE MOD- N- PVA ELE_ ELE_ ELE_ HZ_ HET_ HZ HZ_ HET_ HZ_
    SNP rs # SOURCE (A1) EL MISS OR SE L95 U95 STAT P LUE FREQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs198460 Genotyped G REC 443 1.956 0.2218 1.267 3.021 3.026 0.00248 1 0.51129 0.56021 0.47421 64 86 41 52 135 65
    rs603940 Genotyped G REC 443 0.3862 0.3119 0.2095 0.7117 −3.05 0.00229 0.9214 0.39955 0.37958 0.41468 19 107 65 51 107 94
    rs10021016 Genotyped G GEN 443 6.477 0.03922 0.7144 0.26298 0.29843 0.23611 20 74 97 12 95 145
    rs1003148 Imputed C ADD 427 0.7405 0.1452 0.5572 0.9843 −2.069 0.03853 0.9214 0.42974 0.38798 0.46107 23 96 64 55 115 74
    rs1003148 Imputed C GEN 427 6.652 0.03594 0.9214 0.42974 0.38798 0.46107 23 96 64 55 115 74
    rs1003148 Imputed C REC 427 0.4879 0.2786 0.2826 0.8423 −2.576 0.01 0.9214 0.42974 0.38798 0.46107 23 96 64 55 115 74
    rs10046799 Imputed C ADD 440 0.7946 0.1374 0.607 1.04 −1.672 0.09444 0.4976 0.5625 0.5291 0.58765 61 78 50 82 131 38
    rs10046799 Imputed C GEN 440 9.736 0.00769 0.4976 0.5625 0.5291 0.58765 61 78 50 82 131 38
    rs10051148 Imputed C DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187 0.8242 0.30813 0.2801 0.32937 20 67 104 23 120 109
    rs10054055 Imputed T DOM 440 0.5872 0.2006 0.3963 0.8702 −2.653 0.00797 0.3313 0.32841 0.29365 0.35458 23 65 101 29 120 102
    rs10067895 Imputed A DOM 440 0.577 0.2025 0.388 0.8581 −2.716 0.00661 0.07522 0.34886 0.31316 0.376 27 65 98 35 118 97
    rs1008705 Imputed C DOM 353 2.01 0.2249 1.294 3.124 3.106 0.0019 0.6981 0.28895 0.32667 0.26108 11 76 63 20 66 117
    rs10105871 Imputed C DOM 382 1.492 0.219 0.9712 2.291 1.827 0.06776 0.1311 0.38351 0.41212 0.36175 22 92 51 27 103 87
    rs10116807 Imputed A GEN 436 7.758 0.02068 0.8866 0.21216 0.25263 0.18089 13 70 107 7 75 164
    rs10116807 Imputed A REC 436 2.869 0.4949 1.087 7.568 2.129 0.03322 0.8866 0.21216 0.25263 0.18089 13 70 107 7 75 164
    rs10121941 Imputed C DOM 443 1.177 0.2597 0.7077 1.959 6.29E−01 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs10128638 Genotyped G DOM 443 0.6667 0.2297 0.425 1.046 −1.765 0.07748 1 0.52483 0.49738 0.54563 50 90 51 72 131 49
    rs1012924 Imputed G ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs1012924 Imputed G DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs1016030 Genotyped G ADD 442 1.159 0.1474 0.8678 1.547 0.9985 0.318 1 0.36425 0.3822 0.3506 27 92 72 31 114 106
    rs1016030 Genotyped G GEN 442 1.088 0.5805 1 0.36425 0.3822 0.3506 27 92 72 31 114 106
    rs1017558 Imputed A REC 430 0.7905 0.293 0.4452 1.404 −0.8024 0.4223 0.3984 0.35349 0.32787 0.37247 22 76 85 36 112 99
    rs10183431 Imputed T DOM 438 1.231 0.1969 0.8366 1.81 1.054 0.292 0.4508 0.25342 0.26064 0.248 11 76 101 20 84 146
    rs10195401 Imputed C DOM 440 1.047 0.206 0.6991 1.568 0.2228 0.8237 0.112 0.4 0.40263 0.398 27 99 64 35 129 86
    rs10239416 Imputed A DOM 431 1.361 0.2052 0.9105 2.035 1.503 0.1328 0.8386 0.38399 0.41444 0.36066 31 93 63 31 114 99
    rs1032188 Imputed G GEN 443 6.472 0.03932 0.5638 0.29007 0.27225 0.30357 10 84 97 30 93 129
    rs1032188 Imputed G REC 443 0.3936 0.3872 0.1843 0.8406 −2.408 0.01603 0.5638 0.29007 0.27225 0.30357 10 84 97 30 93 129
    rs10468988 Imputed G ADD 438 1.083 0.1637 0.7858 1.493 0.4879 0.6256 0.7885 0.23174 0.23947 0.22581 9 73 108 13 86 149
    rs10478919 Imputed G DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs10506623 Imputed C DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051 0.6908 0.3948 0.36316 0.41865 26 86 78 45 121 86
    rs10506626 Imputed A DOM 443 0.6807 0.2015 0.4586 1.01 −1.909 0.05621 0.5504 0.39391 0.35602 0.42262 26 84 81 46 121 85
    rs10509477 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131 0.1655 0.33409 0.36911 0.30754 29 83 79 27 101 124
    rs10511071 Imputed C DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs10511072 Imputed G DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs10511199 Imputed C ADD 442 1.021 0.1625 0.7424 1.404 0.1273 0.8987 0.8924 0.22624 0.22895 0.22421 10 67 113 13 87 152
    rs10513283 Imputed G GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs10520072 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs1065639 Imputed C DOM 209 2.955 1.237 0.2613 33.41 0.8755 0.3813 1 0.00718 0.01111 0.0042 0 2 88 0 1 118
    rs10733846 Imputed G ADD 435 0.8325 0.1945 0.5686 1.219 −0.9428 0.3458 0.4814 0.16207 0.14706 0.17339 5 45 137 4 78 166
    rs10733846 Imputed G DOM 435 0.7557 0.2153 0.4955 1.152 −1.301 0.1933 0.4814 0.16207 0.14706 0.17339 5 45 137 4 78 166
    rs10737390 Imputed T DOM 418 1.128 0.213 0.7431 1.712 0.5659 0.5715 0.3626 0.40909 0.41899 0.40167 30 90 59 35 122 82
    rs10749293 Imputed G DOM 441 1.442 0.1947 0.9847 2.113 1.881 0.05998 0.1901 0.322 0.35789 0.29482 26 84 80 26 96 129
    rs10752159 Imputed G DOM 442 1.434 0.2005 0.968 2.124 1.798 0.07223 0.5658 0.20814 0.22513 0.19522 7 72 112 14 70 167
    rs10753760 Imputed T ADD 423 0.9252 0.1361 0.7085 1.208 −0.5713 0.5678 0.01675 0.41844 0.41081 0.42437 36 80 69 50 102 86
    rs10753760 Imputed T GEN 423 0.3766 0.8284 0.01675 0.41844 0.41081 0.42437 36 80 69 50 102 86
    rs10757887 Imputed C DOM 443 1.073 0.1955 0.7315 1.574 0.3608 0.7182 0.05609 0.2754 0.28272 0.26984 19 70 102 23 90 139
    rs10758326 Imputed A ADD 440 0.6884 0.1481 0.515 0.9203 −2.521 0.01172 0.5467 0.38523 0.34211 0.418 16 98 76 46 117 87
    rs10758326 Imputed A GEN 440 9.42 0.009 0.5467 0.38523 0.34211 0.418 16 98 76 46 117 87
    rs10758326 Imputed A REC 440 0.3854 0.3129 0.2087 0.7116 −3.047 0.00231 0.5467 0.38523 0.34211 0.418 16 98 76 46 117 87
    rs10762236 Genotyped G ADD 443 0.93 0.1858 0.6461 1.339 −0.3906 0.6961 0.5219 0.18172 0.17539 0.18651 7 53 131 5 84 163
    rs10765769 Imputed C ADD 441 1.226 0.1457 0.9215 1.631 1.399 0.1618 0.8413 0.38776 0.4127 0.36905 31 94 64 34 118 100
    rs10765769 Imputed C GEN 441 2.026 0.3632 0.8413 0.38776 0.4127 0.36905 31 94 64 34 118 100
    rs10784891 Imputed C ADD 422 0.7472 0.1404 0.5675 0.9839 −2.076 0.03794 0.4305 0.4455 0.40489 0.47689 30 89 65 58 111 69
    rs10784891 Imputed C DOM 422 0.7374 0.2125 0.4862 1.118 −1.433 0.1518 0.4305 0.4455 0.40489 0.47689 30 89 65 58 111 69
    rs10787923 Imputed G DOM 439 1.448 0.1952 0.9878 2.123 1.897 0.05785 0.1572 0.32232 0.35904 0.29482 26 83 79 26 96 129
    rs10787949 Imputed A DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272 0.1377 0.33937 0.37173 0.31474 29 84 78 29 100 122
    rs10787951 Imputed G DOM 441 1.349 0.1976 0.9157 1.987 1.514 0.1299 0.1364 0.339 0.37105 0.31474 29 83 78 29 100 122
    rs10787983 Imputed C DOM 441 1.351 0.1964 0.9194 1.986 1.532 0.1255 0.1642 0.33447 0.36911 0.308 29 83 79 27 100 123
    rs10788380 Imputed C ADD 438 1.318 0.1398 1.002 1.733 1.973 0.04851 0.9239 0.49658 0.53723 0.466 51 100 37 56 121 73
    rs10788380 Imputed C DOM 438 1.663 0.2322 1.055 2.621 2.191 0.02847 0.9239 0.49658 0.53723 0.466 51 100 37 56 121 73
    rs10788380 Imputed C GEN 438 4.897 0.08641 0.9239 0.49658 0.53723 0.466 51 100 37 56 121 73
    rs10814418 Imputed G DOM 442 1.184 0.2598 0.7118 1.97 0.6512 0.5149 0.7613 0.0871 0.09474 0.08135 2 32 156 2 37 213
    rs10831417 Imputed A ADD 443 1.151 0.1492 0.8595 1.543 0.9453 0.3445 0.6065 0.35779 0.37435 0.34524 25 93 73 29 116 107
    rs10831417 Imputed A GEN 443 0.969 0.616 0.6065 0.35779 0.37435 0.34524 25 93 73 29 116 107
    rs10831422 Imputed C ADD 441 1.164 0.1481 0.871 1.557 1.028 0.304 0.918 0.36281 0.38095 0.34921 27 90 72 30 116 106
    rs10831422 Imputed C GEN 441 1.057 0.5895 0.918 0.36281 0.38095 0.34921 27 90 72 30 116 106
    rs10862931 Imputed C GEN 439 6.025 0.04917 0.8337 0.34966 0.38158 0.3253 32 81 77 23 116 110
    rs10865197 Imputed C DOM 438 1.231 0.1969 0.8366 1.81 1.054 0.292 0.4508 0.25342 0.26064 0.248 11 76 101 20 84 146
    rs10871302 Imputed A DOM 443 2.011 0.2218 1.302 3.107 3.15 0.00163 0.4471 0.14447 0.17801 0.11905 3 62 126 8 44 200
    rs10877463 Imputed C DOM 443 0.5826 0.1985 0.3948 0.8597 −2.722 0.0065 0.6802 0.36005 0.31675 0.39286 21 79 91 34 130 88
    rs10877468 Imputed C DOM 442 0.5848 0.1985 0.3963 0.8629 −2.703 0.00688 0.6808 0.35973 0.31675 0.39243 21 79 91 34 129 88
    rs10879240 Imputed C ADD 428 0.7296 0.1403 0.5542 0.9605 −2.247 0.02462 0.434 0.44743 0.40426 0.48125 30 92 66 60 111 69
    rs10879242 Imputed A DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001 0.9197 0.40855 0.37297 0.43644 26 86 73 45 116 75
    rs10879245 Imputed G DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001 0.9197 0.40855 0.37297 0.43644 26 86 73 45 116 75
    rs10879249 Imputed T DOM 440 0.7247 0.2038 0.486 1.081 −1.58 0.1141 0.7662 0.39773 0.36579 0.422 26 87 77 45 121 84
    rs10886452 Imputed A DOM 440 1.376 0.1972 0.9349 2.025 1.619 0.1055 0.1648 0.33523 0.37368 0.306 30 82 78 26 101 123
    rs10886463 Imputed C DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272 0.1118 0.3405 0.37435 0.31474 30 83 78 29 100 122
    rs10886465 Imputed A DOM 441 1.355 0.1976 0.9197 1.995 1.536 0.1245 0.1364 0.339 0.37435 0.312 30 83 78 28 100 122
    rs10886526 Imputed C DOM 439 1.364 0.197 0.9275 2.007 1.578 0.1146 0.2383 0.33257 0.36772 0.306 28 83 78 26 101 123
    rs10902437 Imputed G ADD 393 1.494 0.1583 1.095 2.037 2.534 0.01127 0.6725 0.39186 0.43558 0.36087 34 74 55 24 118 88
    rs10941126 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs10941126 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs10947871 Imputed A DOM 391 2.143 0.2487 1.316 3.49 3.065 0.00218 1 0.11893 0.15805 0.08756 3 49 122 2 34 181
    rs10972978 Imputed G DOM 437 1.24 0.2619 0.7423 2.072 0.8222 0.4109 0.5546 0.08696 0.09626 0.08 2 32 153 2 36 212
    rs10973012 Imputed A DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs10974028 Genotyped G ADD 443 1.203 0.1904 0.8287 1.748 0.9728 0.3306 0.726 0.16027 0.17277 0.15079 5 56 130 5 66 181
    rs10974028 Genotyped G DOM 443 1.224 0.2126 0.807 1.857 0.9516 0.3413 0.726 0.16027 0.17277 0.15079 5 56 130 5 66 181
    rs11021302 Imputed A ADD 441 1.164 0.1481 0.871 1.557 1.028 0.304 0.918 0.36281 0.38095 0.34921 27 90 72 30 116 106
    rs11021302 Imputed A GEN 441 1.057 0.5895 0.918 0.36281 0.38095 0.34921 27 90 72 30 116 106
    rs11099644 Imputed G REC 430 0.7905 0.293 0.4452 1.404 −0.8024 0.4223 0.3984 0.35349 0.32787 0.37247 22 76 85 36 112 99
    rs11138315 Imputed G ADD 443 0.5453 0.2248 0.351 0.8473 −2.697 0.00699 0.2265 0.13544 0.10209 0.16071 2 35 154 9 63 180
    rs11149802 Imputed T DOM 443 2.011 0.2218 1.302 3.107 3.15 0.00163 0.4471 0.14447 0.17801 0.11905 3 62 126 8 44 200
    rs1116596 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs11178531 Imputed A ADD 439 0.7197 0.1371 0.5501 0.9416 −2.399 0.01643 0.3881 0.46811 0.42105 0.50402 34 92 64 67 117 65
    rs11178531 Imputed A DOM 439 0.6936 0.2116 0.4581 1.05 −1.729 0.08386 0.3881 0.46811 0.42105 0.50402 34 92 64 67 117 65
    rs11178575 Imputed C GEN 441 8.684 0.01301 0.3129 0.30385 0.3534 0.266 22 91 78 14 105 131
    rs11178575 Imputed C REC 441 2.252 0.3587 1.115 4.549 2.263 0.02362 0.3129 0.30385 0.3534 0.266 22 91 78 14 105 131
    rs11178577 Imputed T GEN 439 8.67 0.0131 0.2621 0.30752 0.35789 0.26908 22 92 76 14 106 129
    rs11178577 Imputed T REC 439 2.243 0.3588 1.11 4.532 2.252 0.02435 0.2621 0.30752 0.35789 0.26908 22 92 76 14 106 129
    rs11178583 Imputed A DOM 443 0.7338 0.2032 0.4927 1.093 −1.523 0.1277 0.6922 0.39503 0.36387 0.41865 26 87 78 45 121 86
    rs11178589 Imputed T DOM 437 0.7215 0.2047 0.4831 1.078 −1.595 0.1108 0.8419 0.39931 0.36579 0.4251 26 87 77 45 120 82
    rs11178594 Imputed C DOM 441 0.7044 0.202 0.4741 1.046 −1.735 0.08274 1 0.40249 0.36842 0.42829 26 88 76 45 125 81
    rs11178602 Imputed T DOM 439 0.7005 0.2027 0.4709 1.042 −1.757 0.079 1 0.40205 0.36772 0.428 26 87 76 45 124 81
    rs11178648 Imputed T DOM 440 0.6786 0.2027 0.4561 1.01 −1.912 0.05581 0.4852 0.39432 0.35714 0.42231 26 83 80 46 120 85
    rs11198877 Imputed T DOM 441 1.369 0.1971 0.9302 2.014 1.593 0.1113 0.1996 0.3356 0.37368 0.30677 30 82 78 26 102 123
    rs11198942 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131 0.1655 0.33409 0.36911 0.30754 29 83 79 27 101 124
    rs11221075 Imputed A ADD 417 0.4912 0.2448 0.304 0.7936 −2.904 0.00369 1 0.11391 0.07542 0.14286 0 27 152 5 58 175
    rs11242020 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs11242021 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs11242022 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs11242023 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs1149350 Imputed A DOM 443 0.8901 0.2092 0.5906 1.341 −0.5566 0.5778 0.01047 0.21445 0.18848 0.23413 6 60 125 24 70 158
    rs1150143 Imputed G DOM 435 1.007 0.2015 0.6785 1.495 0.03498 0.9721 0.1573 0.38851 0.38978 0.38755 31 83 72 42 109 98
    rs11576627 Imputed T ADD 441 1.439 0.1975 0.977 2.119 1.842 0.06547 0.01289 0.12358 0.15 0.10359 7 43 140 6 40 205
    rs11576627 Imputed T DOM 441 1.57 0.2354 0.9899 2.491 1.917 0.05525 0.01289 0.12358 0.15 0.10359 7 43 140 6 40 205
    rs11602189 Imputed A DOM 440 0.8739 0.1947 0.5967 1.28 −0.6923 0.4888 0.3294 0.32727 0.31579 0.336 17 86 87 25 118 107
    rs11605163 Imputed A DOM 440 1.075 0.249 0.6597 1.751 0.2893 0.7723 0.4443 0.10341 0.11111 0.09761 4 34 151 2 45 204
    rs11615214 Imputed G ADD 437 0.7544 0.1432 0.5697 0.9989 −1.968 0.04908 0.9205 0.39359 0.35526 0.42308 18 99 73 49 111 87
    rs11615214 Imputed G GEN 437 8.718 0.01279 0.9205 0.39359 0.35526 0.42308 18 99 73 49 111 87
    rs11642394 Imputed C DOM 443 2.011 0.2218 1.302 3.107 3.15 0.00163 0.4471 0.14447 0.17801 0.11905 3 62 126 8 44 200
    rs11644943 Imputed A ADD 421 1.464 0.1665 1.056 2.029 2.29 0.02202 0.7836 0.22922 0.26776 0.19958 13 72 98 10 75 153
    rs11656608 Imputed T DOM 442 0.5127 0.2187 0.334 0.7871 −3.055 0.00225 0.8632 0.16403 0.11842 0.19841 2 41 147 9 82 161
    rs11661309 Imputed A ADD 439 0.8005 0.1812 0.5612 1.142 −1.228 0.2194 0.872 0.18109 0.16138 0.196 3 55 131 12 74 164
    rs11661309 Imputed A DOM 439 0.8571 0.2089 0.5691 1.291 −0.7383 0.4603 0.872 0.18109 0.16138 0.196 3 55 131 12 74 164
    rs11666131 Imputed A ADD 441 1.074 0.1682 0.772 1.493 0.4219 0.6731 0.2245 0.22676 0.23158 0.22311 6 76 108 12 88 151
    rs11743355 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11743355 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11746806 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11746806 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11746959 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11746959 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs11749272 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs11901899 Imputed A DOM 426 1.452 0.1995 0.9821 2.147 1.869 0.06157 0.3322 0.27582 0.30707 0.25207 14 85 85 14 94 134
    rs11926319 Imputed G ADD 443 0.9777 0.2632 0.5837 1.638 −0.08556 0.9318 0.4982 0.07675 0.07592 0.07738 0 29 162 1 37 214
    rs11926319 Imputed G DOM 443 1.007 0.269 0.5945 1.706 0.02639 0.9789 0.4982 0.07675 0.07592 0.07738 0 29 162 1 37 214
    rs11956952 Imputed C DOM 418 0.6491 0.2055 0.4339 0.971 −2.103 0.03544 1 0.24282 0.21858 0.2617 12 56 115 12 99 124
    rs12025826 Imputed G DOM 434 1.459 0.2095 0.9676 2.199 1.803 0.07141 1 0.41705 0.4328 0.40524 29 103 54 46 109 93
    rs1204522 Imputed C GEN 422 0.09565 0.9533 0.9146 0.34834 0.35326 0.34454 24 82 78 28 108 102
    rs1204524 Imputed A GEN 422 0.09565 0.9533 0.9146 0.34834 0.35326 0.34454 24 82 78 28 108 102
    rs12153185 Imputed T DOM 441 0.5728 0.2023 0.3853 0.8516 −2.754 0.00589 0.07489 0.35034 0.31316 0.37849 27 65 98 36 118 97
    rs12182651 Imputed T ADD 441 0.982 0.2314 0.624 1.545 −0.07863 0.9373 0.07328 0.0907 0.08947 0.09163 3 28 159 4 38 209
    rs12182651 Imputed T DOM 441 0.9744 0.2621 0.583 1.629 −0.09893 0.9212 0.07328 0.0907 0.08947 0.09163 3 28 159 4 38 209
    rs12193568 Imputed G DOM 361 1.618 0.2464 0.9984 2.623 1.953 0.05077 0.1009 0.14958 0.17296 0.13119 5 45 109 7 39 156
    rs12264914 Imputed C DOM 311 0.4742 0.2385 0.2971 0.7568 −3.128 0.00176 1 0.25723 0.20652 0.29769 8 41 89 12 79 82
    rs12307767 Imputed C DOM 419 0.6033 0.203 0.4053 0.8981 −2.489 0.0128 0.8317 0.3568 0.31564 0.3875 20 73 86 32 122 86
    rs1232298 Imputed G REC 408 1.995 0.3003 1.107 3.593 2.299 0.0215 0.08143 0.34681 0.38483 0.31739 33 71 74 24 98 108
    rs12407412 Imputed C ADD 441 1.439 0.1975 0.977 2.119 1.842 0.06547 0.01289 0.12358 0.15 0.10359 7 43 140 6 40 205
    rs12407412 Imputed C DOM 441 1.57 0.2354 0.9899 2.491 1.917 0.05525 0.01289 0.12358 0.15 0.10359 7 43 140 6 40 205
    rs12420184 Imputed G DOM 438 1.429 0.2168 0.9343 2.185 1.647 0.09966 1 0.14954 0.16931 0.13454 4 56 129 5 57 187
    rs12422750 Imputed A DOM 442 0.5888 0.1966 0.4005 0.8656 −2.694 0.00706 0.2411 0.33597 0.29474 0.36706 17 78 95 27 131 94
    rs12446951 Imputed A ADD 310 1.549 0.2897 0.8777 2.732 1.51 0.1312 0.7534 0.10161 0.12411 0.08284 1 33 107 1 26 142
    rs12446951 Imputed A DOM 310 1.63 0.2998 0.9057 2.933 1.63 0.1032 0.7534 0.10161 0.12411 0.08284 1 33 107 1 26 142
    rs12457400 Imputed G DOM 443 0.578 0.2524 0.3525 0.948 −2.172 0.02987 0.8041 0.10497 0.08115 0.12302 2 27 162 2 58 192
    rs1247340 Imputed C DOM 441 0.9041 0.2098 0.5993 1.364 −0.4802 0.6311 0.0397 0.20522 0.17895 0.2251 4 60 126 22 69 160
    rs1247341 Imputed C DOM 441 0.919 0.2102 0.6087 1.387 −0.4021 0.6876 0.05636 0.20408 0.18063 0.222 4 61 126 21 69 160
    rs12521291 Imputed G ADD 435 1.07 0.1477 0.8008 1.429 0.4556 0.6486 0.9172 0.35747 0.36559 0.35141 21 94 71 35 105 109
    rs12526849 Imputed T ADD 436 1.012 0.1389 0.7712 1.329 0.08887 0.9292 0.4209 0.39106 0.39362 0.38911 34 80 74 37 119 92
    rs12526849 Imputed T GEN 436 1.863 0.394 0.4209 0.39106 0.39362 0.38911 34 80 74 37 119 92
    rs12543110 Imputed G DOM 443 1.32 0.1941 0.9026 1.931 1.432 0.1521 0.6236 0.26298 0.27487 0.25397 9 87 95 19 90 143
    rs12678600 Imputed A DOM 439 0.7992 0.198 0.5421 1.178 −1.132 0.2575 1 0.31663 0.29894 0.33 18 77 94 26 113 111
    rs12719415 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs12831292 Imputed G DOM 436 0.7047 0.2039 0.4725 1.051 −1.716 0.08609 1 0.40367 0.37097 0.428 26 86 74 45 124 81
    rs12923993 Imputed C DOM 443 2.011 0.2218 1.302 3.107 3.15 0.00163 0.4471 0.14447 0.17801 0.11905 3 62 126 8 44 200
    rs12936964 Imputed T DOM 431 1.123 0.2052 0.7508 1.678 0.5634 0.5732 0.2205 0.38167 0.37097 0.3898 23 92 71 46 99 100
    rs12960663 Imputed G ADD 435 0.797 0.1843 0.5553 1.144 −1.231 0.2182 0.8698 0.17701 0.15775 0.19153 3 53 131 11 73 164
    rs13038146 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs13038146 Imputed C GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs13134222 Imputed A GEN 442 4.511 0.1048 0.6117 0.24887 0.28158 0.22421 13 81 96 12 89 151
    rs13172910 Imputed A DOM 417 0.6398 0.2054 0.4278 0.9571 −2.174 0.02974 1 0.2446 0.21858 0.26496 12 56 115 13 98 123
    rs13194907 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs13194907 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs13195745 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs13195745 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs1321432 Imputed A REC 443 0.9755 0.2643 0.5811 1.638 −0.09385 0.9252 0.108 0.38036 0.37696 0.38294 31 82 78 41 111 100
    rs1321457 Imputed G REC 435 0.9425 0.2789 0.5456 1.628 −0.2122 0.8319 0.3005 0.36207 0.3617 0.36235 26 84 78 36 107 104
    rs13265054 Imputed T DOM 434 0.7541 0.1998 0.5098 1.116 −1.413 0.1577 0.8248 0.31567 0.29412 0.33198 17 76 94 25 114 108
    rs13282131 Imputed C GEN 440 6.641 0.03614 0.8464 0.43864 0.47105 0.414 47 85 58 39 129 82
    rs13353526 Imputed C DOM 438 0.8239 0.2338 0.521 1.303 −0.8286 0.4073 1 0.12785 0.11842 0.13508 2 41 147 5 57 186
    rs1336382 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131 0.1655 0.33409 0.36911 0.30754 29 83 79 27 101 124
    rs1336383 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131 0.1655 0.33409 0.36911 0.30754 29 83 79 27 101 124
    rs1336407 Imputed T DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.1663 0.33484 0.36911 0.30876 29 83 79 27 101 123
    rs1336409 Imputed T DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.1663 0.33484 0.36911 0.30876 29 83 79 27 101 123
    rs1336596 Imputed A DOM 440 0.9849 0.205 0.659 1.472 −0.07439 0.9407 0.4737 0.36932 0.37632 0.364 28 87 75 28 126 96
    rs1343560 Imputed T ADD 437 1.717 0.2225 1.11 2.656 2.43 0.01509 0.1757 0.11899 0.14894 0.09639 2 52 134 1 46 202
    rs1343560 Imputed T DOM 437 1.745 0.2319 1.108 2.75 2.402 0.0163 0.1757 0.11899 0.14894 0.09639 2 52 134 1 46 202
    rs1361987 Imputed T GEN 443 0.4112 0.8142 0.8328 0.34199 0.34817 0.3373 25 83 83 28 114 110
    rs1386153 Imputed T ADD 441 0.8596 0.1501 0.6405 1.154 −1.008 0.3137 0.3322 0.32993 0.31316 0.34263 16 87 87 27 118 106
    rs1386153 Imputed T DOM 441 0.8546 0.1947 0.5835 1.252 −0.8069 0.4197 0.3322 0.32993 0.31316 0.34263 16 87 87 27 118 106
    rs1394015 Imputed C DOM 372 2.85 1.231 0.2552 31.84 0.8507 0.3949 1 0.00403 0.00633 0.00234 0 2 156 0 1 213
    rs1407038 Imputed A REC 443 0.9523 0.2749 0.5556 1.632 −0.178 0.8588 0.1496 0.35892 0.35864 0.35913 27 83 81 37 107 108
    rs1407039 Imputed A REC 443 0.9755 0.2643 0.5811 1.638 −0.09385 0.9252 0.108 0.38036 0.37696 0.38294 31 82 78 41 111 100
    rs1412802 Imputed T GEN 428 3.851 0.1458 0.7178 0.27804 0.25543 0.29508 8 78 98 23 98 123
    rs1414865 Imputed T DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272 0.1377 0.33937 0.37173 0.31474 29 84 78 29 100 122
    rs1414873 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.1663 0.33484 0.36911 0.30876 29 83 79 27 101 123
    rs1414876 Imputed C DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.1663 0.33484 0.36911 0.30876 29 83 79 27 101 123
    rs1418671 Imputed C REC 424 1.095 0.2783 0.6345 1.889 0.3255 0.7448 0.6846 0.39623 0.4011 0.39256 29 88 65 35 120 87
    rs1419490 Genotyped T GEN 443 0.3173 0.8533 1 0.33634 0.3377 0.33532 23 83 85 27 115 110
    rs1434507 Imputed A ADD 442 1.053 0.1646 0.7624 1.453 0.3112 0.7556 1 0.22624 0.23037 0.22311 9 70 112 13 86 152
    rs1434508 Imputed T ADD 442 1.053 0.1646 0.7624 1.453 0.3112 0.7556 1 0.22624 0.23037 0.22311 9 70 112 13 86 152
    rs1435205 Imputed A ADD 442 1.021 0.1625 0.7424 1.404 0.1273 0.8987 0.8924 0.22624 0.22895 0.22421 10 67 113 13 87 152
    rs1443928 Imputed C REC 435 0.9918 0.2124 0.6541 1.504 −0.03862 0.9692 0.1711 0.57126 0.56806 0.57377 65 87 39 84 112 48
    rs1452235 Imputed G GEN 443 5.506 0.06375 0.5227 0.33296 0.36911 0.30556 30 81 80 22 110 120
    rs1452236 Imputed G GEN 443 5.506 0.06375 0.5227 0.33296 0.36911 0.30556 30 81 80 22 110 120
    rs1452237 Imputed G GEN 443 5.506 0.06375 0.5227 0.33296 0.36911 0.30556 30 81 80 22 110 120
    rs1452243 Genotyped T GEN 443 5.995 0.04992 0.6732 0.33973 0.37435 0.31349 31 81 79 22 114 116
    rs1463768 Genotyped G REC 443 1.844 0.2673 1.092 3.114 2.29 0.02201 0.5464 0.38262 0.42932 0.34722 38 88 65 30 115 107
    rs1463769 Imputed G REC 443 1.844 0.2673 1.092 3.114 2.29 0.02201 0.5464 0.38262 0.42932 0.34722 38 88 65 30 115 107
    rs1472435 Imputed A ADD 437 0.5361 0.3365 0.2772 1.037 −1.853 0.0639 0.6259 0.05378 0.03704 0.06653 0 14 175 0 33 215
    rs1472435 Imputed A DOM 437 0.5361 0.3365 0.2772 1.037 −1.853 0.0639 0.6259 0.05378 0.03704 0.06653 0 14 175 0 33 215
    rs1476714 Imputed A DOM 439 0.5924 0.2025 0.3983 0.8811 −2.585 0.00974 0.1129 0.3451 0.31316 0.36948 27 65 98 33 118 98
    rs1495159 Imputed G ADD 429 1.318 0.1505 0.9813 1.77 1.835 0.06656 0.6567 0.31935 0.35135 0.29508 18 94 73 28 88 128
    rs1495159 Imputed G GEN 429 9.642 0.00806 0.6567 0.31935 0.35135 0.29508 18 94 73 28 88 128
    rs1495375 Imputed A DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001 0.9197 0.40855 0.37297 0.43644 26 86 73 45 116 75
    rs1495376 Imputed T DOM 424 0.774 0.2264 0.4966 1.206 −1.132 0.2577 0.3834 0.48231 0.45652 0.50208 36 96 52 58 125 57
    rs1495377 Imputed G DOM 425 0.7814 0.2265 0.5013 1.218 −1.089 0.2762 0.4372 0.48118 0.45652 0.5 36 96 52 58 125 58
    rs1495381 Imputed T GEN 442 7.762 0.02063 0.2705 0.38575 0.43421 0.34921 35 95 60 25 126 101
    rs1495381 Imputed T REC 442 2.08 0.2834 1 .194 3.626 2.584 0.00975 0.2705 0.38575 0.43421 0.34921 35 95 60 25 126 101
    rs1498992 Imputed G DOM 428 0.7274 0.1999 0.4916 1.076 −1.592 0.1114 0.4588 0.35047 0.32337 0.3709 22 75 87 34 113 97
    rs1499001 Imputed T DOM 437 0.7573 0.1974 0.5144 1.115 −1.409 0.159 0.2889 0.28375 0.26203 0.3 16 66 105 24 102 124
    rs1512988 Imputed A DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051 0.6908 0.3948 0.36316 0.41865 26 86 78 45 121 86
    rs1512989 Imputed T DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051 0.6908 0.3948 0.36316 0.41865 26 86 78 45 121 86
    rs1512991 Imputed T ADD 425 0.7106 0.1399 0.5401 0.9348 −2.442 0.01462 0.3804 0.45647 0.4071 0.4938 30 89 64 63 113 66
    rs1512991 Imputed T DOM 425 0.6965 0.2131 0.4587 1.057 −1.698 0.08957 0.3804 0.45647 0.4071 0.4938 30 89 64 63 113 66
    rs1516855 Imputed G REC 398 1.236 0.2928 0.6964 2.195 0.7243 0.4689 0.2364 0.36935 0.38571 0.3565 29 77 69 31 97 95
    rs1527450 Imputed T ADD 441 1.146 0.1493 0.8556 1.536 0.9151 0.3601 0.6792 0.35714 0.37302 0.34524 25 91 73 29 116 107
    rs1527450 Imputed T GEN 441 0.8647 0.649 0.6792 0.35714 0.37302 0.34524 25 91 73 29 116 107
    rs1567740 Imputed T DOM 439 0.7204 0.2038 0.4831 1.074 −1.609 0.1076 0.8422 0.39863 0.36579 0.42369 26 87 77 45 121 83
    rs1572573 Imputed A ADD 396 1.012 0.2009 0.6826 1.501 0.05984 0.9523 0.00264 0.18813 0.18786 0.18834 2 61 110 3 78 142
    rs1572573 Imputed A DOM 396 1.019 0.2128 0.6715 1.546 0.08849 0.9295 0.00264 0.18813 0.18786 0.18834 2 61 110 3 78 142
    rs1584003 Imputed C DOM 432 0.6043 0.2157 0.396 0.9221 −2.336 0.0195 0.2438 0.45255 0.42063 0.47737 35 89 65 47 138 58
    rs1584005 Imputed C DOM 427 0.6032 0.2163 0.3947 0.9217 −2.337 0.01944 0.2831 0.45082 0.41979 0.475 35 87 65 46 136 58
    rs1585771 Imputed G ADD 433 0.9914 0.1575 0.728 1.35 −0.05515 0.956 1 0.26559 0.26486 0.26613 13 72 100 17 98 133
    rs1592015 Imputed G DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs1594885 Imputed A ADD 440 1.083 0.1634 0.7863 1.492 0.4891 0.6248 0.7887 0.23182 0.23947 0.226 9 73 108 13 87 150
    rs1603232 Imputed A DOM 412 0.7502 0.2319 0.4761 1.182 −1.239 0.2152 0.49 0.49029 0.46111 0.51293 36 94 50 59 120 53
    rs1614565 Imputed C DOM 439 0.7578 0.2237 0.4888 1.175 −1.24 0.2151 0.6336 0.49089 0.46296 0.512 39 97 53 64 128 58
    rs1648200 Imputed G ADD 411 1.299 0.1675 0.9357 1.804 1.563 0.118 1 0.24331 0.26816 0.22414 14 68 97 10 84 138
    rs16877387 Imputed C GEN 436 2.224 0.3289 0.5854 0.32569 0.31649 0.33266 23 73 92 26 113 109
    rs16877387 Imputed C REC 436 1.186 0.3054 0.6518 2.158 0.5586 0.5764 0.5854 0.32569 0.31649 0.33266 23 73 92 26 113 109
    rs16938626 Imputed G DOM 435 0.7689 0.1982 0.5213 1.134 −1.326 0.1849 0.3923 0.26552 0.24866 0.27823 15 63 109 19 100 129
    rs1694334 Imputed G ADD 399 1.156 0.1835 0.8068 1.657 0.7904 0.4293 0.5371 0.20426 0.21765 0.19432 7 60 103 7 75 147
    rs16998821 Imputed C DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs1700400 Imputed T ADD 417 0.9427 0.1613 0.6872 1.293 −0.3659 0.7144 0.1293 0.23141 0.22652 0.23517 12 58 111 16 79 141
    rs17007620 Imputed G ADD 408 1.033 0.1717 0.7377 1.446 0.1877 0.8511 1 0.22181 0.22599 0.21861 7 66 104 13 75 143
    rs17007620 Imputed G DOM 408 1.127 0.206 0.7523 1.687 0.5784 0.563 1 0.22181 0.22599 0.21861 7 66 104 13 75 143
    rs17023290 Imputed C DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs17047957 Imputed C DOM 439 1.801 0.2129 1.187 2.734 2.765 0.0057 0.6092 0.16856 0.20635 0.14 7 64 118 7 56 187
    rs1705237 Imputed A DOM 439 0.7578 0.2237 0.4888 1.175 −1.24 0.2151 0.6336 0.49089 0.46296 0.512 39 97 53 64 128 58
    rs1705261 Imputed A GEN 442 7.113 0.02854 0.5499 0.39367 0.43947 0.35913 37 93 60 28 125 99
    rs1705261 Imputed A REC 442 2.005 0.2767 1.166 3.449 2.514 0.01192 0.5499 0.39367 0.43947 0.35913 37 93 60 28 125 99
    rs17076972 Imputed C ADD 442 1.031 0.1393 0.7845 1.355 0.2183 0.8272 0.5032 0.45814 0.46335 0.45418 38 101 52 51 126 74
    rs17076972 Imputed C GEN 442 0.2344 0.8894 0.5032 0.45814 0.46335 0.45418 38 101 52 51 126 74
    rs17076972 Imputed C REC 442 0.9776 0.2403 0.6104 1.566 −0.09436 0.9248 0.5032 0.45814 0.46335 0.45418 38 101 52 51 126 74
    rs17189710 Imputed T ADD 430 1.382 0.1457 1.039 1.839 2.22 0.02639 0.3369 0.34535 0.38649 0.31429 33 77 75 23 108 114
    rs17189710 Imputed T GEN 430 6.752 0.03418 0.3369 0.34535 0.38649 0.31429 33 77 75 23 108 114
    rs17196143 Imputed A ADD 443 0.7066 0.186 0.4907 1.017 −1.867 0.06189 1 0.17946 0.15183 0.2004 2 54 135 12 77 163
    rs17353809 Imputed G ADD 433 0.9859 0.1679 0.7095 1.37 −0.0846 0.9326 0.569 0.21478 0.21351 0.21573 10 59 116 12 83 153
    rs17368986 Imputed A GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs17369097 Imputed A GEN 443 1.248 0.5357 0.6275 0.17946 0.19634 0.16667 8 59 124 8 68 176
    rs17434511 Imputed C GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs17434589 Imputed C GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs17434603 Imputed G GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs17434840 Imputed C GEN 443 1.248 0.5357 0.6275 0.17946 0.19634 0.16667 8 59 124 8 68 176
    rs17446418 Imputed G DOM 380 1.044 0.2158 0.6838 1.593 0.1982 0.8429 0.03708 0.32895 0.33537 0.32407 14 82 68 18 104 94
    rs17530747 Imputed T DOM 374 1.033 0.2172 0.6751 1.582 0.1511 0.8799 0.0203 0.3369 0.34375 0.33178 14 82 64 18 106 90
    rs17604285 Imputed C ADD 443 0.9476 0.2663 0.5622 1.597 −0.2023 0.8397 0.09538 0.07788 0.07592 0.07937 0 29 162 0 40 212
    rs17604285 Imputed C DOM 443 0.9476 0.2663 0.5622 1.597 −0.2023 0.8397 0.09538 0.07788 0.07592 0.07937 0 29 162 0 40 212
    rs17662322 Imputed T DOM 443 0.7561 0.2081 0.5029 1.137 −1.344 0.179 0.8723 0.18059 0.15969 0.19643 5 51 135 10 79 163
    rs17769826 Imputed T ADD 433 0.9859 0.1679 0.7095 1.37 −0.0846 0.9326 0.569 0.21478 0.21351 0.21573 10 59 116 12 83 153
    rs17821641 Imputed T ADD 442 1.021 0.1625 0.7424 1.404 0.1273 0.8987 0.8924 0.22624 0.22895 0.22421 10 67 113 13 87 152
    rs1782328 Imputed A ADD 426 0.96 0.1915 0.6595 1.397 −0.213 0.8313 0.305 0.17136 0.16758 0.17418 5 51 126 4 77 163
    rs1796337 Imputed T DOM 428 0.6991 0.2365 0.4398 1.111 −1.514 0.1301 0.1753 0.51285 0.47581 0.54132 38 101 47 67 128 47
    rs1798083 Imputed C DOM 441 0.7428 0.2255 0.4774 1.156 −1.318 0.1874 0.7038 0.5 0.47105 0.52191 41 97 52 67 128 56
    rs1798085 Imputed T DOM 439 0.7578 0.2237 0.4888 1.175 −1.24 0.2151 0.6336 0.49089 0.46296 0.512 39 97 53 64 128 58
    rs1798086 Imputed T DOM 416 0.7565 0.2341 0.4781 1.197 −1.192 0.2332 0.6948 0.50361 0.47826 0.52371 41 94 49 62 119 51
    rs1798089 Imputed C GEN 366 2.947 0.2291 2.13E−06 0.29235 0.31908 0.27336 8 81 63 5 107 102
    rs1798089 Imputed C REC 366 2.307 0.5861 0.7314 7.277 1.426 0.1538 2.13E−06 0.29235 0.31908 0.27336 8 81 63 5 107 102
    rs1798090 Imputed C GEN 367 3.038 0.2189 1.37E−06 0.29292 0.32026 0.27336 8 82 63 5 107 102
    rs1798090 Imputed C REC 367 2.295 0.5861 0.7275 7.238 1.417 0.1564 1.37E−06 0.29292 0.32026 0.27336 8 82 63 5 107 102
    rs1832222 Imputed G DOM 443 1.344 0.1965 0.9144 1.975 1.504 0.1325 0.2005 0.33521 0.36911 0.30952 29 83 79 27 102 123
    rs1838104 Imputed A ADD 440 0.9138 0.1404 0.694 1.203 −0.6418 0.521 0.5608 0.56591 0.55526 0.574 61 89 40 83 121 46
    rs1838104 Imputed A GEN 440 0.6345 0.7281 0.5608 0.56591 0.55526 0.574 61 89 40 83 121 46
    rs1868616 Imputed G ADD 437 0.8179 0.1786 0.5764 1.161 −1.126 0.2602 0.8751 0.18764 0.17021 0.2008 6 52 130 10 80 159
    rs1874313 Imputed A DOM 443 0.7338 0.2032 0.4927 1.093 −1.523 0.1277 0.6922 0.39503 0.36387 0.41865 26 87 78 45 121 86
    rs1884902 Imputed C REC 443 0.9755 0.2643 0.5811 1.638 −0.09385 0.9252 0.108 0.38036 0.37696 0.38294 31 82 78 41 111 100
    rs1913201 Imputed G ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs1913201 Imputed G DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs1913201 Imputed G GEN 432 6.276 0.04338 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs1944279 Imputed A ADD 438 1.083 0.1637 0.7858 1.493 0.4879 0.6256 0.7885 0.23174 0.23947 0.22581 9 73 108 13 86 149
    rs198461 Imputed C DOM 433 0.5222 0.221 0.3386 0.8052 −2.94 0.00328 0.6307 0.48614 0.43548 0.52429 40 82 64 65 129 53
    rs1987179 Imputed T DOM 417 0.5176 0.2237 0.3339 0.8024 −2.944 0.00324 0.8637 0.17266 0.13462 0.20213 6 37 139 7 81 147
    rs1990023 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs2016194 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs2024789 Imputed C ADD 440 0.9942 0.1364 0.7609 1.299 −0.0427 0.9659 0.8491 0.50682 0.50529 0.50797 49 93 47 65 125 61
    rs2024789 Imputed C GEN 440 0.0158 0.9921 0.8491 0.50682 0.50529 0.50797 49 93 47 65 125 61
    rs2024902 Imputed A ADD 442 1.087 0.2583 0.655 1.803 0.3216 0.7477 0.2797 0.07353 0.07592 0.07171 1 27 163 3 30 218
    rs2024902 Imputed A DOM 442 1.157 0.2804 0.6678 2.005 0.52 0.6031 0.2797 0.07353 0.07592 0.07171 1 27 163 3 30 218
    rs2025107 Imputed A ADD 442 0.9899 0.2312 0.6292 1.557 −0.04381 0.9651 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs2025107 Imputed A DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs2025108 Imputed T ADD 442 0.9899 0.2312 0.6292 1.557 −0.04381 0.9651 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs2025108 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs2062448 Imputed T ADD 442 0.913 0.2688 0.5391 1.546 −0.3387 0.7348 0.09556 0.07692 0.07368 0.07937 0 28 162 0 40 212
    rs2062448 Imputed T DOM 442 0.913 0.2688 0.5391 1.546 −0.3387 0.7348 0.09556 0.07692 0.07368 0.07937 0 28 162 0 40 212
    rs2063591 Imputed C ADD 441 0.7255 0.1363 0.5554 0.9478 −2.353 0.01861 0.2947 0.47506 0.42932 0.51 36 92 63 69 117 64
    rs2063591 Imputed C DOM 441 0.6936 0.2125 0.4573 1.052 −1.722 0.08515 0.2947 0.47506 0.42932 0.51 36 92 63 69 117 64
    rs2065604 Imputed C DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs2066238 Imputed T DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs2068051 Imputed G ADD 269 0.9214 0.1888 0.6364 1.334 −0.4337 0.6645 0.3082 0.60223 0.59009 0.61076 36 59 16 57 79 22
    rs2068051 Imputed G GEN 269 0.367 0.8324 0.3082 0.60223 0.59009 0.61076 36 59 16 57 79 22
    rs2077702 Genotyped G GEN 443 8.422 0.01483 0.4324 0.30361 0.3534 0.26587 22 91 78 15 104 133
    rs208757 Imputed G ADD 435 1.552 0.175 1.101 2.187 2.512 0.01201 0.6456 0.19425 0.23545 0.1626 8 73 108 10 60 176
    rs208757 Imputed G DOM 435 1.858 0.2057 1.241 2.78 3.011 0.0026 0.6456 0.19425 0.23545 0.1626 8 73 108 10 60 176
    rs2095586 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.3355 0.33145 0.36649 0.30478 28 84 79 25 103 123
    rs2108426 Imputed C DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs2110664 Imputed A DOM 399 1.47 0.2058 0.9818 2.2 1.871 0.06136 1 0.27569 0.30523 0.2533 14 77 81 16 83 128
    rs2132242 Imputed A DOM 440 0.6978 0.2022 0.4695 1.037 −1.78 0.07505 1 0.40341 0.36842 0.43 26 88 76 45 125 80
    rs2151644 Imputed T DOM 442 1.184 0.2598 0.7118 1.97 0.6512 0.5149 0.7613 0.0871 0.09474 0.08135 2 32 156 2 37 213
    rs2157752 Genotyped A GEN 443 0.5489 0.76 0.372 0.30474 0.29843 0.30952 20 74 97 25 106 121
    rs2158958 Imputed A DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs2158961 Imputed G DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187 0.8242 0.30813 0.2801 0.32937 20 67 104 23 120 109
    rs2164099 Imputed G ADD 441 1.075 0.1633 0.7809 1.481 0.4457 0.6558 0.6902 0.23243 0.23947 0.22709 9 73 108 13 88 150
    rs2173254 Imputed G GEN 438 0.524 0.7695 0.9154 0.34132 0.35185 0.33333 22 89 78 28 110 111
    rs2173254 Imputed G REC 438 1.019 0.3061 0.5595 1.857 0.06273 0.95 0.9154 0.34132 0.35185 0.33333 22 89 78 28 110 111
    rs2188079 Imputed C ADD 443 1.028 0.1399 0.7818 1.353 0.2006 0.841 0.563 0.43905 0.44503 0.43452 39 92 60 43 133 76
    rs2188079 Imputed C GEN 443 1.2 0.5489 0.563 0.43905 0.44503 0.43452 39 92 60 43 133 76
    rs2190304 Imputed G REC 443 1.465 0.2335 0.9272 2.316 1.636 0.1017 1 0.47517 0.47906 0.47222 50 83 58 50 138 64
    rs2190597 Imputed T DOM 440 0.6496 0.2095 0.4309 0.9795 −2.059 0.0395 0.1008 0.44318 0.42021 0.46032 42 74 72 53 126 73
    rs2190598 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs2190600 Imputed A DOM 440 0.577 0.2025 0.388 0.8581 −2.716 0.00661 0.07522 0.34886 0.31316 0.376 27 65 98 35 118 97
    rs2218084 Imputed T GEN 440 5.731 0.05696 0.3138 0.17159 0.17368 0.17 11 44 135 5 75 170
    rs2218084 Imputed T REC 440 2.942 0.5498 1.002 8.643 1.963 0.04966 0.3138 0.17159 0.17368 0.17 11 44 135 5 75 170
    rs2236290 Genotyped C GEN 441 6.206 0.04491 0.9174 0.35488 0.31675 0.384 16 89 86 40 112 98
    rs2243860 Imputed A GEN 354 2.941 0.2298 0.4422 0.4096 0.44737 0.38119 33 70 49 30 94 78
    rs2243860 Imputed A REC 354 1.553 0.289 0.8812 2.736 1.522 0.1279 0.4422 0.4096 0.44737 0.38119 33 70 49 30 94 78
    rs2246564 Imputed T DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs2248236 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.0026 0.8852 0.20655 0.17016 0.23413 9 47 135 9 100 143
    rs2250340 Imputed T DOM 410 1.184 0.2617 0.709 1.978 0.6458 0.5184 0.7706 0.0939 0.10169 0.08798 2 32 143 2 37 194
    rs2257192 Imputed G DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs2270584 Imputed A DOM 441 0.6747 0.2026 0.4536 1.004 −1.942 0.05211 0.4848 0.39342 0.35526 0.42231 26 83 81 46 120 85
    rs2270586 Imputed A DOM 442 0.6883 0.2018 0.4634 1.022 −1.851 0.06423 0.4864 0.39367 0.35602 0.42231 26 84 81 46 120 85
    rs2270589 Imputed A ADD 391 0.6468 0.1498 0.4822 0.8674 −2.909 0.00362 0.7615 0.48082 0.42059 0.52715 30 83 57 62 109 50
    rs2270589 Imputed A DOM 391 0.5799 0.2334 0.367 0.9163 −2.335 0.01956 0.7615 0.48082 0.42059 0.52715 30 83 57 62 109 50
    rs2270589 Imputed A GEN 391 8.473 0.01446 0.7615 0.48082 0.42059 0.52715 30 83 57 62 109 50
    rs2296889 Imputed C DOM 437 0.9005 0.2162 0.5895 1.376 −0.485 0.6277 0.3269 0.17849 0.18182 0.176 10 48 129 7 74 169
    rs2301346 Imputed C ADD 357 1.001 0.1711 0.7159 1.4 0.005922 0.9953 0.4976 0.26611 0.26563 0.2665 12 61 87 16 73 108
    rs2301346 Imputed C DOM 357 1.026 0.2191 0.6675 1.576 0.1152 0.9083 0.4976 0.26611 0.26563 0.2665 12 61 87 16 73 108
    rs2327929 Imputed G REC 441 1.411 0.2475 0.8684 2.291 1.39 0.1645 0.4376 0.42857 0.44764 0.414 42 87 62 43 121 86
    rs2357486 Imputed C REC 436 0.8855 0.316 0.4766 1.645 −0.385 0.7003 0.9136 0.32683 0.32181 0.33065 19 83 86 28 108 112
    rs2373793 Imputed G DOM 435 1.599 0.2233 1.032 2.477 2.103 0.03546 1 0.14253 0.17368 0.11837 6 54 130 3 52 190
    rs2377622 Imputed T GEN 291 8.41 0.01492 1 0.38832 0.33333 0.42857 10 62 51 34 76 58
    rs2377622 Imputed T REC 291 0.2954 0.4232 0.1289 0.677 −2.882 0.00396 1 0.38832 0.33333 0.42857 10 62 51 34 76 58
    rs2383903 Imputed G DOM 443 0.7568 0.1968 0.5146 1.113 −1.416 0.1569 0.4634 0.26411 0.24607 0.27778 15 64 112 19 102 131
    rs2389866 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.0026 0.8852 0.20655 0.17016 0.23413 9 47 135 9 100 143
    rs2389869 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.0026 0.8852 0.20655 0.17016 0.23413 9 47 135 9 100 143
    rs2418541 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs2418542 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs2418548 Imputed C DOM 442 0.6036 0.2017 0.4065 0.8963 −2.503 0.01231 0.01683 0.35633 0.32199 0.38247 29 65 97 39 114 98
    rs2476976 Imputed C DOM 442 1.391 0.1963 0.9466 2.044 1.68 0.09288 0.2817 0.32919 0.36387 0.30279 27 85 79 26 100 125
    rs2483639 Imputed A DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs2483640 Imputed A DOM 443 1.177 0.2597 0.7077 1.959 0.6286 0.5296 0.5598 0.08691 0.09424 0.08135 2 32 157 2 37 213
    rs2544780 Imputed T REC 442 3.054 0.3822 1.444 6.46 2.921 0.00349 0.3055 0.29638 0.33246 0.26892 23 81 87 11 113 127
    rs2586458 Imputed T DOM 372 1.439 0.2465 0.8877 2.333 1.477 0.1397 1 0.13172 0.14744 0.12037 2 42 112 4 44 168
    rs2593272 Imputed G ADD 443 0.9033 0.1559 0.6654 1.226 −0.6524 0.5141 0.1147 0.23702 0.22775 0.24405 12 63 116 19 85 148
    rs2593273 Imputed T ADD 426 0.9769 0.1588 0.7156 1.334 −0.1474 0.8828 0.03674 0.22418 0.2234 0.22479 12 60 116 17 73 148
    rs2622499 Imputed G DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.0026 0.8852 0.20655 0.17016 0.23413 9 47 135 9 100 143
    rs264126 Imputed C DOM 439 0.6379 0.2093 0.4232 0.9615 −2.148 0.03174 0.08131 0.44191 0.41755 0.46016 42 73 73 53 125 73
    rs264129 Imputed T DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187 0.8242 0.30813 0.2801 0.32937 20 67 104 23 120 109
    rs2656822 Imputed T ADD 443 0.9033 0.1559 0.6654 1.226 −0.6524 0.5141 0.1147 0.23702 0.22775 0.24405 12 63 116 19 85 148
    rs2656823 Imputed G ADD 443 0.9033 0.1559 0.6654 1.226 −0.6524 0.5141 0.1147 0.23702 0.22775 0.24405 12 63 116 19 85 148
    rs2656825 Imputed T ADD 420 0.986 0.1592 0.7217 1.347 −0.08844 0.9295 0.03522 0.225 0.2246 0.22532 12 60 115 17 71 145
    rs2764766 Imputed C REC 443 3.069 0.3822 1.451 6.491 2.934 0.00335 0.3053 0.29684 0.33246 0.26984 23 81 87 11 114 127
    rs2793101 Imputed T ADD 442 1.081 0.236 0.6809 1.717 0.3309 0.7407 0.7843 0.09615 0.09948 0.09363 2 34 155 1 45 205
    rs2793101 Imputed T DOM 442 1.046 0.2497 0.6414 1.707 0.1818 0.8557 0.7843 0.09615 0.09948 0.09363 2 34 155 1 45 205
    rs2795871 Imputed A ADD 435 0.5722 0.339 0.2944 1.112 −1.647 0.09966 0.6186 0.05172 0.03763 0.06225 0 14 172 0 31 218
    rs2795886 Imputed A ADD 442 0.5272 0.3735 0.2535 1.096 −1.714 0.08652 1 0.04299 0.02895 0.05357 0 11 179 0 27 225
    rs2795886 Imputed A DOM 442 0.5272 0.3735 0.2535 1.096 −1.714 0.08652 1 0.04299 0.02895 0.05357 0 11 179 0 27 225
    rs2859994 Imputed C GEN 436 0.8834 0.643 0.4109 0.36927 0.37234 0.36694 22 96 70 33 116 99
    rs2870464 Imputed G DOM 441 1.969 0.2225 1.273 3.045 3.045 0.00233 0.4419 0.14399 0.17632 0.11952 3 61 126 8 44 199
    rs2875528 Imputed T DOM 443 0.8843 0.2352 0.5577 1.402 −0.5227 0.6012 1 0.11851 0.10995 0.125 1 40 150 5 53 194
    rs2876227 Imputed C ADD 442 1.389 0.1445 1.046 1.843 2.272 0.02309 0.4631 0.34502 0.38743 0.31275 33 82 76 23 111 117
    rs2876227 Imputed C GEN 442 6.593 0.03701 0.4631 0.34502 0.38743 0.31275 33 82 76 23 111 117
    rs2882097 Imputed A DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131 0.1655 0.33409 0.36911 0.30754 29 83 79 27 101 124
    rs2921983 Imputed C ADD 416 0.8945 0.167 0.6448 1.241 −0.6677 0.5043 0.2479 0.21755 0.20718 0.22553 9 57 115 15 76 144
    rs2987537 Imputed C DOM 438 1.58 0.2184 1.03 2.424 2.095 0.03621 0.718 0.15753 0.18617 0.136 6 58 124 6 56 188
    rs2996416 Imputed C ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs2996416 Imputed C DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015527 Imputed C ADD 398 1.884 0.2353 1.188 2.989 2.693 0.00708 0.3323 0.11558 0.15029 0.08889 2 48 123 1 38 186
    rs3015527 Imputed C DOM 398 1.945 0.2451 1.203 3.144 2.714 0.00664 0.3323 0.11558 0.15029 0.08889 2 48 123 1 38 186
    rs3015530 Imputed C ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015530 Imputed C DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015531 Imputed T ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015531 Imputed T DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015535 Imputed C ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3015535 Imputed C DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs3019407 Imputed A GEN 439 0.7217 0.6971 1 0.33941 0.35185 0.33 22 89 78 28 109 113
    rs3019407 Imputed A REC 439 1.025 0.306 0.5627 1.867 0.08058 0.9358 1 0.33941 0.35185 0.33 22 89 78 28 109 113
    rs36071725 Genotyped C GEN 443 0.6419 0.7255 0.5846 0.31828 0.31414 0.32143 16 88 87 26 110 116
    rs373983 Imputed G DOM 414 1.954 0.2168 1.277 2.988 3.089 0.00201 0.9193 0.41063 0.45355 0.37662 31 104 48 38 98 95
    rs3756154 Imputed C DOM 416 0.5162 0.2209 0.3348 0.7959 −2.993 0.00276 1 0.17668 0.13736 0.20726 6 38 138 7 83 144
    rs3793044 Imputed C ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs3793044 Imputed C DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs3793053 Imputed C ADD 436 0.995 0.236 0.6266 1.58 −0.02103 0.9832 0.06405 0.0883 0.08777 0.08871 3 27 158 4 36 208
    rs3793053 Imputed C DOM 436 0.9919 0.2675 0.5872 1.676 −0.03035 0.9758 0.06405 0.0883 0.08777 0.08871 3 27 158 4 36 208
    rs3796246 Imputed G ADD 442 0.9554 0.2625 0.5711 1.598 −0.1737 0.8621 0.5013 0.07805 0.07592 0.07968 0 29 162 1 38 212
    rs3796246 Imputed G DOM 442 0.9829 0.2682 0.5811 1.663 −0.06425 0.9488 0.5013 0.07805 0.07592 0.07968 0 29 162 1 38 212
    rs3805996 Imputed G ADD 421 1.042 0.2655 0.6195 1.754 0.1561 0.876 0.2844 0.07601 0.07692 0.07531 1 26 155 3 30 206
    rs3805996 Imputed G DOM 421 1.106 0.2862 0.631 1.938 0.3512 0.7254 0.2844 0.07601 0.07692 0.07531 1 26 155 3 30 206
    rs3806003 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs3806003 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923 0.279 0.07336 0.07592 0.07143 1 27 163 3 30 219
    rs3806004 Imputed T ADD 442 0.9899 0.2312 0.6292 1.557 −0.04381 0.9651 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806004 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806010 Imputed T ADD 442 0.9899 0.2312 0.6292 1.557 −0.04381 0.9651 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806010 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806014 Imputed T ADD 430 1.014 0.234 0.6412 1.605 0.06078 0.9515 0.06876 0.0907 0.09016 0.09109 3 27 153 4 37 206
    rs3806014 Imputed T DOM 430 1.002 0.2658 0.5954 1.688 0.008889 0.9929 0.06876 0.0907 0.09016 0.09109 3 27 153 4 37 206
    rs3806015 Imputed A ADD 426 1.004 0.2345 0.634 1.589 0.01643 0.9869 0.07007 0.09155 0.09066 0.09221 3 27 152 4 37 203
    rs3806015 Imputed A DOM 426 0.9945 0.2663 0.5902 1.676 −0.02059 0.9836 0.07007 0.09155 0.09066 0.09221 3 27 152 4 37 203
    rs3806018 Imputed A ADD 442 0.9899 0.2312 0.6292 1.557 −0.04381 0.9651 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806018 Imputed A DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446 0.0729 0.0905 0.08947 0.09127 3 28 159 4 38 210
    rs3806019 Imputed A ADD 438 0.974 0.2319 0.6182 1.534 −0.1137 0.9095 0.07445 0.09132 0.08995 0.09237 3 28 158 4 38 207
    rs3806019 Imputed A DOM 438 0.9676 0.2625 0.5784 1.619 −0.1255 0.9001 0.07445 0.09132 0.08995 0.09237 3 28 158 4 38 207
    rs3806024 Imputed T ADD 442 1.029 0.2268 0.6599 1.605 0.1274 0.8986 0.03996 0.09276 0.09424 0.09163 4 28 159 4 38 209
    rs3806024 Imputed T DOM 442 1.001 0.2605 0.601 1.669 0.005209 0.9958 0.03996 0.09276 0.09424 0.09163 4 28 159 4 38 209
    rs3847825 Imputed G ADD 440 0.7616 0.1432 0.5752 1.008 −1.901 0.05729 1 0.38523 0.34737 0.414 18 96 76 47 113 90
    rs3847825 Imputed G GEN 440 6.939 0.03113 1 0.38523 0.34737 0.414 18 96 76 47 113 90
    rs3852001 Genotyped C GEN 443 0.9298 0.6282 0.6332 0.18172 0.19634 0.17063 8 59 124 8 70 174
    rs3852001 Genotyped C REC 443 1.348 0.5124 0.4937 3.68 0.5827 0.5601 0.6332 0.18172 0.19634 0.17063 8 59 124 8 70 174
    rs3852002 Imputed G GEN 443 1.248 0.5357 0.6275 0.17946 0.19634 0.16667 8 59 124 8 68 176
    rs3852002 Imputed G REC 443 1.348 0.5124 0.4937 3.68 0.5827 0.5601 0.6275 0.17946 0.19634 0.16667 8 59 124 8 68 176
    rs3852003 Imputed A GEN 442 1.289 0.525 0.6277 0.17986 0.19737 0.16667 8 59 123 8 68 176
    rs3852003 Imputed A REC 442 1.351 0.5124 0.4947 3.687 0.5864 0.5576 0.6277 0.17986 0.19737 0.16667 8 59 123 8 68 176
    rs3942254 Imputed T DOM 420 0.6591 0.2081 0.4383 0.991 −2.004 0.04512 0.1836 0.39167 0.35393 0.41942 26 74 78 45 113 84
    rs3945085 Imputed A DOM 441 1.324 0.1969 0.9003 1.948 1.427 0.1537 0.05672 0.34014 0.37435 0.314 31 81 79 29 99 122
    rs399485 Imputed A DOM 437 1.648 0.1968 1.12 2.423 2.538 0.01116 0.3195 0.25973 0.29211 0.23482 10 91 89 15 86 146
    rs4029119 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs4029119 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs412791 Imputed C GEN 432 0.1413 0.9318 0.8291 0.33565 0.33957 0.33265 23 81 83 27 109 109
    rs4146972 Genotyped T DOM 443 1.832 0.2123 1.208 2.777 2.851 0.00436 0.7362 0.17043 0.20942 0.14087 7 66 118 7 57 188
    rs4259369 Imputed C REC 440 0.659 0.2526 0.4017 1.081 −1.651 0.09871 0.3808 0.42727 0.39005 0.45582 30 89 72 55 117 77
    rs4273613 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs4273613 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs4294022 Imputed C DOM 441 1.051 0.1977 0.7133 1.548 0.251 0.8018 0.25 0.2483 0.25132 0.24603 14 67 108 18 88 146
    rs4310554 Genotyped C DOM 443 1.561 0.2379 0.9794 2.489 1.872 0.06115 0.9242 0.52032 0.55497 0.49405 56 100 35 63 123 66
    rs4315598 Imputed T ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs4315598 Imputed T GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs4370878 Imputed G DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682 0.1648 0.33523 0.36842 0.31 29 82 79 27 101 122
    rs4436200 Imputed C ADD 442 0.543 0.2248 0.3494 0.8436 −2.716 0.0066 0.2274 0.13575 0.10209 0.16135 2 35 154 9 63 179
    rs4444612 Imputed G ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs4444612 Imputed G GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs4450660 Imputed C DOM 438 1.275 0.1965 0.8675 1.874 1.236 0.2163 0.378 0.25457 0.26316 0.24798 11 78 101 21 81 146
    rs4463950 Imputed C DOM 438 0.7997 0.211 0.5288 1.209 −1.06 0.2893 0.18 0.46347 0.44415 0.478 41 85 62 60 119 71
    rs4509702 Imputed C DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682 0.1648 0.33523 0.36842 0.31 29 82 79 27 101 122
    rs4533379 Imputed G ADD 441 1.075 0.1633 0.7809 1.481 0.4457 0.6558 0.6902 0.23243 0.23947 0.22709 9 73 108 13 88 150
    rs4569984 Imputed A DOM 426 1.031 0.2026 0.6932 1.534 0.1516 0.8795 0.498 0.23357 0.22973 0.23651 10 65 110 16 82 143
    rs4570530 Imputed C DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682 0.1648 0.33523 0.36842 0.31 29 82 79 27 101 122
    rs4571583 Imputed T DOM 439 1.001 0.1996 0.6767 1.48 0.002892 0.9977 0.3419 0.22665 0.22222 0.23 10 64 115 16 83 151
    rs4586678 Imputed A DOM 442 1.235 0.1959 0.8415 1.813 1.079 0.2807 0.4569 0.25679 0.26316 0.25198 11 78 101 21 85 146
    rs4615971 Imputed C DOM 440 1.347 0.1965 0.9164 1.98 1.516 0.1296 0.2375 0.33182 0.36579 0.306 28 83 79 26 101 123
    rs4629229 Imputed G DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs4632512 Imputed T GEN 443 1.248 0.5357 0.6275 0.17946 0.19634 0.16667 8 59 124 8 68 176
    rs4641552 Imputed A ADD 437 0.6214 0.279 0.3596 1.074 −1.705 0.08817 1 0.07323 0.05585 0.08635 0 21 167 2 39 208
    rs4682527 Imputed C DOM 209 2.955 1.237 0.2613 33.41 0.8755 0.3813 1 0.00718 0.01111 0.0042 0 2 88 0 1 118
    rs4688632 Imputed G REC 429 0.6822 0.2335 0.4316 1.078 −1.638 0.1014 0.00063 0.45338 0.41892 0.47951 38 79 68 68 98 78
    rs4702720 Imputed A ADD 359 0.757 0.1808 0.5311 1.079 −1.54 0.1236 1 0.24652 0.21935 0.26716 10 48 97 12 85 107
    rs4702720 Imputed A DOM 359 0.6462 0.2205 0.4194 0.9956 −1.98 0.04769 1 0.24652 0.21935 0.26716 10 48 97 12 85 107
    rs4714484 Imputed A ADD 439 0.8396 0.1992 0.5682 1.241 −0.8775 0.3802 0.3702 0.15718 0.1455 0.166 3 49 137 5 73 172
    rs4714484 Imputed A DOM 439 0.8278 0.2185 0.5394 1.27 −0.8651 0.387 0.3702 0.15718 0.1455 0.166 3 49 137 5 73 172
    rs4725142 Genotyped G REC 443 1.186 0.2801 0.6847 2.053 0.6082 0.5431 0.1412 0.34537 0.35864 0.33532 28 81 82 32 105 115
    rs4725144 Imputed G REC 438 1.136 0.2871 0.647 1.994 0.4432 0.6576 0.1657 0.33904 0.3484 0.332 26 79 83 31 104 115
    rs4760785 Imputed A ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4760785 Imputed A DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4760894 Imputed T ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4760894 Imputed T DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4760895 Imputed A ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4760895 Imputed A DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs4767184 Imputed C ADD 425 0.7759 0.1466 0.5822 1.034 −1.732 0.08334 0.8408 0.40353 0.3674 0.43033 18 97 66 50 110 84
    rs4767184 Imputed C GEN 425 8.173 0.0168 0.8408 0.40353 0.3674 0.43033 18 97 66 50 110 84
    rs4773487 Imputed T ADD 436 1.73 0.2227 1.118 2.676 2.461 0.01385 0.1754 0.11927 0.14973 0.09639 2 52 133 1 46 202
    rs4780547 Imputed G GEN 442 7.627 0.02207 0.3901 0.26244 0.22775 0.28884 7 73 111 27 91 133
    rs4780547 Imputed G REC 442 0.2881 0.4519 0.1188 0.6985 −2.754 0.00588 0.3901 0.26244 0.22775 0.28884 7 73 111 27 91 133
    rs483159 Imputed T DOM 386 1.953 0.219 1.271 2.999 3.056 0.00225 0.3957 0.18264 0.22561 0.1509 4 66 94 6 55 161
    rs4836502 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs4836507 Imputed C DOM 442 0.5803 0.2019 0.3906 0.862 −2.696 0.00703 0.09482 0.34955 0.31414 0.37649 27 66 98 35 119 97
    rs4851531 Imputed T DOM 442 0.6071 0.2055 0.4058 0.9082 −2.428 0.01517 0.2107 0.44231 0.40052 0.4741 36 81 74 57 124 70
    rs4879931 Imputed G ADD 438 0.7451 0.1533 0.5517 1.006 −1.92 0.05489 0.5791 0.31279 0.28042 0.33735 10 86 93 30 108 111
    rs489441 Imputed G ADD 409 1.224 0.1644 0.8866 1.689 1.228 0.2195 0.6152 0.26773 0.28736 0.25319 11 78 85 16 87 132
    rs489441 Imputed G DOM 409 1.384 0.2043 0.9276 2.066 1.592 0.1114 0.6152 0.26773 0.28736 0.25319 11 78 85 16 87 132
    rs4976276 Imputed T ADD 440 0.9836 0.1502 0.7328 1.32 −0.1103 0.9121 0.5816 0.31591 0.31316 0.318 17 85 88 24 111 115
    rs4977681 Imputed C REC 441 0.9851 0.323 0.523 1.856 −0.04633 0.9631 0.7396 0.31293 0.30105 0.322 19 77 95 26 109 115
    rs4986197 Imputed G ADD 440 1.083 0.1634 0.7863 1.492 0.4891 0.6248 0.7887 0.23182 0.23947 0.226 9 73 108 13 87 150
    rs4986220 Imputed T ADD 442 1.075 0.1653 0.7775 1.486 0.4371 0.6621 1 0.21946 0.22632 0.21429 9 68 113 12 84 156
    rs525462 Imputed A GEN 440 8.36 0.0153 0.4957 0.57045 0.53704 0.59562 62 79 48 85 129 37
    rs552006 Imputed G GEN 443 0.4432 0.8012 0.8062 0.26298 0.26178 0.26389 11 78 102 18 97 137
    rs5756669 Imputed C DOM 443 1.061 0.217 0.6932 1.623 0.2716 0.7859 0.08691 0.48646 0.50262 0.47421 54 84 53 60 119 73
    rs581905 Imputed T DOM 442 2.177 0.2555 1.32 3.593 3.045 0.00232 1 0.09955 0.13089 0.0757 2 46 143 2 34 215
    rs6033138 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6033138 Imputed C GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6040619 Imputed C ADD 439 1.429 0.1436 1.079 1.894 2.487 0.01287 0.3441 0.34852 0.39628 0.31275 34 81 73 24 109 118
    rs6040619 Imputed C GEN 439 7.276 0.02631 0.3441 0.34852 0.39628 0.31275 34 81 73 24 109 118
    rs6040625 Imputed T ADD 442 1.414 0.1431 1.068 1.871 2.419 0.01557 0.3449 0.34729 0.39267 0.31275 34 82 75 24 109 118
    rs6040625 Imputed T GEN 442 6.967 0.0307 0.3449 0.34729 0.39267 0.31275 34 82 75 24 109 118
    rs6040630 Imputed A ADD 441 1.401 0.1436 1.058 1.857 2.349 0.01881 0.2464 0.34467 0.38947 0.31076 34 80 76 24 108 119
    rs6040630 Imputed A GEN 441 6.767 0.03392 0.2464 0.34467 0.38947 0.31076 34 80 76 24 108 119
    rs6040633 Imputed A ADD 442 1.391 0.1433 1.05 1.842 2.302 0.02133 0.2489 0.34502 0.38947 0.31151 34 80 76 24 109 119
    rs6040633 Imputed A GEN 442 6.683 0.03539 0.2489 0.34502 0.38947 0.31151 34 80 76 24 109 119
    rs6040634 Imputed T ADD 441 1.404 0.1433 1.06 1.859 2.368 0.01791 0.295 0.34694 0.39211 0.31275 34 81 75 24 109 118
    rs6040634 Imputed T GEN 441 6.855 0.03246 0.295 0.34694 0.39211 0.31275 34 81 75 24 109 118
    rs6040636 Imputed T ADD 443 1.371 0.1435 1.034 1.816 2.196 0.0281 0.2458 0.34312 0.38482 0.31151 34 79 78 24 109 119
    rs6040636 Imputed T GEN 443 6.529 0.03821 0.2458 0.34312 0.38482 0.31151 34 79 78 24 109 119
    rs6040638 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6040638 Imputed C GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6040644 Imputed A ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6040644 Imputed A GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6040667 Imputed T ADD 424 1.422 0.1447 1.071 1.888 2.432 0.01502 0.3997 0.35731 0.40385 0.32231 34 79 69 24 108 110
    rs6040667 Imputed T GEN 424 7.201 0.02731 0.3997 0.35731 0.40385 0.32231 34 79 69 24 108 110
    rs6040668 Imputed C ADD 440 1.398 0.1448 1.053 1.857 2.314 0.02064 0.5278 0.34659 0.38947 0.314 33 82 75 23 111 116
    rs6040668 Imputed C GEN 440 6.796 0.03345 0.5278 0.34659 0.38947 0.314 33 82 75 23 111 116
    rs6053005 Imputed C DOM 275 0.4506 0.309 0.2459 0.8257 −2.58 0.00989 0.0865 0.56909 0.53361 0.59615 41 45 33 55 76 25
    rs6054405 Imputed A REC 443 0.9755 0.2643 0.5811 1.638 −0.09385 0.9252 0.108 0.38036 0.37696 0.38294 31 82 78 41 111 100
    rs6054427 Genotyped G GEN 443 0.8477 0.6545 0.1259 0.36907 0.35602 0.37897 29 78 84 39 113 100
    rs6075186 Imputed G DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs608278 Imputed A ADD 351 1.166 0.1563 0.8582 1.584 0.9815 0.3263 0.7448 0.43305 0.45364 0.4175 31 75 45 33 101 66
    rs6111540 Imputed A ADD 380 0.9692 0.145 0.7295 1.288 −0.2155 0.8294 0.1209 0.45921 0.45181 0.46495 35 80 51 53 93 68
    rs6131206 Imputed C ADD 424 1.493 0.1554 1.101 2.025 2.581 0.00986 0.2791 0.28066 0.3288 0.24375 23 75 86 15 87 138
    rs6131208 Imputed T ADD 440 1.387 0.1445 1.045 1.841 2.263 0.02364 0.2909 0.34091 0.3836 0.30876 33 79 77 23 109 119
    rs6131208 Imputed T GEN 440 6.748 0.03426 0.2909 0.34091 0.3836 0.30876 33 79 77 23 109 119
    rs6131919 Imputed G DOM 443 1.138 0.2135 0.7487 1.729 0.6045 0.5455 0.2352 0.16817 0.17801 0.16071 8 52 131 8 65 179
    rs6134243 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6134243 Imputed C GEN 443 6.692 0.03523 0.2479 0.34424 0.38743 0.31151 34 80 77 24 109 119
    rs6136020 Imputed A DOM 441 1.061 0.2134 0.6982 1.612 0.2765 0.7822 0.1646 0.1644 0.17016 0.16 8 49 134 8 64 178
    rs613799 Imputed C DOM 420 1.391 0.2013 0.9378 2.065 1.641 0.1008 0.1798 0.32262 0.35912 0.29498 26 78 77 24 93 122
    rs644041 Imputed G ADD 402 1.202 0.1659 0.8685 1.664 1.111 0.2667 0.6136 0.27114 0.28947 0.25758 11 77 83 16 87 128
    rs644041 Imputed G DOM 402 1.351 0.2068 0.9007 2.026 1.454 0.1459 0.6136 0.27114 0.28947 0.25758 11 77 83 16 87 128
    rs6464377 Imputed C DOM 443 1.043 0.2788 0.6037 1.801 0.1498 0.8809 0.4889 0.07223 0.07068 0.07341 0 27 164 3 31 218
    rs6474230 Imputed T DOM 443 1.32 0.1941 0.9026 1.931 1.432 0.1521 0.6236 0.26298 0.27487 0.25397 9 87 95 19 90 143
    rs6476565 Imputed A DOM 442 1.184 0.2598 0.7118 1.97 0.6512 0.5149 0.7613 0.0871 0.09474 0.08135 2 32 156 2 37 213
    rs6511286 Imputed T ADD 442 1.099 0.1394 0.8364 1.444 0.6778 0.4979 0.1082 0.33371 0.34737 0.32341 24 84 82 33 97 122
    rs6541829 Genotyped C REC 443 2.003 0.3363 1.036 3.873 2.066 0.03883 0.1994 0.2833 0.2801 0.28571 24 59 108 17 110 125
    rs6544721 Imputed G DOM 436 1.236 0.1963 0.8409 1.815 1.077 0.2814 0.454 0.25803 0.26455 0.25304 11 78 100 21 83 143
    rs6544728 Imputed T DOM 439 1.333 0.197 0.9058 1.961 1.458 0.1448 0.7087 0.25854 0.26862 0.251 10 81 97 21 84 146
    rs6565910 Imputed G DOM 433 1.047 0.1973 0.7112 1.541 0.2331 0.8157 0.7258 0.28753 0.29144 0.28455 15 79 93 19 102 125
    rs6581985 Imputed G GEN 408 7.356 0.02528 0.3553 0.31127 0.35714 0.27682 22 81 72 13 103 117
    rs6581985 Imputed G REC 408 2.451 0.3667 1.195 5.028 2.445 0.01449 0.3553 0.31127 0.35714 0.27682 22 81 72 13 103 117
    rs6685186 Imputed T ADD 426 1.015 0.1482 0.7591 1.357 0.1003 0.9201 0.3984 0.35329 0.35519 0.35185 23 84 76 26 119 98
    rs6685186 Imputed T GEN 426 0.5003 0.7787 0.3984 0.35329 0.35519 0.35185 23 84 76 26 119 98
    rs670593 Imputed A REC 442 0.3987 0.3133 0.2158 0.7367 −2.935 0.00333 0.7665 0.40045 0.38158 0.41468 19 107 64 50 109 93
    rs6722640 Imputed T DOM 441 0.5987 0.207 0.399 0.8983 −2.478 0.01322 0.2486 0.44671 0.40576 0.478 37 81 73 57 125 68
    rs6746170 Imputed A DOM 442 1.346 0.196 0.9168 1.977 1.517 0.1293 0.8072 0.26471 0.27749 0.25498 11 84 96 21 86 144
    rs6757316 Imputed A GEN 431 3.593 0.1659 0.01072 0.43155 0.45946 0.41057 31 108 46 36 130 80
    rs6805139 Imputed G DOM 442 1.417 0.2237 0.9138 2.197 1.557 0.1194 0.00028 0.52941 0.56283 0.50398 67 81 43 76 101 74
    rs6808571 Imputed G ADD 440 1.138 0.1981 0.7719 1.678 0.6528 0.5139 1 0.14091 0.15 0.134 5 47 138 3 61 186
    rs6816479 Imputed A REC 430 0.7905 0.293 0.4452 1.404 −0.8024 0.4223 0.3984 0.35349 0.32787 0.37247 22 76 85 36 112 99
    rs6865976 Imputed C DOM 401 1.085 0.2308 0.69 1.705 0.352 0.7249 0.2704 0.47382 0.48276 0.46696 38 92 44 46 120 61
    rs687047 Imputed C ADD 443 0.5642 0.2311 0.3587 0.8876 −2.476 0.01329 0.8186 0.11512 0.08377 0.13889 0 32 159 5 60 187
    rs6871041 Imputed G DOM 418 0.6503 0.2006 0.4389 0.9635 −2.145 0.03192 0.6303 0.2823 0.25824 0.30085 16 62 104 15 112 109
    rs688358 Imputed A ADD 427 0.5756 0.2319 0.3653 0.9068 −2.382 0.01723 0.8183 0.1171 0.08602 0.14108 0 32 154 5 58 178
    rs6908481 Imputed C REC 400 1.391 0.2704 0.8186 2.363 1.22 0.2226 0.7579 0.41875 0.43275 0.4083 35 78 58 37 113 79
    rs6917224 Imputed A ADD 441 0.959 0.1367 0.7336 1.254 −0.3058 0.7597 0.1287 0.37642 0.37105 0.38048 33 75 82 37 117 97
    rs6917224 Imputed A GEN 441 2.699 0.2593 0.1287 0.37642 0.37105 0.38048 33 75 82 37 117 97
    rs6920677 Imputed G DOM 438 0.9579 0.2018 0.645 1.422 −0.2133 0.8311 0.6893 0.39384 0.37831 0.40562 25 93 71 45 112 92
    rs6994498 Imputed G DOM 443 1.32 0.1941 0.9026 1.931 1.432 0.1521 0.6236 0.26298 0.27487 0.25397 9 87 95 19 90 143
    rs6998772 Imputed T DOM 442 1.182 0.3637 0.5795 2.411 0.4595 0.6459 1 0.04299 0.04712 0.03984 0 18 173 0 20 231
    rs7022281 Imputed C ADD 441 0.6915 0.1481 0.5172 0.9244 −2.491 0.01275 0.548 0.38776 0.34392 0.42063 16 98 75 47 118 87
    rs7022281 Imputed C GEN 441 9.434 0.00894 0.548 0.38776 0.34392 0.42063 16 98 75 47 118 87
    rs7022281 Imputed C REC 441 0.386 0.3115 0.2096 0.7108 −3.056 0.00224 0.548 0.38776 0.34392 0.42063 16 98 75 47 118 87
    rs7043983 Imputed T DOM 438 1.147 0.2639 0.6835 1.923 0.5181 0.6044 0.5344 0.08447 0.09043 0.08 2 30 156 2 36 212
    rs7077799 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.1663 0.33484 0.36911 0.30876 29 83 79 27 101 123
    rs7088947 Imputed A ADD 436 0.5704 0.339 0.2936 1.108 −1.656 0.0977 0.6185 0.05161 0.03743 0.06225 0 14 173 0 31 218
    rs7089661 Imputed C DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129 0.3355 0.33145 0.36649 0.30478 28 84 79 25 103 123
    rs7102072 Imputed A DOM 439 0.9567 0.1978 0.6492 1.41 −0.224 0.8228 0.5412 0.26651 0.25926 0.272 10 78 101 18 100 132
    rs710832 Genotyped A REC 443 0.4518 0.4871 0.1739 1.174 −1.631 0.1029 0.4404 0.24492 0.21466 0.26786 6 70 115 17 101 134
    rs712531 Imputed A DOM 275 2.784 1.233 0.2485 31.19 0.8305 0.4063 1 0.00545 0.00833 0.00323 0 2 118 0 1 154
    rs7129817 Imputed T ADD 441 0.9401 0.1475 0.7041 1.255 −0.4191 0.6751 0.4609 0.3424 0.33598 0.34722 20 87 82 28 119 105
    rs7134262 Imputed T GEN 438 5.456 0.06536 1 0.3379 0.37632 0.30847 29 85 76 21 111 116
    rs7134262 Imputed T REC 438 1.986 0.3091 1.084 3.641 2.22 0.02641 1 0.3379 0.37632 0.30847 29 85 76 21 111 116
    rs7138300 Imputed C ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs7138300 Imputed C DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546 0.438 0.4537 0.40541 0.48988 30 90 65 63 116 68
    rs722927 Imputed G ADD 435 0.8492 0.2939 0.4774 1.511 −0.5561 0.5782 1 0.06207 0.05645 0.06627 0 21 165 1 31 217
    rs722927 Imputed G DOM 435 0.874 0.3014 0.4842 1.578 −0.4468 0.655 1 0.06207 0.05645 0.06627 0 21 165 1 31 217
    rs726424 Genotyped G ADD 443 0.7827 0.1433 0.5911 1.037 −1.709 0.08742 0.6906 0.38939 0.35602 0.41468 18 100 73 47 115 90
    rs726424 Genotyped G GEN 443 7.021 0.02989 0.6906 0.38939 0.35602 0.41468 18 100 73 47 115 90
    rs7295817 Imputed C ADD 424 0.727 0.1447 0.5475 0.9655 −2.203 0.02761 1 0.42807 0.38187 0.46281 23 93 66 55 114 73
    rs7295817 Imputed C GEN 424 6.629 0.03635 1 0.42807 0.38187 0.46281 23 93 66 55 114 73
    rs7295817 Imputed C REC 424 0.4929 0.2774 0.2862 0.849 −2.55 0.01077 1 0.42807 0.38187 0.46281 23 93 66 55 114 73
    rs7297372 Imputed A ADD 435 0.7305 0.1423 0.5526 0.9655 −2.207 0.02734 1 0.55977 0.51862 0.59109 50 95 43 86 120 41
    rs7297372 Imputed A GEN 435 4.87 0.08761 1 0.55977 0.51862 0.59109 50 95 43 86 120 41
    rs7298255 Imputed A ADD 443 0.7433 0.1356 0.5699 0.9696 −2.188 0.02869 0.2143 0.46163 0.41885 0.49405 34 92 65 67 115 70
    rs7298255 Imputed A DOM 443 0.74 0.2089 0.4914 1.114 −1.442 0.1493 0.2143 0.46163 0.41885 0.49405 34 92 65 67 115 70
    rs7305832 Imputed C GEN 442 5.607 0.06061 1 0.33597 0.37435 0.30677 29 85 77 21 112 118
    rs7305832 Imputed C REC 442 2.008 0.3089 1.096 3.678 2.256 0.02404 1 0.33597 0.37435 0.30677 29 85 77 21 112 118
    rs737542 Imputed A REC 425 2.077 0.347 1.052 4.1 2.107 0.03514 0.1461 0.27765 0.27596 0.27893 23 55 105 16 103 123
    rs742827 Imputed A ADD 437 1.396 0.145 1.051 1.855 2.3 0.02146 0.4608 0.34668 0.38947 0.31377 33 82 75 23 109 115
    rs742827 Imputed A GEN 437 6.499 0.03879 0.4608 0.34668 0.38947 0.31377 33 82 75 23 109 115
    rs7446891 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs7448641 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7448641 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7460605 Imputed G DOM 412 1.481 0.222 0.9584 2.288 1.769 0.07694 0.1313 0.42961 0.46369 0.40343 33 100 46 35 118 80
    rs7468898 Imputed T ADD 426 1.05 0.1419 0.795 1.386 0.3429 0.7317 0.6273 0.47183 0.48077 0.46516 44 87 51 48 131 65
    rs7468898 Imputed T GEN 426 1.795 0.4075 0.6273 0.47183 0.48077 0.46516 44 87 51 48 131 65
    rs7501186 Imputed A DOM 443 2.011 0.2218 1.302 3.107 3.15 0.00163 0.4471 0.14447 0.17801 0.11905 3 62 126 8 44 200
    rs755117 Imputed A DOM 418 0.7161 0.2216 0.4638 1.106 −1.507 0.1319 0.07503 0.16627 0.14641 0.18143 7 39 135 10 66 161
    rs7557560 Imputed T GEN 437 3.838 0.1467 0.05904 0.20938 0.20213 0.21486 14 48 126 12 83 154
    rs7557560 Imputed T REC 437 1.621 0.4101 0.7258 3.622 1.179 0.2386 0.05904 0.20938 0.20213 0.21486 14 48 126 12 83 154
    rs7562462 Imputed T DOM 436 0.6891 0.2101 0.4565 1.04 −1.772 0.07634 0.2049 0.43349 0.40576 0.4551 31 93 67 44 135 66
    rs757173 Genotyped G DOM 443 1.033 0.2035 0.6933 1.54 0.1606 0.8724 0.01107 0.37359 0.3822 0.36706 23 100 68 26 133 93
    rs7607447 Imputed T REC 410 2.337 0.3138 1.264 4.323 2.706 0.00681 0.3717 0.33049 0.37288 0.29828 30 72 75 19 101 113
    rs7639053 Imputed A ADD 443 1.02 0.1656 0.7375 1.411 0.1214 0.9034 0.6744 0.21558 0.21728 0.21429 10 63 118 12 84 156
    rs7648163 Imputed C REC 421 0.941 0.3004 0.5223 1.695 −0.2025 0.8396 0.06007 0.32542 0.32222 0.3278 22 72 86 31 96 114
    rs7651273 Imputed A GEN 442 1.393 0.4984 0.6226 0.17534 0.19211 0.1627 7 59 124 8 66 178
    rs7653190 Imputed C ADD 433 0.9859 0.1679 0.7095 1.37 −0.0846 0.9326 0.569 0.21478 0.21351 0.21573 10 59 116 12 83 153
    rs7653685 Genotyped C DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs7684899 Imputed C DOM 417 0.5176 0.2237 0.3339 0.8024 −2.944 0.00324 0.8637 0.17266 0.13462 0.20213 6 37 139 7 81 147
    rs7701604 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7701604 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7703676 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7703676 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709 2.36E−05 0.07336 0.0733 0.07341 3 22 166 7 23 222
    rs7711358 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.00954 0.1134 0.34312 0.3089 0.36905 26 66 99 34 118 100
    rs7713251 Imputed C REC 433 1.11 0.3089 0.6058 2.033 0.3374 0.7358 0.08847 0.30485 0.29894 0.30943 22 69 98 26 99 119
    rs7737608 Imputed G DOM 399 0.7496 0.2094 0.4973 1.13 −1.376 0.1687 0.912 0.34712 0.32164 0.36623 18 74 79 29 109 90
    rs7755903 Imputed A GEN 426 0.886 0.6421 1 0.41197 0.41129 0.4125 29 95 62 43 112 85
    rs7762993 Imputed A ADD 431 1.066 0.1948 0.7276 1.561 0.3271 0.7436 0.00187 0.18213 0.18548 0.17959 2 65 119 3 82 160
    rs7762993 Imputed A DOM 431 1.079 0.2057 0.7207 1.614 0.3676 0.7132 0.00187 0.18213 0.18548 0.17959 2 65 119 3 82 160
    rs7767265 Imputed G DOM 430 1.155 0.1977 0.7839 1.702 0.7283 0.4664 0.0128 0.24419 0.25936 0.23251 9 79 99 7 99 137
    rs7769415 Imputed C GEN 433 11.76 0.0028 0.2034 0.34642 0.41176 0.29675 35 84 68 23 100 123
    rs7771264 Imputed T DOM 441 1.051 0.1977 0.7133 1.548 0.251 0.8018 0.25 0.2483 0.25132 0.24603 14 67 108 18 88 146
    rs7795792 Imputed T REC 440 0.659 0.2526 0.4017 1.081 −1.651 0.09871 0.3808 0.42727 0.39005 0.45582 30 89 72 55 117 77
    rs7806481 Imputed G REC 443 1.465 0.2335 0.9272 2.316 1.636 0.1017 1 0.47517 0.47906 0.47222 50 83 58 50 138 64
    rs7808536 Imputed G DOM 409 1.374 0.2138 0.904 2.09 1.488 0.1368 0.7448 0.18582 0.2095 0.16739 8 59 112 7 63 160
    rs7814819 Imputed G ADD 250 2.296 0.3362 1.188 4.438 2.472 0.01342 1 0.088 0.12736 0.05903 1 25 80 1 15 128
    rs7814819 Imputed G DOM 250 2.549 0.3553 1.271 5.115 2.634 0.00844 1 0.088 0.12736 0.05903 1 25 80 1 15 128
    rs7815952 Imputed T DOM 442 1.182 0.3637 0.5795 2.411 0.4595 0.6459 1 0.04299 0.04712 0.03984 0 18 173 0 20 231
    rs7834090 Imputed T DOM 442 1.182 0.3637 0.5795 2.411 0.4595 0.6459 1 0.04299 0.04712 0.03984 0 18 173 0 20 231
    rs7859250 Imputed C DOM 442 1.184 0.2598 0.7118 1.97 0.6512 0.5149 0.7613 0.0871 0.09474 0.08135 2 32 156 2 37 213
    rs7863577 Genotyped A ADD 443 1.029 0.2235 0.6639 1.595 0.1275 0.8986 0.01049 0.10835 0.10995 0.10714 6 30 155 5 44 203
    rs7863577 Genotyped A DOM 443 0.9475 0.2573 0.5723 1.569 −0.2095 0.8341 0.01049 0.10835 0.10995 0.10714 6 30 155 5 44 203
    rs7902140 Imputed C ADD 442 0.9423 0.1886 0.6511 1.364 −0.3154 0.7525 0.2408 0.16968 0.16492 0.17331 5 53 133 4 79 168
    rs7921834 Imputed C DOM 440 1.347 0.1965 0.9164 1.98 1.516 0.1296 0.2375 0.33182 0.36579 0.306 28 83 79 26 101 123
    rs7939893 Imputed C ADD 441 0.6916 0.1478 0.5177 0.924 −2.495 0.01261 0.3875 0.32653 0.27895 0.36255 22 62 106 29 124 98
    rs7939893 Imputed C DOM 441 0.506 0.1982 0.3431 0.7463 −3.437 0.00059 0.3875 0.32653 0.27895 0.36255 22 62 106 29 124 98
    rs7955901 Imputed C ADD 440 0.7285 0.1367 0.5573 0.9524 −2.316 0.02054 0.2142 0.46364 0.41842 0.498 34 91 65 67 115 68
    rs7955901 Imputed C DOM 440 0.7139 0.2105 0.4726 1.078 −1.601 0.1093 0.2142 0.46364 0.41842 0.498 34 91 65 67 115 68
    rs7956274 Imputed T ADD 426 0.7156 0.1398 0.5441 0.9412 −2.394 0.01667 0.3288 0.45423 0.40659 0.48975 30 88 64 63 113 68
    rs7956274 Imputed T DOM 426 0.7031 0.2129 0.4633 1.067 −1.655 0.098 0.3288 0.45423 0.40659 0.48975 30 88 64 63 113 68
    rs7957932 Imputed G ADD 439 0.7234 0.1368 0.5533 0.9459 −2.366 0.01797 0.3884 0.47039 0.42408 0.50605 35 92 64 67 117 64
    rs7957932 Imputed G DOM 439 0.6888 0.212 0.4546 1.044 −1.758 0.07871 0.3884 0.47039 0.42408 0.50605 35 92 64 67 117 64
    rs7984294 Imputed A DOM 437 2.115 0.2464 1.305 3.429 3.041 0.00236 0.6016 0.10069 0.13564 0.0743 2 47 139 1 35 213
    rs7994286 Imputed A ADD 436 1.764 0.2224 1.141 2.727 2.552 0.0107 0.1747 0.12041 0.15241 0.09639 2 53 132 1 46 202
    rs7994286 Imputed A DOM 436 1.796 0.2315 1.141 2.828 2.529 0.01143 0.1747 0.12041 0.15241 0.09639 2 53 132 1 46 202
    rs8038229 Genotyped A ADD 443 0.6909 0.1538 0.5111 0.934 −2.404 0.01622 0.8204 0.29684 0.25393 0.32937 12 73 106 28 110 114
    rs8038229 Genotyped A DOM 443 0.666 0.1948 0.4546 0.9756 −2.087 0.03693 0.8204 0.29684 0.25393 0.32937 12 73 106 28 110 114
    rs8043336 Imputed C GEN 418 0.2115 0.8997 0.4595 0.36124 0.35955 0.3625 23 82 73 35 104 101
    rs8043336 Imputed C REC 418 0.9456 0.301 0.5242 1.706 −0.186 0.8525 0.4595 0.36124 0.35955 0.3625 23 82 73 35 104 101
    rs8054431 Imputed T DOM 399 1.148 0.2121 0.7573 1.739 0.6492 0.5162 0.01816 0.36842 0.37791 0.36123 19 92 61 24 116 87
    rs8066502 Imputed T DOM 442 0.5122 0.2187 0.3337 0.7864 −3.059 0.00222 0.7257 0.16176 0.1178 0.19522 2 41 148 8 82 161
    rs8068714 Imputed T DOM 442 0.5127 0.2187 0.334 0.7871 −3.055 0.00225 0.8632 0.16403 0.11842 0.19841 2 41 147 9 82 161
    rs892575 Imputed T ADD 442 1.044 0.1635 0.7579 1.439 0.2645 0.7914 1 0.22624 0.23037 0.22311 9 70 112 13 86 152
    rs892583 Imputed G ADD 438 1.079 0.1657 0.7796 1.492 0.457 0.6477 1 0.22146 0.22872 0.216 9 68 111 12 84 154
    rs915494 Imputed A ADD 422 1.399 0.1473 1.048 1.868 2.281 0.02256 0.1185 0.32227 0.36828 0.28602 29 79 78 22 91 123
    rs915494 Imputed A DOM 422 1.486 0.1999 1.004 2.199 1.982 0.0475 0.1185 0.32227 0.36828 0.28602 29 79 78 22 91 123
    rs917295 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs922594 Imputed T DOM 443 0.5826 0.1985 0.3948 0.8597 −2.722 0.0065 0.6802 0.36005 0.31675 0.39286 21 79 91 34 130 88
    rs9301653 Imputed T ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs9301653 Imputed T DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs9309988 Imputed G DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs9309989 Genotyped C DOM 443 0.771 0.2394 0.4822 1.233 −1.086 0.2774 1 0.11174 0.09686 0.12302 1 35 155 4 54 194
    rs9310221 Imputed A DOM 393 0.8966 0.2237 0.5784 1.39 −0.4881 0.6255 0.1503 0.42875 0.42604 0.4308 29 86 54 36 121 67
    rs9327555 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.00964 0.1134 0.34312 0.31152 0.36706 27 65 99 33 119 100
    rs937890 Imputed G DOM 442 0.5127 0.2187 0.334 0.7871 −3.055 0.00225 0.8632 0.16403 0.11842 0.19841 2 41 147 9 82 161
    rs9454967 Imputed G ADD 441 0.982 0.2314 0.624 1.545 −0.07863 0.9373 0.07328 0.0907 0.08947 0.09163 3 28 159 4 38 209
    rs9454967 Imputed G DOM 441 0.9744 0.2621 0.583 1.629 −0.09893 0.9212 0.07328 0.0907 0.08947 0.09163 3 28 159 4 38 209
    rs9471295 Imputed T DOM 443 1.784 0.2155 1.169 2.721 2.686 0.00722 0.7052 0.14786 0.18586 0.11905 5 61 125 3 54 195
    rs9477007 Imputed A ADD 436 1.012 0.1389 0.7712 1.329 0.08887 0.9292 0.4209 0.39106 0.39362 0.38911 34 80 74 37 119 92
    rs9477007 Imputed A GEN 436 1.863 0.394 0.4209 0.39106 0.39362 0.38911 34 80 74 37 119 92
    rs9487279 Imputed T DOM 420 1.094 0.2113 0.7229 1.655 0.4244 0.6713 0.4873 0.42976 0.41892 0.4383 29 97 59 52 102 81
    rs949016 Imputed C ADD 441 1.063 0.1656 0.7682 1.47 0.3676 0.7132 1 0.21882 0.22487 0.21429 9 67 113 12 84 156
    rs9555973 Imputed G ADD 437 1.732 0.2221 1.12 2.676 2.472 0.01343 0.1748 0.12014 0.15079 0.09677 2 53 134 1 46 201
    rs9555973 Imputed G DOM 437 1.761 0.2314 1.119 2.772 2.446 0.01443 0.1748 0.12014 0.15079 0.09677 2 53 134 1 46 201
    rs9557510 Imputed G ADD 443 1.342 0.1885 0.9272 1.941 1.559 0.119 0.08093 0.14447 0.16754 0.12698 9 46 136 5 54 193
    rs9557510 Imputed G DOM 443 1.316 0.2241 0.848 2.042 1.224 0.2208 0.08093 0.14447 0.16754 0.12698 9 46 136 5 54 193
    rs9560584 Imputed T DOM 435 1.792 0.2322 1.137 2.824 2.512 0.01202 0.1752 0.11954 0.15135 0.096 2 52 131 1 46 203
    rs9588770 Imputed T DOM 443 1.714 0.2282 1.096 2.68 2.36 0.01827 0.8302 0.12754 0.15707 0.10516 3 54 134 3 47 202
    rs9588848 Imputed C ADD 438 1.725 0.2225 1.115 2.668 2.451 0.01426 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs9588848 Imputed C DOM 438 1.754 0.2318 1.113 2.762 2.423 0.01539 0.1759 0.11872 0.14894 0.096 2 52 134 1 46 203
    rs966583 Imputed A ADD 439 0.7596 0.1431 0.5738 1.005 −1.922 0.05464 1 0.40091 0.36579 0.42771 26 87 77 44 125 80
    rs966583 Imputed A DOM 439 0.6781 0.203 0.4555 1.01 −1.913 0.0557 1 0.40091 0.36579 0.42771 26 87 77 44 125 80
    rs974130 Genotyped A REC 443 0.8861 0.2801 0.5118 1.534 −0.4317 0.6659 0.4714 0.3623 0.34293 0.37698 25 81 85 37 116 99
    rs977160 Imputed T ADD 438 0.9972 0.168 0.7174 1.386 −0.0169 0.9865 0.8862 0.21119 0.21011 0.212 9 61 118 11 84 155
    rs9812206 Imputed G ADD 442 1.042 0.2668 0.6177 1.758 0.1545 0.8772 0.09556 0.07692 0.07853 0.0757 0 30 161 0 38 213
    rs9812206 Imputed G DOM 442 1.042 0.2668 0.6177 1.758 0.1545 0.8772 0.09556 0.07692 0.07853 0.0757 0 30 161 0 38 213
    rs9813552 Imputed G ADD 442 1.042 0.2623 0.6235 1.743 0.1586 0.874 0.4984 0.07692 0.07853 0.0757 0 30 161 1 36 214
    rs9813552 Imputed G DOM 442 1.077 0.2681 0.6368 1.821 0.2766 0.7821 0.4984 0.07692 0.07853 0.0757 0 30 161 1 36 214
    rs9815037 Imputed T ADD 443 1.048 0.2622 0.6267 1.752 0.1778 0.8589 0.4982 0.07675 0.07853 0.0754 0 30 161 1 36 215
    rs9815037 Imputed T DOM 443 1.083 0.2681 0.6401 1.831 0.2958 0.7674 0.4982 0.07675 0.07853 0.0754 0 30 161 1 36 215
    rs9825349 Imputed A ADD 443 1.048 0.2622 0.6267 1.752 0.1778 0.8589 0.4982 0.07675 0.07853 0.0754 0 30 161 1 36 215
    rs9825349 Imputed A DOM 443 1.083 0.2681 0.6401 1.831 0.2958 0.7674 0.4982 0.07675 0.07853 0.0754 0 30 161 1 36 215
    rs9834217 Imputed T ADD 443 1.017 0.2611 0.6096 1.696 0.06425 0.9488 0.5011 0.07788 0.07853 0.07738 0 30 161 1 37 214
    rs9834217 Imputed T DOM 443 1.049 0.2668 0.6218 1.77 0.179 0.858 0.5011 0.07788 0.07853 0.07738 0 30 161 1 37 214
    rs9840460 Imputed T ADD 443 1.017 0.2611 0.6096 1.696 0.06425 0.9488 0.5011 0.07788 0.07853 0.07738 0 30 161 1 37 214
    rs9840460 Imputed T DOM 443 1.049 0.2668 0.6218 1.77 0.179 0.858 0.5011 0.07788 0.07853 0.07738 0 30 161 1 37 214
    rs9840756 Imputed A ADD 437 0.9995 0.2614 0.5988 1.668 −0.00192 0.9985 0.5026 0.07895 0.07895 0.07895 0 30 160 1 37 209
    rs9840756 Imputed A DOM 437 1.031 0.2671 0.6105 1.74 0.1127 0.9103 0.5026 0.07895 0.07895 0.07895 0 30 160 1 37 209
    rs9844801 Imputed C DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs985375 Imputed A GEN 423 0.2263 0.893 0.8976 0.25296 0.25137 0.25417 12 68 103 14 94 132
    rs9869187 Imputed C ADD 442 1.037 0.2669 0.6147 1.75 0.1366 0.8914 0.09536 0.07805 0.07895 0.07738 0 30 160 0 39 213
    rs9869187 Imputed C DOM 442 1.037 0.2669 0.6147 1.75 0.1366 0.8914 0.09536 0.07805 0.07895 0.07738 0 30 160 0 39 213
    rs9872327 Imputed T DOM 443 0.8286 0.2404 0.5173 1.327 −0.7821 0.4342 0.8039 0.10722 0.09686 0.11508 1 35 155 3 52 197
    rs9881685 Imputed A ADD 440 1.041 0.2668 0.6172 1.756 0.151 0.88 0.09541 0.07727 0.07895 0.076 0 30 160 0 38 212
    rs9881685 Imputed A DOM 440 1.041 0.2668 0.6172 1.756 0.151 0.88 0.09541 0.07727 0.07895 0.076 0 30 160 0 38 212
    rs9909499 Imputed C DOM 422 1.716 0.1997 1.161 2.539 2.706 0.00681 0.6472 0.3045 0.33516 0.28125 15 92 75 26 83 131
    rs9911847 Imputed G DOM 442 0.5127 0.2187 0.334 0.7871 −3.055 0.00225 0.8632 0.16403 0.11842 0.19841 2 41 147 9 82 161
    rs9958823 Imputed A ADD 438 1.083 0.1637 0.7858 1.493 0.4879 0.6256 0.7885 0.23174 0.23947 0.22581 9 73 108 13 86 149
    rs9965248 Imputed T ADD 437 1.002 0.1681 0.721 1.394 0.01427 0.9886 0.8864 0.21167 0.21123 0.212 9 61 117 11 84 155
  • TABLE 12
    ALLELE
    SNP rs # SOURCE (A1) MODEL P P(R) OR OR(R) Q I
    rs198460 Genotyped G RECESSIVE 2.29E−04 0.000229 1.7469 1.7469 0.3205 0
    rs603940 Genotyped G RECESSIVE 4.77E−03 0.004769 0.6036 0.6036 0.9004 0
    rs10021016 Genotyped G GENOTYPIC 1.53E−03 0.001532 2.2715 2.2715 0.7583 0
    rs1003148 Imputed C ADDITIVE 1.09E−04 0.0001087 0.706 0.706 0.7408 0
    rs1003148 Imputed C GENOTYPIC 0.0001585 0.0001585 0.4899 0.4899 0.518 0
    rs1003148 Imputed C RECESSIVE 0.001753 0.00218 0.5819 0.5829 0.3099 3.02
    rs10046799 Imputed C ADDITIVE 3.21E−04 0.003933 0.724 0.7134 0.2084 36.82
    rs10046799 Imputed C GENOTYPIC 0.0005855 0.003461 0.5342 0.5221 0.2386 28.01
    rs10051148 Imputed C DOMINANT 1.63E−05 1.63E−05 0.5783 0.5783 0.7565 0
    rs10054055 Imputed T DOMINANT 1.71E−05 1.71E−05 0.5791 0.5791 0.7456 0
    rs10067895 Imputed A DOMINANT 1.57E−05 1.57E−05 0.5759 0.5759 0.7904 0
    rs1008705 Imputed C DOMINANT 8.42E−03 0.00842 1.4761 1.4761 0.9317 0
    rs10105871 Imputed C DOMINANT 5.40E−04 0.0005398 1.6092 1.6092 0.4959 0
    rs10116807 Imputed A GENOTYPIC 4.73E−04 0.0004726 3.0952 3.0952 0.9876 0
    rs10116807 Imputed A RECESSIVE 5.24E−04 5.24E−04 3.0277 3.0277 0.956 0
    rs10121941 Imputed C DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs10128638 Genotyped G DOMINANT 3.84E−04 0.0003837 0.6023 0.6023 0.6707 0
    rs1012924 Imputed G ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs1012924 Imputed G DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs1016030 Genotyped G ADDITIVE 7.02E−05 7.02E−05 1.4487 1.4487 0.5994 0
    rs1016030 Genotyped G GENOTYPIC 8.31E−05 8.31E−05 2.1351 2.1351 0.6388 0
    rs1017558 Imputed A RECESSIVE 9.48E−05 9.48E−05 2.016 2.016 0.6946 0
    rs10183431 Imputed T DOMINANT 9.50E−05 9.50E−05 1.6438 1.6438 0.7949 0
    rs10195401 Imputed C DOMINANT 8.08E−05 8.08E−05 1.679 1.679 0.7757 0
    rs10239416 Imputed A DOMINANT 5.37E−05 5.37E−05 0.5939 0.5939 0.6861 0
    rs1032188 Imputed G GENOTYPIC 0.0003684 0.004755 0.411 0.3885 0.2102 36.31
    rs1032188 Imputed G RECESSIVE 0.0009593 0.01499 0.4495 0.4153 0.1711 46.62
    rs10468988 Imputed G ADDITIVE 2.45E−05 2.45E−05 1.5305 1.5305 0.6802 0
    rs10478919 Imputed G DOMINANT 1.10E−05 1.10E−05 0.5722 0.5722 0.6924 0
    rs10506623 Imputed C DOMINANT 1.26E−04 0.0001255 0.6039 0.6039 0.8321 0
    rs10506626 Imputed A DOMINANT 2.45E−05 2.45E−05 0.5722 0.5722 0.8985 0
    rs10509477 Imputed T DOMINANT 1.46E−04 0.000146 1.6135 1.6135 0.3224 0
    rs10511071 Imputed C DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs10511072 Imputed G DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs10511199 Imputed C ADDITIVE 9.67E−05 9.67E−05 1.5246 1.5246 0.8383 0
    rs10513283 Imputed G GENOTYPIC 8.48E−05 8.48E−05 3.6142 3.6142 0.3734 0
    rs10520072 Imputed T DOMINANT 1.41E−05 1.41E−05 0.5759 0.5759 0.7897 0
    rs1065639 Imputed C DOMINANT 6.94E−05 6.94E−05 1.7059 1.7059 0.8002 0
    rs10733846 Imputed G ADDITIVE 8.04E−06 8.04E−06 0.5881 0.5881 0.4857 0
    rs10733846 Imputed G DOMINANT 7.17E−05 7.17E−05 0.5809 0.5809 0.6915 0
    rs10737390 Imputed T DOMINANT 5.78E−05 5.78E−05 0.5929 0.5929 0.5632 0
    rs10749293 Imputed G DOMINANT 9.87E−05 0.0001063 1.6321 1.6316 0.3156 0.71
    rs10752159 Imputed G DOMINANT 0.0003712 0.001012 1.5856 1.5961 0.2786 14.82
    rs10753760 Imputed T ADDITIVE 9.28E−05 9.28E−05 1.4355 1.4355 0.8085 0
    rs10753760 Imputed T GENOTYPIC 8.65E−05 8.65E−05 2.1142 2.1142 0.8438 0
    rs10757887 Imputed C DOMINANT 8.87E−05 8.87E−05 0.604 0.604 0.8342 0
    rs10758326 Imputed A ADDITIVE 8.55E−04 0.0008545 0.7335 0.7335 0.95 0
    rs10758326 Imputed A GENOTYPIC 0.001038 0.001038 0.5194 0.5194 0.7462 0
    rs10758326 Imputed A RECESSIVE 6.13E−03 0.006132 0.603 0.603 0.5469 0
    rs10762236 Genotyped G ADDITIVE 2.14E−05 2.14E−05 0.6093 0.6093 0.584 0
    rs10765769 Imputed C ADDITIVE 2.91E−05 2.91E−05 1.474 1.474 0.756 0
    rs10765769 Imputed C GENOTYPIC 5.17E−05 5.17E−05 2.1499 2.1499 0.7054 0
    rs10784891 Imputed C ADDITIVE 0.0003093 0.0003093 0.711 0.711 0.6979 0
    rs10784891 Imputed C DOMINANT 5.54E−05 5.54E−05 0.5722 0.5722 0.9756 0
    rs10787923 Imputed G DOMINANT 6.47E−05 1.80E−04 1.6581 1.6522 0.2931 9.54
    rs10787949 Imputed A DOMINANT 1.77E−04 0.001337 1.6068 1.5927 0.2585 21.69
    rs10787951 Imputed G DOMINANT 0.0001766 0.001337 1.6068 1.5927 0.2585 21.69
    rs10787983 Imputed C DOMINANT 1.40E−04 0.0004442 1.6153 1.6079 0.2874 11.66
    rs10788380 Imputed C ADDITIVE 0.0005839 0.0005839 1.3678 1.3678 0.66 0
    rs10788380 Imputed C DOMINANT 4.48E−04 4.48E−04 1.7138 1.7138 0.8013 0
    rs10788380 Imputed C GENOTYPIC 0.0004936 0.0004936 1.8999 1.8999 0.7216 0
    rs10814418 Imputed G DOMINANT 8.78E−05 8.78E−05 0.5119 0.5119 0.7369 0
    rs10831417 Imputed A ADDITIVE 1.96E−05 1.96E−05 1.4929 1.4929 0.5559 0
    rs10831417 Imputed A GENOTYPIC 1.73E−05 1.73E−05 2.3097 2.3097 0.6056 0
    rs10831422 Imputed C ADDITIVE 5.92E−05 5.92E−05 1.4561 1.4561 0.7103 0
    rs10831422 Imputed C GENOTYPIC 4.43E−05 4.43E−05 2.2133 2.2133 0.7026 0
    rs10862931 Imputed C GENOTYPIC 9.68E−05 9.68E−05 0.4267 0.4267 0.4634 0
    rs10865197 Imputed C DOMINANT 9.34E−05 9.34E−05 1.6437 1.6437 0.7947 0
    rs10871302 Imputed A DOMINANT 0.009612 0.009612 1.4552 1.4552 0.5024 0
    rs10877463 Imputed C DOMINANT 2.64E−03 0.002642 0.6825 0.6825 0.4291 0
    rs10877468 Imputed C DOMINANT 2.82E−03 0.002816 0.6833 0.6833 0.3554 0
    rs10879240 Imputed C ADDITIVE 5.13E−04 0.001027 0.6811 0.6808 0.2896 10.85
    rs10879242 Imputed A DOMINANT 2.95E−05 2.95E−05 0.5555 0.5555 0.3862 0
    rs10879245 Imputed G DOMINANT 2.95E−05 2.95E−05 0.5555 0.5555 0.3862 0
    rs10879249 Imputed T DOMINANT 1.19E−04 0.0001194 0.6021 0.6021 0.7426 0
    rs10886452 Imputed A DOMINANT 1.77E−04 0.001337 1.6068 1.5927 0.2585 21.69
    rs10886463 Imputed C DOMINANT 1.54E−04 6.44E−04 1.6141 1.6047 0.2786 14.82
    rs10886465 Imputed A DOMINANT 0.00019 0.0006506 1.604 1.596 0.2834 13.1
    rs10886526 Imputed C DOMINANT 1.74E−04 0.0001743 1.6053 1.6053 0.3255 0
    rs10902437 Imputed G ADDITIVE 1.74E−03 1.74E−03 1.3336 1.3336 0.3478 0
    rs10941126 Imputed G ADDITIVE 2.13E−05 2.13E−05 0.1976 0.1976 0.798 0
    rs10941126 Imputed G DOMINANT 3.85E−05 3.85E−05 0.2007 0.2007 0.8145 0
    rs10947871 Imputed A DOMINANT 2.08E−03 0.002076 1.5391 1.5391 0.8556 0
    rs10972978 Imputed G DOMINANT 6.77E−05 6.77E−05 0.5018 0.5018 0.7975 0
    rs10973012 Imputed A DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs10974028 Genotyped G ADDITIVE 9.41E−05 9.41E−05 0.6153 0.6153 0.8548 0
    rs10974028 Genotyped G DOMINANT 1.15E−05 1.15E−05 0.5349 0.5349 0.733 0
    rs11021302 Imputed A ADDITIVE 6.97E−05 6.97E−05 1.4505 1.4505 0.6892 0
    rs11021302 Imputed A GENOTYPIC 4.72E−05 4.72E−05 2.2069 2.2069 0.695 0
    rs11099644 Imputed G RECESSIVE 9.48E−05 9.48E−05 2.016 2.016 0.6946 0
    rs11138315 Imputed G ADDITIVE 0.002501 0.002501 0.6333 0.6333 0.4998 0
    rs11149802 Imputed T DOMINANT 9.61E−03 0.009612 1.4552 1.4552 0.5024 0
    rs1116596 Imputed T DOMINANT 1.10E−05 1.10E−05 0.5722 0.5722 0.6924 0
    rs11178531 Imputed A ADDITIVE 0.001066 0.001066 0.7412 0.7412 0.6947 0
    rs11178531 Imputed A DOMINANT 5.75E−05 5.75E−05 0.572 0.572 0.8111 0
    rs11178575 Imputed C GENOTYPIC 0.002546 0.002546 1.8735 1.8735 0.3907 0
    rs11178575 Imputed C RECESSIVE 0.001194 0.001194 1.8848 1.8848 0.3922 0
    rs11178577 Imputed T GENOTYPIC 0.002616 0.002616 1.87 1.87 0.3948 0
    rs11178577 Imputed T RECESSIVE 0.001154 0.001154 1.8884 1.8884 0.4001 0
    rs11178583 Imputed A DOMINANT 7.82E−05 7.82E−05 0.5918 0.5918 0.6676 0
    rs11178589 Imputed T DOMINANT 0.0001977 0.0001977 0.6108 0.6108 0.7703 0
    rs11178594 Imputed C DOMINANT 8.34E−05 8.34E−05 0.5951 0.5951 0.7778 0
    rs11178602 Imputed T DOMINANT 7.78E−05 7.78E−05 0.5942 0.5942 0.6786 0
    rs11178648 Imputed T DOMINANT 2.45E−05 2.45E−05 0.576 0.576 0.8248 0
    rs11198877 Imputed T DOMINANT 0.0001766 0.001337 1.6068 1.5927 0.2585 21.69
    rs11198942 Imputed T DOMINANT 0.0001123 0.0002521 1.6276 1.6227 0.2973 7.94
    rs11221075 Imputed A ADDITIVE 0.002456 0.002456 0.6561 0.6561 0.6722 0
    rs11242020 Imputed T DOMINANT 8.24E−06 8.24E−06 0.5675 0.5675 0.7214 0
    rs11242021 Imputed T DOMINANT 1.39E−05 1.39E−05 0.5753 0.5753 0.7864 0
    rs11242022 Imputed T DOMINANT 1.90E−05 1.90E−05 0.5805 0.5805 0.7156 0
    rs11242023 Imputed T DOMINANT 1.94E−05 1.94E−05 0.5807 0.5807 0.7577 0
    rs1149350 Imputed A DOMINANT 8.78E−05 8.78E−05 1.6713 1.6713 0.3701 0
    rs1150143 Imputed G DOMINANT 5.41E−05 5.41E−05 1.6852 1.6852 0.741 0
    rs11576627 Imputed T ADDITIVE 2.21E−04 0.0002213 1.6268 1.6268 0.4154 0
    rs11576627 Imputed T DOMINANT 0.0002026 0.0002026 1.7055 1.7055 0.4813 0
    rs11602189 Imputed A DOMINANT 5.90E−05 5.90E−05 0.6007 0.6007 0.9545 0
    rs11605163 Imputed A DOMINANT 6.08E−05 6.08E−05 2.1075 2.1075 0.8875 0
    rs11615214 Imputed G ADDITIVE 3.71E−05 3.71E−05 0.6853 0.6853 0.3765 0
    rs11615214 Imputed G GENOTYPIC 9.43E−05 0.001874 0.4648 0.4738 0.2292 30.83
    rs11642394 Imputed C DOMINANT 0.009359 0.009359 1.4572 1.4572 0.5108 0
    rs11644943 Imputed A ADDITIVE 0.001027 0.001027 1.4247 1.4247 0.3922 0
    rs11656608 Imputed T DOMINANT 4.43E−03 0.004428 0.6695 0.6695 0.7811 0
    rs11661309 Imputed A ADDITIVE 3.52E−05 3.52E−05 0.6163 0.6163 0.8488 0
    rs11661309 Imputed A DOMINANT 8.21E−05 8.21E−05 0.5852 0.5852 0.7907 0
    rs11666131 Imputed A ADDITIVE 6.47E−05 6.47E−05 1.5364 1.5364 0.8474 0
    rs11743355 Imputed C ADDITIVE 2.07E−05 2.07E−05 0.1796 0.1796 0.7144 0
    rs11743355 Imputed C DOMINANT 3.53E−05 3.53E−05 0.1817 0.1817 0.7255 0
    rs11746806 Imputed T ADDITIVE 3.41E−05 3.41E−05 0.2206 0.2206 0.9267 0
    rs11746806 Imputed T DOMINANT 6.55E−05 6.55E−05 0.2253 0.2253 0.9509 0
    rs11746959 Imputed T ADDITIVE 2.13E−05 2.13E−05 0.1976 0.1976 0.798 0
    rs11746959 Imputed T DOMINANT 3.85E−05 3.85E−05 0.2007 0.2007 0.8145 0
    rs11749272 Imputed T DOMINANT 1.23E−05 1.23E−05 0.5734 0.5734 0.7009 0
    rs11901899 Imputed A DOMINANT 0.0003007 0.0003007 1.5824 1.5824 0.3922 0
    rs11926319 Imputed G ADDITIVE 7.83E−07 7.83E−07 0.4343 0.4343 0.3992 0
    rs11926319 Imputed G DOMINANT 1.01E−06 1.01E−06 0.4237 0.4237 0.4489 0
    rs11956952 Imputed C DOMINANT 0.0009505 0.0009505 0.6564 0.6564 0.7028 0
    rs12025826 Imputed G DOMINANT 0.0005142 0.0005142 1.5794 1.5794 0.3682 0
    rs1204522 Imputed C GENOTYPIC 8.61E−05 8.61E−05 0.4353 0.4353 0.6828 0
    rs1204524 Imputed A GENOTYPIC 8.54E−05 8.54E−05 0.4351 0.4351 0.6472 0
    rs12153185 Imputed T DOMINANT 1.57E−05 1.57E−05 0.5759 0.5759 0.7904 0
    rs12182651 Imputed T ADDITIVE 7.03E−06 7.03E−06 2.1926 2.1926 0.7348 0
    rs12182651 Imputed T DOMINANT 1.21E−06 1.21E−06 2.4795 2.4795 0.5648 0
    rs12193568 Imputed G DOMINANT 0.000391 0.004677 1.7403 1.8042 0.2164 34.55
    rs12264914 Imputed C DOMINANT 1.11E−02 0.01109 0.6442 0.6442 0.505 0
    rs12307767 Imputed C DOMINANT 0.001811 0.001811 0.6667 0.6667 0.3444 0
    rs1232298 Imputed G RECESSIVE 0.0006722 0.006032 2.0566 2.0955 0.2088 36.69
    rs12407412 Imputed C ADDITIVE 0.0002213 0.0002213 1.6268 1.6268 0.4154 0
    rs12407412 Imputed C DOMINANT 2.03E−04 0.0002026 1.7055 1.7055 0.4813 0
    rs12420184 Imputed G DOMINANT 6.39E−05 6.39E−05 0.5645 0.5645 0.7037 0
    rs12422750 Imputed A DOMINANT 0.00369 0.00369 0.6919 0.6919 0.3546 0
    rs12446951 Imputed A ADDITIVE 6.52E−05 6.52E−05 2.3413 2.3413 0.3314 0
    rs12446951 Imputed A DOMINANT 0.0001226 0.0001226 2.3135 2.3135 0.3285 0
    rs12457400 Imputed G DOMINANT 0.0009766 0.0009766 0.5884 0.5884 0.6035 0
    rs1247340 Imputed C DOMINANT 8.32E−05 8.32E−05 1.6742 1.6742 0.3604 0
    rs1247341 Imputed C DOMINANT 7.02E−05 7.02E−05 1.684 1.684 0.3274 0
    rs12521291 Imputed G ADDITIVE 6.67E−05 6.67E−05 0.6857 0.6857 0.9769 0
    rs12526849 Imputed T ADDITIVE 7.52E−05 7.52E−05 1.4208 1.4208 0.6829 0
    rs12526849 Imputed T GENOTYPIC 7.73E−05 7.73E−05 2.0445 2.0445 0.7856 0
    rs12543110 Imputed G DOMINANT 0.0001096 0.0001096 1.6401 1.6401 0.5183 0
    rs12678600 Imputed A DOMINANT 9.83E−05 9.83E−05 0.6104 0.6104 0.9092 0
    rs12719415 Imputed T DOMINANT 8.10E−06 8.10E−06 0.5662 0.5662 0.7128 0
    rs12831292 Imputed G DOMINANT 9.77E−05 9.77E−05 0.5982 0.5982 0.6795 0
    rs12923993 Imputed C DOMINANT 0.009359 0.009359 1.4572 1.4572 0.5108 0
    rs12936964 Imputed T DOMINANT 9.02E−05 9.02E−05 1.6688 1.6688 0.7618 0
    rs12960663 Imputed G ADDITIVE 5.61E−05 5.61E−05 0.6241 0.6241 0.7884 0
    rs13038146 Imputed C ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs13038146 Imputed C GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs13134222 Imputed A GENOTYPIC 9.86E−05 9.86E−05 0.3011 0.3011 0.8224 0
    rs13172910 Imputed A DOMINANT 0.0008666 0.0008666 0.6547 0.6547 0.7269 0
    rs13194907 Imputed A ADDITIVE 1.34E−05 1.34E−05 2.303 2.303 0.9028 0
    rs13194907 Imputed A DOMINANT 5.24E−06 5.24E−06 2.505 2.505 0.845 0
    rs13195745 Imputed A ADDITIVE 1.34E−05 1.34E−05 2.303 2.303 0.9028 0
    rs13195745 Imputed A DOMINANT 5.24E−06 5.24E−06 2.505 2.505 0.845 0
    rs1321432 Imputed A RECESSIVE 3.78E−05 3.78E−05 2.1221 2.1221 0.4916 0
    rs1321457 Imputed G RECESSIVE 7.32E−05 7.32E−05 2.0656 2.0656 0.4383 0
    rs13265054 Imputed T DOMINANT 1.26E−04 0.0001261 0.6144 0.6144 0.8838 0
    rs13282131 Imputed C GENOTYPIC 6.83E−04 0.0006831 1.8412 1.8412 0.8885 0
    rs13353526 Imputed C DOMINANT 4.66E−05 4.66E−05 1.9371 1.9371 0.4192 0
    rs1336382 Imputed T DOMINANT 1.46E−04 1.46E−04 1.6135 1.6135 0.3224 0
    rs1336383 Imputed T DOMINANT 0.000146 0.000146 1.6135 1.6135 0.3224 0
    rs1336407 Imputed T DOMINANT 0.000146 0.000146 1.6135 1.6135 0.3224 0
    rs1336409 Imputed T DOMINANT 1.62E−04 0.0002489 1.6085 1.6059 0.3065 4.35
    rs1336596 Imputed A DOMINANT 5.25E−05 5.25E−05 0.5951 0.5951 0.5868 0
    rs1343560 Imputed T ADDITIVE 7.42E−05 7.42E−05 0.5393 0.5393 0.7611 0
    rs1343560 Imputed T DOMINANT 4.91E−05 4.91E−05 0.5034 0.5034 0.6771 0
    rs1361987 Imputed T GENOTYPIC 9.25E−05 9.25E−05 0.4404 0.4404 0.5591 0
    rs1386153 Imputed T ADDITIVE 8.36E−05 8.36E−05 0.6841 0.6841 0.8357 0
    rs1386153 Imputed T DOMINANT 5.01E−05 5.01E−05 0.599 0.599 0.9393 0
    rs1394015 Imputed C DOMINANT 5.43E−05 5.43E−05 1.7294 1.7294 0.6444 0
    rs1407038 Imputed A RECESSIVE 5.83E−05 5.83E−05 2.0823 2.0823 0.4381 0
    rs1407039 Imputed A RECESSIVE 9.91E−05 9.91E−05 2.0129 2.0129 0.5236 0
    rs1412802 Imputed T GENOTYPIC 0.0007205 0.0007205 0.4264 0.4264 0.7234 0
    rs1414865 Imputed T DOMINANT 0.0001766 0.001337 1.6068 1.5927 0.2585 21.69
    rs1414873 Imputed A DOMINANT 0.000122 0.0001815 1.6219 1.6195 0.3077 3.88
    rs1414876 Imputed C DOMINANT 0.000122 0.0001815 1.6219 1.6195 0.3077 3.88
    rs1418671 Imputed C RECESSIVE 9.36E−06 9.36E−06 2.1762 2.1762 0.8027 0
    rs1419490 Genotyped T GENOTYPIC 8.94E−05 8.94E−05 0.4398 0.4398 0.5307 0
    rs1434507 Imputed A ADDITIVE 7.02E−05 7.02E−05 1.4932 1.4932 0.6454 0
    rs1434508 Imputed T ADDITIVE 9.01E−05 9.01E−05 1.4841 1.4841 0.6551 0
    rs1435205 Imputed A ADDITIVE 9.67E−05 9.67E−05 1.5246 1.5246 0.8383 0
    rs1443928 Imputed C RECESSIVE 6.72E−05 6.72E−05 0.5586 0.5586 0.6157 0
    rs1452235 Imputed G GENOTYPIC 7.97E−05 7.97E−05 0.4269 0.4269 0.4549 0
    rs1452236 Imputed G GENOTYPIC 7.57E−05 7.57E−05 0.4257 0.4257 0.4487 0
    rs1452237 Imputed G GENOTYPIC 7.97E−05 7.97E−05 0.4269 0.4269 0.4549 0
    rs1452243 Genotyped T GENOTYPIC 7.97E−05 7.97E−05 0.4269 0.4269 0.4549 0
    rs1463768 Genotyped G RECESSIVE 4.61E−04 0.01223 1.8009 1.8886 0.1522 51.22
    rs1463769 Imputed G RECESSIVE 3.34E−04 0.007743 1.8295 1.9062 0.171 46.65
    rs1472435 Imputed A ADDITIVE 0.0002548 0.001662 0.5022 0.4908 0.2466 25.51
    rs1472435 Imputed A DOMINANT 5.02E−04 0.004002 0.5076 0.4938 0.2238 32.42
    rs1476714 Imputed A DOMINANT 1.19E−05 1.19E−05 0.5726 0.5726 0.7844 0
    rs1495159 Imputed G ADDITIVE 1.61E−05 1.61E−05 0.6509 0.6509 0.7963 0
    rs1495159 Imputed G GENOTYPIC 7.70E−05 7.70E−05 0.3915 0.3915 0.8463 0
    rs1495375 Imputed A DOMINANT 0.0001025 0.0001025 0.5962 0.5962 0.6659 0
    rs1495376 Imputed T DOMINANT 2.01E−05 2.01E−05 0.5347 0.5347 0.3504 0
    rs1495377 Imputed G DOMINANT 3.97E−05 7.56E−05 0.5484 0.5467 0.2993 7.17
    rs1495381 Imputed T GENOTYPIC 0.0009636 0.0009636 1.8616 1.8616 0.5241 0
    rs1495381 Imputed T RECESSIVE 0.0001018 0.0001018 1.9326 1.9326 0.6962 0
    rs1498992 Imputed G DOMINANT 1.48E−04 0.0001483 0.6213 0.6213 0.4944 0
    rs1499001 Imputed T DOMINANT 0.0001967 0.0001967 0.6214 0.6214 0.5607 0
    rs1512988 Imputed A DOMINANT 9.29E−05 9.29E−05 0.5976 0.5976 0.8745 0
    rs1512989 Imputed T DOMINANT 9.29E−05 9.29E−05 0.5976 0.5976 0.8745 0
    rs1512991 Imputed T ADDITIVE 1.02E−03 0.001016 0.7391 0.7391 0.9158 0
    rs1512991 Imputed T DOMINANT 8.22E−05 8.22E−05 0.5816 0.5816 0.9166 0
    rs1516855 Imputed G RECESSIVE 7.25E−05 7.25E−05 2.1755 2.1755 0.4759 0
    rs1527450 Imputed T ADDITIVE 2.46E−05 2.46E−05 1.486 1.486 0.5328 0
    rs1527450 Imputed T GENOTYPIC 2.19E−05 2.19E−05 2.2868 2.2868 0.5806 0
    rs1567740 Imputed T DOMINANT 8.80E−05 8.80E−05 0.596 0.596 0.8322 0
    rs1572573 Imputed A ADDITIVE 2.45E−05 2.45E−05 1.6309 1.6309 0.4087 0
    rs1572573 Imputed A DOMINANT 4.83E−06 4.83E−06 1.8564 1.8564 0.424 0
    rs1584003 Imputed C DOMINANT 3.11E−05 3.11E−05 1.8445 1.8445 0.5284 0
    rs1584005 Imputed C DOMINANT 4.62E−05 4.62E−05 1.8227 1.8227 0.5661 0
    rs1585771 Imputed G ADDITIVE 8.69E−05 8.69E−05 1.4824 1.4824 0.9898 0
    rs1592015 Imputed G DOMINANT 6.94E−05 6.94E−05 0.5728 0.5728 0.3692 0
    rs1594885 Imputed A ADDITIVE 3.75E−05 3.75E−05 1.5121 1.5121 0.6724 0
    rs1603232 Imputed A DOMINANT 8.75E−05 8.75E−05 0.5656 0.5656 0.3264 0
    rs1614565 Imputed C DOMINANT 1.53E−05 1.53E−05 0.5357 0.5357 0.5207 0
    rs1648200 Imputed G ADDITIVE 0.0002847 0.0002847 1.4867 1.4867 0.9072 0
    rs16877387 Imputed C GENOTYPIC 6.36E−05 6.36E−05 2.2411 2.2411 0.7064 0
    rs16877387 Imputed C RECESSIVE 2.50E−05 2.50E−05 2.2227 2.2227 0.938 0
    rs16938626 Imputed G DOMINANT 1.07E−04 0.0001071 0.6116 0.6116 0.7404 0
    rs1694334 Imputed G ADDITIVE 8.91E−05 8.91E−05 0.6436 0.6436 0.6943 0
    rs16998821 Imputed C DOMINANT 6.94E−05 6.94E−05 0.5728 0.5728 0.3692 0
    rs1700400 Imputed T ADDITIVE 4.31E−05 4.31E−05 0.6508 0.6508 0.3976 0
    rs17007620 Imputed G ADDITIVE 2.46E−05 2.46E−05 1.6003 1.6003 0.8148 0
    rs17007620 Imputed G DOMINANT 3.02E−05 3.02E−05 1.7521 1.7521 0.9606 0
    rs17023290 Imputed C DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs17047957 Imputed C DOMINANT 0.001192 0.001192 1.5648 1.5648 0.6233 0
    rs1705237 Imputed A DOMINANT 1.05E−05 1.05E−05 0.5283 0.5283 0.5228 0
    rs1705261 Imputed A GENOTYPIC 0.0008093 0.0008093 1.8782 1.8782 0.4997 0
    rs1705261 Imputed A RECESSIVE 0.0001018 0.0001018 1.9326 1.9326 0.6962 0
    rs17076972 Imputed C ADDITIVE 6.68E−05 6.68E−05 1.4316 1.4316 0.9615 0
    rs17076972 Imputed C GENOTYPIC 4.84E−05 4.84E−05 2.0743 2.0743 0.953 0
    rs17076972 Imputed C RECESSIVE 5.68E−05 5.68E−05 1.8279 1.8279 0.9528 0
    rs17189710 Imputed T ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs17189710 Imputed T GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs17196143 Imputed A ADDITIVE 8.38E−05 8.38E−05 1.5602 1.5602 0.9412 0
    rs17353809 Imputed G ADDITIVE 5.27E−05 5.27E−05 1.5478 1.5478 0.7656 0
    rs17368986 Imputed A GENOTYPIC 8.61E−05 8.61E−05 3.6103 3.6103 0.3631 0
    rs17369097 Imputed A GENOTYPIC 9.78E−05 9.78E−05 3.572 3.572 0.5084 0
    rs17434511 Imputed C GENOTYPIC 8.13E−05 8.13E−05 3.6271 3.6271 0.3688 0
    rs17434589 Imputed C GENOTYPIC 7.42E−05 7.42E−05 3.6546 3.6546 0.3705 0
    rs17434603 Imputed G GENOTYPIC 8.48E−05 8.48E−05 3.6142 3.6142 0.3734 0
    rs17434840 Imputed C GENOTYPIC 9.78E−05 9.78E−05 3.572 3.572 0.5084 0
    rs17446418 Imputed G DOMINANT 3.25E−05 3.25E−05 0.587 0.587 0.3535 0
    rs17530747 Imputed T DOMINANT 2.26E−05 2.63E−05 0.5795 0.5797 0.3143 1.26
    rs17604285 Imputed C ADDITIVE 1.05E−05 1.05E−05 0.4906 0.4906 0.4675 0
    rs17604285 Imputed C DOMINANT 9.86E−06 9.86E−06 0.4707 0.4707 0.5868 0
    rs17662322 Imputed T DOMINANT 0.0001449 0.0001449 0.6002 0.6002 0.4533 0
    rs17769826 Imputed T ADDITIVE 5.88E−05 5.88E−05 1.5431 1.5431 0.7499 0
    rs17821641 Imputed T ADDITIVE 9.67E−05 9.67E−05 1.5246 1.5246 0.8383 0
    rs1782328 Imputed A ADDITIVE 2.46E−05 2.46E−05 0.6019 0.6019 0.8261 0
    rs1796337 Imputed T DOMINANT 0.0001492 0.0001492 0.576 0.576 0.7496 0
    rs1798083 Imputed C DOMINANT 3.81E−05 3.81E−05 0.5525 0.5525 0.4283 0
    rs1798085 Imputed T DOMINANT 1.84E−05 1.84E−05 0.538 0.538 0.506 0
    rs1798086 Imputed T DOMINANT 6.52E−06 6.52E−06 0.5214 0.5214 0.5861 0
    rs1798089 Imputed C GENOTYPIC 0.0003263 0.0003263 1.9613 1.9613 0.6074 0
    rs1798089 Imputed C RECESSIVE 4.85E−05 4.85E−05 1.9649 1.9649 0.6513 0
    rs1798090 Imputed C GENOTYPIC 0.0002913 0.0002913 1.9722 1.9722 0.6702 0
    rs1798090 Imputed C RECESSIVE 6.28E−05 6.28E−05 1.941 1.941 0.6999 0
    rs1832222 Imputed G DOMINANT 0.0001402 0.0004442 1.6153 1.6079 0.2874 11.66
    rs1838104 Imputed A ADDITIVE 6.20E−05 6.20E−05 0.6927 0.6927 0.4982 0
    rs1838104 Imputed A GENOTYPIC 7.67E−05 7.67E−05 0.4828 0.4828 0.4457 0
    rs1868616 Imputed G ADDITIVE 6.07E−05 6.07E−05 0.6201 0.6201 0.3729 0
    rs1874313 Imputed A DOMINANT 7.43E−05 7.43E−05 0.5922 0.5922 0.8066 0
    rs1884902 Imputed C RECESSIVE 6.21E−05 6.21E−05 2.0651 2.0651 0.5825 0
    rs1913201 Imputed G ADDITIVE 0.0004149 0.0004149 0.7177 0.7177 0.6151 0
    rs1913201 Imputed G DOMINANT 9.54E−05 9.54E−05 0.5843 0.5843 0.9445 0
    rs1913201 Imputed G GENOTYPIC 0.001991 0.001991 0.5555 0.5555 0.4282 0
    rs1944279 Imputed A ADDITIVE 2.61E−05 2.61E−05 1.5292 1.5292 0.6713 0
    rs198461 Imputed C DOMINANT 0.0001487 0.0001487 0.5632 0.5632 0.3797 0
    rs1987179 Imputed T DOMINANT 0.003872 0.003872 0.6885 0.6885 0.8528 0
    rs1990023 Imputed T DOMINANT 8.24E−06 8.24E−06 0.5675 0.5675 0.7214 0
    rs2016194 Imputed G DOMINANT 1.39E−05 1.39E−05 0.5753 0.5753 0.7864 0
    rs2024789 Imputed C ADDITIVE 7.32E−05 7.32E−05 0.7001 0.7001 0.5939 0
    rs2024789 Imputed C GENOTYPIC 9.80E−05 9.80E−05 0.4935 0.4935 0.6182 0
    rs2024902 Imputed A ADDITIVE 3.48E−05 3.48E−05 2.1731 2.1731 0.7139 0
    rs2024902 Imputed A DOMINANT 1.02E−05 1.02E−05 2.3955 2.3955 0.7005 0
    rs2025107 Imputed A ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs2025107 Imputed A DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs2025108 Imputed T ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs2025108 Imputed T DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs2062448 Imputed T ADDITIVE 1.78E−05 1.78E−05 0.4975 0.4975 0.4296 0
    rs2062448 Imputed T DOMINANT 1.73E−05 1.73E−05 0.4776 0.4776 0.5425 0
    rs2063591 Imputed C ADDITIVE 0.001202 0.001202 0.7439 0.7439 0.7716 0
    rs2063591 Imputed C DOMINANT 5.22E−05 5.22E−05 0.5704 0.5704 0.86 0
    rs2065604 Imputed C DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs2066238 Imputed T DOMINANT 6.31E−05 6.31E−05 0.5711 0.5711 0.3613 0
    rs2068051 Imputed G ADDITIVE 3.45E−05 3.45E−05 0.6225 0.6225 0.8406 0
    rs2068051 Imputed G GENOTYPIC 5.01E−05 5.01E−05 0.3895 0.3895 0.8309 0
    rs2077702 Genotyped G GENOTYPIC 0.002605 0.002605 1.8705 1.8705 0.3942 0
    rs208757 Imputed G ADDITIVE 0.001261 0.001261 1.4776 1.4776 0.5869 0
    rs208757 Imputed G DOMINANT 0.0009161 0.0009161 1.5787 1.5787 0.6624 0
    rs2095586 Imputed A DOMINANT 0.0001402 0.0004442 1.6153 1.6079 0.2874 11.66
    rs2108426 Imputed C DOMINANT 1.31E−05 1.31E−05 0.5744 0.5744 0.799 0
    rs2110664 Imputed A DOMINANT 0.0005399 0.0005399 1.568 1.568 0.6563 0
    rs2132242 Imputed A DOMINANT 0.0001181 0.0001181 0.6005 0.6005 0.7904 0
    rs2151644 Imputed T DOMINANT 7.40E−05 7.40E−05 0.5083 0.5083 0.7589 0
    rs2157752 Genotyped A GENOTYPIC 7.96E−05 7.96E−05 0.4178 0.4178 0.6318 0
    rs2158958 Imputed A DOMINANT 1.37E−05 1.37E−05 0.5753 0.5753 0.7855 0
    rs2158961 Imputed G DOMINANT 1.89E−05 1.89E−05 0.5806 0.5806 0.7575 0
    rs2164099 Imputed G ADDITIVE 3.91E−05 3.91E−05 1.51 1.51 0.6597 0
    rs2173254 Imputed G GENOTYPIC 4.24E−05 4.24E−05 0.3535 0.3535 0.8105 0
    rs2173254 Imputed G RECESSIVE 7.44E−05 7.44E−05 0.3802 0.3802 0.9734 0
    rs2188079 Imputed C ADDITIVE 1.42E−05 1.42E−05 1.4883 1.4883 0.9498 0
    rs2188079 Imputed C GENOTYPIC 1.20E−05 1.20E−05 2.2697 2.2697 0.9606 0
    rs2190304 Imputed G RECESSIVE 2.19E−05 9.93E−05 0.5028 0.5057 0.2831 13.22
    rs2190597 Imputed T DOMINANT 0.0009376 0.007487 0.6352 0.6427 0.2354 28.98
    rs2190598 Imputed T DOMINANT 1.37E−05 1.37E−05 0.5753 0.5753 0.7855 0
    rs2190600 Imputed A DOMINANT 1.57E−05 1.57E−05 0.8759 0.5759 0.7904 0
    rs2218084 Imputed T GENOTYPIC 0.0004323 0.0004323 4.066 4.066 0.7112 0
    rs2218084 Imputed T RECESSIVE 0.0006382 0.0006382 3.8693 3.8693 0.7945 0
    rs2236290 Genotyped C GENOTYPIC 0.001515 0.001515 0.5241 0.5241 0.9756 0
    rs2243860 Imputed A GENOTYPIC 0.0002795 0.0002795 2.2455 2.2455 0.9794 0
    rs2243860 Imputed A RECESSIVE 0.000191 0.000191 2.1324 2.1324 0.9082 0
    rs2246564 Imputed T DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs2248236 Imputed C DOMINANT 0.00556 0.00556 0.6993 0.6993 0.7827 0
    rs2250340 Imputed T DOMINANT 7.34E−05 7.34E−05 0.4999 0.4999 0.8201 0
    rs2257192 Imputed G DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs2270584 Imputed A DOMINANT 2.79E−05 2.79E−05 0.5781 0.5781 0.841 0
    rs2270586 Imputed A DOMINANT 2.34E−05 2.34E−05 0.5711 0.5711 0.8905 0
    rs2270589 Imputed A ADDITIVE 0.0002129 0.0002129 0.7047 0.7047 0.8921 0
    rs2270589 Imputed A DOMINANT 4.02E−06 4.02E−06 0.5172 0.5172 0.475 0
    rs2270589 Imputed A GENOTYPIC 0.0008832 0.0008832 0.5338 0.5338 0.9242 0
    rs2296889 Imputed C DOMINANT 9.73E−05 9.73E−05 1.7214 1.7214 0.635 0
    rs2301346 Imputed C ADDITIVE 1.33E−05 1.33E−05 1.592 1.592 0.8797 0
    rs2301346 Imputed C DOMINANT 8.84E−06 8.84E−06 1.8528 1.8528 0.6487 0
    rs2327929 Imputed G RECESSIVE 1.47E−05 1.47E−05 1.9741 1.9741 0.5579 0
    rs2357486 Imputed C RECESSIVE 9.81E−05 9.81E−05 2.3629 2.3629 0.3237 0
    rs2373793 Imputed G DOMINANT 0.0004772 0.0004772 1.624 1.624 0.608 0
    rs2377622 Imputed T GENOTYPIC 0.001009 0.001009 0.4327 0.4327 0.9416 0
    rs2377622 Imputed T RECESSIVE 0.001315 0.001315 0.4588 0.4588 0.779 0
    rs2383903 Imputed G DOMINANT 6.50E−05 6.50E−05 0.6039 0.6039 0.8634 0
    rs2389866 Imputed C DOMINANT 0.003524 0.003524 0.6859 0.6859 0.8694 0
    rs2389869 Imputed C DOMINANT 0.003524 0.003524 0.6859 0.6859 0.8694 0
    rs2418541 Imputed A DOMINANT 1.10E−05 1.10E−05 0.5722 0.5722 0.6924 0
    rs2418542 Imputed A DOMINANT 1.10E−05 1.10E−05 0.5722 0.5722 0.6924 0
    rs2418548 Imputed C DOMINANT 6.29E−05 6.29E−05 0.5957 0.5957 0.6795 0
    rs2476976 Imputed C DOMINANT 0.0002836 0.0002836 1.5809 1.5809 0.3487 0
    rs2483639 Imputed A DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs2483640 Imputed A DOMINANT 7.75E−05 7.75E−05 0.5093 0.5093 0.7525 0
    rs2544780 Imputed T RECESSIVE 0.003543 0.003543 1.8115 1.8115 0.7962 0
    rs2586458 Imputed T DOMINANT 9.34E−05 9.34E−05 0.471 0.471 0.709 0
    rs2593272 Imputed G ADDITIVE 7.80E−05 7.80E−05 0.6664 0.6664 0.4045 0
    rs2593273 Imputed T ADDITIVE 5.67E−05 5.67E−05 0.658 0.658 0.4571 0
    rs2622499 Imputed G DOMINANT 0.006454 0.006454 0.7042 0.7042 0.7526 0
    rs264126 Imputed C DOMINANT 0.0009755 0.0163 0.6364 0.6476 0.1951 40.44
    rs264129 Imputed T DOMINANT 1.71E−05 1.71E−05 0.5791 0.5791 0.7456 0
    rs2656822 Imputed T ADDITIVE 7.80E−05 7.80E−05 0.6664 0.6664 0.4045 0
    rs2656823 Imputed G ADDITIVE 7.80E−05 7.80E−05 0.6664 0.6664 0.4045 0
    rs2656825 Imputed T ADDITIVE 7.13E−05 7.13E−05 0.6492 0.6492 0.3189 0
    rs2764766 Imputed C RECESSIVE 0.003593 0.003593 1.7939 1.7939 0.9717 0
    rs2793101 Imputed T ADDITIVE 6.64E−05 6.64E−05 0.545 0.545 0.5015 0
    rs2793101 Imputed T DOMINANT 9.02E−05 9.02E−05 0.5344 0.5344 0.5893 0
    rs2795871 Imputed A ADDITIVE 0.0002982 0.0014 0.504 0.4941 0.2612 20.77
    rs2795886 Imputed A ADDITIVE 0.0002045 0.0002045 0.4388 0.4388 0.3702 0
    rs2795886 Imputed A DOMINANT 0.0003345 0.0003345 0.4401 0.4401 0.3569 0
    rs2859994 Imputed C GENOTYPIC 8.11E−05 8.11E−05 2.2234 2.2234 0.9879 0
    rs2870464 Imputed G DOMINANT 0.007714 0.007714 1.4837 1.4837 0.7312 0
    rs2875528 Imputed T DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs2876227 Imputed C ADDITIVE 0.0003398 0.0003398 1.3941 1.3941 0.991 0
    rs2876227 Imputed C GENOTYPIC 0.0005058 0.0005058 1.9894 1.9894 0.6903 0
    rs2882097 Imputed A DOMINANT 0.000146 0.000146 1.6135 1.6135 0.3224 0
    rs2921983 Imputed C ADDITIVE 3.03E−05 3.03E−05 0.6367 0.6367 0.4592 0
    rs2987537 Imputed C DOMINANT 5.27E−05 5.27E−05 0.5308 0.5308 0.6212 0
    rs2996416 Imputed C ADDITIVE 6.90E−05 6.90E−05 0.5379 0.5379 0.7323 0
    rs2996416 Imputed C DOMINANT 4.54E−05 4.54E−05 0.5019 0.5019 0.6494 0
    rs3015527 Imputed C ADDITIVE 8.85E−05 8.85E−05 0.5427 0.5427 0.6864 0
    rs3015527 Imputed C DOMINANT 6.15E−05 6.15E−05 0.5073 0.5073 0.6044 0
    rs3015530 Imputed C ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs3015530 Imputed C DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs3015531 Imputed T ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs3015531 Imputed T DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs3015535 Imputed C ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs3015535 Imputed C DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs3019407 Imputed A GENOTYPIC 3.61E−05 3.61E−05 0.3507 0.3507 0.848 0
    rs3019407 Imputed A RECESSIVE 5.80E−05 5.80E−05 0.3753 0.3753 0.9087 0
    rs36071725 Genotyped C GENOTYPIC 2.77E−05 2.77E−05 2.4392 2.4392 0.3383 0
    rs373983 Imputed G DOMINANT 0.0002104 0.02216 1.6446 1.5957 0.1398 54.13
    rs3756154 Imputed C DOMINANT 0.003524 0.003524 0.6859 0.6859 0.8694 0
    rs3793044 Imputed C ADDITIVE 1.34E−05 1.34E−05 2.303 2.303 0.9028 0
    rs3793044 Imputed C DOMINANT 5.24E−06 5.24E−06 2.505 2.505 0.845 0
    rs3793053 Imputed C ADDITIVE 2.09E−05 2.09E−05 2.0984 2.0984 0.7421 0
    rs3793053 Imputed C DOMINANT 4.49E−06 4.49E−06 2.3534 2.3534 0.5617 0
    rs3796246 Imputed G ADDITIVE 2.47E−06 6.16E−06 0.4525 0.4504 0.2993 7.17
    rs3796246 Imputed G DOMINANT 2.87E−06 2.87E−06 0.4415 0.4415 0.3413 0
    rs3805996 Imputed G ADDITIVE 2.67E−05 2.67E−05 2.2289 2.2289 0.7845 0
    rs3805996 Imputed G DOMINANT 6.94E−06 6.94E−06 2.4684 2.4684 0.7822 0
    rs3806003 Imputed A ADDITIVE 1.34E−05 1.34E−05 2.303 2.303 0.9028 0
    rs3806003 Imputed A DOMINANT 5.24E−06 5.24E−06 2.505 2.505 0.845 0
    rs3806004 Imputed T ADDITIVE 8.98E−06 8.98E−06 2.1456 2.1456 0.5726 0
    rs3806004 Imputed T DOMINANT 1.26E−06 1.26E−06 2.4405 2.4405 0.4411 0
    rs3806010 Imputed T ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs3806010 Imputed T DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs3806014 Imputed T ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs3806014 Imputed T DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs3806015 Imputed A ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs3806015 Imputed A DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs3806018 Imputed A ADDITIVE 1.24E−05 1.24E−05 2.1211 2.1211 0.6401 0
    rs3806018 Imputed A DOMINANT 1.83E−06 1.83E−06 2.4108 2.4108 0.5006 0
    rs3806019 Imputed A ADDITIVE 4.82E−06 4.82E−06 2.2211 2.2211 0.774 0
    rs3806019 Imputed A DOMINANT 7.89E−07 7.89E−07 2.5148 2.5148 0.6004 0
    rs3806024 Imputed T ADDITIVE 2.13E−05 2.13E−05 2.0967 2.0967 0.7474 0
    rs3806024 Imputed T DOMINANT 4.58E−06 4.58E−06 2.3513 2.3513 0.5665 0
    rs3847825 Imputed G ADDITIVE 0.0001755 0.0001755 0.7117 0.7117 0.6477 0
    rs3847825 Imputed G GENOTYPIC 0.0004069 0.0004069 0.504 0.504 0.39 0
    rs3852001 Genotyped C GENOTYPIC 5.01E−05 5.01E−05 3.7361 3.7361 0.4411 0
    rs3852001 Genotyped C RECESSIVE 6.81E−05 6.81E−05 3.6068 3.6068 0.5248 0
    rs3852002 Imputed G GENOTYPIC 6.98E−05 6.98E−05 3.6551 3.6551 0.4732 0
    rs3852002 Imputed G RECESSIVE 9.73E−05 9.73E−05 3.5189 3.5189 0.5652 0
    rs3852003 Imputed A GENOTYPIC 6.98E−05 6.98E−05 3.6551 3.6551 0.4732 0
    rs3852003 Imputed A RECESSIVE 9.73E−05 9.73E−05 3.5189 3.5189 0.5652 0
    rs3942254 Imputed T DOMINANT 0.0001204 0.0001204 0.5984 0.5984 0.9786 0
    rs3945085 Imputed A DOMINANT 8.89E−05 8.89E−05 1.637 1.637 0.3315 0
    rs399485 Imputed A DOMINANT 0.001889 0.001889 1.4784 1.4784 0.6793 0
    rs4029119 Imputed G ADDITIVE 2.71E−05 2.71E−05 0.1993 0.1993 0.5787 0
    rs4029119 Imputed G DOMINANT 5.28E−05 5.28E−05 0.203 0.203 0.5644 0
    rs412791 Imputed C GENOTYPIC 9.99E−05 9.99E−05 0.4339 0.4339 0.5099 0
    rs4146972 Genotyped T DOMINANT 0.003205 0.003205 1.4961 1.4961 0.5773 0
    rs4259369 Imputed C RECESSIVE 0.0002939 0.00425 0.557 0.5415 0.2009 38.87
    rs4273613 Imputed T ADDITIVE 3.41E−05 3.41E−05 0.2206 0.2206 0.9267 0
    rs4273613 Imputed T DOMINANT 6.55E−05 6.55E−05 0.2253 0.2253 0.9509 0
    rs4294022 Imputed C DOMINANT 8.50E−05 8.50E−05 0.6007 0.6007 0.6113 0
    rs4310554 Genotyped C DOMINANT 0.0005487 0.0005487 1.6987 1.6987 0.7993 0
    rs4315598 Imputed T ADDITIVE 0.0005594 0.0005594 1.3676 1.3676 0.7519 0
    rs4315598 Imputed T GENOTYPIC 0.0006963 0.0006963 1.9242 1.9242 0.8583 0
    rs4370878 Imputed G DOMINANT 0.0001382 0.0001382 1.6143 1.6143 0.3748 0
    rs4436200 Imputed C ADDITIVE 0.00342 0.00342 0.6695 0.6695 0.4811 0
    rs4444612 Imputed G ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs4444612 Imputed G GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs4450660 Imputed C DOMINANT 5.07E−05 5.07E−05 1.6768 1.6768 0.885 0
    rs4463950 Imputed C DOMINANT 9.57E−05 9.57E−05 0.5933 0.5933 0.705 0
    rs4509702 Imputed C DOMINANT 0.0001382 0.0001382 1.6143 1.6143 0.3748 0
    rs4533379 Imputed G ADDITIVE 3.75E−05 3.75E−05 1.5121 1.5121 0.6724 0
    rs4569984 Imputed A DOMINANT 7.78E−05 7.78E−05 0.5998 0.5998 0.4464 0
    rs4570530 Imputed C DOMINANT 0.0001225 0.0001225 1.6207 1.6207 0.3622 0
    rs4571583 Imputed T DOMINANT 9.79E−05 9.79E−05 0.6041 0.6041 0.5 0
    rs4586678 Imputed A DOMINANT 6.09E−05 6.09E−05 1.6655 1.6655 0.8543 0
    rs4615971 Imputed C DOMINANT 0.0001283 0.0006247 1.6223 1.612 0.275 16.09
    rs4629229 Imputed G DOMINANT 6.31E−05 6.31E−05 0.5711 0.5711 0.3613 0
    rs4632512 Imputed T GENOTYPIC 9.78E−05 9.78E−05 3.572 3.572 0.5084 0
    rs4641552 Imputed A ADDITIVE 0.0002608 0.0002608 0.5241 0.5241 0.9002 0
    rs4682527 Imputed C DOMINANT 8.72E−05 8.72E−05 1.6904 1.6904 0.7615 0
    rs4688632 Imputed G RECESSIVE 0.0003309 0.0003309 0.5825 0.5825 0.5195 0
    rs4702720 Imputed A ADDITIVE 0.0001627 0.0001627 0.6287 0.6287 0.5601 0
    rs4702720 Imputed A DOMINANT 0.0004444 0.0004444 0.5961 0.5961 0.3979 0
    rs4714484 Imputed A ADDITIVE 6.98E−05 6.98E−05 0.6183 0.6183 0.8333 0
    rs4714484 Imputed A DOMINANT 5.02E−05 5.02E−05 0.5696 0.5696 0.55 0
    rs4725142 Genotyped G RECESSIVE 7.87E−05 7.87E−05 0.4243 0.4243 0.7642 0
    rs4725144 Imputed G RECESSIVE 6.02E−05 6.02E−05 0.4125 0.4125 0.8332 0
    rs4760785 Imputed A ADDITIVE 0.0006364 0.0006364 0.728 0.728 0.7009 0
    rs4760785 Imputed A DOMINANT 0.0001126 0.0001126 0.5881 0.5881 0.915 0
    rs4760894 Imputed T ADDITIVE 0.0006364 0.0006364 0.728 0.728 0.7009 0
    rs4760894 Imputed T DOMINANT 0.0001126 0.0001126 0.5881 0.5881 0.915 0
    rs4760895 Imputed A ADDITIVE 0.0006364 0.0006364 0.728 0.728 0.7009 0
    rs4760895 Imputed A DOMINANT 0.0001126 0.0001126 0.5881 0.5881 0.915 0
    rs4767184 Imputed C ADDITIVE 0.0002343 0.0002343 0.7168 0.7168 0.7754 0
    rs4767184 Imputed C GENOTYPIC 0.0008747 0.0008747 0.5298 0.5298 0.5351 0
    rs4773487 Imputed T ADDITIVE 9.48E−05 9.48E−05 0.5543 0.5543 0.9938 0
    rs4780547 Imputed G GENOTYPIC 0.002606 0.002606 0.3778 0.3778 0.4518 0
    rs4780547 Imputed G RECESSIVE 0.002641 0.002641 0.3832 0.3832 0.5083 0
    rs483159 Imputed T DOMINANT 0.001618 0.01337 1.5311 1.5114 0.2239 32.38
    rs4836502 Imputed T DOMINANT 1.37E−05 1.37E−05 0.5753 0.5753 0.7855 0
    rs4836507 Imputed C DOMINANT 1.68E−05 1.68E−05 0.5765 0.5765 0.7813 0
    rs4851531 Imputed T DOMINANT 0.00133 0.00133 0.6585 0.6585 0.3468 0
    rs4879931 Imputed G ADDITIVE 0.0002697 0.0002697 0.7001 0.7001 0.5714 0
    rs489441 Imputed G ADDITIVE 6.35E−05 6.35E−05 1.5268 1.5268 0.8611 0
    rs489441 Imputed G DOMINANT 5.90E−05 5.90E−05 1.6921 1.6921 0.6161 0
    rs4976276 Imputed T ADDITIVE 8.75E−05 8.75E−05 1.4687 1.4687 0.8689 0
    rs4977681 Imputed C RECESSIVE 9.61E−05 9.61E−05 2.314 2.314 0.6823 0
    rs4986197 Imputed G ADDITIVE 3.97E−05 3.97E−05 1.5105 1.5105 0.6441 0
    rs4986220 Imputed T ADDITIVE 5.91E−05 5.91E−05 1.5005 1.5005 0.7465 0
    rs525462 Imputed A GENOTYPIC 0.0007973 0.004961 0.5445 0.5308 0.2306 30.4
    rs552006 Imputed G GENOTYPIC 9.06E−05 9.06E−05 2.4662 2.4662 0.4679 0
    rs5756669 Imputed C DOMINANT 7.71E−05 7.71E−05 1.7362 1.7362 0.7477 0
    rs581905 Imputed T DOMINANT 0.008112 0.008112 1.5819 1.5819 0.4663 0
    rs6033138 Imputed C ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs6033138 Imputed C GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs6040619 Imputed C ADDITIVE 0.000474 0.000474 1.3729 1.3729 0.7285 0
    rs6040619 Imputed C GENOTYPIC 0.0005591 0.0005591 1.9442 1.9442 0.9167 0
    rs6040625 Imputed T ADDITIVE 0.0003079 0.0003079 1.3859 1.3859 0.7073 0
    rs6040625 Imputed T GENOTYPIC 0.000416 0.000416 1.9717 1.9717 0.9604 0
    rs6040630 Imputed A ADDITIVE 0.0003026 0.0003026 1.3874 1.3874 0.7384 0
    rs6040630 Imputed A GENOTYPIC 0.0004609 0.0004609 1.9676 1.9676 0.9146 0
    rs6040633 Imputed A ADDITIVE 0.0003456 0.0003456 1.3823 1.3823 0.78 0
    rs6040633 Imputed A GENOTYPIC 0.0005613 0.0005613 1.945 1.945 0.8535 0
    rs6040634 Imputed T ADDITIVE 0.00085 0.00085 1.3491 1.3491 0.6301 0
    rs6040634 Imputed T GENOTYPIC 0.001411 0.001411 1.8378 1.8378 0.9672 0
    rs6040636 Imputed T ADDITIVE 0.0007597 0.0007597 1.3531 1.3531 0.6477 0
    rs6040636 Imputed T GENOTYPIC 0.001336 0.001336 1.8436 1.8436 0.9771 0
    rs6040638 Imputed C ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs6040638 Imputed C GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs6040644 Imputed A ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs6040644 Imputed A GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs6040667 Imputed T ADDITIVE 0.0002261 0.0002261 1.4034 1.4034 0.9253 0
    rs6040667 Imputed T GENOTYPIC 0.0003915 0.0003915 2.0113 2.0113 0.742 0
    rs6040668 Imputed C ADDITIVE 0.0002261 0.0002261 1.4034 1.4034 0.9253 0
    rs6040668 Imputed C GENOTYPIC 0.0003915 0.0003915 2.0113 2.0113 0.742 0
    rs6053005 Imputed C DOMINANT 0.00111 0.01291 0.5203 0.5059 0.1794 44.53
    rs6054405 Imputed A RECESSIVE 5.03E−05 5.03E−05 2.0846 2.0846 0.5572 0
    rs6054427 Genotyped G GENOTYPIC 9.31E−05 9.31E−05 2.1425 2.1425 0.5656 0
    rs6075186 Imputed G DOMINANT 6.31E−05 6.31E−05 0.5711 0.5711 0.3613 0
    rs608278 Imputed A ADDITIVE 7.01E−05 7.01E−05 0.6797 0.6797 0.6622 0
    rs6111540 Imputed A ADDITIVE 8.63E−05 8.63E−05 0.6872 0.6872 0.3404 0
    rs6131206 Imputed C ADDITIVE 0.001921 0.001921 1.3434 1.3434 0.4914 0
    rs6131208 Imputed T ADDITIVE 0.0002261 0.0002261 1.4034 1.4034 0.9253 0
    rs6131208 Imputed T GENOTYPIC 0.0003915 0.0003915 2.0113 2.0113 0.742 0
    rs6131919 Imputed G DOMINANT 6.31E−05 6.31E−05 0.5711 0.5711 0.3613 0
    rs6134243 Imputed C ADDITIVE 0.0005045 0.0005045 1.3708 1.3708 0.7263 0
    rs6134243 Imputed C GENOTYPIC 0.0006517 0.0006517 1.9308 1.9308 0.8764 0
    rs6136020 Imputed A DOMINANT 4.47E−05 4.47E−05 0.564 0.564 0.3277 0
    rs613799 Imputed C DOMINANT 0.0002168 0.0002168 1.6378 1.6378 0.4057 0
    rs644041 Imputed G ADDITIVE 4.10E−05 4.10E−05 1.5491 1.5491 0.9018 0
    rs644041 Imputed G DOMINANT 6.67E−05 6.67E−05 1.6947 1.6947 0.6929 0
    rs6464377 Imputed C DOMINANT 8.03E−05 8.03E−05 2.035 2.035 0.5161 0
    rs6474230 Imputed T DOMINANT 0.0001096 0.0001096 1.6401 1.6401 0.5183 0
    rs6476565 Imputed A DOMINANT 7.38E−05 7.38E−05 0.5063 0.5063 0.7702 0
    rs6511286 Imputed T ADDITIVE 8.56E−05 8.56E−05 1.4548 1.4548 0.3238 0
    rs6541829 Genotyped C RECESSIVE 0.0008971 0.0008971 2.3027 2.3027 0.4111 0
    rs6544721 Imputed G DOMINANT 4.51E−05 4.51E−05 1.6786 1.6786 0.7237 0
    rs6544728 Imputed T DOMINANT 3.81E−05 3.81E−05 1.6924 1.6924 0.7254 0
    rs6565910 Imputed G DOMINANT 6.35E−05 6.35E−05 0.596 0.596 0.7271 0
    rs6581985 Imputed G GENOTYPIC 0.0008728 0.0008728 2.1776 2.1776 0.7023 0
    rs6581985 Imputed G RECESSIVE 0.0003781 0.0003781 2.2212 2.2212 0.8679 0
    rs6685186 Imputed T ADDITIVE 4.04E−05 4.04E−05 1.4552 1.4552 0.5991 0
    rs6685186 Imputed T GENOTYPIC 7.87E−05 7.87E−05 2.1208 2.1208 0.5157 0
    rs670593 Imputed A RECESSIVE 0.004705 0.004705 0.6026 0.6026 0.9153 0
    rs6722640 Imputed T DOMINANT 0.0009277 0.0009277 0.6505 0.6505 0.4929 0
    rs6746170 Imputed A DOMINANT 3.13E−05 3.13E−05 1.7022 1.7022 0.7235 0
    rs6757316 Imputed A GENOTYPIC 0.0002411 0.0002411 1.9498 1.9498 0.7316 0
    rs6805139 Imputed G DOMINANT 0.000179 0.000179 1.7522 1.7522 0.7218 0
    rs6808571 Imputed G ADDITIVE 5.06E−05 5.06E−05 1.6529 1.6529 0.3901 0
    rs6816479 Imputed A RECESSIVE 8.91E−05 8.91E−05 2.0191 2.0191 0.6804 0
    rs6865976 Imputed C DOMINANT 1.69E−05 1.69E−05 0.5245 0.5245 0.8417 0
    rs687047 Imputed C ADDITIVE 0.002064 0.002064 0.6519 0.6519 0.6436 0
    rs6871041 Imputed G DOMINANT 1.86E−05 1.86E−05 0.571 0.571 0.7023 0
    rs688358 Imputed A ADDITIVE 0.001723 0.001723 0.6472 0.6472 0.7547 0
    rs6908481 Imputed C RECESSIVE 2.93E−05 2.93E−05 1.9907 1.9907 0.715 0
    rs6917224 Imputed A ADDITIVE 8.07E−05 8.07E−05 1.4126 1.4126 0.6894 0
    rs6917224 Imputed A GENOTYPIC 6.12E−05 6.12E−05 2.0516 2.0516 0.8021 0
    rs6920677 Imputed G DOMINANT 9.74E−05 9.74E−05 0.6022 0.6022 0.3637 0
    rs6994498 Imputed G DOMINANT 0.0001214 0.0001214 1.6355 1.6355 0.5075 0
    rs6998772 Imputed T DOMINANT 3.05E−05 3.05E−05 2.6244 2.6244 0.9125 0
    rs7022281 Imputed C ADDITIVE 0.0008616 0.0008616 0.7327 0.7327 0.9461 0
    rs7022281 Imputed C GENOTYPIC 0.0008065 0.0008065 0.5109 0.5109 0.8632 0
    rs7022281 Imputed C RECESSIVE 0.003772 0.003772 0.5858 0.5858 0.653 0
    rs7043983 Imputed T DOMINANT 7.81E−05 7.81E−05 0.5075 0.5075 0.763 0
    rs7077799 Imputed A DOMINANT 0.0001618 0.0002489 1.6085 1.6059 0.3065 4.35
    rs7088947 Imputed A ADDITIVE 0.0002561 0.002122 0.5006 0.4865 0.237 28.49
    rs7089661 Imputed C DOMINANT 0.0001402 0.0004442 1.6153 1.6079 0.2874 11.66
    rs7102072 Imputed A DOMINANT 2.00E−05 2.00E−05 0.5832 0.5832 0.7992 0
    rs710832 Genotyped A RECESSIVE 0.0003556 0.0003556 0.3515 0.3515 0.5598 0
    rs712531 Imputed A DOMINANT 4.12E−05 4.12E−05 1.7164 1.7164 0.821 0
    rs7129817 Imputed T ADDITIVE 8.64E−05 8.64E−05 0.6917 0.6917 0.9871 0
    rs7134262 Imputed T GENOTYPIC 0.000667 0.000667 2.0059 2.0059 0.482 0
    rs7134262 Imputed T RECESSIVE 1.92E−05 0.0001342 2.2604 2.2418 0.2719 17.17
    rs7138300 Imputed C ADDITIVE 0.0006364 0.0006364 0.728 0.728 0.7009 0
    rs7138300 Imputed C DOMINANT 0.0001126 0.0001126 0.5881 0.5881 0.915 0
    rs722927 Imputed G ADDITIVE 5.34E−05 5.34E−05 0.4718 0.4718 0.7351 0
    rs722927 Imputed G DOMINANT 5.76E−05 5.76E−05 0.4589 0.4589 0.8222 0
    rs726424 Genotyped G ADDITIVE 0.0002921 0.0002921 0.7216 0.7216 0.7796 0
    rs726424 Genotyped G GENOTYPIC 0.0006575 0.0006575 0.5204 0.5204 0.4936 0
    rs7295817 Imputed C ADDITIVE 4.33E−05 4.33E−05 0.6912 0.6912 0.586 0
    rs7295817 Imputed C GENOTYPIC 6.93E−05 6.93E−05 0.4694 0.4694 0.3851 0
    rs7295817 Imputed C RECESSIVE 0.001037 0.01025 0.5648 0.5757 0.2268 31.55
    rs7297372 Imputed A ADDITIVE 0.0002771 0.0002771 0.7072 0.7072 0.6868 0
    rs7297372 Imputed A GENOTYPIC 0.0002766 0.0002766 0.4963 0.4963 0.7085 0
    rs7298255 Imputed A ADDITIVE 0.0006976 0.0006976 0.7332 0.7332 0.8654 0
    rs7298255 Imputed A DOMINANT 6.68E−05 6.68E−05 0.5792 0.5792 0.9355 0
    rs7305832 Imputed C GENOTYPIC 0.000667 0.000667 2.0059 2.0059 0.482 0
    rs7305832 Imputed C RECESSIVE 1.92E−05 0.0001342 2.2604 2.2418 0.2719 17.17
    rs737542 Imputed A RECESSIVE 0.0006435 0.0007974 2.3828 2.3899 0.3091 3.32
    rs742827 Imputed A ADDITIVE 0.0002216 0.0002216 1.411 1.411 0.9765 0
    rs742827 Imputed A GENOTYPIC 0.0004335 0.0004335 2.0079 2.0079 0.73 0
    rs7446891 Imputed G DOMINANT 1.34E−05 1.34E−05 0.5737 0.5737 0.819 0
    rs7448641 Imputed C ADDITIVE 2.13E−05 2.13E−05 0.1976 0.1976 0.798 0
    rs7448641 Imputed C DOMINANT 3.85E−05 3.85E−05 0.2007 0.2007 0.8145 0
    rs7460605 Imputed G DOMINANT 0.0004965 0.0004965 1.5998 1.5998 0.8118 0
    rs7468898 Imputed T ADDITIVE 4.70E−05 4.70E−05 1.4562 1.4562 0.6548 0
    rs7468898 Imputed T GENOTYPIC 5.27E−05 5.27E−05 2.1254 2.1254 0.7376 0
    rs7501186 Imputed A DOMINANT 0.009359 0.009359 1.4572 1.4572 0.5108 0
    rs755117 Imputed A DOMINANT 8.93E−05 8.93E−05 1.6937 1.6937 0.8341 0
    rs7557560 Imputed T GENOTYPIC 1.52E−05 1.52E−05 4.8002 4.8002 0.5006 0
    rs7557560 Imputed T RECESSIVE 1.73E−05 1.73E−05 4.6869 4.6869 0.4673 0
    rs7562462 Imputed T DOMINANT 3.98E−05 3.98E−05 1.7863 1.7863 0.5531 0
    rs757173 Genotyped G DOMINANT 3.67E−05 3.67E−05 0.5903 0.5903 0.3929 0
    rs7607447 Imputed T RECESSIVE 0.004354 0.004354 1.9039 1.9039 0.9167 0
    rs7639053 Imputed A ADDITIVE 6.32E−05 6.32E−05 1.5389 1.5389 0.7877 0
    rs7648163 Imputed C RECESSIVE 4.30E−05 4.30E−05 2.2905 2.2905 0.3422 0
    rs7651273 Imputed A GENOTYPIC 7.69E−05 7.69E−05 3.6491 3.6491 0.3606 0
    rs7653190 Imputed C ADDITIVE 5.88E−05 5.88E−05 1.5431 1.5431 0.7499 0
    rs7653685 Genotyped C DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs7684899 Imputed C DOMINANT 0.005003 0.005003 0.6963 0.6963 0.8023 0
    rs7701604 Imputed G ADDITIVE 2.13E−05 2.13E−05 0.1976 0.1976 0.798 0
    rs7701604 Imputed G DOMINANT 3.85E−05 3.85E−05 0.2007 0.2007 0.8145 0
    rs7703676 Imputed C ADDITIVE 2.13E−05 2.13E−05 0.1976 0.1976 0.798 0
    rs7703676 Imputed C DOMINANT 3.85E−05 3.85E−05 0.2007 0.2007 0.8145 0
    rs7711358 Imputed A DOMINANT 2.03E−05 2.03E−05 0.5813 0.5813 0.7623 0
    rs7713251 Imputed C RECESSIVE 7.07E−05 7.07E−05 2.2563 2.2563 0.6403 0
    rs7737608 Imputed G DOMINANT 2.24E−05 2.24E−05 1.7514 1.7514 0.3895 0
    rs7755903 Imputed A GENOTYPIC 9.90E−05 9.90E−05 0.4763 0.4763 0.3374 0
    rs7762993 Imputed A ADDITIVE 3.64E−05 3.64E−05 1.5999 1.5999 0.3438 0
    rs7762993 Imputed A DOMINANT 5.71E−06 5.71E−06 1.8249 1.8249 0.3301 0
    rs7767265 Imputed G DOMINANT 1.54E−06 9.09E−05 1.8708 1.8488 0.2364 28.66
    rs7769415 Imputed C GENOTYPIC 0.01222 0.01222 1.7102 1.7102 0.8943 0
    rs7771264 Imputed T DOMINANT 9.73E−05 9.73E−05 0.6028 0.6028 0.5969 0
    rs7795792 Imputed T RECESSIVE 0.0002939 0.00425 0.557 0.5415 0.2009 38.87
    rs7806481 Imputed G RECESSIVE 2.19E−05 9.93E−05 0.5028 0.5057 0.2831 13.22
    rs7808536 Imputed G DOMINANT 0.0002294 0.00065 1.6124 1.6227 0.2799 14.36
    rs7814819 Imputed G ADDITIVE 0.000435 0.000435 2.1517 2.1517 0.4796 0
    rs7814819 Imputed G DOMINANT 0.0002065 0.0002065 2.333 2.333 0.5524 0
    rs7815952 Imputed T DOMINANT 3.05E−05 3.05E−05 2.6244 2.6244 0.9125 0
    rs7834090 Imputed T DOMINANT 3.05E−05 3.05E−05 2.6244 2.6244 0.9125 0
    rs7859250 Imputed C DOMINANT 6.27E−05 6.27E−05 0.5033 0.5033 0.7889 0
    rs7863577 Genotyped A ADDITIVE 5.37E−05 5.37E−05 0.5145 0.5145 0.5515 0
    rs7863577 Genotyped A DOMINANT 8.32E−05 8.32E−05 0.5032 0.5032 0.6829 0
    rs7902140 Imputed C ADDITIVE 8.00E−05 8.00E−05 0.6274 0.6274 0.9605 0
    rs7921834 Imputed C DOMINANT 0.0001402 0.0004442 1.6153 1.6079 0.2874 11.66
    rs7939893 Imputed C ADDITIVE 0.001509 0.001509 0.7466 0.7466 0.4075 0
    rs7939893 Imputed C DOMINANT 0.0007741 0.0007741 0.6536 0.6536 0.8293 0
    rs7955901 Imputed C ADDITIVE 0.0008458 0.0008458 0.7371 0.7371 0.7791 0
    rs7955901 Imputed C DOMINANT 7.14E−05 7.14E−05 0.5799 0.5799 0.9786 0
    rs7956274 Imputed T ADDITIVE 0.001224 0.001224 0.7429 0.7429 0.9488 0
    rs7956274 Imputed T DOMINANT 0.0001094 0.0001094 0.5876 0.5876 0.8703 0
    rs7957932 Imputed G ADDITIVE 0.001498 0.001498 0.7467 0.7467 0.8677 0
    rs7957932 Imputed G DOMINANT 5.69E−05 5.69E−05 0.5706 0.5706 0.9859 0
    rs7984294 Imputed A DOMINANT 0.00858 0.00858 1.5738 1.5738 0.5291 0
    rs7994286 Imputed A ADDITIVE 9.63E−05 9.63E−05 0.549 0.549 0.854 0
    rs7994286 Imputed A DOMINANT 7.82E−05 7.82E−05 0.5161 0.5161 0.7893 0
    rs8038229 Genotyped A ADDITIVE 0.001259 0.01927 0.7324 0.7157 0.155 50.55
    rs8038229 Genotyped A DOMINANT 0.0009849 0.007544 0.6614 0.6497 0.2113 36.01
    rs8043336 Imputed C GENOTYPIC 7.96E−05 7.96E−05 0.3958 0.3958 0.4455 0
    rs8043336 Imputed C RECESSIVE 8.36E−05 8.36E−05 0.4142 0.4142 0.5943 0
    rs8054431 Imputed T DOMINANT 2.45E−05 2.45E−05 1.7571 1.7571 0.4329 0
    rs8066502 Imputed T DOMINANT 0.006801 0.006801 0.683 0.683 0.9956 0
    rs8068714 Imputed T DOMINANT 0.006941 0.006941 0.6836 0.6836 0.8713 0
    rs892575 Imputed T ADDITIVE 5.64E−05 5.64E−05 1.4995 1.4995 0.67 0
    rs892583 Imputed G ADDITIVE 5.66E−05 5.66E−05 1.5024 1.5024 0.7396 0
    rs915494 Imputed A ADDITIVE 0.0008012 0.008128 1.402 1.3898 0.223 32.66
    rs915494 Imputed A DOMINANT 0.0001453 0.01549 1.6314 1.5891 0.1486 52.08
    rs917295 Imputed G DOMINANT 1.41E−05 1.41E−05 0.5759 0.5759 0.7897 0
    rs922594 Imputed T DOMINANT 0.00224 0.00224 0.6774 0.6774 0.3822 0
    rs9301653 Imputed T ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs9301653 Imputed T DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs9309988 Imputed G DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs9309989 Genotyped C DOMINANT 3.87E−05 3.87E−05 1.9491 1.9491 0.3231 0
    rs9310221 Imputed A DOMINANT 9.78E−06 3.80E−05 1.86 1.8519 0.2901 10.65
    rs9327555 Imputed T DOMINANT 1.37E−05 1.37E−05 0.5753 0.5753 0.7855 0
    rs937890 Imputed G DOMINANT 0.005817 0.005817 0.6731 0.6731 0.8017 0
    rs9454967 Imputed G ADDITIVE 7.03E−06 7.03E−06 2.1926 2.1926 0.7348 0
    rs9454967 Imputed G DOMINANT 1.21E−06 1.21E−06 2.4795 2.4795 0.5648 0
    rs9471295 Imputed T DOMINANT 0.002076 0.002076 1.5391 1.5391 0.8556 0
    rs9477007 Imputed A ADDITIVE 5.88E−05 5.88E−05 1.429 1.429 0.6453 0
    rs9477007 Imputed A GENOTYPIC 5.42E−05 5.42E−05 2.0759 2.0759 0.7341 0
    rs9487279 Imputed T DOMINANT 9.53E−05 9.53E−05 0.5948 0.5948 0.7903 0
    rs949016 Imputed C ADDITIVE 4.61E−05 4.61E−05 1.5082 1.5082 0.7183 0
    rs9555973 Imputed G ADDITIVE 9.09E−05 9.09E−05 0.5479 0.5479 0.8574 0
    rs9555973 Imputed G DOMINANT 7.60E−05 7.60E−05 0.5157 0.5157 0.808 0
    rs9557510 Imputed G ADDITIVE 0.0001379 0.0001379 1.6102 1.6102 0.9088 0
    rs9557510 Imputed G DOMINANT 4.86E−05 4.86E−05 1.7706 1.7706 0.9892 0
    rs9560584 Imputed T DOMINANT 8.00E−05 8.00E−05 0.512 0.512 0.7127 0
    rs9588770 Imputed T DOMINANT 8.97E−05 8.97E−05 0.5187 0.5187 0.86 0
    rs9588848 Imputed C ADDITIVE 6.55E−05 6.55E−05 0.5369 0.5369 0.7455 0
    rs9588848 Imputed C DOMINANT 4.31E−05 4.31E−05 0.5009 0.5009 0.6615 0
    rs966583 Imputed A ADDITIVE 0.00064 0.00064 0.7272 0.7272 0.9721 0
    rs966583 Imputed A DOMINANT 6.94E−05 6.94E−05 0.5916 0.5916 0.8081 0
    rs974130 Genotyped A RECESSIVE 9.67E−05 9.67E−05 2.0112 2.0112 0.6677 0
    rs977160 Imputed T ADDITIVE 1.90E−05 1.90E−05 1.5465 1.5465 0.3814 0
    rs9812206 Imputed G ADDITIVE 1.27E−06 1.27E−06 0.4469 0.4469 0.5437 0
    rs9812206 Imputed G DOMINANT 1.72E−06 1.72E−06 0.4369 0.4369 0.61 0
    rs9813552 Imputed G ADDITIVE 2.01E−06 2.01E−06 0.4493 0.4493 0.4991 0
    rs9813552 Imputed G DOMINANT 2.40E−06 2.40E−06 0.4387 0.4387 0.5642 0
    rs9815037 Imputed T ADDITIVE 1.57E−06 1.57E−06 0.4461 0.4461 0.5119 0
    rs9815037 Imputed T DOMINANT 1.83E−06 1.83E−06 0.4354 0.4354 0.5792 0
    rs9825349 Imputed A ADDITIVE 1.57E−06 1.57E−06 0.4461 0.4461 0.5119 0
    rs9825349 Imputed A DOMINANT 1.83E−06 1.83E−06 0.4354 0.4354 0.5792 0
    rs9834217 Imputed T ADDITIVE 1.61E−06 1.61E−06 0.4466 0.4466 0.5093 0
    rs9834217 Imputed T DOMINANT 1.89E−06 1.89E−06 0.4359 0.4359 0.5761 0
    rs9840460 Imputed T ADDITIVE 1.57E−06 1.57E−06 0.4461 0.4461 0.5119 0
    rs9840460 Imputed T DOMINANT 1.83E−06 1.83E−06 0.4354 0.4354 0.5792 0
    rs9840756 Imputed A ADDITIVE 1.55E−06 1.55E−06 0.4458 0.4458 0.5071 0
    rs9840756 Imputed A DOMINANT 1.81E−06 1.81E−06 0.435 0.435 0.5742 0
    rs9844801 Imputed C DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs985375 Imputed A GENOTYPIC 6.39E−05 6.39E−05 2.8891 2.8891 0.9861 0
    rs9869187 Imputed C ADDITIVE 7.35E−06 7.35E−06 0.4651 0.4651 0.7004 0
    rs9869187 Imputed C DOMINANT 2.02E−05 2.02E−05 0.4704 0.4704 0.6809 0
    rs9872327 Imputed T DOMINANT 5.30E−05 8.76E−05 1.9326 1.9381 0.3031 5.72
    rs9881685 Imputed A ADDITIVE 1.31E−06 1.31E−06 0.4438 0.4438 0.4978 0
    rs9881685 Imputed A DOMINANT 1.61E−06 1.61E−06 0.4332 0.4332 0.5585 0
    rs9909499 Imputed C DOMINANT 0.002624 0.002624 1.4669 1.4669 0.7269 0
    rs9911847 Imputed G DOMINANT 0.00547 0.00547 0.6755 0.6755 0.9212 0
    rs9946886 Imputed G RECESSIVE 5.84E−05 5.84E−05 0.3084 0.3084 0.8937 0
    rs9958823 Imputed A ADDITIVE 2.61E−05 2.61E−05 1.5292 1.5292 0.6713 0
    rs9965248 Imputed T ADDITIVE 6.66E−05 6.66E−05 1.4965 1.4965 0.6122 0
  • TABLE 13
    ALLELE
    SNP rs # SOURCE (A1) MODEL P P(R) OR OR(R) Q I
    rs198460 Genotyped G RECESSIVE 2.05E−06 2.05E−06 1.8108 1.8108 0.5587 0
    rs603940 Genotyped G RECESSIVE 7.32E−05 7.32E−05 0.5405 0.5405 0.4588 0
    rs10021016 Genotyped G GENOTYPIC 5.48E−05 5.48E−05 2.3945 2.3945 0.8903 0
    rs1003148 Imputed C ADDITIVE 1.19E−05 1.19E−05 0.7154 0.7154 0.9106 0
    rs1003148 Imputed C GENOTYPIC 8.14E−06 8.14E−06 0.4872 0.4872 0.8101 0
    rs1003148 Imputed C RECESSIVE 5.89E−05 5.89E−05 0.5541 0.5541 0.5169 0
    rs10046799 Imputed C ADDITIVE 8.59E−05 8.59E−05 0.7444 0.7444 0.3859 0
    rs10046799 Imputed C GENOTYPIC 6.10E−05 6.10E−05 0.5427 0.5427 0.4931 0
    rs10051148 Imputed C DOMINANT 1.16E−06 1.16E−06 0.596 0.596 0.8669 0
    rs10054055 Imputed T DOMINANT 4.36E−07 4.36E−07 0.5814 0.5814 0.9471 0
    rs10067895 Imputed A DOMINANT 3.37E−07 3.37E−07 0.5762 0.5762 0.9653 0
    rs1008705 Imputed C DOMINANT 9.36E−05 9.36E−05 1.6202 1.6202 0.516 0
    rs10105871 Imputed C DOMINANT 9.54E−05 9.54E−05 1.5752 1.5752 0.7598 0
    rs10116807 Imputed A GENOTYPIC 2.35E−05 2.35E−05 3.1548 3.1548 0.994 0
    rs10116807 Imputed A RECESSIVE 4.72E−05 4.72E−05 2.9802 2.9802 0.9943 0
    rs10121941 Imputed C DOMINANT 3.10E−03 1.47E−01 0.6558 0.6652 0.0252 72.84
    rs10128638 Genotyped G DOMINANT 7.89E−05 7.89E−05 0.6196 0.6196 0.8513 0
    rs1012924 Imputed G ADDITIVE 6.22E−02 5.77E−01 0.7882 0.8017 0.0001 89.23
    rs1012924 Imputed G DOMINANT 6.06E−02 0.5529 0.7739 0.7744 0.0001 89.62
    rs1016030 Genotyped G ADDITIVE 9.82E−05 9.82E−05 1.3592 1.3592 0.3844 0
    rs1016030 Genotyped G GENOTYPIC 0.0001503 0.0001808 1.8631 1.8624 0.3605 1.98
    rs1017558 Imputed A RECESSIVE 3.63E−03 0.1741 1.5611 1.5084 0.0227 73.6
    rs10183431 Imputed T DOMINANT 1.18E−04 0.0001179 1.5094 1.5094 0.452 0
    rs10195401 Imputed C DOMINANT 5.75E−04 0.01653 1.4645 1.4526 0.1484 47.59
    rs10239416 Imputed A DOMINANT 8.79E−03 0.3403 0.7512 0.7725 0.0026 83.15
    rs1032188 Imputed G GENOTYPIC 3.23E−05 3.23E−05 0.415 0.415 0.4549 0
    rs1032188 Imputed G RECESSIVE 4.57E−05 4.57E−05 0.4331 0.4331 0.3757 0
    rs10468988 Imputed G ADDITIVE 1.19E−04 0.005354 1.3915 1.3736 0.1822 41.27
    rs10478919 Imputed G DOMINANT 3.36E−07 3.36E−07 0.5781 0.5781 0.9145 0
    rs10506623 Imputed C DOMINANT 4.11E−05 4.11E−05 0.6355 0.6355 0.7566 0
    rs10506626 Imputed A DOMINANT 4.77E−06 4.77E−06 0.6029 0.6029 0.7652 0
    rs10509477 Imputed T DOMINANT 5.09E−05 5.09E−05 1.5361 1.5361 0.4725 0
    rs10511071 Imputed C DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs10511072 Imputed G DOMINANT 3.65E−03 1.79E−01 1.4802 1.4969 0.0084 79.08
    rs10511199 Imputed C ADDITIVE 9.12E−04 2.82E−02 1.348 1.3411 0.1188 53.05
    rs10513283 Imputed G GENOTYPIC 3.27E−04 1.14E−02 2.7233 2.5889 0.1701 43.55
    rs10520072 Imputed T DOMINANT 4.33E−07 4.33E−07 0.5808 0.5808 0.9574 0
    rs1065639 Imputed C DOMINANT 5.13E−05 5.13E−05 1.7169 1.7169 0.8785 0
    rs10733846 Imputed G ADDITIVE 1.71E−05 5.53E−04 0.6464 0.6552 0.2454 28.81
    rs10733846 Imputed G DOMINANT 5.14E−05 5.14E−05 0.6265 0.6265 0.543 0
    rs10737390 Imputed T DOMINANT 1.70E−03 0.1499 0.7059 0.7364 0.0305 71.34
    rs10749293 Imputed G DOMINANT 1.78E−05 1.78E−05 1.5736 1.5736 0.524 0
    rs10752159 Imputed G DOMINANT 7.32E−05 7.32E−05 1.5394 1.5394 0.5089 0
    rs10753760 Imputed T ADDITIVE 3.60E−03 0.1365 1.2495 1.2446 0.0275 72.17
    rs10753760 Imputed T GENOTYPIC 3.73E−03 0.1448 1.579 1.5661 0.0247 72.99
    rs10757887 Imputed C DOMINANT 2.10E−03 0.09341 0.7185 0.7262 0.048 67.07
    rs10758326 Imputed A ADDITIVE 3.12E−05 3.12E−05 0.7205 0.7205 0.9344 0
    rs10758326 Imputed A GENOTYPIC 1.46E−05 1.46E−05 0.4748 0.4748 0.6437 0
    rs10758326 Imputed A RECESSIVE 9.28E−05 9.28E−05 0.5372 0.5372 0.3903 0
    rs10762236 Genotyped G ADDITIVE 1.41E−04 1.36E−02 0.6866 0.7015 0.1342 50.22
    rs10765769 Imputed C ADDITIVE 1.89E−05 1.89E−05 1.3977 1.3977 0.5396 0
    rs10765769 Imputed C GENOTYPIC 4.04E−05 4.04E−05 1.9329 1.9329 0.5283 0
    rs10784891 Imputed C ADDITIVE 3.30E−05 3.30E−05 0.7221 0.7221 0.8883 0
    rs10784891 Imputed C DOMINANT 3.17E−05 3.17E−05 0.6171 0.6171 0.6062 0
    rs10787923 Imputed G DOMINANT 1.17E−05 1.17E−05 1.5929 1.5929 0.4856 0
    rs10787949 Imputed A DOMINANT 6.84E−05 6.84E−05 1.5282 1.5282 0.4028 0
    rs10787951 Imputed G DOMINANT 7.02E−05 7.02E−05 1.5272 1.5272 0.4 0
    rs10787983 Imputed C DOMINANT 5.52E−05 5.52E−05 1.5334 1.5334 0.4235 0
    rs10788380 Imputed C ADDITIVE 7.51E−05 7.51E−05 1.3528 1.3528 0.8856 0
    rs10788380 Imputed C DOMINANT 3.53E−05 3.53E−05 1.6982 1.6982 0.9632 0
    rs10788380 Imputed C GENOTYPIC 6.34E−05 6.34E−05 1.8532 1.8532 0.9102 0
    rs10814418 Imputed G DOMINANT 3.49E−03 1.53E−01 0.6592 0.6683 0.0249 72.93
    rs10831417 Imputed A ADDITIVE 3.85E−05 3.11E−04 1.3868 1.3856 0.2831 20.76
    rs10831417 Imputed A GENOTYPIC 4.55E−05 6.53E−04 1.9715 1.9609 0.2571 26.37
    rs10831422 Imputed C ADDITIVE 8.06E−05 8.06E−05 1.366 1.366 0.4125 0
    rs10831422 Imputed C GENOTYPIC 6.96E−05 6.96E−05 1.9315 1.9315 0.3829 0
    rs10862931 Imputed C GENOTYPIC 5.74E−02 0.5627 0.7112 0.7348 0.0002 88.45
    rs10865197 Imputed C DOMINANT 1.16E−04 0.0001158 1.5096 1.5096 0.4518 0
    rs10871302 Imputed A DOMINANT 1.00E−04 0.0001 1.6031 1.6031 0.379 0
    rs10877463 Imputed C DOMINANT 6.35E−05 6.35E−05 0.6518 0.6518 0.5839 0
    rs10877468 Imputed C DOMINANT 7.07E−05 7.07E−05 0.653 0.653 0.5247 0
    rs10879240 Imputed C ADDITIVE 3.80E−05 3.80E−05 0.6993 0.6993 0.5299 0
    rs10879242 Imputed A DOMINANT 1.18E−05 1.18E−05 0.6 0.6 0.4258 0
    rs10879245 Imputed G DOMINANT 1.18E−05 1.18E−05 0.6 0.6 0.4258 0
    rs10879249 Imputed T DOMINANT 4.34E−05 4.34E−05 0.6359 0.6359 0.7079 0
    rs10886452 Imputed A DOMINANT 5.56E−05 5.56E−05 1.5358 1.5358 0.4242 0
    rs10886463 Imputed C DOMINANT 6.07E−05 6.07E−05 1.533 1.533 0.4181 0
    rs10886465 Imputed A DOMINANT 7.14E−05 7.14E−05 1.5271 1.5271 0.4344 0
    rs10886526 Imputed C DOMINANT 6.05E−05 6.05E−05 1.5311 1.5311 0.4839 0
    rs10902437 Imputed G ADDITIVE 6.85E−05 6.85E−05 1.3724 1.3724 0.531 0
    rs10941126 Imputed G ADDITIVE 8.37E−03 1.24E−01 0.5451 0.3771 0.0037 82.12
    rs10941126 Imputed G DOMINANT 1.51E−02 1.69E−01 0.5356 0.3959 0.0036 82.2
    rs10947871 Imputed A DOMINANT 2.83E−05 2.83E−05 1.6668 1.6668 0.5021 0
    rs10972978 Imputed G DOMINANT 4.09E−03 0.1884 0.6606 0.6715 0.0152 76.11
    rs10973012 Imputed A DOMINANT 3.10E−03 0.1472 0.6558 0.6652 0.0252 72.84
    rs10974028 Genotyped G ADDITIVE 6.17E−03 2.38E−01 0.7519 0.7698 0.0127 77.08
    rs10974028 Genotyped G DOMINANT 1.85E−03 2.16E−01 0.6916 0.7096 0.0051 81.08
    rs11021302 Imputed A ADDITIVE 9.21E−05 9.21E−05 1.3623 1.3623 0.4193 0
    rs11021302 Imputed A GENOTYPIC 7.34E−05 7.34E−05 1.9274 1.9274 0.3854 0
    rs11099644 Imputed G RECESSIVE 3.63E−03 1.74E−01 1.5611 1.5084 0.0227 73.6
    rs11138315 Imputed G ADDITIVE 5.97E−05 5.97E−05 0.6045 0.6045 0.6837 0
    rs11149802 Imputed T DOMINANT 1.00E−04 1.00E−04 1.6031 1.6031 0.379 0
    rs1116596 Imputed T DOMINANT 3.36E−07 3.36E−07 0.5781 0.5781 0.9145 0
    rs11178531 Imputed A ADDITIVE 5.04E−05 5.04E−05 0.7345 0.7345 0.9113 0
    rs11178531 Imputed A DOMINANT 1.62E−05 1.62E−05 0.6062 0.6062 0.7273 0
    rs11178575 Imputed C GENOTYPIC 7.77E−05 7.77E−05 2.0518 2.0518 0.4613 0
    rs11178575 Imputed C RECESSIVE 8.55E−05 8.55E−05 1.9633 1.9633 0.6307 0
    rs11178577 Imputed T GENOTYPIC 8.19E−05 8.19E−05 2.0467 2.0467 0.4668 0
    rs11178577 Imputed T RECESSIVE 8.45E−05 8.45E−05 1.9643 1.9643 0.6423 0
    rs11178583 Imputed A DOMINANT 3.48E−05 3.48E−05 0.6311 0.6311 0.6157 0
    rs11178589 Imputed T DOMINANT 6.58E−05 6.58E−05 0.6416 0.6416 0.759 0
    rs11178594 Imputed C DOMINANT 2.21E−05 2.21E−05 0.6259 0.6259 0.7529 0
    rs11178602 Imputed T DOMINANT 1.96E−05 1.96E−05 0.6239 0.6239 0.7278 0
    rs11178648 Imputed T DOMINANT 4.60E−06 4.60E−06 0.6044 0.6044 0.7746 0
    rs11198877 Imputed T DOMINANT 5.89E−05 5.89E−05 1.5335 1.5335 0.418 0
    rs11198942 Imputed T DOMINANT 4.04E−05 4.04E−05 1.5455 1.5455 0.4358 0
    rs11221075 Imputed A ADDITIVE 4.74E−05 4.74E−05 0.6113 0.6113 0.5392 0
    rs11242020 Imputed T DOMINANT 2.55E−07 2.55E−07 0.5746 0.5746 0.9225 0
    rs11242021 Imputed T DOMINANT 4.26E−07 4.26E−07 0.5804 0.5804 0.9558 0
    rs11242022 Imputed T DOMINANT 5.79E−07 5.79E−07 0.5841 0.5841 0.9318 0
    rs11242023 Imputed T DOMINANT 5.92E−07 5.92E−07 0.5843 0.5843 0.9496 0
    rs1149350 Imputed A DOMINANT 2.45E−03 1.30E−01 1.3997 1.3907 0.0257 72.68
    rs1150143 Imputed G DOMINANT 6.34E−04 3.31E−02 1.4503 1.4366 0.0937 57.77
    rs11576627 Imputed T ADDITIVE 4.22E−05 4.22E−05 1.5665 1.5665 0.6281 0
    rs11576627 Imputed T DOMINANT 3.05E−05 3.05E−05 1.6676 1.6676 0.7461 0
    rs11602189 Imputed A DOMINANT 1.82E−04 0.001317 0.6717 0.6744 0.2718 23.24
    rs11605163 Imputed A DOMINANT 0.000708 0.02749 1.6562 1.6712 0.0948 57.56
    rs11615214 Imputed G ADDITIVE 5.75E−06 5.75E−06 0.7047 0.7047 0.5765 0
    rs11615214 Imputed G GENOTYPIC 2.91E−06 2.91E−06 0.4566 0.4566 0.4781 0
    rs11642394 Imputed C DOMINANT 9.69E−05 9.69E−05 1.6046 1.6046 0.3847 0
    rs11644943 Imputed A ADDITIVE 6.34E−05 6.34E−05 1.4362 1.4362 0.687 0
    rs11656608 Imputed T DOMINANT 5.19E−05 5.19E−05 0.6191 0.6191 0.5685 0
    rs11661309 Imputed A ADDITIVE 3.44E−05 3.44E−05 0.6656 0.6656 0.471 0
    rs11661309 Imputed A DOMINANT 2.13E−04 8.96E−04 0.6556 0.657 0.2991 17.16
    rs11666131 Imputed A ADDITIVE 3.25E−04 6.19E−03 1.3849 1.3772 0.1964 38.55
    rs11743355 Imputed C ADDITIVE 1.07E−02 1.27E−01 0.5495 0.3573 0.0028 82.99
    rs11743355 Imputed C DOMINANT 1.87E−02 1.70E−01 0.5389 0.3746 0.0027 83.11
    rs11746806 Imputed T ADDITIVE 8.22E−03 0.1202 0.5498 0.3996 0.0061 80.4
    rs11746806 Imputed T DOMINANT 1.56E−02 1.68E−01 0.5436 0.4204 0.006 80.44
    rs11746959 Imputed T ADDITIVE 8.37E−03 1.24E−01 0.5451 0.3771 0.0037 82.12
    rs11746959 Imputed T DOMINANT 1.51E−02 1.69E−01 0.5356 0.3959 0.0036 82.2
    rs11749272 Imputed T DOMINANT 3.75E−07 3.75E−07 0.5789 0.5789 0.9197 0
    rs11901899 Imputed A DOMINANT 5.05E−05 5.05E−05 1.5436 1.5436 0.6491 0
    rs11926319 Imputed G ADDITIVE 2.62E−05 3.51E−02 0.5502 0.5519 0.0242 73.13
    rs11926319 Imputed G DOMINANT 4.50E−05 0.04527 0.5488 0.5505 0.0199 74.48
    rs11956952 Imputed C DOMINANT 8.97E−05 8.97E−05 0.6544 0.6544 0.9288 0
    rs12025826 Imputed G DOMINANT 9.61E−05 9.61E−05 1.5444 1.5444 0.6337 0
    rs1204522 Imputed C GENOTYPIC 1.76E−03 0.09323 0.5754 0.5955 0.0532 65.92
    rs1204524 Imputed A GENOTYPIC 1.75E−03 0.09548 0.5752 0.5962 0.0519 66.2
    rs12153185 Imputed T DOMINANT 3.02E−07 3.02E−07 0.575 0.575 0.965 0
    rs12182651 Imputed T ADDITIVE 4.03E−04 6.63E−02 1.6379 1.6775 0.0204 74.32
    rs12182651 Imputed T DOMINANT 9.90E−05 0.06125 1.8091 1.8433 0.0126 77.13
    rs12193568 Imputed G DOMINANT 5.33E−05 5.33E−05 1.7043 1.7043 0.4515 0
    rs12264914 Imputed C DOMINANT 9.89E−05 9.89E−05 0.5796 0.5796 0.4664 0
    rs12307767 Imputed C DOMINANT 7.20E−05 7.20E−05 0.6476 0.6476 0.5868 0
    rs1232298 Imputed G RECESSIVE 4.05E−05 4.05E−05 2.0359 2.0359 0.4524 0
    rs12407412 Imputed C ADDITIVE 4.22E−05 4.22E−05 1.5665 1.5665 0.6281 0
    rs12407412 Imputed C DOMINANT 3.05E−05 3.05E−05 1.6676 1.6676 0.7461 0
    rs12420184 Imputed G DOMINANT 1.51E−02 0.4077 0.7481 0.7745 0.0016 84.53
    rs12422750 Imputed A DOMINANT 9.60E−05 9.60E−05 0.6598 0.6598 0.5137 0
    rs12446951 Imputed A ADDITIVE 3.93E−05 1.09E−04 2.0253 2.0349 0.3226 11.62
    rs12446951 Imputed A DOMINANT 4.82E−05 4.82E−05 2.049 2.049 0.3973 0
    rs12457400 Imputed G DOMINANT 7.89E−05 7.89E−05 0.5854 0.5854 0.8723 0
    rs1247340 Imputed C DOMINANT 2.05E−03 0.1157 1.4086 1.4002 0.0296 71.6
    rs1247341 Imputed C DOMINANT 1.57E−03 1.02E−01 1.4213 1.4156 0.0312 71.17
    rs12521291 Imputed G ADDITIVE 1.87E−03 1.09E−01 0.7805 0.7921 0.04 68.92
    rs12526849 Imputed T ADDITIVE 7.17E−04 0.03214 1.2878 1.2722 0.1105 54.59
    rs12526849 Imputed T GENOTYPIC 3.38E−04 5.04E−03 1.7306 1.7075 0.2173 34.49
    rs12543110 Imputed G DOMINANT 5.89E−05 5.89E−05 1.5358 1.5358 0.5248 0
    rs12678600 Imputed A DOMINANT 1.00E−04 1.00E−04 0.6602 0.6602 0.5151 0
    rs12719415 Imputed T DOMINANT 2.53E−07 2.53E−07 0.5739 0.5739 0.9166 0
    rs12831292 Imputed G DOMINANT 2.63E−05 2.63E−05 0.6278 0.6278 0.7312 0
    rs12923993 Imputed C DOMINANT 9.69E−05 9.69E−05 1.6046 1.6046 0.3847 0
    rs12936964 Imputed T DOMINANT 3.11E−04 2.93E−03 1.4884 1.4756 0.2539 27.04
    rs12960663 Imputed G ADDITIVE 4.89E−05 4.89E−05 0.6695 0.6695 0.515 0
    rs13038146 Imputed C ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs13038146 Imputed C GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs13134222 Imputed A GENOTYPIC 1.96E−02 3.26E−01 0.5583 0.5463 0.0028 82.95
    rs13172910 Imputed A DOMINANT 7.00E−05 7.00E−05 0.6505 0.6505 0.9366 0
    rs13194907 Imputed A ADDITIVE 0.0002176 0.02467 1.7666 1.7835 0.0668 63.04
    rs13194907 Imputed A DOMINANT 6.05E−05 0.01168 1.9281 1.9369 0.0827 59.88
    rs13195745 Imputed A ADDITIVE 2.18E−04 2.47E−02 1.7666 1.7835 0.0668 63.04
    rs13195745 Imputed A DOMINANT 6.05E−05 1.17E−02 1.9281 1.9369 0.0827 59.88
    rs1321432 Imputed A RECESSIVE 8.48E−04 0.08213 1.6508 1.6057 0.0423 68.39
    rs1321457 Imputed G RECESSIVE 0.001376 0.1001 1.6314 1.5668 0.0465 67.4
    rs13265054 Imputed T DOMINANT 6.52E−05 6.52E−05 0.6518 0.6518 0.6806 0
    rs13282131 Imputed C GENOTYPIC 6.27E−05 6.27E−05 1.8345 1.8345 0.9895 0
    rs13353526 Imputed C DOMINANT 0.004081 0.1849 1.4667 1.4829 0.0079 79.32
    rs1336382 Imputed T DOMINANT 5.09E−05 5.09E−05 1.5361 1.5361 0.4725 0
    rs1336383 Imputed T DOMINANT 5.09E−05 5.09E−05 1.5361 1.5361 0.4725 0
    rs1336407 Imputed T DOMINANT 5.93E−05 5.93E−05 1.5308 1.5308 0.4544 0
    rs1336409 Imputed T DOMINANT 6.50E−05 6.50E−05 1.5274 1.5274 0.444 0
    rs1336596 Imputed A DOMINANT 5.26E−04 3.65E−02 0.6858 0.7027 0.0985 56.85
    rs1343560 Imputed T ADDITIVE 6.41E−02 5.75E−01 0.7895 0.8024 0.0001 89.05
    rs1343560 Imputed T DOMINANT 6.21E−02 5.51E−01 0.775 0.7751 0.0001 89.44
    rs1361987 Imputed T GENOTYPIC 2.87E−03 1.52E−01 0.5945 0.6201 0.0307 71.3
    rs1386153 Imputed T ADDITIVE 0.0001163 0.0001163 0.7313 0.7313 0.4314 0
    rs1386153 Imputed T DOMINANT 0.0001226 0.0004692 0.6655 0.6672 0.3089 14.88
    rs1394015 Imputed C DOMINANT 4.04E−05 4.04E−05 1.7398 1.7398 0.8288 0
    rs1407038 Imputed A RECESSIVE 1.15E−03 0.09526 1.6392 1.5778 0.0445 67.86
    rs1407039 Imputed A RECESSIVE 1.54E−03 0.08002 1.6009 1.5561 0.0626 63.92
    rs1412802 Imputed T GENOTYPIC 9.49E−05 9.49E−05 0.4269 0.4269 0.9393 0
    rs1414865 Imputed T DOMINANT 6.84E−05 6.84E−05 1.5282 1.5282 0.4028 0
    rs1414873 Imputed A DOMINANT 5.05E−05 5.05E−05 1.5365 1.5365 0.433 0
    rs1414876 Imputed C DOMINANT 5.05E−05 5.05E−05 1.5365 1.5365 0.433 0
    rs1418671 Imputed C RECESSIVE 8.77E−05 1.17E−02 1.79 1.752 0.1097 54.76
    rs1419490 Genotyped T GENOTYPIC 1.69E−03 1.04E−01 0.5757 0.6036 0.051 66.41
    rs1434507 Imputed A ADDITIVE 3.80E−04 1.15E−02 1.3574 1.3388 0.175 42.63
    rs1434508 Imputed T ADDITIVE 4.60E−04 1.09E−02 1.3515 1.3341 0.1863 40.49
    rs1435205 Imputed A ADDITIVE 9.12E−04 2.82E−02 1.348 1.3411 0.1188 53.05
    rs1443928 Imputed C RECESSIVE 9.45E−04 4.30E−02 0.6717 0.6702 0.0739 61.62
    rs1452235 Imputed G GENOTYPIC 5.06E−02 5.71E−01 0.7054 0.7381 0.0001 88.72
    rs1452236 Imputed G GENOTYPIC 4.94E−02 5.70E−01 0.7041 0.7369 0.0001 88.77
    rs1452237 Imputed G GENOTYPIC 5.06E−02 5.71E−01 0.7054 0.7381 0.0001 88.72
    rs1452243 Genotyped T GENOTYPIC 5.39E−02 5.77E−01 0.7092 0.7402 0.0001 88.89
    rs1463768 Genotyped G RECESSIVE 2.87E−05 3.63E−05 1.813 1.8163 0.3578 2.71
    rs1463769 Imputed G RECESSIVE 2.08E−05 2.08E−05 1.8336 1.8336 0.3916 0
    rs1472435 Imputed A ADDITIVE 4.20E−05 4.20E−05 0.5101 0.5101 0.5038 0
    rs1472435 Imputed A DOMINANT 8.16E−05 8.16E−05 0.5146 0.5146 0.4725 0
    rs1476714 Imputed A DOMINANT 3.69E−07 3.69E−07 0.5781 0.5781 0.9536 0
    rs1495159 Imputed G ADDITIVE 0.009749 0.3924 0.8068 0.8189 0.0005 86.97
    rs1495159 Imputed G GENOTYPIC 3.08E−03 1.34E−01 0.5615 0.5708 0.0278 72.1
    rs1495375 Imputed A DOMINANT 3.20E−05 3.20E−05 0.6273 0.6273 0.709 0
    rs1495376 Imputed T DOMINANT 2.76E−05 3.75E−04 0.5966 0.5952 0.2528 27.28
    rs1495377 Imputed G DOMINANT 5.28E−05 0.0006669 0.6086 0.6065 0.2463 28.63
    rs1495381 Imputed T GENOTYPIC 1.97E−05 1.97E−05 1.9868 1.9868 0.6544 0
    rs1495381 Imputed T RECESSIVE 3.14E−06 3.14E−06 1.9704 1.9704 0.904 0
    rs1498992 Imputed G DOMINANT 4.91E−05 4.91E−05 0.6496 0.6496 0.6335 0
    rs1499001 Imputed T DOMINANT 9.99E−05 9.99E−05 0.6588 0.6588 0.5929 0
    rs1512988 Imputed A DOMINANT 3.15E−05 3.15E−05 0.6309 0.6309 0.7406 0
    rs1512989 Imputed T DOMINANT 3.15E−05 3.15E−05 0.6309 0.6309 0.7406 0
    rs1512991 Imputed T ADDITIVE 4.36E−05 4.36E−05 0.7304 0.7304 0.9674 0
    rs1512991 Imputed T DOMINANT 2.35E−05 2.35E−05 0.6133 0.6133 0.7725 0
    rs1516855 Imputed G RECESSIVE 2.16E−04 3.15E−03 1.8266 1.832 0.214 35.15
    rs1527450 Imputed T ADDITIVE 4.98E−05 0.0004174 1.3805 1.3796 0.2782 21.84
    rs1527450 Imputed T GENOTYPIC 5.39E−05 0.0005959 1.9591 1.9507 0.2671 24.24
    rs1567740 Imputed T DOMINANT 3.10E−05 3.10E−05 0.6303 0.6303 0.7208 0
    rs1572573 Imputed A ADDITIVE 2.29E−04 0.04251 1.4476 1.3911 0.0856 59.31
    rs1572573 Imputed A DOMINANT 9.40E−05 4.64E−02 1.562 1.5083 0.0429 68.24
    rs1584003 Imputed C DOMINANT 3.34E−02 0.561 1.2949 1.2466 0.0001 89.29
    rs1584005 Imputed C DOMINANT 4.02E−02 5.68E−01 1.2838 1.2385 0.0001 89
    rs1585771 Imputed G ADDITIVE 1.04E−03 0.04355 1.3199 1.3042 0.0982 56.91
    rs1592015 Imputed G DOMINANT 0.002751 0.1964 0.7042 0.7334 0.018 75.11
    rs1594885 Imputed A ADDITIVE 0.000164 0.004814 1.3801 1.3638 0.201 37.68
    rs1603232 Imputed A DOMINANT 6.82E−05 7.72E−05 0.6125 0.6124 0.3627 1.4
    rs1614565 Imputed C DOMINANT 1.67E−05 2.91E−05 0.5932 0.5932 0.3482 5.22
    rs1648200 Imputed G ADDITIVE 9.92E−05 9.92E−05 1.428 1.428 0.791 0
    rs16877387 Imputed C GENOTYPIC 5.85E−04 2.88E−02 1.7999 1.7462 0.1152 53.73
    rs16877387 Imputed C RECESSIVE 1.06E−04 0.00243 1.8666 1.8409 0.2165 34.65
    rs16938626 Imputed G DOMINANT 6.97E−05 6.97E−05 0.6537 0.6537 0.5901 0
    rs1694334 Imputed G ADDITIVE 3.41E−03 1.76E−01 0.7552 0.7708 0.0228 73.54
    rs16998821 Imputed C DOMINANT 2.75E−03 1.96E−01 0.7042 0.7334 0.018 75.11
    rs1700400 Imputed T ADDITIVE 2.87E−04 1.62E−02 0.7267 0.7259 0.1095 54.78
    rs17007620 Imputed G ADDITIVE 0.0002711 0.02062 1.4055 1.3946 0.0989 56.78
    rs17007620 Imputed G DOMINANT 0.0001384 0.003404 1.5358 1.5258 0.1998 37.9
    rs17023290 Imputed C DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs17047957 Imputed C DOMINANT 2.41E−05 2.41E−05 1.6313 1.6313 0.7603 0
    rs1705237 Imputed A DOMINANT 1.23E−05 3.98E−05 0.5877 0.5877 0.326 10.78
    rs1705261 Imputed A GENOTYPIC 2.16E−05 2.16E−05 1.9729 1.9729 0.7039 0
    rs1705261 Imputed A RECESSIVE 3.71E−06 3.71E−06 1.9521 1.9521 0.9207 0
    rs17076972 Imputed C ADDITIVE 0.0005241 0.01788 1.2997 1.2903 0.1408 48.99
    rs17076972 Imputed C GENOTYPIC 0.0004395 0.02097 1.7025 1.6732 0.1233 52.23
    rs17076972 Imputed C RECESSIVE 7.62E−04 4.50E−02 1.5342 1.5023 0.0868 59.08
    rs17189710 Imputed T ADDITIVE 3.68E−05 3.68E−05 1.3739 1.3739 0.9395 0
    rs17189710 Imputed T GENOTYPIC 2.19E−05 2.19E−05 2.0119 2.0119 0.9089 0
    rs17196143 Imputed A ADDITIVE 1.68E−02 4.65E−01 1.2599 1.2043 0.0013 84.9
    rs17353809 Imputed G ADDITIVE 7.94E−04 4.73E−02 1.3563 1.3441 0.0746 61.48
    rs17368986 Imputed A GENOTYPIC 0.0003311 0.01194 2.721 2.5843 0.1676 44.02
    rs17369097 Imputed A GENOTYPIC 2.42E−04 1.85E−03 2.7571 2.7036 0.2673 24.2
    rs17434511 Imputed C GENOTYPIC 0.0003164 0.0117 2.7302 2.5932 0.1672 44.1
    rs17434589 Imputed C GENOTYPIC 0.0002946 0.01171 2.7449 2.6054 0.1643 44.62
    rs17434603 Imputed G GENOTYPIC 0.0003271 0.01143 2.7233 2.5889 0.1701 43.55
    rs17434840 Imputed C GENOTYPIC 0.0002417 0.001846 2.7571 2.7036 0.2673 24.2
    rs17446418 Imputed G DOMINANT 0.0005194 0.08804 0.6822 0.714 0.0469 67.33
    rs17530747 Imputed T DOMINANT 0.0003577 0.0827 0.6735 0.7062 0.0438 68.03
    rs17604285 Imputed C ADDITIVE 0.0001077 0.01983 0.5857 0.5921 0.0823 59.95
    rs17604285 Imputed C DOMINANT 0.0001272 0.02188 0.5769 0.5823 0.0746 61.48
    rs17662322 Imputed T DOMINANT 8.83E−05 8.83E−05 0.6424 0.6424 0.4888 0
    rs17769826 Imputed T ADDITIVE 0.0008578 0.04731 1.3535 1.3419 0.0766 61.08
    rs17821641 Imputed T ADDITIVE 0.0009123 0.02815 1.348 1.3411 0.1188 53.05
    rs1782328 Imputed A ADDITIVE 0.0002285 0.0184 0.687 0.6954 0.116 53.58
    rs1796337 Imputed T DOMINANT 5.74E−05 5.74E−05 0.6075 0.6075 0.7452 0
    rs1798083 Imputed C DOMINANT 2.91E−05 2.91E−05 0.602 0.602 0.3963 0
    rs1798085 Imputed T DOMINANT 1.95E−05 3.15E−05 0.5952 0.5951 0.3506 4.59
    rs1798086 Imputed T DOMINANT 8.08E−06 1.64E−05 0.5778 0.5781 0.3453 5.95
    rs1798089 Imputed C GENOTYPIC 9.52E−05 9.52E−05 2.0099 2.0099 0.7968 0
    rs1798089 Imputed C RECESSIVE 1.73E−05 1.73E−05 1.9885 1.9885 0.8721 0
    rs1798090 Imputed C GENOTYPIC 8.44E−05 8.44E−05 2.0204 2.0204 0.8325 0
    rs1798090 Imputed C RECESSIVE 2.27E−05 2.27E−05 1.9652 1.9652 0.894 0
    rs1832222 Imputed G DOMINANT 5.87E−05 5.87E−05 1.5311 1.5311 0.4163 0
    rs1838104 Imputed A ADDITIVE 0.0002117 0.003729 0.7525 0.7527 0.2031 37.26
    rs1838104 Imputed A GENOTYPIC 0.0002138 0.002807 0.5646 0.5645 0.2213 33.7
    rs1868616 Imputed G ADDITIVE 7.48E−05 0.0004629 0.6753 0.6791 0.2929 18.56
    rs1874313 Imputed A DOMINANT 3.30E−05 3.30E−05 0.6312 0.6312 0.6562 0
    rs1884902 Imputed C RECESSIVE 0.001151 0.07621 1.6251 1.5839 0.0555 65.41
    rs1913201 Imputed G ADDITIVE 1.89E−05 1.89E−05 0.7164 0.7164 0.8808 0
    rs1913201 Imputed G DOMINANT 2.91E−05 2.91E−05 0.6172 0.6172 0.7641 0
    rs1913201 Imputed G GENOTYPIC 7.80E−05 7.80E−05 0.5351 0.5351 0.6861 0
    rs1944279 Imputed A ADDITIVE 0.0001257 0.005478 1.3904 1.3724 0.1829 41.13
    rs198461 Imputed C DOMINANT 1.66E−06 1.66E−06 0.5498 0.5498 0.6534 0
    rs1987179 Imputed T DOMINANT 7.08E−05 7.08E−05 0.641 0.641 0.5343 0
    rs1990023 Imputed T DOMINANT 2.55E−07 2.55E−07 0.5746 0.5746 0.9225 0
    rs2016194 Imputed G DOMINANT 4.26E−07 4.26E−07 0.5804 0.5804 0.9558 0
    rs2024789 Imputed C ADDITIVE 0.0008551 0.04722 0.7786 0.789 0.0866 59.13
    rs2024789 Imputed C GENOTYPIC 0.001077 0.04627 0.6104 0.625 0.0938 57.75
    rs2024902 Imputed A ADDITIVE 0.0004002 0.02334 1.7111 1.7273 0.0887 58.72
    rs2024902 Imputed A DOMINANT 9.43E−05 0.01112 1.8804 1.8895 0.0981 56.93
    rs2025107 Imputed A ADDITIVE 0.0005021 0.06161 1.6166 1.6531 0.0272 72.27
    rs2025107 Imputed A DOMINANT 0.0001126 0.05784 1.7901 1.8228 0.0156 75.95
    rs2025108 Imputed T ADDITIVE 0.0005021 0.06161 1.6166 1.6531 0.0272 72.27
    rs2025108 Imputed T DOMINANT 0.0001126 0.05784 1.7901 1.8228 0.0156 75.95
    rs2062448 Imputed T ADDITIVE 0.0001197 0.0124 0.5855 0.5897 0.1132 54.1
    rs2062448 Imputed T DOMINANT 0.0001438 0.01375 0.5765 0.5801 0.1057 55.5
    rs2063591 Imputed C ADDITIVE 6.31E−05 6.31E−05 0.7382 0.7382 0.9476 0
    rs2063591 Imputed C DOMINANT 1.50E−05 1.50E−05 0.6047 0.6047 0.7317 0
    rs2065604 Imputed C DOMINANT 0.003098 0.1472 0.6558 0.6652 0.0252 72.84
    rs2066238 Imputed T DOMINANT 0.00258 0.1967 0.7027 0.7323 0.0172 75.39
    rs2068051 Imputed G ADDITIVE 0.0001657 0.004859 0.6917 0.7008 0.2023 37.41
    rs2068051 Imputed G GENOTYPIC 0.0002673 0.007654 0.4817 0.4968 0.1931 39.2
    rs2077702 Genotyped G GENOTYPIC 9.79E−05 9.79E−05 2.0248 2.0248 0.5151 0
    rs208757 Imputed G ADDITIVE 4.49E−05 4.49E−05 1.5013 1.5013 0.8401 0
    rs208757 Imputed G DOMINANT 9.41E−06 9.41E−06 1.6603 1.6603 0.7321 0
    rs2095586 Imputed A DOMINANT 5.72E−05 5.72E−05 1.532 1.532 0.4194 0
    rs2108426 Imputed C DOMINANT 4.02E−07 4.02E−07 0.5797 0.5797 0.9591 0
    rs2110664 Imputed A DOMINANT 8.67E−05 8.67E−05 1.5394 1.5394 0.8744 0
    rs2132242 Imputed A DOMINANT 2.72E−05 2.72E−05 0.6282 0.6282 0.7958 0
    rs2151644 Imputed T DOMINANT 0.003131 0.1517 0.656 0.6657 0.0236 73.31
    rs2157752 Genotyped A GENOTYPIC 0.0009168 0.05016 0.5431 0.5628 0.0902 58.44
    rs2158958 Imputed A DOMINANT 4.20E−07 4.20E−07 0.5804 0.5804 0.9556 0
    rs2158961 Imputed G DOMINANT 1.33E−06 1.33E−06 0.5977 0.5977 0.8737 0
    rs2164099 Imputed G ADDITIVE 0.0001863 0.006344 1.376 1.3584 0.1883 40.11
    rs2173254 Imputed G GENOTYPIC 0.002362 0.118 0.5447 0.533 0.0217 73.89
    rs2173254 Imputed G RECESSIVE 0.002217 0.0789 0.5578 0.5403 0.042 68.46
    rs2188079 Imputed C ADDITIVE 0.0001838 0.02268 1.3319 1.321 0.0862 59.19
    rs2188079 Imputed C GENOTYPIC 0.0001122 0.0128 1.8273 1.7987 0.1109 54.53
    rs2190304 Imputed G RECESSIVE 0.01058 0.4116 0.7116 0.7366 0.0005 86.94
    rs2190597 Imputed T DOMINANT 9.78E−05 9.78E−05 0.6395 0.6395 0.4926 0
    rs2190598 Imputed T DOMINANT 4.20E−07 4.20E−07 0.5804 0.5804 0.9556 0
    rs2190600 Imputed A DOMINANT 3.37E−07 3.37E−07 0.5762 0.5762 0.9653 0
    rs2218084 Imputed T GENOTYPIC 9.58E−05 9.58E−05 3.531 3.531 0.7772 0
    rs2218084 Imputed T RECESSIVE 8.93E−05 8.93E−05 3.5234 3.5234 0.8908 0
    rs2236290 Genotyped C GENOTYPIC 6.42E−05 6.42E−05 0.4993 0.4993 0.9011 0
    rs2243860 Imputed A GENOTYPIC 7.41E−05 7.41E−05 2.0648 2.0648 0.8032 0
    rs2243860 Imputed A RECESSIVE 8.56E−05 8.56E−05 1.9204 1.9204 0.6639 0
    rs2246564 Imputed T DOMINANT 0.003098 0.1472 0.6558 0.6652 0.0252 72.84
    rs2248236 Imputed C DOMINANT 7.76E−05 7.76E−05 0.6498 0.6498 0.545 0
    rs2250340 Imputed T DOMINANT 0.003303 0.1528 0.6523 0.6609 0.0229 73.54
    rs2257192 Imputed G DOMINANT 0.003098 0.1472 0.6558 0.6652 0.0252 72.84
    rs2270584 Imputed A DOMINANT 4.80E−06 4.80E−06 0.605 0.605 0.7982 0
    rs2270586 Imputed A DOMINANT 5.31E−06 5.31E−06 0.6041 0.6041 0.7347 0
    rs2270589 Imputed A ADDITIVE 2.81E−06 2.81E−06 0.6877 0.6877 0.8813 0
    rs2270589 Imputed A DOMINANT 2.60E−07 2.60E−07 0.5336 0.5336 0.71 0
    rs2270589 Imputed A GENOTYPIC 1.28E−05 1.28E−05 0.4977 0.4977 0.7794 0
    rs2296889 Imputed C DOMINANT 0.002588 0.1138 1.4232 1.4076 0.0374 69.56
    rs2301346 Imputed C ADDITIVE 0.0002178 0.0338 1.3978 1.3772 0.0701 62.37
    rs2301346 Imputed C DOMINANT 0.0001352 0.02587 1.5644 1.5455 0.0672 62.97
    rs2327929 Imputed G RECESSIVE 1.06E−05 1.06E−05 1.7928 1.7928 0.4369 0
    rs2357486 Imputed C RECESSIVE 0.00295 0.1854 1.7126 1.6148 0.024 73.18
    rs2373793 Imputed G DOMINANT 4.57E−05 4.57E−05 1.617 1.617 0.8752 0
    rs2377622 Imputed T GENOTYPIC 2.11E−05 2.11E−05 0.3896 0.3896 0.7037 0
    rs2377622 Imputed T RECESSIVE 2.44E−05 2.44E−05 0.4115 0.4115 0.6397 0
    rs2383903 Imputed G DOMINANT 3.69E−05 3.69E−05 0.645 0.645 0.6185 0
    rs2389866 Imputed C DOMINANT 4.60E−05 4.60E−05 0.6408 0.6408 0.6066 0
    rs2389869 Imputed C DOMINANT 4.60E−05 4.60E−05 0.6408 0.6408 0.6066 0
    rs2418541 Imputed A DOMINANT 3.36E−07 3.36E−07 0.5781 0.5781 0.9145 0
    rs2418542 Imputed A DOMINANT 3.36E−07 3.36E−07 0.5781 0.5781 0.9145 0
    rs2418548 Imputed C DOMINANT 2.36E−06 2.36E−06 0.598 0.598 0.9168 0
    rs2476976 Imputed C DOMINANT 7.42E−05 7.42E−05 1.5229 1.5229 0.5546 0
    rs2483639 Imputed A DOMINANT 0.003098 0.1472 0.6558 0.6652 0.0252 72.84
    rs2483640 Imputed A DOMINANT 0.003098 0.1472 0.6558 0.6652 0.0252 72.84
    rs2544780 Imputed T RECESSIVE 7.90E−05 7.90E−05 2.0334 2.0334 0.4674 0
    rs2586458 Imputed T DOMINANT 0.03011 0.336 0.7195 0.6895 0.0016 84.47
    rs2593272 Imputed G ADDITIVE 0.0002545 0.004989 0.7307 0.7296 0.1874 40.27
    rs2593273 Imputed T ADDITIVE 0.0005623 0.03 0.7408 0.7417 0.0868 59.09
    rs2622499 Imputed G DOMINANT 9.25E−05 9.25E−05 0.6531 0.6531 0.5221 0
    rs264126 Imputed C DOMINANT 8.31E−05 8.31E−05 0.6369 0.6369 0.4319 0
    rs264129 Imputed T DOMINANT 1.21E−06 1.21E−06 0.5966 0.5966 0.8652 0
    rs2656822 Imputed T ADDITIVE 0.0002545 0.004989 0.7307 0.7296 0.1874 40.27
    rs2656823 Imputed G ADDITIVE 0.0002545 0.004989 0.7307 0.7296 0.1874 40.27
    rs2656825 Imputed T ADDITIVE 0.0008702 0.04621 0.7415 0.7347 0.0581 64.86
    rs2764766 Imputed C RECESSIVE 8.08E−05 8.08E−05 2.0146 2.0146 0.461 0
    rs2793101 Imputed T ADDITIVE 0.001506 0.1134 0.6664 0.691 0.0408 68.75
    rs2793101 Imputed T DOMINANT 0.001377 0.07663 0.6498 0.6704 0.0666 63.09
    rs2795871 Imputed A ADDITIVE 7.48E−05 7.48E−05 0.5195 0.5195 0.5044 0
    rs2795886 Imputed A ADDITIVE 4.74E−05 4.74E−05 0.4603 0.4603 0.6122 0
    rs2795886 Imputed A DOMINANT 7.68E−05 7.68E−05 0.4623 0.4623 0.6008 0
    rs2859994 Imputed C GENOTYPIC 0.001111 0.04898 1.7472 1.7054 0.0857 59.3
    rs2870464 Imputed G DOMINANT 9.42E−05 9.42E−05 1.6183 1.6183 0.5381 0
    rs2875528 Imputed T DOMINANT 0.00249 0.1329 1.4996 1.5256 0.0141 76.54
    rs2876227 Imputed C ADDITIVE 2.20E−05 2.20E−05 1.3926 1.3926 0.9997 0
    rs2876227 Imputed C GENOTYPIC 1.68E−05 1.68E−05 2.0556 2.0556 0.8801 0
    rs2882097 Imputed A DOMINANT 5.09E−05 5.09E−05 1.5361 1.5361 0.4725 0
    rs2921983 Imputed C ADDITIVE 0.0001118 0.003732 0.7041 0.7047 0.1767 42.31
    rs2987537 Imputed C DOMINANT 0.03897 0.4969 0.7689 0.776 0.0002 88.03
    rs2996416 Imputed C ADDITIVE 0.0637 0.5796 0.7893 0.8032 0.0001 89.2
    rs2996416 Imputed C DOMINANT 0.06194 0.5554 0.775 0.7758 0.0001 89.6
    rs3015527 Imputed C ADDITIVE 0.07495 0.6564 0.7934 0.8312 0.0001 89.8
    rs3015527 Imputed C DOMINANT 0.07947 0.6402 0.7832 0.8084 0 90.3
    rs3015530 Imputed C ADDITIVE 0.06224 0.577 0.7882 0.8017 0.0001 89.23
    rs3015530 Imputed C DOMINANT 0.06057 0.5529 0.7739 0.7744 0.0001 89.62
    rs3015531 Imputed T ADDITIVE 0.06224 0.577 0.7882 0.8017 0.0001 89.23
    rs3015531 Imputed T DOMINANT 0.06057 0.5529 0.7739 0.7744 0.0001 89.62
    rs3015535 Imputed C ADDITIVE 0.06224 0.577 0.7882 0.8017 0.0001 89.23
    rs3015535 Imputed C DOMINANT 0.06057 0.5529 0.7739 0.7744 0.0001 89.62
    rs3019407 Imputed A GENOTYPIC 0.002403 0.1245 0.5457 0.5319 0.0182 75.03
    rs3019407 Imputed A RECESSIVE 0.001969 0.0794 0.5543 0.5343 0.0367 69.74
    rs36071725 Genotyped C GENOTYPIC 0.0009841 0.1525 1.8209 1.6916 0.0188 74.82
    rs373983 Imputed G DOMINANT 1.77E−06 4.87E−05 1.7251 1.7129 0.2675 24.16
    rs3756154 Imputed C DOMINANT 5.58E−05 5.58E−05 0.638 0.638 0.5323 0
    rs3793044 Imputed C ADDITIVE 0.0002176 0.02467 1.7666 1.7835 0.0668 63.04
    rs3793044 Imputed C DOMINANT 6.05E−05 0.01168 1.9281 1.9369 0.0827 59.88
    rs3793053 Imputed C ADDITIVE 0.0006473 0.05829 1.6129 1.6372 0.0373 69.61
    rs3793053 Imputed C DOMINANT 0.0001802 0.05295 1.7738 1.7934 0.0253 72.81
    rs3796246 Imputed G ADDITIVE 4.93E−05 0.03123 0.5626 0.5598 0.033 70.67
    rs3796246 Imputed G DOMINANT 7.61E−05 0.03997 0.5604 0.5582 0.0279 72.06
    rs3805996 Imputed G ADDITIVE 0.0004631 0.03555 1.7203 1.7316 0.0645 63.52
    rs3805996 Imputed G DOMINANT 0.0001039 0.01905 1.8935 1.8966 0.069 62.59
    rs3806003 Imputed A ADDITIVE 0.0002176 0.02467 1.7666 1.7835 0.0668 63.04
    rs3806003 Imputed A DOMINANT 6.05E−05 0.01168 1.9281 1.9369 0.0827 59.88
    rs3806004 Imputed T ADDITIVE 0.0004046 0.06127 1.629 1.6716 0.0232 73.43
    rs3806004 Imputed T DOMINANT 8.69E−05 0.05774 1.806 1.8451 0.013 76.96
    rs3806010 Imputed T ADDITIVE 0.0005021 0.06161 1.6166 1.6531 0.0272 72.27
    rs3806010 Imputed T DOMINANT 0.0001126 0.05784 1.7901 1.8228 0.0156 75.95
    rs3806014 Imputed T ADDITIVE 0.0003765 0.04916 1.6371 1.6672 0.0355 70.04
    rs3806014 Imputed T DOMINANT 8.67E−05 0.04874 1.8125 1.8369 0.0201 74.42
    rs3806015 Imputed A ADDITIVE 0.0004101 0.05336 1.6326 1.6624 0.0328 70.72
    rs3806015 Imputed A DOMINANT 9.18E−05 0.05129 1.8094 1.8329 0.019 74.77
    rs3806018 Imputed A ADDITIVE 0.0005021 0.06161 1.6166 1.6531 0.0272 72.27
    rs3806018 Imputed A DOMINANT 0.0001126 0.05784 1.7901 1.8228 0.0156 75.95
    rs3806019 Imputed A ADDITIVE 0.0003369 0.06994 1.6486 1.6857 0.017 75.46
    rs3806019 Imputed A DOMINANT 7.78E−05 0.06342 1.8244 1.854 0.0108 77.94
    rs3806024 Imputed T ADDITIVE 0.0005633 0.04683 1.6102 1.6476 0.0429 68.25
    rs3806024 Imputed T DOMINANT 0.0001927 0.05215 1.7603 1.7924 0.0243 73.09
    rs3847825 Imputed G ADDITIVE 2.82E−05 2.82E−05 0.7256 0.7256 0.8316 0
    rs3847825 Imputed G GENOTYPIC 1.92E−05 1.92E−05 0.492 0.492 0.6711 0
    rs3852001 Genotyped C GENOTYPIC 0.0001464 0.003339 2.8436 2.7528 0.2138 35.18
    rs3852001 Genotyped C RECESSIVE 0.0002312 0.004125 2.7294 2.6501 0.2177 34.41
    rs3852002 Imputed G GENOTYPIC 0.0001829 0.002345 2.8057 2.7354 0.2427 29.38
    rs3852002 Imputed G RECESSIVE 0.0003087 0.003378 2.6791 2.6162 0.2416 29.6
    rs3852003 Imputed A GENOTYPIC 0.0001804 0.002239 2.8085 2.7392 0.2448 28.95
    rs3852003 Imputed A RECESSIVE 0.0003059 0.003283 2.6808 2.6185 0.243 29.31
    rs3942254 Imputed T DOMINANT 1.57E−05 1.57E−05 0.6155 0.6155 0.9263 0
    rs3945085 Imputed A DOMINANT 4.70E−05 4.70E−05 1.5394 1.5394 0.4131 0
    rs399485 Imputed A DOMINANT 6.74E−05 6.74E−05 1.5257 1.5257 0.824 0
    rs4029119 Imputed G ADDITIVE 0.009526 0.1165 0.5497 0.3516 0.0037 82.15
    rs4029119 Imputed G DOMINANT 0.01808 0.1591 0.5432 0.3678 0.0036 82.19
    rs412791 Imputed C GENOTYPIC 0.001957 0.1114 0.5748 0.6018 0.0485 66.96
    rs4146972 Genotyped T DOMINANT 5.77E−05 5.77E−05 1.5876 1.5876 0.6206 0
    rs4259369 Imputed C RECESSIVE 8.16E−05 8.16E−05 0.5849 0.5849 0.3771 0
    rs4273613 Imputed T ADDITIVE 0.008222 0.1202 0.5498 0.3996 0.0061 80.4
    rs4273613 Imputed T DOMINANT 0.01557 0.1677 0.5436 0.4204 0.006 80.44
    rs4294022 Imputed C DOMINANT 0.001643 0.075 0.7108 0.7149 0.0535 65.84
    rs4310554 Genotyped C DOMINANT 8.90E−05 8.90E−05 1.6571 1.6571 0.9259 0
    rs4315598 Imputed T ADDITIVE 3.44E−05 3.44E−05 1.3737 1.3737 0.9473 0
    rs4315598 Imputed T GENOTYPIC 2.26E−05 2.26E−05 2.0022 2.0022 0.9124 0
    rs4370878 Imputed G DOMINANT 7.67E−05 7.67E−05 1.5204 1.5204 0.455 0
    rs4436200 Imputed C ADDITIVE 9.10E−05 9.10E−05 0.6326 0.6326 0.5686 0
    rs4444612 Imputed G ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs4444612 Imputed G GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs4450660 Imputed C DOMINANT 4.65E−05 4.65E−05 1.546 1.546 0.4995 0
    rs4463950 Imputed C DOMINANT 0.0001125 0.0001125 0.6464 0.6464 0.456 0
    rs4509702 Imputed C DOMINANT 7.67E−05 7.67E−05 1.5204 1.5204 0.455 0
    rs4533379 Imputed G ADDITIVE 0.0001806 0.006299 1.3772 1.3597 0.1875 40.27
    rs4569984 Imputed A DOMINANT 0.001158 0.06124 0.7017 0.7047 0.0591 64.65
    rs4570530 Imputed C DOMINANT 6.91E−05 6.91E−05 1.5246 1.5246 0.4388 0
    rs4571583 Imputed T DOMINANT 0.001089 0.04319 0.7015 0.7036 0.0837 59.69
    rs4586678 Imputed A DOMINANT 7.84E−05 7.84E−05 1.5241 1.5241 0.4333 0
    rs4615971 Imputed C DOMINANT 5.32E−05 5.32E−05 1.5364 1.5364 0.4014 0
    rs4629229 Imputed G DOMINANT 0.00258 0.1967 0.7027 0.7323 0.0172 75.39
    rs4632512 Imputed T GENOTYPIC 0.0002417 0.001846 2.7571 2.7036 0.2673 24.2
    rs4641552 Imputed A ADDITIVE 6.42E−05 6.42E−05 0.5503 0.5503 0.8687 0
    rs4682527 Imputed C DOMINANT 6.46E−05 6.46E−05 1.7014 1.7014 0.8635 0
    rs4688632 Imputed G RECESSIVE 9.44E−05 9.44E−05 0.6102 0.6102 0.6914 0
    rs4702720 Imputed A ADDITIVE 6.79E−05 6.79E−05 0.6668 0.6668 0.5886 0
    rs4702720 Imputed A DOMINANT 5.81E−05 5.81E−05 0.6111 0.6111 0.6679 0
    rs4714484 Imputed A ADDITIVE 0.0001156 0.0001156 0.6714 0.6714 0.4129 0
    rs4714484 Imputed A DOMINANT 0.0001018 0.0005019 0.6342 0.6347 0.2947 18.15
    rs4725142 Genotyped G RECESSIVE 0.006009 0.1578 0.6241 0.5998 0.0142 76.48
    rs4725144 Imputed G RECESSIVE 0.003615 0.1263 0.601 0.5821 0.0196 74.58
    rs4760785 Imputed A ADDITIVE 2.89E−05 2.89E−05 0.7236 0.7236 0.9224 0
    rs4760785 Imputed A DOMINANT 3.37E−05 3.37E−05 0.6199 0.6199 0.7756 0
    rs4760894 Imputed T ADDITIVE 2.89E−05 2.89E−05 0.7236 0.7236 0.9224 0
    rs4760894 Imputed T DOMINANT 3.37E−05 3.37E−05 0.6199 0.6199 0.7756 0
    rs4760895 Imputed A ADDITIVE 2.89E−05 2.89E−05 0.7236 0.7236 0.9224 0
    rs4760895 Imputed A DOMINANT 3.37E−05 3.37E−05 0.6199 0.6199 0.7756 0
    rs4767184 Imputed C ADDITIVE 5.36E−05 5.36E−05 0.7326 0.7326 0.8638 0
    rs4767184 Imputed C GENOTYPIC 4.89E−05 4.89E−05 0.5118 0.5118 0.7734 0
    rs4773487 Imputed T ADDITIVE 0.06464 0.5842 0.7937 0.8107 0.0001 88.81
    rs4780547 Imputed G GENOTYPIC 5.45E−05 5.45E−05 0.3432 0.3432 0.6588 0
    rs4780547 Imputed G RECESSIVE 5.24E−05 5.24E−05 0.3485 0.3485 0.7035 0
    rs483159 Imputed T DOMINANT 1.80E−05 9.87E−05 1.6374 1.6337 0.3052 15.73
    rs4836502 Imputed T DOMINANT 4.20E−07 4.20E−07 0.5804 0.5804 0.9556 0
    rs4836507 Imputed C DOMINANT 3.81E−07 3.81E−07 0.5776 0.5776 0.9618 0
    rs4851531 Imputed T DOMINANT 6.05E−05 6.05E−05 0.6433 0.6433 0.6076 0
    rs4879931 Imputed G ADDITIVE 4.07E−05 4.07E−05 0.7128 0.7128 0.8034 0
    rs489441 Imputed G ADDITIVE 5.61E−05 5.61E−05 1.4311 1.4311 0.5197 0
    rs489441 Imputed G DOMINANT 2.23E−05 2.23E−05 1.5959 1.5959 0.6258 0
    rs4976276 Imputed T ADDITIVE 0.001258 0.05097 1.303 1.2929 0.0811 60.2
    rs4977681 Imputed C RECESSIVE 0.00128 0.05237 1.78 1.7408 0.0817 60.08
    rs4986197 Imputed G ADDITIVE 0.0001721 0.0051 1.3789 1.3622 0.1995 37.96
    rs4986220 Imputed T ADDITIVE 0.0002571 0.00494 1.3704 1.3563 0.2157 34.81
    rs525462 Imputed A GENOTYPIC 8.63E−05 8.63E−05 0.5509 0.5509 0.4841 0
    rs552006 Imputed G GENOTYPIC 0.001362 0.0951 1.9014 1.8396 0.056 65.31
    rs5756669 Imputed C DOMINANT 0.0005154 0.01565 1.5032 1.4817 0.1536 46.63
    rs581905 Imputed T DOMINANT 9.62E−05 9.62E−05 1.7493 1.7493 0.4492 0
    rs6033138 Imputed C ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs6033138 Imputed C GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs6040619 Imputed C ADDITIVE 1.85E−05 1.85E−05 1.3887 1.3887 0.9157 0
    rs6040619 Imputed C GENOTYPIC 1.34E−05 1.34E−05 2.0393 2.0393 0.8907 0
    rs6040625 Imputed T ADDITIVE 1.40E−05 1.40E−05 1.3939 1.3939 0.9254 0
    rs6040625 Imputed T GENOTYPIC 1.13E−05 1.13E−05 2.049 2.049 0.9295 0
    rs6040630 Imputed A ADDITIVE 1.64E−05 1.64E−05 1.3913 1.3913 0.9442 0
    rs6040630 Imputed A GENOTYPIC 1.40E−05 1.40E−05 2.0387 2.0387 0.936 0
    rs6040633 Imputed A ADDITIVE 2.09E−05 2.09E−05 1.3848 1.3848 0.9611 0
    rs6040633 Imputed A GENOTYPIC 1.80E−05 1.80E−05 2.0179 2.0179 0.921 0
    rs6040634 Imputed T ADDITIVE 4.42E−05 4.42E−05 1.3644 1.3644 0.8661 0
    rs6040634 Imputed T GENOTYPIC 4.35E−05 4.35E−05 1.9421 1.9421 0.8577 0
    rs6040636 Imputed T ADDITIVE 5.80E−05 5.80E−05 1.3581 1.3581 0.8982 0
    rs6040636 Imputed T GENOTYPIC 5.08E−05 5.08E−05 1.9311 1.9311 0.8975 0
    rs6040638 Imputed C ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs6040638 Imputed C GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs6040644 Imputed A ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs6040644 Imputed A GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs6040667 Imputed T ADDITIVE 9.98E−06 9.98E−06 1.4087 1.4087 0.9927 0
    rs6040667 Imputed T GENOTYPIC 9.55E−06 9.55E−06 2.0887 2.0887 0.8885 0
    rs6040668 Imputed C ADDITIVE 1.34E−05 1.34E−05 1.4018 1.4018 0.9954 0
    rs6040668 Imputed C GENOTYPIC 1.18E−05 1.18E−05 2.0792 2.0792 0.9007 0
    rs6053005 Imputed C DOMINANT 3.48E−05 3.48E−05 0.4986 0.4986 0.3762 0
    rs6054405 Imputed A RECESSIVE 0.0009988 0.07764 1.6353 1.5918 0.0508 66.45
    rs6054427 Genotyped G GENOTYPIC 0.002955 0.1457 1.6159 1.564 0.0304 71.38
    rs6075186 Imputed G DOMINANT 0.00258 0.1967 0.7027 0.7323 0.0172 75.39
    rs608278 Imputed A ADDITIVE 0.004256 0.2162 0.7899 0.8041 0.0123 77.26
    rs6111540 Imputed A ADDITIVE 0.0006805 0.04588 0.7626 0.7772 0.0894 58.58
    rs6131206 Imputed C ADDITIVE 6.54E−05 6.54E−05 1.3826 1.3826 0.6671 0
    rs6131208 Imputed T ADDITIVE 1.51E−05 1.51E−05 1.3987 1.3987 0.9933 0
    rs6131208 Imputed T GENOTYPIC 1.23E−05 1.23E−05 2.0749 2.0749 0.9062 0
    rs6131919 Imputed G DOMINANT 0.00258 0.1967 0.7027 0.7323 0.0172 75.39
    rs6134243 Imputed C ADDITIVE 3.11E−05 3.11E−05 1.376 1.376 0.9378 0
    rs6134243 Imputed C GENOTYPIC 2.11E−05 2.11E−05 2.0071 2.0071 0.9192 0
    rs6136020 Imputed A DOMINANT 0.001123 0.128 0.6825 0.7095 0.029 71.76
    rs613799 Imputed C DOMINANT 6.64E−05 6.64E−05 1.5582 1.5582 0.563 0
    rs644041 Imputed G ADDITIVE 5.13E−05 5.13E−05 1.4383 1.4383 0.434 0
    rs644041 Imputed G DOMINANT 3.43E−05 3.43E−05 1.5867 1.5867 0.604 0
    rs6464377 Imputed C DOMINANT 0.0006889 0.03533 1.6713 1.6228 0.1067 55.32
    rs6474230 Imputed T DOMINANT 5.89E−05 5.89E−05 1.5358 1.5358 0.5248 0
    rs6476565 Imputed A DOMINANT 0.003196 0.152 0.6555 0.6646 0.0232 73.43
    rs6511286 Imputed T ADDITIVE 0.0002903 0.007727 1.3303 1.3382 0.1549 46.38
    rs6541829 Genotyped C RECESSIVE 9.75E−05 9.75E−05 2.1906 2.1906 0.675 0
    rs6544721 Imputed G DOMINANT 6.03E−05 6.03E−05 1.5337 1.5337 0.3986 0
    rs6544728 Imputed T DOMINANT 2.14E−05 2.14E−05 1.5769 1.5769 0.5608 0
    rs6565910 Imputed G DOMINANT 0.001296 0.07989 0.7061 0.72 0.0544 65.66
    rs6581985 Imputed G GENOTYPIC 2.27E−05 2.27E−05 2.3281 2.3281 0.8 0
    rs6581985 Imputed G RECESSIVE 1.65E−05 1.65E−05 2.2816 2.2816 0.9608 0
    rs6685186 Imputed T ADDITIVE 0.0003893 0.03193 1.3177 1.2933 0.1024 56.12
    rs6685186 Imputed T GENOTYPIC 0.0003148 0.008032 1.8077 1.753 0.2038 37.13
    rs670593 Imputed A RECESSIVE 9.20E−05 9.20E−05 0.5443 0.5443 0.5165 0
    rs6722640 Imputed T DOMINANT 3.75E−05 3.75E−05 0.6354 0.6354 0.7462 0
    rs6746170 Imputed A DOMINANT 1.59E−05 1.59E−05 1.5871 1.5871 0.5677 0
    rs6757316 Imputed A GENOTYPIC 7.94E−05 7.94E−05 1.8639 1.8639 0.8329 0
    rs6805139 Imputed G DOMINANT 6.87E−05 6.87E−05 1.6408 1.6408 0.6877 0
    rs6808571 Imputed G ADDITIVE 0.0001557 0.005296 1.488 1.4637 0.1931 39.2
    rs6816479 Imputed A RECESSIVE 0.003461 0.1734 1.5638 1.5108 0.0221 73.76
    rs6865976 Imputed C DOMINANT 0.000638 0.09658 0.6509 0.6693 0.03 71.48
    rs687047 Imputed C ADDITIVE 8.99E−05 8.99E−05 0.6274 0.6274 0.7784 0
    rs6871041 Imputed G DOMINANT 1.95E−06 1.95E−06 0.5936 0.5936 0.8021 0
    rs688358 Imputed A ADDITIVE 9.13E−05 9.13E−05 0.6275 0.6275 0.8668 0
    rs6908481 Imputed C RECESSIVE 2.63E−05 2.63E−05 1.8066 1.8066 0.4929 0
    rs6917224 Imputed A ADDITIVE 0.001611 0.08952 1.2619 1.2426 0.0537 65.81
    rs6917224 Imputed A GENOTYPIC 0.0004783 0.01846 1.6983 1.6636 0.1376 49.58
    rs6920677 Imputed G DOMINANT 0.0006978 0.02695 0.6902 0.689 0.1022 56.16
    rs6994498 Imputed G DOMINANT 6.45E−05 6.45E−05 1.5326 1.5326 0.525 0
    rs6998772 Imputed T DOMINANT 0.0001667 0.007582 2.0855 2.0402 0.1794 41.79
    rs7022281 Imputed C ADDITIVE 3.37E−05 3.37E−05 0.7208 0.7208 0.9446 0
    rs7022281 Imputed C GENOTYPIC 1.15E−05 1.15E−05 0.4698 0.4698 0.7053 0
    rs7022281 Imputed C RECESSIVE 5.13E−05 5.13E−05 0.5256 0.5256 0.4654 0
    rs7043983 Imputed T DOMINANT 0.002465 0.1237 0.6468 0.6573 0.0334 70.58
    rs7077799 Imputed A DOMINANT 6.50E−05 6.50E−05 1.5274 1.5274 0.444 0
    rs7088947 Imputed A ADDITIVE 6.35E−05 6.35E−05 0.5164 0.5164 0.4696 0
    rs7089661 Imputed C DOMINANT 5.72E−05 5.72E−05 1.532 1.532 0.4194 0
    rs7102072 Imputed A DOMINANT 0.0002045 0.02025 0.6732 0.6851 0.1048 55.66
    rs710832 Genotyped A RECESSIVE 9.58E−05 9.58E−05 0.3757 0.3757 0.7653 0
    rs712531 Imputed A DOMINANT 3.11E−05 3.11E−05 1.7258 1.7258 0.9033 0
    rs7129817 Imputed T ADDITIVE 0.0004049 0.005979 0.7557 0.7602 0.2144 35.05
    rs7134262 Imputed T GENOTYPIC 3.73E−05 3.73E−05 2.0446 2.0446 0.769 0
    rs7134262 Imputed T RECESSIVE 1.57E−06 1.57E−06 2.1811 2.1811 0.5132 0
    rs7138300 Imputed C ADDITIVE 2.89E−05 2.89E−05 0.7236 0.7236 0.9224 0
    rs7138300 Imputed C DOMINANT 3.37E−05 3.37E−05 0.6199 0.6199 0.7756 0
    rs722927 Imputed G ADDITIVE 0.0002059 0.003095 0.5581 0.5621 0.2265 32.66
    rs722927 Imputed G DOMINANT 0.0002882 0.006064 0.554 0.5592 0.1936 39.11
    rs726424 Genotyped G ADDITIVE 6.99E−05 6.99E−05 0.7384 0.7384 0.8568 0
    rs726424 Genotyped G GENOTYPIC 4.04E−05 4.04E−05 0.5084 0.5084 0.769 0
    rs7295817 Imputed C ADDITIVE 3.56E−06 3.56E−06 0.701 0.701 0.8251 0
    rs7295817 Imputed C GENOTYPIC 2.94E−06 2.94E−06 0.4697 0.4697 0.6858 0
    rs7295817 Imputed C RECESSIVE 3.56E−05 3.56E−05 0.5434 0.5434 0.4419 0
    rs7297372 Imputed A ADDITIVE 2.15E−05 2.15E−05 0.7143 0.7143 0.9056 0
    rs7297372 Imputed A GENOTYPIC 2.33E−05 2.33E−05 0.5078 0.5078 0.9111 0
    rs7298255 Imputed A ADDITIVE 5.48E−05 5.48E−05 0.7363 0.7363 0.9823 0
    rs7298255 Imputed A DOMINANT 3.71E−05 3.71E−05 0.6235 0.6235 0.616 0
    rs7305832 Imputed C GENOTYPIC 3.46E−05 3.46E−05 2.0496 2.0496 0.7658 0
    rs7305832 Imputed C RECESSIVE 1.42E−06 1.42E−06 2.1877 2.1877 0.5185 0
    rs737542 Imputed A RECESSIVE 6.40E−05 6.40E−05 2.2711 2.2711 0.5666 0
    rs742827 Imputed A ADDITIVE 1.36E−05 1.36E−05 1.4066 1.4066 0.9977 0
    rs742827 Imputed A GENOTYPIC 1.47E−05 1.47E−05 2.0678 2.0678 0.9063 0
    rs7446891 Imputed G DOMINANT 4.14E−07 4.14E−07 0.5792 0.5792 0.9644 0
    rs7448641 Imputed C ADDITIVE 0.008373 0.1243 0.5451 0.3771 0.0037 82.12
    rs7448641 Imputed C DOMINANT 0.0151 0.1693 0.5356 0.3959 0.0036 82.2
    rs7460605 Imputed G DOMINANT 9.83E−05 9.83E−05 1.5669 1.5669 0.9301 0
    rs7468898 Imputed T ADDITIVE 0.0003194 0.01248 1.3212 1.3172 0.1401 49.12
    rs7468898 Imputed T GENOTYPIC 0.0002964 0.008259 1.7563 1.7465 0.1684 43.86
    rs7501186 Imputed A DOMINANT 9.69E−05 9.69E−05 1.6046 1.6046 0.3847 0
    rs755117 Imputed A DOMINANT 0.01024 0.3598 1.3434 1.288 0.0039 81.94
    rs7557560 Imputed T GENOTYPIC 0.0001246 0.01108 2.8561 3.1286 0.074 61.59
    rs7557560 Imputed T RECESSIVE 6.13E−05 0.00416 2.9547 3.1843 0.1154 53.69
    rs7562462 Imputed T DOMINANT 0.01544 0.4455 1.3282 1.2791 0.0007 86.22
    rs757173 Genotyped G DOMINANT 0.0006476 0.08534 0.6914 0.7167 0.0461 67.51
    rs7607447 Imputed T RECESSIVE 9.84E−05 9.84E−05 2.0418 2.0418 0.8641 0
    rs7639053 Imputed A ADDITIVE 0.00063 0.02671 1.3617 1.3527 0.1105 54.61
    rs7648163 Imputed C RECESSIVE 0.001045 0.07747 1.7344 1.7565 0.0313 71.14
    rs7651273 Imputed A GENOTYPIC 0.0003041 0.01221 2.7407 2.6004 0.1624 44.99
    rs7653190 Imputed C ADDITIVE 0.0008578 0.04731 1.3535 1.3419 0.0766 61.08
    rs7653685 Genotyped C DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs7684899 Imputed C DOMINANT 9.54E−05 9.54E−05 0.6466 0.6466 0.5013 0
    rs7701604 Imputed G ADDITIVE 0.008373 0.1243 0.5451 0.3771 0.0037 82.12
    rs7701604 Imputed G DOMINANT 0.0151 0.1693 0.5356 0.3959 0.0036 82.2
    rs7703676 Imputed C ADDITIVE 0.008373 0.1243 0.5451 0.3771 0.0037 82.12
    rs7703676 Imputed C DOMINANT 0.0151 0.1693 0.5356 0.3959 0.0036 82.2
    rs7711358 Imputed A DOMINANT 6.11E−07 6.11E−07 0.5846 0.5846 0.9519 0
    rs7713251 Imputed C RECESSIVE 0.0004673 0.01381 1.817 1.8103 0.1436 48.48
    rs7737608 Imputed G DOMINANT 0.004374 0.3589 1.3752 1.2994 0.0019 83.98
    rs7755903 Imputed A GENOTYPIC 0.000545 0.01934 0.5737 0.5711 0.1208 52.69
    rs7762993 Imputed A ADDITIVE 0.0001907 0.02185 1.4428 1.3966 0.1265 51.63
    rs7762993 Imputed A DOMINANT 5.98E−05 0.0279 1.5641 1.5155 0.0621 64.02
    rs7767265 Imputed G DOMINANT 1.02E−05 0.01409 1.6165 1.5706 0.0624 63.96
    rs7769415 Imputed C GENOTYPIC 8.18E−05 8.18E−05 2.0029 2.0029 0.4259 0
    rs7771264 Imputed T DOMINANT 0.001814 0.07578 0.7128 0.7164 0.055 65.53
    rs7795792 Imputed T RECESSIVE 8.16E−05 8.16E−05 0.5849 0.5849 0.3771 0
    rs7806481 Imputed G RECESSIVE 0.01058 0.4116 0.7116 0.7366 0.0005 86.94
    rs7808536 Imputed G DOMINANT 8.83E−05 8.83E−05 1.5445 1.5445 0.4545 0
    rs7814819 Imputed G ADDITIVE 1.73E−05 1.73E−05 2.1934 2.1934 0.7688 0
    rs7814819 Imputed G DOMINANT 5.48E−06 5.48E−06 2.3941 2.3941 0.8199 0
    rs7815952 Imputed T DOMINANT 0.0001667 0.007582 2.0855 2.0402 0.1794 41.79
    rs7834090 Imputed T DOMINANT 0.0001667 0.007582 2.0855 2.0402 0.1794 41.79
    rs7859250 Imputed C DOMINANT 0.002865 0.1511 0.6526 0.6624 0.0221 73.76
    rs7863577 Genotyped A ADDITIVE 0.001489 0.09537 0.6564 0.6635 0.037 69.66
    rs7863577 Genotyped A DOMINANT 0.0007401 0.03086 0.6143 0.6263 0.1159 53.59
    rs7902140 Imputed C ADDITIVE 0.0004487 0.01039 0.7037 0.7112 0.1881 40.15
    rs7921834 Imputed C DOMINANT 5.72E−05 5.72E−05 1.5321 1.5321 0.4195 0
    rs7939893 Imputed C ADDITIVE 6.01E−05 6.01E−05 0.7308 0.7308 0.6443 0
    rs7939893 Imputed C DOMINANT 2.83E−06 2.83E−06 0.607 0.607 0.54 0
    rs7955901 Imputed C ADDITIVE 4.86E−05 4.86E−05 0.7344 0.7344 0.959 0
    rs7955901 Imputed C DOMINANT 2.65E−05 2.65E−05 0.617 0.617 0.71 0
    rs7956274 Imputed T ADDITIVE 5.90E−05 5.90E−05 0.7346 0.7346 0.9732 0
    rs7956274 Imputed T DOMINANT 3.36E−05 3.36E−05 0.6194 0.6194 0.7678 0
    rs7957932 Imputed G ADDITIVE 7.64E−05 7.64E−05 0.7393 0.7393 0.9682 0
    rs7957932 Imputed G DOMINANT 1.49E−05 1.49E−05 0.604 0.604 0.7593 0
    rs7984294 Imputed A DOMINANT 9.75E−05 9.75E−05 1.7346 1.7346 0.5063 0
    rs7994286 Imputed A ADDITIVE 0.07908 0.6072 0.8008 0.8163 0.0001 89.29
    rs7994286 Imputed A DOMINANT 0.08583 0.5854 0.7921 0.7921 0.0001 89.54
    rs8038229 Genotyped A ADDITIVE 6.08E−05 9.60E−05 0.7204 0.7188 0.3455 5.89
    rs8038229 Genotyped A DOMINANT 9.63E−05 9.63E−05 0.6627 0.6627 0.4576 0
    rs8043336 Imputed C GENOTYPIC 0.00137 0.05581 0.5451 0.5279 0.0522 66.13
    rs8043336 Imputed C RECESSIVE 0.001089 0.03846 0.5559 0.5432 0.0772 60.96
    rs8054431 Imputed T DOMINANT 8.98E−05 0.00368 1.557 1.5551 0.1739 42.83
    rs8066502 Imputed T DOMINANT 8.43E−05 8.43E−05 0.6277 0.6277 0.5424 0
    rs8068714 Imputed T DOMINANT 8.71E−05 8.71E−05 0.6283 0.6283 0.5356 0
    rs892575 Imputed T ADDITIVE 0.0003596 0.01472 1.3576 1.3374 0.1542 46.51
    rs892583 Imputed G ADDITIVE 0.0002367 0.004322 1.3734 1.3595 0.2211 33.74
    rs915494 Imputed A ADDITIVE 5.04E−05 5.04E−05 1.401 1.401 0.4759 0
    rs915494 Imputed A DOMINANT 1.99E−05 7.05E−05 1.5873 1.5804 0.3261 10.76
    rs917295 Imputed G DOMINANT 4.33E−07 4.33E−07 0.5808 0.5808 0.9574 0
    rs922594 Imputed T DOMINANT 5.29E−05 5.29E−05 0.6483 0.6483 0.5564 0
    rs9301653 Imputed T ADDITIVE 0.06224 0.577 0.7882 0.8017 0.0001 89.23
    rs9301653 Imputed T DOMINANT 0.06057 0.5529 0.7739 0.7744 0.0001 89.62
    rs9309988 Imputed G DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs9309989 Genotyped C DOMINANT 0.005145 0.2346 1.4559 1.4701 0.0036 82.24
    rs9310221 Imputed A DOMINANT 0.0004892 0.152 1.5136 1.4374 0.0126 77.16
    rs9327555 Imputed T DOMINANT 4.20E−07 4.20E−07 0.5804 0.5804 0.9556 0
    rs937890 Imputed G DOMINANT 6.84E−05 6.84E−05 0.6201 0.6201 0.5639 0
    rs9454967 Imputed G ADDITIVE 0.000403 0.06626 1.6379 1.6775 0.0204 74.32
    rs9454967 Imputed G DOMINANT 9.90E−05 0.06125 1.8091 1.8433 0.0126 77.13
    rs9471295 Imputed T DOMINANT 5.22E−05 5.22E−05 1.6081 1.6081 0.834 0
    rs9477007 Imputed A ADDITIVE 0.0006021 0.03371 1.2928 1.2761 0.1007 56.44
    rs9477007 Imputed A GENOTYPIC 0.0002564 0.005808 1.7495 1.7219 0.1967 38.49
    rs9487279 Imputed T DOMINANT 0.002105 0.09969 0.7072 0.7196 0.0492 66.8
    rs949016 Imputed C ADDITIVE 0.0002405 0.007834 1.372 1.3542 0.1841 40.91
    rs9555973 Imputed G ADDITIVE 0.07024 0.5911 0.7954 0.8108 0.0001 89
    rs9555973 Imputed G DOMINANT 0.07631 0.5694 0.7863 0.7867 0.0001 89.22
    rs9557510 Imputed G ADDITIVE 5.36E−05 5.36E−05 1.5231 1.5231 0.7181 0
    rs9557510 Imputed G DOMINANT 4.27E−05 4.27E−05 1.6282 1.6282 0.5332 0
    rs9560584 Imputed T DOMINANT 0.0887 0.5829 0.792 0.7896 0.0001 89.53
    rs9588770 Imputed T DOMINANT 0.07854 0.5309 0.7885 0.772 0.0001 88.8
    rs9588848 Imputed C ADDITIVE 0.06224 0.577 0.7882 0.8017 0.0001 89.23
    rs9588848 Imputed C DOMINANT 0.06057 0.5529 0.7739 0.7744 0.0001 89.62
    rs966583 Imputed A ADDITIVE 9.26E−05 9.26E−05 0.7367 0.7367 0.9674 0
    rs966583 Imputed A DOMINANT 1.20E−05 1.20E−05 0.6161 0.6161 0.8284 0
    rs974130 Genotyped A RECESSIVE 0.002277 0.101 1.5851 1.5579 0.0437 68.05
    rs977160 Imputed T ADDITIVE 0.0002651 0.05569 1.3742 1.3339 0.0564 65.23
    rs9812206 Imputed G ADDITIVE 5.56E−05 0.05202 0.5663 0.5775 0.0221 73.76
    rs9812206 Imputed G DOMINANT 8.50E−05 0.05567 0.5652 0.5728 0.021 74.13
    rs9813552 Imputed G ADDITIVE 9.05E−05 0.0567 0.5743 0.5799 0.0208 74.16
    rs9813552 Imputed G DOMINANT 0.0001441 0.07188 0.5733 0.5795 0.0165 75.64
    rs9815037 Imputed T ADDITIVE 7.92E−05 0.0586 0.5721 0.5786 0.0188 74.84
    rs9815037 Imputed T DOMINANT 0.0001241 0.07373 0.5708 0.5779 0.0148 76.27
    rs9825349 Imputed A ADDITIVE 7.92E−05 0.0586 0.5721 0.5786 0.0188 74.84
    rs9825349 Imputed A DOMINANT 0.0001241 0.07373 0.5708 0.5779 0.0148 76.27
    rs9834217 Imputed T ADDITIVE 6.37E−05 0.04695 0.5683 0.5735 0.024 73.19
    rs9834217 Imputed T DOMINANT 9.99E−05 0.05997 0.5668 0.5725 0.0192 74.7
    rs9840460 Imputed T ADDITIVE 6.24E−05 0.0469 0.5679 0.5732 0.0239 73.23
    rs9840460 Imputed T DOMINANT 9.77E−05 0.05992 0.5664 0.5721 0.0191 74.75
    rs9840756 Imputed A ADDITIVE 5.29E−05 0.04056 0.5646 0.5694 0.0275 72.18
    rs9840756 Imputed A DOMINANT 8.32E−05 0.05269 0.563 0.5684 0.022 73.8
    rs9844801 Imputed C DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs985375 Imputed A GENOTYPIC 0.0005024 0.0184 2.1795 2.1225 0.1411 48.93
    rs9869187 Imputed C ADDITIVE 0.0002129 0.05227 0.587 0.5974 0.0378 69.48
    rs9869187 Imputed C DOMINANT 0.0005049 0.05719 0.5988 0.6038 0.0436 68.07
    rs9872327 Imputed T DOMINANT 0.003653 0.1786 1.4802 1.4969 0.0084 79.08
    rs9881685 Imputed A ADDITIVE 5.96E−05 0.0538 0.5653 0.5735 0.0205 74.27
    rs9881685 Imputed A DOMINANT 8.36E−05 0.0568 0.5632 0.5683 0.0192 74.71
    rs9909499 Imputed C DOMINANT 6.59E−05 6.59E−05 1.5349 1.5349 0.7556 0
    rs9911847 Imputed G DOMINANT 6.59E−05 6.59E−05 0.6229 0.6229 0.5677 0
    rs9946886 Imputed G RECESSIVE 5.84E−05 5.84E−05 0.3084 0.3084 0.8937 0
    rs9958823 Imputed A ADDITIVE 0.0001257 0.005478 1.3904 1.3724 0.1829 41.13
    rs9965248 Imputed T ADDITIVE 0.0006176 0.03664 1.3453 1.3168 0.1086 54.95
  • TABLE 14
    ALLELE
    SNP rs # SOURCE (A1) MODEL NMISS OR SE L95 U95 STAT P
    rs77638540 Genotyped T DOM 800 0.3686 0.3223 0.196 0.6931 −3.097 0.001952
    rs72746987 Genotyped A DOM 800 0.3351 0.3134 0.1813 0.6195 −3.488 0.000487
    rs10021016 Genotyped G GEN 800 7.997 0.01834
    rs10021016 Genotyped G REC 800 2.242 0.2913 1.266 3.967 2.771 0.005589
    rs10051148 Imputed C DOM 796 0.6544 0.1465 0.491 0.8722 −2.893 0.003813
    rs10054055 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs10067895 Imputed A DOM 791 0.6716 0.1473 0.5032 0.8964 −2.703 0.006874
    rs10100725 Imputed C DOM 800 0.5483 0.1594 0.4011 0.7494 −3.769 0.000164
    rs10128531 Imputed T ADD 742 1.482 0.1557 1.092 2.011 2.526 0.01154
    rs10181743 Imputed G ADD 762 1.488 0.1083 1.204 1.84 3.673 0.00024
    rs10199127 Imputed T DOM 780 1.486 0.1462 1.116 1.98 2.712 0.006692
    rs10270624 Imputed G DOM 750 1.438 0.1529 1.066 1.94 2.375 0.01754
    rs1030006 Imputed G REC 797 1.663 0.1726 1.186 2.333 2.947 0.003209
    rs1031811 Imputed A REC 792 1.684 0.2618 1.008 2.813 1.991 0.04646
    rs10430870 Genotyped G GEN 800 8.659 0.01317
    rs10430870 Genotyped G REC 800 2.178 0.2884 1.237 3.833 2.698 0.006973
    rs10469597 Imputed A GEN 739 11.61 0.003011
    rs10469597 Imputed A REC 739 2.519 0.2716 1.479 4.289 3.401 0.00067
    rs10478919 Imputed G DOM 797 0.6489 0.1462 0.4872 0.8644 −2.957 0.003109
    rs10506623 Imputed C ADD 777 0.7349 0.1071 0.5957 0.9066 −2.875 0.004041
    rs10506623 Imputed C DOM 777 0.6128 0.1531 0.454 0.8273 −3.199 0.001381
    rs10506626 Imputed A ADD 795 0.7463 0.105 0.6075 0.9169 −2.786 0.005339
    rs10506626 Imputed A DOM 795 0.5922 0.1495 0.4418 0.7938 −3.504 0.000458
    rs10509477 Imputed T DOM 800 1.654 0.1456 1.243 2.2 3.456 0.000547
    rs10517918 Imputed G REC 798 1.697 0.1851 1.181 2.439 2.858 0.004265
    rs10517924 Imputed A REC 800 1.803 0.1754 1.279 2.543 3.362 0.000773
    rs10519362 Imputed G DOM 784 1.5 0.1539 1.109 2.028 2.634 0.00844
    rs10520072 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs10737390 Imputed T DOM 787 0.5772 0.1513 0.4291 0.7764 −3.632 0.000281
    rs10742851 Imputed T REC 800 0.406 0.2924 0.2289 0.7202 −3.083 0.002051
    rs10743685 Imputed G GEN 795 12.35 0.002076
    rs10743685 Imputed G REC 795 1.943 0.1919 1.334 2.831 3.462 0.000536
    rs10749293 Imputed G DOM 797 1.637 0.1456 1.231 2.178 3.387 0.000706
    rs10749294 Imputed A DOM 798 1.575 0.1455 1.184 2.095 3.123 0.00179
    rs10753760 Imputed T ADD 745 1.391 0.1067 1.128 1.715 3.093 0.001984
    rs10753760 Imputed T GEN 745 9.763 0.007586
    rs10772362 Imputed T ADD 800 0.6338 0.1259 0.4952 0.8112 −3.621 0.000293
    rs10784891 Imputed C ADD 765 0.7164 0.1084 0.5792 0.886 −3.077 0.002092
    rs10784891 Imputed C DOM 765 0.631 0.1608 0.4604 0.8648 −2.863 0.004193
    rs10784891 Imputed C GEN 765 9.725 0.007731
    rs10787923 Imputed G DOM 796 1.647 0.1457 1.238 2.191 3.425 0.000616
    rs10787924 Imputed T DOM 797 1.585 0.1456 1.191 2.109 3.163 0.001564
    rs10787949 Imputed A DOM 800 1.634 0.1456 1.228 2.173 3.373 0.000745
    rs10787951 Imputed G DOM 800 1.634 0.1456 1.228 2.173 3.373 0.000745
    rs10787983 Imputed C DOM 798 1.614 0.1449 1.215 2.144 3.304 0.000953
    rs10794733 Imputed C ADD 786 0.765 0.1126 0.6135 0.9539 −2.379 0.01734
    rs10818280 Imputed C DOM 788 0.7042 0.1448 0.5302 0.9353 −2.422 0.01544
    rs10860586 Imputed A ADD 796 1.322 0.1036 1.079 1.62 2.695 0.007028
    rs10860586 Imputed A GEN 796 7.298 0.02602
    rs10870473 Imputed A ADD 371 0.54 0.1831 0.3772 0.773 −3.366 0.000762
    rs10870473 Imputed A DOM 371 0.4734 0.2198 0.3077 0.7283 −3.402 0.000668
    rs10879240 Imputed C ADD 791 0.7324 0.1067 0.5942 0.9027 −2.92 0.003505
    rs10879240 Imputed C GEN 791 8.522 0.0141
    rs10879242 Imputed A ADD 793 0.741 0.1058 0.6022 0.9117 −2.834 0.0046
    rs10879242 Imputed A DOM 793 0.6085 0.1511 0.4525 0.8182 −3.288 0.00101
    rs10879245 Imputed G ADD 793 0.741 0.1058 0.6022 0.9117 −2.834 0.0046
    rs10879245 Imputed G DOM 793 0.6085 0.1511 0.4525 0.8182 −3.288 0.00101
    rs10879249 Imputed T ADD 795 0.7264 0.1064 0.5897 0.8947 −3.006 0.00265
    rs10879249 Imputed T DOM 795 0.6001 0.151 0.4464 0.8068 −3.382 0.00072
    rs10886429 Imputed A DOM 797 1.634 0.1459 1.228 2.175 3.365 0.000766
    rs10886449 Imputed G DOM 800 1.594 0.145 1.2 2.119 3.217 0.001297
    rs10886451 Imputed G DOM 800 1.594 0.145 1.2 2.119 3.217 0.001297
    rs10886452 Imputed A DOM 800 1.634 0.1456 1.228 2.173 3.373 0.000745
    rs10886456 Imputed G DOM 800 1.594 0.145 1.2 2.119 3.217 0.001297
    rs10886463 Imputed C DOM 800 1.624 0.1458 1.221 2.162 3.327 0.000878
    rs10886465 Imputed A DOM 800 1.664 0.1454 1.251 2.212 3.503 0.000461
    rs10886526 Imputed C DOM 798 1.614 0.1449 1.215 2.144 3.304 0.000953
    rs10922903 Imputed C REC 800 0.4885 0.1995 0.3304 0.7222 −3.591 0.000329
    rs10941126 Imputed G ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs10941126 Imputed G DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs10947980 Imputed G ADD 798 0.7397 0.1176 0.5875 0.9314 −2.564 0.01033
    rs11059376 Imputed T ADD 720 1.559 0.1386 1.188 2.045 3.203 0.001362
    rs11072995 Imputed T GEN 793 9.167 0.01022
    rs11072995 Imputed T REC 793 3.578 0.4502 1.481 8.646 2.832 0.004626
    rs11081202 Genotyped G GEN 800 7.034 0.02969
    rs11081202 Genotyped G REC 800 1.887 0.2769 1.097 3.248 2.294 0.0218
    rs110965 Imputed C GEN 737 5.271 0.07169
    rs11124962 Imputed A DOM 790 1.469 0.1461 1.103 1.956 2.63 0.008532
    rs1116596 Imputed T DOM 794 0.6531 0.1466 0.49 0.8704 −2.907 0.003646
    rs11178531 Imputed A ADD 796 0.7599 0.1049 0.6187 0.9334 −2.618 0.008858
    rs11178531 Imputed A DOM 796 0.6258 0.1604 0.4569 0.857 −2.922 0.003477
    rs11178583 Imputed A ADD 796 0.7274 0.1063 0.5906 0.896 −2.993 0.002762
    rs11178583 Imputed A DOM 796 0.6032 0.1509 0.4488 0.8108 −3.35 0.000809
    rs11178589 Imputed T ADD 787 0.7243 0.1059 0.5885 0.8915 −3.044 0.002334
    rs11178589 Imputed T DOM 787 0.5988 0.1526 0.444 0.8075 −3.362 0.000775
    rs11178594 Imputed C ADD 797 0.7305 0.1059 0.5936 0.8991 −2.964 0.003033
    rs11178594 Imputed C DOM 797 0.5995 0.1509 0.446 0.8058 −3.391 0.000696
    rs11178602 Imputed T ADD 795 0.7265 0.1059 0.5904 0.8941 −3.018 0.002545
    rs11178602 Imputed T DOM 795 0.592 0.1508 0.4405 0.7956 −3.476 0.00051
    rs11178648 Imputed T ADD 794 0.7481 0.1053 0.6086 0.9195 −2.757 0.00584
    rs11178648 Imputed T DOM 794 0.5905 0.1497 0.4403 0.7918 −3.52 0.000432
    rs11198877 Imputed T DOM 800 1.634 0.1456 1.228 2.173 3.373 0.000745
    rs11198942 Imputed T DOM 800 1.654 0.1456 1.243 2.2 3.456 0.000547
    rs11221075 Imputed A ADD 725 0.6446 0.1613 0.4698 0.8842 −2.723 0.006476
    rs11242020 Imputed T DOM 798 0.6462 0.1462 0.4852 0.8606 −2.987 0.002819
    rs11242021 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs11242022 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs11242023 Imputed T DOM 795 0.6676 0.1469 0.5005 0.8904 −2.75 0.00596
    rs1149349 Imputed T DOM 798 1.696 0.1575 1.245 2.309 3.352 0.000802
    rs1149350 Imputed A ADD 789 1.592 0.131 1.232 2.058 3.552 0.000383
    rs1149350 Imputed A DOM 789 1.701 0.1501 1.267 2.282 3.539 0.000401
    rs11576627 Imputed T ADD 800 1.72 0.1612 1.254 2.358 3.364 0.000769
    rs11576627 Imputed T DOM 800 1.805 0.1683 1.298 2.51 3.508 0.000451
    rs11630050 Imputed G GEN 778 8.696 0.01294
    rs11630050 Imputed G REC 778 3.097 0.3961 1.425 6.731 2.854 0.004317
    rs11633024 Imputed C GEN 778 8.696 0.01294
    rs11633024 Imputed C REC 778 3.097 0.3961 1.425 6.731 2.854 0.004317
    rs11636298 Imputed G GEN 800 9.499 0.008657
    rs11636298 Imputed G REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs11637363 Imputed C GEN 774 9.788 0.007493
    rs11637363 Imputed C REC 774 3.309 0.3942 1.528 7.166 3.035 0.002402
    rs11637813 Imputed A GEN 778 8.696 0.01294
    rs11637813 Imputed A REC 778 3.097 0.3961 1.425 6.731 2.854 0.004317
    rs11638043 Imputed C GEN 777 8.808 0.01223
    rs11638043 Imputed C REC 777 2.984 0.3815 1.413 6.303 2.866 0.00416
    rs11638115 Imputed A GEN 793 9.167 0.01022
    rs11638115 Imputed A REC 793 3.578 0.4502 1.481 8.646 2.832 0.004626
    rs11638444 Imputed C GEN 799 9.274 0.009687
    rs11717157 Imputed T ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs11717157 Imputed T GEN 800 9.972 0.006832
    rs11724055 Imputed A DOM 798 0.6341 0.1569 0.4662 0.8624 −2.903 0.003694
    rs11743355 Imputed C ADD 732 0.2056 0.4133 0.0915 0.4623 −3.827 0.00013
    rs11743355 Imputed C DOM 732 0.2102 0.4294 0.0906 0.4878 −3.632 0.000282
    rs11746806 Imputed T ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs11746806 Imputed T DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs11746959 Imputed T ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs11746959 Imputed T DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs11749272 Imputed T DOM 797 0.6489 0.1462 0.4872 0.8644 −2.957 0.003109
    rs11839636 Imputed C GEN 789 12.4 0.002029
    rs11839785 Imputed C GEN 782 12.37 0.002065
    rs11853619 Imputed C GEN 799 9.423 0.008993
    rs11853619 Imputed C REC 799 3.396 0.4296 1.463 7.882 2.846 0.004433
    rs11856780 Imputed A GEN 799 9.423 0.008993
    rs11856780 Imputed A REC 799 3.396 0.4296 1.463 7.882 2.846 0.004433
    rs11901899 Imputed A DOM 767 1.388 0.1476 1.039 1.853 2.22 0.02644
    rs11903290 Imputed C REC 793 1.68 0.2618 1.006 2.807 1.982 0.04748
    rs11909480 Imputed G ADD 797 0.3557 0.3375 0.1836 0.6892 −3.063 0.00219
    rs11909480 Imputed G DOM 797 0.3552 0.3405 0.1822 0.6924 −3.04 0.002368
    rs11910289 Imputed T ADD 765 1.705 0.2347 1.077 2.702 2.274 0.02295
    rs11910289 Imputed T DOM 765 1.77 0.2428 1.1 2.848 2.351 0.01871
    rs11920375 Genotyped C GEN 800 10.36 0.005635
    rs11926319 Imputed G DOM 799 0.5553 0.1951 0.3788 0.8139 −3.015 0.002567
    rs11933744 Imputed T REC 799 2.427 0.2805 1.401 4.206 3.162 0.001567
    rs11934919 Imputed C REC 799 2.427 0.2805 1.401 4.206 3.162 0.001567
    rs11934957 Imputed C REC 799 2.427 0.2805 1.401 4.206 3.162 0.001567
    rs11959206 Imputed A REC 795 0.528 0.177 0.3733 0.7469 −3.609 0.000307
    rs12038613 Imputed C REC 783 0.4896 0.2003 0.3306 0.7249 −3.566 0.000363
    rs12151417 Imputed T DOM 763 1.463 0.1495 1.091 1.961 2.545 0.01093
    rs12153185 Imputed T DOM 792 0.6694 0.1472 0.5016 0.8933 −2.726 0.006403
    rs12182651 Imputed T DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs12235345 Imputed C DOM 793 2.195 0.2213 1.423 3.387 3.553 0.000382
    rs12324786 Imputed T GEN 793 9.167 0.01022
    rs12324786 Imputed T REC 793 3.578 0.4502 1.481 8.646 2.832 0.004626
    rs12336958 Imputed G DOM 738 1.777 0.159 1.301 2.427 3.617 0.000298
    rs12407412 Imputed C ADD 800 1.72 0.1612 1.254 2.358 3.364 0.000769
    rs12407412 Imputed C DOM 800 1.805 0.1683 1.298 2.51 3.508 0.000451
    rs12418971 Imputed C GEN 765 9.69 0.007866
    rs12418971 Imputed C REC 765 2.279 0.2931 1.283 4.048 2.811 0.004945
    rs1241967 Imputed T REC 798 0.3933 0.2549 0.2387 0.6482 −3.661 0.000252
    rs12420184 Imputed G DOM 796 0.5503 0.165 0.3982 0.7604 −3.619 0.000295
    rs12433968 Imputed T DOM 762 0.5602 0.1482 0.419 0.749 −3.91 9.23E−05
    rs12445477 Imputed A DOM 771 0.5609 0.2128 0.3696 0.8512 −2.717 0.006591
    rs12447191 Genotyped T ADD 800 0.6857 0.1355 0.5258 0.8943 −2.785 0.005354
    rs12447191 Genotyped T DOM 800 0.7141 0.1537 0.5284 0.9651 −2.191 0.02846
    rs12465349 Imputed A REC 781 1.474 0.166 1.065 2.041 2.338 0.01938
    rs1247340 Imputed C ADD 798 1.541 0.1317 1.191 1.995 3.286 0.001016
    rs1247340 Imputed C DOM 798 1.679 0.1496 1.252 2.251 3.461 0.000538
    rs1247341 Imputed C ADD 797 1.534 0.1317 1.185 1.986 3.248 0.001161
    rs1247341 Imputed C DOM 797 1.668 0.1498 1.244 2.237 3.416 0.000635
    rs1247343 Imputed C DOM 787 1.673 0.158 1.228 2.281 3.258 0.001121
    rs12509758 Imputed C DOM 799 1.449 0.1495 1.081 1.942 2.48 0.01313
    rs12515472 Imputed A DOM 799 1.337 0.1509 0.9948 1.798 1.925 0.0542
    rs12548906 Imputed G ADD 761 1.308 0.1403 0.9936 1.722 1.914 0.05563
    rs12596240 Imputed G DOM 800 0.5814 0.1491 0.434 0.7787 −3.637 0.000275
    rs12618781 Imputed A DOM 792 0.6189 0.1597 0.4526 0.8463 −3.005 0.002655
    rs12678600 Imputed A DOM 800 0.6105 0.1458 0.4588 0.8125 −3.384 0.000715
    rs12692229 Imputed T ADD 795 1.248 0.1075 1.011 1.541 2.063 0.03912
    rs12713324 Imputed T DOM 779 1.464 0.1484 1.094 1.958 2.566 0.01029
    rs12719415 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 4.86E−03
    rs12820589 Imputed G ADD 757 1.483 0.1384 1.13 1.945 2.846 0.004422
    rs12820589 Imputed G DOM 757 1.498 0.1543 1.107 2.028 2.621 0.008774
    rs12831292 Imputed G ADD 788 0.73 0.1065 0.5925 0.8994 −2.955 0.003122
    rs12831292 Imputed G DOM 788 0.5953 0.1521 0.4418 0.802 −3.411 0.000647
    rs13012636 Imputed G REC 794 1.692 0.2617 1.013 2.827 2.01 0.04442
    rs13038146 Imputed C ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs13038146 Imputed C GEN 800 9.956 0.006888
    rs13038146 Imputed C REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs13089860 Imputed A DOM 653 0.647 0.1731 0.4609 0.9083 −2.516 0.01188
    rs13102419 Imputed T REC 779 1.798 0.1756 1.274 2.536 3.339 0.000841
    rs13194907 Imputed A ADD 800 1.998 0.2096 1.325 3.013 3.302 0.00096
    rs13194907 Imputed A DOM 800 2.076 0.2229 1.341 3.213 3.276 1.05E−03
    rs13195745 Imputed A ADD 799 1.993 0.2097 1.322 3.006 3.29 0.001001
    rs13195745 Imputed A DOM 799 2.07 0.223 1.337 3.204 3.263 0.001101
    rs13265054 Imputed T DOM 798 0.6161 0.146 0.4628 0.8202 −3.318 0.000908
    rs13273002 Imputed A GEN 798 12.57 0.001864
    rs13282131 Imputed C ADD 797 1.33 0.1054 1.081 1.635 2.702 0.006897
    rs13282131 Imputed C GEN 797 7.883 0.01942
    rs13282131 Imputed C REC 797 1.605 0.1832 1.121 2.299 2.583 0.009794
    rs1330052 Imputed G GEN 800 15.12 0.00052
    rs1335721 Imputed A REC 783 0.4896 0.2003 0.3306 0.7249 −3.566 0.000363
    rs1336382 Imputed T DOM 795 1.652 0.146 1.241 2.2 3.438 0.000587
    rs1336383 Imputed T DOM 800 1.654 0.1456 1.243 2.2 3.456 0.000547
    rs1336407 Imputed T DOM 800 1.62 0.1448 1.22 2.152 3.335 0.000854
    rs1336409 Imputed T DOM 800 1.62 0.1448 1.22 2.152 3.335 0.000854
    rs1336596 Imputed A DOM 796 0.5452 0.1487 0.4073 0.7298 −4.078 4.54E−05
    rs13387284 Imputed A DOM 760 0.6185 0.1611 0.451 0.8482 −2.982 0.002863
    rs13401462 Imputed C DOM 760 1.748 0.1697 1.254 2.438 3.292 0.000996
    rs13409045 Imputed T ADD 792 0.7208 0.1088 0.5824 0.8921 −3.01 0.002612
    rs1349284 Imputed C GEN 800 9.296 0.009578
    rs1355715 Imputed T ADD 800 0.4791 0.2123 0.316 0.7263 −3.467 0.000527
    rs1357696 Imputed A GEN 782 10.92 0.004251
    rs1357698 Imputed A GEN 781 11.09 0.003915
    rs1357699 Imputed T GEN 781 11.09 0.003915
    rs1363273 Imputed C REC 780 0.5424 0.1801 0.3811 0.772 −3.397 0.000682
    rs1373601 Imputed A DOM 731 0.6665 0.1502 0.4966 0.8946 −2.702 0.006895
    rs1375829 Imputed C GEN 800 9.296 0.009578
    rs1395748 Imputed G DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs1414865 Imputed T DOM 800 1.634 0.1456 1.228 2.173 3.373 0.000745
    rs1414873 Imputed A DOM 800 1.62 0.1448 1.22 2.152 3.335 0.000854
    rs1414876 Imputed C DOM 800 1.62 0.1448 1.22 2.152 3.335 0.000854
    rs1424643 Imputed G ADD 778 1.348 0.1253 1.054 1.723 2.38 0.0173
    rs1424643 Imputed G DOM 778 1.485 0.149 1.109 1.988 2.654 0.007946
    rs1424648 Imputed T DOM 784 1.357 0.1474 1.017 1.812 2.073 0.03819
    rs1429321 Imputed A DOM 797 1.456 0.1473 1.091 1.943 2.549 0.01079
    rs1429326 Imputed T ADD 792 1.336 0.1238 1.048 1.702 2.338 0.01941
    rs1429326 Imputed T DOM 792 1.48 0.1477 1.108 1.977 2.653 0.007971
    rs1444741 Imputed A DOM 728 0.6595 0.1504 0.4911 0.8857 −2.767 0.005653
    rs1449916 Imputed C DOM 588 0.5892 0.1909 0.4052 0.8566 −2.771 0.005596
    rs1459523 Imputed A ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs1459523 Imputed A GEN 800 9.972 0.006832
    rs1466352 Imputed T GEN 797 9.958 0.00688
    rs1466353 Imputed G GEN 796 10.02 0.006658
    rs1476714 Imputed A DOM 797 0.6618 0.1469 0.4962 0.8826 −2.81 0.004957
    rs1486723 Imputed C REC 800 0.4458 0.2394 0.2789 0.7127 −3.375 0.000739
    rs1495375 Imputed A ADD 793 0.741 0.1058 0.6022 0.9117 −2.834 0.0046
    rs1495375 Imputed A DOM 793 0.6085 0.1511 0.4525 0.8182 −3.288 0.00101
    rs1495381 Imputed T GEN 799 8.222 0.01639
    rs1495381 Imputed T REC 799 1.776 0.2004 1.199 2.631 2.867 0.004141
    rs1498061 Imputed C ADD 385 0.4939 0.2066 0.3294 0.7405 −3.414 0.00064
    rs1498992 Imputed G DOM 795 0.5981 0.1449 0.4502 0.7944 −3.549 0.000387
    rs1499001 Imputed T DOM 763 0.5667 0.1498 0.4225 0.76 −3.793 0.000149
    rs1512988 Imputed A ADD 795 0.7274 0.1066 0.5903 0.8964 −2.987 0.002819
    rs1512988 Imputed A DOM 795 0.6077 0.151 0.452 0.817 −3.298 0.000973
    rs1512989 Imputed T ADD 795 0.7274 0.1066 0.5903 0.8964 −2.987 0.002819
    rs1512989 Imputed T DOM 795 0.6077 0.151 0.452 0.817 −3.298 0.000973
    rs1512991 Imputed T ADD 795 0.7286 0.1054 0.5926 0.8957 −3.005 0.002655
    rs1512991 Imputed T DOM 795 0.6184 0.1596 0.4523 0.8456 −3.011 0.002605
    rs1512991 Imputed T GEN 795 9.858 0.007235
    rs1524303 Imputed T GEN 793 9.356 0.009296
    rs1524306 Imputed C ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs1524306 Imputed C GEN 800 9.972 0.006832
    rs1524310 Imputed G ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs1524310 Imputed G GEN 800 9.972 0.006832
    rs1524321 Imputed C GEN 796 10.02 0.006673
    rs1527059 Imputed A DOM 799 0.5689 0.2041 0.3813 0.8488 −2.763 0.005727
    rs152707 Imputed A ADD 800 0.684 0.1058 0.5559 0.8415 −3.592 0.000328
    rs152707 Imputed A GEN 800 13.34 0.001266
    rs152712 Genotyped C ADD 799 0.6783 0.106 0.5511 0.8349 −3.663 0.00025
    rs152712 Genotyped C GEN 799 14.09 0.00087
    rs1533994 Imputed T GEN 799 10.31 0.005765
    rs1535866 Imputed G DOM 793 1.391 0.148 1.041 1.86 2.232 0.02564
    rs1563773 Imputed T GEN 798 10.17 0.006179
    rs1563774 Imputed T GEN 794 9.994 0.006759
    rs1567740 Imputed T ADD 796 0.7274 0.1063 0.5906 0.896 −2.993 0.002762
    rs1567740 Imputed T DOM 796 0.6032 0.1509 0.4488 0.8108 −3.35 0.000809
    rs1572573 Imputed A DOM 770 1.748 0.1541 1.292 2.365 3.624 0.00029
    rs1577497 Imputed C REC 786 0.4912 0.2002 0.3317 0.7272 −3.551 0.000384
    rs1581514 Imputed T ADD 795 1.353 0.108 1.095 1.671 2.797 0.005152
    rs1581514 Imputed T GEN 795 9.607 0.008202
    rs1582321 Imputed T DOM 800 0.5814 0.1491 0.434 0.7787 −3.637 0.000275
    rs1582322 Imputed A DOM 799 0.5859 0.1493 0.4373 0.785 −3.581 0.000342
    rs1582323 Imputed A DOM 798 0.5825 0.1494 0.4346 0.7807 −3.617 0.000298
    rs1592485 Imputed C DOM 799 0.5835 0.15 0.4349 0.7829 −3.592 0.000328
    rs1600954 Imputed T ADD 759 1.379 0.106 1.12 1.697 3.029 0.002457
    rs1600954 Imputed T GEN 759 11.97 0.002519
    rs16938626 Imputed G DOM 797 0.612 0.1451 0.4605 0.8132 −3.385 0.000711
    rs16964300 Imputed G ADD 800 0.6771 0.135 0.5197 0.8821 −2.889 0.003862
    rs16964300 Imputed G DOM 800 0.7073 0.1536 0.5234 0.9558 −2.254 0.02418
    rs16986282 Imputed G DOM 800 0.3124 0.3551 0.1558 0.6267 −3.276 0.001053
    rs17007620 Imputed G ADD 696 1.421 0.1303 1.101 1.834 2.696 0.007027
    rs17007620 Imputed G DOM 696 1.572 0.1588 1.152 2.146 2.85 0.004376
    rs17014326 Imputed G DOM 794 0.5837 0.145 0.4393 0.7755 −3.713 0.000205
    rs17047957 Imputed C DOM 785 1.47 0.1535 1.088 1.986 2.51 0.01207
    rs1705261 Imputed A REC 798 1.775 0.1989 1.202 2.622 2.885 0.003908
    rs17073341 Imputed A ADD 800 2.568 0.2635 1.532 4.305 3.58 0.000344
    rs17073341 Imputed A DOM 800 2.569 0.2659 1.525 4.326 3.548 0.000388
    rs17138702 Imputed G ADD 797 0.5527 0.1573 0.406 0.7522 −3.77 0.000163
    rs17189710 Imputed T ADD 795 1.359 0.1063 1.103 1.673 2.882 0.003957
    rs17189710 Imputed T GEN 795 10.06 0.006549
    rs17189710 Imputed T REC 795 1.896 0.2108 1.254 2.866 3.034 0.002411
    rs17310176 Imputed T ADD 800 0.6381 0.1364 0.4884 0.8336 −3.294 0.000988
    rs17310176 Imputed T DOM 800 0.5794 0.1584 0.4248 0.7903 −3.446 0.00057
    rs17358860 Imputed A DOM 800 0.6291 0.1568 0.4626 0.8555 −2.955 0.003129
    rs17370541 Imputed T GEN 752 13.88 0.000967
    rs17370541 Imputed T REC 752 2.075 0.2103 1.374 3.133 3.469 0.000522
    rs17526574 Imputed G GEN 800 11.97 0.002516
    rs17530747 Imputed T DOM 797 0.5794 0.1476 0.4338 0.7738 −3.698 0.000218
    rs17649114 Imputed C DOM 800 1.543 0.1498 1.151 2.07 2.898 0.00376
    rs17766172 Imputed A REC 770 0.3869 0.2703 0.2278 0.6573 −3.512 0.000444
    rs1818885 Imputed G GEN 794 10.03 0.006649
    rs1832222 Imputed G DOM 799 1.612 0.1449 1.214 2.142 3.295 0.000984
    rs1861327 Imputed G DOM 800 0.5814 0.1491 0.434 0.7787 −3.637 0.000275
    rs1868581 Imputed G ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs1868581 Imputed G GEN 800 9.972 0.006832
    rs1874313 Imputed A ADD 797 0.7419 0.1059 0.6029 0.913 −2.819 0.004818
    rs1874313 Imputed A DOM 797 0.615 0.1508 0.4577 0.8265 −3.224 0.001263
    rs1876409 Imputed C DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs1913201 Imputed G ADD 771 0.7218 0.1078 0.5844 0.8916 −3.025 0.002485
    rs1913201 Imputed G DOM 771 0.6464 0.1598 0.4726 0.8841 −2.731 0.006318
    rs1913201 Imputed G GEN 771 9.268 0.009717
    rs1916922 Imputed T GEN 800 9.972 0.006832
    rs1936871 Genotyped G DOM 800 0.571 0.1536 0.4226 0.7716 −3.647 0.000265
    rs1961157 Imputed T REC 800 0.6068 0.1891 0.4189 0.8791 −2.642 0.00825
    rs1987179 Imputed T ADD 800 0.7138 0.1326 0.5504 0.9257 −2.542 0.01103
    rs1987179 Imputed T DOM 800 0.6634 0.1489 0.4955 0.8883 −2.756 0.005859
    rs1990023 Imputed T DOM 798 0.6462 0.1462 0.4852 0.8606 −2.987 0.002819
    rs1995025 Imputed C DOM 775 1.608 0.1638 1.167 2.217 2.901 0.003714
    rs2016194 Imputed G DOM 799 0.6626 0.1466 0.4971 0.8832 −2.807 0.004996
    rs2023651 Imputed T ADD 797 0.682 0.1247 0.5341 0.8707 −3.07 0.002139
    rs2024902 Imputed A ADD 800 1.998 0.2096 1.325 3.013 3.302 0.00096
    rs2024902 Imputed A DOM 800 2.076 0.2229 1.341 3.213 3.276 0.001053
    rs2025107 Imputed A DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs2025108 Imputed T DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs2031987 Imputed T GEN 795 12.3 0.002134
    rs2052428 Imputed C DOM 784 0.5903 0.1642 0.4279 0.8144 −3.21 0.001327
    rs2053230 Imputed C ADD 722 0.5414 0.1548 0.3998 0.7333 −3.964 7.36E−05
    rs2062448 Imputed T DOM 788 0.5462 0.1963 0.3718 0.8024 −3.081 0.00206
    rs2063420 Imputed C REC 780 1.755 0.1868 1.217 2.531 3.01 0.002608
    rs2063591 Imputed C ADD 797 0.7519 0.1046 0.6125 0.9229 −2.727 0.006392
    rs2063591 Imputed C DOM 797 0.6237 0.1609 0.4551 0.855 −2.934 0.003349
    rs208026 Genotyped A DOM 800 1.457 0.1466 1.093 1.941 2.565 0.01032
    rs208029 Imputed T DOM 786 1.41 0.1496 1.052 1.891 2.298 0.02157
    rs208757 Imputed G DOM 799 1.423 0.1463 1.068 1.895 2.411 0.01592
    rs2095586 Imputed A DOM 785 1.655 0.1465 1.242 2.205 3.438 0.000586
    rs2095606 Imputed A DOM 786 0.5466 0.1493 0.4079 0.7324 −4.046 5.20E−05
    rs2102374 Imputed A ADD 790 0.6269 0.1219 0.4937 0.7961 −3.831 0.000128
    rs2102374 Imputed A DOM 790 0.5989 0.1465 0.4494 0.798 −3.501 0.000464
    rs2108426 Imputed C DOM 799 0.6626 0.1466 0.4971 0.8832 −2.807 0.004996
    rs2110664 Imputed A DOM 744 1.429 0.1493 1.066 1.915 2.391 0.01682
    rs2132242 Imputed A ADD 793 0.7317 0.1056 0.5948 0.9 −2.957 0.003104
    rs2132242 Imputed A DOM 793 0.6043 0.1522 0.4484 0.8143 −3.309 0.000936
    rs2158958 Imputed A DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs2158961 Imputed G DOM 796 0.6544 0.1465 0.491 0.8722 −2.893 0.003813
    rs2163046 Imputed A DOM 775 1.474 0.149 1.101 1.973 2.603 0.009245
    rs2180286 Imputed G DOM 798 0.6211 0.164 0.4503 0.8566 −2.903 0.003694
    rs2180684 Imputed A DOM 800 1.684 0.1876 1.166 2.433 2.779 0.005451
    rs2188079 Imputed C ADD 798 1.333 0.1034 1.088 1.632 2.775 0.005514
    rs2188079 Imputed C GEN 798 10.2 0.006111
    rs2190598 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs2190600 Imputed A DOM 791 0.6716 0.1473 0.5032 0.8964 −2.703 0.006874
    rs2224184 Genotyped T DOM 800 0.6357 0.1621 0.4626 0.8735 −2.794 0.005199
    rs2247066 Imputed A DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs2248236 Imputed C ADD 728 0.6377 0.1466 0.4784 0.85 −3.068 0.002153
    rs2248236 Imputed C DOM 728 0.6049 0.1624 0.44 0.8317 −3.095 0.00197
    rs2265733 Imputed C ADD 790 0.6269 0.1219 0.4937 0.7961 −3.831 0.000128
    rs2265733 Imputed C DOM 790 0.5989 0.1465 0.4494 0.798 −3.501 0.000464
    rs2270584 Imputed A ADD 796 0.7437 0.1051 0.6052 0.9138 −2.818 0.004834
    rs2270584 Imputed A DOM 796 0.5859 0.1496 0.437 0.7855 −3.574 0.000351
    rs2270586 Imputed A ADD 795 0.7444 0.1051 0.6059 0.9147 −2.808 0.004978
    rs2270586 Imputed A DOM 795 0.5879 0.1496 0.4385 0.7883 −3.55 0.000385
    rs229775 Imputed A REC 798 0.3933 0.2549 0.2387 0.6482 −3.661 0.000252
    rs229815 Imputed T REC 762 0.4053 0.2727 0.2375 0.6916 −3.312 0.000925
    rs229829 Imputed C REC 797 0.5066 0.2182 0.3303 0.7769 −3.117 0.001827
    rs229831 Imputed A REC 797 0.3945 0.2549 0.2394 0.6501 −3.65 0.000263
    rs2317057 Imputed T ADD 623 0.7125 0.1358 0.546 0.9298 −2.496 0.01256
    rs2322100 Genotyped T REC 800 1.768 0.28 1.021 3.061 2.035 0.04187
    rs2322101 Imputed A REC 799 1.764 0.28 1.019 3.053 2.026 0.04276
    rs2327929 Imputed G REC 799 1.996 0.1838 1.392 2.862 3.761 0.000169
    rs2332844 Imputed A ADD 681 1.802 0.1484 1.347 2.41 3.969 7.22E−05
    rs2332844 Imputed A REC 681 1.849 0.1698 1.326 2.579 3.62 0.000295
    rs2349170 Imputed G DOM 797 1.638 0.1487 1.224 2.192 3.319 0.000903
    rs2356722 Imputed G DOM 798 0.5863 0.1447 0.4416 0.7785 −3.691 0.000223
    rs2364956 Imputed T ADD 772 1.439 0.1382 1.098 1.887 2.634 0.008429
    rs2373793 Imputed G ADD 792 1.379 0.1411 1.046 1.818 2.279 0.02264
    rs2373793 Imputed G DOM 792 1.446 0.1627 1.051 1.989 2.265 0.0235
    rs238252 Imputed G ADD 799 1.66 0.1458 1.248 2.209 3.478 0.000505
    rs238252 Imputed G DOM 799 1.848 0.1687 1.328 2.573 3.642 0.000271
    rs2383903 Imputed G DOM 797 0.6249 0.1456 0.4698 0.8313 −3.229 0.001242
    rs2387945 Imputed G DOM 792 1.587 0.1626 1.154 2.182 2.84 0.004513
    rs2389863 Imputed A DOM 784 0.6722 0.1503 0.5007 0.9025 −2.643 0.008221
    rs2389866 Imputed C DOM 800 0.6634 0.1489 0.4955 0.8883 −2.756 0.005859
    rs2389869 Imputed C DOM 800 0.6634 0.1489 0.4955 0.8883 −2.756 0.005859
    rs2389870 Genotyped C DOM 800 0.6413 0.1561 0.4723 0.8709 −2.846 0.004433
    rs2418494 Imputed G ADD 777 0.8166 0.101 0.67 0.9953 −2.006 0.04483
    rs2418494 Imputed G GEN 777 4.805 0.0905
    rs2418541 Imputed A DOM 798 0.6462 0.1462 0.4852 0.8606 −2.987 0.002819
    rs2418542 Imputed A DOM 797 0.6489 0.1462 0.4872 0.8644 −2.957 0.003109
    rs2423556 Imputed C DOM 796 0.6175 0.1654 0.4465 0.8539 −2.915 0.003556
    rs2437688 Imputed C ADD 799 1.457 0.1639 1.056 2.008 2.294 0.02177
    rs2456809 Imputed G DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs2456811 Imputed T ADD 789 0.6292 0.1219 0.4955 0.799 −3.8 0.000144
    rs2456811 Imputed T DOM 789 0.6017 0.1465 0.4515 0.8019 −3.466 0.000527
    rs2476976 Imputed C DOM 799 1.596 0.1449 1.201 2.12 3.225 0.001258
    rs2484911 Imputed A DOM 797 1.56 0.1448 1.175 2.073 3.071 0.002132
    rs2488557 Imputed C DOM 787 0.5503 0.1765 0.3894 0.7777 −3.384 0.000713
    rs250162 Imputed C ADD 777 0.7333 0.1252 0.5738 0.9373 −2.477 0.01324
    rs250162 Imputed C DOM 777 0.6818 0.1495 0.5086 0.9139 −2.562 0.0104
    rs2560708 Imputed T ADD 770 0.6815 0.1471 0.5108 0.9092 −2.607 0.009133
    rs2617841 Imputed G DOM 737 0.679 0.1512 0.5048 0.9132 −2.56 0.01045
    rs2622499 Imputed G DOM 798 0.6691 0.149 0.4996 0.8961 −2.696 0.007022
    rs264129 Imputed T DOM 798 0.653 0.1461 0.4904 0.8695 −2.917 0.003536
    rs2642936 Imputed T ADD 767 1.403 0.1248 1.098 1.791 2.712 0.006694
    rs2660633 Imputed A DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs2660634 Imputed C DOM 800 0.6151 0.1445 0.4634 0.8164 −3.364 0.000769
    rs2660648 Imputed A ADD 790 0.6269 0.1219 0.4937 0.7961 −3.831 0.000128
    rs2660648 Imputed A DOM 790 0.5989 0.1465 0.4494 0.798 −3.501 0.000464
    rs2681505 Imputed T ADD 800 0.6338 0.1259 0.4952 0.8112 −3.621 0.000293
    rs277411 Imputed G DOM 797 0.346 0.3255 0.1828 0.6549 −3.261 0.001112
    rs2832634 Imputed G ADD 767 1.706 0.2347 1.077 2.702 2.276 0.02282
    rs2832637 Imputed T ADD 767 1.706 0.2347 1.077 2.702 2.276 0.02282
    rs2843167 Imputed A DOM 789 0.5976 0.1456 0.4493 0.795 −3.536 0.000406
    rs2876227 Imputed C ADD 780 1.336 0.1077 1.082 1.65 2.692 0.007104
    rs2876227 Imputed C GEN 780 9.11 0.01051
    rs2882097 Imputed A DOM 800 1.654 0.1456 1.243 2.2 3.456 0.000547
    rs2909862 Imputed G DOM 680 1.87 0.1696 1.341 2.608 3.692 0.000223
    rs3001945 Imputed T DOM 792 1.587 0.1626 1.154 2.182 2.84 0.004513
    rs3011020 Imputed C DOM 791 1.591 0.1626 1.157 2.188 2.856 0.004284
    rs36071725 Genotyped C ADD 800 1.524 0.1104 1.228 1.892 3.818 0.000134
    rs36071725 Genotyped C GEN 800 18.94 7.72E−05
    rs373983 Imputed G DOM 782 1.553 0.154 1.148 2.1 2.858 0.004263
    rs3743794 Imputed G DOM 797 0.587 0.1492 0.4382 0.7864 −3.571 0.000356
    rs3756154 Imputed C ADD 800 0.7138 0.1326 0.5504 0.9257 −2.542 0.01103
    rs3756154 Imputed C DOM 800 0.6634 0.1489 0.4955 0.8883 −2.756 0.005859
    rs3775850 Imputed A DOM 797 0.6253 0.1569 0.4598 0.8505 −2.992 0.002768
    rs3775851 Imputed C DOM 798 0.6341 0.1569 0.4662 0.8624 −2.903 0.003694
    rs3793044 Imputed C ADD 800 1.998 0.2096 1.325 3.013 3.302 0.00096
    rs3793044 Imputed C DOM 800 2.076 0.2229 1.341 3.213 3.276 0.001053
    rs3793053 Imputed C DOM 784 1.878 0.1992 1.271 2.775 3.163 0.001559
    rs3796246 Imputed G DOM 797 0.5889 0.193 0.4034 0.8595 −2.744 0.006063
    rs3806003 Imputed A ADD 800 1.998 0.2096 1.325 3.013 3.302 0.00096
    rs3806003 Imputed A DOM 800 2.076 0.2229 1.341 3.213 3.276 0.001053
    rs3806004 Imputed T DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs3806010 Imputed T DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs3806014 Imputed T DOM 796 1.865 0.1984 1.264 2.752 3.143 0.001675
    rs3806015 Imputed A DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs3806018 Imputed A DOM 790 1.834 0.1988 1.242 2.708 3.051 0.002279
    rs3806019 Imputed A DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs3806024 Imputed T DOM 784 1.878 0.1992 1.271 2.775 3.163 0.001559
    rs3915080 Imputed A GEN 785 10.95 0.004188
    rs3942254 Imputed T ADD 789 0.7293 0.107 0.5913 0.8995 −2.95 0.003182
    rs3942254 Imputed T DOM 789 0.6079 0.1519 0.4513 0.8187 −3.277 0.00105
    rs3945085 Imputed A DOM 797 1.637 0.1456 1.231 2.178 3.387 0.000706
    rs3976737 Imputed G ADD 753 0.5945 0.1454 0.4471 0.7905 −3.577 0.000348
    rs399485 Imputed A DOM 794 1.449 0.145 1.09 1.925 2.556 0.01057
    rs4029119 Imputed G ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs4029119 Imputed G DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs4076201 Imputed G GEN 776 8.852 0.01196
    rs4076201 Imputed G REC 776 2.978 0.3815 1.41 6.29 2.86 0.004234
    rs41395945 Imputed G ADD 767 1.706 0.2347 1.077 2.702 2.276 0.02282
    rs41395945 Imputed G DOM 767 1.77 0.2427 1.1 2.849 2.353 0.0186
    rs4146972 Genotyped T DOM 800 1.441 0.1516 1.071 1.94 2.41 0.01594
    rs4238087 Imputed G DOM 789 0.719 0.1681 0.5172 0.9995 −1.963 0.04968
    rs4251569 Imputed T ADD 791 0.7164 0.1513 0.5325 0.9637 −2.204 0.02753
    rs4251569 Imputed T DOM 791 0.7189 0.1681 0.5171 0.9993 −1.964 0.04952
    rs4273613 Imputed T ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs4273613 Imputed T DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs4291049 Imputed T REC 798 0.5495 0.1747 0.3902 0.7739 −3.428 0.000609
    rs4315598 Imputed T ADD 799 1.348 0.1061 1.095 1.66 2.813 0.004904
    rs4315598 Imputed T GEN 799 9.777 0.007533
    rs4315598 Imputed T REC 799 1.885 0.2107 1.247 2.849 3.009 0.002624
    rs4321395 Imputed A DOM 760 0.6185 0.1611 0.451 0.8482 −2.982 0.002863
    rs4321596 Genotyped T REC 800 2.132 0.296 1.194 3.809 2.559 0.0105
    rs4324417 Imputed T DOM 800 1.724 0.1627 1.254 2.372 3.349 0.000812
    rs4328619 Genotyped G DOM 800 0.6851 0.1653 0.4955 0.9472 −2.288 0.02212
    rs4338909 Imputed T ADD 798 1.366 0.1028 1.116 1.67 3.031 0.002435
    rs4370878 Imputed G DOM 798 1.625 0.1458 1.221 2.162 3.327 0.000877
    rs4379434 Genotyped T DOM 800 1.624 0.1546 1.199 2.199 3.136 0.001712
    rs4416407 Imputed T DOM 791 1.831 0.1801 1.287 2.606 3.359 0.000782
    rs4417899 Imputed C REC 793 0.544 0.18 0.3823 0.7742 −3.382 0.000721
    rs4442732 Imputed A ADD 658 0.6071 0.133 0.4678 0.7879 −3.752 0.000176
    rs4444612 Imputed G ADD 795 1.36 0.1064 1.104 1.675 2.888 0.003879
    rs4444612 Imputed G GEN 795 10.03 0.006632
    rs4444612 Imputed G REC 795 1.891 0.2107 1.251 2.858 3.023 0.002503
    rs4450660 Imputed C DOM 791 1.503 0.1459 1.129 2 2.791 0.005256
    rs4509702 Imputed C DOM 798 1.625 0.1458 1.221 2.162 3.327 0.000877
    rs4526920 Imputed G GEN 795 12.3 0.002134
    rs4533145 Imputed T DOM 788 0.4949 0.1927 0.3392 0.7219 −3.652 0.000261
    rs4557006 Imputed A DOM 753 0.6286 0.1619 0.4577 0.8634 −2.867 0.00414
    rs4570530 Imputed C DOM 798 1.625 0.1458 1.221 2.162 3.327 0.000877
    rs4615971 Imputed C DOM 798 1.614 0.1449 1.215 2.144 3.304 0.000953
    rs4628119 Imputed A DOM 800 0.6745 0.1474 0.5052 0.9004 −2.672 0.007537
    rs4664443 Imputed G ADD 799 0.7174 0.1085 0.5799 0.8874 −3.06 0.002211
    rs4688259 Imputed T DOM 792 1.832 0.1801 1.287 2.608 3.363 0.000772
    rs4688632 Imputed G REC 797 0.5583 0.1725 0.3981 0.783 −3.378 0.000731
    rs4695284 Imputed A ADD 469 2.105 0.2029 1.414 3.133 3.667 0.000245
    rs4700302 Imputed A ADD 725 0.5167 0.1985 0.3501 0.7624 −3.327 0.000879
    rs4702720 Imputed A ADD 628 0.6094 0.1416 0.4617 0.8044 −3.497 0.00047
    rs4702720 Imputed A DOM 628 0.5402 0.171 0.3863 0.7553 −3.601 0.000317
    rs4711091 Genotyped G GEN 800 13.3 0.001292
    rs4714484 Imputed A ADD 799 0.6694 0.1425 0.5063 0.8852 −2.816 0.004864
    rs4736802 Imputed G DOM 794 1.64 0.1547 1.211 2.221 3.196 0.001395
    rs4760785 Imputed A ADD 771 0.7218 0.1078 0.5844 0.8916 −3.025 0.002485
    rs4760785 Imputed A DOM 771 0.6464 0.1598 0.4726 0.8841 −2.731 0.006318
    rs4760785 Imputed A GEN 771 9.268 0.009717
    rs4760894 Imputed T ADD 771 0.7218 0.1078 0.5844 0.8916 −3.025 0.002485
    rs4760894 Imputed T DOM 771 0.6464 0.1598 0.4726 0.8841 −2.731 0.006318
    rs4760894 Imputed T GEN 771 9.268 0.009717
    rs4760895 Imputed A ADD 771 0.7218 0.1078 0.5844 0.8916 −3.025 0.002485
    rs4760895 Imputed A DOM 771 0.6464 0.1598 0.4726 0.8841 −2.731 0.006318
    rs4760895 Imputed A GEN 771 9.268 0.009717
    rs4764738 Imputed A ADD 785 1.331 0.1042 1.085 1.633 2.742 0.0061
    rs4764738 Imputed A GEN 785 7.557 0.02286
    rs4764974 Imputed T ADD 796 1.322 0.1036 1.079 1.62 2.695 0.007028
    rs4764974 Imputed T GEN 796 7.298 0.02602
    rs4798366 Imputed G REC 780 1.597 0.2447 0.9889 2.58 1.915 0.05555
    rs483159 Imputed T DOM 718 1.425 0.1565 1.048 1.936 2.262 0.0237
    rs4836502 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs4836507 Imputed C DOM 791 0.6716 0.1473 0.5032 0.8964 −2.703 0.006874
    rs4836744 Imputed A ADD 797 0.7163 0.1117 0.5755 0.8916 −2.988 0.002809
    rs4836744 Imputed A DOM 797 0.6971 0.144 0.5257 0.9245 −2.505 0.01224
    rs4848944 Genotyped C REC 800 0.6741 0.1744 0.4789 0.9488 −2.261 0.02373
    rs4851529 Imputed A DOM 798 0.6968 0.1498 0.5195 0.9346 −2.411 0.0159
    rs4851531 Imputed T DOM 785 0.7275 0.1515 0.5406 0.9789 −2.101 0.03565
    rs4858046 Genotyped T GEN 800 9.709 0.007792
    rs4878214 Imputed A ADD 628 0.5979 0.1405 0.454 0.7875 −3.661 0.000252
    rs4880803 Imputed A ADD 789 0.7753 0.1121 0.6223 0.9658 −2.27 0.02319
    rs489441 Imputed G ADD 748 1.446 0.1212 1.14 1.834 3.044 0.002335
    rs489441 Imputed G DOM 748 1.584 0.1496 1.181 2.123 3.074 0.002112
    rs4896568 Imputed T DOM 774 0.6713 0.1492 0.5011 0.8993 −2.672 0.007546
    rs4938851 Imputed T DOM 800 1.543 0.1498 1.151 2.07 2.898 0.00376
    rs4964416 Imputed C DOM 799 0.598 0.1645 0.4332 0.8256 −3.125 0.001776
    rs5756669 Imputed C DOM 800 1.724 0.1627 1.254 2.372 3.349 0.000812
    rs6033138 Imputed C ADD 796 1.371 0.105 1.116 1.685 3.008 0.002629
    rs6033138 Imputed C GEN 796 10.23 0.005998
    rs6033138 Imputed C REC 796 1.836 0.2034 1.232 2.736 2.987 0.002813
    rs6040619 Imputed C ADD 800 1.337 0.1054 1.088 1.644 2.757 0.005839
    rs6040619 Imputed C GEN 800 9.282 0.009648
    rs6040619 Imputed C REC 800 1.844 0.2095 1.223 2.78 2.92 0.003504
    rs6040625 Imputed T ADD 800 1.343 0.1053 1.093 1.651 2.802 0.005079
    rs6040625 Imputed T GEN 800 9.403 0.009081
    rs6040625 Imputed T REC 800 1.844 0.2095 1.223 2.78 2.92 0.003504
    rs6040630 Imputed A ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs6040630 Imputed A GEN 800 9.956 0.006888
    rs6040630 Imputed A REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs6040633 Imputed A ADD 799 1.35 0.1061 1.096 1.662 2.826 0.004712
    rs6040633 Imputed A GEN 799 9.841 0.007297
    rs6040633 Imputed A REC 799 1.888 0.2106 1.249 2.853 3.016 0.002559
    rs6040634 Imputed T ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs6040634 Imputed T GEN 800 9.956 0.006888
    rs6040634 Imputed T REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs6040636 Imputed T ADD 799 1.359 0.1061 1.103 1.673 2.888 0.00388
    rs6040636 Imputed T GEN 799 10.05 0.006571
    rs6040636 Imputed T REC 799 1.892 0.2107 1.252 2.859 3.027 0.002467
    rs6040638 Imputed C ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs6040638 Imputed C GEN 800 9.956 0.006888
    rs6040638 Imputed C REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs6040644 Imputed A ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs6040644 Imputed A GEN 800 9.956 0.006888
    rs6040644 Imputed A REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs6040667 Imputed T ADD 787 1.352 0.1076 1.095 1.67 2.804 0.005046
    rs6040667 Imputed T GEN 787 9.469 0.008785
    rs6040667 Imputed T REC 787 1.878 0.2152 1.232 2.864 2.93 0.003389
    rs6040668 Imputed C ADD 787 1.352 0.1076 1.095 1.67 2.804 0.005046
    rs6040668 Imputed C GEN 787 9.469 0.008785
    rs6040668 Imputed C REC 787 1.878 0.2152 1.232 2.864 2.93 0.003389
    rs6043066 Genotyped G DOM 800 1.67 0.1467 1.253 2.227 3.497 0.000471
    rs6048146 Imputed G DOM 800 2.46 0.3199 1.314 4.605 2.814 0.004893
    rs6082725 Genotyped T DOM 800 2.46 0.3199 1.314 4.605 2.814 0.004893
    rs6131206 Imputed C ADD 778 1.252 0.1109 1.007 1.556 2.026 0.04277
    rs6131208 Imputed T ADD 788 1.358 0.1075 1.1 1.676 2.846 0.004434
    rs6131208 Imputed T GEN 788 9.654 0.00801
    rs6131208 Imputed T REC 788 1.885 0.2151 1.237 2.874 2.948 0.0032
    rs6134243 Imputed C ADD 800 1.353 0.1061 1.099 1.666 2.854 0.004317
    rs6134243 Imputed C GEN 800 9.956 0.006888
    rs6134243 Imputed C REC 800 1.892 0.2107 1.252 2.859 3.026 0.002474
    rs6136020 Imputed A DOM 799 0.5431 0.1594 0.3974 0.7422 −3.831 0.000128
    rs613799 Imputed C DOM 686 1.64 0.1564 1.207 2.228 3.161 0.00157
    rs644041 Imputed G ADD 736 1.415 0.1215 1.116 1.796 2.86 0.004237
    rs644041 Imputed G DOM 736 1.556 0.1508 1.158 2.092 2.932 0.003363
    rs647645 Imputed C ADD 796 0.6924 0.1019 0.567 0.8454 −3.608 0.000308
    rs647645 Imputed C GEN 796 13.04 0.001476
    rs647645 Imputed C REC 796 0.5812 0.182 0.4068 0.8303 −2.982 0.002867
    rs6495554 Imputed C GEN 800 9.326 0.009436
    rs6495554 Imputed C REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs6495555 Imputed C GEN 800 9.326 0.009436
    rs6495555 Imputed C REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs6544728 Imputed T DOM 794 1.526 0.1458 1.147 2.032 2.901 0.003725
    rs6550705 Imputed C ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs6550705 Imputed C GEN 800 9.972 0.006832
    rs6550707 Imputed T GEN 797 9.958 0.00688
    rs658108 Imputed A DOM 798 1.56 0.1448 1.174 2.071 3.069 0.002149
    rs6593441 Imputed A DOM 785 1.577 0.1691 1.132 2.196 2.693 0.007076
    rs668732 Imputed A DOM 787 1.778 0.1671 1.281 2.467 3.444 0.000574
    rs671041 Imputed A DOM 798 1.56 0.1448 1.174 2.071 3.069 0.002149
    rs6719700 Imputed A ADD 695 1.427 0.1498 1.064 1.914 2.374 0.01759
    rs6719700 Imputed A DOM 695 1.536 0.1676 1.106 2.133 2.559 0.01049
    rs6722640 Imputed T DOM 797 0.682 0.1502 0.5081 0.9154 −2.548 0.01082
    rs6743092 Imputed T ADD 789 1.36 0.1049 1.108 1.671 2.935 0.003334
    rs6743092 Imputed T GEN 789 8.823 0.01214
    rs6743092 Imputed T REC 789 1.57 0.1704 1.124 2.192 2.646 0.008151
    rs6744759 Imputed G REC 794 1.692 0.2617 1.013 2.827 2.01 0.04442
    rs6746170 Imputed A DOM 797 1.528 0.1455 1.149 2.032 2.914 0.003568
    rs6759922 Imputed A DOM 760 0.6185 0.1611 0.451 0.8482 −2.982 0.002863
    rs6769864 Imputed T GEN 800 9.838 0.007307
    rs6773932 Imputed C GEN 782 10.92 0.004251
    rs6774353 Imputed A GEN 800 9.838 0.007307
    rs6781670 Imputed C GEN 800 9.296 0.009578
    rs6786431 Imputed A GEN 782 10.92 0.004251
    rs6789091 Imputed T GEN 782 10.92 0.004251
    rs6791296 Imputed T ADD 757 0.6225 0.164 0.4514 0.8586 −2.889 0.00386
    rs6792662 Imputed G DOM 792 1.844 0.1801 1.296 2.624 3.398 0.000678
    rs6797574 Imputed G GEN 782 10.92 0.004251
    rs6797882 Imputed G GEN 776 11.03 0.004027
    rs6805139 Imputed G DOM 797 1.812 0.1727 1.292 2.542 3.442 0.000577
    rs6806043 Imputed C ADD 800 1.366 0.1079 1.105 1.688 2.889 0.00386
    rs6806043 Imputed C GEN 800 9.972 0.006832
    rs6850716 Imputed C GEN 799 12.52 0.001916
    rs6867153 Imputed A REC 795 0.528 0.177 0.3733 0.7469 −3.609 0.000307
    rs687047 Imputed C ADD 800 0.6526 0.1561 0.4806 0.8861 −2.734 0.006248
    rs6871041 Imputed G DOM 666 0.6 0.1598 0.4387 0.8207 −3.196 0.001391
    rs688358 Imputed A ADD 795 0.6534 0.156 0.4812 0.8872 −2.727 0.006386
    rs6888012 Imputed A REC 795 0.528 0.177 0.3733 0.7469 −3.609 0.000307
    rs6908481 Imputed C REC 784 1.96 0.1947 1.338 2.871 3.458 0.000545
    rs7032231 Imputed A ADD 789 1.212 0.1105 0.9756 1.504 1.737 0.08246
    rs7067638 Imputed T DOM 795 1.6 0.1731 1.14 2.247 2.717 0.00659
    rs7077799 Imputed A DOM 745 1.625 0.1513 1.208 2.185 3.208 0.001335
    rs7082163 Imputed A ADD 800 1.58 0.1552 1.166 2.142 2.948 0.003195
    rs7082163 Imputed A DOM 800 1.684 0.1729 1.2 2.364 3.014 0.002574
    rs7089661 Imputed C DOM 800 1.62 0.1448 1.22 2.152 3.335 0.000854
    rs7101319 Imputed C ADD 797 1.567 0.1554 1.156 2.125 2.891 0.003836
    rs7101319 Imputed C DOM 797 1.667 0.1733 1.187 2.341 2.95 0.003178
    rs710832 Genotyped A GEN 800 10.04 0.006605
    rs710832 Genotyped A REC 800 0.3805 0.3178 0.2041 0.7092 −3.041 0.002357
    rs7134262 Imputed T GEN 796 18.44 9.88E−05
    rs7134262 Imputed T REC 796 2.449 0.2188 1.595 3.76 4.092 4.27E−05
    rs7134671 Imputed T GEN 786 6.843 0.03266
    rs7138300 Imputed C ADD 771 0.7218 0.1078 0.5844 0.8916 −3.025 0.002485
    rs7138300 Imputed C DOM 771 0.6464 0.1598 0.4726 0.8841 −2.731 0.006318
    rs7138300 Imputed C GEN 771 9.268 0.009717
    rs7163931 Imputed G GEN 800 9.326 0.009436
    rs7163931 Imputed G REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs7171486 Genotyped G DOM 800 0.7681 0.1448 0.5783 1.02 −1.821 0.06855
    rs7172611 Imputed G GEN 800 9.499 0.008657
    rs7172611 Imputed G REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs7172689 Imputed T GEN 800 9.499 0.008657
    rs7172689 Imputed T REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs7175701 Imputed C GEN 799 8.043 0.01793
    rs7180245 Imputed A GEN 800 9.499 0.008657
    rs7180245 Imputed A REC 800 3.433 0.4298 1.478 7.972 2.87 0.004111
    rs7220603 Genotyped A ADD 800 0.7182 0.1147 0.5737 0.8992 −2.886 0.003898
    rs7282518 Imputed T ADD 673 1.688 0.1538 1.249 2.283 3.405 0.000662
    rs7283476 Imputed T ADD 800 0.3701 0.3146 0.1998 0.6857 −3.159 0.001582
    rs7283476 Imputed T DOM 800 0.3345 0.3297 0.1753 0.6385 −3.321 0.000898
    rs7295817 Imputed C GEN 795 10.28 0.005851
    rs7298255 Imputed A ADD 800 0.7363 0.1048 0.5997 0.9041 −2.922 0.003477
    rs7298255 Imputed A DOM 800 0.6348 0.1584 0.4654 0.8659 −2.87 0.004111
    rs7305832 Imputed C GEN 798 18.44 9.88E−05
    rs7305832 Imputed C REC 798 2.46 0.2188 1.602 3.777 4.113 3.91E−05
    rs7331467 Imputed A GEN 800 15.12 0.00052
    rs7392620 Imputed C ADD 783 0.7778 0.1122 0.6242 0.9691 −2.239 0.02513
    rs742827 Imputed A ADD 727 1.41 0.1113 1.134 1.754 3.087 0.002021
    rs742827 Imputed A GEN 727 10.58 0.005035
    rs742827 Imputed A REC 727 1.914 0.2166 1.252 2.926 2.998 0.002718
    rs7446891 Imputed G DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs7448641 Imputed C ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs7448641 Imputed C DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs7484728 Imputed T GEN 788 6.971 0.03064
    rs7499402 Genotyped A ADD 800 1.746 0.1907 1.202 2.538 2.924 0.00346
    rs7529851 Imputed A ADD 800 0.7957 0.1062 0.6462 0.9799 −2.151 0.03144
    rs7529851 Imputed A GEN 800 5.275 0.07153
    rs7573951 Imputed G ADD 799 0.7174 0.1085 0.5799 0.8874 −3.06 0.002211
    rs7599198 Imputed T DOM 717 0.6201 0.1648 0.4489 0.8565 −2.9 0.003737
    rs7600050 Imputed C ADD 763 1.294 0.1099 1.043 1.605 2.343 0.01915
    rs7607712 Imputed T ADD 784 1.401 0.1287 1.088 1.803 2.618 0.008843
    rs7607712 Imputed T DOM 784 1.477 0.1494 1.102 1.979 2.609 0.009089
    rs7613492 Imputed G GEN 792 9.987 0.006783
    rs7621663 Imputed G ADD 749 1.413 0.113 1.132 1.763 3.057 0.002237
    rs7621663 Imputed G GEN 749 12.37 0.002057
    rs7621663 Imputed G REC 749 2.257 0.239 1.413 3.606 3.406 0.000658
    rs7626584 Imputed G ADD 799 0.4778 0.2123 0.3152 0.7244 −3.478 0.000505
    rs7684899 Imputed C ADD 800 0.7138 0.1326 0.5504 0.9257 −2.542 0.01103
    rs7684899 Imputed C DOM 800 0.6634 0.1489 0.4955 0.8883 −2.756 0.005859
    rs7701604 Imputed G ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs7701604 Imputed G DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs7703676 Imputed C ADD 800 0.2198 0.3906 0.1022 0.4726 −3.878 0.000105
    rs7703676 Imputed C DOM 800 0.2258 0.4052 0.102 0.4995 −3.673 0.00024
    rs7708491 Imputed C REC 797 0.5462 0.1754 0.3873 0.7703 −3.448 0.000565
    rs7711358 Imputed A DOM 797 0.6489 0.1462 0.4872 0.8644 −2.957 0.003109
    rs7719448 Imputed G REC 796 0.525 0.1769 0.3712 0.7425 −3.643 0.000269
    rs7724761 Imputed T REC 795 0.528 0.177 0.3733 0.7469 −3.609 0.000307
    rs7742476 Imputed T DOM 734 1.752 0.1551 1.293 2.374 3.615 0.0003
    rs7762993 Imputed A ADD 797 1.568 0.1276 1.221 2.013 3.524 0.000425
    rs7762993 Imputed A DOM 797 1.808 0.1517 1.343 2.434 3.904 9.47E−05
    rs7767265 Imputed G ADD 794 1.626 0.1195 1.287 2.056 4.068 4.74E−05
    rs7767265 Imputed G DOM 794 1.904 0.1484 1.424 2.547 4.34 1.43E−05
    rs7768128 Imputed G REC 768 0.3796 0.3438 0.1935 0.7448 −2.817 0.004846
    rs7771264 Imputed T DOM 769 0.6735 0.1496 0.5024 0.9029 −2.643 0.008215
    rs7773151 Genotyped C DOM 800 0.6804 0.1475 0.5096 0.9086 −2.61 0.009059
    rs7773210 Genotyped A DOM 800 0.6745 0.1474 0.5052 0.9004 −2.672 0.007537
    rs7808536 Imputed G DOM 793 1.395 0.1494 1.041 1.87 2.231 0.02571
    rs7843510 Genotyped G DOM 800 1.623 0.1544 1.199 2.197 3.137 0.001708
    rs7894867 Imputed T DOM 795 1.6 0.1731 1.14 2.247 2.717 0.00659
    rs7921834 Imputed C DOM 798 1.614 0.1449 1.215 2.144 3.304 0.000953
    rs7939893 Imputed C ADD 792 0.7358 0.1051 0.5988 0.904 −2.92 0.003502
    rs7939893 Imputed C DOM 792 0.6755 0.145 0.5084 0.8976 −2.705 0.006832
    rs7944513 Imputed T GEN 790 13.06 0.001463
    rs7944513 Imputed T REC 790 3.574 0.3533 1.788 7.143 3.605 0.000313
    rs7949720 Imputed G ADD 756 0.57 0.1619 0.415 0.7828 −3.472 0.000516
    rs7949720 Imputed G DOM 756 0.5191 0.1768 0.3671 0.7341 −3.708 0.000209
    rs7955901 Imputed C ADD 786 0.7383 0.1058 0.6 0.9085 −2.867 0.004143
    rs7955901 Imputed C DOM 786 0.6461 0.1592 0.4729 0.8826 −2.744 0.006061
    rs7956274 Imputed T ADD 795 0.7286 0.1054 0.5926 0.8957 −3.005 0.002655
    rs7956274 Imputed T DOM 795 0.6184 0.1596 0.4523 0.8456 −3.011 0.002605
    rs7956274 Imputed T GEN 795 9.858 0.007235
    rs7957932 Imputed G ADD 796 0.7518 0.1046 0.6125 0.9228 −2.729 0.006355
    rs7957932 Imputed G DOM 796 0.6254 0.1609 0.4562 0.8572 −2.918 0.003526
    rs7984504 Imputed C GEN 800 11.72 0.002847
    rs7999518 Imputed A REC 738 0.6515 0.1778 0.4598 0.9232 −2.409 0.01598
    rs8026245 Imputed G GEN 778 8.696 0.01294
    rs8026245 Imputed G REC 778 3.097 0.3961 1.425 6.731 2.854 0.004317
    rs8060725 Genotyped A ADD 800 0.7255 0.1166 0.5772 0.9118 −2.752 0.005931
    rs8103016 Genotyped A ADD 800 1.537 0.1267 1.199 1.97 3.391 0.000697
    rs8103016 Genotyped A DOM 800 1.604 0.1508 1.194 2.156 3.135 0.001718
    rs8104182 Imputed G ADD 799 1.45 0.1279 1.129 1.863 2.906 0.00366
    rs8104182 Imputed G DOM 799 1.504 0.1519 1.117 2.025 2.686 0.007239
    rs8129461 Imputed G ADD 800 0.3701 0.3146 0.1998 0.6857 −3.159 0.001582
    rs8129461 Imputed G DOM 800 0.3345 0.3297 0.1753 0.6385 −3.321 0.000898
    rs8130021 Imputed G ADD 800 0.3701 0.3146 0.1998 0.6857 −3.159 0.001582
    rs8130021 Imputed G DOM 800 0.3345 0.3297 0.1753 0.6385 −3.321 0.000898
    rs879961 Imputed T ADD 791 0.6288 0.1219 0.4951 0.7985 −3.805 0.000142
    rs879961 Imputed T DOM 791 0.6015 0.1465 0.4513 0.8016 −3.469 0.000522
    rs906353 Imputed A DOM 795 0.622 0.1448 0.4683 0.8261 −3.279 0.001041
    rs915491 Imputed C DOM 800 1.594 0.145 1.2 2.119 3.217 0.001297
    rs915493 Imputed T DOM 800 1.594 0.145 1.2 2.119 3.217 0.001297
    rs915494 Imputed A ADD 796 1.39 0.114 1.112 1.738 2.888 0.003875
    rs915494 Imputed A DOM 796 1.637 0.146 1.229 2.179 3.375 0.000738
    rs917295 Imputed G DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs9284851 Imputed A GEN 794 10.63 0.004929
    rs9293464 Imputed T REC 796 0.525 0.1769 0.3712 0.7425 −3.643 0.000269
    rs9295154 Genotyped G DOM 800 1.438 0.161 1.049 1.972 2.255 0.02411
    rs9310221 Imputed A DOM 747 1.847 0.1614 1.346 2.534 3.801 0.000144
    rs9310699 Genotyped T GEN 800 9.296 0.009578
    rs9310700 Imputed C ADD 771 1.383 0.1116 1.111 1.721 2.907 0.003644
    rs9310700 Imputed C GEN 771 10.95 0.004186
    rs9310701 Imputed G GEN 797 9.958 0.00688
    rs9310704 Imputed G GEN 784 11.11 0.003861
    rs9319185 Imputed C GEN 790 12.94 0.001552
    rs9319186 Imputed T GEN 795 12.3 0.002134
    rs9327555 Imputed T DOM 800 0.6617 0.1466 0.4964 0.882 −2.816 0.004859
    rs9403367 Imputed C DOM 800 0.6745 0.1474 0.5052 0.9004 −2.672 0.007537
    rs9419608 Imputed G REC 797 1.836 0.1694 1.317 2.559 3.586 0.000336
    rs9426437 Imputed T DOM 760 0.5666 0.1548 0.4183 0.7675 −3.669 0.000244
    rs9454967 Imputed G DOM 799 1.856 0.1976 1.26 2.734 3.131 0.001743
    rs9635511 Imputed T DOM 791 0.5772 0.1505 0.4297 0.7753 −3.651 0.000262
    rs966583 Imputed A ADD 795 0.7274 0.1066 0.5903 0.8964 −2.987 0.002819
    rs966583 Imputed A DOM 795 0.6077 0.151 0.452 0.817 −3.298 0.000973
    rs980263 Imputed T GEN 796 10.4 0.00552
    rs980264 Imputed T GEN 796 10.4 0.00552
    rs9812206 Imputed G ADD 799 0.526 0.1802 0.3695 0.7488 −3.565 0.000364
    rs9812206 Imputed G DOM 799 0.4862 0.1936 0.3327 0.7106 −3.725 0.000196
    rs9813552 Imputed G ADD 800 0.5703 0.1786 0.4019 0.8093 −3.145 0.001661
    rs9813552 Imputed G DOM 800 0.5318 0.191 0.3657 0.7733 −3.306 0.000946
    rs9815037 Imputed T ADD 799 0.5621 0.1845 0.3915 0.8069 −3.123 0.001792
    rs9815037 Imputed T DOM 799 0.5176 0.1969 0.3519 0.7613 −3.345 0.000822
    rs9819583 Imputed T GEN 798 9.421 0.008999
    rs9825349 Imputed A ADD 798 0.5607 0.1845 0.3906 0.8049 −3.136 0.001712
    rs9825349 Imputed A DOM 798 0.5163 0.1969 0.351 0.7593 −3.358 0.000784
    rs9833118 Imputed G ADD 794 1.352 0.1082 1.094 1.672 2.791 0.005247
    rs9833118 Imputed G GEN 794 9.638 0.008076
    rs9834217 Imputed T ADD 799 0.5621 0.1845 0.3915 0.8069 −3.123 0.001792
    rs9834217 Imputed T DOM 799 0.5176 0.1969 0.3519 0.7613 −3.345 0.000822
    rs9838563 Imputed C GEN 797 9.958 0.00688
    rs9840460 Imputed T ADD 799 0.5621 0.1845 0.3915 0.8069 −3.123 0.001792
    rs9840460 Imputed T DOM 799 0.5176 0.1969 0.3519 0.7613 −3.345 0.000822
    rs9840756 Imputed A ADD 799 0.5621 0.1845 0.3915 0.8069 −3.123 0.001792
    rs9840756 Imputed A DOM 799 0.5176 0.1969 0.3519 0.7613 −3.345 0.000822
    rs9847999 Imputed C GEN 794 10.29 0.005829
    rs9864769 Imputed C GEN 797 9.958 0.00688
    rs9866421 Genotyped C REC 800 0.5528 0.191 0.3802 0.8038 −3.104 0.00191
    rs987296 Imputed T GEN 800 9.296 0.009578
    rs9881685 Imputed A ADD 799 0.526 0.1802 0.3695 0.7488 −3.565 0.000364
    rs9881685 Imputed A DOM 799 0.4862 0.1936 0.3327 0.7106 −3.725 0.000196
    rs992695 Imputed C ADD 790 0.6317 0.1218 0.4976 0.8019 −3.773 0.000161
    rs992695 Imputed C DOM 790 0.6056 0.1463 0.4546 0.8068 −3.427 0.00061
    rs9936999 Imputed G DOM 485 1.885 0.192 1.294 2.746 3.302 0.000961
    PRAVA_ PLACEBO_ PLACEBO_
    PRAVA_ PLACEBO_ A1_ PRAVA_ PRAVA_ A1_ PLACEBO_ A2_
    HW_ ALLELE_ ALLELE_ ALLELE_ HZ_ HET_ A2_HZ HZ_ HET_ HZ_
    SNP rs # PVALUE FREQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs77638540 0.3047 0.0375 0.021008 0.05079 1 13 343 1 43 399
    rs72746987 1 0.04 0.019608 0.056433 0 14 343 1 48 394
    rs10021016 0.8563 0.26563 0.294118 0.242664 35 140 182 20 175 248
    rs10021016 0.8563 0.26563 0.294118 0.242664 35 140 182 20 175 248
    rs10051148 0.8139 0.34296 0.315493 0.365079 44 136 175 51 220 170
    rs10054055 0.9376 0.345 0.317927 0.366817 44 139 174 52 221 170
    rs10067895 0.6933 0.34324 0.316901 0.364679 44 137 174 52 214 170
    rs10100725 0.2765 0.17813 0.141457 0.207675 12 77 268 18 148 277
    rs10128531 0.7542 0.13612 0.159159 0.117359 7 92 234 5 86 318
    rs10181743 0.5529 0.42126 0.473837 0.37799 72 182 90 59 198 161
    rs10199127 0.4327 0.28846 0.315714 0.266279 28 165 157 32 165 233
    rs10270624 0.5731 0.20333 0.224036 0.186441 11 129 197 17 120 276
    rs1030006 0.8313 0.46926 0.495775 0.447964 96 160 99 81 234 127
    rs1031811 0.5994 0.2822 0.291785 0.274487 37 132 184 29 183 227
    rs10430870 0.1303 0.24938 0.282913 0.222348 36 130 191 22 153 268
    rs10430870 0.1303 0.24938 0.282913 0.222348 36 130 191 22 153 268
    rs10469597 0.04142 0.27267 0.308735 0.243243 43 119 170 23 152 232
    rs10469597 0.04142 0.27267 0.308735 0.243243 43 119 170 23 152 232
    rs10478919 0.7533 0.34316 0.314607 0.366213 44 136 176 52 219 170
    rs10506623 1 0.39961 0.362069 0.43007 50 152 146 74 221 134
    rs10506623 1 0.39961 0.362069 0.43007 50 152 146 74 221 134
    rs10506626 0.8818 0.39308 0.356742 0.422551 53 148 155 71 229 139
    rs10506626 0.8818 0.39308 0.356742 0.422551 53 148 155 71 229 139
    rs10509477 0.9326 0.29688 0.329132 0.27088 31 173 153 40 160 243
    rs10517918 0.7175 0.42669 0.460674 0.399321 81 166 109 67 219 156
    rs10517924 0.4338 0.45625 0.488796 0.430023 96 157 104 76 229 138
    rs10519362 1 0.17985 0.201705 0.162037 9 124 219 16 108 308
    rs10520072 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs10737390 0.7109 0.40089 0.365819 0.429561 58 143 153 71 230 132
    rs10742851 1 0.29 0.268908 0.306998 17 158 182 50 172 221
    rs10743685 0.1392 0.39937 0.443662 0.363636 79 157 119 58 204 178
    rs10743685 0.1392 0.39937 0.443662 0.363636 79 157 119 58 204 178
    rs10749293 0.8656 0.29674 0.328652 0.270975 31 172 153 40 159 242
    rs10749294 0.7216 0.27256 0.300562 0.25 24 166 166 33 155 254
    rs10753760 0.5446 0.4094 0.456061 0.372289 71 159 100 58 193 164
    rs10753760 0.5446 0.4094 0.456061 0.372289 71 159 100 58 193 164
    rs10772362 0.2824 0.2375 0.194678 0.272009 7 125 225 32 177 234
    rs10784891 0.3414 0.44575 0.404692 0.478774 54 168 119 91 224 109
    rs10784891 0.3414 0.44575 0.404692 0.478774 54 168 119 91 224 109
    rs10784891 0.3414 0.44575 0.404692 0.478774 54 168 119 91 224 109
    rs10787923 0.8652 0.29648 0.328652 0.270455 31 172 153 40 158 242
    rs10787924 0.7885 0.27227 0.300562 0.249433 24 166 166 33 154 254
    rs10787949 1 0.29688 0.330532 0.269752 32 172 153 38 163 242
    rs10787951 1 0.29688 0.330532 0.269752 32 172 153 38 163 242
    rs10787983 0.8644 0.29261 0.32493 0.26644 30 172 155 37 161 243
    rs10794733 0.934 0.31361 0.2849 0.336782 31 138 182 47 199 189
    rs10818280 0.7332 0.29759 0.26204 0.326437 25 135 193 47 190 198
    rs10860586 0.8315 0.48995 0.523876 0.4625 97 179 80 92 223 125
    rs10860586 0.8315 0.48995 0.523876 0.4625 97 179 80 92 223 125
    rs10870473 0.894 0.2655 0.207317 0.311594 7 54 103 18 93 96
    rs10870473 0.894 0.2655 0.207317 0.311594 7 54 103 18 93 96
    rs10879240 0.2791 0.43805 0.40085 0.468037 53 177 123 91 228 119
    rs10879240 0.2791 0.43805 0.40085 0.468037 53 177 123 91 228 119
    rs10879242 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs10879242 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs10879245 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs10879245 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs10879249 1 0.3956 0.357746 0.426136 50 154 151 74 227 139
    rs10879249 1 0.3956 0.357746 0.426136 50 154 151 74 227 139
    rs10886429 0.9325 0.29737 0.328652 0.272109 31 172 153 40 160 241
    rs10886449 0.7887 0.27188 0.302521 0.247178 25 166 166 32 155 256
    rs10886451 0.7887 0.27188 0.302521 0.247178 25 166 166 32 155 256
    rs10886452 1 0.29688 0.330532 0.269752 32 172 153 38 163 242
    rs10886456 7.89E−01 0.27188 0.302521 0.247178 25 166 166 32 155 256
    rs10886463 0.9328 0.29875 0.330532 0.273138 32 172 153 40 162 241
    rs10886465 1 0.295 0.329132 0.267494 31 173 153 38 161 244
    rs10886526 0.8644 0.29261 0.32493 0.26644 30 172 155 37 161 243
    rs10922903 0.8845 0.41813 0.37535 0.452596 44 180 133 97 207 139
    rs10941126 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs10941126 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs10947980 0.7851 0.26504 0.232493 0.291383 19 128 210 35 187 219
    rs11059376 0.8067 0.18681 0.222741 0.157895 16 111 194 10 106 283
    rs11072995 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs11072995 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs11081202 0.04263 0.29875 0.305322 0.293454 35 148 174 24 212 207
    rs11081202 0.04263 0.29875 0.305322 0.293454 35 148 174 24 212 207
    rs110965 0.4545 0.33175 0.354545 0.313268 44 146 140 32 191 184
    rs11124962 0.00528 0.23418 0.26204 0.21167 15 155 183 14 157 266
    rs1116596 0.8136 0.34446 0.316384 0.367045 44 136 174 52 219 169
    rs11178531 0.4338 0.46734 0.432394 0.495465 68 171 116 100 237 104
    rs11178531 0.4338 0.46734 0.432394 0.495465 68 171 116 100 237 104
    rs11178583 0.9411 0.39573 0.358146 0.426136 50 155 151 74 227 139
    rs11178583 0.9411 0.39573 0.358146 0.426136 50 155 151 74 227 139
    rs11178589 0.9413 0.40915 0.368946 0.441514 52 155 144 79 227 130
    rs11178589 0.9413 0.40915 0.368946 0.441514 52 155 144 79 227 130
    rs11178594 1 0.39837 0.360563 0.428733 51 154 150 75 229 138
    rs11178594 1 0.39837 0.360563 0.428733 51 154 150 75 229 138
    rs11178602 0.9411 0.39748 0.358757 0.428571 51 152 151 75 228 138
    rs11178602 0.9411 0.39748 0.358757 0.428571 51 152 151 75 228 138
    rs11178648 0.9407 0.39232 0.356338 0.421412 53 147 155 70 230 139
    rs11178648 0.9407 0.39232 0.356338 0.421412 53 147 155 70 230 139
    rs11198877 1 0.29688 0.330532 0.269752 32 172 153 38 163 242
    rs11198942 0.9326 0.29688 0.329132 0.27088 31 173 153 40 160 243
    rs11221075 0.2665 0.13586 0.107256 0.158088 2 64 251 15 99 294
    rs11242020 0.754 0.34336 0.314607 0.366516 44 136 176 52 220 170
    rs11242021 0.7549 0.34625 0.317927 0.369074 44 139 174 54 219 170
    rs11242022 0.7549 0.34625 0.317927 0.369074 44 139 174 54 219 170
    rs11242023 0.7538 0.34403 0.317416 0.365604 44 138 174 52 217 170
    rs1149349 0.6129 0.16729 0.19888 0.141723 11 120 226 9 107 325
    rs1149350 0.3353 0.21103 0.249288 0.180365 17 141 193 13 132 293
    rs1149350 0.3353 0.21103 0.249288 0.180365 17 141 193 13 132 293
    rs11576627 0.04851 0.12313 0.154062 0.098194 3 104 250 3 81 359
    rs11576627 0.04851 0.12313 0.154062 0.098194 3 104 250 3 81 359
    rs11630050 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11630050 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11633024 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11633024 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11636298 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs11636298 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs11637363 1 0.20607 0.231778 0.185615 23 113 207 10 140 281
    rs11637363 1 0.20607 0.231778 0.185615 23 113 207 10 140 281
    rs11637813 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11637813 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs11638043 0.9134 0.20785 0.232558 0.188222 23 114 207 11 141 281
    rs11638043 0.9134 0.20785 0.232558 0.188222 23 114 207 11 141 281
    rs11638115 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs11638115 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs11638444 0.8201 0.19149 0.217087 0.170814 20 115 222 8 135 299
    rs11717157 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs11717157 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs11724055 0.2128 0.17043 0.140845 0.194131 6 88 261 12 148 283
    rs11743355 0.01351 0.03689 0.01548 0.05379 0 10 313 4 36 369
    rs11743355 0.01351 0.03689 0.01548 0.05379 0 10 313 4 36 369
    rs11746806 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs11746806 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs11746959 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs11746959 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs11749272 0.7533 0.34316 0.314607 0.366213 44 136 176 52 219 170
    rs11839636 0.3879 0.29087 0.336158 0.254023 42 154 158 30 161 244
    rs11839785 0.2578 0.289 0.334758 0.25174 42 151 158 30 157 244
    rs11853619 0.9088 0.19086 0.217087 0.169683 20 115 222 8 134 300
    rs11853619 0.9088 0.19086 0.217087 0.169683 20 115 222 8 134 300
    rs11856780 0.9088 0.19086 0.217087 0.169683 20 115 222 8 134 300
    rs11856780 0.9088 0.19086 0.217087 0.169683 20 115 222 8 134 300
    rs11901899 0.4548 0.26206 0.288406 0.240521 24 151 170 24 155 243
    rs11903290 0.598 0.28121 0.29096 0.273349 37 132 185 29 182 228
    rs11909480 0.591 0.03325 0.016854 0.046485 0 12 344 1 39 401
    rs11909480 0.591 0.03325 0.016854 0.046485 0 12 344 1 39 401
    rs11910289 1 0.05556 0.070175 0.043735 1 46 295 1 35 387
    rs11910289 1 0.05556 0.070175 0.043735 1 46 295 1 35 387
    rs11920375 0.9394 0.3675 0.407563 0.335214 63 165 129 44 209 190
    rs11926319 0.6789 0.09449 0.071429 0.113122 3 45 309 5 90 347
    rs11933744 1 0.27722 0.30112 0.257919 39 137 181 22 184 236
    rs11934919 1 0.27722 0.30112 0.257919 39 137 181 22 184 236
    rs11934957 1 0.27722 0.30112 0.257919 39 137 181 22 184 236
    rs11959206 1 0.48805 0.44051 0.526018 62 187 104 127 211 104
    rs12038613 0.9417 0.42209 0.376791 0.458525 44 175 130 96 206 132
    rs12151417 0.7585 0.2287 0.255814 0.206444 19 138 187 19 135 265
    rs12153185 0.6938 0.34343 0.316901 0.364989 44 137 174 52 215 170
    rs12182651 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs12235345 0.3614 0.06368 0.086402 0.045455 0 61 292 1 38 401
    rs12324786 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs12324786 0.9062 0.18474 0.210452 0.164009 19 111 224 7 130 302
    rs12336958 0.2787 0.38821 0.428135 0.356448 49 182 96 55 183 173
    rs12407412 0.04851 0.12313 0.154062 0.098194 3 104 250 3 81 359
    rs12407412 0.04851 0.12313 0.154062 0.098194 3 104 250 3 81 359
    rs12418971 0.1822 0.2549 0.290698 0.225653 36 128 180 21 148 252
    rs12418971 0.1822 0.2549 0.290698 0.225653 36 128 180 21 148 252
    rs1241967 0.2143 0.35088 0.308451 0.384876 23 173 159 67 207 169
    rs12420184 0.5898 0.15515 0.125 0.179545 10 69 277 11 136 293
    rs12433968 0.1676 0.29921 0.25 0.338863 20 130 190 40 206 176
    rs12445477 0.2176 0.07847 0.058997 0.09375 1 38 300 1 79 352
    rs12447191 0.8153 0.18625 0.159664 0.207675 5 104 248 21 142 280
    rs12447191 0.8153 0.18625 0.159664 0.207675 5 104 248 21 142 280
    rs12465349 0.3161 0.52369 0.555085 0.497658 108 177 69 99 227 101
    rs1247340 0.1597 0.20551 0.240169 0.177602 14 143 199 13 131 298
    rs1247340 0.1597 0.20551 0.240169 0.177602 14 143 199 13 131 298
    rs1247341 0.1917 0.20514 0.239437 0.177602 14 142 199 13 131 298
    rs1247341 0.1917 0.20514 0.239437 0.177602 14 142 199 13 131 298
    rs1247343 0.6121 0.169 0.2 0.144165 11 118 221 9 108 320
    rs12509758 0.5762 0.19712 0.219101 0.179458 11 134 211 17 125 301
    rs12515472 0.6528 0.19524 0.20927 0.183973 11 127 218 17 129 297
    rs12548906 0.7959 0.16886 0.188235 0.153207 14 100 226 6 117 298
    rs12596240 0.824 0.3925 0.348739 0.427765 49 151 157 76 227 140
    rs12618781 0.7209 0.46338 0.428977 0.490909 69 164 119 98 236 106
    rs12678600 0.5684 0.31813 0.280112 0.348758 30 140 187 47 215 181
    rs12692229 0.7574 0.35723 0.383853 0.335973 47 177 129 52 193 197
    rs12713324 0.8375 0.22465 0.252149 0.202326 19 138 192 19 136 275
    rs12719415 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs12820589 0.07407 0.18758 0.219298 0.161446 12 126 204 7 120 288
    rs12820589 0.07407 0.18758 0.219298 0.161446 12 126 204 7 120 288
    rs12831292 0.941 0.40102 0.362857 0.431507 51 152 147 75 228 135
    rs12831292 0.941 0.40102 0.362857 0.431507 51 152 147 75 228 135
    rs13012636 0.5987 0.28149 0.291785 0.273243 37 132 184 29 183 229
    rs13038146 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs13038146 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs13038146 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs13089860 5.01E−07 0.49617 0.446735 0.535912 72 116 103 121 146 95
    rs13102419 0.3489 0.46213 0.494253 0.436195 96 152 100 77 222 132
    rs13194907 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs13194907 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs13195745 0.2638 0.06946 0.092437 0.050905 4 58 295 2 41 399
    rs13195745 0.2638 0.06946 0.092437 0.050905 4 58 295 2 41 399
    rs13265054 0.4633 0.3183 0.281513 0.348073 30 141 186 46 215 180
    rs13273002 0.4182 0.22619 0.190141 0.255079 9 117 229 36 154 253
    rs13282131 0.5189 0.44668 0.480282 0.419683 82 177 96 72 227 143
    rs13282131 0.5189 0.44668 0.480282 0.419683 82 177 96 72 227 143
    rs13282131 0.5189 0.44668 0.480282 0.419683 82 177 96 72 227 143
    rs1330052 0.2006 0.32813 0.379552 0.286682 52 167 138 42 170 231
    rs1335721 0.9417 0.42209 0.376791 0.458525 44 175 130 96 206 132
    rs1336382 0.8653 0.29686 0.328652 0.271071 31 172 153 40 158 241
    rs1336383 0.9326 0.29688 0.329132 0.27088 31 173 153 40 160 243
    rs1336407 0.9322 0.29313 0.32493 0.267494 30 172 155 38 161 244
    rs1336409 0.9322 0.29313 0.32493 0.267494 30 172 155 38 161 244
    rs1336596 0.3514 0.35239 0.312676 0.384354 45 132 178 60 219 162
    rs13387284 0.8837 0.45526 0.420588 0.483333 65 156 119 91 224 105
    rs13401462 0.7164 0.47632 0.507396 0.451422 79 185 74 96 189 137
    rs13409045 0.5973 0.37942 0.338983 0.4121 40 160 154 70 221 147
    rs1349284 0.7594 0.36125 0.397759 0.331828 60 164 133 42 210 191
    rs1355715 0.6107 0.07375 0.047619 0.094808 1 32 324 4 76 363
    rs1357696 0.5414 0.37404 0.411932 0.343023 63 164 125 42 211 177
    rs1357698 0.5411 0.37452 0.413105 0.343023 63 164 124 42 211 177
    rs1357699 0.5411 0.37452 0.413105 0.343023 63 164 124 42 211 177
    rs1363273 0.5195 0.48397 0.448276 0.512731 60 192 96 118 207 107
    rs1373601 0.3096 0.32216 0.286585 0.351117 32 124 172 50 183 170
    rs1375829 0.7594 0.36125 0.397759 0.331828 60 164 133 42 210 191
    rs1395748 0.5437 0.285 0.239496 0.32167 19 133 205 42 201 200
    rs1414865 1 0.29688 0.330532 0.269752 32 172 153 38 163 242
    rs1414873 0.9322 0.29313 0.32493 0.267494 30 172 155 38 161 244
    rs1414876 0.9322 0.29313 0.32493 0.267494 30 172 155 38 161 244
    rs1424643 0.538 0.22494 0.252857 0.202103 18 141 191 18 137 273
    rs1424643 0.538 0.22494 0.252857 0.202103 18 141 191 18 137 273
    rs1424648 0.4118 0.22449 0.248563 0.205275 18 137 193 17 145 274
    rs1429321 0.838 0.22208 0.2493 0.2 19 140 198 19 138 283
    rs1429326 0.8363 0.22033 0.247887 0.197941 18 140 197 19 135 283
    rs1429326 0.8363 0.22033 0.247887 0.197941 18 140 197 19 135 283
    rs1444741 0.3937 0.31868 0.282875 0.34788 31 123 173 48 183 170
    rs1449916 0.7419 0.4915 0.450368 0.526899 59 127 86 85 163 68
    rs1459523 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1459523 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1466352 0.821 0.37641 0.412676 0.347285 65 163 127 46 215 181
    rs1466353 0.8212 0.37626 0.412429 0.347285 65 162 127 46 215 181
    rs1476714 0.8142 0.34567 0.31831 0.367647 44 138 173 53 219 170
    rs1486723 0.8155 0.3475 0.315126 0.373589 28 169 160 70 191 182
    rs1495375 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs1495375 0.941 0.40038 0.364789 0.429224 52 155 148 74 228 136
    rs1495381 0.2696 0.40175 0.431373 0.377828 69 170 118 52 230 160
    rs1495381 0.2696 0.40175 0.431373 0.377828 69 170 118 52 230 160
    rs1498061 0.07449 0.1961 0.144118 0.237209 3 43 124 6 90 119
    rs1498992 0.571 0.3239 0.280282 0.359091 33 133 189 54 208 178
    rs1499001 0.5785 0.26606 0.218475 0.304502 18 113 210 39 179 204
    rs1512988 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs1512988 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs1512989 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs1512989 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs1512991 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs1512991 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs1512991 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs1524303 0.7608 0.36948 0.407303 0.338673 62 166 128 44 208 185
    rs1524306 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1524306 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1524310 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1524310 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1524321 0.8212 0.37626 0.412429 0.347285 65 162 127 46 215 181
    rs1527059 0.3612 0.08573 0.067416 0.100451 5 38 313 3 83 357
    rs152707 0.6633 0.42063 0.372549 0.459368 45 176 136 93 221 129
    rs152707 0.6633 0.42063 0.372549 0.459368 45 176 136 93 221 129
    rs152712 0.5157 0.42553 0.376751 0.464932 45 179 133 95 221 126
    rs152712 0.5157 0.42553 0.376751 0.464932 45 179 133 95 221 126
    rs1533994 0.763 0.37484 0.411765 0.345023 65 164 128 45 215 182
    rs1535866 0.9166 0.21564 0.239437 0.196347 18 134 203 18 136 284
    rs1563773 0.7628 0.37531 0.411765 0.345805 65 164 128 45 215 181
    rs1563774 0.5981 0.37846 0.414326 0.349315 65 165 126 45 216 177
    rs1567740 0.9411 0.39573 0.358146 0.426136 50 155 151 74 227 139
    rs1567740 0.9411 0.39573 0.358146 0.426136 50 155 151 74 227 139
    rs1572573 0.5616 0.19221 0.22929 0.163194 15 125 198 16 109 307
    rs1577497 0.9417 0.42112 0.377143 0.456422 44 176 130 96 206 134
    rs1581514 0.5417 0.36541 0.403361 0.334475 60 168 129 42 209 187
    rs1581514 0.5417 0.36541 0.403361 0.334475 60 168 129 42 209 187
    rs1582321 0.824 0.3925 0.348739 0.427765 49 151 157 76 227 140
    rs1582322 0.824 0.39299 0.351124 0.426637 50 150 156 75 228 140
    rs1582323 0.8238 0.39286 0.350704 0.426637 50 149 156 75 228 140
    rs1592485 0.5061 0.39737 0.355742 0.430995 53 148 156 78 225 139
    rs1600954 0.8845 0.48748 0.531343 0.45283 87 182 66 92 200 132
    rs1600954 0.8845 0.48748 0.531343 0.45283 87 182 66 92 200 132
    rs16938626 1 0.28043 0.24507 0.308824 26 122 207 36 201 205
    rs16964300 0.9076 0.1875 0.159664 0.209932 5 104 248 22 142 279
    rs16964300 0.9076 0.1875 0.159664 0.209932 5 104 248 22 142 279
    rs16986282 0.5896 0.03313 0.016807 0.046275 1 10 346 0 41 402
    rs17007620 0.8349 0.23922 0.269868 0.215736 20 123 159 21 128 245
    rs17007620 0.8349 0.23922 0.269868 0.215736 20 123 159 21 128 245
    rs17014326 0.7323 0.29408 0.246479 0.332574 22 131 202 44 204 191
    rs17047957 0.6344 0.1828 0.203704 0.165899 10 123 218 18 108 308
    rs1705261 0.3391 0.40351 0.435393 0.377828 70 170 116 53 228 161
    rs17073341 1 0.04375 0.064426 0.027088 1 44 312 0 24 419
    rs17073341 1 0.04375 0.064426 0.027088 1 44 312 0 24 419
    rs17138702 0.3509 0.13174 0.095506 0.160998 2 64 290 15 112 314
    rs17189710 0.3973 0.36038 0.40113 0.327664 64 156 134 45 199 197
    rs17189710 0.3973 0.36038 0.40113 0.327664 64 156 134 45 199 197
    rs17189710 0.3973 0.36038 0.40113 0.327664 64 156 134 45 199 197
    rs17310176 0.22 0.17375 0.138655 0.202032 10 79 268 19 141 283
    rs17310176 0.22 0.17375 0.138655 0.202032 10 79 268 19 141 283
    rs17358860 0.2583 0.17 0.140056 0.194131 6 88 263 12 148 283
    rs17370541 0.3116 0.37434 0.426647 0.332536 67 151 116 45 188 185
    rs17370541 0.3116 0.37434 0.426647 0.332536 67 151 116 45 188 185
    rs17526574 0.2278 0.28875 0.333333 0.252822 43 152 162 31 162 250
    rs17530747 0.9395 0.36951 0.320225 0.409297 39 150 167 69 223 149
    rs17649114 0.5766 0.19625 0.22409 0.173815 13 134 210 15 124 304
    rs17766172 0.3748 0.33571 0.324047 0.344988 20 181 140 61 174 194
    rs1818885 0.5911 0.36146 0.400568 0.330317 59 164 129 41 210 191
    rs1832222 0.9321 0.29349 0.32493 0.2681 30 172 155 38 161 243
    rs1861327 0.824 0.3925 0.348739 0.427765 49 151 157 76 227 140
    rs1868581 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1868581 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1874313 0.8824 0.3946 0.359155 0.423077 51 153 151 74 226 142
    rs1874313 0.8824 0.3946 0.359155 0.423077 51 153 151 74 226 142
    rs1876409 0.5437 0.285 0.239496 0.32167 19 133 205 42 201 200
    rs1913201 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs1913201 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs1913201 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs1916922 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs1936871 0.6638 0.42188 0.394958 0.443567 67 148 142 72 249 122
    rs1961157 0.6171 0.45 0.413165 0.479684 55 185 117 103 219 121
    rs1987179 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs1987179 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs1990023 0.754 0.34336 0.314607 0.366516 44 136 176 52 220 170
    rs1995025 0.4655 0.14323 0.17192 0.119718 8 104 237 5 92 329
    rs2016194 0.8145 0.34543 0.317927 0.367647 44 139 174 53 219 170
    rs2023651 0.1305 0.22773 0.191011 0.25737 14 108 234 35 157 249
    rs2024902 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs2024902 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs2025107 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs2025108 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs2031987 0.2253 0.28616 0.331461 0.249431 42 152 162 30 159 250
    rs2052428 0.0995 0.46939 0.431818 0.5 67 170 115 94 244 94
    rs2053230 4.60E−06 0.18767 0.145511 0.221805 1 92 230 7 163 229
    rs2062448 0.1524 0.09708 0.072443 0.116972 4 43 305 7 88 341
    rs2063420 0.8266 0.43013 0.464183 0.402552 81 162 106 65 217 149
    rs2063591 0.5698 0.47177 0.435211 0.501131 69 171 115 104 235 103
    rs2063591 0.5698 0.47177 0.435211 0.501131 69 171 115 104 235 103
    rs208026 0.8428 0.23188 0.259104 0.209932 21 143 193 23 140 280
    rs208029 0.9177 0.22137 0.242165 0.204598 17 136 198 22 134 279
    rs208757 0.4251 0.22966 0.256303 0.208145 23 137 197 23 138 281
    rs2095586 0.8644 0.29745 0.331412 0.270548 30 170 147 38 161 239
    rs2095606 0.8151 0.35242 0.311966 0.385057 42 135 174 57 221 157
    rs2102374 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2102374 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2108426 0.8145 0.34543 0.317927 0.367647 44 139 174 53 219 170
    rs2110664 0.5169 0.27218 0.300898 0.24878 26 149 159 25 154 231
    rs2132242 0.8835 0.40984 0.371469 0.440774 53 157 144 79 229 131
    rs2132242 0.8835 0.40984 0.371469 0.440774 53 157 144 79 229 131
    rs2158958 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs2158961 0.8139 0.34296 0.315493 0.365079 44 136 175 51 220 170
    rs2163046 0.8374 0.22516 0.252874 0.202576 19 138 191 19 135 273
    rs2180286 0.3579 0.49875 0.469188 0.522676 89 157 111 116 229 96
    rs2180684 0.05232 0.10313 0.120448 0.089165 5 76 276 9 61 373
    rs2188079 0.7718 0.42043 0.461972 0.387133 81 166 108 62 219 162
    rs2188079 0.7718 0.42043 0.461972 0.387133 81 166 108 62 219 162
    rs2190598 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs2190600 0.6933 0.34324 0.316901 0.364679 44 137 174 52 214 170
    rs2224184 0.2036 0.495 0.466387 0.518059 89 155 113 116 227 100
    rs2247066 0.5437 0.285 0.239496 0.32167 19 133 205 42 201 200
    rs2248236 0.1692 0.18063 0.147516 0.206897 6 83 233 12 144 250
    rs2248236 0.1692 0.18063 0.147516 0.206897 6 83 233 12 144 250
    rs2265733 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2265733 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2270584 0.8821 0.39322 0.356338 0.422902 53 147 155 71 231 139
    rs2270584 0.8821 0.39322 0.356338 0.422902 53 147 155 71 231 139
    rs2270586 0.8818 0.39308 0.356338 0.422727 53 147 155 71 230 139
    rs2270586 0.8818 0.39308 0.356338 0.422727 53 147 155 71 230 139
    rs229775 0.2143 0.35088 0.308451 0.384876 23 173 159 67 207 169
    rs229815 0.1243 0.33727 0.297935 0.368794 20 162 157 57 198 168
    rs229829 0.3711 0.38896 0.344633 0.424379 35 174 145 79 218 146
    rs229831 0.2138 0.35132 0.309322 0.384876 23 173 158 67 207 169
    rs2317057 0.3235 0.23917 0.20471 0.266571 14 85 177 26 133 188
    rs2322100 0.2233 0.28375 0.285714 0.282167 33 138 186 24 202 217
    rs2322101 0.2237 0.28348 0.285714 0.281674 33 138 186 24 201 217
    rs2327929 0.09589 0.4224 0.470506 0.383747 89 157 110 65 210 168
    rs2332844 0.4407 0.81718 0.86526 0.77748 230 73 5 228 124 21
    rs2332844 0.4407 0.81718 0.86526 0.77748 230 73 5 228 124 21
    rs2349170 0.1438 0.21706 0.245787 0.193878 12 151 193 18 135 288
    rs2356722 0.6103 0.29449 0.247191 0.332579 22 132 202 44 206 192
    rs2364956 1 0.16969 0.196581 0.147268 12 114 225 10 104 307
    rs2373793 0.1524 0.14583 0.169492 0.126712 12 96 246 10 91 337
    rs2373793 0.1524 0.14583 0.169492 0.126712 12 96 246 10 91 337
    rs238252 0.02096 0.13329 0.169468 0.104072 13 95 249 9 74 359
    rs238252 0.02096 0.13329 0.169468 0.104072 13 95 249 9 74 359
    rs2383903 0.9292 0.27478 0.240169 0.302721 24 123 209 35 197 209
    rs2387945 0.4666 0.14141 0.169014 0.118993 8 104 243 5 94 338
    rs2389863 0.03874 0.20791 0.181948 0.228736 10 107 232 14 171 250
    rs2389866 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs2389869 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs2389870 0.2661 0.1725 0.142857 0.196388 6 90 261 13 148 282
    rs2418494 0.06196 0.51351 0.485549 0.535963 84 168 94 134 194 103
    rs2418494 0.06196 0.51351 0.485549 0.535963 84 168 94 134 194 103
    rs2418541 0.754 0.34336 0.314607 0.366516 44 136 176 52 220 170
    rs2418542 0.7533 0.34316 0.314607 0.366213 44 136 176 52 219 170
    rs2423556 0.3955 0.50251 0.473239 0.526077 90 156 109 117 230 94
    rs2437688 0.01205 0.10451 0.122191 0.090293 8 71 277 8 64 371
    rs2456809 0.604 0.28563 0.240896 0.32167 20 132 205 42 201 200
    rs2456811 0.781 0.25919 0.212034 0.296591 14 120 215 37 187 216
    rs2456811 0.781 0.25919 0.212034 0.296591 14 120 215 37 187 216
    rs2476976 0.7326 0.29287 0.323529 0.2681 29 173 155 37 163 242
    rs2484911 0.5269 0.26725 0.296348 0.243764 23 165 168 30 155 256
    rs2488557 0.5179 0.12643 0.096264 0.150342 4 59 285 6 120 313
    rs250162 0.8414 0.23423 0.205279 0.256881 15 110 216 26 172 238
    rs250162 0.8414 0.23423 0.205279 0.256881 15 110 216 26 172 238
    rs2560708 0.07361 0.17078 0.14058 0.195294 3 91 251 12 142 271
    rs2617841 0.6955 0.2517 0.218373 0.279012 15 115 202 29 168 208
    rs2622499 0.0308 0.20677 0.180282 0.227991 10 108 237 14 174 255
    rs264129 0.8136 0.34211 0.314607 0.364253 44 136 176 51 220 171
    rs2642936 0.8364 0.22555 0.259475 0.198113 22 134 187 18 132 274
    rs2660633 0.5437 0.285 0.239496 0.32167 19 133 205 42 201 200
    rs2660634 0.5437 0.285 0.239496 0.32167 19 133 205 42 201 200
    rs2660648 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2660648 0.781 0.25886 0.211429 0.296591 14 120 216 37 187 216
    rs2681505 0.2824 0.2375 0.194678 0.272009 7 125 225 32 177 234
    rs277411 1 0.03639 0.018207 0.051136 0 13 344 1 43 396
    rs2832634 1 0.05541 0.069971 0.043632 1 46 296 1 35 388
    rs2832637 1 0.05541 0.069971 0.043632 1 46 296 1 35 388
    rs2843167 0.6009 0.2858 0.241477 0.32151 21 128 203 40 201 196
    rs2876227 0.5865 0.35897 0.396848 0.328306 61 155 133 43 197 191
    rs2876227 0.5865 0.35897 0.396848 0.328306 61 155 133 43 197 191
    rs2882097 0.9326 0.29688 0.329132 0.27088 31 173 153 40 160 243
    rs2909862 0.5231 0.40147 0.447712 0.363636 53 168 85 52 168 154
    rs3001945 0.4666 0.14141 0.169014 0.118993 8 104 243 5 94 338
    rs3011020 0.4664 0.14159 0.169492 0.118993 8 104 242 5 94 338
    rs36071725 0.4813 0.34438 0.396359 0.302483 60 163 134 30 208 205
    rs36071725 0.4813 0.34438 0.396359 0.302483 60 163 134 30 208 205
    rs373983 0.3368 0.41113 0.451149 0.379032 70 174 104 69 191 174
    rs3743794 0.8817 0.39084 0.34887 0.424379 49 149 156 74 228 141
    rs3756154 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs3756154 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs3775850 0.212 0.17127 0.140845 0.195701 6 88 261 12 149 281
    rs3775851 0.2128 0.17043 0.140845 0.194131 6 88 261 12 148 283
    rs3793044 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs3793044 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs3793053 0.8339 0.09311 0.116715 0.074371 4 73 270 3 59 375
    rs3796246 0.6868 0.09598 0.074648 0.113122 3 47 305 5 90 347
    rs3806003 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs3806003 0.2635 0.06938 0.092437 0.05079 4 58 295 2 41 400
    rs3806004 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs3806010 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs3806014 0.8338 0.09234 0.115493 0.073696 4 74 277 3 59 379
    rs3806015 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs3806018 0.8349 0.09304 0.115819 0.074541 4 74 276 3 59 374
    rs3806019 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs3806024 0.8339 0.09311 0.116715 0.074371 4 73 270 3 59 375
    rs3915080 0.647 0.37134 0.409348 0.340278 63 163 127 42 210 180
    rs3942254 0.9408 0.39607 0.358571 0.425968 49 153 148 74 226 139
    rs3942254 0.9408 0.39607 0.358571 0.425968 49 153 148 74 226 139
    rs3945085 0.8656 0.29674 0.328652 0.270975 31 172 153 40 159 242
    rs3976737 0.3603 0.16799 0.126866 0.200957 7 71 257 18 132 268
    rs399485 0.7862 0.26763 0.299157 0.242009 29 155 172 26 160 252
    rs4029119 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs4029119 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs4076201 0.913 0.20747 0.232558 0.1875 23 114 207 11 140 281
    rs4076201 0.913 0.20747 0.232558 0.1875 23 114 207 11 140 281
    rs41395945 1 0.05541 0.069971 0.043632 1 46 296 1 35 388
    rs41395945 1 0.05541 0.069971 0.043632 1 46 296 1 35 388
    rs4146972 0.8159 0.18688 0.207283 0.170429 11 126 220 18 115 310
    rs4238087 0.6536 0.13688 0.117564 0.152523 4 75 274 12 109 315
    rs4251569 0.6528 0.13654 0.117232 0.152174 4 75 275 12 109 316
    rs4251569 0.6528 0.13654 0.117232 0.152174 4 75 275 12 109 316
    rs4273613 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs4273613 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs4291049 0.8875 0.49185 0.44507 0.529345 65 186 104 129 211 103
    rs4315598 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs4315598 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs4315598 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs4321395 0.8837 0.45526 0.420588 0.483333 65 156 119 91 224 105
    rs4321596 0.0184 0.23625 0.247899 0.226862 35 107 215 22 157 264
    rs4324417 0.6702 0.46375 0.504202 0.431151 85 190 82 90 202 151
    rs4328619 0.357 0.47688 0.448179 0.5 71 178 108 104 235 104
    rs4338909 0.4636 0.40664 0.448179 0.373016 70 180 107 67 195 179
    rs4370878 0.9327 0.29762 0.328652 0.272624 31 172 153 40 161 241
    rs4379434 0.7172 0.42063 0.446779 0.399549 63 193 101 81 192 170
    rs4416407 0.8311 0.52212 0.553824 0.496575 97 197 59 117 201 120
    rs4417899 0.9432 0.47415 0.442254 0.5 59 196 100 120 198 120
    rs4442732 0.1382 0.33739 0.284483 0.379076 21 123 146 45 189 134
    rs4444612 0.3988 0.36101 0.401408 0.328409 64 157 134 45 199 196
    rs4444612 0.3988 0.36101 0.401408 0.328409 64 157 134 45 199 196
    rs4444612 0.3988 0.36101 0.401408 0.328409 64 157 134 45 199 196
    rs4450660 0.0061 0.23831 0.267606 0.21445 16 158 181 15 157 264
    rs4509702 0.9327 0.29762 0.328652 0.272624 31 172 153 40 161 241
    rs4526920 0.2253 0.28616 0.331461 0.249431 42 152 162 30 159 250
    rs4533145 0.7024 0.10279 0.072443 0.127294 3 45 304 6 99 331
    rs4557006 0.8835 0.45684 0.422849 0.484375 65 155 117 91 221 104
    rs4570530 0.9327 0.29762 0.328652 0.272624 31 172 153 40 161 241
    rs4615971 0.8644 0.29261 0.32493 0.26644 30 172 155 37 161 243
    rs4628119 0.4259 0.23125 0.20028 0.256208 17 109 231 30 167 246
    rs4664443 0.7083 0.38235 0.341292 0.41535 41 161 154 73 222 148
    rs4688259 0.9433 0.52525 0.556497 0.5 99 196 59 120 198 120
    rs4688632 1 0.49812 0.463483 0.526077 67 196 93 131 202 108
    rs4695284 0.4244 0.1322 0.176744 0.094488 7 62 146 3 42 209
    rs4700302 0.1879 0.0931 0.066066 0.116071 0 44 289 3 85 304
    rs4702720 0.1125 0.2285 0.183099 0.265988 14 76 194 26 131 187
    rs4702720 0.1125 0.2285 0.183099 0.265988 14 76 194 26 131 187
    rs4711091 0.3943 0.47 0.519608 0.430023 102 167 88 81 219 143
    rs4714484 0.7969 0.16333 0.133053 0.187783 6 83 268 14 138 290
    rs4736802 0.7154 0.41877 0.445225 0.39726 62 193 101 80 188 170
    rs4760785 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760785 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760785 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760894 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760894 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760894 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760895 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760895 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4760895 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs4764738 0.8865 0.49236 0.527143 0.464368 97 175 78 92 220 123
    rs4764738 0.8865 0.49236 0.527143 0.464368 97 175 78 92 220 123
    rs4764974 0.8315 0.48995 0.523876 0.4625 97 179 80 92 223 125
    rs4764974 0.8315 0.48995 0.523876 0.4625 97 179 80 92 223 125
    rs4798366 0.1069 0.33269 0.338109 0.328306 42 152 155 34 215 182
    rs483159 0.6567 0.21379 0.236196 0.195153 16 122 188 19 115 258
    rs4836502 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs4836507 0.6933 0.34324 0.316901 0.364679 44 137 174 52 214 170
    rs4836744 0.6748 0.30176 0.262712 0.332957 24 138 192 51 193 199
    rs4836744 0.6748 0.30176 0.262712 0.332957 24 138 192 51 193 199
    rs4848944 0.6208 0.48438 0.47619 0.490971 69 202 86 115 205 123
    rs4851529 0.883 0.40288 0.375 0.425339 54 159 143 74 228 140
    rs4851531 0.8825 0.40764 0.382184 0.427918 54 158 136 75 224 138
    rs4858046 0.544 0.37 0.406162 0.340858 62 166 129 43 216 184
    rs4878214 0.5024 0.23248 0.181159 0.272727 8 84 184 29 134 189
    rs4880803 0.9344 0.31559 0.288352 0.337529 32 139 181 47 201 189
    rs489441 0.4584 0.26939 0.307808 0.238554 27 151 155 23 152 240
    rs489441 0.4584 0.26939 0.307808 0.238554 27 151 155 23 152 240
    rs4896568 0.4888 0.23902 0.208455 0.263341 18 107 218 30 167 234
    rs4938851 0.4999 0.19563 0.222689 0.173815 12 135 210 15 124 304
    rs4964416 0.1781 0.48123 0.442577 0.512443 71 174 112 104 245 93
    rs5756669 0.6702 0.46375 0.504202 0.431151 85 190 82 90 202 151
    rs6033138 0.3261 0.37437 0.415493 0.34127 68 159 128 50 201 190
    rs6033138 0.3261 0.37437 0.415493 0.34127 68 159 128 50 201 190
    rs6033138 0.3261 0.37437 0.415493 0.34127 68 159 128 50 201 190
    rs6040619 0.4439 0.36188 0.40056 0.3307 64 158 135 46 201 196
    rs6040619 0.4439 0.36188 0.40056 0.3307 64 158 135 46 201 196
    rs6040619 0.4439 0.36188 0.40056 0.3307 64 158 135 46 201 196
    rs6040625 0.3996 0.36125 0.40056 0.329571 64 158 135 46 200 197
    rs6040625 0.3996 0.36125 0.40056 0.329571 64 158 135 46 200 197
    rs6040625 0.3996 0.36125 0.40056 0.329571 64 158 135 46 200 197
    rs6040630 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040630 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040630 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040633 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs6040633 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs6040633 0.3986 0.35982 0.39916 0.328054 64 157 136 45 200 197
    rs6040634 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040634 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040634 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040636 0.3574 0.3592 0.39916 0.326923 64 157 136 45 199 198
    rs6040636 0.3574 0.3592 0.39916 0.326923 64 157 136 45 199 198
    rs6040636 0.3574 0.3592 0.39916 0.326923 64 157 136 45 199 198
    rs6040638 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040638 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040638 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040644 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040644 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040644 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6040667 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6040667 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6040667 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6040668 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6040668 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6040668 0.5346 0.35642 0.396011 0.324541 61 156 134 43 197 196
    rs6043066 0.7679 0.235 0.268908 0.207675 19 154 184 23 138 282
    rs6048146 0.00359 0.0375 0.04902 0.028217 1 33 323 4 17 422
    rs6082725 0.00359 0.0375 0.04902 0.028217 1 33 323 4 17 422
    rs6131206 0.4542 0.31362 0.343109 0.290618 45 144 152 36 182 219
    rs6131208 0.5343 0.35596 0.396011 0.323799 61 156 134 43 197 197
    rs6131208 0.5343 0.35596 0.396011 0.323799 61 156 134 43 197 197
    rs6131208 0.5343 0.35596 0.396011 0.323799 61 156 134 43 197 197
    rs6134243 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6134243 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6134243 0.3983 0.35938 0.39916 0.327314 64 157 136 45 200 198
    rs6136020 0.5335 0.17146 0.135854 0.200226 11 75 271 15 147 280
    rs613799 0.7076 0.28426 0.317434 0.257853 23 147 134 30 137 215
    rs644041 0.5161 0.2731 0.309451 0.243873 27 149 152 24 151 233
    rs644041 0.5161 0.2731 0.309451 0.243873 27 149 152 24 151 233
    rs647645 0.08529 0.44284 0.391854 0.484091 58 163 135 110 206 124
    rs647645 0.08529 0.44284 0.391854 0.484091 58 163 135 110 206 124
    rs647645 0.08529 0.44284 0.391854 0.484091 58 163 135 110 206 124
    rs6495554 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs6495554 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs6495555 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs6495555 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs6544728 0.01412 0.23678 0.266949 0.2125 16 157 181 16 155 269
    rs6550705 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs6550705 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs6550707 0.821 0.37641 0.412676 0.347285 65 163 127 46 215 181
    rs658108 0.471 0.26817 0.296919 0.244898 23 166 168 30 156 255
    rs6593441 0.7536 0.12994 0.152422 0.111751 7 93 251 7 83 344
    rs668732 0.2538 0.48729 0.545455 0.44023 106 172 74 89 205 141
    rs671041 0.471 0.26817 0.296919 0.244898 23 166 168 30 156 255
    rs6719700 0.5793 0.16403 0.190323 0.142857 8 102 200 8 94 283
    rs6719700 0.5793 0.16403 0.190323 0.142857 8 102 200 8 94 283
    rs6722640 0.8836 0.40715 0.377465 0.430995 56 156 143 77 227 138
    rs6743092 0.4767 0.4924 0.533803 0.458525 99 181 75 87 224 123
    rs6743092 0.4767 0.4924 0.533803 0.458525 99 181 75 87 224 123
    rs6743092 0.4767 0.4924 0.533803 0.458525 99 181 75 87 224 123
    rs6744759 0.5987 0.28149 0.291785 0.273243 37 132 184 29 183 229
    rs6746170 0.0061 0.23839 0.269014 0.213801 16 159 180 15 159 268
    rs6759922 0.8837 0.45526 0.420588 0.483333 65 156 119 91 224 105
    rs6769864 0.5931 0.36375 0.403361 0.331828 60 168 129 42 210 191
    rs6773932 0.5414 0.37404 0.411932 0.343023 63 164 125 42 211 177
    rs6774353 0.5931 0.36375 0.403361 0.331828 60 168 129 42 210 191
    rs6781670 0.7594 0.36125 0.397759 0.331828 60 164 133 42 210 191
    rs6786431 0.5414 0.37404 0.411932 0.343023 63 164 125 42 211 177
    rs6789091 0.5414 0.37404 0.411932 0.343023 63 164 125 42 211 177
    rs6791296 0.6116 0.12285 0.095588 0.145084 2 61 277 11 99 307
    rs6792662 0.8868 0.52588 0.557746 0.5 100 196 59 120 197 120
    rs6797574 0.5414 0.37404 0.411932 0.343023 63 164 125 42 211 177
    rs6797882 0.4454 0.37693 0.415473 0.345433 63 164 122 42 211 174
    rs6805139 0.7769 0.50439 0.539216 0.476136 95 195 67 110 199 131
    rs6806043 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs6806043 0.6465 0.36313 0.403361 0.3307 60 168 129 42 209 192
    rs6850716 0.7677 0.23467 0.270308 0.205882 29 135 193 13 156 273
    rs6867153 1 0.48805 0.44051 0.526018 62 187 104 127 211 104
    rs687047 0.2074 0.12813 0.102241 0.148984 2 69 286 15 102 326
    rs6871041 0.6287 0.27628 0.239057 0.306233 20 102 175 28 170 171
    rs688358 0.2666 0.12893 0.103107 0.14966 2 69 283 15 102 324
    rs6888012 1 0.48805 0.44051 0.526018 62 187 104 127 211 104
    rs6908481 0.2049 0.39796 0.438395 0.365517 77 152 120 56 206 173
    rs7032231 0.3821 0.33714 0.357955 0.320366 40 172 140 44 192 201
    rs7067638 0.4039 0.12075 0.142655 0.103175 7 87 260 7 77 357
    rs7077799 0.9311 0.3047 0.33689 0.279376 30 161 137 38 157 222
    rs7082163 0.4017 0.12 0.145658 0.099323 8 88 261 6 76 361
    rs7082163 0.4017 0.12 0.145658 0.099323 8 88 261 6 76 361
    rs7089661 0.9322 0.29313 0.32493 0.267494 30 172 155 38 161 244
    rs7101319 0.3994 0.11982 0.14507 0.099548 8 87 260 6 76 360
    rs7101319 0.3994 0.11982 0.14507 0.099548 8 87 260 6 76 360
    rs710832 0.2223 0.25125 0.232493 0.266366 14 138 205 43 150 250
    rs710832 0.2223 0.25125 0.232493 0.266366 14 138 205 43 150 250
    rs7134262 0.8191 0.36621 0.394958 0.342825 67 148 142 38 225 176
    rs7134262 0.8191 0.36621 0.394958 0.342825 67 148 142 38 225 176
    rs7134671 0.7059 0.38168 0.416193 0.353687 63 167 122 54 199 181
    rs7138300 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs7138300 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs7138300 0.3076 0.44617 0.405523 0.478923 54 171 119 92 225 110
    rs7163931 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs7163931 0.9088 0.19063 0.215686 0.170429 20 114 223 8 135 300
    rs7171486 0.04585 0.35875 0.343137 0.371332 54 137 166 62 205 176
    rs7172611 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7172611 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7172689 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7172689 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7175701 1 0.20901 0.231742 0.190745 23 119 214 12 145 286
    rs7180245 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7180245 0.9089 0.19125 0.217087 0.170429 20 115 222 8 135 300
    rs7220603 0.9321 0.29375 0.257703 0.322799 22 140 195 46 194 203
    rs7282518 0.08317 0.17608 0.213816 0.144986 11 108 185 3 101 265
    rs7283476 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs7283476 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs7295817 0.2702 0.40377 0.359551 0.439636 46 164 146 91 204 144
    rs7298255 0.4767 0.45875 0.420168 0.489842 63 174 120 100 234 109
    rs7298255 0.4767 0.45875 0.420168 0.489842 63 174 120 100 234 109
    rs7305832 0.8787 0.36529 0.394958 0.34127 67 148 142 38 225 178
    rs7305832 0.8787 0.36529 0.394958 0.34127 67 148 142 38 225 178
    rs7331467 0.2006 0.32813 0.379552 0.286682 52 167 138 42 170 231
    rs7392620 0.6765 0.31034 0.282857 0.332564 31 136 183 47 194 192
    rs742827 0.692 0.37345 0.419255 0.337037 61 148 113 43 187 175
    rs742827 0.692 0.37345 0.419255 0.337037 61 148 113 43 187 175
    rs742827 0.692 0.37345 0.419255 0.337037 61 148 113 43 187 175
    rs7446891 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs7448641 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7448641 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7484728 0.7064 0.38135 0.416193 0.353211 63 167 122 54 200 182
    rs7499402 0.8111 0.08125 0.103641 0.063205 4 66 287 0 56 387
    rs7529851 0.1689 0.4225 0.393557 0.445824 48 185 124 85 225 133
    rs7529851 0.1689 0.4225 0.393557 0.445824 48 185 124 85 225 133
    rs7573951 0.7083 0.38235 0.341292 0.41535 41 161 154 73 222 148
    rs7599198 0.8207 0.447 0.410938 0.476071 60 143 117 85 208 104
    rs7600050 0.6944 0.3578 0.391496 0.330569 49 169 123 46 187 189
    rs7607712 0.3346 0.2111 0.241477 0.186343 17 136 199 13 135 284
    rs7607712 0.3346 0.2111 0.241477 0.186343 17 136 199 13 135 284
    rs7613492 0.6445 0.36111 0.400568 0.329545 59 164 129 41 208 191
    rs7621663 0.6276 0.34312 0.386228 0.308434 53 152 129 32 192 191
    rs7621663 0.6276 0.34312 0.386228 0.308434 53 152 129 32 192 191
    rs7621663 0.6276 0.34312 0.386228 0.308434 53 152 129 32 192 191
    rs7626584 0.6111 0.07384 0.047619 0.095023 1 32 324 4 76 362
    rs7684899 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs7684899 0.03097 0.20625 0.179272 0.227991 10 108 239 14 174 255
    rs7701604 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7701604 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7703676 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7703676 0.0147 0.03563 0.015406 0.051919 0 11 346 4 38 401
    rs7708491 1 0.48934 0.443662 0.526018 64 187 104 127 211 104
    rs7711358 0.7533 0.34316 0.314607 0.366213 44 136 176 52 219 170
    rs7719448 1 0.48807 0.440678 0.526018 62 188 104 127 211 104
    rs7724761 1 0.48805 0.44051 0.526018 62 187 104 127 211 104
    rs7742476 0.1575 0.21662 0.255319 0.185185 20 128 181 21 108 276
    rs7762993 0.3626 0.19322 0.232394 0.161765 17 131 207 17 109 316
    rs7762993 0.3626 0.19322 0.232394 0.161765 17 131 207 17 109 316
    rs7767265 0.1075 0.22922 0.27762 0.190476 27 142 184 23 122 296
    rs7767265 0.1075 0.22922 0.27762 0.190476 27 142 184 23 122 296
    rs7768128 0.2237 0.23112 0.222063 0.238663 12 131 206 35 130 254
    rs7771264 0.5527 0.23927 0.209677 0.26285 18 107 216 29 167 232
    rs7773151 0.3706 0.23063 0.20028 0.255079 17 109 231 30 166 247
    rs7773210 0.4259 0.23125 0.20028 0.256208 17 109 231 30 167 246
    rs7808536 0.5044 0.19924 0.21875 0.183673 11 132 209 17 128 296
    rs7843510 0.6638 0.42125 0.446779 0.400677 63 193 101 82 191 170
    rs7894867 0.4039 0.12075 0.142655 0.103175 7 87 260 7 77 357
    rs7921834 0.8644 0.29261 0.32493 0.26644 30 172 155 37 161 243
    rs7939893 0.01403 0.33965 0.3 0.371854 38 137 180 69 187 181
    rs7939893 0.01403 0.33965 0.3 0.371854 38 137 180 69 187 181
    rs7944513 0.5615 0.24304 0.271307 0.22032 31 129 192 12 169 257
    rs7944513 0.5615 0.24304 0.271307 0.22032 31 129 192 12 169 257
    rs7949720 0.8773 0.13624 0.102985 0.162708 5 59 271 8 121 292
    rs7949720 0.8773 0.13624 0.102985 0.162708 5 59 271 8 121 292
    rs7955901 0.389 0.4542 0.416193 0.485023 60 173 119 96 229 109
    rs7955901 0.389 0.4542 0.416193 0.485023 60 173 119 96 229 109
    rs7956274 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs7956274 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs7956274 0.4324 0.46101 0.421127 0.493182 63 173 119 100 234 106
    rs7957932 0.5703 0.47173 0.435211 0.501134 69 171 115 104 234 103
    rs7957932 0.5703 0.47173 0.435211 0.501134 69 171 115 104 234 103
    rs7984504 0.1757 0.2975 0.341737 0.261851 45 154 158 34 164 245
    rs7999518 0.2381 0.48238 0.459877 0.5 65 168 91 115 184 115
    rs8026245 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs8026245 1 0.20373 0.227666 0.184455 22 114 211 10 139 282
    rs8060725 0.09267 0.30125 0.266106 0.329571 18 154 185 44 204 195
    rs8103016 0.5109 0.2025 0.239496 0.172686 22 127 208 14 125 304
    rs8103016 0.5109 0.2025 0.239496 0.172686 22 127 208 14 125 304
    rs8104182 0.4289 0.19462 0.226124 0.1693 20 121 215 14 122 307
    rs8104182 0.4289 0.19462 0.226124 0.1693 20 121 215 14 122 307
    rs8129461 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs8129461 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs8130021 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs8130021 0.3047 0.0375 0.019608 0.051919 1 12 344 1 44 398
    rs879961 0.8526 0.2579 0.210826 0.295455 14 120 217 37 186 217
    rs879961 0.8526 0.2579 0.210826 0.295455 14 120 217 37 186 217
    rs906353 0.6019 0.28428 0.239496 0.320776 19 133 205 42 197 199
    rs915491 0.7887 0.27188 0.302521 0.247178 25 166 166 32 155 256
    rs915493 0.7887 0.27188 0.302521 0.247178 25 166 166 32 155 256
    rs915494 0.932 0.2946 0.329577 0.26644 32 170 153 36 163 242
    rs915494 0.932 0.2946 0.329577 0.26644 32 170 153 36 163 242
    rs917295 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs9284851 0.7057 0.3772 0.415014 0.346939 65 163 125 45 216 180
    rs9293464 1 0.48807 0.440678 0.526018 62 188 104 127 211 104
    rs9295154 0.5656 0.14375 0.165266 0.126411 8 102 247 6 100 337
    rs9310221 0.2965 0.42838 0.465774 0.39781 66 181 89 78 171 162
    rs9310699 0.7594 0.36125 0.397759 0.331828 60 164 133 42 210 191
    rs9310700 0.4286 0.35019 0.390671 0.317757 54 160 129 35 202 191
    rs9310700 0.4286 0.35019 0.390671 0.317757 54 160 129 35 202 191
    rs9310701 0.821 0.37641 0.412676 0.347285 65 163 127 46 215 181
    rs9310704 0.6466 0.37181 0.410511 0.340278 63 163 126 42 210 180
    rs9319185 0.3434 0.29177 0.338028 0.254023 43 154 158 30 161 244
    rs9319186 0.2253 0.28616 0.331461 0.249431 42 152 162 30 159 250
    rs9327555 0.8149 0.34563 0.317927 0.367946 44 139 174 53 220 170
    rs9403367 0.4259 0.23125 0.20028 0.256208 17 109 231 30 167 246
    rs9419608 0.9435 0.48996 0.533708 0.454649 108 164 84 84 233 124
    rs9426437 0.5994 0.40921 0.3739 0.437947 59 137 145 72 223 124
    rs9454967 0.8332 0.09199 0.115169 0.073363 4 74 278 3 59 381
    rs9635511 0.7663 0.39444 0.351275 0.429224 50 148 155 75 226 137
    rs966583 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs966583 1 0.39371 0.355932 0.424036 49 154 151 74 226 141
    rs980263 0.7627 0.37563 0.412676 0.345805 65 163 127 45 215 181
    rs980264 0.7627 0.37563 0.412676 0.345805 65 163 127 45 215 181
    rs9812206 0.4346 0.10075 0.070028 0.125566 3 44 310 7 97 338
    rs9812206 0.4346 0.10075 0.070028 0.125566 3 44 310 7 97 338
    rs9813552 0.6984 0.10125 0.07423 0.123025 3 47 307 6 97 340
    rs9813552 0.6984 0.10125 0.07423 0.123025 3 47 307 6 97 340
    rs9815037 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9815037 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9819583 0.7593 0.36153 0.398876 0.331448 60 164 132 42 209 191
    rs9825349 0.6792 0.09461 0.06882 0.115385 3 43 310 5 92 345
    rs9825349 0.6792 0.09461 0.06882 0.115385 3 43 310 5 92 345
    rs9833118 0.4927 0.3665 0.404494 0.335616 60 168 128 42 210 186
    rs9833118 0.4927 0.3665 0.404494 0.335616 60 168 128 42 210 186
    rs9834217 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9834217 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9838563 0.821 0.37641 0.412676 0.347285 65 163 127 46 215 181
    rs9840460 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9840460 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9840756 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9840756 0.6789 0.09449 0.06882 0.115124 3 43 310 5 92 346
    rs9847999 0.7623 0.37657 0.412429 0.347727 65 162 127 45 216 179
    rs9864769 0.821 0.37641 0.412676 0.347285 65 163 127 46 215 181
    rs9866421 0.6672 0.44063 0.411765 0.463883 50 194 113 102 207 134
    rs987296 0.7594 0.36125 0.397759 0.331828 60 164 133 42 210 191
    rs9881685 0.4346 0.10075 0.070028 0.125566 3 44 310 7 97 338
    rs9881685 0.4346 0.10075 0.070028 0.125566 3 44 310 7 97 338
    rs992695 0.7811 0.25949 0.212857 0.296591 14 121 215 37 187 216
    rs992695 0.7811 0.25949 0.212857 0.296591 14 121 215 37 187 216
    rs9936999 0.4247 0.35052 0.389952 0.320652 22 119 68 33 111 132
  • TABLE 15
    ALLELE
    SNP rs # SOURCE (A1) MODEL NMISS OR SE L95 U95 STAT P
    rs77638540 Genotyped T DOM 431 0.6846 0.4051 0.3095 1.515 −0.935 0.3497
    rs72746987 Genotyped A DOM 431 0.3415 0.4723 0.1353 0.8617 −2.275 0.02291
    rs10021016 Genotyped G GEN 431 4.358 0.1131
    rs10021016 Genotyped G REC 431 2.151 0.4014 0.9794 4.724 1.908 0.05637
    rs10051148 Imputed C DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs10054055 Imputed T DOM 431 0.7019 0.1964 0.4777 1.031 −1.803 0.0714
    rs10067895 Imputed A DOM 423 0.6884 0.1986 0.4665 1.016 −1.88 0.0601
    rs10100725 Imputed C DOM 431 0.6909 0.2229 0.4464 1.069 −1.659 0.09719
    rs10128531 Imputed T ADD 422 1.446 0.1929 0.9906 2.11 1.911 0.05601
    rs10181743 Imputed G ADD 419 1.259 0.1434 0.9504 1.668 1.605 0.1084
    rs10199127 Imputed T DOM 426 1.892 0.1994 1.28 2.797 3.197 0.00139
    rs10270624 Imputed G DOM 426 1.873 0.2081 1.245 2.816 3.014 0.00258
    rs1030006 Imputed G REC 431 1.973 0.2532 1.201 3.24 2.684 0.00728
    rs1031811 Imputed A REC 425 1.901 0.3376 0.9811 3.684 1.903 0.057
    rs10430870 Genotyped G GEN 431 1.662 0.4357
    rs10430870 Genotyped G REC 431 1.672 0.4618 0.6765 4.134 1.114 0.2654
    rs10469597 Imputed A GEN 397 5.33 0.06962
    rs10469597 Imputed A REC 397 2.363 0.3863 1.108 5.039 2.226 0.02598
    rs10478919 Imputed G DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs10506623 Imputed C ADD 431 0.6851 0.1503 0.5103 0.9198 −2.516 0.01187
    rs10506623 Imputed C DOM 431 0.6216 0.2072 0.4141 0.9329 −2.295 0.02171
    rs10506626 Imputed A ADD 430 0.644 0.1506 0.4794 0.8651 −2.922 0.00348
    rs10506626 Imputed A DOM 430 0.5681 0.2056 0.3796 0.85 −2.75 0.00596
    rs10509477 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs10517918 Imputed G REC 424 2.104 0.2569 1.272 3.481 2.896 0.00378
    rs10517924 Imputed A REC 430 1.646 0.2374 1.033 2.621 2.098 0.03593
    rs10519362 Imputed G DOM 431 1.479 0.2285 0.9448 2.314 1.711 0.087
    rs10520072 Imputed T DOM 429 0.6749 0.197 0.4587 0.993 −1.996 0.04596
    rs10737390 Imputed T DOM 426 0.6833 0.203 0.459 1.017 −1.876 0.06061
    rs10742851 Imputed T REC 431 0.2879 0.5067 0.1066 0.7773 −2.457 0.014
    rs10743685 Imputed G GEN 431 4.792 0.0911
    rs10743685 Imputed G REC 431 1.602 0.2855 0.9156 2.803 1.651 0.09875
    rs10749293 Imputed G DOM 431 1.52 0.1971 1.033 2.237 2.125 0.03357
    rs10749294 Imputed A DOM 431 1.505 0.1973 1.022 2.216 2.073 0.03821
    rs10753760 Imputed T ADD 406 1.468 0.1459 1.103 1.954 2.632 0.00849
    rs10753760 Imputed T GEN 406 6.957 0.03085
    rs10772362 Imputed T ADD 431 0.6724 0.1684 0.4834 0.9355 −2.356 0.01848
    rs10784891 Imputed C ADD 429 0.7576 0.1448 0.5705 1.006 −1.918 0.05515
    rs10784891 Imputed C DOM 429 0.5886 0.2107 0.3895 0.8896 −2.516 0.01189
    rs10784891 Imputed C GEN 429 6.516 0.03846
    rs10787923 Imputed G DOM 430 1.509 0.1972 1.025 2.221 2.086 0.03699
    rs10787924 Imputed T DOM 431 1.505 0.1973 1.022 2.216 2.073 0.03821
    rs10787949 Imputed A DOM 430 1.433 0.1969 0.9742 2.108 1.827 0.06765
    rs10787951 Imputed G DOM 430 1.433 0.1969 0.9742 2.108 1.827 0.06765
    rs10787983 Imputed C DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs10794733 Imputed C ADD 421 0.7588 0.1519 0.5634 1.022 −1.818 0.06914
    rs10818280 Imputed C DOM 426 0.6701 0.1985 0.4541 0.9889 −2.016 0.04375
    rs10860586 Imputed A ADD 430 1.512 0.1414 1.146 1.995 2.923 0.00347
    rs10860586 Imputed A GEN 430 8.948 0.0114
    rs10870473 Imputed A ADD 182 0.6204 0.2357 0.3909 0.9846 −2.026 0.04278
    rs10870473 Imputed A DOM 182 0.4859 0.3065 0.2665 0.886 −2.355 0.01853
    rs10879240 Imputed C ADD 430 0.7653 0.1438 0.5773 1.014 −1.86 0.06286
    rs10879240 Imputed C GEN 430 6.525 0.03829
    rs10879242 Imputed A ADD 431 0.6996 0.1493 0.5222 0.9374 −2.393 0.0167
    rs10879242 Imputed A DOM 431 0.6354 0.2073 0.4232 0.9539 −2.188 0.02869
    rs10879245 Imputed G ADD 431 0.6996 0.1493 0.5222 0.9374 −2.393 0.0167
    rs10879245 Imputed G DOM 431 0.6354 0.2073 0.4232 0.9539 −2.188 0.02869
    rs10879249 Imputed T ADD 430 0.6776 0.1506 0.5044 0.9103 −2.584 0.00976
    rs10879249 Imputed T DOM 430 0.6103 0.2074 0.4065 0.9164 −2.381 0.01726
    rs10886429 Imputed A DOM 429 1.47 0.1974 0.9985 2.165 1.952 0.05092
    rs10886449 Imputed G DOM 430 1.441 0.1971 0.9794 2.121 1.854 0.06367
    rs10886451 Imputed G DOM 430 1.441 0.1971 0.9794 2.121 1.854 0.06367
    rs10886452 Imputed A DOM 430 1.433 0.1969 0.9742 2.108 1.827 0.06765
    rs10886456 Imputed G DOM 430 1.441 0.1971 0.9794 2.121 1.854 0.06367
    rs10886463 Imputed C DOM 431 1.444 0.1968 0.9818 2.123 1.867 0.06193
    rs10886465 Imputed A DOM 431 1.444 0.1968 0.9818 2.123 1.867 0.06193
    rs10886526 Imputed C DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs10922903 Imputed C REC 430 0.6266 0.2724 0.3674 1.069 −1.716 0.08622
    rs10941126 Imputed G ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs10941126 Imputed G DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs10947980 Imputed G ADD 431 0.6089 0.157 0.4476 0.8282 −3.161 0.00157
    rs11059376 Imputed T ADD 412 1.592 0.1898 1.097 2.309 2.45 0.01428
    rs11072995 Imputed T GEN 430 5.185 0.07483
    rs11072995 Imputed T REC 430 2.796 0.4515 1.154 6.774 2.277 0.0228
    rs11081202 Genotyped G GEN 431 6.987 0.0304
    rs11081202 Genotyped G REC 431 2.426 0.3357 1.256 4.684 2.64 0.00829
    rs110965 Imputed C GEN 413 4.153 0.1254
    rs11124962 Imputed A DOM 431 1.812 0.2023 1.219 2.693 2.937 0.00331
    rs1116596 Imputed T DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs11178531 Imputed A ADD 431 0.7781 0.1437 0.5871 1.031 −1.746 0.0808
    rs11178531 Imputed A DOM 431 0.6138 0.212 0.4051 0.93 −2.303 0.0213
    rs11178583 Imputed A ADD 430 0.6776 0.1506 0.5044 0.9103 −2.584 0.00976
    rs11178583 Imputed A DOM 430 0.6103 0.2074 0.4065 0.9164 −2.381 0.01726
    rs11178589 Imputed T ADD 431 0.6759 0.1506 0.5031 0.908 −2.601 0.0093
    rs11178589 Imputed T DOM 431 0.6066 0.2072 0.4042 0.9105 −2.413 0.01583
    rs11178594 Imputed C ADD 431 0.6841 0.1503 0.5096 0.9184 −2.527 0.01152
    rs11178594 Imputed C DOM 431 0.62 0.207 0.4133 0.9302 −2.31 0.0209
    rs11178602 Imputed T ADD 431 0.6841 0.1503 0.5096 0.9184 −2.527 0.01152
    rs11178602 Imputed T DOM 431 0.62 0.207 0.4133 0.9302 −2.31 0.0209
    rs11178648 Imputed T ADD 431 0.6858 0.1487 0.5125 0.9178 −2.537 0.01119
    rs11178648 Imputed T DOM 431 0.6021 0.2055 0.4025 0.9008 −2.468 0.01358
    rs11198877 Imputed T DOM 431 1.444 0.1968 0.9818 2.123 1.867 0.06193
    rs11198942 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs11221075 Imputed A ADD 426 0.7175 0.2252 0.4614 1.116 −1.474 0.1405
    rs11242020 Imputed T DOM 430 0.7107 0.1967 0.4834 1.045 −1.736 0.08258
    rs11242021 Imputed T DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs11242022 Imputed T DOM 428 0.6944 0.1971 0.4719 1.022 −1.85 0.06431
    rs11242023 Imputed T DOM 428 0.6944 0.1971 0.4719 1.022 −1.85 0.06431
    rs1149349 Imputed T DOM 431 1.606 0.2234 1.037 2.489 2.122 0.03382
    rs1149350 Imputed A ADD 430 1.546 0.1741 1.099 2.176 2.504 0.0123
    rs1149350 Imputed A DOM 430 1.835 0.2102 1.215 2.77 2.886 0.0039
    rs11576627 Imputed T ADD 427 1.4 0.1931 0.9592 2.045 1.744 0.08112
    rs11576627 Imputed T DOM 427 1.426 0.2259 0.9158 2.22 1.571 0.1162
    rs11630050 Imputed G GEN 431 6.07 0.04808
    rs11630050 Imputed G REC 431 2.977 0.4471 1.239 7.15 2.44 0.01469
    rs11633024 Imputed C GEN 431 6.07 0.04808
    rs11633024 Imputed C REC 431 2.977 0.4471 1.239 7.15 2.44 0.01469
    rs11636298 Imputed G GEN 431 6.084 0.04773
    rs11636298 Imputed G REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs11637363 Imputed C GEN 430 6.108 0.04718
    rs11637363 Imputed C REC 430 2.964 0.4471 1.234 7.119 2.43 0.01509
    rs11637813 Imputed A GEN 431 6.07 0.04808
    rs11637813 Imputed A REC 431 2.977 0.4471 1.239 7.15 2.44 0.01469
    rs11638043 Imputed C GEN 430 6.108 0.04718
    rs11638043 Imputed C REC 430 2.964 0.4471 1.234 7.119 2.43 0.01509
    rs11638115 Imputed A GEN 430 5.185 0.07483
    rs11638115 Imputed A REC 430 2.796 0.4515 1.154 6.774 2.277 0.0228
    rs11638444 Imputed C GEN 431 6.093 0.04752
    rs11682946 Imputed A ADD 96 5.356 0.4472 2.229 12.87 3.753 0.00018
    rs11682946 Imputed A DOM 96 5.538 0.4642 2.23 13.76 3.688 0.00023
    rs11717157 Imputed T ADD 430 1.45 0.1393 1.104 1.906 2.67 0.00759
    rs11717157 Imputed T GEN 430 7.13 0.0283
    rs11724055 Imputed A DOM 431 0.7804 0.2073 0.5199 1.172 −1.196 0.2317
    rs11743355 Imputed C ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11743355 Imputed C DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11746806 Imputed T ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11746806 Imputed T DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11746959 Imputed T ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11746959 Imputed T DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs11749272 Imputed T DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs11839636 Imputed C GEN 431 7.984 0.01846
    rs11839785 Imputed C GEN 431 7.984 0.01846
    rs11853619 Imputed C GEN 431 6.084 0.04773
    rs11853619 Imputed C REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs11856780 Imputed A GEN 431 6.084 0.04773
    rs11856780 Imputed A REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs11901899 Imputed A DOM 426 1.822 0.199 1.234 2.692 3.016 0.00256
    rs11903290 Imputed C REC 425 1.901 0.3376 0.9811 3.684 1.903 0.057
    rs11909480 Imputed G ADD 431 0.5964 0.404 0.2701 1.317 −1.279 0.2008
    rs11909480 Imputed G DOM 431 0.61 0.4187 0.2685 1.386 −1.181 0.2377
    rs11910289 Imputed T ADD 428 2.254 0.3513 1.132 4.487 2.313 0.02074
    rs11910289 Imputed T DOM 428 2.226 0.3621 1.095 4.527 2.21 0.02707
    rs11920375 Genotyped C GEN 431 6.381 0.04115
    rs11926319 Imputed G DOM 429 0.5229 0.2621 0.3128 0.874 −2.474 0.01336
    rs11933744 Imputed T REC 431 3.01 0.47 1.198 7.563 2.345 0.01904
    rs11934919 Imputed C REC 431 3.01 0.47 1.198 7.563 2.345 0.01904
    rs11934957 Imputed C REC 431 3.01 0.47 1.198 7.563 2.345 0.01904
    rs11959206 Imputed A REC 428 0.5862 0.2628 0.3502 0.9812 −2.032 0.04213
    rs12038613 Imputed C REC 429 0.5999 0.2756 0.3495 1.03 −1.854 0.06381
    rs12151417 Imputed T DOM 428 1.573 0.1977 1.067 2.317 2.29 0.02204
    rs12153185 Imputed T DOM 426 0.6973 0.1977 0.4733 1.027 −1.824 0.06815
    rs12182651 Imputed T DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs12235345 Imputed C DOM 430 1.42 0.2727 0.8321 2.423 1.286 0.1985
    rs12324786 Imputed T GEN 430 5.185 0.07483
    rs12324786 Imputed T REC 430 2.796 0.4515 1.154 6.774 2.277 0.0228
    rs12336958 Imputed G DOM 403 1.46 0.211 0.9657 2.208 1.794 0.07276
    rs12407412 Imputed C ADD 431 1.382 0.1928 0.9468 2.016 1.676 0.09367
    rs12407412 Imputed C DOM 431 1.401 0.2256 0.9007 2.181 1.496 0.1346
    rs12418971 Imputed C GEN 423 1.464 0.481
    rs12418971 Imputed C REC 423 1.699 0.4623 0.6866 4.204 1.147 0.2515
    rs1241967 Imputed T REC 431 0.5915 0.3332 0.3078 1.136 −1.576 0.115
    rs12420184 Imputed G DOM 430 0.6518 0.2209 0.4227 1.005 −1.938 0.05266
    rs12433968 Imputed T DOM 396 0.7213 0.2052 0.4825 1.078 −1.592 0.1114
    rs12445477 Imputed A DOM 423 0.4063 0.2966 0.2272 0.7267 −3.036 0.0024
    rs12447191 Genotyped T ADD 431 0.6489 0.1758 0.4598 0.9158 −2.461 0.01387
    rs12447191 Genotyped T DOM 431 0.5081 0.2092 0.3372 0.7656 −3.237 0.00121
    rs12465349 Imputed A REC 426 1.587 0.2245 1.022 2.464 2.056 0.03975
    rs1247340 Imputed C ADD 431 1.51 0.1734 1.075 2.122 2.377 0.01746
    rs1247340 Imputed C DOM 431 1.767 0.2092 1.173 2.663 2.721 0.0065
    rs1247341 Imputed C ADD 430 1.524 0.1738 1.084 2.143 2.426 0.01527
    rs1247341 Imputed C DOM 430 1.795 0.2098 1.19 2.707 2.788 0.0053
    rs1247343 Imputed C DOM 430 1.681 0.2249 1.081 2.612 2.308 0.02099
    rs12509758 Imputed C DOM 430 1.856 0.204 1.244 2.768 3.03 0.00245
    rs12515472 Imputed A DOM 431 1.531 0.205 1.024 2.287 2.076 0.03785
    rs12548906 Imputed G ADD 420 1.496 0.1799 1.052 2.129 2.241 0.02504
    rs12596240 Imputed G DOM 430 0.6708 0.2061 0.4479 1.005 −1.937 0.05268
    rs12618781 Imputed A DOM 407 0.5446 0.2216 0.3528 0.8408 −2.743 0.00609
    rs12678600 Imputed A DOM 431 0.6479 0.1972 0.4402 0.9536 −2.201 0.02773
    rs12692229 Imputed T ADD 430 1.315 0.1467 0.9861 1.753 1.864 0.06226
    rs12713324 Imputed T DOM 427 1.584 0.1981 1.074 2.335 2.321 0.02028
    rs12719415 Imputed T DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs12820589 Imputed G ADD 418 1.758 0.1836 1.227 2.519 3.073 0.00212
    rs12820589 Imputed G DOM 418 1.936 0.214 1.273 2.946 3.088 0.00202
    rs12831292 Imputed G ADD 431 0.6841 0.1503 0.5096 0.9184 −2.527 0.01152
    rs12831292 Imputed G DOM 431 0.62 0.207 0.4133 0.9302 −2.31 0.0209
    rs13012636 Imputed G REC 425 1.901 0.3376 0.9811 3.684 1.903 0.057
    rs13038146 Imputed C ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs13038146 Imputed C GEN 431 6.605 0.0368
    rs13038146 Imputed C REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs13089860 Imputed A DOM 358 0.6221 0.23 0.3963 0.9764 −2.064 0.03904
    rs13102419 Imputed T REC 429 1.668 0.2387 1.045 2.663 2.144 0.03201
    rs13194907 Imputed A ADD 431 1.964 0.3063 1.077 3.579 2.203 0.02757
    rs13194907 Imputed A DOM 431 2.136 0.3162 1.15 3.97 2.401 0.01635
    rs13195745 Imputed A ADD 431 1.964 0.3063 1.077 3.579 2.203 0.02757
    rs13195745 Imputed A DOM 431 2.136 0.3162 1.15 3.97 2.401 0.01635
    rs13265054 Imputed T DOM 421 0.6754 0.199 0.4573 0.9976 −1.972 0.04863
    rs13273002 Imputed A GEN 429 3.598 0.1655
    rs13282131 Imputed C ADD 431 1.415 0.1363 1.084 1.849 2.549 0.0108
    rs13282131 Imputed C GEN 431 6.498 0.03882
    rs13282131 Imputed C REC 431 1.595 0.2279 1.02 2.493 2.048 0.04058
    rs1330052 Imputed G GEN 431 11.32 0.00349
    rs1335721 Imputed A REC 429 0.5999 0.2756 0.3495 1.03 −1.854 0.06381
    rs1336382 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1336383 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1336407 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1336409 Imputed T DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1336596 Imputed A DOM 430 0.6728 0.2004 0.4543 0.9965 −1.978 0.04797
    rs13387284 Imputed A DOM 400 0.5278 0.2223 0.3414 0.816 −2.875 0.00404
    rs13401462 Imputed C DOM 424 2.137 0.2339 1.351 3.38 3.245 0.00117
    rs13409045 Imputed T ADD 431 0.6931 0.1457 0.521 0.9221 −2.517 0.01184
    rs1349284 Imputed C GEN 431 7.563 0.02279
    rs1355715 Imputed T ADD 430 0.5755 0.3625 0.2828 1.171 −1.524 0.1275
    rs1357696 Imputed A GEN 426 5.96 0.05078
    rs1357698 Imputed A GEN 426 5.96 0.05078
    rs1357699 Imputed T GEN 426 5.96 0.05078
    rs1363273 Imputed C REC 404 0.5817 0.2679 0.344 0.9834 −2.023 0.04312
    rs1373601 Imputed A DOM 400 0.5287 0.2065 0.3527 0.7925 −3.086 0.00203
    rs1375829 Imputed C GEN 431 7.563 0.02279
    rs1395748 Imputed G DOM 431 0.6603 0.1967 0.4491 0.9708 −2.11 0.03482
    rs1414865 Imputed T DOM 430 1.433 0.1969 0.9742 2.108 1.827 0.06765
    rs1414873 Imputed A DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1414876 Imputed C DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1424643 Imputed G ADD 423 1.554 0.1651 1.124 2.148 2.669 0.00761
    rs1424643 Imputed G DOM 423 1.592 0.199 1.078 2.351 2.336 0.01947
    rs1424648 Imputed T DOM 431 1.619 0.1972 1.1 2.383 2.444 0.01451
    rs1429321 Imputed A DOM 426 1.545 0.1979 1.048 2.277 2.198 0.02793
    rs1429326 Imputed T ADD 423 1.514 0.1654 1.094 2.093 2.505 0.01223
    rs1429326 Imputed T DOM 423 1.573 0.1984 1.066 2.321 2.284 0.02236
    rs1444741 Imputed A DOM 407 0.5155 0.205 0.3449 0.7703 −3.233 0.00122
    rs1449916 Imputed C DOM 338 0.4287 0.2519 0.2617 0.7025 −3.362 0.00077
    rs1459523 Imputed A ADD 430 1.45 0.1393 1.104 1.906 2.67 0.00759
    rs1459523 Imputed A GEN 430 7.13 0.0283
    rs1466352 Imputed T GEN 431 6.792 0.0335
    rs1466353 Imputed G GEN 431 6.792 0.0335
    rs1476714 Imputed A DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs1486723 Imputed C REC 431 0.6161 0.3308 0.3222 1.178 −1.464 0.1431
    rs1495375 Imputed A ADD 431 0.6996 0.1493 0.5222 0.9374 −2.393 0.0167
    rs1495375 Imputed A DOM 431 0.6354 0.2073 0.4232 0.9539 −2.188 0.02869
    rs1495381 Imputed T GEN 431 4.34 0.1142
    rs1495381 Imputed T REC 431 1.661 0.2511 1.015 2.717 2.021 0.04331
    rs1498061 Imputed C ADD 201 0.614 0.2646 0.3655 1.031 −1.843 0.06527
    rs1498992 Imputed G DOM 430 0.7209 0.1965 0.4905 1.06 −1.666 0.09577
    rs1499001 Imputed T DOM 428 0.7112 0.1982 0.4823 1.049 −1.719 0.08562
    rs1512988 Imputed A ADD 429 0.6768 0.1508 0.5037 0.9096 −2.589 0.00964
    rs1512988 Imputed A DOM 429 0.6068 0.2078 0.4038 0.9117 −2.405 0.01618
    rs1512989 Imputed T ADD 429 0.6768 0.1508 0.5037 0.9096 −2.589 0.00964
    rs1512989 Imputed T DOM 429 0.6068 0.2078 0.4038 0.9117 −2.405 0.01618
    rs1512991 Imputed T ADD 431 0.7609 0.1446 0.5731 1.01 −1.89 0.05873
    rs1512991 Imputed T DOM 431 0.5996 0.2103 0.3971 0.9055 −2.432 0.01501
    rs1512991 Imputed T GEN 431 6.036 0.04889
    rs1524303 Imputed T GEN 429 6.951 0.03095
    rs1524306 Imputed C ADD 431 1.457 0.1392 1.109 1.914 2.705 0.00682
    rs1524306 Imputed C GEN 431 7.32 0.02573
    rs1524310 Imputed G ADD 428 1.471 0.1406 1.117 1.937 2.744 0.00606
    rs1524310 Imputed G GEN 428 7.531 0.02315
    rs1524321 Imputed C GEN 423 7.53 0.02317
    rs1527059 Imputed A DOM 428 0.7558 0.266 0.4487 1.273 −1.052 0.2927
    rs152707 Imputed A ADD 431 0.7681 0.1426 0.5808 1.016 −1.85 0.06428
    rs152707 Imputed A GEN 431 3.606 0.1648
    rs152712 Genotyped C ADD 431 0.7606 0.1429 0.5748 1.007 −1.914 0.05557
    rs152712 Genotyped C GEN 431 3.917 0.1411
    rs1533994 Imputed T GEN 431 6.792 0.0335
    rs1535866 Imputed G DOM 431 1.83 0.206 1.222 2.74 2.933 0.00336
    rs1563773 Imputed T GEN 429 6.416 0.04044
    rs1563774 Imputed T GEN 431 6.792 0.0335
    rs1567740 Imputed T ADD 430 0.6776 0.1506 0.5044 0.9103 −2.584 0.00976
    rs1567740 Imputed T DOM 430 0.6103 0.2074 0.4065 0.9164 −2.381 0.01726
    rs1572573 Imputed A DOM 413 1.458 0.2093 0.9676 2.198 1.802 0.07148
    rs1577497 Imputed C REC 429 0.5999 0.2756 0.3495 1.03 −1.854 0.06381
    rs1581514 Imputed T ADD 418 1.482 0.1411 1.124 1.954 2.79 0.00527
    rs1581514 Imputed T GEN 418 7.786 0.02039
    rs1582321 Imputed T DOM 431 0.6673 0.206 0.4456 0.9992 −1.964 0.04955
    rs1582322 Imputed A DOM 426 0.6832 0.2069 0.4554 1.025 −1.841 0.06568
    rs1582323 Imputed A DOM 427 0.6891 0.2068 0.4595 1.034 −1.8 0.07179
    rs1592485 Imputed C DOM 430 0.6849 0.2064 0.4571 1.026 −1.834 0.06669
    rs1600954 Imputed T ADD 418 1.458 0.1435 1.1 1.931 2.627 0.00863
    rs1600954 Imputed T GEN 418 7.629 0.02204
    rs16938626 Imputed G DOM 417 0.6482 0.201 0.4371 0.9612 −2.157 0.03103
    rs16964300 Imputed G ADD 431 0.6489 0.1758 0.4598 0.9158 −2.461 0.01387
    rs16964300 Imputed G DOM 431 0.5081 0.2092 0.3372 0.7656 −3.237 0.00121
    rs16986282 Imputed G DOM 429 0.6518 0.4222 0.2849 1.491 −1.014 0.3106
    rs17007620 Imputed G ADD 387 1.684 0.1701 1.206 2.35 3.063 0.00219
    rs17007620 Imputed G DOM 387 1.898 0.2093 1.259 2.861 3.062 0.0022
    rs17014326 Imputed G DOM 429 0.6773 0.1968 0.4605 0.9961 −1.98 0.04771
    rs17047957 Imputed C DOM 430 1.575 0.2288 1.006 2.466 1.986 0.047
    rs1705261 Imputed A REC 430 1.6 0.2523 0.9755 2.623 1.862 0.06263
    rs17073341 Imputed A ADD 431 1.335 0.3929 0.618 2.883 0.735 0.4624
    rs17073341 Imputed A DOM 431 1.335 0.3929 0.618 2.883 0.735 0.4624
    rs17138702 Imputed G ADD 429 0.7112 0.2144 0.4672 1.083 −1.59 0.1119
    rs17189710 Imputed T ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs17189710 Imputed T GEN 431 6.605 0.0368
    rs17189710 Imputed T REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs17310176 Imputed T ADD 431 0.8153 0.1969 0.5542 1.199 −1.037 0.2997
    rs17310176 Imputed T DOM 431 0.8122 0.2102 0.5379 1.226 −0.989 0.3224
    rs17358860 Imputed A DOM 431 0.7804 0.2073 0.5199 1.172 −1.196 0.2317
    rs17370541 Imputed T GEN 417 4.709 0.09495
    rs17370541 Imputed T REC 417 1.782 0.2901 1.009 3.147 1.991 0.04643
    rs17526574 Imputed G GEN 431 7.984 0.01846
    rs17530747 Imputed T DOM 422 0.7249 0.1996 0.4902 1.072 −1.612 0.107
    rs17649114 Imputed C DOM 429 1.27 0.2011 0.8563 1.884 1.189 0.2346
    rs17766172 Imputed A REC 419 0.6013 0.3147 0.3245 1.114 −1.616 0.1061
    rs1818885 Imputed G GEN 431 7.055 0.02938
    rs1832222 Imputed G DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs1861327 Imputed G DOM 431 0.6673 0.206 0.4456 0.9992 −1.964 0.04955
    rs1868581 Imputed G ADD 431 1.471 0.1402 1.117 1.936 2.75 0.00596
    rs1868581 Imputed G GEN 431 7.563 0.02279
    rs1874313 Imputed A ADD 430 0.671 0.151 0.4991 0.9022 −2.642 0.00825
    rs1874313 Imputed A DOM 430 0.5994 0.208 0.3987 0.9009 −2.462 0.01383
    rs1876409 Imputed C DOM 428 0.6523 0.1975 0.443 0.9607 −2.163 0.03053
    rs1913201 Imputed G ADD 429 0.7714 0.144 0.5817 1.023 −1.803 0.07146
    rs1913201 Imputed G DOM 429 0.5986 0.2106 0.3961 0.9045 −2.436 0.01484
    rs1913201 Imputed G GEN 429 6.21 0.04484
    rs1916922 Imputed T GEN 415 6.677 0.03549
    rs1936871 Genotyped G DOM 431 0.7159 0.1987 0.485 1.057 −1.682 0.09248
    rs1961157 Imputed T REC 431 0.4785 0.2451 0.296 0.7736 −3.007 0.00264
    rs1987179 Imputed T ADD 431 0.7399 0.1691 0.5312 1.031 −1.782 0.07475
    rs1987179 Imputed T DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs1990023 Imputed T DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs1995025 Imputed C DOM 431 1.335 0.2271 0.8555 2.084 1.273 0.203
    rs2016194 Imputed G DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs2023651 Imputed T ADD 429 0.5946 0.1842 0.4144 0.8532 −2.822 0.00477
    rs2024902 Imputed A ADD 431 1.964 0.3063 1.077 3.579 2.203 0.02757
    rs2024902 Imputed A DOM 431 2.136 0.3162 1.15 3.97 2.401 0.01635
    rs2025107 Imputed A DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs2025108 Imputed T DOM 431 2.069 0.3044 1.14 3.758 2.389 0.01687
    rs2031987 Imputed T GEN 431 7.984 0.01846
    rs2052428 Imputed C DOM 426 0.6505 0.2223 0.4208 1.006 −1.935 0.05303
    rs2053230 Imputed C ADD 269 0.6927 0.629 0.2019 2.376 −0.584 0.5594
    rs2062448 Imputed T DOM 429 0.5357 0.2593 0.3223 0.8905 −2.407 0.01607
    rs2063420 Imputed C REC 430 1.886 0.2499 1.156 3.079 2.54 0.01109
    rs2063591 Imputed C ADD 429 0.7822 0.144 0.5899 1.037 −1.705 0.08815
    rs2063591 Imputed C DOM 429 0.6108 0.2122 0.403 0.9258 −2.324 0.02015
    rs208026 Genotyped A DOM 431 1.516 0.1978 1.029 2.233 2.102 0.03554
    rs208029 Imputed T DOM 426 1.45 0.2007 0.9788 2.15 1.853 0.06389
    rs208757 Imputed G DOM 425 1.473 0.2014 0.9925 2.186 1.923 0.05453
    rs2095586 Imputed A DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs2095606 Imputed A DOM 424 0.6502 0.2018 0.4378 0.9657 −2.133 0.03293
    rs2102374 Imputed A ADD 431 0.7364 0.156 0.5424 0.9998 −1.961 0.04987
    rs2102374 Imputed A DOM 431 0.6065 0.198 0.4114 0.894 −2.526 0.01155
    rs2108426 Imputed C DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs2110664 Imputed A DOM 421 1.806 0.2004 1.219 2.675 2.95 0.00318
    rs2132242 Imputed A ADD 431 0.6841 0.1503 0.5096 0.9184 −2.527 0.01152
    rs2132242 Imputed A DOM 431 0.62 0.207 0.4133 0.9302 −2.31 0.0209
    rs2158958 Imputed A DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs2158961 Imputed G DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs2163046 Imputed A DOM 430 1.511 0.1971 1.027 2.224 2.095 0.0362
    rs2180286 Imputed G DOM 431 0.7195 0.2291 0.4592 1.127 −1.437 0.1507
    rs2180684 Imputed A DOM 427 1.612 0.2668 0.9556 2.719 1.79 0.07349
    rs2188079 Imputed C ADD 430 1.535 0.1452 1.154 2.04 2.948 0.00319
    rs2188079 Imputed C GEN 430 8.853 0.01196
    rs2190598 Imputed T DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs2190600 Imputed A DOM 423 0.6884 0.1986 0.4665 1.016 −1.88 0.0601
    rs2224184 Genotyped T DOM 431 0.7175 0.2276 0.4593 1.121 −1.458 0.1447
    rs2247066 Imputed A DOM 431 0.6603 0.1967 0.4491 0.9708 −2.11 0.03482
    rs2248236 Imputed C ADD 430 0.7444 0.1691 0.5344 1.037 −1.746 0.08088
    rs2248236 Imputed C DOM 430 0.6416 0.2031 0.431 0.9552 −2.186 0.02885
    rs2265733 Imputed C ADD 431 0.7364 0.156 0.5424 0.9998 −1.961 0.04987
    rs2265733 Imputed C DOM 431 0.6065 0.198 0.4114 0.894 −2.526 0.01155
    rs2270584 Imputed A ADD 431 0.6858 0.1487 0.5125 0.9178 −2.537 0.01119
    rs2270584 Imputed A DOM 431 0.6021 0.2055 0.4025 0.9008 −2.468 0.01358
    rs2270586 Imputed A ADD 431 0.6858 0.1487 0.5125 0.9178 −2.537 0.01119
    rs2270586 Imputed A DOM 431 0.6021 0.2055 0.4025 0.9008 −2.468 0.01358
    rs229775 Imputed A REC 431 0.5915 0.3332 0.3078 1.136 −1.576 0.115
    rs229815 Imputed T REC 428 0.5493 0.3402 0.282 1.07 −1.761 0.07822
    rs229829 Imputed C REC 431 0.6223 0.2965 0.3481 1.113 −1.6 0.1096
    rs229831 Imputed A REC 431 0.646 0.3469 0.3273 1.275 −1.26 0.2077
    rs2317057 Imputed T ADD 363 0.7197 0.1827 0.5031 1.029 −1.801 0.07173
    rs2322100 Genotyped T REC 431 2.767 0.3609 1.364 5.612 2.82 0.0048
    rs2322101 Imputed A REC 429 2.779 0.3611 1.369 5.639 2.83 0.00465
    rs2327929 Imputed G REC 431 1.493 0.244 0.9255 2.408 1.642 0.1005
    rs2332844 Imputed A ADD 240 1.78 0.4323 0.7629 4.154 1.334 0.1823
    rs2332844 Imputed A REC 240 1.78 0.4323 0.7629 4.154 1.334 0.1823
    rs2349170 Imputed G DOM 430 1.327 0.204 0.8895 1.979 1.386 0.1657
    rs2356722 Imputed G DOM 431 0.6675 0.1966 0.4541 0.9812 −2.057 0.03972
    rs2364956 Imputed T ADD 423 1.693 0.1737 1.204 2.379 3.031 0.00244
    rs2373793 Imputed G ADD 430 1.58 0.174 1.124 2.223 2.629 0.00855
    rs2373793 Imputed G DOM 430 1.878 0.2064 1.253 2.815 3.055 0.00225
    rs238252 Imputed G ADD 427 1.531 0.1916 1.052 2.229 2.223 0.02622
    rs238252 Imputed G DOM 427 1.593 0.2148 1.046 2.427 2.169 0.03007
    rs2383903 Imputed G DOM 430 0.6499 0.1976 0.4413 0.9572 −2.181 0.02915
    rs2387945 Imputed G DOM 431 1.335 0.2271 0.8555 2.084 1.273 0.203
    rs2389863 Imputed A DOM 426 0.6341 0.2035 0.4255 0.9449 −2.238 0.0252
    rs2389866 Imputed C DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs2389869 Imputed C DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs2389870 Genotyped C DOM 431 0.7988 0.2067 0.5327 1.198 −1.087 0.2772
    rs2418494 Imputed G ADD 423 0.7065 0.1402 0.5367 0.93 −2.477 0.01323
    rs2418494 Imputed G GEN 423 8.762 0.01252
    rs2418541 Imputed A DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs2418542 Imputed A DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs2423556 Imputed C DOM 431 0.7195 0.2291 0.4592 1.127 −1.437 0.1507
    rs2437688 Imputed C ADD 431 1.486 0.2416 0.9251 2.385 1.638 0.1014
    rs2456809 Imputed G DOM 426 0.6547 0.1977 0.4444 0.9645 −2.143 0.03215
    rs2456811 Imputed T ADD 431 0.7364 0.156 0.5424 0.9998 −1.961 0.04987
    rs2456811 Imputed T DOM 431 0.6065 0.198 0.4114 0.894 −2.526 0.01155
    rs2476976 Imputed C DOM 429 1.409 0.1971 0.9578 2.074 1.741 0.08162
    rs2484911 Imputed A DOM 431 1.477 0.1971 1.004 2.173 1.979 0.04785
    rs2488557 Imputed C DOM 428 0.6282 0.2326 0.3982 0.991 −1.999 0.04561
    rs250162 Imputed C ADD 425 0.5822 0.1715 0.416 0.8149 −3.153 0.00162
    rs250162 Imputed C DOM 425 0.5055 0.2024 0.3399 0.7517 −3.37 0.00075
    rs2560708 Imputed T ADD 427 0.5918 0.2008 0.3992 0.8772 −2.612 0.00899
    rs2617841 Imputed G DOM 397 0.5505 0.2134 0.3623 0.8365 −2.797 0.00516
    rs2622499 Imputed G DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs264129 Imputed T DOM 414 0.7088 0.2008 0.4781 1.051 −1.714 0.08655
    rs2642936 Imputed T ADD 427 1.703 0.1807 1.195 2.427 2.947 0.00321
    rs2660633 Imputed A DOM 428 0.6523 0.1975 0.443 0.9607 −2.163 0.03053
    rs2660634 Imputed C DOM 428 0.6523 0.1975 0.443 0.9607 −2.163 0.03053
    rs2660648 Imputed A ADD 431 0.7364 0.156 0.5424 0.9998 −1.961 0.04987
    rs2660648 Imputed A DOM 431 0.6065 0.198 0.4114 0.894 −2.526 0.01155
    rs2681505 Imputed T ADD 431 0.6724 0.1684 0.4834 0.9355 −2.356 0.01848
    rs277411 Imputed G DOM 430 0.2825 0.5064 0.1047 0.7621 −2.496 0.01254
    rs2832634 Imputed G ADD 430 2.272 0.3513 1.141 4.523 2.335 0.01952
    rs2832637 Imputed T ADD 430 2.272 0.3513 1.141 4.523 2.335 0.01952
    rs2843167 Imputed A DOM 430 0.6655 0.1968 0.4525 0.9788 −2.069 0.03855
    rs2876227 Imputed C ADD 420 1.382 0.142 1.046 1.825 2.277 0.02278
    rs2876227 Imputed C GEN 420 5.885 0.05274
    rs2882097 Imputed A DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs2909862 Imputed G DOM 381 1.471 0.2415 0.9162 2.361 1.597 0.1102
    rs3001945 Imputed T DOM 408 1.39 0.2492 0.8531 2.266 1.323 0.186
    rs3011020 Imputed C DOM 431 1.335 0.2271 0.8555 2.084 1.273 0.203
    rs36071725 Genotyped C ADD 431 1.458 0.1473 1.093 1.946 2.562 0.01039
    rs36071725 Genotyped C GEN 431 7.178 0.02762
    rs373983 Imputed G DOM 424 1.332 0.2094 0.8836 2.008 1.369 0.171
    rs3743794 Imputed G DOM 426 0.6969 0.2073 0.4642 1.046 −1.742 0.08148
    rs3756154 Imputed C ADD 431 0.7399 0.1691 0.5312 1.031 −1.782 0.07475
    rs3756154 Imputed C DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs3775850 Imputed A DOM 431 0.7804 0.2073 0.5199 1.172 −1.196 0.2317
    rs3775851 Imputed C DOM 431 0.7804 0.2073 0.5199 1.172 −1.196 0.2317
    rs3793044 Imputed C ADD 431 1.892 0.308 1.035 3.461 2.071 0.0384
    rs3793044 Imputed C DOM 431 2.057 0.3182 1.102 3.838 2.266 0.02342
    rs3793053 Imputed C DOM 425 2.254 0.3145 1.217 4.175 2.583 0.00979
    rs3796246 Imputed G DOM 431 0.4542 0.2717 0.2667 0.7737 −2.904 0.00368
    rs3806003 Imputed A ADD 431 1.892 0.308 1.035 3.461 2.071 0.0384
    rs3806003 Imputed A DOM 431 2.057 0.3182 1.102 3.838 2.266 0.02342
    rs3806004 Imputed T DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806010 Imputed T DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806014 Imputed T DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806015 Imputed A DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806018 Imputed A DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806019 Imputed A DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs3806024 Imputed T DOM 425 2.254 0.3145 1.217 4.175 2.583 0.00979
    rs3915080 Imputed A GEN 426 6.343 0.04195
    rs3942254 Imputed T ADD 423 0.6915 0.1524 0.513 0.9322 −2.421 0.01549
    rs3942254 Imputed T DOM 423 0.6256 0.2108 0.4139 0.9456 −2.225 0.02605
    rs3945085 Imputed A DOM 431 1.52 0.1971 1.033 2.237 2.125 0.03357
    rs3976737 Imputed G ADD 430 0.6593 0.2103 0.4366 0.9956 −1.981 0.0476
    rs399485 Imputed A DOM 431 1.467 0.1973 0.9965 2.159 1.942 0.05212
    rs4029119 Imputed G ADD 429 0.361 0.577 0.1165 1.118 −1.766 0.0774
    rs4029119 Imputed G DOM 429 0.361 0.577 0.1165 1.118 −1.766 0.0774
    rs4076201 Imputed G GEN 430 6.108 0.04718
    rs4076201 Imputed G REC 430 2.964 0.4471 1.234 7.119 2.43 0.01509
    rs41395945 Imputed G ADD 430 2.272 0.3513 1.141 4.523 2.335 0.01952
    rs41395945 Imputed G DOM 430 2.245 0.362 1.104 4.564 2.234 0.02549
    rs4146972 Genotyped T DOM 431 1.557 0.2271 0.9976 2.43 1.949 0.05125
    rs4238087 Imputed G DOM 425 0.5314 0.2341 0.3358 0.8408 −2.7 0.00692
    rs4251569 Imputed T ADD 425 0.5471 0.2243 0.3525 0.8491 −2.689 0.00716
    rs4251569 Imputed T DOM 425 0.5314 0.2341 0.3358 0.8408 −2.7 0.00692
    rs4273613 Imputed T ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs4273613 Imputed T DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs4291049 Imputed T REC 428 0.5862 0.2628 0.3502 0.9812 −2.032 0.04213
    rs4315598 Imputed T ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs4315598 Imputed T GEN 431 6.605 0.0368
    rs4315598 Imputed T REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs4321395 Imputed A DOM 400 0.5278 0.2223 0.3414 0.816 −2.875 0.00404
    rs4321596 Genotyped T REC 431 3.01 0.5138 1.099 8.238 2.145 0.03199
    rs4324417 Imputed T DOM 431 1.541 0.2104 1.02 2.328 2.055 0.03989
    rs4328619 Genotyped G DOM 431 0.6446 0.2226 0.4167 0.9973 −1.972 0.04857
    rs4338909 Imputed T ADD 431 1.42 0.1425 1.074 1.878 2.462 0.01381
    rs4370878 Imputed G DOM 431 1.497 0.197 1.017 2.202 2.046 0.04075
    rs4379434 Genotyped T DOM 431 1.603 0.203 1.077 2.386 2.323 0.02015
    rs4416407 Imputed T DOM 429 1.502 0.2225 0.9712 2.324 1.829 0.06743
    rs4417899 Imputed C REC 429 0.6657 0.2225 0.4304 1.03 −1.829 0.06743
    rs4442732 Imputed A ADD 335 0.7543 0.1867 0.5231 1.088 −1.511 0.1309
    rs4444612 Imputed G ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs4444612 Imputed G GEN 431 6.605 0.0368
    rs4444612 Imputed G REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs4450660 Imputed C DOM 430 1.776 0.2015 1.196 2.636 2.849 0.00438
    rs4509702 Imputed C DOM 431 1.497 0.197 1.017 2.202 2.046 0.04075
    rs4526920 Imputed G GEN 431 7.984 0.01846
    rs4533145 Imputed T DOM 430 0.6617 0.2453 0.4092 1.07 −1.683 0.09231
    rs4557006 Imputed A DOM 395 0.5409 0.225 0.348 0.8407 −2.731 0.00631
    rs4570530 Imputed C DOM 431 1.497 0.197 1.017 2.202 2.046 0.04075
    rs4615971 Imputed C DOM 429 1.474 0.1973 1.001 2.17 1.965 0.04937
    rs4628119 Imputed A DOM 431 0.5304 0.202 0.357 0.7881 −3.139 0.0017
    rs4664443 Imputed G ADD 431 0.6931 0.1457 0.521 0.9221 −2.517 0.01184
    rs4688259 Imputed T DOM 429 1.502 0.2225 0.9712 2.324 1.829 0.06743
    rs4688632 Imputed G REC 426 0.6718 0.2217 0.435 1.038 −1.794 0.07285
    rs4695284 Imputed A ADD 231 1.566 0.2722 0.9182 2.669 1.647 0.09965
    rs4700302 Imputed A ADD 368 0.5418 0.2966 0.303 0.9689 −2.067 0.03877
    rs4702720 Imputed A ADD 363 0.7075 0.1961 0.4817 1.039 −1.765 0.07759
    rs4702720 Imputed A DOM 363 0.7149 0.2239 0.461 1.109 −1.499 0.1339
    rs4711091 Genotyped G GEN 431 3.583 0.1667
    rs4714484 Imputed A ADD 431 0.5609 0.1882 0.3879 0.8112 −3.071 0.00213
    rs4736802 Imputed G DOM 430 1.614 0.2031 1.084 2.404 2.357 0.01841
    rs4760785 Imputed A ADD 429 0.7714 0.144 0.5817 1.023 −1.803 0.07146
    rs4760785 Imputed A DOM 429 0.5986 0.2106 0.3961 0.9045 −2.436 0.01484
    rs4760785 Imputed A GEN 429 6.21 0.04484
    rs4760894 Imputed T ADD 429 0.7714 0.144 0.5817 1.023 −1.803 0.07146
    rs4760894 Imputed T DOM 429 0.5986 0.2106 0.3961 0.9045 −2.436 0.01484
    rs4760894 Imputed T GEN 429 6.21 0.04484
    rs4760895 Imputed A ADD 429 0.7714 0.144 0.5817 1.023 −1.803 0.07146
    rs4760895 Imputed A DOM 429 0.5986 0.2106 0.3961 0.9045 −2.436 0.01484
    rs4760895 Imputed A GEN 429 6.21 0.04484
    rs4764738 Imputed A ADD 425 1.555 0.1426 1.176 2.056 3.095 0.00197
    rs4764738 Imputed A GEN 425 9.814 0.00739
    rs4764974 Imputed T ADD 430 1.512 0.1414 1.146 1.995 2.923 0.00347
    rs4764974 Imputed T GEN 430 8.948 0.0114
    rs4798366 Imputed G REC 426 2.304 0.315 1.243 4.271 2.65 0.00806
    rs483159 Imputed T DOM 418 1.412 0.2046 0.9455 2.108 1.686 0.09181
    rs4836502 Imputed T DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs4836507 Imputed C DOM 423 0.6884 0.1986 0.4665 1.016 −1.88 0.0601
    rs4836744 Imputed A ADD 429 0.7704 0.1539 0.5698 1.042 −1.694 0.09021
    rs4836744 Imputed A DOM 429 0.6637 0.1983 0.4499 0.979 −2.067 0.03872
    rs4848944 Genotyped C REC 431 0.464 0.245 0.287 0.75 −3.134 0.00172
    rs4851529 Imputed A DOM 431 0.5663 0.2029 0.3805 0.8429 −2.802 0.00507
    rs4851531 Imputed T DOM 430 0.5588 0.2033 0.3751 0.8325 −2.862 0.00421
    rs4858046 Genotyped T GEN 431 6.792 0.0335
    rs4878214 Imputed A ADD 343 0.7413 0.1824 0.5185 1.06 −1.641 0.1007
    rs4880803 Imputed A ADD 421 0.7588 0.1519 0.5634 1.022 −1.818 0.06914
    rs489441 Imputed G ADD 408 1.6 0.1627 1.163 2.2 2.888 0.00387
    rs489441 Imputed G DOM 408 1.651 0.2035 1.108 2.46 2.463 0.01378
    rs4896568 Imputed T DOM 430 0.5426 0.2032 0.3643 0.8081 −3.008 0.00263
    rs4938851 Imputed T DOM 431 1.301 0.2004 0.8785 1.927 1.313 0.1891
    rs4964416 Imputed C DOM 428 0.6799 0.2267 0.436 1.06 −1.702 0.08872
    rs5756669 Imputed C DOM 431 1.541 0.2104 1.02 2.328 2.055 0.03989
    rs6033138 Imputed C ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6033138 Imputed C GEN 431 6.605 0.0368
    rs6033138 Imputed C REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040619 Imputed C ADD 427 1.488 0.1435 1.123 1.972 2.771 0.00559
    rs6040619 Imputed C GEN 427 7.811 0.02013
    rs6040619 Imputed C REC 427 1.688 0.2858 0.964 2.956 1.832 0.06702
    rs6040625 Imputed T ADD 425 1.479 0.1442 1.115 1.962 2.714 0.00665
    rs6040625 Imputed T GEN 425 7.591 0.02248
    rs6040625 Imputed T REC 425 1.634 0.2879 0.9294 2.873 1.706 0.08806
    rs6040630 Imputed A ADD 431 1.42 0.1417 1.076 1.875 2.476 0.01327
    rs6040630 Imputed A GEN 431 6.71 0.03491
    rs6040630 Imputed A REC 431 1.462 0.2807 0.8433 2.534 1.353 0.1762
    rs6040633 Imputed A ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6040633 Imputed A GEN 431 6.605 0.0368
    rs6040633 Imputed A REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040634 Imputed T ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6040634 Imputed T GEN 431 6.605 0.0368
    rs6040634 Imputed T REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040636 Imputed T ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6040636 Imputed T GEN 431 6.605 0.0368
    rs6040636 Imputed T REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040638 Imputed C ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6040638 Imputed C GEN 431 6.605 0.0368
    rs6040638 Imputed C REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040644 Imputed A ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6040644 Imputed A GEN 431 6.605 0.0368
    rs6040644 Imputed A REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6040667 Imputed T ADD 427 1.391 0.1412 1.055 1.835 2.338 0.0194
    rs6040667 Imputed T GEN 427 6.078 0.04788
    rs6040667 Imputed T REC 427 1.416 0.2791 0.8195 2.447 1.247 0.2125
    rs6040668 Imputed C ADD 422 1.386 0.1419 1.049 1.83 2.3 0.02147
    rs6040668 Imputed C GEN 422 5.936 0.05141
    rs6040668 Imputed C REC 422 1.401 0.2794 0.8101 2.422 1.206 0.2277
    rs6043066 Genotyped G DOM 431 1.208 0.1979 0.8196 1.781 0.955 0.3397
    rs6048146 Imputed G DOM 431 3.484 0.6015 1.072 11.33 2.075 0.03796
    rs6082725 Genotyped T DOM 431 3.484 0.6015 1.072 11.33 2.075 0.03796
    rs6131206 Imputed C ADD 429 1.424 0.1456 1.07 1.894 2.425 0.01529
    rs6131208 Imputed T ADD 429 1.398 0.1412 1.06 1.843 2.371 0.01776
    rs6131208 Imputed T GEN 429 6.201 0.04504
    rs6131208 Imputed T REC 429 1.431 0.2791 0.828 2.472 1.284 0.1993
    rs6134243 Imputed C ADD 431 1.407 0.1412 1.067 1.855 2.418 0.01561
    rs6134243 Imputed C GEN 431 6.605 0.0368
    rs6134243 Imputed C REC 431 1.414 0.279 0.8186 2.444 1.243 0.214
    rs6136020 Imputed A DOM 431 0.7169 0.227 0.4595 1.119 −1.466 0.1426
    rs613799 Imputed C DOM 414 1.45 0.2012 0.9772 2.15 1.845 0.06502
    rs644041 Imputed G ADD 401 1.555 0.164 1.127 2.144 2.69 0.00715
    rs644041 Imputed G DOM 401 1.611 0.2049 1.078 2.407 2.327 0.01999
    rs647645 Imputed C ADD 430 0.7227 0.1429 0.5462 0.9563 −2.273 0.02304
    rs647645 Imputed C GEN 430 8.278 0.01594
    rs647645 Imputed C REC 430 0.4895 0.2484 0.3008 0.7965 −2.876 0.00403
    rs6495554 Imputed C GEN 431 6.084 0.04773
    rs6495554 Imputed C REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs6495555 Imputed C GEN 431 6.084 0.04773
    rs6495555 Imputed C REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs6544728 Imputed T DOM 429 1.888 0.2031 1.268 2.811 3.128 0.00176
    rs6550705 Imputed C ADD 430 1.45 0.1393 1.104 1.906 2.67 0.00759
    rs6550705 Imputed C GEN 430 7.13 0.0283
    rs6550707 Imputed T GEN 430 6.869 0.03224
    rs658108 Imputed A DOM 431 1.477 0.1971 1.004 2.173 1.979 0.04785
    rs6593441 Imputed A DOM 404 1.885 0.2414 1.175 3.026 2.627 0.00862
    rs668732 Imputed A DOM 431 1.56 0.2218 1.01 2.409 2.004 0.04506
    rs671041 Imputed A DOM 431 1.507 0.1971 1.024 2.217 2.08 0.03752
    rs6719700 Imputed A ADD 412 1.583 0.1792 1.114 2.249 2.562 0.0104
    rs6719700 Imputed A DOM 412 1.517 0.2015 1.022 2.252 2.07 0.03845
    rs6722640 Imputed T DOM 431 0.5555 0.2033 0.373 0.8273 −2.892 0.00382
    rs6743092 Imputed T ADD 431 1.365 0.1398 1.038 1.796 2.226 0.02603
    rs6743092 Imputed T GEN 431 4.984 0.08273
    rs6743092 Imputed T REC 431 1.555 0.2336 0.9841 2.458 1.891 0.05858
    rs6744759 Imputed G REC 424 1.89 0.3377 0.9751 3.664 1.885 0.0594
    rs6746170 Imputed A DOM 425 1.805 0.2035 1.211 2.69 2.901 0.00372
    rs6759922 Imputed A DOM 399 0.537 0.2229 0.3469 0.8311 −2.79 0.00527
    rs6769864 Imputed T GEN 431 7.055 0.02938
    rs6773932 Imputed C GEN 426 5.96 0.05078
    rs6774353 Imputed A GEN 431 7.055 0.02938
    rs6781670 Imputed C GEN 431 7.563 0.02279
    rs6786431 Imputed A GEN 426 5.96 0.05078
    rs6789091 Imputed T GEN 426 5.96 0.05078
    rs6791296 Imputed T ADD 414 0.6404 0.2337 0.4051 1.012 −1.907 0.05647
    rs6792662 Imputed G DOM 429 1.502 0.2225 0.9712 2.324 1.829 0.06743
    rs6797574 Imputed G GEN 426 5.96 0.05078
    rs6797882 Imputed G GEN 426 5.96 0.05078
    rs6805139 Imputed G DOM 428 1.519 0.2225 0.9819 2.348 1.878 0.06041
    rs6806043 Imputed C ADD 430 1.47 0.1394 1.118 1.931 2.761 0.00577
    rs6806043 Imputed C GEN 430 7.621 0.02214
    rs6850716 Imputed C GEN 431 4.671 0.09677
    rs6867153 Imputed A REC 428 0.5862 0.2628 0.3502 0.9812 −2.032 0.04213
    rs687047 Imputed C ADD 431 0.7129 0.2248 0.4589 1.107 −1.506 0.1321
    rs6871041 Imputed G DOM 425 0.6929 0.1978 0.4702 1.021 −1.855 0.06367
    rs688358 Imputed A ADD 427 0.6788 0.2285 0.4338 1.062 −1.695 0.08999
    rs6888012 Imputed A REC 428 0.5862 0.2628 0.3502 0.9812 −2.032 0.04213
    rs6908481 Imputed C REC 428 1.658 0.2609 0.9942 2.764 1.938 0.05267
    rs7032231 Imputed A ADD 429 1.467 0.1469 1.1 1.957 2.609 0.00908
    rs7067638 Imputed T DOM 431 1.82 0.2397 1.138 2.911 2.498 0.01249
    rs7077799 Imputed A DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs7082163 Imputed A ADD 430 1.817 0.2063 1.213 2.722 2.895 0.0038
    rs7082163 Imputed A DOM 430 1.875 0.239 1.173 2.995 2.629 0.00856
    rs7089661 Imputed C DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs7101319 Imputed C ADD 430 1.817 0.2063 1.213 2.722 2.895 0.0038
    rs7101319 Imputed C DOM 430 1.875 0.239 1.173 2.995 2.629 0.00856
    rs710832 Genotyped A GEN 431 6.307 0.0427
    rs710832 Genotyped A REC 431 0.256 0.5608 0.0853 0.7684 −2.43 0.01511
    rs7134262 Imputed T GEN 418 3.095 0.2128
    rs7134262 Imputed T REC 418 1.627 0.2899 0.9217 2.871 1.679 0.09319
    rs7134671 Imputed T GEN 428 10.66 0.00484
    rs7138300 Imputed C ADD 429 0.7714 0.144 0.5817 1.023 −1.803 0.07146
    rs7138300 Imputed C DOM 429 0.5986 0.2106 0.3961 0.9045 −2.436 0.01484
    rs7138300 Imputed C GEN 429 6.21 0.04484
    rs7163931 Imputed G GEN 431 6.084 0.04773
    rs7163931 Imputed G REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs7171486 Genotyped G DOM 431 0.5774 0.203 0.3878 0.8595 −2.706 0.00681
    rs7172611 Imputed G GEN 431 6.084 0.04773
    rs7172611 Imputed G REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs7172689 Imputed T GEN 431 6.084 0.04773
    rs7172689 Imputed T REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs7175701 Imputed C GEN 431 6.07 0.04808
    rs7180245 Imputed A GEN 431 6.084 0.04773
    rs7180245 Imputed A REC 431 3.183 0.4709 1.265 8.011 2.459 0.01395
    rs7220603 Genotyped A ADD 431 0.6302 0.1616 0.4591 0.865 −2.857 0.00428
    rs7282518 Imputed T ADD 375 1.518 0.1836 1.06 2.176 2.275 0.02291
    rs7283476 Imputed T ADD 429 0.6337 0.4061 0.2859 1.405 −1.123 0.2614
    rs7283476 Imputed T DOM 429 0.6518 0.4222 0.2849 1.491 −1.014 0.3106
    rs7295817 Imputed C GEN 427 1.689 0.4298
    rs7298255 Imputed A ADD 430 0.7591 0.1447 0.5717 1.008 −1.905 0.05677
    rs7298255 Imputed A DOM 430 0.594 0.2105 0.3932 0.8973 −2.475 0.01332
    rs7305832 Imputed C GEN 431 3.043 0.2184
    rs7305832 Imputed C REC 431 1.616 0.2891 0.9169 2.847 1.66 0.09694
    rs7331467 Imputed A GEN 431 11.32 0.00349
    rs7392620 Imputed C ADD 421 0.7494 0.1521 0.5562 1.01 −1.896 0.05801
    rs742827 Imputed A ADD 423 1.374 0.1417 1.041 1.814 2.245 0.02479
    rs742827 Imputed A GEN 423 5.635 0.05977
    rs742827 Imputed A REC 423 1.393 0.2794 0.8055 2.408 1.186 0.2357
    rs7446891 Imputed G DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs7448641 Imputed C ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7448641 Imputed C DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7484728 Imputed T GEN 429 10.78 0.00456
    rs7499402 Genotyped A ADD 431 1.39 0.2523 0.8476 2.279 1.305 0.1919
    rs7529851 Imputed A ADD 412 0.6637 0.1466 0.498 0.8846 −2.796 0.00517
    rs7529851 Imputed A GEN 412 7.96 0.01868
    rs7573951 Imputed G ADD 431 0.6931 0.1457 0.521 0.9221 −2.517 0.01184
    rs7599198 Imputed T DOM 373 0.5474 0.2267 0.351 0.8537 −2.658 0.00787
    rs7600050 Imputed C ADD 408 1.511 0.1483 1.13 2.02 2.782 0.00541
    rs7607712 Imputed T ADD 416 1.551 0.1747 1.101 2.185 2.513 0.01197
    rs7607712 Imputed T DOM 416 1.544 0.2007 1.042 2.289 2.165 0.03037
    rs7613492 Imputed G GEN 430 7.139 0.02817
    rs7621663 Imputed G ADD 431 1.447 0.1393 1.102 1.901 2.655 0.00794
    rs7621663 Imputed G GEN 431 7.055 0.02938
    rs7621663 Imputed G REC 431 1.785 0.2775 1.036 3.075 2.089 0.03675
    rs7626584 Imputed G ADD 431 0.5782 0.3624 0.2842 1.176 −1.511 0.1307
    rs7684899 Imputed C ADD 431 0.7399 0.1691 0.5312 1.031 −1.782 0.07475
    rs7684899 Imputed C DOM 431 0.6359 0.2028 0.4273 0.9464 −2.232 0.02564
    rs7701604 Imputed G ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7701604 Imputed G DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7703676 Imputed C ADD 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7703676 Imputed C DOM 431 0.309 0.5694 0.1012 0.9434 −2.062 0.03918
    rs7708491 Imputed C REC 428 0.5862 0.2628 0.3502 0.9812 −2.032 0.04213
    rs7711358 Imputed A DOM 431 0.7035 0.1964 0.4787 1.034 −1.791 0.07336
    rs7719448 Imputed G REC 429 0.5823 0.2627 0.348 0.9745 −2.058 0.03958
    rs7724761 Imputed T REC 418 0.5608 0.2705 0.3301 0.953 −2.138 0.03252
    rs7742476 Imputed T DOM 420 1.408 0.2046 0.9428 2.103 1.672 0.09449
    rs7762993 Imputed A ADD 431 1.384 0.1852 0.963 1.99 1.756 0.07907
    rs7762993 Imputed A DOM 431 1.506 0.206 1.006 2.255 1.987 0.04689
    rs7767265 Imputed G ADD 423 1.375 0.168 0.9889 1.91 1.894 0.05828
    rs7767265 Imputed G DOM 423 1.584 0.2032 1.064 2.359 2.263 0.02363
    rs7768128 Imputed G REC 407 0.4807 0.4606 0.1949 1.186 −1.59 0.1118
    rs7771264 Imputed T DOM 431 0.5289 0.2031 0.3552 0.7874 −3.137 0.00171
    rs7773151 Genotyped C DOM 431 0.5304 0.202 0.357 0.7881 −3.139 0.0017
    rs7773210 Genotyped A DOM 431 0.5304 0.202 0.357 0.7881 −3.139 0.0017
    rs7808536 Imputed G DOM 429 1.939 0.2082 1.289 2.916 3.18 0.00147
    rs7843510 Genotyped G DOM 431 1.603 0.203 1.077 2.386 2.323 0.02015
    rs7894867 Imputed T DOM 430 1.833 0.2398 1.146 2.932 2.527 0.01151
    rs7921834 Imputed C DOM 430 1.458 0.197 0.9908 2.145 1.913 0.05576
    rs7939893 Imputed C ADD 431 0.8337 0.1482 0.6235 1.115 −1.227 0.22
    rs7939893 Imputed C DOM 431 0.7294 0.1979 0.4949 1.075 −1.594 0.1109
    rs7944513 Imputed T GEN 410 5.096 0.07823
    rs7944513 Imputed T REC 410 2.257 0.4179 0.9952 5.12 1.949 0.05135
    rs7949720 Imputed G ADD 406 0.6348 0.2219 0.4109 0.9807 −2.048 0.0406
    rs7949720 Imputed G DOM 406 0.6285 0.2538 0.3822 1.034 −1.83 0.06728
    rs7955901 Imputed C ADD 429 0.7576 0.1448 0.5705 1.006 −1.918 0.05515
    rs7955901 Imputed C DOM 429 0.5886 0.2107 0.3895 0.8896 −2.516 0.01189
    rs7956274 Imputed T ADD 429 0.7688 0.1449 0.5788 1.021 −1.815 0.06949
    rs7956274 Imputed T DOM 429 0.6074 0.2105 0.402 0.9176 −2.369 0.01786
    rs7956274 Imputed T GEN 429 5.764 0.05601
    rs7957932 Imputed G ADD 429 0.7693 0.1441 0.58 1.02 −1.819 0.06884
    rs7957932 Imputed G DOM 429 0.5936 0.2123 0.3915 0.8999 −2.457 0.01402
    rs7984504 Imputed C GEN 431 7.984 0.01846
    rs7999518 Imputed A REC 385 0.6295 0.2746 0.3675 1.078 −1.686 0.09185
    rs8026245 Imputed G GEN 431 6.07 0.04808
    rs8026245 Imputed G REC 431 2.977 0.4471 1.239 7.15 2.44 0.01469
    rs8060725 Genotyped A ADD 431 0.7775 0.173 0.5539 1.091 −1.455 0.1456
    rs8103016 Genotyped A ADD 431 1.589 0.1785 1.12 2.254 2.594 0.0095
    rs8103016 Genotyped A DOM 431 1.683 0.2037 1.129 2.508 2.555 0.01061
    rs8104182 Imputed G ADD 431 1.613 0.1788 1.136 2.289 2.672 0.00754
    rs8104182 Imputed G DOM 431 1.716 0.204 1.151 2.56 2.648 0.00811
    rs8129461 Imputed G ADD 429 0.6337 0.4061 0.2859 1.405 −1.123 0.2614
    rs8129461 Imputed G DOM 429 0.6518 0.4222 0.2849 1.491 −1.014 0.3106
    rs8130021 Imputed G ADD 429 0.6337 0.4061 0.2859 1.405 −1.123 0.2614
    rs8130021 Imputed G DOM 429 0.6518 0.4222 0.2849 1.491 −1.014 0.3106
    rs879961 Imputed T ADD 430 0.7316 0.1563 0.5386 0.9938 −2 0.04552
    rs879961 Imputed T DOM 430 0.5986 0.1985 0.4057 0.8831 −2.586 0.00971
    rs906353 Imputed A DOM 431 0.6603 0.1967 0.4491 0.9708 −2.11 0.03482
    rs915491 Imputed C DOM 431 1.452 0.1969 0.9867 2.135 1.892 0.0585
    rs915493 Imputed T DOM 431 1.452 0.1969 0.9867 2.135 1.892 0.0585
    rs915494 Imputed A ADD 392 1.279 0.1636 0.9278 1.762 1.502 0.1331
    rs915494 Imputed A DOM 392 1.409 0.207 0.9389 2.114 1.656 0.0978
    rs917295 Imputed G DOM 429 0.6749 0.197 0.4587 0.993 −1.996 0.04596
    rs9284851 Imputed A GEN 426 6.343 0.04195
    rs9293464 Imputed T REC 429 0.5823 0.2627 0.348 0.9745 −2.058 0.03958
    rs9295154 Genotyped G DOM 431 1.917 0.2188 1.249 2.943 2.974 0.00294
    rs9310221 Imputed A DOM 389 1.407 0.2186 0.917 2.16 1.563 0.118
    rs9310699 Genotyped T GEN 431 7.563 0.02279
    rs9310700 Imputed C ADD 431 1.447 0.1393 1.102 1.901 2.655 0.00794
    rs9310700 Imputed C GEN 431 7.055 0.02938
    rs9310701 Imputed G GEN 430 6.869 0.03224
    rs9310704 Imputed G GEN 426 6.343 0.04195
    rs9319185 Imputed C GEN 431 7.984 0.01846
    rs9319186 Imputed T GEN 431 7.984 0.01846
    rs9327555 Imputed T DOM 429 0.6887 0.197 0.4682 1.013 −1.893 0.05831
    rs9403367 Imputed C DOM 431 0.5304 0.202 0.357 0.7881 −3.139 0.0017
    rs9419608 Imputed G REC 427 1.589 0.2251 1.022 2.47 2.059 0.03954
    rs9426437 Imputed T DOM 426 0.6833 0.203 0.459 1.017 −1.876 0.06061
    rs9454967 Imputed G DOM 431 2.24 0.3143 1.21 4.147 2.566 0.0103
    rs9635511 Imputed T DOM 427 0.7034 0.2071 0.4687 1.055 −1.699 0.08928
    rs966583 Imputed A ADD 431 0.6846 0.1496 0.5106 0.9178 −2.533 0.01131
    rs966583 Imputed A DOM 431 0.6092 0.2075 0.4056 0.915 −2.388 0.01694
    rs980263 Imputed T GEN 431 6.792 0.0335
    rs980264 Imputed T GEN 431 6.792 0.0335
    rs9812206 Imputed G ADD 431 0.4853 0.2571 0.2932 0.8033 −2.812 0.00493
    rs9812206 Imputed G DOM 431 0.4903 0.2646 0.2919 0.8236 −2.693 0.00707
    rs9813552 Imputed G ADD 431 0.5098 0.2537 0.3101 0.8382 −2.656 0.00792
    rs9813552 Imputed G DOM 431 0.5166 0.2615 0.3095 0.8625 −2.526 0.01154
    rs9815037 Imputed T ADD 430 0.4609 0.2606 0.2765 0.7681 −2.972 0.00296
    rs9815037 Imputed T DOM 430 0.4643 0.2679 0.2746 0.7848 −2.864 0.00418
    rs9819583 Imputed T GEN 431 7.563 0.02279
    rs9825349 Imputed A ADD 431 0.4629 0.2606 0.2778 0.7715 −2.955 0.00312
    rs9825349 Imputed A DOM 431 0.4664 0.2679 0.2759 0.7884 −2.847 0.00441
    rs9833118 Imputed G ADD 419 1.479 0.1411 1.122 1.95 2.774 0.00554
    rs9833118 Imputed G GEN 419 7.693 0.02135
    rs9834217 Imputed T ADD 430 0.4658 0.2606 0.2795 0.7764 −2.931 0.00338
    rs9834217 Imputed T DOM 430 0.4695 0.2679 0.2777 0.7937 −2.822 0.00477
    rs9838563 Imputed C GEN 430 6.869 0.03224
    rs9840460 Imputed T ADD 431 0.4629 0.2606 0.2778 0.7715 −2.955 0.00312
    rs9840460 Imputed T DOM 431 0.4664 0.2679 0.2759 0.7884 −2.847 0.00441
    rs9840756 Imputed A ADD 431 0.4629 0.2606 0.2778 0.7715 −2.955 0.00312
    rs9840756 Imputed A DOM 431 0.4664 0.2679 0.2759 0.7884 −2.847 0.00441
    rs9847999 Imputed C GEN 426 6.343 0.04195
    rs9864769 Imputed C GEN 431 6.792 0.0335
    rs9866421 Genotyped C REC 431 0.6994 0.2578 0.4219 1.159 −1.387 0.1655
    rs987296 Imputed T GEN 430 7.666 0.02164
    rs9881685 Imputed A ADD 431 0.4853 0.2571 0.2932 0.8033 −2.812 0.00493
    rs9881685 Imputed A DOM 431 0.4903 0.2646 0.2919 0.8236 −2.693 0.00707
    rs992695 Imputed C ADD 431 0.7364 0.156 0.5424 0.9998 −1.961 0.04987
    rs992695 Imputed C DOM 431 0.6065 0.198 0.4114 0.894 −2.526 0.01155
    rs9936999 Imputed G DOM 249 1.779 0.2695 1.049 3.017 2.137 0.03256
    PRAVA_ PLACEBO_ PLACEBO_
    PRAVA_ PLACEBO_ A1_ PRAVA_ PRAVA_ A1_ PLACEBO_ A2_
    HW_ ALLELE_ ALLELE_ ALLELE_ HZ_ HET_ A2_HZ HZ_ HET_ HZ_
    SNP rs # PVALUE FREQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs77638540 0.407 0.0348 0.02717 0.04049 0 10 174 1 18 228
    rs72746987 0.01335 0.03596 0.02174 0.04656 2 4 178 1 21 225
    rs10021016 0.8982 0.25174 0.28533 0.22672 17 71 96 11 90 146
    rs10021016 0.8982 0.25174 0.28533 0.22672 17 71 96 11 90 146
    rs10051148 0.8246 0.31903 0.29348 0.33806 19 70 95 26 115 106
    rs10054055 0.9114 0.31439 0.28804 0.33401 18 70 96 25 115 107
    rs10067895 0.8235 0.32151 0.29444 0.34156 19 68 93 26 114 103
    rs10100725 1 0.14849 0.11957 0.17004 1 42 141 8 68 171
    rs10128531 0.04404 0.17773 0.20718 0.1556 5 65 111 2 71 168
    rs10181743 0.7667 0.44511 0.47727 0.42181 42 84 50 39 127 77
    rs10199127 0.2788 0.277 0.32692 0.23975 14 91 77 14 89 141
    rs10270624 0.8741 0.18662 0.22826 0.15496 7 70 107 7 61 174
    rs1030006 0.6962 0.43387 0.47826 0.40081 45 86 53 34 130 83
    rs1031811 0.909 0.30471 0.32597 0.28893 23 72 86 17 107 120
    rs10430870 0.1902 0.24246 0.24457 0.24089 11 68 105 9 101 137
    rs10430870 0.1902 0.24246 0.24457 0.24089 11 68 105 9 101 137
    rs10469597 0.4689 0.29471 0.32941 0.26872 19 74 77 12 98 117
    rs10469597 0.4689 0.29471 0.32941 0.26872 19 74 77 12 98 117
    rs10478919 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs10506623 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs10506623 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs10506626 0.2655 0.39186 0.33424 0.43496 19 85 80 41 132 73
    rs10506626 0.2655 0.39186 0.33424 0.43496 19 85 80 41 132 73
    rs10509477 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs10517918 0.765 0.42099 0.46448 0.38797 45 80 58 32 123 86
    rs10517924 0.9228 0.46512 0.49454 0.44332 48 85 50 44 131 72
    rs10519362 0.1367 0.13109 0.15489 0.11336 6 45 133 5 46 196
    rs10520072 1 0.31585 0.28689 0.3374 18 69 96 25 116 105
    rs10737390 0.7588 0.38498 0.35714 0.40574 25 80 77 36 126 82
    rs10742851 0.8969 0.2471 0.2038 0.27935 5 65 114 22 94 131
    rs10743685 0.9175 0.36543 0.40217 0.33806 30 88 66 28 111 108
    rs10743685 0.9175 0.36543 0.40217 0.33806 30 88 66 28 111 108
    rs10749293 0.4125 0.29002 0.32065 0.26721 18 82 84 22 88 137
    rs10749294 0.3324 0.27262 0.29891 0.25304 15 80 89 21 83 143
    rs10753760 0.6768 0.39039 0.44253 0.35129 35 84 55 29 105 98
    rs10753760 0.6768 0.39039 0.44253 0.35129 35 84 55 29 105 98
    rs10772362 0.6967 0.24594 0.20652 0.2753 7 62 115 17 102 128
    rs10784891 0.4895 0.42657 0.38736 0.45547 30 81 71 44 137 66
    rs10784891 0.4895 0.42657 0.38736 0.45547 30 81 71 44 137 66
    rs10784891 0.4895 0.42657 0.38736 0.45547 30 81 71 44 137 66
    rs10787923 0.4129 0.2907 0.32065 0.26829 18 82 84 22 88 136
    rs10787924 0.3324 0.27262 0.29891 0.25304 15 80 89 21 83 143
    rs10787949 0.4183 0.29535 0.32337 0.27439 19 81 84 22 91 133
    rs10787951 0.4183 0.29535 0.32337 0.27439 19 81 84 22 91 133
    rs10787983 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs10794733 0.9124 0.33017 0.29558 0.35625 13 81 87 32 107 101
    rs10818280 0.2268 0.32864 0.30055 0.34979 17 76 90 23 124 96
    rs10860586 1 0.49186 0.55163 0.44715 57 89 38 47 126 73
    rs10860586 1 0.49186 0.55163 0.44715 57 89 38 47 126 73
    rs10870473 0.4798 0.2967 0.2439 0.34 7 26 49 11 46 43
    rs10870473 0.4798 0.2967 0.2439 0.34 7 26 49 11 46 43
    rs10879240 5.55E−01 0.42674 0.38859 0.45528 31 81 72 44 136 66
    rs10879240 0.5549 0.42674 0.38859 0.45528 31 81 72 44 136 66
    rs10879242 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs10879242 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs10879245 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs10879245 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs10879249 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs10879249 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs10886429 0.4134 0.29138 0.31967 0.27033 18 81 84 22 89 135
    rs10886449 0.3355 0.27674 0.30163 0.25813 16 79 89 21 85 140
    rs10886451 0.3355 0.27674 0.30163 0.25813 16 79 89 21 85 140
    rs10886452 0.4183 0.29535 0.32337 0.27439 19 81 84 22 91 133
    rs10886456 0.3355 0.27674 0.30163 0.25813 16 79 89 21 85 140
    rs10886463 0.4176 0.29466 0.32337 0.27328 19 81 84 22 91 134
    rs10886465 0.3545 0.29582 0.32337 0.2753 19 81 84 23 90 134
    rs10886526 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs10922903 0.7664 0.41395 0.39946 0.4248 25 97 62 47 115 84
    rs10941126 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs10941126 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs10947980 0.3433 0.28422 0.22554 0.32794 15 53 116 24 114 109
    rs11059376 0.8625 0.17233 0.21023 0.14407 7 60 109 4 60 172
    rs11072995 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs11072995 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs11081202 0.2973 0.29466 0.33152 0.26721 26 70 88 16 100 131
    rs11081202 0.2973 0.29466 0.33152 0.26721 26 70 88 16 100 131
    rs110965 0.739 0.3293 0.36782 0.30126 22 84 68 21 102 116
    rs11124962 0.7696 0.20766 0.24728 0.17814 7 77 100 10 68 169
    rs1116596 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs11178531 0.4337 0.43735 0.40217 0.46356 32 84 68 46 137 64
    rs11178531 0.4337 0.43735 0.40217 0.46356 32 84 68 46 137 64
    rs11178583 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs11178583 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs11178589 0.1086 0.40139 0.35054 0.43927 20 89 75 41 135 71
    rs11178589 0.1086 0.40139 0.35054 0.43927 20 89 75 41 135 71
    rs11178594 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs11178594 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs11178602 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs11178602 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs11178648 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs11178648 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs11198877 0.4176 0.29466 0.32337 0.27328 19 81 84 22 91 134
    rs11198942 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs11221075 0.8093 0.11385 0.09669 0.12653 2 31 148 4 54 187
    rs11242020 0.7399 0.32093 0.29781 0.33806 20 69 94 26 115 106
    rs11242021 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs11242022 1 0.31659 0.28962 0.33673 18 70 95 25 115 105
    rs11242023 1 0.31659 0.28962 0.33673 18 70 95 25 115 105
    rs1149349 1 0.13689 0.16033 0.11943 2 55 127 6 47 194
    rs1149350 0.1416 0.1814 0.22283 0.15041 9 64 111 10 54 182
    rs1149350 0.1416 0.1814 0.22283 0.15041 9 64 111 10 54 182
    rs11576627 0.1506 0.13817 0.16298 0.11992 7 45 129 5 49 192
    rs11576627 0.1506 0.13817 0.16298 0.11992 7 45 129 5 49 192
    rs11630050 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11630050 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11633024 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11633024 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11636298 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11636298 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11637363 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs11637363 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs11637813 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11637813 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs11638043 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs11638043 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs11638115 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs11638115 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs11638444 1 0.22506 0.25272 0.20445 15 63 106 7 87 153
    rs11682946 1 0.19792 0.32927 0.1 3 21 17 0 11 44
    rs11682946 1 0.19792 0.32927 0.1 3 21 17 0 11 44
    rs11717157 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs11717157 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs11724055 0.6351 0.18794 0.1712 0.2004 5 53 126 8 83 156
    rs11743355 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11743355 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11746806 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11746806 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11746959 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11746959 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs11749272 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs11839636 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs11839785 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs11853619 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11853619 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11856780 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11856780 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs11901899 0.5562 0.28873 0.34254 0.24898 20 84 77 18 86 141
    rs11903290 0.909 0.30471 0.32597 0.28893 23 72 86 17 107 120
    rs11909480 0.3857 0.03364 0.02446 0.04049 0 9 175 1 18 228
    rs11909480 0.3857 0.03364 0.02446 0.04049 0 9 175 1 18 228
    rs11910289 0.5361 0.04206 0.06011 0.02857 1 20 162 0 14 231
    rs11910289 0.5361 0.04206 0.06011 0.02857 1 20 162 0 14 231
    rs11920375 0.02563 0.34571 0.39674 0.30769 33 80 71 29 94 124
    rs11926319 0.7867 0.10023 0.07065 0.12245 0 26 158 3 54 188
    rs11933744 1 0.22738 0.25272 0.2085 15 63 106 7 89 151
    rs11934919 1 0.22738 0.25272 0.2085 15 63 106 7 89 151
    rs11934957 1 0.22738 0.25272 0.2085 15 63 106 7 89 151
    rs11959206 0.3793 0.44509 0.42896 0.45714 26 105 52 54 116 75
    rs12038613 0.6194 0.41492 0.39891 0.42683 24 98 61 47 116 83
    rs12151417 0.04209 0.28037 0.32418 0.24797 15 88 79 10 102 134
    rs12153185 0.8238 0.32042 0.29396 0.34016 19 69 94 26 114 104
    rs12182651 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs12235345 1 0.07674 0.08696 0.06911 0 32 152 2 30 214
    rs12324786 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs12324786 0.5795 0.22209 0.2459 0.20445 15 60 108 8 85 154
    rs12336958 0.3339 0.366 0.39759 0.34388 22 88 56 27 109 101
    rs12407412 0.1056 0.13689 0.16033 0.11943 7 45 132 5 49 193
    rs12407412 0.1056 0.13689 0.16033 0.11943 7 45 132 5 49 193
    rs12418971 0.2341 0.24232 0.2486 0.2377 11 67 101 9 98 137
    rs12418971 0.2341 0.24232 0.2486 0.2377 11 67 101 9 98 137
    rs1241967 0.519 0.33875 0.33152 0.34413 15 92 77 31 108 108
    rs12420184 0.2101 0.16163 0.12772 0.18699 3 41 140 12 68 166
    rs12433968 1 0.28914 0.26946 0.30349 15 60 92 18 103 108
    rs12445477 0.5364 0.08629 0.05307 0.11066 1 17 161 3 48 193
    rs12447191 0.6616 0.20766 0.16848 0.23684 10 42 132 10 97 140
    rs12447191 0.6616 0.20766 0.16848 0.23684 10 42 132 10 97 140
    rs12465349 1 0.50587 0.55163 0.47107 56 91 37 53 122 67
    rs1247340 0.1479 0.18329 0.22283 0.15385 9 64 111 10 56 181
    rs1247340 0.1479 0.18329 0.22283 0.15385 9 64 111 10 56 181
    rs1247341 0.1445 0.18256 0.22283 0.15244 9 64 111 10 55 181
    rs1247341 0.1445 0.18256 0.22283 0.15244 9 64 111 10 55 181
    rs1247343 0.8388 0.13488 0.16033 0.11585 2 55 127 6 45 195
    rs12509758 0.7673 0.20465 0.25543 0.16667 12 70 102 7 68 171
    rs12515472 0.3479 0.18794 0.21196 0.17004 4 70 110 8 68 171
    rs12548906 0.1402 0.20833 0.24444 0.18125 7 74 99 6 75 159
    rs12596240 0.08793 0.4 0.38043 0.41463 28 84 72 32 140 74
    rs12618781 0.7652 0.45332 0.41124 0.48319 32 75 62 50 130 58
    rs12678600 0.7429 0.32599 0.28261 0.3583 14 76 94 30 117 100
    rs12692229 0.8275 0.33023 0.36413 0.30488 26 82 76 22 106 118
    rs12713324 0.08929 0.27518 0.31868 0.24286 15 86 81 10 99 136
    rs12719415 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs12820589 0.4989 0.17584 0.225 0.13866 9 63 108 6 54 178
    rs12820589 0.4989 0.17584 0.225 0.13866 9 63 108 6 54 178
    rs12831292 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs12831292 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs13012636 0.909 0.30471 0.32597 0.28893 23 72 86 17 107 120
    rs13038146 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs13038146 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs13038146 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs13089860 0.02583 0.46229 0.41503 0.49756 32 63 58 55 94 56
    rs13102419 0.7714 0.46503 0.49728 0.44082 48 87 49 43 130 72
    rs13194907 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs13194907 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs13195745 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs13195745 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs13265054 0.8246 0.32423 0.28453 0.35417 14 75 92 29 112 99
    rs13273002 0.88 0.19814 0.1712 0.21837 3 57 124 13 81 151
    rs13282131 0.2104 0.47332 0.52446 0.43522 53 87 44 50 115 82
    rs13282131 0.2104 0.47332 0.52446 0.43522 53 87 44 50 115 82
    rs13282131 0.2104 0.47332 0.52446 0.43522 53 87 44 50 115 82
    rs1330052 0.4097 0.37007 0.39674 0.3502 38 70 76 25 123 99
    rs1335721 0.6194 0.41492 0.39891 0.42683 24 98 61 47 116 83
    rs1336382 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1336383 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1336407 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1336409 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1336596 0.2989 0.36512 0.33967 0.38415 23 79 82 29 131 86
    rs13387284 0.7625 0.44625 0.39458 0.48291 28 75 63 50 126 58
    rs13401462 0.6266 0.48113 0.53352 0.44286 47 97 35 54 109 82
    rs13409045 0.6898 0.40371 0.35598 0.43927 22 87 75 46 125 76
    rs1349284 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs1355715 1 0.04535 0.03261 0.05488 0 12 172 0 27 219
    rs1357696 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs1357698 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs1357699 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs1363273 0.6881 0.44554 0.42105 0.46352 25 94 52 53 110 70
    rs1373601 0.00407 0.32125 0.27326 0.35746 23 48 101 31 101 96
    rs1375829 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs1395748 0.6452 0.29698 0.26902 0.31781 18 63 103 22 113 112
    rs1414865 0.4183 0.29535 0.32337 0.27439 19 81 84 22 91 133
    rs1414873 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1414876 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1424643 0.0693 0.27896 0.32402 0.2459 15 86 78 10 100 134
    rs1424643 0.0693 0.27896 0.32402 0.2459 15 86 78 10 100 134
    rs1424648 0.04199 0.28074 0.32065 0.25101 13 92 79 12 100 135
    rs1429321 0.04156 0.28169 0.32418 0.25 15 88 79 10 102 132
    rs1429326 0.08559 0.27305 0.31421 0.24167 14 87 82 10 96 134
    rs1429326 0.08559 0.27305 0.31421 0.24167 14 87 82 10 96 134
    rs1444741 0.00416 0.31818 0.26857 0.3556 23 48 104 31 103 98
    rs1449916 0.3854 0.49556 0.41045 0.55147 25 60 49 62 101 41
    rs1459523 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs1459523 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs1466352 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs1466353 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs1476714 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs1486723 0.6673 0.33875 0.33424 0.34211 15 93 76 32 105 110
    rs1495375 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs1495375 0.1622 0.40371 0.35598 0.43927 21 89 74 42 133 72
    rs1495381 0.9218 0.42923 0.45652 0.40891 43 82 59 37 128 82
    rs1495381 0.9218 0.42923 0.45652 0.40891 43 82 59 37 128 82
    rs1498061 0.2527 0.19154 0.14881 0.22222 1 23 60 9 34 74
    rs1498992 0.9083 0.29651 0.27174 0.31504 15 70 99 22 111 113
    rs1499001 0.8032 0.26168 0.23913 0.27869 12 64 108 16 104 124
    rs1512988 0.1315 0.40093 0.34973 0.43902 20 88 75 41 134 71
    rs1512988 0.1315 0.40093 0.34973 0.43902 20 88 75 41 134 71
    rs1512989 0.1315 0.40093 0.34973 0.43902 20 88 75 41 134 71
    rs1512989 0.1315 0.40093 0.34973 0.43902 20 88 75 41 134 71
    rs1512991 0.4308 0.42691 0.38859 0.45547 30 83 71 44 137 66
    rs1512991 0.4308 0.42691 0.38859 0.45547 30 83 71 44 137 66
    rs1512991 0.4308 0.42691 0.38859 0.45547 30 83 71 44 137 66
    rs1524303 0.02511 0.34615 0.39946 0.30612 34 79 71 28 94 123
    rs1524306 0.0248 0.34455 0.39946 0.30364 34 79 71 28 94 125
    rs1524306 0.0248 0.34455 0.39946 0.30364 34 79 71 28 94 125
    rs1524310 0.04097 0.34229 0.39835 0.30081 33 79 70 27 94 125
    rs1524310 0.04097 0.34229 0.39835 0.30081 33 79 70 27 94 125
    rs1524321 0.06463 0.33806 0.39286 0.29668 32 79 71 25 93 123
    rs1527059 0.7591 0.08762 0.07418 0.09756 0 27 155 2 44 200
    rs152707 0.7628 0.39559 0.36141 0.42105 25 83 76 44 120 83
    rs152707 0.7628 0.39559 0.36141 0.42105 25 83 76 44 120 83
    rs152712 0.8406 0.39675 0.36141 0.42308 25 83 76 44 121 82
    rs152712 0.8406 0.39675 0.36141 0.42308 25 83 76 44 121 82
    rs1533994 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs1535866 0.531 0.1891 0.22554 0.16194 5 73 106 8 64 175
    rs1563773 0.04296 0.34848 0.39946 0.3102 34 79 71 28 96 121
    rs1563774 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs1567740 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs1567740 0.1092 0.40116 0.35054 0.43902 20 89 75 41 134 71
    rs1572573 0.1958 0.18523 0.20904 0.16737 4 66 107 6 67 163
    rs1577497 0.6194 0.41492 0.39891 0.42683 24 98 61 47 116 83
    rs1581514 0.0181 0.34928 0.4073 0.30625 34 77 67 28 91 121
    rs1581514 0.0181 0.34928 0.4073 0.30625 34 77 67 28 91 121
    rs1582321 0.08774 0.40023 0.38043 0.41498 28 84 72 32 141 74
    rs1582322 0.107 0.40023 0.38187 0.41393 28 83 71 32 138 74
    rs1582323 0.1066 0.40047 0.38251 0.41393 28 84 71 32 138 74
    rs1592485 0.1326 0.40349 0.38315 0.4187 28 85 71 34 138 74
    rs1600954 0.9216 0.45574 0.50833 0.41597 48 87 45 38 122 78
    rs1600954 0.9216 0.45574 0.50833 0.41597 48 87 45 38 122 78
    rs16938626 0.5372 0.27218 0.23276 0.30041 9 63 102 19 108 116
    rs16964300 0.6616 0.20766 0.16848 0.23684 10 42 132 10 97 140
    rs16964300 0.6616 0.20766 0.16848 0.23684 10 42 132 10 97 140
    rs16986282 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs17007620 1 0.25452 0.30838 0.21364 14 75 78 11 72 137
    rs17007620 1 0.25452 0.30838 0.21364 14 75 78 11 72 137
    rs17014326 0.5678 0.30303 0.27717 0.32245 19 64 101 23 112 110
    rs17047957 0.1374 0.1314 0.15847 0.11134 6 46 131 5 45 197
    rs1705261 0.7675 0.42442 0.44565 0.40854 42 80 62 37 127 82
    rs17073341 1 0.03248 0.03804 0.02834 0 14 170 0 14 233
    rs17073341 1 0.03248 0.03804 0.02834 0 14 170 0 14 233
    rs17138702 0.6615 0.12704 0.10383 0.14431 1 36 146 7 57 182
    rs17189710 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs17189710 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs17189710 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs17310176 0.02653 0.17053 0.15761 0.18016 2 54 128 4 81 162
    rs17310176 0.02653 0.17053 0.15761 0.18016 2 54 128 4 81 162
    rs17358860 0.6351 0.18794 0.1712 0.2004 5 53 126 8 83 156
    rs17370541 0.9164 0.3693 0.38764 0.35565 31 76 71 25 120 94
    rs17370541 0.9164 0.3693 0.38764 0.35565 31 76 71 25 120 94
    rs17526574 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs17530747 1 0.34834 0.33152 0.36134 24 74 86 27 118 93
    rs17649114 0.7799 0.22145 0.24176 0.20648 10 68 104 12 78 157
    rs17766172 0.4468 0.3401 0.31768 0.35714 17 81 83 35 100 103
    rs1818885 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs1832222 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs1861327 0.08774 0.40023 0.38043 0.41498 28 84 72 32 141 74
    rs1868581 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs1868581 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs1874313 0.1082 0.40233 0.35054 0.44106 20 89 75 41 135 70
    rs1874313 0.1082 0.40233 0.35054 0.44106 20 89 75 41 135 70
    rs1876409 0.8167 0.29673 0.26923 0.31707 18 62 102 21 114 111
    rs1913201 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs1913201 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs1913201 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs1916922 0.2165 0.32289 0.375 0.28452 27 78 71 22 92 125
    rs1936871 0.4071 0.36659 0.3288 0.39474 21 79 84 41 113 93
    rs1961157 1 0.48376 0.42935 0.52429 30 98 56 71 117 59
    rs1987179 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs1987179 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs1990023 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs1995025 0.674 0.12993 0.1413 0.12146 2 48 134 6 48 193
    rs2016194 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs2023651 0.7575 0.19347 0.14946 0.22653 3 49 132 14 83 148
    rs2024902 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs2024902 1 0.05568 0.07609 0.04049 0 28 156 1 18 228
    rs2025107 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs2025108 0.2262 0.06265 0.08424 0.04656 1 29 154 2 19 226
    rs2031987 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs2052428 0.06403 0.46479 0.45278 0.47358 39 85 56 43 147 56
    rs2053230 1 0.0223 0.01724 0.02614 0 4 112 0 8 145
    rs2062448 0.2895 0.1014 0.07377 0.12195 0 27 156 2 56 188
    rs2063420 0.6935 0.42791 0.46721 0.39879 45 81 57 36 125 86
    rs2063591 0.4321 0.4359 0.40164 0.46138 32 83 68 45 137 64
    rs2063591 0.4321 0.4359 0.40164 0.46138 32 83 68 45 137 64
    rs208026 0.295 0.24362 0.27989 0.2166 12 79 93 9 89 149
    rs208029 0.4837 0.223 0.25138 0.20204 9 73 99 9 81 155
    rs208757 1 0.22235 0.24862 0.20287 9 72 100 12 75 157
    rs2095586 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs2095606 0.209 0.36439 0.33607 0.38589 22 79 82 28 130 83
    rs2102374 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2102374 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2108426 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs2110664 0.4046 0.28622 0.33989 0.24691 20 81 77 18 84 141
    rs2132242 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs2132242 0.132 0.40023 0.35054 0.43725 20 89 75 41 134 72
    rs2158958 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs2158961 0.8246 0.31903 0.29348 0.33806 19 70 95 26 115 106
    rs2163046 0.03049 0.27791 0.31694 0.24899 14 88 81 10 103 134
    rs2180286 0.3351 0.51856 0.47826 0.54858 42 92 50 79 113 55
    rs2180684 0.525 0.08431 0.10165 0.07143 1 35 146 3 29 213
    rs2188079 0.6891 0.40116 0.45902 0.3583 36 96 51 31 115 101
    rs2188079 0.6891 0.40116 0.45902 0.3583 36 96 51 31 115 101
    rs2190598 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs2190600 0.8235 0.32151 0.29444 0.34156 19 68 93 26 114 103
    rs2224184 0.289 0.51508 0.47554 0.54453 42 91 51 78 113 56
    rs2247066 0.6452 0.29698 0.26902 0.31781 18 63 103 22 113 112
    rs2248236 0.8894 0.22326 0.19565 0.2439 10 52 122 12 96 138
    rs2248236 0.8894 0.22326 0.19565 0.2439 10 52 122 12 96 138
    rs2265733 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2265733 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2270584 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs2270584 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs2270586 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs2270586 0.3138 0.39559 0.34511 0.4332 21 85 78 41 132 74
    rs229775 0.519 0.33875 0.33152 0.34413 15 92 77 31 108 108
    rs229815 0.4505 0.33762 0.32787 0.3449 14 92 77 31 107 107
    rs229829 0.7583 0.37587 0.36141 0.38664 20 93 71 39 113 95
    rs229831 0.8231 0.31439 0.30978 0.31781 14 86 84 27 103 117
    rs2317057 0.03577 0.20523 0.17208 0.22967 4 45 105 18 60 131
    rs2322100 0.4748 0.28074 0.31522 0.25506 24 68 92 13 100 134
    rs2322101 0.4732 0.28089 0.31694 0.25407 24 68 91 13 99 134
    rs2327929 0.5607 0.45244 0.46467 0.44332 43 85 56 42 135 70
    rs2332844 1 0.94167 0.95909 0.92692 101 9 0 111 19 0
    rs2332844 1 0.94167 0.95909 0.92692 101 9 0 111 19 0
    rs2349170 0.1032 0.20581 0.22011 0.19512 9 63 112 15 66 165
    rs2356722 0.9089 0.30162 0.27446 0.32186 18 65 101 22 115 110
    rs2364956 0.00724 0.17849 0.22652 0.14256 10 62 109 12 45 185
    rs2373793 0.7647 0.2 0.23913 0.17073 8 72 104 10 64 172
    rs2373793 0.7647 0.2 0.23913 0.17073 8 72 104 10 64 172
    rs238252 0.8581 0.15925 0.19126 0.13525 6 58 119 4 58 182
    rs238252 0.8581 0.15925 0.19126 0.13525 6 58 119 4 58 182
    rs2383903 0.5438 0.27209 0.23497 0.2996 10 66 107 19 110 118
    rs2387945 0.674 0.12993 0.1413 0.12146 2 48 134 6 48 193
    rs2389863 0.8901 0.22535 0.19672 0.24691 10 52 121 12 96 135
    rs2389866 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs2389869 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs2389870 0.7543 0.19026 0.17663 0.2004 6 53 125 8 83 156
    rs2418494 0.6254 0.53073 0.47778 0.56996 46 80 54 76 125 42
    rs2418494 0.6254 0.53073 0.47778 0.56996 46 80 54 76 125 42
    rs2418541 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs2418542 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs2423556 0.3351 0.51856 0.47826 0.54858 42 92 50 79 113 55
    rs2437688 0.5494 0.08701 0.10598 0.07287 3 33 148 1 34 212
    rs2456809 0.7299 0.30047 0.27473 0.31967 19 62 101 21 114 109
    rs2456811 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2456811 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2476976 0.293 0.29138 0.31522 0.27347 18 80 86 23 88 134
    rs2484911 0.2786 0.27494 0.29891 0.25709 15 80 89 22 83 142
    rs2488557 0.3091 0.13902 0.10656 0.16327 2 35 146 9 62 174
    rs250162 0.5202 0.25176 0.1989 0.29098 8 56 117 16 110 118
    rs250162 0.5202 0.25176 0.1989 0.29098 8 56 117 16 110 118
    rs2560708 0.5877 0.15808 0.12088 0.18571 2 40 140 10 71 164
    rs2617841 0.773 0.22418 0.18235 0.25551 8 46 116 13 90 124
    rs2622499 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs264129 0.9112 0.32729 0.30226 0.34599 19 69 89 26 112 99
    rs2642936 1 0.18735 0.23077 0.1551 10 64 108 5 66 174
    rs2660633 0.8167 0.29673 0.26923 0.31707 18 62 102 21 114 111
    rs2660634 0.8167 0.29673 0.26923 0.31707 18 62 102 21 114 111
    rs2660648 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2660648 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs2681505 0.6967 0.24594 0.20652 0.2753 7 62 115 17 102 128
    rs277411 0.01107 0.03488 0.01902 0.04675 2 3 179 1 21 224
    rs2832634 0.5344 0.04186 0.06011 0.02834 1 20 162 0 14 233
    rs2832637 0.5344 0.04186 0.06011 0.02834 1 20 162 0 14 233
    rs2843167 0.6437 0.29651 0.27174 0.31504 19 62 103 21 113 112
    rs2876227 0.11 0.35595 0.39779 0.32427 30 84 67 31 93 115
    rs2876227 0.11 0.35595 0.39779 0.32427 30 84 67 31 93 115
    rs2882097 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs2909862 0.06435 0.46457 0.48171 0.45161 30 98 36 43 110 64
    rs3001945 0.7949 0.10662 0.1185 0.09787 1 39 133 4 38 193
    rs3011020 0.674 0.12993 0.1413 0.12146 2 48 134 6 48 193
    rs36071725 0.9158 0.35035 0.39674 0.31579 26 94 64 26 104 117
    rs36071725 0.9158 0.35035 0.39674 0.31579 26 94 64 26 104 117
    rs373983 1 0.41038 0.425 0.39959 29 95 56 42 111 91
    rs3743794 0.1305 0.40258 0.38462 0.41598 28 84 70 33 137 74
    rs3756154 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs3756154 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs3775850 0.6351 0.18794 0.1712 0.2004 5 53 126 8 83 156
    rs3775851 0.6351 0.18794 0.1712 0.2004 5 53 126 8 83 156
    rs3793044 1 0.05452 0.07337 0.04049 0 27 157 1 18 228
    rs3793044 1 0.05452 0.07337 0.04049 0 27 157 1 18 228
    rs3793053 0.1831 0.06 0.08287 0.04303 1 28 152 2 17 225
    rs3796246 0.7838 0.09629 0.0625 0.12146 0 23 161 3 54 190
    rs3806003 1 0.05452 0.07337 0.04049 0 27 157 1 18 228
    rs3806003 1 0.05452 0.07337 0.04049 0 27 157 1 18 228
    rs3806004 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806010 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806014 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806015 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806018 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806019 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs3806024 0.1831 0.06 0.08287 0.04303 1 28 152 2 17 225
    rs3915080 0.03262 0.34859 0.39946 0.30992 34 79 71 28 94 120
    rs3942254 0.07006 0.4078 0.35955 0.44286 20 88 70 41 135 69
    rs3942254 0.07006 0.4078 0.35955 0.44286 20 88 70 41 135 69
    rs3945085 0.4125 0.29002 0.32065 0.26721 18 82 84 22 88 137
    rs3976737 0.2881 0.1314 0.10383 0.15182 1 36 146 9 57 181
    rs399485 0.6505 0.30626 0.33424 0.28543 17 89 78 21 99 127
    rs4029119 1 0.02098 0.01087 0.02857 0 4 180 0 14 231
    rs4029119 1 0.02098 0.01087 0.02857 0 4 180 0 14 231
    rs4076201 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs4076201 0.893 0.23372 0.25272 0.21951 16 61 107 8 92 146
    rs41395945 0.5344 0.04186 0.06011 0.02834 1 20 162 0 14 233
    rs41395945 0.5344 0.04186 0.06011 0.02834 1 20 162 0 14 233
    rs4146972 0.2068 0.13341 0.16033 0.11336 6 47 131 5 46 196
    rs4238087 0.1486 0.13765 0.1 0.16531 1 34 145 3 75 167
    rs4251569 0.1486 0.13765 0.1 0.16531 1 34 145 3 75 167
    rs4251569 0.1486 0.13765 0.1 0.16531 1 34 145 3 75 167
    rs4273613 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs4273613 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs4291049 0.3793 0.44509 0.42896 0.45714 26 105 52 54 116 75
    rs4315598 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4315598 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4315598 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4321395 0.7625 0.44625 0.39458 0.48291 28 75 63 50 126 58
    rs4321596 0.6475 0.19606 0.21196 0.18421 12 54 118 6 79 162
    rs4324417 0.7663 0.41763 0.44022 0.40081 32 98 54 45 108 94
    rs4328619 0.8472 0.49536 0.44837 0.53036 37 91 56 70 122 55
    rs4338909 0.9195 0.39211 0.44022 0.35628 36 90 58 31 114 102
    rs4370878 0.4153 0.29118 0.32065 0.26923 18 82 84 22 89 136
    rs4379434 0.6081 0.37471 0.4375 0.32794 38 85 61 25 112 110
    rs4416407 0.06631 0.49068 0.51913 0.46951 50 90 43 63 105 78
    rs4417899 0.06631 0.50932 0.48087 0.53049 43 90 50 78 105 63
    rs4442732 0.4915 0.27313 0.24632 0.29146 8 51 77 14 88 97
    rs4444612 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4444612 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4444612 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs4450660 0.5652 0.21279 0.25137 0.18421 7 78 98 10 71 166
    rs4509702 0.4153 0.29118 0.32065 0.26923 18 82 84 22 89 136
    rs4526920 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs4533145 1 0.11395 0.0929 0.12955 2 30 151 3 58 186
    rs4557006 0.6853 0.45063 0.40123 0.48498 28 74 60 50 126 57
    rs4570530 0.4153 0.29118 0.32065 0.26923 18 82 84 22 89 136
    rs4615971 0.3529 0.29371 0.32065 0.27347 18 82 84 23 88 134
    rs4628119 0.1465 0.24014 0.20109 0.26923 9 56 119 10 113 124
    rs4664443 0.6898 0.40371 0.35598 0.43927 22 87 75 46 125 76
    rs4688259 0.06631 0.49068 0.51913 0.46951 50 90 43 63 105 78
    rs4688632 0.3819 0.52465 0.49727 0.54527 44 94 45 78 109 56
    rs4695284 0.7943 0.14719 0.17935 0.1259 3 27 62 1 33 105
    rs4700302 1 0.08152 0.05806 0.09859 0 18 137 2 38 173
    rs4702720 0.7438 0.19835 0.16774 0.22115 3 46 106 10 72 126
    rs4702720 0.7438 0.19835 0.16774 0.22115 3 46 106 10 72 126
    rs4711091 0.63 0.47564 0.51359 0.44737 48 93 43 52 117 78
    rs4714484 0.1396 0.17749 0.12772 0.21457 6 35 143 12 82 153
    rs4736802 0.6067 0.37442 0.4375 0.32724 38 85 61 25 111 110
    rs4760785 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760785 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760785 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760894 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760894 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760894 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760895 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760895 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4760895 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs4764738 1 0.49412 0.55801 0.44672 57 88 36 47 124 73
    rs4764738 1 0.49412 0.55801 0.44672 57 88 36 47 124 73
    rs4764974 1 0.49186 0.55163 0.44715 57 89 38 47 126 73
    rs4764974 1 0.49186 0.55163 0.44715 57 89 38 47 126 73
    rs4798366 0.8267 0.33099 0.36264 0.30738 29 74 79 19 112 113
    rs483159 0.6559 0.20694 0.23034 0.18958 7 68 103 9 73 158
    rs4836502 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs4836507 0.8235 0.32151 0.29444 0.34156 19 68 93 26 114 103
    rs4836744 0.1943 0.33566 0.30435 0.35918 17 78 89 25 126 94
    rs4836744 0.1943 0.33566 0.30435 0.35918 17 78 89 25 126 94
    rs4848944 0.6299 0.48028 0.42935 0.51822 30 98 56 72 112 63
    rs4851529 0.5411 0.38399 0.35326 0.40688 28 74 82 32 137 78
    rs4851531 0.4774 0.38488 0.35326 0.40854 28 74 82 32 137 77
    rs4858046 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs4878214 0.6774 0.26531 0.23179 0.29167 8 54 89 14 84 94
    rs4880803 0.9124 0.33017 0.29558 0.35625 13 81 87 32 107 101
    rs489441 0.2387 0.29779 0.35174 0.25847 19 83 70 12 98 126
    rs489441 0.2387 0.29779 0.35174 0.25847 19 83 70 12 98 126
    rs4896568 0.2215 0.2314 0.19022 0.2622 7 56 121 11 107 128
    rs4938851 0.6787 0.2239 0.24728 0.20648 11 69 104 12 78 157
    rs4964416 0.1753 0.48715 0.46961 0.5 41 88 52 53 141 53
    rs5756669 0.7663 0.41763 0.44022 0.40081 32 98 54 45 108 94
    rs6033138 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6033138 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6033138 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040619 0.202 0.34895 0.39946 0.3107 31 85 68 27 97 119
    rs6040619 0.202 0.34895 0.39946 0.3107 31 85 68 27 97 119
    rs6040619 0.202 0.34895 0.39946 0.3107 31 85 68 27 97 119
    rs6040625 0.2386 0.34706 0.39617 0.30992 30 85 68 27 96 119
    rs6040625 0.2386 0.34706 0.39617 0.30992 30 85 68 27 96 119
    rs6040625 0.2386 0.34706 0.39617 0.30992 30 85 68 27 96 119
    rs6040630 0.1692 0.35151 0.39674 0.31781 30 86 68 30 97 120
    rs6040630 0.1692 0.35151 0.39674 0.31781 30 86 68 30 97 120
    rs6040630 0.1692 0.35151 0.39674 0.31781 30 86 68 30 97 120
    rs6040633 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040633 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040633 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040634 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040634 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040634 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040636 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040636 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040636 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040638 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040638 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040638 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040644 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040644 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040644 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6040667 0.09068 0.35246 0.3956 0.32041 30 84 68 31 95 119
    rs6040667 0.09068 0.35246 0.3956 0.32041 30 84 68 31 95 119
    rs6040667 0.09068 0.35246 0.3956 0.32041 30 84 68 31 95 119
    rs6040668 0.1109 0.35545 0.39779 0.32365 30 84 67 31 94 116
    rs6040668 0.1109 0.35545 0.39779 0.32365 30 84 67 31 94 116
    rs6040668 0.1109 0.35545 0.39779 0.32365 30 84 67 31 94 116
    rs6043066 0.8951 0.23898 0.24185 0.23684 7 75 102 18 81 148
    rs6048146 1 0.01624 0.02717 0.0081 0 10 174 0 4 243
    rs6082725 1 0.01624 0.02717 0.0081 0 10 174 0 4 243
    rs6131206 0.1797 0.31585 0.35989 0.2834 25 81 76 24 92 131
    rs6131208 0.1119 0.35198 0.3956 0.31984 30 84 68 31 96 120
    rs6131208 0.1119 0.35198 0.3956 0.31984 30 84 68 31 96 120
    rs6131208 0.1119 0.35198 0.3956 0.31984 30 84 68 31 96 120
    rs6134243 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6134243 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6134243 0.1149 0.35267 0.39674 0.31984 30 86 68 31 96 120
    rs6136020 0.2387 0.14385 0.12228 0.15992 4 37 143 8 63 176
    rs613799 0.3305 0.2814 0.30398 0.26471 15 77 84 22 82 134
    rs644041 0.2323 0.29676 0.34706 0.25974 18 82 70 12 96 123
    rs644041 0.2323 0.29676 0.34706 0.25974 18 82 70 12 96 123
    rs647645 0.5622 0.48372 0.44022 0.51626 29 104 51 68 118 60
    rs647645 0.5622 0.48372 0.44022 0.51626 29 104 51 68 118 60
    rs647645 0.5622 0.48372 0.44022 0.51626 29 104 51 68 118 60
    rs6495554 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs6495554 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs6495555 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs6495555 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs6544728 0.7694 0.20746 0.25 0.17611 7 77 98 10 67 170
    rs6550705 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs6550705 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs6550707 0.03283 0.34651 0.39946 0.30691 34 79 71 28 95 123
    rs658108 0.2786 0.27494 0.29891 0.25709 15 80 89 22 83 142
    rs6593441 0.04333 0.12624 0.16667 0.09471 8 43 126 3 37 187
    rs668732 0.9229 0.46752 0.49728 0.44534 42 99 43 53 114 80
    rs671041 0.3349 0.2761 0.30163 0.25709 15 81 88 22 83 142
    rs6719700 0.00157 0.25243 0.29261 0.22246 10 83 83 4 97 135
    rs6719700 0.00157 0.25243 0.29261 0.22246 10 83 83 4 97 135
    rs6722640 0.4151 0.38399 0.35326 0.40688 28 74 82 31 139 77
    rs6743092 0.9233 0.471 0.51359 0.43927 49 91 44 47 123 77
    rs6743092 0.9233 0.471 0.51359 0.43927 49 91 44 47 123 77
    rs6743092 0.9233 0.471 0.51359 0.43927 49 91 44 47 123 77
    rs6744759 0.9086 0.30425 0.32597 0.28807 23 72 86 17 106 120
    rs6746170 0.7693 0.20941 0.24862 0.18033 7 76 98 10 68 166
    rs6759922 0.7616 0.44737 0.39697 0.48291 28 75 62 50 126 58
    rs6769864 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs6773932 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs6774353 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs6781670 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs6786431 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs6789091 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs6791296 0.6349 0.11836 0.09483 0.13542 2 29 143 2 61 177
    rs6792662 0.06631 0.49068 0.51913 0.46951 50 90 43 63 105 78
    rs6797574 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs6797882 0.03445 0.35563 0.40489 0.31818 34 81 69 30 94 118
    rs6805139 0.2865 0.47897 0.51099 0.45528 47 92 43 57 110 79
    rs6806043 0.02491 0.34535 0.40164 0.30364 34 79 70 28 94 125
    rs6806043 0.02491 0.34535 0.40164 0.30364 34 79 70 28 94 125
    rs6850716 1 0.19838 0.21739 0.18421 12 56 116 5 81 161
    rs6867153 0.3793 0.44509 0.42896 0.45714 26 105 52 54 116 75
    rs687047 0.8081 0.11253 0.09511 0.12551 2 31 151 4 54 189
    rs6871041 0.7349 0.30941 0.28177 0.32992 16 70 95 23 115 106
    rs688358 0.6295 0.11124 0.09116 0.12602 2 29 150 4 54 188
    rs6888012 0.3793 0.44509 0.42896 0.45714 26 105 52 54 116 75
    rs6908481 0.5523 0.41939 0.42857 0.4126 38 80 64 34 135 77
    rs7032231 0.6651 0.3345 0.38251 0.29878 25 90 68 25 97 124
    rs7067638 0.03157 0.11717 0.15489 0.08907 8 41 135 3 38 206
    rs7077799 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs7082163 0.03378 0.1186 0.15847 0.08907 8 42 133 3 38 206
    rs7082163 0.03378 0.1186 0.15847 0.08907 8 42 133 3 38 206
    rs7089661 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs7101319 0.03378 0.1186 0.15847 0.08907 8 42 133 3 38 206
    rs7101319 0.03378 0.1186 0.15847 0.08907 8 42 133 3 38 206
    rs710832 0.1673 0.2587 0.24185 0.27126 4 81 99 19 96 132
    rs710832 0.1673 0.2587 0.24185 0.27126 4 81 99 19 96 132
    rs7134262 0.4064 0.38038 0.39888 0.36667 30 82 66 26 124 90
    rs7134262 0.4064 0.38038 0.39888 0.36667 30 82 66 26 124 90
    rs7134671 0.03787 0.37033 0.4235 0.33061 42 71 70 27 108 110
    rs7138300 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs7138300 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs7138300 0.554 0.42774 0.39071 0.45528 31 81 71 44 136 66
    rs7163931 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7163931 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7171486 1 0.38747 0.33424 0.42713 21 81 82 44 123 80
    rs7172611 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7172611 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7172689 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7172689 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7175701 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs7180245 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7180245 0.8893 0.22274 0.25 0.20243 15 62 107 7 86 154
    rs7220603 0.04531 0.31671 0.2663 0.35425 8 82 94 26 123 98
    rs7282518 0.08335 0.184 0.225 0.15349 12 48 100 6 54 155
    rs7283476 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs7283476 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs7295817 0.9199 0.40281 0.37912 0.42041 28 82 72 42 122 81
    rs7298255 0.4311 0.42674 0.38798 0.45547 30 82 71 44 137 66
    rs7298255 0.4311 0.42674 0.38798 0.45547 30 82 71 44 137 66
    rs7305832 0.471 0.37355 0.3913 0.36032 30 84 70 26 126 95
    rs7305832 0.471 0.37355 0.3913 0.36032 30 84 70 26 126 95
    rs7331467 0.4097 0.37007 0.39674 0.3502 38 70 76 25 123 99
    rs7392620 0.8266 0.33135 0.29558 0.35833 13 81 87 32 108 100
    rs742827 0.1106 0.35461 0.3956 0.32365 30 84 68 31 94 116
    rs742827 0.1106 0.35461 0.3956 0.32365 30 84 68 31 94 116
    rs742827 0.1106 0.35461 0.3956 0.32365 30 84 68 31 94 116
    rs7446891 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs7448641 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7448641 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7484728 0.03857 0.37063 0.4235 0.3313 42 71 70 27 109 110
    rs7499402 0.7458 0.08005 0.09511 0.06883 2 31 151 1 32 214
    rs7529851 0.8387 0.41141 0.35593 0.45319 23 80 74 48 117 70
    rs7529851 0.8387 0.41141 0.35593 0.45319 23 80 74 48 117 70
    rs7573951 0.6898 0.40371 0.35598 0.43927 22 87 75 46 125 76
    rs7599198 0.599 0.42895 0.37742 0.4656 23 71 61 43 117 58
    rs7600050 0.6132 0.42892 0.48295 0.38793 41 88 47 31 118 83
    rs7607712 0.00491 0.25962 0.30114 0.22917 11 84 81 6 98 136
    rs7607712 0.00491 0.25962 0.30114 0.22917 11 84 81 6 98 136
    rs7613492 0.02491 0.34535 0.39946 0.30488 34 79 71 28 94 124
    rs7621663 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs7621663 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs7621663 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs7626584 1 0.04524 0.03261 0.05466 0 12 172 0 27 220
    rs7684899 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs7684899 0.8902 0.2239 0.19565 0.24494 10 52 122 12 97 138
    rs7701604 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7701604 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7703676 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7703676 1 0.0232 0.01087 0.03239 0 4 180 0 16 231
    rs7708491 0.3793 0.44509 0.42896 0.45714 26 105 52 54 116 75
    rs7711358 0.7398 0.32019 0.2962 0.33806 20 69 95 26 115 106
    rs7719448 0.3789 0.44522 0.42935 0.45714 26 106 52 54 116 75
    rs7724761 0.4268 0.439 0.42179 0.45188 24 103 52 52 112 75
    rs7742476 0.6585 0.20952 0.23333 0.19167 9 66 105 11 70 159
    rs7762993 0.2535 0.18097 0.20652 0.16194 4 68 112 6 68 173
    rs7762993 0.2535 0.18097 0.20652 0.16194 4 68 112 6 68 173
    rs7767265 0.6667 0.21513 0.24586 0.19215 9 71 101 12 69 161
    rs7767265 0.6667 0.21513 0.24586 0.19215 9 71 101 12 69 161
    rs7768128 0.4044 0.23219 0.21637 0.24364 7 60 104 18 79 139
    rs7771264 0.1775 0.23318 0.19022 0.26518 7 56 121 11 109 127
    rs7773151 0.1465 0.24014 0.20109 0.26923 9 56 119 10 113 124
    rs7773210 0.1465 0.24014 0.20109 0.26923 9 56 119 10 113 124
    rs7808536 1 0.18531 0.22951 0.15244 7 70 106 7 61 178
    rs7843510 0.6081 0.37471 0.4375 0.32794 38 85 61 25 112 110
    rs7894867 0.03174 0.11744 0.15574 0.08907 8 41 134 3 38 206
    rs7921834 0.4158 0.29419 0.32065 0.27439 18 82 84 23 89 134
    rs7939893 0.6712 0.34455 0.32337 0.36032 21 77 86 28 122 97
    rs7939893 0.6712 0.34455 0.32337 0.36032 21 77 86 28 122 97
    rs7944513 0.8957 0.25 0.28902 0.22152 16 68 89 10 85 142
    rs7944513 0.8957 0.25 0.28902 0.22152 16 68 89 10 85 142
    rs7949720 0.09887 0.12192 0.09281 0.14226 2 27 138 8 52 179
    rs7949720 0.09887 0.12192 0.09281 0.14226 2 27 138 8 52 179
    rs7955901 0.4895 0.42657 0.38736 0.45547 30 81 71 44 137 66
    rs7955901 0.4895 0.42657 0.38736 0.45547 30 81 71 44 137 66
    rs7956274 0.3761 0.42541 0.38859 0.45306 30 83 71 43 136 66
    rs7956274 0.3761 0.42541 0.38859 0.45306 30 83 71 43 136 66
    rs7956274 0.3761 0.42541 0.38859 0.45306 30 83 71 43 136 66
    rs7957932 0.4321 0.4359 0.39946 0.46327 32 83 69 45 137 63
    rs7957932 0.4321 0.4359 0.39946 0.46327 32 83 69 45 137 63
    rs7984504 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs7999518 0.305 0.45065 0.42857 0.46652 24 90 47 49 111 64
    rs8026245 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs8026245 0.7883 0.23202 0.25272 0.2166 16 61 107 8 91 148
    rs8060725 0.774 0.21346 0.19022 0.23077 4 62 118 14 86 147
    rs8103016 0.4503 0.19722 0.23641 0.16802 8 71 105 6 71 170
    rs8103016 0.4503 0.19722 0.23641 0.16802 8 71 105 6 71 170
    rs8104182 0.5407 0.19606 0.23641 0.16599 8 71 105 6 70 171
    rs8104182 0.5407 0.19606 0.23641 0.16599 8 71 105 6 70 171
    rs8129461 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs8129461 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs8130021 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs8130021 0.3657 0.03263 0.02459 0.03862 0 9 174 1 17 228
    rs879961 0.5449 0.27442 0.2377 0.30162 15 57 111 20 109 118
    rs879961 0.5449 0.27442 0.2377 0.30162 15 57 111 20 109 118
    rs906353 0.6452 0.29698 0.26902 0.31781 18 63 103 22 113 112
    rs915491 0.3349 0.2761 0.30163 0.25709 16 79 89 21 85 141
    rs915493 0.3349 0.2761 0.30163 0.25709 16 79 89 21 85 141
    rs915494 0.5983 0.25765 0.28485 0.23789 13 68 84 15 78 134
    rs915494 0.5983 0.25765 0.28485 0.23789 13 68 84 15 78 134
    rs917295 1 0.31585 0.28689 0.3374 18 69 96 25 116 105
    rs9284851 0.03262 0.34859 0.39946 0.30992 34 79 71 28 94 120
    rs9293464 0.3789 0.44522 0.42935 0.45714 26 106 52 54 116 75
    rs9295154 0.274 0.15777 0.19022 0.1336 5 60 119 9 48 190
    rs9310221 1 0.40746 0.41768 0.4 23 91 50 41 98 86
    rs9310699 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs9310700 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs9310700 0.02563 0.34571 0.39946 0.30567 34 79 71 28 95 124
    rs9310701 0.03283 0.34651 0.39946 0.30691 34 79 71 28 95 123
    rs9310704 0.03262 0.34859 0.39946 0.30992 34 79 71 28 94 120
    rs9319185 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs9319186 0.5855 0.32831 0.3587 0.30567 30 72 82 19 113 115
    rs9327555 1 0.31702 0.28962 0.3374 18 70 95 25 116 105
    rs9403367 0.1465 0.24014 0.20109 0.26923 9 56 119 10 113 124
    rs9419608 0.08119 0.48595 0.51381 0.46545 55 76 50 55 119 72
    rs9426437 0.7588 0.38498 0.35714 0.40574 25 80 77 36 126 82
    rs9454967 0.1777 0.05916 0.08152 0.04251 1 28 155 2 17 228
    rs9635511 0.108 0.40281 0.38525 0.41598 28 85 70 33 137 74
    rs966583 0.1622 0.40371 0.35326 0.4413 21 88 75 42 134 71
    rs966583 0.1622 0.40371 0.35326 0.4413 21 88 75 42 134 71
    rs980263 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs980264 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs9812206 0.7864 0.09977 0.06793 0.12348 0 25 159 3 55 189
    rs9812206 0.7864 0.09977 0.06793 0.12348 0 25 159 3 55 189
    rs9813552 0.6016 0.10093 0.07065 0.12348 0 26 158 3 55 189
    rs9813552 0.6016 0.10093 0.07065 0.12348 0 26 158 3 55 189
    rs9815037 0.785 0.09884 0.06522 0.12398 0 24 160 3 55 188
    rs9815037 0.785 0.09884 0.06522 0.12398 0 24 160 3 55 188
    rs9819583 0.04132 0.34107 0.39674 0.2996 33 80 71 27 94 126
    rs9825349 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9825349 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9833118 0.02381 0.34964 0.4073 0.30705 34 77 67 28 92 121
    rs9833118 0.02381 0.34964 0.4073 0.30705 34 77 67 28 92 121
    rs9834217 0.785 0.09884 0.06557 0.12348 0 24 159 3 55 189
    rs9834217 0.785 0.09884 0.06557 0.12348 0 24 159 3 55 189
    rs9838563 0.03283 0.34651 0.39946 0.30691 34 79 71 28 95 123
    rs9840460 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9840460 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9840756 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9840756 0.7849 0.09861 0.06522 0.12348 0 24 160 3 55 189
    rs9847999 0.03262 0.34859 0.39946 0.30992 34 79 71 28 94 120
    rs9864769 0.0334 0.34687 0.39946 0.30769 34 79 71 28 96 123
    rs9866421 0.8452 0.43387 0.44022 0.42915 29 104 51 51 110 86
    rs987296 0.03184 0.3407 0.39674 0.29878 33 80 71 27 93 126
    rs9881685 0.7864 0.09977 0.06793 0.12348 0 25 159 3 55 189
    rs9881685 0.7864 0.09977 0.06793 0.12348 0 25 159 3 55 189
    rs992695 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs992695 0.5472 0.27494 0.23913 0.30162 15 58 111 20 109 118
    rs9936999 0.6862 0.37349 0.42991 0.33099 18 56 33 15 64 63
  • TABLE 16
    ALLELE
    SNP rs # SOURCE (A1) MODEL NMISS OR SE L95 U95 STAT P
    rs77638540 Genotyped T DOM 443 0.3879 0.3691 0.1881 0.7996 −2.566 0.0103
    rs72746987 Genotyped A DOM 443 1.033 0.3495 0.5209 2.05 0.09422 0.9249
    rs10021016 Genotyped G GEN 443 6.477 0.03922
    rs10021016 Genotyped G REC 443 2.482 0.3826 1.172 5.253 2.375 0.01753
    rs10051148 Imputed C DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187
    rs10054055 Imputed T DOM 440 0.5872 0.2006 0.3963 0.8702 −2.653 0.007974
    rs10067895 Imputed A DOM 440 0.577 0.2025 0.388 0.8581 −2.716 0.006612
    rs10100725 Imputed C DOM 443 1.055 0.2111 0.6977 1.596 0.2549 0.7988
    rs10128531 Imputed T ADD 415 1.662 0.2062 1.11 2.49 2.465 0.0137
    rs10181743 Imputed G ADD 417 1.137 0.1442 0.8575 1.509 0.8934 0.3716
    rs10199127 Imputed T DOM 431 1.032 0.2018 0.6945 1.532 0.1537 0.8779
    rs10270624 Imputed G DOM 409 1.374 0.2138 0.904 2.09 1.488 0.1368
    rs1030006 Imputed G REC 434 0.87 0.2356 0.5483 1.381 −0.591 0.5545
    rs1031811 Imputed A REC 434 2.698 0.3294 1.415 5.145 3.013 0.002589
    rs10430870 Genotyped G GEN 443 8.277 0.01594
    rs10430870 Genotyped G REC 443 3.43 0.4334 1.467 8.021 2.84E+00 0.004451
    rs10469597 Imputed A GEN 411 2.673 0.2627
    rs10469597 Imputed A REC 411 1.249 0.4024 0.5677 2.749 0.5528 0.5804
    rs10478919 Imputed G DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs10506623 Imputed C ADD 442 0.7806 0.1427 0.5901 1.033 −1.735 0.08266
    rs10506623 Imputed C DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051
    rs10506626 Imputed A ADD 443 0.7544 0.1415 0.5717 0.9954 −1.992 0.04634
    rs10506626 Imputed A DOM 443 0.6807 0.2015 0.4586 1.01 −1.909 0.05621
    rs10509477 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131
    rs10517918 Imputed G REC 433 0.972 0.2598 0.5841 1.618 −0.1092 0.9131
    rs10517924 Imputed A REC 442 1.079 0.2382 0.6766 1.721 0.3198 0.7491
    rs10519362 Imputed G DOM 434 1.656 0.2162 1.084 2.529 2.333 0.01967
    rs10520072 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs10737390 Imputed T DOM 418 1.128 0.213 0.7431 1.712 0.5659 0.5715
    rs10742851 Imputed T REC 443 1.673 0.3727 0.8057 3.473 1.38 0.1675
    rs10743685 Imputed G GEN 435 1.895 0.3878
    rs10743685 Imputed G REC 435 1.446 0.2691 0.8531 2.45 1.37 0.1708
    rs10749293 Imputed G DOM 441 1.442 0.1947 0.9847 2.113 1.881 0.05998
    rs10749294 Imputed A DOM 443 1.341 0.1934 0.9176 1.959 1.516 0.1296
    rs10753760 Imputed T ADD 423 0.9252 0.1361 0.7085 1.208 −0.5713 0.5678
    rs10753760 Imputed T GEN 423 0.3766 0.8284
    rs10772362 Imputed T ADD 443 0.8356 0.1722 0.5962 1.171 −1.043 0.297
    rs10784891 Imputed C ADD 422 0.7472 0.1404 0.5675 0.9839 −2.076 0.03794
    rs10784891 Imputed C DOM 422 0.7374 0.2125 0.4862 1.118 −1.433 0.1518
    rs10784891 Imputed C GEN 422 4.661 0.09727
    rs10787923 Imputed G DOM 439 1.448 0.1952 0.9878 2.123 1.897 0.05785
    rs10787924 Imputed T DOM 443 1.341 0.1934 0.9176 1.959 1.516 0.1296
    rs10787949 Imputed A DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272
    rs10787951 Imputed G DOM 441 1.349 0.1976 0.9157 1.987 1.514 0.1299
    rs10787983 Imputed C DOM 441 1.351 0.1964 0.9194 1.986 1.532 0.1255
    rs10794733 Imputed C ADD 439 0.6594 0.1519 0.4896 0.888 −2.742 0.006112
    rs10818280 Imputed C DOM 432 0.6208 0.201 0.4186 0.9206 −2.371 0.01772
    rs10860586 Imputed A ADD 431 0.9019 0.1389 0.6869 1.184 −0.7436 0.4571
    rs10860586 Imputed A GEN 431 0.568 0.7528
    rs10870473 Imputed A ADD 177 1.273 0.2526 0.7757 2.088 0.9544 0.3399
    rs10870473 Imputed A DOM 177 1.887 0.3386 0.9717 3.664 1.875 0.06077
    rs10879240 Imputed C ADD 428 0.7296 0.1403 0.5542 0.9605 −2.247 0.02462
    rs10879240 Imputed C GEN 428 5.7 0.05785
    rs10879242 Imputed A ADD 421 0.7715 0.1445 0.5812 1.024 −1.795 0.07269
    rs10879242 Imputed A DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001
    rs10879245 Imputed G ADD 421 0.7715 0.1445 0.5812 1.024 −1.795 0.07269
    rs10879245 Imputed G DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001
    rs10879249 Imputed T ADD 440 0.7823 0.1427 0.5914 1.035 −1.72 0.08541
    rs10879249 Imputed T DOM 440 0.7247 0.2038 0.486 1.081 −1.58 0.1141
    rs10886429 Imputed A DOM 441 1.296 0.1967 0.8811 1.905 1.316 0.1881
    rs10886449 Imputed G DOM 440 1.337 0.1968 0.9089 1.966 1.475 0.1403
    rs10886451 Imputed G DOM 440 1.337 0.1968 0.9089 1.966 1.475 0.1403
    rs10886452 Imputed A DOM 440 1.376 0.1972 0.9349 2.025 1.619 0.1055
    rs10886456 Imputed G DOM 440 1.337 0.1968 0.9089 1.966 1.475 0.1403
    rs10886463 Imputed C DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272
    rs10886465 Imputed A DOM 441 1.355 0.1976 0.9197 1.995 1.536 0.1245
    rs10886526 Imputed C DOM 439 1.364 0.197 0.9275 2.007 1.578 0.1146
    rs10922903 Imputed C REC 440 0.9678 0.2533 0.5891 1.59 −0.1294 0.897
    rs10941126 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs10941126 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs10947980 Imputed G ADD 439 1.004 0.1592 0.7347 1.371 0.0233 0.9814
    rs11059376 Imputed T ADD 401 1.086 0.1953 0.7409 1.593 0.424 0.6716
    rs11072995 Imputed T GEN 439 3.28 0.194
    rs11072995 Imputed T REC 439 2.198 0.4614 0.8897 5.43 1.707 0.08787
    rs11081202 Genotyped G GEN 443 8.643 0.01328
    rs11081202 Genotyped G REC 443 3.218 0.3982 1.475 7.022 2.935 0.003332
    rs110965 Imputed C GEN 420 11.84 0.002689
    rs11124962 Imputed A DOM 437 1.26 0.1969 0.8568 1.854 1.175 0.2401
    rs1116596 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs11178531 Imputed A ADD 439 0.7197 0.1371 0.5501 0.9416 −2.399 0.01643
    rs11178531 Imputed A DOM 439 0.6936 0.2116 0.4581 1.05 −1.729 0.08386
    rs11178583 Imputed A ADD 443 0.7883 0.1424 0.5963 1.042 −1.671 0.09473
    rs11178583 Imputed A DOM 443 0.7338 0.2032 0.4927 1.093 −1.523 0.1277
    rs11178589 Imputed T ADD 437 0.7796 0.1432 0.5888 1.032 −1.739 0.08199
    rs11178589 Imputed T DOM 437 0.7215 0.2047 0.4831 1.078 −1.595 0.1108
    rs11178594 Imputed C ADD 441 0.7716 0.1422 0.584 1.02 −1.824 0.06814
    rs11178594 Imputed C DOM 441 0.7044 0.202 0.4741 1.046 −1.735 0.08274
    rs11178602 Imputed T ADD 439 0.7699 0.1424 0.5824 1.018 −1.836 0.06634
    rs11178602 Imputed T DOM 439 0.7005 0.2027 0.4709 1.042 −1.757 0.079
    rs11178648 Imputed T ADD 440 0.754 0.1419 0.5709 0.9958 −1.99 0.04664
    rs11178648 Imputed T DOM 440 0.6786 0.2027 0.4561 1.01 −1.912 0.05581
    rs11198877 Imputed T DOM 441 1.369 0.1971 0.9302 2.014 1.593 0.1113
    rs11198942 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131
    rs11221075 Imputed A ADD 417 0.4912 0.2448 0.304 0.7936 −2.904 0.003685
    rs11242020 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs11242021 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs11242022 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs11242023 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs1149349 Imputed T DOM 434 1.154 0.221 0.7482 1.779 0.6474 0.5174
    rs1149350 Imputed A ADD 443 0.7733 0.1679 0.5564 1.075 −1.531 0.1258
    rs1149350 Imputed A DOM 443 0.8901 0.2092 0.5906 1.341 −0.5566 0.5778
    rs11576627 Imputed T ADD 441 1.439 0.1975 0.977 2.119 1.842 0.06547
    rs11576627 Imputed T DOM 441 1.57 0.2354 0.9899 2.491 1.917 0.05525
    rs11630050 Imputed G GEN 442 2.296 0.3173
    rs11630050 Imputed G REC 442 1.888 0.4309 0.8114 4.394 1.475 0.1402
    rs11633024 Imputed C GEN 442 2.296 0.3173
    rs11633024 Imputed C REC 442 1.888 0.4309 0.8114 4.394 1.475 0.1402
    rs11636298 Imputed G GEN 443 2.593 0.2734
    rs11636298 Imputed G REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs11637363 Imputed C GEN 420 2.573 0.2762
    rs11637363 Imputed C REC 420 1.982 0.4368 0.842 4.666 1.566 0.1173
    rs11637813 Imputed A GEN 442 2.296 0.3173
    rs11637813 Imputed A REC 442 1.888 0.4309 0.8114 4.394 1.475 0.1402
    rs11638043 Imputed C GEN 420 2.573 0.2762
    rs11638043 Imputed C REC 420 1.982 0.4368 0.842 4.666 1.566 0.1173
    rs11638115 Imputed A GEN 439 3.28 0.194
    rs11638115 Imputed A REC 439 2.198 0.4614 0.8897 5.43 1.707 0.08787
    rs11638444 Imputed C GEN 442 2.07 0.3552
    rs11682946 Imputed A ADD 86 3.591 0.6209 1.063 12.13 2.059 0.03949
    rs11682946 Imputed A DOM 86 3.591 0.6209 1.063 12.13 2.059 0.03949
    rs11717157 Imputed T ADD 442 1.051 0.1481 0.786 1.405 0.3342 0.7382
    rs11717157 Imputed T GEN 442 0.8899 0.6408
    rs11724055 Imputed A DOM 443 0.5373 0.2207 0.3486 0.828 −2.816 0.004869
    rs11743355 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs11743355 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs11746806 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs11746806 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs11746959 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs11746959 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs11749272 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs11839636 Imputed C GEN 441 0.9349 0.6266
    rs11839785 Imputed C GEN 441 0.9349 0.6266
    rs11853619 Imputed C GEN 440 2.44 0.2953
    rs11853619 Imputed C REC 440 1.946 0.4474 0.8098 4.677 1.488 0.1367
    rs11856780 Imputed A GEN 440 2.44 0.2953
    rs11856780 Imputed A REC 440 1.946 0.4474 0.8098 4.677 1.488 0.1367
    rs11901899 Imputed A DOM 426 1.452 0.1995 0.9821 2.147 1.869 0.06157
    rs11903290 Imputed C REC 434 2.698 0.3294 1.415 5.145 3.013 0.002589
    rs11909480 Imputed G ADD 439 0.4305 0.3702 0.2084 0.8894 −2.277 0.02282
    rs11909480 Imputed G DOM 439 0.3714 0.3963 0.1708 0.8077 −2.499 0.01246
    rs11910289 Imputed T ADD 440 1.815 0.2555 1.1 2.995 2.334 0.01959
    rs11910289 Imputed T DOM 440 1.911 0.2846 1.094 3.339 2.276 0.02285
    rs11920375 Genotyped C GEN 443 1.788 0.4089
    rs11926319 Imputed G DOM 443 1.007 0.269 0.5945 1.706 0.02639 0.9789
    rs11933744 Imputed T REC 440 0.8701 0.3394 0.4473 1.692 −0.4099 0.6819
    rs11934919 Imputed C REC 441 0.8636 0.341 0.4426 1.685 −0.43 0.6672
    rs11934957 Imputed C REC 441 0.8636 0.341 0.4426 1.685 −0.43 0.6672
    rs11959206 Imputed A REC 434 1.201 0.2381 0.7533 1.916 0.7701 0.4412
    rs12038613 Imputed C REC 404 0.8998 0.2554 0.5454 1.484 −0.4136 0.6791
    rs12151417 Imputed T DOM 442 1.517 0.199 1.027 2.241 2.095 0.03616
    rs12153185 Imputed T DOM 441 0.5728 0.2023 0.3853 0.8516 −2.754 0.005893
    rs12182651 Imputed T DOM 441 0.9744 0.2621 0.583 1.629 −0.09893 0.9212
    rs12235345 Imputed C DOM 443 1.768 0.3192 0.9457 3.305 1.785 0.07424
    rs12324786 Imputed T GEN 439 3.28 0.194
    rs12324786 Imputed T REC 439 2.198 0.4614 0.8897 5.43 1.707 0.08787
    rs12336958 Imputed G DOM 407 0.7989 0.209 0.5304 1.203 −1.074 0.2826
    rs12407412 Imputed C ADD 441 1.439 0.1975 0.977 2.119 1.842 0.06547
    rs12407412 Imputed C DOM 441 1.57 0.2354 0.9899 2.491 1.917 0.05525
    rs12418971 Imputed C GEN 436 8.323 0.01558
    rs12418971 Imputed C REC 436 3.381 0.4338 1.445 7.911 2.808 0.004979
    rs1241967 Imputed T REC 443 0.6598 0.3096 0.3596 1.211 −1.343 0.1794
    rs12420184 Imputed G DOM 438 1.429 0.2168 0.9343 2.185 1.647 0.09966
    rs12433968 Imputed T DOM 419 1.059 0.1998 0.7158 1.566 0.2862 0.7747
    rs12445477 Imputed A DOM 427 0.7231 0.2709 0.4252 1.23 −1.197 0.2315
    rs12447191 Genotyped T ADD 443 0.7641 0.1931 0.5233 1.116 −1.393 0.1636
    rs12447191 Genotyped T DOM 443 0.6902 0.216 0.452 1.054 −1.716 0.08611
    rs12465349 Imputed A REC 434 1.865 0.2195 1.213 2.867 2.839 0.004525
    rs1247340 Imputed C ADD 441 0.7681 0.1723 0.548 1.077 −1.531 0.1257
    rs1247340 Imputed C DOM 441 0.9041 0.2098 0.5993 1.364 −0.4802 0.6311
    rs1247341 Imputed C ADD 441 0.7805 0.1735 0.5555 1.097 −1.428 0.1532
    rs1247341 Imputed C DOM 441 0.919 0.2102 0.6087 1.387 −0.4021 0.6876
    rs1247343 Imputed C DOM 441 1.064 0.2203 0.6907 1.638 0.2798 0.7797
    rs12509758 Imputed C DOM 436 1.34 0.2022 0.9013 1.991 1.446 0.1481
    rs12515472 Imputed A DOM 443 1.913 0.2164 1.252 2.923 2.997 0.002728
    rs12548906 Imputed G ADD 415 1.763 0.1813 1.236 2.516 3.128 0.00176
    rs12596240 Imputed G DOM 443 0.9009 0.205 0.6028 1.346 −0.509 0.6107
    rs12618781 Imputed A DOM 440 1.082 0.2178 0.7061 1.658 0.3618 0.7175
    rs12678600 Imputed A DOM 439 0.7992 0.198 0.5421 1.178 −1.132 0.2575
    rs12692229 Imputed T ADD 443 1.608 0.1488 1.202 2.153 3.194 0.001404
    rs12713324 Imputed T DOM 443 1.501 0.1987 1.017 2.215 2.043 0.04105
    rs12719415 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs12820589 Imputed G ADD 418 0.882 0.1789 0.6212 1.252 −0.7022 0.4826
    rs12820589 Imputed G DOM 418 0.926 0.2078 0.6162 1.392 −0.3697 0.7116
    rs12831292 Imputed G ADD 436 0.7739 0.1429 0.5848 1.024 −1.794 0.0728
    rs12831292 Imputed G DOM 436 0.7047 0.2039 0.4725 1.051 −1.716 0.08609
    rs13012636 Imputed G REC 433 2.717 0.3295 1.424 5.183 3.034 0.002417
    rs13038146 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs13038146 Imputed C GEN 443 6.692 0.03523
    rs13038146 Imputed C REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs13089860 Imputed A DOM 364 0.5987 0.2307 0.3809 0.941 −2.224 0.02617
    rs13102419 Imputed T REC 439 1.104 0.2389 0.6915 1.764 0.4158 0.6775
    rs13194907 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367
    rs13194907 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923
    rs13195745 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367
    rs13195745 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923
    rs13265054 Imputed T DOM 434 0.7541 0.1998 0.5098 1.116 −1.413 0.1577
    rs13273002 Imputed A GEN 443 0.08764 0.9571
    rs13282131 Imputed C ADD 440 1.295 0.1396 0.9848 1.702 1.85 0.06426
    rs13282131 Imputed C GEN 440 6.641 0.03614
    rs13282131 Imputed C REC 440 1.884 0.247 1.161 3.057 2.564 0.01034
    rs1330052 Imputed G GEN 443 1.596 0.4502
    rs1335721 Imputed A REC 406 0.8982 0.2552 0.5447 1.481 −0.4207 0.674
    rs1336382 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131
    rs1336383 Imputed T DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131
    rs1336407 Imputed T DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs1336409 Imputed T DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs1336596 Imputed A DOM 440 0.9849 0.205 0.659 1.472 −0.07439 0.9407
    rs13387284 Imputed A DOM 408 1.094 0.2214 0.7089 1.689 0.4062 0.6846
    rs13401462 Imputed C DOM 417 0.8697 0.2292 0.555 1.363 −0.609 0.5425
    rs13409045 Imputed T ADD 442 1.009 0.1374 0.7712 1.321 0.06836 0.9455
    rs1349284 Imputed C GEN 443 0.308 0.8573
    rs1355715 Imputed T ADD 442 0.6617 0.3179 0.3549 1.234 −1.299 0.1939
    rs1357696 Imputed A GEN 434 2.08 0.3535
    rs1357698 Imputed A GEN 436 1.977 0.3722
    rs1357699 Imputed T GEN 436 1.977 0.3722
    rs1363273 Imputed C REC 421 0.9417 0.2317 0.598 1.483 −0.2592 0.7955
    rs1373601 Imputed A DOM 404 0.9323 0.2122 0.6151 1.413 −0.3303 0.7412
    rs1375829 Imputed C GEN 443 0.308 0.8573
    rs1395748 Imputed G DOM 441 1.231 0.195 0.8402 1.804 1.067 0.2859
    rs1414865 Imputed T DOM 442 1.352 0.1976 0.9177 1.991 1.525 0.1272
    rs1414873 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs1414876 Imputed C DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs1424643 Imputed G ADD 430 1.447 0.1648 1.048 1.999 2.244 0.02486
    rs1424643 Imputed G DOM 430 1.694 0.2023 1.14 2.518 2.606 0.009171
    rs1424648 Imputed T DOM 438 1.609 0.2007 1.085 2.384 2.368 0.01786
    rs1429321 Imputed A DOM 432 1.519 0.2006 1.025 2.251 2.084 0.03713
    rs1429326 Imputed T ADD 433 1.404 0.1719 1.003 1.967 1.975 0.04831
    rs1429326 Imputed T DOM 433 1.574 0.2049 1.053 2.352 2.213 0.02687
    rs1444741 Imputed A DOM 407 0.9777 0.2088 0.6493 1.472 −0.1082 0.9138
    rs1449916 Imputed C DOM 270 0.7246 0.2903 0.4102 1.28 −1.11 0.2671
    rs1459523 Imputed A ADD 442 1.051 0.1481 0.786 1.405 0.3342 0.7382
    rs1459523 Imputed A GEN 442 0.8899 0.6408
    rs1466352 Imputed T GEN 443 1.33 0.5142
    rs1466353 Imputed G GEN 443 1.33 0.5142
    rs1476714 Imputed A DOM 439 0.5924 0.2025 0.3983 0.8811 −2.585 0.009742
    rs1486723 Imputed C REC 434 0.5711 0.3144 0.3084 1.058 −1.782 0.07477
    rs1495375 Imputed A ADD 421 0.7715 0.1445 0.5812 1.024 −1.795 0.07269
    rs1495375 Imputed A DOM 421 0.7102 0.2081 0.4724 1.068 −1.644 0.1001
    rs1495381 Imputed T GEN 442 7.762 0.02063
    rs1495381 Imputed T REC 442 2.08 0.2834 1.194 3.626 2.584 0.009753
    rs1498061 Imputed C ADD 200 0.6227 0.2741 0.3639 1.066 −1.728 0.084
    rs1498992 Imputed G DOM 428 0.7274 0.1999 0.4916 1.076 −1.592 0.1114
    rs1499001 Imputed T DOM 437 0.7573 0.1974 0.5144 1.115 −1.409 0.159
    rs1512988 Imputed A ADD 442 0.7806 0.1427 0.5901 1.033 −1.735 0.08266
    rs1512988 Imputed A DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051
    rs1512989 Imputed T ADD 442 0.7806 0.1427 0.5901 1.033 −1.735 0.08266
    rs1512989 Imputed T DOM 442 0.7185 0.204 0.4817 1.072 −1.621 0.1051
    rs1512991 Imputed T ADD 425 0.7106 0.1399 0.5401 0.9348 −2.442 0.01462
    rs1512991 Imputed T DOM 425 0.6965 0.2131 0.4587 1.057 −1.698 0.08957
    rs1512991 Imputed T GEN 425 6.384 0.0411
    rs1524303 Imputed T GEN 436 1.005 0.6051
    rs1524306 Imputed C ADD 441 1.05 0.1481 0.7851 1.403 0.3265 0.744
    rs1524306 Imputed C GEN 441 0.8672 0.6482
    rs1524310 Imputed G ADD 438 1.063 0.1488 0.7944 1.424 0.4133 0.6794
    rs1524310 Imputed G GEN 438 0.7768 0.6781
    rs1524321 Imputed C GEN 441 1.192 0.5511
    rs1527059 Imputed A DOM 441 0.4524 0.2645 0.2693 0.7598 −2.999 0.002712
    rs152707 Imputed A ADD 443 1.066 0.1385 0.8128 1.399 0.4637 0.6429
    rs152707 Imputed A GEN 443 0.2887 0.8656
    rs152712 Genotyped C ADD 443 1.066 0.1385 0.8128 1.399 0.4637 0.6429
    rs152712 Genotyped C GEN 443 0.2887 0.8656
    rs1533994 Imputed T GEN 443 1.33 0.5142
    rs1535866 Imputed G DOM 440 1.405 0.2003 0.9487 2.081 1.697 0.08971
    rs1563773 Imputed T GEN 439 1.172 0.5564
    rs1563774 Imputed T GEN 439 1.172 0.5564
    rs1567740 Imputed T ADD 439 0.7805 0.1427 0.59 1.032 −1.736 0.08253
    rs1567740 Imputed T DOM 439 0.7204 0.2038 0.4831 1.074 −1.609 0.1076
    rs1572573 Imputed A DOM 396 1.019 0.2128 0.6715 1.546 0.08849 0.9295
    rs1577497 Imputed C REC 408 0.899 0.2549 0.5455 1.481 −0.418 0.676
    rs1581514 Imputed T ADD 429 1.06 0.1488 0.7919 1.419 0.3912 0.6957
    rs1581514 Imputed T GEN 429 1.004 0.6052
    rs1582321 Imputed T DOM 443 0.9009 0.205 0.6028 1.346 −0.509 0.6107
    rs1582322 Imputed A DOM 438 0.8697 0.2066 0.5801 1.304 −0.6757 0.4992
    rs1582323 Imputed A DOM 437 0.8751 0.2067 0.5836 1.312 −0.6457 0.5185
    rs1592485 Imputed C DOM 443 0.8723 0.2093 0.5787 1.315 −0.653 0.5138
    rs1600954 Imputed T ADD 423 1.193 0.1389 0.909 1.567 1.273 0.203
    rs1600954 Imputed T GEN 423 1.735 0.4199
    rs16938626 Imputed G DOM 435 0.7689 0.1982 0.5213 1.134 −1.326 0.1849
    rs16964300 Imputed G ADD 439 0.7656 0.1898 0.5278 1.111 −1.407 0.1593
    rs16964300 Imputed G DOM 439 0.6717 0.2145 0.4411 1.023 −1.855 0.06358
    rs16986282 Imputed G DOM 442 0.3565 0.3985 0.1632 0.7784 −2.589 0.009634
    rs17007620 Imputed G ADD 408 1.033 0.1717 0.7377 1.446 0.1877 0.8511
    rs17007620 Imputed G DOM 408 1.127 0.206 0.7523 1.687 0.5784 0.563
    rs17014326 Imputed G DOM 441 1.215 0.196 0.8276 1.785 0.9949 0.3198
    rs17047957 Imputed C DOM 439 1.801 0.2129 1.187 2.734 2.765 0.005699
    rs1705261 Imputed A REC 442 2.005 0.2767 1.166 3.449 2.514 0.01192
    rs17073341 Imputed A ADD 441 2.051 0.3685 0.9962 4.224 1.95 0.05123
    rs17073341 Imputed A DOM 441 2.316 0.4002 1.057 5.074 2.098 0.03591
    rs17138702 Imputed G ADD 443 1.127 0.1808 0.7906 1.606 0.6601 0.5092
    rs17189710 Imputed T ADD 430 1.382 0.1457 1.039 1.839 2.22 0.02639
    rs17189710 Imputed T GEN 430 6.752 0.03418
    rs17189710 Imputed T REC 430 2.127 0.2957 1.192 3.797 2.553 0.01069
    rs17310176 Imputed T ADD 443 0.6446 0.1904 0.4438 0.9362 −2.306 0.02109
    rs17310176 Imputed T DOM 443 0.6022 0.2152 0.395 0.9182 −2.357 0.01845
    rs17358860 Imputed A DOM 416 0.5513 0.2173 0.3601 0.844 −2.74 0.006139
    rs17370541 Imputed T GEN 397 0.1403 0.9322
    rs17370541 Imputed T REC 397 1.119 0.3013 0.62 2.02 0.3735 0.7088
    rs17526574 Imputed G GEN 443 0.4224 0.8096
    rs17530747 Imputed T DOM 374 1.033 0.2172 0.6751 1.582 0.1511 0.8799
    rs17649114 Imputed C DOM 440 1.776 0.2066 1.185 2.663 2.781 0.00542
    rs17766172 Imputed A REC 428 0.5776 0.3128 0.3129 1.066 −1.755 0.07928
    rs1818885 Imputed G GEN 443 0.8065 0.6682
    rs1832222 Imputed G DOM 443 1.344 0.1965 0.9144 1.975 1.504 0.1325
    rs1861327 Imputed G DOM 433 0.8914 0.2099 0.5908 1.345 −0.5476 0.584
    rs1868581 Imputed G ADD 436 1.033 0.1486 0.7722 1.383 0.2208 0.8253
    rs1868581 Imputed G GEN 436 0.5916 0.7439
    rs1874313 Imputed A ADD 443 0.7883 0.1424 0.5963 1.042 −1.671 0.09473
    rs1874313 Imputed A DOM 443 0.7338 0.2032 0.4927 1.093 −1.523 0.1277
    rs1876409 Imputed C DOM 443 1.204 0.1943 0.8227 1.762 0.9553 0.3394
    rs1913201 Imputed G ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572
    rs1913201 Imputed G DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546
    rs1913201 Imputed G GEN 432 6.276 0.04338
    rs1916922 Imputed T GEN 435 0.5208 0.7707
    rs1936871 Genotyped G DOM 443 0.7975 0.2097 0.5287 1.203 −1.079 0.2807
    rs1961157 Imputed T REC 442 1.145 0.2401 0.7152 1.833 0.5643 0.5725
    rs1987179 Imputed T ADD 417 0.617 0.1957 0.4205 0.9055 −2.467 0.01361
    rs1987179 Imputed T DOM 417 0.5176 0.2237 0.3339 0.8024 −2.944 0.00324
    rs1990023 Imputed T DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs1995025 Imputed C DOM 433 1.717 0.216 1.124 2.621 2.501 0.01238
    rs2016194 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs2023651 Imputed T ADD 429 1.235 0.1824 0.864 1.766 1.159 0.2466
    rs2024902 Imputed A ADD 442 1.087 0.2583 0.655 1.803 0.3216 0.7477
    rs2024902 Imputed A DOM 442 1.157 0.2804 0.6678 2.005 0.52 0.6031
    rs2025107 Imputed A DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446
    rs2025108 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446
    rs2031987 Imputed T GEN 443 0.4224 0.8096
    rs2052428 Imputed C DOM 427 0.7089 0.2176 0.4628 1.086 −1.581 0.1138
    rs2053230 Imputed C ADD 391 0.8193 0.2084 0.5446 1.233 −0.9565 0.3388
    rs2062448 Imputed T DOM 442 0.913 0.2688 0.5391 1.546 −0.3387 0.7348
    rs2063420 Imputed C REC 442 0.8647 0.2574 0.5221 1.432 −0.5649 0.5721
    rs2063591 Imputed C ADD 441 0.7255 0.1363 0.5554 0.9478 −2.353 0.01861
    rs2063591 Imputed C DOM 441 0.6936 0.2125 0.4573 1.052 −1.722 0.08515
    rs208026 Genotyped A DOM 443 1.559 0.1973 1.059 2.295 2.25 0.02446
    rs208029 Imputed T DOM 422 1.924 0.2083 1.279 2.894 3.142 0.001679
    rs208757 Imputed G DOM 435 1.858 0.2057 1.241 2.78 3.011 0.002601
    rs2095586 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs2095606 Imputed A DOM 436 0.9481 0.2038 0.6359 1.414 −0.2614 0.7938
    rs2102374 Imputed A ADD 437 1.135 0.1587 0.8318 1.549 0.7991 0.4242
    rs2102374 Imputed A DOM 437 1.187 0.1949 0.8099 1.739 0.8784 0.3797
    rs2108426 Imputed C DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs2110664 Imputed A DOM 399 1.47 0.2058 0.9818 2.2 1.871 0.06136
    rs2132242 Imputed A ADD 440 0.7679 0.1423 0.5811 1.015 −1.856 0.06344
    rs2132242 Imputed A DOM 440 0.6978 0.2022 0.4695 1.037 −1.78 0.07505
    rs2158958 Imputed A DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs2158961 Imputed G DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187
    rs2163046 Imputed A DOM 436 1.529 0.2 1.033 2.263 2.124 0.03363
    rs2180286 Imputed G DOM 443 0.587 0.2201 0.3813 0.9037 −2.42 0.01553
    rs2180684 Imputed A DOM 433 1.876 0.2393 1.174 2.999 2.629 0.00857
    rs2188079 Imputed C ADD 443 1.028 0.1399 0.7818 1.353 0.2006 0.841
    rs2188079 Imputed C GEN 443 1.2 0.5489
    rs2190598 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs2190600 Imputed A DOM 440 0.577 0.2025 0.388 0.8581 −2.716 0.006612
    rs2224184 Genotyped T DOM 443 0.587 0.2201 0.3813 0.9037 −2.42 0.01553
    rs2247066 Imputed A DOM 441 1.231 0.195 0.8402 1.804 1.067 0.2859
    rs2248236 Imputed C ADD 443 0.6625 0.1753 0.4699 0.9342 −2.348 0.01888
    rs2248236 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.002602
    rs2265733 Imputed C ADD 437 1.135 0.1587 0.8318 1.549 0.7991 0.4242
    rs2265733 Imputed C DOM 437 1.187 0.1949 0.8099 1.739 0.8784 0.3797
    rs2270584 Imputed A ADD 441 0.7517 0.1419 0.5692 0.9927 −2.011 0.04429
    rs2270584 Imputed A DOM 441 0.6747 0.2026 0.4536 1.004 −1.942 0.05211
    rs2270586 Imputed A ADD 442 0.7586 0.1416 0.5748 1.001 −1.952 0.05099
    rs2270586 Imputed A DOM 442 0.6883 0.2018 0.4634 1.022 −1.851 0.06423
    rs229775 Imputed A REC 443 0.6598 0.3096 0.3596 1.211 −1.343 0.1794
    rs229815 Imputed T REC 432 0.6306 0.295 0.3537 1.124 −1.563 0.1181
    rs229829 Imputed C REC 413 0.5855 0.2981 0.3264 1.05 −1.795 0.07258
    rs229831 Imputed A REC 441 0.6194 0.315 0.3341 1.148 −1.521 0.1283
    rs2317057 Imputed T ADD 368 0.5936 0.1943 0.4056 0.8687 −2.685 0.007256
    rs2322100 Genotyped T REC 443 2.61 0.3935 1.207 5.644 2.438 0.01477
    rs2322101 Imputed A REC 440 2.67 0.3944 1.233 5.784 2.491 0.01275
    rs2327929 Imputed G REC 441 1.411 0.2475 0.8684 2.291 1.39 0.1645
    rs2332844 Imputed A ADD 282 1.301 0.2435 0.807 2.096 1.079 0.2804
    rs2332844 Imputed A REC 282 1.427 0.2711 0.8386 2.427 1.311 0.19
    rs2349170 Imputed G DOM 443 1.414 0.198 0.9594 2.085 1.751 0.07997
    rs2356722 Imputed G DOM 443 1.255 0.1956 0.8553 1.841 1.161 0.2457
    rs2364956 Imputed T ADD 415 1.168 0.1854 0.8122 1.68 0.838 0.402
    rs2373793 Imputed G ADD 435 1.56 0.1996 1.055 2.307 2.227 0.02596
    rs2373793 Imputed G DOM 435 1.599 0.2233 1.032 2.477 2.103 0.03546
    rs238252 Imputed G ADD 434 1.155 0.2029 0.7763 1.72 0.712 0.4765
    rs238252 Imputed G DOM 434 1.191 0.2236 0.7681 1.846 0.7803 0.4352
    rs2383903 Imputed G DOM 443 0.7568 0.1968 0.5146 1.113 −1.416 0.1569
    rs2387945 Imputed G DOM 436 1.747 0.2151 1.146 2.663 2.593 0.009513
    rs2389863 Imputed A DOM 432 0.5655 0.2068 0.377 0.8481 −2.756 0.005845
    rs2389866 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.002602
    rs2389869 Imputed C DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.002602
    rs2389870 Genotyped C DOM 443 0.5285 0.2176 0.345 0.8096 −2.931 0.003382
    rs2418494 Imputed G ADD 423 0.6959 0.1462 0.5225 0.9268 −2.48 0.01314
    rs2418494 Imputed G GEN 423 6.342 0.04195
    rs2418541 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs2418542 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs2423556 Imputed C DOM 433 0.5931 0.2244 0.382 0.9206 −2.328 0.01989
    rs2437688 Imputed C ADD 443 2.041 0.2367 1.284 3.247 3.014 0.002576
    rs2456809 Imputed G DOM 438 1.173 0.1954 0.7998 1.721 0.8168 0.414
    rs2456811 Imputed T ADD 436 1.146 0.1589 0.8394 1.565 0.8588 0.3905
    rs2456811 Imputed T DOM 436 1.202 0.1953 0.8198 1.763 0.9425 0.346
    rs2476976 Imputed C DOM 442 1.391 0.1963 0.9466 2.044 1.68 0.09288
    rs2484911 Imputed A DOM 443 1.347 0.1959 0.9174 1.977 1.52 0.1285
    rs2488557 Imputed C DOM 431 0.924 0.2286 0.5904 1.446 −0.3457 0.7296
    rs250162 Imputed C ADD 429 0.6714 0.1771 0.4745 0.9501 −2.249 0.02451
    rs250162 Imputed C DOM 429 0.6417 0.2018 0.4321 0.953 −2.199 0.02791
    rs2560708 Imputed T ADD 436 0.7416 0.1846 0.5164 1.065 −1.619 0.1054
    rs2617841 Imputed G DOM 412 0.7326 0.2034 0.4917 1.092 −1.53 0.1261
    rs2622499 Imputed G DOM 443 0.5404 0.2044 0.362 0.8067 −3.011 0.002602
    rs264129 Imputed T DOM 443 0.6399 0.1948 0.4368 0.9373 −2.293 0.02187
    rs2642936 Imputed T ADD 428 0.9768 0.1833 0.682 1.399 −0.1281 0.8981
    rs2660633 Imputed A DOM 443 1.204 0.1943 0.8227 1.762 0.9553 0.3394
    rs2660634 Imputed C DOM 443 1.204 0.1943 0.8227 1.762 0.9553 0.3394
    rs2660648 Imputed A ADD 437 1.135 0.1587 0.8318 1.549 0.7991 0.4242
    rs2660648 Imputed A DOM 437 1.187 0.1949 0.8099 1.739 0.8784 0.3797
    rs2681505 Imputed T ADD 443 0.8499 0.1719 0.6068 1.19 −0.9458 0.3442
    rs277411 Imputed G DOM 442 1.109 0.3436 0.5658 2.175 0.3022 0.7625
    rs2832634 Imputed G ADD 442 1.764 0.2529 1.075 2.896 2.245 0.02478
    rs2832637 Imputed T ADD 442 1.764 0.2529 1.075 2.896 2.245 0.02478
    rs2843167 Imputed A DOM 442 1.111 0.1972 0.7547 1.635 0.5327 0.5943
    rs2876227 Imputed C ADD 442 1.389 0.1445 1.046 1.843 2.272 0.02309
    rs2876227 Imputed C GEN 442 6.593 0.03701
    rs2882097 Imputed A DOM 443 1.364 0.1959 0.9291 2.003 1.584 0.1131
    rs2909862 Imputed G DOM 416 1.083 0.2178 0.7067 1.659 0.3656 0.7146
    rs3001945 Imputed T DOM 435 1.72 0.2156 1.127 2.625 2.515 0.0119
    rs3011020 Imputed C DOM 436 1.747 0.2151 1.146 2.663 2.593 0.009513
    rs36071725 Genotyped C ADD 443 0.9696 0.1509 0.7214 1.303 −0.2047 0.8378
    rs36071725 Genotyped C GEN 443 0.6419 0.7255
    rs373983 Imputed G DOM 414 1.954 0.2168 1.277 2.988 3.089 0.002005
    rs3743794 Imputed G DOM 434 0.8871 0.2078 0.5903 1.333 −0.5765 0.5643
    rs3756154 Imputed C ADD 416 0.6137 0.1939 0.4196 0.8975 −2.518 0.01182
    rs3756154 Imputed C DOM 416 0.5162 0.2209 0.3348 0.7959 −2.993 0.00276
    rs3775850 Imputed A DOM 443 0.5373 0.2207 0.3486 0.828 −2.816 0.004869
    rs3775851 Imputed C DOM 443 0.5373 0.2207 0.3486 0.828 −2.816 0.004869
    rs3793044 Imputed C ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367
    rs3793044 Imputed C DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923
    rs3793053 Imputed C DOM 436 0.9919 0.2675 0.5872 1.676 −0.03035 0.9758
    rs3796246 Imputed G DOM 442 0.9829 0.2682 0.5811 1.663 −0.06425 0.9488
    rs3806003 Imputed A ADD 443 1.091 0.2583 0.6574 1.81 0.3362 0.7367
    rs3806003 Imputed A DOM 443 1.162 0.2804 0.6707 2.013 0.5355 0.5923
    rs3806004 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446
    rs3806010 Imputed T DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446
    rs3806014 Imputed T DOM 430 1.002 0.2658 0.5954 1.688 0.00889 0.9929
    rs3806015 Imputed A DOM 426 0.9945 0.2663 0.5902 1.676 −0.02059 0.9836
    rs3806018 Imputed A DOM 442 0.982 0.2619 0.5877 1.641 −0.06944 0.9446
    rs3806019 Imputed A DOM 438 0.9676 0.2625 0.5784 1.619 −0.1255 0.9001
    rs3806024 Imputed T DOM 442 1.001 0.2605 0.601 1.669 0.00521 0.9958
    rs3915080 Imputed A GEN 436 1.977 0.3722
    rs3942254 Imputed T ADD 420 0.7577 0.1442 0.5712 1.005 −1.925 0.05425
    rs3942254 Imputed T DOM 420 0.6591 0.2081 0.4383 0.991 −2.004 0.04512
    rs3945085 Imputed A DOM 441 1.324 0.1969 0.9003 1.948 1.427 0.1537
    rs3976737 Imputed G ADD 377 1.239 0.1939 0.8469 1.811 1.103 0.27
    rs399485 Imputed A DOM 437 1.648 0.1968 1.12 2.423 2.538 0.01116
    rs4029119 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs4029119 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs4076201 Imputed G GEN 420 2.573 0.2762
    rs4076201 Imputed G REC 420 1.982 0.4368 0.842 4.666 1.566 0.1173
    rs41395945 Imputed G ADD 441 1.822 0.2555 1.104 3.006 2.348 0.01887
    rs41395945 Imputed G DOM 441 1.919 0.2846 1.099 3.352 2.29 0.022
    rs4146972 Genotyped T DOM 443 1.832 0.2123 1.208 2.777 2.851 0.004361
    rs4238087 Imputed G DOM 402 0.5579 0.251 0.3411 0.9125 −2.325 0.02009
    rs4251569 Imputed T ADD 441 0.645 0.2176 0.4211 0.9882 −2.015 0.04394
    rs4251569 Imputed T DOM 441 0.5571 0.243 0.346 0.897 −2.407 0.01607
    rs4273613 Imputed T ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs4273613 Imputed T DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs4291049 Imputed T REC 432 1.16 0.2386 0.727 1.852 0.6237 0.5328
    rs4315598 Imputed T ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs4315598 Imputed T GEN 443 6.692 0.03523
    rs4315598 Imputed T REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs4321395 Imputed A DOM 408 1.094 0.2214 0.7089 1.689 0.4062 0.6846
    rs4321596 Genotyped T REC 443 2.583 0.4532 1.063 6.278 2.094 0.03627
    rs4324417 Imputed T DOM 443 1.061 0.217 0.6932 1.623 0.2716 0.7859
    rs4328619 Genotyped G DOM 443 0.5613 0.2195 0.365 0.8631 −2.631 0.008525
    rs4338909 Imputed T ADD 440 0.998 0.1323 0.7701 1.293 −0.01507 0.988
    rs4370878 Imputed G DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682
    rs4379434 Genotyped T DOM 443 0.9929 0.2031 0.6669 1.478 −0.03512 0.972
    rs4416407 Imputed T DOM 437 1.387 0.2325 0.8796 2.188 1.408 0.1591
    rs4417899 Imputed C REC 437 0.7208 0.2325 0.457 1.137 −1.408 0.1591
    rs4442732 Imputed A ADD 335 0.9155 0.1782 0.6456 1.298 −0.4952 0.6205
    rs4444612 Imputed G ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs4444612 Imputed G GEN 443 6.692 0.03523
    rs4444612 Imputed G REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs4450660 Imputed C DOM 438 1.275 0.1965 0.8675 1.874 1.236 0.2163
    rs4509702 Imputed C DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682
    rs4526920 Imputed G GEN 443 0.4224 0.8096
    rs4533145 Imputed T DOM 441 1.764 0.2281 1.128 2.759 2.489 0.0128
    rs4557006 Imputed A DOM 401 1.096 0.2227 0.7085 1.696 0.4124 0.6801
    rs4570530 Imputed C DOM 440 1.312 0.1971 0.8916 1.931 1.378 0.1682
    rs4615971 Imputed C DOM 440 1.347 0.1965 0.9164 1.98 1.516 0.1296
    rs4628119 Imputed A DOM 442 1.055 0.1992 0.7139 1.559 0.268 0.7887
    rs4664443 Imputed G ADD 442 1.009 0.1374 0.7712 1.321 0.06836 0.9455
    rs4688259 Imputed T DOM 438 1.386 0.2325 0.8791 2.187 1.405 0.1599
    rs4688632 Imputed G REC 429 0.6822 0.2335 0.4316 1.078 −1.638 0.1014
    rs4695284 Imputed A ADD 194 1.444 0.3862 0.6775 3.079 0.9518 0.3412
    rs4700302 Imputed A ADD 399 1.136 0.2485 0.6982 1.85 0.5147 0.6067
    rs4702720 Imputed A ADD 359 0.757 0.1808 0.5311 1.079 −1.54 0.1236
    rs4702720 Imputed A DOM 359 0.6462 0.2205 0.4194 0.9956 −1.98 0.04769
    rs4711091 Genotyped G GEN 443 1.334 0.5133
    rs4714484 Imputed A ADD 439 0.8396 0.1992 0.5682 1.241 −0.8775 0.3802
    rs4736802 Imputed G DOM 442 0.9844 0.2032 0.661 1.466 −0.07725 0.9384
    rs4760785 Imputed A ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572
    rs4760785 Imputed A DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546
    rs4760785 Imputed A GEN 432 6.276 0.04338
    rs4760894 Imputed T ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572
    rs4760894 Imputed T DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546
    rs4760894 Imputed T GEN 432 6.276 0.04338
    rs4760895 Imputed A ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572
    rs4760895 Imputed A DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546
    rs4760895 Imputed A GEN 432 6.276 0.04338
    rs4764738 Imputed A ADD 430 0.9549 0.142 0.723 1.261 −0.3248 0.7454
    rs4764738 Imputed A GEN 430 0.6545 0.7209
    rs4764974 Imputed T ADD 431 0.9019 0.1389 0.6869 1.184 −0.7436 0.4571
    rs4764974 Imputed T GEN 431 0.568 0.7528
    rs4798366 Imputed G REC 429 2.754 0.3596 1.361 5.574 2.817 0.004844
    rs483159 Imputed T DOM 386 1.953 0.219 1.271 2.999 3.056 0.002245
    rs4836502 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs4836507 Imputed C DOM 442 0.5803 0.2019 0.3906 0.862 −2.696 0.007028
    rs4836744 Imputed A ADD 443 0.7176 0.155 0.5296 0.9724 −2.141 0.03229
    rs4836744 Imputed A DOM 443 0.6515 0.1952 0.4444 0.9552 −2.195 0.02818
    rs4848944 Genotyped C REC 443 0.7027 0.2417 0.4375 1.128 −1.46 0.1443
    rs4851529 Imputed A DOM 442 0.6342 0.203 0.426 0.944 −2.244 0.02485
    rs4851531 Imputed T DOM 442 0.6071 0.2055 0.4058 0.9082 −2.428 0.01517
    rs4858046 Genotyped T GEN 443 1.33 0.5142
    rs4878214 Imputed A ADD 261 0.7554 0.1893 0.5212 1.095 −1.481 0.1385
    rs4880803 Imputed A ADD 439 0.6594 0.1519 0.4896 0.888 −2.742 0.006112
    rs489441 Imputed G ADD 409 1.224 0.1644 0.8866 1.689 1.228 0.2195
    rs489441 Imputed G DOM 409 1.384 0.2043 0.9276 2.066 1.592 0.1114
    rs4896568 Imputed T DOM 410 1.056 0.2054 0.7057 1.579 0.2631 0.7925
    rs4938851 Imputed T DOM 443 1.781 0.2035 1.195 2.654 2.835 0.004584
    rs4964416 Imputed C DOM 443 0.6905 0.2178 0.4506 1.058 −1.701 0.08902
    rs5756669 Imputed C DOM 443 1.061 0.217 0.6932 1.623 0.2716 0.7859
    rs6033138 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs6033138 Imputed C GEN 443 6.692 0.03523
    rs6033138 Imputed C REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs6040619 Imputed C ADD 439 1.429 0.1436 1.079 1.894 2.487 0.01287
    rs6040619 Imputed C GEN 439 7.276 0.02631
    rs6040619 Imputed C REC 439 2.094 0.2899 1.186 3.695 2.549 0.01081
    rs6040625 Imputed T ADD 442 1.414 0.1431 1.068 1.871 2.419 0.01557
    rs6040625 Imputed T GEN 442 6.967 0.0307
    rs6040625 Imputed T REC 442 2.067 0.2898 1.171 3.646 2.505 0.01224
    rs6040630 Imputed A ADD 441 1.401 0.1436 1.058 1.857 2.349 0.01881
    rs6040630 Imputed A GEN 441 6.767 0.03392
    rs6040630 Imputed A REC 441 2.062 0.2897 1.168 3.637 2.497 0.01252
    rs6040633 Imputed A ADD 442 1.391 0.1433 1.05 1.842 2.302 0.02133
    rs6040633 Imputed A GEN 442 6.683 0.03539
    rs6040633 Imputed A REC 442 2.063 0.2897 1.169 3.641 2.5 0.01242
    rs6040634 Imputed T ADD 441 1.404 0.1433 1.06 1.859 2.368 0.01791
    rs6040634 Imputed T GEN 441 6.855 0.03246
    rs6040634 Imputed T REC 441 2.069 0.2898 1.173 3.652 2.509 0.0121
    rs6040636 Imputed T ADD 443 1.371 0.1435 1.034 1.816 2.196 0.0281
    rs6040636 Imputed T GEN 443 6.529 0.03821
    rs6040636 Imputed T REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs6040638 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs6040638 Imputed C GEN 443 6.692 0.03523
    rs6040638 Imputed C REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs6040644 Imputed A ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs6040644 Imputed A GEN 443 6.692 0.03523
    rs6040644 Imputed A REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs6040667 Imputed T ADD 424 1.422 0.1447 1.071 1.888 2.432 0.01502
    rs6040667 Imputed T GEN 424 7.201 0.02731
    rs6040667 Imputed T REC 424 2.108 0.2894 1.195 3.717 2.576 0.009982
    rs6040668 Imputed C ADD 440 1.398 0.1448 1.053 1.857 2.314 0.02064
    rs6040668 Imputed C GEN 440 6.796 0.03345
    rs6040668 Imputed C REC 440 2.097 0.2944 1.178 3.735 2.516 0.01186
    rs6043066 Genotyped G DOM 443 1.485 0.2038 0.9963 2.215 1.942 0.05215
    rs6048146 Imputed G DOM 443 2.548 0.4417 1.072 6.055 2.117 0.03423
    rs6082725 Genotyped T DOM 443 2.548 0.4417 1.072 6.055 2.117 0.03423
    rs6131206 Imputed C ADD 424 1.493 0.1554 1.101 2.025 2.581 0.009855
    rs6131208 Imputed T ADD 440 1.387 0.1445 1.045 1.841 2.263 0.02364
    rs6131208 Imputed T GEN 440 6.748 0.03426
    rs6131208 Imputed T REC 440 2.109 0.2945 1.184 3.756 2.534 0.01129
    rs6134243 Imputed C ADD 443 1.389 0.1433 1.049 1.839 2.291 0.02197
    rs6134243 Imputed C GEN 443 6.692 0.03523
    rs6134243 Imputed C REC 443 2.069 0.2898 1.172 3.65 2.508 0.01214
    rs6136020 Imputed A DOM 441 1.061 0.2134 0.6982 1.612 0.2765 0.7822
    rs613799 Imputed C DOM 420 1.391 0.2013 0.9378 2.065 1.641 0.1008
    rs644041 Imputed G ADD 402 1.202 0.1659 0.8685 1.664 1.111 0.2667
    rs644041 Imputed G DOM 402 1.351 0.2068 0.9007 2.026 1.454 0.1459
    rs647645 Imputed C ADD 441 0.9195 0.1447 0.6925 1.221 −0.5801 0.5619
    rs647645 Imputed C GEN 441 2.764 0.2511
    rs647645 Imputed C REC 441 1.143 0.2499 0.7005 1.866 0.5357 0.5922
    rs6495554 Imputed C GEN 443 2.593 0.2734
    rs6495554 Imputed C REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs6495555 Imputed C GEN 443 2.593 0.2734
    rs6495555 Imputed C REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs6544728 Imputed T DOM 439 1.333 0.197 0.9058 1.961 1.458 0.1448
    rs6550705 Imputed C ADD 443 1.048 0.1481 0.7837 1.401 0.3148 0.7529
    rs6550705 Imputed C GEN 443 0.8065 0.6682
    rs6550707 Imputed T GEN 442 1.263 0.5317
    rs658108 Imputed A DOM 443 1.347 0.1959 0.9174 1.977 1.52 0.1285
    rs6593441 Imputed A DOM 412 1.402 0.2318 0.89 2.208 1.457 0.1451
    rs668732 Imputed A DOM 442 0.9925 0.2194 0.6457 1.526 −0.0343 0.9726
    rs671041 Imputed A DOM 443 1.347 0.1959 0.9174 1.977 1.52 0.1285
    rs6719700 Imputed A ADD 434 1.378 0.1747 0.9785 1.941 1.836 0.06643
    rs6719700 Imputed A DOM 434 1.551 0.207 1.034 2.327 2.121 0.03391
    rs6722640 Imputed T DOM 441 0.5987 0.207 0.399 0.8983 −2.478 0.01322
    rs6743092 Imputed T ADD 434 1.239 0.1411 0.9401 1.634 1.522 0.128
    rs6743092 Imputed T GEN 434 9.618 0.008155
    rs6743092 Imputed T REC 434 1.9 0.2284 1.214 2.973 2.809 0.004962
    rs6744759 Imputed G REC 436 2.691 0.3293 1.411 5.132 3.006 0.002648
    rs6746170 Imputed A DOM 442 1.346 0.196 0.9168 1.977 1.517 0.1293
    rs6759922 Imputed A DOM 408 1.094 0.2214 0.7089 1.689 0.4062 0.6846
    rs6769864 Imputed T GEN 436 1.045 0.5932
    rs6773932 Imputed C GEN 436 1.977 0.3722
    rs6774353 Imputed A GEN 443 0.8065 0.6682
    rs6781670 Imputed C GEN 443 0.308 0.8573
    rs6786431 Imputed A GEN 436 1.977 0.3722
    rs6789091 Imputed T GEN 436 1.977 0.3722
    rs6791296 Imputed T ADD 426 0.6456 0.2242 0.416 1.002 −1.952 0.05092
    rs6792662 Imputed G DOM 434 1.389 0.2326 0.8802 2.191 1.411 0.1581
    rs6797574 Imputed G GEN 436 1.977 0.3722
    rs6797882 Imputed G GEN 436 1.977 0.3722
    rs6805139 Imputed G DOM 442 1.417 0.2237 0.9138 2.197 1.557 0.1194
    rs6806043 Imputed C ADD 441 1.05 0.1481 0.7851 1.403 0.3265 0.744
    rs6806043 Imputed C GEN 441 0.8672 0.6482
    rs6850716 Imputed C GEN 443 1.373 0.5034
    rs6867153 Imputed A REC 434 1.201 0.2381 0.7533 1.916 0.7701 0.4412
    rs687047 Imputed C ADD 443 0.5642 0.2311 0.3587 0.8876 −2.476 0.01329
    rs6871041 Imputed G DOM 418 0.6503 0.2006 0.4389 0.9635 −2.145 0.03192
    rs688358 Imputed A ADD 427 0.5756 0.2319 0.3653 0.9068 −2.382 0.01723
    rs6888012 Imputed A REC 432 1.203 0.2383 0.7542 1.919 0.7764 0.4375
    rs6908481 Imputed C REC 400 1.391 0.2704 0.8186 2.363 1.22 0.2226
    rs7032231 Imputed A ADD 423 1.514 0.148 1.133 2.023 2.802 0.005072
    rs7067638 Imputed T DOM 442 1.413 0.2274 0.905 2.207 1.521 0.1283
    rs7077799 Imputed A DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs7082163 Imputed A ADD 440 1.236 0.2162 0.809 1.888 0.9797 0.3273
    rs7082163 Imputed A DOM 440 1.386 0.2298 0.8837 2.175 1.422 0.1551
    rs7089661 Imputed C DOM 442 1.347 0.1964 0.9168 1.98 1.518 0.129
    rs7101319 Imputed C ADD 431 1.259 0.2167 0.8235 1.926 1.064 0.2873
    rs7101319 Imputed C DOM 431 1.425 0.2303 0.9076 2.239 1.539 0.1238
    rs710832 Genotyped A GEN 443 3.803 0.1494
    rs710832 Genotyped A REC 443 0.4518 0.4871 0.1739 1.174 −1.631 0.1029
    rs7134262 Imputed T GEN 438 5.456 0.06536
    rs7134262 Imputed T REC 438 1.986 0.3091 1.084 3.641 2.22 0.02641
    rs7134671 Imputed T GEN 443 1.45 0.4843
    rs7138300 Imputed C ADD 432 0.7137 0.1396 0.5429 0.9384 −2.415 0.01572
    rs7138300 Imputed C DOM 432 0.7026 0.2117 0.464 1.064 −1.667 0.09546
    rs7138300 Imputed C GEN 432 6.276 0.04338
    rs7163931 Imputed G GEN 443 2.593 0.2734
    rs7163931 Imputed G REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs7171486 Genotyped G DOM 443 0.591 0.1997 0.3996 0.8741 −2.634 0.008445
    rs7172611 Imputed G GEN 443 2.593 0.2734
    rs7172611 Imputed G REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs7172689 Imputed T GEN 443 2.593 0.2734
    rs7172689 Imputed T REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs7175701 Imputed C GEN 440 2.427 0.2972
    rs7180245 Imputed A GEN 443 2.593 0.2734
    rs7180245 Imputed A REC 443 1.965 0.4472 0.8177 4.72 1.51 0.1311
    rs7220603 Genotyped A ADD 443 1.419 0.1547 1.048 1.921 2.261 0.02374
    rs7282518 Imputed T ADD 387 1.054 0.205 0.7055 1.576 0.2585 0.796
    rs7283476 Imputed T ADD 441 0.413 0.3729 0.1989 0.8579 −2.371 0.01774
    rs7283476 Imputed T DOM 441 0.3545 0.3985 0.1623 0.7741 −2.602 0.009257
    rs7295817 Imputed C GEN 424 6.629 0.03635
    rs7298255 Imputed A ADD 443 0.7433 0.1356 0.5699 0.9696 −2.188 0.02869
    rs7298255 Imputed A DOM 443 0.74 0.2089 0.4914 1.114 −1.442 0.1493
    rs7305832 Imputed C GEN 442 5.607 0.06061
    rs7305832 Imputed C REC 442 2.008 0.3089 1.096 3.678 2.256 0.02404
    rs7331467 Imputed A GEN 443 1.596 0.4502
    rs7392620 Imputed C ADD 437 0.6521 0.1533 0.4829 0.8807 −2.789 0.005287
    rs742827 Imputed A ADD 437 1.396 0.145 1.051 1.855 2.3 0.02146
    rs742827 Imputed A GEN 437 6.499 0.03879
    rs742827 Imputed A REC 437 2.051 0.2943 1.152 3.652 2.441 0.01464
    rs7446891 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs7448641 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs7448641 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs7484728 Imputed T GEN 443 1.45 0.4843
    rs7499402 Genotyped A ADD 443 2.08 0.2847 1.191 3.634 2.573 0.01008
    rs7529851 Imputed A ADD 401 0.7324 0.1517 0.544 0.986 −2.053 0.04006
    rs7529851 Imputed A GEN 401 4.232 0.1205
    rs7573951 Imputed G ADD 442 1.009 0.1374 0.7712 1.321 0.06836 0.9455
    rs7599198 Imputed T DOM 371 0.9895 0.2386 0.6199 1.579 −0.04427 0.9647
    rs7600050 Imputed C ADD 416 1.316 0.1481 0.9845 1.759 1.855 0.06365
    rs7607712 Imputed T ADD 441 1.357 0.1708 0.9708 1.897 1.787 0.074
    rs7607712 Imputed T DOM 441 1.496 0.2035 1.004 2.23 1.98 0.04765
    rs7613492 Imputed G GEN 443 0.8065 0.6682
    rs7621663 Imputed G ADD 443 1.048 0.1481 0.7837 1.401 0.3148 0.7529
    rs7621663 Imputed G GEN 443 0.8065 0.6682
    rs7621663 Imputed G REC 443 0.8874 0.3167 0.4771 1.651 −0.3773 0.706
    rs7626584 Imputed G ADD 442 0.6617 0.3179 0.3549 1.234 −1.299 0.1939
    rs7684899 Imputed C ADD 417 0.617 0.1957 0.4205 0.9055 −2.467 0.01361
    rs7684899 Imputed C DOM 417 0.5176 0.2237 0.3339 0.8024 −2.944 0.00324
    rs7701604 Imputed G ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs7701604 Imputed G DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs7703676 Imputed C ADD 443 0.9741 0.2886 0.5532 1.715 −0.09096 0.9275
    rs7703676 Imputed C DOM 443 1.136 0.3415 0.5817 2.218 0.3732 0.709
    rs7708491 Imputed C REC 435 1.179 0.2374 0.7405 1.878 0.6947 0.4872
    rs7711358 Imputed A DOM 443 0.593 0.2016 0.3994 0.8804 −2.592 0.009541
    rs7719448 Imputed G REC 436 1.235 0.2366 0.777 1.965 0.8936 0.3715
    rs7724761 Imputed T REC 435 1.207 0.2381 0.7571 1.925 0.791 0.429
    rs7742476 Imputed T DOM 386 1.23 0.2098 0.8155 1.856 0.988 0.3231
    rs7762993 Imputed A ADD 431 1.066 0.1948 0.7276 1.561 0.3271 0.7436
    rs7762993 Imputed A DOM 431 1.079 0.2057 0.7207 1.614 0.3676 0.7132
    rs7767265 Imputed G ADD 430 1.18 0.1729 0.8411 1.656 0.9587 0.3377
    rs7767265 Imputed G DOM 430 1.155 0.1977 0.7839 1.702 0.7283 0.4664
    rs7768128 Imputed G REC 439 0.3066 0.5174 0.1112 0.8451 −2.285 0.0223
    rs7771264 Imputed T DOM 441 1.051 0.1977 0.7133 1.548 0.251 0.8018
    rs7773151 Genotyped C DOM 443 1.038 0.1992 0.7027 1.534 0.1891 0.85
    rs7773210 Genotyped A DOM 443 1.038 0.1992 0.7027 1.534 0.1891 0.85
    rs7808536 Imputed G DOM 409 1.374 0.2138 0.904 2.09 1.488 0.1368
    rs7843510 Genotyped G DOM 443 0.9929 0.2031 0.6669 1.478 −0.03512 0.972
    rs7894867 Imputed T DOM 441 1.426 0.2276 0.9129 2.228 1.559 0.1189
    rs7921834 Imputed C DOM 440 1.347 0.1965 0.9164 1.98 1.516 0.1296
    rs7939893 Imputed C ADD 441 0.6916 0.1478 0.5177 0.924 −2.495 0.01261
    rs7939893 Imputed C DOM 441 0.506 0.1982 0.3431 0.7463 −3.437 0.000589
    rs7944513 Imputed T GEN 418 4.036 0.1329
    rs7944513 Imputed T REC 418 1.787 0.3844 0.8411 3.795 1.51 0.1311
    rs7949720 Imputed G ADD 418 1.485 0.2216 0.9616 2.292 1.783 0.07457
    rs7949720 Imputed G DOM 418 1.52 0.2398 0.9502 2.433 1.747 0.08065
    rs7955901 Imputed C ADD 440 0.7285 0.1367 0.5573 0.9524 −2.316 0.02054
    rs7955901 Imputed C DOM 440 0.7139 0.2105 0.4726 1.078 −1.601 0.1093
    rs7956274 Imputed T ADD 426 0.7156 0.1398 0.5441 0.9412 −2.394 0.01667
    rs7956274 Imputed T DOM 426 0.7031 0.2129 0.4633 1.067 −1.655 0.098
    rs7956274 Imputed T GEN 426 6.165 0.04584
    rs7957932 Imputed G ADD 439 0.7234 0.1368 0.5533 0.9459 −2.366 0.01797
    rs7957932 Imputed G DOM 439 0.6888 0.212 0.4546 1.044 −1.758 0.07871
    rs7984504 Imputed C GEN 443 0.4224 0.8096
    rs7999518 Imputed A REC 423 0.4462 0.248 0.2745 0.7255 −3.254 0.001137
    rs8026245 Imputed G GEN 442 2.296 0.3173
    rs8026245 Imputed G REC 442 1.888 0.4309 0.8114 4.394 1.475 0.1402
    rs8060725 Genotyped A ADD 443 0.6772 0.162 0.493 0.9303 −2.406 0.01613
    rs8103016 Genotyped A ADD 443 1.223 0.1622 0.8901 1.681 1.242 0.2142
    rs8103016 Genotyped A DOM 443 1.343 0.1996 0.9084 1.987 1.479 0.1391
    rs8104182 Imputed G ADD 440 1.298 0.1657 0.9382 1.796 1.575 0.1152
    rs8104182 Imputed G DOM 440 1.4 0.1997 0.9468 2.071 1.686 0.09175
    rs8129461 Imputed G ADD 441 0.3726 0.3715 0.1799 0.7717 −2.657 0.007877
    rs8129461 Imputed G DOM 441 0.3187 0.3953 0.1469 0.6915 −2.893 0.003814
    rs8130021 Imputed G ADD 442 0.4152 0.3729 0.1999 0.8624 −2.357 0.01842
    rs8130021 Imputed G DOM 442 0.3565 0.3985 0.1632 0.7784 −2.589 0.009634
    rs879961 Imputed T ADD 440 1.178 0.1585 0.8634 1.607 1.033 0.3014
    rs879961 Imputed T DOM 440 1.245 0.1948 0.8502 1.825 1.127 0.2598
    rs906353 Imputed A DOM 434 1.22 0.1967 0.8295 1.794 1.01 0.3127
    rs915491 Imputed C DOM 441 1.329 0.1967 0.9042 1.955 1.448 0.1476
    rs915493 Imputed T DOM 441 1.329 0.1967 0.9042 1.955 1.448 0.1476
    rs915494 Imputed A ADD 422 1.399 0.1473 1.048 1.868 2.281 0.02256
    rs915494 Imputed A DOM 422 1.486 0.1999 1.004 2.199 1.982 0.0475
    rs917295 Imputed G DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs9284851 Imputed A GEN 436 1.977 0.3722
    rs9293464 Imputed T REC 435 1.207 0.2381 0.7571 1.925 0.791 0.429
    rs9295154 Genotyped G DOM 443 1.463 0.2215 0.9479 2.259 1.719 0.08569
    rs9310221 Imputed A DOM 393 0.8966 0.2237 0.5784 1.39 −0.4881 0.6255
    rs9310699 Genotyped T GEN 443 0.308 0.8573
    rs9310700 Imputed C ADD 443 1.048 0.1481 0.7837 1.401 0.3148 0.7529
    rs9310700 Imputed C GEN 443 0.8065 0.6682
    rs9310701 Imputed G GEN 443 1.33 0.5142
    rs9310704 Imputed G GEN 436 1.977 0.3722
    rs9319185 Imputed C GEN 441 0.9349 0.6266
    rs9319186 Imputed T GEN 443 0.4224 0.8096
    rs9327555 Imputed T DOM 443 0.5934 0.2016 0.3997 0.881 −2.589 0.009637
    rs9403367 Imputed C DOM 443 1.038 0.1992 0.7027 1.534 0.1891 0.85
    rs9419608 Imputed G REC 430 0.5885 0.2576 0.3552 0.9749 −2.059 0.03953
    rs9426437 Imputed T DOM 424 1.067 0.2164 0.6984 1.631 0.3009 0.7635
    rs9454967 Imputed G DOM 441 0.9744 0.2621 0.583 1.629 −0.09893 0.9212
    rs9635511 Imputed T DOM 436 0.8692 0.2057 0.5809 1.301 −0.6814 0.4956
    rs966583 Imputed A ADD 439 0.7596 0.1431 0.5738 1.005 −1.922 0.05464
    rs966583 Imputed A DOM 439 0.6781 0.203 0.4555 1.01 −1.913 0.0557
    rs980263 Imputed T GEN 443 1.33 0.5142
    rs980264 Imputed T GEN 443 1.33 0.5142
    rs9812206 Imputed G ADD 442 1.042 0.2668 0.6177 1.758 0.1545 0.8772
    rs9812206 Imputed G DOM 442 1.042 0.2668 0.6177 1.758 0.1545 0.8772
    rs9813552 Imputed G ADD 442 1.042 0.2623 0.6235 1.743 0.1586 0.874
    rs9813552 Imputed G DOM 442 1.077 0.2681 0.6368 1.821 0.2766 0.7821
    rs9815037 Imputed T ADD 443 1.048 0.2622 0.6267 1.752 0.1778 0.8589
    rs9815037 Imputed T DOM 443 1.083 0.2681 0.6401 1.831 0.2958 0.7674
    rs9819583 Imputed T GEN 443 0.308 0.8573
    rs9825349 Imputed A ADD 443 1.048 0.2622 0.6267 1.752 0.1778 0.8589
    rs9825349 Imputed A DOM 443 1.083 0.2681 0.6401 1.831 0.2958 0.7674
    rs9833118 Imputed G ADD 443 1.048 0.1481 0.7837 1.401 0.3148 0.7529
    rs9833118 Imputed G GEN 443 0.8065 0.6682
    rs9834217 Imputed T ADD 443 1.017 0.2611 0.6096 1.696 0.06425 0.9488
    rs9834217 Imputed T DOM 443 1.049 0.2668 0.6218 1.77 0.179 0.858
    rs9838563 Imputed C GEN 437 1.084 0.5817
    rs9840460 Imputed T ADD 443 1.017 0.2611 0.6096 1.696 0.06425 0.9488
    rs9840460 Imputed T DOM 443 1.049 0.2668 0.6218 1.77 0.179 0.858
    rs9840756 Imputed A ADD 437 0.9995 0.2614 0.5988 1.668 −0.00192 0.9985
    rs9840756 Imputed A DOM 437 1.031 0.2671 0.6105 1.74 0.1127 0.9103
    rs9847999 Imputed C GEN 436 1.977 0.3722
    rs9864769 Imputed C GEN 443 1.33 0.5142
    rs9866421 Genotyped C REC 443 0.5895 0.2541 0.3583 0.9701 −2.08 0.03756
    rs987296 Imputed T GEN 441 0.3297 0.848
    rs9881685 Imputed A ADD 440 1.041 0.2668 0.6172 1.756 0.151 0.88
    rs9881685 Imputed A DOM 440 1.041 0.2668 0.6172 1.756 0.151 0.88
    rs992695 Imputed C ADD 442 1.16 0.158 0.8507 1.581 0.9366 0.3489
    rs992695 Imputed C DOM 442 1.216 0.194 0.8313 1.778 1.008 0.3136
    rs9936999 Imputed G DOM 266 0.7758 0.254 0.4716 1.276 −0.9992 0.3177
    ATORVA_ PRAVA_ ATORVA_ ATORVA_ ATORVA_ PRAVA_ PRAVA_ PRAVA_
    HW_ ALLELE_ ALLELE_ ALLELE_ HZ_ HET_ A2_HZ_ A1_HZ_ HET_ A2_HZ_
    SNP rs # PVALUE FREQ FREQ FREQ COUNT COUNT COUNT COUNT COUNT COUNT
    rs77638540 0.3489 0.05305 0.0314 0.0694 1 10 180 1 33 218
    rs72746987 1 0.04176 0.0419 0.0417 0 16 175 0 21 231
    rs10021016 0.7144 0.26298 0.2984 0.2361 20 74 97 12 95 145
    rs10021016 0.7144 0.26298 0.2984 0.2361 20 74 97 12 95 145
    rs10051148 0.8242 0.30813 0.2801 0.3294 20 67 104 23 120 109
    rs10054055 0.3313 0.32841 0.2937 0.3546 23 65 101 29 120 102
    rs10067895 0.07522 0.34886 0.3132 0.376 27 65 98 35 118 97
    rs10100725 0.3323 0.17833 0.1859 0.1726 9 53 129 8 71 173
    rs10128531 0.677 0.13735 0.1742 0.1097 6 50 122 3 46 188
    rs10181743 0.6902 0.43046 0.4469 0.4181 35 90 54 40 119 79
    rs10199127 0.3263 0.32831 0.3155 0.3381 17 84 86 34 97 113
    rs10270624 0.7448 0.18582 0.2095 0.1674 8 59 112 7 63 160
    rs1030006 0.7002 0.47005 0.4599 0.4777 40 92 55 58 120 69
    rs1031811 0.7388 0.31567 0.361 0.2814 29 77 81 16 107 124
    rs10430870 0.7024 0.24831 0.2853 0.2202 20 69 102 9 93 150
    rs10430870 0.7024 0.24831 0.2853 0.2202 20 69 102 9 93 150
    rs10469597 0.5359 0.27494 0.2599 0.2863 13 66 98 15 104 115
    rs10469597 0.5359 0.27494 0.2599 0.2863 13 66 98 15 104 115
    rs10478919 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs10506623 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs10506623 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs10506626 0.5504 0.39391 0.356 0.4226 26 84 81 46 121 85
    rs10506626 0.5504 0.39391 0.356 0.4226 26 84 81 46 121 85
    rs10509477 0.1655 0.33409 0.3691 0.3075 29 83 79 27 101 124
    rs10517918 0.4917 0.42725 0.4309 0.4245 32 98 58 43 122 80
    rs10517924 1 0.46154 0.466 0.4582 42 94 55 52 126 73
    rs10519362 0.5877 0.15668 0.1882 0.1331 6 58 122 6 54 188
    rs10520072 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs10737390 0.3626 0.40909 0.419 0.4017 30 90 59 35 122 82
    rs10742851 0.4903 0.29007 0.3037 0.2798 18 80 93 16 109 127
    rs10743685 0.1663 0.41379 0.4335 0.3988 34 95 59 33 131 83
    rs10743685 0.1663 0.41379 0.4335 0.3988 34 95 59 33 131 83
    rs10749293 0.1901 0.322 0.3579 0.2948 26 84 80 26 96 129
    rs10749294 0.2987 0.29007 0.3246 0.2639 23 78 90 19 95 138
    rs10753760 0.01675 0.41844 0.4108 0.4244 36 80 69 50 102 86
    rs10753760 0.01675 0.41844 0.4108 0.4244 36 80 69 50 102 86
    rs10772362 0.5807 0.22122 0.2068 0.2321 7 65 119 12 93 147
    rs10784891 0.4305 0.4455 0.4049 0.4769 30 89 65 58 111 69
    rs10784891 0.4305 0.4455 0.4049 0.4769 30 89 65 58 111 69
    rs10784891 0.4305 0.4455 0.4049 0.4769 30 89 65 58 111 69
    rs10787923 0.1572 0.32232 0.359 0.2948 26 83 79 26 96 129
    rs10787924 0.2987 0.29007 0.3246 0.2639 23 78 90 19 95 138
    rs10787949 0.1377 0.33937 0.3717 0.3147 29 84 78 29 100 122
    rs10787951 0.1364 0.339 0.3711 0.3147 29 83 78 29 100 122
    rs10787983 0.1642 0.33447 0.3691 0.308 29 83 79 27 100 123
    rs10794733 0.578 0.31093 0.2605 0.3494 13 73 104 32 110 107
    rs10818280 0.347 0.28588 0.2433 0.3184 10 71 106 21 114 110
    rs10860586 0.9232 0.5058 0.4892 0.5183 44 93 48 67 121 58
    rs10860586 0.9232 0.5058 0.4892 0.5183 44 93 48 67 121 58
    rs10870473 1 0.29944 0.3209 0.2864 4 35 28 12 39 59
    rs10870473 1 0.29944 0.3209 0.2864 4 35 28 12 39 59
    rs10879240 0.434 0.44743 0.4043 0.4813 30 92 66 60 111 69
    rs10879240 0.434 0.44743 0.4043 0.4813 30 92 66 60 111 69
    rs10879242 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs10879242 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs10879245 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs10879245 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs10879249 0.7662 0.39773 0.3658 0.422 26 87 77 45 121 84
    rs10879249 0.7662 0.39773 0.3658 0.422 26 87 77 45 121 84
    rs10886429 0.1642 0.33447 0.3665 0.31 29 82 80 27 101 122
    rs10886449 0.1168 0.30795 0.3474 0.278 28 76 86 21 97 132
    rs10886451 0.1168 0.30795 0.3474 0.278 28 76 86 21 97 132
    rs10886452 0.1648 0.33523 0.3737 0.306 30 82 78 26 101 123
    rs10886456 0.1168 0.30795 0.3474 0.278 28 76 86 21 97 132
    rs10886463 0.1118 0.3405 0.3743 0.3147 30 83 78 29 100 122
    rs10886465 0.1364 0.339 0.3743 0.312 30 83 78 28 100 122
    rs10886526 0.2383 0.33257 0.3677 0.306 28 83 78 26 101 123
    rs10922903 0.8458 0.43068 0.4418 0.4223 34 99 56 46 120 85
    rs10941126 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs10941126 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs10947980 0.4609 0.2631 0.2632 0.2631 10 80 100 17 97 135
    rs11059376 1 0.16459 0.1695 0.1608 3 53 118 8 57 162
    rs11072995 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs11072995 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs11081202 0.456 0.25621 0.288 0.2321 22 66 103 10 97 145
    rs11081202 0.456 0.25621 0.288 0.2321 22 66 103 10 97 145
    rs110965 0.9143 0.34643 0.3984 0.3067 34 77 71 17 112 109
    rs11124962 0.3787 0.25515 0.2632 0.249 11 78 101 21 81 145
    rs1116596 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs11178531 0.3881 0.46811 0.4211 0.504 34 92 64 67 117 65
    rs11178531 0.3881 0.46811 0.4211 0.504 34 92 64 67 117 65
    rs11178583 0.6922 0.39503 0.3639 0.4187 26 87 78 45 121 86
    rs11178583 0.6922 0.39503 0.3639 0.4187 26 87 78 45 121 86
    rs11178589 0.8419 0.39931 0.3658 0.4251 26 87 77 45 120 82
    rs11178589 0.8419 0.39931 0.3658 0.4251 26 87 77 45 120 82
    rs11178594 1 0.40249 0.3684 0.4283 26 88 76 45 125 81
    rs11178594 1 0.40249 0.3684 0.4283 26 88 76 45 125 81
    rs11178602 1 0.40205 0.3677 0.428 26 87 76 45 124 81
    rs11178602 1 0.40205 0.3677 0.428 26 87 76 45 124 81
    rs11178648 0.4852 0.39432 0.3571 0.4223 26 83 80 46 120 85
    rs11178648 0.4852 0.39432 0.3571 0.4223 26 83 80 46 120 85
    rs11198877 0.1996 0.3356 0.3737 0.3068 30 82 78 26 102 123
    rs11198942 0.1655 0.33409 0.3691 0.3075 29 83 79 27 101 124
    rs11221075 1 0.11391 0.0754 0.1429 0 27 152 5 58 175
    rs11242020 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs11242021 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs11242022 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs11242023 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs1149349 0.4627 0.15323 0.1508 0.1551 1 55 133 11 54 180
    rs1149350 0.01047 0.21445 0.1885 0.2341 6 60 125 24 70 158
    rs1149350 0.01047 0.21445 0.1885 0.2341 6 60 125 24 70 158
    rs11576627 0.01289 0.12358 0.15 0.1036 7 43 140 6 40 205
    rs11576627 0.01289 0.12358 0.15 0.1036 7 43 140 6 40 205
    rs11630050 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11630050 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11633024 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11633024 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11636298 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs11636298 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs11637363 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs11637363 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs11637813 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11637813 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs11638043 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs11638043 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs11638115 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs11638115 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs11638444 0.4848 0.21606 0.2368 0.2004 13 64 113 10 81 161
    rs11682946 1 0.09884 0.15 0.0543 0 12 28 0 5 41
    rs11682946 1 0.09884 0.15 0.0543 0 12 28 0 5 41
    rs11717157 0.662 0.319 0.3246 0.3147 19 86 86 28 102 121
    rs11717157 0.662 0.319 0.3246 0.3147 19 86 86 28 102 121
    rs11724055 0.6032 0.16253 0.1283 0.1885 6 37 148 7 81 164
    rs11743355 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11743355 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11746806 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11746806 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11746959 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11746959 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs11749272 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs11839636 0.4378 0.31293 0.2989 0.3234 17 79 93 30 103 119
    rs11839785 0.4378 0.31293 0.2989 0.3234 17 79 93 30 103 119
    rs11853619 0.5684 0.2125 0.2342 0.196 13 63 114 9 80 161
    rs11853619 0.5684 0.2125 0.2342 0.196 13 63 114 9 80 161
    rs11856780 0.5684 0.2125 0.2342 0.196 13 63 114 9 80 161
    rs11856780 0.5684 0.2125 0.2342 0.196 13 63 114 9 80 161
    rs11901899 0.3322 0.27582 0.3071 0.2521 14 85 85 14 94 134
    rs11903290 0.7388 0.31567 0.361 0.2814 29 77 81 16 107 124
    rs11909480 0.2386 0.0467 0.0263 0.0622 1 8 181 1 29 219
    rs11909480 0.2386 0.0467 0.0263 0.0622 1 8 181 1 29 219
    rs11910289 0.1085 0.08409 0.1099 0.0643 4 34 153 2 28 219
    rs11910289 0.1085 0.08409 0.1099 0.0643 4 34 153 2 28 219
    rs11920375 0.8294 0.32844 0.3351 0.3234 19 90 82 30 103 119
    rs11926319 0.4982 0.07675 0.0759 0.0774 0 29 162 1 37 214
    rs11933744 0.3677 0.30455 0.2804 0.3227 18 70 101 27 108 116
    rs11934919 0.4994 0.30159 0.2778 0.3194 17 71 101 26 109 117
    rs11934957 0.4994 0.30159 0.2778 0.3194 17 71 101 26 109 117
    rs11959206 0.923 0.45853 0.4545 0.4615 43 84 60 49 130 68
    rs12038613 0.9202 0.44678 0.4483 0.4457 33 90 51 47 111 72
    rs12151417 0.8879 0.21493 0.2435 0.1932 9 75 107 12 73 166
    rs12153185 0.07489 0.35034 0.3132 0.3785 27 65 98 36 118 97
    rs12182651 0.07328 0.0907 0.0895 0.0916 3 28 159 4 38 209
    rs12235345 0.3489 0.05305 0.0707 0.0397 2 23 166 0 20 232
    rs12324786 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs12324786 0.295 0.19932 0.2237 0.1807 13 59 118 8 74 167
    rs12336958 0.9166 0.38452 0.3621 0.4013 23 80 71 38 111 84
    rs12407412 0.01289 0.12358 0.15 0.1036 7 43 140 6 40 205
    rs12407412 0.01289 0.12358 0.15 0.1036 7 43 140 6 40 205
    rs12418971 0.6068 0.24771 0.2884 0.2166 20 69 100 9 89 149
    rs12418971 0.6068 0.24771 0.2884 0.2166 20 69 100 9 89 149
    rs1241967 0.6028 0.35214 0.3429 0.3591 18 95 78 34 113 105
    rs12420184 1 0.14954 0.1693 0.1345 4 56 129 5 57 187
    rs12433968 0.0315 0.31623 0.3197 0.3136 14 89 80 18 112 106
    rs12445477 0.3613 0.08899 0.0788 0.0967 3 23 158 2 43 198
    rs12447191 0.8583 0.15801 0.1387 0.1726 5 43 143 5 77 170
    rs12447191 0.8583 0.15801 0.1387 0.1726 5 43 143 5 77 170
    rs12465349 0.8461 0.55069 0.5775 0.5304 69 78 40 61 140 46
    rs1247340 0.0397 0.20522 0.1789 0.2251 4 60 126 22 69 160
    rs1247340 0.0397 0.20522 0.1789 0.2251 4 60 126 22 69 160
    rs1247341 0.05636 0.20408 0.1806 0.222 4 61 126 21 69 160
    rs1247341 0.05636 0.20408 0.1806 0.222 4 61 126 21 69 160
    rs1247343 0.03783 0.1644 0.15 0.1753 1 55 134 17 54 180
    rs12509758 0.1442 0.20757 0.2193 0.1988 7 68 112 17 65 167
    rs12515472 0.8546 0.1535 0.1937 0.123 6 62 123 5 52 195
    rs12548906 1 0.19639 0.2458 0.1597 10 67 100 6 64 168
    rs12596240 0.9223 0.41986 0.3953 0.4385 26 99 66 51 119 82
    rs12618781 0.8483 0.47045 0.4709 0.4701 40 98 51 56 124 71
    rs12678600 1 0.31663 0.2989 0.33 18 77 94 26 113 111
    rs12692229 0.4038 0.35102 0.4084 0.3075 31 94 66 19 117 116
    rs12713324 0.8886 0.21558 0.2435 0.1944 9 75 107 12 74 166
    rs12719415 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs12820589 1 0.19856 0.1875 0.2073 5 59 120 11 75 148
    rs12820589 1 0.19856 0.1875 0.2073 5 59 120 11 75 148
    rs12831292 1 0.40367 0.371 0.428 26 86 74 45 124 81
    rs12831292 1 0.40367 0.371 0.428 26 86 74 45 124 81
    rs13012636 0.739 0.3164 0.3629 0.2814 29 77 80 16 107 124
    rs13038146 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs13038146 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs13038146 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs13089860 0.02707 0.46429 0.4325 0.49 39 63 61 50 97 54
    rs13102419 1 0.46128 0.4684 0.4558 42 94 54 51 125 73
    rs13194907 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs13194907 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs13195745 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs13195745 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs13265054 0.8248 0.31567 0.2941 0.332 17 76 94 25 114 108
    rs13273002 0.8776 0.19074 0.1859 0.1944 6 59 126 9 80 163
    rs13282131 0.8464 0.43864 0.4711 0.414 47 85 58 39 129 82
    rs13282131 0.8464 0.43864 0.4711 0.414 47 85 58 39 129 82
    rs13282131 0.8464 0.43864 0.4711 0.414 47 85 58 39 129 82
    rs1330052 1 0.34876 0.3325 0.3611 19 89 83 35 112 105
    rs1335721 0.9203 0.44581 0.4486 0.4437 33 91 51 47 111 73
    rs1336382 0.1655 0.33409 0.3691 0.3075 29 83 79 27 101 124
    rs1336383 0.1655 0.33409 0.3691 0.3075 29 83 79 27 101 124
    rs1336407 0.1663 0.33484 0.3691 0.3088 29 83 79 27 101 123
    rs1336409 0.1663 0.33484 0.3691 0.3088 29 83 79 27 101 123
    rs1336596 0.4737 0.36932 0.3763 0.364 28 87 75 28 126 96
    rs13387284 0.2701 0.4424 0.4454 0.4402 31 93 50 43 120 71
    rs13401462 0.6243 0.5024 0.5056 0.5 50 80 48 58 123 58
    rs13409045 0.2878 0.43891 0.4398 0.4382 36 96 59 55 110 86
    rs1349284 0.5114 0.31828 0.322 0.3155 20 83 88 28 103 121
    rs1355715 1 0.05769 0.0471 0.0657 0 18 173 1 31 219
    rs1357696 0.9152 0.34332 0.3503 0.3381 19 93 75 31 105 111
    rs1357698 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs1357699 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs1363273 0.9225 0.49169 0.4809 0.5 43 90 50 58 122 58
    rs1373601 0.3414 0.37871 0.3882 0.3718 26 80 64 27 120 87
    rs1375829 0.5114 0.31828 0.322 0.3155 20 83 88 28 103 121
    rs1395748 0.6571 0.30952 0.322 0.3 17 89 85 23 104 123
    rs1414865 0.1377 0.33937 0.3717 0.3147 29 84 78 29 100 122
    rs1414873 0.1663 0.33484 0.3691 0.3088 29 83 79 27 101 123
    rs1414876 0.1663 0.33484 0.3691 0.3088 29 83 79 27 101 123
    rs1424643 0.4845 0.22209 0.2609 0.1931 11 74 99 13 69 164
    rs1424643 0.4845 0.22209 0.2609 0.1931 11 74 99 13 69 164
    rs1424648 0.5746 0.21804 0.2526 0.1915 11 74 105 12 71 165
    rs1429321 0.6699 0.21644 0.246 0.1939 10 72 105 12 71 162
    rs1429326 0.6569 0.20208 0.234 0.1776 9 70 109 10 67 168
    rs1429326 0.6569 0.20208 0.234 0.1776 9 70 109 10 67 168
    rs1444741 0.2366 0.35627 0.3713 0.3453 24 79 68 22 119 95
    rs1449916 0.464 0.52222 0.5042 0.5362 33 53 32 44 75 33
    rs1459523 0.662 0.319 0.3246 0.3147 19 86 86 28 102 121
    rs1459523 0.662 0.319 0.3246 0.3147 19 86 86 28 102 121
    rs1466352 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs1466353 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs1476714 0.1129 0.3451 0.3132 0.3695 27 65 98 33 118 98
    rs1486723 0.3533 0.36866 0.3351 0.3936 17 90 78 37 122 90
    rs1495375 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs1495375 0.9197 0.40855 0.373 0.4364 26 86 73 45 116 75
    rs1495381 0.2705 0.38575 0.4342 0.3492 35 95 60 25 126 101
    rs1495381 0.2705 0.38575 0.4342 0.3492 35 95 60 25 126 101
    rs1498061 0.4882 0.19 0.1446 0.2222 1 22 60 8 36 73
    rs1498992 0.4588 0.35047 0.3234 0.3709 22 75 87 34 113 97
    rs1499001 0.2889 0.28375 0.262 0.3 16 66 105 24 102 124
    rs1512988 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs1512988 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs1512989 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs1512989 0.6908 0.3948 0.3632 0.4187 26 86 78 45 121 86
    rs1512991 0.3804 0.45647 0.4071 0.4938 30 89 64 63 113 66
    rs1512991 0.3804 0.45647 0.4071 0.4938 30 89 64 63 113 66
    rs1512991 0.3804 0.45647 0.4071 0.4938 30 89 64 63 113 66
    rs1524303 0.7421 0.32225 0.3298 0.3165 19 86 83 28 101 119
    rs1524306 0.6626 0.31973 0.3246 0.316 19 86 86 28 102 120
    rs1524306 0.6626 0.31973 0.3246 0.316 19 86 86 28 102 120
    rs1524310 0.6604 0.31735 0.3237 0.3125 19 85 86 27 101 120
    rs1524310 0.6604 0.31735 0.3237 0.3125 19 85 86 27 101 120
    rs1524321 1 0.33107 0.3429 0.322 20 91 80 28 105 117
    rs1527059 0.1053 0.09977 0.0684 0.1235 1 24 165 0 62 189
    rs152707 0.8451 0.41422 0.4241 0.4067 34 94 63 43 119 90
    rs152707 0.8451 0.41422 0.4241 0.4067 34 94 63 43 119 90
    rs152712 0.8451 0.41422 0.4241 0.4067 34 94 63 43 119 90
    rs152712 0.8451 0.41422 0.4241 0.4067 34 94 63 43 119 90
    rs1533994 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs1535866 0.6667 0.21023 0.2263 0.198 7 72 111 14 71 165
    rs1563773 0.9151 0.33599 0.3439 0.33 20 90 79 30 105 115
    rs1563774 0.9151 0.33599 0.3439 0.33 20 90 79 30 105 115
    rs1567740 0.8422 0.39863 0.3658 0.4237 26 87 77 45 121 83
    rs1567740 0.8422 0.39863 0.3658 0.4237 26 87 77 45 121 83
    rs1572573 0.00264 0.18813 0.1879 0.1883 2 61 110 3 78 142
    rs1577497 0.9204 0.44485 0.446 0.444 33 91 52 47 112 73
    rs1581514 0.8269 0.32751 0.3351 0.3217 19 86 80 28 101 115
    rs1581514 0.8269 0.32751 0.3351 0.3217 19 86 80 28 101 115
    rs1582321 0.9223 0.41986 0.3953 0.4385 26 99 66 51 119 82
    rs1582322 0.7686 0.41895 0.3947 0.4375 26 98 66 49 119 80
    rs1582323 0.6949 0.41762 0.3947 0.4352 26 98 66 48 119 80
    rs1592485 0.5 0.44131 0.4162 0.4603 32 95 64 58 116 78
    rs1600954 0.6267 0.47754 0.5027 0.458 47 92 46 52 114 72
    rs1600954 0.6267 0.47754 0.5027 0.458 47 92 46 52 114 72
    rs16938626 0.3923 0.26552 0.2487 0.2782 15 63 109 19 100 129
    rs16964300 0.863 0.16515 0.1455 0.18 6 43 140 5 80 165
    rs16964300 0.863 0.16515 0.1455 0.18 6 43 140 5 80 165
    rs16986282 0.2362 0.04638 0.0262 0.0618 1 8 182 1 29 221
    rs17007620 1 0.22181 0.226 0.2186 7 66 104 13 75 143
    rs17007620 1 0.22181 0.226 0.2186 7 66 104 13 75 143
    rs17014326 0.9106 0.30499 0.3141 0.298 16 88 87 24 101 125
    rs17047957 0.6092 0.16856 0.2063 0.14 7 64 118 7 56 187
    rs1705261 0.5499 0.39367 0.4395 0.3591 37 93 60 28 125 99
    rs17073341 0.09324 0.03515 0.05 0.0239 1 17 172 1 10 240
    rs17073341 0.09324 0.03515 0.05 0.0239 1 17 172 1 10 240
    rs17138702 0.1045 0.15463 0.1649 0.1468 9 45 137 6 62 184
    rs17189710 0.3369 0.34535 0.3865 0.3143 33 77 75 23 108 114
    rs17189710 0.3369 0.34535 0.3865 0.3143 33 77 75 23 108 114
    rs17189710 0.3369 0.34535 0.3865 0.3143 33 77 75 23 108 114
    rs17310176 0.8641 0.16704 0.1335 0.1925 4 43 144 9 79 164
    rs17310176 0.8641 0.16704 0.1335 0.1925 4 43 144 9 79 164
    rs17358860 0.3352 0.1887 0.1547 0.2149 9 38 134 9 83 143
    rs17370541 0.287 0.38035 0.3844 0.3772 24 85 64 28 113 83
    rs17370541 0.287 0.38035 0.3844 0.3772 24 85 64 28 113 83
    rs17526574 0.3222 0.31603 0.3063 0.3234 19 79 93 30 103 119
    rs17530747 0.0203 0.3369 0.3438 0.3318 14 82 64 18 106 90
    rs17649114 0.06 0.18864 0.2302 0.1574 12 63 114 10 59 182
    rs17766172 0.4542 0.34579 0.3242 0.3618 17 84 81 38 102 106
    rs1818885 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs1832222 0.2005 0.33521 0.3691 0.3095 29 83 79 27 102 123
    rs1861327 0.8446 0.42494 0.3989 0.4449 26 98 64 51 116 78
    rs1868581 0.5814 0.31881 0.3218 0.3165 19 83 86 28 101 119
    rs1868581 0.5814 0.31881 0.3218 0.3165 19 83 86 28 101 119
    rs1874313 0.6922 0.39503 0.3639 0.4187 26 87 78 45 121 86
    rs1874313 0.6922 0.39503 0.3639 0.4187 26 87 78 45 121 86
    rs1876409 0.8255 0.31264 0.322 0.3056 17 89 85 25 104 123
    rs1913201 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs1913201 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs1913201 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs1916922 0.6579 0.31724 0.3218 0.3138 19 83 86 27 101 119
    rs1936871 0.7727 0.44357 0.4346 0.4504 40 86 65 49 129 74
    rs1961157 0.5032 0.45814 0.466 0.4522 41 96 54 48 131 72
    rs1987179 0.8637 0.17266 0.1346 0.2021 6 37 139 7 81 147
    rs1987179 0.8637 0.17266 0.1346 0.2021 6 37 139 7 81 147
    rs1990023 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs1995025 0.1894 0.15012 0.1855 0.1235 4 61 121 2 57 188
    rs2016194 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs2023651 0.08904 0.21911 0.2391 0.2041 13 62 109 14 72 159
    rs2024902 0.2797 0.07353 0.0759 0.0717 1 27 163 3 30 218
    rs2024902 0.2797 0.07353 0.0759 0.0717 1 27 163 3 30 218
    rs2025107 0.0729 0.0905 0.0895 0.0913 3 28 159 4 38 210
    rs2025108 0.0729 0.0905 0.0895 0.0913 3 28 159 4 38 210
    rs2031987 0.3222 0.31603 0.3063 0.3234 19 79 93 30 103 119
    rs2052428 0.2452 0.47892 0.4622 0.4917 46 79 60 58 122 62
    rs2053230 6.29E−06 0.19309 0.1794 0.2036 0 61 109 2 86 133
    rs2062448 0.09556 0.07692 0.0737 0.0794 0 28 162 0 40 212
    rs2063420 0.2891 0.43778 0.4342 0.4405 32 101 57 47 128 77
    rs2063591 0.2947 0.47506 0.4293 0.51 36 92 63 69 117 64
    rs2063591 0.2947 0.47506 0.4293 0.51 36 92 63 69 117 64
    rs208026 0.4931 0.22348 0.2539 0.2004 8 81 102 11 79 162
    rs208029 1 0.20024 0.2432 0.1674 7 75 101 10 60 169
    rs208757 0.6456 0.19425 0.2354 0.1626 8 73 108 10 60 176
    rs2095586 0.3355 0.33145 0.3665 0.3048 28 84 79 25 103 123
    rs2095606 0.105 0.38073 0.385 0.3775 27 90 70 28 132 89
    rs2102374 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2102374 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2108426 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs2110664 1 0.27569 0.3052 0.2533 14 77 81 16 83 128
    rs2132242 1 0.40341 0.3684 0.43 26 88 76 45 125 80
    rs2132242 1 0.40341 0.3684 0.43 26 88 76 45 125 80
    rs2158958 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs2158961 0.8242 0.30813 0.2801 0.3294 20 67 104 23 120 109
    rs2163046 0.8879 0.21674 0.246 0.1943 9 75 105 12 72 163
    rs2180286 0.3923 0.50564 0.4712 0.5317 49 82 60 69 130 53
    rs2180684 0.3529 0.11778 0.1478 0.0951 3 49 134 5 37 205
    rs2188079 0.563 0.43905 0.445 0.4345 39 92 60 43 133 76
    rs2188079 0.563 0.43905 0.445 0.4345 39 92 60 43 133 76
    rs2190598 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs2190600 0.07522 0.34886 0.3132 0.376 27 65 98 35 118 97
    rs2224184 0.447 0.50451 0.4712 0.5298 49 82 60 68 131 53
    rs2247066 0.6571 0.30952 0.322 0.3 17 89 85 23 104 123
    rs2248236 0.8852 0.20655 0.1702 0.2341 9 47 135 9 100 143
    rs2248236 0.8852 0.20655 0.1702 0.2341 9 47 135 9 100 143
    rs2265733 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2265733 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2270584 0.4848 0.39342 0.3553 0.4223 26 83 81 46 120 85
    rs2270584 0.4848 0.39342 0.3553 0.4223 26 83 81 46 120 85
    rs2270586 0.4864 0.39367 0.356 0.4223 26 84 81 46 120 85
    rs2270586 0.4864 0.39367 0.356 0.4223 26 84 81 46 120 85
    rs229775 0.6028 0.35214 0.3429 0.3591 18 95 78 34 113 105
    rs229815 0.4755 0.38194 0.3824 0.3816 20 103 64 39 109 97
    rs229829 0.7558 0.38741 0.3857 0.3887 19 97 59 41 103 94
    rs229831 0.466 0.35261 0.3421 0.3606 17 96 77 34 113 104
    rs2317057 0.6434 0.21467 0.1687 0.2512 4 47 112 11 81 113
    rs2322100 0.7091 0.25734 0.2906 0.2321 20 71 100 11 95 146
    rs2322101 0.7102 0.25909 0.2937 0.2331 20 71 98 11 95 145
    rs2327929 0.4376 0.42857 0.4476 0.414 42 87 62 43 121 86
    rs2332844 0.8232 0.8422 0.8583 0.8302 89 28 3 110 49 3
    rs2332844 0.8232 0.8422 0.8583 0.8302 89 28 3 110 49 3
    rs2349170 0.06576 0.23702 0.2723 0.2103 18 68 105 14 78 160
    rs2356722 0.8223 0.30135 0.3141 0.2917 16 88 87 23 101 128
    rs2364956 0.09486 0.15783 0.1713 0.1477 5 51 122 10 50 177
    rs2373793 1 0.14253 0.1737 0.1184 6 54 130 3 52 190
    rs2373793 1 0.14253 0.1737 0.1184 6 54 130 3 52 190
    rs238252 1 0.13364 0.1436 0.126 3 48 137 4 54 188
    rs238252 1 0.13364 0.1436 0.126 3 48 137 4 54 188
    rs2383903 0.4634 0.26411 0.2461 0.2778 15 64 112 19 102 131
    rs2387945 0.1892 0.15023 0.1862 0.123 4 62 122 2 57 189
    rs2389863 1 0.20602 0.172 0.2317 9 46 131 9 96 141
    rs2389866 0.8852 0.20655 0.1702 0.2341 9 47 135 9 100 143
    rs2389869 0.8852 0.20655 0.1702 0.2341 9 47 135 9 100 143
    rs2389870 0.8641 0.16704 0.1309 0.1944 6 38 147 7 84 161
    rs2418494 0.3781 0.54137 0.4917 0.5785 40 98 43 79 122 41
    rs2418494 0.3781 0.54137 0.4917 0.5785 40 98 43 79 122 41
    rs2418541 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs2418542 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs2423556 0.3868 0.51155 0.4808 0.5339 49 77 56 69 130 52
    rs2437688 0.6021 0.10158 0.1361 0.0754 3 46 142 0 38 214
    rs2456809 0.9116 0.31393 0.3218 0.308 17 87 84 25 104 121
    rs2456811 0.1583 0.28555 0.2989 0.2753 13 87 89 16 104 127
    rs2456811 0.1583 0.28555 0.2989 0.2753 13 87 89 16 104 127
    rs2476976 0.2817 0.32919 0.3639 0.3028 27 85 79 26 100 125
    rs2484911 0.1443 0.30474 0.3403 0.2778 26 78 87 22 96 134
    rs2488557 0.4009 0.12993 0.121 0.1367 0 45 141 5 57 183
    rs250162 0.0772 0.2296 0.1935 0.2572 5 62 119 11 103 129
    rs250162 0.0772 0.2296 0.1935 0.2572 5 62 119 11 103 129
    rs2560708 0.6189 0.17546 0.1526 0.1931 5 48 137 10 75 161
    rs2617841 0.6968 0.25364 0.2386 0.2648 14 56 106 14 97 125
    rs2622499 0.8852 0.20655 0.1702 0.2341 9 47 135 9 100 143
    rs264129 0.8242 0.30813 0.2801 0.3294 20 67 104 23 120 109
    rs2642936 0.2772 0.19276 0.1913 0.1939 6 58 119 6 83 156
    rs2660633 0.8255 0.31264 0.322 0.3056 17 89 85 25 104 123
    rs2660634 0.8255 0.31264 0.322 0.3056 17 89 85 25 104 123
    rs2660648 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2660648 0.1584 0.2849 0.2974 0.2753 13 87 90 16 104 127
    rs2681505 0.493 0.22235 0.2094 0.2321 7 66 118 12 93 147
    rs277411 1 0.04412 0.0447 0.0437 0 17 173 0 22 230
    rs2832634 0.113 0.08484 0.1099 0.0657 4 34 153 2 29 220
    rs2832637 0.113 0.08484 0.1099 0.0657 4 34 153 2 29 220
    rs2843167 0.9102 0.29977 0.3037 0.2968 16 84 91 23 103 125
    rs2876227 0.4631 0.34502 0.3874 0.3127 33 82 76 23 111 117
    rs2876227 0.4631 0.34502 0.3874 0.3127 33 82 76 23 111 117
    rs2882097 0.1655 0.33409 0.3691 0.3075 29 83 79 27 101 124
    rs2909862 0.08505 0.40625 0.4167 0.3983 29 92 59 31 126 79
    rs3001945 0.1899 0.14943 0.1845 0.123 4 61 122 2 57 189
    rs3011020 0.1892 0.15023 0.1862 0.123 4 62 122 2 57 189
    rs36071725 0.5846 0.31828 0.3141 0.3214 16 88 87 26 110 116
    rs36071725 0.5846 0.31828 0.3141 0.3214 16 88 87 26 110 116
    rs373983 0.9193 0.41063 0.4536 0.3766 31 104 48 38 98 95
    rs3743794 0.6221 0.4182 0.3963 0.435 26 97 65 47 120 79
    rs3756154 1 0.17668 0.1374 0.2073 6 38 138 7 83 144
    rs3756154 1 0.17668 0.1374 0.2073 6 38 138 7 83 144
    rs3775850 0.6032 0.16253 0.1283 0.1885 6 37 148 7 81 164
    rs3775851 0.6032 0.16253 0.1283 0.1885 6 37 148 7 81 164
    rs3793044 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs3793044 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs3793053 0.06405 0.0883 0.0878 0.0887 3 27 158 4 36 208
    rs3796246 0.5013 0.07805 0.0759 0.0797 0 29 162 1 38 212
    rs3806003 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs3806003 0.279 0.07336 0.0759 0.0714 1 27 163 3 30 219
    rs3806004 0.0729 0.0905 0.0895 0.0913 3 28 159 4 38 210
    rs3806010 0.0729 0.0905 0.0895 0.0913 3 28 159 4 38 210
    rs3806014 0.06876 0.0907 0.0902 0.0911 3 27 153 4 37 206
    rs3806015 0.07007 0.09155 0.0907 0.0922 3 27 152 4 37 203
    rs3806018 0.0729 0.0905 0.0895 0.0913 3 28 159 4 38 210
    rs3806019 0.07445 0.09132 0.0899 0.0924 3 28 158 4 38 207
    rs3806024 0.03996 0.09276 0.0942 0.0916 4 28 159 4 38 209
    rs3915080 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs3942254 0.1836 0.39167 0.3539 0.4194 26 74 78 45 113 84
    rs3942254 0.1836 0.39167 0.3539 0.4194 26 74 78 45 113 84
    rs3945085 0.05672 0.34014 0.3743 0.314 31 81 79 29 99 122
    rs3976737 0.4634 0.16976 0.1867 0.1575 9 41 108 4 61 154
    rs399485 0.3195 0.25973 0.2921 0.2348 10 91 89 15 86 146
    rs4029119 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs4029119 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs4076201 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs4076201 0.7866 0.23452 0.2527 0.2203 14 65 105 10 84 142
    rs41395945 0.1081 0.0839 0.1099 0.064 4 34 153 2 28 220
    rs41395945 0.1081 0.0839 0.1099 0.064 4 34 153 2 28 220
    rs4146972 0.7362 0.17043 0.2094 0.1409 7 66 118 7 57 188
    rs4238087 0.4923 0.12562 0.1 0.1444 4 26 140 4 59 169
    rs4251569 0.4959 0.12018 0.0942 0.14 4 28 159 4 62 184
    rs4251569 0.4959 0.12018 0.0942 0.14 4 28 159 4 62 184
    rs4273613 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs4273613 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs4291049 1 0.46065 0.4565 0.4637 42 84 58 50 130 68
    rs4315598 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4315598 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4315598 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4321395 0.2701 0.4424 0.4454 0.4402 31 93 50 43 120 71
    rs4321596 0.3429 0.22573 0.2565 0.2024 16 66 109 10 82 160
    rs4324417 0.08691 0.48646 0.5026 0.4742 54 84 53 60 119 73
    rs4328619 1 0.44018 0.4188 0.4563 41 78 72 45 140 67
    rs4338909 0.06541 0.43295 0.4339 0.4323 40 84 65 52 113 86
    rs4370878 0.1648 0.33523 0.3684 0.31 29 82 79 27 101 122
    rs4379434 0.2061 0.42099 0.4267 0.4167 39 85 67 46 118 88
    rs4416407 0.00049 0.55149 0.5824 0.5281 70 79 39 81 101 67
    rs4417899 0.00049 0.44851 0.4176 0.4719 39 79 70 67 101 81
    rs4442732 0.1439 0.3403 0.3333 0.3452 19 54 65 26 84 87
    rs4444612 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4444612 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4444612 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs4450660 0.378 0.25457 0.2632 0.248 11 78 101 21 81 146
    rs4509702 0.1648 0.33523 0.3684 0.31 29 82 79 27 101 122
    rs4526920 0.3222 0.31603 0.3063 0.3234 19 79 93 30 103 119
    rs4533145 0.6582 0.12358 0.1534 0.1012 2 54 133 3 45 204
    rs4557006 0.3625 0.44389 0.4454 0.4427 31 93 50 43 115 69
    rs4570530 0.1648 0.33523 0.3684 0.31 29 82 79 27 101 122
    rs4615971 0.2375 0.33182 0.3658 0.306 28 83 79 26 101 123
    rs4628119 0.3439 0.22624 0.2251 0.2271 10 66 115 16 82 153
    rs4664443 0.2878 0.43891 0.4398 0.4382 36 96 59 55 110 86
    rs4688259 0.0007 0.55137 0.5824 0.528 70 79 39 81 102 67
    rs4688632 0.00063 0.45338 0.4189 0.4795 38 79 68 68 98 78
    rs4695284 1 0.08763 0.1053 0.0763 0 16 60 1 16 101
    rs4700302 1 0.09398 0.1012 0.0885 1 33 139 2 36 188
    rs4702720 1 0.24652 0.2194 0.2672 10 48 97 12 85 107
    rs4702720 1 0.24652 0.2194 0.2672 10 48 97 12 85 107
    rs4711091 0.634 0.47743 0.4607 0.4901 37 102 52 61 125 66
    rs4714484 0.3702 0.15718 0.1455 0.166 3 49 137 5 73 172
    rs4736802 0.2044 0.42081 0.4263 0.4167 39 84 67 46 118 88
    rs4760785 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760785 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760785 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760894 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760894 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760894 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760895 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760895 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4760895 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs4764738 0.699 0.53488 0.5294 0.5391 55 88 44 70 122 51
    rs4764738 0.699 0.53488 0.5294 0.5391 55 88 44 70 122 51
    rs4764974 0.9232 0.5058 0.4892 0.5183 44 93 48 67 121 58
    rs4764974 0.9232 0.5058 0.4892 0.5183 44 93 48 67 121 58
    rs4798366 0.9088 0.30186 0.3289 0.281 25 73 89 13 110 119
    rs483159 0.3957 0.18264 0.2256 0.1509 4 66 94 6 55 161
    rs4836502 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs4836507 0.09482 0.34955 0.3141 0.3765 27 66 98 35 119 97
    rs4836744 0.5022 0.30587 0.267 0.3353 13 76 102 25 119 108
    rs4836744 0.5022 0.30587 0.267 0.3353 13 76 102 25 119 108
    rs4848944 1 0.46501 0.4162 0.502 35 89 67 61 131 60
    rs4851529 0.3797 0.42081 0.3868 0.4464 34 79 77 49 127 76
    rs4851531 0.2107 0.44231 0.4005 0.4741 36 81 74 57 124 70
    rs4858046 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs4878214 0.01259 0.3046 0.2672 0.3345 11 40 65 22 53 70
    rs4880803 0.578 0.31093 0.2605 0.3494 13 73 104 32 110 107
    rs489441 0.6152 0.26773 0.2874 0.2532 11 78 85 16 87 132
    rs489441 0.6152 0.26773 0.2874 0.2532 11 78 85 16 87 132
    rs4896568 0.3356 0.23415 0.233 0.235 10 62 104 16 78 140
    rs4938851 0.05052 0.19752 0.2408 0.1647 13 66 112 11 61 180
    rs4964416 0.3418 0.49323 0.4817 0.502 52 80 59 61 131 60
    rs5756669 0.08691 0.48646 0.5026 0.4742 54 84 53 60 119 73
    rs6033138 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6033138 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6033138 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040619 0.3441 0.34852 0.3963 0.3127 34 81 73 24 109 118
    rs6040619 0.3441 0.34852 0.3963 0.3127 34 81 73 24 109 118
    rs6040619 0.3441 0.34852 0.3963 0.3127 34 81 73 24 109 118
    rs6040625 0.3449 0.34729 0.3927 0.3127 34 82 75 24 109 118
    rs6040625 0.3449 0.34729 0.3927 0.3127 34 82 75 24 109 118
    rs6040625 0.3449 0.34729 0.3927 0.3127 34 82 75 24 109 118
    rs6040630 0.2464 0.34467 0.3895 0.3108 34 80 76 24 108 119
    rs6040630 0.2464 0.34467 0.3895 0.3108 34 80 76 24 108 119
    rs6040630 0.2464 0.34467 0.3895 0.3108 34 80 76 24 108 119
    rs6040633 0.2489 0.34502 0.3895 0.3115 34 80 76 24 109 119
    rs6040633 0.2489 0.34502 0.3895 0.3115 34 80 76 24 109 119
    rs6040633 0.2489 0.34502 0.3895 0.3115 34 80 76 24 109 119
    rs6040634 0.295 0.34694 0.3921 0.3127 34 81 75 24 109 118
    rs6040634 0.295 0.34694 0.3921 0.3127 34 81 75 24 109 118
    rs6040634 0.295 0.34694 0.3921 0.3127 34 81 75 24 109 118
    rs6040636 0.2458 0.34312 0.3848 0.3115 34 79 78 24 109 119
    rs6040636 0.2458 0.34312 0.3848 0.3115 34 79 78 24 109 119
    rs6040636 0.2458 0.34312 0.3848 0.3115 34 79 78 24 109 119
    rs6040638 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040638 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040638 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040644 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040644 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040644 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6040667 0.3997 0.35731 0.4038 0.3223 34 79 69 24 108 110
    rs6040667 0.3997 0.35731 0.4038 0.3223 34 79 69 24 108 110
    rs6040667 0.3997 0.35731 0.4038 0.3223 34 79 69 24 108 110
    rs6040668 0.5278 0.34659 0.3895 0.314 33 82 75 23 111 116
    rs6040668 0.5278 0.34659 0.3895 0.314 33 82 75 23 111 116
    rs6040668 0.5278 0.34659 0.3895 0.314 33 82 75 23 111 116
    rs6043066 0.6163 0.25282 0.2749 0.2361 10 85 96 16 87 149
    rs6048146 0.128 0.03837 0.0497 0.0298 0 19 172 2 11 239
    rs6082725 0.128 0.03837 0.0497 0.0298 0 19 172 2 11 239
    rs6131206 0.2791 0.28066 0.3288 0.2438 23 75 86 15 87 138
    rs6131208 0.2909 0.34091 0.3836 0.3088 33 79 77 23 109 119
    rs6131208 0.2909 0.34091 0.3836 0.3088 33 79 77 23 109 119
    rs6131208 0.2909 0.34091 0.3836 0.3088 33 79 77 23 109 119
    rs6134243 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6134243 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6134243 0.2479 0.34424 0.3874 0.3115 34 80 77 24 109 119
    rs6136020 0.1646 0.1644 0.1702 0.16 8 49 134 8 64 178
    rs613799 0.1798 0.32262 0.3591 0.295 26 78 77 24 93 122
    rs644041 0.6136 0.27114 0.2895 0.2576 11 77 83 16 87 128
    rs644041 0.6136 0.27114 0.2895 0.2576 11 77 83 16 87 128
    rs647645 0.6983 0.43537 0.4237 0.4442 37 87 66 44 135 72
    rs647645 0.6983 0.43537 0.4237 0.4442 37 87 66 44 135 72
    rs647645 0.6983 0.43537 0.4237 0.4442 37 87 66 44 135 72
    rs6495554 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs6495554 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs6495555 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs6495555 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs6544728 0.7087 0.25854 0.2686 0.251 10 81 97 21 84 146
    rs6550705 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs6550705 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs6550707 0.9152 0.33484 0.3429 0.3287 20 91 80 30 105 116
    rs658108 0.1443 0.30474 0.3403 0.2778 26 78 87 22 96 134
    rs6593441 0.1752 0.12621 0.1397 0.1159 0 50 129 3 48 182
    rs668732 0.2955 0.47738 0.4895 0.4681 46 95 50 49 137 65
    rs671041 0.1443 0.30474 0.3403 0.2778 26 78 87 22 96 134
    rs6719700 0.6439 0.19355 0.2222 0.1714 8 68 113 10 64 171
    rs6719700 0.6439 0.19355 0.2222 0.1714 8 68 113 10 64 171
    rs6722640 0.2486 0.44671 0.4058 0.478 37 81 73 57 125 68
    rs6743092 1 0.5023 0.5294 0.4818 59 80 48 50 138 59
    rs6743092 1 0.5023 0.5294 0.4818 59 80 48 50 138 59
    rs6743092 1 0.5023 0.5294 0.4818 59 80 48 50 138 59
    rs6744759 0.7394 0.31537 0.359 0.2823 29 77 82 16 108 124
    rs6746170 0.8072 0.26471 0.2775 0.255 11 84 96 21 86 144
    rs6759922 0.2701 0.4424 0.4454 0.4402 31 93 50 43 120 71
    rs6769864 0.7436 0.32339 0.3316 0.3173 19 86 82 28 102 119
    rs6773932 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs6774353 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs6781670 0.5114 0.31828 0.322 0.3155 20 83 88 28 103 121
    rs6786431 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs6789091 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs6791296 0.08628 0.13146 0.1056 0.1504 1 36 143 2 70 174
    rs6792662 0.00046 0.55069 0.5829 0.5263 70 78 39 80 100 67
    rs6797574 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs6797882 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs6805139 0.00028 0.52941 0.5628 0.504 67 81 43 76 101 74
    rs6806043 0.6626 0.31973 0.3246 0.316 19 86 86 28 102 120
    rs6806043 0.6626 0.31973 0.3246 0.316 19 86 86 28 102 120
    rs6850716 0.8929 0.22912 0.2094 0.244 9 62 120 15 93 144
    rs6867153 0.923 0.45853 0.4545 0.4615 43 84 60 49 130 68
    rs687047 0.8186 0.11512 0.0838 0.1389 0 32 159 5 60 187
    rs6871041 0.6303 0.2823 0.2582 0.3008 16 62 104 15 112 109
    rs688358 0.8183 0.1171 0.086 0.1411 0 32 154 5 58 178
    rs6888012 0.9228 0.45949 0.457 0.4614 43 84 59 49 129 68
    rs6908481 0.7579 0.41875 0.4327 0.4083 35 78 58 37 113 79
    rs7032231 0.09405 0.32033 0.3736 0.2801 31 74 77 20 95 126
    rs7067638 0.1751 0.11991 0.1342 0.1091 0 51 139 3 49 200
    rs7077799 0.1663 0.33484 0.3691 0.3088 29 83 79 27 101 123
    rs7082163 0.49 0.11818 0.1303 0.1091 0 49 139 4 47 201
    rs7082163 0.49 0.11818 0.1303 0.1091 0 49 139 4 47 201
    rs7089661 0.3355 0.33145 0.3665 0.3048 28 84 79 25 103 123
    rs7101319 0.3713 0.12065 0.1344 0.1102 0 50 136 4 46 195
    rs7101319 0.3713 0.12065 0.1344 0.1102 0 50 136 4 46 195
    rs710832 0.4404 0.24492 0.2147 0.2679 6 70 115 17 101 134
    rs710832 0.4404 0.24492 0.2147 0.2679 6 70 115 17 101 134
    rs7134262 1 0.3379 0.3763 0.3085 29 85 76 21 111 116
    rs7134262 1 0.3379 0.3763 0.3085 29 85 76 21 111 116
    rs7134671 1 0.38939 0.4058 0.377 29 97 65 38 114 100
    rs7138300 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs7138300 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs7138300 0.438 0.4537 0.4054 0.4899 30 90 65 63 116 68
    rs7163931 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7163931 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7171486 0.7558 0.35553 0.2984 0.3988 15 84 92 39 123 90
    rs7172611 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7172611 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7172689 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7172689 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7175701 1 0.23409 0.254 0.2191 14 68 107 10 90 151
    rs7180245 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7180245 0.5733 0.21332 0.2356 0.1964 13 64 114 9 81 162
    rs7220603 0.3685 0.30135 0.3403 0.2718 19 92 80 17 103 132
    rs7282518 0.7019 0.15504 0.1605 0.1511 3 46 113 5 58 162
    rs7283476 0.237 0.04649 0.0262 0.062 1 8 182 1 29 220
    rs7283476 0.237 0.04649 0.0262 0.062 1 8 182 1 29 220
    rs7295817 1 0.42807 0.3819 0.4628 23 93 66 55 114 73
    rs7298255 0.2143 0.46163 0.4188 0.494 34 92 65 67 115 70
    rs7298255 0.2143 0.46163 0.4188 0.494 34 92 65 67 115 70
    rs7305832 1 0.33597 0.3743 0.3068 29 85 77 21 112 118
    rs7305832 1 0.33597 0.3743 0.3068 29 85 77 21 112 118
    rs7331467 1 0.34876 0.3325 0.3611 19 89 83 35 112 105
    rs7392620 0.7378 0.31121 0.2593 0.3508 12 74 103 32 110 106
    rs742827 0.4608 0.34668 0.3895 0.3138 33 82 75 23 109 115
    rs742827 0.4608 0.34668 0.3895 0.3138 33 82 75 23 109 115
    rs742827 0.4608 0.34668 0.3895 0.3138 33 82 75 23 109 115
    rs7446891 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs7448641 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7448641 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7484728 1 0.38939 0.4058 0.377 29 97 65 38 114 100
    rs7499402 1 0.06546 0.089 0.0476 0 34 157 1 22 229
    rs7529851 0.3514 0.40648 0.3571 0.4421 22 76 70 49 108 76
    rs7529851 0.3514 0.40648 0.3571 0.4421 22 76 70 49 108 76
    rs7573951 0.2878 0.43891 0.4398 0.4382 36 96 59 55 110 86
    rs7599198 0.1175 0.46092 0.4565 0.4643 30 87 44 41 113 56
    rs7600050 0.9138 0.34736 0.3812 0.3213 27 84 70 24 103 108
    rs7607712 0.6555 0.19955 0.2277 0.178 9 69 113 10 69 171
    rs7607712 0.6555 0.19955 0.2277 0.178 9 69 113 10 69 171
    rs7613492 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs7621663 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs7621663 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs7621663 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs7626584 1 0.05769 0.0471 0.0657 0 18 173 1 31 219
    rs7684899 0.8637 0.17266 0.1346 0.2021 6 37 139 7 81 147
    rs7684899 0.8637 0.17266 0.1346 0.2021 6 37 139 7 81 147
    rs7701604 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7701604 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7703676 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7703676 2.36E−05 0.07336 0.0733 0.0734 3 22 166 7 23 222
    rs7708491 0.8472 0.45977 0.4545 0.4637 43 84 60 50 130 68
    rs7711358 0.1134 0.34312 0.3089 0.369 26 66 99 34 118 100
    rs7719448 0.847 0.45872 0.4574 0.4597 44 84 60 49 130 69
    rs7724761 0.9232 0.45862 0.4545 0.4617 43 84 60 49 131 68
    rs7742476 0.00424 0.23316 0.2544 0.2166 7 72 90 4 86 127
    rs7762993 0.00187 0.18213 0.1855 0.1796 2 65 119 3 82 160
    rs7762993 0.00187 0.18213 0.1855 0.1796 2 65 119 3 82 160
    rs7767265 0.0128 0.24419 0.2594 0.2325 9 79 99 7 99 137
    rs7767265 0.0128 0.24419 0.2594 0.2325 9 79 99 7 99 137
    rs7768128 0.7859 0.22779 0.2275 0.228 5 76 108 19 76 155
    rs7771264 0.25 0.2483 0.2513 0.246 14 67 108 18 88 146
    rs7773151 0.3391 0.2246 0.2225 0.2262 10 65 116 16 82 154
    rs7773210 0.3391 0.2246 0.2225 0.2262 10 65 116 16 82 154
    rs7808536 0.7448 0.18582 0.2095 0.1674 8 59 112 7 63 160
    rs7843510 0.1444 0.42325 0.4293 0.4187 40 84 67 47 117 88
    rs7894867 0.1751 0.12018 0.1349 0.1091 0 51 138 3 49 200
    rs7921834 0.2375 0.33182 0.3658 0.306 28 83 79 26 101 123
    rs7939893 0.3875 0.32653 0.2789 0.3625 22 62 106 29 124 98
    rs7939893 0.3875 0.32653 0.2789 0.3625 22 62 106 29 124 98
    rs7944513 0.145 0.24522 0.2793 0.2197 17 66 96 14 77 148
    rs7944513 0.145 0.24522 0.2793 0.2197 17 66 96 14 77 148
    rs7949720 1 0.11603 0.1378 0.0987 3 45 137 2 42 189
    rs7949720 1 0.11603 0.1378 0.0987 3 45 137 2 42 189
    rs7955901 0.2142 0.46364 0.4184 0.498 34 91 65 67 115 68
    rs7955901 0.2142 0.46364 0.4184 0.498 34 91 65 67 115 68
    rs7956274 0.3288 0.45423 0.4066 0.4898 30 88 64 63 113 68
    rs7956274 0.3288 0.45423 0.4066 0.4898 30 88 64 63 113 68
    rs7956274 0.3288 0.45423 0.4066 0.4898 30 88 64 63 113 68
    rs7957932 0.3884 0.47039 0.4241 0.506 35 92 64 67 117 64
    rs7957932 0.3884 0.47039 0.4241 0.506 35 92 64 67 117 64
    rs7984504 0.3222 0.31603 0.3063 0.3234 19 79 93 30 103 119
    rs7999518 0.6979 0.49882 0.4385 0.543 29 99 51 74 117 53
    rs8026245 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs8026245 1 0.23416 0.2539 0.2191 14 69 108 10 90 151
    rs8060725 0.8062 0.26298 0.2225 0.2937 11 63 117 18 112 122
    rs8103016 0.4981 0.22573 0.2461 0.2103 11 72 108 14 78 160
    rs8103016 0.4981 0.22573 0.2461 0.2103 11 72 108 14 78 160
    rs8104182 0.8882 0.21591 0.2407 0.1972 10 71 108 11 77 163
    rs8104182 0.8882 0.21591 0.2407 0.1972 10 71 108 11 77 163
    rs8129461 0.2921 0.04989 0.0262 0.068 1 8 182 1 32 217
    rs8129461 0.2921 0.04989 0.0262 0.068 1 8 182 1 32 217
    rs8130021 0.2362 0.04638 0.0262 0.0618 1 8 182 1 29 221
    rs8130021 0.2362 0.04638 0.0262 0.0618 1 8 182 1 29 221
    rs879961 0.1949 0.28182 0.2974 0.27 13 87 90 16 103 131
    rs879961 0.1949 0.28182 0.2974 0.27 13 87 90 16 103 131
    rs906353 0.651 0.3053 0.3172 0.2964 16 86 84 22 103 123
    rs915491 0.1184 0.30839 0.3474 0.2789 28 76 86 21 98 132
    rs915493 0.1184 0.30839 0.3474 0.2789 28 76 86 21 98 132
    rs915494 0.1185 0.32227 0.3683 0.286 29 79 78 22 91 123
    rs915494 0.1185 0.32227 0.3683 0.286 29 79 78 22 91 123
    rs917295 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs9284851 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs9293464 0.9232 0.45862 0.4545 0.4617 43 84 60 49 131 68
    rs9295154 0.2326 0.13995 0.1545 0.129 3 53 135 9 47 196
    rs9310221 0.1503 0.42875 0.426 0.4308 29 86 54 36 121 67
    rs9310699 0.5114 0.31828 0.322 0.3155 20 83 88 28 103 121
    rs9310700 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs9310700 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs9310701 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs9310704 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs9319185 0.4378 0.31293 0.2989 0.3234 17 79 93 30 103 119
    rs9319186 0.3222 0.31603 0.3063 0.3234 19 79 93 30 103 119
    rs9327555 0.1134 0.34312 0.3115 0.3671 27 65 99 33 119 100
    rs9403367 0.3391 0.2246 0.2225 0.2262 10 65 116 16 82 154
    rs9419608 0.3324 0.45814 0.4098 0.4939 28 94 61 57 130 60
    rs9426437 0.3217 0.43042 0.4355 0.4265 33 96 57 40 123 75
    rs9454967 0.07328 0.0907 0.0895 0.0916 3 28 159 4 38 209
    rs9635511 0.7678 0.41399 0.3915 0.4312 26 96 67 47 119 81
    rs966583 1 0.40091 0.3658 0.4277 26 87 77 44 125 80
    rs966583 1 0.40091 0.3658 0.4277 26 87 77 44 125 80
    rs980263 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs980264 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs9812206 0.09556 0.07692 0.0785 0.0757 0 30 161 0 38 213
    rs9812206 0.09556 0.07692 0.0785 0.0757 0 30 161 0 38 213
    rs9813552 0.4984 0.07692 0.0785 0.0757 0 30 161 1 36 214
    rs9813552 0.4984 0.07692 0.0785 0.0757 0 30 161 1 36 214
    rs9815037 0.4982 0.07675 0.0785 0.0754 0 30 161 1 36 215
    rs9815037 0.4982 0.07675 0.0785 0.0754 0 30 161 1 36 215
    rs9819583 0.5114 0.31828 0.322 0.3155 20 83 88 28 103 121
    rs9825349 0.4982 0.07675 0.0785 0.0754 0 30 161 1 36 215
    rs9825349 0.4982 0.07675 0.0785 0.0754 0 30 161 1 36 215
    rs9833118 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs9833118 0.7429 0.31941 0.3246 0.3155 19 86 86 28 103 121
    rs9834217 0.5011 0.07788 0.0785 0.0774 0 30 161 1 37 214
    rs9834217 0.5011 0.07788 0.0785 0.0774 0 30 161 1 37 214
    rs9838563 1 0.33066 0.3413 0.3226 20 89 80 28 104 116
    rs9840460 0.5011 0.07788 0.0785 0.0774 0 30 161 1 37 214
    rs9840460 0.5011 0.07788 0.0785 0.0774 0 30 161 1 37 214
    rs9840756 0.5026 0.07895 0.0789 0.0789 0 30 160 1 37 209
    rs9840756 0.5026 0.07895 0.0789 0.0789 0 30 160 1 37 209
    rs9847999 1 0.34633 0.3537 0.3407 20 93 75 32 105 111
    rs9864769 0.9151 0.33409 0.3429 0.3274 20 91 80 30 105 117
    rs9866421 0.2848 0.42551 0.3979 0.4464 29 94 68 57 111 84
    rs987296 0.5103 0.31859 0.322 0.316 20 83 88 28 102 120
    rs9881685 0.09541 0.07727 0.0789 0.076 0 30 160 0 38 212
    rs9881685 0.09541 0.07727 0.0789 0.076 0 30 160 0 38 212
    rs992695 0.1596 0.28281 0.2974 0.2718 13 87 90 16 105 131
    rs992695 0.1596 0.28281 0.2974 0.2718 13 87 90 16 105 131
    rs9936999 0.2862 0.35714 0.3571 0.3571 20 40 52 18 74 62
  • TABLE 17
    SNP rs # SOURCE ALLELE (A1) MODEL P P(R) OR OR(R) Q I
    rs77638540 Genotyped T DOMINANT 2.65E−03 0.0159 0.4686 0.4785 0.2317 30.09
    rs72746987 Genotyped A DOMINANT 3.12E−05 3.12E−05 0.337 0.337 0.9734 0
    rs10021016 Genotyped G GENOTYPIC 4.88E−04 0.000488 2.3201 2.3201 0.9885 0
    rs10021016 Genotyped G RECESSIVE 7.69E−04 0.0007685 2.2102 2.2102 0.9334 0
    rs10051148 Imputed C DOMINANT 0.000697 0.000697 0.6715 0.6715 0.7678 0
    rs10054055 Imputed T DOMINANT 0.0008519 0.0008519 0.6758 0.6758 0.8098 0
    rs10067895 Imputed A DOMINANT 9.99E−04 0.0009994 0.6775 0.6775 0.9204 0
    rs10100725 Imputed C DOMINANT 5.54E−05 5.54E−05 0.5929 0.5929 0.3989 0
    rs10128531 Imputed T ADDITIVE 1.54E−03 0.001541 1.4677 1.4677 0.921 0
    rs10181743 Imputed G ADDITIVE 9.76E−05 9.76E−05 1.4004 1.4004 0.3524 0
    rs10199127 Imputed T DOMINANT 4.59E−05 4.59E−05 1.6169 1.6169 0.3286 0
    rs10270624 Imputed G DOMINANT 2.16E−04 0.0003017 1.5776 1.5804 0.3061 4.53
    rs1030006 Imputed G RECESSIVE 7.93E−05 7.93E−05 1.7557 1.7557 0.577 0
    rs1031811 Imputed A RECESSIVE 6.16E−03 0.006159 1.7624 1.7624 0.7766 0
    rs10430870 Genotyped G GENOTYPIC 3.07E−03 3.07E−03 2.094 2.094 0.4823 0
    rs10430870 Genotyped G RECESSIVE 0.003991 0.003991 2.0223 2.0223 0.6273 0
    rs10469597 Imputed A GENOTYPIC 4.70E−05 4.70E−05 2.5398 2.5398 0.9742 0
    rs10469597 Imputed A RECESSIVE 4.85E−05 4.85E−05 2.4663 2.4663 0.8923 0
    rs10478919 Imputed G DOMINANT 5.77E−04 0.0005772 0.6679 0.6679 0.7414 0
    rs10506623 Imputed C ADDITIVE 0.0001433 0.0001433 0.7177 0.7177 0.7038 0
    rs10506623 Imputed C DOMINANT 8.28E−05 8.28E−05 0.6159 0.6159 0.9559 0
    rs10506626 Imputed A ADDITIVE 7.58E−05 7.58E−05 0.7112 0.7112 0.422 0
    rs10506626 Imputed A DOMINANT 8.52E−06 8.52E−06 0.5838 0.5838 0.8702 0
    rs10509477 Imputed T DOMINANT 8.97E−05 8.97E−05 1.5819 1.5819 0.6066 0
    rs10517918 Imputed G RECESSIVE 6.05E−05 6.05E−05 1.8264 1.8264 0.4972 0
    rs10517924 Imputed A RECESSIVE 7.80E−05 7.80E−05 1.7459 1.7459 0.7576 0
    rs10519362 Imputed G DOMINANT 0.001678 0.001678 1.4934 1.4934 0.9592 0
    rs10520072 Imputed T DOMINANT 0.0005579 0.0005579 0.6664 0.6664 0.9359 0
    rs10737390 Imputed T DOMINANT 5.50E−05 5.50E−05 0.6131 0.6131 0.5051 0
    rs10742851 Imputed T RECESSIVE 9.69E−05 9.69E−05 0.3726 0.3726 0.5568 0
    rs10743685 Imputed G GENOTYPIC 6.86E−05 6.86E−05 2.0019 2.0019 0.8416 0
    rs10743685 Imputed G RECESSIVE 1.49E−04 0.0001485 1.8297 1.8297 0.5748 0
    rs10749293 Imputed G DOMINANT 6.75E−05 6.75E−05 1.5947 1.5947 0.7622 0
    rs10749294 Imputed A DOMINANT 1.82E−04 1.82E−04 1.55 1.55 0.8529 0
    rs10753760 Imputed T ADDITIVE 5.13E−05 5.13E−05 1.4174 1.4174 0.7656 0
    rs10753760 Imputed T GENOTYPIC 5.49E−05 5.49E−05 2.0466 2.0466 0.7902 0
    rs10772362 Imputed T ADDITIVE 1.62E−05 1.62E−05 0.6474 0.6474 0.7786 0
    rs10784891 Imputed C ADDITIVE 3.04E−04 0.0003039 0.7309 0.7309 0.7572 0
    rs10784891 Imputed C DOMINANT 1.43E−04 1.43E−04 0.6151 0.6151 0.793 0
    rs10784891 Imputed C GENOTYPIC 1.13E−03 1.13E−03 0.564 0.564 0.5692 0
    rs10787923 Imputed G DOMINANT 6.49E−05 6.49E−05 1.5969 1.5969 0.7212 0
    rs10787924 Imputed T DOMINANT 1.60E−04 0.0001596 1.5563 1.5563 0.8327 0
    rs10787949 Imputed A DOMINANT 0.0001459 0.0001459 1.5599 1.5599 0.592 0
    rs10787951 Imputed G DOMINANT 0.0001459 0.0001459 1.5599 1.5599 0.592 0
    rs10787983 Imputed C DOMINANT 0.0001474 0.0001474 1.5574 1.5574 0.6777 0
    rs10794733 Imputed C ADDITIVE 0.00276 0.00276 0.7628 0.7628 0.9657 0
    rs10818280 Imputed C DOMINANT 1.66E−03 0.00166 0.6922 0.6922 0.8399 0
    rs10860586 Imputed A ADDITIVE 9.56E−05 9.56E−05 1.3855 1.3855 0.4436 0
    rs10860586 Imputed A GENOTYPIC 9.35E−05 9.35E−05 1.9196 1.9196 0.4483 0
    rs10870473 Imputed A ADDITIVE 9.61E−05 9.61E−05 0.569 0.569 0.6419 0
    rs10870473 Imputed A DOMINANT 3.52E−05 3.52E−05 0.4776 0.4776 0.9449 0
    rs10879240 Imputed C ADDITIVE 5.56E−04 0.0005557 0.7439 0.7439 0.8062 0
    rs10879240 Imputed C GENOTYPIC 0.001627 0.001627 0.5771 0.5771 0.5726 0
    rs10879242 Imputed A ADDITIVE 2.20E−04 0.0002198 0.7269 0.7269 0.7534 0
    rs10879242 Imputed A DOMINANT 7.97E−05 7.97E−05 0.6177 0.6177 0.8661 0
    rs10879245 Imputed G ADDITIVE 2.20E−04 0.0002198 0.7269 0.7269 0.7534 0
    rs10879245 Imputed G DOMINANT 7.97E−05 7.97E−05 0.6177 0.6177 0.8661 0
    rs10879249 Imputed T ADDITIVE 7.98E−05 7.98E−05 0.7098 0.7098 0.7061 0
    rs10879249 Imputed T DOMINANT 3.54E−05 3.54E−05 0.6036 0.6036 0.9476 0
    rs10886429 Imputed A DOMINANT 1.10E−04 1.10E−04 1.5741 1.5741 0.6665 0
    rs10886449 Imputed G DOMINANT 0.0002256 0.0002256 1.5385 1.5385 0.68 0
    rs10886451 Imputed G DOMINANT 2.26E−04 0.0002256 1.5385 1.5385 0.68 0
    rs10886452 Imputed A DOMINANT 0.0001459 0.0001459 1.5599 1.5599 0.592 0
    rs10886456 Imputed G DOMINANT 0.0002256 0.0002256 1.5385 1.5385 0.68 0
    rs10886463 Imputed C DOMINANT 0.0001545 0.0001545 1.5578 1.5578 0.6315 0
    rs10886465 Imputed A DOMINANT 8.63E−05 8.63E−05 1.5827 1.5827 0.5622 0
    rs10886526 Imputed C DOMINANT 1.47E−04 0.0001474 1.5574 1.5574 0.6777 0
    rs10922903 Imputed C RECESSIVE 9.19E−05 9.19E−05 0.5329 0.5329 0.4609 0
    rs10941126 Imputed G ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs10941126 Imputed G DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs10947980 Imputed G ADDITIVE 7.93E−05 7.93E−05 0.6897 0.6897 0.3212 0
    rs11059376 Imputed T ADDITIVE 5.53E−05 5.53E−05 1.5704 1.5704 0.929 0
    rs11072995 Imputed T GENOTYPIC 0.0002433 0.0002433 3.2596 3.2596 0.6428 0
    rs11072995 Imputed T RECESSIVE 0.0003025 0.0003025 3.164 3.164 0.6989 0
    rs11081202 Genotyped G GENOTYPIC 2.03E−03 0.002028 1.979 1.979 0.4228 0
    rs11081202 Genotyped G RECESSIVE 5.63E−04 0.0005629 2.0891 2.0891 0.5637 0
    rs110965 Imputed C GENOTYPIC 6.88E−03 6.88E−03 1.7493 1.7493 0.9979 0
    rs11124962 Imputed A DOMINANT 0.000116 0.000116 1.5786 1.5786 0.4004 0
    rs1116596 Imputed T DOMINANT 6.74E−04 0.000674 0.6707 0.6707 0.7616 0
    rs11178531 Imputed A ADDITIVE 1.67E−03 1.67E−03 0.7662 0.7662 0.8942 0
    rs11178531 Imputed A DOMINANT 2.00E−04 0.0001996 0.6214 0.6214 0.9419 0
    rs11178583 Imputed A ADDITIVE 8.27E−05 8.27E−05 0.7104 0.7104 0.7004 0
    rs11178583 Imputed A DOMINANT 3.96E−05 3.96E−05 0.6056 0.6056 0.9636 0
    rs11178589 Imputed T ADDITIVE 6.68E−05 6.68E−05 0.7079 0.7079 0.7072 0
    rs11178589 Imputed T DOMINANT 3.53E−05 3.53E−05 0.6015 0.6015 0.9599 0
    rs11178594 Imputed C ADDITIVE 0.0001049 0.0001049 0.7148 0.7148 0.7211 0
    rs11178594 Imputed C DOMINANT 4.13E−05 4.13E−05 0.6065 0.6065 0.8956 0
    rs11178602 Imputed T ADDITIVE 8.81E−05 8.81E−05 0.7122 0.7122 0.7436 0
    rs11178602 Imputed T DOMINANT 3.05E−05 3.05E−05 0.6016 0.6016 0.8568 0
    rs11178648 Imputed T ADDITIVE 0.0002031 0.0002031 0.7267 0.7267 0.6332 0
    rs11178648 Imputed T DOMINANT 1.72E−05 1.72E−05 0.5945 0.5945 0.939 0
    rs11198877 Imputed T DOMINANT 1.33E−04 0.0001326 1.5641 1.5641 0.6136 0
    rs11198942 Imputed T DOMINANT 8.97E−05 8.97E−05 1.5819 1.5819 0.6066 0
    rs11221075 Imputed A ADDITIVE 0.002129 0.002129 0.6684 0.6684 0.6989 0
    rs11242020 Imputed T DOMINANT 0.0005976 0.0005976 0.6685 0.6685 0.6979 0
    rs11242021 Imputed T DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs11242022 Imputed T DOMINANT 0.0007669 0.0007669 0.6732 0.6732 0.8443 0
    rs11242023 Imputed T DOMINANT 0.0009289 0.0009289 0.677 0.677 0.8728 0
    rs1149349 Imputed T DOMINANT 7.39E−05 7.39E−05 1.6656 1.6656 0.8419 0
    rs1149350 Imputed A ADDITIVE 1.42E−05 1.42E−05 1.5752 1.5752 0.893 0
    rs1149350 Imputed A DOMINANT 5.15E−06 5.15E−06 1.7451 1.7451 0.7691 0
    rs11576627 Imputed T ADDITIVE 0.0002162 0.0002162 1.5806 1.5806 0.4132 0
    rs11576627 Imputed T DOMINANT 1.75E−04 0.0001751 1.6594 1.6594 0.4028 0
    rs11630050 Imputed G GENOTYPIC 0.0001769 0.0001769 3.0849 3.0849 0.8542 0
    rs11630050 Imputed G RECESSIVE 0.0001739 0.0001739 3.0436 3.0436 0.9473 0
    rs11633024 Imputed C GENOTYPIC 0.0001769 0.0001769 3.0849 3.0849 0.8542 0
    rs11633024 Imputed C RECESSIVE 0.0001739 0.0001739 3.0436 3.0436 0.9473 0
    rs11636298 Imputed G GENOTYPIC 0.0001106 0.0001106 3.4591 3.4591 0.8474 0
    rs11636298 Imputed G RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs11637363 Imputed C GENOTYPIC 0.0001099 0.0001099 3.1869 3.1869 0.7516 0
    rs11637363 Imputed C RECESSIVE 0.0001027 0.0001027 3.1534 3.1534 0.8534 0
    rs11637813 Imputed A GENOTYPIC 0.0001769 0.0001769 3.0849 3.0849 0.8542 0
    rs11637813 Imputed A RECESSIVE 0.0001739 0.0001739 3.0436 3.0436 0.9473 0
    rs11638043 Imputed C GENOTYPIC 1.79E−04 0.0001788 3.0118 3.0118 0.8819 0
    rs11638043 Imputed C RECESSIVE 0.0001717 0.0001717 2.9756 2.9756 0.9909 0
    rs11638115 Imputed A GENOTYPIC 0.0002433 0.0002433 3.2596 3.2596 0.6428 0
    rs11638115 Imputed A RECESSIVE 0.0003025 0.0003025 3.164 3.164 0.6989 0
    rs11638444 Imputed C GENOTYPIC 0.0001194 0.0001194 3.4378 3.4378 0.8647 0
    rs11717157 Imputed T ADDITIVE 8.91E−05 8.91E−05 1.3969 1.3969 0.7348 0
    rs11717157 Imputed T GENOTYPIC 5.30E−05 5.30E−05 2.0995 2.0995 0.9749 0
    rs11724055 Imputed A DOMINANT 0.00239 0.00239 0.6839 0.6839 0.4246 0
    rs11743355 Imputed C ADDITIVE 1.64E−05 1.64E−05 0.2366 0.2366 0.5626 0
    rs11743355 Imputed C DOMINANT 3.44E−05 3.44E−05 0.2417 0.2417 0.589 0
    rs11746806 Imputed T ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs11746806 Imputed T DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs11746959 Imputed T ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs11746959 Imputed T DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs11749272 Imputed T DOMINANT 0.0005772 0.0005772 0.6679 0.6679 0.7414 0
    rs11839636 Imputed C GENOTYPIC 7.59E−05 7.59E−05 2.2506 2.2506 0.9705 0
    rs11839785 Imputed C GENOTYPIC 7.97E−05 7.97E−05 2.2456 2.2456 0.9638 0
    rs11853619 Imputed C GENOTYPIC 0.0001175 0.0001175 3.4406 3.4406 0.8594 0
    rs11853619 Imputed C RECESSIVE 0.0001702 0.0001702 3.2975 3.2975 0.9191 0
    rs11856780 Imputed A GENOTYPIC 0.0001175 0.0001175 3.4406 3.4406 0.8594 0
    rs11856780 Imputed A RECESSIVE 0.0001702 0.0001702 3.2975 3.2975 0.9191 0
    rs11901899 Imputed A DOMINANT 3.44E−04 0.001093 1.5287 1.539 0.2722 17.07
    rs11903290 Imputed C RECESSIVE 0.006295 0.006295 1.7598 1.7598 0.7724 0
    rs11909480 Imputed G ADDITIVE 0.001521 0.001521 0.4399 0.4399 0.3262 0
    rs11909480 Imputed G DOMINANT 0.001914 0.001964 0.4405 0.4406 0.3163 0.41
    rs11910289 Imputed T ADDITIVE 0.001496 0.001496 1.8584 1.8584 0.5088 0
    rs11910289 Imputed T DOMINANT 0.001453 0.001453 1.9004 1.9004 0.599 0
    rs11920375 Genotyped C GENOTYPIC 7.94E−05 7.94E−05 2.0435 2.0435 0.8995 0
    rs11926319 Imputed G DOMINANT 9.79E−05 9.79E−05 0.5435 0.5435 0.854 0
    rs11933744 Imputed T RECESSIVE 9.01E−05 9.01E−05 2.5682 2.5682 0.6941 0
    rs11934919 Imputed C RECESSIVE 9.01E−05 9.01E−05 2.5682 2.5682 0.6941 0
    rs11934957 Imputed C RECESSIVE 9.01E−05 9.01E−05 2.5682 2.5682 0.6941 0
    rs11959206 Imputed A RECESSIVE 3.66E−05 3.66E−05 0.5455 0.5455 0.7414 0
    rs12038613 Imputed C RECESSIVE 7.06E−05 7.06E−05 0.5252 0.5252 0.5509 0
    rs12151417 Imputed T DOMINANT 6.45E−04 0.0006449 1.5021 1.5021 0.7699 0
    rs12153185 Imputed T DOMINANT 0.001052 0.001052 0.6792 0.6792 0.8684 0
    rs12182651 Imputed T DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs12235345 Imputed C DOMINANT 3.59E−04 0.005622 1.8464 1.8177 0.2149 34.98
    rs12324786 Imputed T GENOTYPIC 0.0002433 0.0002433 3.2596 3.2596 0.6428 0
    rs12324786 Imputed T RECESSIVE 0.0003025 0.0003025 3.164 3.164 0.6989 0
    rs12336958 Imputed G DOMINANT 7.27E−05 7.27E−05 1.6549 1.6549 0.457 0
    rs12407412 Imputed C ADDITIVE 0.0002548 0.0002548 1.5719 1.5719 0.384 0
    rs12407412 Imputed C DOMINANT 2.10E−04 2.10E−04 1.6487 1.6487 0.368 0
    rs12418971 Imputed C GENOTYPIC 0.001802 0.001802 2.2011 2.2011 0.4612 0
    rs12418971 Imputed C RECESSIVE 0.002813 0.002813 2.095 2.095 0.5916 0
    rs1241967 Imputed T RECESSIVE 0.000111 0.000111 0.4573 0.4573 0.3307 0
    rs12420184 Imputed G DOMINANT 4.91E−05 4.91E−05 0.5847 0.5847 0.5393 0
    rs12433968 Imputed T DOMINANT 4.10E−05 4.10E−05 0.6109 0.6109 0.318 0
    rs12445477 Imputed A DOMINANT 6.95E−05 6.95E−05 0.5027 0.5027 0.3771 0
    rs12447191 Genotyped T ADDITIVE 0.0002095 0.0002095 0.6717 0.6717 0.8037 0
    rs12447191 Genotyped T DOMINANT 2.32E−04 0.004396 0.6338 0.6204 0.1898 41.82
    rs12465349 Imputed A RECESSIVE 0.00192 0.00192 1.513 1.513 0.7914 0
    rs1247340 Imputed C ADDITIVE 5.07E−05 5.07E−05 1.5296 1.5296 0.9256 0
    rs1247340 Imputed C DOMINANT 1.08E−05 1.08E−05 1.7083 1.7083 0.8426 0
    rs1247341 Imputed C ADDITIVE 5.04E−05 5.04E−05 1.5303 1.5303 0.9761 0
    rs1247341 Imputed C DOMINANT 1.08E−05 1.08E−05 1.7098 1.7098 0.7759 0
    rs1247343 Imputed C DOMINANT 6.53E−05 6.53E−05 1.6756 1.6756 0.9862 0
    rs12509758 Imputed C DOMINANT 0.0001489 0.0001489 1.5799 1.5799 0.3277 0
    rs12515472 Imputed A DOMINANT 0.005408 0.005408 1.4022 1.4022 0.5945 0
    rs12548906 Imputed G ADDITIVE 3.90E−03 3.90E−03 1.3761 1.3761 0.5561 0
    rs12596240 Imputed G DOMINANT 4.46E−05 4.46E−05 0.6107 0.6107 0.5739 0
    rs12618781 Imputed A DOMINANT 5.33E−05 5.33E−05 0.5924 0.5924 0.6396 0
    rs12678600 Imputed A DOMINANT 5.58E−05 5.58E−05 0.6235 0.6235 0.8084 0
    rs12692229 Imputed T ADDITIVE 5.68E−03 0.005681 1.271 1.271 0.7737 0
    rs12713324 Imputed T DOMINANT 0.0005653 0.0005653 1.5061 1.5061 0.7503 0
    rs12719415 Imputed T DOMINANT 6.99E−04 6.99E−04 0.6712 0.6712 0.8706 0
    rs12820589 Imputed G ADDITIVE 3.73E−05 3.73E−05 1.5773 1.5773 0.4594 0
    rs12820589 Imputed G DOMINANT 8.50E−05 8.50E−05 1.6354 1.6354 0.3309 0
    rs12831292 Imputed G ADDITIVE 1.08E−04 0.0001082 0.7143 0.7143 0.7244 0
    rs12831292 Imputed G DOMINANT 3.86E−05 3.86E−05 0.6038 0.6038 0.8742 0
    rs13012636 Imputed G RECESSIVE 0.005887 0.005887 1.7676 1.7676 0.7851 0
    rs13038146 Imputed C ADDITIVE 0.0001909 0.0001909 1.3722 1.3722 0.8246 0
    rs13038146 Imputed C GENOTYPIC 0.0002206 0.0002206 1.9531 1.9531 0.7476 0
    rs13038146 Imputed C RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs13089860 Imputed A DOMINANT 0.001151 0.001151 0.6379 0.6379 0.8916 0
    rs13102419 Imputed T RECESSIVE 7.45E−05 7.45E−05 1.7512 1.7512 0.8001 0
    rs13194907 Imputed A ADDITIVE 7.20E−05 7.20E−05 1.9871 1.9871 0.9631 0
    rs13194907 Imputed A DOMINANT 4.88E−05 4.88E−05 2.0957 2.0957 0.9413 0
    rs13195745 Imputed A ADDITIVE 7.54E−05 7.54E−05 1.9837 1.9837 0.9685 0
    rs13195745 Imputed A DOMINANT 5.13E−05 5.13E−05 2.0917 2.0917 0.9353 0
    rs13265054 Imputed T DOMINANT 0.0001224 0.0001224 0.6362 0.6362 0.7096 0
    rs13273002 Imputed A GENOTYPIC 8.64E−05 8.64E−05 0.2714 0.2714 0.8433 0
    rs13282131 Imputed C ADDITIVE 0.000217 0.000217 1.3612 1.3612 0.7192 0
    rs13282131 Imputed C GENOTYPIC 0.00017 0.00017 1.8797 1.8797 0.7696 0
    rs13282131 Imputed C RECESSIVE 0.0009795 0.0009795 1.6011 1.6011 0.9829 0
    rs1330052 Imputed G GENOTYPIC 8.27E−05 8.27E−05 2.0747 2.0747 0.9516 0
    rs1335721 Imputed A RECESSIVE 7.06E−05 7.06E−05 0.5252 0.5252 0.5509 0
    rs1336382 Imputed T DOMINANT 9.54E−05 9.54E−05 1.5804 1.5804 0.6104 0
    rs1336383 Imputed T DOMINANT 8.97E−05 8.97E−05 1.5819 1.5819 0.6066 0
    rs1336407 Imputed T DOMINANT 1.35E−04 0.0001345 1.5612 1.5612 0.6665 0
    rs1336409 Imputed T DOMINANT 0.0001345 0.0001345 1.5612 1.5612 0.6665 0
    rs1336596 Imputed A DOMINANT 8.41E−06 8.41E−06 0.5875 0.5875 0.3994 0
    rs13387284 Imputed A DOMINANT 4.10E−05 4.10E−05 0.5856 0.5856 0.5635 0
    rs13401462 Imputed C DOMINANT 4.87E−06 4.87E−06 1.8734 1.8734 0.4869 0
    rs13409045 Imputed T ADDITIVE 8.99E−05 8.99E−05 0.7108 0.7108 0.8294 0
    rs1349284 Imputed C GENOTYPIC 7.91E−05 7.91E−05 2.0683 2.0683 0.8608 0
    rs1355715 Imputed T ADDITIVE 0.0001691 0.0001691 0.5021 0.5021 0.6625 0
    rs1357696 Imputed A GENOTYPIC 8.12E−05 8.12E−05 2.0503 2.0503 0.8139 0
    rs1357698 Imputed A GENOTYPIC 7.29E−05 7.29E−05 2.0604 2.0604 0.7974 0
    rs1357699 Imputed T GENOTYPIC 7.29E−05 7.29E−05 2.0604 2.0604 0.7974 0
    rs1363273 Imputed C RECESSIVE 7.91E−05 7.91E−05 0.5543 0.5543 0.8284 0
    rs1373601 Imputed A DOMINANT 6.34E−05 6.34E−05 0.6152 0.6152 0.3644 0
    rs1375829 Imputed C GENOTYPIC 7.91E−05 7.91E−05 2.0683 2.0683 0.8608 0
    rs1395748 Imputed G DOMINANT 7.51E−05 7.51E−05 0.6306 0.6306 0.7714 0
    rs1414865 Imputed T DOMINANT 1.46E−04 0.0001459 1.5599 1.5599 0.592 0
    rs1414873 Imputed A DOMINANT 0.0001345 0.0001345 1.5612 1.5612 0.6665 0
    rs1414876 Imputed C DOMINANT 1.35E−04 1.35E−04 1.5612 1.5612 0.6665 0
    rs1424643 Imputed G ADDITIVE 4.44E−04 0.0004437 1.4199 1.4199 0.4926 0
    rs1424643 Imputed G DOMINANT 4.24E−04 0.0004238 1.5226 1.5226 0.7796 0
    rs1424648 Imputed T DOMINANT 1.80E−03 1.80E−03 1.4456 1.4456 0.4734 0
    rs1429321 Imputed A DOMINANT 7.84E−04 7.84E−04 1.4871 1.4871 0.8099 0
    rs1429326 Imputed T ADDITIVE 0.0007358 0.0007358 1.3974 1.3974 0.5449 0
    rs1429326 Imputed T DOMINANT 0.0004785 0.0004785 1.5125 1.5125 0.8054 0
    rs1444741 Imputed A DOMINANT 3.42E−05 3.42E−05 0.605 0.605 0.3326 0
    rs1449916 Imputed C DOMINANT 2.24E−05 2.52E−05 0.5247 0.5244 0.3143 1.22
    rs1459523 Imputed A ADDITIVE 8.91E−05 8.91E−05 1.3969 1.3969 0.7348 0
    rs1459523 Imputed A GENOTYPIC 5.30E−05 5.30E−05 2.0995 2.0995 0.9749 0
    rs1466352 Imputed T GENOTYPIC 7.67E−05 7.67E−05 2.0358 2.0358 0.8969 0
    rs1466353 Imputed G GENOTYPIC 7.61E−05 7.61E−05 2.0365 2.0365 0.898 0
    rs1476714 Imputed A DOMINANT 0.0007134 0.0007134 0.6713 0.6713 0.8712 0
    rs1486723 Imputed C RECESSIVE 0.0003279 0.0003279 0.4982 0.4982 0.4282 0
    rs1495375 Imputed A ADDITIVE 0.0002198 0.0002198 0.7269 0.7269 0.7534 0
    rs1495375 Imputed A DOMINANT 7.97E−05 7.97E−05 0.6177 0.6177 0.8661 0
    rs1495381 Imputed T GENOTYPIC 0.00257 0.00257 1.6918 1.6918 0.6996 0
    rs1495381 Imputed T RECESSIVE 0.0004641 0.0004641 1.7303 1.7303 0.8349 0
    rs1498061 Imputed C ADDITIVE 1.30E−04 0.0001304 0.5363 0.5363 0.5167 0
    rs1498992 Imputed G DOMINANT 1.21E−04 0.0001213 0.6388 0.6388 0.4443 0
    rs1499001 Imputed T DOMINANT 4.88E−05 4.88E−05 0.6155 0.6155 0.3606 0
    rs1512988 Imputed A ADDITIVE 8.41E−05 8.41E−05 0.7101 0.7101 0.6962 0
    rs1512988 Imputed A DOMINANT 4.47E−05 4.47E−05 0.6074 0.6074 0.9954 0
    rs1512989 Imputed T ADDITIVE 8.41E−05 8.41E−05 0.7101 0.7101 0.6962 0
    rs1512989 Imputed T DOMINANT 4.47E−05 4.47E−05 0.6074 0.6074 0.9954 0
    rs1512991 Imputed T ADDITIVE 0.000399 0.000399 0.7396 0.7396 0.8085 0
    rs1512991 Imputed T DOMINANT 0.0001092 0.0001092 0.6115 0.6115 0.9069 0
    rs1512991 Imputed T GENOTYPIC 0.001397 0.001397 0.5777 0.5777 0.6436 0
    rs1524303 Imputed T GENOTYPIC 8.11E−05 8.11E−05 2.0455 2.0455 0.9122 0
    rs1524306 Imputed C ADDITIVE 8.11E−05 8.11E−05 1.3995 1.3995 0.7142 0
    rs1524306 Imputed C GENOTYPIC 4.94E−05 4.94E−05 2.1056 2.1056 0.9589 0
    rs1524310 Imputed G ADDITIVE 7.36E−05 7.36E−05 1.404 1.404 0.6761 0
    rs1524310 Imputed G GENOTYPIC 4.72E−05 4.72E−05 2.1176 2.1176 0.9271 0
    rs1524321 Imputed C GENOTYPIC 6.09E−05 6.09E−05 2.0756 2.0756 0.7818 0
    rs1527059 Imputed A DOMINANT 0.004607 0.004607 0.6321 0.6321 0.3968 0
    rs152707 Imputed A ADDITIVE 6.74E−05 6.74E−05 0.7127 0.7127 0.5137 0
    rs152707 Imputed A GENOTYPIC 9.17E−05 9.17E−05 0.4993 0.4993 0.3954 0
    rs152712 Genotyped C ADDITIVE 4.47E−05 4.47E−05 0.7064 0.7064 0.5198 0
    rs152712 Genotyped C GENOTYPIC 5.75E−05 5.75E−05 0.4894 0.4894 0.3791 0
    rs1533994 Imputed T GENOTYPIC 6.29E−05 6.29E−05 2.0565 2.0565 0.9308 0
    rs1535866 Imputed G DOMINANT 0.0004273 0.001126 1.5272 1.5369 0.2795 14.48
    rs1563773 Imputed T GENOTYPIC 8.07E−05 8.07E−05 2.0358 2.0358 0.9519 0
    rs1563774 Imputed T GENOTYPIC 8.07E−05 8.07E−05 2.0374 2.0374 0.8993 0
    rs1567740 Imputed T ADDITIVE 8.27E−05 8.27E−05 0.7104 0.7104 0.7004 0
    rs1567740 Imputed T DOMINANT 3.96E−05 3.96E−05 0.6056 0.6056 0.9636 0
    rs1572573 Imputed A DOMINANT 6.70E−05 6.70E−05 1.64 1.64 0.4852 0
    rs1577497 Imputed C RECESSIVE 7.41E−05 7.41E−05 0.5263 0.5263 0.5573 0
    rs1581514 Imputed T ADDITIVE 8.95E−05 8.95E−05 1.3993 1.3993 0.6083 0
    rs1581514 Imputed T GENOTYPIC 5.07E−05 5.07E−05 2.1081 2.1081 0.8699 0
    rs1582321 Imputed T DOMINANT 4.17E−05 4.17E−05 0.6096 0.6096 0.5879 0
    rs1582322 Imputed A DOMINANT 6.86E−05 6.86E−05 0.6175 0.6175 0.5471 0
    rs1582323 Imputed A DOMINANT 6.70E−05 6.70E−05 0.6171 0.6171 0.5101 0
    rs1592485 Imputed C DOMINANT 6.80E−05 6.80E−05 0.6167 0.6167 0.53 0
    rs1600954 Imputed T ADDITIVE 6.34E−05 6.34E−05 1.4064 1.4064 0.7548 0
    rs1600954 Imputed T GENOTYPIC 5.95E−05 5.95E−05 1.9926 1.9926 0.7001 0
    rs16938626 Imputed G DOMINANT 6.17E−05 6.17E−05 0.6242 0.6242 0.8167 0
    rs16964300 Imputed G ADDITIVE 0.0001511 0.0001511 0.6665 0.6665 0.8478 0
    rs16964300 Imputed G DOMINANT 0.0001894 0.003074 0.6299 0.618 0.2025 38.44
    rs16986282 Imputed G DOMINANT 0.001578 0.02315 0.4237 0.4355 0.1825 43.73
    rs17007620 Imputed G ADDITIVE 6.23E−05 6.23E−05 1.5131 1.5131 0.4281 0
    rs17007620 Imputed G DOMINANT 3.79E−05 3.79E−05 1.684 1.684 0.4732 0
    rs17014326 Imputed G DOMINANT 3.13E−05 3.13E−05 0.6151 0.6151 0.5429 0
    rs17047957 Imputed C DOMINANT 0.001421 0.001421 1.5018 1.5018 0.8023 0
    rs1705261 Imputed A RECESSIVE 0.0006289 0.0006289 1.7058 1.7058 0.7466 0
    rs17073341 Imputed A ADDITIVE 0.000719 0.03367 2.0963 1.9757 0.1667 47.71
    rs17073341 Imputed A DOMINANT 0.0008057 0.0341 2.0915 1.9741 0.1677 47.47
    rs17138702 Imputed G ADDITIVE 6.91E−05 6.91E−05 0.6037 0.6037 0.343 0
    rs17189710 Imputed T ADDITIVE 0.00017 0.00017 1.3762 1.3762 0.8443 0
    rs17189710 Imputed T GENOTYPIC 0.000209 0.000209 1.959 1.959 0.738 0
    rs17189710 Imputed T RECESSIVE 0.001525 0.001525 1.7043 1.7043 0.4016 0
    rs17310176 Imputed T ADDITIVE 0.0009735 0.001436 0.6909 0.6922 0.3063 4.46
    rs17310176 Imputed T DOMINANT 0.0008163 0.01496 0.6548 0.6669 0.1994 39.27
    rs17358860 Imputed A DOMINANT 0.002078 0.002078 0.6804 0.6804 0.407 0
    rs17370541 Imputed T GENOTYPIC 9.33E−05 9.33E−05 2.055 2.055 0.3333 0
    rs17370541 Imputed T RECESSIVE 6.92E−05 6.92E−05 1.969 1.969 0.671 0
    rs17526574 Imputed G GENOTYPIC 7.89E−05 7.89E−05 2.2297 2.2297 0.9421 0
    rs17530747 Imputed T DOMINANT 8.45E−05 8.45E−05 0.6272 0.6272 0.3668 0
    rs17649114 Imputed C DOMINANT 0.002429 0.002429 1.4394 1.4394 0.4375 0
    rs17766172 Imputed A RECESSIVE 0.0002007 0.0005167 0.4665 0.4683 0.2878 11.48
    rs1818885 Imputed G GENOTYPIC 5.46E−05 5.46E−05 2.1046 2.1046 0.983 0
    rs1832222 Imputed G DOMINANT 0.0001515 0.0001515 1.5562 1.5562 0.6814 0
    rs1861327 Imputed G DOMINANT 4.17E−05 4.17E−05 0.6096 0.6096 0.5879 0
    rs1868581 Imputed G ADDITIVE 7.20E−05 7.20E−05 1.4042 1.4042 0.6755 0
    rs1868581 Imputed G GENOTYPIC 4.84E−05 4.84E−05 2.1147 2.1147 0.9348 0
    rs1874313 Imputed A ADDITIVE 0.0001307 0.0001307 0.7177 0.7177 0.586 0
    rs1874313 Imputed A DOMINANT 5.03E−05 5.03E−05 0.6096 0.6096 0.9203 0
    rs1876409 Imputed C DOMINANT 6.56E−05 6.56E−05 0.6278 0.6278 0.8104 0
    rs1913201 Imputed G ADDITIVE 0.0004633 0.0004633 0.7392 0.7392 0.7118 0
    rs1913201 Imputed G DOMINANT 0.0002642 0.0002642 0.6285 0.6285 0.7714 0
    rs1913201 Imputed G GENOTYPIC 0.001515 0.001515 0.574 0.574 0.5208 0
    rs1916922 Imputed T GENOTYPIC 8.22E−05 8.22E−05 2.1096 2.1096 0.9454 0
    rs1936871 Genotyped G DOMINANT 9.04E−05 9.04E−05 0.6214 0.6214 0.3679 0
    rs1961157 Imputed T RECESSIVE 8.54E−05 8.54E−05 0.5553 0.5553 0.4429 0
    rs1987179 Imputed T ADDITIVE 0.001935 0.001935 0.7236 0.7236 0.8673 0
    rs1987179 Imputed T DOMINANT 0.000396 0.000396 0.6536 0.6536 0.8664 0
    rs1990023 Imputed T DOMINANT 0.0005303 0.0005303 0.6661 0.6661 0.7286 0
    rs1995025 Imputed C DOMINANT 0.001961 0.001961 1.5088 1.5088 0.5064 0
    rs2016194 Imputed G DOMINANT 0.0007182 0.0007182 0.6718 0.6718 0.875 0
    rs2023651 Imputed T ADDITIVE 3.73E−05 3.73E−05 0.6532 0.6532 0.5375 0
    rs2024902 Imputed A ADDITIVE 7.20E−05 7.20E−05 1.9871 1.9871 0.9631 0
    rs2024902 Imputed A DOMINANT 4.88E−05 4.88E−05 2.0957 2.0957 0.9413 0
    rs2025107 Imputed A DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs2025108 Imputed T DOMINANT 8.65E−05 8.65E−05 1.9168 1.9168 0.7647 0
    rs2031987 Imputed T GENOTYPIC 7.93E−05 7.93E−05 2.2431 2.2431 0.9603 0
    rs2052428 Imputed C DOMINANT 0.0001903 0.0001903 0.6109 0.6109 0.7253 0
    rs2053230 Imputed C ADDITIVE 6.65E−05 6.65E−05 0.5491 0.5491 0.7036 0
    rs2062448 Imputed T DOMINANT 9.26E−05 9.26E−05 0.5424 0.5424 0.9524 0
    rs2063420 Imputed C RECESSIVE 8.43E−05 8.43E−05 1.8009 1.8009 0.8175 0
    rs2063591 Imputed C ADDITIVE 0.001336 0.001336 0.7622 0.7622 0.8243 0
    rs2063591 Imputed C DOMINANT 0.0001828 0.0001828 0.619 0.619 0.9374 0
    rs208026 Genotyped A DOMINANT 0.0009159 0.0009159 1.4777 1.4777 0.8719 0
    rs208029 Imputed T DOMINANT 0.0032 0.0032 1.4242 1.4242 0.911 0
    rs208757 Imputed G DOMINANT 0.002063 0.002063 1.4401 1.4401 0.8897 0
    rs2095586 Imputed A DOMINANT 9.55E−05 9.55E−05 1.582 1.582 0.6057 0
    rs2095606 Imputed A DOMINANT 6.15E−06 6.15E−06 0.5812 0.5812 0.4893 0
    rs2102374 Imputed A ADDITIVE 2.38E−05 2.38E−05 0.6664 0.6664 0.4161 0
    rs2102374 Imputed A DOMINANT 1.59E−05 1.59E−05 0.6016 0.6016 0.9592 0
    rs2108426 Imputed C DOMINANT 0.0007182 0.0007182 0.6718 0.6718 0.875 0
    rs2110664 Imputed A DOMINANT 0.0002336 0.0002336 1.5536 1.5536 0.3488 0
    rs2132242 Imputed A ADDITIVE 0.0001077 0.0001077 0.7156 0.7156 0.7142 0
    rs2132242 Imputed A DOMINANT 5.48E−05 5.48E−05 0.6098 0.6098 0.9205 0
    rs2158958 Imputed A DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs2158961 Imputed G DOMINANT 0.000697 0.000697 0.6715 0.6715 0.7678 0
    rs2163046 Imputed A DOMINANT 0.0008376 0.0008376 1.4873 1.4873 0.9201 0
    rs2180286 Imputed G DOMINANT 0.001385 0.001385 0.6528 0.6528 0.6017 0
    rs2180684 Imputed A DOMINANT 0.0009602 0.0009602 1.6598 1.6598 0.8934 0
    rs2188079 Imputed C ADDITIVE 7.00E−05 7.00E−05 1.3978 1.3978 0.4286 0
    rs2188079 Imputed C GENOTYPIC 4.81E−05 4.81E−05 2.0195 2.0195 0.6225 0
    rs2190598 Imputed T DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs2190600 Imputed A DOMINANT 0.0009994 0.0009994 0.6775 0.6775 0.9204 0
    rs2224184 Genotyped T DOMINANT 0.001793 0.001793 0.6621 0.6621 0.6649 0
    rs2247066 Imputed A DOMINANT 7.51E−05 7.51E−05 0.6306 0.6306 0.7714 0
    rs2248236 Imputed C ADDITIVE 0.0005358 0.0005358 0.6815 0.6815 0.4894 0
    rs2248236 Imputed C DOMINANT 0.0001555 0.0001555 0.619 0.619 0.8208 0
    rs2265733 Imputed C ADDITIVE 2.38E−05 2.38E−05 0.6664 0.6664 0.4161 0
    rs2265733 Imputed C DOMINANT 1.59E−05 1.59E−05 0.6016 0.6016 0.9592 0
    rs2270584 Imputed A ADDITIVE 0.0001667 0.0001667 0.7239 0.7239 0.6562 0
    rs2270584 Imputed A DOMINANT 1.41E−05 1.41E−05 0.5915 0.5915 0.9146 0
    rs2270586 Imputed A ADDITIVE 0.0001716 0.0001716 0.7243 0.7243 0.6525 0
    rs2270586 Imputed A DOMINANT 1.54E−05 1.54E−05 0.5928 0.5928 0.9252 0
    rs229775 Imputed A RECESSIVE 0.000111 0.000111 0.4573 0.4573 0.3307 0
    rs229815 Imputed T RECESSIVE 0.0002282 0.0002282 0.4565 0.4565 0.4856 0
    rs229829 Imputed C RECESSIVE 0.0005435 0.0005435 0.5446 0.5446 0.5763 0
    rs229831 Imputed A RECESSIVE 0.0002275 0.002067 0.469 0.4773 0.2519 23.81
    rs2317057 Imputed T ADDITIVE 0.002089 0.002089 0.7151 0.7151 0.9648 0
    rs2322100 Genotyped T RECESSIVE 0.000848 0.000848 2.0921 2.0921 0.3268 0
    rs2322101 Imputed A RECESSIVE 0.0008488 0.0008488 2.0923 2.0923 0.3199 0
    rs2327929 Imputed G RECESSIVE 6.56E−05 6.56E−05 1.7968 1.7968 0.3419 0
    rs2332844 Imputed A ADDITIVE 2.83E−05 2.83E−05 1.7997 1.7997 0.9786 0
    rs2332844 Imputed A RECESSIVE 0.0001148 0.0001148 1.8396 1.8396 0.9347 0
    rs2349170 Imputed G DOMINANT 0.0004675 0.0004675 1.5226 1.5226 0.4042 0
    rs2356722 Imputed G DOMINANT 2.78E−05 2.78E−05 0.6136 0.6136 0.5952 0
    rs2364956 Imputed T ADDITIVE 7.88E−05 7.88E−05 1.5326 1.5326 0.464 0
    rs2373793 Imputed G ADDITIVE 0.0006153 0.0006153 1.4555 1.4555 0.5436 0
    rs2373793 Imputed G DOMINANT 0.0002422 0.0002422 1.5984 1.5984 0.3199 0
    rs238252 Imputed G ADDITIVE 3.92E−05 3.92E−05 1.6115 1.6115 0.7369 0
    rs238252 Imputed G DOMINANT 2.65E−05 2.65E−05 1.7462 1.7462 0.5867 0
    rs2383903 Imputed G DOMINANT 9.89E−05 9.89E−05 0.6336 0.6336 0.873 0
    rs2387945 Imputed G DOMINANT 0.002288 0.002288 1.4967 1.4967 0.5359 0
    rs2389863 Imputed A DOMINANT 0.0005489 0.0005489 0.6585 0.6585 0.8176 0
    rs2389866 Imputed C DOMINANT 0.000396 0.000396 0.6536 0.6536 0.8664 0
    rs2389869 Imputed C DOMINANT 0.000396 0.000396 0.6536 0.6536 0.8664 0
    rs2389870 Genotyped C DOMINANT 0.003433 0.003433 0.6945 0.6945 0.3965 0
    rs2418494 Imputed G ADDITIVE 0.002097 0.002097 0.7772 0.7772 0.4019 0
    rs2418494 Imputed G GENOTYPIC 0.001772 0.001772 0.5989 0.5989 0.3574 0
    rs2418541 Imputed A DOMINANT 0.0005303 0.0005303 0.6661 0.6661 0.7286 0
    rs2418542 Imputed A DOMINANT 0.0005772 0.0005772 0.6679 0.6679 0.7414 0
    rs2423556 Imputed C DOMINANT 0.001354 0.001354 0.6507 0.6507 0.5885 0
    rs2437688 Imputed C ADDITIVE 0.004791 0.004791 1.4661 1.4661 0.9462 0
    rs2456809 Imputed G DOMINANT 6.91E−05 6.91E−05 0.6286 0.6286 0.7989 0
    rs2456811 Imputed T ADDITIVE 2.64E−05 2.64E−05 0.6679 0.6679 0.4268 0
    rs2456811 Imputed T DOMINANT 1.79E−05 1.79E−05 0.6034 0.6034 0.9743 0
    rs2476976 Imputed C DOMINANT 0.0002835 0.0002835 1.5277 1.5277 0.6105 0
    rs2484911 Imputed A DOMINANT 0.0002659 0.0002659 1.5304 1.5304 0.8231 0
    rs2488557 Imputed C DOMINANT 9.46E−05 9.46E−05 0.5776 0.5776 0.6502 0
    rs250162 Imputed C ADDITIVE 0.000113 0.0003838 0.6768 0.6731 0.2772 15.32
    rs250162 Imputed C DOMINANT 4.84E−05 0.0006095 0.6135 0.6056 0.2344 29.27
    rs2560708 Imputed T ADDITIVE 0.0002656 0.0002656 0.6487 0.6487 0.5707 0
    rs2617841 Imputed G DOMINANT 0.0002103 0.0002103 0.633 0.633 0.4225 0
    rs2622499 Imputed G DOMINANT 0.0004741 0.0004741 0.6573 0.6573 0.8397 0
    rs264129 Imputed T DOMINANT 0.0007594 0.0007594 0.6718 0.6718 0.7413 0
    rs2642936 Imputed T ADDITIVE 9.35E−05 9.35E−05 1.4936 1.4936 0.3776 0
    rs2660633 Imputed A DOMINANT 6.56E−05 6.56E−05 0.6278 0.6278 0.8104 0
    rs2660634 Imputed C DOMINANT 6.56E−05 6.56E−05 0.6278 0.6278 0.8104 0
    rs2660648 Imputed A ADDITIVE 2.38E−05 2.38E−05 0.6664 0.6664 0.4161 0
    rs2660648 Imputed A DOMINANT 1.59E−05 1.59E−05 0.6016 0.6016 0.9592 0
    rs2681505 Imputed T ADDITIVE 1.62E−05 1.62E−05 0.6474 0.6474 0.7786 0
    rs277411 Imputed G DOMINANT 4.27E−05 4.27E−05 0.3261 0.3261 0.7363 0
    rs2832634 Imputed G ADDITIVE 0.001422 0.001422 1.8637 1.8637 0.4977 0
    rs2832637 Imputed T ADDITIVE 0.001422 0.001422 1.8637 1.8637 0.4977 0
    rs2843167 Imputed A DOMINANT 4.64E−05 4.64E−05 0.6208 0.6208 0.6602 0
    rs2876227 Imputed C ADDITIVE 0.0004318 0.0004318 1.3526 1.3526 0.8494 0
    rs2876227 Imputed C GENOTYPIC 0.0004406 0.0004406 1.9073 1.9073 0.726 0
    rs2882097 Imputed A DOMINANT 8.97E−05 8.97E−05 1.5819 1.5819 0.6066 0
    rs2909862 Imputed G DOMINANT 8.19E−05 8.19E−05 1.7275 1.7275 0.4161 0
    rs3001945 Imputed T DOMINANT 0.001929 0.001929 1.5254 1.5254 0.656 0
    rs3011020 Imputed C DOMINANT 0.002194 0.002194 1.4992 1.4992 0.5299 0
    rs36071725 Genotyped C ADDITIVE 4.45E−06 4.45E−06 1.4999 1.4999 0.8099 0
    rs36071725 Genotyped C GENOTYPIC 2.95E−06 1.95E−05 2.5235 2.5053 0.2811 13.92
    rs373983 Imputed G DOMINANT 0.001847 0.001847 1.4715 1.4715 0.5548 0
    rs3743794 Imputed G DOMINANT 9.02E−05 9.02E−05 0.6224 0.6224 0.5016 0
    rs3756154 Imputed C ADDITIVE 0.001935 0.001935 0.7236 0.7236 0.8673 0
    rs3756154 Imputed C DOMINANT 0.000396 0.000396 0.6536 0.6536 0.8664 0
    rs3775850 Imputed A DOMINANT 0.001884 0.001884 0.6779 0.6779 0.3941 0
    rs3775851 Imputed C DOMINANT 0.00239 0.00239 0.6839 0.6839 0.4246 0
    rs3793044 Imputed C ADDITIVE 9.83E−05 9.83E−05 1.9638 1.9638 0.8837 0
    rs3793044 Imputed C DOMINANT 6.76E−05 6.76E−05 2.0697 2.0697 0.9811 0
    rs3793053 Imputed C DOMINANT 5.01E−05 5.01E−05 1.9787 1.9787 0.624 0
    rs3796246 Imputed G DOMINANT 8.90E−05 8.90E−05 0.5398 0.5398 0.4358 0
    rs3806003 Imputed A ADDITIVE 9.83E−05 9.83E−05 1.9638 1.9638 0.8837 0
    rs3806003 Imputed A DOMINANT 6.76E−05 6.76E−05 2.0697 2.0697 0.9811 0
    rs3806004 Imputed T DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs3806010 Imputed T DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs3806014 Imputed T DOMINANT 5.67E−05 5.67E−05 1.9649 1.9649 0.6221 0
    rs3806015 Imputed A DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs3806018 Imputed A DOMINANT 7.82E−05 7.82E−05 1.9419 1.9419 0.5908 0
    rs3806019 Imputed A DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs3806024 Imputed T DOMINANT 5.01E−05 5.01E−05 1.9787 1.9787 0.624 0
    rs3915080 Imputed A GENOTYPIC 5.44E−05 5.44E−05 2.0907 2.0907 0.9248 0
    rs3942254 Imputed T ADDITIVE 0.0001416 0.0001416 0.7166 0.7166 0.775 0
    rs3942254 Imputed T DOMINANT 7.52E−05 7.52E−05 0.6139 0.6139 0.912 0
    rs3945085 Imputed A DOMINANT 6.75E−05 6.75E−05 1.5947 1.5947 0.7622 0
    rs3976737 Imputed G ADDITIVE 4.73E−05 4.73E−05 0.6147 0.6147 0.6857 0
    rs399485 Imputed A DOMINANT 0.001322 0.001322 1.4553 1.4553 0.9598 0
    rs4029119 Imputed G ADDITIVE 2.65E−05 2.65E−05 0.2569 0.2569 0.4764 0
    rs4029119 Imputed G DOMINANT 5.81E−05 5.81E−05 0.2637 0.2637 0.5057 0
    rs4076201 Imputed G GENOTYPIC 0.0001779 0.0001779 3.0129 3.0129 0.881 0
    rs4076201 Imputed G RECESSIVE 0.0001745 0.0001745 2.9721 2.9721 0.9936 0
    rs41395945 Imputed G ADDITIVE 0.001422 0.001422 1.8637 1.8637 0.4977 0
    rs41395945 Imputed G DOMINANT 0.001383 0.001383 1.9054 1.9054 0.5854 0
    rs4146972 Genotyped T DOMINANT 0.002023 0.002023 1.4758 1.4758 0.7768 0
    rs4238087 Imputed G DOMINANT 0.001528 0.002511 0.6487 0.6459 0.2941 9.14
    rs4251569 Imputed T ADDITIVE 0.000865 0.000865 0.6585 0.6585 0.319 0
    rs4251569 Imputed T DOMINANT 0.001524 0.002494 0.6487 0.6458 0.2944 9.05
    rs4273613 Imputed T ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs4273613 Imputed T DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs4291049 Imputed T RECESSIVE 6.91E−05 6.91E−05 0.5605 0.5605 0.8377 0
    rs4315598 Imputed T ADDITIVE 0.0002132 0.0002132 1.369 1.369 0.8084 0
    rs4315598 Imputed T GENOTYPIC 0.0002436 0.0002436 1.9445 1.9445 0.7616 0
    rs4315598 Imputed T RECESSIVE 0.001637 0.001637 1.6981 1.6981 0.4109 0
    rs4321395 Imputed A DOMINANT 4.10E−05 4.10E−05 0.5856 0.5856 0.5635 0
    rs4321596 Genotyped T RECESSIVE 0.001013 0.001013 2.3233 2.3233 0.5608 0
    rs4324417 Imputed T DOMINANT 9.41E−05 9.41E−05 1.6531 1.6531 0.6731 0
    rs4328619 Genotyped G DOMINANT 0.002587 0.002587 0.6704 0.6704 0.826 0
    rs4338909 Imputed T ADDITIVE 9.61E−05 9.61E−05 1.3842 1.3842 0.8254 0
    rs4370878 Imputed G DOMINANT 9.82E−05 9.82E−05 1.5785 1.5785 0.7378 0
    rs4379434 Genotyped T DOMINANT 9.48E−05 9.48E−05 1.6163 1.6163 0.9593 0
    rs4416407 Imputed T DOMINANT 0.0001694 0.0001694 1.6929 1.6929 0.489 0
    rs4417899 Imputed C RECESSIVE 0.000157 0.000157 0.5892 0.5892 0.4805 0
    rs4442732 Imputed A ADDITIVE 8.41E−05 8.41E−05 0.6531 0.6531 0.3436 0
    rs4444612 Imputed G ADDITIVE 0.0001677 0.0001677 1.3768 1.3768 0.8476 0
    rs4444612 Imputed G GENOTYPIC 0.00021 0.00021 1.9589 1.9589 0.738 0
    rs4444612 Imputed G RECESSIVE 0.001571 0.001571 1.7015 1.7015 0.4057 0
    rs4450660 Imputed C DOMINANT 8.36E−05 8.36E−05 1.5918 1.5918 0.5023 0
    rs4509702 Imputed C DOMINANT 9.82E−05 9.82E−05 1.5785 1.5785 0.7378 0
    rs4526920 Imputed G GENOTYPIC 7.93E−05 7.93E−05 2.2431 2.2431 0.9603 0
    rs4533145 Imputed T DOMINANT 9.22E−05 9.22E−05 0.5529 0.5529 0.3518 0
    rs4557006 Imputed A DOMINANT 8.75E−05 8.75E−05 0.5972 0.5972 0.5878 0
    rs4570530 Imputed C DOMINANT 9.82E−05 9.82E−05 1.5785 1.5785 0.7378 0
    rs4615971 Imputed C DOMINANT 0.0001298 0.0001298 1.5635 1.5635 0.7109 0
    rs4628119 Imputed A DOMINANT 6.11E−05 6.11E−05 0.6205 0.6205 0.3365 0
    rs4664443 Imputed G ADDITIVE 7.56E−05 7.56E−05 0.7086 0.7086 0.8496 0
    rs4688259 Imputed T DOMINANT 0.0001678 0.0001678 1.6935 1.6935 0.4878 0
    rs4688632 Imputed G RECESSIVE 0.0001642 0.0001642 0.5987 0.5987 0.51 0
    rs4695284 Imputed A ADDITIVE 8.64E−05 8.64E−05 1.894 1.894 0.3836 0
    rs4700302 Imputed A ADDITIVE 9.09E−05 9.09E−05 0.5243 0.5243 0.8943 0
    rs4702720 Imputed A ADDITIVE 0.0001094 0.0001094 0.6414 0.6414 0.5372 0
    rs4702720 Imputed A DOMINANT 0.0001621 0.0001621 0.5989 0.5989 0.3199 0
    rs4711091 Genotyped G GENOTYPIC 9.08E−05 9.08E−05 1.8967 1.8967 0.4866 0
    rs4714484 Imputed A ADDITIVE 4.13E−05 4.13E−05 0.6276 0.6276 0.4538 0
    rs4736802 Imputed G DOMINANT 7.12E−05 7.12E−05 1.6304 1.6304 0.9501 0
    rs4760785 Imputed A ADDITIVE 0.0004633 0.0004633 0.7392 0.7392 0.7118 0
    rs4760785 Imputed A DOMINANT 0.0002642 0.0002642 0.6285 0.6285 0.7714 0
    rs4760785 Imputed A GENOTYPIC 0.001515 0.001515 0.574 0.574 0.5208 0
    rs4760894 Imputed T ADDITIVE 0.0004633 0.0004633 0.7392 0.7392 0.7118 0
    rs4760894 Imputed T DOMINANT 0.0002642 0.0002642 0.6285 0.6285 0.7714 0
    rs4760894 Imputed T GENOTYPIC 0.001515 0.001515 0.574 0.574 0.5208 0
    rs4760895 Imputed A ADDITIVE 0.0004633 0.0004633 0.7392 0.7392 0.7118 0
    rs4760895 Imputed A DOMINANT 0.0002642 0.0002642 0.6285 0.6285 0.7714 0
    rs4760895 Imputed A GENOTYPIC 0.001515 0.001515 0.574 0.574 0.5208 0
    rs4764738 Imputed A ADDITIVE 5.30E−05 5.30E−05 1.4051 1.4051 0.3785 0
    rs4764738 Imputed A GENOTYPIC 5.29E−05 5.29E−05 1.9728 1.9728 0.3836 0
    rs4764974 Imputed T ADDITIVE 9.56E−05 9.56E−05 1.3855 1.3855 0.4436 0
    rs4764974 Imputed T GENOTYPIC 9.35E−05 9.35E−05 1.9196 1.9196 0.4483 0
    rs4798366 Imputed G RECESSIVE 0.001711 0.001711 1.8332 1.8332 0.3582 0
    rs483159 Imputed T DOMINANT 0.004772 0.004772 1.4202 1.4202 0.9716 0
    rs4836502 Imputed T DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs4836507 Imputed C DOMINANT 0.0009994 0.0009994 0.6775 0.6775 0.9204 0
    rs4836744 Imputed A ADDITIVE 0.0006425 0.0006425 0.7345 0.7345 0.7018 0
    rs4836744 Imputed A DOMINANT 0.001186 0.001186 0.6854 0.6854 0.8412 0
    rs4848944 Genotyped C RECESSIVE 0.0002524 0.003005 0.5945 0.5819 0.2143 35.17
    rs4851529 Imputed A DOMINANT 0.0003125 0.0003125 0.6476 0.6476 0.4109 0
    rs4851531 Imputed T DOMINANT 0.000688 0.0011 0.6621 0.6602 0.2981 7.64
    rs4858046 Genotyped T GENOTYPIC 7.90E−05 7.90E−05 2.0533 2.0533 0.925 0
    rs4878214 Imputed A ADDITIVE 9.56E−05 9.56E−05 0.6477 0.6477 0.3504 0
    rs4880803 Imputed A ADDITIVE 0.003664 0.003664 0.7694 0.7694 0.9093 0
    rs489441 Imputed G ADDITIVE 3.10E−05 3.10E−05 1.4992 1.4992 0.6179 0
    rs489441 Imputed G DOMINANT 8.27E−05 8.27E−05 1.6072 1.6072 0.8697 0
    rs4896568 Imputed T DOMINANT 8.36E−05 8.36E−05 0.6231 0.6231 0.3985 0
    rs4938851 Imputed T DOMINANT 0.001901 0.001901 1.4515 1.4515 0.4953 0
    rs4964416 Imputed C DOMINANT 0.0004167 0.0004167 0.6251 0.6251 0.6468 0
    rs5756669 Imputed C DOMINANT 9.41E−05 9.41E−05 1.6531 1.6531 0.6731 0
    rs6033138 Imputed C ADDITIVE 0.000116 0.000116 1.3837 1.3837 0.8829 0
    rs6033138 Imputed C GENOTYPIC 0.0001829 0.0001829 1.9484 1.9484 0.7574 0
    rs6033138 Imputed C RECESSIVE 0.001659 0.001659 1.6769 1.6769 0.4494 0
    rs6040619 Imputed C ADDITIVE 0.0001132 0.0001132 1.3881 1.3881 0.5479 0
    rs6040619 Imputed C GENOTYPIC 9.53E−05 9.53E−05 2.0334 2.0334 0.8541 0
    rs6040619 Imputed C RECESSIVE 0.0005843 0.0005843 1.7879 1.7879 0.803 0
    rs6040625 Imputed T ADDITIVE 0.0001123 0.0001123 1.3888 1.3888 0.589 0
    rs6040625 Imputed T GENOTYPIC 0.0001128 0.0001128 2.0214 2.0214 0.9212 0
    rs6040625 Imputed T RECESSIVE 0.0007645 0.0007645 1.7684 1.7684 0.7342 0
    rs6040630 Imputed A ADDITIVE 0.0001671 0.0001671 1.3767 1.3767 0.7848 0
    rs6040630 Imputed A GENOTYPIC 0.0001796 0.0001796 1.9741 1.9741 0.807 0
    rs6040630 Imputed A RECESSIVE 0.001227 0.001227 1.7241 1.7241 0.4626 0
    rs6040633 Imputed A ADDITIVE 0.000204 0.000204 1.3703 1.3703 0.8149 0
    rs6040633 Imputed A GENOTYPIC 0.0002355 0.0002355 1.9475 1.9475 0.7566 0
    rs6040633 Imputed A RECESSIVE 0.001596 0.001596 1.6999 1.6999 0.4082 0
    rs6040634 Imputed T ADDITIVE 0.0001909 0.0001909 1.3722 1.3722 0.8246 0
    rs6040634 Imputed T GENOTYPIC 0.0002206 0.0002206 1.9531 1.9531 0.7476 0
    rs6040634 Imputed T RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs6040636 Imputed T ADDITIVE 0.0001672 0.0001672 1.3761 1.3761 0.8442 0
    rs6040636 Imputed T GENOTYPIC 0.0002085 0.0002085 1.9585 1.9585 0.7388 0
    rs6040636 Imputed T RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs6040638 Imputed C ADDITIVE 0.0001909 0.0001909 1.3722 1.3722 0.8246 0
    rs6040638 Imputed C GENOTYPIC 0.0002206 0.0002206 1.9531 1.9531 0.7476 0
    rs6040638 Imputed C RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs6040644 Imputed A ADDITIVE 0.0001909 0.0001909 1.3722 1.3722 0.8246 0
    rs6040644 Imputed A GENOTYPIC 0.0002206 0.0002206 1.9531 1.9531 0.7476 0
    rs6040644 Imputed A RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs6040667 Imputed T ADDITIVE 0.0002664 0.0002664 1.3662 1.3662 0.8727 0
    rs6040667 Imputed T GENOTYPIC 0.0003065 0.0003065 1.9386 1.9386 0.7287 0
    rs6040667 Imputed T RECESSIVE 0.002069 0.002069 1.6903 1.6903 0.423 0
    rs6040668 Imputed C ADDITIVE 0.0002909 0.0002909 1.3643 1.3643 0.8891 0
    rs6040668 Imputed C GENOTYPIC 0.0003326 0.0003326 1.9325 1.9325 0.7115 0
    rs6040668 Imputed C RECESSIVE 0.00224 0.00224 1.6839 1.6839 0.406 0
    rs6043066 Genotyped G DOMINANT 0.000733 0.01784 1.4888 1.4596 0.1886 42.14
    rs6048146 Imputed G DOMINANT 0.0005426 0.0005426 2.6562 2.6562 0.6095 0
    rs6082725 Genotyped T DOMINANT 0.0005426 0.0005426 2.6562 2.6562 0.6095 0
    rs6131206 Imputed C ADDITIVE 0.002048 0.002048 1.3126 1.3126 0.4818 0
    rs6131208 Imputed T ADDITIVE 0.0002137 0.0002137 1.3725 1.3725 0.8701 0
    rs6131208 Imputed T GENOTYPIC 0.0002553 0.0002553 1.9551 1.9551 0.7372 0
    rs6131208 Imputed T RECESSIVE 0.00182 0.00182 1.7011 1.7011 0.4342 0
    rs6134243 Imputed C ADDITIVE 0.0001909 0.0001909 1.3722 1.3722 0.8246 0
    rs6134243 Imputed C GENOTYPIC 0.0002206 0.0002206 1.9531 1.9531 0.7476 0
    rs6134243 Imputed C RECESSIVE 0.00156 0.00156 1.7021 1.7021 0.4049 0
    rs6136020 Imputed A DOMINANT 6.99E−05 7.15E−05 0.5953 0.5953 0.3168 0.19
    rs613799 Imputed C DOMINANT 0.0002827 0.0002827 1.5657 1.5657 0.629 0
    rs644041 Imputed G ADDITIVE 9.69E−05 9.69E−05 1.4631 1.4631 0.6439 0
    rs644041 Imputed G DOMINANT 0.0001835 0.0001835 1.5751 1.5751 0.8914 0
    rs647645 Imputed C ADDITIVE 2.08E−05 2.08E−05 0.7025 0.7025 0.8072 0
    rs647645 Imputed C GENOTYPIC 1.62E−05 1.62E−05 0.4822 0.4822 0.9069 0
    rs647645 Imputed C RECESSIVE 4.05E−05 4.05E−05 0.5474 0.5474 0.5771 0
    rs6495554 Imputed C GENOTYPIC 0.0001138 0.0001138 3.4509 3.4509 0.8527 0
    rs6495554 Imputed C RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs6495555 Imputed C GENOTYPIC 0.0001138 0.0001138 3.4509 3.4509 0.8527 0
    rs6495555 Imputed C RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs6544728 Imputed T DOMINANT 2.92E−05 2.92E−05 1.6406 1.6406 0.3945 0
    rs6550705 Imputed C ADDITIVE 8.91E−05 8.91E−05 1.3969 1.3969 0.7348 0
    rs6550705 Imputed C GENOTYPIC 5.30E−05 5.30E−05 2.0995 2.0995 0.9749 0
    rs6550707 Imputed T GENOTYPIC 7.67E−05 7.67E−05 2.0358 2.0358 0.8969 0
    rs658108 Imputed A DOMINANT 0.0002659 0.0002659 1.5304 1.5304 0.8231 0
    rs6593441 Imputed A DOMINANT 0.0002048 0.0002048 1.6724 1.6724 0.545 0
    rs668732 Imputed A DOMINANT 7.59E−05 7.59E−05 1.6958 1.6958 0.6376 0
    rs671041 Imputed A DOMINANT 0.0002098 0.0002098 1.5412 1.5412 0.8876 0
    rs6719700 Imputed A ADDITIVE 0.0005301 0.0005301 1.4892 1.4892 0.6569 0
    rs6719700 Imputed A DOMINANT 0.0009974 0.0009974 1.5282 1.5282 0.9621 0
    rs6722640 Imputed T DOMINANT 0.0001647 0.0001647 0.6343 0.6343 0.417 0
    rs6743092 Imputed T ADDITIVE 0.0002329 0.0002329 1.3618 1.3618 0.9832 0
    rs6743092 Imputed T GENOTYPIC 0.0002232 0.0002232 1.8571 1.8571 0.9791 0
    rs6743092 Imputed T RECESSIVE 0.001144 0.001144 1.5648 1.5648 0.9735 0
    rs6744759 Imputed G RECESSIVE 0.006086 0.006086 1.7637 1.7637 0.7956 0
    rs6746170 Imputed A DOMINANT 4.95E−05 4.95E−05 1.6166 1.6166 0.5054 0
    rs6759922 Imputed A DOMINANT 5.10E−05 5.10E−05 0.5892 0.5892 0.6074 0
    rs6769864 Imputed T GENOTYPIC 5.78E−05 5.78E−05 2.0921 2.0921 0.9627 0
    rs6773932 Imputed C GENOTYPIC 8.12E−05 8.12E−05 2.0503 2.0503 0.8139 0
    rs6774353 Imputed A GENOTYPIC 5.78E−05 5.78E−05 2.0921 2.0921 0.9627 0
    rs6781670 Imputed C GENOTYPIC 7.91E−05 7.91E−05 2.0683 2.0683 0.8608 0
    rs6786431 Imputed A GENOTYPIC 8.12E−05 8.12E−05 2.0503 2.0503 0.8139 0
    rs6789091 Imputed T GENOTYPIC 8.12E−05 8.12E−05 2.0503 2.0503 0.8139 0
    rs6791296 Imputed T ADDITIVE 0.0005376 0.0005376 0.6284 0.6284 0.9209 0
    rs6792662 Imputed G DOMINANT 0.0001499 0.0001499 1.7002 1.7002 0.4736 0
    rs6797574 Imputed G GENOTYPIC 8.12E−05 8.12E−05 2.0503 2.0503 0.8139 0
    rs6797882 Imputed G GENOTYPIC 7.58E−05 7.58E−05 2.0585 2.0585 0.8005 0
    rs6805139 Imputed G DOMINANT 0.0001083 0.0001083 1.6957 1.6957 0.5312 0
    rs6806043 Imputed C ADDITIVE 6.97E−05 6.97E−05 1.4041 1.4041 0.6772 0
    rs6806043 Imputed C GENOTYPIC 4.41E−05 4.41E−05 2.1162 2.1162 0.9314 0
    rs6850716 Imputed C GENOTYPIC 6.01E−05 6.01E−05 3.2642 3.2642 0.9641 0
    rs6867153 Imputed A RECESSIVE 3.66E−05 3.66E−05 0.5455 0.5455 0.7414 0
    rs687047 Imputed C ADDITIVE 0.001907 0.001907 0.6716 0.6716 0.7468 0
    rs6871041 Imputed G DOMINANT 0.0002601 0.0002601 0.6351 0.6351 0.5713 0
    rs688358 Imputed A ADDITIVE 0.001332 0.001332 0.6614 0.6614 0.8904 0
    rs6888012 Imputed A RECESSIVE 3.66E−05 3.66E−05 0.5455 0.5455 0.7414 0
    rs6908481 Imputed C RECESSIVE 8.53E−05 8.53E−05 1.8461 1.8461 0.6072 0
    rs7032231 Imputed A ADDITIVE 0.003089 0.004335 1.2986 1.3011 0.2989 7.33
    rs7067638 Imputed T DOMINANT 0.0002484 0.0002484 1.6722 1.6722 0.663 0
    rs7077799 Imputed A DOMINANT 0.0002066 0.0002066 1.5609 1.5609 0.6624 0
    rs7082163 Imputed A ADDITIVE 4.21E−05 4.21E−05 1.6619 1.6619 0.5882 0
    rs7082163 Imputed A DOMINANT 6.78E−05 6.78E−05 1.7473 1.7473 0.7157 0
    rs7089661 Imputed C DOMINANT 0.0001345 0.0001345 1.5612 1.5612 0.6665 0
    rs7101319 Imputed C ADDITIVE 5.11E−05 5.11E−05 1.6533 1.6533 0.5666 0
    rs7101319 Imputed C DOMINANT 8.45E−05 8.45E−05 1.7359 1.7359 0.6904 0
    rs710832 Genotyped A GENOTYPIC 0.0003218 0.0003218 0.3641 0.3641 0.5473 0
    rs710832 Genotyped A RECESSIVE 0.0001214 0.0001214 0.3456 0.3456 0.5387 0
    rs7134262 Imputed T GENOTYPIC 0.0005116 0.0005116 1.9228 1.9228 0.357 0
    rs7134262 Imputed T RECESSIVE 1.88E−05 0.0002297 2.1112 2.0864 0.2602 21.12
    rs7134671 Imputed T GENOTYPIC 8.82E−05 8.82E−05 1.9952 1.9952 0.3861 0
    rs7138300 Imputed C ADDITIVE 0.0004633 0.0004633 0.7392 0.7392 0.7118 0
    rs7138300 Imputed C DOMINANT 0.0002642 0.0002642 0.6285 0.6285 0.7714 0
    rs7138300 Imputed C GENOTYPIC 0.001515 0.001515 0.574 0.574 0.5208 0
    rs7163931 Imputed G GENOTYPIC 0.0001138 0.0001138 3.4509 3.4509 0.8527 0
    rs7163931 Imputed G RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs7171486 Genotyped G DOMINANT 0.002255 0.00726 0.6976 0.69 0.2524 23.66
    rs7172611 Imputed G GENOTYPIC 0.0001106 0.0001106 3.4591 3.4591 0.8474 0
    rs7172611 Imputed G RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs7172689 Imputed T GENOTYPIC 0.0001106 0.0001106 3.4591 3.4591 0.8474 0
    rs7172689 Imputed T RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs7175701 Imputed C GENOTYPIC 0.0002485 0.0002485 2.9103 2.9103 0.9903 0
    rs7180245 Imputed A GENOTYPIC 0.0001106 0.0001106 3.4591 3.4591 0.8474 0
    rs7180245 Imputed A RECESSIVE 0.0001586 0.0001586 3.317 3.317 0.9056 0
    rs7220603 Genotyped A ADDITIVE 6.15E−05 6.15E−05 0.6874 0.6874 0.5095 0
    rs7282518 Imputed T ADDITIVE 4.72E−05 4.72E−05 1.6157 1.6157 0.6576 0
    rs7283476 Imputed T ADDITIVE 0.001444 0.002668 0.4528 0.4555 0.2951 8.76
    rs7283476 Imputed T DOMINANT 0.001188 0.01352 0.4307 0.4432 0.213 35.52
    rs7295817 Imputed C GENOTYPIC 0.001617 0.007423 0.5763 0.5838 0.2587 21.63
    rs7298255 Imputed A ADDITIVE 0.0004959 0.0004959 0.7441 0.7441 0.8645 0
    rs7298255 Imputed A DOMINANT 0.0001567 0.0001567 0.6197 0.6197 0.8009 0
    rs7305832 Imputed C GENOTYPIC 0.0004601 0.0004601 1.9292 1.9292 0.3332 0
    rs7305832 Imputed C RECESSIVE 1.85E−05 0.0003707 2.1109 2.0804 0.2465 25.55
    rs7331467 Imputed A GENOTYPIC 8.27E−05 8.27E−05 2.0747 2.0747 0.9516 0
    rs7392620 Imputed C ADDITIVE 0.003409 0.003409 0.7677 0.7677 0.844 0
    rs742827 Imputed A ADDITIVE 0.0001374 0.0001374 1.3962 1.3962 0.8859 0
    rs742827 Imputed A GENOTYPIC 0.0002152 0.0002152 1.9872 1.9872 0.5834 0
    rs742827 Imputed A RECESSIVE 0.001964 0.001964 1.6988 1.6988 0.3688 0
    rs7446891 Imputed G DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs7448641 Imputed C ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs7448641 Imputed C DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs7484728 Imputed T GENOTYPIC 8.08E−05 8.08E−05 2.0019 2.0019 0.395 0
    rs7499402 Genotyped A ADDITIVE 0.001818 0.001818 1.6071 1.6071 0.4709 0
    rs7529851 Imputed A ADDITIVE 0.0007167 0.0007351 0.7475 0.7475 0.3163 0.4
    rs7529851 Imputed A GENOTYPIC 0.0007339 0.0007339 0.5463 0.5463 0.4438 0
    rs7573951 Imputed G ADDITIVE 7.56E−05 7.56E−05 0.7086 0.7086 0.8496 0
    rs7599198 Imputed T DOMINANT 9.29E−05 9.29E−05 0.5939 0.5939 0.6564 0
    rs7600050 Imputed C ADDITIVE 0.000398 0.000398 1.3671 1.3671 0.401 0
    rs7607712 Imputed T ADDITIVE 0.0003189 0.0003189 1.452 1.452 0.6392 0
    rs7607712 Imputed T DOMINANT 0.0007082 0.0007082 1.5005 1.5005 0.8593 0
    rs7613492 Imputed G GENOTYPIC 5.46E−05 5.46E−05 2.1046 2.1046 0.983 0
    rs7621663 Imputed G ADDITIVE 5.19E−05 5.19E−05 1.4264 1.4264 0.8945 0
    rs7621663 Imputed G GENOTYPIC 1.68E−05 1.68E−05 2.2926 2.2926 0.7204 0
    rs7621663 Imputed G RECESSIVE 8.03E−05 8.03E−05 2.0424 2.0424 0.5218 0
    rs7626584 Imputed G ADDITIVE 0.000166 0.000166 0.5017 0.5017 0.6498 0
    rs7684899 Imputed C ADDITIVE 0.001935 0.001935 0.7236 0.7236 0.8673 0
    rs7684899 Imputed C DOMINANT 0.000396 0.000396 0.6536 0.6536 0.8664 0
    rs7701604 Imputed G ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs7701604 Imputed G DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs7703676 Imputed C ADDITIVE 1.27E−05 1.27E−05 0.2451 0.2451 0.6218 0
    rs7703676 Imputed C DOMINANT 2.81E−05 2.81E−05 0.2509 0.2509 0.6535 0
    rs7708491 Imputed C RECESSIVE 6.44E−05 6.44E−05 0.5582 0.5582 0.823 0
    rs7711358 Imputed A DOMINANT 0.0005772 0.0005772 0.6679 0.6679 0.7414 0
    rs7719448 Imputed G RECESSIVE 3.03E−05 3.03E−05 0.5422 0.5422 0.7436 0
    rs7724761 Imputed T RECESSIVE 2.79E−05 2.79E−05 0.5376 0.5376 0.8521 0
    rs7742476 Imputed T DOMINANT 9.96E−05 9.96E−05 1.6177 1.6177 0.3946 0
    rs7762993 Imputed A ADDITIVE 9.68E−05 9.68E−05 1.5062 1.5062 0.5789 0
    rs7762993 Imputed A DOMINANT 1.55E−05 1.55E−05 1.6955 1.6955 0.475 0
    rs7767265 Imputed G ADDITIVE 1.02E−05 1.02E−05 1.5369 1.5369 0.4161 0
    rs7767265 Imputed G DOMINANT 1.30E−06 1.30E−06 1.786 1.786 0.4646 0
    rs7768128 Imputed G RECESSIVE 0.001331 0.001331 0.4131 0.4131 0.6812 0
    rs7771264 Imputed T DOMINANT 6.68E−05 6.68E−05 0.6186 0.6186 0.338 0
    rs7773151 Genotyped C DOMINANT 7.51E−05 7.51E−05 0.624 0.624 0.3194 0
    rs7773210 Genotyped A DOMINANT 6.11E−05 6.11E−05 0.6205 0.6205 0.3365 0
    rs7808536 Imputed G DOMINANT 0.0002477 0.003942 1.5602 1.593 0.1988 39.43
    rs7843510 Genotyped G DOMINANT 9.47E−05 9.47E−05 1.6156 1.6156 0.9612 0
    rs7894867 Imputed T DOMINANT 0.0002327 0.0002327 1.6763 1.6763 0.6457 0
    rs7921834 Imputed C DOMINANT 0.0001474 0.0001474 1.5574 1.5574 0.6777 0
    rs7939893 Imputed C ADDITIVE 0.001994 0.001994 0.7672 0.7672 0.4917 0
    rs7939893 Imputed C DOMINANT 0.00178 0.00178 0.6939 0.6939 0.7543 0
    rs7944513 Imputed T GENOTYPIC 3.70E−05 3.70E−05 3.1057 3.1057 0.4987 0
    rs7944513 Imputed T RECESSIVE 6.05E−05 6.05E−05 2.9509 2.9509 0.4009 0
    rs7949720 Imputed G ADDITIVE 6.02E−05 6.02E−05 0.5917 0.5917 0.6951 0
    rs7949720 Imputed G DOMINANT 4.34E−05 4.34E−05 0.5526 0.5526 0.5364 0
    rs7955901 Imputed C ADDITIVE 0.0005679 0.0005679 0.745 0.745 0.8856 0
    rs7955901 Imputed C DOMINANT 0.0002109 0.0002109 0.6246 0.6246 0.7241 0
    rs7956274 Imputed T ADDITIVE 0.000471 0.000471 0.7423 0.7423 0.7644 0
    rs7956274 Imputed T DOMINANT 0.0001278 0.0001278 0.6144 0.6144 0.9458 0
    rs7956274 Imputed T GENOTYPIC 0.001643 0.001643 0.582 0.582 0.6004 0
    rs7957932 Imputed G ADDITIVE 0.001051 0.001051 0.7578 0.7578 0.8972 0
    rs7957932 Imputed G DOMINANT 0.0001397 0.0001397 0.6136 0.6136 0.8447 0
    rs7984504 Imputed C GENOTYPIC 9.33E−05 9.33E−05 2.1895 2.1895 0.8871 0
    rs7999518 Imputed A RECESSIVE 0.003293 0.003293 0.6449 0.6449 0.9164 0
    rs8026245 Imputed G GENOTYPIC 0.0001769 0.0001769 3.0849 3.0849 0.8542 0
    rs8026245 Imputed G RECESSIVE 0.0001739 0.0001739 3.0436 3.0436 0.9473 0
    rs8060725 Genotyped A ADDITIVE 0.001967 0.001967 0.7414 0.7414 0.74 0
    rs8103016 Genotyped A ADDITIVE 1.97E−05 1.97E−05 1.5542 1.5542 0.8792 0
    rs8103016 Genotyped A DOMINANT 5.37E−05 5.37E−05 1.6315 1.6315 0.8495 0
    rs8104182 Imputed G ADDITIVE 8.91E−05 8.91E−05 1.5032 1.5032 0.628 0
    rs8104182 Imputed G DOMINANT 0.000187 0.000187 1.5764 1.5764 0.6041 0
    rs8129461 Imputed G ADDITIVE 0.001444 0.002668 0.4528 0.4555 0.2951 8.76
    rs8129461 Imputed G DOMINANT 0.001188 0.01352 0.4307 0.4432 0.213 35.52
    rs8130021 Imputed G ADDITIVE 0.001444 0.002668 0.4528 0.4555 0.2951 8.76
    rs8130021 Imputed G DOMINANT 0.001188 0.01352 0.4307 0.4432 0.213 35.52
    rs879961 Imputed T ADDITIVE 2.33E−05 2.33E−05 0.6659 0.6659 0.4449 0
    rs879961 Imputed T DOMINANT 1.51E−05 1.51E−05 0.6005 0.6005 0.9844 0
    rs906353 Imputed A DOMINANT 9.95E−05 9.95E−05 0.6352 0.6352 0.8067 0
    rs915491 Imputed C DOMINANT 0.0002054 0.0002054 1.5426 1.5426 0.7028 0
    rs915493 Imputed T DOMINANT 0.0002054 0.0002054 1.5426 1.5426 0.7028 0
    rs915494 Imputed A ADDITIVE 0.001238 0.001238 1.3527 1.3527 0.6764 0
    rs915494 Imputed A DOMINANT 0.0002045 0.0002045 1.5574 1.5574 0.5538 0
    rs917295 Imputed G DOMINANT 0.0005579 0.0005579 0.6664 0.6664 0.9359 0
    rs9284851 Imputed A GENOTYPIC 6.86E−05 6.86E−05 2.0519 2.0519 0.9886 0
    rs9293464 Imputed T RECESSIVE 3.03E−05 3.03E−05 0.5422 0.5422 0.7436 0
    rs9295154 Genotyped G DOMINANT 0.0003436 0.0007175 1.5908 1.5981 0.2899 10.73
    rs9310221 Imputed A DOMINANT 6.72E−05 6.93E−05 1.6779 1.6777 0.3166 0.28
    rs9310699 Genotyped T GENOTYPIC 7.91E−05 7.91E−05 2.0683 2.0683 0.8608 0
    rs9310700 Imputed C ADDITIVE 8.64E−05 8.64E−05 1.4077 1.4077 0.7999 0
    rs9310700 Imputed C GENOTYPIC 3.31E−05 3.31E−05 2.2015 2.2015 0.8601 0
    rs9310701 Imputed G GENOTYPIC 7.67E−05 7.67E−05 2.0358 2.0358 0.8969 0
    rs9310704 Imputed G GENOTYPIC 4.87E−05 4.87E−05 2.1011 2.1011 0.908 0
    rs9319185 Imputed C GENOTYPIC 5.38E−05 5.38E−05 2.2836 2.2836 0.9842 0
    rs9319186 Imputed T GENOTYPIC 7.93E−05 7.93E−05 2.2431 2.2431 0.9603 0
    rs9327555 Imputed T DOMINANT 0.000699 0.000699 0.6712 0.6712 0.8706 0
    rs9403367 Imputed C DOMINANT 6.11E−05 6.11E−05 0.6205 0.6205 0.3365 0
    rs9419608 Imputed G RECESSIVE 4.08E−05 4.08E−05 1.7425 1.7425 0.608 0
    rs9426437 Imputed T DOMINANT 5.00E−05 5.00E−05 0.607 0.607 0.4632 0
    rs9454967 Imputed G DOMINANT 5.94E−05 5.94E−05 1.9576 1.9576 0.6125 0
    rs9635511 Imputed T DOMINANT 7.73E−05 7.73E−05 0.618 0.618 0.4399 0
    rs966583 Imputed A ADDITIVE 9.56E−05 9.56E−05 0.7127 0.7127 0.7413 0
    rs966583 Imputed A DOMINANT 4.65E−05 4.65E−05 0.6082 0.6082 0.9923 0
    rs980263 Imputed T GENOTYPIC 6.16E−05 6.16E−05 2.059 2.059 0.935 0
    rs980264 Imputed T GENOTYPIC 6.16E−05 6.16E−05 2.059 2.059 0.935 0
    rs9812206 Imputed G ADDITIVE 5.80E−06 5.80E−06 0.5122 0.5122 0.7976 0
    rs9812206 Imputed G DOMINANT 4.29E−06 4.29E−06 0.4876 0.4876 0.9796 0
    rs9813552 Imputed G ADDITIVE 4.13E−05 4.13E−05 0.5495 0.5495 0.7178 0
    rs9813552 Imputed G DOMINANT 3.19E−05 3.19E−05 0.5265 0.5265 0.9286 0
    rs9815037 Imputed T ADDITIVE 1.99E−05 1.99E−05 0.5261 0.5261 0.5342 0
    rs9815037 Imputed T DOMINANT 1.13E−05 1.13E−05 0.4982 0.4982 0.7438 0
    rs9819583 Imputed T GENOTYPIC 7.12E−05 7.12E−05 2.0778 2.0778 0.8761 0
    rs9825349 Imputed A ADDITIVE 1.98E−05 1.98E−05 0.5259 0.5259 0.5483 0
    rs9825349 Imputed A DOMINANT 1.13E−05 1.13E−05 0.4982 0.4982 0.7598 0
    rs9833118 Imputed G ADDITIVE 9.63E−05 9.63E−05 1.3977 1.3977 0.6136 0
    rs9833118 Imputed G GENOTYPIC 5.01E−05 5.01E−05 2.1101 2.1101 0.8729 0
    rs9834217 Imputed T ADDITIVE 2.21E−05 2.21E−05 0.5279 0.5279 0.5562 0
    rs9834217 Imputed T DOMINANT 1.26E−05 1.26E−05 0.5002 0.5002 0.7692 0
    rs9838563 Imputed C GENOTYPIC 7.67E−05 7.67E−05 2.0358 2.0358 0.8969 0
    rs9840460 Imputed T ADDITIVE 2.08E−05 2.08E−05 0.5268 0.5268 0.5431 0
    rs9840460 Imputed T DOMINANT 1.18E−05 1.18E−05 0.499 0.499 0.7541 0
    rs9840756 Imputed A ADDITIVE 2.08E−05 2.08E−05 0.5268 0.5268 0.5431 0
    rs9840756 Imputed A DOMINANT 1.18E−05 1.18E−05 0.499 0.499 0.7541 0
    rs9847999 Imputed C GENOTYPIC 9.15E−05 9.15E−05 2.0254 2.0254 0.9674 0
    rs9864769 Imputed C GENOTYPIC 7.67E−05 7.67E−05 2.0358 2.0358 0.8969 0
    rs9866421 Genotyped C RECESSIVE 0.0009027 0.0009027 0.6009 0.6009 0.4635 0
    rs987296 Imputed T GENOTYPIC 7.90E−05 7.90E−05 2.0683 2.0683 0.8607 0
    rs9881685 Imputed A ADDITIVE 5.80E−06 5.80E−06 0.5122 0.5122 0.7976 0
    rs9881685 Imputed A DOMINANT 4.29E−06 4.29E−06 0.4876 0.4876 0.9796 0
    rs992695 Imputed C ADDITIVE 2.92E−05 2.92E−05 0.6695 0.6695 0.4384 0
    rs992695 Imputed C DOMINANT 2.06E−05 2.06E−05 0.6059 0.6059 0.9952 0
    rs9936999 Imputed G DOMINANT 8.52E−05 8.52E−05 1.8486 1.8486 0.8612 0
  • TABLE 18
    SNP rs # SOURCE ALLELE (A1) MODEL P P(R) OR OR(R) Q I
    rs77638540 Genotyped T DOMINANT 8.53E−05 8.53E−05 0.4412 0.4412 0.4473 0
    rs72746987 Genotyped A DOMINANT 1.04E−03 0.07511 0.5034 0.4987 0.037 69.66
    rs10021016 Genotyped G GENOTYPIC 1.77E−05 1.77E−05 2.4195 2.4195 0.946 0
    rs10021016 Genotyped G RECESSIVE 3.95E−05 3.95E−05 2.2819 2.2819 0.9639 0
    rs10051148 Imputed C DOMINANT 4.37E−05 4.37E−05 0.663 0.663 0.936 0
    rs10054055 Imputed T DOMINANT 2.45E−05 2.45E−05 0.652 0.652 0.8092 0
    rs10067895 Imputed A DOMINANT 2.54E−05 2.54E−05 0.6504 0.6504 0.7871 0
    rs10100725 Imputed C DOMINANT 9.58E−04 0.1048 0.6943 0.7246 0.0468 67.33
    rs10128531 Imputed T ADDITIVE 6.93E−05 6.93E−05 1.5153 1.5153 0.8693 0
    rs10181743 Imputed G ADDITIVE 1.45E−04 7.58E−04 1.3254 1.3179 0.3011 16.69
    rs10199127 Imputed T DOMINANT 3.21E−04 0.02399 1.4423 1.433 0.098 56.95
    rs10270624 Imputed G DOMINANT 7.89E−05 7.89E−05 1.5242 1.5242 0.5064 0
    rs1030006 Imputed G RECESSIVE 2.14E−03 0.1294 1.4544 1.4242 0.0332 70.63
    rs1031811 Imputed A RECESSIVE 8.78E−05 8.78E−05 1.988 1.988 0.5276 0
    rs10430870 Genotyped G GENOTYPIC 6.56E−05 6.56E−05 2.3812 2.3812 0.4518 0
    rs10430870 Genotyped G RECESSIVE 9.42E−05 9.42E−05 2.2976 2.2976 0.5059 0
    rs10469597 Imputed A GENOTYPIC 2.56E−04 7.98E−03 2.0793 2.008 0.1981 38.23
    rs10469597 Imputed A RECESSIVE 1.31E−04 3.67E−04 2.1038 2.0871 0.3313 9.47
    rs10478919 Imputed G DOMINANT 1.88E−05 1.88E−05 0.6481 0.6481 0.8316 0
    rs10506623 Imputed C ADDITIVE 3.33E−05 3.33E−05 0.7343 0.7343 0.8201 0
    rs10506623 Imputed C DOMINANT 2.58E−05 2.58E−05 0.6418 0.6418 0.8101 0
    rs10506626 Imputed A ADDITIVE 1.01E−05 1.01E−05 0.7226 0.7226 0.6798 0
    rs10506626 Imputed A DOMINANT 1.59E−06 1.59E−06 0.608 0.608 0.7968 0
    rs10509477 Imputed T DOMINANT 2.98E−05 2.98E−05 1.5214 1.5214 0.7093 0
    rs10517918 Imputed G RECESSIVE 6.32E−04 0.04182 1.5595 1.5312 0.0872 59.01
    rs10517924 Imputed A RECESSIVE 3.69E−04 0.007266 1.5408 1.514 0.2104 35.84
    rs10519362 Imputed G DOMINANT 9.95E−05 9.95E−05 1.5338 1.5338 0.9176 0
    rs10520072 Imputed T DOMINANT 1.82E−05 1.82E−05 0.647 0.647 0.881 0
    rs10737390 Imputed T DOMINANT 1.26E−03 1.43E−01 0.7118 0.7485 0.0363 69.84
    rs10742851 Imputed T RECESSIVE 1.44E−02 3.23E−01 0.5988 0.593 0.0033 82.54
    rs10743685 Imputed G GENOTYPIC 4.32E−05 4.32E−05 1.8534 1.8534 0.6642 0
    rs10743685 Imputed G RECESSIVE 7.41E−05 7.41E−05 1.7214 1.7214 0.6436 0
    rs10749293 Imputed G DOMINANT 1.17E−05 1.17E−05 1.5526 1.5526 0.866 0
    rs10749294 Imputed A DOMINANT 6.69E−05 6.69E−05 1.4909 1.4909 0.8006 0
    rs10753760 Imputed T ADDITIVE 1.83E−03 1.26E−01 1.2546 1.2395 0.0287 71.84
    rs10753760 Imputed T GENOTYPIC 2.08E−03 1.35E−01 1.5862 1.5469 0.0269 72.33
    rs10772362 Imputed T ADDITIVE 2.16E−05 2.16E−05 0.691 0.691 0.4243 0
    rs10784891 Imputed C ADDITIVE 3.13E−05 3.13E−05 0.7354 0.7354 0.9449 0
    rs10784891 Imputed C DOMINANT 6.41E−05 6.41E−05 0.6454 0.6454 0.7393 0
    rs10784891 Imputed C GENOTYPIC 9.84E−05 9.84E−05 0.5575 0.5575 0.8437 0
    rs10787923 Imputed G DOMINANT 1.08E−05 1.08E−05 1.556 1.556 0.8555 0
    rs10787924 Imputed T DOMINANT 5.94E−05 5.94E−05 1.4953 1.4953 0.7873 0
    rs10787949 Imputed A DOMINANT 5.22E−05 5.22E−05 1.503 1.503 0.7135 0
    rs10787951 Imputed G DOMINANT 5.35E−05 5.35E−05 1.5021 1.5021 0.7092 0
    rs10787983 Imputed C DOMINANT 5.23E−05 5.23E−05 1.5007 1.5007 0.7558 0
    rs10794733 Imputed C ADDITIVE 7.05E−05 7.05E−05 0.7343 0.7343 0.7115 0
    rs10818280 Imputed C DOMINANT 9.18E−05 9.18E−05 0.6734 0.6734 0.8782 0
    rs10860586 Imputed A ADDITIVE 3.08E−03 0.1633 1.2361 1.2211 0.0224 73.69
    rs10860586 Imputed A GENOTYPIC 3.00E−03 1.63E−01 1.5291 1.4908 0.0225 73.63
    rs10870473 Imputed A ADDITIVE 3.61E−03 2.33E−01 0.6941 0.7378 0.0195 74.59
    rs10870473 Imputed A DOMINANT 5.37E−03 4.68E−01 0.6441 0.7381 0.0016 84.48
    rs10879240 Imputed C ADDITIVE 3.83E−05 3.83E−05 0.74 0.74 0.9636 0
    rs10879240 Imputed C GENOTYPIC 9.34E−05 9.34E−05 0.5585 0.5585 0.7993 0
    rs10879242 Imputed A ADDITIVE 4.26E−05 4.26E−05 0.7384 0.7384 0.8941 0
    rs10879242 Imputed A DOMINANT 2.29E−05 2.29E−05 0.6402 0.6402 0.8341 0
    rs10879245 Imputed G ADDITIVE 4.26E−05 4.26E−05 0.7384 0.7384 0.8941 0
    rs10879245 Imputed G DOMINANT 2.29E−05 2.29E−05 0.6402 0.6402 0.8341 0
    rs10879249 Imputed T ADDITIVE 2.01E−05 2.01E−05 0.7287 0.7287 0.7861 0
    rs10879249 Imputed T DOMINANT 1.30E−05 1.30E−05 0.6335 0.6335 0.7421 0
    rs10886429 Imputed A DOMINANT 6.44E−05 6.44E−05 1.4958 1.4958 0.6357 0
    rs10886449 Imputed G DOMINANT 8.67E−05 8.67E−05 1.4833 1.4833 0.761 0
    rs10886451 Imputed G DOMINANT 8.67E−05 8.67E−05 1.4833 1.4833 0.761 0
    rs10886452 Imputed A DOMINANT 4.28E−05 4.28E−05 1.5097 1.5097 0.7458 0
    rs10886456 Imputed G DOMINANT 8.67E−05 8.67E−05 1.4833 1.4833 0.761 0
    rs10886463 Imputed C DOMINANT 5.51E−05 5.51E−05 1.5014 1.5014 0.737 0
    rs10886465 Imputed A DOMINANT 3.16E−05 3.16E−05 1.5202 1.5202 0.6725 0
    rs10886526 Imputed C DOMINANT 4.73E−05 4.73E−05 1.5047 1.5047 0.7756 0
    rs10922903 Imputed C RECESSIVE 7.51E−04 0.04061 0.6326 0.6533 0.1055 55.53
    rs10941126 Imputed G ADDITIVE 2.88E−03 0.1046 0.5269 0.4225 0.0055 80.81
    rs10941126 Imputed G DOMINANT 5.93E−03 0.1502 0.5204 0.4449 0.0058 80.6
    rs10947980 Imputed G ADDITIVE 0.0007135 0.04303 0.7602 0.7647 0.0779 60.82
    rs11059376 Imputed T ADDITIVE 2.09E−04 2.16E−03 1.4335 1.4217 0.2602 25.72
    rs11072995 Imputed T GENOTYPIC 5.56E−05 5.56E−05 2.911 2.911 0.7416 0
    rs11072995 Imputed T RECESSIVE 8.05E−05 8.05E−05 2.8127 2.8127 0.7514 0
    rs11081202 Genotyped G GENOTYPIC 4.78E−05 4.78E−05 2.2039 2.2039 0.4315 0
    rs11081202 Genotyped G RECESSIVE 9.57E−06 9.57E−06 2.3008 2.3008 0.5359 0
    rs110965 Imputed C GENOTYPIC 5.25E−05 5.42E−05 2.0397 2.04 0.3665 0.36
    rs11124962 Imputed A DOMINANT 9.31E−05 9.31E−05 1.4868 1.4868 0.434 0
    rs1116596 Imputed T DOMINANT 2.21E−05 2.21E−05 0.6501 0.6501 0.8309 0
    rs11178531 Imputed A ADDITIVE 8.31E−05 8.31E−05 0.753 0.753 0.9192 0
    rs11178531 Imputed A DOMINANT 4.55E−05 4.55E−05 0.64 0.64 0.9035 0
    rs11178583 Imputed A ADDITIVE 2.33E−05 2.33E−05 0.7308 0.7308 0.7646 0
    rs11178583 Imputed A DOMINANT 1.65E−05 1.65E−05 0.6373 0.6373 0.7197 0
    rs11178589 Imputed T ADDITIVE 1.62E−05 1.62E−05 0.7264 0.7264 0.7893 0
    rs11178589 Imputed T DOMINANT 1.26E−05 1.26E−05 0.6312 0.6312 0.7472 0
    rs11178594 Imputed C ADDITIVE 2.03E−05 2.03E−05 0.7297 0.7297 0.8443 0
    rs11178594 Imputed C DOMINANT 1.05E−05 1.05E−05 0.6313 0.6313 0.8109 0
    rs11178602 Imputed T ADDITIVE 1.67E−05 1.67E−05 0.7273 0.7273 0.8496 0
    rs11178602 Imputed T DOMINANT 7.52E−06 7.52E−06 0.6264 0.6264 0.7997 0
    rs11178648 Imputed T ADDITIVE 2.57E−05 2.57E−05 0.7339 0.7339 0.8706 0
    rs11178648 Imputed T DOMINANT 3.00E−06 3.00E−06 0.6155 0.6155 0.8521 0
    rs11198877 Imputed T DOMINANT 4.14E−05 4.14E−05 1.5107 1.5107 0.7435 0
    rs11198942 Imputed T DOMINANT 2.98E−05 2.98E−05 1.5214 1.5214 0.7093 0
    rs11221075 Imputed A ADDITIVE 4.53E−05 4.53E−05 0.6241 0.6241 0.5015 0
    rs11242020 Imputed T DOMINANT 1.95E−05 1.95E−05 0.6485 0.6485 0.8129 0
    rs11242021 Imputed T DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs11242022 Imputed T DOMINANT 2.55E−05 2.55E−05 0.6519 0.6519 0.8477 0
    rs11242023 Imputed T DOMINANT 3.12E−05 3.12E−05 0.6547 0.6547 0.8417 0
    rs1149349 Imputed T DOMINANT 0.0001762 0.0002852 1.5177 1.5147 0.3503 4.68
    rs1149350 Imputed A ADDITIVE 0.004059 0.341 1.2908 1.2455 0.0015 84.55
    rs1149350 Imputed A DOMINANT 2.56E−04 1.03E−01 1.4706 1.4199 0.0201 74.39
    rs11576627 Imputed T ADDITIVE 3.90E−05 3.90E−05 1.5393 1.5393 0.6597 0
    rs11576627 Imputed T DOMINANT 2.57E−05 2.57E−05 1.6368 1.6368 0.6902 0
    rs11630050 Imputed G GENOTYPIC 7.79E−05 7.79E−05 2.665 2.665 0.6771 0
    rs11630050 Imputed G RECESSIVE 8.54E−05 8.54E−05 2.6107 2.6107 0.6577 0
    rs11633024 Imputed C GENOTYPIC 7.79E−05 7.79E−05 2.665 2.665 0.6771 0
    rs11633024 Imputed C RECESSIVE 8.54E−05 8.54E−05 2.6107 2.6107 0.6577 0
    rs11636298 Imputed G GENOTYPIC 4.65E−05 4.65E−05 2.9093 2.9093 0.6341 0
    rs11636298 Imputed G RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs11637363 Imputed C GENOTYPIC 4.03E−05 4.03E−05 2.7783 2.7783 0.6785 0
    rs11637363 Imputed C RECESSIVE 4.23E−05 4.23E−05 2.7253 2.7253 0.6672 0
    rs11637813 Imputed A GENOTYPIC 7.79E−05 7.79E−05 2.665 2.665 0.6771 0
    rs11637813 Imputed A RECESSIVE 8.54E−05 8.54E−05 2.6107 2.6107 0.6577 0
    rs11638043 Imputed C GENOTYPIC 6.02E−05 6.02E−05 2.6802 2.6802 0.7627 0
    rs11638043 Imputed C RECESSIVE 6.43E−05 6.43E−05 2.6274 2.6274 0.7406 0
    rs11638115 Imputed A GENOTYPIC 5.56E−05 5.56E−05 2.911 2.911 0.7416 0
    rs11638115 Imputed A RECESSIVE 8.05E−05 8.05E−05 2.8127 2.8127 0.7514 0
    rs11638444 Imputed C GENOTYPIC 8.18E−05 8.18E−05 2.781 2.781 0.5241 0
    rs11682946 Imputed A ADDITIVE 2.15E−05 2.15E−05 4.6724 4.6724 0.6013 0
    rs11682946 Imputed A DOMINANT 2.84E−05 2.84E−05 4.7413 4.7413 0.5763 0
    rs11717157 Imputed T ADDITIVE 3.66E−04 4.28E−03 1.3013 1.2939 0.2362 30.7
    rs11717157 Imputed T GENOTYPIC 4.70E−04 0.02682 1.7552 1.6884 0.1274 51.46
    rs11724055 Imputed A DOMINANT 5.58E−05 5.58E−05 0.6449 0.6449 0.4625 0
    rs11743355 Imputed C ADDITIVE 3.93E−03 1.07E−01 0.5325 0.414 0.005 81.12
    rs11743355 Imputed C DOMINANT 7.85E−03 1.52E−01 0.5256 0.4354 0.0052 80.99
    rs11746806 Imputed T ADDITIVE 2.88E−03 1.05E−01 0.5269 0.4225 0.0055 80.81
    rs11746806 Imputed T DOMINANT 5.93E−03 1.50E−01 0.520 40.4449 0.0058 80.6
    rs11746959 Imputed T ADDITIVE 2.88E−03 0.1046 0.5269 0.4225 0.0055 80.81
    rs11746959 Imputed T DOMINANT 5.93E−03 1.50E−01 0.5204 0.4449 0.0058 80.6
    rs11749272 Imputed T DOMINANT 1.88E−05 1.88E−05 0.6481 0.6481 0.8316 0
    rs11839636 Imputed C GENOTYPIC 3.90E−03 2.09E−01 1.6569 1.5719 0.0165 75.65
    rs11839785 Imputed C GENOTYPIC 4.03E−03 2.10E−01 1.6541 1.57 0.0167 75.56
    rs11853619 Imputed C GENOTYPIC 5.35E−05 5.35E−05 2.8832 2.8832 0.6237 0
    rs11853619 Imputed C RECESSIVE 8.59E−05 8.59E−05 2.7639 2.7639 0.6266 0
    rs11856780 Imputed A GENOTYPIC 5.35E−05 5.35E−05 2.8832 2.8832 0.6237 0
    rs11856780 Imputed A RECESSIVE 8.59E−05 8.59E−05 2.7639 2.7639 0.6266 0
    rs11901899 Imputed A DOMINANT 5.52E−05 5.52E−05 1.5083 1.5083 0.5339 0
    rs11903290 Imputed C RECESSIVE 9.00E−05 9.00E−05 1.9859 1.9859 0.5245 0
    rs11909480 Imputed G ADDITIVE 9.50E−05 9.50E−05 0.4368 0.4368 0.6169 0
    rs11909480 Imputed G DOMINANT 7.23E−05 7.23E−05 0.418 0.418 0.5676 0
    rs11910289 Imputed T ADDITIVE 8.16E−05 8.16E−05 1.8423 1.8423 0.8017 0
    rs11910289 Imputed T DOMINANT 9.10E−05 9.10E−05 1.904 1.904 0.8708 0
    rs11920375 Genotyped C GENOTYPIC 7.95E−04 4.33E−02 1.703 1.6282 0.1117 54.37
    rs11926319 Imputed G DOMINANT 7.96E−04 0.02707 0.6352 0.6499 0.1381 49.5
    rs11933744 Imputed T RECESSIVE 3.12E−03 0.1216 1.7872 1.8072 0.0315 71.09
    rs11934919 Imputed C RECESSIVE 3.17E−03 0.1247 1.7868 1.804 0.0307 71.3
    rs11934957 Imputed C RECESSIVE 3.17E−03 0.1247 1.7868 1.804 0.0307 71.3
    rs11959206 Imputed A RECESSIVE 1.87E−03 0.191 0.678 0.7117 0.0177 75.21
    rs12038613 Imputed C RECESSIVE 3.47E−04 0.01168 0.613 0.6271 0.1717 43.24
    rs12151417 Imputed T DOMINANT 6.25E−05 6.25E−05 1.506 1.506 0.9573 0
    rs12153185 Imputed T DOMINANT 2.47E−05 2.47E−05 0.6504 0.6504 0.757 0
    rs12182651 Imputed T DOMINANT 8.64E−04 5.43E−02 1.5996 1.5843 0.071 62.2
    rs12235345 Imputed C DOMINANT 6.65E−05 6.65E−05 1.8285 1.8285 0.4602 0
    rs12324786 Imputed T GENOTYPIC 5.56E−05 5.56E−05 2.911 2.911 0.7416 0
    rs12324786 Imputed T RECESSIVE 8.05E−05 8.05E−05 2.8127 2.8127 0.7514 0
    rs12336958 Imputed G DOMINANT 4.62E−03 2.90E−01 1.3599 1.2903 0.009 78.77
    rs12407412 Imputed C ADDITIVE 4.55E−05 4.55E−05 1.5333 1.5333 0.6371 0
    rs12407412 Imputed C DOMINANT 3.07E−05 3.07E−05 1.6289 1.6289 0.6561 0
    rs12418971 Imputed C GENOTYPIC 3.47E−05 3.47E−05 2.4809 2.4809 0.4834 0
    rs12418971 Imputed C RECESSIVE 6.71E−05 6.71E−05 2.3563 2.3563 0.5471 0
    rs1241967 Imputed T RECESSIVE 7.19E−05 7.19E−05 0.5103 0.5103 0.3812 0
    rs12420184 Imputed G DOMINANT 9.08E−03 4.26E−01 0.7449 0.7927 0.0017 84.33
    rs12433968 Imputed T DOMINANT 7.59E−04 1.18E−01 0.707 0.741 0.0375 69.54
    rs12445477 Imputed A DOMINANT 6.41E−05 8.38E−05 0.5585 0.5583 0.357 2.92
    rs12447191 Genotyped T ADDITIVE 8.95E−05 8.95E−05 0.6925 0.6925 0.818 0
    rs12447191 Genotyped T DOMINANT 5.17E−05 5.17E−05 0.6473 0.6473 0.3993 0
    rs12465349 Imputed A RECESSIVE 3.69E−05 3.69E−05 1.6009 1.6009 0.6932 0
    rs1247340 Imputed C ADDITIVE 7.69E−03 3.65E−01 1.2697 1.2218 0.0029 82.86
    rs1247340 Imputed C DOMINANT 0.0003633 0.0921 1.4554 1.406 0.0314 71.11
    rs1247341 Imputed C ADDITIVE 0.006355 0.3353 1.2777 1.2307 0.004 81.86
    rs1247341 Imputed C DOMINANT 3.13E−04 0.07821 1.4625 1.4174 0.0367 69.74
    rs1247343 Imputed C DOMINANT 3.36E−04 7.38E−03 1.4916 1.47 0.2058 36.74
    rs12509758 Imputed C DOMINANT 6.36E−05 6.36E−05 1.5131 1.5131 0.4849 0
    rs12515472 Imputed A DOMINANT 9.90E−05 9.90E−05 1.5106 1.5106 0.3966 0
    rs12548906 Imputed G ADDITIVE 4.27E−05 4.27E−05 1.4718 1.4718 0.4259 0
    rs12596240 Imputed G DOMINANT 1.60E−04 0.003727 0.6751 0.6862 0.2247 33.03
    rs12618781 Imputed A DOMINANT 1.01E−03 0.07896 0.6934 0.7084 0.0532 65.92
    rs12678600 Imputed A DOMINANT 5.24E−05 5.24E−05 0.665 0.665 0.5424 0
    rs12692229 Imputed T ADDITIVE 6.42E−05 6.42E−05 1.3491 1.3491 0.3777 0
    rs12713324 Imputed T DOMINANT 6.12E−05 6.12E−05 1.5047 1.5047 0.9505 0
    rs12719415 Imputed T DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs12820589 Imputed G ADDITIVE 1.70E−03 1.48E−01 1.3433 1.3243 0.0167 75.57
    rs12820589 Imputed G DOMINANT 1.50E−03 9.38E−02 1.4056 1.3931 0.0399 68.95
    rs12831292 Imputed G ADDITIVE 2.24E−05 2.24E−05 0.7299 0.7299 0.8379 0
    rs12831292 Imputed G DOMINANT 1.03E−05 1.03E−05 0.6291 0.6291 0.7999 0
    rs13012636 Imputed G RECESSIVE 7.97E−05 7.97E−05 1.996 1.996 0.5232 0
    rs13038146 Imputed C ADDITIVE 1.20E−05 1.20E−05 1.3766 1.3766 0.9732 0
    rs13038146 Imputed C GENOTYPIC 7.24E−06 7.24E−06 2.0174 2.0174 0.8918 0
    rs13038146 Imputed C RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs13089860 Imputed A DOMINANT 8.44E−05 8.44E−05 0.6273 0.6273 0.9636 0
    rs13102419 Imputed T RECESSIVE 2.95E−04 0.003722 1.5536 1.5326 0.2434 29.22
    rs13194907 Imputed A ADDITIVE 4.90E−04 0.01486 1.6504 1.6306 0.1555 46.27
    rs13194907 Imputed A DOMINANT 0.0002179 0.004282 1.7592 1.7417 0.2106 35.82
    rs13195745 Imputed A ADDITIVE 5.08E−04 1.48E−02 1.6483 1.629 0.1573 45.94
    rs13195745 Imputed A DOMINANT 2.27E−04 4.24E−03 1.7567 1.7397 0.2126 35.41
    rs13265054 Imputed T DOMINANT 5.66E−05 5.66E−05 0.6647 0.6647 0.7133 0
    rs13273002 Imputed A GENOTYPIC 4.84E−04 1.49E−02 0.3723 0.3925 0.1872 40.32
    rs13282131 Imputed C ADDITIVE 3.71E−05 3.71E−05 1.3435 1.3435 0.8944 0
    rs13282131 Imputed C GENOTYPIC 1.60E−05 1.60E−05 1.8634 1.8634 0.9531 0
    rs13282131 Imputed C RECESSIVE 3.52E−05 3.52E−05 1.6677 1.6677 0.8497 0
    rs1330052 Imputed G GENOTYPIC 4.52E−03 2.69E−01 1.5788 1.4648 0.0124 77.22
    rs1335721 Imputed A RECESSIVE 3.43E−04 1.13E−02 0.6128 0.6267 0.1732 42.96
    rs1336382 Imputed T DOMINANT 3.16E−05 3.16E−05 1.5202 1.5202 0.7133 0
    rs1336383 Imputed T DOMINANT 2.98E−05 2.98E−05 1.5214 1.5214 0.7093 0
    rs1336407 Imputed T DOMINANT 4.97E−05 4.97E−05 1.5023 1.5023 0.7397 0
    rs1336409 Imputed T DOMINANT 4.97E−05 4.97E−05 1.5023 1.5023 0.7397 0
    rs1336596 Imputed A DOMINANT 0.0001018 0.03965 0.6696 0.6977 0.0654 63.33
    rs13387284 Imputed A DOMINANT 8.75E−04 0.08529 0.688 0.7034 0.044 67.99
    rs13401462 Imputed C DOMINANT 3.10E−04 1.15E−01 1.5296 1.4898 0.0127 77.09
    rs13409045 Imputed T ADDITIVE 1.07E−03 4.28E−02 0.786 0.7926 0.0962 57.29
    rs1349284 Imputed C GENOTYPIC 0.00058 0.0204 1.7388 1.6882 0.1518 46.96
    rs1355715 Imputed T ADDITIVE 9.33E−05 9.33E−05 0.5378 0.5378 0.685 0
    rs1357696 Imputed A GENOTYPIC 0.0009292 0.05615 1.6955 1.6136 0.0952 57.47
    rs1357698 Imputed A GENOTYPIC 8.00E−04 4.78E−02 1.7026 1.6275 0.1002 56.54
    rs1357699 Imputed T GENOTYPIC 0.0008002 0.04784 1.7026 1.6275 0.1002 56.54
    rs1363273 Imputed C RECESSIVE 5.45E−04 1.84E−02 0.6477 0.6596 0.1541 46.53
    rs1373601 Imputed A DOMINANT 2.77E−04 0.01048 0.6816 0.6853 0.1561 46.15
    rs1375829 Imputed C GENOTYPIC 5.80E−04 0.0204 1.7388 1.6882 0.1518 46.96
    rs1395748 Imputed G DOMINANT 4.33E−03 2.60E−01 0.7518 0.7852 0.0125 77.17
    rs1414865 Imputed T DOMINANT 5.22E−05 5.22E−05 1.503 1.503 0.7135 0
    rs1414873 Imputed A DOMINANT 4.97E−05 4.97E−05 1.5023 1.5023 0.7397 0
    rs1414876 Imputed C DOMINANT 4.97E−05 4.97E−05 1.5023 1.5023 0.7397 0
    rs1424643 Imputed G ADDITIVE 3.10E−05 3.10E−05 1.4271 1.4271 0.7865 0
    rs1424643 Imputed G DOMINANT 1.30E−05 1.30E−05 1.5651 1.5651 0.8673 0
    rs1424648 Imputed T DOMINANT 9.94E−05 9.94E−05 1.486 1.486 0.6958 0
    rs1429321 Imputed A DOMINANT 7.77E−05 7.77E−05 1.4953 1.4953 0.9675 0
    rs1429326 Imputed T ADDITIVE 9.21E−05 9.21E−05 1.399 1.399 0.8323 0
    rs1429326 Imputed T DOMINANT 3.60E−05 3.60E−05 1.5277 1.5277 0.9565 0
    rs1444741 Imputed A DOMINANT 2.75E−04 2.69E−02 0.6829 0.6887 0.0868 59.09
    rs1449916 Imputed C DOMINANT 1.95E−05 1.95E−05 0.5625 0.5625 0.3711 0
    rs1459523 Imputed A ADDITIVE 3.66E−04 4.28E−03 1.3013 1.2939 0.2362 30.7
    rs1459523 Imputed A GENOTYPIC 4.70E−04 0.02682 1.7552 1.6884 0.1274 51.46
    rs1466352 Imputed T GENOTYPIC 0.0005775 0.02214 1.7187 1.6652 0.1488 47.51
    rs1466353 Imputed G GENOTYPIC 0.0005742 0.02215 1.7191 1.6655 0.1486 47.55
    rs1476714 Imputed A DOMINANT 2.39E−05 2.39E−05 0.6504 0.6504 0.8559 0
    rs1486723 Imputed C RECESSIVE 6.53E−05 6.53E−05 0.5173 0.5173 0.6824 0
    rs1495375 Imputed A ADDITIVE 4.26E−05 4.26E−05 0.7384 0.7384 0.8941 0
    rs1495375 Imputed A DOMINANT 2.29E−05 2.29E−05 0.6402 0.6402 0.8341 0
    rs1495381 Imputed T GENOTYPIC 6.50E−05 6.50E−05 1.8347 1.8347 0.5926 0
    rs1495381 Imputed T RECESSIVE 1.60E−05 1.60E−05 1.8065 1.8065 0.8326 0
    rs1498061 Imputed C ADDITIVE 3.02E−05 3.02E−05 0.5576 0.5576 0.7263 0
    rs1498992 Imputed G DOMINANT 3.76E−05 3.76E−05 0.6602 0.6602 0.6375 0
    rs1499001 Imputed T DOMINANT 2.63E−05 2.63E−05 0.6507 0.6507 0.4397 0
    rs1512988 Imputed A ADDITIVE 2.04E−05 2.04E−05 0.7286 0.7286 0.7895 0
    rs1512988 Imputed A DOMINANT 1.46E−05 1.46E−05 0.6349 0.6349 0.7791 0
    rs1512989 Imputed T ADDITIVE 2.04E−05 2.04E−05 0.7286 0.7286 0.7895 0
    rs1512989 Imputed T DOMINANT 1.46E−05 1.46E−05 0.6349 0.6349 0.7791 0
    rs1512991 Imputed T ADDITIVE 1.75E−05 1.75E−05 0.7317 0.7317 0.9424 0
    rs1512991 Imputed T DOMINANT 2.76E−05 2.76E−05 0.6327 0.6327 0.8654 0
    rs1512991 Imputed T GENOTYPIC 5.58E−05 5.58E−05 0.5525 0.5525 0.7914 0
    rs1524303 Imputed T GENOTYPIC 0.0005851 0.02098 1.7312 1.675 0.1554 46.29
    rs1524306 Imputed C ADDITIVE 0.000344 0.004662 1.3028 1.295 0.2276 32.44
    rs1524306 Imputed C GENOTYPIC 4.48E−04 2.71E−02 1.7589 1.6915 0.1248 51.94
    rs1524310 Imputed G ADDITIVE 2.72E−04 2.93E−03 1.3102 1.3039 0.2464 28.62
    rs1524310 Imputed G GENOTYPIC 0.0003497 0.01684 1.7827 1.724 0.1509 47.13
    rs1524321 Imputed C GENOTYPIC 3.30E−04 8.74E−03 1.772 1.7335 0.1931 39.2
    rs1527059 Imputed A DOMINANT 6.83E−05 6.83E−05 0.577 0.577 0.3905 0
    rs152707 Imputed A ADDITIVE 0.001601 0.1313 0.7957 0.8167 0.0376 69.53
    rs152707 Imputed A GENOTYPIC 1.86E−03 1.35E−01 0.6257 0.6605 0.0389 69.2
    rs152712 Genotyped C ADDITIVE 0.001213 0.1285 0.7908 0.812 0.0331 70.67
    rs152712 Genotyped C GENOTYPIC 0.001349 0.1341 0.6169 0.6528 0.0328 70.74
    rs1533994 Imputed T GENOTYPIC 0.0004988 0.02256 1.7311 1.674 0.142 48.77
    rs1535866 Imputed G DOMINANT 9.86E−05 9.86E−05 1.4938 1.4938 0.5229 0
    rs1563773 Imputed T GENOTYPIC 0.0006151 0.02321 1.7166 1.6611 0.1482 47.61
    rs1563774 Imputed T GENOTYPIC 0.0006165 0.02322 1.7172 1.6635 0.1469 47.87
    rs1567740 Imputed T ADDITIVE 1.99E−05 1.99E−05 0.7287 0.7287 0.7926 0
    rs1567740 Imputed T DOMINANT 1.35E−05 1.35E−05 0.634 0.634 0.765 0
    rs1572573 Imputed A DOMINANT 0.0004861 0.03203 1.4535 1.4085 0.1213 52.6
    rs1577497 Imputed C RECESSIVE 0.000359 0.01133 0.6139 0.6277 0.1749 42.64
    rs1581514 Imputed T ADDITIVE 0.0003311 0.003803 1.3057 1.2997 0.2373 30.49
    rs1581514 Imputed T GENOTYPIC 0.0004261 0.02325 1.7652 1.7041 0.1328 50.48
    rs1582321 Imputed T DOMINANT 0.0001513 0.003601 0.6742 0.6852 0.2244 33.07
    rs1582322 Imputed A DOMINANT 0.0001591 0.0008772 0.674 0.6797 0.3001 16.91
    rs1582323 Imputed A DOMINANT 0.0001659 0.001455 0.6747 0.6823 0.2779 21.9
    rs1592485 Imputed C DOMINANT 0.000161 0.001019 0.6729 0.6792 0.294 18.31
    rs1600954 Imputed T ADDITIVE 4.63E−05 4.63E−05 1.3445 1.3445 0.5721 0
    rs1600954 Imputed T GENOTYPIC 4.57E−05 4.57E−05 1.8147 1.8147 0.542 0
    rs16938626 Imputed G DOMINANT 3.76E−05 3.76E−05 0.659 0.659 0.6465 0
    rs16964300 Imputed G ADDITIVE 6.56E−05 6.56E−05 0.6892 0.6892 0.8019 0
    rs16964300 Imputed G DOMINANT 3.18E−05 3.18E−05 0.6401 0.6401 0.4292 0
    rs16986282 Imputed G DOMINANT 4.72E−05 4.72E−05 0.4011 0.4011 0.3857 0
    rs17007620 Imputed G ADDITIVE 0.00042 0.01992 1.3669 1.3587 0.1192 52.98
    rs17007620 Imputed G DOMINANT 0.0001365 0.003601 1.5086 1.5037 0.1945 38.93
    rs17014326 Imputed G DOMINANT 0.00215 0.2476 0.7351 0.7739 0.0097 78.44
    rs17047957 Imputed C DOMINANT 3.23E−05 3.23E−05 1.5756 1.5756 0.7413 0
    rs1705261 Imputed A RECESSIVE 2.52E−05 2.52E−05 1.7737 1.7737 0.834 0
    rs17073341 Imputed A ADDITIVE 9.48E−05 9.48E−05 2.0844 2.0844 0.3839 0
    rs17073341 Imputed A DOMINANT 7.90E−05 7.90E−05 2.1417 2.1417 0.3765 0
    rs17138702 Imputed G ADDITIVE 0.004 0.216 0.7417 0.7591 0.0117 77.5
    rs17189710 Imputed T ADDITIVE 1.26E−05 1.26E−05 1.3776 1.3776 0.9806 0
    rs17189710 Imputed T GENOTYPIC 7.08E−06 7.08E−06 2.0265 2.0265 0.8812 0
    rs17189710 Imputed T RECESSIVE 5.89E−05 5.89E−05 1.7991 1.7991 0.569 0
    rs17310176 Imputed T ADDITIVE 6.02E−05 6.02E−05 0.6787 0.6787 0.5641 0
    rs17310176 Imputed T DOMINANT 4.51E−05 4.51E−05 0.6409 0.6409 0.4149 0
    rs17358860 Imputed A DOMINANT 5.45E−05 5.45E−05 0.6457 0.6457 0.4986 0
    rs17370541 Imputed T GENOTYPIC 0.0003366 0.01452 1.7812 1.7046 0.176 42.44
    rs17370541 Imputed T RECESSIVE 0.0002644 0.004097 1.7173 1.6801 0.2409 29.74
    rs17526574 Imputed G GENOTYPIC 0.002555 0.1386 1.6824 1.6185 0.0319 70.98
    rs17530747 Imputed T DOMINANT 0.0007294 0.06795 0.7034 0.7357 0.0872 59.01
    rs17649114 Imputed C DOMINANT 5.86E−05 5.86E−05 1.5179 1.5179 0.5026 0
    rs17766172 Imputed A RECESSIVE 4.67E−05 4.67E−05 0.4975 0.4975 0.483 0
    rs1818885 Imputed G GENOTYPIC 0.0004892 0.02726 1.756 1.6897 0.1265 51.64
    rs1832222 Imputed G DOMINANT 5.68E−05 5.68E−05 1.4978 1.4978 0.7483 0
    rs1861327 Imputed G DOMINANT 0.0001308 0.002055 0.67 0.6796 0.2521 27.42
    rs1868581 Imputed G ADDITIVE 0.0003858 0.009401 1.3009 1.2907 0.1844 40.85
    rs1868581 Imputed G GENOTYPIC 0.0004728 0.03115 1.7583 1.6889 0.1157 53.63
    rs1874313 Imputed A ADDITIVE 3.53E−05 3.53E−05 0.7362 0.7362 0.736 0
    rs1874313 Imputed A DOMINANT 2.05E−05 2.05E−05 0.6403 0.6403 0.7327 0
    rs1876409 Imputed C DOMINANT 0.003381 0.227 0.746 0.7766 0.0157 75.94
    rs1913201 Imputed G ADDITIVE 2.15E−05 2.15E−05 0.7321 0.7321 0.9128 0
    rs1913201 Imputed G DOMINANT 6.73E−05 6.73E−05 0.6474 0.6474 0.8659 0
    rs1913201 Imputed G GENOTYPIC 6.26E−05 6.26E−05 0.5503 0.5503 0.7315 0
    rs1916922 Imputed T GENOTYPIC 0.0006243 0.02368 1.7596 1.7018 0.1488 47.52
    rs1936871 Genotyped G DOMINANT 8.55E−05 8.55E−05 0.6616 0.6616 0.3925 0
    rs1961157 Imputed T RECESSIVE 0.002404 0.1282 0.68 0.6899 0.0283 71.94
    rs1987179 Imputed T ADDITIVE 9.76E−05 9.76E−05 0.6985 0.6985 0.7616 0
    rs1987179 Imputed T DOMINANT 6.37E−06 6.37E−06 0.6204 0.6204 0.6462 0
    rs1990023 Imputed T DOMINANT 1.72E−05 1.72E−05 0.6468 0.6468 0.8317 0
    rs1995025 Imputed C DOMINANT 7.87E−05 7.87E−05 1.5633 1.5633 0.7042 0
    rs2016194 Imputed G DOMINANT 2.38E−05 2.38E−05 0.651 0.651 0.8576 0
    rs2023651 Imputed T ADDITIVE 0.002541 0.2484 0.7624 0.7886 0.0082 79.2
    rs2024902 Imputed A ADDITIVE 0.0005049 0.01577 1.6486 1.6285 0.152 46.92
    rs2024902 Imputed A DOMINANT 0.0002252 0.004699 1.7569 1.739 0.2058 36.74
    rs2025107 Imputed A DOMINANT 0.0008183 0.05061 1.6029 1.5881 0.0749 61.42
    rs2025108 Imputed T DOMINANT 0.001038 0.04754 1.5831 1.5581 0.0932 57.86
    rs2031987 Imputed T GENOTYPIC 0.002645 0.1394 1.6843 1.6228 0.0311 71.19
    rs2052428 Imputed C DOMINANT 6.07E−05 6.07E−05 0.6359 0.6359 0.7925 0
    rs2053230 Imputed C ADDITIVE 0.0001481 0.003644 0.6297 0.6429 0.2766 22.2
    rs2062448 Imputed T DOMINANT 0.0003871 0.004058 0.6188 0.6264 0.2457 28.76
    rs2063420 Imputed C RECESSIVE 0.001837 0.1146 1.4963 1.443 0.0468 67.35
    rs2063591 Imputed C ADDITIVE 7.27E−05 7.27E−05 0.7518 0.7518 0.9305 0
    rs2063591 Imputed C DOMINANT 4.26E−05 4.26E−05 0.6381 0.6381 0.8973 0
    rs208026 Genotyped A DOMINANT 6.33E−05 6.33E−05 1.4986 1.4986 0.9606 0
    rs208029 Imputed T DOMINANT 3.75E−05 3.75E−05 1.5349 1.5349 0.4541 0
    rs208757 Imputed G DOMINANT 3.01E−05 3.01E−05 1.5343 1.5343 0.5566 0
    rs2095586 Imputed A DOMINANT 3.68E−05 3.68E−05 1.5163 1.5163 0.6839 0
    rs2095606 Imputed A DOMINANT 5.61E−05 0.01913 0.6593 0.6816 0.0926 57.97
    rs2102374 Imputed A ADDITIVE 0.001363 0.2021 0.7686 0.7983 0.0117 77.54
    rs2102374 Imputed A DOMINANT 0.001202 0.1846 0.7215 0.7489 0.0116 77.55
    rs2108426 Imputed C DOMINANT 2.38E−05 2.38E−05 0.651 0.651 0.8576 0
    rs2110664 Imputed A DOMINANT 3.76E−05 3.76E−05 1.532 1.532 0.6276 0
    rs2132242 Imputed A ADDITIVE 1.93E−05 1.93E−05 0.7293 0.7293 0.8549 0
    rs2132242 Imputed A DOMINANT 1.23E−05 1.23E−05 0.6323 0.6323 0.8457 0
    rs2158958 Imputed A DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs2158961 Imputed G DOMINANT 4.37E−05 4.37E−05 0.663 0.663 0.936 0
    rs2163046 Imputed A DOMINANT 7.62E−05 7.62E−05 1.4981 1.4981 0.988 0
    rs2180286 Imputed G DOMINANT 6.63E−05 6.63E−05 0.6345 0.6345 0.8013 0
    rs2180684 Imputed A DOMINANT 2.68E−05 2.68E−05 1.7201 1.7201 0.9033 0
    rs2188079 Imputed C ADDITIVE 0.0004508 0.01972 1.2881 1.2834 0.1244 52.01
    rs2188079 Imputed C GENOTYPIC 0.0002443 0.007437 1.7178 1.7019 0.1776 42.15
    rs2190598 Imputed T DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs2190600 Imputed A DOMINANT 2.54E−05 2.54E−05 0.6504 0.6504 0.7871 0
    rs2224184 Genotyped T DOMINANT 8.75E−05 8.75E−05 0.6414 0.6414 0.8155 0
    rs2247066 Imputed A DOMINANT 0.004329 0.2604 0.7518 0.7852 0.0125 77.17
    rs2248236 Imputed C ADDITIVE 2.90E−05 2.90E−05 0.676 0.676 0.7802 0
    rs2248236 Imputed C DOMINANT 1.58E−06 1.58E−06 0.596 0.596 0.8313 0
    rs2265733 Imputed C ADDITIVE 0.001363 0.2021 0.7686 0.7983 0.0117 77.54
    rs2265733 Imputed C DOMINANT 0.001202 0.1846 0.7215 0.7489 0.0116 77.55
    rs2270584 Imputed A ADDITIVE 2.02E−05 2.02E−05 0.7312 0.7312 0.8826 0
    rs2270584 Imputed A DOMINANT 2.32E−06 2.32E−06 0.6123 0.6123 0.8509 0
    rs2270586 Imputed A ADDITIVE 2.39E−05 2.39E−05 0.7334 0.7334 0.8691 0
    rs2270586 Imputed A DOMINANT 3.16E−06 3.16E−06 0.6167 0.6167 0.8138 0
    rs229775 Imputed A RECESSIVE 7.19E−05 7.19E−05 0.5103 0.5103 0.3812 0
    rs229815 Imputed T RECESSIVE 9.48E−05 9.48E−05 0.5099 0.5099 0.5285 0
    rs229829 Imputed C RECESSIVE 9.98E−05 9.98E−05 0.5548 0.5548 0.8369 0
    rs229831 Imputed A RECESSIVE 8.91E−05 8.91E−05 0.5096 0.5096 0.3946 0
    rs2317057 Imputed T ADDITIVE 6.41E−05 6.41E−05 0.6839 0.6839 0.7046 0
    rs2322100 Genotyped T RECESSIVE 4.07E−05 4.07E−05 2.2062 2.2062 0.5484 0
    rs2322101 Imputed A RECESSIVE 3.66E−05 3.66E−05 2.218 2.218 0.5273 0
    rs2327929 Imputed G RECESSIVE 3.43E−05 3.43E−05 1.6873 1.6873 0.4473 0
    rs2332844 Imputed A ADDITIVE 3.09E−05 3.09E−05 1.6598 1.6598 0.5134 0
    rs2332844 Imputed A RECESSIVE 6.54E−05 6.54E−05 1.7248 1.7248 0.7183 0
    rs2349170 Imputed G DOMINANT 9.67E−05 9.67E−05 1.4926 1.4926 0.6711 0
    rs2356722 Imputed G DOMINANT 0.002651 0.2845 0.7401 0.7804 0.0062 80.31
    rs2364956 Imputed T ADDITIVE 0.000127 0.0002252 1.4305 1.4298 0.3433 6.47
    rs2373793 Imputed G ADDITIVE 4.62E−05 4.62E−05 1.4791 1.4791 0.7939 0
    rs2373793 Imputed G DOMINANT 2.34E−05 2.34E−05 1.5985 1.5985 0.6098 0
    rs238252 Imputed G ADDITIVE 8.76E−05 0.0001795 1.4845 1.4806 0.3424 6.69
    rs238252 Imputed G DOMINANT 6.01E−05 0.0004281 1.5806 1.5679 0.292 18.76
    rs2383903 Imputed G DOMINANT 4.71E−05 4.71E−05 0.6638 0.6638 0.7307 0
    rs2387945 Imputed G DOMINANT 7.60E−05 7.60E−05 1.5615 1.5615 0.6844 0
    rs2389863 Imputed A DOMINANT 1.22E−05 1.22E−05 0.6334 0.6334 0.7957 0
    rs2389866 Imputed C DOMINANT 4.66E−06 4.66E−06 0.6225 0.6225 0.7145 0
    rs2389869 Imputed C DOMINANT 4.66E−06 4.66E−06 0.6225 0.6225 0.7145 0
    rs2389870 Genotyped C DOMINANT 6.46E−05 6.46E−05 0.6493 0.6493 0.3855 0
    rs2418494 Imputed G ADDITIVE 9.79E−05 9.79E−05 0.7569 0.7569 0.5664 0
    rs2418494 Imputed G GENOTYPIC 9.28E−05 9.28E−05 0.5712 0.5712 0.5491 0
    rs2418541 Imputed A DOMINANT 1.72E−05 1.72E−05 0.6468 0.6468 0.8317 0
    rs2418542 Imputed A DOMINANT 1.88E−05 1.88E−05 0.6481 0.6481 0.8316 0
    rs2423556 Imputed C DOMINANT 7.99E−05 7.99E−05 0.635 0.635 0.8112 0
    rs2437688 Imputed C ADDITIVE 7.95E−05 7.95E−05 1.591 1.591 0.4782 0
    rs2456809 Imputed G DOMINANT 0.002716 0.1918 0.7406 0.7699 0.0226 73.61
    rs2456811 Imputed T ADDITIVE 0.001617 0.2162 0.7717 0.802 0.0106 77.99
    rs2456811 Imputed T DOMINANT 0.001438 0.1994 0.7251 0.7532 0.0104 78.1
    rs2476976 Imputed C DOMINANT 6.91E−05 6.91E−05 1.4908 1.4908 0.8073 0
    rs2484911 Imputed A DOMINANT 9.19E−05 9.19E−05 1.4801 1.4801 0.8339 0
    rs2488557 Imputed C DOMINANT 0.000454 0.009593 0.6571 0.6684 0.1949 38.85
    rs250162 Imputed C ADDITIVE 7.89E−06 7.89E−06 0.6754 0.6754 0.5537 0
    rs250162 Imputed C DOMINANT 3.91E−06 3.91E−06 0.6207 0.6207 0.4842 0
    rs2560708 Imputed T ADDITIVE 8.04E−05 8.04E−05 0.6746 0.6746 0.7071 0
    rs2617841 Imputed G DOMINANT 7.42E−05 7.42E−05 0.6584 0.6584 0.6003 0
    rs2622499 Imputed G DOMINANT 5.66E−06 5.66E−06 0.6251 0.6251 0.6966 0
    rs264129 Imputed T DOMINANT 4.75E−05 4.75E−05 0.6631 0.6631 0.9256 0
    rs2642936 Imputed T ADDITIVE 0.0008203 0.04658 1.3495 1.3354 0.0879 58.88
    rs2660633 Imputed A DOMINANT 0.003381 0.227 0.746 0.7766 0.0157 75.94
    rs2660634 Imputed C DOMINANT 0.003381 0.227 0.746 0.7766 0.0157 75.94
    rs2660648 Imputed A ADDITIVE 0.001363 0.2021 0.7686 0.7983 0.0117 77.54
    rs2660648 Imputed A DOMINANT 0.001202 0.1846 0.7215 0.7489 0.0116 77.55
    rs2681505 Imputed T ADDITIVE 2.69E−05 2.69E−05 0.6941 0.6941 0.3782 0
    rs277411 Imputed G DOMINANT 0.002587 0.1087 0.5246 0.4938 0.0195 74.6
    rs2832634 Imputed G ADDITIVE 9.75E−05 9.75E−05 1.8259 1.8259 0.7829 0
    rs2832637 Imputed T ADDITIVE 9.75E−05 9.75E−05 1.8259 1.8259 0.7829 0
    rs2843167 Imputed A DOMINANT 0.001237 0.1278 0.7224 0.7509 0.0362 69.86
    rs2876227 Imputed C ADDITIVE 2.82E−05 2.82E−05 1.362 1.362 0.97 0
    rs2876227 Imputed C GENOTYPIC 1.54E−05 1.54E−05 1.9854 1.9854 0.8563 0
    rs2882097 Imputed A DOMINANT 2.98E−05 2.98E−05 1.5214 1.5214 0.7093 0
    rs2909862 Imputed G DOMINANT 0.0004342 0.0219 1.5096 1.4698 0.1401 49.11
    rs3001945 Imputed T DOMINANT 7.34E−05 7.34E−05 1.5785 1.5785 0.8106 0
    rs3011020 Imputed C DOMINANT 7.27E−05 7.27E−05 1.5634 1.5634 0.6833 0
    rs36071725 Genotyped C ADDITIVE 0.0001148 0.05399 1.3419 1.3062 0.0432 68.17
    rs36071725 Genotyped C GENOTYPIC 0.0001469 0.1424 1.9245 1.7281 0.0116 77.56
    rs373983 Imputed G DOMINANT 2.26E−05 2.26E−05 1.5782 1.5782 0.441 0
    rs3743794 Imputed G DOMINANT 0.0002394 0.002286 0.6809 0.6895 0.2695 23.73
    rs3756154 Imputed C ADDITIVE 8.74E−05 8.74E−05 0.6973 0.6973 0.7453 0
    rs3756154 Imputed C DOMINANT 5.57E−06 5.57E−06 0.6194 0.6194 0.6345 0
    rs3775850 Imputed A DOMINANT 4.28E−05 4.28E−05 0.6406 0.6406 0.4572 0
    rs3775851 Imputed C DOMINANT 5.58E−05 5.58E−05 0.6449 0.6449 0.4625 0
    rs3793044 Imputed C ADDITIVE 0.0006211 0.01526 1.6363 1.6145 0.1659 44.33
    rs3793044 Imputed C DOMINANT 0.0002821 0.004123 1.7429 1.7248 0.2257 32.82
    rs3793053 Imputed C DOMINANT 0.0006344 0.04352 1.6268 1.6074 0.0815 60.12
    rs3796246 Imputed G DOMINANT 0.0006434 0.02777 0.6293 0.6362 0.1152 53.73
    rs3806003 Imputed A ADDITIVE 0.0006211 0.01526 1.6363 1.6145 0.1659 44.33
    rs3806003 Imputed A DOMINANT 0.0002821 0.004123 1.7429 1.7248 0.2257 32.82
    rs3806004 Imputed T DOMINANT 0.0008183 0.05061 1.6029 1.5881 0.0749 61.42
    rs3806010 Imputed T DOMINANT 0.0008183 0.05061 1.6029 1.5881 0.0749 61.42
    rs3806014 Imputed T DOMINANT 0.0006528 0.0397 1.6219 1.6045 0.0892 58.62
    rs3806015 Imputed A DOMINANT 0.0007014 0.04258 1.6162 1.5981 0.0866 59.13
    rs3806018 Imputed A DOMINANT 0.001012 0.05137 1.5918 1.5803 0.0785 60.71
    rs3806019 Imputed A DOMINANT 0.0009044 0.0577 1.5971 1.581 0.0678 62.83
    rs3806024 Imputed T DOMINANT 0.0006532 0.0428 1.619 1.6067 0.0793 60.54
    rs3915080 Imputed A GENOTYPIC 0.0006483 0.0458 1.7202 1.6467 0.095 57.52
    rs3942254 Imputed T ADDITIVE 2.13E−05 2.13E−05 0.7274 0.7274 0.9089 0
    rs3942254 Imputed T DOMINANT 9.53E−06 9.53E−06 0.6253 0.6253 0.9519 0
    rs3945085 Imputed A DOMINANT 3.27E−05 3.27E−05 1.519 1.519 0.687 0
    rs3976737 Imputed G ADDITIVE 0.003945 0.2806 0.7457 0.7798 0.0081 79.23
    rs399485 Imputed A DOMINANT 4.97E−05 4.97E−05 1.5032 1.5032 0.8617 0
    rs4029119 Imputed G ADDITIVE 0.004166 0.1177 0.5395 0.4424 0.0069 79.92
    rs4029119 Imputed G DOMINANT 0.008687 0.1677 0.5356 0.4664 0.0072 79.71
    rs4076201 Imputed G GENOTYPIC 5.99E−05 5.99E−05 2.6809 2.6809 0.7622 0
    rs4076201 Imputed G RECESSIVE 6.53E−05 6.53E−05 2.6253 2.6253 0.7419 0
    rs41395945 Imputed G ADDITIVE 7.48E−05 7.48E−05 1.8482 1.8482 0.7926 0
    rs41395945 Imputed G DOMINANT 8.37E−05 8.37E−05 1.9099 1.9099 0.8616 0
    rs4146972 Genotyped T DOMINANT 3.95E−05 3.95E−05 1.5614 1.5614 0.6547 0
    rs4238087 Imputed G DOMINANT 9.82E−05 9.82E−05 0.6268 0.6268 0.5018 0
    rs4251569 Imputed T ADDITIVE 9.93E−05 9.93E−05 0.6551 0.6551 0.6066 0
    rs4251569 Imputed T DOMINANT 8.05E−05 8.05E−05 0.6254 0.6254 0.4972 0
    rs4273613 Imputed T ADDITIVE 0.002876 0.1046 0.5269 0.4225 0.0055 80.81
    rs4273613 Imputed T DOMINANT 0.005931 0.1502 0.5204 0.4449 0.0058 80.6
    rs4291049 Imputed T RECESSIVE 0.002115 0.1545 0.6826 0.7124 0.0331 70.66
    rs4315598 Imputed T ADDITIVE 1.33E−05 1.33E−05 1.3742 1.3742 0.9673 0
    rs4315598 Imputed T GENOTYPIC 8.02E−06 8.02E−06 2.0108 2.0108 0.8929 0
    rs4315598 Imputed T RECESSIVE 6.81E−05 6.81E−05 1.7847 1.7847 0.5993 0
    rs4321395 Imputed A DOMINANT 0.0008748 0.08529 0.688 0.7034 0.044 67.99
    rs4321596 Genotyped T RECESSIVE 9.95E−05 9.95E−05 2.3838 2.3838 0.8271 0
    rs4324417 Imputed T DOMINANT 0.0004684 0.01009 1.4729 1.4477 0.1952 38.79
    rs4328619 Genotyped G DOMINANT 8.16E−05 8.16E−05 0.6393 0.6393 0.768 0
    rs4338909 Imputed T ADDITIVE 0.0009962 0.03681 1.2613 1.2511 0.1094 54.81
    rs4370878 Imputed G DOMINANT 5.08E−05 5.08E−05 1.5041 1.5041 0.6831 0
    rs4379434 Genotyped T DOMINANT 0.0008974 0.03349 1.4182 1.3922 0.1216 52.53
    rs4416407 Imputed T DOMINANT 7.89E−05 7.89E−05 1.6055 1.6055 0.6011 0
    rs4417899 Imputed C RECESSIVE 7.35E−05 7.35E−05 0.6217 0.6217 0.5918 0
    rs4442732 Imputed A ADDITIVE 0.0002973 0.01275 0.7154 0.7312 0.1721 43.17
    rs4444612 Imputed G ADDITIVE 1.05E−05 1.05E−05 1.38 1.38 0.9803 0
    rs4444612 Imputed G GENOTYPIC 6.88E−06 6.88E−06 2.022 2.022 0.8907 0
    rs4444612 Imputed G RECESSIVE 6.51E−05 6.51E−05 1.7874 1.7874 0.5969 0
    rs4450660 Imputed C DOMINANT 6.12E−05 6.12E−05 1.5007 1.5007 0.4999 0
    rs4509702 Imputed C DOMINANT 5.08E−05 5.08E−05 1.5041 1.5041 0.6831 0
    rs4526920 Imputed G GENOTYPIC 0.002645 0.1394 1.6843 1.6228 0.0311 71.19
    rs4533145 Imputed T DOMINANT 0.06008 0.6325 0.7887 0.8292 0.0001 89.37
    rs4557006 Imputed A DOMINANT 0.001528 0.089 0.6986 0.7133 0.0548 65.56
    rs4570530 Imputed C DOMINANT 5.08E−05 5.08E−05 1.5041 1.5041 0.6831 0
    rs4615971 Imputed C DOMINANT 4.82E−05 4.82E−05 1.5038 1.5038 0.7548 0
    rs4628119 Imputed A DOMINANT 0.0009573 0.07481 0.7135 0.7203 0.0461 67.51
    rs4664443 Imputed G ADDITIVE 0.0009373 0.04269 0.7841 0.7912 0.0927 57.96
    rs4688259 Imputed T DOMINANT 7.88E−05 7.88E−05 1.6056 1.6056 0.5986 0
    rs4688632 Imputed G RECESSIVE 4.49E−05 4.49E−05 0.6188 0.6188 0.7162 0
    rs4695284 Imputed A ADDITIVE 6.68E−05 6.68E−05 1.8181 1.8181 0.5549 0
    rs4700302 Imputed A ADDITIVE 0.002913 0.1394 0.6642 0.6808 0.0345 70.31
    rs4702720 Imputed A ADDITIVE 4.29E−05 4.29E−05 0.6727 0.6727 0.6127 0
    rs4702720 Imputed A DOMINANT 2.14E−05 2.14E−05 0.6116 0.6116 0.5842 0
    rs4711091 Genotyped G GENOTYPIC 0.003111 0.235 1.5203 1.4091 0.02 74.42
    rs4714484 Imputed A ADDITIVE 6.43E−05 0.0001399 0.6741 0.6745 0.3377 7.89
    rs4736802 Imputed G DOMINANT 0.0007866 0.03886 1.4239 1.3953 0.1046 55.7
    rs4760785 Imputed A ADDITIVE 2.15E−05 2.15E−05 0.7321 0.7321 0.9128 0
    rs4760785 Imputed A DOMINANT 6.73E−05 6.73E−05 0.6474 0.6474 0.8659 0
    rs4760785 Imputed A GENOTYPIC 6.26E−05 6.26E−05 0.5503 0.5503 0.7315 0
    rs4760894 Imputed T ADDITIVE 2.15E−05 2.15E−05 0.7321 0.7321 0.9128 0
    rs4760894 Imputed T DOMINANT 6.73E−05 6.73E−05 0.6474 0.6474 0.8659 0
    rs4760894 Imputed T GENOTYPIC 6.26E−05 6.26E−05 0.5503 0.5503 0.7315 0
    rs4760895 Imputed A ADDITIVE 2.15E−05 2.15E−05 0.7321 0.7321 0.9128 0
    rs4760895 Imputed A DOMINANT 6.73E−05 6.73E−05 0.6474 0.6474 0.8659 0
    rs4760895 Imputed A GENOTYPIC 6.26E−05 6.26E−05 0.5503 0.5503 0.7315 0
    rs4764738 Imputed A ADDITIVE 0.0009266 0.07954 1.2709 1.2594 0.0439 68.01
    rs4764738 Imputed A GENOTYPIC 0.001005 0.08625 1.6088 1.5782 0.0404 68.83
    rs4764974 Imputed T ADDITIVE 0.003078 0.1633 1.2361 1.2211 0.0224 73.69
    rs4764974 Imputed T GENOTYPIC 0.003002 0.1626 1.5291 1.4908 0.0225 73.63
    rs4798366 Imputed G RECESSIVE 4.20E−05 4.20E−05 2.0082 2.0082 0.3989 0
    rs483159 Imputed T DOMINANT 7.40E−05 7.40E−05 1.5348 1.5348 0.4489 0
    rs4836502 Imputed T DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs4836507 Imputed C DOMINANT 2.65E−05 2.65E−05 0.6512 0.6512 0.7993 0
    rs4836744 Imputed A ADDITIVE 5.65E−05 5.65E−05 0.7302 0.7302 0.9215 0
    rs4836744 Imputed A DOMINANT 9.27E−05 9.27E−05 0.6763 0.6763 0.9561 0
    rs4848944 Genotyped C RECESSIVE 9.83E−05 9.83E−05 0.6206 0.6206 0.3871 0
    rs4851529 Imputed A DOMINANT 2.19E−05 2.19E−05 0.6441 0.6441 0.7104 0
    rs4851531 Imputed T DOMINANT 3.21E−05 3.21E−05 0.6474 0.6474 0.5448 0
    rs4858046 Genotyped T GENOTYPIC 0.0006163 0.0233 1.7237 1.6703 0.1446 48.29
    rs4878214 Imputed A ADDITIVE 3.88E−05 3.88E−05 0.6738 0.6738 0.5061 0
    rs4880803 Imputed A ADDITIVE 9.69E−05 9.69E−05 0.7391 0.7391 0.6783 0
    rs489441 Imputed G ADDITIVE 2.53E−05 2.53E−05 1.4225 1.4225 0.5025 0
    rs489441 Imputed G DOMINANT 2.68E−05 2.68E−05 1.5463 1.5463 0.8089 0
    rs4896568 Imputed T DOMINANT 0.001111 0.06921 0.7129 0.7224 0.06 64.45
    rs4938851 Imputed T DOMINANT 3.87E−05 3.87E−05 1.5301 1.5301 0.5447 0
    rs4964416 Imputed C DOMINANT 9.70E−05 9.70E−05 0.6422 0.6422 0.8344 0
    rs5756669 Imputed C DOMINANT 0.0004684 0.01009 1.4729 1.4477 0.1952 38.79
    rs6033138 Imputed C ADDITIVE 7.29E−06 7.29E−06 1.3851 1.3851 0.9889 0
    rs6033138 Imputed C GENOTYPIC 6.04E−06 6.04E−06 2.0122 2.0122 0.8928 0
    rs6033138 Imputed C RECESSIVE 7.08E−05 7.08E−05 1.7649 1.7649 0.6157 0
    rs6040619 Imputed C ADDITIVE 4.47E−06 4.47E−06 1.3986 1.3986 0.8222 0
    rs6040619 Imputed C GENOTYPIC 2.25E−06 2.25E−06 2.1003 2.1003 0.9241 0
    rs6040619 Imputed C RECESSIVE 2.09E−05 2.09E−05 1.861 1.861 0.8676 0
    rs6040625 Imputed T ADDITIVE 5.19E−06 5.19E−06 1.395 3 1.3953 0.8592 0
    rs6040625 Imputed T GENOTYPIC 3.08E−06 3.08E−06 2.0812 2.0812 0.9469 0
    rs6040625 Imputed T RECESSIVE 3.05E−05 3.05E−05 1.8401 1.8401 0.8473 0
    rs6040630 Imputed A ADDITIVE 9.20E−06 9.20E−06 1.383 1.383 0.9581 0
    rs6040630 Imputed A GENOTYPIC 5.55E−06 5.55E−06 2.0375 2.0375 0.9148 0
    rs6040630 Imputed A RECESSIVE 5.12E−05 5.12E−05 1.8039 1.8039 0.6621 0
    rs6040633 Imputed A ADDITIVE 1.25E−05 1.25E−05 1.3756 1.3756 0.969 0
    rs6040633 Imputed A GENOTYPIC 7.70E−06 7.70E−06 2.0134 2.0134 0.8921 0
    rs6040633 Imputed A RECESSIVE 6.75E−05 6.75E−05 1.7849 1.7849 0.6011 0
    rs6040634 Imputed T ADDITIVE 1.00E−05 1.00E−05 1.3804 1.3804 0.9666 0
    rs6040634 Imputed T GENOTYPIC 6.55E−06 6.55E−06 2.0241 2.0241 0.8798 0
    rs6040634 Imputed T RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs6040636 Imputed T ADDITIVE 1.31E−05 1.31E−05 1.3748 1.3748 0.9806 0
    rs6040636 Imputed T GENOTYPIC 7.73E−06 7.73E−06 2.0134 2.0134 0.9037 0
    rs6040636 Imputed T RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs6040638 Imputed C ADDITIVE 1.20E−05 1.20E−05 1.3766 1.3766 0.9732 0
    rs6040638 Imputed C GENOTYPIC 7.24E−06 7.24E−06 2.0174 2.0174 0.8918 0
    rs6040638 Imputed C RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs6040644 Imputed A ADDITIVE 1.20E−05 1.20E−05 1.3766 1.3766 0.9732 0
    rs6040644 Imputed A GENOTYPIC 7.24E−06 7.24E−06 2.0174 2.0174 0.8918 0
    rs6040644 Imputed A RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs6040667 Imputed T ADDITIVE 1.20E−05 1.20E−05 1.3804 1.3804 0.9597 0
    rs6040667 Imputed T GENOTYPIC 7.88E−06 7.88E−06 2.0249 2.0249 0.8444 0
    rs6040667 Imputed T RECESSIVE 7.44E−05 7.44E−05 1.7892 1.7892 0.5844 0
    rs6040668 Imputed C ADDITIVE 1.73E−05 1.73E−05 1.373 1.373 0.98 0
    rs6040668 Imputed C GENOTYPIC 1.05E−05 1.05E−05 2.0115 2.0115 0.8502 0
    rs6040668 Imputed C RECESSIVE 9.40E−05 9.40E−05 1.7793 1.7793 0.5751 0
    rs6043066 Genotyped G DOMINANT 9.84E−05 9.84E−05 1.4879 1.4879 0.4214 0
    rs6048146 Imputed G DOMINANT 5.02E−05 5.02E−05 2.6243 2.6243 0.8749 0
    rs6082725 Genotyped T DOMINANT 5.02E−05 5.02E−05 2.6243 2.6243 0.8749 0
    rs6131206 Imputed C ADDITIVE 7.67E−05 7.67E−05 1.3544 1.3544 0.6023 0
    rs6131208 Imputed T ADDITIVE 1.43E−05 1.43E−05 1.3763 1.3763 0.9848 0
    rs6131208 Imputed T GENOTYPIC 8.33E−06 8.33E−06 2.0252 2.0252 0.879 0
    rs6131208 Imputed T RECESSIVE 7.25E−05 7.25E−05 1.7953 1.7953 0.6033 0
    rs6134243 Imputed C ADDITIVE 1.20E−05 1.20E−05 1.3766 1.3766 0.9732 0
    rs6134243 Imputed C GENOTYPIC 7.24E−06 7.24E−06 2.0174 2.0174 0.8918 0
    rs6134243 Imputed C RECESSIVE 6.47E−05 6.47E−05 1.7879 1.7879 0.5965 0
    rs6136020 Imputed A DOMINANT 0.001161 0.126 0.6966 0.7316 0.042 68.46
    rs613799 Imputed C DOMINANT 7.75E−05 7.75E−05 1.5158 1.5158 0.7849 0
    rs644041 Imputed G ADDITIVE 8.78E−05 8.78E−05 1.391 1.391 0.5335 0
    rs644041 Imputed G DOMINANT 7.42E−05 7.42E−05 1.5143 1.5143 0.8073 0
    rs647645 Imputed C ADDITIVE 6.86E−05 0.001002 0.7509 0.7567 0.2638 24.95
    rs647645 Imputed C GENOTYPIC 9.70E−05 0.006546 0.5657 0.581 0.1711 43.36
    rs647645 Imputed C RECESSIVE 0.001082 0.1079 0.6612 0.6805 0.034 70.43
    rs6495554 Imputed C GENOTYPIC 4.76E−05 4.76E−05 2.9048 2.9048 0.6375 0
    rs6495554 Imputed C RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs6495555 Imputed C GENOTYPIC 4.76E−05 4.76E−05 2.9048 2.9048 0.6375 0
    rs6495555 Imputed C RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs6544728 Imputed T DOMINANT 1.47E−05 1.47E−05 1.5526 1.5526 0.4629 0
    rs6550705 Imputed C ADDITIVE 0.00038 0.004853 1.3004 1.2925 0.2297 32.02
    rs6550705 Imputed C GENOTYPIC 0.0004703 0.0268 1.7552 1.6884 0.1275 51.46
    rs6550707 Imputed T GENOTYPIC 0.0005925 0.02351 1.7169 1.6622 0.1452 48.18
    rs658108 Imputed A DOMINANT 9.19E−05 9.19E−05 1.4801 1.4801 0.8339 0
    rs6593441 Imputed A DOMINANT 8.32E−05 8.32E−05 1.5966 1.5966 0.6727 0
    rs668732 Imputed A DOMINANT 0.0007713 0.04322 1.4673 1.4272 0.1016 56.26
    rs671041 Imputed A DOMINANT 7.41E−05 7.41E−05 1.4878 1.4878 0.8316 0
    rs6719700 Imputed A ADDITIVE 9.48E−05 9.48E−05 1.4547 1.4547 0.8457 0
    rs6719700 Imputed A DOMINANT 9.05E−05 9.05E−05 1.5345 1.5345 0.997 0
    rs6722640 Imputed T DOMINANT 6.69E−06 6.69E−06 0.6251 0.6251 0.6987 0
    rs6743092 Imputed T ADDITIVE 8.16E−05 8.16E−05 1.3286 1.3286 0.8471 0
    rs6743092 Imputed T GENOTYPIC 7.98E−05 7.98E−05 1.7638 1.7638 0.836 0
    rs6743092 Imputed T RECESSIVE 2.27E−05 2.27E−05 1.6478 1.6478 0.7669 0
    rs6744759 Imputed G RECESSIVE 8.79E−05 8.79E−05 1.9877 1.9877 0.536 0
    rs6746170 Imputed A DOMINANT 2.07E−05 2.07E−05 1.5394 1.5394 0.5817 0
    rs6759922 Imputed A DOMINANT 0.001026 0.0855 0.6912 0.7071 0.0483 66.99
    rs6769864 Imputed T GENOTYPIC 0.0004564 0.02145 1.7578 1.6967 0.1428 48.63
    rs6773932 Imputed C GENOTYPIC 0.000867 0.04735 1.6964 1.6233 0.1035 55.91
    rs6774353 Imputed A GENOTYPIC 0.0005033 0.02669 1.7503 1.6851 0.1298 51.02
    rs6781670 Imputed C GENOTYPIC 0.00058 0.0204 1.7388 1.6882 0.1518 46.96
    rs6786431 Imputed A GENOTYPIC 0.000867 0.04735 1.6964 1.6233 0.1035 55.91
    rs6789091 Imputed T GENOTYPIC 0.000867 0.04735 1.6964 1.6233 0.1035 55.91
    rs6791296 Imputed T ADDITIVE 7.12E−05 7.12E−05 0.6329 0.6329 0.9898 0
    rs6792662 Imputed G DOMINANT 6.98E−05 6.98E−05 1.6112 1.6112 0.5862 0
    rs6797574 Imputed G GENOTYPIC 0.000867 0.04735 1.6964 1.6233 0.1035 55.91
    rs6797882 Imputed G GENOTYPIC 0.0008269 0.04785 1.7009 1.6266 0.1009 56.4
    rs6805139 Imputed G DOMINANT 3.85E−05 3.85E−05 1.6152 1.6152 0.6499 0
    rs6806043 Imputed C ADDITIVE 0.0003052 0.005086 1.306 1.2979 0.2161 34.72
    rs6806043 Imputed C GENOTYPIC 0.0004109 0.02711 1.7655 1.6976 0.1213 52.6
    rs6850716 Imputed C GENOTYPIC 0.003416 0.1872 2.0499 1.9631 0.0177 75.23
    rs6867153 Imputed A RECESSIVE 0.00187 0.191 0.678 0.7117 0.0177 75.21
    rs687047 Imputed C ADDITIVE 9.00E−05 9.00E−05 0.6446 0.6446 0.7637 0
    rs6871041 Imputed G DOMINANT 2.29E−05 2.29E−05 0.6393 0.6393 0.8477 0
    rs688358 Imputed A ADDITIVE 7.44E−05 7.44E−05 0.6401 0.6401 0.8637 0
    rs6888012 Imputed A RECESSIVE 0.001885 0.1924 0.6781 0.7121 0.0175 75.29
    rs6908481 Imputed C RECESSIVE 5.99E−05 5.99E−05 1.7201 1.7201 0.5809 0
    rs7032231 Imputed A ADDITIVE 6.99E−05 6.99E−05 1.352 1.352 0.3922 0
    rs7067638 Imputed T DOMINANT 8.99E−05 8.99E−05 1.5963 1.5963 0.7456 0
    rs7077799 Imputed A DOMINANT 7.58E−05 7.58E−05 1.4996 1.4996 0.7406 0
    rs7082163 Imputed A ADDITIVE 5.34E−05 5.34E−05 1.5444 1.5444 0.4266 0
    rs7082163 Imputed A DOMINANT 3.46E−05 3.46E−05 1.641 1.641 0.6461 0
    rs7089661 Imputed C DOMINANT 4.97E−05 4.97E−05 1.5023 1.5023 0.7397 0
    rs7101319 Imputed C ADDITIVE 5.28E−05 5.28E−05 1.5457 1.5457 0.468 0
    rs7101319 Imputed C DOMINANT 3.22E−05 3.22E−05 1.6456 1.6456 0.7067 0
    rs710832 Genotyped A GENOTYPIC 6.03E−05 6.03E−05 0.3754 0.3754 0.8143 0
    rs710832 Genotyped A RECESSIVE 3.36E−05 3.36E−05 0.3689 0.3689 0.7382 0
    rs7134262 Imputed T GENOTYPIC 2.96E−05 2.96E−05 1.9763 1.9763 0.627 0
    rs7134262 Imputed T RECESSIVE 1.46E−06 1.46E−06 2.0802 2.0802 0.5227 0
    rs7134671 Imputed T GENOTYPIC 0.0002855 0.005252 1.7315 1.725 0.1999 37.89
    rs7138300 Imputed C ADDITIVE 2.15E−05 2.15E−05 0.7321 0.7321 0.9128 0
    rs7138300 Imputed C DOMINANT 6.73E−05 6.73E−05 0.6474 0.6474 0.8659 0
    rs7138300 Imputed C GENOTYPIC 6.26E−05 6.26E−05 0.5503 0.5503 0.7315 0
    rs7163931 Imputed G GENOTYPIC 4.76E−05 4.76E−05 2.9048 2.9048 0.6375 0
    rs7163931 Imputed G RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs7171486 Genotyped G DOMINANT 7.21E−05 7.21E−05 0.6684 0.6684 0.4022 0
    rs7172611 Imputed G GENOTYPIC 4.65E−05 4.65E−05 2.9093 2.9093 0.6341 0
    rs7172611 Imputed G RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs7172689 Imputed T GENOTYPIC 4.65E−05 4.65E−05 2.9093 2.9093 0.6341 0
    rs7172689 Imputed T RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs7175701 Imputed C GENOTYPIC 9.05E−05 9.05E−05 2.5914 2.5914 0.7706 0
    rs7180245 Imputed A GENOTYPIC 4.65E−05 4.65E−05 2.9093 2.9093 0.6341 0
    rs7180245 Imputed A RECESSIVE 7.67E−05 7.67E−05 2.7833 2.7833 0.6295 0
    rs7220603 Genotyped A ADDITIVE 0.02391 0.5255 0.8346 0.8604 0.0003 87.88
    rs7282518 Imputed T ADDITIVE 0.0002567 0.008981 1.453 1.4275 0.1773 42.19
    rs7283476 Imputed T ADDITIVE 7.31E−05 7.31E−05 0.4402 0.4402 0.566 0
    rs7283476 Imputed T DOMINANT 3.52E−05 3.52E−05 0.4064 0.4064 0.4235 0
    rs7295817 Imputed C GENOTYPIC 7.67E−05 7.67E−05 0.5483 0.5483 0.4481 0
    rs7298255 Imputed A ADDITIVE 3.91E−05 3.91E−05 0.7439 0.7439 0.9855 0
    rs7298255 Imputed A DOMINANT 6.89E−05 6.89E−05 0.65 0.65 0.7442 0
    rs7305832 Imputed C GENOTYPIC 2.48E−05 2.48E−05 1.9853 1.9853 0.5975 0
    rs7305832 Imputed C RECESSIVE 1.31E−06 1.31E−06 2.0856 2.0856 0.5058 0
    rs7331467 Imputed A GENOTYPIC 0.004523 0.2685 1.5788 1.4648 0.0124 77.22
    rs7392620 Imputed C ADDITIVE 8.20E−05 8.20E−05 0.7361 0.7361 0.6441 0
    rs742827 Imputed A ADDITIVE 8.46E−06 8.46E−06 1.3961 1.3961 0.9898 0
    rs742827 Imputed A GENOTYPIC 7.47E−06 7.47E−06 2.0465 2.0465 0.8196 0
    rs742827 Imputed A RECESSIVE 9.50E−05 9.50E−05 1.7817 1.7817 0.5729 0
    rs7446891 Imputed G DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs7448641 Imputed C ADDITIVE 0.002876 0.1046 0.5269 0.4225 0.0055 80.81
    rs7448641 Imputed C DOMINANT 0.005931 0.1502 0.5204 0.4449 0.0058 80.6
    rs7484728 Imputed T GENOTYPIC 0.000266 0.005086 1.736 1.7289 0.1995 37.97
    rs7499402 Genotyped A ADDITIVE 7.41E−05 7.41E−05 1.7018 1.7018 0.5603 0
    rs7529851 Imputed A ADDITIVE 7.64E−05 7.64E−05 0.7438 0.7438 0.6011 0
    rs7529851 Imputed A GENOTYPIC 8.65E−05 8.65E−05 0.5413 0.5413 0.7417 0
    rs7573951 Imputed G ADDITIVE 0.0009373 0.04269 0.7841 0.7912 0.0927 57.96
    rs7599198 Imputed T DOMINANT 0.0005956 0.01854 0.6706 0.6818 0.1584 45.74
    rs7600050 Imputed C ADDITIVE 6.57E−05 6.57E−05 1.3535 1.3535 0.6858 0
    rs7607712 Imputed T ADDITIVE 6.22E−05 6.22E−05 1.4258 1.4258 0.846 0
    rs7607712 Imputed T DOMINANT 8.77E−05 8.77E−05 1.4994 1.4994 0.9843 0
    rs7613492 Imputed G GENOTYPIC 0.0004892 0.02726 1.756 1.6897 0.1265 51.64
    rs7621663 Imputed G ADDITIVE 0.0002694 0.00593 1.3166 1.3062 0.1995 37.97
    rs7621663 Imputed G GENOTYPIC 0.0002328 0.03627 1.849 1.7635 0.0774 60.91
    rs7621663 Imputed G RECESSIVE 0.001212 0.0888 1.6632 1.577 0.0599 64.48
    rs7626584 Imputed G ADDITIVE 9.18E−05 9.18E−05 0.5375 0.5375 0.6785 0
    rs7684899 Imputed C ADDITIVE 9.76E−05 9.76E−05 0.6985 0.6985 0.7616 0
    rs7684899 Imputed C DOMINANT 6.37E−06 6.37E−06 0.6204 0.6204 0.6462 0
    rs7701604 Imputed G ADDITIVE 0.002876 0.1046 0.5269 0.4225 0.0055 80.81
    rs7701604 Imputed G DOMINANT 0.005931 0.1502 0.5204 0.4449 0.0058 80.6
    rs7703676 Imputed C ADDITIVE 0.002876 0.1046 0.5269 0.4225 0.0055 80.81
    rs7703676 Imputed C DOMINANT 0.005931 0.1502 0.5204 0.4449 0.0058 80.6
    rs7708491 Imputed C RECESSIVE 0.002355 0.1727 0.6852 0.7155 0.0267 72.41
    rs7711358 Imputed A DOMINANT 1.88E−05 1.88E−05 0.6481 0.6481 0.8316 0
    rs7719448 Imputed G RECESSIVE 0.002108 0.2193 0.6815 0.7163 0.012 77.4
    rs7724761 Imputed T RECESSIVE 0.001686 0.19 0.6737 0.7045 0.0154 76.06
    rs7742476 Imputed T DOMINANT 0.0001163 0.0001163 1.5074 1.5074 0.3696 0
    rs7762993 Imputed A ADDITIVE 0.0003347 0.004615 1.3933 1.3716 0.2531 27.21
    rs7762993 Imputed A DOMINANT 9.42E−05 0.01287 1.507 1.4653 0.1301 50.97
    rs7767265 Imputed G ADDITIVE 1.59E−05 0.000172 1.4422 1.4296 0.296 17.87
    rs7767265 Imputed G DOMINANT 6.30E−06 0.003597 1.5886 1.5475 0.1294 51.09
    rs7768128 Imputed G RECESSIVE 9.37E−05 9.37E−05 0.3867 0.3867 0.8076 0
    rs7771264 Imputed T DOMINANT 0.00106 0.07475 0.7141 0.7193 0.046 67.53
    rs7773151 Genotyped C DOMINANT 0.000959 0.06482 0.7135 0.7189 0.055 65.52
    rs7773210 Genotyped A DOMINANT 0.0008239 0.06306 0.7105 0.7165 0.0539 65.76
    rs7808536 Imputed G DOMINANT 8.84E−05 8.84E−05 1.5126 1.5126 0.3832 0
    rs7843510 Genotyped G DOMINANT 0.0008947 0.03339 1.418 1.392 0.1219 52.48
    rs7894867 Imputed T DOMINANT 7.78E−05 7.78E−05 1.6032 1.6032 0.7494 0
    rs7921834 Imputed C DOMINANT 5.41E−05 5.41E−05 1.4996 1.4996 0.7497 0
    rs7939893 Imputed C ADDITIVE 8.65E−05 8.65E−05 0.7474 0.7474 0.6566 0
    rs7939893 Imputed C DOMINANT 9.08E−06 9.08E−06 0.6395 0.6395 0.3716 0
    rs7944513 Imputed T GENOTYPIC 1.13E−05 1.13E−05 2.6894 2.6894 0.5228 0
    rs7944513 Imputed T RECESSIVE 3.32E−05 3.32E−05 2.5007 2.5007 0.3973 0
    rs7949720 Imputed G ADDITIVE 0.01083 0.46 0.7505 0.8044 0.0015 84.54
    rs7949720 Imputed G DOMINANT 0.009467 0.4625 0.7247 0.7836 0.0012 85.09
    rs7955901 Imputed C ADDITIVE 3.31E−05 3.31E−05 0.7403 0.7403 0.9802 0
    rs7955901 Imputed C DOMINANT 6.34E−05 6.34E−05 0.6473 0.6473 0.8105 0
    rs7956274 Imputed T ADDITIVE 2.32E−05 2.32E−05 0.7349 0.7349 0.9325 0
    rs7956274 Imputed T DOMINANT 3.52E−05 3.52E−05 0.6366 0.6366 0.8605 0
    rs7956274 Imputed T GENOTYPIC 7.30E−05 7.30E−05 0.5575 0.5575 0.7749 0
    rs7957932 Imputed G ADDITIVE 5.54E−05 5.54E−05 0.7481 0.7481 0.9512 0
    rs7957932 Imputed G DOMINANT 3.06E−05 3.06E−05 0.6329 0.6329 0.8798 0
    rs7984504 Imputed C GENOTYPIC 0.002726 0.1381 1.6689 1.6043 0.0349 70.18
    rs7999518 Imputed A RECESSIVE 2.72E−05 2.72E−05 0.5848 0.5848 0.4425 0
    rs8026245 Imputed G GENOTYPIC 7.79E−05 7.79E−05 2.665 2.665 0.6771 0
    rs8026245 Imputed G RECESSIVE 8.54E−05 8.54E−05 2.6107 2.6107 0.6577 0
    rs8060725 Genotyped A ADDITIVE 9.99E−05 9.99E−05 0.7239 0.7239 0.8435 0
    rs8103016 Genotyped A ADDITIVE 1.98E−05 1.98E−05 1.4503 1.4503 0.4547 0
    rs8103016 Genotyped A DOMINANT 2.45E−05 2.45E−05 1.5482 1.5482 0.694 0
    rs8104182 Imputed G ADDITIVE 3.24E−05 3.24E−05 1.4421 1.4421 0.671 0
    rs8104182 Imputed G DOMINANT 4.77E−05 4.77E−05 1.5265 1.5265 0.7687 0
    rs8129461 Imputed G ADDITIVE 3.70E−05 3.70E−05 0.4263 0.4263 0.5257 0
    rs8129461 Imputed G DOMINANT 1.72E−05 1.72E−05 0.3933 0.3933 0.3761 0
    rs8130021 Imputed G ADDITIVE 7.55E−05 7.55E−05 0.4409 0.4409 0.5674 0
    rs8130021 Imputed G DOMINANT 3.64E−05 3.64E−05 0.4071 0.4071 0.4256 0
    rs879961 Imputed T ADDITIVE 0.002059 0.2563 0.7763 0.8081 0.0066 80.11
    rs879961 Imputed T DOMINANT 0.001811 0.2398 0.7301 0.7595 0.0059 80.5
    rs906353 Imputed A DOMINANT 0.004624 0.2465 0.7527 0.7852 0.0165 75.63
    rs915491 Imputed C DOMINANT 8.48E−05 8.48E−05 1.4838 1.4838 0.752 0
    rs915493 Imputed T DOMINANT 8.48E−05 8.48E−05 1.4838 1.4838 0.752 0
    rs915494 Imputed A ADDITIVE 7.86E−05 7.86E−05 1.3658 1.3658 0.8997 0
    rs915494 Imputed A DOMINANT 2.62E−05 2.62E−05 1.5383 1.5383 0.8223 0
    rs917295 Imputed G DOMINANT 1.82E−05 1.82E−05 0.647 0.647 0.881 0
    rs9284851 Imputed A GENOTYPIC 0.0007416 0.04371 1.7018 1.6321 0.1049 55.65
    rs9293464 Imputed T RECESSIVE 0.00171 0.194 0.6758 0.7101 0.0158 75.88
    rs9295154 Genotyped G DOMINANT 7.58E−05 7.58E−05 1.5572 1.5572 0.5416 0
    rs9310221 Imputed A DOMINANT 0.001363 0.158 1.4328 1.353 0.0322 70.9
    rs9310699 Genotyped T GENOTYPIC 0.00058 0.0204 1.7388 1.6882 0.1518 46.96
    rs9310700 Imputed C ADDITIVE 0.0003931 0.005395 1.3049 1.2966 0.2216 33.63
    rs9310700 Imputed C GENOTYPIC 0.0003693 0.03198 1.8013 1.7265 0.1006 56.46
    rs9310701 Imputed G GENOTYPIC 0.0005775 0.02214 1.7187 1.6652 0.1488 47.51
    rs9310704 Imputed G GENOTYPIC 0.000597 0.04612 1.7265 1.6511 0.0921 58.07
    rs9319185 Imputed C GENOTYPIC 0.003084 0.2063 1.6765 1.5851 0.0147 76.3
    rs9319186 Imputed T GENOTYPIC 0.002645 0.1394 1.6843 1.6228 0.0311 71.19
    rs9327555 Imputed T DOMINANT 2.31E−05 2.31E−05 0.6505 0.6505 0.8585 0
    rs9403367 Imputed C DOMINANT 0.0008239 0.06306 0.7105 0.7165 0.0539 65.76
    rs9419608 Imputed G RECESSIVE 0.007479 0.5441 1.3778 1.2224 0.0008 85.89
    rs9426437 Imputed T DOMINANT 0.0007324 0.08646 0.6967 0.7283 0.0587 64.74
    rs9454967 Imputed G DOMINANT 0.0008641 0.05434 1.5996 1.5843 0.071 62.2
    rs9635511 Imputed T DOMINANT 0.0001778 0.001844 0.6752 0.6837 0.2682 24.02
    rs966583 Imputed A ADDITIVE 1.48E−05 1.48E−05 0.725 0.725 0.8807 0
    rs966583 Imputed A DOMINANT 7.60E−06 7.60E−06 0.626 0.626 0.8999 0
    rs980263 Imputed T GENOTYPIC 0.000492 0.02264 1.7325 1.6751 0.1412 48.92
    rs980264 Imputed T GENOTYPIC 0.000492 0.02264 1.7325 1.6751 0.1412 48.92
    rs9812206 Imputed G ADDITIVE 9.92E−05 0.03775 0.6049 0.6297 0.0642 63.57
    rs9812206 Imputed G DOMINANT 0.0001008 0.04527 0.592 0.6174 0.049 66.85
    rs9813552 Imputed G ADDITIVE 0.0004552 0.03885 0.6393 0. 0.0966 57.21
    rs9813552 Imputed G DOMINANT 0.0005252 0.05892 0.629 0.6531 0.0685 62.71
    rs9815037 Imputed T ADDITIVE 0.0003061 0.04794 0.6241 0.6399 0.0613 64.17
    rs9815037 Imputed T DOMINANT 0.0002862 0.06392 0.6094 0.6301 0.0425 68.34
    rs9819583 Imputed T GENOTYPIC 0.0005347 0.02047 1.7449 1.6926 0.1487 47.53
    rs9825349 Imputed A ADDITIVE 0.0003046 0.04763 0.624 0.6401 0.062 64.03
    rs9825349 Imputed A DOMINANT 0.0002859 0.0639 0.6094 0.6304 0.0427 68.28
    rs9833118 Imputed G ADDITIVE 0.0004117 0.006196 1.3 1.293 0.2139 35.15
    rs9833118 Imputed G GENOTYPIC 0.0004555 0.02726 1.7602 1.6961 0.123 52.28
    rs9834217 Imputed T ADDITIVE 0.0002698 0.03497 0.6218 0.6356 0.0789 60.62
    rs9834217 Imputed T DOMINANT 0.0002509 0.0487 0.607 0.6256 0.0556 65.39
    rs9838563 Imputed C GENOTYPIC 0.0004051 0.008482 1.7473 1.7073 0.2054 36.83
    rs9840460 Imputed T ADDITIVE 0.0002575 0.03523 0.6208 0.6345 0.0768 61.03
    rs9840460 Imputed T DOMINANT 0.0002389 0.04871 0.6059 0.6244 0.0543 65.67
    rs9840756 Imputed A ADDITIVE 0.0002251 0.02861 0.618 0.6307 0.0873 58.99
    rs9840756 Imputed A DOMINANT 0.0002087 0.04085 0.603 0.6206 0.0622 63.99
    rs9847999 Imputed C GENOTYPIC 0.0009186 0.04314 1.6854 1.6208 0.1128 54.17
    rs9864769 Imputed C GENOTYPIC 0.0005775 0.02214 1.7187 1.6652 0.1488 47.51
    rs9866421 Genotyped C RECESSIVE 8.99E−05 8.99E−05 0.5978 0.5978 0.7628 0
    rs987296 Imputed T GENOTYPIC 0.0006125 0.02328 1.7346 1.6817 0.1438 48.43
    rs9881685 Imputed A ADDITIVE 9.85E−05 0.03734 0.6048 0.6295 0.0647 63.48
    rs9881685 Imputed A DOMINANT 0.0001 0.04485 0.5918 0.6172 0.0494 66.76
    rs992695 Imputed C ADDITIVE 0.002041 0.2367 0.7764 0.8067 0.0089 78.81
    rs992695 Imputed C DOMINANT 0.001822 0.2163 0.7308 0.7583 0.009 78.78
    rs9936999 Imputed G DOMINANT 0.004771 0.2439 1.4561 1.3895 0.0142 76.48
  • TABLE 19
    allele CARE WOSCOPS
    A1 allele Pla- Pla-
    (non- A2 OR. Prava cebo OR OR P Prava cebo OR OR P End- Mod-
    SNP ref) (ref) P.R. R. Count count OR L95 U95 value Count Count OR L95 U95 value point el
    rs11556924 A G 0.00196 1.33  42/  43/ 1.26 1.01 1.58 0.0449 28/  22/ 1.48 1.09 2.02 0.0123 CHD add
    141/ 157/ 79/ 104/
    117 182 52  98
  • TABLE 20
    GEN- EV-
    O_ ENTS_
    GEN- EV- TO- P_ PLA- PLA-
    mAF O_ STA- ENTS TAL_ HR_ L95_ U95_ P_ INT_ CE- CE-
    SNP hCV # SNP rs # Chrom CEU MODE RESP TIN RESP RESP RESP RESP RESP RESP RESP BO BO
    hCV11841860 rs10757278 9p21 0.5 GEN GG Prava- 24  410 1.08 0.602 1.94 0.7931 0.1691 GG 21
    statin
    hCV11841860 rs10757278 9p21 0.5 GEN GG Pla- 21  390 ref . . . 0.1691 .
    cebo
    hCV11841860 rs10757278 9p21 0.5 GEN GA Prava- 27  653 0.54 0.34 0.86 0.0096 0.1691 GA 52
    statin
    hCV11841860 rs10757278 9p21 0.5 GEN GA Pla- 52  689 ref . . . 0.1691 .
    cebo
    hCV11841860 rs10757278 9p21 0.5 GEN AA Prava- 15  334 0.9 0.438 1.84 0.7666 0.1691 AA 15
    statin
    hCV11841860 rs10757278 9p21 0.5 GEN AA Pla- 15  289 ref . . . 0.1691 .
    cebo
    hCV11841860 rs10757278 9p21 0.5 DOM GA + Prava- 51 1063 0.7 0.491 1.01 0.0533 0.6037 GA + 73
    GG statin GG
    hCV11841860 rs10757278 9p21 0.5 DOM GA + Pla- 73 1079 ref . . . 0.6037 .
    GG cebo
    hCV11841860 rs10757278 9p21 0.5 REC GA + Prava- 42  987 0.62 0.42 0.91 0.0146 0.118 GG 21
    AA statin
    hCV11841860 rs10757278 9p21 0.5 REC GA + Pla- 67  978 ref . . . 0.118 .
    AA cebo
    hCV1754666 rs1333049 9p21 0.492 GEN GG Prava- 16  335 0.96 0.474 1.94 0.9086 0.1288 GG 15
    statin
    hCV1754666 rs1333049 9p21 0.492 GEN GG Pla- 15  291 ref . . . 0.1288 .
    cebo
    hCV1754666 rs1333049 9p21 0.492 GEN GC Prava- 27  659 0.54 0.336 0.85 0.0085 0.1288 GC 52
    statin
    hCV1754666 rs1333049 9p21 0.492 GEN GC Pla- 52  689 ref . . . 0.1288 .
    cebo
    hCV1754666 rs1333049 9p21 0.492 GEN CC Prava- 24  405 1.11 0.616 1.99 0.7346 0.1288 CC 21
    statin
    hCV1754666 rs1333049 9p21 0.492 GEN CC Pla- 21  393 ref . . . 0.1288 .
    cebo
    hCV1754666 rs1333049 9p21 0.492 DOM GC + Prava- 43  994 0.63 0.429 0.92 0.018 0.1139 GC + 67
    GG statin GG
    hCV1754666 rs1333049 9p21 0.492 DOM GC + Pla- 67  980 ref . . . 0.1139 .
    GG cebo
    hCV1754666 rs1333049 9p21 0.492 REC GC + Prava- 51 1064 0.7 0.493 1.01 0.0549 0.4877 GG 15
    CC statin
    hCV1754666 rs1333049 9p21 0.492 REC GC + Pla- 73 1082 ref . . . 0.4877 .
    CC cebo
    hCV12094896 rs12425791 12p13 0.175 GEN AA Prava-  2  60 0.28 0.058 1.35 0.1119 0.1255 AA  7
    statin
    hCV12094896 rs12425791 12p13 0.175 GEN AA Pla-  7  60 ref . . . 0.1255 .
    cebo
    hCV12094896 rs12425791 12p13 0.175 GEN AG Prava- 22  485 0.56 0.331 0.96 0.0353 0.1255 AG 35
    statin
    hCV12094896 rs12425791 12p13 0.175 GEN AG Pla- 35  442 ref . . . 0.1255 .
    cebo
    hCV12094896 rs12425791 12p13 0.175 GEN GG Prava- 43  852 0.95 0.628 1.44 0.8138 0.1255 GG 46
    statin
    hCV12094896 rs12425791 12p13 0.175 GEN GG Pla- 46  867 ref . . . 0.1255 .
    cebo
    hCV12094896 rs12425791 12p13 0.175 DOM AG + Prava- 24  545 0.52 0.314 0.86 0.0101 0.0653 AG + 42
    AA statin AA
    hCV12094896 rs12425791 12p13 0.175 DOM AG + Pla- 42  502 ref . . . 0.0653 .
    AA cebo
    hCV12094896 rs12425791 12p13 0.175 REC AG + Prava- 65 1337 0.78 0.565 1.09 0.1411 0.1736 AA  7
    GG statin
    hCV12094896 rs12425791 12p13 0.175 REC AG + Pla- 81 1309 ref . . . 0.1736 .
    GG cebo
    hCV1665834 rs11833579 12p13 0.225 GEN AA Prava-  3  99 0.26 0.072 0.95 0.0417 0.1885 AA 10
    statin
    hCV1665834 rs11833579 12p13 0.225 GEN AA Pla- 10  91 ref . . . 0.1885 .
    cebo
    hCV1665834 rs11833579 12p13 0.225 GEN AG Prava- 29  566 0.75 0.46 1.22 0.2425 0.1885 AG 37
    statin
    hCV1665834 rs11833579 12p13 0.225 GEN AG Pla- 37  541 ref . . . 0.1885 .
    cebo
    hCV1665834 rs11833579 12p13 0.225 GEN GG Prava- 35  730 0.86 0.55 1.36 0.5258 0.1885 GG 41
    statin
    hCV1665834 rs11833579 12p13 0.225 GEN GG Pla- 41  739 ref . . . 0.1885 .
    cebo
    hCV1665834 rs11833579 12p13 0.225 DOM AG + Prava- 32  665 0.64 0.409 1 0.0523 0.3522 AG + 47
    AA statin AA
    hCV1665834 rs11833579 12p13 0.225 DOM AG + Pla- 47  632 ref . . . 0.3522 .
    AA cebo
    hCV1665834 rs11833579 12p13 0.225 REC AG + Prava- 64 1296 0.81 0.581 1.13 0.2091 0.0756 AA 10
    GG statin
    hCV1665834 rs11833579 12p13 0.225 REC AG + Pla- 78 1280 ref . . . 0.0756 .
    GG cebo
    P_
    TO- HR_ L95_ U95_ P_ DF2_
    TAL_ PLA- PLA- PLA- PLA- PLA- GEN- EV- TO- P_
    PLA- CE- CE- CE- CE- CE- O_ ENTS TAL_ HR_ L95_ U95_ P_ DF2_
    SNP hCV # CEBO BO BO BO BO BO ALL ALL ALL ALL ALL ALL ALL ALL
    hCV11841860 390 1.06 0.545 2.052 0.8676 0.2663 GG 45 800 1.18 0.744 1.876 0.479 0.639
    hCV11841860 . . . . . . . . . . . . .
    hCV11841860 689 1.47 0.826 2.607 0.1905 0.2663 GA 79 1342 1.22 0.803 1.862 0.3478 0.639
    hCV11841860 . . . . . . . . . . . . .
    hCV11841860 289 ref . . . 0.2663 AA 30 623 ref . . . 0.639
    hCV11841860 . . . . . . . . . . . . .
    hCV11841860 1079 1.32 0.758 2.302 0.3269 . GA + 124 2142 1.21 0.81 1.8 0.3537 .
    GG
    hCV11841860 . . . . . . . . . . . . .
    hCV11841860 390 0.8 0.488 1.3 0.3624 . GG 45 800 1.03 0.725 1.451 0.8868 .
    hCV11841860 . . . . . . . . . . . . .
    hCV1754666 291 0.95 0.488 1.836 0.8702 0.2539 GG 31 626 0.87 0.549 1.371 0.5427 0.727
    hCV1754666 . . . . . . . . . . . . .
    hCV1754666 689 1.4 0.842 2.319 0.1961 0.2539 GC 79 1348 1.03 0.711 1.478 0.8939 0.727
    hCV1754666 . . . . . . . . . . . . .
    hCV1754666 393 ref . . . 0.2539 CC 45 798 ref . . . 0.727
    hCV1754666 . . . . . . . . . . . . .
    hCV1754666 980 1.26 0.773 2.061 0.3517 . GC + 110 1974 0.98 0.689 1.379 0.8869 .
    GG
    hCV1754666 . . . . . . . . . . . . .
    hCV1754666 291 0.75 0.433 1.316 0.3212 . GG 31 626 0.85 0.576 1.266 0.4317 .
    hCV1754666 . . . . . . . . . . . . .
    hCV12094896 60 2.18 0.984 4.831 0.0547 0.0584 AA 9 120 1.42 0.715 2.817 0.317 0.421
    hCV12094896 . . . . . . . . . . . . .
    hCV12094896 442 1.51 0.971 2.339 0.0674 0.0584 AG 57 927 1.19 0.854 1.66 0.3045 0.421
    hCV12094896 . . . . . . . . . . . . .
    hCV12094896 867 ref . . . 0.0584 GG 89 1719 ref . . . 0.421
    hCV12094896 . . . . . . . . . . . . .
    hCV12094896 502 1.59 1.046 2.414 0.0301 . AG + 66 1047 1.22 0.885 1.673 0.2267 .
    AA
    hCV12094896 . . . . . . . . . . . . .
    hCV12094896 60 1.86 0.861 4.034 0.1142 . AA 9 120 1.33 0.679 2.609 0.4055 .
    hCV12094896 . . . . . . . . . . . . .
    hCV1665834 91 2 1 3.985 0.05 0.1371 AA 13 190 1.3 0.721 2.339 0.3837 0.555
    hCV1665834 . . . . . . . . . . . . .
    hCV1665834 541 1.24 0.795 1.933 0.344 0.1371 AG 66 1107 1.15 0.83 1.605 0.3942 0.555
    hCV1665834 . . . . . . . . . . . . .
    hCV1665834 739 ref . . . 0.1371 GG 76 1469 ref . . . 0.555
    hCV1665834 . . . . . . . . . . . . .
    hCV1665834 632 1.35 0.887 2.049 0.1622 . AG + 79 1297 1.18 0.858 1.612 0.3124 .
    AA
    hCV1665834 . . . . . . . . . . . . .
    hCV1665834 91 1.81 0.939 3.503 0.0764 . AA 13 190 1.22 0.69 2.15 0.4957 .
    hCV1665834 . . . . . . . . . . . . .
  • TABLE 21
    GEN- EV- TO-
    EV- TO- P_ O_ ENTS_ TAL_
    GENO_ ENTS_ TAL_ HR_ L95_ U95_ P_ INT_ PLA- PLA- PLA-
    SNP hCV # SNP rs # MODE RESP STATIN RESP RESP RESP RESP RESP RESP RESP CEBO CEBO CEBO
    hCV2652047 rs873134 GEN CC Pravastatin 27  354 2.01 1.036 3.89 0.0391 0.00164 CC 13 338
    hCV2652047 rs873134 GEN CC Placebo 13  338 ref . . . 0.00164 . .
    hCV2652047 rs873134 GEN CT Pravastatin 24  680 0.5 0.308 0.818 0.0057 0.00164 CT 49 697
    hCV2652047 rs873134 GEN CT Placebo 49  697 ref . . . 0.00164 . .
    hCV2652047 rs873134 GEN TT Pravastatin 16  366 0.54 0.291 1.01 0.0538 0.00164 TT 26 336
    hCV2652047 rs873134 GEN TT Placebo 26  336 ref . . . 0.00164 . .
    hCV2652047 rs873134 DOM CT + CC Pravastatin 51 1034 0.83 0.571 1.199 0.3163 0.25372 CT + 62 1035
    CC
    hCV2652047 rs873134 DOM CT + CC Placebo 62 1035 ref . . . 0.25372 . .
    hCV2652047 rs873134 REC CT + TT Pravastatin 40 1046 0.52 0.355 0.765 0.0009 0.00037 CC 13 338
    hCV2652047 rs873134 REC CT + TT Placebo 75 1033 ref . . . 0.00037 . .
    P_ HW
    HR_ L95_ U95_ P_ DF2_ GEN- EV- TO- P_ (ALL)
    PLA- PLA- PLA- PLA- PLA- O_ ENTS_ TAL_ HR_ L95_ U95_ P_ DF2 p-
    SNP hCV # CEBO CEBO CEBO CEBO CEBO ALL ALL ALL ALL ALL ALL ALL ALL Exact
    hCV2652047 0.48 0.248 0.939 0.032 0.0851 CC 40 692 0.96 0.626 1.488 0.8714 0.8089 0.761
    hCV2652047 . . . . . . . . . . . . 0.761
    hCV2652047 0.89 0.551 1.428 0.6225 0.0851 CT 73 1377 0.89 0.607 1.298 0.539 0.8089 0.761
    hCV2652047 . . . . . . . . . . . . 0.761
    hCV2652047 ref . . . 0.0851 TT 42 702 ref . . . 0.8089 0.761
    hCV2652047 . . . . . . . . . . . . 0.761
    hCV2652047 0.75 0.477 1.193 0.2284 CT + 113 2069 0.91 0.641 1.302 0.6173 . 0.761
    CC
    hCV2652047 . . . . . . . . . . . . 0.761
    hCV2652047 0.52 0.29 0.942 0.0308 CC 40 692 1.04 0.728 1.494 0.8199 . 0.761
    hCV2652047 . . . . . . . . . . . . 0.761
  • TABLE 22
    EV- TO-
    EV- TO- GENO_ ENTS_ TAL_
    GENO_ ENTS_ TAL_ HR_ L95_ U95_ P_ P_INT_ PLA- PLA- PLA-
    SNP hCV # SNP rs # MODE RESP STATIN RESP RESP RESP RESP RESP RESP RESP CEBO CEBO CEBO
    hCV2652047 rs873134 GEN TT Pravastatin 25 364 0.57 0.339 0.952 0.0317 0.05825 TT 37 333
    hCV2652047 rs873134 GEN TT Placebo 37 333 ref . . . 0.05825 . .
    hCV2652047 rs873134 GEN TC Pravastatin 63 676 1 0.705 1.405 0.9783 0.05825 TC 67 693
    hCV2652047 rs873134 GEN TC Placebo 67 693 ref . . . 0.05825 . .
    hCV2652047 rs873134 GEN CC Pravastatin 23 352 0.48 0.29 0.809 0.0056 0.05825 CC 42 335
    hCV2652047 rs873134 GEN CC Placebo 42 335 ref . . . 0.05825 . .
    hCV2652047 rs873134 DOM TC + TT Pravastatin 88 1040 0.85 0.64 1.133 0.2714 0.06887 TC + TT 104 1026
    hCV2652047 rs873134 DOM TC + TT Placebo 104 1026 ref . . . 0.06887 . .
    HR_ L95_ U95_ P_ P_DF2_ EV- TO-
    PLA- PLA- PLA- PLA- PLA- GENO_ ENTS_ TAL_ HR_ L95_ U95_ P_ P_DF2
    SNP hCV # CEBO CEBO CEBO CEBO CEBO ALL ALL ALL ALL ALL ALL ALL ALL
    hCV2652047 0.87 0.555 1.349 0.5232 0.3415 TT 62 697 0.93 0.654 1.313 0.6696 0.8281
    hCV2652047 . . . . . . . . . . . .
    hCV2652047 0.75 0.509 1.105 0.1454 0.3415 TC 130 1369 1.02 0.756 1.372 0.9047 0.8281
    hCV2652047 . . . . . . . . . . . .
    hCV2652047 ref . . . 0.3415 CC 65 687 ref . . . 0.8281
    hCV2652047 . . . . . . . . . . . .
    hCV2652047 0.79 0.549 1.128 0.1924 . TC + TT 192 2066 0.99 0.745 1.308 0.9269 .
    hCV2652047 . . . . . . . . . . . .

Claims (32)

1. A method for determining whether a human's risk for cardiovascular disease (CVD) is reduced by treatment with an HMG-CoA reductase inhibitor, the method comprising testing nucleic acid from said human for the presence or absence of an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, wherein the presence of said allele indicates said human's risk for CVD is reduced by treatment with said HMG-CoA reductase inhibitor.
2-3. (canceled)
4. The method of claim 1, wherein said HMG-CoA reductase inhibitor is a hydrophilic statin.
5. The method of claim 1, wherein said HMG-CoA reductase inhibitor is a hydrophobic statin.
6. The method of claim 1, wherein said HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), simvastatin (Zocor®), fluvastatin (Lescol®), and lovastatin (Mevacor®), or any combination thereof.
7. The method of claim 1, wherein said HMG-CoA reductase inhibitor comprises an HMG-CoA reductase inhibitor in combination with at least one additional therapeutic agent.
8. The method of claim 7, wherein said HMG-CoA reductase inhibitor is selected from the group consisting of:
simvastatin in combination with ezetimibe (Vytorin®);
lovastatin in combination with niacin (Advicor®);
atorvastatin in combination with amlodipine besylate (Caduet®); and
simvastatin in combination with niacin (Simcor®).
9-12. (canceled)
13. The method of claim 1, wherein said testing comprises nucleic acid amplification.
14. The method of claim 13, wherein said nucleic acid amplification is carried out by polymerase chain reaction.
15. The method of claim 1, wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).
16. The method of claim 1, wherein said testing is performed using an allele-specific method.
17. The method of claim 16, wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
18. (canceled)
19. The method of claim 1, wherein said human is homozygous for said allele.
20. The method of claim 1, wherein said human is heterozygous for said allele.
21. The method of claim 1, wherein said CVD is coronary heart disease (CHD).
22. The method of claim 21, wherein said CHD is myocardial infarction (MI).
23. The method of claim 1, wherein said CVD is stroke.
24. The method of claim 1, wherein said human did not have CVD prior to said testing.
25. The method of claim 1, wherein said human did have CVD prior to said testing.
26. The method of claim 1, further comprising administering an HMG-CoA reductase inhibitor to said human who has said allele.
27. The method of claim 1, further comprising administering a therapeutic agent that is not an HMG-CoA reductase inhibitor to said human who does not have said allele, wherein said therapeutic agent is selected from the group consisting of niacin, fibrates, and ezetimibe (Zetia® or Ezetrol®).
28. (canceled)
29. A method for determining whether a human has an increased risk for cardiovascular disease (CVD), comprising testing nucleic acid from said human for the presence or absence of an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, wherein the presence of said allele indicates said human has an increased risk for CVD.
30. The method of claim 29, further comprising administering an HMG-CoA reductase inhibitor to said human who has said increased risk for CVD.
31. A method for reducing risk of cardiovascular disease (CVD) in a human, comprising administering to said human an effective amount of an HMG-CoA reductase inhibitor, wherein said human has been identified as having an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, and wherein the presence of said allele indicates said human's risk for CVD is reduced by treatment with said HMG-CoA reductase inhibitor.
32. The method of claim 31, wherein said method comprises testing nucleic acid from said human for the presence or absence of said allele.
33-34. (canceled)
35. A detection reagent for carrying out the method of claim 1, wherein said detection reagent is an allele-specific probe or an allele-specific primer.
36. A test kit comprising one or more containers containing the detection reagent of claim 35 and one or more components selected from the group consisting of an enzyme, polymerase enzyme, ligase enzyme, buffer, amplification primer pair, dNTPs, ddNTPs, positive control nucleic acid, negative control, nucleic acid extraction reagent, and instructions for using said test kit which instruct that the presence of said allele indicates that said risk for CVD is reduced by treatment with said HMG-CoA reductase inhibitor.
37-38. (canceled)
US14/834,946 2010-04-19 2015-08-25 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof Abandoned US20160108473A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/834,946 US20160108473A1 (en) 2010-04-19 2015-08-25 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US15/952,792 US10563263B2 (en) 2010-04-19 2018-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US16/728,333 US11827937B2 (en) 2010-04-19 2019-12-27 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32568910P 2010-04-19 2010-04-19
US33250910P 2010-05-07 2010-05-07
US40597210P 2010-10-22 2010-10-22
US13/085,955 US20110269735A1 (en) 2010-04-19 2011-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US13/833,905 US20140235605A1 (en) 2010-04-19 2013-03-15 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US14/834,946 US20160108473A1 (en) 2010-04-19 2015-08-25 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/833,905 Continuation US20140235605A1 (en) 2010-04-19 2013-03-15 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/952,792 Continuation US10563263B2 (en) 2010-04-19 2018-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Publications (1)

Publication Number Publication Date
US20160108473A1 true US20160108473A1 (en) 2016-04-21

Family

ID=44834462

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/085,955 Abandoned US20110269735A1 (en) 2010-04-19 2011-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US13/833,905 Abandoned US20140235605A1 (en) 2010-04-19 2013-03-15 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US14/834,946 Abandoned US20160108473A1 (en) 2010-04-19 2015-08-25 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US15/952,792 Active US10563263B2 (en) 2010-04-19 2018-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US16/728,333 Active 2032-11-27 US11827937B2 (en) 2010-04-19 2019-12-27 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/085,955 Abandoned US20110269735A1 (en) 2010-04-19 2011-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US13/833,905 Abandoned US20140235605A1 (en) 2010-04-19 2013-03-15 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/952,792 Active US10563263B2 (en) 2010-04-19 2018-04-13 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US16/728,333 Active 2032-11-27 US11827937B2 (en) 2010-04-19 2019-12-27 Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Country Status (5)

Country Link
US (5) US20110269735A1 (en)
EP (4) EP2561352B1 (en)
JP (8) JP5918216B2 (en)
CA (2) CA3060628A1 (en)
WO (1) WO2011133418A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257646A1 (en) * 2008-02-29 2010-12-08 ISIS Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
HUE029534T2 (en) * 2011-08-05 2017-02-28 Gendiag Exe Sl Genetic markers for cardiovascular disease risk assessment
EP2766728B1 (en) 2011-10-13 2017-09-06 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US9976143B2 (en) 2014-10-03 2018-05-22 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2016081471A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US11058779B2 (en) 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017066579A1 (en) * 2015-10-14 2017-04-20 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
CA3005249A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of kidney diseases
US11702466B2 (en) * 2017-01-30 2023-07-18 National Research Council Of Canada Fusion protein comprising a blood-brain barrier (BBB)-crossing single domain antibody Fc5, an immunoglobulin Fc fragment and a beta-amyloid binding polypeptide (ABP)
JP2019022483A (en) * 2017-07-21 2019-02-14 ポーラ化成工業株式会社 Method for detecting risk of skin troubles, detection reagent and reagent for discriminating skin condition to be used for method, and method for selecting cosmetic or quasi drug
CN111278991B (en) 2017-08-25 2022-04-01 斯托克制药公司 Antisense oligomers for the treatment of conditions and diseases
KR102205831B1 (en) * 2018-09-21 2021-01-21 주식회사 녹십자지놈 Markers for predicting concentration of statin in blood
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
JP2022029001A (en) * 2020-07-31 2022-02-17 株式会社三洋物産 Game machine
CN114230626A (en) * 2021-11-05 2022-03-25 康龙化成(宁波)科技发展有限公司 Method for synthesizing quaternary cyclic lactam on oligomeric nucleic acid by one-pot method

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US117329A (en) 1871-07-25 Improvement in parlor-skates
US620333A (en) 1899-02-28 Benjamin g
US620332A (en) 1899-02-28 Reel mechanism
US3320311A (en) 1963-07-17 1967-05-16 Union Oil Co N-cycloalkylidene-n'-cycloalkyl-1-enyl-thioureas and method of preparation
US3330311A (en) 1964-10-19 1967-07-11 Allen Electronics Inc Mechanism for filling receptacles or packets with dry powdered material
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NO870613L (en) 1986-03-05 1987-09-07 Molecular Diagnostics Inc DETECTION OF MICROORGANISMS IN A SAMPLE CONTAINING NUCLEIC ACID.
US5004565A (en) 1986-07-17 1991-04-02 The Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5856522A (en) 1995-05-04 1999-01-05 Tropix, Inc. Method of using synthesis of 1,2-dioxetanes and kits therefore
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1989011548A1 (en) 1988-05-20 1989-11-30 Cetus Corporation Immobilized sequence-specific probes
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5994073A (en) 1990-08-30 1999-11-30 Tropix, Inc. Enhancement of chemiluminescent assays
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
ATE198358T1 (en) 1992-04-27 2001-01-15 Dartmouth College DETECTION OF GENE SEQUENCES IN BIOLOGICAL LIQUIDS
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
EP1262564A3 (en) 1993-01-07 2004-03-31 Sequenom, Inc. Dna sequencing by mass spectrometry
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6027923A (en) 1993-07-23 2000-02-22 Bio-Rad Laboratories, Inc. Linked linear amplification of nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4331012A1 (en) 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
JPH09507121A (en) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ Nucleic acid probe array on biological chip
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5705333A (en) 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
US5773628A (en) 1994-11-14 1998-06-30 Tropix, Inc. 1,2-dioxetane compounds with haloalkoxy groups, methods preparation and use
US5591591A (en) 1995-02-09 1997-01-07 Tropix, Inc. Dioxetane compounds for the chemiluminescent detection of proteases, methods of use and kits therefore
US5589136A (en) 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
US5679803A (en) 1995-10-25 1997-10-21 Tropix, Inc. 1,2 chemiluminescent dioxetanes of improved performance
AU735440B2 (en) 1996-02-09 2001-07-05 Cornell Research Foundation Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US5885470A (en) 1997-04-14 1999-03-23 Caliper Technologies Corporation Controlled fluid transport in microfabricated polymeric substrates
WO1997040462A2 (en) 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
EP1736554B1 (en) 1996-05-29 2013-10-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
IL131873A0 (en) 1997-03-13 2001-03-19 First Opinion Corp Disease management system
AU727083B2 (en) 1997-04-25 2000-11-30 Caliper Life Sciences, Inc. Microfluidic devices incorporating improved channel geometries
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
WO2002072889A2 (en) 2001-01-12 2002-09-19 Applera Corporation Methods and compositions for microarray control
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
WO2006099365A2 (en) * 2005-03-11 2006-09-21 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
US7799530B2 (en) * 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7912068B2 (en) * 2007-07-20 2011-03-22 Oracle America, Inc. Low-latency scheduling in large switches
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
EP2811758B1 (en) 2013-06-06 2016-11-02 Harman Becker Automotive Systems GmbH Audio signal mixing
CN104538553B (en) * 2014-12-31 2017-08-04 北京维信诺科技有限公司 A kind of organic electroluminescence device of Color tunable

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BGI (dbSNP ss104538553, rs13279522, September 10, 2008)-. *
Iakoubova et al. (J. of the Am. College of Cardiology, Vol. 51, No. 4, pages 449-455, 2008)- *
Keskitalo et al. (Br. J. of Clinical Pharmacology, Vol. 68,No. 2, pages 207-213, 2009) *
Shiffman et al. (PLoS ONE, Vol. 7, No. 5, pages e38240, May 2012)- *
Wilke et al. (Nature, Vol. 92, No. 1, pages 112-117, May 23, 2012)-- *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
US11468355B2 (en) 2019-03-04 2022-10-11 Iocurrents, Inc. Data compression and communication using machine learning

Also Published As

Publication number Publication date
JP2018161156A (en) 2018-10-18
JP7175371B2 (en) 2022-11-18
EP3396376A1 (en) 2018-10-31
EP3056899A1 (en) 2016-08-17
US20190032136A1 (en) 2019-01-31
EP3660508A1 (en) 2020-06-03
CA3060628A1 (en) 2011-10-27
EP3056899B1 (en) 2018-03-28
JP2013524810A (en) 2013-06-20
US20140235605A1 (en) 2014-08-21
US20110269735A1 (en) 2011-11-03
US10563263B2 (en) 2020-02-18
JP2016029952A (en) 2016-03-07
EP2561352A4 (en) 2013-08-21
JP2017063795A (en) 2017-04-06
CA2796880A1 (en) 2011-10-27
JP2022033878A (en) 2022-03-02
EP2561352B1 (en) 2016-03-30
EP3396376B1 (en) 2020-01-29
US20200270689A1 (en) 2020-08-27
CA2796880C (en) 2020-12-01
US11827937B2 (en) 2023-11-28
EP3660508B1 (en) 2021-08-18
JP2020096638A (en) 2020-06-25
JP6839779B2 (en) 2021-03-10
EP2561352A1 (en) 2013-02-27
JP2022033877A (en) 2022-03-02
WO2011133418A1 (en) 2011-10-27
JP2020096637A (en) 2020-06-25
JP6157571B2 (en) 2017-07-05
JP5918216B2 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
US11827937B2 (en) Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US11401555B2 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
US20210348232A1 (en) Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20220340970A1 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
US20170022563A1 (en) Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
CA3060628C (en) Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION